nct_id,title,primary_drug,all_drug_names,drug_count,study_type,phases,primary_phase,overall_status,primary_condition,lead_sponsor,collected_date,has_drug_interventions,is_synthetic,data_source,dpc_smiles,smiles_source,official_title,primary_purpose,all_conditions,keywords,why_stopped,start_date,completion_date,primary_outcomes,secondary_outcomes,outcome_count,min_age,max_age,sex,healthy_volunteers,sponsor_class,collaborator_count,enrollment_count,enrollment_type,api_version,is_interventional,is_completed,is_failed,has_safety_outcomes,failure_reason
NCT02688101,"Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors",DpC,['DpC'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Advanced Solid Tumors,Unknown,2025-09-04T01:07:00,True,False,clinicaltrials_gov_api,S=C(N/N=C(C1=NC=CC=C1)\C2=NC=CC=C2)N(C3CCCCC3)C,USER_PROVIDED,,,,,,,,,,,,,,,,,,,,,,,,
NCT03691935,Erector Spinae Plane Block (ESPB): in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.,Ropivacaine,"['Sham anesthetic', 'Naropin', 'Ropivacaine', 'Normal saline']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Nephrectomy,Milton S. Hershey Medical Center,2025-09-01T16:18:07.013290,True,,,,,Erector Spinae Plane Block (ESPB): A New Technique for Perioperative Pain Control in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.,,"['Nephrectomy', 'Partial Nephrectomy', 'Incision Site Discomfort']","['kidney', 'surgery', 'analgesia', 'surgical incision', 'opioid sparing', 'flank pain', 'local anesthesia']",Slow enrollment related to global pandemic and changes to surgical practice.,2018-09-28,2024-02-02,"[{'measure': 'Pain Scores Using the Visual Analogue Pain Scale From Zero Pain to Level Ten Pain', 'description': 'Data will be collected via the electronic medical record and begin following patient randomization. The Visual Analogue Scale pain scales will be administered and collected on Post Operative Days 1, 2 and 3. Minimum value = 0 No Pain, Maximum value = 10 Worst possible, unbearable, excruciating pain', 'timeFrame': 'Aggregate pain scores for average length of hospital stay which is 3 days'}]",[],1.0,18 Years,85 Years,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,False,True,False,Slow enrollment related to global pandemic and changes to surgical practice.
NCT05099835,Ultrasound-Guided Stellate Ganglion Block With Botulinum,Botox,"['Botox', 'triamcinolonacetonide']",2,INTERVENTIONAL,['NA'],,COMPLETED,Change From Baseline House-Brackmann,Assiut University,2025-09-01T16:18:07.013310,True,,,,,Ultrasound-Guided Stellate Ganglion Block With Botulinum Toxin Versus Steroid in Refractory Bell's Palsy,,['Change From Baseline House-Brackmann'],[],,2021-11-01,2022-07-01,"[{'measure': 'Change from Baseline House-Brackmann', 'description': 'Change from Baseline House-Brackmann', 'timeFrame': ': Baseline ,change from baseline House-Brackmann at 7th day,one month,two month, three month'}]",[],1.0,18 Years,60 Years,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT03535935,"Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease",Astragalus Powder,['Astragalus Powder'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Diabetic Nephropathies,The University of Hong Kong,2025-09-01T16:18:07.013324,True,,,,,"Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease (READY) - An Open-label Randomised Controlled Trial With Responder Regression Analysis",,"['Diabetic Nephropathies', 'Diabetic Kidney Disease']","['Chinese medicine', 'Astragalus', 'Pragmatic trial']",,2018-07-01,2022-12-31,"[{'measure': 'Change in estimated GFR', 'description': 'Efficacy and safety', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in spot urine albumin-to-creatinine ratio', 'description': 'Efficacy and safety', 'timeFrame': 'From baseline to 48 weeks after treatment'}]","[{'measure': 'Change in glycated haemoglobin (HbA1c)', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in urinary monocyte chemotactic protein 1 (MCP-1)', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in urinary Cystatin C', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in lipids', 'timeFrame': 'From baseline to 48 weeks after treatment'}]",6.0,35 Years,80 Years,ALL,False,OTHER,1.0,118.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04882735,Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN),Acoramidis,"['Acoramidis', 'AG10']",2,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy,"Eidos Therapeutics, a BridgeBio company",2025-09-01T16:18:07.013461,True,,,,,"A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Acoramidis in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Study)",,['Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy'],"['TTR', 'ATTR-PN', 'Familial ATTR-PN', 'Amyloidosis', 'Amyloid', 'Transthyretin', 'Polyneuropathy', 'TTR-mediated amyloidosis', 'Amyloidosis, hereditary', 'Familial Amyloid Polyneuropathies', 'Amyloidosis, Hereditary, Transthyretin-Related']",Sponsor's decision to cancel study,2021-09-08,2026-10,"[{'measure': 'Change from baseline to Month 18 in mNIS+7', 'description': 'To determine the efficacy of acoramidis in subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN) by evaluating the change in Modified Neuropathy Impairment Score +7 (mNIS+7) from baseline to 18 months.', 'timeFrame': '18 Months'}, {'measure': 'Safety: TESAEs will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN)', 'description': 'To evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN)', 'timeFrame': '60 Months'}, {'measure': 'Safety: Adverse Events leading to treatment discontinuation will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN)', 'description': 'To evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN)', 'timeFrame': '60 Months'}, {'measure': 'Safety: Adverse Events will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN)', 'description': 'To evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN)', 'timeFrame': '60 Months'}, {'measure': 'Safety: Incidence of abnormal physical exam will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN)', 'description': 'To evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN)', 'timeFrame': '60 Months'}, {'measure': 'Safety: Incidence of abnormal vital signs will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN)', 'description': 'To evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN)', 'timeFrame': '60 Months'}, {'measure': 'Safety: Columbia-Suicide Severity Rating Scale (C-SSRS) will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN)', 'description': 'To evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic transthyretin amyloid polyneuropathy (ATTR-PN)', 'timeFrame': '60 Months'}]","[{'measure': 'Change from baseline to Month 18 in Norfolk QOL-DN', 'description': 'To evaluate the effects of acoramidis in subjects with symptomatic ATTR-PN on Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN)', 'timeFrame': '18 Months'}, {'measure': 'Change from baseline to Month 18 in mBMI', 'description': 'To evaluate the effects of acoramidis in subjects with symptomatic ATTR-PN on Modified body mass index (mBMI)', 'timeFrame': '18 Months'}, {'measure': 'Change from baseline to Month 18 in COMPASS-31', 'description': 'To evaluate the effects of acoramidis in subjects with symptomatic ATTR-PN on Composite Autonomic Score (COMPASS-31)', 'timeFrame': '18 Months'}]",10.0,18 Years,90 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Sponsor's decision to cancel study
NCT02121535,Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use,T80/A5 mg FDC tablet,"['T80/A5/H12.5 mg FDC tablet', 'H12.5 mg tablet', 'H12.5 mf tablet', 'T80/A5/H12.5 ng FDC tablet', 'T80/A5 mg FDC tablet']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:07.013511,True,,,,,"Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Hydrochlorothiazide 12.5 mg Tablet in Healthy Male Subjects : an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study",,['Healthy'],[],,2014-04,2014-08,"[{'measure': 'Area Under the Concentration-time Curve of the Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC0-tz)', 'description': 'Area under the concentration-time curve of the telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h after drug administration'}, {'measure': 'Cmax for Telmisartan', 'description': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h after drug administration'}, {'measure': 'AUC0-tz for Amlodipine', 'description': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)', 'timeFrame': '3hours(h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h, 144h after drug administration'}, {'measure': 'Cmax for Amlodipine', 'description': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': '3hours(h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h, 144h after drug administration'}, {'measure': 'Cmax for Hydrochlorothiazide', 'description': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h after drug administration'}, {'measure': 'AUC0-tz for Hydrochlorothiazide', 'description': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h after drug administration'}]","[{'measure': 'AUC0-∞ for Telmisartan', 'description': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h after drug administration'}, {'measure': 'AUC0-∞ for Amlodipine', 'description': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': '3hours(h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h, 144h after drug administration'}, {'measure': 'AUC0-∞ for Hydrochlorothiazide', 'description': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h after drug administration'}]",9.0,20 Years,35 Years,MALE,True,INDUSTRY,0.0,72.0,ACTUAL,v2_robust,True,True,False,False,
NCT06485635,Real-life-persistence to Antifibrotic Treatments,Nintedanib,"['Pirfenidone', 'Nintedanib']",2,OBSERVATIONAL,[],,ACTIVE_NOT_RECRUITING,Idiopathic Pulmonary Fibrosis,Boehringer Ingelheim,2025-09-01T16:18:07.013557,True,,,,,Real-life-Persistence to Antifibrotic Treatments,,['Idiopathic Pulmonary Fibrosis'],[],,2024-10-16,2025-09-01,"[{'measure': 'Persistence to antifibrotic (AF) treatment (measured as percentage of patients still treated up to 30 months after AF treatment initiation)', 'timeFrame': 'up to 30 months'}]","[{'measure': 'AF prevalence in French population', 'timeFrame': 'up to 5 years'}, {'measure': 'AF incidence in French population', 'timeFrame': 'up to 4 years'}, {'measure': 'Number of AF treated patients split by indication', 'description': 'Indications:\n\n* Idiopathic Pulmonary Fibrosis (IPF)\n* Interstitial Lung Disease associated with Systemic Sclerosis (SSc-ILD)\n* Progressive Pulmonary Fibrosis (PPF)', 'timeFrame': 'up to 2 years'}, {'measure': 'Number of patients adherent to AF treatment', 'description': 'In incident AF patients, percentage of days covered (PDC) will be calculated at different time point to measure the adherence to AF treatment for patients persistent to treatment at this time point.\n\nThe PDC is the ratio dividing the number of days exposed by the number of days in the period evaluated.\n\nA PDC≥ 80% is considered as a good adherence to medication.', 'timeFrame': 'up to 30 months'}, {'measure': 'Percentage of the target cumulative dose of treatment received by the patients', 'timeFrame': 'up to 30 months'}, {'measure': 'Influence of factors (yes/no) associated with persistence to AF treatments', 'description': 'For a pre-determined list of variables (as defined in the study protocol) in incident AF patients, a multivariate time-dependant Cox model will test several covariates to check if they are associated with persistence to AF treatment.', 'timeFrame': 'up to 30 months'}, {'measure': 'Number of patients with switch from one AF treatment to the another with no treatment stop', 'timeFrame': 'up to 5 years'}, {'measure': 'Number of patients at site of follow-up (identified as 2 lung function tests performed in the center)', 'timeFrame': 'up to 5 years'}, {'measure': 'Overall Survival (defined as time from index date (first reimbursement of AF treatment) to death from any cause)', 'timeFrame': 'up to5 years'}, {'measure': 'Event-free survival', 'description': 'Defined as the time from index date to\n\n* oxygenotherapy onset\n* hospitalisation for respiratory exacerbations\n* hospitalisation for other respiratory diseases\n* ath from any cause', 'timeFrame': 'up to 5 years'}]",11.0,,,ALL,False,INDUSTRY,0.0,10646.0,ACTUAL,v2_robust,False,False,False,False,
NCT00932035,Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer,isosulfan blue based lymphatic mapping,"['Lymphazurin blue dye', 'isosulfan blue dye', 'isosulfan blue based lymphatic mapping']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Breast Cancer,City of Hope Medical Center,2025-09-01T16:18:07.013684,True,,,,,Reducing Extremity Lymphedema Through Axillary Lymphatic Preservation Surgery,,['Breast Cancer'],"['breast cancer', 'axillary mapping', 'lymphedema']",Loss of principal investigator,2009-06,2014-05,"[{'measure': 'Percentage of Patients With Arm Lymphatics Above, at, or Below the Axillary Vein', 'description': ""A Fisher's exact test with a one-sided alpha of 0.05 will be used to determine if the percentage of patients with arm lymphatics above, around, or below the axillary vein in the standard dissection group is superior to the experimental dissection group."", 'timeFrame': 'Up to 4 years'}, {'measure': 'Percentage of Patients With Positive Axillary Reverse Mapping (ARM) Identified Nodes', 'description': ""A Fisher's exact test with a one-sided alpha of 0.05 will be used to determine if the percentage of patients with positive ARM identified nodes excised in the standard dissection group is superior to the experimental dissection group."", 'timeFrame': 'Up to 4 years'}, {'measure': 'Percentage of Patients With Lymphedema', 'description': 'Difference between arms in patients developing lymphedema at any point during the study will be evaluated using chi-squared tests.', 'timeFrame': 'Up to 4 years'}]",[],3.0,,,FEMALE,False,OTHER,1.0,39.0,ACTUAL,v2_robust,True,False,True,False,Loss of principal investigator
NCT01019408,Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan,Chloroquine,"['CQ', 'Chloroquine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Malaria, Falciparum",London School of Hygiene and Tropical Medicine,2025-09-01T16:18:07.013748,True,,,,,Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan,,"['Malaria, Falciparum']","['Clinical Trial', 'Chloroquine', 'Refugees', 'Afghanistan', 'Pakistan']",,1993-11,1995-01,"[{'measure': 'therapeutic and parasitological cure with no recrudescence', 'timeFrame': '60 days'}]","[{'measure': 'parasite clearance time', 'timeFrame': '28 days'}, {'measure': 'fever clearance time', 'timeFrame': '28 days'}, {'measure': 'gametocytaemia', 'timeFrame': '28 days'}]",4.0,6 Months,60 Years,ALL,False,OTHER,3.0,163.0,ACTUAL,v2_robust,True,True,False,False,
NCT01328808,Metabolism and Toxicity of Acetaminophen,Acetaminophen/APAP,"['Acetaminophen/APAP', 'Tylenol']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Pain,John van den Anker,2025-09-01T16:18:07.013758,True,,,,,Metabolism and Toxicity of Acetaminophen in Preterm Infants,,['Pain'],"['Acetaminophen', 'Preterm Infants']",,2011-10,2022-12,"[{'measure': 'primary endpoint PK analysis', 'description': 'Blood and urine levels of APAP and metabolites', 'timeFrame': '48 hours'}]","[{'measure': 'Developmental stage', 'description': 'To assess both the magnitude and statistical significance of any evidence of relationship between developmental stage and toxicity-associated metabolite levels.\n\nThe analyses will also hold constant APAP dose, BID or TID and possible confounding variables such as birth order, maternal smoking status, and maternal age. We will plot the relationship between stage of development and measures of APAP Metabolism, taken at different gestational and postnatal ages. A hierarchical, cross sectional time series models will be used.', 'timeFrame': '48 hours'}]",2.0,22 Weeks,37 Weeks,ALL,False,OTHER,0.0,31.0,ACTUAL,v2_robust,True,False,False,False,
NCT00725608,Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444),buprenorphine/naloxone,"['buprenorphine/naloxone', 'Suboxone, SCH 000484']",2,OBSERVATIONAL,[],,COMPLETED,Opioid-Related Disorders,Indivior Inc.,2025-09-01T16:18:07.013773,True,,,,,"Evaluation of Transfer From Subutex or Other Treatment for Opioid Drug Dependence to Suboxone: Acceptability, Safety and Impact on Medication Dispensing",,"['Opioid-Related Disorders', 'Opiate Dependence', 'Drug Abuse']","['Suboxone', 'Subutex', 'Buprenorphine', 'Naloxone']",,2008-05,2011-04,"[{'measure': 'Retention Rate', 'description': 'The primary objective of this study was to determine the retention rate of patients after 6 and 12 months of treatment with buprenorphine/naloxone measured by the percentage of patients remaining in the study', 'timeFrame': 'month 6, month 12'}]","[{'measure': 'Dosing of Suboxone (Buprenorphine Plus Naloxone)', 'description': 'One of the secondary objectives was to evaluate the effect of the switch to buprenorphine/naloxone on medication dispensing measured by dose.', 'timeFrame': 'day 1, month 6, month 12'}, {'measure': 'Dispensing of Suboxone (Buprenorphine Plus Naloxone)', 'description': 'Another of the secondary objectives was to evaluate the effect of the switch to Suboxone (buprenorphine plus naloxone) on medication dispensing measured by frequency of visits to the treating physician or pharmacy to receive the medication (daily, biweekly, once weekly, monthly, other)', 'timeFrame': 'month 6, month 12'}]",3.0,15 Years,,ALL,False,INDUSTRY,0.0,339.0,ACTUAL,v2_robust,False,True,False,False,
NCT01265108,Effects of Iron on Exercise Capacity During Hypoxia,Iron sucrose.,"['Iron sucrose = Venofer', 'Normal saline', 'Iron sucrose.']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,University of Oxford,2025-09-01T16:18:07.014040,True,,,,,Effects of Intravenous Iron Supplementation on Exercise Capacity During Sustained Alveolar Hypoxia in Healthy Humans.,,['Healthy Volunteers'],[],,2010-11,2015-04,"[{'measure': 'Maximal exercise capacity during hypoxia, assessed by maximal oxygen consumption.', 'description': 'Volunteers will receive either intravenous iron or saline placebo, before exposure to 8 hours of alveolar hypoxia. They will then undergo an exercise test while breathing an hypoxic gas mixture. The primary outcome measure will be exercise capacity as determined by maximal oxygen consumption during this test. Volunteers will receive both interventions, via a crossover design. Due to uncertainty about the duration of action of iron at a cellular level, all volunteers will receive saline infusion on the first study day, and iron sucrose infusion on a second study day, at least one week later.', 'timeFrame': 'After 8-h exposure to alveolar hypoxia.'}]","[{'measure': 'Maximal exercise capacity, assessed by peak power output.', 'timeFrame': 'After 8-h exposure to alveolar hypoxia.'}, {'measure': 'Pulmonary artery systolic pressure.', 'timeFrame': 'After 8-h exposure to alveolar hypoxia.'}, {'measure': 'Blood levels of oxygen-regulated proteins.', 'timeFrame': 'After 8-h exposure to alveolar hypoxia'}]",4.0,18 Years,60 Years,ALL,True,OTHER,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,
NCT00000208,Methadone/Buprenorphine Cross-Over Study - 4,Buprenorphine,['Buprenorphine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Opioid-Related Disorders,National Institute on Drug Abuse (NIDA),2025-09-01T16:18:07.014075,True,,,,,Methadone/Buprenorphine Cross-Over Study,,['Opioid-Related Disorders'],[],,1992-02,,"[{'measure': 'Drug use'}, {'measure': 'Withdrawal symptoms'}, {'measure': 'Opiate craving'}]",[],3.0,21 Years,50 Years,ALL,False,NIH,0.0,0.0,,v2_robust,True,True,False,False,
NCT04169308,Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty,Restylane-L® Filler injection,['Restylane-L® Filler injection'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Deformity of Nasal Cartilage,DeNova Research,2025-09-01T16:18:07.014117,True,,,,,Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty on First Impressions and Quality of Life (FACE-Q Scale),,['Deformity of Nasal Cartilage'],[],,2019-01-01,2020-07-21,"[{'measure': 'To determine the effects of Restylane-L® Filler injection into the nose on first impressions and quality of life based on the validated questionnaires using FACE-Q scales.', 'description': 'We will measure changes in first impressions using a questionnaire with categories which include social skills, academic performance, dating success, occupational success, attractiveness, financial success, relationship success, and athletic skills. The 300 independent reviewers will grade each photo on a scale of 1(least favorable) to 10 (best). Evaluation of effects on quality of life will be reported through comparison of pre/post injection quality of life survey scores filled out by patients using the validated FACE-Q PRO survey measure (categories include appraisal of nasal appearance, psychological well-being, social function, and psychological distress). Maximal reported score is 4 (very satisfied) and lowest reported score is 1 (very dissatisfied).', 'timeFrame': '4 weeks'}]","[{'measure': 'To determine the efficacy of Restylane-L® Filler injection to the nose in reduction of convexity of the nasal dorsum as measured on pre/post injection 2D photographs.', 'description': 'Secondary assessment of this study is to determine the efficacy of Restylane-L® filler injection into the nose as defined by the reduction of the nasal dorsal convexity to 0mm (+/- 10% of pre injection value) as measured by differences in length of a line (from pre to post injection photos) from the highest tip of the nasal dorsum to a line drawn from the Radix to the supratip region on a lateral view 2D photograph. This will be performed through calculation of changes in nasal dorsal hump convexity for all patients. All measures will be performed in triplicate and the mean of the 3 measures will be used.', 'timeFrame': '4 weeks'}, {'measure': 'To measure changes in nasal projection and rotation after injection with Restylane-L® Filler in subset of patients who underwent nasal tip augmentation.', 'description': 'Subgroup analysis will be performed for the patients who also underwent augmentation of the nasal tip to measure changes in projection (in mm) and rotation (in degrees) achieved from injection of filler. We will be using the Goode method for measuring nasal projection. We will be reporting the following measurements:\n\nNasal projection is the perpendicular distance between the tip-defining point and a line passing through the nasion and alar crease.\n\nNasal length is the distance between the nasion and the tip-defining point. The ideal Goode ratio of 0.55 to 0.60 is the perpendicular distance between the tip-defining point and a line passing through the nasion and alar crease divided by nasal length.\n\nNasal tip rotation or the nasolabial angle (normal 90-120 degrees), is the angle defined by the columellar point-to-subnasale line intersecting with subnasale-to-labrale superius line.\n\nThe mean of the 3 measurements in (mm for distance) or (degrees for rotation) will be reported.', 'timeFrame': '4 weeks'}, {'measure': 'To determine the safety of Restylane-L® Filler injection to the nose for non-surgical rhinoplasty by recording the number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'The safety profile of injecting Restylane-L® into the nose will be measured by continually monitoring for AEs during the duration of the study and reporting the total number and description of events.', 'timeFrame': '4 weeks'}]",4.0,21 Years,,ALL,True,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,True,
NCT06413108,"Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali",TB31F,['TB31F'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,ACTIVE_NOT_RECRUITING,"Malaria,Falciparum",Radboud University Medical Center,2025-09-01T16:18:07.014175,True,,,,,"A Phase 1/2a Single Centre, Randomised, Placebo-controlled, Double-blind, Dose-escalation, Age De-escalation, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Malaria-exposed Malian Adults and Children",,"['Malaria,Falciparum']","['transmission-reducing', 'monoclonal antibody']",,2024-07-12,2026-01,"[{'measure': 'Occurrence of at least possibly related solicited local and systemic adverse events', 'timeFrame': 'within 7 days of monoclonal antibody TB31F administration'}, {'measure': 'Occurrence of at least possibly related unsolicited adverse events', 'timeFrame': 'within 28 days of monoclonal antibody TB31F administration'}, {'measure': 'Occurrence of at least possibly related serious adverse events', 'timeFrame': 'from enrollment to the end of follow-up at 28 or 84 days'}, {'measure': 'Terminal serum half-life (t½) of monoclonal antibody TB31F in serum', 'timeFrame': 'day 0 [baseline], day 1, day 5, day 7, day 14, day 21, day 28, day 42, day 56, day 84.'}, {'measure': 'Maximum observed serum concentration (Cmax) of monoclonal antibody TB31F in serum', 'timeFrame': 'day 0 [baseline], day 1, day 5, day 7, day 14, day 21, day 28, day 42, day 56, day 84.'}, {'measure': 'Time to reach maximum serum concentration (tmax) of monoclonal antibody TB31F in serum', 'timeFrame': 'day 0 [baseline], day 1, day 5, day 7, day 14, day 21, day 28, day 42, day 56, day 84.'}, {'measure': 'Accumulation index (Racc) of monoclonal antibody TB31F in serum', 'timeFrame': 'day 0 [baseline], day 1, day 5, day 7, day 14, day 21, day 28, day 42, day 56, day 84.'}, {'measure': 'Area under the serum concentration-time curve (AUC0-τ, AUC0-t and AUC) of monoclonal antibody TB31F in serum', 'timeFrame': 'day 0 [baseline], day 1, day 5, day 7, day 14, day 21, day 28, day 42, day 56, day 84.'}, {'measure': 'Within-group percent reduction in the proportion of mosquitoes infected at day 5 post-treatment compared to baseline (day 0), assessed through direct membrane feeding assays and measured as oocyst prevalence', 'timeFrame': 'day 0 [baseline] & 5'}]","[{'measure': 'Within-group percent reduction in the proportion of mosquitoes infected in direct skin feeding assay (DSF), compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, and 5'}, {'measure': 'Within-group percent reduction in the proportion of mosquitoes infected in direct membrane feeding assays (DMFA), compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, 5, and 14'}, {'measure': 'Mosquito infection prevalence, assessed by direct skin feed and measured as the proportion dissected mosquitoes with any number of oocysts, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, and 5'}, {'measure': 'Mosquito infection prevalence, assessed by DMFA and measured as the proportion dissected with any number of oocysts, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, 5, and 14'}, {'measure': 'Mosquito infection intensity, assessed by direct skin feed and measured as the number of oocysts in dissected mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, and 5'}, {'measure': 'Mosquito infection intensity, assessed by DMFA and measured as the average number of oocysts in dissected mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, 5, and 14'}, {'measure': 'Participant infection prevalence, assessed by DSF as the proportion of individuals infectious to any number of mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, and 5'}, {'measure': 'Participant infection prevalence, assessed by DMFA as the proportion of individuals infectious to any number of mosquitoes, compared within groups between baseline and all feeding time points, and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 1, 5, and 14'}, {'measure': 'Transmission-reducing activity in school-age children and adults, measured as the percent reduction in mean oocyst intensity compared to experimental controls, compared within groups and between groups at all feeding timepoints.', 'timeFrame': 'day 0 [baseline], 5, 14, 28, 56, and 84'}]",18.0,10 Years,50 Years,ALL,True,OTHER,2.0,165.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06957808,Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia,Diroximel fumarate (DRF),"['Diroximel fumarate (DRF)', 'Vumerity', 'Placebo']",3,INTERVENTIONAL,['NA'],,RECRUITING,Schizophrenia Disorders,King's College London,2025-09-01T16:18:07.014184,True,,,,,Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia,,['Schizophrenia Disorders'],"['psychosis', 'schizophrenia', 'inflammation', 'diroximel fumarate', 'neuroimaging', 'antioxidant', 'glutathione']",,2025-01-10,2026-06,"[{'measure': 'MRS glutathione (GSH) levels in ACC', 'description': 'Glutathione levels in the Anterior Cingulate Cortex (ACC) measured by magnetic resonance spectroscopy (1HMRS)', 'timeFrame': 'Within one year of conclusion of the Research'}]","[{'measure': 'MMN Amplitude', 'description': 'Mismatch negativity Amplitude measured by electroencephalography (EEG)', 'timeFrame': 'Within one year of conclusion of the Research'}]",2.0,18 Years,65 Years,ALL,False,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02835508,Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants,JNJ-56021927 60 Milligram,"['JNJ-56021927 120 Milligram', 'apalutamide', 'JNJ-56021927 60 Milligram', 'JNJ-56021927 240 Milligram']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Janssen Pharmaceutical K.K.,2025-09-01T16:18:07.014195,True,,,,,"A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetic Profile of JNJ-56021927 When Administered as the Tablet Formulation in Healthy Male Japanese Subjects",,['Healthy'],[],,2016-06,2016-12,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'Maximum observed plasma concentration (Cmax) will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'description': 'Actual sampling time to reach maximum observed analyte concentration (Tmax) will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Area Under Concentration from time zero to the last quantifiable AUC (0-last)', 'description': 'AUC from time zero to the last quantifiable concentration will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])', 'description': 'The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (0-last) and C (0-last)/lambda(z); wherein AUC (0-last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda (z) is elimination rate constant. AUC (0-infinity) will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Time to Last Quantifiable Plasma Concentration (Tlast)', 'description': 'The Tlast, time to last observed quantifiable plasma concentration will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Percentage of Area Under the Plasma Concentration-Time Curve Extrapolated From Last Measurable Concentration to Infinite Time (%AUC,ext)', 'description': 'Percentage of area under the plasma concentration-time curve extrapolated from last measurable concentration to infinite time (%AUC,ext) is calculated as (AUC \\[0-infinity\\] minus AUC \\[0-last\\])/ AUC \\[0-infinity\\])\\*100.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Apparent Clearance (CL/F)', 'description': 'Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F will be calculated as CL/F = Dose/AUC \\[0-infinity\\]', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Apparent Terminal Elimination Half-life (t1/2term)', 'description': 'Apparent terminal elimination half-life, calculated as 0.693/apparent terminal elimination rate constant (λz)', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Apparent Terminal Elimination Rate Constant (lambda z)', 'description': 'Apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log transformed concentration vs time data', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Apparent Volume of Distribution (Vd/F)', 'description': 'Apparent volume of distribution based on the terminal phase following oral administration calculated as Vd/F = Dose/ apparent terminal elimination rate constant (λz)\\*AUC \\[0-infinity\\]', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Metabolite to Parent Drug Ratio for Maximum Observed Plasma Concentration (MPR Cmax)', 'description': 'Metabolite to parent drug ratio for Cmax will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Metabolite to Parent Drug Ratio for Area Under Concentration from time zero to the last quantifiable concentration (MPR AUC [0-last])', 'description': 'Metabolite to parent drug ratio for AUC \\[0-last\\] will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Metabolite to Parent Drug Ratio for Area Under Curve from time zero extrapolated to infinity (MPR AUC [0-infinity])', 'description': 'Metabolite to parent drug ratio for AUC \\[0-infinity\\] will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Area Under Curve from time of administration to 24 hours post dosing', 'description': 'AUC from time of administration to 24 hours post dosing will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}, {'measure': 'Area Under Curve from time of administration to 168 hours post dosing', 'description': 'AUC from time of administration to 168 hours post dosing will be assessed.', 'timeFrame': 'Predose, Up to Day 57'}]","[{'measure': 'Number of Participants With Adverse Events as a Measure of Safety and Tolerability', 'timeFrame': 'Up to Day 57'}]",16.0,20 Years,55 Years,MALE,True,INDUSTRY,0.0,18.0,ACTUAL,v2_robust,True,True,False,True,
NCT06258408,A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors,BB102 tablet,"['BB102 tablet', 'BB102']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Advanced Solid Tumor,"BrodenBio Co., Ltd.",2025-09-01T16:18:07.014266,True,,,,,"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Efficacy of Oral BB102 Tablets in Patients With Advanced Solid Tumors",,['Advanced Solid Tumor'],"['BB102', 'FGFR4', 'First-in-Human', 'Dose Escalation', 'FGF19']",,2022-12-29,2025-07,"[{'measure': 'Number of subjects with dose limiting toxicities (DLTs)', 'description': 'To assess the safety and tolerability of BB102 tablet as monotherapy in subjects with advanced solid tumors and to determine the maximum tolerated dose (MTD) of BB102 tablet, and to provide a basis for determination of the recommended dose (RP2D) for Phase II clinical trials.', 'timeFrame': 'Single dose to the end of Cycle 1 (each cycle is 21 days)'}, {'measure': 'Number of subjects with adverse events (AEs) and serious adverse events (SAEs)', 'description': 'AEs and SAEs will be characterized by type, seriousness, relationship to study treatment, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\] version 5.0) and timing.\n\nFGF19 or FGFR4 positive advanced primary HCC or other advanced solid tumors.', 'timeFrame': 'From screening (Day -28 to Day -1) through up to 12 months or until disease progression'}]","[{'measure': 'Pharmacokinetic Assessments: Peak Plasma Concentration (Cmax)', 'description': 'Blood samples will be collected for PK analyses', 'timeFrame': 'Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)'}, {'measure': 'Pharmacokinetic Assessments: Time to Peak Concentration (Tmax)', 'description': 'Blood samples will be collected for PK analyses', 'timeFrame': 'Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)'}, {'measure': 'Pharmacokinetic Assessments: Area under the plasma concentration-time curve (AUC)', 'description': 'Blood samples will be collected for PK analyses', 'timeFrame': 'Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)'}, {'measure': 'Pharmacokinetic Assessments: Elimination half-life (t½)', 'description': 'Blood samples will be collected for PK analyses', 'timeFrame': 'Day 1, Day 8, Day 15 and at the end of Cycle 1 (each cycle is 21 days)'}, {'measure': 'Objective response rate (ORR)', 'description': 'Tumor response measured by radiologic imaging techniques at baseline and throughout the study.', 'timeFrame': 'From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}, {'measure': 'Duration of response (DOR)', 'description': 'Tumor response measured by radiologic imaging techniques at baseline and throughout the study.', 'timeFrame': 'From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'Tumor response measured by radiologic imaging techniques at baseline and throughout the study.', 'timeFrame': 'From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Tumor response measured by radiologic imaging techniques at baseline and throughout the study.', 'timeFrame': 'From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}]",10.0,18 Years,78 Years,ALL,False,INDUSTRY,0.0,78.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05145608,Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg,Lamotrigine ER tablet 50mg,"['Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg', 'Lamotrigine ER tablet 50mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Bioequivalence,Alembic Pharmaceuticals Ltd.,2025-09-01T16:18:07.014308,True,,,,,Single Dose Two Way Crossover Comparative Bioavailability Study of Lamotrigine Extended-Release Tablets USP 50 mg in Healthy Male and Female Volunteers Fasting State,,['Bioequivalence'],[],,2018-01-10,2018-02-21,"[{'measure': 'Cmax', 'description': 'Peak Plasma Concentration (Cmax)', 'timeFrame': 'Up to 192 hours'}, {'measure': 'AUC0-T', 'description': 'Area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Up to 192 hours'}, {'measure': 'AUC0-∞', 'description': 'Area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Up to 192 hours'}]",[],3.0,18 Years,54 Years,ALL,True,INDUSTRY,0.0,22.0,ACTUAL,v2_robust,True,True,False,False,
NCT05728008,Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.,Ustekinumab,"['Ustekinumab', 'Tofacitinib']",2,OBSERVATIONAL,[],,COMPLETED,Ulcerative Colitis,IRCCS San Raffaele,2025-09-01T16:18:07.014331,True,,,,,Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.,,['Ulcerative Colitis'],[],,2022-04-05,2022-07-05,"[{'measure': 'Determine which drug between ustekinumab and tofacitinib as a third-line treatment, in cases refractory to both anti-TNFα and vedolizumab, is the best option to achieve disease control in terms of hospitalization rate, surgery rate, drug optimization.', 'description': 'The aim of this retrospective multicentric observational study is to determine which between ustekinumab (anti-IL12-23) and tofacitinib (pan JAK inhibitor) as third-line therapy in UC cases refractory to both anti-TNFα and vedolizumab (inhibitor of α4β7 integrin) is the best compound to achieve disease control.The primary goal is to compare the hospitalization rate, surgery rate, drug optimization rate and the drug discontinuation rate, as a composite primary objective, in patients on either of the two drugs.\n\nThe induction phase of Ustekinumab consists of approximately 6mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks. The induction phase of Tofacitinib consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.', 'timeFrame': '2 months'}]","[{'measure': 'IBD outcomes', 'description': '* hospitalization rate (e.g. hospitalization, admission to intensive care unit)\n* surgery rate (type of surgery, occurrence colorectal dysplasia and/or colorectal cancer)\n* drug optimization rate (start of systemic steroids, immunosuppressants, or biologics, dose optimization, interval optimization), switch to another drug, or swap to another drug\n* drug discontinuation rate alone (need to switch or to swap to another drug)', 'timeFrame': '2 months'}]",2.0,18 Years,,ALL,,OTHER,0.0,100.0,ACTUAL,v2_robust,False,True,False,False,
NCT06265025,"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors",GM103 (Part A),"['GM103 (Part A)', 'GM103 and Pembrolizumab (Part C)', 'GM103 (Part B)']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Head and Neck Cancer,"GeneMedicine Co., Ltd.",2025-09-01T16:18:07.014371,True,,,,,"A Phase I/II, Open-label, Dose-escalation With Expansion Study of GM103 Via Intratumoral Injection, Alone and in Combination With Pembrolizumab in Adult Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors",,"['Head and Neck Cancer', 'Malignant Melanoma', 'Colorectal Cancer', 'Renal Cell Carcinoma', 'Cervical Cancer', 'Breast Cancer']","['Oncolytic Virus', 'OV', 'Solid tumor']",,2024-02-20,2028-10-30,"[{'measure': 'Percentage of patients with DLTs by cohorts', 'description': 'To determine the MTD and RP2D based on safety and tolerability of GM103 as monotherapy (Parts A, B).', 'timeFrame': 'during the first 28 days of treatment'}, {'measure': 'Percentage of patients with DLTs', 'description': 'To determine the MTD and RP2D based on safety and tolerability of GM103 in combination with pembrolizumab (Part C)', 'timeFrame': 'during the first 21 days of treatment'}, {'measure': 'Incidence of AEs, AESIs, SAEs, AEs leading to discontinuation, and AEs resulting in death', 'description': 'To evaluate overall safety profile of GM103 as monotherapy (Parts A, B) and in combination with pembrolizumab (Part C)', 'timeFrame': 'through study completion, and average 1 year'}]","[{'measure': 'ORR', 'description': '* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, as monotherapy (Parts A and B)\n* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, in combination with pembrolizumab (Part C)', 'timeFrame': 'through study completion, and average 1 year'}, {'measure': 'DCR defined as the proportion of patients whose BOR was CR, PR and SD', 'description': '* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, as monotherapy (Parts A and B)\n* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, in combination with pembrolizumab (Part C)', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Median PFS defined as the time from the date of the first administration of study drug to the date of disease progression or death', 'description': '* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, as monotherapy (Parts A and B)\n* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, in combination with pembrolizumab (Part C)', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Incidence of GM103 detection', 'description': '* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, as monotherapy (Parts A and B)\n* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, in combination with pembrolizumab (Part C)', 'timeFrame': 'every cycle, through study completion, an average of 1 year [up to 12 treatment cycles, Part A&B: each cycle will consist of 14 days(2 weeks) / Part C: each cycle will consist of 21 days(3 weeks)]'}, {'measure': 'Changes in the level of anti-adenovirus antibodies(ADA) in blood compared to baseline (ADA in genome copies/mL using qPCR)', 'description': '* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, as monotherapy (Parts A and B)\n* To assess preliminary anti-tumor efficacy of GM103 at the RP2D, in combination with pembrolizumab (Part C)', 'timeFrame': 'every 2 cycles after the first cycle, through study completion, an average of 1 year [up to 12 treatment cycles, Part A&B: each cycle will consist of 14 days(2 weeks) / Part C: each cycle will consist of 21 days(3 weeks)]'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,125.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03117725,Melatonin Study Between Diminished and Normal Responder in IVF,Melatonin adminstration,"['placebo administration', 'Melatonin adminstration']",2,INTERVENTIONAL,['NA'],,UNKNOWN,"Infertility, Female",Bundang CHA Hospital,2025-09-01T16:18:07.014389,True,,,,,Comparison of IVF Outcome and Endometrium Effect in Infertility Patients Between Diminished and Normal Ovarian Reserve After Melatonin Administration.,,"['Infertility, Female']","['oxidative stress', 'antioxidants', 'diminished ovarian reserve']",,2017-05-12,2019-10-31,"[{'measure': 'IVF outcome - oocyte quality', 'description': 'Evaluate oocyte quality on morphological standard as following category- Mature oocyte, Intermediate oocyte, atretic oocyte, post mature oocyte', 'timeFrame': '3 days after oocyte retrieval'}, {'measure': 'IVF outcome - embryo quality', 'description': 'grade the embryos\\& blastocysts according to the Lucinda Veeck \\& Gardner', 'timeFrame': '3 to 5 days after oocyte retrieval'}, {'measure': 'IVF outcome -biochemical pregnancy rate', 'description': 'serum human chorionic gonadotropin level\\>10 IU', 'timeFrame': 'on day 12~14 after embryo transfer'}, {'measure': 'IVF outcome - clinical pregnancy rate', 'description': 'presence of G-sac in the uterine cavity', 'timeFrame': 'at 6-8 weeks of gestation'}]","[{'measure': 'acquired oocyte No', 'description': 'number', 'timeFrame': '20weeks'}, {'measure': 'fertilization rate', 'description': 'ratio of no. of fertilized egg/ no of total retrieved eggs', 'timeFrame': '20weeks'}, {'measure': 'Comparing Pittsburgh sleep quality index', 'description': 'questionaires to evaluate the participants quality of the sleep. cut off : 13 points This questionaire is to be asked to the participants twice, before and after the administration of the drug', 'timeFrame': '20weeks'}, {'measure': 'marker(melatonin level, receptor, 8-OHdg) in serum, follicular fluid and endometrium during IVF', 'description': ':pg/ml units are used', 'timeFrame': '20weeks'}]",8.0,20 Years,40 Years,FEMALE,True,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00862225,MOA Study of Ze 339 in Seasonal Allergic Rhinitis,Placebo,"['IG-RD-001 / Ze 339', 'Desloratadin', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Seasonal Allergic Rhinitis,Max Zeller Soehne AG,2025-09-01T16:18:07.014408,True,,,,,"Randomized, Double-blind Prospective Clinical Study to Examine the Mechanism of Action of IG-RD-001 (Ze-339) Compared to Desloratadine and Placebo in Patients With Seasonal Allergic Rhinitis Who Are Sensitized to Grasses",,['Seasonal Allergic Rhinitis'],"['rhinomanometry', 'mode of action', 'grass pollen']",,2008-01,2008-12,"[{'measure': 'The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.', 'timeFrame': '0-24 hours post nasal provocation test'}]","[{'measure': 'Clinical symptom score (rhinorrhoea, nasal congestion, nasal itching and sneezing), assessment by the investigator (nasal secretion, irritation, occurrence of systemic symptoms), mediators in the serum, nasal secretion, nasal curettage and biopsy', 'timeFrame': '0-24h post nasal provocation test'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT01132625,Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan,AUY922,['AUY922'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Advanced Solid Tumors,Novartis Pharmaceuticals,2025-09-01T16:18:07.014418,True,,,,,"A Japanese Phase I, Multi-center, Open-label, Study of AUY922 Administered Intravenously on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies",,['Advanced Solid Tumors'],"['HSP90', 'molecular chaperone', 'advanced solid tumors', 'Japan']",,2008-11,2012-05,"[{'measure': 'establish maximum tolerate dose (safety and tolerability)', 'timeFrame': 'about 3 years'}]","[{'measure': 'Safety assessed by type, frequency and severity of adverse events', 'timeFrame': 'about 4 years'}, {'measure': 'Efficacy assessed by RECIST', 'timeFrame': 'about 4 years'}, {'measure': 'Pharmacokinetic assessed by Cmax, Tmax, AUC', 'timeFrame': 'about 3 years'}, {'measure': 'Pharmacodynamic assessed by blood and tumor biomarkers at baseline and post AUY922', 'timeFrame': 'about 4 years'}]",5.0,20 Years,,ALL,False,INDUSTRY,0.0,37.0,ACTUAL,v2_robust,True,True,False,True,
NCT04097925,Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals,Doravirine,"['Doravirine', 'TAF/FTC', 'Descovy', 'MK-1439']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV-1-infection,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",2025-09-01T16:18:07.014425,True,,,,,Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals,,['HIV-1-infection'],['Doravirine'],,2020-02-18,2020-08-24,"[{'measure': 'Concentration of Doravirine in Seminal Plasma Fluid', 'description': 'Concentration of Doravirine in seminal plasma fluid in HIV-1 infected male individuals', 'timeFrame': '8 weeks after switching (from baseline visit) to Doravirine plus TAF/FTC'}, {'measure': 'Concentration of Doravirine in Cervicovaginal Fluid', 'description': 'Concentration of Doravirine in cervicovaginal fluid in HIV-1 infected female individuals', 'timeFrame': '8 weeks after switching to Doravirine plus TAF/FTC'}, {'measure': 'Number of Participants With HIV-1 RNA Seminal Plasma <40 Copies/mL', 'description': 'Number of participants with HIV-1 RNA seminal plasma \\<40 Copies / mL of HIV measured by real-Time Reverse Transcriptase Polymerase Chain Reaction Amplification', 'timeFrame': '8 weeks after switching (from baseline visit) to Doravirine plus TAF/FTC'}, {'measure': 'Quantification of Participants With HIV-1 RNA <40 Copies / mL in Cervicovaginal Fluid', 'description': 'Number of participants with HIV-1 RNA cervicovaginal fluid\\<40 Copies / mL of HIV measured by real-Time Reverse Transcriptase Polymerase Chain Reaction Amplification', 'timeFrame': '8 weeks after switching (from baseline visit) to Doravirine plus TAF/FTC'}]",[],4.0,18 Years,,ALL,False,OTHER,2.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT00745225,Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients,Pioglitazone,"['placebo comparator', 'Actos', 'Pioglitazone', 'Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,End-stage Renal Disease,The University of Hong Kong,2025-09-01T16:18:07.014483,True,,,,,"Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial)",,['End-stage Renal Disease'],"['peritoneal dialysis, cardiovascular, PPAR-gamma']",,2006-02,2014-12,"[{'measure': 'Change in carotid intima-media thickness', 'description': 'Change in carotid intima-media thickness', 'timeFrame': 'over 48 weeks'}, {'measure': 'change in flow mediated dilatation (marker of endothelial function)', 'description': 'change in flow mediated dilatation (marker of endothelial function)', 'timeFrame': 'over 48 weeks'}]","[{'measure': 'change in aortic pulse wave velocity', 'description': 'change in aortic pulse wave velocity', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in augmentation index-heart rate adjusted', 'description': 'change in augmentation index-heart rate adjusted', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in nitroglycerin-mediated dilatation', 'description': 'change in nitroglycerin-mediated dilatation', 'timeFrame': 'over 48 weeks'}, {'measure': 'change in coronary artery calcium score', 'description': 'change in coronary artery calcium score', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in heart valves calcium score', 'description': 'change in heart valves calcium score', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in carotid artery calcium score', 'description': 'change in carotid artery calcium score', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in abdominal visceral fat', 'description': 'change in abdominal visceral fat', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in subcutaneous fat', 'description': 'change in subcutaneous fat', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in blood pressure', 'description': 'change in blood pressure', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in C-reactive protein', 'description': 'change in C-reactive protein', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in residual kidney function', 'description': 'change in residual kidney function', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in HOMA index (among those not on insulin)', 'description': 'Change in insulin resistance index', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in D/P creatinine ratio', 'description': 'Change in peritoneal solute transport parameter', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in peritoneal ultrafiltration with 2.5% during PET', 'description': 'Change in peritoneal ultrafiltration volume', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in handgrip strength', 'description': 'change in handgrip strength', 'timeFrame': 'over 96 weeks'}, {'measure': 'Change in cardiac biomarkers', 'description': 'change in cardiac biomarkers', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in insulin dose (among those on insulin)', 'description': 'change in insulin dose', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in endothelial progenitor cells', 'description': 'change in endothelial progenitor cells', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in central systolic blood pressure', 'description': 'change in central systolic blood pressure', 'timeFrame': 'over 96 weeks'}, {'measure': 'Change in central diastolic blood pressure', 'description': 'change in central diastolic blood pressure', 'timeFrame': 'over 96 weeks'}, {'measure': 'change in glycemic control (fasting glucose, and glycosylated hemoglobin)', 'description': 'change in glycemic control', 'timeFrame': 'over 96 weeks'}]",23.0,20 Years,75 Years,ALL,False,OTHER,1.0,160.0,ACTUAL,v2_robust,True,True,False,False,
NCT00032825,Ketoconazole Plus Docetaxel to Treat Prostate Cancer,Ketaconazole,"['Ketaconazole', 'Docetaxel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Prostatic Neoplasms,National Cancer Institute (NCI),2025-09-01T16:18:07.014552,True,,,,,A Phase I Trial of High Dose Ketoconazole Plus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer,,['Prostatic Neoplasms'],"['Combination', 'Microtubule', 'Hormonal', 'Chemotherapy', 'Pharmacokinetics', 'Prostate Cancer', 'Prostate']",,2002-03-19,2011-06-13,[],[],0.0,18 Years,,MALE,False,NIH,0.0,674.0,ACTUAL,v2_robust,True,True,False,False,
NCT02016625,Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus,Faldaprevir,"['Tacrolimus', 'Cyclosporine', 'Faldaprevir']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:07.014617,True,,,,,"Investigation of Potential Drug-drug Interactions Between Faldaprevir and Immunosuppressants (Cyclosporine and Tacrolimus) in Healthy Male and Female Subjects (Open-label, Fixed-sequence Trial)",,['Healthy'],[],,2013-12,2014-04,"[{'measure': 'AUC 0-infinity (Area Under the Concentration-time Curve of the Cyclo in Plasma Over the Time Interval From 0 Extrapolated to Infinity)', 'description': 'AUC 0-infinity (area under the concentration-time curve of the cyclo in plasma over the time interval from 0 extrapolated to infinity).\n\nPK sampling (relative to the first cyclo administration \\[h:min\\])\n\nPeriod 1:\n\nfor cyclo 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h.\n\nperiod 2 for cyclo 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h.', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'AUC 0-tz (Area Under the Concentration-time Curve of the Cyclo in Plasma Over the Time Interval From 0 to the Last Quantifiable Point)', 'description': 'AUC 0-tz (area under the concentration-time curve of the cyclo in plasma over the time interval from 0 to the last quantifiable point).\n\nPK sampling (relative to the first cyclo administration \\[h:min\\]):\n\nPeriod 1:\n\nfor cyclo 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h period 2 for cyclo 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h.', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'Cmax (Maximum Measured Concentration of the Cyclo in Plasma)', 'description': 'Cmax (maximum measured concentration of the cyclo in plasma).\n\nPK sampling (relative to the first cyclo administration \\[h:min\\]):\n\nPeriod 1: for cyclo 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h period 2 for cyclo 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'Cmax,ss (Maximum Measured Concentration of the FDV [Followed by Cyclo Treatment] in Plasma at Steady State Over a Uniform Dosing Interval τ)', 'description': 'Cmax,ss (maximum measured concentration of the FDV \\[followed by cyclo treatment\\] in plasma at steady state over a uniform dosing interval τ).\n\nPK sampling (relative to the first cyclo administration \\[h:min\\]):\n\nperiod 2 For FDV\n\n-144:00h, -120:00h, -96:00h, -72:00h, -48:00h, -24:00h, -23:30h, -23:00h, -22:30h, -22:00h, -21:00h, -20:00h, -18:00h, -16:00h, -14:00h, -12:00h, -8:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'C24,ss (Maximum Measured Concentration of the FDV in Plasma at Steady State Over a 24 Hour Dosing Interval)', 'description': 'PK sampling (relative to the first cyclo administration \\[h:min\\]):\n\nperiod 2 For FDV\n\n-144:00h, -120:00h, -96:00h, -72:00h, -48:00h, -24:00h, -23:30h, -23:00h, -22:30h, -22:00h, -21:00h, -20:00h, -18:00h, -16:00h, -14:00h, -12:00h, -8:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'AUC τ,ss (Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ)', 'description': 'AUC τ,ss (area under the concentration-time curve of the FDV in plasma at steady state over a uniform dosing interval τ).\n\nPK sampling (relative to the first cyclo administration \\[h:min\\]):\n\nperiod 2 For FDV\n\n-144:00h, -120:00h, -96:00h, -72:00h, -48:00h, -24:00h, -23:30h, -23:00h, -22:30h, -22:00h, -21:00h, -20:00h, -18:00h, -16:00h, -14:00h, -12:00h, -8:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'AUC 0-infinity (Area Under the Concentration-time Curve of the Tac in Plasma Over the Time Interval From 0 Extrapolated to Infinity)', 'description': 'AUC 0-infinity (area under the concentration-time curve of the tac in plasma over the time interval from 0 extrapolated to infinity).\n\nPK sampling (relative to the first tac administration):\n\nPeriod 1: for tac 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 144:00h, 168:00h, 192:00h period 2 for tac\n\n-192:00h, -168:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h', 'timeFrame': 'up to 192 hours (details in description)'}, {'measure': 'AUC 0-tz (Area Under the Concentration-time Curve of the Tac in Plasma Over the Time Interval From 0 to the Last Quantifiable Point)', 'description': 'AUC 0-tz (area under the concentration-time curve of the tac in plasma over the time interval from 0 to the last quantifiable point).\n\nPK sampling (relative to the first tac administration \\[h:min\\]):\n\nPeriod 1: for tac\n\n0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 144:00h, 168:00h, 192:00h\n\nPeriod 2 For tac\n\n-192:00h, -168:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h', 'timeFrame': 'up to 192 hours (details in description)'}, {'measure': 'Cmax (Maximum Measured Concentration of the Tac in Plasma)', 'description': 'Cmax (maximum measured concentration of the tac in plasma).\n\nPK sampling (relative to the first tac administration \\[h:min\\]):\n\nPeriod 1:\n\nfor tac 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 144:00h, 168:00h, 192:00h Period 2 For tac\n\n-192:00h, -168:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h', 'timeFrame': 'up to 192 hours (details in description)'}, {'measure': 'Cmax,ss (Maximum Measured Concentration of the FDV [Followed by Tac Treatment] in Plasma at Steady State Over a Uniform Dosing Interval τ)', 'description': 'Cmax,ss (maximum measured concentration of the FDV \\[followed by tac treatment\\] in plasma at steady state over a uniform dosing interval τ).\n\nPK sampling (relative to the first tac administration \\[h:min\\]):\n\nperiod 2 For FDV\n\n-144:00h, -120:00h, -96:00h, -72:00h, -48:00h, -24:00h, -23:30h, -23:00h, -22:30h, -22:00h, -21:00h, -20:00h, -18:00h, -16:00h, -14:00h, -12:00h, -8:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h.', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'C24,ss (Maximum Measured Concentration of the FDV [Followed by Tac Treatment] in Plasma at Steady State Over a 24 Hour Dosing Interval)', 'description': 'PK sampling (relative to the first tac administration \\[h:min\\]):\n\nperiod 2 For FDV\n\n-144:00h, -120:00h, -96:00h, -72:00h, -48:00h, -24:00h, -23:30h, -23:00h, -22:30h, -22:00h, -21:00h, -20:00h, -18:00h, -16:00h, -14:00h, -12:00h, -8:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h.', 'timeFrame': 'up to 168 hours (details in description)'}, {'measure': 'AUC τ,ss (Area Under the Concentration-time Curve of the FDV [Followed by Tac Treatment] in Plasma at Steady State Over a Uniform Dosing Interval τ)', 'description': 'AUC τ,ss (area under the concentration-time curve of the FDV \\[followed by tac treatment\\] in plasma at steady state over a uniform dosing interval τ).\n\nPK sampling (relative to the first cyclo administration \\[h:min\\]):\n\nperiod 2 For FDV\n\n-144:00h, -120:00h, -96:00h, -72:00h, -48:00h, -24:00h, -23:30h, -23:00h, -22:30h, -22:00h, -21:00h, -20:00h, -18:00h, -16:00h, -14:00h, -12:00h, -8:00h, 0:00h, 0:30h, 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 16:00h, 24:00h, 48:00h, 72:00h, 96:00h, 120:00h, 144:00h, 168:00h.', 'timeFrame': 'up to 168 hours (details in description)'}]",[],12.0,18 Years,50 Years,ALL,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT05552625,The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19,TADIOS,"['Lactose hydrate', 'TADIOS', 'Herbs', 'Placebo']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,WITHDRAWN,COVID-19,"Helixmith Co., Ltd.",2025-09-01T16:18:07.014768,True,,,,,"Multicenter, Double-blind, Placebo-controlled, Maximum 10 Days Administration Study to Evaluate the Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19",,['COVID-19'],"['COVID-19', 'Antioxidative biomarker', 'Inflammatory biomarker', 'TADIOS']",This Phase I study was conducted in India and no subject data was provided to sponsor.,2021-05-06,2022-02-24,"[{'measure': 'Evaluation of antioxidative and inflammatory Biomarkers', 'description': 'Change from baseline in Antioxidative and inflamatory biomarkers: TNF-α, CRP, IL-6, IL-1ra, Hb, and ferritin.', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Clinical measurements - Ordinal Scale for COVID-19 Assessment', 'description': 'Change from baseline in Covid-19 8-point Ordinal Scale: 0 = Uninfected, 1 = Ambulatory without limitation of activity, 2 = Ambulatory with limitation of activity, 3 = Hospitalized mild disease, no oxygen, 4 = Hospitalized mild disease, supplemental oxygen, 5 = Hospitalized severe disease, non-invasive ventilation or high-flow oxygen, 6 = Hospitalized severe disease, intubation and mechanical ventilation, 7 = Hospitalized severe disease, ventilation plus additional organ support, 8 = Death.', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Clinical measurements - Clinical Recovery Scale for COVID-19 Assessment', 'description': 'Time to clinical recovery in COVID-19 Clinical Symptom Scale: The clinical symptom scale has been designed for this study to access the clinical state and time taken to relieve the clinical symptoms of COVID-19 (fever, dry cough, tiredness, aches and pains, sore throat, diarrhea, headache, loss of taste, loss of smell, difficulty in breathing or shortness of breath and chest pain or pressure).', 'timeFrame': 'Every day from screening till discharge and Day 14 after last IP administration'}, {'measure': 'Clinical measurements Clinical Improvement Scale for COVID-19 Assessment', 'description': 'Proportion of Clinical Improvement in Clinical Symptom Scale (Count of subjects with and without a symptom by treatment group on each day with the previous day counts during the study period).', 'timeFrame': 'Daily from screening to discharge or Day 14 after last IP administration'}, {'measure': 'Assessment of Quality of life - WHO-5 Well-Being Index', 'description': 'Change from baseline in WHO-5 Well-Being Index: The total raw score, ranging from 0 to 25, will be multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Assessment of Quality of life - Fatigue Severity Score', 'description': ""Change from baseline in Fatigue Severity Score: Minimum total score possible is nine and the maximum is 63. The higher the score, the more severe the fatigue is and the more it affects the person's activities."", 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Hospitalization - Time to discharge', 'description': '1. Duration of hospitalization\n2. Time to discharge', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10)'}]","[{'measure': 'Safety and tolerability assessment after administration of TADIOS 1', 'description': 'Subject incidence of Treatment-Emergent Adverse Events (TEAEs) and total number of unique TEAEs.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Hematology', 'description': 'Change from baseline in Hematology, Complete Blood Count results WBC, RBC, Hb, HCT, MCV, MCH, MCHC, PLT, MPV, differential count of WBC (Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil), and ESR.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Serum Chemistry', 'description': 'Change from baseline in Serum Chemistry results: total protein, albumin, globulin, A/G ratio, total bilirubin, AST, ALT, GGT, Random glucose, BUN, creatinine, estimated GFR, Ca2+, phosphate, Na+, K+, Cl-, CRP, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Urinalysis', 'description': 'Change from baseline in Urinalysis results: Color, pH, Specific gravity, albumin, bilirubin, glucose, urobilinogen, ketone, nitrite, hematuria, leukocyte and microscopy.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Blood Pressure', 'description': 'Change from baseline in Blood Pressure in mm Hg.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Body Temperature', 'description': 'Change from baseline in Body Temperature ℃.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Pulse Rate', 'description': 'Change from baseline in Pulse Rate in beats per minute.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Respiration Rate', 'description': 'Change from baseline in Respiration Rate in breaths per minute.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}]",15.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,This Phase I study was conducted in India and no subject data was provided to sponsor.
NCT00247325,RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography,Iodixanol(Drug),['Iodixanol(Drug)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Kidney Failure,Seoul National University Hospital,2025-09-01T16:18:07.014806,True,,,,,"Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Renal Insufficiency Undergoing Coronary Angiography: The RECOVER Study, A Randomized Controlled Trial",,['Kidney Failure'],"['Kidney failure', 'Contrast media', 'Iodixanol', 'Ioxaglate']",,2004-01,2004-12,"[{'measure': 'Incidence of contrast induced nephropathy, defined as either a relative increase in serum creatinine from baseline of >=25% or an absolute increase of >=0.5mg/dL(44.2µmol/L) during days 1 and 2'}]","[{'measure': 'proportion of patients exhibiting an increase in serum creatinine of >=0.5mg/dL(44.2µmol/L), the proportion with a >=1.0 mg/dL(88.4µmol/L) increase in serum creatinine, and the mean peak increase in serum creatinine'}]",2.0,19 Years,,ALL,False,OTHER,0.0,,,v2_robust,True,True,False,False,
NCT05156125,VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis,VTX002,"['OPL-002', 'Placebo', 'VTX002']",3,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,"Colitis, Ulcerative",Oppilan Pharma Ltd,2025-09-01T16:18:07.014847,True,,,,,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative Colitis",,"['Colitis, Ulcerative']","['S1P; sphingosine 1 phosphate receptor;', 'Ventyx; Oppilan;', 'moderate or severe ulcerative colitis']",,2021-11-30,2026-08-31,"[{'measure': 'Clinical Remission at 13 Weeks', 'description': 'The percentage of participants with clinical remission at Week 13. Clinical remission was based on the modified Mayo score (MMS), which is a composite score of participant-reported symptoms and endoscopies which were assessed by a central reader. Clinical remission was defined as stool frequency (SF) subscore = 0 or 1, rectal bleeding (RB) subscore = 0, and endoscopic subscore (ES) ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'Day 1 of Induction treatment period to Week 13'}]","[{'measure': 'Endoscopic Improvement at Week 13', 'description': 'The percentage of participants with endoscopic improvement at Week 13. Endoscopic improvement was assessed from endoscopies assessed by a central reader. Endoscopic improvement was defined as ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).', 'timeFrame': 'Day 1 of Induction Treatment Period to Week 13'}, {'measure': 'Symptomatic Remission at Week 13', 'description': 'The percentage of participants with symptomatic remission at Week 13. Symptomatic remission was measured using participant-reported symptoms and was defined as SF subscore = 0 or 1 and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.', 'timeFrame': 'Day 1 of Induction Treatment Period to Week 13'}, {'measure': 'Histologic Remission at Week 13', 'description': 'The percentage of participants with histologic remission at Week 13. Histologic remission was assessed using the Geboes Index score and defined for this outcome measure as a Geboes score \\< 2.0. The Geboes score grading system is a validated score for evaluating histologic disease activity in ulcerative colitis and is graded on a scale of 0 to 5. A higher Geboes score indicates more severe disease.', 'timeFrame': 'Day 1 of Induction Treatment Period to Week 13'}, {'measure': 'Endoscopic Improvement-Histologic Remission at Week 13', 'description': 'The percentage of participants with endoscopic improvement-histologic remission at Week 13. This outcome measure was assessed by endoscopic histologic scores and defined as ES ≤ 1 (excluding friability) and a Geboes Index score \\< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in ulcerative colitis and is graded on a scale of 0 to 5. A higher Geboes score indicates more severe disease.', 'timeFrame': 'Day 1 of Induction Treatment Period to Week 13'}, {'measure': 'PK of VTX002', 'description': 'Plasma concentrations of VTX002 in samples obtained predose at Weeks 1, 4, 8, and 13 in the Induction Treatment Period', 'timeFrame': 'Weeks 1, 4, 8, and 13 of the Induction Treatment Period'}]",6.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,213.0,ACTUAL,v2_robust,True,False,False,False,
NCT00334425,The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.,MENOPUR; GONAL-F,['MENOPUR; GONAL-F'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Infertility,Central Jutland Regional Hospital,2025-09-01T16:18:07.014916,True,,,,,"The Effect of LH-Priming During Early Follicular Phase on Ovarian Response and Pregnancy Outcome in GnRHa Down-Regulated Women, Stimulated With Exogenous Gonadotrophins in IVF Treatment",,['Infertility'],[],,2006-04,,[{'measure': 'Circulatory levels of Estradiol on the day of hCG'}],"[{'measure': 'Total number of follicles as well as the numbers of follicles <10mm, 10-14 mm, >14mm day during gonadotrophin treatment and at the end of stimulation prior to hCG injection'}, {'measure': 'E2 per follicle >14 mm'}, {'measure': 'Total number of oocytes retrieved'}, {'measure': 'fertilization rate'}, {'measure': 'serum hCG > 10 IU/l on day 12-14 after embryo transfer'}, {'measure': 'implantation rate'}, {'measure': 'transferable embryos'}, {'measure': 'Clinical pregnancy rate'}, {'measure': 'Ongoing pregnancy rate'}, {'measure': 'embryo quality'}, {'measure': 'Serum; LH, FSH, Androstenedione, Progesterone, hCG and Inhibin-B. Progesterone seven days after ET day'}, {'measure': 'Intra follicular levels of; endocrine parameters'}, {'measure': 'Endometrial thickness; hCG day (minus 0-2 days)'}, {'measure': 'Total gonadotrophin dose administered'}]",15.0,18 Years,38 Years,FEMALE,False,OTHER,0.0,150.0,,v2_robust,True,False,False,False,
NCT00093925,Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC),clevidipine,"['clevidipine', 'nicardipine', 'clevidipine, Cleviprex']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hypertension,The Medicines Company,2025-09-01T16:18:07.014951,True,,,,,Evaluation of Clevidipine in the Postoperative Treatment of Hypertension Assessing Safety Events (With Nicardipine as Active Comparator) (ECLIPSE-NIC),,['Hypertension'],['Postoperative hypertension'],,2004-05,2006-09,"[{'measure': 'Incidence of death, stroke, MI, and renal dysfunction', 'timeFrame': 'Initiation of study drug infusion through post-operative Day 30'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,739.0,ACTUAL,v2_robust,True,True,False,False,
NCT01245725,Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention,Tirofiban (Aggrastat),"['Tirofiban (Aggrastat)', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Myocardial Infarction,Medicure,2025-09-01T16:18:07.014960,True,,,,,"A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention",,"['Myocardial Infarction', 'Acute Coronary Syndromes', 'Unstable Angina', 'Percutaneous Coronary Intervention']",[],"Study was not initiated, change in clinical development",,,"[{'measure': 'A composite incidence of death, myocardial infarction and urgent target vessel revascularization.', 'timeFrame': '48 hours'}]","[{'measure': 'The occurrence of myocardial infarction.', 'timeFrame': '48 hours'}]",2.0,18 Years,,ALL,False,INDUSTRY,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,"Study was not initiated, change in clinical development"
NCT01652625,Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis,Yunnan Baiyao toothpaste,"['Placebo toothpaste', 'Yunnan Baiyao toothpaste']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Recurrent Aphthous Stomatitis,Peking University,2025-09-01T16:18:07.014969,True,,,,,Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis,,['Recurrent Aphthous Stomatitis'],"['Yunnan Baiyao', 'recurrent aphthous stomatitis', 'clinical trial']",,2010-03,2011-03,"[{'measure': 'Ulcer size', 'description': 'The assessment of the surface area of the ulcer was measured in millimeters by a dental probe. Ulcer size was assessed as the product of maximum diameter and its vertical diameter.', 'timeFrame': 'one year'}]","[{'measure': 'Pain Scores with Visual Analog Scale', 'description': 'Pain intensity was measured using a VAS, where the amount of pain recorded ranged from 0 (no pain) to 10 (unbearable pain). Pain was assessed by irritating the ulcer with the periodontal probe. The values were collected by the assigned investigators.', 'timeFrame': 'one year'}, {'measure': 'Number of the participants with adverse events', 'description': 'Any noted adverse reactions were recorded.', 'timeFrame': 'one year'}]",3.0,18 Years,65 Years,ALL,False,OTHER,0.0,227.0,ACTUAL,v2_robust,True,True,False,True,
NCT03578276,Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen,Pred-Gati-Brom,"['Gatifloxacin Ophthalmic', 'Pred-Gati-Brom', 'Bromfenac 0.075% Oph Solution', 'LessDrops', 'Prednisolone acetate 1% ophthalmic suspension']",5,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Cataract,"Carolina Eyecare Physicians, LLC",2025-09-01T16:18:07.015317,True,,,,,Lessdrops™ Prophylactic Treatment After Routine Phacoemulsification Compared to Standard Drops Regimen,,['Cataract'],"['cataract surgery', 'Prophylaxis']",,2018-06-22,2019-12-04,"[{'measure': 'Change From Baseline (Preoperative Exam) in Macular Thickness', 'description': 'Thickness of the macula measured in microns, recorded as the change from baseline.', 'timeFrame': 'Month 1'}]","[{'measure': 'Change From Baseline (Preoperative Exam) in Pachymetry (Corneal Thickness)', 'description': 'Thickness of the cornea measured in microns, measured as the change from baseline', 'timeFrame': 'Month 1'}, {'measure': 'Change From Baseline (Preoperative Exam) in Intraocular Pressure (IOP)', 'description': 'Measurement of the pressure inside the eye in mmHg, recorded as the change from baseline', 'timeFrame': 'Month 1'}]",3.0,50 Years,99 Years,ALL,False,OTHER,2.0,35.0,ACTUAL,v2_robust,True,True,False,False,
NCT02117076,"Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome",Gabapentin immediate release,"['Gabapentin enacarbil extended release', 'Neurontin', 'Horizant', 'Gabapentin immediate release']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Restless Leg Syndrome,"Theresa Zesiewicz, MD",2025-09-01T16:18:07.015329,True,,,,,"Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome",,['Restless Leg Syndrome'],"['Restless leg syndrome', 'RLS', 'gabapentin', 'gabapentin enacarbil', 'Neurontin', 'Horizant']",Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.,2014-04,2016-06,"[{'measure': 'International Restless Leg Syndrome Rating Scale (IRLS)', 'description': 'The IRLS is a measure of severity of Restless Legs Syndrome. It includes 10 items, measured on a scale of 0-4. A score of 1-10 indicates mild severity, 11-20 indicates moderate severity, 21-30 is severe and 31-40 is very severe. Primary outcome is the difference in IRLS scores for each of the treatment regimens.\n\nfrom 0 to 4.', 'timeFrame': '10 weeks'}]","[{'measure': 'Restless Leg Syndrome Quality of Life Scale (RLSQoL)', 'description': 'The Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) assesses the impact of RLS on daily life, emotional well-being, social life, and work life.', 'timeFrame': 'Baseline, day 35, day 54.'}]",2.0,18 Years,80 Years,ALL,False,OTHER,0.0,5.0,ACTUAL,v2_robust,True,False,True,False,Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.
NCT06182176,Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control,Sulphadoxine-pyrimethamine and Amodiaquine,"['SPAQ', 'Sulphadoxine-pyrimethamine and Amodiaquine']",2,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Malaria,London School of Hygiene and Tropical Medicine,2025-09-01T16:18:07.015342,True,,,,,Evaluating the Effectiveness and Cost-effectiveness of Integrating Mass Drug Administration for Helminth Control With Seasonal Malaria Chemoprevention in Ghanaian Children,,"['Malaria', 'Soil Transmitted Helminths', 'Schistosomiasis', 'Seasonal Malaria Chemoprevention', 'Mass Drug Administration With Anthelminthic Drugs']",[],,2024-05-27,2026-01-12,"[{'measure': 'Change in Haemoglobin (Hb) concentration measured by HemoCue®', 'description': 'Comparison of the pre- and post-intervention values of Hb concentration of study children', 'timeFrame': 'On the day of inclusion, and post-intervention at the end of malaria transmission season i.e. one month after the last SMC cycle.'}]","[{'measure': 'Incidence of clinical malaria, defined as fever of >37.5C', 'description': 'History of fever in the preceding 48 hours, and a positive malaria blood film with a parasite density of \\>0 per µl', 'timeFrame': 'Detected by passive case detection during the surveillance period, an average of 5 months after co-administration of the study medications'}, {'measure': 'Change in prevalence of anaemia on the day of inclusion, and post-intervention at the end of malaria transmission season; anaemia will be defined as Hb less than 11 g/dL', 'description': 'Comparison of the pre- and post-intervention values of Hb concentration of study children', 'timeFrame': 'On the day of inclusion, and post-intervention at the end of malaria transmission season i.e. one month after the last SMC cycle.'}, {'measure': 'Incidence of solicited adverse events and adverse drug reactions', 'description': 'Safety assessment to be related to the study medications', 'timeFrame': 'During a period of six consecutive days after co-administration of study medications'}, {'measure': 'Prevalence of P.falciparum and helminth co-infection', 'description': 'Prevalence of malaria-helminth co-infection', 'timeFrame': 'On the day of inclusion, and post-intervention at the end of malaria transmission season i.e. one month after the last SMC cycle.'}, {'measure': 'Density of P.falciparum and helminth co-infection', 'description': 'Density of malaria-helminth co-infection', 'timeFrame': 'On the day of inclusion, and post-intervention at the end of malaria transmission season i.e. one month after the last SMC cycle.'}]",6.0,1 Year,14 Years,ALL,True,OTHER,1.0,1200.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03979976,"Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus",Ramipril,"['Ramipril', 'angiotensin-converting enzyme inhibitor (ACEI)']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Systemic Lupus Erythematosus,Federal University of São Paulo,2025-09-01T16:18:07.015371,True,,,,,Ramipril Improves Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus: a Randomized and Controlled Study.,,['Systemic Lupus Erythematosus'],"['systemic lupus erythematosus', 'endothelium', 'ramipril']",,2011-03,2013-09,"[{'measure': 'Endothelial function - Variation of Flow mediated dilation percentage', 'description': 'Patients were evaluated at baseline and after 12 weeks by high-resolution ultrasound of brachial artery in resting conditions, after reactive hyperaemia (flow-mediated dilation-FMD) and after oral glyceryl trinitrate to assess endothelial function', 'timeFrame': '12 weeks'}, {'measure': 'Number of endothelial progenitor cells (EPC)', 'description': 'Patients were evaluated at baseline and after 12 weeks. EPCs were evaluated by flow cytometry using anti-CD34 (cluster of differentiation 34) (FITC), anti-CD133 (PE) and anti-kinase domain receptor (KDR) (APC) and by cell culture with quantification of colony formation units (CFUs).', 'timeFrame': '12 weeks'}]",[],2.0,18 Years,,FEMALE,False,OTHER,1.0,37.0,ACTUAL,v2_robust,True,True,False,False,
NCT00303576,A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel,dapivirine (TMC120) vaginal gel,['dapivirine (TMC120) vaginal gel'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,HIV Infections,"International Partnership for Microbicides, Inc.",2025-09-01T16:18:07.015437,True,,,,,"A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.",,['HIV Infections'],"['HIV-1', 'HIV Seronegativity']",,2005-10,2006-07,[{'measure': 'Local and systemic safety and tolerability.'}],[],1.0,18 Years,50 Years,FEMALE,True,INDUSTRY,0.0,112.0,,v2_robust,True,True,False,True,
NCT02596776,Cold Induced Changes in White Adipose,Propranolol and fat biopsy,['Propranolol and fat biopsy'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Obese,Philip Kern,2025-09-01T16:18:07.015443,True,,,,,Cold Induced Changes in Human Subcutaneous White Adipose,,"['Obese', 'Normal Body Weight', 'Prediabetes', 'Metabolic Syndrome']",[],,2016-03,2018-08-20,"[{'measure': 'WAT changes during repeated exposure to cold temperatures', 'description': 'Adipose biopsies will be performed', 'timeFrame': '28 Weeks (Summer and Winter Seasons)'}, {'measure': 'WAT changes following Propranolol dosing', 'description': 'Subjects will be prescribed propranolol and adipose biopsies will be obtained.', 'timeFrame': '17 days in the summer season'}, {'measure': 'In vivo measurement of adipose lipolysis and triglyceride (TG) turnover', 'description': 'The heavy water will be given to and adipose biopsies will be obtained.', 'timeFrame': '5 weeks per season (summer and winter)'}]",[],3.0,35 Years,60 Years,FEMALE,True,OTHER,1.0,26.0,ACTUAL,v2_robust,True,True,False,False,
NCT00343876,Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial,aspirin,"['clopidogrel', 'aspirin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Coronary Artery Disease,"Intermountain Health Care, Inc.",2025-09-01T16:18:07.015529,True,,,,,"A Single Center, Double-Blind, Randomized Trial to Evaluate the Effects of Aspirin 325 mg + Clopidogrel 75 mg v. Aspirin 325 mg + Placebo on Plasma Concentration of C-Reactive Protein: The CATER Trial Protocol",,['Coronary Artery Disease'],"['hs-CRP', 'aspirin', 'clopidogrel']",,2005-07,2006-11,"[{'measure': 'The primary endpoint is the observation of the effect of aspirin + clopidogrel vs.'}, {'measure': 'aspirin + placebo on CRP levels.'}]",[],2.0,18 Years,,ALL,False,OTHER,2.0,100.0,ESTIMATED,v2_robust,True,True,False,False,
NCT04776876,Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome,Telotristat Ethyl,['Telotristat Ethyl'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Advanced Neuroendocrine Neoplasm,M.D. Anderson Cancer Center,2025-09-01T16:18:07.015537,True,,,,,"A Phase II, Open-Label, Single-Arm Study of INCMGA00012 and Telotristat Ethyl in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome",,"['Advanced Neuroendocrine Neoplasm', 'Carcinoid Syndrome']",[],The study will not be opening. Support was withdrawn.,2021-03-01,2021-09-02,"[{'measure': 'Overall best response rate (partial response or complete response)', 'description': 'Will estimate the best response rate and its 95% exact confidence interval using the Clopper and Pearson method.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Objective response', 'description': 'Will be determined by an independent radiologist according to immune-modified RECIST.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression free survival', 'description': 'Will be determined by an independent radiologist according to RECIST v1.1. Will be estimated using the Kaplan-Meier method. The log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model may be utilized to include multiple covariates in the time-to-event analysis.', 'timeFrame': 'Time from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first, assessed up to 2 years'}, {'measure': 'Duration of response', 'description': 'Will be determined by an independent radiologist according to RECIST v1.1. Will be estimated using the Kaplan-Meier method. The log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model may be utilized to include multiple covariates in the time-to-event analysis.', 'timeFrame': 'Time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, assessed up to 2 years'}, {'measure': 'Disease control', 'description': 'Will be determined by an independent radiologist according to RECIST v1.1.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'description': 'Will be estimated using the Kaplan-Meier method. The log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model may be utilized to include multiple covariates in the time-to-event analysis.', 'timeFrame': 'Time from enrollment to death from any cause, assessed up to 2 years'}, {'measure': 'Occurrence and severity of adverse events', 'description': 'Will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Toxicity data will be summarized by frequency tables.', 'timeFrame': 'Up to 30 days post-intervention'}]",7.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,The study will not be opening. Support was withdrawn.
NCT06636617,177Lu-JH04 in Patients with FAP-Positive Tumors,3.70 GBq (100 mCi) of 177Lu-JH04,"['7.40 GBq (200 mCi) of 177Lu-JH04', '3.70 GBq (100 mCi) of 177Lu-JH04', '5.55 GBq (150 mCi) of 177Lu-JH04']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,RECRUITING,Patients with Advanced Metastatic FAP-Positive Tumors,First Affiliated Hospital of Fujian Medical University,2025-09-01T16:18:07.015637,True,,,,,"Safety, Dosimetry and Treatment Response of 177Lu-JH04 in Patients with FAP-Positive Tumors",,['Patients with Advanced Metastatic FAP-Positive Tumors'],"['Lu-177', 'FAP', 'Tumor']",,2024-08-21,2025-08-31,"[{'measure': 'Toxic and side effect', 'description': 'The white blood cell count, granulocyte count, platelet count, hemoglobin count and serum biochemicals of each patient before and after each treatment were recorded and compared. And the weight (in kilograms) of the patients was monitored. Adverse events were categorized using the Common Toxicity Criteria for Adverse Events 5.0.', 'timeFrame': 'through study completion, an average of 2 weeks'}]","[{'measure': 'Dosimetry of normal organs and tumors', 'description': 'The semiquantitative dosimetry will be performed based on SPECT/CT acquisitions after the first administration of 177Lu-JH04. The dose delivered to normal organs and tumors will be recorded.', 'timeFrame': 'through study completion, an average of 4 weeks'}]",2.0,18 Years,80 Years,ALL,False,OTHER,0.0,9.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01376817,Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis,"Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids","['Fat emulsion with MCT and LCT', 'Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Severe Acute Pancreatitis,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,2025-09-01T16:18:07.015679,True,,,,,"Comparative Study About the Impact of Two Oil Emulsions, One of Them Formulated With MCT, LCT, Olive Oil and Omega 3 Fatty Acids Versus Another One Formulated With MCT and LCT, Administered Intravenously on Severe Acute Pancreatitis Clinical Evolution",,['Severe Acute Pancreatitis'],"['Severe acute pancreatitis', 'total parenteral nutrition', 'fat emulsions', 'omega 3 fatty acids']",,2008-07,2011-12,"[{'measure': 'Inflammatory markers', 'description': 'LTB4, TXB2, PG2, IL-6, alfa-TNF, C-reactive protein (CRP) Day 1 (before treatment), 5 and 10', 'timeFrame': 'Day 10'}]","[{'measure': 'Evolution of the degree of severity of acute severe pancreatitis', 'description': 'At hospital admission: age, BMI, organ failure. Evolution of the degree of severity of acute severe pancreatitis: severity risk factors at the hospital admission (age, BMI, organ failure), pronostic signs of severity during the first 72 hours after admission : APACHE-II, Ranson criteria, serum hematocrit, CT-scan with Balthazar index, CRP.\n\nDay 10: CT-scan with Balthazar index, CRP.', 'timeFrame': 'During the first 72 hours after admission'}, {'measure': 'Complications of acute severe pancreatitis', 'description': 'From day 1 to day 10. Complications of acute severe pancreatitis: local complications (necrosis, pseudocyst, abscess, surgery, ERCP), systemic complications (SIRS, sepsis, organ failure, other ones, mortality).', 'timeFrame': 'Day 10.'}]",3.0,18 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02286817,"Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder",NFC-1,['NFC-1'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Attention-deficit Hyperactivity Disorder (ADHD),"Aevi Genomic Medicine, LLC, a Cerecor company",2025-09-01T16:18:07.015707,True,,,,,"Phase I Single Dose, Open-label, Pharmacokinetic Study Followed by Single-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Plasma Concentration Profiles, and Targeted Efficacy of NFC-1 in Adolescents (12-17 Years of Age) With Attention-Deficit Hyperactivity Disorder and Genetic Disruption Impacting Metabotropic Glutamate Receptor Genes (NFC1-GREAT)",,['Attention-deficit Hyperactivity Disorder (ADHD)'],[],,2015-01,2016-03,"[{'measure': 'Assessing the safety and tolerability of NFC-1 at each dose level based on assessment of adverse events and other safety measurements including vital signs, electrocardiogram, laboratory safety tests.', 'timeFrame': '24 hours'}, {'measure': 'Profile pharmacokinetics of NFC-1 in adolescents when administered orally as single dose.', 'timeFrame': '24 hours'}, {'measure': 'Assessing the safety and tolerability of NFC-1 during 4 weeks of continuous daily administration based on assessment of adverse events and other safety measurements including vital signs, electrocardiogram, laboratory safety tests.', 'timeFrame': '1-4 weeks'}]","[{'measure': 'The change in Vanderbilt scores during and following 4-week treatment with NFC-1', 'timeFrame': '1-4 weeks'}, {'measure': 'The change in Actigraphy scores during and following 4-week treatment with NFC-1', 'timeFrame': '1-4 weeks'}, {'measure': 'The change in Quotient ADHD test scores during and following 4-week treatment with NFC-1', 'timeFrame': '1-4 weeks'}, {'measure': 'The change in PERMP-MATH test scores during and following 4-week treatment with NFC-1', 'timeFrame': '1-4 weeks'}, {'measure': 'The change in Clinical Global Impressions Severity/Improvement scores during and following 4-week treatment with NFC-1', 'timeFrame': '1-4 weeks'}]",8.0,12 Years,17 Years,ALL,False,INDUSTRY,3.0,30.0,ACTUAL,v2_robust,True,True,False,True,
NCT01736917,Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors,Fosaprepitant,"['Fosaprepitant', 'Dexamethasone', '5HT3']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Chemotherapy-Induced Nausea and Vomiting,Lawrence Einhorn,2025-09-01T16:18:07.015748,True,,,,,Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153,,['Chemotherapy-Induced Nausea and Vomiting'],"['Fosaprepitant', '5HT3 Receptor Antagonists', 'Dexamethasone', 'Germ Cell Tumors', 'Testis Cancer', 'Rescue Medications']",,2013-01,2015-06,"[{'measure': 'Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting', 'description': 'complete response (CR) of both acute (days 1 through 5) and delayed (days 6 through 8) CINV, defined by no emetic episodes or use of rescue medications', 'timeFrame': 'Days 1-8 of chemotherapy regimen'}]","[{'measure': 'Total Number of Emetic Episodes', 'description': 'total number of emetic episodes', 'timeFrame': 'Days 1-8 of chemotherapy regimen'}, {'measure': 'Use of Rescue Medications.', 'description': 'Total number of patients who received rescue medications.', 'timeFrame': 'Days 1-8 of chemotherapy regimen'}, {'measure': 'Self-Reported Assessment of Nausea', 'description': ""the patient's self-reported assessment of nausea Days 1-8 using a 0-100mm visual analog scale (VAS) median.\n\nThe Visual Analouge (VAS) 100mm Scale Score for Chemotherapy Induced Nausea and Vomiting (CINV). Participants were asked to mark a linear scale 100mm in length representing their level of nausea with 0mm indicating no nausea and 100mm indicating severe nausea. Median VAS scores (in mm) are reported, per day."", 'timeFrame': 'Days 1-8 of chemotherapy regimen'}]",4.0,15 Years,,MALE,False,OTHER,2.0,65.0,ACTUAL,v2_robust,True,True,False,False,
NCT00353717,Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma,cetuximab paclitaxel,"['cetuximab paclitaxel', 'weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Breast Neoplasms,Hadassah Medical Organization,2025-09-01T16:18:07.015765,True,,,,,Phase II of Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma,,['Breast Neoplasms'],"['breast', 'basal like', 'carcinoma', 'metastatic', 'EGFR']",,2006-11,2009-09,"[{'measure': 'tumor markers tumor size by ct', 'timeFrame': 'two years'}]",[],1.0,18 Years,,FEMALE,False,OTHER,0.0,25.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02318017,Psychostimulants Effects on Brain Functional Connectivity in Youth With Attention Deficit Hyperactivity Disorder,Methylphenidate,"['MPH', 'Placebo', 'Methylphenidate']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Adhd,Sheba Medical Center,2025-09-01T16:18:07.015772,True,,,,,An Electroencephalography Study of the Effects of Psychostimulants on Dynamic Patterns of Cognitive Task-based Functional Connectivity in Youths With Attention Deficit Hyperactivity Disorder,,['Adhd'],"['adhd', 'global network', 'eeg']",,2014-12,2017-12,"[{'measure': 'Baseline Complex Network connectivity before treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at baseline before MPH\\\\Placebo according to the above time frames.', 'timeFrame': '0 minutes'}, {'measure': 'Baseline Complex Network connectivity after treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at baseline after MPH\\\\Placebo according to the above time frames.', 'timeFrame': '90 minutes'}]","[{'measure': 'Complex Network connectivity at Sustained Attention task before treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at Sustained attention task before MPH\\\\Placebo according to the above time frames.', 'timeFrame': '11 minutes'}, {'measure': 'Complex Network connectivity at N-Back task before treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at N-Back task before MPH\\\\Placebo according to the above time frames.', 'timeFrame': '24 minutes'}, {'measure': 'Complex Network connectivity at the Stroop task before treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at the Stroop task before MPH\\\\Placebo according to the above time frames.', 'timeFrame': '30 minutes'}, {'measure': 'Complex Network connectivity at Sustained Attention task after treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at Sustained Attention task after MPH\\\\Placebo according to the above time frames.', 'timeFrame': '101 minutes'}, {'measure': 'Complex Network connectivity at N-Back task after treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at N-Back task after MPH\\\\Placebo according to the above time frames.', 'timeFrame': '114 minutes'}, {'measure': 'Complex Network connectivity at the Stroop task after treatment - using electrodes signal correlation (P-value)', 'description': 'Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at the Stroop task after MPH\\\\Placebo according to the above time frames.', 'timeFrame': '120 minutes'}]",8.0,6 Years,18 Years,ALL,True,OTHER_GOV,1.0,75.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04318717,Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma,Pembrolizumab,"['Pembrolizumab', 'Keytruda']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Mucosal Melanoma of the Head and Neck,Washington University School of Medicine,2025-09-01T16:18:07.015856,True,,,,,Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma,,['Mucosal Melanoma of the Head and Neck'],[],,2020-05-29,2029-02-12,"[{'measure': 'Local tumor control rate', 'timeFrame': '1 year after completion of treatment (estimated to be 2 years)'}]","[{'measure': 'Number of treatment-related grade 3 or greater adverse events', 'timeFrame': 'Baseline through 30 days after end of treatment (estimated to be 13 months)'}, {'measure': 'Number of treatment discontinuations due to treatment-related adverse events', 'timeFrame': 'Through end of treatment (estimated to be 1 year)'}, {'measure': 'Relapse-free survival (RFS)', 'description': '-Defined as the duration of time from the start date of study treatment to the date of earliest disease relapse or death, whichever occurs first. Patients who neither relapse nor die by the data cutoff date will be censored at the last follow up date.', 'timeFrame': 'At 3 years after completion of treatment (estimated to be 4 years)'}, {'measure': 'Distant metastasis-free survival', 'description': '-Defined as the duration of time from the start date of study treatment to the date of appearance of a distant metastasis or death, whichever occurs first. Patients who neither develop distant metastasis nor die by the data cutoff date will be censored at the last follow up date.', 'timeFrame': 'At 3 years after completion of treatment (estimated to be 4 years)'}, {'measure': 'Overall survival', 'description': '-Defined as the duration of time from the start date of study treatment to death from any cause. Patients who are alive by the data cutoff date will be censored at the last follow up date.', 'timeFrame': 'At 3 years after completion of treatment (estimated to be 4 years)'}]",6.0,16 Years,,ALL,False,OTHER,0.0,16.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01800617,A Study of T3 Therapy in Patients With Hypothyroidism,"Liothyronine, Sodium","['Liothyronine, Sodium']",1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hypothyroidism,"Ipe, LLC",2025-09-01T16:18:07.015865,True,,,,,Phase II Single Daily-Dose Response Study of a New Liothyronine Sodium (T3) Preparation With Sustained Effects in Hypothyroid Patients,,['Hypothyroidism'],[],,2013-03,,"[{'measure': 'Measurement of Blood Levels of Thyroid Hormone Sensitive Parameters', 'description': 'Serum Total T3, TSH', 'timeFrame': 'Six Weeks.'}]","[{'measure': 'Measurement of Oxygen Consumption', 'description': 'Resting Metabolic Rate', 'timeFrame': 'Six Weeks.'}]",2.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT06537817,Study to Evaluate HT-4253 in Healthy Subjects,HT-4253,"['HT-4253', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Normal Healthy Subjects,"Halia Therapeutics, Inc.",2025-09-01T16:18:07.015882,True,,,,,"A Phase 1, First-in-Human, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) of Oral HT-4253 in Healthy Adults",,['Normal Healthy Subjects'],[],,2024-09-17,2025-05-12,"[{'measure': 'To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adults', 'description': 'Incidence of adverse events (AEs)', 'timeFrame': 'up to 6 weeks'}, {'measure': 'To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adults', 'description': 'Serious adverse events (SAEs)', 'timeFrame': 'up to 6 weeks'}, {'measure': 'To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adults', 'description': 'Treatment-related adverse events (TRAEs)', 'timeFrame': 'up to 6 weeks'}, {'measure': 'To evaluate the safety and tolerability of single and multiple ascending', 'description': 'Incidence of withdrawals due to AE', 'timeFrame': 'up to 6 weeks'}]","[{'measure': 'To evaluate the plasma pharmacokinetics (PK) of single and multiple ascending doses of oral HT-4253 in healthy adults', 'description': 'Maximum plasma concentration (Cmax)', 'timeFrame': 'up to 6 weeks'}, {'measure': 'To evaluate the plasma pharmacokinetics (PK) of single and multiple ascending doses of oral HT-4253 in healthy adults', 'description': 'Area under the concentration-time curve (AUC)', 'timeFrame': 'up to 6 weeks'}, {'measure': 'To evaluate the plasma pharmacokinetics (PK) of single and multiple ascending doses of oral HT-4253 in healthy adults', 'description': 'Elimination half-life (t1/2) plasma concentration of HT-4253', 'timeFrame': 'up to 6 weeks'}, {'measure': 'To evaluate the plasma pharmacokinetics (PK) of single and multiple ascending doses of oral HT-4253 in healthy adults', 'description': 'Trough plasma concentration of HT-4253', 'timeFrame': 'up to 6 weeks'}]",8.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,80.0,ACTUAL,v2_robust,True,True,False,True,
NCT02350517,Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer,Paclitaxel+Nedaplatin+Endostar,"['Paclitaxel+Nedaplatin+Endostar', 'Paclitaxl', 'Recombinant Human Endostatin Injection', 'Endostar', 'Nedaplatin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Esophageal Squamous Cell Carcinoma,Yuhong Li,2025-09-01T16:18:07.015905,True,,,,,A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer,,['Esophageal Squamous Cell Carcinoma'],[],,2015-01,2022-12,"[{'measure': 'Progression free survival', 'timeFrame': 'From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}]","[{'measure': 'Overall survival', 'timeFrame': 'From the date of first drug administration until the date of death, assessed up to 36 months'}, {'measure': 'Overall response rate (ORR)', 'timeFrame': 'From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}, {'measure': 'Number of participants with AEs and SAEs as a measure of Safety', 'description': 'Each follow up visit, assessed up to 3 years. Date will be assessed at each study visiting using NCI CTCAE version 4.0.', 'timeFrame': 'Each follow up vist, assessed up to 2 years'}, {'measure': 'Quality of life', 'description': 'Quality of life will be assessed at each study visit using EORTC QLQ-C30 and QLQ-OES18', 'timeFrame': 'Time from day 1 to date of death, assessed up to 3 years'}]",5.0,18 Years,75 Years,ALL,False,OTHER,0.0,52.0,ACTUAL,v2_robust,True,True,False,True,
NCT02519140,Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections,Cook Medical EMR Gel,"['Cook Medical EMR Gel will be injected submucosally', 'Cook Medical EMR Gel']",2,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Gastric Cancer,Antonios Likourezos,2025-09-01T16:18:07.015917,True,,,,,Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections,,"['Gastric Cancer', 'Colon Cancer']","['Gastric cancer', 'colon cancer', 'EMR', 'biopsy', 'bariatric surgery']",,2014-08-01,2022-11-30,"[{'measure': 'Lift Efficacy', 'description': 'Lifting characteristics which would be measured by height of the mucosa after submucosal gel injection.', 'timeFrame': '1 hour'}]","[{'measure': 'Dissection Adequacy', 'description': 'Dissection adequacy which would be measured by time which the gel stays within the tissues. Anything less than one hour will be considered failure.', 'timeFrame': '1 hour'}]",2.0,18 Years,65 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,
NCT06216340,Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes,Henagliflozin,"['diet-exercise therapy', 'Henagliflozin', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Obese,The First People's Hospital of Changzhou,2025-09-01T16:18:07.015927,True,,,,,"Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial",,"['Obese', 'Weight Loss', 'Pre-diabetes']","['Henagliflozin', 'Obese', 'Weight loss', 'Glucose']",,2024-02-15,2026-10-01,"[{'measure': 'Weight change', 'description': 'Proportion of weight change from baseline', 'timeFrame': '3 months (12 weeks)'}]","[{'measure': 'Proportion of ≥5% weight loss', 'description': 'Proportion of patients who lost at least 5% of their body weight from baseline', 'timeFrame': '3 months (12 weeks)'}, {'measure': 'Incident diabetes', 'description': 'New-onset diabetes during follow up', 'timeFrame': '1 month (4 weeks), 2 months (8 weeks), 3 months (12 weeks), 6 months (24 weeks), 9 months (36 weeks), 12 months (48 weeks)'}]",3.0,18 Years,65 Years,ALL,False,OTHER,9.0,300.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00615940,Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer,WX-671,"['WX-671', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Metastatic Breast Cancer,Heidelberg Pharma AG,2025-09-01T16:18:07.015941,True,,,,,"A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer",,['Metastatic Breast Cancer'],['HER2negative'],,2008-07,2012-04,"[{'measure': 'Efficacy in terms of progression-free survival (PFS)', 'timeFrame': 'disease staging with CT/MRI/bone scans at regular intervals'}]","[{'measure': 'Secondary endpoints are objective response rate (ORR), overall survival, safety and pharmacokinetics.', 'timeFrame': '2 years'}]",2.0,18 Years,,FEMALE,False,INDUSTRY,1.0,132.0,ACTUAL,v2_robust,True,True,False,True,
NCT04467840,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",Opaganib,"['Opaganib', 'Placebo', 'ABC294640', 'Yeliva']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,COVID-19,RedHill Biopharma Limited,2025-09-01T16:18:07.015950,True,,,,,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia",,"['COVID-19', 'Lung Infection']",['Therapeutic Use'],,2020-08-21,2021-07-18,"[{'measure': 'Supplemental Oxygen Requirement', 'description': 'To compare the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by Day 14 between subjects taking opaganib and those on placebo.', 'timeFrame': '14 days maintained up to 42 days'}]","[{'measure': 'Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42', 'description': 'Compare ≥2 category improvement on the WHO Ordinal Scale for Clinical Improvement from 0(uninfected) to 8(death) for subjects taking opaganib and those on placebo, lower scores indicate improvement. Success was defined as subject who reached improvement of at least two points on the WHO Ordinal Scale by Day 14, maintained by the end of study visit, and failure otherwise.', 'timeFrame': '14 days maintained up to 42 days'}, {'measure': 'Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement With a Scale Ranging From 8 Down to 0', 'description': 'Compare scores of subjects taking opaganib and those on placebo, lower scores indicate improvement to determine time to recovery as defined by improvement to a score of 3 or less on the WHO Ordinal Scale for Clinical Improvement with a scale ranging from 0 (uninfected) to 8 (death)', 'timeFrame': '14 days maintained up to 42 days'}, {'measure': 'Number of Participants With Low Oxygen Flow Via Nasal Cannula', 'description': 'To compare the time to low oxygen flow via nasal cannula e.g. from high oxygen flow via nasal cannula or CPAP, if high oxygen flow is not an available option between subjects taking opaganib and those on placebo.', 'timeFrame': '14 days maintained up to 42 days'}, {'measure': 'Time to Discharge From Hospital Measured at 14 Days', 'description': 'Time to subject discharge from hospital', 'timeFrame': '14 days'}, {'measure': 'Patients Requiring Intubation and Mechanical Ventilation by Day 42', 'description': 'To compare the proportion of patients requiring intubation and mechanical ventilation between subjects taking opaganib and those on placebo.', 'timeFrame': '42 days'}, {'measure': 'Number of Patients With Two Consecutive Negative Swabs for SARS-CoV-2 at Day 14', 'description': 'To compare the number of patients with two consecutive negative swabs for SARS-CoV-2 by PCR at Day 14 between subjects taking opaganib and those on placebo.', 'timeFrame': '14 days'}, {'measure': 'Patients With Negative Swabs for SARS-CoV-2 at Day 14', 'description': 'To compare the proportion of patients with two consecutive negative swabs for SARS-CoV-2 by PCR at Day 14 between subjects taking opaganib and those on placebo.', 'timeFrame': '14 days'}, {'measure': 'Mortality Due to Any Cause', 'description': 'To compare mortality 28 days post-baseline between subjects taking opaganib and those taking placebo', 'timeFrame': '28 days'}, {'measure': 'Mortality Due to Any Cause', 'description': 'To compare mortality 42 days post-baseline between subjects taking opaganib and those taking placebo', 'timeFrame': '42 days'}]",10.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,475.0,ACTUAL,v2_robust,True,True,False,False,
NCT00110240,Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes,vildagliptin,['vildagliptin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Diabetes Mellitus, Type 2",Novartis Pharmaceuticals,2025-09-01T16:18:07.016055,True,,,,,Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes,,"['Diabetes Mellitus, Type 2']","['Type 2 diabetes', 'vildagliptin']",,2005-04,2006-10,[{'measure': 'Change from baseline in HbA1c at 24 weeks'}],"[{'measure': 'Change from baseline in HbA1c at 24 weeks for subset of Chinese patients'}, {'measure': 'Overall adverse event profile after 24 weeks of treatment'}, {'measure': 'Gastrointestinal side effect profiles after 24 weeks of treatment'}, {'measure': 'Change from baseline in fasting plasma glucose at 24 weeks'}, {'measure': 'Patients with endpoint HbA1c <7% after 24 weeks'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,594.0,ACTUAL,v2_robust,True,True,False,True,
NCT03197740,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",Donepezil patch,"['aricept Tab', 'Donepezil patch']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Alzheimer Disease,Icure Pharmaceutical Inc.,2025-09-01T16:18:07.016097,True,,,,,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",,['Alzheimer Disease'],[],,2017-10-12,2020-07-20,"[{'measure': 'ADAS-cog', 'description': 'Change at Week 24 of treatment with the study drug from baseline (0d) in ADAS-cog scores', 'timeFrame': 'week 24'}]","[{'measure': 'CIBIC-plus', 'description': 'CIBIC-plus score at the end of treatment (Week 24)', 'timeFrame': 'week 24'}]",2.0,50 Years,85 Years,ALL,False,INDUSTRY,0.0,399.0,ACTUAL,v2_robust,True,True,False,False,
NCT00006040,Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia,etoposide,['etoposide'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Leukemia,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:07.016108,True,,,,,Phase I Study of Yttrium-90 Labeled HuM195 Combined With Etoposide as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients With Advanced Myelodysplastic Syndrome and Refractory Leukemia,,"['Leukemia', 'Myelodysplastic Syndromes', 'Myelodysplastic/Myeloproliferative Neoplasms']","['recurrent adult acute myeloid leukemia', 'recurrent adult acute lymphoblastic leukemia', 'relapsing chronic myelogenous leukemia', 'accelerated phase chronic myelogenous leukemia', 'blastic phase chronic myelogenous leukemia', 'previously treated myelodysplastic syndromes', 'atypical chronic myeloid leukemia, BCR-ABL1 negative', 'myelodysplastic/myeloproliferative neoplasm, unclassifiable']",,2000-04,2003-11,[],[],0.0,18 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,True,False,False,
NCT00892840,Multiple-Ascending Dose Study,BMS-820836,"['Placebo', 'BMS-820836']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Depression,Bristol-Myers Squibb,2025-09-01T16:18:07.016148,True,,,,,"Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-820836 in Healthy Subjects",,['Depression'],[],,2009-05,2010-11,"[{'measure': 'To assess the safety and tolerability of BMS-820836 following multiple-dose administration', 'timeFrame': 'Within 27 days (+/- 2 days) of first dose'}]","[{'measure': 'To assess the pharmacodynamics of BMS-820836', 'timeFrame': 'Within 27 days of first dose'}]",2.0,21 Years,55 Years,ALL,True,INDUSTRY,0.0,57.0,ACTUAL,v2_robust,True,True,False,True,
NCT00273689,Exercise Induced Bronchospasm in Children,montelukast vs pretreatment with albuterol,"['Singulair is the brand name for montelukast.', 'Brand name for montelukast: Singulair', 'montelukast', 'montelukast vs pretreatment with albuterol']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Exercise Induced Bronchospasm,University of New Mexico,2025-09-01T16:18:07.016162,True,,,,,"""Pretreatment With Albuterol vs. Montelukast in Exercise Induced Bronchospasm in Children.""",,['Exercise Induced Bronchospasm'],[],,2005-12,2007-09,"[{'measure': 'The primary outcome will be the comparison of the effect of inhaled albuterol and oral montelukast on EIB as percent attenuation in FEV1 after exercise challenge.', 'timeFrame': 'Fall in FEV1 immediately after exercise'}]","[{'measure': 'Additional objectives will be to compare the differences in response to montelukast with regard to LTB4 concentrations from EBC and FeNO level', 'timeFrame': 'immediately after exercise'}]",2.0,7 Years,17 Years,ALL,False,OTHER,1.0,13.0,ACTUAL,v2_robust,True,True,False,False,
NCT02939989,Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study,Sofosbuvir,"['Glecaprevir/Pibrentasvir', 'Ribavirin', 'MAVIRET', 'MAVYRET', 'ABT-493/ABT-530', 'Sofosbuvir', 'SOVALDI']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hepatitis C Virus Infection,AbbVie,2025-09-01T16:18:07.016173,True,,,,,"An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)",,['Hepatitis C Virus Infection'],"['Chronic Hepatitis C (HCV)', 'HCV Genotype 1 (HCV GT1)', 'HCV Genotype 2 (HCV GT2)', 'HCV Genotype 3 (HCV GT3)', 'HCV Genotype 4 (HCV GT4)', 'HCV Genotype 5 (HCV GT5)', 'HCV Genotype 6 (HCV GT6)', 'Compensated Cirrhosis', 'Non-cirrhotics', 'Virologic failure']",,2016-11-21,2021-07-30,"[{'measure': 'Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)', 'description': 'SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (LLOQ; 15 IU/mL) 12 weeks after the last dose of study drug.', 'timeFrame': '12 weeks after the last actual dose of study drug, Week 24 or Week 28 depending on the treatment regimen.'}]","[{'measure': 'Percentage of Participants With On-treatment Virologic Failure', 'description': 'On-treatment virologic failure was defined as meeting one of the following:\n\n* confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements \\> 1 log10 IU/mL above nadir) at any time point during the treatment period; or\n* confirmed HCV RNA greater than or equal to 100 IU/mL after HCV RNA \\< 15 IU/mL during the treatment period, or\n* HCV RNA ≥ 15 IU/mL at end of treatment with at least 6 weeks of treatment.', 'timeFrame': '12 or 16 weeks depending on the treatment regimen'}, {'measure': 'Percentage of Participants With Post-treatment Relapse', 'description': 'Post-treatment relapse was defined as confirmed HCV RNA greater than or equal to 15 IU/mL between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \\< 15 IU/mL at the end of treatment, and had post-treatment HCV RNA data; participants who had been shown to be re-infected were not considered to have relapsed.', 'timeFrame': 'From the end of treatment (Week 12 or 16) through 12 weeks after the last dose of study drug (Weeks 24 or 28 depending on the treatment regimen).'}]",3.0,12 Years,99 Years,ALL,False,INDUSTRY,0.0,33.0,ACTUAL,v2_robust,True,True,False,False,
NCT01039389,Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease,Ivabradine,"['Placebo control', 'Ivabradine', 'Placebo', 'Procoralan, I(f)-inhibitor']",4,INTERVENTIONAL,['NA'],,COMPLETED,Coronary Artery Disease,"Insel Gruppe AG, University Hospital Bern",2025-09-01T16:18:07.016214,True,,,,,Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease,,['Coronary Artery Disease'],"['Coronary Artery Disease', 'Stable', 'Coronary Collaterals', 'Therapeutic Collateral Promotion', 'Arteriogenesis', 'Bradycardia']",,2009-10,2013-03,"[{'measure': 'Collateral flow index (CFI)', 'timeFrame': '6 months'}]","[{'measure': 'Myocardial blood flow (MBF) during hyperemia', 'timeFrame': '6 months'}]",2.0,18 Years,90 Years,ALL,False,OTHER,0.0,43.0,ACTUAL,v2_robust,True,True,False,False,
NCT00005889,Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion,alanine,"['glucagon', 'glycerol', 'glutamine', 'glucose', 'insulin', 'alanine', 'leucine', 'urea', 'amino acids', 'lipids']",10,INTERVENTIONAL,['NA'],,UNKNOWN,"Infant, Low Birth Weight",National Center for Research Resources (NCRR),2025-09-01T16:18:07.016224,True,,,,,Study of Gluconeogenesis in Very Low Birth Weight Infants Receiving Total Parenteral Nutrition,,"['Infant, Low Birth Weight', 'Hyperglycemia']","['endocrine disorders', 'hyperglycemia', 'low birth weight', 'neonatal disorders', 'rare disease']",,1999-10,,[],[],0.0,4 Days,6 Days,ALL,False,NIH,1.0,96.0,,v2_robust,True,False,False,False,
NCT01630889,Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease,Roxadustat,"['FG-4592', 'Roxadustat']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Chronic Kidney Disease,FibroGen,2025-09-01T16:18:07.016245,True,,,,,Open-Label Extension Study to Evaluate the Efficacy and Safety of FG-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients With Chronic Kidney Disease,,"['Chronic Kidney Disease', 'End Stage Renal Disease', 'Anemia']","['Kidney', 'ESRD', 'End Stage Renal Disease', 'Anemia', 'Oral anemia treatment', 'Hemoglobin levels', 'Hemodialysis', 'CKD', 'Chronic Kidney Disease', 'Peritoneal', 'HD', 'PD', 'Hb', 'Erythropoietin', 'Blood count']",,2012-05-18,2019-12-12,"[{'measure': 'Change From Baseline in Hb Over Time', 'description': 'Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting. The specific duration over which the participants were assessed was identified as ""over time"" for the endpoint in the study protocol. Therefore, to be consistent with the endpoint in the study protocol, an individual timepoint was not identified for this primary outcome measure.', 'timeFrame': 'Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 252, 264, 288, 312, 336, 360, and 384'}]","[{'measure': 'Number of Participants With Hb ≥10 g/dL', 'description': 'Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting.', 'timeFrame': 'Baseline up to Week 384'}, {'measure': 'Number of Participants Receiving Rescue Therapy (Composite of Blood Transfusions, Intravenous [IV] Iron, Erythropoiesis-Stimulating Agent [ESA])', 'timeFrame': 'Baseline up to Week 385'}, {'measure': 'Mean Weekly Dose of Study Drug Over Time', 'description': 'Weekly dose amount was the actual total dose amounts within a week, windowed by 7-day period from Day 1. The mean weekly dose is presented for selected time periods based on timepoints reported in Outcome Measures 1 and 2.', 'timeFrame': 'Baseline up to Week 384'}, {'measure': 'Number of Participants With Dose Adjustments up to Week 52', 'description': 'Dose adjustments include dose increases, dose interruptions, and dose reductions.', 'timeFrame': 'Baseline up to Week 52'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs', 'description': 'An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Baseline up to Week 385'}]",6.0,18 Years,,ALL,False,INDUSTRY,2.0,15.0,ACTUAL,v2_robust,True,True,False,True,
NCT03245489,Anti-platelet + Pembro for H&N Tumors,Pembrolizumab,"['Pembrolizumab', 'Keytruda', 'aspirin', 'acetylsalicylic acid', 'Clopidogrel', 'ASA', 'Plavix']",7,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Head and Neck Cancer,Medical University of South Carolina,2025-09-01T16:18:07.016279,True,,,,,Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,,['Head and Neck Cancer'],[],,2018-03-06,2024-11-20,"[{'measure': 'Effect of Pembro + antiplatelet on major cellular parameters', 'description': 'Immunologic response profile will be measured by changes in major cellular parameters in peripheral blood mononuclear cells pheotyped by flow cytometry for MDSCs, T and B cell activation markers and polyclonal IFNy-production by CD4 and CD8 response after P/I stimulation) in pembrolizumab alone and pembrolizumab + antiplatelet therapy. Markers will be measured at baseline, end of the first regimen and end of the second regimen. Changes in cellular parameters from the previous timepoint will be evaluated using a repeated measures ANOVA model. Cellular parameters will be evaluated in aggregate to report the immunologic response.', 'timeFrame': '12 weeks'}]","[{'measure': 'Effect of Pembro + antiplatelets on immunologic markers', 'description': 'Immunologic markers will be measured in patients who have been treated with two cycles of pembrolizumab alone and who are pembrolizumab naive. Markers will be evaluated by looking at phyenotyping by flow cytometry and changes of 65-panel systemic cytokines and chemokine levels. Markers will be measured at baseline, end of the first regimen and end of the second regimen. Changes to markers will be reported in aggregate to show the overall immunologic effect of the combination of pembrolizumab + Anti-platelets in patients.', 'timeFrame': '12 weeks'}, {'measure': 'Frequency of adverse events reported', 'description': 'Safety data will be tabulated by type and grade of adverse event and will use CTCAE v. 4.0', 'timeFrame': '12 weeks'}, {'measure': 'Tumor response rate', 'description': 'Objective response will be evaluated with computed tomography (CT) of the neck, chest and abdomen at baseline and post-treatment using RECIST 1.1 criteria.', 'timeFrame': '12 weeks'}]",4.0,18 Years,,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,
NCT01307189,Effects of Tiotropium on Walking Capacity in Patients With COPD,Tiotropium,"['Tiotropium', 'Spiriva', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Obstructive Pulmonary Disease,Laval University,2025-09-01T16:18:07.016296,True,,,,,Effects of Tiotropium on Walking Capacity in Patients With COPD,,['Chronic Obstructive Pulmonary Disease'],"['Chronic Obstructive Pulmonary Disease (COPD)', 'Exercise', 'Endurance shuttle walking test', 'Bronchodilation', 'Tiotropium']",,2005-04,2010-08,"[{'measure': 'Endurance time during an endurance shuttle walk', 'timeFrame': 'acute response (2.5 hours) following the administration of the active and comparison drug'}]","[{'measure': 'Compare the long-term bronchodilator-induced changes in exercise tolerance during the endurance shuttle walk', 'timeFrame': 'three weeks'}, {'measure': 'Evaluate the impact of long-term bronchodilation on activity of daily living evaluated using the London Chest Activity Daily Living scale', 'timeFrame': 'three weeks'}, {'measure': 'Cardio-respiratory responses during an endurance shutlle walk', 'timeFrame': 'acute response following the administration of the study medication'}]",4.0,50 Years,85 Years,ALL,False,OTHER,1.0,33.0,ACTUAL,v2_robust,True,True,False,False,
NCT02449889,A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation,highly purified human chorionic gonadotropin,"['recombinant human chorionic gonadotropin', 'BREVACTID', 'CHORAPUR', 'OVIDREL', 'highly purified human chorionic gonadotropin', 'OVITRELLE']",6,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Infertility,Ferring Pharmaceuticals,2025-09-01T16:18:07.016396,True,,,,,"A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy and Safety of Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation",,['Infertility'],[],,2016-04,2018-03-01,"[{'measure': 'Number of Oocytes Retrieved', 'description': 'Oocyte retrieval took place 36 h (±2h) after hCG administration. At oocyte retrieval the number of oocytes retrieved was recorded.', 'timeFrame': 'Approximately 36 hours after hCG administration'}]","[{'measure': 'Number of Metaphase II (MII) Oocytes', 'description': 'Only applicable for insemination using intracytoplasmic sperm injection (ICSI). The MII oocytes were counted prior to insemination.', 'timeFrame': 'Prior to insemination (within 6 hours after oocyte retrieval)'}, {'measure': 'Number of Fertilized (2 Pronuclei (2PN)) Oocytes', 'description': 'Fertilization was assessed by counting the number of pronuclei, which was recorded as 0, 1, 2 or \\>2. Correct fertilization was defined as oocytes with 2PN.', 'timeFrame': 'One day after oocyte retrieval'}, {'measure': 'Positive β Unit of Human Chorionic Gonadotropin (βhCG) Rate', 'description': 'Defined as percentage of subjects with positive beta hCG. A positive β hCG was confirmed by a blood test obtained 13-15 days after transfer.', 'timeFrame': '13-15 days after transfer'}, {'measure': 'Clinical Pregnancy Rate', 'description': 'Defined as percentage of subjects with clinical pregnancy. Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.', 'timeFrame': '5-6 weeks after transfer'}, {'measure': 'Frequency of Adverse Events (AEs)', 'description': 'The number of treatment-emergent AEs (TEAEs) in each treatment group will be presented.', 'timeFrame': 'AEs were collected from signing informed consent until end of trial visit = maximum period approximately 5 months. However, only TEAEs are presented'}, {'measure': 'Intensity of AEs', 'description': 'The intensity of an TEAE would be classified using the following 3-point scale: mild (awareness of signs or symptoms, but no disruption of usual activity), moderate (event sufficient to affect usual activity \\[disturbing\\]) or severe (inability to work or perform usual activities \\[unacceptable\\]).', 'timeFrame': 'AEs were collected from signing informed consent until end of trial visit = maximum period approximately 5 months. However, only TEAEs are presented.'}]",7.0,18 Years,39 Years,FEMALE,False,INDUSTRY,0.0,176.0,ACTUAL,v2_robust,True,True,False,True,
NCT07015489,Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer,induction chemotherapy and immunotherapy,['induction chemotherapy and immunotherapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,ESCC,The First Affiliated Hospital with Nanjing Medical University,2025-09-01T16:18:07.016438,True,,,,,"A Prospective, Single-center Phase II Clinical Study of Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer",,['ESCC'],['induction immunochemotherapy'],,2022-01-01,2025-05-01,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'The time from the start of treatment to tumor progression (of any form) or death from any cause.', 'timeFrame': 'From treatment initiation through study completion (up to 3 years)'}]","[{'measure': 'OS (overall survival)', 'timeFrame': 'From treatment initiation through study completion (up to 3 years)'}, {'measure': 'Adverse Event (AE)', 'timeFrame': 'Up to 3 years'}]",3.0,18 Years,,ALL,False,OTHER,0.0,44.0,ACTUAL,v2_robust,True,True,False,True,
NCT04964089,A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD),KSI-301,"['KSI-301', 'Aflibercept', 'Eylea']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Wet Age-related Macular Degeneration,Kodiak Sciences Inc,2025-09-01T16:18:07.016474,True,,,,,"A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)",,['Wet Age-related Macular Degeneration'],"['AMD', 'Wet AMD', 'neovascularization secondary to age-related macular degeneration', 'KSI-301', 'Aflibercept', 'Vascular endothelial growth factor', 'VEGF', 'Anti-VEGF', 'Antibody biopolymer conjugate', 'Macular Degeneration', 'wAMD', 'Retinal Degeneration', 'Retinal Diseases', 'Eye Diseases', 'Vision Disorders', 'Vision, Low', 'Kodiak']",,2021-06-23,2023-04-06,"[{'measure': 'Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48.', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.', 'timeFrame': 'Day 1 to Week 48'}]","[{'measure': 'Mean Change in Best Corrected Visual Acuity (BCVA) by Visit Over Time', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Proportion of Patients Who Gain ≥ 5, ≥10 and ≥15 Letters From Baseline Over Time', 'description': 'Categorical improvements in Best Corrected Visual Acuity (BCVA) of clinically relevant BCVA measurements corresponding to 1, 2 and 3 lines of the ETDRS vision testing chart', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Proportion of Patients Who Lost ≥ 5, ≥10 and ≥15 Letters From Baseline Over Time', 'description': 'Categorical worsening in Best Corrected Visual Acuity (BCVA) of clinically relevant BCVA measurements corresponding to 1, 2 and 3 lines of the ETDRS vision testing chart', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Proportion of Participants With BCVA Snellen Equivalent of 20/40 or Better Over Time (≥69 ETDRS Letters)', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Proportion of Participants With BCVA Snellen Equivalent of 20/200 or Worse Over Time (≤38 ETDRS Letters)', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Mean Change in OCT Central Subfield Retinal Thickness (CST) From Baseline to the Average of Weeks 40, 44 and 48 and Over Time', 'description': 'Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) as assessed by a central reading center.', 'timeFrame': 'Day 1 to Week 48'}]",7.0,50 Years,,ALL,False,INDUSTRY,0.0,557.0,ACTUAL,v2_robust,True,True,False,False,
NCT03776968,A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics,HC1119,['HC1119'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Metastatic Castration Resistant Prostate Cancer,Hinova Pharmaceuticals Inc.,2025-09-01T16:18:07.016514,True,,,,,A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics in Healthy Chinese Adults,,['Metastatic Castration Resistant Prostate Cancer'],[],,2017-10-24,2018-07-03,"[{'measure': 'Area under the plasma concentration-time curve from time 0 to infinity (∞) (AUC0-∞)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration(AUC0-t)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Peak concentration (Cmax)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Peak time (Tmax)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Elimination half life (t1/2)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Apparent clearance (CL/F) (prototype)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Apparent volume of distribution (Vd/F) (prototype)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Mean residence time (MRT)', 'timeFrame': 'From the first dose of the study drug to day 50'}]","[{'measure': 'Number of patients with adverse events', 'description': 'Safety measures', 'timeFrame': 'From the first dose of the study drug to day 50'}]",9.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,47.0,ACTUAL,v2_robust,True,True,False,True,
NCT02821468,Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN,Droglican,"['Droglican', 'Paracetamol or oral NSAIDs excluding COX2 inhibitors']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,"Osteoarthritis, Knee",Bioiberica,2025-09-01T16:18:07.016532,True,,,,,Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN: a Pilot Study,,"['Osteoarthritis, Knee']",[],,2016-06,2018-06,"[{'measure': 'Evaluate change of composition of cartilage trough imaging marker (dGEMRIC)', 'description': 'To evaluate the techniques for studying proteoglycans content: the delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC), after 6 months of treatment with DROGLICAN versus untreated control.', 'timeFrame': '6 months'}]","[{'measure': 'Consumption of Rescue Medication', 'description': 'Use of rescue treatments (Paracetamol or oral NSAIDs excluding COX2 inhibitors)', 'timeFrame': '6 months'}]",2.0,40 Years,,ALL,False,INDUSTRY,1.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00463268,Osteoporosis Prevention With Low Dose Alendronate,alendronate,"['alendronate', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Osteopenia,University Hospital of Mont-Godinne,2025-09-01T16:18:07.016543,True,,,,,"Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.",,['Osteopenia'],"['osteopenia', 'osteoporosis prevention', 'alendronate']",,2007-09,2012-01,"[{'measure': 'percentage of lumbar BMD modification after 2 years', 'timeFrame': '2 years'}]","[{'measure': 'percentage of hip BMD modification (total hip and sub-regions)', 'timeFrame': '2 years'}, {'measure': 'percentage of modification of bone remodeling markers', 'timeFrame': '2 years'}]",3.0,45 Years,60 Years,FEMALE,False,OTHER,0.0,83.0,ACTUAL,v2_robust,True,True,False,False,
NCT00424268,Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128),Roflumilast,"['Roflumilast', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Obstructive Pulmonary Disease,AstraZeneca,2025-09-01T16:18:07.016561,True,,,,,"Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study",,['Chronic Obstructive Pulmonary Disease'],"['COPD', 'Roflumilast']",,2007-01,2008-07,"[{'measure': 'Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)', 'description': 'Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \\[L\\]', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}]","[{'measure': 'Post-bronchodilator FEV1', 'description': 'Mean change from baseline during the treatment period in post-bronchodilator FEV1 \\[L\\]', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}, {'measure': 'COPD Exacerbation Rate (Moderate or Severe)', 'description': ""Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \\[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\\]."", 'timeFrame': '24 weeks treatment period'}, {'measure': 'Transition Dyspnea Index (TDI) Focal Score', 'description': 'The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}, {'measure': 'Shortness of Breath Questionnaire (SOBQ) Total Score', 'description': 'Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is ""not at all breathless"" and five is ""maximally breathless or too breathless to do the activity"".', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}]",5.0,40 Years,,ALL,False,INDUSTRY,0.0,743.0,ACTUAL,v2_robust,True,True,False,False,
NCT00264368,Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy,intravenous (IV) ganciclovir,['intravenous (IV) ganciclovir'],1,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Acute Renal Failure,University of Oslo School of Pharmacy,2025-09-01T16:18:07.016588,True,,,,,Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy,,"['Acute Renal Failure', 'Cytomegalovirus Infections', 'Multi Organ Failure']","['Renal replacement therapy', 'CMV disease']",,2005-12,2007-06,"[{'measure': 'comparing the total clearance with the RRT derived clearance of GCV'}, {'measure': 'comparing the volume of distribution with historic controls of non Intensive Care Unit (ICU) patients'}]","[{'measure': 'comparing GCV plasma concentration and population model derived estimates of these concentrations when including different relevant clinical co-factors such as: weight, S-creatinine, CL-creatinine, hydration, albumin, rest function of native kidneys etc.'}, {'measure': 'determine RRT derived GCV clearance during the different filtration/dialysis settings of the RRT machine'}]",4.0,18 Years,,ALL,False,OTHER,0.0,6.0,ESTIMATED,v2_robust,True,False,True,False,
NCT04819568,Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.,Terlipressin,['Terlipressin'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Liver Cirrhosis,"Institute of Liver and Biliary Sciences, India",2025-09-01T16:18:07.016698,True,,,,,Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock: A Randomized Controlled Trial,,['Liver Cirrhosis'],[],,2021-06-25,2022-03-19,"[{'measure': 'Reversal of shock', 'description': 'DISCONTINUATION OF NOREPINEPHRINE IS CONSIDERED AS REVERSAL OF SHOCK.', 'timeFrame': '72 hours'}]","[{'measure': 'Time to reversal of shock', 'timeFrame': '1 Year'}, {'measure': 'Incidence of adverse effects and discontinuation of therapy due to adverse effects', 'timeFrame': '24 hours'}, {'measure': 'Incidence of adverse effects and discontinuation of therapy due to adverse effects', 'timeFrame': 'Day 3'}, {'measure': 'Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT)', 'description': 'AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION.\n\nREMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT.', 'timeFrame': '24 hours'}, {'measure': 'Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT)', 'description': 'AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION.\n\nREMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT.', 'timeFrame': 'Day 3'}, {'measure': 'Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT)', 'description': 'AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION.\n\nREMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT.', 'timeFrame': 'Day 7'}, {'measure': 'Mortality', 'timeFrame': '28 days'}, {'measure': 'Improvement in SOFA score', 'description': 'IMPROVEMENT BY ATLEAST 2 POINTS', 'timeFrame': '24 hours'}, {'measure': 'Improvement in SOFA score', 'description': 'IMPROVEMENT BY ATLEAST 2 POINTS', 'timeFrame': 'Day 3'}, {'measure': 'Lactate clearance', 'timeFrame': '6 hours'}, {'measure': 'Lactate clearance', 'description': 'DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE \\*100%', 'timeFrame': '12 hours'}, {'measure': 'Lactate clearance', 'description': 'DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE \\*100%', 'timeFrame': '24 hous'}, {'measure': 'Lactate clearance', 'description': 'DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE \\*100%', 'timeFrame': '72 hours'}, {'measure': 'Days of mechanical ventilation', 'timeFrame': '1 year'}, {'measure': 'Days of Intensive Care Unit stay', 'timeFrame': '1 month'}]",16.0,18 Years,70 Years,ALL,False,OTHER,0.0,310.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00484068,Chicken-Diet vs. Enalapril to Reduce Albuminuria,enalapril,['enalapril'],1,INTERVENTIONAL,['NA'],,COMPLETED,Microalbuminuria,Hospital de Clinicas de Porto Alegre,2025-09-01T16:18:07.016760,True,,,,,Effect of Chicken-Based Diet Versus Enalapril on Albuminuria in Patients With Type 2 Diabetes and Microalbuminuria: a One-Year Randomized Controlled Study,,"['Microalbuminuria', 'Diabetic Nephropathy']","['type 2 diabetes', 'microalbuminuria', 'chicken-based diet', 'ACE inhibitor']",,2003-01,2006-06,"[{'measure': 'urinary albumin excretion', 'timeFrame': 'during study'}, {'measure': 'serum lipids', 'timeFrame': 'during study'}, {'measure': 'nutritional status', 'timeFrame': 'during study'}]",[],3.0,18 Years,,ALL,False,OTHER,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,
NCT01273168,Endoxifen in Adults With Hormone Receptor Positive Solid Tumors,Z-Endoxifen,['Z-Endoxifen'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Hormone Receptor-Positive Breast,National Cancer Institute (NCI),2025-09-01T16:18:07.016796,True,,,,,"Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors",,"['Hormone Receptor-Positive Breast', 'Gynecologic', 'Desmoid', 'Hormone Receptor-Positive Neoplasms']","['Pharmacokinetics', 'Advanced Cancer', 'Cytochrome P450', 'Selective Estrogen Receptor Modulator', 'Tamoxifen Metabolite', 'Gynecologic Cancer', 'Breast Cancer', 'Desmoid Tumor', 'Endometrial Cancer', 'Ovarian Cancer', 'Uterine Cancer', 'Fallopian Tube Cancer', 'Peritoneal Cancer']",,2011-03-01,2026-06-01,"[{'measure': 'Establish safety and MTD of Z-endoxifen', 'description': 'Adverse events will be graded as described in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.', 'timeFrame': '28 days (1 cycle)'}]","[{'measure': 'Determine the pharmacokinetics of Z-endoxifen (free base and HCl forms)', 'timeFrame': '28 days (1 cycle)'}]",2.0,18 Years,120 Years,ALL,False,NIH,0.0,40.0,ACTUAL,v2_robust,True,False,False,True,
NCT00559468,Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028),Sugammadex,"['Ultane®', 'Diprivan®', 'Rocuronium Bromide', 'Esmeron®', 'Sevoflurane', 'Sugammadex', 'MK-8616', 'Org 25969', 'Rocuronium', 'Propofol']",10,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Anesthesia, General",Merck Sharp & Dohme LLC,2025-09-01T16:18:07.016805,True,,,,,"A Multi -Center, Randomized, Parallel Group, Safety Assessor Blinded Trial Comparing Efficacy and Safety of 4.0 mg.Kg-1 Sugammadex , Administered at T1 3-10% After Continuous Infusion of Rocuronium, and Pharmacokinetics of Rocuronium, Between Subjects Receiving Maintenance Anesthesia Using Propofol and Subjects Receiving Maintenance Anesthesia Using Sevoflurane",,"['Anesthesia, General']",[],,2006-12-07,2007-03-02,"[{'measure': 'Mean Time From Start Administration of Sugammadex to Recovery of Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9', 'description': 'Neuromuscular functioning was monitored by applying repetitive Train of Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 ratio (expressed as a decimal from 0 \\[loss of T4\\] up to 1.0 \\[no NMB\\]) indicates the extent of recovery from NMB. In this study, twitch responses were recorded until the T4/T1 Ratio reached \\>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 ratio to 0.9 indicates a faster recovery from NMB.', 'timeFrame': 'Up to 3 minutes after sugammadex administration'}]","[{'measure': 'Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.7', 'description': 'Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 ratio (expressed as a decimal from 0 \\[loss of T4\\] up to 1.0 \\[no NMB\\]) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 ratio to 0.7 indicates a faster recovery from NMB.', 'timeFrame': 'Up to 3 minutes after sugammadex administration'}, {'measure': 'Mean Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.8', 'description': 'Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 ratio (expressed as a decimal from 0 \\[loss of T4\\] up to 1.0 \\[no NMB\\]) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 ratio to 0.8 indicates a faster recovery from NMB.', 'timeFrame': 'Up to 3 minutes after sugammadex administration'}]",3.0,20 Years,65 Years,ALL,False,INDUSTRY,0.0,52.0,ACTUAL,v2_robust,True,True,False,False,
NCT00937768,Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy,Goserelin Acetate,"['Leuprorelin Acetate', 'Lucrin Depot', 'Lupron Depot-3 Month', 'Leuplin', 'Procrin', 'Ginecrin', 'Lucrin', 'Lupron', 'Trenantone', 'Enantone', 'Abbott 43818', 'TAP-144', 'ZDX', 'Lupron Depot-Ped', 'Lupron Depot', 'Carcinil', 'Enanton', 'Abbott-43818', 'Viadur', 'LEUP', 'Uno-Enantone', 'Lupron Depot-4 Month', 'Leuprolide Acetate', 'Zoladex', 'Eligard', 'Procren', 'Goserelin Acetate', 'Depo-Eligard', 'A-43818', 'Enantone-Gyn', 'Prostap']",31,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Prostate Adenocarcinoma,Mayo Clinic,2025-09-01T16:18:07.016856,True,,,,,Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy,,"['Prostate Adenocarcinoma', 'Stage IIA Prostate Cancer', 'Stage IIB Prostate Cancer', 'Stage III Prostate Cancer', 'Stage IV Prostate Cancer']",[],,2009-07,2012-07,"[{'measure': 'Biochemical Progression-free Survival Rate', 'description': 'Biochemical progression-free survival (BPFS) was defined as the time from randomization to the time of biochemical progression. If a patient dies without a documentation of biochemical progression, the patient will be considered to have had progressed at the time of death.', 'timeFrame': '2 years'}]","[{'measure': 'Number of Deaths', 'description': 'The number of deaths due to any cause are reported below.', 'timeFrame': '2 years'}, {'measure': 'Percentage of Participants With Grade 3 or Higher Adverse Events Regardless of Attribution', 'description': 'Percentage of Participants with Grade 3 or Higher Adverse Events regardless of attribution per NCI CTCAE Version 3', 'timeFrame': '2 years'}, {'measure': 'Average Overall FACT-P Total Score at Baseline, Months 3 and 6', 'description': 'The overall FACT-P Total Score at Baseline and months 3 and 6 mean and standard deviations are reported below. The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which is the sum of all 5 domain scores and ranges from 0 to 156 where higher scores represent better quality of life.', 'timeFrame': 'Baseline and months 3 and 6'}, {'measure': 'Average LASA Overall Quality of Life at Baseline, Months 3 and 6', 'description': 'LASA Overall Quality of Life at Baseline, Months 3 and 6. Quality of Life (QOL) was measured using the single-item Linear Analogue Self Assessment (LASA) on a 0-10 scale, with 0=as bad as it can be and 10=as good as it can be. The average and standard deviation of the LASA overall quality of life score are reported below at baseline, months 3 and 6.', 'timeFrame': 'Baseline to Months 3 and 6'}]",5.0,18 Years,,MALE,False,OTHER,1.0,16.0,ACTUAL,v2_robust,True,False,True,True,
NCT03805568,A Postoperative Sore Throat After Thyroidectomy,dexmedetomidine infusion group,"['dexmedetomidine infusion group', 'remifentanil infusion group']",2,INTERVENTIONAL,['NA'],,COMPLETED,Post Operative Sore Throat,Yeungnam University College of Medicine,2025-09-01T16:18:07.016869,True,,,,,The Effect of Dexmedetomidine and Remifentanil on the Postoperative Sore Throat After Thyroidectomy,,['Post Operative Sore Throat'],"['postoperative sore throat', 'dexmedetomidine', 'remifentanil', 'thyroidectomy']",,2017-07-05,2018-07-25,"[{'measure': 'incidence of postoperative sore throat at rest', 'description': '0=none; 1=occur', 'timeFrame': '6 hours after surgery'}, {'measure': 'incidence of postoperative sore throat at swallowing', 'description': '0=none; 1=occur', 'timeFrame': '6 hours after surgery'}, {'measure': 'severity of postoperative sore throat at rest', 'description': '4-point scale (0=none; 1=mild; 2=moderate; 3=severe)', 'timeFrame': '6 hours after surgery'}, {'measure': 'severity of postoperative sore throat at swallowing', 'description': '4-point scale (0=none; 1=mild; 2=moderate; 3=severe)', 'timeFrame': '6 hours after surgery'}]",[],4.0,20 Years,65 Years,ALL,False,OTHER,0.0,74.0,ACTUAL,v2_robust,True,True,False,False,
NCT05114668,"Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours",EVT801,['EVT801'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,"Solid Tumor, Adult",Kazia Therapeutics Limited,2025-09-01T16:18:07.016880,True,,,,,"A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours",,"['Solid Tumor, Adult']","['cancer', 'solid tumors', 'advanced or metastatic tumors', 'renal cell carcinoma', 'soft tissue sarcoma']",,2021-11-03,2025-06,"[{'measure': 'MTD and / or a RP2D of EVT801 when administered daily to subjects with advanced or metastatic solid tumours.', 'description': 'The MTD is defined as the highest dose administered at which fewer than one-third of patients experienced a DLT.\n\nThe RP2D will be determined for Stage 1 on the basis of an overall assessment of safety, pharmacokinetics, and other information. The RP2D may be equal to, or lower than, the MTD.', 'timeFrame': '24 months'}, {'measure': 'Adverse event (AE) safety information for EVT801', 'description': 'To provide safety information for EVT801 by assessing adverse events, per CTCAE v5.0.', 'timeFrame': '36 months'}]","[{'measure': 'Cmax pharmacokinetic (PK) parameter of EVT801 following administration in an oral capsule formulation.', 'timeFrame': '12 months'}, {'measure': 'Tmax pharmacokinetic (PK) parameter of EVT801 following administration in an oral capsule formulation.', 'timeFrame': '12 months'}, {'measure': 'T1/2 pharmacokinetic (PK) parameter of EVT801 following administration in an oral capsule formulation.', 'timeFrame': '12 months'}, {'measure': 'AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) parameter of EVT801 following administration in an oral capsule formulation.', 'timeFrame': '12 months'}, {'measure': 'CL pharmacokinetic (PK) parameter of EVT801 following administration in an oral capsule formulation.', 'timeFrame': '12 months'}, {'measure': 'Preliminary anti-tumour activity of EVT801 via assessment of overall response rate (ORR).', 'description': 'ORR will be defined as the proportion of patients in a given analysis population that demonstrate a best overall response of Complete Response (CR) or Partial Response (PR), based on investigator assessment using RECIST (v1.1) criteria', 'timeFrame': '36 months'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,False,False,True,
NCT06480968,CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction,CTH120,['CTH120'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Fragile X Syndrome,"Connecta Therapeutics, S.L.",2025-09-01T16:18:07.016924,True,,,,,"Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction",,['Fragile X Syndrome'],"['Fragile X Syndrome', 'FXS', 'Fragile X', 'Neurodevelopmental Disorders', 'Central Nervous System Diseases', 'Intellectual Disability', 'Neurobehavioral Manifestations', 'Genetic Diseases, X-Linked', 'Congenital Abnormalities', 'Orphan Diseases', 'Rare Diseases']",,2023-06-23,2024-11-11,"[{'measure': 'Treatment-emergent adverse events (TEAEs).', 'description': ""Primary Safety and Tolerability endpoint for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• AEs will be described in terms of result, frequency, intensity, medical decision, relation with study drug, as well as treatment received and subject retirement, duration, and time elapsed. AEs will also be listed and coded using the MedDRA Dictionary (version 26.0) for the term's codification."", 'timeFrame': 'From Day 1 to End-of-study: EOS will be on Day 8 (± 1 day) for FIH-CTH120-SAD and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in blood pressure (mmHg)', 'description': 'Primary Safety and Tolerability endpoint for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• Blood pressure (mmHg) will be measured in the supine position following a 5 min rest.', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in pulse rate (bpm)', 'description': 'Primary Safety and Tolerability endpoint for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• Pulse rate (bpm) will be measured in the supine position following a 5 min rest.', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in oral body temperature (ºC)', 'description': 'Primary Safety and Tolerability endpoint for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• Oral body temperature (ºC) will be measured using an automated vital sign monitor device.', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: normal sinus rhythm (NSR)', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI)\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: normal sinus rhythm (NSR).', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: heart rate (bpm)', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI)\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: heart rate (bpm).', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: PR interval (ms)', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI)\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: PR interval (ms).', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: QRS duration (ms)', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI)\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s.Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: QRS duration (ms).', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: QT (ms)', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI)\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s.Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: QT (ms).', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: QTcF (ms)', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI)\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s.Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: QTcF (ms).', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: haematology', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI). The following tests will be performed:\n\n• Haematology: complete blood count (complete blood count \\[CBC\\]; including haemoglobin, haematocrit, red blood cell \\[RBC\\], white blood cell (WBC), platelet count, and percent and absolute differential count (neutrophils, lymphocytes, eosinophils, monocytes, basophils, and other cells).', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: serum chemistry', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI). The following tests will be performed:\n\n• Serum chemistry: sodium, potassium, chloride, non-fasting glucose, urea, creatinine, calcium, phosphate, magnesium, total and direct bilirubin, total protein, albumin, ALT, AST, ALP, lactate dehydrogenase.', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: coagulation', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI). The following tests will be performed:\n\n• Coagulation parameters: activated partial thromboplastin time (aPTT), PT and INR.', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: urinalysis', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI). The following tests will be performed:\n\n• Urinalysis parameters:\n\n* Macroscopic examination: specific gravity, pH, protein, glucose, ketones, blood, bilirubin, leukocyte, urobilinogen, and nitrite.\n* Microscopic examination: RBCs, WBCs, epithelial cells, casts, crystals, bacteria, and yeast.', 'timeFrame': 'From Day 1 to End-of-study (EOS): on Day 8 (± 1 day) for FIH-CTH120-SAD, and on Day 15 (+ 2 days) for FIH-CTH120-MAD'}, {'measure': 'Psychometric tests: Hospital Anxiety/Depression rating Scale (HADS)', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• HADS: Self-reported questionnaire used to detect depression and anxiety. It consists of 14 items (7 related to depression and 7 to anxiety) scored using a 4-point Likert scale (each item ranging from 0 to 3). Two scores are generated one for depression and one for anxiety each score ranging from 0 to 21. Higher scores indicate greater levels of anxiety or depression. Both scores can be categorized into: Normality (0-7); Probable case of anxiety or depression (8-10); Case of anxiety or depression (11-21).', 'timeFrame': 'FIH-CTH120-SAD: on Day -1 and Day 2; FIH-CTH120-MAD: on Day -1, Day 1, and Day 7'}, {'measure': 'Psychometric tests:Immediate Mood Scaler (IMS).', 'description': 'Primary Safety and Tolerability endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• IMS: The IMS is a tool to remotely and quickly track mood changes related to depression and anxiety in the moment. It consists of 22 items, scored between 1 and 7. The total score for this scale is the sum of the scores on all 22 items: ranging from 22 to 154. Lower scores reflect more negative mood states.', 'timeFrame': 'FIH-CTH120-SAD: on Day -1 and Day 2; FIH-CTH120-MAD: on Day -1, Day 1, and Day 7'}, {'measure': 'Area under the concentration-time curve (AUC0-24h, AUC0-t, AUC0-∞) after fed and fasting conditions.', 'description': 'Primary Pharmacokinetic endpoint for FIH-CTH120-FI (Not applicable for FIH-CTH120-SAD and FIH-CTH120-MAD).\n\n• Plasma PK parameter calculated using a non-compartmental model: AUC0-24h (h \\* ng/mL), AUC0-t (h \\* ng/mL) AUC0-∞ (h \\* ng/mL).', 'timeFrame': 'FIH-CTH120-FI: AUC0-24h on Day 1; AUC0-t, AUC0-∞ where t is the last or the latest timepoint observed'}, {'measure': 'Observed maximum concentration (Cmax) after fed and fasting conditions.', 'description': 'Primary Pharmacokinetic endpoint for FIH-CTH120-FI (Not applicable for FIH-CTH120-SAD and FIH-CTH120-MAD)\n\n• Plasma PK parameter calculated using a non-compartmental model: Cmax (ng/mL).', 'timeFrame': 'FIH-CTH120-FI: On Day 1 of Period 1, and on Day 14/21/25 of Period 2'}, {'measure': 'Time to observed maximum concentration (tmax) after fed and fasting conditions.', 'description': 'Primary Pharmacokinetic endpoint for FIH-CTH120-FI (Not applicable for FIH-CTH120-SAD and FIH-CTH120-MAD)\n\n• Plasma PK parameter calculated using a non-compartmental model: tmax (h).', 'timeFrame': 'FIH-CTH120-FI: On Day 1 of Period 1, and on Day 14/21/25 of Period 2'}]","[{'measure': 'Observed maximum concentration (Cmax).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• Plasma PK parameter calculated using a non-compartmental model: Cmax (ng/mL).', 'timeFrame': 'FIH-CTH120-SAD: On Day 1; FIH-CTH120-MAD: on Day 1, and Day 7'}, {'measure': 'Observed minimum concentration (Cmin).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD, FIH-CTH120-MAD and FIH-CTH120-FI.\n\n• Plasma PK parameter calculated using a non-compartmental model: Cmin (ng/mL).', 'timeFrame': 'FIH-CTH120-SAD: On Day 2; FIH-CTH120-MAD: from Day 2 to Day 7 pre-dose and regularly after the last dose; FIH-CTH120-FI: on Day 2 of Period 1 and Day 15/22/29 of Period 2'}, {'measure': 'Time to observed maximum concentration (tmax).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• Plasma PK parameter calculated using a non-compartmental model: tmax (h).', 'timeFrame': 'FIH-CTH120-SAD: On Day 1; FIH-CTH120-MAD: on Day 1, and Day 7'}, {'measure': 'Time to first measurable plasma concentration (tlag).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD, FIH-CTH120-MAD and FIH-CTH120-FI.\n\n• Plasma PK parameter calculated using a non-compartmental model: tlag (h).', 'timeFrame': 'FIH-CTH120-SAD: On Day 1; FIH-CTH120-MAD: on Day 1, and Day 7; FIH-CTH120-FI: on Day 1 of Period 1 and on Day 14/21/25 of Period 2'}, {'measure': 'Time to last measurable plasma concentration (tlast).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD, FIH-CTH120-MAD, and FIH-CTH120-FI.\n\n• Plasma PK parameter calculated using a non-compartmental model: tlast (h).', 'timeFrame': 'FIH-CTH120-SAD: On Day 2; FIH-CTH120-MAD: on Day 1, and Day 7; FIH-CTH120-FI: on Day 2 of Period 1 and Day 15/22/29 of Period 2'}, {'measure': 'Area under the concentration-time curve (AUC0-24h, AUC0-t, AUC0-∞).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\n• Plasma PK parameter calculated using a non-compartmental model: AUC0-24h (h \\* ng/mL), AUC0-t (h \\* ng/mL) AUC0-∞ (h \\* ng/mL).', 'timeFrame': 'FIH-CTH120-SAD: AUC0-24h on Day 1; AUC0-t, AUC0-∞ where t is Day 8 (+/- 1 days) or the latest timepoint observed; FIH-CTH120-MAD: ""AUC0-24h on Day 1 and Day 7; AUC0-t, AUC0-∞ after last dose, where t is Day 15 (+ 2 days) or the last timepoint observed'}, {'measure': 'Terminal elimination half-life (t1/2).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD, FIH-CTH120-MAD, and FIH-CTH120-FI.\n\n• Plasma PK parameter calculated using a non-compartmental model: t1/2 (h).', 'timeFrame': 'FIH-CTH120-SAD: from Day 1 to Day 8; FIH-CTH120-MAD: from Day 1 to Day 15; FIH-CTH120-FI: from Day 1 to Day28/35/42'}, {'measure': 'Apparent clearance (CL/F).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD, FIH-CTH120-MAD, and FIH-CTH120-FI.\n\n• Plasma PK parameter calculated using a non-compartmental model: CL/F (mL/h \\* kg).', 'timeFrame': 'FIH-CTH120-SAD: from Day 1 to Day 8; FIH-CTH120-MAD: from Day 1 to Day 15; FIH-CTH120-FI: from Day 1 to Day28/35/42'}, {'measure': 'Apparent volume of distribution: Vd/F.', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD, FIH-CTH120-MAD, and FIH-CTH120-FI.\n\n• Plasma PK parameter calculated using a non-compartmental model: Vd/F (mL/kg).', 'timeFrame': 'FIH-CTH120-SAD: from Day 1 to Day 8; FIH-CTH120-MAD: from Day 1 to Day 15; FIH-CTH120-FI: from Day 1 to Day28/35/42'}, {'measure': 'Elimination rate constant (λz).', 'description': 'Secondary Pharmacokinetics endpoints for FIH-CTH120-SAD, FIH-CTH120-MAD, and FIH-CTH120-FI.\n\n• Plasma PK parameter calculated using a non-compartmental model: λz (1/h).', 'timeFrame': 'FIH-CTH120-SAD: from Day 1 to Day 8; FIH-CTH120-MAD: from Day 1 to Day 15; FIH-CTH120-FI: from Day 1 to Day28/35/42'}, {'measure': 'Serotonin (5-HT) metabolite profile.', 'description': 'Secondary Pharmacodynamic endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\nConcentrations of 5-Hydroxy indoleacetic acid (5-HIAA) (ng/mL).', 'timeFrame': 'FIH-CTH120-SAD: on Day 1 and Day 2; FIH-CTH120-MAD: on Day 1, Day 2, Day 7, and Day 8'}, {'measure': 'Noradrenaline (NA) metabolite profile.', 'description': 'Secondary Pharmacodynamic endpoints for FIH-CTH120-SAD and FIH-CTH120-MAD (Not applicable for FIH-CTH120-FI).\n\nConcentrations of 3-Methoxy-4-hydroxyphenylglycol (MHPG) (ng/mL).', 'timeFrame': 'FIH-CTH120-SAD: on Day 1 and Day 2; FIH-CTH120-MAD: on Day 1, Day 2, Day 7, and Day 8'}, {'measure': 'Treatment-emergent AEs (TAES).', 'description': ""Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• AEs will be described in terms of result, frequency, intensity, medical decision, relation with study drug, as well as treatment received and subject retirement, duration, and time elapsed. AEs will also be listed and coded using the MedDRA Dictionary (version 26.0) for the term's codification."", 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in vital signs: blood pressure (mmHg)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Blood pressure (mmHg) will be measured in the supine position following a 5 min rest.', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in vital signs: pulse rate (bpm)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Pulse rate (bpm) will be measured in the supine position following a 5 min rest.', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in vital signs: Oral body temperature (ºC)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Oral body temperature (ºC) will be measured using an automated vital sign monitor device.', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in ECG values: normal sinus rhythm (NSR)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: normal sinus rhythm (NSR).', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in ECG values: heart rate (bpm)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameters will be recorded: heart rate (bpm).', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in ECG values: PR interval (ms)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: PR interval (ms)', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in ECG values: QRS duration (ms)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: QRS duration (ms).', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in ECG values: QT (ms)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: QT (ms).', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in ECG values: QTcF (ms)', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• Computerized 12-lead electrocardiogram (ECG) recordings will be obtained. Each lead shall be recorded for at least 3 beats at a speed of 25 mm/s. Triplicate recordings will be made at the time points evaluated. The following parameter will be recorded: QTcF (ms).', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in safety laboratory parameters: haematology', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI). The following tests will be performed:\n\n• Haematology: complete blood count (complete blood count \\[CBC\\]; including haemoglobin, haematocrit, red blood cell \\[RBC\\], white blood cell (WBC), platelet count, and percent and absolute differential count (neutrophils, lymphocytes, eosinophils, monocytes, basophils, and other cells).', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in safety laboratory parameters: serum chemistry', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI). The following tests will be performed:\n\n• Serum chemistry: sodium, potassium, chloride, non-fasting glucose, urea, creatinine, calcium, phosphate, magnesium, total and direct bilirubin, total protein, albumin, ALT, AST, ALP, lactate dehydrogenase.', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in safety laboratory parameters: coagulation', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI). The following tests will be performed:\n\n• Coagulation parameters: activated partial thromboplastin time (aPTT), PT and INR.', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Treatment-emergent PSCAs in safety laboratory parameters: urinalysis', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI). The following tests will be performed:\n\n• Urinalysis parameters:\n\n* Macroscopic examination: specific gravity, pH, protein, glucose, ketones, blood, bilirubin, leukocyte, urobilinogen, and nitrite.\n* Microscopic examination: RBCs, WBCs, epithelial cells, casts, crystals, bacteria, and yeast.', 'timeFrame': 'FIH-CTH120-FI: from Day 1 to End-of-study. EOS will be on Day 28, or 35 or 42 (±1 day) depending on the length of the washout period determined'}, {'measure': 'Psychometric tests: HADS', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• HADS: Self-reported questionnaire used to detect depression and anxiety. It consists of 14 items (7 related to depression and 7 to anxiety) scored using a 4-point Likert scale (each item ranging from 0 to 3). Two scores are generated one for depression and one for anxiety ranging each score ranging from 0 to 21. Higher scores indicate greater levels of anxiety or depression. Both scores can be categorized into: Normality (0-7); Probable case of anxiety or depression (8-10); Case of anxiety or depression (11-21).', 'timeFrame': 'FIH-CTH120-FI: On Day -1, Day 2, Day 13/20/27 and Day 15/22/29'}, {'measure': 'Psychometric tests: IMS', 'description': 'Secondary Safety and tolerability endpoints (FIH-CTH120-FI).\n\n• IMS: The IMS is a tool to remotely and quickly track mood changes related to depression and anxiety in the moment. It consists of 22 items, scored between 1 and 7. The total score for this scale is the sum of the scores on all 22 items: ranging from 22 to 154. Lower scores reflect more negative mood states.', 'timeFrame': 'FIH-CTH120-FI: On Day -1, Day 2, Day 13/20/27 and Day 15/22/29'}]",47.0,18 Years,55 Years,ALL,True,INDUSTRY,3.0,76.0,ACTUAL,v2_robust,True,True,False,True,
NCT01832350,Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease,Nuedexta (20/10),"['Nuedexta (20/10)', 'Dextromethorphan/Quinidine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Alzheimer's Disease,"St. Joseph's Hospital and Medical Center, Phoenix",2025-09-01T16:18:07.016970,True,,,,,"Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease",,"[""Alzheimer's Disease"", 'Pseudobulbar Affect (PBA)']",[],Sponsor decided to stop study early,2012-08-28,2016-12-01,"[{'measure': 'reduction of PBA frequency', 'timeFrame': '1, 13, and 26 weeks after initiation of treatment'}]","[{'measure': 'reduction of PBA severity', 'timeFrame': '1, 13, and 26 weeks after initiation of treatment'}]",2.0,55 Years,90 Years,ALL,False,OTHER,1.0,34.0,ACTUAL,v2_robust,True,False,True,False,Sponsor decided to stop study early
NCT05646550,Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer,CC-1 Infusion,['CC-1 Infusion'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Prostate Cancer Recurrent,University Hospital Tuebingen,2025-09-01T16:18:07.016978,True,,,,,"Phase I Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer",,['Prostate Cancer Recurrent'],[],,2022-11-11,2026-12,"[{'measure': 'Dose escalation part: To define the maximum tolerated dose (MTD) of CC-1 as 3 hours infusion', 'description': 'Data Safety and Monitoring Board (DSMB) and Sponsor meeting about determination of the MTD for each cohort and the dose expansion phase', 'timeFrame': 'during the procedure'}, {'measure': 'Dose expansion part: To define the recommended phase-II dose of CC-1', 'description': 'Data Safety and Monitoring Board and Sponsor meeting about determination of the recommended phase II dose of CC-1 for potential phase II trials.', 'timeFrame': 'up to 1 month after procedure'}]","[{'measure': 'To evaluate safety and tolerability of CC-1', 'description': 'Number of participants with Adverse Events (AEs) and with abnormal laboratory test results', 'timeFrame': 'during the procedure'}, {'measure': 'To assess efficacy in terms of Prostata-Specific-Antigen (PSA) response and no PSA progression after CC-1 treatment', 'description': 'PSA response will be defined as ≥50% PSA decrease. In addition, ""No PSA doubling"", defined as PSA measured at visits C1-6, End Of Treatment (EOT), End Of Safety follow up (EOSf) and Follow-up (FU)1-5 divided by PSA measured at baseline, will be assessed as further efficacy endpoint. Furthermore, percentage of patients with no clinical relapse, no salvage and no subsequent antineoplastic therapy will be assessed', 'timeFrame': 'during the procedure and through study completion, an average of 6 months'}, {'measure': 'To assess clinical outcome in terms of progression-free survival, treatment-free survival, overall survival', 'description': 'Overall and progression free survival status as percentage of patients alive at EOSf and each follow-up assessment', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'To assess CC-1 serum concentrations', 'description': 'CC-1 serum concentrations assessed prior to and after start of infusion on each treatment day in the first cycle (each cycle is 28 days).', 'timeFrame': 'during the procedure prior to and after start of infusion on each treatment day in the first cycle (each cycle is 28 days).'}, {'measure': 'To assess quality of life', 'description': 'Quality of life is defined as overall quality of life scores European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ).', 'timeFrame': 'through study completion, an average of 1 year'}]",7.0,18 Years,,MALE,False,OTHER,0.0,56.0,ESTIMATED,v2_robust,True,False,False,True,
NCT07079150,"Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study",Peg IFN-α-2b,['Peg IFN-α-2b'],1,OBSERVATIONAL,[],,RECRUITING,"Hepatitis B, Chronic (CHB)",First Affiliated Hospital Xi'an Jiaotong University,2025-09-01T16:18:07.017050,True,,,,,"Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study",,"['Hepatitis B, Chronic (CHB)', 'Hepatitis B', 'Hepatitis B Virus (HBV)']","['hepatitis B', 'family cluster', 'interferon', 'antiviral therapy', 'cirrhosis', 'hepatocellular carcinoma']",,2025-01-01,2032-01,"[{'measure': 'the number and percentage of cases of cirrhosis and HCC occurring in the non-cirrhosis population', 'timeFrame': 'From enrollment to the end of treatment at 5 years and 7 years'}, {'measure': 'the number and percentage of cases of decompensated cirrhosis and HCC occurring in the compensated cirrhosis population', 'timeFrame': 'From enrollment to the end of treatment at 5 years and 7 years'}]","[{'measure': 'Overall survival time of patients in each treatment subgroup', 'timeFrame': 'From enrollment to the end of treatment at 5 years and 7 years'}, {'measure': 'the time of cirrhosis and HCC occurring in the non-cirrhosis population', 'timeFrame': 'From enrollment to the end of treatment at 5 years and 7 years'}, {'measure': 'the time of decompensated cirrhosis and HCC occurring in the compensated-cirrhosis population', 'timeFrame': 'From enrollment to the end of treatment at 5 years and 7 years'}, {'measure': 'the number and percentage of HBsAg seroconversion cases, the number and percentage of HBeAg seroconversion cases (for those who are HBeAg-positive) per 24 weeks', 'timeFrame': 'From enrollment to the end of treatment at 5 years and 7 years'}, {'measure': 'HBV DNA levels, HBsAg levels, and HBeAg levels per 24 weeks', 'timeFrame': 'From enrollment to the end of treatment at 5 years and 7 years'}]",7.0,18 Years,70 Years,ALL,False,OTHER,0.0,1500.0,ESTIMATED,v2_robust,False,False,False,False,
NCT04527250,A Study of the Relative Bioavailability of ASC41 in Healthy Subjects,ASC41,"['ASC41', 'ASC41 placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Ascletis Pharmaceuticals Co., Ltd.",2025-09-01T16:18:07.017147,True,,,,,"Comparison of the Pharmacokinetic Parameters of ASC41, a Randomized, Double-blind, Placebo-controlled in Healthy Subjects After Single and Multiple Doses",,['Healthy'],[],,2020-09-16,2020-12-30,"[{'measure': 'Evaluation of the safety and tolerability of ASC41 in healthy volunteers', 'description': 'Evaluation of the safety and tolerability of ASC41 in healthy volunteers', 'timeFrame': 'Up to 32 days'}]","[{'measure': 'Cmax of ASC41', 'description': 'Evaluate the Peak Plasma Concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.', 'timeFrame': 'On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.'}, {'measure': 'Tmax of ASC41', 'description': 'Evaluate the Time to reach the maximum plasma concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.', 'timeFrame': 'On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.'}, {'measure': 'AUC of ASC41', 'description': 'Evaluate the Area under the plasma concentration versus time curve after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.', 'timeFrame': 'On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.'}, {'measure': 't1/2 of ASC41', 'description': 'Evaluate the Terminal-Phase Half-Life after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers volunteers.', 'timeFrame': 'On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.'}, {'measure': 'CL/F of ASC41', 'description': 'Evaluate the Apparent Systemic Clearance after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.', 'timeFrame': 'On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.'}, {'measure': 'Vd/F of ASC41', 'description': 'Evaluate the Apparent Volume of Distribution after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.', 'timeFrame': 'On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.'}]",7.0,18 Years,45 Years,ALL,True,INDUSTRY,1.0,60.0,ACTUAL,v2_robust,True,True,False,True,
NCT04407650,Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus,Metformin,"['Ursodeoxycholic Acid', 'Metformin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,ACTIVE_NOT_RECRUITING,Gestational Diabetes,King's College London,2025-09-01T16:18:07.017154,True,,,,,Randomised Controlled Trial of Gestational Treatment With Ursodeoxycholic Acid Compared to Metformin to Reduce Effects of Diabetes Mellitus,,['Gestational Diabetes'],[],,2021-07-01,2025-05-31,"[{'measure': 'Glycaemic control', 'description': 'Maternal fasting glucose concentration in blood sample', 'timeFrame': 'Gestational week 36'}]","[{'measure': 'Acceptability', 'description': 'To assess the acceptability of UDCA compared to metformin using the Diabetes Treatment Satisfaction Questionnaire GB-DTSQs\\_Jul94 with scales ranging from 6 (increased satisfaction/acceptability) - 0 (dissatisfaction)', 'timeFrame': 'Gestational week 36'}, {'measure': 'Biomedical outcomes: continuous glucose monitoring', 'description': 'Glucose metabolism control measured by continuous glucose monitors to establish whether continuous glucose monitoring gives more informative overall assessment of maternal glycaemic control', 'timeFrame': 'Baseline (week 28), Follow up 1 (week 32), Follow up 2 (week 36)'}, {'measure': 'Biomedical outcomes: 1,5-anhydroglucitol', 'description': 'Glucose metabolism control measured by serum concentrations of 1,5-anhydroglucitol', 'timeFrame': 'Baseline (week 28), Follow up 1 (week 32), Follow up 2 (week 36)'}, {'measure': 'Biomedical outcomes: glucose control by HbA1c', 'description': 'Glucose metabolism control measured by HbA1c concentration', 'timeFrame': 'Baseline (week 28), Follow up 2 (week 36)'}, {'measure': 'Biomedical outcomes: lipids', 'description': 'Lipid metabolism assessed by blood triglyceride, total cholesterol, calculated LDL-cholesterol, HDL-cholesterol and free fatty acid concentrations, all in mmol/L', 'timeFrame': 'Follow up 2 (week 36)'}, {'measure': 'Biomedical analyses: bilirubin', 'description': 'Maternal liver function tests: bilirubin', 'timeFrame': 'Follow up 2 (week 36)'}, {'measure': 'Biomedical analyses: ALT', 'description': 'Maternal liver function tests: ALT', 'timeFrame': 'Follow up 2 (week 36)'}, {'measure': 'Biomedical analyses: bile acids', 'description': 'Maternal liver function tests: bile acids', 'timeFrame': 'Follow up 2 (week 36)'}, {'measure': 'Biomedical analyses: CRP', 'description': 'Maternal liver function tests: C reactive protein', 'timeFrame': 'Follow up 2 (week 36)'}, {'measure': 'Clinical maternal outcomes: insulin', 'description': 'Proportion of women requiring insulin treatment (time until treatment and dose)', 'timeFrame': 'From enrolment to birth'}, {'measure': 'Clinical maternal outcomes: weight', 'description': 'Maternal weight change', 'timeFrame': 'Follow up 2 (week 36) compared to first trimester'}, {'measure': 'Maternal vascular responses (I)', 'description': 'maternal pulse wave velocity (PWV)', 'timeFrame': 'Follow up 1 (week 32), Follow up 2 (week 36)'}, {'measure': 'Maternal vascular responses (II)', 'description': 'systolic and diastolic blood pressure', 'timeFrame': 'Follow up 1 (week 32), Follow up 2 (week 36)'}, {'measure': 'Maternal vascular responses (III)', 'description': 'central arterial pressure (cP)', 'timeFrame': 'Follow up 1 (week 32), Follow up 2 (week 36)'}, {'measure': 'Maternal vascular responses (IV)', 'description': 'Augmentation index (AIx)', 'timeFrame': 'Follow up 1 (week 32), Follow up 2 (week 36)'}, {'measure': 'Blood loss', 'description': 'Estimated blood loss during birth', 'timeFrame': 'Delivery'}, {'measure': 'Neonatal outcomes: mode of birth', 'description': 'Amongts all participants, caesarean section (elective \\& emergency), assisted vaginal birth and spontaneous vaginal delivery numbers will be measured', 'timeFrame': 'Delivery'}, {'measure': 'Neonatal outcomes: gestational age', 'description': 'Gestational age at birth', 'timeFrame': 'Delivery'}, {'measure': 'Neonatal outcomes: apgar scores', 'description': 'Apgar scores at 5 minutes post birth', 'timeFrame': 'Delivery'}, {'measure': 'Neonatal outcomes: shoulder dystocia', 'description': 'Occurrence of shoulder dystocia', 'timeFrame': 'Delivery'}, {'measure': 'Neonatal outcomes: weight', 'description': 'Infant birth weight will be collected to analyse the percentage proportion of babies born large for gestational age and proportion of babies born small for gestational age', 'timeFrame': 'Delivery'}, {'measure': 'Neonatal outcomes: morbidity', 'description': 'Treatment for neonatal hypoglycaemia, neonatal jaundice, respiratory distress or birth trauma', 'timeFrame': 'Delivery'}, {'measure': 'Neonatal outcomes: rate of special care unit admission.', 'description': 'Neonatal intensive care and special care unit admission (duration of hospital stay)', 'timeFrame': '28 days post delivery'}, {'measure': 'Stillbirth and neonatal death', 'description': 'Occurrence of stillbirth and neonatal death', 'timeFrame': 'Delivery'}, {'measure': 'Biomedical neonatal outcomes', 'description': 'Cord blood C-peptide, triglyceride, total cholesterol, calculated LDL-cholesterol, HDL-cholesterol and free fatty acid concentrations all in mmol/L', 'timeFrame': 'Delivery'}]",26.0,16 Years,45 Years,FEMALE,False,OTHER,1.0,64.0,ACTUAL,v2_robust,True,False,False,False,
NCT06332950,Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy,"Adebrelimab, Irinotecan Liposome (II)","['Adebrelimab, Irinotecan Liposome (II), Famitinib', 'Adebrelimab, Irinotecan Liposome (II)']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,NOT_YET_RECRUITING,Extensive-stage Small-cell Lung Cancer,Baohui Han,2025-09-01T16:18:07.017354,True,,,,,"A Randomized, Multi-cohort, Multi-center Phase Ib/II Study of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in Patients With ES-SCLC Pre-treated With Immune Checkpoint Inhibitor(s)",,['Extensive-stage Small-cell Lung Cancer'],[],,2024-04-01,2027-04-01,"[{'measure': '6-month progression-free survival', 'description': 'Proportion of disease progression or death from randomization to 6 months of treatment.', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Safety', 'description': 'Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.', 'timeFrame': 'Up to 3 months after the last dose'}, {'measure': 'Objective response rate', 'description': 'Objective response rate, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Progression-free survival', 'description': 'Progression Free Survival, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Overall survival', 'description': 'Overall survival is the time from randomization to death due to any reason or loss of follow-up.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Disease control rate', 'description': 'Disease Control Rate, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Duration of response', 'description': 'Duration of Response, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}]",7.0,18 Years,75 Years,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02228850,"Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis",Alprostadil,['Alprostadil'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Raynaud's Phenomenon Secondary to Systemic Sclerosis,"NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)",2025-09-01T16:18:07.017394,True,,,,,"A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)",,"[""Raynaud's Phenomenon Secondary to Systemic Sclerosis""]","[""Secondary Raynaud's Phenomenon"", ""Secondary Raynaud's Disease"", 'Scleroderma', ""Raynaud's Disease secondary to systemic sclerosis"", 'CREST', 'Apricus Biosciences', 'laser doppler', 'thermography']",,2014-11,2015-12,"[{'measure': 'Pharmacodynamic evaluation: digital perfusion by laser Doppler capillary velocimetry and on digital temperature recovery with thermography.', 'timeFrame': 'two hours (intermittently) after cold-challenge and post-dose'}, {'measure': 'Safety assessments based on review of adverse events, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests.', 'timeFrame': 'One month'}]",[],2.0,18 Years,79 Years,ALL,False,INDUSTRY,0.0,35.0,ACTUAL,v2_robust,True,True,False,True,
NCT03796650,Fecal Transplantation for Primary Clostridium Difficile Infection,Vancomycin,['Vancomycin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Clostridium Difficile Infection,Oslo University Hospital,2025-09-01T16:18:07.017403,True,,,,,COmparative Effectiveness of IntestinaL MicrobiOta Versus VaNcomycin for Primary C. Difficile Infection - RandomiZEd Trials,,['Clostridium Difficile Infection'],"['Clostridium difficile', 'Intestinal microbiota therapy', 'Fecal microbiota transplantation', 'Investigator-initiated', 'Antibiotics', 'Diarrhea']",Pre-specified non-inferiority criterion met at interim analysis.,2019-07-17,2024-04-02,"[{'measure': 'Patients with durable cure', 'description': 'Proportion of patients with primary clinical cure at day 14 after treatment start and no recurrent C. difficile infection during 60 days after treatment start, with the assigned treatment alone.', 'timeFrame': '60 days'}]","[{'measure': 'Patients with durable cure with additional treatment.', 'description': 'Proportion of patients with primary clinical cure at day 14 after treatment start and no recurrent C. difficile infection during 60 days after treatment start, with or without the need of additional treatment (FMT, metronidazole or vancomycin).', 'timeFrame': '60 days'}, {'measure': 'Treatment adverse events', 'description': 'Proportion of patients with adverse events.', 'timeFrame': '60 and 365 days'}, {'measure': 'Patients with long-time cure', 'description': 'Proportion of patients with primary clinical cure at day 14 after treatment start and no recurrent C. difficile infection during 60 days after treatment start, and without recurrent C. difficile infection within 365 days after treatment start.', 'timeFrame': '365 days'}, {'measure': 'Health-economic evaluation', 'description': 'Health-economic analysis of the two compared treatment modalities', 'timeFrame': '365 days'}]",5.0,18 Years,,ALL,False,OTHER,16.0,104.0,ACTUAL,v2_robust,True,False,True,True,Pre-specified non-inferiority criterion met at interim analysis.
NCT05160350,Probiotic in Treatment of Adult Patients With Drug-resistant Epilepsy,Probiotic,"['Probiotic', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Epilepsy,Mazandaran University of Medical Sciences,2025-09-01T16:18:07.017415,True,,,,,Investigation of Probiotic Effect on Seizure Frequency of Adult Patients With Drug-resistant Epilepsy; A Randomized Double-blind Parallel Placebo-controlled Clinical Trial,,"['Epilepsy', 'Treatment']",[],,2021-04-21,2021-10-30,"[{'measure': 'Change in seizure frequency', 'timeFrame': '12 weeks'}]",[],1.0,16 Years,60 Years,ALL,False,OTHER,0.0,42.0,ACTUAL,v2_robust,True,True,False,False,
NCT02595450,A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer,Erlotinib,"['Tarceva', 'Erlotinib']",2,OBSERVATIONAL,[],,COMPLETED,Non-Small Cell Lung Cancer,Hoffmann-La Roche,2025-09-01T16:18:07.017446,True,,,,,A Non Interventional Trial of Tarceva Metastatic Non Small Lung Cancer.,,['Non-Small Cell Lung Cancer'],['Non-small cell lung cancer'],,2008-09,2014-11,"[{'measure': 'Progression-free Survival (PFS) Time', 'description': 'Time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. Progression was defined as at least 20 percent (%) increase in the sum of diameters of target lesions, or unequivocal progression of existing non-target lesions. Kaplan-Meier estimates were used for calculating PFS.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Percentage of Participants With Best Overall Response', 'description': 'Percentage of participants with best overall response of complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) were reported. Per RECIST Version 1.1: CR was defined as complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis less than \\[\\<\\] 10 millimeter \\[mm\\]). No new lesions. PR was defined as greater than or equal to (\\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least 20% increase in the sum of diameters of target lesions, or unequivocal progression of existing non-target lesions. SD was defined as not qualifying for CR, PR, PD.', 'timeFrame': 'Up to 6 years'}]","[{'measure': 'Overall Survival (OS) Time', 'description': 'Time from the start of study treatment to date of death due to any cause. Kaplan-Meier estimates were used for calculating OS.', 'timeFrame': 'Up to 6 years'}]",3.0,35 Years,86 Years,ALL,False,INDUSTRY,0.0,299.0,ACTUAL,v2_robust,False,True,False,False,
NCT02850250,Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery,Cefuroxime,"['Ceftin', 'Cefuroxime']",2,OBSERVATIONAL,[],,WITHDRAWN,Cardiac Event,Alder Hey Children's NHS Foundation Trust,2025-09-01T16:18:07.017496,True,,,,,Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery,,['Cardiac Event'],"['Observational', 'pharmacokinetic', 'cardiac', 'Cefuroxime', 'Paediatric']",CI left the country so study has never opened,2018-07,2019-10,"[{'measure': 'Plasma concentrations', 'description': 'To measure plasma concentrations of Cefuroxime in this patient population', 'timeFrame': '12 months'}]",[],1.0,,3 Months,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,False,False,True,False,CI left the country so study has never opened
NCT01503450,"Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition",Olanzapine OD Tablets 5 mg,"['Olanzapine OD Tablets 5 mg', 'Zyprexa Zydis']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Fed,Dr. Reddy's Laboratories Limited,2025-09-01T16:18:07.017574,True,,,,,"An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fed Conditions",,['Fed'],[],,2006-11,2006-12,"[{'measure': 'Bioequivalence is based on Cmax and AUC parameters', 'timeFrame': '2 months'}]",[],1.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,False,
NCT05289050,Analgesic Effect of Intraoperative Intravenous S-Ketamine During Total Knee Arthroplasty Surgery,sodium chloride (NaCl; 0.9%),"['sodium chloride (NaCl; 0.9%)', 'S-ketamine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,"Postoperative Pain, Acute",Ling Dong,2025-09-01T16:18:07.017581,True,,,,,Analgesic Effect of Intraoperative Intravenous S-Ketamine During Total Knee Arthroplasty Surgery:A Randomized Controlled Clinical Trial,,"['Postoperative Pain, Acute', 'Anaesthetic']","['Postoperative pain', 'total knee arthroplasty surgery', 'anaesthetic', 'S-ketamine infusion']",,2022-04-19,2024-12-01,"[{'measure': 'at rest and movement, evaluated NRS at 24hours after surgery in the surgical ward.', 'description': 'NRS = (numerical rating scale) is widely used to measure pain intensity after surgery.NRS is evaluated on a 11-point NRS (0 = no pain, 10 = worst pain imaginable)', 'timeFrame': 'the patient at 24hours after operation.'}]","[{'measure': 'at rest and movement, evaluated NRS at 2 hours after surgery in the surgical ward.', 'description': 'NRS = (numerical rating scale) is widely used to measure pain intensity after surgery.NRS is evaluated on a 11-point NRS (0 = no pain, 10 = worst pain imaginable)', 'timeFrame': 'the patient at 2 hours after operation.'}, {'measure': 'at rest and movement, evaluated NRS at 48hours after surgery in the surgical ward.', 'description': 'NRS = (numerical rating scale) is widely used to measure pain intensity after surgery.NRS is evaluated on a 11-point NRS (0 = no pain, 10 = worst pain imaginable)', 'timeFrame': 'the patient at 48hours after operation'}, {'measure': 'The cumulative Opioids consumption during the first 48h after operation', 'description': 'The cumulative Opioids consumption such as demerol,sufentanil,morphine', 'timeFrame': 'Within 48hours after surgery'}, {'measure': 'The number of patients who required additional analgesics during the first 48h after operation', 'description': 'The number of patients who required additional analgesics such as opioids(demerol,sufentanil,morphine)or non-steroid anti-inflammatory drugs(acetaminophen,diclofenac).', 'timeFrame': 'Within 48hours after surgery'}, {'measure': 'The Opioids or non-steroid anti-inflammatory drugs total consumption during the first 48h after operation', 'description': 'The opioids (such as demerol,sufentanil,morphine) or non-steroid anti-inflammatory drugs (such as acetaminophen,diclofenac)total consumption.', 'timeFrame': 'Within 48hours after surgery'}, {'measure': 'The incidence of PONV and adverse central nervous system (CNS) events.', 'description': '(Postoperative nausea and vomiting)Nausea is defined as subjective,unpleasant sensation associated with awareness of the urge to vomit. Retching is defined as the laboured, spastic, rhythmic contraction of the respiratory muscles without expulsion of the gastric contents.Vomiting is defined as the forceful expulsion of gastric contents from the mouth.The adverse central nervous system (CNS) events(such as nightmares, hallucinations, dizziness, itchy skin) were recorded (yes/no) at the patient leaves the PACU and at 24, 48hours in the surgical ward.', 'timeFrame': 'at2, 24, 48hours after operation.'}]",7.0,65 Years,90 Years,ALL,False,OTHER,0.0,144.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06780150,A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS),Ocrelizumab,"['RO4964913, Ocrevus', 'Ocrelizumab']",2,OBSERVATIONAL,[],,RECRUITING,Multiple Sclerosis,Hoffmann-La Roche,2025-09-01T16:18:07.017605,True,,,,,SurfSubQ - A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis,,['Multiple Sclerosis'],[],,2024-09-26,2026-11-30,"[{'measure': 'Number of Participants Their Level of by Satisfaction With Ocrelizumab SC After 12 Months Assessed Using TASQ-SC', 'description': 'TASQ-SC is a 12-item, participant-reported questionnaire measuring the impact of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each of the domain/scale scores is scored on a scale of 1-100, where higher scores indicate higher overall satisfaction with the therapy.', 'timeFrame': 'Month 12'}]","[{'measure': 'Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After the First Injection and After 6 Months Assessed Using TASQ-SC', 'description': 'TASQ-SC is a 12-item, participant-reported questionnaire measuring the impact of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each of the domain/scale scores is scored on a scale of 1-100, where higher scores indicate higher overall satisfaction with the therapy.', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Change From Baseline in NfL Protein Levels in Serum', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Concentration of NfL Protein Levels in Serum', 'timeFrame': 'Baseline, Month 6, Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With MS Relapse', 'description': 'The changes in levels of NfL protein levels in serum and its correlation with MS relapse will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With Expanded Disability Status Scale (EDSS)', 'description': 'The changes in levels of NfL protein levels in serum and its correlation with EDSS will be analyzed using Pearson or Spearman correlation coefficients. EDSS is a scale for assessing neurologic impairment in MS. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With Previous MS Disease Modifying Therapy (DMT)', 'description': 'The changes in levels of NfL protein in serum and its correlation with DMT will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With NfL Confounder - Serum Creatinine', 'description': 'The changes in levels of NfL protein in serum and its correlation with serum creatinine will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With NfL Confounder - Co-morbidities', 'description': 'The changes in levels of NfL protein in serum and its correlation with co-morbidities will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With NfL Confounder - Age', 'description': 'The changes in levels of NfL protein in serum and its correlation with age will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With NfL Confounder - Body Mass Index [BMI]', 'description': 'The changes in levels of NfL protein in serum and its correlation with BMI will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With Magnetic Resonance Imaging (MRI) Lesion Count', 'description': 'The changes in levels of NfL protein in serum and its correlation with MRI lesion count will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With Glial Fibrillary Acidic Protein (GFAP) Levels', 'description': 'The changes in levels of NfL protein in serum and its correlation with GFAP levels will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Correlation Between NfL Protein Levels in Serum With No Evidence of Disease Activity-3 (NEDA-3)', 'description': 'NEDA-3 is defined by no confirmed MS relapse, no new or enlarging T2 lesions, no Gadolinium-positive T1 lesions, and no six-month confirmed disability worsening. The changes in levels of NfL protein in serum and its correlation with NEDA-3 will be analyzed using Pearson or Spearman correlation coefficients.', 'timeFrame': 'Up to Month 12'}, {'measure': 'Change From Baseline in Participant Satisfaction With Ocrelizumab SC Assessed Using Treatment Satisfaction Questionnaire for Medication (TSQM) 1.4', 'description': 'TSQM version 1.4 is a 14-item questionnaire used to measure level of satisfaction or dissatisfaction with the medication on 4 domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Each of the domain is scored on likert-type scales of 5 or 7 points ranging from 1 (least satisfied) to 5 or 7 (most satisfied). Item scores are summarized to give four domain scores, which are in turn transformed to a scale of 0-100. Higher scores indicate higher overall satisfaction with the therapy.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Number of Participants by Their Level of Satisfaction With Ocrelizumab SC Assessed by Physician Survey', 'timeFrame': 'Baseline, Month 6, Month 12'}, {'measure': 'Annualized Relapse Rate', 'timeFrame': 'Month 12'}, {'measure': 'Percentage of Participants With Progression Independent of Relapse Activity (PIRA)', 'timeFrame': 'Up to Month 12'}, {'measure': 'Number of Participants With Non-serious Adverse Events (nsAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)', 'timeFrame': 'Up to Month 12'}]",19.0,18 Years,,ALL,False,INDUSTRY,0.0,349.0,ESTIMATED,v2_robust,False,False,False,True,
NCT02260791,A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients,FKB327,"['FKB327', 'Humira®']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Arthritis, Rheumatoid","Fujifilm Kyowa Kirin Biologics Co., Ltd.",2025-09-01T16:18:07.017703,True,,,,,"A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate",,"['Arthritis, Rheumatoid']","['Rheumatoid', 'Arthritis']",,2014-12,2016-07,"[{'measure': 'American College of Rheumatology (ACR) 20 Response Rate', 'description': 'The primary efficacy endpoint was the ACR20 response rate at Week 24.\n\nAn ACR20 response meant that the patient achieved a 20% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health Assessment Questionnaire Disability Index \\[HAQ-DI\\])', 'timeFrame': 'Week 24'}]","[{'measure': 'Disease Activity Score 28 (DAS28) Based on C-reactive Protein (DAS28-CRP) Score', 'description': ""The DAS28-CRP assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The DAS28-CRP is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24'}, {'measure': 'ACR20 Response Rates Over Time', 'description': 'An ACR20 response meant that the patient achieved a 20% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health Assessment Questionnaire Disability Index \\[HAQ-DI\\])', 'timeFrame': 'Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24'}, {'measure': 'ACR50 Response Rates Over Time', 'description': 'An ACR50 response meant that the patient achieved a 50% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health AssessmentQuestionnaire Disability Index \\[HAQ-DI\\])', 'timeFrame': 'Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24'}, {'measure': 'ACR70 Response Rates Over Time', 'description': 'An ACR70 response meant that the patient achieved a 70% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below.\n\n* Acute phase reactant (CRP)\n* Patient global assessment of disease activity\n* Physician global assessment of disease activity\n* Patient pain scale\n* Disability/functional questionnaire (patient completed Health AssessmentQuestionnaire Disability Index \\[HAQ-DI\\])', 'timeFrame': 'Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24'}, {'measure': 'Swollen Joint Count', 'description': 'Counts of swollen joints from amongst 66 selected joints performed by a trained and qualified joint assessor using standardised techniques recommended by the European League Against Rheumatism (EULAR). Joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66 with higher scores indicating severe disease. Swollen joint count is a value of the individual ACR core set variables.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Tender Joint Count', 'description': 'Counts of tender joints from amongst 68 selected joints were performed by a trained and qualified joint assessor using standardised techniques recommended by the European League Against Rheumatism (EULAR). Joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68 with higher scores indicating severe disease.Tender joint count is a value of the individual ACR core set variables.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Analysis of Serum C-Reactive Protein (CRP) Concentration', 'description': 'Analysis of serum C-Reactive Protein (CRP) concentrations for inclusion in the ACR20/50/70 and DAS28-CRP scores was performed by a central laboratory. Elevation of CRP is a nonspecific marker of inflammation. Values above 10 mg/L were considered to be abnormally high. Decrease in level of CRP indicates reduction in inflammation.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Patient Assessment of Disease Activity', 'description': 'Patient assessment of disease activity visual analogue scale (VAS) will be assessed on 100-point scales (ranging from very well (0) to extremely bad (100)).The patient assessment of disease activity VAS will contribute to the calculation of the DAS28 score. The patient assessment of disease activity VAS will contribute to the calculation of ACR20, ACR50 and ACR70 response.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Physician Assessment of Disease Activity', 'description': 'Physician assessment of disease activity visual analogue scale (VAS) will be assessed on 100-point scale (ranging from very low (0) to very high (100)). The physician assessment of disease activity VAS will contribute to the calculation of ACR20, ACR50 and ACR70 response.', 'timeFrame': 'Baseline and Week 24'}, {'measure': ""Patient's Assessment of Pain"", 'description': 'An injection site pain visual analogue score (VAS) will be administered to the patient. To determine the extent of the pain, patients will be asked to place a small vertical mark on a horizontal scale from 0 to 100, the ends of which are labelled with the extreme responses to be measured (""No pain"" at 0 and ""Intolerable pain"" at 100). Patient\'s assessment of pain is a value of the individual ACR core set variables.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Health Assessment Questionnaire Disability Index (HAQ-DI)', 'description': ""The HAQ-DI is a 20-question, self-administered instrument that measures the patient's functional ability on a 4-level difficulty scale (0 to 3, with 0 representing normal or no difficulty and 3 representing inability to perform). Eight categories of functioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. This scale is sensitive to change and is a good predictor of future disability. HAQ-DI is a value of the individual ACR core set variables."", 'timeFrame': 'Baseline and Week 24'}, {'measure': 'DAS28-CRP Score Over Time', 'description': ""The DAS28 score is a combined index that has been developed to measure the disease activity in patients with RA and has been extensively validated for its use in clinical studies. The DAS28-CRP assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The individual results are summed using a formula. The DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity."", 'timeFrame': 'Baseline and Week 24'}, {'measure': 'DAS28 Score Based on Erythrocyte Sedimentation Rate (DAS28-ESR)', 'description': ""The DAS28 score is a combined index that has been developed to measure the disease activity in patients with RA and has been extensively validated for its use in clinical studies. The DAS28-ESR assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum ESR, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The individual results are summed using a formula. The DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity."", 'timeFrame': 'Baseline, Week 12 and Week 24'}]",14.0,18 Years,,ALL,False,INDUSTRY,0.0,728.0,ACTUAL,v2_robust,True,True,False,False,
NCT02064491,Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC,Erlotinib,"['Tarceva', 'Erlotinib', 'Chemotherapy', 'Cisplatin, Carboplatin, Docetaxel, Paclitaxel, Pemetrexed']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Non-small Cell Lung Cancer,Finnish Lung Cancer Group,2025-09-01T16:18:07.017831,True,,,,,Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC,,['Non-small Cell Lung Cancer'],"['Non-small cell lung cancer', 'EGFR mutant', 'Erlotinib', 'Treatment Beyond Progression']",,2014-02,2017-05-31,"[{'measure': 'Progression-free survival of the whole study population and in the strata 1-2', 'timeFrame': 'An expected average of 36 weeks after last subject enrolled into our study'}]","[{'measure': 'Overall Survival', 'timeFrame': 'An expected average of 52 weeks after last subject enrolled into our study'}, {'measure': 'Overall Response Rate', 'timeFrame': 'An expected average of 36 weeks after last subject enrolled into our study'}, {'measure': 'Rate of non-progression at 9 and 18 weeks', 'timeFrame': '18 weeks after date of randomization of a last patient'}, {'measure': 'Safety and toxicity', 'description': 'Number of Participants with Adverse Events as a Measure of Safety and Tolerability', 'timeFrame': 'An expected average of 52 weeks after last subject enrolled into our study'}]",5.0,18 Years,,ALL,False,OTHER,1.0,18.0,ACTUAL,v2_robust,True,True,False,True,
NCT01059591,First Study in Humans With GSK424887,GSK424887,"['GSK424887', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Depressive Disorder and Anxiety Disorders,GlaxoSmithKline,2025-09-01T16:18:07.017844,True,,,,,"A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK424887 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin- Receceptor Occupancy",,['Depressive Disorder and Anxiety Disorders'],"['NK1 antagonist and SSRI', 'Healthy subjects', 'Safety', 'First time in Human']",,2006-05-25,2007-01-25,"[{'measure': 'Adverse event monitoring, vital signs (blood pressure, heart rate, ECGs, clinical laboratory assessments (standard laboratory parameters); Area under the concentration-time curve (AUC), Maximum observed concentration (Cmax) , tmax', 'timeFrame': '12 weeks'}]","[{'measure': 'Brain receptor occupancy', 'timeFrame': '2 weeks'}]",2.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,True,
NCT03226691,Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients,Plerixafor,"['Mozobil®', 'Plerixafor']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Sickle Cell Disease,"National Heart, Lung, and Blood Institute (NHLBI)",2025-09-01T16:18:07.017888,True,,,,,Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor,,['Sickle Cell Disease'],"['Plerixafor', 'Leukapheresis', 'Mobilization', 'Stem Cells', 'Sickle Cell Disease']",,2017-07-25,2019-02-27,"[{'measure': 'Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events', 'description': 'Sufficient collection of HSCs (target 2.0x106 CD34+ cells/kg) from the PB after plerixafor mobilization without serious adverse events (SAEs)', 'timeFrame': '1 day'}]",[],1.0,18 Years,,ALL,False,NIH,1.0,15.0,ACTUAL,v2_robust,True,True,False,True,
NCT03159091,Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease,Rengalin,"['Rengalin', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Obstructive Pulmonary Disease,Materia Medica Holding,2025-09-01T16:18:07.017903,True,,,,,Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease,,['Chronic Obstructive Pulmonary Disease'],[],,2017-06-16,2019-04-25,"[{'measure': 'Percentage of Patients With a Positive Treatment Response', 'description': 'Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in daytime and at night in points where 0 - no cough, 5 - continuous exhausting cough in daytime and at night. Response criterion: ≥1 lower total CSS score compared to baseline.', 'timeFrame': 'in 4 weeks of the treatment'}]","[{'measure': 'Severity of Cough After 4 Weeks Compared to Baseline', 'description': 'Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime, and at night.', 'timeFrame': 'Baseline and 4 weeks after the treatment'}, {'measure': 'Percentage of Patients With ≥50% Lesser Cough Severity at 4 Weeks', 'description': 'Number of Participants with a Decrease from Baseline of ≥50% in Cough Severity at 4 weeks. Based on the total Cough Severity Scale (CSS) score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime and at night.', 'timeFrame': 'in 4 weeks of the treatment'}, {'measure': 'Changes in Clinical Symptoms of Chronic Obstructive Pulmonary Disease (COPD)', 'description': 'Based on the total COPD Assessment Test (CAT) score. CAT consists of 8 items. Each item ranges from ""0"" to ""5"" balls. The total score ranges from minimum ""0"" to maximum ""40"" points. Higher values represent a worse outcome.', 'timeFrame': 'in 4 weeks of the treatment'}, {'measure': 'Percentage of Patients With no Exacerbation of COPD', 'description': 'COPD exacerbation is defined as an acute event characterized by aggravation of the event within 2-3 or more days. Exacerbation manifests in intensification of respiratory disorders beyond their regular daily fluctuations and require administration of products in addition to the previously prescribed basic therapy as well as a rescue drug for symptom relief (salbutamol). Additional products include antibacterial drugs, systemic corticosteroids and/or emergency therapy (ambulance call) or hospitalization for COPD exacerbation.\n\nCOPD exacerbation is recorded as an adverse event. If a COPD exacerbation develops within the first week of the subject participation in the study, it will not be considered as a secondary inefficacy criterion', 'timeFrame': 'in 4 weeks of the treatment'}]",5.0,40 Years,80 Years,ALL,False,INDUSTRY,0.0,238.0,ACTUAL,v2_robust,True,True,False,True,
NCT01333891,Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure,Phenylephrine,"['Sodium-Nitroprusside', 'Phenylephrine']",2,INTERVENTIONAL,['NA'],,TERMINATED,Healthy,Medical University of Vienna,2025-09-01T16:18:07.018096,True,,,,,Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure,,['Healthy'],[],,2012-12,,"[{'measure': 'Choroidal thickness', 'timeFrame': '18 months'}]","[{'measure': 'Systolic/diastolic blood pressure (non-invasive)', 'timeFrame': '18 months'}, {'measure': 'Intraocular pressure (IOP)', 'timeFrame': '18 months'}]",3.0,18 Years,35 Years,ALL,True,OTHER,0.0,1.0,ACTUAL,v2_robust,True,False,True,False,
NCT01175291,FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer,MK-0646,"['bevacizumab', 'Placebo', 'leucovorin', 'Fluorouracil', '5-Fluorouracil', 'MK-0646', '5-FU', 'oxaliplatin']",8,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Metastatic Colorectal Cancer,H. Lee Moffitt Cancer Center and Research Institute,2025-09-01T16:18:07.018120,True,,,,,"Randomized, Double Blind Phase II Study of FOLFOX/Bevacizumab Combined With MK-0646 Versus FOLFOX/Bevacizumab Combined With Placebo in First-Line Treatment of Metastatic Colorectal Cancer",,['Metastatic Colorectal Cancer'],"['colon', 'rectum', 'colorectal', 'metastatic', 'adenocarcinoma']",treatment deemed ineffective so accrual was closed,2010-09,2012-07,"[{'measure': 'Progression Free Survival', 'description': 'To determine whether the administration of MK-0646 with FOLFOX and bevacizumab (experimental arm) improves progression-free survival (PFS) versus FOLFOX and bevacizumab combined with placebo (control arm).', 'timeFrame': 'Average of 12 months'}]","[{'measure': 'Objective Radiographic Response', 'description': 'To determine whether the objective radiographic response (ORR) is higher in patients treated with FOLFOX and bevacizumab combined with MK-0646 (experimental arm) versus FOLFOX and bevacizumab combined with placebo (control arm).', 'timeFrame': 'Average of 12 months'}, {'measure': 'Overall Survival', 'description': 'To determine whether overall survival (OS) is higher in patients treated with FOLFOX and bevacizumab combined with MK-0646 (experimental arm) versus FOLFOX and bevacizumab combined with placebo (control arm).', 'timeFrame': 'Average of 12 Months'}, {'measure': 'Number of Participants with Adverse Events', 'description': 'To determine the safety and tolerability of MK-0646 combined with FOLFOX and bevacizumab. Safety and tolerability will be assessed according to the NIH/NCI CTC Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.', 'timeFrame': 'Average of 12 months'}]",4.0,18 Years,,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,True,treatment deemed ineffective so accrual was closed
NCT06632574,A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors,paclitaxel cationic liposomes,['paclitaxel cationic liposomes'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Advanced Solid Tumor,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",2025-09-01T16:18:07.018251,True,,,,,"A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Characteristics of Paclitaxel Cationic Liposome for Injection in the Treatment of Patients With Advanced Solid Tumors Via Transcatheter Arterial Infusion Therapy.",,['Advanced Solid Tumor'],[],,2014-03-19,2027-03-31,"[{'measure': 'The incidence of dose-limiting toxicity (DLT)', 'timeFrame': 'At the end of Cycle 1 ( each cycle is 21 days)'}, {'measure': 'Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)(according to NCI-CTCAE 5.0)', 'timeFrame': 'Up to approximately 3 years'}]","[{'measure': 'AUC0-t', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'AUC0-∞', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Cmax', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Kel', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Tmax', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Vd', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 't1/2', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'CL', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Overall response rate (ORR)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Duration of Response (DoR)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Progression-Free-Survival (PFS)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Up to approximately 3 years'}]",15.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02104674,A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma,lebrikizumab,"['montelukast [Singulair]', 'lebrikizumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Asthma,Hoffmann-La Roche,2025-09-01T16:18:07.018260,True,,,,,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA",,['Asthma'],[],,2014-06,2016-05,"[{'measure': 'Absolute change in pre-bronchodilator forced expiratory volume in 1 second (FEV1)', 'timeFrame': 'From Baseline to Week 12'}]","[{'measure': 'Relative change in morning pre-bronchodilator peak expiratory flow (PEF)', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Time to treatment failure', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Change in asthma rescue medication use', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Incidence of adverse events', 'timeFrame': 'Approximately 20 weeks'}, {'measure': 'Pharmacodynamics: Relative change in fractional exhaled nitric oxide (FeNO)', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Pharmacodynamics: Change in blood eosinophil count', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Pharmacokinetics: Maximum serum lebrikizumab concentration after the first dose (Cmax)', 'timeFrame': 'Week 1'}, {'measure': 'Change in patient-reported outcome, as measured by the Standardized Asthma Quality of Life Questionnaire (AQLQ(S))', 'timeFrame': 'From Baseline to Week 12'}]",9.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,313.0,ACTUAL,v2_robust,True,True,False,True,
NCT02775474,Does Intraoperative Methadone Prevent Postoperative Pain in Bariatric Surgery?,Use of Intraoperative Intravenous Methadone,"['Use of Intraoperative Intravenous Methadone', 'Methadone', 'Use of Intraoperative Intravenous Fentanyl']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Pain, Postoperative",University of Sao Paulo General Hospital,2025-09-01T16:18:07.018329,True,,,,,Does Intraoperative Methadone Prevent Postoperative Pain in Bariatric Surgery?,,"['Pain, Postoperative', 'Chronic Pain']","['Methadone', 'Pain, Postoperative', 'Chronic Pain', 'Bariatric Surgery']",,2016-06,2017-01,"[{'measure': 'Postoperative Pain', 'description': 'Postoperative pain will be evaluated using a verbal numerical pain scale (ranging from 0 to 10)', 'timeFrame': 'Until 3 months postoperatively'}]","[{'measure': 'Postoperative opioid consumption', 'description': 'Postoperative opioid consumption will be evaluated at fixed postoperative times: 2h, 6h, 24h, 48h, 72h and 3 months', 'timeFrame': 'Until 3 months postoperatively'}, {'measure': 'Side effects', 'description': 'Nausea, vomiting, itching, urinary retention, respiratory depression, sedation will be evaluated at fixed postoperative times: 2h, 6h, 24h, 48h, 72h and 3 months', 'timeFrame': 'Until 3 months postoperatively'}, {'measure': 'Chronic postoperative pain', 'description': 'Patients will be evaluated for chronic pain 3 months postoperatively through a questionnaire which includes questions about numerical verbal scale of pain in the last three months, analgesic consumption and satisfaction with analgesia regimen', 'timeFrame': '3 months postoperatively'}]",4.0,18 Years,65 Years,ALL,False,OTHER,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT05900674,Endovascular Stroke Treatment And Reteplase Protocol,Reteplase Injection,['Reteplase Injection'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Ischemic Stroke,Zeenat Qureshi Stroke Institute,2025-09-01T16:18:07.018357,True,,,,,Endovascular Stroke Treatment And Reteplase Protocol,,['Ischemic Stroke'],[],Sponsor,2023-07,2024-07,"[{'measure': 'Angiographic recanalization', 'description': 'Angiographic outcome will be evaluated based on post IV trial intervention CT angiogram or pre-thrombectomy angiogram and post procedure angiogram according to modified Thrombolysis in Cerebral Infarction (TICI) perfusion flow categories: 0 = No perfusion. No antegrade flow beyond the point of occlusion.\n\n1. = Perfusion past the initial obstruction but limited distal branch filling with little or slow distal perfusion\n2. A = Perfusion of less than half of the vascular distribution of the occluded artery (eg, filling and perfusion through 1 M2 division)\n\n2B = Perfusion of half or greater of the vascular distribution of the occluded artery (eg, filling and perfusion through 2 or more M2 divisions) 3 = Full perfusion with filling of all distal branches', 'timeFrame': '12 months'}, {'measure': 'Early neurological improvement', 'description': 'The proportion of patients with improvement in the NIHSS of ≥8 points or achieving a score of 0-1 at 3 days after the onset of stroke will be determined by comparing the NIHSS score at baseline and at 24 hours post enrollment.', 'timeFrame': '12 months'}, {'measure': 'Symptomatic ICH at 27 ±3hrs post randomization:', 'description': 'Any hematoma within ischemic field with some mild space occupying effect but involving ≤ 30% of the infarcted area, hematoma within ischemic field with space-occupying effect involving \\&gt;30% of the infarcted area, any intraparenchymal hemorrhage remote from the ischemic field, subarachnoid hemorrhage, or intraventricular hemorrhage associated with a 4 points or more worsening on the NIHSS within 24 hrs.', 'timeFrame': '12 months'}]","[{'measure': 'Favorable outcome (deﬁned as a mRS Scale score of 0-2) 90 days after ischemic stroke.', 'description': '0, No symptoms at all; 1, No significant disability despite symptoms; able to carry out all usual duties and activities; 2, Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance.', 'timeFrame': '12 months'}]",4.0,18 Years,90 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Sponsor
NCT02605174,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Lasmiditan 50 mg,"['Lasmiditan 100 mg', 'Placebo', 'LY573144', 'Lasmiditan 50 mg', 'Lasmiditan 200 mg']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Migraine With or Without Aura,Eli Lilly and Company,2025-09-01T16:18:07.018403,True,,,,,"A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)",,['Migraine With or Without Aura'],[],,2016-05,2017-06-30,"[{'measure': 'Percentage of Participants Headache Pain Free at 2 Hours Post Dose', 'description': 'The percentage of participants defined as mild, moderate, or severe headache pain becoming none.', 'timeFrame': '2 hours post dose'}, {'measure': 'Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free', 'description': 'The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.', 'timeFrame': '2 hours post dose'}]",[],2.0,18 Years,,ALL,False,INDUSTRY,1.0,3005.0,ACTUAL,v2_robust,True,True,False,False,
NCT00548574,"Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis",SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine,"['Mesalazine', 'SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine', 'LIALDA', 'ASACOL']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Ulcerative Colitis,Shire,2025-09-01T16:18:07.018438,True,,,,,"A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, in Subjects With Mild to Moderate Ulcerative Colitis",,['Ulcerative Colitis'],[],,2003-12-04,2004-10-20,"[{'measure': 'Percentage of subjects in remission (UC-DAI score <=1, with scores of 0 for rectal bleeding and stool frequency and a sigmoidoscopy score reduction of 1 point or more from baseline)', 'timeFrame': '8 weeks'}]","[{'measure': 'Clinical improvement as defined by a drop of => 3 points from baseline in the overall UC-DAI score', 'timeFrame': '8 weeks'}, {'measure': 'Change from baseine in UC-DAI score, symptoms, sigmoidscopy score, and PGA', 'timeFrame': '8 weeks'}, {'measure': 'Clinical remission defined as subjects who scored 0 for both the total stool frequency and the total rectal bleeding score', 'timeFrame': '8 weeks'}, {'measure': 'Treatment failure defined as unchanged, worsened missing or imcomplete UC-DAI score', 'timeFrame': '8 weeks'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,343.0,ACTUAL,v2_robust,True,True,False,False,
NCT01367574,Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction,SC MNTX,['SC MNTX'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Bowel Dysfunction,"Bausch Health Americas, Inc.",2025-09-01T16:18:07.018481,True,,,,,"A Phase II Double-Blind, Randomized, Parallel Group, Dose Ranging Study of Subcutaneous Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction",,['Bowel Dysfunction'],['Opioid-induced bowel dysfunction'],,2002-04,2003-05,"[{'measure': 'Number of subjects who have a bowel movement within four hours of dosing', 'description': 'To access the efficacy of various fixed unit doses of MNTX SC in patients with advanced medical illnesses and poorly controlled opioid-induced constipation.', 'timeFrame': 'Up to 4 weeks'}]","[{'measure': 'Number of subject with Adverse Events', 'description': 'To access the tolerability of various fixed unit doses of MNTX SC in patients with advanced medical illnesses and poorly controlled opioid-induced constipation.', 'timeFrame': 'Up to 4 weeks'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,39.0,ACTUAL,v2_robust,True,True,False,True,
NCT00236418,A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures,topiramate,['topiramate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Epilepsy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",2025-09-01T16:18:07.018526,True,,,,,Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures,,"['Epilepsy', 'Seizures']","['Epilepsy', 'Seizures', 'Topiramate', 'Prophylaxis', 'Antiepileptic', 'Tonic-clonic seizures', 'Grand mal seizures']",,1994-12,1996-12,"[{'measure': ""Percent reduction from baseline in primary generalized tonic-clonic seizure rates and percent responders (>=50% reduction in PGTC seizure rate from baseline), during the double-blind phase. Subjects' global evaluation of improvement in seizure severity.""}]","[{'measure': 'Percent reduction from baseline of all seizure types and percent of treatment responders in all seizure types, during the double-blind phase. Safety evaluations conducted throughout the study.'}]",2.0,4 Years,,ALL,False,INDUSTRY,0.0,80.0,ACTUAL,v2_robust,True,True,False,True,
NCT01895218,Treatment of Women After Postpartum Haemorrhage,Iron isomaltoside 1000,"['Iron isomaltoside 1000', 'Monofer®']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Postpartum Haemorrhage,Pharmacosmos A/S,2025-09-01T16:18:07.018671,True,,,,,"A, Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Standard Medical Care in Women After Postpartum Haemorrhage",,['Postpartum Haemorrhage'],[],,2013-06,2014-12,"[{'measure': 'Physical fatigue', 'description': 'The primary objective of this study is to compare efficacy of IV high single dose infusion of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical fatigue.', 'timeFrame': 'From exposure to 12 weeks post-exposure'}]","[{'measure': 'Change in Hb concentration', 'timeFrame': 'From exposure to week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in concentrations of p-ferritin', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in Fatigue symptoms', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in postpartum depression symptoms', 'timeFrame': 'From exposure to 12 weeks post-exposure'}, {'measure': 'Breastfeeding', 'timeFrame': 'From exposure to 12 weeks post-exposure'}, {'measure': 'RCB transfusions', 'timeFrame': 'From exposure to 12 weeks post-exposure'}, {'measure': 'Adverse drug reactions (ADRs)', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in concentrations of p-iron', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in concentrations of p-transferrin', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in concentrations of transferrin saturation (TSAT)', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in concentrations of reticulocyte count', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in concentrations of mean reticulocyte haemoglobin content (CHr)', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}, {'measure': 'Change in haematology parameters', 'timeFrame': 'From exposure to day 3, week 1, 3, 8 and 12 post-exposure'}]",14.0,18 Years,,FEMALE,False,INDUSTRY,1.0,200.0,ACTUAL,v2_robust,True,True,False,True,
NCT00463918,A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers,varenicline,"['Chantix, Champix', 'varenicline']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Smoking Cessation,Pfizer,2025-09-01T16:18:07.018781,True,,,,,"Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers",,['Smoking Cessation'],[],,2007-05,2007-12,"[{'measure': 'Pharmacokinetic parameters: Population mean estimate for apparent plasma clearance (CL/F), central volume of distribution (V2/F) and steady-state volume of distribution (Vss/F).'}]","[{'measure': 'Pharmacokinetic parameters: Individual predicted estimates of Cmax, Tmax, and AUCτ on Day 14 (steady-state) using the final PK model and individual post-hoc estimates of the PK parameters.'}]",2.0,12 Years,16 Years,ALL,True,INDUSTRY,0.0,73.0,ACTUAL,v2_robust,True,True,False,False,
NCT00245518,Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy,Isoflavone,"['Placebos', 'Isoflavone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hot Flashes,Johns Hopkins University,2025-09-01T16:18:07.018820,True,,,,,"Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy",,['Hot Flashes'],"['prostate cancer', 'soy', 'androgen deprivation', 'quality of life', 'isoflavones']",,2005-06,2008-09,"[{'measure': 'Cognitive Function as Assessed by the National Adult Reading Test (NART)', 'description': 'the NART estimates intelligence levels of English-speaking patients. It consists of 50 short words with irregular spelling or phonetic appearance which the participant must read and pronounce. The higher the score, the higher number of correct responses. Scores are 0-50.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score', 'description': 'The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, \\& 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index', 'description': 'The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, \\& 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score= higher cognitive function.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained', 'description': 'The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, and 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives.A higher score= higher cognitive function.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognitive Function as Assessed by the F-A-S Test', 'description': 'The F-A-S Test, a subtest of the Neurosensory Center Comprehensive Examination for Aphasia (NCCEA), is a measure of phonemic word fluency, which is a type of verbal fluency. It assesses phonemic fluency by requesting an individual to orally produce as many words as possible that begin with the letters F, A, and S within a prescribed time frame (1 minute)', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds)', 'description': 'The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole. A faster time, indicates greater cognitive functioning.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds)', 'description': 'The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the non-dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops', 'description': 'The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops', 'description': 'The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall', 'description': ""The test measures recognition memory for the elements of the Rey complex figure, and assesses the respondent's ability to use cues to retrieve information. Scoring of drawings is based on the widely used 36-point scoring system. Each of the 18 scoring units is scored based on accuracy and placement criteria. Items of the figure can earn points:\n\n1. Correct Image: placed properly (2 points), placed poorly (1 point)\n2. Distorted or Incomplete Image, but recognizable: placed properly (1 point), placed poorly (1/2) point\n3. Absent or not recognizable: 0 points\n\nScale ranges 0-36. with 36 being greatest cognitive function."", 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall', 'description': ""The test measures recognition memory for the elements of the Rey complex figure, and assesses the respondent's ability to use cues to retrieve information after 25-30 minutes. Scoring of drawings is based on the widely used 36-point scoring system. Each of the 18 scoring units is scored based on accuracy and placement criteria. Items of the figure can earn points:\n\n1. Correct Image: placed properly (2 points), placed poorly (1 point)\n2. Distorted or Incomplete Image, but recognizable: placed properly (1 point), placed poorly (1/2) point\n3. Absent or not recognizable: 0 points\n\nScale ranges 0-36, with 36 representing maximum cognition ."", 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score', 'description': 'The WSFQ contains 17 items that assess the domains of sexual desire/libido (6 items), arousal (1 item), orgasm/erectile function (7 items), and satisfaction(3 items). A five-point Likert-type scale ranging from ""always"" to ""never"" is used to generate a total score and four domain scores. The possible range of total sexual function scores is 17 to 85. Higher scores indicate better sexual function.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido', 'description': 'The domain of sexual desire/libido consists of 6 items. A five-point Likert-type scale ranging from ""always"" to ""never"" is used to generate a score, ranging from 6-30. Higher scores indicate increased libido/sexual desire.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function', 'description': 'The domain of erectile function/orgasm consists of 7 items. A five-point Likert-type scale ranging from ""always"" to ""never"" is used to generate a score, ranging from 7-35. Higher scores indicate increased erectile function/achievement of orgasm.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal', 'description': 'The domains of arousal (1 item subscale of the WSFQ), is assessed using a five-point Likert-type scale ranging from ""always"" to ""never"" to generate the score for arousal. The higher the number (range 1-5), the more the participant is able to experience arousal.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification', 'description': 'The domains of satisfaction (3 items), is assessed using a five-point Likert-type scale ranging from ""always"" to ""never"" to generate the score, ranging from 3-15. The higher the number, the higher the level of satisfaction with sexual function.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score', 'description': 'IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions which refer to the past 4 weeks only. The questions are split into the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The total score ranges from 6-75 with 6 being minimal erectile function and 75 representing maximal erectile function.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function', 'description': 'IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. Erectile function is one domain, making up 6 out of 15 questions. The score ranges from 1-30, with the lowest score representing minimal erectile function.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction', 'description': 'IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being satisfaction with intercourse. A score of 0-5 is awarded to each of the 3 questions which refer to the past 4 weeks only. The score rangers from 0-15, with a score of 0 indicating that no intercourse was attempted in the last 4 weeks, 1= almost or little to no sanctification, 15= very highly satisfied.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function', 'description': 'IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being satisfaction with orgasm. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 1-10, with a score of 0 indicating that no sexual stimulation or intercourse was attempted in the last 4 weeks, 1= almost never or never ejaculated, 10= almost always or always', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire', 'description': 'IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being sexual desire. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 2-10, with a score of 2 indicating very low or none at all, and 10 representing almost always/very high.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction', 'description': 'IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being sexual satisfaction. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 2-10, with a score of 2 indicating very dissatisfied and 10 being very satisfied.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS)', 'description': ""The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'."", 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component)', 'description': 'Hot flashes were assessed using symptom severity 0= none, slight=1, moderate=2, and severe = 3. Hot flashes have a weighting factor of 4 on the overall Blatt-Kuppermann index, making score ranges 0-12, with 12 being the most severe hot flashes.', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Mental Health as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Physical Health as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Fatigue as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Physical Functioning as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Body Pain as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'General Health Perceptions as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}, {'measure': 'Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire', 'description': 'The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health', 'timeFrame': 'baseline, 6 weeks, 12 weeks'}]",[],33.0,21 Years,,MALE,True,OTHER,2.0,39.0,ACTUAL,v2_robust,True,True,False,False,
NCT00352118,Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer,cisplatin,"['fluorouracil', 'cisplatinum', '5-FU', 'Adrucil', 'cisplatin', 'Platinol AQ', 'docetaxel', 'cis-diamminedichloridoplatinum', '5-fluorouracil', 'Taxotere(R)', 'CDDP']",11,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Head and Neck Cancer,"Masonic Cancer Center, University of Minnesota",2025-09-01T16:18:07.018996,True,,,,,"Phase II Pilot Study of TPF (Docetaxel, Cisplatin, and 5-FU) Induction Chemotherapy Followed by Concurrent Cisplatin and Reduced Dose Radiation in Locally Advanced Head and Neck Cancer",,['Head and Neck Cancer'],"['oral complications of radiation therapy', 'oral complications of chemotherapy', 'mucositis', 'xerostomia', 'stage III squamous cell carcinoma of the hypopharynx', 'stage IV squamous cell carcinoma of the hypopharynx', 'stage III squamous cell carcinoma of the larynx', 'stage IV squamous cell carcinoma of the larynx', 'stage III squamous cell carcinoma of the lip and oral cavity', 'stage IV squamous cell carcinoma of the lip and oral cavity', 'stage III squamous cell carcinoma of the oropharynx', 'stage IV squamous cell carcinoma of the oropharynx']",Low dose radiation treatment was not appropriate for these patients.,2006-03,2008-04,"[{'measure': 'Number of Patients With Feeding Tube Dependency', 'description': 'All patients were non-evaluable and study was terminated early. There is no measure of outcome.', 'timeFrame': 'at 12 months'}]","[{'measure': 'Number of Days With Progression-free Survival', 'description': 'All patients were non-evaluable and study was terminated early. There is no measure of outcome. Utilizing RECIST criteria.', 'timeFrame': 'Between date of registration to date of first treatment failure or death.'}, {'measure': 'Number of Days - Overall Survival', 'description': 'All patients were non-evaluable and study was terminated early. There is no measure of outcome. Utilizing RECIST criteria.', 'timeFrame': 'Between date of registration to date of death.'}, {'measure': 'Number of Days With Disease Free Survival', 'description': 'All patients were non-evaluable and study was terminated early. There is no measure of outcome. RECIST criteria measurement.', 'timeFrame': 'From Date of Registration to Date of First Treatment Failure or Death'}, {'measure': 'Time to Treatment Failure', 'description': 'All patients were non-evaluable and study was terminated early. There is no measure of outcome. Measure using RECIST criteria.', 'timeFrame': 'Number of Days from Complete or Partial Response to First Date of Recurrence or Progression'}, {'measure': 'Swallowing Ability - Quality of Life Scores', 'description': 'All patients were non-evaluable and study was terminated early. There is no measure of outcome. Utilizing Swallowing Portion of ASHA Functional Communication Measure for Swallowing (FCM) and Dysphagia Outcome and Severity Scale (DOSS).', 'timeFrame': 'Baseline, before chemoradiation, 30 days after last radiation treatment, every 3 months for the first year, then every 6 months for year 2.'}, {'measure': 'Quality of Life (QOL) by Functional Assessment of Cancer Therapy-H&N QOL Questionnaire', 'description': 'All patients were non-evaluable and study was terminated early. There is no measure of outcome.', 'timeFrame': 'baseline, before chemoradiotherapy, 1 month after the last radiation treatment, every 3 months for 1 year, and then every 6 months for 1 year'}]",7.0,18 Years,,ALL,False,OTHER,1.0,4.0,ACTUAL,v2_robust,True,False,True,False,Low dose radiation treatment was not appropriate for these patients.
NCT01528618,Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma,gemcitabine and cisplatin,"['FP', '5-Fluorouracil and cisplatin', 'GP', 'gemcitabine and cisplatin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Nasopharyngeal Neoplasms,Sun Yat-sen University,2025-09-01T16:18:07.019049,True,,,,,"A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)",,['Nasopharyngeal Neoplasms'],"['Advanced Nasopharyngeal Carcinoma', 'treatment']",,2012-02-21,2020-12-20,"[{'measure': 'Progression free survival (PFS) assessed by independent image committee and the investigators', 'timeFrame': '36 months'}]","[{'measure': 'Overall survival (OS)', 'timeFrame': '36 months'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': '36 months'}, {'measure': 'Number of Participants with Adverse Events', 'timeFrame': '36 months'}]",4.0,18 Years,,ALL,False,OTHER,0.0,362.0,ACTUAL,v2_robust,True,True,False,True,
NCT05012618,A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).,LUNA18,"['Cetuximab', 'LUNA18']",2,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Locally Advanced or Metastatic Solid Tumors,Chugai Pharmaceutical,2025-09-01T16:18:07.019067,True,,,,,"A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors",,['Locally Advanced or Metastatic Solid Tumors'],[],,2021-10-08,2026-08-31,"[{'measure': 'Safety and tolerability of LUNA18 (Dose-limiting toxicities) when administered as a single agent [Part A] and in combination with other anti-cancer drugs [Part D]', 'description': 'Incidence and nature of dose-limiting toxicities (DLTs)', 'timeFrame': 'From Cycle 0 Day 1 until Cycle 1 Day 28 (Cycle 0 is 6-9 days, and Cycle 1 is 28 days)'}, {'measure': 'Safety and tolerability of LUNA18 (Adverse Events) [Part A, AA, B, C, D and E]', 'description': 'Incidence, nature and severity of adverse events, with severity determined per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)', 'timeFrame': 'From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)'}, {'measure': 'Plasma concentrations of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]', 'description': 'Plasma concentrations of LUNA18', 'timeFrame': 'From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)'}, {'measure': 'Maximum plasma concentration (Cmax) of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]', 'description': 'Maximum plasma concentration (Cmax) of LUNA18', 'timeFrame': 'From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)'}, {'measure': 'Time to reach maximum plasma drug concentration (Tmax) of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]', 'description': 'Time to reach maximum plasma drug concentration (Tmax) of LUNA18', 'timeFrame': 'From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)'}, {'measure': 'Area under the concentration versus time curve (AUC) of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]', 'description': 'Area under the concentration versus time curve (AUC) of LUNA18', 'timeFrame': 'From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)'}, {'measure': 'Phosphorylation level of ERK protein (pERK) in tumor tissues [Part B]', 'description': 'Phosphorylation level of ERK protein (pERK) in tumor tissues biomarkers as applicable in tumor tissues', 'timeFrame': 'From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible'}, {'measure': 'Preliminary anti-tumor activity of LUNA18 when administered as a single agent [Part B, C] and in combination with other anti-cancer drugs [Part E]', 'description': 'Objective response, defined as a confirmed complete response (CR) or partial response (PR) as best overall response per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)', 'timeFrame': 'From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)'}]","[{'measure': 'Preliminary anti-tumor activity of LUNA18 when administered as a single agent [Part A, Part AA] and in combination with other anti-cancer drugs [Part D]', 'description': 'Objective response, defined as CR or PR as best overall response per RECIST v1.1', 'timeFrame': 'From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)'}, {'measure': 'Preliminary anti-tumor activity of LUNA18 [Part A, AA, B, C, D and E]', 'description': 'Disease control, defined as CR, PR and stable disease (SD) per RECIST v1.1', 'timeFrame': 'From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)'}, {'measure': 'Preliminary anti-tumor activity of LUNA18 [Part A, AA, B, C, D and E]', 'description': 'Duration of response (DoR), defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first', 'timeFrame': 'From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)'}, {'measure': 'Preliminary anti-tumor activity of LUNA18 [Part A, AA, B, C, D and E]', 'description': 'Progression free survival (PFS), defined as the time from the first study treatment to the first occurrence of progression per RECIST v1.1 or death from any cause, whichever occurs first', 'timeFrame': 'From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)'}, {'measure': 'Anti-drug antibody to LUNA18[Part A, AA, B, C, D and E]', 'description': 'Incidence of anti-LUNA18 antibodies', 'timeFrame': 'From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)'}, {'measure': 'Plasma concentrations of LUNA18 [Part B, C and E]', 'description': 'Plasma concentrations of LUNA18', 'timeFrame': 'From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)'}, {'measure': 'Phosphorylation level of ERK protein (pERK) in tumor tissues [Part A, AA, C, D, E]', 'description': 'Phosphorylation level of ERK protein (pERK) in tumor tissues biomarkers as applicable in tumor tissues', 'timeFrame': 'From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible'}]",15.0,18 Years,,ALL,False,INDUSTRY,0.0,195.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00526318,Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma,carboplatin,"['dacarbazine', 'doxorubicin hydrochloride', 'cyclophosphamide', 'ifosfamide', 'topotecan hydrochloride', 'melphalan', 'vincristine sulfate', 'cisplatin', 'carboplatin', 'etoposide phosphate', 'isotretinoin', 'vindesine']",12,INTERVENTIONAL,['NA'],,UNKNOWN,Neuroblastoma,German Society for Pediatric Oncology and Hematology GPOH gGmbH,2025-09-01T16:18:07.019077,True,,,,,Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR),,['Neuroblastoma'],"['localized resectable neuroblastoma', 'localized unresectable neuroblastoma', 'regional neuroblastoma', 'stage 4S neuroblastoma', 'disseminated neuroblastoma']",,2007-01,,[{'measure': 'Event-free survival (EFS)'}],"[{'measure': 'Overall survival (OS)'}, {'measure': 'Impact of well established clinical and molecular risk factors on EFS and OS'}, {'measure': 'Early response, measured after 2 courses of induction chemotherapy'}, {'measure': 'Response to induction therapy, measured before autologous stem cell transplantation'}, {'measure': 'Toxicity during the first 2 courses and the last 6 courses of induction chemotherapy'}, {'measure': 'Impact of the extent of initial and best surgery on outcome and frequency of complications'}, {'measure': 'Acute and late toxicity of radiotherapy'}, {'measure': 'Correlation of MIBG activity with whole-body radiation dose'}, {'measure': 'Molecular markers (MYCN and status of chromosome 1p and 11q)'}]",10.0,,21 Years,ALL,False,OTHER,0.0,360.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02920918,Treatment of Diabetes in Patients With Systolic Heart Failure,Canagliflozin,"['Sitagliptin', 'Invokana', 'Januvia', 'Canagliflozin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Heart Failure, Systolic",Virginia Commonwealth University,2025-09-01T16:18:07.019158,True,,,,,A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure,,"['Heart Failure, Systolic', 'Diabetes Mellitus, Type 2']","['Systolic Heart Failure', 'Canagliflozin', 'Sitagliptin Phosphate', 'Type 2 Diabetes', 'SGLT2 inhibitor', 'DPPIV inhibitor']",,2016-10,2018-09,"[{'measure': 'Change From Baseline Aerobic Exercise Capacity at 12 Weeks', 'description': 'Peak oxygen consumption (VO2) measured by maximal cardiopulmonary exercise test', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'Change From Baseline Ventilatory Efficiency at 12 Weeks', 'description': 'Minute ventilation (VE) relative to CO2 production (VCO2) slope measured by cardiopulmonary exercise test', 'timeFrame': 'baseline and 12 weeks'}]",[],2.0,18 Years,,ALL,False,OTHER,1.0,36.0,ACTUAL,v2_robust,True,True,False,False,
NCT06564818,"""A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder""",CYB003,"['Placebo', 'CYB003']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Major Depressive Disorder,Cybin IRL Limited,2025-09-01T16:18:07.019168,True,,,,,"A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder",,['Major Depressive Disorder'],"['Major Depressive Disorder', 'MDD', 'Psilocybin', 'Psychedelic', 'Psilocin', 'CYB003', 'CYB003-001', 'Depression']",,2024-11-15,2026-05,"[{'measure': 'Montgomery-Åsberg Depression Rating Scale (MADRS)', 'description': 'The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phrased questions about symptoms to more detailed ones allowing a precise rating of severity.', 'timeFrame': 'Screening Day-45, Baseline Day-1, Day 2, Day 10, Day 21, Day 23, Day 31, and Day 42 (End of Treatment)'}]","[{'measure': 'The Beck Depression Inventory-Second Edition (BDI-II)', 'description': 'The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.', 'timeFrame': 'Baseline Day-1, Day 21, and Day 42 (End of Treatment)'}, {'measure': 'The Clinical Global Impression Scale (CGI-S)', 'description': 'The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement, and efficacy index. Only the severity of illness and global improvement measures will be utilized for this trial.', 'timeFrame': 'Screening Day-45, Baseline Day-1, and Day 42 (End of Treatment)'}, {'measure': 'The Generalized Anxiety Disorder 7-item scale (GAD-7)', 'description': 'The Generalized Anxiety Disorder 7-item scale (GAD-7) is a 7-item self-reported assessment that measures the severity of generalized anxiety disorder symptoms.', 'timeFrame': 'Baseline Day-1, Day 21, and Day 42 (End of Treatment)'}, {'measure': 'The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)', 'description': 'The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self-reported measure used to evaluate intervention-related changes in quality of life, divided into the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.', 'timeFrame': 'Baseline Day-1, Day 21, and Day 42 (End of Treatment)'}]",5.0,18 Years,85 Years,ALL,False,INDUSTRY,1.0,220.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00277290,Study of XL999 in Patients With Previously Treated Ovarian Cancer,XL999,['XL999'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Ovarian Cancer,"Symphony Evolution, Inc.",2025-09-01T16:18:07.019217,True,,,,,A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer,,['Ovarian Cancer'],"['Cancer', 'Recurrent', 'Platinum-resistant', 'Platinum-sensitive']",Study was terminated due to cardiac toxicities in the subjects,2006-01,2006-11,"[{'measure': 'Response rate', 'timeFrame': 'Inclusion until disease progression'}, {'measure': 'Safety and tolerability', 'timeFrame': 'Inclusion until 30 days post last treatment'}]","[{'measure': 'Progression-free survival', 'timeFrame': 'Inclusion until disease progression'}, {'measure': 'Duration of response', 'timeFrame': 'Inclusion until disease progression'}, {'measure': 'Overall survival', 'timeFrame': 'inclusion until 180-Day Follow-up after last treatment or death'}, {'measure': 'Pharmacokinetic (PK) and pharmacodynamics (PD) parameters', 'timeFrame': 'Samples will be collected pre-dose and immediatelyat the end of infusion for the 8-week Study Treatment Period for subjects in the second stage of the study'}]",6.0,18 Years,,FEMALE,False,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,False,True,True,Study was terminated due to cardiac toxicities in the subjects
NCT02849990,"A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy",Abiraterone Acetate,"['Abiraterone Acetate', 'Paracort', 'ARN 509', 'Degarelix', 'Prednidib', 'JNJ 56021927', 'Deltasone', 'Ofisolona', 'Indomethacin', 'ARN-509', 'Indocin', 'Deltra', 'ARN509', 'JNJ-56021927', 'Prednisone', 'Delta 1-Cortisone', 'Delta-Dome', 'Prednitone', 'Deltison', 'Econosone', 'Prednicen-M', 'Promifen', 'Adasone', '.delta.1-Cortisone', '1, 2-Dehydrocortisone', 'Indometacin', 'Decorton', 'Deltacortisone', 'Prednilonga', 'Panafcort', 'Predicor', 'Servisone', 'DeCortin', 'Orasone', 'Predicorten', 'Dacortin', 'Meprosona-F', 'PRED', 'Meticorten', 'FE200486', 'Metacortandracin', 'Panasol-S', 'Predniment', 'Decortisyl', 'Deltacortene', 'Zytiga', 'Apalutamide', 'Cortancyl', 'Deltadehydrocortisone', 'Prednicort', 'Prednisonum', 'CB7630', 'Firmagon', 'SK-Prednisone', 'Lisacort']",55,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Stage III Prostate Adenocarcinoma AJCC v7,University of Washington,2025-09-01T16:18:07.019255,True,,,,,"A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy",,"['Stage III Prostate Adenocarcinoma AJCC v7', 'Stage III Prostate Cancer AJCC v7', 'Stage IV Prostate Adenocarcinoma AJCC v7', 'Stage IV Prostate Cancer AJCC v7']",[],,2017-03-09,2020-12-10,"[{'measure': 'Pathologic Complete Response Rate as Assessed From Prostatectomy Specimens Following Neoadjuvant Treatment', 'description': 'Pathologic complete response is defined as no evidence of cancer on fully submitted prostatectomy specimens using standard surgical pathology assessments (i.e. H\\&E assessment will be used for the purpose of defining pathologic complete response per protocol) at 3 months.', 'timeFrame': 'At 3 months'}]","[{'measure': 'Apoptotic Index (i.e. Percentage of Tumor Cells Undergoing Apoptosis)', 'description': 'Will be determined by cleaved caspase-3 immunohistochemistry.', 'timeFrame': 'At 3 months'}, {'measure': 'Number of Patients With a Negative Margin After 3 Months of Treatment', 'description': 'The absence of tumor cells at the prostate margin will be assessed using standard pathological practices on prostatectomy specimens (i.e. after 3 months of treatment).', 'timeFrame': 'At 3 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Will will report the number of participants alive at 2-years following enrollment.', 'timeFrame': 'At 2 years'}, {'measure': 'Number of Patients With a Near Pathologic Complete Response After 3 Months of Treatment', 'description': 'The near pathologic complete response will be defined as =\\< 5 mm of residual tumor as assessed on prostatectomy specimens after 3 months of treatment.', 'timeFrame': 'At 3 months'}, {'measure': 'Number of Patients With no Nodal Metastases After 3 Months of Treatment.', 'description': 'The presence of tumor cells within surgically excised lymph nodes will be assessed after 3 months of treament.', 'timeFrame': 'At 3 months'}, {'measure': 'Number of Patients With Pathologic T3 Disease After 3 Months of Treatment.', 'description': 'The presence of T3 disease (e.g. extraprostatic tumor not invading adjacent structures) will be determine from the prostatectomy specimen after 3 months of treament.', 'timeFrame': 'At 3 months'}, {'measure': 'Number of Participants Without Biochemical Failure at 2 Years', 'description': 'Prostate-specific antigen progression (i.e. biochemical failure) will be defined per the American Urological Association guidelines (i.e. confirmed prostate-specific antigen post-radical prostatectomy \\>= 0.2 ng/mL). We will report the number of patients without biochemical failure at 2 years.', 'timeFrame': 'At 2 years'}, {'measure': 'The Proportion of Men Who Receive Adjuvant Radiation Therapy', 'description': 'Patients that received radiation following prostatetomy', 'timeFrame': 'Up to 1 year post prostatectomy'}]",9.0,18 Years,,MALE,False,OTHER,2.0,22.0,ACTUAL,v2_robust,True,True,False,False,
NCT00214890,Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir,Tenofovir,"['Tenofovir', '(ABC, Ziagen)', 'Abacavir', '(TDF)']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV Infections,"University of California, San Diego",2025-09-01T16:18:07.019284,True,,,,,CCTG584: Viral Dynamics and Pharmacokinetics of Tenofovir and Abacavir Monotherapy Versus the Combination Therapy of TDF-ABC in HIV-Infected Treatment Naive Patients,,['HIV Infections'],"['HIV', 'nucleoside pharmacology', 'drug-drug interaction', 'Treatment Naive', 'Drug resistance', 'Drug pharmacokinetics']",,2004-12-07,2010-04-27,"[{'measure': 'Change in Short-term Virologic Response', 'description': 'Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) compared to the dual NRTI regimen of TDF+ABC as assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy, baseline and day 49 for dual therapy.)', 'timeFrame': '49 days'}, {'measure': 'Compare the Plasma Data of the Two Monotherapy Regimens to the Dual NRTI Regimen', 'description': 'At day 49 of Sequence 2 a 24-hour post dose plasma sample should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL plasma samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK:\n\nBlood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days\n\nPlasma NRTI and intracellular ddNTP concentrations were measured 7 days after treatment with ABC or TDF alone and were compared to levels obtained after 7 days of treatment with both drugs', 'timeFrame': '49 days'}, {'measure': 'Compare the Intracellular Pharmacokinetic (PK) Data of the Two Monotherapy Regimens to the Dual NRTI Regimen', 'description': 'At day 49 of Sequence 2 a 24-hour post dose intracellular (PBMC) should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL intracellular (PBMC) samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK:\n\nBlood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days\n\nIntracellular ddNTP concentrations were measured after 7 days on monotherapy and after 7 days on dual therapy', 'timeFrame': '49 days'}]","[{'measure': 'Evaluate Change in Cellular Regulatory Enzymes Involved With Nucleoside Analogue Transport Across Cell Membranes as Assessed by RT-PCR of Specific mRNA Transcripts', 'description': 'At day 1 and day 63 a PBMC sample for RT-PCR of nucleoside analogue transport enzymes (enzymes for efflux, influx) will be collected. The day 1 specimen should be stored and sent with day 8 PK specimens to USC. Day 63 specimen should be sent to USC after collection and processing.\n\nBlood volume: 20 mL Blood volume: 20 mL', 'timeFrame': 'Day 1 and Day 63'}, {'measure': 'Determine Total Number of NRTI-associated Mutations After 7 Days of ABC or TDF Monotherapy or After 7 Days of Dual NRTI Therapy With ABC + TDF', 'description': 'Subjects will be randomized to either TDF or ABC PO route for 7 days, which involves a fixed number of subjects. A sample size of 20 subjects (10 ABC and 10 TDF monotherapy and 20 ABC+TDF dual-therapy in HIV-positive patients). We determined the count of NRTI-associated mutations that emerged after 7 days of ABC or TDF monotherapy or after 7 days of dual NRTI therapy with ABC + TDF.', 'timeFrame': '7 days'}, {'measure': 'Compare the Relative Viral Potency of TDF Monotherapy Versus ABC Monotherapy', 'description': 'Eligible patients will be randomized into two monotherapy arms (TDF and ABC) for a short (one week) viral dynamics and pharmacokinetics evaluation to determine their potency. After a one-month washout period, all patients will start a dual-therapy of ABC+TDF. Viral dynamics and pharmacokinetics of the dual-therapy will be evaluated during the first week of the treatment. EFV will be added to the regimen after one week of the dual-therapy administered. Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy)', 'timeFrame': 'Baseline and day 7'}]",6.0,18 Years,,ALL,False,OTHER,6.0,21.0,ACTUAL,v2_robust,True,True,False,False,
NCT04147390,Immunosuppression After Repeat Keratoplasty,prescribe topical 0.03 % tacrolimus,"['prescribe mycophenolate mofetil(MMF)', 'prescribe topical 0.03 % tacrolimus']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Keratopathy,Shahid Beheshti University of Medical Sciences,2025-09-01T16:18:07.019377,True,,,,,Topical 0.03% Tacrolimus Versus Systemic Mycophenolate Mofetil for Preventing Graft Rejection After Repeat Keratoplasty: One-year Results of a Randomized Clinical Trial,,['Keratopathy'],[],,2019-11,2020-08,"[{'measure': 'graft rejection', 'description': 'clinical examination', 'timeFrame': '12 months'}]",[],1.0,18 Years,80 Years,ALL,True,OTHER,0.0,58.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06881290,Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus,Vunakizumab (IL-17A inhibitor),['Vunakizumab (IL-17A inhibitor)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,"Lupus Erythematosus, Systemic",Chinese SLE Treatment And Research Group,2025-09-01T16:18:07.019434,True,,,,,Pilot Study on the Treatment of Vunakizumab in Mild to Moderate Systemic Lupus Erythematosus,,"['Lupus Erythematosus, Systemic']","['Vunakizumab', 'Systemic lupus erythematosus']",,2025-05-19,2027-12-01,"[{'measure': 'the percentage of patients achieving an BICLA response at the end of 24 weeks', 'description': 'The BICLA response was defined as a reduction of all severe (BILAG-2004 A) or moderately severe (BILAG-2004 B) disease activity at baseline to lower levels (BILAG-2004 B, C, or D and C or D, respectively) and no worsening in other organ systems (with worsening defined as ≥1 new BILAG-2004 A item or ≥2 new BILAG-2004 B items); no worsening in disease activity, as determined by the SLEDAI-2K score (no increase from baseline) and by the PGA score (no increase of ≥0.3 points from baseline)', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}]","[{'measure': 'the percentage of patients achieving an BICLA response at the end of 12 weeks', 'description': 'The BICLA response was defined as a reduction of all severe (BILAG-2004 A) or moderately severe (BILAG-2004 B) disease activity at baseline to lower levels (BILAG-2004 B, C, or D and C or D, respectively) and no worsening in other organ systems (with worsening defined as ≥1 new BILAG-2004 A item or ≥2 new BILAG-2004 B items); no worsening in disease activity, as determined by the SLEDAI-2K score (no increase from baseline) and by the PGA score (no increase of ≥0.3 points from baseline)', 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}, {'measure': 'the percentage of patients achieving SRI-4 response at the end of 24 weeks.', 'description': ""The SRI-4 (SLE Responder Index-4) response was defined as a reduction of at least 4 points in SLEDAI score compared with the baseline level, no new British Isles Lupus Assessment Group (BILAG) A organ domain score or no more than one new BILAG B organ domain score, and no worsening in the Physician's Global Assessment (PGA) (\\<0.3 points worsening from the baseline level)."", 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'the percentage of patients achieving SRI-4 response at the end of 12 weeks.', 'description': ""The SRI-4（SLE Responder Index-4） response was defined as a reduction of at least 4 points in SLEDAI score compared with the baseline level, no new British Isles Lupus Assessment Group (BILAG) A organ domain score or no more than one new BILAG B organ domain score, and no worsening in the Physician's Global Assessment (PGA) (\\<0.3 points worsening from the baseline level)."", 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}, {'measure': 'Changes from baseline in SLEDAI at 24 weeks', 'description': 'SLEDAI stands for Systemic Lupus Erythematosus Disease Activity Index, with a score of 0-6 representing mild disease activity, 7-12 representing moderate disease activity, and 12-16 representing severe disease activity', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'Changes from baseline in CLASI at 24 weeks.', 'description': 'CLASI stands for Cutaneous Lupus Erythematosus Disease Area and Severity Index. It is a measure of the severity of skin disease, with scores ranging from 0 to 70, with higher scores indicating more severe disease activity', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'Changes from baseline in PGA at 24 weeks', 'description': ""PGA stands for Physician's Global Assessment (PGA ) . It is used to assess the activity of systemic lupus erythematosus on a scale ranging from 0 to 3, where 0 indicates no disease activity and 3 indicates the most severe disease activity."", 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'Changes from baseline of the SJC and TJC at 24 weeks', 'description': 'Swollen Joint Count(SJC) and Tender Joint Count(TJC) indicate the number of swollen and tender joints in 28 joints, respectively. 28 joints refer to both shoulders, both elbows, both wrists, both knees, 10 metacarpophalangeal joints, and 10 proximal interphalangeal joints, which ranging from 0 to 28, the higher value means more serious disease activity.', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}]",8.0,18 Years,65 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT07100990,Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX),High-dose corticosteroids (HDCS),"['Rescue Plex', 'High-dose corticosteroids (HDCS)', 'High-dose corticosteroids (HDCS) and PLEX', 'Early Plex']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Optic Neuritis,Mayo Clinic,2025-09-01T16:18:07.019520,True,,,,,"A Randomized Controlled, Open-Label, Rater-Blinded Pragmatic Trial, Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)",,"['Optic Neuritis', 'Myelitis', 'Myelitis, Transverse']","['Plasma Exchange', 'Plasmapheresis', 'Apheresis', 'Pheresis']",,2025-07-11,2031-04-30,"[{'measure': 'High contrast visual acuity', 'description': 'The Optic Neuritis subjects will have high contrast visual acuity measured by ETDRS 100% high-contrast Sloan letter charts. A high contrast visual acuity of 20/20 is considered ""normal,"" a high contrast visual acuity of 20/40 or better is required to be able to drive without restrictions, and a high contrast visual acuity of 20/200 or worse is considered legally blind.', 'timeFrame': '6 months'}, {'measure': 'Expanded Disability Status Score (EDSS)', 'description': 'The level of disability in Transverse Myelitis subjects will be assessed using the Expanded Disability Status Scale (EDSS). The EDSS assesses various neurological functional systems, including pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, and cereberal functions and ranges from 0 (normal neurological examination) to 10 (death). Higher scores indicate greater disability. Visual and cerebral functional system scores will be excluded from the EDSS calculation for quantification of Transverse Myelitis-related disability.', 'timeFrame': '6 months'}]","[{'measure': 'Low contrast (2.5%) visual acuity', 'description': 'Optic Neuritis subjects will have low contrast visual acuity (best corrected) assessed with 2.5% low-contrast Sloan letter charts', 'timeFrame': '6 months'}, {'measure': 'Peri-papillary retinal nerve fiber layer (RNFL thickness)', 'description': 'Optic Neuritis subjects will have RNFL thickness measured via Retinal Optical Coherence Tomography (OCT).', 'timeFrame': '6 months'}, {'measure': 'Macular ganglion cell-inner plexiform layer (GCIPL) thicknesses', 'description': 'Optic Neuritis subjects will have GCIPL thickness measured via Retinal Optical Coherence Tomography (OCT).', 'timeFrame': '6 months'}, {'measure': 'Hardy Rand and Rittler (HRR) color plates', 'description': 'The Hardy-Rand-Rittler (HRR) color plates test will be administered to Optic Neuritis subjects. The HRR is scored based on the number of correct responses to the diagnostic plates, with the total number of correct figures out of 28 being the primary score.', 'timeFrame': '6 months'}, {'measure': 'National Eye Institute (NEI) 10-Item Neuro-Ophthalmic Supplement', 'description': 'Optic Neuritis subjects will complete the 10-Item Neuro-Ophthalmic Supplement, a 10-item questionnaire used to assess visual dysfunction in patients with neuro-ophthalmologic disorders. It is scored on a scale of 0 to 100, with higher scores indicating better visual functioning.', 'timeFrame': '6 months'}, {'measure': 'Ambulatory disability', 'description': 'Transverse Myelitis subjects will be assessed for ambulatory disability using the Hauser Ambulation Index, a timed 25 foot, 6 minute walk.', 'timeFrame': '6 months'}, {'measure': 'Manual dexterity (Nine-Hole Peg Test)', 'description': 'The Nine-Hole Peg Test will be administered to the Transverse Myelitis subjects. Subjects will be asked to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. They will then remove the pegs, one by one, from the board as quickly as possible. Scores are based on the time taken to complete the activity and are reported in seconds.', 'timeFrame': '6 months'}, {'measure': 'Patient Determined Disease Steps (PDDS)', 'description': 'Transverse Myelitis subjects will complete the Patient-Determined Disease Steps (PDDS), a self-reported disability scale with 9 levels ranging from no disability to bedridden.', 'timeFrame': '6 months'}, {'measure': 'Spinal Cord Injury Quality of Life questionnaire (SCI-QoL)', 'description': 'Transverse Myelitis subjects will complete the The Spinal Cord Injury Quality of Life questionnaire (SCI-QoL), which includes assessments of specific domains related to bladder/bowel dysfunction, pain, pressure ulcers, mobility/ambulation, fine motor skills, self-care, and wheelchair mobility.', 'timeFrame': '6 months'}, {'measure': 'PLEX Complications', 'description': 'Total number of adverse events categorized according to the Common Terminology Criteria for Adverse Events v5.0', 'timeFrame': '2 weeks, 1 month'}, {'measure': 'National Eye Institute (NEI) Visual Function Questionnaire (VFQ)-25', 'description': 'Optic Neuritis subjects will complete the National Eye Institute Visual Functioning Questionnaire-25. The questionnaire consists of 25 items, covering 11 vision-related domains, plus a single global-rating item. Items are scored and converted to a 0- to 100-point scale where higher scores indicate better functioning.', 'timeFrame': '6 months'}]",13.0,18 Years,,ALL,False,OTHER,1.0,382.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05369390,A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity,NNC0487-0111 A,"['NNC0487-0111 A', 'NNC0487-0111 B']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Obesity,Novo Nordisk A/S,2025-09-01T16:18:07.019595,True,,,,,"Safety, Tolerability and Pharmacokinetics of NNC0487-0111 in Participants With Overweight or Obesity",,['Obesity'],['overweight'],,2022-05-11,2024-01-09,"[{'measure': 'Number of treatment emergent adverse events (TEAE)', 'description': 'Number of events', 'timeFrame': 'Part A: From pre-dose on Day 1 to 22 days; Part B: From pre-dose on Day 1 to 31 days; Part C and D: From pre-dose on Day 1 to 105 days'}]","[{'measure': 'Part A: AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose', 'description': 'Hours\\*Nanomoles per liter (h\\*nmol/L)', 'timeFrame': 'From pre-dose on Day 1 until completion of the end of study visit (Day 22)'}, {'measure': 'Part A: Cmax,SD; the maximum plasma concentration of NNC0487- 0111 after a single dose', 'description': 'Nanomoles per liter (nmol/L)', 'timeFrame': 'From pre-dose on Day 1 until completion of the end of study visit (Day 22)'}, {'measure': 'Part B: AUC0-24h,MD; the area under the NNC0487-011 plasma concentration-time curve from time 0 to 24 hours after last multiple dose', 'description': 'h\\*nmol/L', 'timeFrame': 'From pre-dose on Day 10 until Day 11 (24 hours post-dose)'}, {'measure': 'Part B: Cmax,MD; the maximum plasma concentration of NNC0487- 0111 after last multiple dose', 'description': 'nmol/L', 'timeFrame': 'From pre-dose on Day 10 until Day 22'}, {'measure': 'Part C and D: AUC0-24h,MD; the area under the NNC0487-011 plasma concentration-time curve from time 0 to 24 hours after last multiple dose', 'description': 'h\\*nmol/L', 'timeFrame': 'From pre-dose on Day 84 until Day 85 (24 hours post-dose)'}, {'measure': 'Part C and D: Cmax,MD; the maximum plasma concentration of NNC0487- 0111 after last multiple dose', 'description': 'nmol/L', 'timeFrame': 'From pre-dose on Day 84 until completion of the end of study visit (Day 105)'}]",7.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,144.0,ACTUAL,v2_robust,True,True,False,True,
NCT04149990,Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI,Entresto Pill,"['Entresto Pill', 'Valsartan+ sacubitril']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Myocardial Infarction,Jacob Moller,2025-09-01T16:18:07.019616,True,,,,,Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI,,"['Myocardial Infarction', 'Diastolic Dysfunction']",[],Low recruitment,2018-10-12,2023-06-06,"[{'measure': 'Central hemodynamics', 'description': 'The primary endpoint will be the ratio of mean PCWP at peak exercise divided by cardiac index at peak exercise.', 'timeFrame': '26 weeks'}]","[{'measure': 'cardiac MRI', 'description': 'Amount of hyperenhancement on cardiac MRI using a semiquantitative assessment of late gadolinium hyperenhancement in a 17 segment model of the LV.', 'timeFrame': '26 weeks'}, {'measure': 'Biomarker 1', 'description': 'ST2 concentration at rest.', 'timeFrame': '26 weeks'}, {'measure': 'Biomarker 2', 'description': 'MR-proANP at rest.', 'timeFrame': '26 weeks'}, {'measure': 'Biomarker 3', 'description': 'NT-proBNP at rest.', 'timeFrame': '26 weeks'}, {'measure': 'Echocardiographic 1', 'description': 'Left atrial volume by echocardiography and left atrial emptying fraction by echocardiography at rest.', 'timeFrame': '26 weeks'}, {'measure': 'Echocardiographic 2', 'description': 'Proportion of patients with moderate or severe diastolic dysfunction at rest.echocardiography at rest.', 'timeFrame': '26 weeks'}]",7.0,50 Years,,ALL,False,OTHER,3.0,51.0,ACTUAL,v2_robust,True,False,True,False,Low recruitment
NCT06922890,"First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury",STUP-001,['STUP-001'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Spinal Cord Injury,Yonsei University,2025-09-01T16:18:07.019632,True,,,,,"A Single-center, Prospective Investigator-initiated Trial to Evaluate the Safety and Exploratory Efficacy of STUP-001 in Patients With Chronic Spinal Cord Injury of AIS-A or B Level",,"['Spinal Cord Injury', 'Chronic Spinal Cord Injury']","['Direct Lineage Reprogramming', 'Cell Fate Conversion', 'First-in-Human Multi-Cistronic Vector Application']",,2025-07-30,2027-12-31,"[{'measure': 'Dos-limit toxicity evaluation post STUP-001 administration', 'description': 'National Cancer Institute-Comone Terminology Criteria for Adverse Events V5.0 (NCI-CTCAE V5.0)', 'timeFrame': '4weeks post STUP-001 administration'}]",[],1.0,19 Years,60 Years,ALL,False,OTHER,1.0,9.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00473590,A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER),Bevacizumab,"['Bortezomib', 'Bevacizumab', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Multiple Myeloma,"Genentech, Inc.",2025-09-01T16:18:07.019647,True,,,,,"A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma",,['Multiple Myeloma'],"['Avastin', 'AMBER', 'Myeloma', 'Velcade']",,2007-06,2009-11,"[{'measure': 'Progression-free Survival (PFS)', 'description': ""Progression-free survival (PFS) was defined as the time from randomization to disease progression or death on study from any cause within 30 days of the last response assessment. Disease progression was determined by the investigator using the International Myeloma Working Group's (IMWG) uniform response criteria. Median PFS was estimated using Kaplan-Meier methodology. For patients who were alive at the time of the analysis and whose disease had not yet progressed, PFS was censored at the time of the last response assessment."", 'timeFrame': 'From randomization to disease progression or death on study (up to 116 weeks).'}]","[{'measure': 'Number of Participants With an Overall Response', 'description': ""Overall response was defined as a stringent complete response, complete response, very good partial response, or partial response (sCR, CR, VGPR, and PR, respectively) determined on two consecutive assessments ≤ 6 weeks apart and before the initiation of any new anti-tumor therapy, as assessed by the investigator using the International Myeloma Working Group's (IMWG's) uniform response criteria. Patients without a post-baseline response assessment or who died prior to their first scheduled response assessment were considered non-responders."", 'timeFrame': 'From randomization to the end of study (clinical cut-off; up to 116 weeks).'}, {'measure': 'Percentage of Participants With an Overall Response', 'description': ""Overall response was defined as a stringent complete response, complete response, very good partial response, or partial response (sCR, CR, VGPR, and PR) determined on two consecutive assessments ≤ 6 weeks apart and before the initiation of any new anti-tumor therapy, as assessed by the investigator using the IMWG's uniform response criteria. Patients without a post-baseline response assessment or who died prior to their first scheduled response assessment were considered non-responders."", 'timeFrame': 'From randomization to the end of study (clinical cut-off; up to 116 weeks).'}, {'measure': 'Duration of Response', 'description': ""Duration of response was defined as the time from the initial response to disease progression or death on study. Disease progression was determined by the investigator using the IMWG's uniform response criteria and defined as an increase of ≥25% from best response in: Serum M-protein and/or Urine M-protein and/or Marrow plasma cells; or new or increased plasmacytomas or bone lesions; or hypercalcemia due to myeloma. Duration of response was estimated using Kaplan-Meier. For patients who had not progressed or died, duration of response was censored at the date of the last response assessment."", 'timeFrame': 'From randomization to the end of study (clinical cut-off; up to 116 weeks).'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall survival was defined as the duration of time from randomization until death from any cause. All deaths were included, whether they occurred on study treatment or following treatment discontinuation. Overall survival was estimated using Kaplan-Meier. For patients who had not died, overall survival was censored at the date that the patient was last known to be alive.', 'timeFrame': 'From randomization until death from any cause, up until the end of study (clinical cut-off; up to 116 weeks).'}, {'measure': 'Number of Participants With Selected Adverse Events (AEs)', 'description': 'Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0. All serious adverse events are listed in the Adverse Event Reporting section.', 'timeFrame': 'Participants were monitored for AEs from initiation of treatment to 30 days after treatment termination (up to 122 weeks).'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,102.0,ACTUAL,v2_robust,True,True,False,True,
NCT00230490,Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201,pradefovir mesylate,"['pradefovir mesylate', 'adefovir dipivoxyl']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,"Hepatitis B, Chronic","Bausch Health Americas, Inc.",2025-09-01T16:18:07.019708,True,,,,,Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201,,"['Hepatitis B, Chronic']","['Hepatitis B, Chronic', 'Hepatitis B Virus', 'Pradefovir Mesylate', 'Adefovir Dipivoxyl']",Adverse findings from nonclinical carcinogenicity studies.,2005-06,2007-05,"[{'measure': '- Safety: Clinical examinations of laboratory tests'}, {'measure': '- Efficacy: Change in viral load over time'}]",[{'measure': '- Efficacy: Proportion of patients with undetectable viral load'}],3.0,18 Years,60 Years,ALL,False,INDUSTRY,0.0,150.0,,v2_robust,True,False,True,True,Adverse findings from nonclinical carcinogenicity studies.
NCT01039090,Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease,Continuous Apomorphine infusion,"['Usual dopaminergic per os treatment', 'Continuous Apomorphine infusion']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Parkinsons's Disease,Rennes University Hospital,2025-09-01T16:18:07.019759,True,,,,,"Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study",,"[""Parkinsons's Disease""]","['Not eligible for deep brain stimulation', ""Parkinsons's patients""]",,2009-02,2015-02,"[{'measure': 'Neuropsychological results: Montgomery-Åsberg Depression Rating Scale (MADRS), The Lille Apathy Rating Scale (LARS), Spielberger', 'timeFrame': '6 months'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,21.0,ACTUAL,v2_robust,True,True,False,False,
NCT01169090,"A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy",SK-0403,"['Sitagliptin', 'Placebo', 'SK-0403']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Type 2 Diabetes,"Kowa Research Institute, Inc.",2025-09-01T16:18:07.019778,True,,,,,"A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Phase 2 Dose Finding Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy",,['Type 2 Diabetes'],[],,2010-07,2011-08,"[{'measure': 'Change in HbA1c from baseline to Week 16.', 'description': 'Change in HbA1c from baseline to Week 16 with last observation carried forward (LOCF).', 'timeFrame': 'Baseline, 16 weeks'}]","[{'measure': 'Change from baseline in Fasting Plasma Glucose (FPG)', 'timeFrame': 'Baseline, 16 weeks'}]",2.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,620.0,ESTIMATED,v2_robust,True,True,False,False,
NCT03109990,A Pilot Study to Evaluate the Impact of Dexmedetomidine on Breast Cancer Recurrence After Surgery,Dexmedetomidine,"['Saline', 'Dexmedetomidine']",2,INTERVENTIONAL,['NA'],,COMPLETED,Breast Cancer,RenJi Hospital,2025-09-01T16:18:07.019786,True,,,,,A Pilot Study to Evaluate the Impact of Dexmedetomidine on Postoperative Tumor Recurrence in Patients With Primary Breast Cancer,,['Breast Cancer'],[],,2016-05,2021-09-30,"[{'measure': 'study feasibility', 'description': 'recruitment and dropout rates', 'timeFrame': 'from May 2015 to August 2019'}]","[{'measure': 'recurrence-free survival', 'description': 'time from surgery to the earliest date of recurrence/metastasis', 'timeFrame': 'up to 5 years after surgery'}, {'measure': 'overall survival', 'description': 'time from surgery to the date of all-cause death', 'timeFrame': 'up to 5 years after surgery'}, {'measure': 'the number of blood CD3+ cells', 'timeFrame': 'at 24 hours after surgery'}, {'measure': 'the number/percentage of blood CD4+ cells', 'timeFrame': 'at 24 hours after surgery'}, {'measure': 'the number/percentage of blood CD8+ cells', 'timeFrame': 'at 24 hours after surgery'}, {'measure': 'the number/percentage of blood NK cells', 'timeFrame': 'at 24 hours after surgery'}, {'measure': 'the ratio of CD4+ cells / CD8+ cells', 'timeFrame': 'at 24 hours after surgery'}, {'measure': 'the number/percentage of blood CD19+ cells', 'timeFrame': 'at 24 hours after surgery'}]",9.0,18 Years,75 Years,FEMALE,False,OTHER,0.0,148.0,ACTUAL,v2_robust,True,True,False,False,
NCT01315990,FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema,FOLFIRI + Cetuximab,['FOLFIRI + Cetuximab'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Colorectal Cancer Metastatic,Dr. Carl Schimanski,2025-09-01T16:18:07.019802,True,,,,,Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema,,['Colorectal Cancer Metastatic'],"['Phase IV Study', 'Metastatic Colorectal Cancer (mCRC', 'Cetuximab (Erbitux)', 'first-line treatment', 'acneiform follicular exanthema', 'rash', 'vitamin K1']",,2011-01,2018-03,"[{'measure': 'Progression-free survival', 'description': 'Progression-free survival rate at 12 months', 'timeFrame': '12 months'}]","[{'measure': 'Progression-free survival', 'timeFrame': 'up to end of follow-up-phase (36 months)'}, {'measure': 'ORR', 'description': 'Objective response rate over the entire treatment period', 'timeFrame': 'approximately 12 months'}, {'measure': 'OS', 'description': 'Overall survival time', 'timeFrame': 'The time from regsitration date to the date of death'}, {'measure': 'Duration until development of acneiforme follicular exanthema >= grade 2', 'description': 'Duration until development of acneiforme follicular exanthema \\>= grade 2 during treatment-phase', 'timeFrame': 'approximately 12 months'}, {'measure': 'Development of paronychia', 'description': 'Development of paronychia during treatment-phase', 'timeFrame': 'approximately 12 months'}, {'measure': 'Development of skin fissure (hand and foot)', 'description': 'Development of skin fissure (hand and foot) during treatment-phase', 'timeFrame': 'approximately 12 months'}, {'measure': 'Rate of secondary resections of metastasis of liver with a curative approach', 'description': 'Rate of secondary resections of metastasis of liver with a curative approach during treatment-phase', 'timeFrame': 'approximately 12 months'}, {'measure': 'Assessment of safety and tolerability', 'description': 'Assessment of safety and tolerability during treatment phase', 'timeFrame': 'approximately 12 months'}, {'measure': 'Development of acneiforme follicular exanthema >= grade2', 'description': 'Development of acneiforme follicular exanthema \\>= grade2 during treatment phase', 'timeFrame': 'approximately 12 months'}]",10.0,18 Years,,ALL,False,OTHER,0.0,165.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03572790,Effects of Seven Day Prucalopride Administration in Healthy Volunteers,Prucalopride,"['Resolor', 'Prucalopride']",2,INTERVENTIONAL,['NA'],,COMPLETED,Molecular Mechanisms of Pharmacological Action,University of Oxford,2025-09-01T16:18:07.019822,True,,,,,The Effect of Seven Day Prucalopride Administration on Emotional Processing in Healthy Volunteers,,"['Molecular Mechanisms of Pharmacological Action', 'Depression', 'Depressive Disorder', 'Mood Disorders', 'Mental Disorders', 'Antidepressive Agents', 'Cognition']","['5-HT4', 'Prucalopride', 'Resolor', 'Functional Magnetic Resonance Imaging (fMRI)', 'Emotional Processing', 'Healthy Volunteers']",,2018-06-11,2019-05-17,"[{'measure': 'Recognition of positive and negative facial expressions', 'description': 'Accuracy to recognise positive and negative facial expressions (anger, disgust, fear, happy , sad, surprise)', 'timeFrame': 'Completed on Day 7'}, {'measure': 'Performance on Auditory Verbal Learning Task (AVLT)', 'description': 'Accuracy on AVLT (number of items recalled across blocks)', 'timeFrame': 'Completed on Day 7'}]","[{'measure': 'Neural response to emotional faces', 'description': 'Blood Oxygen Level Dependent (BOLD) signal in a network including the amygdala, anterior cingulate cortex, and orbitofrontal cortex', 'timeFrame': 'Completed on Day 6'}, {'measure': 'Neural response to novel vs repeated scenes', 'description': 'BOLD signal to scenes that have previously been seen compared to novel scenes in a network including the hippocampus and parahippocampal regions', 'timeFrame': 'Completed on Day 6'}, {'measure': 'Reward sensitivity', 'description': 'Sensitivity to reward as measured by the Probabilistic Instrumental Learning Task (PILT)', 'timeFrame': 'Completed on Day 7'}, {'measure': 'Categorisation, recall, and recognition of emotional words', 'description': 'Accuracy and reaction time to categorise positive and negative descriptor words; number of words correctly (hits) and incorrectly (false alarms) recalled and recognised', 'timeFrame': 'Completed on Day 7'}, {'measure': 'Vigilance to fearful and happy faces on the Facial Dot Probe Task (FDOT)', 'description': 'Vigilance derived from reaction time', 'timeFrame': 'Completed on Day 7'}, {'measure': 'Resting state connectivity', 'description': 'Resting state connectivity (using resting state fMRI) including the default mode network, salience network, affective network, and limbic system, identified via correlations between spontaneous BOLD activity in spatially independent regions while participants are not actively engaged in an experimental task', 'timeFrame': 'Completed on Day 6'}, {'measure': 'Relative and global cerebral blood flow', 'description': 'Arterial spin labelling (ASL) global and cerebral blood flow', 'timeFrame': 'Completed on Day 6'}, {'measure': 'Visual short term memory on the Oxford Memory Test (OMT)', 'description': 'Proportion of correct probe selections, absolute error for probe location, reaction time, and proportion of misbinding errors', 'timeFrame': 'Completed on Day 7'}]",10.0,18 Years,40 Years,ALL,True,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT06995690,Ketamine for Preventing Post-Spinal Hypotension in Orthopedic Surgery,Ketamine,"['Ketamine', 'Normal Saline']",2,INTERVENTIONAL,['NA'],,RECRUITING,Post-spinal Hypotension,Ain Shams University,2025-09-01T16:18:07.019847,True,,,,,Impact of Sub-anesthetic Dose of Ketamine in the Prevention of Post Spinal Hypotension in Patients Undergoing Orthopedic Surgeries,,"['Post-spinal Hypotension', 'Orthopedic Surgery', 'Spinal Aneshtesia']","['Ketamine', 'Sub-anesthetic dose', 'Hypotension prevention', 'Neuraxial anesthesia', 'Hemodynamic stability', 'regional anesthesia', 'ASA I-II', 'Double-blind randomized trial', 'Blood pressure monitoring', 'Ephedrine use']",,2025-06-01,2025-11-01,"[{'measure': 'Incidence of Post-Spinal Hypotension', 'description': 'Hypotension is defined as a mean arterial pressure (MAP) less than 20% below baseline. MAP will be calculated using the formula: MAP = DBP + (SBP - DBP)/3.\n\nHypotension will be treated with boluses of IV Ephedrine (3mg) and repeated if needed. The total dose of ephedrine required to correct hypotension and raise the MAP to the baseline will be recorded.', 'timeFrame': 'From spinal injection to end of surgery'}]","[{'measure': 'Incidence of Hallucinations', 'description': 'Visual or auditory disturbances post ketamine administration. Midazolam (2 mg IV) will be given pre-injection to mitigate risk.', 'timeFrame': 'From spinal injection to end of surgery'}, {'measure': 'Incidence of Bradycardia', 'description': 'Bradycardia is defined as Heart Rate less than 50 beats per minute. Bradycardia will be treated with IV atropine (0.04 mg/kg) and repeated if needed.', 'timeFrame': 'From spinal injection to end of surgery'}, {'measure': 'Incidence of Nausea and Vomiting', 'description': 'Nausea is defined as an unpleasant subjective urge to vomit and Vomiting is defined as propulsive abdominal muscular spasms associated with the expulsion of gastric contents.\n\nNausea and vomiting will be treated with 3 mg IV Granisetron.', 'timeFrame': 'From spinal injection to end of surgery'}]",4.0,18 Years,,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05282797,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test",ANEB-001,"['ANEB-001', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acute Cannabinoid Intoxication,Anebulo Pharmaceuticals,2025-09-01T16:18:07.019890,True,,,,,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of CB1 Antagonist ANEB-001 in Healthy Occasional Cannabis Users in a THC Challenge Test.",,['Acute Cannabinoid Intoxication'],[],,2021-12-15,2023-08-26,"[{'measure': 'Subjective Feeling High', 'description': 'Feeling High on a visual analog scale (mm)', 'timeFrame': 'Day 1'}, {'measure': 'Postural stability', 'description': 'Body sway (mm);', 'timeFrame': 'Day 1'}, {'measure': 'Subjective Alertness', 'description': 'Alertness on a visual analog scale (mm)', 'timeFrame': 'Day 1'}, {'measure': 'Heart Rate', 'description': 'Heart Rate in beats/min', 'timeFrame': 'Day 1'}]","[{'measure': 'Subjective Mood', 'description': 'Mood on a visual analog scale (mm)', 'timeFrame': 'Day 1'}, {'measure': 'Subjective Calmness', 'description': 'Calmness on a visual analog scale (mm)', 'timeFrame': 'Day 1'}, {'measure': 'Feeling of Drug Effect', 'description': 'Feeling of drug effect on a visual analog scale (mm)', 'timeFrame': 'Day 1'}, {'measure': 'Symbol Digit Substitution Test (SDST)', 'description': 'Part C Only', 'timeFrame': 'Day 1'}, {'measure': 'Visual Verbal Learning Test (VVLT)', 'description': 'Part C Only', 'timeFrame': 'Day 1'}, {'measure': 'Timed Up-and-Go test (TUG)', 'description': 'Part C Only', 'timeFrame': 'Day 1'}, {'measure': 'Alternate Finger Tapping (AFT)', 'description': 'Part C Only', 'timeFrame': 'Day 1'}, {'measure': 'Basic Symptom Inventory (BSI)', 'description': 'Part C Only', 'timeFrame': 'Day 1'}, {'measure': 'Brief Psychiatric Rating Scale (BPRS)', 'description': 'Part C Only', 'timeFrame': 'Day 1'}, {'measure': 'Clinical Global Impression of Severity (CGIS)', 'description': 'Part C Only', 'timeFrame': 'Day 1'}]",14.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,154.0,ACTUAL,v2_robust,True,True,False,False,
NCT00129597,Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy,ketalar,['ketalar'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Pain,Hospices Civils de Lyon,2025-09-01T16:18:07.019912,True,,,,,Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy,,"['Pain', 'Breast Cancer']","['Ketalar', 'NMDA', 'mastectomy', 'postoperative chronic pain', 'Chronic pain after mastectomy for breast cancer']",,2004-12,,"[{'measure': 'To evaluate the effect of perioperative ketalar on pain intensity 3 months after a mastectomy'}, {'measure': 'Pain intensity is evaluated by an appropriate questionnaire 1 and 3 months after surgery.'}]","[{'measure': 'To evaluate the incidence of chronic pain after mastectomy, the impact on life quality, and the area of hyperalgesia'}]",3.0,18 Years,80 Years,FEMALE,False,OTHER,0.0,40.0,,v2_robust,True,False,False,False,
NCT00276497,Role of Pioglitazone in Preventing Diabetes,Pioglitazone,['Pioglitazone'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Diabetes,M.V. Hospital for Diabetes,2025-09-01T16:18:07.019921,True,,,,,,,['Diabetes'],"['Impaired glucose tolerance', 'Intervention', 'Prevention']",,2003-10,2008-05,[{'measure': 'Reduction in conversion of IGT to diabetes'}],[{'measure': 'benefits of the drug on anthropometric variables and biochemical parameters'}],2.0,35 Years,55 Years,ALL,True,OTHER,1.0,,,v2_robust,True,True,False,False,
NCT00091897,Rituximab to Treat Stiff Person Syndrome,Rituximab,"['Rituxan', 'Rituximab', 'rituximab or placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Stiff Person Syndrome,National Institute of Neurological Disorders and Stroke (NINDS),2025-09-01T16:18:07.019935,True,,,,,Efficacy of Rituximab in Patients With Stiff Person Syndrome With Anti-GAD Antibodies: A Randomized Placebo-Controlled Trial,,['Stiff Person Syndrome'],"['RITUXAN', 'GABA', 'B Cells', 'Humanized Monoclonal Antibodies', 'GAD', 'Stiff Person Syndrome', 'SPS']",,2004-09,2009-05,"[{'measure': 'To evaluate the efficacy, safety of the chimeric monoclonal antibody Rituximab to deplete B lymphocytes in patients with Stiff Person Syndrome with high anti-GAD antibodies.', 'timeFrame': '2 Years'}]","[{'measure': 'The Heightened Sensitivity Scale will be used as a secondary outcome measure.', 'timeFrame': '2 Years'}]",2.0,25 Years,80 Years,ALL,False,NIH,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,
NCT07001397,Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA,EPAG-pfos,['EPAG-pfos'],1,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Aplastic Anemias,Peking Union Medical College Hospital,2025-09-01T16:18:07.019942,True,,,,,Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA,,['Aplastic Anemias'],"['Aplastic anemia', 'rhTPO', 'EPAG-pfos']",,2025-06-23,2027-03-23,"[{'measure': 'overall response rate', 'timeFrame': '1 month, 3 month'}]",[],1.0,,,ALL,False,OTHER,0.0,70.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01488097,"Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency",sebelipase alfa,"['Kanuma®', 'sebelipase alfa', 'SBC-102']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cholesterol Ester Storage Disease (CESD),"Alexion Pharmaceuticals, Inc.",2025-09-01T16:18:07.020028,True,,,,,"An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01",,"['Cholesterol Ester Storage Disease (CESD)', 'Lysosomal Acid Lipase Deficiency', 'LAL-Deficiency']","['Enzyme replacement therapy (ERT)', 'Lysosomal storage disease', 'Late onset lysosomal acid lipase (LAL) deficiency', 'Acid cholesteryl ester hydrolase deficiency, type 2', 'Acid lipase disease', 'Cholesterol ester hydrolase deficiency', 'LAL deficiency', 'LIPA enzyme deficiency']",,2011-12-12,2017-06-21,"[{'measure': 'Number Of Participants Reporting TEAEs And IARs', 'description': 'Safety and tolerability of sebelipase alfa was primarily assessed by monitoring the number of participants reporting treatment-emergent adverse events (TEAEs), including serious adverse events, and infusion-associated reactions (IARs). The number of participants who discontinued from the study due to a TEAE is also presented. An IAR was defined as any adverse event that occurred during the 2-hour infusion or within 4 hours after the end of the infusion and was assessed by the investigator as at least possibly related to study drug. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. TEAEs that occurred after the first dose administration at Week 1 through the End of Study (EOS) are presented. End of study was 30 days (+ 7 days) after the last dose of study drug (at Week 260).', 'timeFrame': 'From after first dose administration post-Baseline through EOS during study LAL-CL04'}]","[{'measure': 'Changes From Baseline In ALT And AST', 'description': 'Changes from Baseline to Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS for alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Baseline values were defined as the last measurement prior to the first infusion of sebelipase alfa in Study LAL-CL04.', 'timeFrame': 'Baseline, Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS'}, {'measure': 'Changes From Baseline In Liver Volume', 'description': 'Changes in liver volume from Baseline to Week 10 or 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS was assessed by magnetic resonance imaging (MRI). Baseline values were defined as the last measurement prior to the first infusion of sebelipase alfa in Study LAL-CL04. Liver volume was expressed as multiples of normal (MN), where normal is defined as 2.5% of body weight.', 'timeFrame': 'Baseline, Week 10 or 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS'}, {'measure': 'Changes From Baseline In Liver Fat Content', 'description': 'Changes in liver fat content from Baseline to Week 10 or 12, Week 24, Week 52, Week 104, Week 156, Week 208, and Week 260, as assessed by multi-echo gradient-echo MRI. Baseline values were defined as the last measurement prior to the first infusion of sebelipase alfa in Study LAL-CL04.', 'timeFrame': 'Baseline, Week 10 or 12, Week 24, Week 52, Week 104, Week 156, Week 208, and Week 260'}, {'measure': 'Changes From Baseline In GGT And ALP', 'description': 'Changes from Baseline to Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS for gamma glutamyltransferase (GGT) and alkaline phosphatase (ALP). Baseline values were defined as the last measurement prior to the first infusion of sebelipase alfa in Study LAL-CL04.', 'timeFrame': 'Baseline, Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS'}, {'measure': 'Changes From Baseline In Serum Lipids', 'description': 'Lipid changes from Baseline to Week 10 or 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS were measured in serum for total cholesterol (Total-C), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), and triglycerides (TG). Baseline values were defined as the last measurement prior to the first infusion of sebelipase alfa in Study LAL-CL04.', 'timeFrame': 'Baseline, Week 10 or 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS'}, {'measure': 'Changes From Baseline In Serum Ferritin', 'description': 'Changes from Baseline to Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS for serum ferritin. Baseline values were defined as the last measurement prior to the first infusion of sebelipase alfa in Study LAL-CL04.', 'timeFrame': 'Baseline, Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS'}, {'measure': 'Changes From Baseline In Hs-CRP', 'description': 'Changes from Baseline to Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS for high sensitivity C-reactive protein (hs-CRP). Baseline values were defined as the last measurement prior to the first infusion of sebelipase alfa in Study LAL-CL04.', 'timeFrame': 'Baseline, Week 12, Week 24, Week 52, Week 104, Week 156, Week 208, Week 260, and EOS'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,8.0,ACTUAL,v2_robust,True,True,False,True,
NCT01406197,Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor,Experimental: Vaginal progesterone,"['No other name available', 'Experimental: Topical progesterone', 'Experimental: Vaginal progesterone', 'Watson Laboratories', 'Prochieve, Columbia Laboratories', 'Experimental: Intramuscular progesterone']",6,INTERVENTIONAL,['NA'],,WITHDRAWN,Preterm Labor,"St. Joseph's Hospital and Medical Center, Phoenix",2025-09-01T16:18:07.020051,True,,,,,Uterine Abdominal Electromyography Measurements Before and After Progesterone Treatments for Preterm Labor,,['Preterm Labor'],"['Progesterone', 'Progestins', 'Preterm labor', 'Premature birth', 'Uterine electromyography', 'Uterine contractility']",Investigator left organization prior to study initiation,2011-07,2013-10,"[{'measure': 'Inhibition of uterine electromyographic (EMG) activity by various formulations of progesterone.', 'description': 'Uterine electrical activity will be recorded (for 30 minutes at each time point) from the abdominal surface of pregnant patients before (30 minutes before treatment) and following treatment (at 2, 4, 8, 12, 24 and up to 48 hours) with either vehicles or progesterone treatments to evaluate if the treatments reduce EMG activity and therefore may be potential candidates for possible interventions for treating a preterm labor.', 'timeFrame': 'EMG will be measured at various times including 0 time pretreatment and up to 48 hours after treatments'}]","[{'measure': 'Effects of progesterone on uterine EMG activity and preterm birth', 'description': 'Secondary measures: Patients will be followed (up to 16 weeks) until delivery by vaginal or Cesarian section to see if any intervention (progesterone treatment) affects timing of birth.', 'timeFrame': 'Various times after treatments up to 16 weeks to determine when the patients deliver'}]",2.0,17 Years,40 Years,FEMALE,True,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Investigator left organization prior to study initiation
NCT00167297,Atomoxetine for the Treatment of Cannabis Dependence,Atomoxetine,['Atomoxetine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cannabis Dependence,National Institute on Drug Abuse (NIDA),2025-09-01T16:18:07.020080,True,,,,,A Pilot Trial of Atomoxetine to Enhance Motivational Interviewing Therapy for the Treatment of Cannabis Dependence,,['Cannabis Dependence'],"['atomoxetine', 'cannabis dependence', 'treatment']",,2004-11,2005-07,"[{'measure': 'Marijuana use in patients treated with atomoxetine and Motivational Interviewing Therapy measured using weekly urine drug screens.', 'timeFrame': '8 weeks'}]","[{'measure': 'Tolerability of atomoxetine: Tolerability will be assessed by examining the rates of certain adverse events during the treatment phase.', 'timeFrame': '8 weeks'}]",2.0,18 Years,65 Years,ALL,False,NIH,1.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT04436497,HEALEY ALS Platform Trial - Regimen A Zilucoplan,Zilucoplan,"['Zilucoplan', 'Matching Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Amyotrophic Lateral Sclerosis,"Merit E. Cudkowicz, MD",2025-09-01T16:18:07.020128,True,,,,,HEALEY ALS Platform Trial - Regimen A Zilucoplan,,['Amyotrophic Lateral Sclerosis'],"['ALS', 'Placebo-Controlled', 'Double-Blind', 'Regimen-Specific Appendix', ""Lou Gehrig's Disease"", 'Zilucoplan', 'Ra Pharmaceuticals']",,2020-07-29,2022-05-04,"[{'measure': 'Disease Progression as Assessed by the ALSFRS-R Total Score', 'description': 'Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality. Each of 12 questions assessing distinct functional ability is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.', 'timeFrame': 'Baseline through 24 Weeks'}, {'measure': 'Mortality Event Rate', 'description': 'Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.', 'timeFrame': 'Baseline through 24 Weeks'}]","[{'measure': 'Respiratory Function', 'description': 'Change in respiratory function as assessed by slow vital capacity (SVC).', 'timeFrame': 'Baseline and 24 Weeks'}, {'measure': 'Muscle Strength', 'description': 'Change in muscle strength as measured isometrically using hand-held dynamometry (HHD).', 'timeFrame': 'Baseline and 24 Weeks'}, {'measure': 'Number of Participants That Experienced Death or Death Equivalent', 'description': 'The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.', 'timeFrame': 'Baseline through 24 Weeks'}]",5.0,18 Years,,ALL,False,OTHER,1.0,162.0,ACTUAL,v2_robust,True,True,False,False,
NCT02760797,A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,Emactuzumab,"['RO7009789', 'Emactuzumab', 'RO5509554']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Neoplasms,Hoffmann-La Roche,2025-09-01T16:18:07.020162,True,,,,,"An Open-Label, Multicenter, Dose-Escalation Phase Ib Study With Expansion Phase to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Emactuzumab and RO7009789 Administered in Combination in Patients With Advanced Solid Tumors",,['Neoplasms'],[],,2016-05-09,2018-04-06,"[{'measure': 'Percentage of Participants with Dose-Limiting Toxicities (DLTs)', 'timeFrame': 'Up to 6 weeks from Day (D) 1 of Cycle (C) 1 (cycle = 3 weeks)'}]","[{'measure': 'Percentage of Participants with Anti-Drug Antibodies (ADAs) to Emactuzumab', 'timeFrame': 'Predose (PrD) (0 hours [H]) on D1 each cycle (cycle = 3 weeks) until progressive disease (PD) (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants with ADAs to RO7009789', 'timeFrame': 'PrD (0 H) on D1 each cycle (cycle = 3 weeks) until PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Serum Maximum Concentration (Cmax) of Emactuzumab', 'description': 'PrD (0 H), end of infusion (EOI) (infusion = 90 minutes \\[min\\]), postdose \\[5 H\\] D1 of C1/C4 (cycle = 3 weeks); on D2, 5, 8, 12, 15, 19 of C1/C4; on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Serum Trough Concentration (Ctrough) of Emactuzumab', 'timeFrame': 'PrD (0 H) on D1 of C2 onwards (cycle = 3 weeks) until PD (up to 2 years)'}, {'measure': 'Area Under the Concentration-Time Curve (AUC) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Total Clearance (CL) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Volume of Distribution at Steady State (Vss) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Accumulation Ratio of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Terminal Elimination Half-Life (T1/2) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Concentration at Time of Tumor Progression (Cprog) of Emactuzumab According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1', 'timeFrame': 'At time of PD (up to 2 years)'}, {'measure': 'Concentration of Emactuzumab at Time of Tumor Response (Complete or Partial Response) According to RECIST v1.1', 'timeFrame': 'At time of tumor response (up to 2 years)'}, {'measure': 'Concentration of Emactuzumab at Time of Infusion-Related Reaction (IRR) or Hypersensitivity Reaction', 'timeFrame': 'At time of IRR or hypersensitivity reaction (up to 2 years)'}, {'measure': 'Cmax of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Ctrough of RO7009789', 'timeFrame': 'PrD (0 H) on D1 of C2 onwards (cycle = 3 weeks) until PD (up to 2 years)'}, {'measure': 'AUC of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'CL of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Vss of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Accumulation Ratio of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'T1/2 of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Total Tumor-Associated Macrophages (TAMs) in Paired-Tumor Biopsies', 'timeFrame': 'Baseline; on D1 of C2 (cycle = 3 weeks); and optionally at time of PD (up to 2 years)'}, {'measure': 'Total Dermal Macrophages in Paired-Skin Biopsies', 'timeFrame': 'Baseline; on D1 of C2 (cycle = 3 weeks); and optionally at time of PD (up to 2 years)'}, {'measure': 'Levels of Functional Tumor-Infiltrating Lymphocytes', 'timeFrame': 'Baseline; on D1 of C2 (cycle = 3 weeks); and optionally at time of PD (up to 2 years)'}, {'measure': 'Circulating Colony-Stimulating Factor (CSF)-1 Serum Levels', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1 (cycle = 3 weeks); on D2, 5, 15 of C3; PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Total Monocyte Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Total Dendritic Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Circulating Cluster of Differentiation (CD) 4 T Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Circulating CD8 T Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Circulating B Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Metabolic Response of Target Lesions Assessed as the Change in Maximum Standardized Uptake Value (SUVmax) on [18F]-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)', 'timeFrame': 'Baseline; on D15 of C1; PrD (+/- 4 days) on D1 of C3 (cycle = 3 weeks)'}, {'measure': 'Percentage of Participants by Best Overall Response as Assessed by RECIST v1.1', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Overall Response as Assessed by RECIST v1.1', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Progressive-Free Survival (PFS) as Assessed by RECIST v1.1', 'timeFrame': 'From Baseline until death or PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Duration of Response (DOR) as Assessed by RECIST v1.1', 'timeFrame': 'From OR until PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Clinical Benefit as Assessed by RECIST v1.1', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants by Best Overall Response as Assessed by Modified RECIST', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Overall Response as Assessed by Modified RECIST', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Progressive-Free Survival (PFS) as Assessed by Modified RECIST', 'timeFrame': 'From Baseline until death or PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Duration of Response (DOR) as Assessed by Modified RECIST', 'timeFrame': 'From OR until PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Clinical Benefit as Assessed by Modified RECIST', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}]",40.0,18 Years,,ALL,False,INDUSTRY,0.0,38.0,ACTUAL,v2_robust,True,True,False,False,
NCT04858997,Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients,Palbociclib,"['Palbociclib', 'Ibrabce', 'AI']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Breast Neoplasms,Zhejiang Cancer Hospital,2025-09-01T16:18:07.020244,True,,,,,"An Open-label, Prospective Study of Tumor Response Time of Palbociclib in Combination With AI in Real-world First-line Treatment of Postmenopausal Chinese Patients With ER (+) HER2 (-) Metastatic Breast Cancer",,['Breast Neoplasms'],[],,2021-04-22,2023-06-30,"[{'measure': 'Early Tumor Shrinkage (ETS)', 'description': '10% change in the sum of the longest diameters (SLD) of target lesions at the first scan after 4weeks and 8weeks of treatment.', 'timeFrame': '4 weeks, 8weeks'}, {'measure': 'Time To Response (TTR)', 'description': 'Time to first documented complete of partial response.', 'timeFrame': 'Up to approximately 24 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the overall complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1)', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of participants with Adverse Events per CTCAE version 4.03 and type', 'description': 'Safety will be determined by type, severity of adverse events per CTCAE version 4.03 and type', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (QOL) Scale Score of the EORTC QLQ-C30', 'description': 'At least 10% relative to baseline worsening of the corresponding scale score (without further improvement above the threshold) or death due to any cause.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Overall Survival (OS)', 'description': 'time to death due to any cause', 'timeFrame': 'Randomization to death from any cause, through the end of study (approximately 60months)]'}]",6.0,18 Years,,FEMALE,False,OTHER,1.0,150.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01801410,Induction With Foley OR Misoprostol (INFORM) Study,Misoprostol,"['Misoprostol', 'Cytotec']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Pre-eclampsia,University of Liverpool,2025-09-01T16:18:07.020404,True,,,,,Induction of Labour in Pre-eclamptic Women: a Randomised Trial Comparing the Foley Balloon Catheter With Oral Misoprostol,,"['Pre-eclampsia', 'Fetus or Newborn; Effects of Induction of Labor']","['pre-eclampsia', 'labor induction', 'misoprostol', 'Foley catheter']",,2013-12,2015-06,"[{'measure': 'Attainment of vaginal delivery within 24 hours.', 'timeFrame': '24 hours'}]",[],1.0,18 Years,,FEMALE,False,OTHER,3.0,602.0,ACTUAL,v2_robust,True,True,False,False,
NCT06706310,Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection,Placebo,"['TQA3334 Tablet', 'Nucleoside (acid) analogs (NAs)', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Chronic Hepatitis B,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:07.020411,True,,,,,Evaluate TQ-A3334 Tablets Combined Nucleoside (Acid) Analogs in the Initial Treatment/Chronic Hepatitis B Virus (HBV) Infection Subjects of Chronic HBV Infection,,['Chronic Hepatitis B'],[],,2024-12-04,2026-06,"[{'measure': 'At 24 weeks, the changes in serum HBSAG relative to the baseline', 'description': 'Evaluate the subject of chronic HBV infection in the early treatment/treatment of chronic HBV infection, TQ-A3334 combined with oral nucleoside (acid) drugs comparative placebo and oral nucleoside (acid) drugs, can it significantly improve the treatment for 24 weeks Serum HBSAG relative to the changes in the baseline', 'timeFrame': 'Up to 24 weeks'}]","[{'measure': 'The incidence of adverse events（AEs）', 'description': 'To investigate the incidence of adverse events (AEs) during treatment', 'timeFrame': 'Up to 48 weeks'}, {'measure': 'Severity of adverse events (AEs)', 'description': 'To study the severity of adverse events (AEs) during treatment', 'timeFrame': 'Up to 48 weeks'}, {'measure': 'Incidence of serious adverse events (SAEs)', 'description': 'To investigate the incidence of serious adverse events (SAEs) during treatment', 'timeFrame': 'Up to 48 weeks'}, {'measure': 'Severity of serious adverse events（SAEs）', 'description': 'To investigate the severity of serious adverse events (SAEs) during treatment', 'timeFrame': 'Up to 28 weeks'}, {'measure': 'HBsAg<100 IU/ml and HBV DNA <20 IU/ml subject', 'description': 'The proportion of subjects of HBsAg\\<100 IU/ml and HBV DNA \\<20 IU/ml.', 'timeFrame': 'Week 24, 48 weeks, 60 weeks, 72 weeks'}, {'measure': 'HBSAG self -based lines drop ≥0.5, ≥1 Log10IU/ml', 'description': ""Awarded by HBSAG's self -base line decrease ≥0.5, ≥1 Log10IU/ml."", 'timeFrame': 'Week 24, 48 weeks, 60 weeks, 72 weeks'}, {'measure': 'The proportion of subjects of HBSAG serological removal and/or serum transformation during the study period', 'description': 'HBSAG serum science clearance and/or serum transition ratio proportion', 'timeFrame': 'Week 24, 48 weeks, 60 weeks, 72 weeks'}, {'measure': 'The proportion of subjects of HBEAG serological removal and/or serum conversion during the study period', 'description': 'The proportion of subjects of HBEAG serological removal and/or serum transformation during the study.', 'timeFrame': 'Week 24, 48 weeks, 60 weeks, 72 weeks'}, {'measure': 'Peak time (Tmax)', 'description': 'Time to peak blood concentration after a single dose.', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}, {'measure': 'Peak Concentration', 'description': 'The highest plasma drug concentration that can be achieved after medication.', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}, {'measure': 'Area under blood concentration-time curve (AUC)', 'description': 'The amount of drug absorbed into the human circulation after a single dose can be estimated using the area under the blood concentration-time curve.', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}, {'measure': 'Apparent volume of distribution (Vd/F)', 'description': 'When a drug reaches homeostasis in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}, {'measure': 'Plasma clearance', 'description': 'How many milliliters of plasma can the kidneys completely clear in unit time (per minute)', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, D15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, D57 and D85 0hour pre-dose.'}, {'measure': 'Elimination half-life time', 'description': 'The time it takes for the plasma concentration to drop by half.', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}, {'measure': 'Peaking Time', 'description': 'The time required to reach peak steady-state concentration after administration.', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, D15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, D57 and D85 0hour pre-dose.'}, {'measure': 'Steady state maximum concentration', 'description': 'The highest blood concentration that occurs after stabilization.', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}, {'measure': 'Steady state minimal concentration', 'description': 'The lowest blood concentration that occurs after stabilization', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}, {'measure': 'Area under steady-state blood concentration-time curve', 'description': 'After the dosage of a single agent, the amount of dosage of the blood circulation of the person can be used with blood concentration-the area of the area under the time curve.', 'timeFrame': 'Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose'}]",19.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,116.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06564610,Laparoscopic Transversus Abdominis Plane Block Versus Erector Spinae Plane Block in Bariatric Surgery,Propofol,['Propofol'],1,INTERVENTIONAL,['NA'],,COMPLETED,"Pain, Postoperative",Cairo University,2025-09-01T16:18:07.020470,True,,,,,Laparoscopic Transversus Abdominis Plane Block Versus Erector Spinae Plane Block in Obese Patients Undergoing Bariatric Surgery: a Randomized Controlled Trial,,"['Pain, Postoperative', 'Obesity', 'Analgesia']",[],,2024-08-25,2025-01-09,"[{'measure': 'Numerical rating scale', 'description': 'This is a scale for pain assessment which ranges between 0 and 10 with the highest level of pain having score 10 and lowest level of pain having score 0', 'timeFrame': '24 hours after surgery'}]","[{'measure': 'Consumption of analgesia', 'description': 'This is the total consumption of nalbuphine by the patient measured in milligrams', 'timeFrame': '24 hours after surgery'}, {'measure': 'Heart rate', 'description': 'This is the number of heart beats measured as frequency of heart beats in one minute.', 'timeFrame': '24 hours after surgery'}, {'measure': 'Systolic blood pressure', 'description': 'This is the systolic arterial blood pressure measured in mmHg.', 'timeFrame': '24 hours after surgery'}, {'measure': 'Vomiting', 'description': 'This is the incidence of vomiting after surgery measured as the frequency of patients with vomiting.', 'timeFrame': '24 hours'}, {'measure': 'Diastolic blood pressure', 'description': 'This is the diastolic arterial blood pressure measured in mmHg.', 'timeFrame': '24 hours'}]",6.0,18 Years,65 Years,ALL,False,OTHER,0.0,96.0,ACTUAL,v2_robust,True,True,False,False,
NCT01289210,VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas,VTX-2337 plus radiotherapy,['VTX-2337 plus radiotherapy'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Low Grade B Cell Lymphoma,Celgene,2025-09-01T16:18:07.020486,True,,,,,A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas,,['Low Grade B Cell Lymphoma'],"['B cell', 'lymphoma']",The study was stopped due to slow rate of recruitment.,2011-07,2012-10,"[{'measure': 'Number of Participants Whose Tumors Responded to Treatment With Intratumoral Injection of VTX-2337 in Combination With Low-Dose Local Radiation.', 'description': 'Tumor response was assessed via CT scans of the chest, abdomen, pelvis or other medically appropriate imaging modality to evaluate all areas of disease. Cheson Criteria were used for calculation of response.', 'timeFrame': 'Tumor assessment conducted at 12 weeks and every 3-6 months thereafter'}]","[{'measure': 'Assess the Safety and Feasibility of the Combination Regimen.', 'timeFrame': 'Safety assessed throughout study period.'}]",2.0,18 Years,,ALL,False,INDUSTRY,1.0,2.0,ACTUAL,v2_robust,True,False,True,True,The study was stopped due to slow rate of recruitment.
NCT01190410,Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol,certolizumab pegol,"[""Crohn's Disease"", 'Cimzia®', 'certolizumab pegol']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Crohn's Disease,UCB Pharma,2025-09-01T16:18:07.020522,True,,,,,"An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035",,"[""Crohn's Disease""]","['Certolizumab Pegol', 'Cimzia®', ""Crohn's Disease"", ""Children and Adolescents with Crohn's Disease""]",,2010-08,2017-11-27,"[{'measure': 'Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During Study Treatment (up to 303 Weeks)', 'description': 'Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.', 'timeFrame': 'During study treatment (up to 303 weeks)'}]","[{'measure': 'Number of Subjects Discontinuing Treatment Due to a Treatment-Emergent Adverse Event (TEAE)', 'description': 'Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.', 'timeFrame': 'During study treatment (up to 303 weeks)'}, {'measure': 'Number of Subjects Who Develop Anti-nuclear Antibodies During the Study', 'description': 'Anti-nuclear antibodies (ANA) are autoantibodies. ANA titers will be determined every 12 weeks starting at Week 14, and at the Completion/Early Termination and Safety Follow-Up (SFU) Visits.', 'timeFrame': 'At the time of completion or termination visit (up to 298 weeks)'}, {'measure': 'Number of Subjects Who Develop Double-stranded Deoxyribonucleic Acid (dsDNA) Antibodies During the Study', 'description': 'Anti-dsDNA are autoantibodies. Anti-dsDNA titers will be determined every 12 weeks starting at Week 14, and at the Completion/Early Termination and Safety Follow-Up (SFU) Visits.', 'timeFrame': 'At the time of completion or termination visit (up to 298 weeks)'}, {'measure': 'Percentage of Subjects in Clinical Remission', 'description': ""Percentage of subjects in clinical remission (clinical remission is defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score ≤ 10)"", 'timeFrame': 'At the time of completion or termination visit (up to 298 weeks)'}]",5.0,6 Years,17 Years,ALL,False,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT06248710,Dog Presence and Oxytocin on Trust Towards Therapists,Oxytocin nasal spray,"['Oxytocin nasal spray', 'Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,RECRUITING,Depressive Symptoms,Dr. Karin Hediger,2025-09-01T16:18:07.020531,True,,,,,Effects of Intranasal Oxytocin on Trust Towards Therapists and Dogs: A Randomized Controlled Trial in Healthy Adults,,"['Depressive Symptoms', 'Human-Animal Interaction']","['Depressive Symptoms', 'Human-Animal Interaction', 'Animal-Assisted Interventions', 'Trust']",,2024-01-29,2024-12-31,"[{'measure': 'Trust in the therapist', 'description': 'The main outcome is trust in the therapist, measured by the Trust and Respect Scale.\n\nThe current questionnaire contains 8 items, four for trust and four for respect. Each item is measured on a 7-point Likert scale (1 = ""strongly disagree"" to 7 = ""strongly agree""), of which 4 are formulated negatively. High values indicate high trust toward the therapist for the positively framed items, and for the negatively framed items low values mean high trust toward the therapist.', 'timeFrame': 'immediately after the intervention'}]","[{'measure': 'Trust in the dog', 'description': 'The secondary outcome ""trust in the dog"" will be measured with a Visual Analog Scale (VAS).\n\nThe following extremes will be used: no trust to complete trust. High values indicate high trust in the dog.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'perceived emotional closeness to the dog', 'description': 'The Coleman Dog Attitude Scale (C-DAS) is a reliable and validated measure designed to assess attitudes towards dogs.\n\nThe C-DAS is a 24-item self-report measure with an alpha ranging from 0.98 to 0.99.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'perceived stress', 'description': 'The secondary outcome ""perceived stress"" will be measured with a Visual Analog Scale (VAS).\n\nThe following extremes will be used: no stress to extreme stress. High values indicate that participants perceive a lot of stress.', 'timeFrame': 'pre-intervention'}, {'measure': 'perceived stress', 'description': 'The secondary outcome ""perceived stress"" will be measured with a Visual Analog Scale (VAS).\n\nThe following extremes will be used: no stress to extreme stress. High values indicate that participants perceive a lot of stress.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'level of difficulty', 'description': 'The secondary outcome ""level of difficulty"" in talking about a selected stressful event will be measured with a Visual Analog Scale (VAS).\n\nThe following extremes will be used: no difficulty to extreme difficulty. High values indicate that participants find it extremely difficult to talk about a selected stressful event.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'therapeutic alliance', 'description': 'The Therapy Session Questionnaire (in German ""Therapiesitzungsbogen für Patienten und Therapeuten"") will be used to assess the secondary outcome of ""therapeutic alliance"".\n\nThe current questionnaire contains 20 items. Each item is measured on a 7-point Likert scale (-3 = ""not at all"" to +3 = ""yes, exactly""). High values indicate high therapeutic alliance.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'therapeutic climate', 'description': 'Therapy Session Questionnaire (in German ""Therapiesitzungsbogen für Patienten und Therapeuten"") will be used to assess the secondary outcome of ""therapeutic climate"".\n\nThe current questionnaire contains 20 items. Each item is measured on a 7-point Likert scale (-3 = ""not at all"" to +3 = ""yes, exactly""). High values indicate a good therapeutic climate.', 'timeFrame': 'immediately after the intervention'}, {'measure': 'psychological flexibility', 'description': 'The secondary outcome ""psychological flexibility"" will be measured with the psychological flexibility questionnaire (Psy-Flex).\n\nThe Psy-Flex questionnaire consists of six items, which are representative for the six skills. Items are rated on a Likert scale (5 = ""very often"" to 1 = ""very rarely"") and are then summed up. Higher scores represent higher psychological flexibility.', 'timeFrame': 'pre-intervention'}, {'measure': 'psychological flexibility', 'description': 'The secondary outcome ""psychological flexibility"" will be measured with the psychological flexibility questionnaire (Psy-Flex).\n\nThe Psy-Flex questionnaire consists of six items, which are representative for the six skills. Items are rated on a Likert scale (5 = ""very often"" to 1 = ""very rarely"") and are then summed up. Higher scores represent higher psychological flexibility.', 'timeFrame': 'immediately after the intervention'}]",10.0,18 Years,,ALL,True,OTHER,0.0,176.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05624710,A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment,INCB054707,"['Povorcitinib', 'INCB054707']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Renal Insufficiency,Incyte Corporation,2025-09-01T16:18:07.020602,True,,,,,"A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment",,"['Renal Insufficiency', 'Kidney Diseases']","['renal impairment', 'hemodialysis', 'Kidney failure', 'end-stage renal disease']",,2022-12-08,2023-06-30,"[{'measure': 'Pharmacokinetics Parameter: Cmax of INCBC054707', 'description': 'Defined as maximum observed plasma concentration of INCB054707', 'timeFrame': 'Days 1 - 5'}, {'measure': 'Pharmacokinetics Parameter: AUC(0-t) of INCB054707', 'description': 'Defined as the area under the concentration- time curve up to the last measurable concentration of INCB54707.', 'timeFrame': 'Days 1 - 5'}, {'measure': 'Pharmacokinetics Parameter: AUC(0-∞) of INCB054707', 'description': 'Defined as area under the concentration-time curve From 0 to Infinity of INCB054707', 'timeFrame': 'Days 1 - 5'}]","[{'measure': ""Number of Treatment Emergent Adverse Events (TEAE'S)"", 'description': 'Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.', 'timeFrame': 'up to 15 days'}, {'measure': 'Pharmacokinetics Parameter: tmax of INCB054707', 'description': 'Defined as time to reach maximum plasma concentration of INCB054707', 'timeFrame': 'Days 1 - 5'}, {'measure': 'Pharmacokinetics Parameter: t1/2 0f INCB054707', 'description': 'Defined as apparent terminal phase disposition half-life of INCB54707', 'timeFrame': 'Days 1 - 5'}, {'measure': 'Pharmacokinetics Parameter: CL/F of INCB054707', 'description': 'Defined as oral dose clearance of INCB054707', 'timeFrame': 'Days 1 - 5'}, {'measure': 'Pharmacokinetics Parameter:: Vz/F of INCB054707', 'description': 'Defined as apparent oral dose volume of distribution of INCB054707', 'timeFrame': 'Days 1 - 5'}]",8.0,18 Years,80 Years,ALL,True,INDUSTRY,0.0,25.0,ACTUAL,v2_robust,True,True,False,True,
NCT04924413,L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma,Tislelizumab,"['Tislelizumab', 'L-TIL']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Malignant Melanoma,Quanli Gao,2025-09-01T16:18:07.020665,True,,,,,L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma,,['Malignant Melanoma'],[],Slow enrollment,2021-07-01,2024-07-02,"[{'measure': 'Efficacy (ORR)', 'description': 'The objective response rate (ORR) at 8 weeks from baseline.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy (ORR)', 'description': 'The objective response rate (ORR) at 16 weeks.', 'timeFrame': '16 weeks'}, {'measure': 'Efficacy (DOR)', 'description': 'The duration of response (DOR) at 1-year.', 'timeFrame': '1 year'}, {'measure': 'Efficacy (DOR)', 'description': 'The duration of response (DOR) at 2-year.', 'timeFrame': '2 years'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'The PFS rate at 1 year.', 'timeFrame': '1 year'}, {'measure': 'Progression free survival (PFS)', 'description': 'The PFS rate at 2-year.', 'timeFrame': '2 years'}, {'measure': 'Overall survival (OS)', 'description': 'The OS rate at 1 year.', 'timeFrame': '1 year'}, {'measure': 'Overall survival (OS)', 'description': 'The OS rate at 2-year.', 'timeFrame': '2 years'}, {'measure': 'Safety (adverse events)', 'description': 'The adverse events followed by treatment.', 'timeFrame': '2 years'}]",9.0,18 Years,75 Years,ALL,False,OTHER_GOV,0.0,9.0,ACTUAL,v2_robust,True,False,True,True,Slow enrollment
NCT03965013,A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes,NNC0268-0965,"['insulin glargine', 'NNC0268-0965', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 1",Novo Nordisk A/S,2025-09-01T16:18:07.020719,True,,,,,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0268-0965 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus",,"['Diabetes Mellitus, Type 1', 'Healthy Volunteers']",[],,2019-06-05,2019-12-14,"[{'measure': 'Number of treatment-emergent adverse events', 'description': 'Number of events', 'timeFrame': 'From trial product administration at day 1 until completion of post-treatment end-of-trial visit at day 10'}]","[{'measure': 'Number of treatment-emergent hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'From trial product administration at day 1 until completion of post-treatment end-of-trial visit at day 10'}, {'measure': 'Area under the serum NNC0268-0965 concentration-time curve after a single dose', 'description': 'pmol\\*h/L', 'timeFrame': 'From 0 hours until infinity after trial product administration (day 1)'}, {'measure': 'Maximum observed serum NNC0268-0965 concentration after a single dose', 'description': 'pmol/L', 'timeFrame': 'From 0 hours until last measurement time after trial product administration (day 1)'}]",4.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,78.0,ACTUAL,v2_robust,True,True,False,True,
NCT02189213,Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep,Sertraline,"['Sertraline', 'Zoloft']",2,INTERVENTIONAL,['NA'],,TERMINATED,Generalized Anxiety Disorder,New York State Psychiatric Institute,2025-09-01T16:18:07.020757,True,,,,,Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep,,"['Generalized Anxiety Disorder', 'Separation Anxiety Disorder', 'Social Phobia']","['anxiety', 'SSRI', 'biomarker', 'sleep', 'children', 'adolescents', 'young adults']",Insufficient funding,2014-07,2019-12,"[{'measure': 'Clinical Global Impression-Improvement (CGI-I) Score', 'description': 'The CGI-I score at the final visit will determine treatment response.\n\nThe CGI-Improvement scale comprises a one-item measures evaluating the following change from the initiation of treatment on a seven-point scale.\n\nThe following one query is rated on a seven-point scale: ""Compared to the patient\'s condition at admission to the project \\[prior to medication initiation\\], this patient\'s condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.\n\nCGI-I scale of 1-2 is considered response to treatment. Anything below that is considered non-response to sertraline treatment.', 'timeFrame': 'Final visit, at 12 weeks of treatment'}]",[],1.0,8 Years,25 Years,ALL,True,OTHER,1.0,14.0,ACTUAL,v2_robust,True,False,True,False,Insufficient funding
NCT06823713,RTX001 Autologous Engineered Macrophages for Liver Cirrhosis,RTX001,['RTX001'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,End-stage Liver Disease (ESLD),Resolution Therapeutics Limited,2025-09-01T16:18:07.020826,True,,,,,"An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)",,"['End-stage Liver Disease (ESLD)', 'Cirrhosis, Liver', 'Cirrhosis, Decompensated', 'Liver Diseases', 'Fibrosis and Cirrhosis of Liver', 'Decompensated Liver Cirrhosis', 'Decompensated Cirrhosis', 'Steatotic Liver Disease']","['Liver cirrhosis', 'Cirrhotic', 'Hepatic Cirrhosis', 'Chronic Liver Disease', 'Liver Fibrosis', 'Decompensated Liver Cirrhosis', 'Child-Pugh Score', 'MELD Score', 'Liver Function Tests', 'Hepatic Encephalopathy', 'End Stage Liver Disease (ESLD)', 'Variceal Bleeding', 'Jaundice', 'Retractable Ascites', 'Autologous', 'Cell Therapy', 'Macrophage', 'Steatotic Liver Disease']",,2024-10-15,2028-11-29,"[{'measure': 'Safety and Tolerability', 'description': 'Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)', 'timeFrame': '2.5 years'}, {'measure': 'Safety and Tolerability', 'description': 'Incidence and severity of infusion reactions', 'timeFrame': 'At each infusion; day of infusion up to two weeks post-infusion'}]","[{'measure': 'Time to clinical event', 'description': 'Time to clinical event, defined as all hepatic decompensation events including SBP and/or HRS-AKI, new listing for liver transplantation, liver transplantation, or death.', 'timeFrame': '2.5 years'}, {'measure': 'Time to mortality', 'description': 'Time-to all-cause mortality (hepatic related and all-cause).', 'timeFrame': '2.5 years'}, {'measure': 'Change in Model for End Stage Liver Disease score 3.0 (MELD3.0)', 'description': 'To evaluate changes in Model for End Stage Liver Disease (MELD3.0) scores, from baseline to end of study in the Stabilised Group participants.', 'timeFrame': '2.5 years'}]",5.0,18 Years,75 Years,ALL,False,NETWORK,0.0,30.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02246660,RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial),Resveratrol,"['Resveratrol', 'Polygonum cuspidatum', 'No active study medication', 'Placebo']",4,INTERVENTIONAL,['NA'],,COMPLETED,Peripheral Arterial Disease,Northwestern University,2025-09-01T16:18:07.020895,True,,,,,RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial),,['Peripheral Arterial Disease'],"['Peripheral Artery Disease', 'Peripheral Arterial Disease', 'PAD']",,2015-01,2016-09,"[{'measure': '6-Minute Walk Distance, Meters', 'description': 'Six month changes in 6-Minute Walk Distance (meters) in response to resveratrol therapy in patients with Peripheral Artery Disease were measured.', 'timeFrame': 'Baseline and 6 month follow-up'}]",[],1.0,65 Years,,ALL,False,OTHER,1.0,66.0,ACTUAL,v2_robust,True,True,False,False,
NCT01306760,The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy,Ketamine,"['Propofol', 'Ketamine', 'Diprivan 1%', 'Ketalar']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Depression,University of Aberdeen,2025-09-01T16:18:07.020916,True,,,,,The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy (ECT) for Depression: Does it Improve Treatment Outcome?,,['Depression'],"['depression', 'electroconvulsive therapy', 'ketamine']",,2011-03,2014-02,"[{'measure': 'Change in depressive symptoms', 'description': 'The primary outcome measure will be change in depressive symptoms after the fourth ECT treatment. This will be assessed by the change in MADRS and 17-item HDRS scores between start of treatment and this timepoint.', 'timeFrame': 'After 4th treatment'}]","[{'measure': 'Cognitive side-effects', 'description': 'This will be assessed using the spatial recognition test from the CANTAB battery. This test was chosen as previous research has shown that this test is most sensitive to anterograde memory impairments associated with ECT. By administering this test before, during (after 4th treatment) and after treatment (immediately following and at 1 month follow-up) we will be able to determine whether ketamine can reduce the anterograde memory dysfunction as compared to propofol.', 'timeFrame': '2 months'}, {'measure': 'Change in depressive symptoms after treatment', 'description': 'The secondary measure of treatment efficacy will be assessed by the change in MADRS and 17-item HADRS scores immediately after treatment and at 1 month follow-up. Secondly, this will be assessed by the number of treatments required to achieve remission of symptoms, as judged by treating clinicians. By monitoring the number of treatments required we will be able to assess whether ketamine can reduce the number of ECT treatments required.', 'timeFrame': '2 months'}]",3.0,18 Years,65 Years,ALL,False,OTHER,2.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT00279760,Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis,Belatacept,"['Abatacept', 'Belatacept']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Rheumatoid Arthritis,Bristol-Myers Squibb,2025-09-01T16:18:07.020942,True,,,,,"A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis",,['Rheumatoid Arthritis'],[],,,,[{'measure': 'Assess the relative safety and preliminary efficacy (clinical activity) of BMS-188667 and BMS-224818 in subjects with rheumatoid arthritis (RA)'}],"[{'measure': 'Assess the immunogenicity of BMS-188667 and BMS-224818 in subjects with RA, and in a site specific substudy to the protocol, the pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-188667 and BMS-224818 in subjects with RA'}]",2.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,210.0,,v2_robust,True,True,False,True,
NCT01162460,Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures,Eslicarbazepine acetate (BIA 2-093),['Eslicarbazepine acetate (BIA 2-093)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Epilepsy,Bial - Portela C S.A.,2025-09-01T16:18:07.020984,True,,,,,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study",,['Epilepsy'],[],,2010-12,2016-09,"[{'measure': 'The primary efficacy variable will be the proportion of subjects in the PP set who are seizure free for the entire 26-week Evaluation Period at the last received dose level.', 'timeFrame': '26 weeks'}]","[{'measure': 'Proportion of subjects in the ITT set without a seizure during the 26-week Evaluation Period at the last evaluated dose.', 'timeFrame': '26 weeks'}, {'measure': 'Proportion of subjects without a seizure during the 26-week Evaluation Period at the last evaluated dose.', 'timeFrame': '26 weeks'}, {'measure': 'Proportion of seizure-free subjects during 1 year of treatment at the last evaluated dose, where the end of the 1-year period is defined as the same start date as for the 26-week evaluation +365 days.', 'timeFrame': '52 weeks'}, {'measure': 'Time to first seizure at the last evaluated dose set.', 'timeFrame': 'up to 183 weeks'}, {'measure': 'QOLIE-31 and Bond-Lader VAS', 'description': 'Changes in quality of life assessed using the QOLIE-31 (Overall score, subscores covering emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects and assessment of overall health).', 'timeFrame': '26 weeks; up to 183 weeks'}, {'measure': 'Treatment retention time at the last evaluated dose', 'description': 'Treatment retention time at the last evaluated dose, where treatment retention time is defined as the time of the first occurrence of one of the following:\n\n* Withdrawal of IMP due to AEs.\n* Withdrawal of IMP due to lack of efficacy.', 'timeFrame': '26 weeks'}, {'measure': 'Time to treatment failure at the first evaluated dose', 'description': 'Time to treatment failure at the first evaluated dose, where time to treatment failure is defined as the time of the first occurrence of 1 of the following:\n\n* Seizure\n* Withdrawal of IMP due to AEs.\n* Withdrawal of IMP due to lack of efficacy.', 'timeFrame': '26 weeks'}, {'measure': 'seizure freedom', 'description': 'Dose level at which subjects reached 26-week seizure freedom.', 'timeFrame': '26 weeks'}, {'measure': 'Adverse Event monitoring', 'description': 'Incidence of AEs, SAEs, withdrawals, out-of-range laboratory values, abnormal 12-lead ECG and physical examination findings.', 'timeFrame': 'up to 183 weeks'}]",10.0,18 Years,,ALL,False,INDUSTRY,0.0,815.0,ACTUAL,v2_robust,True,True,False,True,
NCT01495260,"A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants",N-acetylcysteine,"['vitamin E', 'lipoic acid', 'N-acetylcysteine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Adrenomyeloneuropathy,"Pujol, Aurora, M.D.",2025-09-01T16:18:07.021016,True,,,,,"A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E",,['Adrenomyeloneuropathy'],"['XALD', 'AMN']",,2011-09,2013-11,"[{'measure': 'oxidative lesion biomarkers', 'description': 'oxidative lesion biomarkers: protein, DNA and peroxidation biomarkers', 'timeFrame': '12 months'}]","[{'measure': 'clinical parameters', 'description': 'spasticity, disability,electroneurograms and evocated potentials. Cranial and spinal NMR will be done at the beginning and the end of the trial.', 'timeFrame': '2, 6 and 12 months'}]",2.0,18 Years,64 Years,ALL,False,INDIV,2.0,13.0,ACTUAL,v2_robust,True,True,False,False,
NCT03511560,Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation,Tacrolimus Extended Release Oral Tablet,"['Envarsus XR', 'Prograf', 'Tacrolimus', 'Tacrolimus Extended Release Oral Tablet']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Renal Transplant Rejection,Columbia University,2025-09-01T16:18:07.021035,True,,,,,To Understand the Impact of Immunosuppression Using Once-per-day Envarsus XR on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation,,"['Renal Transplant Rejection', 'Kidney Transplant Failure and Rejection']","['Envarsus XR', 'Tacrolimus', 'Kidney Transplantation']",,2018-07-26,2021-07-17,"[{'measure': 'Mean C/D Ratio', 'description': 'Tacrolimus metabolism was determined for all dates of tacrolimus blood trough concentration collection after renal transplantation by dividing the tacrolimus blood trough concentration (C) by the corresponding total daily tacrolimus dose (D).\n\nC/D ratio (ng/mL\\*1/mg) = blood tacrolimus trough level (ng/mL)/total daily tacrolimus dose (mg).', 'timeFrame': 'Every Month for up to 1 year'}]","[{'measure': 'Mean Serum Creatinine Level', 'description': 'Serum creatinine levels were measured to assess kidney function following transplantation', 'timeFrame': '12 months'}, {'measure': 'Patient Survival Rate', 'description': 'Patient survival is any subject that is known to be alive at the study conclusion.', 'timeFrame': '12 months'}, {'measure': 'Graft Survival Rate', 'description': 'Graft survival is defined as any subject that does not fit the following definition of graft loss: subject death, re-transplantation, transplant nephrectomy, or return to dialysis for a period of ≥6 weeks by study end.', 'timeFrame': '12 months'}, {'measure': 'Number of Rejection Episodes', 'description': 'For study purposes, diagnoses of rejection require biopsy confirmation.', 'timeFrame': '12 months'}]",5.0,18 Years,80 Years,ALL,False,OTHER,1.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT06204120,Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery,LPM3480392 Injection,"['LPM3480392 Injection', 'morphine hydrochloride injection', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Pain, Postoperative",Luye Pharma Group Ltd.,2025-09-01T16:18:07.021133,True,,,,,"A Multicenter, Randomized, Double-blind, Placebo, Positive Drug Parallel Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery",,"['Pain, Postoperative']",[],,2022-11-25,2023-07-04,"[{'measure': 'SPID24(the Sum of Pain Intensity Differences in Pain Score from baseline Over 24 Hours)', 'description': 'Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 24 hours.', 'timeFrame': 'one day'}]","[{'measure': 'Cumulative dose of rescue analgesic drugs within 24 h', 'timeFrame': 'one day'}, {'measure': 'Percentage of subjects not using rescue analgesic medication within 24 h', 'timeFrame': 'one day'}, {'measure': 'Time of the first rescue analgesic drug', 'timeFrame': 'one day'}, {'measure': 'Total number of compressions within 24 hours.', 'timeFrame': 'one day'}, {'measure': 'Incidence and severity of adverse events within 24 h', 'timeFrame': 'one day'}, {'measure': 'Sedation scale score', 'timeFrame': 'one day'}, {'measure': 'Respiratory depression events (defined as respiratory rate ≤ 8 breaths/min and/or saturation < 90%)', 'timeFrame': 'one day'}]",8.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,150.0,ACTUAL,v2_robust,True,True,False,True,
NCT03150420,A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients,Sodium Thiosulfate,"['Placebo-Normal Saline', 'Intravenous Sodium Thiosulfate Injection', '0.9% sodium chloride solution', 'Sodium Thiosulfate']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Calciphylaxis,Hope Pharmaceuticals,2025-09-01T16:18:07.021198,True,,,,,"A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial",,['Calciphylaxis'],"['calciphylaxis', 'calcific uremic arteriolopathy, calcinosis', 'calcium metabolism disorders', 'metabolic diseases', 'sodium thiosulfate']","Inability to accrue subjects that met the exclusion criterion ""Any prior (within the past 30 days) or current Sodium Thiosulfate treatment"".",2017-05-24,2020-04-15,"[{'measure': 'Number of patients with 30% improvement in pain severity', 'description': 'To compare the effects of treatment with intravenous Sodium Thiosulfate Injection vs. placebo for the proportion of patients (responders) who achieve a ≥ 30% reduction based upon pain intensity score (modified BPI/SF).', 'timeFrame': 'randomization to 3 weeks'}]","[{'measure': 'Secondary Endpoint-a: Number of patients with stabilization or improvement in calciphylaxis skin lesions.', 'description': 'Proportion of patients who achieve improvement or stabilization (i.e., not worsening) of skin lesions.', 'timeFrame': 'randomization to 3 weeks'}, {'measure': 'Secondary Endpoint-b: Occurence of surgical debridement of skin lesions and/or amputation.', 'description': 'Occurence of surgical debridement of skin lesions and/or amputation.', 'timeFrame': 'during week 3'}, {'measure': 'Secondary Endpoint-c: Occurrence of surgical debridement of skin lesions and/or amputation.', 'description': 'Occurrence of surgical debridement of skin lesions and/or amputation.', 'timeFrame': 'randomization to 3 weeks'}, {'measure': 'Secondary Endpoint-d: Time to achieve ≥ 30% improvement in pain severity', 'description': 'Time in days when a patient achieves a ≥ 30% improvement based upon pain intensity score (modified BPI/SF).', 'timeFrame': 'randomization to 3 weeks'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,29.0,ACTUAL,v2_robust,True,False,True,False,"Inability to accrue subjects that met the exclusion criterion ""Any prior (within the past 30 days) or current Sodium Thiosulfate treatment""."
NCT01392820,A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers,TC-5214,"['TC-5214', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,AstraZeneca,2025-09-01T16:18:07.021227,True,,,,,"A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers",,['Healthy'],"['Phase I', 'Japan', 'Elderly', 'PK', 'SAD', 'MAD']",,2011-07,2011-10,"[{'measure': 'assess the safety and tolerability during single and multiple ascending oral doses by assessment of AEs, brief neurological examinations, vital signs, eye symptoms question, physical examinations, laboratory parameters, and ECGs, and C-SSRS.', 'timeFrame': 'During the whole study period, ca. 50 days'}]","[{'measure': 'characterise the PK of TC-5214 in plasma and urine during single and multiple ascending oral doses to Japanese healthy elderly volunteers.', 'timeFrame': 'PK samplings are taken at defined timepoints during residential periods, 4 days for SAD part and/or 9 days for MAD part.'}]",2.0,65 Years,,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,
NCT02608320,A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants,Duragesic (Fentanyl Transdermal System [TDS] Small Patches),"['Duragesic (Fentanyl TDS Large Patches)', 'New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)', 'Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)', 'Duragesic (Fentanyl Transdermal System [TDS] Small Patches)', 'Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)', 'New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Janssen Research & Development, LLC",2025-09-01T16:18:07.021267,True,,,,,"A Randomized, Partially-blinded, Two-arm, Single-application, 3-way Crossover Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Subjects",,['Healthy'],"['Healthy', 'JNJ-35685-AAA-G016', 'JNJ-35685-AAA-G021', 'DURAGESIC', 'Fentanyl']",,2015-11-17,2016-04-13,"[{'measure': 'Cumulative Adhesion Percentage', 'description': 'The actual percentages of patch adhesion will be estimated according to the Food and Drug Administration (FDA) 0-4 scoring system. An estimated percentage of adhesion, to a whole integer, will be obtained (FDA 0-4 \\[%\\] scoring) where 0=greater than or equal to (\\>=) 90% adhered (essentially no lift off the skin); 1= \\>= 75% to \\< 90% adhered (some edges only lifting off the skin); 2 = ≥ 50% to \\< 75% adhered (less than half of the patch lifting off the skin); 3 = \\> 0% to \\< 50% adhered but not detached (more than half of the patch lifting off the skin without falling off); 4 = 0% adhered - patch detached (patch completely off the skin).', 'timeFrame': 'Time of patch application up to patch removal (up to 72 hours)'}]","[{'measure': 'Time to First Unacceptable Score', 'description': 'Time to first unacceptable score that is \\< 75% adhered will be assessed.', 'timeFrame': '12, 24, 36, 48, 60, and 72 hour following patch application'}]",2.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,52.0,ACTUAL,v2_robust,True,True,False,False,
NCT01737320,Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia,short-course antibiotic treatment,"['accepted prolonged antibiotic treatment', 'short-course antibiotic treatment']",2,INTERVENTIONAL,['NA'],,COMPLETED,Gram Negative Bacteremia,Rabin Medical Center,2025-09-01T16:18:07.021292,True,,,,,Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia - a Randomized Controlled Trial,,['Gram Negative Bacteremia'],"['gram negative bacteremia', 'Duration of antibiotic treatment', 'safety', 'efficacy', 'short-course']",,2013-01,2018-03-04,"[{'measure': 'composite of the following', 'description': 'The primary outcome is a composite of the following outcome measures', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'All -cause mortality', 'description': 'All- cause mortality', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Treatment Failure', 'description': 'Failure including any of the following:\n\n1. Relapse: a recurrent bacteraemia due to the same microorganism occurring from day of randomization and until day 9013\n2. Local suppurative complication that was not present at infection onset (e.g. renal abscess in pyelonephritis, empyema in pneumonia)\n3. Distant complications of initial infection, defined by growth of the same bacteria as in the initial bacteremia', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Hospital re-admissions or extended hospitalization', 'description': 'We will define re-admission as a new hospitalization for any cause occurring more than14 days from start of appropriate antibiotic treatment. Patients hospitalized after day 14 (were never discharged or 7-day regimen who were readmitted between days 7-14) will be counted as failures for this outcome.\n\nWe will define re-admission as a new hospitalization for any cause occurring more than14 days from start of appropriate antibiotic treatment. Patients hospitalized after day 14 (were never discharged or 7-day regimen who were readmitted between days 7-14) will be counted as failures for this outcome.', 'timeFrame': 'Until day 90 after randomization'}]","[{'measure': 'Clostridium difficile associated diarrhea', 'description': 'Clostridium difficile associated diarrhea', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Development of Antibiotic resistance', 'description': 'Development of resistance, defined as clinical isolates resistant to antibiotics previously used in the bacteremia episode. Surveillance sampling will not be conducted.', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Carriage of carbapenem resistant Klebsiella pneumonia.', 'description': 'Carriage of carbapenem resistant Klebsiella pneumonia (screened routinely)', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Total in hospital days', 'description': 'Total in hospital days within 30 and 90 days', 'timeFrame': 'Until day 90 after randomization.'}, {'measure': 'Total antibiotic days', 'description': 'Total antibiotic days', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Adverse events', 'description': '* Any diarrhea\n* Liver function test abnormalities, defined as elevated bilirubin x 1.5 of upper limit of normal or transaminases x 2.5 of upper limit of normal\n* Antibiotic rash\n* Acute kidney injury - defined according to RIFLE criteria as increased creatinine level x 1.5 from baseline or glomerular filtration rate (GFR) decrease \\>25% or urine output of \\<0.5 ml/kg/h for 6 hours22', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Infection caused by other than gram-negative bacteremia', 'description': 'Development of either clinically or microbiologically documented infection other than gram-negative bacteremia. We will use the 2008 CDC/NHSN surveillance definitions of health-care associated infections for bacterial infections', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Number of hospital re-admissions', 'description': 'Number of hospital re-admissions until day 90', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Functional capacity and time to return to baseline activity', 'description': 'Functional capacity and time to return to baseline activity', 'timeFrame': 'Until day 30 after randomization'}]",13.0,18 Years,,ALL,False,OTHER,0.0,604.0,ACTUAL,v2_robust,True,True,False,True,
NCT05320120,Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI,56mg esketamine (2x Spravato® 28 mg nasal spray),"['56mg esketamine (2x Spravato® 28 mg nasal spray)', '0.9% saline solution nasal spray']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Ketamine Treatment,Rupert Lanzenberger,2025-09-01T16:18:07.021406,True,,,,,"Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI: a Placebo Controlled, Randomized, Cross-over Trial",,['Ketamine Treatment'],[],,2022-06-01,2023-06-21,"[{'measure': 'BOLD response assessed with fMRI to arousal task', 'description': 'Blood oxygen level (BOLD) response assessed with functional magnetic resonance imaging (fMRI) during an arousal task', 'timeFrame': 'up to two weeks'}]",[],1.0,18 Years,55 Years,ALL,True,OTHER,0.0,33.0,ACTUAL,v2_robust,True,True,False,False,
NCT00452920,"Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer",docetaxel,['docetaxel'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,WITHDRAWN,Cervical Cancer,University of Miami,2025-09-01T16:18:07.021468,True,,,,,A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026),,['Cervical Cancer'],"['cervical squamous cell carcinoma', 'stage IIB cervical cancer', 'stage III cervical cancer', 'stage IVA cervical cancer']",,2003-09,2009-06,"[{'measure': 'Recommended phase II dose (Phase I)'}, {'measure': 'Progression-free survival (Phase II)'}]","[{'measure': 'Response (Phase II)'}, {'measure': 'Toxicity (Phase II)'}]",4.0,18 Years,120 Years,FEMALE,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,
NCT03102320,Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors,Cisplatin,"['Gemcitabine', 'Anetumab ravtansine (BAY94-9343)', 'Cisplatin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Neoplasms,Bayer,2025-09-01T16:18:07.021477,True,,,,,Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies,,['Neoplasms'],"['cholangiocarcinoma', 'pancreatic cancer', 'triple-negative breast cancer', 'non-small cell lung cancer', 'thymic carcinoma', 'gastric including gastroesophageal junction cancer']",,2017-05-26,2021-07-26,"[{'measure': 'Number of patients in the safety lead-in (SLI) phase who completed Cycle 1 or had a DLT and were not replaced.', 'description': 'During SLI, patients with cholangiocarcinoma received anetumab ravtansine in combination with cisplatin and patients with pancreatic adenocarcinoma received anetumab ravtansine in combination with gemcitabine. The highest dose of anetumab ravtansine that can be given so that not more than 1 out of 6 patients experiences a dose-limiting toxicity (DLT) during the DLT evaluation period were declared as the MTD for anetumab ravtansine in combination with cisplatin or with gemcitabine.', 'timeFrame': 'At least 3 weeks after the last patient starts treatment'}, {'measure': 'Objective response (qualitative improvement from baseline) of anetumab ravtansine for monotherapy and combination therapy in mesothelin expressing advanced solid tumors', 'description': 'A patient is a responder if the patient has a best response compared to baseline of complete response (CR) or partial response (PR) among all post-baseline tumor assessments, as determined per RECIST 1.1 criteria (ITMIG modified RECIST 1.1 criteria for thymic carcinoma)', 'timeFrame': 'Up to approximately 26 months after patient starts treatment'}, {'measure': 'Durable disease control (lack of progression from baseline) of anetumab ravtansine in indications pancreatic and gastric cancer (co-primary endpoint)', 'description': 'A patient experiences durable disease control if the patient has a tumor response compared to baseline of CR, PR or stable disease (SD) among the post-baseline tumor assessments made at least 180 days from first treatment, without prior disease progression', 'timeFrame': 'Up to approximately 26 months after patient starts treatment'}]","[{'measure': 'Number of serious and non-serious adverse events (AEs)', 'description': 'Include treatment-emergent AEs, SAEs, treatment-related AEs, AEs of special interest, and deaths.', 'timeFrame': 'Approximately 26 months (Until 30 days after the last day of study treatment, or until later resolution of adverse events or determination by the investigator that the event will not improve)'}, {'measure': 'Disease control rate (DCR)', 'description': 'The DCR is defined as the number of patients with disease control divided by the number of treated patients.', 'timeFrame': 'Up to approximately 24 months after last patient starts treatment, or until earlier disease progression [assessed every 6 weeks for the first 6 months, every 9 weeks until end of year 1 and every 12 weeks thereafter]'}, {'measure': 'Duration of response (DOR)', 'description': 'DOR is defined in responders as the time from documentation of tumor response (CR or PR) to earlier of disease progression or death', 'timeFrame': 'Up to approximately 24 months after last patient starts treatment, or until earlier disease progression [assessed every 6 weeks for the first 6 months, every 9 weeks until end of year 1 and every 12 weeks thereafter]'}, {'measure': 'Durable response rate (DRR)', 'description': 'A durable responder is defined as a responder (CR or PR) with a duration of response per RECIST 1.1 criteria (ITMIG modified RECIST 1.1 criteria for thymic carcinoma) of 180 days or more. The DRR is the number of durable responders divided by the number of treated patients.', 'timeFrame': 'Up to approximately 24 months after last patient starts treatment, or until earlier disease progression [assessed every 6 weeks for the first 6 months, every 9 weeks until end of year 1 and every 12 weeks thereafter]'}, {'measure': 'Progression free survival (PFS)', 'description': 'PFS is defined as time from start of treatment until disease progression according to RECIST 1.1 (ITMIG modified RECIST 1.1 criteria for thymic carcinoma) or death.', 'timeFrame': 'Up to approximately 24 months after last patient starts treatment, or until earlier disease progression [assessed every 6 weeks for the first 6 months, every 9 weeks until end of year 1 and every 12 weeks thereafter]'}, {'measure': 'Durable disease control rate (DDCR) of anetumab ravtansine in indications other than pancreatic and gastric cancer', 'description': 'A patient experiences durable disease control if the patient has a tumor response of CR, PR or SD with CR, PR or SD assessed at least 180 days from first treatment, without prior progression.', 'timeFrame': 'Up to approximately 24 months after last patient starts treatment, or until earlier disease progression [assessed every 6 weeks for the first 6 months, every 9 weeks until end of year 1 and every 12 weeks thereafter]'}]",9.0,18 Years,,ALL,False,INDUSTRY,2.0,173.0,ACTUAL,v2_robust,True,True,False,True,
NCT02807220,Efficacy and Safety of Imuneks 10 mg Capsules in the Prophylaxis of Cold,Imuneks 10mg,"['Imuneks 10mg', 'micronized Beta-1,3/1,6-D-glucan']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Cold Symptoms,Imuneks Farma ilac San. Tic. A.S.,2025-09-01T16:18:07.021494,True,,,,,"A Phase 4, Single Arm Trial Assessing the Efficacy and Safety of Imuneks 10 mg Capsules in the Prophylaxis of Cold and the Maintenance of the Good Health State in Healthy Subjects",,['Cold Symptoms'],['Imuneks'],,2017-02-27,2017-04-13,"[{'measure': 'Prophylaxis of common cold and the change in blood lymphocyte, macrophage, neutrophil, eosinophil and monocyte counts from baseline values after first, third and sixth weeks after the oral use of the study medication.', 'description': 'The baseline will be established by taking blood samples from the participants at their first visits.\n\nEach participant will report to the study staff any symptoms such as runny nose, cough, nasal congestion and sneezing during 6 weeks after administering the first dose of the study medication. Cold symptoms seen in the first week will be excluded from the evaluations as prophylactic effect will not be assessable before this period.', 'timeFrame': '6 weeks'}]","[{'measure': 'The number of participants who took sick leaves.', 'description': 'The participants who will take sick leaves form their work during the study will be reported.', 'timeFrame': '6 weeks'}, {'measure': 'Number of Participants with Adverse Events That Are Related to The Study Medication.', 'description': 'The number of Participants with Adverse Events that are related to the study medication during the study period will be reported.', 'timeFrame': '6 weeks'}]",3.0,18 Years,65 Years,ALL,True,INDUSTRY,1.0,70.0,ACTUAL,v2_robust,True,True,False,True,
NCT02873520,Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer,Chemotherapy,['Chemotherapy'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Precision Cell Immunotherapy,Ningbo Cancer Hospital,2025-09-01T16:18:07.021518,True,,,,,Clinical Study Using Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer,,"['Precision Cell Immunotherapy', 'Chemotherapy', 'Advanced Gastric Cancer']","['Precision Cell Immunotherapy', 'Chemotherapy', 'Advanced Gastric Cancer']",,2016-08,2018-08,"[{'measure': 'Overall survival', 'timeFrame': '2 years'}, {'measure': 'Progress-free survival', 'timeFrame': '2 years'}, {'measure': 'Quality of life', 'description': 'Questionnaire will be used.', 'timeFrame': '2 years'}]",[],3.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04609020,Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment,BOTOX,['BOTOX'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Facial Rhytides,Allergan,2025-09-01T16:18:07.021526,True,,,,,"Prospective, Multi-site Study to Evaluate Subject Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment",,"['Facial Rhytides', 'Skin Folds', 'Loss of Volume and Skin Quality']",[],,2023-02-15,2024-05-10,"[{'measure': 'Change From Baseline in the Rasch-transformed Score of the FACE-Q Satisfaction With Facial Appearance Scale.', 'description': ""The FACE-Q questionnaire focuses on patient's satisfaction with facial appearance at the final study visit compared to before starting study treatment and is a 10- item questionnaire. Overall scores range from 0 to 100 with higher scores representing higher satisfaction."", 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}]","[{'measure': 'Change From Baseline in the FACE-Q Aging Appraisal', 'description': 'The FACE-Q questionnaire is a 7-item questionnaire with overall scores that range from 0 to 100 and higher scores reflecting a better outcome.', 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}, {'measure': 'Change From Baseline in the Rasch-transformed Score of the FACE-Q Psychological Function Scale', 'description': 'The FACE-Q questionnaire is a 10-item questionnaire with overall scores that range from 0 to 100 and higher scores reflecting a better outcome.', 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}, {'measure': 'Change From Baseline in the Rasch-transformed Score of the FACE-Q Social Function Scale', 'description': 'The FACE-Q questionnaire is a 8-item questionnaire with overall scores that range from 0 to 100 and higher scores reflecting a better outcome.', 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}, {'measure': 'Change From Baseline in the Rasch-transformed Score of the FACE-Q Satisfaction With Skin', 'description': 'The FACE-Q questionnaire is a 12- item questionnaire. Overall scores range from 0 to 100 with higher scores representing higher satisfaction.', 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}, {'measure': 'Change From Baseline Self-Perception of Age', 'description': ""Subject's assessment of self-perception of age as measured by SPA. Subject's selected one of 3 options based on how they felt their facial appearance looked compared to their age on the day they completed the assessment, writing in the number of years when appropriate."", 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}, {'measure': ""Investigator's Assessment Using Global Aesthetic Improvement Scale (GAIS)"", 'description': 'Five point ordinal scale measuring the change in facial aesthetic improvement from -2 (Much Worse) to 2 (Much Improved) assessed by the Investigator.', 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}, {'measure': ""Subject's Assessment Using Global Aesthetic Improvement Scale (GAIS)"", 'description': 'Five point ordinal scale measuring the change in facial aesthetic improvement from -2 (Much Worse) to 2 (Much Improved) assessed by the subject.', 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}, {'measure': 'Change From Baseline to End of Study of Periorbital Aesthetic Appearance Questionnaire (PAAQ)', 'description': ""Questionnaire evaluating the subject's overall eye appearance from 0 (Never) to 4 (All of the Time) for each of the 9 items. All items were transformed to a scale from 0 (no negative impact) to 100 (high negative impact).\n\nTotal transformed score is based on 9 individual items each item has a range of 0 to 4, the transformed score ranges from 0 to 100.\n\nPsychological domain is based on the average of the sum of transformed scores of individual items 2, 4, 6, 7, and 8. Score will also range from 0 to 100 with same interpretation as the total transformed score.\n\nAppearance domain is based on the average of the sum of transformed scores of individual items 1, 3, and 5. Score will also range from 0 to 100 with same interpretation as the total transformed score.\n\nCoping domain is the transformed score of item 9. Score will also range from 0 to 100 with same interpretation as the total transformed score."", 'timeFrame': 'Visit 0 (Day 1) to Visit 7 (Up to approximately 5 months)'}]",9.0,35 Years,65 Years,ALL,False,INDUSTRY,0.0,64.0,ACTUAL,v2_robust,True,True,False,False,
NCT02186782,Concomitant CC and E2 Versus CC Alone in Ovulation Induction,Clomiphene citrate and Estradiol,"['Clomiphene citrate and Estradiol', 'Clomid and Placebo', 'Clomid and Estradiol valerate', 'Clomiphene citrate and Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Infertility,Maher elesawi kamel elesawi,2025-09-01T16:18:07.021664,True,,,,,Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial,,"['Infertility', 'Anovulation']","['Clomiphene citrate', 'Estradiol', 'Endometrial thickness']",,2014-06,2018-08,"[{'measure': 'Clinical pregnancy rate', 'description': 'Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women', 'timeFrame': '6-8 weeks gestational age'}]","[{'measure': 'Endometrial thickness on day of HCG administration', 'description': 'Endometrial thickness by TVS on day of HCG administration', 'timeFrame': '3 months'}]",2.0,20 Years,39 Years,FEMALE,False,OTHER,0.0,600.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06825182,Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes,Outpatient newly diagnosed type 2 diabetes subjects,"['Outpatient newly diagnosed type 2 diabetes subjects', 'Inpatient newly diagnosed type 2 diabetes subjects']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Type 2 Diabetes Mellitus,"Nanjing First Hospital, Nanjing Medical University",2025-09-01T16:18:07.021675,True,,,,,"Survey on the Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes and Interventional Study of GLP-1RA: a Multicenter, Prospective Study",,['Type 2 Diabetes Mellitus'],"['Islet Alpha Cell Function', 'Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)']",,2024-11-07,2025-12-31,"[{'measure': 'Glucagon levels', 'description': 'Compare the glucagon levels in diabetic subjects during hyperglycemia and hypoglycemia, and the changes in GCG after 3 months of GLP-1RA treatment', 'timeFrame': '19 months'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,1000.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03247582,Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong),Edoxaban,"['Edoxaban', 'Lixiana']",2,OBSERVATIONAL,[],,COMPLETED,Atrial Fibrillation,"Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company",2025-09-01T16:18:07.021749,True,,,,,Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong),,['Atrial Fibrillation'],"['Real World Evidence', 'Non-valvular Atrial Fibrillation', 'Observational Safety']",,2017-08-02,2022-05-03,"[{'measure': 'Number of participants with real world safety events', 'timeFrame': '2 years'}]","[{'measure': 'Number of participants with patient relevant outcomes', 'description': 'Categories: Strokes (ischaemic and haemorrhagic), Systemic Embolic Events (SEE), Transient Ischemic Attack (TIA), Major Adverse Cardiovascular Events (MACE), Venous Thromboembolism (VTE), Acute Coronary Syndrome (ACS), Hospitalisations related to cardiovascular (CV) condition', 'timeFrame': '2 years'}, {'measure': 'Average duration of exposure to edoxaban', 'timeFrame': 'within 2 years'}, {'measure': 'Number of participants compliant with edoxaban therapy', 'timeFrame': '2 years'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,234.0,ACTUAL,v2_robust,False,True,False,True,
NCT02951182,A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis,TEZ,"['VX-770', 'IVA', 'ivacaftor', 'TEZ', 'VX-440', 'VX-661', 'Matched Placebo', 'tezacaftor']",8,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,2025-09-01T16:18:07.021896,True,,,,,"A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis",,['Cystic Fibrosis'],[],,2016-10,2017-08,"[{'measure': 'Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'From first dose of Study Drug in the Treatment Period through Safety Follow-up Visit (Up to Day 57 for Part 1 and Day 85 for Part 2)'}, {'measure': 'Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)', 'description': 'FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.', 'timeFrame': 'From Baseline through Day 29'}]","[{'measure': 'Absolute Change in Sweat Chloride Concentrations', 'description': 'Sweat samples were collected using an approved collection device.', 'timeFrame': 'From Baseline through Day 29'}, {'measure': 'Relative Change in ppFEV1', 'description': 'FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.', 'timeFrame': 'From Baseline through Day 29'}, {'measure': 'Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score', 'description': 'The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.', 'timeFrame': 'From Baseline at Day 29'}, {'measure': 'Pre-dose Plasma Concentration (Ctrough) of VX-440, TEZ, M1-TEZ, IVA and M1-IVA', 'timeFrame': 'Predose at Day 8, Day 15 and Day 29'}]",6.0,12 Years,,ALL,False,INDUSTRY,0.0,74.0,ACTUAL,v2_robust,True,True,False,True,
NCT00429182,Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer,Carboplatin,"['Carboplatin', 'Paraplatin', 'Cyclophosphamide', 'Neosar', 'Cytoxan', 'Thiotepa']",6,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Breast Cancer,M.D. Anderson Cancer Center,2025-09-01T16:18:07.021952,True,,,,,Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients,,"['Breast Cancer', 'Metastatic Breast Carcinoma', 'Invasive Breast Carcinoma']","['Breast Cancer', 'breast carcinoma', 'Carboplatin', 'Paraplatin', 'Cyclophosphamide', 'Neosar', 'Cytoxan', 'Thiotepa', 'Purged Autologous Stem Cells', 'Circulating Tumor Cells', 'CTCs']",,2007-06,2012-02,"[{'measure': 'Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products', 'description': 'Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.', 'timeFrame': 'Baseline to 1 month post AHST'}]","[{'measure': 'Median Progression Free Survival (PFS)', 'description': 'Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression. PFS time measured in months.', 'timeFrame': 'Overall study (baseline to disease progression)'}]",2.0,18 Years,55 Years,ALL,False,OTHER,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT06593782,Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting,HSK21542,"['Dolasetron', 'HSK21542']",2,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,"Nausea and Vomiting, Chemotherapy-Induced",First Affiliated Hospital of Wenzhou Medical University,2025-09-01T16:18:07.021984,True,,,,,"A Multicenter, Randomized, Double-blind, Active-Controlled Dose-Finding Study of HSK21542 Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)",,"['Nausea and Vomiting, Chemotherapy-Induced']",[],,2024-09-16,2025-09-01,"[{'measure': 'Acute Complete response', 'description': 'Acute Complete response was defined as no vomiting/retching and no rescue therapy over the first 24 hours after the initiation of high emetic chemotherapy regimen', 'timeFrame': '0 to 24 hours'}]","[{'measure': 'Overall Complete response', 'description': 'Overall Complete response was defined as no vomiting/retching and no rescue therapy over the first 120 hours after the initiation of high emetic chemotherapy regimen', 'timeFrame': '0 to 120 hours'}, {'measure': 'Delayed Complete response', 'description': 'Delayed Complete response was defined as no vomiting/retching and no rescue therapy over the 24 to 120 hours after the initiation of high emetic chemotherapy regimen', 'timeFrame': '24 to 120 hours'}]",3.0,18 Years,,ALL,False,OTHER,0.0,180.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01280682,Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes,rituximab,"['rituximab', 'anti-CD20 monoclonal antibody']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Type 1 Diabetes,Yang Tao,2025-09-01T16:18:07.022038,True,,,,,Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes,,['Type 1 Diabetes'],"['type 1 diabetes', 'age', 'course of disease', 'autoantibodies', 'C-peptide levels']",,2010-07,2018-12,"[{'measure': 'Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide', 'description': 'Change of 3-hour mean area under the curve (AUC) of C-peptide at 6 months from baseline. AUC was calculated from C-peptide timing measurements during the 3-hour mixed meal tolerance test with the trapezoidal rule. The mean AUC for C-peptide is equal to the calculated AUC divided by the 3 h interval (i.e., AUC/180). All mean C-peptide AUC data were transformed as log (mean AUC) for analysis.', 'timeFrame': '6 months after participants completed the injection'}]","[{'measure': 'Change of Fasting C-peptide', 'description': 'The change of fasting level of C-peptide during the 3-hour of a mixed meal tolerance test at 6 months from baseline. All fasting C-peptide data were transformed as log (fasting C-peptide) for analysis.', 'timeFrame': '6 months after participants completed the injection'}, {'measure': 'Change of Peak C-peptide', 'description': 'The change of peak level of C-peptide during the 3-hour of a mixed meal tolerance test at 6 months from baseline. All peak C-peptide data were transformed as log (peak C-peptide) for analysis.', 'timeFrame': '6 months after participants completed the injection'}, {'measure': 'HbA1c Levels', 'description': 'Glycated hemoglobin (HbA1c) levels (%)', 'timeFrame': '6 months after participants completed the injection'}]",4.0,8 Years,70 Years,ALL,False,OTHER,0.0,120.0,ACTUAL,v2_robust,True,True,False,False,
NCT06461182,Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma,Ga-68-CXCR4,"['Ga-68-CXCR4', 'PET/CT']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Indolent B-Cell Non-Hodgkin Lymphoma,Koo Foundation Sun Yat-Sen Cancer Center,2025-09-01T16:18:07.022166,True,,,,,"Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma",,['Indolent B-Cell Non-Hodgkin Lymphoma'],"['Ga-68-CXCR4 PET/CT', 'indolent B-cell lymphoma']",,2024-04-29,2027-04,"[{'measure': 'Performance of Ga-68-CXCR4 PET/CT in indolent B cell lymphoma', 'description': 'Detection rate = number of positive scan / total number of scan Sensitivity = number of true positive scan / total number of proven recurrent patient Specificity = number of true negative scan / total number of proven free of disease patient Accuracy = number of (true positive scan + true negative scan) / total number of scan Positive predictive value = number of true positive scan / number of positive scan Negative predictive value = number of true negative scan / number of negative scan', 'timeFrame': 'up to 24 months'}]","[{'measure': 'Ga-68-CXCR4 compared to F-18-FDG PET/CT', 'description': 'McNemar test, Two-tailed，P\\<.05', 'timeFrame': 'up to 24 months'}, {'measure': 'Clinical impact of Ga-68-CXCR4 compared to F-18-FDG PET/CT', 'description': 'Treatment plan questionnaires before and after Ga-68-CXCR4 PET/CT', 'timeFrame': 'up to 24 months'}, {'measure': 'Prognostic value of Ga-68-CXCR4 PET/CT scan', 'description': 'The correlation between the radiomic features of Ga-68-CXCR4 PET/CT scan and progression free survival.\n\nCXCR4 radiomics : Feature extraction was performed with the open-source Python package pyradiomics. For each volume of interest (VOI), including first-order statistics, shape features, grey level co-occurrence matrix (GLCM), grey level run length matrix (GLRLM), grey level size-zone matrix (GLSZM), neighborhood grey level different matrix (NGLDM), and grey level dependence matrix (GLDM).', 'timeFrame': 'up to 36 months'}]",4.0,20 Years,100 Years,ALL,False,OTHER,0.0,15.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01532882,Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs,Diosmin,"['Diosmin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Venous Disease of Lower Limbs,Laboratoire Innotech International,2025-09-01T16:18:07.022256,True,,,,,"Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups",,['Chronic Venous Disease of Lower Limbs'],[],,2012-01,2013-04,"[{'measure': 'Change of Visual analog Scale score for assessment of the painful venous symptomatology', 'timeFrame': 'baseline and after 28 days'}]","[{'measure': '- Painful symptom intensity (daily VAS score) Area Under the Curve', 'timeFrame': '28 days'}, {'measure': '- Daily VAS score for Response rate', 'timeFrame': '28 days'}, {'measure': '- Daily VAS score for Time to response', 'timeFrame': '28 days'}, {'measure': '- Score of Quality of life questionnaire (SQOR-V)', 'timeFrame': 'Between baseline and 28 days'}, {'measure': ""- Patient's and physician's global satisfaction score"", 'timeFrame': 'At 28 days'}, {'measure': 'Adverse Events (numbers and frequency)', 'timeFrame': '28 days'}, {'measure': '- Unusual intakes of analgesic treatments (rate of patients)', 'timeFrame': '28 days'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,378.0,ACTUAL,v2_robust,True,True,False,True,
NCT00085982,Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance,Metreleptin,['Metreleptin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Severe Insulin Resistance,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),2025-09-01T16:18:07.022294,True,,,,,Phase II Trial of Effect of Metreleptin Therapy in Severe Insulin Resistance,,['Severe Insulin Resistance'],"['Rabson Mendenhall', 'Type B Insulin Resistance', 'Type A Insulin Resistance']",,2003-08-21,2030-01-01,"[{'measure': 'Change in HbA1C', 'description': 'Change in HbA1C at month 12 from baseline.', 'timeFrame': 'Change at month 12 from baseline'}]","[{'measure': 'Change in Fasting Insulin Level', 'description': 'Change in fasting insulin level at month 12 from baseline', 'timeFrame': 'Change at month 12 from baseline'}, {'measure': 'Change in Fasting Blood Glucose', 'description': 'Change in fasting blood glucose at month 12 from baseline.', 'timeFrame': 'Change at month 12 from baseline'}]",3.0,5 Years,,ALL,False,NIH,0.0,11.0,ACTUAL,v2_robust,True,False,False,False,
NCT02429882,Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis,Brodalumab 210 mg,"['Brodalumab 210 mg', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Axial Spondyloarthritis,Amgen,2025-09-01T16:18:07.022307,True,,,,,"A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis",,['Axial Spondyloarthritis'],['Ankylosing Spondyloarthritis; non-radiographic axial spondyloarthritis'],"Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab, study is being cancelled/closed.",2015-05,2015-05,"[{'measure': 'Assessment of SpondyloArthritis international Society (ASAS)', 'description': 'Achievement of Assessment of SpondyloArthritis international Society (ASAS) 20 response at week 16', 'timeFrame': 'Week 16'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,"Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab, study is being cancelled/closed."
NCT02336724,A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor,Famitinib,['Famitinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Gastrointestinal Stromal Tumor,"Jiangsu HengRui Medicine Co., Ltd.",2025-09-01T16:18:07.022397,True,,,,,"A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor",,['Gastrointestinal Stromal Tumor'],"['gastrointestinal stromal tumor', 'famitinib']",,2012-03,2019-06,"[{'measure': 'Disease Control Rate', 'timeFrame': '12 weeks'}]","[{'measure': 'Objective Response Rate', 'timeFrame': '12 weeks'}, {'measure': 'Progression free survival', 'timeFrame': '24 months'}, {'measure': 'Overall survival', 'timeFrame': '96 months'}, {'measure': 'Incidence of adverse events', 'timeFrame': '24 months'}]",5.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,88.0,ACTUAL,v2_robust,True,False,False,True,
NCT04611724,A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer,FOLFIRINOX,['FOLFIRINOX'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Urachal Cancer,Asan Medical Center,2025-09-01T16:18:07.022453,True,,,,,A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer,,['Urachal Cancer'],"['Urachal Cancer', 'FOLFIRINOX']",,2020-12-01,2024-09-30,"[{'measure': 'Objective response rate', 'description': 'Objective response rate', 'timeFrame': 'up to 2 years'}]","[{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': 'every 2 weeks up to 30 weeks.'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS)', 'timeFrame': 'up to 2years.'}, {'measure': 'Overall survival (OS),', 'description': 'Overall survival (OS),', 'timeFrame': 'up to 5 years.'}, {'measure': 'Incidence of febrile neutropenia', 'description': 'Incidence of febrile neutropenia', 'timeFrame': 'After study completion (an average of 2 year)'}]",5.0,19 Years,65 Years,ALL,False,OTHER,2.0,35.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03740724,A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea),veledimex,"['a small-molecule activator ligand for the RheoSwitch (RTS®) system', 'veledimex']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Morphea,"Castle Creek Biosciences, LLC.",2025-09-01T16:18:07.022482,True,,,,,A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea),,"['Morphea', 'Scleroderma, Localized', 'Scleroderma']",['Morphea'],Sponsor decision,2019-12-18,2022-04-21,"[{'measure': 'Evaluate the Safety of FCX-013 Plus Veledimex', 'description': 'Safety evaluations include assessment of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs); change in clinical laboratory values; change in vital signs; change in electrocardiograms (ECGs); and incidence of replication-competent lentivirus (RCL) antibodies.', 'timeFrame': 'Study initiation through study completion'}]","[{'measure': 'Evaluate the Antifibrotic Effects of FCX-013 Plus Veledimex', 'description': 'Evaluate the antifibrotic effects of FCX-013 plus veledimex', 'timeFrame': 'Week 4'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,1.0,ACTUAL,v2_robust,True,False,True,True,Sponsor decision
NCT00169624,Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin,Metformin,"['Gliclazide', 'Metformin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Coronary and Peripheral Endothelial Dysfunction,Hospices Civils de Lyon,2025-09-01T16:18:07.022490,True,,,,,The DIAMET Study: Peripheral and Coronary Endothelial Dysfunction in Type 2diabetic Patients- Evaluation of Reversibility Following 3 Months of Metformin Treatment,,['Coronary and Peripheral Endothelial Dysfunction'],"['Diabetes,', 'coronary endothelial dysfunction,', 'metformin,', 'glyclazide,', 'MRI.']",,2005-10,,[{'measure': 'Flow dependent and independent Brachial artery vasoreactivity assessed using Doppler technology at 3 month vs baseline'}],[{'measure': 'Myocardial perfusion improvement following improved vasoreactivity assessed using myocardial perfusion imaging at 3 month vs baseline'}],2.0,18 Years,70 Years,ALL,False,OTHER,0.0,30.0,,v2_robust,True,False,True,False,
NCT02765724,Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects,Pacritinib,"['Pacritinib', 'Pacritinib 400mg capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Myelofibrosis,CTI BioPharma,2025-09-01T16:18:07.022511,True,,,,,"A Phase 1 Open Label, Single Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Impaired Hepatic Function in Comparison With Healthy Subjects",,['Myelofibrosis'],[],,2015-01,2015-06,"[{'measure': 'To characterize the pharmacokinetic profile of a single 400-mg dose of pacritinib and its major metabolites in patients with hepatic impairment as compared to gender-, age-, and body mass index -matched healthy subjects with normal liver function', 'description': 'Plasma concentrations of pacritinib and any major metabolites were determined by a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric assay. The lower limit of quantitation of the assay is 20 ng/mL for pacritinib and 4 ng/mL for PAC-M1 metabolite in plasma', 'timeFrame': 'Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose'}]","[{'measure': 'To evaluate the safety of pacritinib and tolerability of a single 400-mg dose of pacritinib in patients with hepatic impairment and healthy subjects;', 'description': 'Adverse events, vital signs, physical examinations, clinical laboratory valuations, and ECGs', 'timeFrame': '00:00 of ICF signature until 1 min before IP admin and from the date-time of IP administration until 23:59 of the day of last contact'}]",2.0,18 Years,85 Years,ALL,True,INDUSTRY,1.0,28.0,ACTUAL,v2_robust,True,True,False,True,
NCT03547024,A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol,JNJ-55308942 High Dose,"['JNJ-55308942 Low Dose', 'Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)', 'Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)', 'Microgynon 30', 'JNJ-55308942 High Dose']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Janssen-Cilag International NV,2025-09-01T16:18:07.022535,True,,,,,"An Open-Label Drug Interaction Study in Healthy Subjects to Evaluate the Effects of Multiple Doses of JNJ55308942 on the Cytochrome P450 CYP3A4, CYP2D6 and CYP2C19 Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol",,['Healthy'],[],,2018-06-08,2018-08-30,"[{'measure': 'Parts 1 and 3: Maximum Observed Analyte Concentration (Cmax) of Each Probe Substrate in Cocktail', 'description': 'Cmax of probe substrates in cocktail containing selective probes of CYP enzymes (CYP3A, CYP2D6 and CYP2C19) will be determined.', 'timeFrame': 'Predose, 15 minute (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 18h on Days 1 and 12'}, {'measure': 'Parts 1 and 3: Area Under the Analyte Concentration-Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUC[0-last]) of Each Probe Substrate in Cocktail', 'description': 'AUC(0-last) of probe substrates in cocktail containing selective probes of CYP enzymes (CYP3A, CYP2D6 and CYP2C19) will be determined.', 'timeFrame': 'Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 18h on Days 1 and 12'}, {'measure': 'Parts 1 and 3: Area Under the Analyte Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Each Probe Substrate in Cocktail', 'description': 'AUC (0-infinity) of probe substrates in cocktail containing selective probes of CYP enzymes (CYP3A, CYP2D6 and CYP2C19) will be determined.', 'timeFrame': 'Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 18h on Days 1 and 12'}, {'measure': 'Part 2: Cmax of Levonorgestrel and Ethinyl Estradiol', 'description': 'Cmax is the maximum observed analyte concentration.', 'timeFrame': 'Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 18h on Days 1 and 14'}, {'measure': 'Part 2: AUC(0-last) of Levonorgestrel and Ethinyl Estradiol', 'description': 'AUC(0-last) is defined as the area under the analyte concentration-time curve from time 0 to time of the last quantifiable concentration.', 'timeFrame': 'Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 18h on Days 1 and 14'}, {'measure': 'Part 2: AUC(0-infinity) of Levonorgestrel and Ethinyl Estradiol', 'description': 'AUC (0-infinity) is the area under the analyte concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the analyte concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.', 'timeFrame': 'Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 18h on Days 1 and 14'}]","[{'measure': 'Parts 1, 2 and 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability', 'description': 'An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.', 'timeFrame': 'Approximately 10 weeks'}, {'measure': 'Parts 1, 2 and 3: Observed Analyte Concentration Just Prior to the Beginning or at the end of a Dosing Interval (Ctrough) of JNJ-55308942', 'description': 'Ctrough is the observed analyte concentration just prior to the beginning or at the end of a dosing interval in a multiple dosing regimen.', 'timeFrame': 'Predose on Days 4 to 11, predose, up to 72 hours postdose on Day 12 (Parts 1 and 3); Predose on Days 5 to 13, predose, up to 120 hour postdose on Day 14 (Part 2)'}]",8.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,14.0,ACTUAL,v2_robust,True,True,False,True,
NCT03118024,Perioperative Management of DIEP Flaps,Crystalloid Solutions,"['Norephinephrine', 'Crystalloid Solutions', 'Catecholamines']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Mammaplasty,University of Regensburg,2025-09-01T16:18:07.022584,True,,,,,Perioperative Management of Deep Inferior Epgastric Perforator (DIEP) Flap for Breast Reconstruction,,"['Mammaplasty', 'Microsurgery', 'Free Tissue Flaps']","['deep inferior epigastric perforator flap', 'fluid restriction', 'catecholamine restriction']",,2017-03-13,2019-03,"[{'measure': 'Free flap survival rate', 'description': 'Rates of (partial) flap loss in each study arm', 'timeFrame': '5 days postoperatively'}]","[{'measure': 'Period of hospitalization', 'description': 'Length of postoperative hospitalization in each study arm', 'timeFrame': 'up to 14 days'}]",2.0,18 Years,80 Years,FEMALE,True,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02221024,Normal Saline Flushes at 12 vs 24 Hours Intervals for Maintaining Peripheral Intravenous Catheters Patency,Normal saline,"['Physiological saline solution', 'Isotonic saline solution', 'Normal saline']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Pain,IRCCS Burlo Garofolo,2025-09-01T16:18:07.022610,True,,,,,Randomized Controlled Trial to Evaluate the Efficacy of Normal Saline Flushes at 12 and 24 Hours Intervals in Maintaining Peripheral Intravenous Catheters Patency,,['Pain'],"['Peripheral intravenous catheter', 'Peripheral intravenous lock', 'Normal saline', 'Patency', 'Management', 'of peripheral', 'intravenous catheter']",,2011-07,2013-09,"[{'measure': 'Number of participants with peripheral intravenous catheter patency', 'description': 'Patency was defined as the possibility of flushing the cannula with a 3 ml Becton Dickinson syringe filled with 3 ml of normal saline in less than 20 seconds without resistance at infusion, pain or erythema', 'timeFrame': 'Until catheter use (i.e. drug infusion) or removal (catether related complication or no further need of use), with an expected avarage of 48 hours'}]","[{'measure': 'Number of participants with blood extravasation', 'description': ""Presence of blood extravasation in the site of catheter insertion, defined as the presence of changes in the site's appearence and temperature (i.e. edema, blanching, coolness) at the time of nurse's evaluation"", 'timeFrame': 'Until catheter use (i.e. drug infusion) or removal (catether related complication or no further need of use), with an expected avarage of 48 hours'}, {'measure': 'Number of participants with pain', 'description': 'Any pain at the site of catheter insertion referred by patients to nurses', 'timeFrame': 'Until catheter use (i.e. drug infusion) or removal (catether related complication or no further need of use), with an expected avarage of 48 hours'}, {'measure': 'Number of participants with skin redness', 'description': ""Presence of skin redness at the site of catheter insertion at the time of nurse's evaluation"", 'timeFrame': 'Until catheter use (i.e. drug infusion) or removal (catether related complication or no further need of use), with an expected avarage of 48 hours'}, {'measure': 'Number of participants with swelling', 'description': ""Presence of swelling in the site of catheter insertion at the time of nurse's evaluation"", 'timeFrame': 'Until catheter use (i.e. drug infusion) or removal (catether related complication or no further need of use), with an expected avarage of 48 hours'}]",5.0,1 Year,17 Years,ALL,False,OTHER,0.0,400.0,ACTUAL,v2_robust,True,True,False,False,
NCT01571024,BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,BKM120,"['buparlisib', 'mFOLFOX6', 'BKM120', 'Fluorouracil (5-FU)', 'Folinic acid (leucovorin)', 'Oxaliplatin (Eloxatin)']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Advanced Solid Tumors,UNC Lineberger Comprehensive Cancer Center,2025-09-01T16:18:07.022631,True,,,,,A Phase I Study of BKM120 With mFOLFOX6 in Patients With Advanced Solid Tumors With Expansion Cohort in Metastatic Pancreatic Cancers.,,"['Advanced Solid Tumors', 'Metastatic Colorectal Cancer', 'Metastatic Pancreatic Cancer']","['FOLFOX6', 'BKM120', 'Advanced Solid Tumors', 'Metastatic', 'Colorectal Cancer', 'Pancreatic Cancer']",,2012-05,2016-03,"[{'measure': 'Dose-limiting toxicity (DLT)', 'description': 'A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications, and occurs within the first cycle of therapy (4 weeks)of BKM120 when administered with mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.', 'timeFrame': '3 years'}, {'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'The MTD is defined as a dose with a Dose Limiting Toxicity rate of 20% for BKM120 when administered with mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.', 'timeFrame': '3 years'}]","[{'measure': 'Number of subjects experiencing adverse events', 'description': 'Using CTCAE criteria, we will identify acute and chronic toxicities of BKM120 in combination with mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer', 'timeFrame': '3 years'}, {'measure': 'Progression Free Survival (PFS)', 'description': ""The length of time subject's disease does not get worse from time of start of treatment with BKM120 in combination with mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer."", 'timeFrame': '4 years'}, {'measure': 'Overall Survival(OS)', 'description': 'Length of survival after treatment with the MTD of BKM120 in combination with mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.', 'timeFrame': '7 years'}, {'measure': 'Biomarkers of Clinical Benefit', 'description': 'To examine potential correlations between blood and tissue biomarkers and clinical benefit of BKM120 when administered with mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.', 'timeFrame': '3 years'}]",6.0,18 Years,,ALL,False,OTHER,0.0,17.0,ACTUAL,v2_robust,True,True,False,True,
NCT05213624,A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis,BI 764198,"['Placebo', 'BI 764198']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Kidney Disease, Chronic",Boehringer Ingelheim,2025-09-01T16:18:07.022720,True,,,,,"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis",,"['Kidney Disease, Chronic']",[],,2022-05-03,2025-01-03,"[{'measure': 'Number of patients achieving at least 25% reduction in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at week 12', 'timeFrame': 'up to 12 weeks'}]","[{'measure': 'Change in 24-hour UPCR relative to visit 3 at week 12', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Change in 24-hour UPCR relative to baseline at week 13', 'timeFrame': 'up to 13 weeks'}, {'measure': 'Change in 24-hour urinary protein excretion relative to baseline at week 12', 'timeFrame': 'up to 12 weeks'}, {'measure': 'If feasible: Pre-dose plasma concentration at steady state (Cpre,ss) of BI 764198 at week 4', 'timeFrame': 'up to 4 weeks'}, {'measure': 'If feasible: Pre-dose plasma concentration at steady state (Cpre,ss) of BI 764198 at week 12', 'timeFrame': 'up to 12 weeks'}]",6.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,67.0,ACTUAL,v2_robust,True,True,False,False,
NCT00607724,GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors,GDC-0449,"['Hedgehog Pathway Inhibitor', 'GDC-0449']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Unspecified Adult Solid Tumor, Protocol Specific","Genentech, Inc.",2025-09-01T16:18:07.022733,True,,,,,"An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists",,"['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",,2007-04,2009-11,"[{'measure': 'Percentage of Participants With Dose-Limiting Toxicities (DLTs)', 'description': 'A DLT was defined as any Grade 3 or 4 hematologic or major organ toxicity as graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 3.0) that occurred during the first 35 days after the initiation of study drug (Days 1-35) and was attributable to GDC-0449.', 'timeFrame': 'Up to Week 6'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) After a Single Dose of GDC-0449', 'description': 'Phase I comprised of two stages, a dose-escalation stage with the goal of estimating the maximum tolerated dose (Stage 1), and an expanded cohort to collect additional safety, PK, and pharmacodynamic (PD) data at the proposed Phase II dose (Stage 2). Phase II represented the additional cohort initiated with 150 mg hard gelatin capsule identified from the safety, PK and PD data from Stage 1 of the trial.', 'timeFrame': '-5 minutes (pre-dose) and 0.5, 1, 2, 4, 8, 24 hours post-dose on Day 1; additionally for stage 1 arms: 48 hours (Day 3), 72 hours (Day 4) post-dose and - 5 minutes (pre-dose) on Day 8'}, {'measure': 'Cmax After Multiple Doses of GDC-0449', 'description': 'Cmax was estimated if there were extensive PK sampling in more that 50% of the participants to form a curve.', 'timeFrame': '-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) After a Single Dose of GDC-0449', 'description': 'Phase I comprised of two stages, a dose-escalation stage with the goal of estimating the maximum tolerated dose (Stage 1), and an expanded cohort to collect additional safety, PK, and PD data at the proposed Phase II dose (Stage 2). Phase II represented the additional cohort initiated with 150 mg hard gelatin capsule identified from the safety, PK and PD data from Stage 1 of the trial.', 'timeFrame': '-5 minutes (pre-dose) and 0.5, 1, 2, 4, 8, 24 hours post-dose on Day 1; additionally for stage 1 arms: 48 hours (Day 3), 72 hours (Day 4) post-dose and - 5 minutes (pre-dose) on Day 8'}, {'measure': 'Tmax After Multiple Doses of GDC-0449', 'description': 'Tmax was estimated if there were extensive PK sampling in more that 50% of the participants to form a curve.', 'timeFrame': '-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years'}, {'measure': 'Average Plasma Concentration at Steady State (Css, Avg) After Multiple Doses of GDC-0449', 'description': 'Steady state GDC-0449 plasma concentrations (Css) were calculated as an average of plasma concentrations from Study Day 21 (Stage 2) or Study Day 28 (Stage 1) onward.', 'timeFrame': '-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24) After a Single Dose of GDC-0449', 'description': 'AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Phase I comprised of two stages, a dose-escalation stage with the goal of estimating the maximum tolerated dose (Stage 1), and an expanded cohort to collect additional safety, PK, and PD data at the proposed Phase II dose (Stage 2). Phase II represented the additional cohort initiated with 150 mg hard gelatin capsule identified from the safety, PK and PD data from Stage 1 of the trial.', 'timeFrame': '-5 minutes (pre-dose) and 0.5, 1, 2, 4, 8, 24 hours post-dose on Day 1; additionally for stage 1 arms: 48 hours (Day 3), 72 hours (Day 4) post-dose and - 5 minutes (pre-dose) on Day 8'}, {'measure': 'AUC0-24 After Multiple Doses of GDC-0449', 'description': 'AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUC was estimated if there were extensive PK sampling in more that 50% of the participants to form a curve.', 'timeFrame': '-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years'}, {'measure': 'Accumulation Index (AI) After Multiple Doses of GDC-0449', 'description': 'AI was calculated using the formula \\[AI = AUC(0-24) on Day 15/AUC(0-24) on Day 1\\]. AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AI was estimated if there were extensive PK sampling in more that 50% of the participants to form a curve.', 'timeFrame': '-5 minutes (pre-dose), 0.5,1,2,4,8 hours post-dose on Day [D] 1; 2,3,4; -5 minutes (pre-dose) on D8,15,22,29,36,64,92,120,148,176,204,232,260,288,316,344;every 4 weeks after D345; end of treatment and study (up to 28 days after last dose), up to 2 years'}]","[{'measure': 'Percentage of Participants With a Greater Than (>) 2-Fold Down-Modulation of GLI1 Expression in Skin Biopsy-Derived or Hair Follicle-Derived Messenger Ribonucleic Acid (mRNA)', 'description': 'Ribonucleic acid (RNA) was extracted from biopsy specimens of noninvolved skin or hair follicles at baseline and at 7 and 21 days after the start of daily drug therapy. Control mRNA was obtained from formalin-fixed, paraffin-embedded samples of normal skin and hair follicles from participants who were not enrolled in the study.', 'timeFrame': 'Baseline up to Day 29'}, {'measure': 'Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR): All Participants', 'description': 'BOR was defined as the best objective response (complete or partial response determined by two consecutive investigator assessments which were at least 28 days apart) observed during the treatment period according to RECIST v1.0. CR: disappearance of all target lesions (TLs), with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 millimeters (mm). PR: at least a 30 percent (%) decrease in the sum of diameters of TLs, taking as reference the baseline (BL) sum diameters.', 'timeFrame': 'Screening, at Week 8 thereafter every 8 weeks, up to Week 116'}, {'measure': 'Percentage of Participants With a BOR of CR or PR: Participants With Basal Cell Carcinoma', 'description': 'BOR was defined as the best objective response observed during the treatment period according to RECIST v1.0. CR: disappearance of all TLs, with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 mm. PR: at least a 30% decrease in the sum of diameters of TLs, taking as reference the BL sum diameters.', 'timeFrame': 'Screening, at Week 8 thereafter every 8 weeks, up to Week 116'}, {'measure': 'Duration of Objective Response: All Participants', 'description': 'Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow-up for progression of disease during first line therapy.', 'timeFrame': 'Screening, at Week 8 thereafter every 8 weeks, up to Week 116'}, {'measure': 'Duration of Objective Response: Participants With BCC', 'description': 'Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow-up for progression of disease during first line therapy.', 'timeFrame': 'Screening, at Week 8 thereafter every 8 weeks, up to Week 116'}, {'measure': 'Progression-Free Survival (PFS): All Participants', 'description': 'PFS was defined as the time from first dose of GDC-0449 to documented disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using RECIST v1.0) or death from any cause within 30 days of the last dose of GDC-0449, whichever occurred first.', 'timeFrame': 'Screening, at Week 8 thereafter every 8 weeks, up to Week 116'}, {'measure': 'PFS: Participants With BCC', 'description': 'PFS was defined as the time from first dose of GDC-0449 to documented disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using RECIST v1.0) or death from any cause within 30 days of the last dose of GDC-0449, whichever occurred first.', 'timeFrame': 'Screening, at Week 8 thereafter every 8 weeks, up to Week 116'}]",16.0,18 Years,,ALL,False,INDUSTRY,2.0,68.0,ACTUAL,v2_robust,True,True,False,True,
NCT00874523,Raltegravir and Atazanavir Dosing Strategy Study,atazanavir plus raltegravir,"['Reyataz', 'atazanavir plus raltegravir', 'Isentress']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,HIV Infection,Kirby Institute,2025-09-01T16:18:07.022796,True,,,,,"A Randomised, Open-label, Cross-over Study to Examine the Pharmacokinetics and Short-term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-infected Patients",,['HIV Infection'],"['raltegravir', 'atazanavir', 'HIV infections', 'pharmacokinetics', 'antiretroviral agents', 'treatment experienced']",,2009-07,2011-07,"[{'measure': 'comparison of the mean steady-state atazanavir trough plasma concentrations for once (C24) and twice (C12) daily dosing strategies', 'timeFrame': '4 and 8 weeks'}]","[{'measure': 'comparison of mean steady-state raltegravir trough plasma concentrations for once (C24) and twice (C12) daily dosing', 'timeFrame': '4 and 8 weeks'}, {'measure': 'comparison of steady-state pharmacokinetic profiles of once and twice-daily atazanavir', 'timeFrame': '4 and 8 weeks'}, {'measure': 'comparison of the steady-state pharmacokinetic profiles of once and twice-daily raltegravir', 'timeFrame': '4 and 8 weeks'}, {'measure': 'change from baseline in fasting lipid and glycaemic parameters', 'timeFrame': 'weeks 4 and 8 and overall'}, {'measure': 'change from baseline in CD4+ T-lymphocyte count', 'timeFrame': 'weeks 4 and 8 and overall'}, {'measure': 'change from baseline in HIV-RNA', 'timeFrame': 'weeks 4 and 8 and overall'}, {'measure': 'all adverse events attributable to study treatment', 'timeFrame': 'week 8'}, {'measure': 'all serious, grade 3 or 4 clinical adverse events, and any adverse event leading to premature cessation of study treatment', 'timeFrame': 'week 8'}]",9.0,18 Years,,ALL,False,OTHER_GOV,0.0,26.0,ACTUAL,v2_robust,True,True,False,True,
NCT06970223,A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV,Cabotegravir long-acting,"['Lenacapavir long-acting', 'Cabotegravir', 'Cabotegravir long-acting']",3,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,HIV Infections,ViiV Healthcare,2025-09-01T16:18:07.022813,True,,,,,"Phase 1, Open-Label, Randomised Crossover Study Assessing the Tolerability and Acceptability of Long Acting Cabotegravir Intramuscular and Lenacapavir Subcutaneous Injections Over Time in Healthy Adults Without HIV",,['HIV Infections'],"['Long-acting', 'Tolerability', 'Acceptability', 'Injection site reactions', 'Cabotegravir', 'Lenacapavir', 'Healthy adults']",,2025-04-22,2026-07-10,"[{'measure': 'Percentage of participants reporting very acceptable or totally acceptable local reactions', 'description': 'The analysis is performed using the 21-item perception of injection (PIN) questionnaire which includes 21 items grouped into 4 multi-item domains: \'Acceptance of ISR\' scale score (2 items); \'Bother from ISR\' scale score (6 items); \'Leg movement\' scale score (4 items); \'Sleep\' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain.\n\n""Acceptance of ISR"" is reported in this outcome measure for 2 scores: ""very acceptable ISR: and ""totally acceptable ISR"".', 'timeFrame': '7 days after each injection (injections administered on Day 1 and Day 15)'}]","[{'measure': 'Percentage of participants reporting very acceptable or totally acceptable local reactions at days 43 and 190', 'description': 'The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: \'Acceptance of ISR\' scale score (2 items); \'Bother from ISR\' scale score (6 items); \'Leg movement\' scale score (4 items); \'Sleep\' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain.\n\n""Acceptance of ISR"" is reported in this outcome measure for 2 scores: ""very acceptable ISR: and ""totally acceptable ISR"".', 'timeFrame': 'At Day 43 (28 days after second injection) and Day 190 (26 weeks after second injection)'}, {'measure': 'Mean injection site reaction scores, over time, post-injection, at days 8 and 22', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 8 and Day 22 (7 days after each injection visit)'}, {'measure': 'Median injection site reaction scores, over time, post-injection, at days 8 and 22', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 8 and Day 22 (7 days after each injection visit)'}, {'measure': 'Mean injection site reaction scores, over time, post-injection, at days 43 and 190', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 43 (28 days after second injection) and Day 190 (26 weeks after second injection)'}, {'measure': 'Median injection site reaction scores, over time, post-injection, at days 43 and 190', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 43 (28 days after second injection) and Day 190 (26 weeks after second injection)'}, {'measure': 'Change in the intensity of post-injection site pain assessed over time', 'description': 'The analysis is performed using the numerical rating scale (NRS), which is a visual analogue scale that assesses the maximum level of pain experienced with injections ranging from 0 (no pain) to 10 (extreme pain). An NRS related to each injection is self-administered electronically at the clinic visits at the same timepoints after each injection', 'timeFrame': 'At days 1, 2, 5 and 8 for the first injection and days 15, 16, 19, and 22 for the second injection'}, {'measure': 'Percentage of participants with ISRs overall and by severity', 'description': 'The ISRs severity is graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening. A higher grade indicates greater severity.', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Percentage of participants with specific ISRs of interest', 'description': 'The ISRs of interest are nodules (maximum diameter and visibility over time), pigmentation changes (assessed surface area, distinction of hyperpigmentation vs hypopigmentation), and induration/ swelling (visibility over time).', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Mean duration of ISRs', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Median duration of ISRs', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Percentage of participants with adverse events (AEs) overall and by severity', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The AEs severity is graded using the DAIDS criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening. A higher grade indicates greater severity.', 'timeFrame': 'Up to 6 months post a single dose of CAB LA and LEN LA sequentially administered'}, {'measure': 'Number of participants with laboratory abnormalities', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Number of participants with change in laboratory parameters over time', 'timeFrame': 'Up to 6 months post any injection compared to Baseline (Day 1)'}, {'measure': 'Maximum change in toxicity grade from baseline in laboratory values', 'description': 'Toxicity is graded using the DAIDS criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening. A higher grade indicates greater severity.', 'timeFrame': 'Up to 6 months post any injection compared to Baseline (Day 1)'}]",15.0,18 Years,,ALL,True,INDUSTRY,0.0,57.0,ACTUAL,v2_robust,True,False,False,True,
NCT00442923,"""The Evaluation of Stimulant Withdrawal""",Coreg,['Coreg'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Anxiety,Aaron J. Janowsky,2025-09-01T16:18:07.022907,True,,,,,Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse,,"['Anxiety', 'Relapse', 'Substance Addiction']","['Methamphetamine', 'Coreg', 'Withdrawal', 'anxiety', 'Substance Addiction']",This study was withdrawn for lack of progress. No subjects were recruited.,2007-07-01,2011-06-30,[],[],0.0,18 Years,65 Years,ALL,True,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,This study was withdrawn for lack of progress. No subjects were recruited.
NCT00179023,The Autonomic Nervous System and Obesity,Trimethaphan,"['Pseudoephedrine', 'Sudafed', 'Trimethaphan']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,OBESITY,Vanderbilt University,2025-09-01T16:18:07.022916,True,,,,,The Autonomic Nervous System and Obesity,,"['OBESITY', 'HYPERTENSION', 'PURE AUTONOMIC FAILURE', 'SHY-DRAGER SYNDROME']","['OBESITY', 'RESTING ENERGY EXPENDITURE', 'SYMPATHETIC NERVOUS SYSTEM', 'HYPERTENSION', 'AUTONOMIC FAILURE']",,2003-04,2017-01,"[{'measure': 'Change in supine systolic blood pressure after achieving complete ganglionic blockade.', 'timeFrame': '1-2 hour'}]","[{'measure': 'Change in resting energy expenditure after achieving complete autonomic blockade.', 'timeFrame': '1-2 hour'}]",2.0,18 Years,80 Years,ALL,True,OTHER,0.0,128.0,ACTUAL,v2_robust,True,True,False,False,
NCT04003623,Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208),Pemigatinib,"['INCB054828', 'Pemigatinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Advanced or Metastatic Solid Tumors,Incyte Corporation,2025-09-01T16:18:07.023069,True,,,,,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)",,"['Advanced or Metastatic Solid Tumors', 'FGFR Mutations', 'FGFR Translocations']","['Advanced solid tumor', 'metastatic solid tumor', 'FGFR inhibitor', 'FGFR mutation', 'FGFR translocation']",The study was closed due to lack of enrollment.,2019-10-31,2020-06-12,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'Defined as the proportion of participants in each cohort who achieve a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)', 'timeFrame': 'Up to approximately 6 months'}]","[{'measure': 'Progression-free Survival (PFS)', 'description': 'Defined as the time from first dose until progressive disease (per RECIST v1.1 or Response Assessment in Neuro-Oncology \\[RANO\\]) or death (whichever is first) in each cohort.', 'timeFrame': 'Up to approximately 6 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Defined as the time from the date of first assessment of CR or PR until the date of the first progressive disease (per RECIST v1.1 or RANO) or death (whichever is first) in each cohort.', 'timeFrame': 'Up to approximately 6 months'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Defined as the proportion of participants who achieved best overall response of CR, PR, or stable disease per RECIST v1.1 or RANO.', 'timeFrame': 'Up to approximately 6 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Defined as the time from first dose of study drug to death of any cause in each cohort.', 'timeFrame': 'Up to approximately 6 months'}, {'measure': 'Number of Treatment-related Adverse Events', 'description': 'Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.', 'timeFrame': 'Up to approximately 6 months'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,1.0,ACTUAL,v2_robust,True,False,True,True,The study was closed due to lack of enrollment.
NCT00506259,Treatment Strategies for Children With Smith-Magenis Syndrome,dTR Melatonin (NIH CC PDS),"['Melatonin CR', 'dTR Melatonin (NIH CC PDS)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Developmental Delay Disorders,National Human Genome Research Institute (NHGRI),2025-09-01T16:18:07.023094,True,,,,,A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS),,"['Developmental Delay Disorders', 'Chromosome Deletion', 'Mental Retardation', 'Sleep Disorders, Circadian Rhythm', 'Self Injurious Behavior']","['Deletion 17p11.2', 'Melatonin', 'Phototherapy', 'Behavioral Phenotype', 'Developmental Delay/MR', 'Smith-Magenis Syndrome', 'Sleep Disturbance', 'SMS', 'Sleep Disorder']",,2007-07-17,2018-05-22,[{'measure': 'Change in level of melatonin (pg/ml) from baseline'}],[{'measure': 'Improved sleep parameters (actigraphy). Increased daytime vigilance. Decreased maladaptive behaviors.'}],2.0,3 Years,45 Years,ALL,False,NIH,0.0,23.0,ACTUAL,v2_robust,True,True,False,False,
NCT01812759,Fentanyl for Breakthrough Pain in the Emergency Department,Fentanyl Nasal Spray,"['Lazanda', 'Hydromorphone PCA', 'Fentanyl Nasal Spray', 'Dilaudid']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Pain,M.D. Anderson Cancer Center,2025-09-01T16:18:07.023323,True,,,,,A Randomized Controlled Double-Blind Trial of Fentanyl Nasal Spray (Lazanda) Plus Hydromorphone Demand PCA Versus Placebo Nasal Spray Plus Hydromorphone Demand PCA for Treatment of Breakthrough Cancer Pain in the Emergency Department,,['Pain'],"['Pain', 'Breakthrough cancer pain', 'Emergency Department', 'ED', 'Fentanyl nasal spray', 'Lazanda', 'Placebo nasal spray', 'Hydromorphone PCA', 'Dilaudid']",,2014-01-10,2014-10-22,"[{'measure': 'Number of Participants With Total Pain Relief Score (TOTPAR4) at Four Hours After Treatment Initiation.', 'description': 'Primary outcome is total pain relief score (TOTPAR4) at 4 hours after treatment initiation. TOTPAR4 defined as the sum of hourly pain relief scores after baseline to four hours after the first administered dose of Lazanda or placebo. Scores range from -1 (worse pain) to 4 (complete relief). Range of possible TOTPAR4 summed scores is -4 to 16. A TOTPAR4 score greater than or equal to 8 is considered a positive response.', 'timeFrame': '4 hours'}]",[],1.0,18 Years,75 Years,ALL,False,OTHER,1.0,3.0,ACTUAL,v2_robust,True,False,True,False,
NCT00767559,Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery,warfarin,"['Fondaparinux:', 'warfarin', 'Arixtra', 'Coumadin', 'coumadin']",5,INTERVENTIONAL,['NA'],,UNKNOWN,Pulmonary Embolism,The New England Baptist Hospital,2025-09-01T16:18:07.023335,True,,,,,Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities,,['Pulmonary Embolism'],"['Deep Vein Thrombosis, anticoagulants, surgery, pulmonary embolus, warfarin, fondaparinox']",,2008-11,2012-10,"[{'measure': 'Primary Outcome based upon intent to treat: Composite outcome of', 'timeFrame': '28 days'}, {'measure': 'Ultrasound or venogram confirmed deep vein thrombosis.', 'timeFrame': '28 days'}, {'measure': 'Lung scan, pulmonary angiogram or CTA confirmed pulmonary embolus.', 'timeFrame': '28 days'}, {'measure': 'Death due to TED', 'timeFrame': '28 days'}]","[{'measure': 'Patient compliance with preoperative and post-operative medication schedule. Not enough space to note all measures', 'timeFrame': '28 days'}, {'measure': 'Distribution of proximal vs distal deep vein thrombosis of the leg', 'timeFrame': '28 days'}, {'measure': 'Amount of intraoperative bleeding', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Amount of postoperative bleeding A. transfusion requirement B. Hematomas requiring intervention, or other bleed clinically thought to be related to study drug. C. Other hemorrhagic events.', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': ""Number of ultrasounds and V/Q or CTA's required"", 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Costs associated with each study arm, including that of drug, laboratory monitors, radiology procedures required, lengths of stay, and management of complications', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Determine if negative D-D dimer can eliminate need for ultrasound analysis at follow-up visit.', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Death due to any other cause than TED', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Use of low molecular weight dextran', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Use of nonsteroidal anti-inflammatory drugs', 'timeFrame': 'follow until Dec. 31, 2010'}]",14.0,20 Years,,ALL,True,OTHER,0.0,330.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06616259,"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study",mCapOX plus Cetuximab,"['mFOLFOX6 plus Cetuximab', 'mCapOX plus Cetuximab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Colorectal Cancer (CRC),Meng Qiu,2025-09-01T16:18:07.023360,True,,,,,"First-line Treatment of MCapOX in Combination with Cetuximab Versus MFOLFOX6 in Combination with Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided Metastatic Colorectal Cancer: a Multicenter, Randomized, Controlled, Phase III Study",,"['Colorectal Cancer (CRC)', 'Capecitabine', 'Cetuximab']",['CAPCET-III'],,2024-09-26,2029-09-30,"[{'measure': 'Progression free survival (PFS)', 'description': 'Progression free survival is defined as the period from randomization to disease progress or death. Includes first-line induction therapy and maintenance therapy.', 'timeFrame': 'up to 3 years'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Defined as the proportion of participants acquired Complete response (CR) or Partial response (PR) during treatment. Based on RECIST 1.1.', 'timeFrame': '6 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'Defined as the proportion of patients who acquired Complete response (CR), Partial response (PR), or Stable disease (SD) during treatment. Based on RECIST 1.1.', 'timeFrame': '6 months'}, {'measure': 'Time to Failure of Strategy (TFS)', 'description': 'Defined as the time from the date of randomization to \\[secondary disease progression after reintroduction of first-line induction chemotherapy following maintenance therapy disease progression\\] or \\[all-cause death\\].\n\nIf participants progressed on maintenance therapy after first-line induction chemotherapy without reintroduction of first-line induction chemotherapy or progressed during first-line induction chemotherapy, TFS equals PFS', 'timeFrame': 'up to 3 years'}, {'measure': 'Overall Survival (OS)', 'description': 'Defined as the period from randomization to death from any cause', 'timeFrame': 'up to 5 years'}, {'measure': 'Adverse Event rate', 'description': 'The rate of adverse event after treatment', 'timeFrame': 'up to 3 years'}, {'measure': 'Pharmacoeconomic', 'description': 'Including CERs (Cost-Effectiveness Ratios) and ICERs (Incremental Cost-Effectiveness Ratios).\n\nCERs：Defined as the ratio of the total costs of a medical intervention to the health benefits gained from that intervention.\n\nICERs：Defined as the ratio of the difference in costs between two alternative interventions（Arm A and Arm B） to the difference in their effectiveness.', 'timeFrame': 'up to 3 years'}, {'measure': 'Quality of Life', 'description': 'Assessment of quality of life through the Quality of Life Questionnaire (QLQ)', 'timeFrame': 'up to 3 years'}]",8.0,18 Years,,ALL,False,OTHER,0.0,452.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02215980,STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS,Lenalidomide,"['Lenalidomide', 'Dexamethasone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Multiple Myeloma,Fondazione EMN Italy Onlus,2025-09-01T16:18:07.023457,True,,,,,"A PHASE III, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS",,['Multiple Myeloma'],"['Multiple myeloma', 'Diagnosis', 'Elderly and unfit patients', 'Lenalidomide plus steroids']",,2014-07,2024-07-01,"[{'measure': 'Event-free survival', 'description': 'Determine the Event-free survival defined as:\n\n* Progression\n* Death for any cause\n* Discontinuation of lenalidomide therapy\n* Occurrence of any haematological grade 4 or non-haematological grade 3-4 adverse events (AES), including Secondary Primary Malignancies (SPMs)', 'timeFrame': '3 years'}]","[{'measure': 'Progression-free survival (PFS)', 'timeFrame': '5 years'}, {'measure': 'Overall survival (OS)', 'timeFrame': '5 years'}, {'measure': 'Time to progression (TTP)', 'timeFrame': '5 years'}, {'measure': 'Overall response rate (ORR)', 'timeFrame': '5 years'}, {'measure': 'Time to response (TTR)', 'timeFrame': '5 years'}, {'measure': 'Duration of response (DOR)', 'timeFrame': '5 years'}, {'measure': 'Time to the next therapy (TNT)', 'timeFrame': '5 years'}, {'measure': 'Incidence of dose reduction and drug discontinuation', 'timeFrame': '5 years'}, {'measure': 'Health care cost', 'timeFrame': '5 years'}, {'measure': 'Correlation between tumor response and outcome with baseline prognostic factors', 'description': 'Analysis of tumor response and outcome stratification by prognostic factors', 'timeFrame': '5 years'}, {'measure': 'Quality of life assessment (HRQOL)', 'timeFrame': '5 years'}]",12.0,65 Years,,ALL,False,OTHER,0.0,210.0,ACTUAL,v2_robust,True,True,False,True,
NCT00503880,"Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes",clofarabine,"['clofarabine', 'cytarabine', 'cytosine arabinoside', 'Clolar']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Myelodysplastic Syndromes,University of Nebraska,2025-09-01T16:18:07.023554,True,,,,,"A Dose Escalation Phase I/II Study of Clofarabine Plus Cytarabine With Growth Factor Priming in Patients Who Are Not Felt to be Candidates for More Aggressive Treatment, With Int-2 and High-Risk MDS",,['Myelodysplastic Syndromes'],"['de novo myelodysplastic syndromes', 'previously treated myelodysplastic syndromes', 'secondary myelodysplastic syndromes']",Genzyme discontinued Funding,2007-05-07,2009-10-13,"[{'measure': 'Maximum Tolerated Dose of Clofarabine (Phase I)', 'description': 'Maximum Tolerated Dose (MTD) is defined to be the dose cohort below which 2 out of 6 patients experience dose limiting toxicities or the highest dose cohort, if 2 limiting toxicities are not observed at any dose cohort. These will be presented as actual rates. Dose limiting toxicity (DLT) will be defined according to oncology standards based on NCI CTC version 2 grading criteria (DLT = \\> grade 3 non-hematological toxicity or any \\> 4 hematological toxicity that persists for more than 4 weeks and in the opinion of the investigator is felt not to be due to disease).', 'timeFrame': '7 months'}, {'measure': 'Presence of Hematologic Response (Phase II)', 'description': 'These are measured in patients with pretreatment abnormalities defined as:\n\nHemoglobin \\< 11 g/dL or transfusion dependence \\[erythroid- E\\] Platelets less than 100 x 109/L or platelet-transfusion dependence \\[platelet- P\\] Absolute neutrophil count (ANC) less than 1.0 x 109/L \\[neutrophil- N\\] Pretreatment baseline measures of cytopenias are averages of at least 2 measurements (not influenced by transfusions)- at least 1 week apart.', 'timeFrame': 'Following phase I, responses must last at least 8 weeks.'}]","[{'measure': 'Assess Quality of Life', 'description': 'To assess effects on quality of life of this patient population (questionnaire).', 'timeFrame': '7 months'}, {'measure': 'Time to Acute Myelooid Leukemia Transformation or Death.', 'description': 'To assess the time to acute myeloid leukemia transformation or death.', 'timeFrame': '7months'}, {'measure': 'Cytogenetic Response Rates', 'description': 'To assess cytogenetic response rates.', 'timeFrame': '7 months'}, {'measure': 'Changes in Flow of Cytometric Patterns.', 'description': 'To assess changes in flow cytometric patterns.', 'timeFrame': '7 months'}]",6.0,19 Years,120 Years,ALL,False,OTHER,1.0,2.0,ACTUAL,v2_robust,True,False,True,False,Genzyme discontinued Funding
NCT01589380,"A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)",Fimasartan,"['Fimasartan (BR-A-657; CAS : 247257-48-3; Kanarb)', 'Fimasartan', 'Lactose Hydrate', 'Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Critical Stenosis of Aortic Valve,Seoul National University Hospital,2025-09-01T16:18:07.023664,True,,,,,"Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis",,['Critical Stenosis of Aortic Valve'],"['Aortic stenosis', 'Exercise performance', 'cardiopulmonary exercise test', 'fimasartan']",,2012-04,2014-12,"[{'measure': 'Change of VmaxO2 in Cardiopulmonary Exercise Test', 'description': 'Change of VmaxO2 from baseline to 1 year follow-up. VmaxO2 is defined as the highest oxygen uptake, averaged over 5 consecutive breaths, during the last minute of symptom-limited cardiopulmonary exercise test. For each patient, the change in VamxO2 is calculated as (VmaxO2 at 1 year follow-up) - (VmaxO2 at baseline)', 'timeFrame': 'Baseline and 1 year'}]","[{'measure': 'Change of peak aortic jet velocity in echocardiography', 'description': 'Change of peak aortic jet velocity which defined as (peak aortic jet velocity at 1 year follow-up) - (peak aortic jet velocity at baseline) on Doppler echocardiography.', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Change of mean pressure gradient across aortic valve', 'description': 'Change of mean pressure gradient which will be measured in echocardiography from baseline to study end.', 'timeFrame': 'Baseline and 1 year'}, {'measure': ""Diastolic function - LA area (cm2), E/E' value"", 'description': ""Change of LA area (cm2), E/E' value measured with Doppler echocardiography from baseline to study end"", 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Left ventricular mass index (LVMI)', 'description': 'Change of LVMI from baseline to study end.', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Development of aortic stenosis symptoms', 'description': 'Development of aortic stenosis symptoms angina, dyspnea, or syncope', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Admission for heart failure', 'description': 'During 1 year follow-up, admission due to congestiv eheart failure will be evaluated as secondary clinical outcome.', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Development of left ventricular dysfunction (LVEF <50%)', 'description': 'During follow-up, the development of LV dysfunction in echocardiography will be evaluated.', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Aortic valve surgery', 'description': 'During 1 year follow-up, the incidence of aortic valver surgery will be evaluated.', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Cardiac death including Sudden cardiac death', 'description': 'Cardiac death', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'All-cause death', 'description': 'All-cause mortality', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Composite Clinical Endpoint', 'description': 'Composite Endpoint which is consist of following:\n\nDevelopment of symptom of aortic stenosis: angina, dyspnea, or syncope Admission for heart failure Development of left ventricular dysfunction (LVEF \\<50%) Aortic valve surgery Cardiac death including Sudden cardiac death (will be collected separately) All-cause death Individual components of composite endpoint will be investigated separately also', 'timeFrame': 'Baseline and 1 year'}, {'measure': '6-minutes walk distance', 'description': '6-minutes walk distance from baseline to 1 year follow-up. For each patient, the change in 6-minutes walk distance is calculated as (6-minutes walk distance at 1 year follow-up) - (6-minutes walk distance at baseline)', 'timeFrame': 'Baseline and 1 year'}, {'measure': 'Safety Endpoint', 'description': '1. Development of symptomatic hypotension (dizziness, orthostatic hypotension with BP \\< 90/60)\n2. Development of overt azotemia (serum creatinine \\> 2.0mg/dL)\n3. Intolerance or development of other adverse drug reactions related with study drug.', 'timeFrame': 'Baseline and 1 year'}]",14.0,20 Years,75 Years,ALL,False,OTHER,7.0,100.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00117780,Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes,insulin detemir,"['insulin detemir', 'insulin aspart']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Diabetes,Novo Nordisk A/S,2025-09-01T16:18:07.023712,True,,,,,Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes,,"['Diabetes', 'Diabetes Mellitus, Type 1']",[],,2005-06,2006-10,"[{'measure': 'Mean HbA1c', 'timeFrame': 'after 4 months of insulin detemir treatment'}]","[{'measure': 'HbA1c'}, {'measure': 'Adverse events'}, {'measure': 'Insulin dose requirements during initial 4 months of treatment and during 3 months extension'}, {'measure': 'Weight'}, {'measure': 'Blood glucose'}, {'measure': 'Hypoglycaemia'}]",7.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,520.0,ACTUAL,v2_robust,True,True,False,True,
NCT04662580,ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer,ARX517,"['Abiraterone acetate', 'Apalutamide', 'Prednisone', 'ARX517']",4,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Metastatic Prostate Cancer,"Janssen Research & Development, LLC",2025-09-01T16:18:07.023927,True,,,,,"A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",,['Metastatic Prostate Cancer'],"['ADC', 'Antibody drug conjugate', 'Prostate neoplasia', 'Metastatic castration-resistant prostate cancer', 'PSMA', 'Prostate specific membrane antigen', 'PSMA ADC', 'Prostate Cancer']",,2024-12-09,2028-12-29,"[{'measure': 'Assess incidence of adverse events', 'description': 'Incidence and severity of adverse events or serious adverse events of ARX517 alone or in combination with ARPIs will be assessed to determine the safety and tolerability of the treatment using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5 (CTCAE).', 'timeFrame': '1.5 Years'}]","[{'measure': 'Area under the serum concentration-time curve (AUC) for ARX517 alone or in combination with ARPIs', 'description': 'Pharmacokinetic parameter area under the serum concentration-time curve (AUC) will be analyzed through different analytes such as ADC, total antibody, and pAF-AS269', 'timeFrame': '3 Year'}, {'measure': 'Maximum serum concentration (Cmax) for ARX517 alone or in combination with ARPIs', 'description': 'Pharmacokinetic parameter maximum serum concentration (Cmax) will be analyzed through different analytes such as, ADC, total antibody, and pAF-AS269', 'timeFrame': '3 Year'}, {'measure': 'Trough concentration (Ctrough) for ARX517 alone or in combination with ARPIs', 'description': 'Pharmacokinetic parameter trough concentration (Ctrough) will be analyzed through different analytes such as, ADC, total antibody, and pAF-AS269', 'timeFrame': '3 Year'}, {'measure': 'Incidence of ADA against ARX517 alone or in combination with ARPIs', 'description': 'To assess the incidence of anti-drug antibodies (ADA) against ARX517 at selected timepoints', 'timeFrame': '3 year'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive.', 'timeFrame': '3 year'}, {'measure': 'Assess changes in serum prostate specific antigen (PSA) levels', 'description': 'Proportion of subjects who show a confirmed reduction of 30%, 50%,and 90% from baseline in serum prostate specific antigen (PSA) levels (PSA30, PSA50, PSA 90)', 'timeFrame': '3 year'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy', 'timeFrame': '3 year'}]",8.0,18 Years,,MALE,False,INDUSTRY,0.0,253.0,ESTIMATED,v2_robust,True,False,False,True,
NCT07037680,Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT,Anlotinib,['Anlotinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Locally Advanced Non-Small Cell Lung Cancer,JIANYANG WANG,2025-09-01T16:18:07.023959,True,,,,,Efficiency and Safety of Radiotherapy Combined With Anlotinib in Locally Advanced Non-small Cell Lung Cancer Patients Intolerable to Concurrent Chemoradiotherapy: A Phase II Single-arm Trial,,"['Locally Advanced Non-Small Cell Lung Cancer', 'Thoracic Radiotherapy', 'Safety']","['thoracic radiotherapy', 'non-small cell lung carcinoma', 'locally advanced', 'safety', 'Anlotinib']",,2024-01-01,2026-06-30,"[{'measure': '2-year progression-free survival (PFS)', 'timeFrame': 'From the first day of radiotherapy to the occurrence of objective tumor progression or death due to any cause, whichever occurs first, assessed up to 60 months'}]","[{'measure': 'Overall Survival(OS)', 'timeFrame': 'From the first day of radiotherapy to the occurrence of death due to any cause, assessed up to 60 months'}, {'measure': 'Local regional recurrence (LR)', 'timeFrame': 'From the first day of radiotherapy to the occurrence of clinical and/or biopsy-proven recurrence within the bronchial stump, ipsilateral hilum, mediastinum, or supraclavicular, whichever occurs first, assessed up to 60 months'}, {'measure': 'Distant metastasis (DM)', 'timeFrame': 'From the first day of radiotherapy to the occurrence of any evidence of metastatic disease beyond the locoregional regions previously mentioned, assessed up to 60 months'}, {'measure': 'Acute toxicity', 'timeFrame': 'From the first day of radiotherapy and up to the 3-month post-radiotherapy follow-up visit'}]",5.0,18 Years,,ALL,False,OTHER,0.0,44.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03778879,Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B,CCX872-B,['CCX872-B'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,WITHDRAWN,Adenocarcinoma of the Pancreas,Alan Katz,2025-09-01T16:18:07.023973,True,,,,,A Phase 1b Trial of Neoadjuvant Stereotactic Body Radiotherapy With or Without CCR2 Inhibitor (CCX872-B) Immunotherapy for Preoperative Treatment of Resectable Pancreatic Cancer,,"['Adenocarcinoma of the Pancreas', 'Pancreas Cancer']","['Adenocarcinoma', 'Pancreas', 'Radiation Therapy', 'CCX872-B']",CCX872-B will not be available in sufficient quantity to conduct the study.,2019-08-01,2019-08-31,"[{'measure': 'Percentage of patients who complete radiation therapy, drug treatment and surgery', 'description': 'Number of patients who proceed through radiation and drug treatment and undergo surgical resection in a timely manner.', 'timeFrame': '6 weeks'}, {'measure': 'Percentage of patients who are ineligible for surgical resection due to toxicity from SBRT + CCX872-B or SBRT alone', 'description': 'Assessment of whether patients are made ineligible for surgical resection solely due to toxicities from SBRT + CCX872-B or SBRT alone.\n\nMeasure of Grade 3 toxicity directly attributable to SBRT+ CCX872-B or SBRT alone.\n\nAnalyze rate of grade 2 or greater acute toxicity caused by SBRT with or without CCX872-B.\n\nDetermination of intraoperative and postoperative surgical morbidity following neoadjuvant treatment including the amount of fibrosis and total operative time.', 'timeFrame': '12 weeks'}]","[{'measure': 'Number of participants with no further growth of cancer at original site', 'description': 'Count subjects with no further growth of cancer at original site', 'timeFrame': '2 years'}, {'measure': 'Number of subjects with recurrence of cancer in other body sites', 'description': 'Compare recurrence locations (metastases to other organs or non-regional adenopathy) of treated patients relative to historical controls', 'timeFrame': '2 years'}, {'measure': 'Mean time to progression of pancreatic cancer', 'description': 'Duration of progression free survival of treated patients', 'timeFrame': '4 years'}, {'measure': 'Mean time to death', 'description': 'Measure duration of survival of treated patients', 'timeFrame': '4 years'}]",6.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,CCX872-B will not be available in sufficient quantity to conduct the study.
NCT05295979,Chinese Medicine for Patients With Psoriasis,Inflammatory skin disease formula,"['ISDF', 'Inflammatory skin disease formula', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Psoriasis,Chinese University of Hong Kong,2025-09-01T16:18:07.023993,True,,,,,"Development of a Novel Chinese Medicine Formula for the Treatment of Psoriasis: A Randomized, Double-blinded, Placebo-controlled Trial",,['Psoriasis'],[],,2023-03-20,2024-08-31,"[{'measure': 'Psoriasis Area and Severity Index (PASI)', 'description': 'The change in Psoriasis Area and Severity Index (PASI) score will be assessed. PASI scores include area involved, erythema, induration and scaling. It will be scored on a scale of 0 to 4 (0, meaning none; 1, mild; 2, moderate; 3, severe; and 4, very severe). It will be performed by 2 blinded assessors who have been trained. Four main areas were assessed for calculation of the PASI scores: the head, the trunk, the upper extremities, and the lower extremities, corresponding to 10%,20%,30%, and 40% of the total body area, respectively. The maximum score for PASI is 72.', 'timeFrame': 'Week 12'}, {'measure': 'Static Physician Global Assessment score (sPGA)', 'description': 'Participants are requested to expose their skin thoroughly before the photographs are taken at each visit. The sPGA is an investigator-rated assessment of overall disease severity to be evaluated on a 5-point scale, where 0=clear and 4=severe. The severity of erythema, scaling, and plaque are considered for assessment. It will be performed by 2 blinded assessors who have received training.', 'timeFrame': 'Week 12'}]","[{'measure': 'Psoriasis Area and Severity Index (PASI)', 'description': 'The change in Psoriasis Area and Severity Index (PASI) score will be assessed. PASI scores include area involved, erythema, induration and scaling. It will be scored on a scale of 0 to 4 (0, meaning none; 1, mild; 2, moderate; 3, severe; and 4, very severe). It will be performed by 2 blinded assessors who have been trained. Four main areas were assessed for calculation of the PASI scores: the head, the upper extremities, the trunk, and the lower extremities, corresponding to 10%,20%,30%, and 40% of the total body area, respectively. The maximum score for PASI is 72.', 'timeFrame': 'Week 6'}, {'measure': 'Psoriasis Area and Severity Index (PASI)', 'description': 'The change in Psoriasis Area and Severity Index (PASI) score will be assessed. PASI scores include area involved, erythema, induration and scaling. It will be scored on a scale of 0 to 4 (0, meaning none; 1, mild; 2, moderate; 3, severe; and 4, very severe). It will be performed by 2 blinded assessors who have been trained. Four main areas were assessed for calculation of the PASI scores: the head, the upper extremities, the trunk, and the lower extremities, corresponding to 10%,20%,30%, and 40% of the total body area, respectively. The maximum score for PASI is 72.', 'timeFrame': 'Week 18'}, {'measure': 'Static Physician Global Assessment score (sPGA)', 'description': 'Participants are requested to expose their skin thoroughly before the photographs are taken at each visit. The sPGA is an investigator-rated assessment of overall disease severity to be evaluated on a 5-point scale, where 0=clear and 4=severe. The severity of erythema, scaling, and plaque are considered for assessment. It will be performed by 2 blinded assessors who have received training.', 'timeFrame': 'Week 6'}, {'measure': 'Static Physician Global Assessment score (sPGA)', 'description': 'Participants are requested to expose their skin thoroughly before the photographs are taken at each visit. The sPGA is an investigator-rated assessment of overall disease severity to be evaluated on a 5-point scale, where 0=clear and 4=severe. The severity of erythema, scaling, and plaque are considered for assessment. It will be performed by 2 blinded assessors who have received training.', 'timeFrame': 'Week 18'}, {'measure': 'Impact of Psoriasis Questionnaire (IPSO)', 'description': ""The change in Impact of Psoriasis Questionnaire (IPSO) score will be assessed. IPSO is a validated 16-item psoriasis-specific instrument for quality of life of psoriasis patients. The IPSO is intended predominantly to assess the psychosocial impact of psoriasis on patient's lives. The IPSO uses an ordinal rating scale, with responses of 'none', 'some', 'moderately', 'quite a bit' and 'extremely' scored 1, 2, 3, 4 and 5, respectively. The scores for item 4 were reversed. The higher the summed score, the greater the impact experienced due to psoriasis."", 'timeFrame': 'Week 12'}, {'measure': 'Short Form 36 survey (SF36)', 'description': ""The change in the score of quality of life using Short Form 36 survey (SF36) will be assessed. SF36 is generic instrument to measure general health status that is complementary to those derived from dermatological questionnaires. It will be used to assess the patient's health status using 8 different dimensions including vitality, physical functioning, bodily pain, general health perceptions, role limitations due to physical health, role limitations due to emotional health, social role functioning and mental health. The possible score ranges from 0 to 100 points whereby 0 points represent the greatest possible limitation of health, while 100 points represent the absence of health restrictions."", 'timeFrame': 'Week 12'}, {'measure': 'Use of rescue therapy', 'description': 'The frequent use of rescue therapy during study period', 'timeFrame': 'Up to Week 18'}, {'measure': 'Adverse events', 'description': 'Adverse events related to study treatment', 'timeFrame': 'Up to Week 18'}, {'measure': 'Serum markers (IL-17A, IL-22, IL-23, CRP and BD-2)', 'description': 'The changes in levels of serum markers \\[IL-17A, IL-22, IL-23, C-reactive protein (CRP) and Beta-Defensin 2 (BD2)\\].', 'timeFrame': 'Week 12'}, {'measure': 'Oral and Gut microbiota composition in saliva and stools', 'description': 'The changes in the oral and gut microbiota composition in saliva and stools', 'timeFrame': 'Week 12'}, {'measure': 'Psoriasis Itch Visual Analog Scale (Itch VAS)', 'description': 'Psoriasis itch VAS is a validated tool to assess treatment benefit of plaque psoriasis. It was developed to measure itch intensity within the last 24 hours. A horizontal line with a length of 100mm is to be used to represented the range of itch intensity from 0 (no itch at all) to 100 (worst itch you can imagine). Subjects rated the maximal intensity of itch during the previous 24 hours by putting a vertical mark through the horizontal line at the the spot he/she felt best reflected their maximal itch intensity.', 'timeFrame': 'Week 12'}, {'measure': 'Psoriasis-involved body surface area (BSA)', 'description': 'BSA represents the affected skin surface. It is an objective measure of psoriasis severity. The head, the upper extremities, the trunk, and the lower extremities, corresponding to 10%,20%,30%, and 40% of the total body area, respectively. The range of BSA is 0-100. It will be performed by 2 blinded assessors who have received training.', 'timeFrame': 'Week 6'}, {'measure': 'Psoriasis-involved body surface area (BSA)', 'description': 'BSA represents the affected skin surface. It is an objective measure of psoriasis severity. The head, the upper extremities, the trunk, and the lower extremities, corresponding to 10%,20%,30%, and 40% of the total body area, respectively. The range of BSA is 0-100. It will be performed by 2 blinded assessors who have received training.', 'timeFrame': 'Week 12'}, {'measure': 'Psoriasis-involved body surface area (BSA)', 'description': 'BSA represents the affected skin surface. It is an objective measure of psoriasis severity. The head, the upper extremities, the trunk, and the lower extremities, corresponding to 10%,20%,30%, and 40% of the total body area, respectively. The range of BSA is 0-100. It will be performed by 2 blinded assessors who have received training.', 'timeFrame': 'Week 18'}]",16.0,18 Years,75 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,
NCT07079579,Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients,Enarodustat 2mg,"['Enarodustat 4mg', 'Enarodustat 2mg', 'Enarodustat 3mg']",3,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Renal Anemia in Non-dialysis Chronic Kidney Disease,"Shenzhen Salubris Pharmaceuticals Co., Ltd.",2025-09-01T16:18:07.024044,True,,,,,"A Prospective, Single-arm, Open-label Study to Evaluate Different Initial Doses of Enarodustat Tablets for the Treatment of Anemia in Patients With Non-dialysis Chronic Kidney Disease",,['Renal Anemia in Non-dialysis Chronic Kidney Disease'],"['Renal Anemia in Non-dialysis Chronic Kidney Disease', 'Enarodustat']",,2025-08,2027-12,"[{'measure': 'Mean Hb level at Week 16 of treatment', 'timeFrame': 'week 16'}]","[{'measure': 'Cumulative proportion of subjects with Hb levels of ≥100 g/L and ≤120 g/L at each visit', 'timeFrame': 'week 0,2,4,8,12,16'}, {'measure': 'Cumulative proportion of subjects with Hb levels of ≥110 g/L and <130 g/L at each visit', 'timeFrame': 'week 0,2,4,8,12,16'}, {'measure': 'ESA-treated group: cumulative proportion of subjects with Hb levels ±10 g/L from baseline at Weeks 12-16 of treatment;', 'timeFrame': 'week12- 16'}, {'measure': 'Hb levels at each visit', 'timeFrame': 'week 0,2,4,8,12,16'}, {'measure': 'Change in Hb level from baseline at each visit', 'timeFrame': 'week 0,2,4,8,12,16'}, {'measure': 'Dosage of administration of the investigational drug throughout the treatment period', 'timeFrame': '16 weeks'}]",7.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,120.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01778179,A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy,Tri-luma,['Tri-luma'],1,INTERVENTIONAL,['NA'],,COMPLETED,Solar Lentigines,Brazilan Center for Studies in Dermatology,2025-09-01T16:18:07.024121,True,,,,,Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy.,,['Solar Lentigines'],"['Lentigines', 'Cryotherapy', 'hyperpigmentation']",,2011-04,2012-12,"[{'measure': 'Solar Lentigines Count', 'description': 'Solar lentigines count up to 13 weeks', 'timeFrame': 'up to 13 weeks'}]","[{'measure': 'Change From Baseline in Melanin Levels', 'description': 'This assessment was made using a narrowband reﬂectance spectrophotometer (Mexameter MX18®, Courage-Khazaka, Germany). The measurement is based on absorption/reflection. The probe of the Mexameter® MX 18 emits three specific light wavelengths. A receiver measures the light reflected by the skin. As the quantity of emitted light is defined, the quantity of light absorbed by the skin can be calculated. The melanin is measured by two specific wavelengths (red: 660 nm and near infrared: 880 nm) chosen to correspond to different absorption rates by the pigments.\n\nThe quantification of melanin is presented as a value that varies from 0-999. The higher the value, the larger is the amount of melanin on the skin.', 'timeFrame': 'Baseline and up to 13 weeks'}]",2.0,40 Years,65 Years,ALL,True,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT01746979,Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,TH-302,"['Gemcitabine', 'Placebo (5 percent dextrose - D5W)', 'TH-302']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,ImmunoGenesis,2025-09-01T16:18:07.024160,True,,,,,"A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma",,['Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma'],"['TH-302', 'Evofosfamide', 'Pancreatic Cancer', 'EMR200592-001']",,2012-12,2016-05,"[{'measure': 'Overall Survival', 'description': 'Overall survival is defined as time from randomization to death or last day known to be alive.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years'}]","[{'measure': 'Progression Free Survival', 'description': 'Progression Free Survival is defined as the time from randomization to either first observation of progressive disease or occurrence of death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years'}]",2.0,18 Years,,ALL,False,INDUSTRY,1.0,693.0,ACTUAL,v2_robust,True,True,False,False,
NCT05752279,Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis,Plasma-Lyte 148,"['0.9% sodium chloride', 'Plasma-Lyte 148', 'Balanced multi-electrolyte solution', 'normal saline']",4,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Diabetic Ketoacidosis,The George Institute,2025-09-01T16:18:07.024184,True,,,,,Balanced Multi-electrolyte Solution Versus 0.9% Sodium Chloride as Fluid Therapy for Patients Presenting With Moderate to Severe Diabetic Ketoacidosis,,['Diabetic Ketoacidosis'],[],,2024-03,2026-06,"[{'measure': 'Hospital free days (HFD) up to day-28 after study enrolment', 'description': 'Number of hospital free days from time of hospital discharge', 'timeFrame': 'from time of enrolment to 28 days'}]","[{'measure': 'ICU free days up to 28 days after study enrolment', 'description': 'Number of ICU free days from time of ICU discharge', 'timeFrame': '28 days after enrolment'}, {'measure': 'ICU and hospital readmissions up to 28 days after study enrolment', 'description': 'Number of days free from ICU and hospital from time of hospital discharge', 'timeFrame': '28 days after enrolment'}, {'measure': 'Acute kidney injury assessed by comparing serum creatinine using Kidney Disease: Improving Global Outcomes (KDIGO) criteria', 'description': 'injury assessed by comparing change in serum creatinine using Kidney Disease: Improving Global Outcomes (KDIGO) criteria', 'timeFrame': '28 days after enrolment'}, {'measure': 'Episodes of post-study enrolment decrease in Glasgow Coma Scale (GCS) by more than 2 in the first 24 hours', 'description': 'decrease in Glasgow Coma Score by more than 2 points', 'timeFrame': 'first 24 hours from enrolment'}, {'measure': 'Time to resolution of ketosis', 'description': 'resolution of acidosis', 'timeFrame': 'from time of enrolment to day 28'}, {'measure': 'Cumulative insulin dosage in the first 48 hours', 'description': 'Total amount of insulin given to the patient from enrolment to 48 hours', 'timeFrame': 'first 48 hours from time of enrolment'}, {'measure': 'Duration of IV insulin infusion', 'description': 'Total amount of IV insulin given to the patient from time of enrolment to day 28', 'timeFrame': 'from time of enrolment to day 28'}, {'measure': 'Cumulative potassium replacement', 'description': 'Total amount of potassium given to the patient from time of enrolment to day 28', 'timeFrame': 'from time of enrolment to day 28'}]",9.0,18 Years,,ALL,False,OTHER,0.0,680.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02981979,Takayasu Arteritis Clinical Trial in China,Leflunomide(LEF),"['Prednisone Acetate Tablets', 'Placebos', 'Leflunomide(LEF)']",3,INTERVENTIONAL,['NA'],,COMPLETED,Takayasu Arteritis,Jiang lindi,2025-09-01T16:18:07.024250,True,,,,,Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combined With Basic Prednisone Therapy in Patients With Active Takayasu Arteritis: a Randomized Double-blind Controlled Clinical Trial,,['Takayasu Arteritis'],"['Takayasu Arteritis', 'Leflunomide']",,2016-12-22,2022-11-22,"[{'measure': 'Achievement of clinical remission at week 24', 'description': 'Clinical remission is defined as follows:\n\n(i) have no systemic symptoms (e.g., fever, fatigue, weight loss); (ii) have no new onset of ischemic symptoms and signs; (iii) have a normal level of erythrocyte sedimentation rate (ESR). If not achieved, the investigator excluded other influencing factors (especially infection), re-measure the ESR after 1 week, and use the re-examined value in the analyses.\n\nSubject achieving clinical remission should meet all these criteria above.\n\nThe clinical remission rate and its difference between LEF and placebo group with 95% confidence interval (CI) at week 24 was estimated by Newcombe-Wilson procedure. If the lower limit of the 95%CI of the difference \\>10%, it is considered that the efficacy of LEF is significantly superior to placebo.', 'timeFrame': 'From the date of randomization until the end of induced remission therapy, assessed up to 24 weeks'}]","[{'measure': 'Time to clinical remission', 'timeFrame': 'From the date of randomization until the date of first documented clinical remission, assessed up to 24 weeks'}, {'measure': 'The mean prednisone dose at week 24', 'timeFrame': 'At the end of induced remission therapy, assessed up to 24 weeks'}, {'measure': 'Achievement of clinical remission at week 52 in those who switched from placebo to LEF from week 25', 'timeFrame': 'From the time of switch from placebo to LEF treatment (week 25), assessed up to week 52'}, {'measure': 'Disease recurrence through week 25 to week 52', 'description': ""Disease recurrence is defined as NIH score ≥2 or not meeting ≥2 criteria for clinical remission.\n\nNIH score:\n\n1\\) presence of systemic symptoms as fever, fatigue and weight loss (1');\n\n2）presence of ischemic symptoms or signs (1');\n\n3\\) abnormal serum ESR levels (1');\n\n4\\) progression or new site of vascular lesions on MRA or CTA compared to baseline(1')."", 'timeFrame': 'From the beginning of week 25 to the end of follow up, assessed up to week 52'}, {'measure': 'Time to recurrence', 'timeFrame': 'from the beginning of achieving clinical remission to the date of the first documented disease recurrence, assessed up to 52 weeks'}, {'measure': 'Imaging changes at the end of week 24 and week 52 compared to the baseline', 'timeFrame': 'From the date of randomization until the end of week 24 and week 52'}, {'measure': 'Safety-adverse events', 'description': ""For safety analysis, the incidence and severity of AEs, adverse drug reactions and laboratory values in the LEF and placebo group would be estimated and compared using the χ2 test or Fisher's exact test. The association of an abnormal laboratory index and adverse event with the investigational drug would be evaluated."", 'timeFrame': 'From the date of randomization until the end of this trial, assessed up to 52 weeks'}]",8.0,18 Years,65 Years,ALL,False,OTHER,0.0,116.0,ACTUAL,v2_robust,True,True,False,True,
NCT03997279,Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii,Saccharomyces boulardii,"['Clarithromycin', 'Amoxicillin', 'Placebo', 'Rabeprazole', 'Saccharomyces boulardii', 'Metronidazole']",6,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Helicobacter Pylori Infection,Clinical Centre of Serbia,2025-09-01T16:18:07.024380,True,,,,,"Double-blind, Placebo-controlled, Randomized Study for Assesment of the Efficiency and Safety Quadruple Therapy for Helicobacter Pylori Infection With or Without the Addition of Saccharomyces Boulardi Probiotic",,['Helicobacter Pylori Infection'],"['Helicobacter Pylori', 'Saccharomyces boulardi', 'Eradication therapy']",,2019-06,2020-06,"[{'measure': 'Result of urea breath test (Eradication of H.pylori)', 'description': 'Test remains positive (Eradication of H.pylori unsuccessful) or test becomes negative (eradication of H.pylori successful)', 'timeFrame': 'baseline to 8 weeks after the introduction of the therapy'}]","[{'measure': 'Side effects of eradication therapy', 'description': 'Number and severity of adverse events of standard eradication therapy', 'timeFrame': 'baseline to 8 weeks after the introduction of the therapy'}, {'measure': 'Compliance of eradication therapy', 'description': 'Patient successfully completed prescribed therapy', 'timeFrame': 'baseline to 8 weeks after the introduction of the therapy'}]",3.0,18 Years,50 Years,ALL,False,OTHER,0.0,200.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05849779,Inhaled Sevoflurane for ARDS Prevention,Inhaled sedation with sevoflurane,"['Inhaled sedation with sevoflurane', 'Control', 'Intravenous sedation (current practice)', 'Experimental']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Acute Respiratory Distress Syndrome,"University Hospital, Clermont-Ferrand",2025-09-01T16:18:07.024390,True,,,,,Randomized Clinical Trial of Inhaled Sedation With Sevoflurane in Critically Ill Patients at Risk of Developing the Acute Respiratory Distress Syndrome,,['Acute Respiratory Distress Syndrome'],"['ARDS', 'Sedation', 'Inhaled sevoflurane']",,2023-07-24,2026-07-31,"[{'measure': 'PaO2/FiO2 ratio', 'description': 'longitudinal evolution in the PaO2/FiO2 ratio', 'timeFrame': 'within 5 days from randomization'}]","[{'measure': 'Progression to ARDS', 'description': 'Progression to ARDS will be assessed according to the Berlin criteria, including chest radiographs', 'timeFrame': 'within 5 days from randomization'}, {'measure': 'Rate of pneumonia', 'description': 'Pneumonia will be defined according to the 3 following criteria:\n\n* Two chest radiographs showing signs of pneumonia, or one in absence of cardiomyopathy or underlying pulmonary condition.\n* One item among: body temperature ≥38.3°C without evident cause, leukocytes \\<4000/mm3 or ≥12000/mm3\n* Two items among: purulent secretions, cough or dyspnea, increased need for oxygen supplementation or ventilatory assistance.', 'timeFrame': 'Presence of pneumonia will be assessed daily until Day 5, and at Day 28 or ICU discharge, whichever comes first.'}, {'measure': 'Ventilator-free days to day 28', 'description': 'Ventilator free days to day 28 are defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a patient returns to assisted breathing and subsequently achieves unassisted breathing to day 28, VFDs will be counted from the end of the last period of assisted breathing to day 28. A period of assisted breathing lasting less than 24 hours and for the purpose of a surgical procedure will not count against the VFD calculation. If a patient was receiving assisted breathing at day 27 or dies prior to day 28, VFDs will be zero.', 'timeFrame': '28 days after randomization'}, {'measure': 'Organ failure to day 5', 'description': 'Organ failure is defined as present when the most abnormal vital signs or clinically available lab value meets the definition of clinically significant organ failure according to SOFA scores. Patients will be followed daily from randomization to day 5 for development of organ failures.', 'timeFrame': '5 days after randomization'}, {'measure': 'Mortality at day 28', 'description': 'The occurrence of death in the ICU will be recorded until day 28.', 'timeFrame': '28 days after randomization'}, {'measure': 'Length of ICU-stay up to 28 days', 'description': 'The total number of days from admission to ICU discharge will be recorded until day 28', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: Oxygenation', 'description': '\\- Oxygenation Index on study days 1-5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: PaCO2', 'description': '\\- PaCO2 on study days 1-5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: pH', 'description': '\\- Arterial pH on study days 1-5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: PEEP', 'description': '\\- Level of PEEP (and static auto-PEEP in patients under controlled ventilation) on study days 1-5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: Plateau pressure', 'description': '\\- Plateau pressure, static compliance of the respiratory system on study day 1-5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: Pneumothorax', 'description': '\\- Development of pneumothorax through day 28', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: Switch from controlled to pressure-support ventilation', 'description': '\\- Time to switching from controlled to pressure-support ventilation through day 5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: Airway occlusion pressure', 'description': '\\- Airway occlusion pressure at 0.1 s (P0.1), an index of respiratory drive, on the day the patient is switched to pressure-support ventilation if within 5 days since randomization', 'timeFrame': '28 days after randomization'}, {'measure': 'Hemodynamic measures', 'description': '\\- Hemodynamic measures (mean arterial pressure, dose of infused norepinephrine or other vasopressor, serum lactate level) on study days 1-5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: Acute kidney injury', 'description': '\\- KDIGO criteria for acute kidney injury 24 through day 5', 'timeFrame': '28 days after randomization'}, {'measure': 'Physiological measures: Supraventricular tachycardia', 'description': '\\- Supraventricular tachycardia (SVT) or new onset atrial fibrillation through day 5', 'timeFrame': '28 days after randomization'}, {'measure': 'ICU-acquired delirium', 'description': 'The Confusion Assessment Method for the ICU (CAM-ICU, Appendix C )97 will be assessed daily from study entry to study day 28, death or ICU discharge, whichever comes first.', 'timeFrame': '28 days after randomization'}, {'measure': 'Biomarker measurements', 'description': 'Plasma samples will be collected from indwelling catheters (when available) at study entry and on days 1, 2, 3, 4, 5 in order to assemble a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane in patients with ARDS.\n\nThe investigators will also collect whole blood samples at study entry and on day 2 for future studies of macrophage activation profiles and RNA and DNA studies.', 'timeFrame': 'from inclusion to 5 days'}]",20.0,18 Years,,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01665079,Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response,Propofol,['Propofol'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Obesity,Universidad del Desarrollo,2025-09-01T16:18:07.024450,True,,,,,Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response.,,['Obesity'],"['anaesthetics iv', 'propofol', 'pharmacokinetics', 'pharmacodynamic']",,2011-04,2011-11,"[{'measure': 'Profile of Pharmacokinetic and Pharmacodynamic of an induction bolus dose of propofol in obese patients.', 'description': 'Pharmacokinetic parameters (V1, V2, V3, CL, Q)\n\nPharmacodynamic parameters (E0, Emax, C50, Gamma, t1/2Ke0, T peak )', 'timeFrame': '1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75'}]",[],1.0,20 Years,60 Years,ALL,True,OTHER,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,
NCT00593879,Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder,Mecamylamine,"['Mecamylamine', 'Inversine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Major Depressive Disorder,Targacept Inc.,2025-09-01T16:18:07.024468,True,,,,,"A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of Mecamylamine 5.0 to 10 mg, in the Treatment of Major Depressive Disorder With Subjects Who Are Partial or Non- Responders to Citalopram Therapy.",,['Major Depressive Disorder'],"['MDD', 'Depression', 'Mecamylamine', 'Add-on Therapy', 'Major Depressive Disorder']",,2005-02,2006-08,"[{'measure': 'HAMD-17 group mean change from baseline to endpoint and/or the proportion of subjects considered to be full responders or in remission with a HAMD-17 score less than or equal to 7 at the end of treatment.', 'timeFrame': '8 weeks'}]","[{'measure': 'Montgomery Asbery depression rating sclae, Clinical Global Impression Scale - Severity, Clinical Global Impression Sacle - Change, Sheehan irritability scale, Sheehan disability scale', 'timeFrame': '8 weeks'}, {'measure': 'Blood biochemistry, urnie analysis, blood pressure, heart rate, ECG', 'timeFrame': '8 weeks'}, {'measure': 'Citalopram plasma bloods at week 6 and 14.', 'timeFrame': '8 weeks'}]",4.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,450.0,ACTUAL,v2_robust,True,True,False,False,
NCT00251979,A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer,Esomeprazole,['Esomeprazole'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Gastrointestinal Hemorrhage,AstraZeneca,2025-09-01T16:18:07.024480,True,,,,,"A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.",,['Gastrointestinal Hemorrhage'],[],,2005-10,2007-12,"[{'measure': 'Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo', 'timeFrame': 'Within 72 hours'}]","[{'measure': 'Clinically Significant Rebleeding Within 7 Days', 'timeFrame': 'Within 7 days'}, {'measure': 'Clinically Significant Rebleeding Within 30 Days', 'timeFrame': 'Within 30 days'}, {'measure': 'Death Within 72 Hours', 'timeFrame': 'Within 72 hours'}, {'measure': 'Death Within 30 Days', 'timeFrame': 'Within 30 days'}, {'measure': 'Death Related to Rebleeding Within 30 Days as Judged by the EpC', 'timeFrame': 'Within 30 days'}, {'measure': 'Requirement for Surgery Within 72 Hours', 'timeFrame': 'Within 72 hours'}, {'measure': 'Requirement for Surgery Within 30 Days', 'timeFrame': 'Within 30 days'}, {'measure': 'Requirement for Endoscopic Re-treatment Within 72 Hours', 'timeFrame': 'Within 72 hours'}, {'measure': 'Requirement for Endoscopic Re-treatment Within 30 Days', 'timeFrame': 'Within 30 days'}, {'measure': 'Number of Blood Units Transfused Within 72 Hours', 'timeFrame': 'Within 72 hours'}, {'measure': 'Number of Blood Units Transfused Within 30 Days', 'timeFrame': 'within 30 days'}, {'measure': 'Number of Days Hospitalized Due to Rebleeding During the 30-day Treatment Period', 'timeFrame': 'Within 30 days'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,1312.0,ACTUAL,v2_robust,True,True,False,False,
NCT02495896,Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors,Cisplatin,"['nab-paclitaxel', ""Peyrone's Chloride"", 'DDP', 'Cisplatyl', 'Metaplatin', 'Neoplatin', 'Paclitaxel Albumin-Stabilized Nanoparticle Formulation', 'Placis', 'Platinol', 'Platinum Diamminodichloride', 'Citoplatino', 'Albumin-bound Paclitaxel', 'Platinoxan', 'Platistin', 'Cis-diamminedichloridoplatinum', 'Taxotere Injection Concentrate', 'Gemzar', 'ABI 007', 'Nanoparticle Paclitaxel', 'Cysplatyna', 'Cis-platinous Diamine Dichloride', 'Platinum', 'Platinex', 'Taxotere', ""Peyrone's Salt"", 'Blastolem', 'ABI-007', 'Cis-platinum II', 'Cisplatinum', 'Platinol-AQ', 'Plastistil', 'Docetaxel', 'Lederplatin', 'Platiran', 'Nanoparticle Albumin-bound Paclitaxel', 'dFdCyd', 'Abiplatin', 'Cis-diamminedichloro Platinum (II)', 'Cisplatin', 'Gemcitabine Hydrochloride', 'Cis-diammine-dichloroplatinum', 'Platamine', 'Briplatin', 'Cis-diamminedichloroplatinum', 'Abraxane', 'Albumin-Stabilized Nanoparticle Paclitaxel', 'Platiblastin-S', 'CDDP', 'Platinol- AQ', 'Platinol-AQ VHA Plus', 'Difluorodeoxycytidine Hydrochloride', 'Platiblastin', 'Cis-platinum', 'Citosin', 'Cisplatina', 'Platosin', 'protein-bound paclitaxel', 'RP56976', 'Cis-dichloroammine Platinum (II)', 'LY-188011', 'Cismaplat', 'Cis-platinum II Diamine Dichloride']",62,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Head and Neck Squamous Cell Carcinoma,University of Southern California,2025-09-01T16:18:07.024507,True,,,,,A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors,,"['Head and Neck Squamous Cell Carcinoma', 'Metastatic Pancreatic Adenocarcinoma', 'Non-Resectable Cholangiocarcinoma', 'Pancreatic Adenocarcinoma', 'Recurrent Gallbladder Carcinoma', 'Recurrent Non-Small Cell Lung Carcinoma', 'Stage III Pancreatic Cancer', 'Stage IIIA Gallbladder Cancer', 'Stage IIIA Non-Small Cell Lung Cancer', 'Stage IIIB Gallbladder Cancer', 'Stage IIIB Non-Small Cell Lung Cancer', 'Stage IV Gallbladder Cancer', 'Stage IV Non-Small Cell Lung Cancer', 'Stage IV Pancreatic Cancer', 'Unresectable Gallbladder Carcinoma', 'Unresectable Pancreatic Cancer']",[],Lack of funding,2015-09-03,2019-05-29,"[{'measure': 'Duration of overall response or SD', 'timeFrame': 'From first occurrence of CR, PR or SD to the time of documented disease progression, as determined by investigator review of tumor assessments using RECIST v1.1, or death from any cause, assessed up to 2 years'}, {'measure': 'Incidence of toxicities, graded according to Common Terminology Criteria for Adverse Events version 4', 'timeFrame': 'Up to 2 years'}, {'measure': 'Objective response using RECIST version 1.1', 'description': 'Patients whose best overall response is CR or PR will be classified as having a major objective response.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'timeFrame': 'Time from start of treatment with recombinant EphB4-HSA fusion protein (start of 2nd course) to death for any cause, assessed up to 2 years'}, {'measure': 'Progression-free survival', 'timeFrame': 'Time from start of treatment to 1st documentation of PD or death due to any cause, or death from any cause, assessed up to 2 years'}]",[],5.0,18 Years,,ALL,False,OTHER,2.0,61.0,ACTUAL,v2_robust,True,False,True,True,Lack of funding
NCT05852496,Vit D and Peripheral Neuropathy in Taxane Naive Patients,Vitamin D,['Vitamin D'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Vitamin D Deficiency,Assiut University,2025-09-01T16:18:07.024516,True,,,,,Vit D and Peripheral Neuropathy in Taxane Naive Patients,,"['Vitamin D Deficiency', 'Peripheral Neuropathy']",[],,2023-07-01,2024-09-01,"[{'measure': 'Grades of neuropathy according to the World Health Organization rating scale', 'description': 'Grade 0 corresponds to no symptoms of neuropathy, grade 1 corresponds to paresthesias (a tingling, tickling or prickling sensation) and/or decreased tendon reflexes, grade 2 corresponds to severe paresthesias and/or mild weakness, grade 3 corresponds to intolerable paresthesias and /or marked motor loss, Grade 4 Paralysis', 'timeFrame': 'after 6 months'}]","[{'measure': 'The Toronto Clinical Neuropathy Score (TCNS)', 'description': 'Valid and reliable scale for use in common non-diabetic polyneuropathies. Primarily for the feet. Most of the testing is done on or near the toes. Light touch testing is done with a 10 gm monofilament on the dorsum of the large toe', 'timeFrame': 'after 6 months'}]",2.0,19 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00053196,Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer,busulfan,"['busulfan', 'mycophenolate mofetil', 'methotrexate', 'allopurinol', 'fludarabine phosphate', 'tacrolimus']",6,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Leukemia,Alliance for Clinical Trials in Oncology,2025-09-01T16:18:07.024530,True,,,,,Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation,,"['Leukemia', 'Lymphoma', 'Multiple Myeloma', 'Plasma Cell Neoplasm', 'Myelodysplastic Syndromes', 'Myeloproliferative Neoplasms']","['refractory chronic lymphocytic leukemia', 'prolymphocytic leukemia', 'recurrent adult Hodgkin lymphoma', 'stage I multiple myeloma', 'stage II multiple myeloma', 'stage III multiple myeloma', 'refractory multiple myeloma', 'previously treated myelodysplastic syndromes', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult Burkitt lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'secondary myelodysplastic syndromes', 'de novo myelodysplastic syndromes', 'recurrent adult acute myeloid leukemia', 'recurrent childhood acute myeloid leukemia', 'recurrent childhood large cell lymphoma', 'recurrent childhood lymphoblastic lymphoma', 'recurrent childhood small noncleaved cell lymphoma', 'recurrent/refractory childhood Hodgkin lymphoma', 'atypical chronic myeloid leukemia, BCR-ABL negative', 'myelodysplastic/myeloproliferative neoplasm, unclassifiable', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma', 'adult acute myeloid leukemia with t(8;21)(q22;q22)', 'adult acute myeloid leukemia with t(16;16)(p13;q22)', 'adult acute myeloid leukemia with inv(16)(p13;q22)', 'adult acute myeloid leukemia with 11q23 (MLL) abnormalities', 'adult acute myeloid leukemia with t(15;17)(q22;q12)', 'childhood myelodysplastic syndromes']",,2002-12,2010-08,"[{'measure': 'Treatment-related mortality', 'timeFrame': '6 months post transplant'}]","[{'measure': 'Per cent donor chimerism', 'timeFrame': '30, 60, 90, 180 days post transplant'}, {'measure': 'Disease-free survival', 'timeFrame': '12 months up to 5 years post study entry'}, {'measure': 'Graft-versus-host disease incidence', 'timeFrame': '6 months post transplant'}, {'measure': 'Response Rates', 'timeFrame': '6 and 12 months'}]",5.0,,69 Years,ALL,False,OTHER,1.0,82.0,ACTUAL,v2_robust,True,True,False,False,
NCT00271596,Citalopram to Enhance Cognition in HD,20mg daily citalopram,"['20mg daily citalopram', 'Matching daily placebo', 'Celexa', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Huntington Disease,University of Iowa,2025-09-01T16:18:07.024588,True,,,,,"A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)",,"['Huntington Disease', 'Chorea', 'Executive Dysfunction']","['Huntington Disease', 'Citalopram', 'Celexa', 'Chorea', 'Focus', 'ADD', 'ADHD', 'HD', 'SSRI']",,2005-11,2011-11,"[{'measure': 'Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort.', 'description': 'Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) \\& 6 (week 15) for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}]","[{'measure': 'Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) \\& 6 (week 15) for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) \\& 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) \\& 6 (week 15) for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say ""red"" to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to ""connect-the-dots"" of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': ""Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort."", 'timeFrame': 'after 15 weeks of treatment'}, {'measure': 'Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort', 'description': 'Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort.', 'timeFrame': 'after 15 weeks of treatment'}]",10.0,18 Years,75 Years,ALL,False,OTHER,4.0,33.0,ACTUAL,v2_robust,True,True,False,False,
NCT03745196,The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases,PC945,"['PC945', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Asthma,Pulmocide Ltd,2025-09-01T16:18:07.024663,True,,,,,"A Double-blind, Placebo-controlled Study to Assess the Effects of Inhaled PC945 in the Treatment of Culture-positive Aspergillus or Candida Fungal Bronchitis in Subjects With Moderate to Severe Asthma or Other Chronic Respiratory Diseases.",,"['Asthma', 'Respiratory Candidiasis', 'Respiratory Aspergillosis', 'COPD', 'Bronchiectasis']",[],The study is being terminated early as a result of the coronavirus (COVID-19) outbreak.,2018-11-15,2020-06-01,"[{'measure': 'Presence or absence of Aspergillus fumigatus (A. fumigatus) complex / Aspergillus niger (A. niger) complex colonies on sputum culture', 'description': 'This is a binary endpoint', 'timeFrame': 'Baseline to Day 32-35'}, {'measure': 'Reduction in the numbed of colonies of Candida species (spp) on sputum culture', 'description': 'Substantial reduction in colony forming unit (CFU) count by at least 50%', 'timeFrame': 'Baseline to Day 32-35'}]","[{'measure': 'Predicted post bronchodilator forced expiratory volume in 1 second (FEV1) values', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Forced vital capacity (FVC) values', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'The number of sputum A. fumigatus complex / A. niger complex CFUs in fungal culture', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Sputum A. fumigatus measured by quantitative polymerase chain reaction (qPCR)', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Spontaneous sputum weight (24-hour collection)', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'The number of sputum Candida spp. CFUs in fungal culture', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'C. albicans measured by qPCR in sputum', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'The concentration of A. fumigatus-specific immunoglobulin G (IgG) as measured in serum', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Serum Total immunoglobulin E (IgE) levels', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'A. fumigatus-specific IgE levels', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Change in Asthma control questionnaire - 6 item [ACQ6] (Total score) in asthma patients only', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Change in Asthma Quality of Life Questionnaire - Juniper [AQLQ-J] (Total score) in asthma patients only', 'timeFrame': 'Baseline to Day 84'}, {'measure': ""Change in St George's Respiratory Questionnaire [SGRQ] (Total score)"", 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Change in Leicester Cough Questionnaire (Total score)', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Breathlessness visual analogue scale rating, change over time', 'description': 'Symptom severity rated from ""Best ever"" to ""Worst possible""', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Correlation between A. fumigatus measured by qPCR and clinical response', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Correlation between Candida albicans measured by qPCR and clinical response', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Area undertake curve from time 0 to 2h post dose (AUC(0-2))', 'description': 'Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Last quantifiable plasma concentration (Ct)', 'description': 'Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'maximum observed concentration (Cmax)', 'description': 'Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'concentration at the end of the dosage interval (Ctrough)', 'description': 'Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Adverse events (AEs) incidence (safety and tolerability)', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Twelve-lead electrocardiogram (ECG) (Safety parameter)', 'description': 'including QT interval corrected for Bazetts formula, QT interval, QRS Interval, PR Interval and ventricular rate).', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Proportion of participants who meet the markedly abnormal criteria for vital signs assessment at lease once post dose', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Proportion of participants who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Change in peak expiratory flow rate [PEFR]', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Antibiotic use', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Sputum characteristics - consistency and presence of blood (fresh morning sputum samples)', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Sputum colour (fresh morning sputum samples)', 'timeFrame': 'Baseline to Day 84'}]",31.0,18 Years,,ALL,False,INDUSTRY,0.0,13.0,ACTUAL,v2_robust,True,False,True,True,The study is being terminated early as a result of the coronavirus (COVID-19) outbreak.
NCT04128696,Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,feladilimab,"['Pembrolizumab', 'feladilimab', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,"Neoplasms, Head and Neck",GlaxoSmithKline,2025-09-01T16:18:07.024700,True,,,,,"A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",,"['Neoplasms, Head and Neck']","['GSK3359609', 'Pembrolizumab', 'Programmed death receptor 1-ligand 1', 'Head and neck squamous cell carcinoma/cancer', 'Inducible T cell co-stimulatory receptor', 'Keynote-A01', 'Head & neck', 'Phase III']",The trial was stopped by the sponsor based on assessment of the clinical data,2019-11-21,2023-06-20,"[{'measure': 'Overall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population', 'description': 'OS was defined as the time from the date of randomization to the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'OS in the PD-L1 Expression High (CPS ≥20) Population', 'description': 'OS was defined as the time from the date of randomization to the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 Population', 'description': 'PFS per RECIST version (v)1.1 was defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.', 'timeFrame': 'Up to approximately 16 months'}]","[{'measure': 'PFS Per Immune-based RECIST (iRECIST) in the PD-L1 CPS ≥1 Population', 'description': 'PFS per iRECIST was defined as the interval of time from the date of randomization to the date of the first documented disease progression confirmed consecutively per iRECIST based on investigator assessment, or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'PFS Per RECIST in the PD-L1 CPS ≥20 Population', 'description': 'PFS per RECIST v1.1 was defined as the time from the date of randomization to the date of first documented disease progression per RECIST v1.1. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'PFS Per iRECIST (iPFS) in the PD-L1 CPS ≥20 Population', 'description': 'PFS per iRECIST was defined as the interval of time from the date of randomization to the date of the first documented disease progression confirmed consecutively per iRECIST based on investigator assessment, or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'Milestone OS Rate at 12 Months in the PD-L1 CPS ≥1 Population', 'description': 'Milestone OS rate at 12 months was estimated using the Kaplan-Meier method. Associated 95% confidence intervals are estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': '12 months'}, {'measure': 'Milestone OS Rate at 24 Months in the PD-L1 CPS ≥1 Population', 'description': 'Milestone OS rate at 24 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': '24 months'}, {'measure': 'Milestone OS Rate at 12 Months in the PD-L1 CPS ≥20 Population', 'description': 'Milestone OS rate at 12 months was estimated using the Kaplan-Meier method. Associated 95% confidence intervals are estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': '12 months'}, {'measure': 'Milestone OS Rate at 24 Months in the PD-L1 CPS ≥20 Population', 'description': 'Milestone OS rate at 24 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': '24 months'}, {'measure': 'Overall Response Rate (ORR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population', 'description': 'ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'ORR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population', 'description': 'ORR per RECIST v1.1 was defined as the proportion of the participants who have a CR or PR as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'Disease Control Rate (DCR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population', 'description': 'DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'DCR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population', 'description': 'DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'Duration of Response (DoR) Per RECIST v1.1 in the PD-L1 CPS ≥1 Population', 'description': 'DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'DoR Per RECIST v1.1 in the PD-L1 CPS ≥20 Population', 'description': 'DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement.', 'timeFrame': 'Up to approximately 43 months'}, {'measure': 'Number of Participants With AEs by Severity', 'description': 'An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of each AE was reported during the study and was assigned a grade according to the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE). AEs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE.', 'timeFrame': 'Up to approximately 43 months'}, {'measure': 'Number of Participants With SAEs by Severity', 'description': 'An SAE was defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity of each SAE was reported during the study and was assigned a grade according to the NCI-CTCAE. SAEs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing SAEs of Grade ≥3 have been presented.', 'timeFrame': 'Up to approximately 43 months'}, {'measure': 'Number of Participants With Adverse Events of Special Interest (AESI)', 'description': 'AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Such events recently reported after treatment with other immune modulatory therapy include colitis, uveitis, hepatitis, pneumonitis, diarrhea, endocrine disorders, and specific cutaneous toxicities, as well as other events that may be immune mediated.', 'timeFrame': 'Up to approximately 43 months'}, {'measure': 'Number of Participants With AESI by Severity', 'description': 'AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Such events recently reported after treatment with other immune modulatory therapy include colitis, uveitis, hepatitis, pneumonitis, diarrhea, endocrine disorders, and specific cutaneous toxicities, as well as other events that may be immune mediated. Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing AESIs of Grade ≥3 have been presented.', 'timeFrame': 'Up to approximately 43 months'}, {'measure': 'Number of Participants With Dose Modifications', 'description': 'Number of participants with dose modifications (including dose interruptions, dose delays and treatment discontinuations) were reported by each interventional component.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'Time to Deterioration (TTD) in Pain in the PD-L1 CPS ≥1 Population', 'description': 'TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the European Organization for Research and Treatment of Cancer Item Library(EORTC IL51) pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC Quality of Life Questionnaire 35-Item Head and Neck Module (QLQ-H\\&N35) is a head and neck specific module with multi-item scales. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'TTD in Pain in the PD-L1 CPS ≥20 Population', 'description': 'TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the EORTC IL51 pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC QLQ-H\\&N35 is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'TTD in Physical Function in the PD-L1 CPS ≥1 Population', 'description': 'TTD in physical function is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c. The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'TTD in Physical Function in the PD-L1 CPS ≥20 Population', 'description': 'TTD in physical function is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c. The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. Data are presented for the PD-L1 CPS \\>=1 participants from mITT population. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.', 'timeFrame': 'Up to approximately 16 months'}]",26.0,18 Years,,ALL,False,INDUSTRY,1.0,315.0,ACTUAL,v2_robust,True,False,True,True,The trial was stopped by the sponsor based on assessment of the clinical data
NCT05298696,Efficacy of Cilostazol in Prevention of Peripheral Neuropathy,Cilostazol,"['Cilostazol', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Peripheral Neuropathy,Mansoura University,2025-09-01T16:18:07.024851,True,,,,,Safety and Efficacy of Cilostazol in Prevention of Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients,,"['Peripheral Neuropathy', 'Breast Cancer']",[],,2022-03-28,2022-12-30,"[{'measure': 'Incidence of chemotherapy induced-peripheral neuropathy using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria', 'description': 'Number of patients reported neuropathy from paclitaxel', 'timeFrame': '8 weeks post intervention'}]","[{'measure': 'Severity of chemotherapy induced-peripheral neuropathy', 'description': 'Severity of paclitaxel induced peripheral neuropathy using VAS visual analogue scale.', 'timeFrame': '8 weeks'}, {'measure': 'the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity(FACT-GOG-NTX) subscale', 'description': 'Measures quality of life related to signs and symptoms of paclitaxel induced peripheral neuropathy', 'timeFrame': '8 weeks'}, {'measure': 'Serum nerve growth factor', 'description': 'measuring serum level of nerve growth factor using ELISA KIT', 'timeFrame': '8 weeks'}, {'measure': 'Serum malionaldehyde', 'description': 'measuring serum level of maliomaldehyde using spectrophometric kit', 'timeFrame': '8 weeks'}]",5.0,18 Years,80 Years,ALL,False,OTHER,0.0,71.0,ACTUAL,v2_robust,True,True,False,True,
NCT03819296,Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer,Prednisone,"['Paracort', 'Prednidib', 'Deltasone', 'Ofisolona', 'Deltra', 'Prednisone', 'Delta 1-Cortisone', 'Delta-Dome', 'Prednitone', 'Deltison', 'Econosone', 'Prednicen-M', 'Perrigo Prednisone', 'Promifen', 'Adasone', '.delta.1-Cortisone', '1, 2-Dehydrocortisone', 'Decorton', 'Deltacortisone', 'Prednilonga', 'Panafcort', 'Predicor', 'Servisone', 'DeCortin', 'Orasone', 'Predicorten', 'Dacortin', 'Meprosona-F', 'PRED', 'Meticorten', 'Rayos', 'Metacortandracin', 'Panasol-S', 'Prednisone Intensol', 'Predniment', 'Decortisyl', 'Deltacortene', 'Cortancyl', 'Deltadehydrocortisone', 'Prednicort', 'Prednisonum', 'SK-Prednisone', 'Lisacort']",43,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Clinical Stage 0 Cutaneous Melanoma AJCC v8,M.D. Anderson Cancer Center,2025-09-01T16:18:07.024947,True,,,,,Role of Microbiome in the Realm of Immune-Checkpoint Inhibitor Induced GI Complications In Cancer Population,,"['Clinical Stage 0 Cutaneous Melanoma AJCC v8', 'Clinical Stage I Cutaneous Melanoma AJCC v8', 'Clinical Stage IA Cutaneous Melanoma AJCC v8', 'Clinical Stage IB Cutaneous Melanoma AJCC v8', 'Clinical Stage II Cutaneous Melanoma AJCC v8', 'Clinical Stage IIA Cutaneous Melanoma AJCC v8', 'Clinical Stage IIB Cutaneous Melanoma AJCC v8', 'Clinical Stage IIC Cutaneous Melanoma AJCC v8', 'Clinical Stage III Cutaneous Melanoma AJCC v8', 'Clinical Stage IV Cutaneous Melanoma AJCC v8', 'Colitis', 'Lung Non-Small Cell Carcinoma', 'Malignant Genitourinary System Neoplasm', 'Malignant Solid Neoplasm', 'Pathologic Stage 0 Cutaneous Melanoma AJCC v8', 'Pathologic Stage I Cutaneous Melanoma AJCC v8', 'Pathologic Stage IA Cutaneous Melanoma AJCC v8', 'Pathologic Stage IB Cutaneous Melanoma AJCC v8', 'Pathologic Stage II Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIA Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIB Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIC Cutaneous Melanoma AJCC v8', 'Pathologic Stage III Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIIA Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIIB Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIIC Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIID Cutaneous Melanoma AJCC v8', 'Pathologic Stage IV Cutaneous Melanoma AJCC v8', 'Stage 0 Lung Cancer AJCC v8', 'Stage I Lung Cancer AJCC v8', 'Stage IA1 Lung Cancer AJCC v8', 'Stage IA2 Lung Cancer AJCC v8', 'Stage IA3 Lung Cancer AJCC v8', 'Stage IB Lung Cancer AJCC v8', 'Stage II Lung Cancer AJCC v8', 'Stage IIA Lung Cancer AJCC v8', 'Stage IIB Lung Cancer AJCC v8', 'Stage III Lung Cancer AJCC v8', 'Stage IIIA Lung Cancer AJCC v8', 'Stage IIIB Lung Cancer AJCC v8', 'Stage IIIC Lung Cancer AJCC v8', 'Stage IV Lung Cancer AJCC v8', 'Stage IVA Lung Cancer AJCC v8', 'Stage IVB Lung Cancer AJCC v8']",[],,2021-02-21,2025-10-31,"[{'measure': 'Difference in stool microbiome pattern', 'description': 'The primary endpoint is alpha diversity of bacteria species (measured using inverse Simpson index). It is a measure of diversity which takes into account the number of species present, as well as the relative abundance of each species. As species richness and evenness increase, so diversity increases.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Incidence of adverse events (AE) of fecal microbiota transplantation (FMT) (Project 3)', 'description': 'Adverse events will be recorded by Common Terminology Criteria for Adverse Events version 5 as well as FMT-specific events. All events will be recorded with grade and attribution to FMT. Adverse events that are related to fecal microbiota transplantation will be summarized using frequency and percentage by AE grade, type and attributions.', 'timeFrame': 'Up to 1 year'}]","[{'measure': 'Immune profile factors associated with onset of ICPI-related colitis in blood and colon tissue', 'description': 'Immunohistochemistry study for inflammatory markers will be performed on colon biopsies to measure the change in pattern after treatment. Blood and stool samples will be compared before and after immunosuppressive treatment longitudinally and also horizontally between quick response patients and slow/refractory patient.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Genetic factors associated with onset of ICPI-related colitis in blood and colon tissue', 'description': 'Genomic bacterial DNA will be extracted from fecal samples, with the addition of a bead-beating lysis step. Genomic 16S ribosomal-RNA V4 variable region will be amplified and sequenced on the Illumina MiSeq platform to obtain the microbiome structure and composition.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Endoscopic and histologic features of ICPI-related colitis before and after medical treatment', 'description': 'We will assess the resolution of the following endoscopic presentations of ICPI-related colitis including large, deep ulcerations, erosions, diffuse or patchy erythema, inflammatory exudate, loss of vascular pattern, aphthae, and edema after medical treatment.\n\nWe will assess the resolution of the following histological features of acute colitis and lymphocytic colitis including neutrophilic infiltration, cryptitis, crypt abscess, eosinophilia, intraepithelial apoptosis, and increased intraepithelial lymphocytic infiltration after medical treatment.', 'timeFrame': 'Baseline up to 1 year'}, {'measure': 'Changes of ICPI-related symptoms', 'description': 'We will use MD Anderson Symptom Inventory (MDASI)-Colitis module to capture ICPI-related symptoms, which include 22 physical, psychological, and cognitive symptoms and colitis related symptoms. The ratings are on 0-10 numeric scales, ranging from ""not present"" to ""as bad as you can imagine.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Changes of quality of life (QoL)', 'description': 'MD Anderson Symptom Inventory (MDASI)-Colitis module includes 6 symptom interference items which could capture the impact of therapy on patient\'s physical and affective functioning. The ratings are on 0-10 numeric scales, ranging from ""did not interfere "" to ""interfered completely "".', 'timeFrame': 'Up to 1 year'}, {'measure': 'Cytokine features that are associated with good response to FMT', 'description': 'We will compare the levels of many cytokines/chemokines by Luminex assays including IL-6, IL-17A, TNF-α, etc. between patients with good response and poor response to FMT.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Genetic factors associated with onset of ICPI-related colitis in blood and colon tissue', 'description': 'Genomic bacterial DNA will be extracted from fecal samples, with the addition of a bead-beating lysis step. Genomic 16S ribosomal-RNA V4 variable region will be amplified and sequenced on the Illumina MiSeq platform to obtain the microbiome structure and composition. We will evaluate these factors between patients with good response and poor response to FMT.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Changes of endoscopic and histologic features of ICPI-related colitis before and after fecal microbiota transplantation', 'description': 'We will assess the resolution of the following endoscopic presentations of ICPI-related colitis including large, deep ulcerations, erosions, diffuse or patchy erythema, inflammatory exudate, loss of vascular pattern, aphthae, and edema after FMT.\n\nWe will assess the resolution of the following histological features of acute colitis and lymphocytic colitis including neutrophilic infiltration, cryptitis, crypt abscess, eosinophilia, intraepithelial apoptosis, and increased intraepithelial lymphocytic infiltration after FMT.', 'timeFrame': 'Baseline up to 1 year'}]",10.0,18 Years,,ALL,False,OTHER,1.0,800.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01328496,Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen,Preparative Regimen,['Preparative Regimen'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hematologic Malignancies,St. Jude Children's Research Hospital,2025-09-01T16:18:07.024961,True,,,,,Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen,,"['Hematologic Malignancies', 'Disorder Related to Transplantation', 'Hematopoietic Malignancy']","['Hematologic Malignancies', 'Umbilical Cord Blood transplantation', 'Hematopoietic Cell Transplantation']",,2011-06-15,2016-10-31,"[{'measure': 'Event Free Survival (EFS) for Research Participants', 'description': 'Estimate EFS for research participants at one-year post transplant by using single unit umbilical cord blood. The event is defined as relapse, graft failure, death due to any cause. The number of participants who did not experience any of those events (relapse, graft failure, death due to any cause) at year 1 post-transplant was given.', 'timeFrame': '1 year post-transplant'}]","[{'measure': 'Number of Observational Arm Participants Engrafted', 'description': 'For patients enrolled in the observational arm (undergoing a double unit UCBT), the number of patients engrafted was given.', 'timeFrame': '1 year'}, {'measure': 'Number of Observational Arm Patients Who Relapsed', 'description': 'The number of observational arm patients who relapsed was given.', 'timeFrame': '1 year'}, {'measure': 'Number of Deaths of Observational Arm Patients', 'description': 'The number of observational arm patients who died was given.', 'timeFrame': '1 year'}, {'measure': 'Number of Observational Arm Patients With Transplant-related Mortality (TRM)', 'description': 'The number of patients with TRM within the first 100 days post transplant was given.', 'timeFrame': 'First 100 days'}, {'measure': 'Number of Participants With Acute GVHD', 'description': 'The number of participants with incidence of acute GVHD by grade was given. Participants are graded on a scale from 1 to 4, with 1 being mild and 4 being severe.', 'timeFrame': '1 year'}, {'measure': 'Number of Participants With Chronic GVHD', 'description': 'Due to the small sample size, cumulative incidence analysis was not done. The incidence of chronic GVHD was evaluated using NIH Consensus Global Severity Scoring. The number of patients with incidence of chronic GVHD by severity was provided.', 'timeFrame': '1 year'}, {'measure': 'Time to Engraftment of Research Arm Participants', 'description': 'Platelet engraftment was defined as platelet count ≥20,000/mm\\^3 for 3 consecutive tests performed on different days with no platelet transfusions in the preceding 7 days. Neutrophil engraftment will be defined as achieving ANC ≥ 500/mm3 for 3 consecutive tests performed on different days with evidence of donor cell engraftment. Descriptive statistics are provided.', 'timeFrame': 'first 100 days post transplant'}, {'measure': 'Incidence of Transplant-related Mortality (TRM)', 'description': 'TRM is death occurring in patients in continuous complete remission. The numbers of patients with TRM was given.', 'timeFrame': 'first 100 days post transplant'}, {'measure': 'The Number of Participants With Transplant-related Morbidity', 'description': 'Any patient who had adverse events listed either as probable or definite in the first 100 days post-transplant are counted as transplant related morbidity. The number of patients with transplant-related morbidity was given.', 'timeFrame': 'first 100 days post transplant'}]",10.0,,21 Years,ALL,False,OTHER,2.0,14.0,ACTUAL,v2_robust,True,True,False,True,
NCT05427162,A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist,Prostacyclin Receptor Agonist,['Prostacyclin Receptor Agonist'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pulmonary Arterial Hypertension,Actelion,2025-09-01T16:18:07.025042,True,,,,,"Open-Label, Randomized Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Different Formulations of an IP Receptor Agonist",,['Pulmonary Arterial Hypertension'],[],,2022-06-21,2023-12-05,"[{'measure': 'Number of Participants with Treatment-emergent Adverse Events (TEAEs)', 'description': 'An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants With Serious TEAEs', 'description': 'A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Serious TEAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants with TEAEs by Severity', 'description': 'Number of participants with TEAEs by severity will be evaluated. An assessment of severity grade will be made using the following general categorical descriptors, such as Mild (Awareness of symptoms that are easily tolerated, causing minimal discomfort, and not interfering with everyday activities), Moderate (Sufficient discomfort is present to cause interference with normal activity), and Severe (Extreme distress, causing significant impairment of functioning or incapacitation, and prevents normal everyday activities).', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants with TEAEs Leading to Discontinuation', 'description': 'Number of participants with TEAEs leading to discontinuation will be reported.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants With Change from Baseline in Clinical Laboratory Values', 'description': 'Number of participants with change from baseline in clinical laboratory values (chemistry, hematology, and urinalysis) will be evaluated.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants With Injection Site Reactions', 'description': 'Number of participants with injection site reactions will be evaluated.', 'timeFrame': 'Up to 114 days'}]","[{'measure': 'Treatment Period 1: Maximum Observed Plasma Concentration of Prostacyclin Receptor Agonist at Steady State (Cmax[ss])', 'description': 'Cmax(ss) is the maximum observed plasma concentration of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 1: Time to Reach Maximum Observed Plasma Concentration of Prostacyclin Receptor Agonist at Steady State (Tmax[ss])', 'description': 'Tmax(ss) is the actual sampling time to reach maximum observed plasma concentration of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 1: Area Under the Curve From Time Zero to tau of Prostacyclin Receptor Agonist at Steady State (AUC[0-tau{ss}])', 'description': 'AUC(0-tau\\[ss\\]) is defined as area under the curve from time 0 to tau hours post dose of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 1: Plasma Concentration at the End of One Dose Interval of Prostacyclin Receptor Agonist at Steady State (Ctrough[ss])', 'description': 'Ctrough(ss) is the plasma concentration at the end of one dose interval of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Maximum Observed Plasma Concentration (Cmax) of Prostacyclin Receptor Agonist', 'description': 'Cmax is the maximum observed plasma concentration of prostacyclin receptor agonist, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prostacyclin Receptor Agonist', 'description': 'Tmax is the actual sampling time to reach maximum observed plasma concentration of prostacyclin receptor agonist, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve from time Zero to time t (AUC[0-t]) of Prostacyclin Receptor Agonist', 'description': 'Area under the plasma concentration-time curve from time zero to time t of the last measured concentration above the limit of concentration of prostacyclin receptor agonist, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time calculated as the sum of AUC (0-last) and C (0-last)/ lambda(z); wherein AUC (0-last) is area under the plasma concentration time curve from time zero to last quantifiable time, C(0-last) is the last observed quantifiable concentration of prostacyclin receptor agonist, and lambda (z) is elimination rate constant, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve From Zero to Time 24 Hours (AUC [0-24h]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-24h) is the area under the plasma concentration-time curve from zero to time 24 hours, during treatment period 2.', 'timeFrame': 'Predose up to 24 hours post dose'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve From Zero to Day 14 (AUC [0-Day 14]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-Day 14) is the area under the plasma concentration-time curve from zero to Day 14, during treatment period 2.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC [0-Day 28]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-Day 28) is the area under the plasma concentration-time curve from zero to Day 28, during treatment period 2.', 'timeFrame': 'Up to Day 28'}, {'measure': 'Treatment Period 2: Plasma Concentration of Prostacyclin Receptor Agonist at Day 14 (C[Day 14])', 'description': 'C(Day 14) is the plasma concentration of prostacyclin receptor agonist at Day 14, during treatment period 2', 'timeFrame': 'Up to Day 14'}, {'measure': 'Treatment Period 2: Plasma Concentration of Prostacyclin Receptor Agonist at Day 28 (C[Day 28])', 'description': 'C(Day 28) is the plasma concentration of prostacyclin receptor agonist at Day 28, during treatment period 2.', 'timeFrame': 'Up to Day 28'}]",19.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,88.0,ACTUAL,v2_robust,True,True,False,True,
NCT06289062,Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer,Camrelizumab,"['Nab paclitaxel', 'Cisplatin', 'Camrelizumab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Cervical Cancer,Tongji Hospital,2025-09-01T16:18:07.025069,True,,,,,Neoadjuvant Chemotherapy Plus Camrelizumab (NACI Therapy) for Fertility Preservation in FIGO Stage IB1 Cervical Cancer,,"['Cervical Cancer', 'Neoadjuvant Chemoimmunotherapy', 'Fertility Preservation']",[],,2024-05-08,2030-12-01,"[{'measure': 'Pathologic complete response', 'description': 'Proportion of patients with no tumor cells on postoperative pathology and negative lymph node metastasis', 'timeFrame': ""At the end of the patient's treatment, up to 2 years.""}]","[{'measure': 'The negative conversion of HPV', 'description': 'Proportion of patients with known HPV infection at screening who are HPV-negative after treatment', 'timeFrame': 'At the end of treatment, up to 2 years.'}, {'measure': 'Pregnancy rate', 'description': 'the ratio of the number of women with a successful pregnancy to the total number of women who attempted to become pregnant', 'timeFrame': 'Until the end of the 5-year follow-up period, up to 7 years.'}, {'measure': 'Miscarriage rate', 'description': 'the ratio of miscarriage events that occur during pregnancy in women who are pregnant', 'timeFrame': 'Until the end of the 5-year follow-up period, up to 7 years.'}, {'measure': 'Live birth rate', 'description': 'The live birth rate is the ratio of the number of babies successfully delivered and surviving to the total number of women who attempted pregnancy', 'timeFrame': 'Until the end of the 5-year follow-up period, up to 7 years.'}, {'measure': 'Preterm birth rate', 'description': 'The preterm birth rate is the proportion of babies born at less than 37 weeks of gestation', 'timeFrame': 'Until the end of the 5-year follow-up period, up to 7 years.'}, {'measure': 'Adverse Event', 'description': 'Adverse Effects of immunotherapy and chemotherapy', 'timeFrame': 'during the treatment, up to 5 years.'}, {'measure': 'Number of Participants with surgical complications', 'description': 'intraoperative bleeding, vascular injuries, bladder injuries, rectal injuries, and ureteral injuries, as defined by the need for suture repair; occlusive nerve injuries, as defined by complete severance; and vascular injuries, as defined by the need to document the site of injury. Postoperative complications included: cervical stenosis, cervical insufficiency, ureteral/bladder/rectal/vaginal fistula, internal hemorrhage, pelvic infection, lymphocyst, lymphatic fistula, lower extremity edema, lower extremity venous thrombosis, urinary retention, nerve injury, and bowel obstruction.', 'timeFrame': 'During and after the surgery, up to 2 years.'}, {'measure': 'Patient Reported Outcomes (EORTC QLQ-C30)', 'description': 'Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score', 'timeFrame': 'From enrollment to the end of the 5-year follow-up period. 5 years.'}, {'measure': 'Patient Reported Outcomes (EORTC QLQ-CX24)', 'description': 'The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) is a questionnaire that rates the symptoms common to women with cervical cancer and evaluates the impact of disease and/or treatments. The 24 items use a 4-point scale (1=not at all to 4=very much) and are classified into 3 multi-item scales, 11 items with symptom experience, 3 items with body image, and 4 items with sexual/ vaginal functioning. The other items of the questionnaire are lymphedema, peripheral neuropathy, menopausal symptom, sexual worry, sexual activity, and sexual enjoyment. The change from baseline in EORTC QLQ-CX24 score will be presented.', 'timeFrame': 'From enrollment to the end of the 5-year follow-up period. 5 years.'}, {'measure': 'Event-free survival (EFS)', 'description': ""the time between the enrollment and any documented tumor progression, recurrence, or death from any cause; the analysis of EFS includes the results of tumor evaluations during the study treatment and follow-up periods. If a patient had several indicators of progressive disease (PD) or recurrence, the EFS analysis was performed using the indicator that appeared first; PD, recurrence, or death were considered to have reached the study endpoint; patients who were treated with other systemic or antitumor therapies directed at the target lesion of observation were also considered to be in PD; for patients who did not have PD, recurrence, or death at the end of the study, the time when the patient's failure to have a recurrence was last obtained was used as the time to censor the data."", 'timeFrame': 'Until the end of the 5-year follow-up period, up to 7 years.'}, {'measure': 'Overall survival (OS)', 'description': 'the time from the start of enrollment to death from any cause', 'timeFrame': 'Until the end of the 5-year follow-up period, up to 7 years.'}]",12.0,18 Years,45 Years,FEMALE,False,OTHER,13.0,40.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00198562,Hypertension Control Based on Home Blood Pressure,"Amlodipine, Losartan","['Amlodipine, Losartan', 'other antihypertensive drugs (if required)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Hypertension,"Ministry of Health, Labour and Welfare, Japan",2025-09-01T16:18:07.025094,True,,,,,Hypertension Control Based on Home Systolic Pressure Study (HOSP Study),,['Hypertension'],"['Antihypertensive therapy', 'Home blood pressure', 'Systolic blood pressure', 'Morning blood pressure', 'Calcium antagonist', 'Angiotensin receptor antagonist']",,2000-04,2012-03,"[{'measure': 'Combined cardiovascular events', 'timeFrame': '5 years'}]","[{'measure': 'Total mortality', 'timeFrame': '5 years'}, {'measure': 'Cardiovascular mortality', 'timeFrame': '5 years'}, {'measure': 'Myocardial infarction and new-onset angina', 'timeFrame': '5 years'}, {'measure': 'Stroke and transient ischemic attack', 'timeFrame': '5 years'}, {'measure': 'Renal failure', 'timeFrame': '5 years'}, {'measure': 'Aortic and peripheral artery diseases', 'timeFrame': '5 years'}, {'measure': 'Left ventricular mass and function', 'timeFrame': '5 years'}, {'measure': 'Urinary albumin and renal function', 'timeFrame': '5 years'}]",9.0,40 Years,79 Years,ALL,False,OTHER_GOV,1.0,2600.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01389362,The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes,Chinese herbal medicine (Radix Rehmanniae and Radix Astragali),"['Placebo comparator', 'Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Diabetic Foot Ulcer,Chinese University of Hong Kong,2025-09-01T16:18:07.025109,True,,,,,"The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes: A Randomized, Placebo-Controlled Study",,['Diabetic Foot Ulcer'],"['Diabetes', 'foot ulcer', 'Chinese herbal medicine']",,2009-05,2011-05,"[{'measure': 'Resolution/progression of foot ulcer based on PEDIS', 'timeFrame': '6 months'}]","[{'measure': 'Hospital admission/attendance/stay', 'timeFrame': '6 months'}]",2.0,20 Years,75 Years,ALL,False,OTHER,0.0,16.0,ACTUAL,v2_robust,True,True,False,False,
NCT00479362,Anticoagulant Therapy During Pacemaker Implantation,Warfarin,"['Aspirin', 'Primaspan, ATC code B01AC06', 'Marevan, ATC code B01AA03', 'Acethyl Salcylic Acid', 'Warfarin', 'Disperin, ATC code B01AC06', 'Aspirin Cardio, ATC code B01AC06', 'Marevan Forte, ATC code B01AA03']",8,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hemorrhage,University of Turku,2025-09-01T16:18:07.025135,True,,,,,Randomized Trial of Uninterrupted Versus Interrupted Anticoagulant Therapy in Patients Undergoing Cardiac Pacing Device Implantation,,"['Hemorrhage', 'Thrombosis', 'Embolism']","['Pacemaker', 'Cardioverter-defibrillator', 'Hemorrhage', 'Hematoma', 'Thrombosis', 'Embolism']",,2005-09,2012-09,"[{'measure': 'Measure: rate of haemorrhagic and thromboembolic complications', 'timeFrame': 'within first four weeks'}]",[],1.0,18 Years,,ALL,False,OTHER,3.0,447.0,ACTUAL,v2_robust,True,True,False,False,
NCT01200862,"Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men",Investigational new drug company code: BGS649,"['Investigational new drug company code: BGS649', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Obese Hypogonadotropic Hypogonadism,Mereo BioPharma,2025-09-01T16:18:07.025141,True,,,,,"An Open-label Dose Finding Study Followed by a Parallel Group, Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Pharmacodynamics of 12 Week BGS649 Treatment in Obese, Hypogonadotropic Hypogonadal Men",,['Obese Hypogonadotropic Hypogonadism'],"['Obese', 'obesity', 'hypogonadism', 'hypogonadotropic', 'hyperestrogenemic', 'testosterone', 'hypogonadal']",,2010-08,2012-08,"[{'measure': 'Percentage of Patients Achieving Normal Testosterone Levels', 'description': 'Percentage of patients achieving normal testosterone (2.50 - 9.50 ng/mL) levels at Week 4 and Week 12', 'timeFrame': 'At Week 4 and 12'}, {'measure': 'Part 2: Change From Baseline at Homeostatic Model Assessment of Insulin Resistance (HOMA-IR & QUICKI Scores) at Week 4 and 12', 'description': 'Pharmacodynamic change from baseline in HOMA-IR. Score at week 4 and week 12 as an assessment of insulin resistance. Low score representing high insulin sensitivity and a high score representing low insulin sensitivity or insulin resistance. HOMA-IR is a ration of Fasting insulin (mIU/L) : Fasting glucose (mmol). Pharmacodynamic change in QUICKI score at week 4 and week 12 as an assessment of insulin resistance. The QUICKI scale is a log score and a high score representing high insulin sensitivity and low score indicating low insulin sensitivity. Patients with a score below 0.3 are considered diabetic. Week 12 data is missing because there were inaccuracies in dosing of patients and so the study was terminated, only safety data was collected.', 'timeFrame': 'Baseline, Week 4 and Week 12'}]","[{'measure': ""Part 2: Area Under the Concentration-time Curve From Time Zero to Time 't' (AUC0-168)"", 'description': 'PK sampling was performed at 0hr (pre-dose), 1 hr, 8 hr, 24 hr, 72 hr, and 168 hr on the following occasions Week 1, Week 4 and week 11. The AUC 0-168 measures the amount of drug within the subjects blood over the 168h post-dosing at these timepoints.', 'timeFrame': '11 weeks'}, {'measure': 'Part 2: Pharmacokinetics of BGS649: Maximum (Peak) Observed Blood Drug Concentration After Single Dose Administration (Cmax)', 'description': 'PK sampling was performed at 0hr (pre-dose), 1 hr, 8 hr, 24 hr, 72 hr, and 168 hr on the following occasions Week 1, Week 4 and week 11.', 'timeFrame': 'Week 1 to Week 11'}, {'measure': 'Part 2: Pharmacokinetics of BGS649: Time to Reach Maximum (Peak) Blood Drug Concentration After Single Dose Administration (Tmax)', 'description': 'PK sampling was performed at 0hr (pre-dose), 1 hr, 8 hr, 24 hr, 72 hr, and 168 hr on the following occasions Week 1, Week 4 and week 11.', 'timeFrame': 'Week 1 to Week 11'}, {'measure': 'PK of BGS649 Elimination Half-life Associated With the Terminal Slope of a Semi Logarithmic Concentration-time Curve (T1/2)', 'description': 'PK sampling was performed at 0hr (pre-dose), 1 hr, 8 hr, 24 hr, 72 hr, and 168 hr on the following occasions Week 1, Week 4 and week 11.', 'timeFrame': 'Week 1 to Week 11'}]",6.0,30 Years,65 Years,MALE,False,INDUSTRY,1.0,29.0,ACTUAL,v2_robust,True,False,True,True,
NCT01637662,Natriuretic Peptide's Headache Inducing Characteristics and Effects on the Cerebral Blood Flow,Natriuretic peptides,['Natriuretic peptides'],1,INTERVENTIONAL,['NA'],,COMPLETED,Headache,Danish Headache Center,2025-09-01T16:18:07.025217,True,,,,,Mechanisms and Biological Markers During Headache Induced by Natriuretic Peptides,,"['Headache', 'Migraine']",[],,2012-07,,"[{'measure': 'Headache intensity, mean velocity of blood flow in the middle cerebral artery (VmeanMCA), superfical temporal artery diameter, PetCO2, adverse events and vital signs were recorded at T-10, T0 and then every 10 min until 120 min after start of infusion.', 'timeFrame': 'Every 10 min.'}]","[{'measure': 'All subjects were asked to complete a headache diary every hour until 10 h after the discharge. The diary included headache characteristics and accompanying symptoms according to the International Headache Society (IHS 2004)', 'timeFrame': '10 hours after discharge'}]",2.0,18 Years,40 Years,ALL,True,OTHER,0.0,6.0,ACTUAL,v2_robust,True,True,False,True,
NCT02082262,AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis,AGN-229666,['AGN-229666'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Conjunctivitis, Allergic",Allergan,2025-09-01T16:18:07.025224,True,,,,,,,"['Conjunctivitis, Allergic']",[],,2014-03,2014-07,"[{'measure': 'Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale', 'description': 'Ocular itching frequency is assessed on a 6-poing scale, where 0 = did not occur, 1 = once in 3 days, 2 = twice in 3 days, 3 = once every day, 4 = 2 or more times every day, and 5 = virtually all the time over the past 3 days. Ocular itching frequency is evaluated over the 3 days prior to the visit. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.', 'timeFrame': 'Baseline, Day 70'}]",[],1.0,10 Years,,ALL,False,INDUSTRY,0.0,140.0,ACTUAL,v2_robust,True,True,False,False,
NCT02512562,A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers,AL-335,"['Olysio', 'AL-335', 'Simeprevir', 'ACH-3102']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Chronic Hepatitis C,Alios Biopharma Inc.,2025-09-01T16:18:07.025291,True,,,,,"A Phase-1, Open-label, Two Group, Fixed-Sequence Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers",,['Chronic Hepatitis C'],[],,2015-07-31,2015-08-31,"[{'measure': 'Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 on AL-335 and metabolites', 'description': 'To evaluate the effect of multiple oral doses of ACH-3102, on the multiple oral dose PK of AL-335 and metabolites', 'timeFrame': 'From screening to Day 28 follow-up visit'}, {'measure': 'Multiple dose PK Profile, Cmax and AUC: effect of Simeprevir on AL-335 and metabolites', 'description': 'To evaluate the effect of multiple oral doses of Simeprevir, on the multiple oral dose PK of AL-335 and metabolites', 'timeFrame': 'From screening to Day 24 visit'}, {'measure': 'Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 and Simeprevir on AL-335 and metabolites', 'description': 'To evaluate the effect of multiple oral doses of ACH-3102 and Simeprevir, on the multiple oral dose PK of AL-335 and metabolites', 'timeFrame': 'From screening to Day 28 follow-up visit'}]","[{'measure': 'Safety Data: Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results', 'description': 'Tabulation of the number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results (including chemistry, hematology, and urine).', 'timeFrame': 'From screening to Day 28 follow-up visit'}, {'measure': 'Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and ACH-3102 on Simeprevir', 'description': 'To determine the potential effect of AL-335 and/or ACH-3102 on the steady-state PK of Simeprevir.', 'timeFrame': 'From screening to Day 28 follow-up visit'}, {'measure': 'Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and Simeprevir on ACH-3102', 'description': 'To determine the potential effect of AL-335 and/or Simeprevir on the steady-state PK of ACH-3102.', 'timeFrame': 'From screening to Day 28 follow-up visit'}]",6.0,18 Years,60 Years,ALL,True,INDUSTRY,1.0,32.0,ACTUAL,v2_robust,True,True,False,True,
NCT04251962,Role of Opioids in Epidural Solutions,Bupivacaine,"['Fentanyl', 'Beatryl', 'Marcaine', 'Bupivacaine']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postoperative Pain,Tel-Aviv Sourasky Medical Center,2025-09-01T16:18:07.025305,True,,,,,The Role of Epidural Opioids in Pain Management After Abdominal Surgery in Adult Patients - a Randomized Clinical Trial,,['Postoperative Pain'],[],,2020-08-01,2022-03-02,"[{'measure': 'Postoperative analgesia', 'description': 'A joint outcome of the difference in average pain score and a ratio of opioid consumption (in mg morphine equivalents) between the 2 study groups', 'timeFrame': '48 postoperative hours'}]","[{'measure': 'Clinically significant postoperative hypotension', 'description': 'Number of participants experiencing a composite of use of IV fluid boluses prescribed for hemodynamic support; sympathomimetic drugs administration; and holding or early discontinuation of the epidural infusion in order to recover blood pressure.', 'timeFrame': '48 postoperative hours'}]",2.0,18 Years,85 Years,ALL,False,OTHER_GOV,1.0,135.0,ACTUAL,v2_robust,True,True,False,False,
NCT05715346,LEV102 Topical Gel in Acquired Blepharoptosis,LEV102 1.0%,"['LEV102 1.0%', 'LEV102 2.0%', 'Vehicle']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Acquired Blepharoptosis,"Levation Pharma, Ltd.",2025-09-01T16:18:07.025339,True,,,,,A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis,,['Acquired Blepharoptosis'],['Blepharoptosis'],,2023-02-23,2023-06-24,"[{'measure': 'Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability])', 'description': 'Adverse events', 'timeFrame': 'Day 2-5'}]","[{'measure': 'Upper Eyelid Height', 'description': 'Percentage of subjects with increase in Margin reflex distance 1 (MRD1) of 1 mm at Hours 2 and 6 on Day 1', 'timeFrame': 'Day 1'}]",2.0,25 Years,99 Years,ALL,False,INDUSTRY,0.0,33.0,ACTUAL,v2_robust,True,True,False,True,
NCT01582646,Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain,Terbutaline sustained release 5 mg,['Terbutaline sustained release 5 mg'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Postthoracotomy Pain,"University Hospital, Strasbourg, France",2025-09-01T16:18:07.025345,True,,,,,Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain,,"['Postthoracotomy Pain', 'Postthoracoscopy Neuropathic Pain']",[],difficulty of recruitment,2012-01,2017-09,"[{'measure': 'Change from baseline in the average intensity of pain during the last 24 hours reported by the patient on a 11 points Numeric Scale', 'timeFrame': 'Day one, day 14 and day 28 of each 4 weeks period'}]",[],1.0,18 Years,75 Years,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,False,True,False,difficulty of recruitment
NCT04453046,Hemopurifier Plus Pembrolizumab in Head and Neck Cancer,Pembrolizumab 200mg IV,['Pembrolizumab 200mg IV'],1,INTERVENTIONAL,['NA'],,TERMINATED,Squamous Cell Carcinoma of the Head and Neck,Aethlon Medical Inc.,2025-09-01T16:18:07.025353,True,,,,,Depleting Exosomes to Improve Response to Immune Therapy in Head and Neck Squamous Cell Cancer: An Early Feasibility Phase I Clinical Trial,,['Squamous Cell Carcinoma of the Head and Neck'],"['Head- Neck Cancer', 'Hemopurifier', 'Pembrolizumab', 'Keytruda', 'Exosome', 'Immuno-oncology', 'Checkpoint inhibitor']",Lack of Eligible subjects at study site,2020-10-22,2022-11-14,"[{'measure': 'Safety as measured by adverse events', 'description': 'Safety will be determined in an Early Feasibility Phase I clinical trial for patients with recurrent/metastatic HNSCC who will undergo therapy with first line Pembrolizumab per standard of care combined with Hemopurifier treatments . All patients will be treated with Pembrolizumab every 21 days and, during active treatment, imaging will be done after every 3rd cycle as per standard of care. As part of the first two cycles of Pembrolizumab patients will receive Hemopurifier therapy immediately prior to Pembrolizumab infusion. The Hemopurifier therapy will last 4h and patients will receive their Pembrolizumab dose as soon as logistically possible, after Hemopurifier therapy on the same day.', 'timeFrame': 'Through study completion - Safety assessments will be completed at each study visits and up to two years after entry on protocol or until disease progression'}, {'measure': 'Adverse Events', 'description': 'Adverse events will be graded using CTCAE v5. The proportion of patients experiencing serious adverse events at least possibly related to treatment with Hemopurifier plus Pembrolizumab will be estimated with an exact 95% binomial confidence interval. Toxicity will be assessed continuously, and the trial will be paused if any patient experiences a treatment-related Grade 3 or worse adverse event. The rule is based on a beta-binomial model with an uninformative prior (α=1, β=1), where the trial is paused if P(P(Toxicity\\|Data and Prior)\\>0.3)\\>0.75.', 'timeFrame': 'Day 1, Day 21, through study completion, up to two years'}]","[{'measure': 'Levels of exosomes', 'description': 'Kinetics of exosome depletion will be studied by drawing venous blood hourly starting immediately before, hourly during and immediately after each Hemopurifier treatment until Pembrolizumab treatment begins, for measuring total exosome protein level (TEP) and immunoinhibitory protein and miRNA profiles in the systemic circulation. Kinetics of exosome recovery will be studied by measuring TEP levels immediately prior to Pembrolizumab administration, and on days 7 and 14 after the first 2 cycles where patients are treated with Hemopurifier plus Pembrolizumab. Blood will be collected prior to each Hemopurifier treatment and each Pembrolizumab infusion for serial monitoring of TEP levels and immunoinhibitory protein and miRNA profiles.', 'timeFrame': 'Through study completion - up to two years after entry on protocol or until disease progression'}, {'measure': 'Tumor response', 'description': 'CT imaging will be done after every 3rd cycle as per standard of car. If the patient 2 years of treatment and remains with CR/PR or SD, patient will undergo imaging every 3 months or sooner at the discretion of the treating physician. If a patient is taken off the study for progression, adverse events, or any other reason they will be seen 30 days afterwards for follow up followed by survival follow up every 3 months in the first year and every 6 months in the second year after withdrawal from study.', 'timeFrame': 'Through study completion- up to two years or until disease progression'}, {'measure': 'Survival', 'description': 'Overall survival', 'timeFrame': 'Through study completion - up to two years or until disease progression'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,2.0,ACTUAL,v2_robust,True,False,True,True,Lack of Eligible subjects at study site
NCT01962246,Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction,Oxaliplatin; Capecitabine,"['Xeloda', 'Oxaliplatin', 'Oxaliplatin; Capecitabine']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Gastroesophageal Junction Adenocarcinoma,Hebei Medical University,2025-09-01T16:18:07.025491,True,,,,,Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer,,['Gastroesophageal Junction Adenocarcinoma'],"['Capecitabine', 'Oxaliplatin', 'Preoperative Concurrent Chemoradiotherapy', 'Gastroesophageal Junction Adenocarcinoma']",,2012-02,2021-08,"[{'measure': 'Disease-free survival(DFS)', 'timeFrame': '3 year'}]","[{'measure': 'R0-resection rate', 'timeFrame': 'within 3 weeks after surgery'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': 'within 3 weeks after surgery'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'within 3 weeks after surgery'}, {'measure': 'Down-staging Rate', 'timeFrame': 'within 3 weeks after surgery'}, {'measure': 'Overall survival (OS)', 'timeFrame': '3years'}, {'measure': 'Adverse events', 'description': ""Side effects during observation\\] Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. The number of Participants with adverse events will be recorded at each treatment visit."", 'timeFrame': '3 year'}, {'measure': 'Death related to operation', 'timeFrame': '4 weeks'}]",8.0,18 Years,75 Years,ALL,False,OTHER,0.0,169.0,ACTUAL,v2_robust,True,True,False,True,
NCT01104246,Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men,Testerone Transdermal System,"['Testerone Transdermal System', 'Testosterone']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hypogonadism,Watson Pharmaceuticals,2025-09-01T16:18:07.025504,True,,,,,"An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of Testosterone Transdermal Systems in Hypogonadal Men",,['Hypogonadism'],"['Hypogonadism', 'Testosterone', 'Hormone replacement therapy']",,2010-04,2010-09,"[{'measure': 'Time-average (Cavg) Steady State Testosterone Concentration Over 24 Hours', 'description': 'A 24-hour pharmacokinetic sampling was performed on Day 28/29 after the start of dosing.', 'timeFrame': 'Day 28/29'}]",[],1.0,18 Years,,MALE,False,INDUSTRY,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT00597246,Imaging Brain Tumors With FACBC and Methionine,"FACBC, Methionine","['FACBC, Methionine']",1,INTERVENTIONAL,['NA'],,COMPLETED,Brain Cancer,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:07.025511,True,,,,,Imaging Brain Tumors With FACBC and Methionine,,"['Brain Cancer', 'CNS Cancer']","['Brain', 'CNS', 'Central Nervous System']",,2003-05-13,2019-11-27,"[{'measure': 'Maximum Standardized Uptake Value of 3-[18F]-FACBC', 'description': 'Determine clearance of 3-\\[18F\\]-FACBC in different tissues/organs of body.', 'timeFrame': 'Duration of scan, an average of 1 hour'}]","[{'measure': 'Rate of 18F-Fluciclovine Transport (k1) Into Tumors', 'description': ""Look for potential correlations bet subsequent MR \\& PET results obtained from patients enrolled and patients' subsequent medical treatment, progression of tumor \\& survival."", 'timeFrame': 'Duration of scan, an average of 1 hour'}]",2.0,,,ALL,False,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT02795546,Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.,Alendronate sodium,"['fossamax, osteofos', 'Alendronate sodium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Intrabony Periodontal Defect,Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre,2025-09-01T16:18:07.025523,True,,,,,"Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects: A Randomized, Controlled Clinical Trial.",,['Intrabony Periodontal Defect'],['periodontal regeneration'],,2015-01,2016-04,"[{'measure': 'Linear bone growth', 'description': 'Linear bone growth (LBG) was calculated as the difference between the cemento-enamel junction(CEJ) to base of defect (BD) distance at baseline and CEJ to BD distance at 6 months in radiographs.', 'timeFrame': 'change from baseline and 6 months'}]","[{'measure': 'clinical attachment level (CAL)', 'description': 'distance between the cemento-enamel junction and base of the pocket', 'timeFrame': 'change from baseline and 6 months'}]",2.0,30 Years,50 Years,ALL,True,OTHER,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT07038746,"Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges",Inhaled Epinephrine,['Inhaled Epinephrine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,NOT_YET_RECRUITING,Hypersensitivity,Dr. George Luciuk,2025-09-01T16:18:07.025538,True,,,,,"A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges",,"['Hypersensitivity', 'Anaphylaxis']","['Immunotherapy', 'Epinephrine', 'Upper airway laryngeal edema', 'Upper airway pharyngeal edema', 'Hypersensitivity', 'Hypersensitivity, immediate', 'Anaphylaxis', 'Vasoconstrictor agents', 'Adrenergic alpha-Agonists', 'Adrenergic beta-Agonists', 'Bronchodilator agents']",,2025-07,2026-07,"[{'measure': 'Time to resolution of systemic symptoms', 'description': ""Defined as a reduction in systemic allergic reaction (SAR) Grade to ≤ 1. Grade 0 is considered the absence of any symptoms and per World Allergy Organisation's Grading System for Systemic Allergic Reactions, Grade 1 is least severe and Grade 5 is most severe."", 'timeFrame': 'From first dose administration to 60 minutes following first dose administration'}, {'measure': 'Time to complete resolution of systemic symptoms', 'description': ""Defined as a reduction in systemic allergic reaction (SAR) Grade to 0. Grade 0 is considered the absence of any symptoms and per World Allergy Organisation's Grading System for Systemic Allergic Reactions, Grade 1 is least severe and Grade 5 is most severe."", 'timeFrame': 'From first dose administration to 60 minutes following first dose administration'}]",[],2.0,12 Years,,ALL,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06782646,"Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine",Berberine,"['Berberine', 'Berberine (500 mg orally twice a day)', 'Placebo (500 mg orally twice a day)', 'Placebo']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,ENROLLING_BY_INVITATION,Hyperlipidemia,The University of Hong Kong,2025-09-01T16:18:07.025636,True,,,,,"Assessing the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine Using Randomized, Placebo-controlled, Double-masked Trial",,['Hyperlipidemia'],"['Hyperlipidemia', 'berberine', 'lipoprotein', 'lipid', 'sex-hormones', 'apoA1', 'apoB', 'Lp(a)']",,2024-08-01,2026-03,"[{'measure': 'Total cholesterol in mmol/L', 'description': 'Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'LDL-cholesterol in mmol/L', 'description': 'Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Triglycerides in mmol/L', 'description': 'Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Apolipoprotein B in mg/dL', 'description': 'Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Lipoprotein (a) in mg/dL', 'description': 'Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}]","[{'measure': 'HDL-cholesterol in mmol/L', 'description': 'Other relevant lipids and lipoproteins.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Non-HDL-cholesterol in mmol/L', 'description': 'Other relevant lipids and lipoproteins.as liver and kidney function.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Apolipoprotein A1 in mg/dL', 'description': 'Other relevant lipids and lipoproteins.', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Estradiol (E2) in pg/mL', 'description': 'Examine the sex-specific effects of berberine on apoA1, apoB, Lp(a) and lipids', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Sex hormone binding globulin (SHBG) in nmol/L', 'description': 'Examine the sex-specific effects of berberine on apoA1, apoB, Lp(a) and lipids', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}, {'measure': 'Testosterone in ng/dL', 'description': 'Examine the sex-specific effects of berberine on apoA1, apoB, Lp(a) and lipids', 'timeFrame': '4 months for biomarker assessment, 6 months for data analysis'}]",11.0,20 Years,65 Years,FEMALE,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01638546,Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,Temozolomide,"['PARP-1 inhibitor ABT-888', 'Methazolastone', 'ABT-888', 'SCH 52365', 'Temizole', 'M and B 39831', 'ABT888', 'RP-46161', 'Veliparib', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', 'TMZ', 'Temomedac', 'Gliotem', 'M & B 39831', 'Temodal', 'Temcad', 'ABT 888', 'Temozolomide', 'Temodar']",20,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Recurrent Lung Small Cell Carcinoma,National Cancer Institute (NCI),2025-09-01T16:18:07.025679,True,,,,,"A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer",,['Recurrent Lung Small Cell Carcinoma'],[],,2012-07-27,2026-03-25,"[{'measure': 'Progression-free Survival, Calculated as the Proportion of Patients Alive and Without Evidence of Disease', 'description': 'Compared across the two arms using a Fisher exact test.', 'timeFrame': 'From randomization to time of progression or death, whichever occurs first, assessed at 4 months'}]","[{'measure': 'Overall Response (ORR) by RECIST 1.1 Criteria', 'description': 'Corresponding exact two-sided 95% confidence intervals will be calculated and reported in both arms of the study. Comparisons between treatment arms will be performed using Fisher-exact test.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months'}, {'measure': 'Overall Survival', 'description': 'Estimated in each treatment group using Kaplan-Meier method. Group comparisons will be performed using log-rank test.', 'timeFrame': 'From randomization to time of death'}, {'measure': 'Number of Participants With Adverse Events', 'description': 'Tabulated According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Summary level.', 'timeFrame': 'From the start of treatment until 30 days from coming off treatment'}]",4.0,18 Years,,ALL,False,NIH,0.0,97.0,ACTUAL,v2_robust,True,False,False,True,
NCT01261546,Clinical Trial Corticoids For Empyema And Pleural Effusion In Children,Dexamethasone,"['Dexamethasone', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Parapneumonic Pleural Effusion,Hospital Infanta Sofia,2025-09-01T16:18:07.025696,True,,,,,"MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN",,"['Parapneumonic Pleural Effusion', 'Empyema']","['pleural effusion, empyema, corticoids, dexamethasone']",,2010-12,2015-05,"[{'measure': 'time to resolution', 'description': 'days from diagnosis until criteria for cure', 'timeFrame': '1 month after admission'}]","[{'measure': 'number of children with complications.', 'description': 'number of children with complications.', 'timeFrame': '3 months after diagnosis'}, {'measure': 'Number of children with complications attributable to corticoids', 'description': 'Hyperglycemia Signs of gastrointestinal bleeding Need of transfusion Oropharyngeal Candidiasis Allergic reaction', 'timeFrame': '3 months'}]",3.0,1 Month,14 Years,ALL,False,OTHER,2.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT05983146,Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies,HRS-7053 Injection,['HRS-7053 Injection'],1,INTERVENTIONAL,['PHASE1'],PHASE1,WITHDRAWN,Advanced Malignant Cancer,"Jiangsu HengRui Medicine Co., Ltd.",2025-09-01T16:18:07.025706,True,,,,,"A Phase I, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-7053 Injection in Patients With Advanced Malignancies",,['Advanced Malignant Cancer'],[],The sponsor's R\&D strategy is adjusted.,2023-09-01,2025-05-30,"[{'measure': 'Incidence and severity of adverse events (AES)', 'timeFrame': 'up to 3 years'}, {'measure': 'MTD', 'timeFrame': 'up to 3 years'}, {'measure': 'RP2D', 'timeFrame': 'up to 3 years'}]","[{'measure': 'Time to maximum concentration (Tmax)', 'timeFrame': 'up to 3 years'}, {'measure': 'Maximum concentration (Cmax)', 'timeFrame': 'up to 3 years'}, {'measure': 'Area under the time curve from 0 to the last measurable concentration time point t (AUC0-t)', 'timeFrame': 'up to 3 years'}, {'measure': 'Objective response rate （ORR）', 'timeFrame': 'up to 3 years]'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'up to 3 years'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': 'up to 3 years'}, {'measure': 'Duration of response (DoR)', 'timeFrame': 'up to 3 years'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'up to 3 years'}]",11.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,The sponsor's R\&D strategy is adjusted.
NCT03993288,"Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.","Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)","['Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)', 'MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Mild and Moderate Iron-deficiency Anaemia,Sandoz,2025-09-01T16:18:07.025730,True,,,,,"Multicenter, Open-label Active-controlled Randomized Study of Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia) Compared With Maltofer® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Vifor S.A., Switzerland), in Treatment of Patients With Mild and Moderate Iron-deficiency Anaemia.",,['Mild and Moderate Iron-deficiency Anaemia'],"['Ferrum Lek® (iron (III) hydroxide polymaltosate)', 'mild and moderate iron-deficiency anaemia']",,2019-06-27,2020-06-18,"[{'measure': 'Change From Baseline in Blood Hemoglobin Level (g/L)', 'description': 'Changes in blood hemoglobin level (g/L) after 12-weeks of iron-deficiency anaemia treatment, a non-inferiority comparison, as compared with the baseline value (screening visit) between Ferrum Lek® and MALTOFER® groups', 'timeFrame': 'Baseline and Week 12'}]","[{'measure': 'Change From Baseline in Serum Iron', 'description': 'Change in average values of iron metabolism parameter serum iron during the treatment period', 'timeFrame': 'Baseline, Week 4, 8 and 12'}, {'measure': 'Change From Baseline in Transferrin', 'description': 'Change in average values of iron metabolism parameter transferrin during the treatment period', 'timeFrame': 'Baseline, Week 4, 8 and 12'}, {'measure': 'Change From Baseline in Percent Transferrin Saturation', 'description': 'Change in average values of iron metabolism parameter percent transferrin saturation during the treatment period', 'timeFrame': 'Baseline, Week 4, 8 and 12'}, {'measure': 'Change From Baseline in Ferritin', 'description': 'Change in average values of iron metabolism parameter ferritin during the treatment period', 'timeFrame': 'Baseline, Week 4, 8 and 12'}, {'measure': 'Number of Participants With Response to the Therapy', 'description': 'Response to the therapy is determined as an increase in hemoglobin level by 20 g/L and more after 12-weeks of treatment', 'timeFrame': 'Baseline and Week 12'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,267.0,ACTUAL,v2_robust,True,True,False,False,
NCT04125888,Impact of AIT on Allergic Rhinitis and Asthma,Allergy immunotherapy (AIT),['Allergy immunotherapy (AIT)'],1,OBSERVATIONAL,[],,COMPLETED,Allergy,ALK-Abelló A/S,2025-09-01T16:18:07.025789,True,,,,,Impact of AIT on Allergic Rhinitis and Asthma Using Real World Evidence,,"['Allergy', 'Respiratory Disease']",[],,2019-07-22,2021-04-16,"[{'measure': 'Allergic rhinitis medication use', 'description': 'Number of patients with an AR prescription and number of prescriptions by drug class', 'timeFrame': 'From pre-index year to follow-up year(s), assessed from 2007 and up to 2017'}]","[{'measure': 'Asthma medication use', 'description': 'Number of patients with an asthma prescription and number of prescriptions by drug class', 'timeFrame': 'From pre-index to follow-up year(s), assessed from 2007 and up to 2017'}, {'measure': 'Change in asthma disease severity', 'description': 'Change in asthma disease severity assessed by asthma diagnoses, asthma medication use and severe asthma exacerbation', 'timeFrame': 'From pre-index to follow-up year(s), assessed from 2007 and up to 2017'}]",3.0,,,ALL,,INDUSTRY,0.0,92048.0,ACTUAL,v2_robust,False,True,False,False,
NCT02283788,Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization,BIA 2-093,"['ESL, Eslicarbazepine acetate', 'BIA 2-093', 'Moxifloxacin', 'avalox', 'Placebo', 'PLC']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Epilepsy,Bial - Portela C S.A.,2025-09-01T16:18:07.025875,True,,,,,"A Randomized, Double-blind, Placebo-controlled and Open Label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization in Healthy Adult Men and Women",,['Epilepsy'],[],,2007-03,2007-06,"[{'measure': 'QTcI - QT Interval Individually Corrected for Heart Rate - Day 5', 'timeFrame': '-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose'}]","[{'measure': ""QTcB - QT Interval Corrected for Heart Rate Using Bazett's Formula"", 'timeFrame': '-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose'}, {'measure': ""QTcF - QT Interval Corrected Using Fridericia's Formula"", 'timeFrame': '-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose'}]",3.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,67.0,ACTUAL,v2_robust,True,True,False,False,
NCT02682888,Trait Anxiety and Defensive Networks,Oxytocin,"['Placebo', 'Oxytocin']",2,INTERVENTIONAL,['NA'],,COMPLETED,Healthy,University of Electronic Science and Technology of China,2025-09-01T16:18:07.025919,True,,,,,Trait Anxiety Modulates Resting State Functional Connectivity of Defensive Networks,,['Healthy'],['brain functional connectivity changes'],,2015-12-08,2021-11-20,"[{'measure': 'the resting state functional connectivity changes in the defensive network', 'description': 'The resting-state activity can be accessed using functional magnetic resonance imaging (fMRI) by measuring spontaneous and low-frequency fluctuations (\\< 0.1 Hz) when the brain is at rest. Group differences will be calculated in the high trait anxiety group relative to the low trait anxiety group and in the oxytocin group relative to the placebo group.', 'timeFrame': 'one day'}]",[],1.0,18 Years,35 Years,ALL,True,OTHER,0.0,131.0,ACTUAL,v2_robust,True,True,False,False,
NCT04332588,Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI,[18F]FMISO PET/MRI imaging,['[18F]FMISO PET/MRI imaging'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,HER2-positive Breast Cancer,University of Alabama at Birmingham,2025-09-01T16:18:07.025993,True,,,,,Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI,,['HER2-positive Breast Cancer'],[],,2022-03-25,2027-08,"[{'measure': 'Baseline measure of PET standardized uptake value (SUV).', 'description': 'Compare baseline metrics from PET/MRI', 'timeFrame': 'Baseline'}, {'measure': 'Baseline measure of apparent diffusion coefficient (ADC) in mm2/sec from MRI.', 'description': 'Compare baseline metrics from PET/MRI', 'timeFrame': 'Baseline'}, {'measure': 'Baseline measure of signal enhancement ratio (SER) from MRI.', 'description': 'Compare baseline metrics from PET/MRI', 'timeFrame': 'Baseline'}, {'measure': 'Changes in SER from MRI', 'description': 'Compare percent change of SER from imaging visit 3 to the baseline.', 'timeFrame': 'Baseline through 6 months'}, {'measure': 'Changes in ADC from MRI', 'description': 'Compare percent change of ADC (mm2/sec) from imaging visit 3 to the baseline.', 'timeFrame': 'Baseline through 6 months'}, {'measure': 'Changes in SUV from PET', 'description': 'Compare percent change of SUV from imaging visit 3 to the baseline.', 'timeFrame': 'Baseline through 6 months'}]","[{'measure': 'Follow-up', 'description': 'Compare changes in imaging metrics to neoadjuvant response (defined as pathological complete response, near-pathological response, residual disease).', 'timeFrame': 'Baseline through 5 years'}, {'measure': 'Follow-up', 'description': 'Compare changes in imaging metrics to clinical response (defined as disease free-survival or recurrence).', 'timeFrame': 'Baseline through 5 years'}, {'measure': 'Changes in ADC (mm2/sec) from MRI.', 'description': 'Compare percent change from imaging visit 2 to the baseline.', 'timeFrame': 'Baseline through 2 months'}, {'measure': 'Changes in SER from MRI.', 'description': 'Compare percent change from imaging visit 2 to the baseline.', 'timeFrame': 'Baseline through 2 months'}, {'measure': 'Changes in SUV from PET.', 'description': 'Compare percent change from imaging visit 2 to the baseline.', 'timeFrame': 'Baseline through 2 months'}]",11.0,18 Years,,FEMALE,False,OTHER,0.0,25.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06915688,A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations,Doxycycline,"['Doxycycline', 'Levofloxacin']",2,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,COPD,Amina Aslam,2025-09-01T16:18:07.026023,True,,,,,Comparison of Clinical Cure Rate of Doxycycline and Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease,,['COPD'],['COPD'],,2025-04-15,2025-07-31,"[{'measure': 'Clinical Cure Rate', 'description': '1. A decrease in the respiratory rate by 20% from the baseline measurement.\n2. Restoration of Oxygen saturation levels to within the range of 88-92% on room air.\n3. CRP\\<10ng/ml\n4. decrease in sputum quantity\n5. reduction in body temperature below 99•F\n6. TLC \\<11,000', 'timeFrame': '7 days'}]",[],1.0,40 Years,70 Years,ALL,True,OTHER_GOV,0.0,188.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00616603,The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks,Ropivacaine,"['Normal Saline', 'Ropivacaine', 'Dexamethasone']",3,INTERVENTIONAL,['NA'],,TERMINATED,Total Knee Arthroplasty,Loma Linda University,2025-09-01T16:18:07.026085,True,,,,,The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks,,['Total Knee Arthroplasty'],"['Total Knee Arthroplasty.', 'Sciatic nerve Blocks.', 'Dexamethasone.']",PI is no longer here.,2007-08,2011-05,"[{'measure': 'Duration of Sciatic Nerve Block', 'description': 'Intraoperative opioid requirement PACU opioid requirement Floor opioid usage Time of onset of motor block (or weakness) Time of onset of sensory block Return of motor function Return of sensation Pain scores', 'timeFrame': 'from the time the block was placed up to 24 hours'}]",[],1.0,18 Years,80 Years,ALL,False,OTHER,0.0,43.0,ACTUAL,v2_robust,True,False,True,False,PI is no longer here.
NCT01219803,Trial of Different Dosages' Ge Gen Qin Lian Decoction in the Treatment of Type 2 Diabetes,High Dose GGQL Decoction,"['High Dose Ge Gen Qin Lian Decoction', 'Mild dose GGQL Decoction', 'Placebo', 'High Dose GGQL Decoction', 'Low dose Ge Gen Qin Lian Decoction', 'Mild dose Ge Gen Qin Lian Decoction', 'placebo of Ge-Gen-Qin-Lian Decoction', 'Low dose GGQL Decoction']",8,INTERVENTIONAL,['NA'],,UNKNOWN,"Diabetes Mellitus, Type 2",Guang'anmen Hospital of China Academy of Chinese Medical Sciences,2025-09-01T16:18:07.026158,True,,,,,Dosage-efficacy Relationship Clinical Trial of Ge Gen Qin Lian Decoction,,"['Diabetes Mellitus, Type 2', 'Dose-Response Relationship, Drug']","['Dose-Response Relationship, type 2 diabetes,TCM']",,2010-08,2014-08,"[{'measure': 'HbA1c', 'timeFrame': '12 weeks after treatment'}]","[{'measure': 'Fasting plasma glucose (FPG)、postprandial 2 hours plasma glucose(2hPG)', 'timeFrame': '12 weeks after treatment'}, {'measure': 'blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests', 'timeFrame': '12 weeks after treatment'}, {'measure': 'Ins(0h,1h,2h),blood lipids', 'timeFrame': '12 weeks after treatment'}]",4.0,30 Years,65 Years,ALL,False,OTHER,0.0,240.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00606203,Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke?,milnacipran,"['milnacipran', 'placebo']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Ischemic Stroke,Chang Gung Memorial Hospital,2025-09-01T16:18:07.026185,True,,,,,,,"['Ischemic Stroke', 'Depression']",[],,2007-09,2011-09,"[{'measure': 'Hamilton Depression rating scale', 'timeFrame': '0,1,3,6,9,12th'}]","[{'measure': 'Taiwanese depression questionnaire, quality of life, london handicap scale', 'timeFrame': '0,1,3,6,9,12th month'}]",2.0,18 Years,,ALL,False,OTHER,0.0,120.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02242903,A Study of LY3079514 in Healthy Participants,LY3079514,"['LY3079514', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,Eli Lilly and Company,2025-09-01T16:18:07.026335,True,,,,,"A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3079514 in Healthy Subjects",,['Healthy Volunteers'],[],,2014-10,2015-06,"[{'measure': 'Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'description': 'An SAE is an adverse event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. A summary of SAEs, regardless of causality, is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline to Study Completion (Up to 12 Weeks)'}]","[{'measure': 'Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3079514', 'timeFrame': 'SC Dosing-Predose,4hr,12hr,24hr,Day(D)3,D5,D8,D11,D15,D22,D29,D43,D57,D85; IV Dosing- D1 and D2 End of Infusion,4hr,12hr,24hr,D3,D8,D15,D22,D29,D36,D43,D57,D85'}, {'measure': 'PK: Area Under the Concentration Curve Zero to Infinity (AUC 0-∞) of LY3079514', 'timeFrame': 'SC Dosing-Predose,4hr,12hr,24hr,Day(D)3,D5,D8,D11,D15,D22,D29,D43,D57,D85; IV Dosing- D1 and D2 End of Infusion,4hr,12hr,24hr,D3,D8,D15,D22,D29,D36,D43,D57,D85'}]",3.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,
NCT04185103,Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan,Sacubitril-Valsartan,['Sacubitril-Valsartan'],1,OBSERVATIONAL,[],,UNKNOWN,Heart Failure,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,2025-09-01T16:18:07.026375,True,,,,,Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan,,['Heart Failure'],"['Heart Failure', 'Sacubitril-Valsartan', 'T-wave changes alternans']",,2019-10-15,2020-12-15,"[{'measure': 'Analyze the changes in the T-wave alternans', 'description': 'Comparison of the results in the same patient just before the beginning of the Sacubitril-Valsartan pharmacological treatment versus 6 months after its beginning, in patients with grade II heart failure and left systolic disfunction (left ventricle ejection fraction\\<40%).', 'timeFrame': 'Up to 6 months after the beginning of the Sacubitril-Valsartan treatment'}]","[{'measure': 'Evaluate the results in the life quality questionnaire.', 'description': 'Comparison of the life quality questionnaires results before and after the Sacubitril-Valsartan treatment.', 'timeFrame': 'Up to 6 months after the beginning of the Sacubitril-Valsartan treatment'}, {'measure': 'Study the levels of the n-terminal type B natriuretic propeptide', 'description': 'Comparison of the n-terminal type B natriuretic propeptide levels before and after the Sacubitril-Valsartan treatment.', 'timeFrame': 'Up to 6 months after the beginning of the Sacubitril-Valsartan treatment'}, {'measure': 'Evaluate the echocardiographic results', 'description': 'The echocardiographic results will be assessed by a combination of the measurement of the parameters: left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) and left ventricle diastolic function, that will be compared before and after the Sacubitril-Valsartan treatment to evaluate its effect in patients with heart failure.', 'timeFrame': 'Up to 6 months after the beginning of the Sacubitril-Valsartan treatment'}]",4.0,18 Years,80 Years,ALL,False,OTHER,1.0,20.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01825603,"ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer",ADH-1,"[""Peyrone's Chloride"", 'DDP', 'Cisplatyl', 'Metaplatin', 'Neoplatin', 'Placis', 'Platinol', 'Platinum Diamminodichloride', 'Citoplatino', 'Platinoxan', 'Platistin', 'Cis-diamminedichloridoplatinum', 'Gemzar', 'Cysplatyna', 'Cis-platinous Diamine Dichloride', 'Platinum', 'Platinex', ""Peyrone's Salt"", 'Blastolem', 'Cis-platinum II', 'Exherin', 'Cisplatinum', 'Platinol-AQ', 'Plastistil', 'ADH-1', 'Lederplatin', 'Platiran', 'dFdCyd', 'Abiplatin', 'Cis-diamminedichloro Platinum (II)', 'Cisplatin', 'Gemcitabine Hydrochloride', 'Cis-diammine-dichloroplatinum', 'Platamine', 'Briplatin', 'Cis-diamminedichloroplatinum', 'Platiblastin-S', 'CDDP', 'Platinol- AQ', 'Platinol-AQ VHA Plus', 'Difluorodeoxycytidine Hydrochloride', 'Platiblastin', 'Cis-platinum', 'Citosin', 'Cisplatina', 'Platosin', 'Cis-dichloroammine Platinum (II)', 'LY-188011', 'Cismaplat', 'Cis-platinum II Diamine Dichloride']",50,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Ampulla of Vater Adenocarcinoma,University of Nebraska,2025-09-01T16:18:07.026401,True,,,,,A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers,,"['Ampulla of Vater Adenocarcinoma', 'Gallbladder Adenocarcinoma', 'Metastatic Pancreatic Adenocarcinoma', 'Pancreatic Adenocarcinoma', 'Stage III Ampulla of Vater Cancer', 'Stage III Intrahepatic Cholangiocarcinoma', 'Stage III Pancreatic Cancer', 'Stage IIIA Gallbladder Cancer', 'Stage IIIA Hilar Cholangiocarcinoma', 'Stage IIIB Gallbladder Cancer', 'Stage IIIB Hilar Cholangiocarcinoma', 'Stage IV Ampulla of Vater Cancer', 'Stage IVA Gallbladder Cancer', 'Stage IVA Hilar Cholangiocarcinoma', 'Stage IVA Intrahepatic Cholangiocarcinoma', 'Stage IVA Pancreatic Cancer', 'Stage IVB Gallbladder Cancer', 'Stage IVB Hilar Cholangiocarcinoma', 'Stage IVB Intrahepatic Cholangiocarcinoma', 'Stage IVB Pancreatic Cancer']",[],,2013-04-09,2017-06-01,"[{'measure': 'Recommended dose of ADH-1, defined as the highest dose tested which results in dose-limiting toxicities in no more than 1 of 6 evaluable patients based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0', 'description': 'The incidence rates of adverse events will be described by dose level. The frequency of occurrence of overall toxicity, categorized by toxicity grades, will be described.', 'timeFrame': '21 days'}]","[{'measure': 'Changes in the levels of ICAM-1, E-selectin, VEGF, soluble VEGFR and B-FGF', 'description': 'Summarized using descriptive statistics', 'timeFrame': 'After all patients complete cycle 1, about 2 years after initial patient enrolled'}, {'measure': 'Progression-free survival', 'description': 'Plotted following the method of Kaplan and Meier.', 'timeFrame': 'From the first date of therapy until the first notation of clinical progression, relapse or death from any cause, assessed up to 2 years'}, {'measure': 'Survival', 'description': 'Plotted following the method of Kaplan and Meier.', 'timeFrame': 'From the first date of therapy until the date of death from any cause, assessed up to 2 years'}]",4.0,19 Years,,ALL,False,OTHER,2.0,17.0,ACTUAL,v2_robust,True,True,False,True,
NCT01727427,Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients,"Heparin, fondaparinux, vitamin-K antagonists, aspirin","['Warfarin (Coumadin)', 'Apixaban (Eliquis)', 'Dabigatran (Pradaxa)', 'Acenocoumarol (Sintrom)', 'Fondaparinux (Arixtra)', 'Tinzaparin (Innohep)', 'Nadroparin (Fraxiparin)', 'Phenprocoumon (Marcoumar)', 'Heparin, fondaparinux, vitamin-K antagonists, aspirin', 'Dalteparin (Fragmin)', 'Rivaroxaban (Xarelto)', 'Bemiparin (Ivor)', 'Acetylsalicylic acid (Aspirin)', 'Enoxaparin (Clexane)']",14,OBSERVATIONAL,[],,COMPLETED,Unsuspected Pulmonary Embolism,G. d'Annunzio University,2025-09-01T16:18:07.026413,True,,,,,Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients,,['Unsuspected Pulmonary Embolism'],"['Unsuspected', 'pulmonary embolism', 'cancer']",,2012-11,2017-12,"[{'measure': 'Recurrent (symptomatic) vein thromboembolism, including pulmonary embolism and deep vein thrombosis', 'description': 'Suspected recurrent PE with one of the following:\n\n1. new intra-luminal filling defect on CT scan, MRI scan, or pulmonary angiogram;\n2. new perfusion defect of at least 75% on V/Q lung scan;\n3. inconclusive spiral CT, pulmonary angiography or lung scan with demonstration of DVT in the lower extremities by CUS or venography\n\nFatal PE is:\n\n1. PE based on objective diagnostic testing or autopsy or\n2. death not attributed to a documented cause and for which DVT/PE cannot be ruled out.\n\nSuspected (recurrent) DVT with one of the following findings:\n\n1. abnormal CUS;\n2. an intra-luminal filling defect on venography.', 'timeFrame': 'one year'}]","[{'measure': 'Major, clinically relevant non-major bleeding, and minor bleeding', 'description': 'Major bleeding will be defined as overt bleeding associated with: a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or bleeding that occurs in a critical site: intracranial, intra-spinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or contributing to death.\n\nOther clinically relevant non-major bleeding will be defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or associated with discomfort for the patient such as pain, or impairment of activities of daily life. All other bleeding events will be classified as minor.', 'timeFrame': 'one year'}]",2.0,18 Years,,ALL,False,OTHER,0.0,695.0,ACTUAL,v2_robust,False,True,False,False,
NCT04042727,Controlling Rapid Atrial Fibrillation With Dexmedetomidine,Dexmedetomidine Hydrochloride,"['Dexmedetomidine Hydrochloride', 'Precedex']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Rapid Atrial Fibrillation,Stony Brook University,2025-09-01T16:18:07.026530,True,,,,,Controlling Rapid Atrial Fibrillation With Dexmedetomidine (C-RAD) Trial,,"['Rapid Atrial Fibrillation', 'Heart Rate Control']","['Dexmedetomidine', 'Critical Care', 'Atrial Fibrillation']","Futility, as a result of COVID-19 impact",2019-08-21,2021-12-31,"[{'measure': 'Mean Systolic Blood Pressure', 'description': 'Assess mean systolic blood pressure measurements between the two arms', 'timeFrame': 'During Study Drug Infusion Period'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,13.0,ACTUAL,v2_robust,True,False,True,False,"Futility, as a result of COVID-19 impact"
NCT02329561,PK PD of the Enantiomers of Tramadol and O-desmethyltramadol in Elderly and Young Subjects,Tramadol extended release 200 mg,"['sugar pill', 'Tramadol extended release 200 mg', 'Tramadol Contramid 200 mg extended-release', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Aging,Université de Montréal,2025-09-01T16:18:07.026582,True,,,,,"Comparative, Randomized, Double-Blind, Single-Dose, 2-way Crossover Study to Evaluate the Pharmacokinetics and Analgesic Effect of Labopharm Tramadol Contramid® OAD 200 mg Tablets or Placebo in Healthy Young and Elderly Adult Volunteers",,"['Aging', 'Pain']","['Pharmacokinetics', 'Opioid', 'Geriatric', 'Pharmacodynamics']",,2007-01,2007-02,"[{'measure': 'To characterise and compare the pharmacokinetic parameters of AUC 0-t, AUCinf, Cmax, tmax, t½, CL/F, Varea/F, Ae 0 48, Rmax and CLr for the enantiomers of tramadol and O-desmethyltramadol in young and elderly subjects', 'description': 'To characterise and compare the pharmacokinetic parameters of AUC 0-t, AUCinf, Cmax, tmax, t½, CL/F, Varea/F, Ae 0 48, Rmax and CLr for the enantiomers of tramadol and O-desmethyltramadol in healthy adult young and elderly subjects. Plasma samples were taken at 16 timepoints throughout 48 hours and evaluated for plasma concentrations of (+)- and (-)- tramadol', 'timeFrame': '48 hours'}]","[{'measure': 'To characterise and compare threshold of current perception in young and elderly subjects', 'description': 'Healthy adult young and elderly subjects were tested to determine the milliamperes of current that resulted in perception of an electrical stimulus in the non-dominant forefinger at 15 timepoints throughout 30 hours using an electrically stimulated pain model after treatment with active drug and placebo with random assignment of treatment sequence (placebo then tramadol or tramadol then placebo)', 'timeFrame': '30 hours'}, {'measure': 'To characterise and compare threshold of pain tolerance in young and elderly subjects', 'description': 'Healthy adult young and elderly subjects were tested to determine the milliamperes of current they were willing to tolerate at 15 timepoints throughout 30 hours using an electrically stimulated pain model after treatment with active drug and placebo with random assignment of treatment sequence (placebo then tramadol or tramadol then placebo)', 'timeFrame': '30 hours'}]",3.0,18 Years,75 Years,ALL,True,OTHER,2.0,35.0,ACTUAL,v2_robust,True,True,False,False,
NCT01632761,Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia,omega-3 fatty acids (fish oil),['omega-3 fatty acids (fish oil)'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Anemia,Brigham and Women's Hospital,2025-09-01T16:18:07.026661,True,,,,,Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia in the Elderly,,['Anemia'],"['anemia', 'vitamin D3', 'omega-3 fatty acids', 'fish oil', 'primary prevention']",,2012-11,2019-06,"[{'measure': 'Incidence of Anemia', 'description': 'We will compare the number of participants who took vitamin D supplements who developed anemia and the number of participants who did not take vitamin D who developed anemia to current rates of development of anemia in the U.S. We will further examine whether the effect of vitamin D supplementation on anemia risk varies by race/ethnicity, gender, or baseline levels of 25(OH)D.', 'timeFrame': '2 years'}, {'measure': 'Long-term Changes in Blood Protein Levels', 'description': 'We will examine the samples from the 900 boston participants and determine whether vitamin D supplementation affects long-term changes in hemoglobin, red blood cell (RBC) indices, hepcidin, and erythropoietin (EPO) levels. These protein levels will be assessed in both anemic and non-anemic individuals in fresh samples at baseline \\[pre-randomization\\] and at 2 years of follow-up post-randomization.', 'timeFrame': '2 years'}]","[{'measure': 'Incidence of Anemia', 'description': 'We will compare the number of participants taking fish oil supplements who developed anemia and the number of participants not taking fish oil supplements who developed anemia to the current rates of development of anemia in the U.S. We will also study the number participants diagnosed with anemia over 4 years of follow-up and whether the effect of taking fish oil supplements on anemia risk varies by race/ethnicity, gender, or baseline levels of omega-3 fatty acid.', 'timeFrame': '2 years'}, {'measure': 'Long-term Changes in Protein Levels', 'description': 'We will examine the samples collected from the 900 Boston participants and determine whether fish oil supplementation affects long-term changes in hemoglobin, red blood cell(RBC) indices, hepcidin, and erythropoietin (EPO) levels. These protein levels will be assessed in both anemic and non-anemic individuals in fresh samples at baseline \\[pre-randomization\\] and at 2 years of follow-up post-randomization.', 'timeFrame': '2 years'}]",4.0,50 Years,,ALL,True,OTHER,3.0,2000.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03426761,Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections,Dalbavancin,"['Cefazolin', 'Zevan', 'Nafcillin', 'Xydalba', 'Daptomycin', 'Vancomycin', 'Dalvance', 'Dalbavancin']",8,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Bone Infection,"Infectious Diseases Physicians, Inc.",2025-09-01T16:18:07.026764,True,,,,,Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections,,"['Bone Infection', 'Osteomyelitis', 'Septic Arthritis', 'Joint Infection', 'Prosthetic Joint Infection']",[],,2018-01-25,2022-12-31,"[{'measure': 'Clinical response (non-failure) to assigned treatment at day #42', 'description': 'This is defined as the absence of wound drainage, sinus tract formation, fever or joint instability at study day 42, without having switched or extended treatment for any reason. This will be reported as the % of participants from each treatment arm, who are determined to be a treatment responder.', 'timeFrame': 'Evaluated at Day 42'}]","[{'measure': 'Sustained Clinical Response at day #90', 'description': 'This is defined as the absence of drainage, sinus tract formation, fever, cellulitis, infectious effusion (culture +) or joint instability.', 'timeFrame': 'Evaluated at Day 90'}, {'measure': 'Sustained Clinical Response at day #180', 'description': 'This is defined as the absence of drainage, cellulitis, infectious effusion (culture +) or joint instability.', 'timeFrame': 'Evaluated at Day 180'}, {'measure': 'Sustained Clinical Response at day #365', 'description': 'This is defined as the absence of drainage, cellulitis, infectious effusion (culture +) or joint instability.', 'timeFrame': 'Evaluated at Day 365'}, {'measure': 'CRP Improvement at day #90', 'description': 'Normalized or, at least 75% reduction from baseline', 'timeFrame': 'Evaluated at Day 90'}, {'measure': 'CRP Improvement at day #180', 'description': 'Normalized or, at least 75% reduction from baseline', 'timeFrame': 'Evaluated at Day 180'}, {'measure': 'CRP Improvement at day #365', 'description': 'Normalized or, at least 75% reduction from baseline', 'timeFrame': 'Evaluated at Day 365'}]",7.0,18 Years,80 Years,ALL,False,OTHER,1.0,41.0,ACTUAL,v2_robust,True,True,False,False,
NCT01093261,Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury,Placebo,"['Hydrocortisone Fludrocortisone', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Traumatic Brain Injury,Nantes University Hospital,2025-09-01T16:18:07.026795,True,,,,,Phase 3 Study of Hydrocortisone and Fludrocortisone in Glucocorticoid Insufficiency Related to Traumatic Brain Injury,,"['Traumatic Brain Injury', 'Trauma', 'Adrenal Insufficiency', 'Pneumonia']","['trauma', 'trauma brain injury', 'multiple trauma', 'head trauma', 'hydrocortisone', 'fludrocortisone', 'glucocorticoid insufficiency related to ICU', 'adrenal Insufficiency', 'pneumonia', 'intensive care unit', 'shock', 'neurological recovery']",,2010-08,2012-12,"[{'measure': 'rate of hospital acquired pneumonia', 'description': 'Presence of at least two signs (body fever greater than 38°C; leukocytosis greater than 12000/ml or leukopenia below 4000/ml, purulent pulmonary secretions) associated with the appearance of a new infiltrate or modification of an existing infiltrate on chest-X-ray. Confirmation by a lower respiratory tract sample using a quantitative culture with a predefined positive threshold. Hospital-acquired pneumonia was defined as a pneumonia that occurs 48 hours after admission, which was not incubating at time of admission (Am J Respir Crit Care Med 2005; 171, 388-416).', 'timeFrame': 'day-28'}]","[{'measure': 'Neurological recovery', 'description': 'in adapated and insufficient glucocorticoid function (Glasgow Outcome Scale, Barthel index, MIF) (Ancillary study)', 'timeFrame': '1-year'}, {'measure': 'other infections', 'description': 'Tracheobronchitis 1: Association of at least two signs (fever above 38.0°C, Leucocytosis above 12000/ml or purulent pulmonary secretions) with isolation of bacteria in a lower respiratory tract sample without modification of chest-X-Ray; Urinary tract infection : Fever above 38.2°C associated with leucocyturia (\\>10000/ml) and bacteriuria (\\>103 UFC/ml) without other infection; Bacteriemia : One positive blood culture (two positive blood cultures for Staphiloccocus coagulase negative); Surgical wound infection : sputum from surgical incision or scare dehiscence associated with fever.', 'timeFrame': 'day-28'}, {'measure': 'Organ failures', 'description': 'Acute Lung Injury or Acute Respiratory Distress Syndrom: PaO2/FiO2 below 300 with bilateral infiltrates on chest-X-ray without elevation of left atrial pressure; Acute kydney injury: oliguria (\\<0.3 ml/kg/hour for 24 hours or more) or raise in basal creatinemia of more than 300%; Myocardial insufficiency: indexed cardiac output below 2 l/min/m2; Hematologic insufficiency: platelet count below 50 000/ml; Hepatic insufficiency: bilirubinemia (\\<50 mmol.l-1) with a prothrombin (\\<40%), SOFA score (First week)', 'timeFrame': 'day-28'}, {'measure': 'Length of ICU stay', 'description': 'in adapated and insufficient glucocorticoid function', 'timeFrame': '6 months'}, {'measure': 'Duration of mechanical ventilation support', 'description': 'in adapated and insufficient glucocorticoid function', 'timeFrame': '6 months'}, {'measure': 'Mortality from all causes', 'description': 'in adapated and insufficient glucorticoid function', 'timeFrame': 'day-28'}, {'measure': 'Mortality from all causes', 'description': 'in adapated and insufficient glucorticoid function', 'timeFrame': '1 year'}, {'measure': 'Time to amines withdrawal', 'timeFrame': 'day-28'}, {'measure': 'Post traumatic stress disorder', 'description': 'Assessment of psychological status (ancillary study)', 'timeFrame': '12 months'}, {'measure': 'Glucocorticoid function', 'description': 'Short corticotropin test', 'timeFrame': 'on day 11-12'}]",11.0,15 Years,65 Years,ALL,False,OTHER,1.0,336.0,ACTUAL,v2_robust,True,True,False,False,
NCT02030561,NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer,Trastuzumab + NK cells,"['Herceptin', 'Trastuzumab + NK cells']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Breast Cancer,"National University Hospital, Singapore",2025-09-01T16:18:07.026839,True,,,,,"Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer",,"['Breast Cancer', 'Gastric Cancer']","['NK cells', 'trastuzumab', 'immunotherapy']",,2014-01,2018-08,"[{'measure': 'Number of Participants with Serious and Non-Serious Adverse Events', 'description': 'During cycle 1 (21 days) and for at least 21 days following a second NK cell infusion if administered:\n\n\\- Patients will be reviewed twice a week with\n\n* Limited physical examination to include blood pressure, heart rate, weight\n* Full blood count, renal function and liver function tests\n* Toxicity rating using the NCI CTC scale\n* Concomitant medication notation and number of units required for transfusions\n\nAny significant abnormalities or significant toxicities have to be followed until recovery to baseline or 30 days after patient withdraws from the study, whichever occurs later.\n\nDuring other cycles when only trastuzumab is administered (without NK cells infusion or IL-2) Patients will be reviewed once every cycle of every 3-weekly cycle', 'timeFrame': 'Up to 12-18 weeks'}, {'measure': 'Duration of Tumor Response Measure', 'description': 'Among tumor responders, the duration of tumor response is measured from the date of enrolment until the first date of documented disease progression or death due to any cause, whichever occurs first. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Time-to-Event Outcome Measure', 'description': 'Time to documented disease progression is defined as the time from the date of enrolment to the first date of documented disease progression. Time to documented disease progression will be censored at the date of death for patients who have not had documented disease progression. For patients who are still alive at the time of analysis and who have not had documented disease progression, time to documented disease progression will be censored at the date of the last follow-up visit.', 'timeFrame': 'Up to 36 months'}]",[],3.0,21 Years,99 Years,ALL,False,OTHER,1.0,29.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02213861,"Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma",SHAPE,"['SHP-141', 'SHAPE']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Cutaneous T-Cell Lymphoma (CTCL),TetraLogic Pharmaceuticals,2025-09-01T16:18:07.026853,True,,,,,"A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma",,['Cutaneous T-Cell Lymphoma (CTCL)'],"['CTCL', 'Cutaneous T-Cell Lymphoma', 'Early-stage', 'SHAPE', 'SHP-141', 'topical', 'Histone deacetylase inhibitor', 'CAILS', 'mSWAT', 'mycosis fungoides']",,2014-11,2016-10,"[{'measure': 'Lesion severity using CAILS (Composite Assessment of Index Lesion Severity)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks thereafter for patients who continue on study (up to 52 weeks).'}]","[{'measure': 'modified Severity Weighted Assessment Tool (mSWAT)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks therafter for patients who continue on study (up to 52 weeks).'}, {'measure': 'Patient assessment of pruritis using a Visual Analog Scale (VAS)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks thereafter for patients who continue on study (up to 52 weeks).'}, {'measure': 'Skindex-29 Quality of Life Tool', 'timeFrame': 'Every 4 weeks for 26 weeks'}, {'measure': 'modified Composite Assessment of Index Lesion Severity (CAILS)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks therafter for patients who continue on study (up to 52 weeks).'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04621461,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Corona Virus Infection,"St. Francis Hospital, New York",2025-09-01T16:18:07.026906,True,,,,,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting",,['Corona Virus Infection'],"['COVID-19', 'Zinc']",,2020-12-20,2021-02-08,"[{'measure': 'Number of participants hospitalized and/or requiring repeat emergency room visits', 'description': 'COVID-19 related complications that require the participant to be hospitalized or have an emergency room visit', 'timeFrame': '21 days'}, {'measure': 'Number of participants admitted to the Intensive care unit (ICU)', 'description': 'If hospitalized, number of participants admitted to the ICU, and number of days in the ICU', 'timeFrame': '30 days'}, {'measure': 'Number of participants on a ventilator', 'description': 'If placed on ventilator, number of days on a ventilator', 'timeFrame': '30 days'}]","[{'measure': 'All-cause mortality', 'description': 'Total number of deaths in the cohort.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Time to resolution of COVID-19 symptoms', 'description': 'Time at which the patient is completely symptom free.', 'timeFrame': 'Evaluated at day 2, 6, day 14, and day 21'}, {'measure': 'Severity of symptoms', 'description': 'Scored by the participant for feverishness, sore throat, cough, shortness of breath, myalgias. (0 =none; 1 = mild; 2 = moderate; 3 = severe)', 'timeFrame': 'Evaluated at day 2, 6, day 14, and day 21'}]",6.0,30 Years,,ALL,False,OTHER,0.0,3.0,ACTUAL,v2_robust,True,True,False,False,
NCT01056861,Effects of Botulinum Toxin in Cervical Dystonia,Botulinum Toxin A,"['Botulinum Toxin A', 'Botox, Botulinum toxin A']",2,OBSERVATIONAL,[],,COMPLETED,Torticollis,Henry Ford Health System,2025-09-01T16:18:07.026942,True,,,,,Effects of Botulinum on the Afferent Input Modulation of Neuronal Circuits Involved in Cervical Dystonia,,"['Torticollis', 'Cervical Dystonia']","['cervical dystonia', 'torticollis', 'Botulinum toxin', 'magnetoencephalography', 'MEG', 'cortical organizational changes detected by MEG after botulinum toxin in patients with torticollis, correlating with improvement in the symptoms']",,2010-01,2014-07,"[{'measure': 'Evidence of Cortical organizational changes with botulinum toxin treatment in patients with torticollis utilizing magnetoencephalography', 'timeFrame': 'two to eight weeks following treatment'}]","[{'measure': 'Tsui Torticollis Rating scale', 'timeFrame': 'Two-eight weeks'}]",2.0,18 Years,90 Years,ALL,True,OTHER,1.0,7.0,ACTUAL,v2_robust,False,True,False,False,
NCT01316861,Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus,EMS Acarbose,"['Bayer Acarbose', 'EMS Acarbose']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 2 Diabetes Mellitus,EMS,2025-09-01T16:18:07.027012,True,,,,,"A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus",,['Type 2 Diabetes Mellitus'],[],,2012-09,2013-05,"[{'measure': 'Glycosylated hemoglobin (HbA1c)', 'timeFrame': 'Change from baseline to day 98'}]","[{'measure': 'Decrease in mean Fasting Plasma Glucose (FPG)', 'timeFrame': 'Change from baseline to day 14, 28, 42, 70 and 98'}, {'measure': 'Safety will be evaluated by the Adverse events occurence', 'description': 'Adverse events will be collected and followed in order to evaluate safety and tolerability', 'timeFrame': 'Day 105'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,79.0,ACTUAL,v2_robust,True,True,False,True,
NCT05665361,Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC),Sasanlimab,"['Palbocicilib', 'Sasanlimab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Advanced Clear Cell Renal Carcinoma (Ccrcc),National Cancer Institute (NCI),2025-09-01T16:18:07.027038,True,,,,,A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC),,"['Advanced Clear Cell Renal Carcinoma (Ccrcc)', 'Papillary Renal Cell Carcinoma (Prcc)']","['Papillary Renal Cell Carcinoma', 'Kidney Neoplasms', 'Kidney Cancer', 'Clear Cell Renal Cell Carcinoma', 'Translocation Renal Cell Carcinoma', 'TFE3-rearranged renal cell cancer']",,2024-04-24,2027-06-01,"[{'measure': 'Phase I: To determine RP2D of palbociclib in combination with sasanlimab', 'description': 'Number of DLTs within DLT period', 'timeFrame': '28 days'}, {'measure': 'Phase II: Objective response rate (ORR)', 'description': 'Responses (PR+CR) in participants based on imaging \\[CT scan of chest, abdomen, and pelvis (or MRI of abdomen and pelvis with CT chest without contrast when appropriate)\\] performed every 8 (+/-1) weeks for 32 weeks and every 12 (+/-1) weeks after that until the first of either disease progression or 6 years after enrollment', 'timeFrame': '6 years'}]","[{'measure': 'Disease Control Rate (DCR) defined as PR + CR+ SD in participants re-treated with the study drug combination by RECIST 1.1', 'description': 'DCR as assessed by imaging \\[CT scan of chest, abdomen, and pelvis (or MRI of abdomen and pelvis with CT chest without contrast when appropriate)\\] performed every 8 (+/-1) weeks for 32 weeks and every 12 (+/-1) weeks after that until the first of either disease progression or 6 years after enrollment', 'timeFrame': '6 years'}, {'measure': 'progression-free survival (PFS)', 'description': 'Progression free survival determined by imaging \\[CT scan of chest, abdomen, and pelvis (or MRI of abdomen and pelvis with CT chest without contrast when appropriate)\\] performed every 8 (+/-1) weeks for 32 weeks and every 12 (+/-1) weeks after that until the first of either disease progression or 6 years after enrollment', 'timeFrame': '6 years'}, {'measure': 'safety of the combination of palbociclib and sasanlimab', 'description': 'Any toxicities identified between Day 1 of Cycle 1 through 90 days after the study agent (s) was/were last administered will be collected and reported by type and grade. Beyond 90 days after the last intervention, only adverse events which are serious and related to the study intervention will be recorded and reported. Note: during re-treatment AEs will be documented from the re-start of the study intervention through 90 days after the study agent (s) was/were last administered. Beyond 90 days after the last intervention, only adverse events which are serious and related to the study intervention need to be recorded', 'timeFrame': '6 years'}, {'measure': 'overall survival (OS)', 'description': 'Participants assessed at Day 1 of every cycle, safety follow up visits at days 30, 60, 90, every 12 weeks until progression and/or every 6 months after progression for 6 years after enrollment.', 'timeFrame': '6 years'}]",6.0,18 Years,100 Years,ALL,False,NIH,0.0,100.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01115842,Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI),Vitamin D,['Vitamin D'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Acute Coronary Syndrome,Meir Medical Center,2025-09-01T16:18:07.027105,True,,,,,"Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels",,"['Acute Coronary Syndrome', 'Cytokines']","['Vitamin D', 'Acute coronary syndrome', 'inflammatory cytokines']",,2010-06,2011-01,"[{'measure': 'inflammatory cytokine levels', 'description': 'CRP, TNF-α. Il-2, IL-6, IL-12 and IL-10', 'timeFrame': '5 days of treatment'}]","[{'measure': 'MACE and all cause mortality', 'description': 'Major acute coronary events (MACE)include:\n\n* revascularization\n* acute coronary syndrome\n* unstable angina pectoris', 'timeFrame': 'within 6 months'}]",2.0,18 Years,,ALL,False,OTHER,1.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT07095842,Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK),Ketamine,"['Ketamine', 'Midazolam']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,RECRUITING,Convulsive Status EPILEPTICUS,Sohag University,2025-09-01T16:18:07.027128,True,,,,,Efficacy of Add-on Ketamine With Second-dose Midazolam for Prehospital Treatment of Epileptic Children With Status Epilepticus,,['Convulsive Status EPILEPTICUS'],[],,2025-08-03,2026-08-01,"[{'measure': 'Number of participants with cessation of seizures at the time of hospital arrival', 'description': 'Number of participants with cessation of clinically evident seizures at the time of hospital arrival', 'timeFrame': 'At the time of hospital arrival (up to 1 hour)'}]","[{'measure': 'Number of participants with sustained cessation of seizures', 'description': 'Number of participants with sustained cessation of clinically evident seizures at 10 minutes after study drug administration to 60-min after hospital arrival with improved responsiveness (verbal communication, obeying commands, or purposeful reaction to painful stimuli) and no endotracheal intubation or use of any additional antiseizure medications or anticonvulsant sedatives', 'timeFrame': 'From 10 minutes after study drug administration to 60-minutes after hospital arrival'}, {'measure': 'Number of participants with recurrence of seizures', 'description': 'Number of participants with recurrence of clinically evident seizures after initial control at 10 minutes after study drug adminstration till 60-minutes after hospital arrival', 'timeFrame': 'From 10 minutes after study drug administration to 60-minutes after hospital arrival'}, {'measure': 'Number of participants underwent endotracheal intubation', 'description': 'Number of participants underwent endotracheal intubation at 60 minutes after hospital arrival', 'timeFrame': '60 minutes after hospital arrival'}, {'measure': 'Number of participants with severe hypotension', 'description': 'Number of participants with severe hypotension at the time of hospital arrival', 'timeFrame': 'At the time of hospital arrival (up to 1 hour)'}, {'measure': 'Number of participants with severe hypertension', 'description': 'Number of participants with severe hypertension at the time of hospital arrival', 'timeFrame': 'At the time of hospital arrival (up to 1 hour)'}, {'measure': 'Number of participants with severe cardiac arrhythmia', 'description': 'Number of participants with severe cardiac arrhythmia at the time of hospital arrival', 'timeFrame': 'At the time of hospital arrival (up to 1 hour)'}, {'measure': 'Number of participants with emergence reactions', 'description': 'Number of participants with emergence reactions (hallucination, delirium, vivid dreams, blurred/double vision, hypersalivation) following study drug administration till hospital arrival', 'timeFrame': 'At the time of hospital arrival (up to 1 hour)'}]",8.0,2 Years,16 Years,ALL,False,OTHER,0.0,668.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04491942,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",Cisplatin,"[""Peyrone's Chloride"", 'DDP', 'ATR Kinase Inhibitor BAY1895344', 'BAY-1895344', 'Cisplatyl', 'Metaplatin', 'Neoplatin', 'Placis', 'Platinol', 'Platinum Diamminodichloride', 'Citoplatino', 'Platinoxan', 'Platistin', 'Cis-diamminedichloridoplatinum', 'BAY1895344', 'Gemcitabine HCI', 'ATR Inhibitor BAY1895344', 'Gemzar', 'Cysplatyna', 'Cis-platinous Diamine Dichloride', 'Platinum', 'Platinex', ""Peyrone's Salt"", 'Blastolem', 'Cis-platinum II', 'Cisplatinum', 'Platinol-AQ', 'Plastistil', 'LY188011', 'Lederplatin', 'Platiran', 'dFdCyd', 'Abiplatin', 'Cis-diamminedichloro Platinum (II)', 'Cisplatin', 'Gemcitabine Hydrochloride', 'Cis-diammine-dichloroplatinum', 'Platamine', 'Briplatin', 'BAY 1895344', 'Cis-diamminedichloroplatinum', 'Platiblastin-S', 'CDDP', 'Platinol- AQ', 'Platinol-AQ VHA Plus', 'Difluorodeoxycytidine Hydrochloride', 'Platiblastin', 'Cis-platinum', 'Citosin', 'Cisplatina', 'Platosin', 'Elimusertib', 'Cis-dichloroammine Platinum (II)', 'LY-188011', 'LY 188011', 'Cismaplat', 'Cis-platinum II Diamine Dichloride']",57,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Advanced Bile Duct Carcinoma,National Cancer Institute (NCI),2025-09-01T16:18:07.027159,True,,,,,A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma,,"['Advanced Bile Duct Carcinoma', 'Advanced Breast Carcinoma', 'Advanced Cervical Carcinoma', 'Advanced Endometrial Carcinoma', 'Advanced Esophageal Carcinoma', 'Advanced Gastric Carcinoma', 'Advanced Head and Neck Carcinoma', 'Advanced Lung Non-Small Cell Carcinoma', 'Advanced Lung Small Cell Carcinoma', 'Advanced Malignant Solid Neoplasm', 'Advanced Ovarian Carcinoma', 'Advanced Penile Carcinoma', 'Advanced Pleural Malignant Mesothelioma', 'Advanced Urothelial Carcinoma', 'Anatomic Stage III Breast Cancer AJCC v8', 'Anatomic Stage IV Breast Cancer AJCC v8', 'Clinical Stage III Gastric Cancer AJCC v8', 'Clinical Stage IV Gastric Cancer AJCC v8', 'Stage III Cervical Cancer AJCC v8', 'Stage III Distal Bile Duct Cancer AJCC v8', 'Stage III Intrahepatic Bile Duct Cancer AJCC v8', 'Stage III Lung Cancer AJCC v8', 'Stage III Ovarian Cancer AJCC v8', 'Stage III Penile Cancer AJCC v8', 'Stage III Pleural Malignant Mesothelioma AJCC v8', 'Stage IV Cervical Cancer AJCC v8', 'Stage IV Distal Bile Duct Cancer AJCC v8', 'Stage IV Intrahepatic Bile Duct Cancer AJCC v8', 'Stage IV Lung Cancer AJCC v8', 'Stage IV Ovarian Cancer AJCC v8', 'Stage IV Penile Cancer AJCC v8', 'Stage IV Pleural Malignant Mesothelioma AJCC v8', 'Triple-Negative Breast Carcinoma', 'Unresectable Urothelial Carcinoma']",[],,2021-08-25,2026-06-30,"[{'measure': 'Incidence of adverse events', 'description': 'Toxicities will be tabulated and reported according to dose level, grade, type, cycle, and attribution. Tables will be created to summarize these toxicities and side effects, overall and by cohort. Proportions and associated 95% confidence intervals will be calculated for each cohort separately. Cumulative incidence curves will be used to estimate the proportion of patients who will discontinue therapy for reasons of toxicity or general inability to tolerate the regimen.', 'timeFrame': 'Up to 28 days after completion of study treatment'}, {'measure': 'Recommended phase 2 dose (RP2D) of BAY 1895344', 'timeFrame': 'Up to 21 days from treatment start date'}]","[{'measure': 'Pharmacokinetic (PK) parameter - maximum concentration (Cmax)', 'description': 'Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine).', 'timeFrame': 'Day 2 and day 9 after treatment start date'}, {'measure': 'PK parameter - area under the concentration-time curve (AUC)', 'description': 'Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). The impact of cisplatin on BAY 1895344 exposure will be evaluated by calculation of the AUC ratio of (day 9 / day 2) and testing non-parametrically with a null hypothesis of a ratio = 1.', 'timeFrame': 'Day 2 and day 9 after treatment start date'}, {'measure': 'Deoxyribonucleic acid (DNA) damage repair (DDR) mutations', 'description': 'The association between DDR mutations and responses will be described, with a table outlining patients who achieved by progressive disease, stable disease, partial or complete responses and DDR mutation status.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Response rate', 'description': 'The percent of responders will be calculated and associated exact 95% confidence intervals will be constructed.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Kaplan-Meier plots will be used to summarize PFS.', 'timeFrame': 'Up to 2 years'}]",7.0,18 Years,,ALL,False,NIH,0.0,74.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03277742,"Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz",Standard of care,['Standard of care'],1,INTERVENTIONAL,['NA'],,WITHDRAWN,Pulmonary Tuberculosis,"Instituto Nacional de Salud Publica, Mexico",2025-09-01T16:18:07.027170,True,,,,,"Evaluation of an Integral Strategy for Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz.",,"['Pulmonary Tuberculosis', 'Diabetes Mellitus, Type 2']",[],Due to safety reasons. The region was considered too dangerous.,2017-09-20,2020-12,"[{'measure': 'Treatment success', 'description': 'Bacteriological cure using sputum smear and culture', 'timeFrame': 'Up to 6 months'}, {'measure': 'Blood glucose control', 'description': 'mg/dl', 'timeFrame': 'Up to 6 months'}]",[],2.0,20 Years,,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Due to safety reasons. The region was considered too dangerous.
NCT04662242,The Prognostic Impact of Selenium On Critical Surgical Patients,Selenium Supplement,"['Zelnite', 'Selenium Supplement', 'normal saline']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Critical Illness,Chang Gung Memorial Hospital,2025-09-01T16:18:07.027204,True,,,,,The Prognostic Impact of Selenium On Critical Surgical Patients,,"['Critical Illness', 'Selenium Deficiency', 'Trace Element Deficiency', 'Acute Abdomen', 'Sepsis']",[],,2020-12-01,2022-11-16,"[{'measure': 'mortality rate', 'description': 'mortality rate in 30 days', 'timeFrame': '30 day'}]","[{'measure': 'hospital length', 'description': 'hospital length for current admission', 'timeFrame': '1 year'}, {'measure': 'ventilator length', 'description': 'ventilator length for current admission', 'timeFrame': '1 year'}, {'measure': 'complication rate', 'description': 'complication rate within 30 days', 'timeFrame': '30 days'}, {'measure': 'organ failure rate', 'description': 'organ failure rate within 30 days', 'timeFrame': '30 days'}]",5.0,20 Years,,ALL,False,OTHER,0.0,36.0,ACTUAL,v2_robust,True,True,False,False,
NCT01408342,Alemtuzumab and Rituximab in Aplastic Anemia,Alemtuzumab and Rituximab,"['Mabthera', 'Campath', 'Kikuzubam', 'Alemtuzumab and Rituximab', 'Mabcampath']",5,INTERVENTIONAL,['NA'],,WITHDRAWN,Aplastic Anemia,Hospital Universitario Dr. Jose E. Gonzalez,2025-09-01T16:18:07.027357,True,,,,,Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia,,['Aplastic Anemia'],"['Alemtuzumab', 'Rituximab', 'Aplastic anemia', 'cyclosporine']",,2011-07,2014-01,"[{'measure': 'Evaluate efficacy of alemtuzumab and rituximab in aplastic anemia.', 'description': 'Evaluate the hematological response after the administration of alemtuzumab and rituximab', 'timeFrame': '12 months'}]","[{'measure': 'Measuring the side effects of alemtuzumab and rituximab combination through clinical evaluation', 'timeFrame': '12 months'}]",2.0,12 Months,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,
NCT01269242,The Effects of Bindarit in Preventing Stent Restenosis,bindarit,"['bindarit', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Coronary Restenosis,Aziende Chimiche Riunite Angelini Francesco S.p.A,2025-09-01T16:18:07.027388,True,,,,,A Pilot Study to Evaluate the Efficacy and Safety of Different Bindarit Dosages in Preventing Stent Restenosis,,['Coronary Restenosis'],"['coronary restenosis', 'angioplasty', 'stent', 'MCP-1/CCL2', 'MCP-3/CCL7']",,2009-01,2011-04,"[{'measure': 'in-segment late loss (in-stent and 5 mm proximally and distally to the stent) measured by QCA', 'description': 'Late loss is defined as the difference between post-procedural minimum lumen diameter and 6-month minimum lumen diameter measured in-stent and in-segment.', 'timeFrame': '6 months from the index procedure'}]","[{'measure': 'Major Adverse Cardiac Events (MACE)', 'description': 'MACE are defined as the occurrence of death, Myocardial Infarction (MI), target vessel revascularization and target lesion revascularization(CABG or PTCA).', 'timeFrame': '9 months'}, {'measure': 'the assessment of the safety profile of the two bindarit dosages compared to placebo', 'description': ""Safety will be assessed by monitoring the frequency of adverse events in each treatment group. Changes from baseline in physical examination, vital signs, and ECG will be also assessed. Laboratory analyses will be evaluated on the basis of the normal range, the Investigator's judgement, and mean changes from baseline (when applicable)."", 'timeFrame': '9 months'}, {'measure': 'the imaging parameters evaluated with OCT as an optional procedure performed on a subgroup of patients.', 'description': 'The following parameters will be evaluated:\n\n* the neointimal proliferation on the surface of the stent struts;\n* the frequency of stent malapposition.', 'timeFrame': '6 months from the index procedure'}, {'measure': 'the assessment of inflammatory biomarkers in order to investigate the bindarit mechanism of action.', 'description': 'determination of the plasma levels of several circulating inflammatory biomarkers (i.e. MCP-1/CCL-2, MCP-3/CCL7) involved in the neointimal hyperplasia and tissue proliferation occurring in site or adjacent to the stent sites.', 'timeFrame': '9 months'}]",5.0,19 Years,,ALL,False,INDUSTRY,0.0,148.0,ACTUAL,v2_robust,True,True,False,True,
NCT06596642,A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan,Luspatercept,['Luspatercept'],1,OBSERVATIONAL,[],,ACTIVE_NOT_RECRUITING,β-Thalassemia Major,Bristol-Myers Squibb,2025-09-01T16:18:07.027404,True,,,,,Taiwan β-Thalassemia Major Real-World Study for Luspatercept,,['β-Thalassemia Major'],['β-Thalassemia major'],,2024-08-21,2026-12-17,"[{'measure': 'Number of Red Blood Cell (RBC) transfusion units received by participants', 'timeFrame': 'Baseline, every 3 weeks thereafter until week 96'}, {'measure': 'Participant hemoglobin (Hb) level results', 'timeFrame': 'Baseline, every 3 weeks thereafter until week 96'}, {'measure': 'Participant serum ferritin results', 'timeFrame': 'Baseline, week 12, 24, 36, 48, 60, 72, 84 and 96'}]","[{'measure': 'Participant platelet level results', 'timeFrame': 'Baseline, and every 3 weeks thereafter up to week 96'}, {'measure': 'Participant white blood cell count results', 'timeFrame': 'Baseline, and every 3 weeks thereafter up to week 96'}, {'measure': 'Participant reticulocytes/normoblast count results', 'timeFrame': 'Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Participant Hemoglobin F (HbF) levels', 'timeFrame': 'Baseline and weeks 6 and 12'}, {'measure': 'Participant uric acid level results', 'timeFrame': 'Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Participant lactate dehydrogenase (LDH) level results', 'timeFrame': 'Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Participant aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio', 'timeFrame': 'Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Participant creatinine level results', 'timeFrame': 'Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Participant bilirubin (total and direct) laboratory values', 'timeFrame': 'Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Type of iron chelating therapy prescribed to participants', 'timeFrame': 'Baseline, every 3 weeks thereafter until week 96'}, {'measure': 'Iron chelating therapy treatment dosage prescribed to participants', 'timeFrame': 'Baseline, every 3 weeks thereafter until week 96'}, {'measure': 'Participant Adverse Events (AEs)', 'timeFrame': 'Baseline and every 3 weeks until week 12, then weeks 24, 36, 48, 60, 72, 84 and 96'}, {'measure': 'Participant health-related quality of life as assessed by Transfusion-dependent Quality of Life (TranQoL) questionnaire', 'timeFrame': 'Baseline, week 12, 24, 48, 72 and 96'}, {'measure': 'Participant health-related quality of life as assessed by EQ-5D-5L questionnaire', 'timeFrame': 'Baseline, week 12, 24, 48, 72 and 96'}, {'measure': 'Luspatercept treatment dosage prescribed to participants', 'timeFrame': 'Baseline, every 3 weeks thereafter until week 96'}, {'measure': 'Duration of luspatercept treatment', 'timeFrame': 'Baseline, every 3 weeks thereafter until week 96'}, {'measure': 'Participant reason(s) for luspatercept treatment discontinuation as assessed by the treating clinician', 'timeFrame': 'Baseline, every 3 weeks thereafter until week 96'}, {'measure': 'Participant demographics', 'timeFrame': 'Baseline'}, {'measure': 'Participant weight', 'timeFrame': 'Baseline'}, {'measure': 'Participant β0/β0 genotype status', 'timeFrame': 'Baseline'}, {'measure': 'Participant disease status', 'timeFrame': 'Baseline'}, {'measure': 'Participant comorbidities', 'timeFrame': 'Baseline'}, {'measure': 'Participant concomitant medication', 'timeFrame': 'Baseline'}, {'measure': 'Participant β-thalassemia treatment history', 'timeFrame': 'Baseline'}, {'measure': 'Participant surgical history (splenectomy and/or cholecystectomy)', 'timeFrame': 'Baseline'}]",28.0,18 Years,,ALL,False,INDUSTRY,0.0,61.0,ACTUAL,v2_robust,False,False,False,True,
NCT00004242,Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors,fluorouracil,"['fluorouracil', 'oxaliplatin', 'gemcitabine hydrochloride']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Unspecified Adult Solid Tumor, Protocol Specific",National Cancer Institute (NCI),2025-09-01T16:18:07.027428,True,,,,,Phase I Study of Oxaliplatin in Combination With 5-Fluorouracil and Gemcitabine in Patients With Solid Tumors,,"['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",,1999-10,,[],[],0.0,18 Years,,ALL,False,NIH,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT00373542,12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome,ropinirole CR-RLS,['ropinirole CR-RLS'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Restless Legs Syndrome (RLS),GlaxoSmithKline,2025-09-01T16:18:07.027450,True,,,,,"A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep",,"['Restless Legs Syndrome (RLS)', 'Restless Legs Syndrome']","['Restless Legs Syndrome', 'ropinirole', 'polysomnography', 'RLS', 'PSG']",,2006-10,2007-06,"[{'measure': 'Change from baseline in the Periodic Limb Movements in Sleep associated with Arousal/hour of sleep (PLMAI) at Week 12 Change from baseline in sleep Latency at Week 12.', 'timeFrame': '12 Weeks'}]","[{'measure': 'Assess safety, tolerability, polysomnography efficacy measures, and patient reported outcomes.', 'timeFrame': '12 Weeks'}]",2.0,18 Years,79 Years,ALL,False,INDUSTRY,0.0,39.0,ACTUAL,v2_robust,True,True,False,True,
NCT01130142,A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer,IPI-926 plus gemcitabine,"['Gemzar', 'Hedgehog', 'Hedgehog pathway inhibitor', 'Placebo plus gemcitabine', 'Gemcitabine', 'IPI-926', 'IPI-926 plus gemcitabine']",7,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Metastatic Pancreatic Cancer,"Infinity Pharmaceuticals, Inc.",2025-09-01T16:18:07.027475,True,,,,,A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer,,['Metastatic Pancreatic Cancer'],[],,2010-04,2012-05,"[{'measure': 'Evaluation of safety profile including MTD', 'description': 'To determine the safety profile, including maximum tolerated dose, of IPI-926 plus gemcitabine in patients with previously untreated metastatic pancreatic cancer.', 'timeFrame': 'Once per week for 3 weeks of a 4 week cycle'}, {'measure': 'Overall survival comparison', 'description': '* To compare the overall survival (OS) of patients with previously untreated metastatic pancreatic cancer treated with IPI-926 plus gemcitabine or placebo plus gemcitabine.\n* To evaluate the safety of IPI-926 plus gemcitabine or placebo plus gemcitabine.', 'timeFrame': 'An average of 6 months'}]","[{'measure': 'Measurement of the maximum plasma concentration (Cmax) and area under the concentration versus time curve (AUC0-t) of IPI-926 and gemcitabine.', 'description': '\\- To evalutate pharmacokinetics (PK) of IPI-926, gemcitabine, and their relevant metabolites.', 'timeFrame': 'During the 3rd week of the first 4 week cycle'}, {'measure': 'Comparison of PFS, TTP and ORR', 'description': '\\- To compare the progression free survival (PFS), time to progression (TTP) and overall response rate (ORR) of patients treated with IPI-926 plus gemcitabine or placebo plus gemcitabine.', 'timeFrame': 'An average of 6 months'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,122.0,ACTUAL,v2_robust,True,True,False,True,
NCT00382642,Pharmacological Treatment for Alcoholism,Ondansetron + Cognitive Behavioral Therapy,"['Sugar Pill', 'Ondansetron + Cognitive Behavioral Therapy', 'Placebo + Cognitive Behavioral Therapy', 'Zofran']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Alcohol Dependence,Bankole Johnson,2025-09-01T16:18:07.027483,True,,,,,Pharmacological Treatment for Alcoholism,,['Alcohol Dependence'],"['alcoholism, alcohol disorder, drinking,alcohol']",,2006-06,2009-12,"[{'measure': 'Self-reported measure of alcohol consumption (Drinks per Day, Drinks per Drinking Day, Percent Days Abstinent), CDT (ondansetron level), GGT, BAC', 'timeFrame': 'Throughout the study'}]","[{'measure': 'Pill count, CIWA-Ar, OCDS, Age of onset, SFQ, AASE, ADBS, CGI, TCI, MAC, attendace at psychosocial services', 'description': 'medication compliance, withdrawal, alcohol craving, social functioning and motivation', 'timeFrame': 'Throughout the study'}]",2.0,18 Years,,ALL,False,OTHER,1.0,283.0,ACTUAL,v2_robust,True,True,False,False,
NCT00607542,Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity,baclofen,"['baclofen', 'Lioresal']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Spasticity,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),2025-09-01T16:18:07.027492,True,,,,,Pediatric Pharmacokinetic and Pharmacodynamic Study of Oral Baclofen for the Treatment of Spasticity Associated With Cerebral Palsy,,"['Spasticity', 'Cerebral Palsy']","['spasticity', 'cerebral palsy', 'baclofen', 'pharmacokinetics', 'pharmacodynamics', 'dosing', 'safety', 'efficacy']",,2008-11,2011-01,"[{'measure': 'Determine pharmacokinetic parameters of oral baclofen in children with spasticity associated with cerebral palsy (CP).', 'timeFrame': '1 year'}, {'measure': 'Describe the relationship between plasma concentrations of oral baclofen and clinical measures of spasticity.', 'timeFrame': '1 year'}, {'measure': 'Determine optimal dosing range and interval for administration of oral baclofen for use in a randomized clinical trial of safety and efficacy.', 'timeFrame': '1 year'}]","[{'measure': 'Describe the relationship between plasma concentrations of oral baclofen and measures of strength, function, ease of care, pain/comfort and health related quality of life.', 'timeFrame': '1 year'}, {'measure': 'Describe the safety and tolerability of oral baclofen in children with spasticity associated with CP.', 'timeFrame': '1 year'}, {'measure': 'Investigate preliminarily whether oral baclofen improves dystonia', 'timeFrame': '1 year'}]",6.0,2 Years,16 Years,ALL,False,NIH,0.0,61.0,ACTUAL,v2_robust,True,True,False,True,
NCT06326086,"Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.",Chemotherapy drug,"['Immunotherapy', 'Chemotherapy drug', 'Targeted Agent']",3,OBSERVATIONAL,[],,RECRUITING,Advanced Lung Cancer,Prince of Songkla University,2025-09-01T16:18:07.027519,True,,,,,"Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.",,"['Advanced Lung Cancer', 'Sarcopenia']","['Chemotherapy, targeted therapy, immunotherapy, NSCLC, sarcopenia, physical performance.']",,2022-08-01,2024-08-01,"[{'measure': 'To determine the differences in the rate of decline in CT defined skeletal muscle index at L3 vertebra and physical performance in advanced NSCLC patients receiving chemotherapy and targeted therapy/ immunotherapy, before and after treatment.', 'description': 'To determine the differences in the rate of decline in CT defined skeletal muscle index at L3 vertebra and physical performance in advanced NSCLC patients receiving chemotherapy and targeted therapy/ immunotherapy, before and after treatment.', 'timeFrame': '1 year'}]","[{'measure': 'To determine validity of gender based cut off for CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) based on recommendation of JSH/AWGS in Thai population.', 'description': '1\\. To determine validity of gender based cut off for CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) based on recommendation of JSH/AWGS in Thai population.', 'timeFrame': '1 year'}]",2.0,18 Years,,ALL,True,OTHER,0.0,240.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01369186,Drug Drug Interactions of Aspirin and P2Y12-inhibitors,Morphine,"['Vendal', 'Sodium chloride 0,9%', 'Morphine', 'Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Drug Interaction Potentiation,Medical University of Vienna,2025-09-01T16:18:07.027533,True,,,,,Drug Drug Interactions of Antiplatelet Drugs and Morphine,,"['Drug Interaction Potentiation', 'Myocardial Infarction']",[],,2011-05,2015-01,"[{'measure': 'Platelet function', 'timeFrame': '14 days'}]","[{'measure': 'Tmax', 'timeFrame': '14 days'}, {'measure': 'Cmax', 'timeFrame': '14 days'}]",3.0,18 Years,,ALL,True,OTHER,0.0,95.0,ACTUAL,v2_robust,True,True,False,False,
NCT04165486,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)",ION464,"['ION464', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Multiple System Atrophy,"Ionis Pharmaceuticals, Inc.",2025-09-01T16:18:07.027560,True,,,,,"A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy",,['Multiple System Atrophy'],[],,2022-07-21,2027-09,"[{'measure': 'Number of Participants with Adverse Events (AEs)', 'timeFrame': 'Baseline up to approximately 36 weeks'}, {'measure': 'Number of Participants with Serious Adverse Events (SAEs)', 'timeFrame': 'Baseline up to approximately 36 weeks'}]","[{'measure': 'Change From Baseline in Cerebrospinal Fluid (CSF) Levels of Total alpha-synuclein (α-syn)', 'timeFrame': 'Baseline up to approximately 36 weeks'}, {'measure': 'Serum Concentration of ION464', 'timeFrame': 'Baseline up to approximately 36 weeks'}, {'measure': 'Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration of ION464', 'timeFrame': 'Baseline up to approximately 36 weeks'}, {'measure': 'Maximum Observed Concentration (Cmax) of ION464', 'timeFrame': 'Baseline up to approximately 36 weeks'}, {'measure': 'Time to Reach Maximum Observed Concentration (Tmax) of ION464', 'timeFrame': 'Baseline up to approximately 36 weeks'}]",7.0,40 Years,70 Years,ALL,False,INDUSTRY,0.0,40.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06566586,A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma,TQB3702 tablets+Chemotherapy regimen,['TQB3702 tablets+Chemotherapy regimen'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,B-cell Lymphoma,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:07.027577,True,,,,,A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma,,['B-cell Lymphoma'],[],,2024-11-06,2027-12,"[{'measure': 'Overall response rate (ORR)', 'description': 'According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Complete response rate (CRR)', 'description': 'The rate of complete tumor remission', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Adverse events (AE) and serious adverse events (SAE)', 'description': 'Incidence and severity of adverse events (AE) and serious adverse events (SAE), as well as abnormal laboratory test indicators', 'timeFrame': 'Baseline to up to 28 days'}, {'measure': 'ORR and CRR at the end of combination therapy', 'description': 'Objective response rate and complete remission rate at the end of combination therapy.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Duration of response (DOR)', 'description': 'The period from the participants first achieving CR or PR to disease progression', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'OS is defined as the time from the first administration to all-cause death', 'timeFrame': 'Up to all-cause death'}, {'measure': '1-year PFS and OS', 'description': '1-year Progression-free survival and Overall survival rates', 'timeFrame': 'Up to 1 year'}, {'measure': '2-years PFS and OS', 'description': '2-years Progression-free survival and Overall survival rates', 'timeFrame': 'Up to 2 years'}]",9.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,80.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00908986,Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis,Rituximab,"['Rituxan', 'Rituximab']",2,INTERVENTIONAL,['NA'],,WITHDRAWN,Lupus Nephritis,Northwell Health,2025-09-01T16:18:07.027590,True,,,,,Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis,,['Lupus Nephritis'],['Lupus Membranous Nephritis'],Terminated by sponsor,2008-12,2009-11,"[{'measure': 'Efficacy at 6 months post treatment and durability of response at 12 months post treatment will be determined by: reduction in 24 hour urinary protein excretion, reciprocal creatinine, urinary sediment', 'timeFrame': '12 months'}]","[{'measure': 'Change from baseline at 6 and 12 months in non-renal SLE disease activity (BILAG), lupus serologies (anti-dsDNA antibodies) and complement consumption (C3, C4), serum albumin, cholesterol, triglycerides', 'timeFrame': '12 months'}]",2.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Terminated by sponsor
NCT06787586,"Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus",ATTO-1310,"['ATTO-1310', 'ATTO-1310 Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Normal Volunteers,Attovia Therapeutics Inc,2025-09-01T16:18:07.027692,True,,,,,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus",,"['Normal Volunteers', 'Atopic Dermatitis (AD)', 'Atopic Eczema', 'Chronic Pruritus']","['Atopic dermatitis', 'AD', 'Atopic eczema', 'Eczema', 'Chronic pruritis', 'Itch', 'Pruritus']",,2025-01-14,2026-05,"[{'measure': 'Incidence of AEs', 'description': 'The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 26.1 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Incidence of laboratory abnormalities', 'description': 'Clinical laboratory parameters (hematologic and blood chemistry) will be summarized for each post-baseline visit.', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Incidence of ECG abnormalities', 'description': 'ECG findings (including QT abnormalities) will be summarized for each post-baseline visit.', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Incidence of vital sign abnormalities', 'description': 'Vital signs (systolic and diastolic blood pressure, temperature, heart rate) will be summarized for each post-baseline visit.', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}]","[{'measure': 'Incidence of Anti-Drug Antibodies', 'description': 'Baseline prevalence of ADA, Changes in ADA status from prior to the first dose of IP to each post-dose timepoint and ADA titer values for samples confirmed positive for ADA will be evaluated to assess the immunogenicity of single and multiple dose levels of ATTO-1310.', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Peak plasma concentration (Cmax) ATTO-1310', 'description': 'The pharmacokinetics of single and multiple dose levels of ATTO-1310 in participants will include maximum concentration (Cmax)of ATTO-1310', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Circulating half-life of ATTO-1310 (t1/2)', 'description': 'The pharmacokinetics of single and multiple dose levels of ATTO-1310 in participants will include half-life (t1/2) of ATTO-1310', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve (AUC)', 'description': 'The pharmacokinetics of single and multiple dose levels of ATTO-1310 in participants will include area under the plasma concentration-time curve (AUC).', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Clearance rate (C) of ATTO-1310', 'description': 'The pharmacokinetics of single and multiple dose levels of ATTO-1310 in participants will include characterization of the Clearance rate (C) of ATTO-1310', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Volume of Distribution (V) of ATTO-1310', 'description': 'The pharmacokinetics of single and multiple dose levels of ATTO-1310 in participants will include characterization of the Volume of distribution (V) of ATTO-1310', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}, {'measure': 'Bioavailability (F) of ATTO-1310', 'description': 'The pharmacokinetics of single and multiple dose levels of ATTO-1310 in participants will include characterization of the Bioavailability (F) of ATTO-1310', 'timeFrame': '0-113 Days for SAD; 0-143 Days for MAD'}]",11.0,18 Years,85 Years,ALL,True,INDUSTRY,0.0,104.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01328886,"Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children",Omalizumab,['Omalizumab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Allergic Asthma,Novartis Pharmaceuticals,2025-09-01T16:18:07.027722,True,,,,,"An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment",,['Allergic Asthma'],"['omalizumab', 'allergic asthma', 'pediatric patients']",,2011-03,2013-12,"[{'measure': 'To assess the long-term safety and tolerability of omalizumab by measuring AEs, serious AEs, physical examination, medical history, laboratory assessments and vital signs', 'timeFrame': 'Every 3 months for approximately 2 years'}]","[{'measure': 'To explore the efficacy of omalizumab by JPAC questionnaire; JPAC is the Japan Pediatric Asthma Control Program (JPAC)', 'timeFrame': 'Every 3 months for approximately 2 years'}, {'measure': 'To explore the efficacy of omalizumab by QOL questionnaire score (Quality of life questionnaires for pediatric patients with bronchial asthma and their parents or caregivers (Gifu))', 'timeFrame': 'Every 3 months for approximately 2 years'}, {'measure': 'To explore the efficacy of omalizumab by use of asthma long-term control medications', 'timeFrame': 'Every 3 months for approximately 2 years'}, {'measure': 'To explore the efficacy of omalizumab by Pulmonary function (FEV1, FVC, V(・)50, V(・)25 and FEF25-75%)', 'timeFrame': 'Every 3 months for approximately 2 years'}, {'measure': 'To collect the data on the number of hospitalizations, emergency room (ER) visits due to asthma', 'timeFrame': 'Every 3 months for approximately 2 years'}]",6.0,6 Years,15 Years,ALL,False,INDUSTRY,0.0,38.0,ACTUAL,v2_robust,True,True,False,True,
NCT04915586,Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management,Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg,"['Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg', 'Combination Tissue Plasminogen Activator (t-PA) and Pulmozyme (DNase)']",2,INTERVENTIONAL,['NA'],,COMPLETED,Loculated Empyema,National University of Malaysia,2025-09-01T16:18:07.027810,True,,,,,Short Duration High Intensity Intrapleural Alteplase With Pulmozyme (DNase) in Pleural Infection Management- Single Centre Experience,,['Loculated Empyema'],"['Intrapleural fibrinolysis, pleural infection']",,2019-12-30,2020-12-31,"[{'measure': 'Radiographic improvement in pleural opacity on chest radiograph', 'description': 'measured in percentage', 'timeFrame': 'Day 7'}]","[{'measure': 'pleural fluid volume drained', 'description': 'measured in mls', 'timeFrame': 'Day 7'}, {'measure': 'changes in inflammatory markers C-Reactive Protein (CRP )', 'description': 'reduction of inflammatory markers trend', 'timeFrame': 'Day 7'}, {'measure': 'White cell count', 'description': 'changes in inflammatory markers trend', 'timeFrame': 'Day 7'}, {'measure': 'length of hospitalisation', 'description': 'days', 'timeFrame': 'upto 30 days'}, {'measure': 'the need of surgical referral', 'description': 'if evidence of clinical deterioration post intrapleural therapy such as intrapleural haemorrhage or hypotension or less than 50% resolution of effusion on chest-xray post intrapleural therapy', 'timeFrame': 'upto 30 days'}, {'measure': 'adverse events post therapy', 'description': 'pain, bleeding events, hemodynamic stability', 'timeFrame': 'Day 7'}, {'measure': 'mortality rate at day 30 post intervention', 'description': 'days', 'timeFrame': '30 days'}]",8.0,18 Years,,ALL,False,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,True,
NCT02678286,Evaluation of N1539 Following Abdominoplasty Surgery,N1539,"['Intravenous meloxicam', 'N1539', 'Intravenous Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Pain, Post-operative",Baudax Bio,2025-09-01T16:18:07.027870,True,,,,,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Abdominoplasty Surgery",,"['Pain, Post-operative']","['Abdominoplasty', 'Pain', 'Analgesia', 'N1539', 'Phase 3']",,2016-01,2016-11,"[{'measure': 'Summed Pain Intensity Difference Over the First 24 Hours (SPID24)', 'description': 'Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better.', 'timeFrame': '24 Hours'}]","[{'measure': 'Summed Pain Intensity Difference (SPID) at Other Intervals', 'description': 'Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better.', 'timeFrame': '48 Hours'}, {'measure': 'Time to First Dose of Rescue Analgesia', 'description': 'Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request. Time to first rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia.', 'timeFrame': '48 Hours'}, {'measure': 'Number of Subjects Utilizing Rescue Analgesia', 'description': 'Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request.', 'timeFrame': '48 Hours'}, {'measure': 'Number of Doses of Rescue Analgesia Utilized Per Subject', 'description': 'Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request.', 'timeFrame': '48 Hours'}, {'measure': 'Time to Perceptible Pain Relief (TTPPR)', 'description': 'Time to perceptible and meaningful pain relief was measured using the double stopwatch method. For each randomized subject, two stopwatches were started immediately after administration of the first study dose (Hour 0). The subject was to stop the first watch when they first perceived pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they first experienced meaningful pain relief (time to meaningful relief).', 'timeFrame': '12 Hours'}, {'measure': 'Time to Meaningful Pain Relief (TTMPR)', 'description': 'Time to perceptible and meaningful pain relief was measured using the double stopwatch method. For each randomized subject, two stopwatches were started immediately after administration of the first study dose (Hour 0). The subject was to stop the first watch when they first perceived pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they first experienced meaningful pain relief (time to meaningful relief).', 'timeFrame': '12 Hours'}, {'measure': 'Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 6', 'description': 'Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 6 = 100 \\* SPID6 / (BaselinePI \\* 6 \\* 60), and SPID6 \\< 0 as an indication for improvement.', 'timeFrame': '6 Hours'}, {'measure': 'Subjects With ≥ 30% Improvement in Pain From Baseline to Hour 24', 'description': 'Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 24 = 100 \\* SPID24 / (BaselinePI\n\n\\* 24 \\* 60), and SPID24 \\< 0 as an indication for improvement.', 'timeFrame': '24 Hours'}, {'measure': 'Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 6', 'description': 'Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 6 = 100 \\* SPID6 / (BaselinePI \\* 6 \\* 60), and SPID6 \\< 0 as an indication for improvement.', 'timeFrame': '6 Hours'}, {'measure': 'Subjects With ≥ 50% Improvement in Pain From Baseline to Hour 24', 'description': 'Percent improvement in pain is the cumulative pain intensity percent reduction from baseline over the defined interval (6 or 24 hours), calculated as SPID for the defined interval (SPID6 or SPID24) divided by the baseline pain intensity (BaselinePI) extrapolated across that interval. Example: % Improvement through Hour 24 = 100 \\* SPID24 / (BaselinePI\n\n\\* 24 \\* 60), and SPID24 \\< 0 as an indication for improvement.', 'timeFrame': '24 Hours'}, {'measure': 'Patient Global Assessment (PGA) of Pain Control at Hour 24', 'description': 'PGA of pain control was evaluated at Hour 24 and Hour 48 with subject reported degree of pain control over the preceding interval according to a 5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent.', 'timeFrame': '24 Hours'}, {'measure': 'Patient Global Assessment (PGA) of Pain Control at Hour 48', 'description': 'PGA of pain control was evaluated at Hour 24 and Hour 48 with subject reported degree of pain control over the preceding interval according to a 5 point scale (0-4) with categories of 0-poor, 1-fair, 2-good, 3-very good, or 4-excellent.', 'timeFrame': '48 Hours'}]",13.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,219.0,ACTUAL,v2_robust,True,True,False,False,
NCT02614586,Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia,TAK-058,"['Ondansetron', 'TAK-058 Placebo', 'TAK-058', 'Ondansetron Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Schizophrenia,Takeda,2025-09-01T16:18:07.027941,True,,,,,A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of TAK-058 and Ondansetron on P50 Auditory Gating in Subjects With Stable Schizophrenia,,['Schizophrenia'],['Drug Therapy'],,2015-12,2016-04,"[{'measure': 'Change From Baseline in P50 Ratio S2/S1 at Central (Cz) Electrode Following Administration of TAK-058', 'description': 'Participants were planned to check for P50 gating ratio. Stimulus signal of 90 decibel pulses of 0.1 millisecond (msec) was to be generated and recorded the event-related potential waveforms. 32 pairs of auditory clicks were to be presented every 10 seconds, with a 500 msec interclick interval. S1 is defined as the conditioning P50 wave with the most positive peak between 30 and 90 msec after the conditioning stimulus. S2 is defined as the test P50 wave with the positive peak after the test stimulus that was closest in latency to the conditioning P50. Amplitude is the difference between the positive peak and the preceding negative trough for both waves. The data from the vertex (Cz site) was to be collected and the P50 gating ratio (S2/S1) was to be calculated as the ratio of the test P50 amplitude to the conditioning P50 amplitude.', 'timeFrame': 'Part 2: Day 1 pre-dose and at multiple time points (up to 2 hours) post-dose in each period.'}]","[{'measure': 'Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)', 'timeFrame': 'Part 2: Day 1 of Intervention Period 1 up to Day 21'}]",2.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,11.0,ACTUAL,v2_robust,True,False,True,True,
NCT00812786,Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients,"cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)","['cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)']",1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Heart Transplant,"University Hospital, Limoges",2025-09-01T16:18:07.027983,True,,,,,"Multicentre, Open Study for the Setting up of Population Pharmacokinetic Models and Bayesian Estimators for Individual Dose Adjustment of Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Everolimus) During the First Year Post-grafting in Adult Heart Transplant Recipients.",,['Heart Transplant'],"['heart transplantation', 'immunosuppressive drugs', 'individual dose adjustment', 'harmacokinetics', 'modelling']",,2007-07,2012-05,[{'measure': 'Estimation of the pharmacokinetic properties and parameters of the immunosuppressive drugs.'}],"[{'measure': 'Investigation of relationships between physiological and pathological characteristics and individual pharmacokinetic parameters.'}, {'measure': 'Characterisation of the exposure-clinical effects relationships for the difference immunosuppressive drugs.'}]",3.0,18 Years,80 Years,ALL,False,OTHER,0.0,42.0,ACTUAL,v2_robust,True,True,False,False,
NCT04252586,"A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",GWP42003-P,"['GWP42003-P', 'Epidiolex', 'Cannabidiol', 'CBD', 'CBD-OS']",5,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Rett Syndrome,Jazz Pharmaceuticals,2025-09-01T16:18:07.027993,True,,,,,"An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",,"['Rett Syndrome', 'RTT']","['Cannabidiol', 'CBD', 'Epidiolex', 'GWP42003-P']",Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).,2020-02-28,2021-06-09,"[{'measure': 'Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs', 'description': 'Adverse events (AEs) were defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings when relevant) or diagnosis or worsening of a pre-existing condition that occurs during the study. TEAEs were defined as the AEs that started or worsened in severity or seriousness following the first dose of GWP42003-P. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 16 (Day 767) in the OLE'}, {'measure': 'Number of Participants With Treatment-emergent Clinical Laboratory Parameters From the Baseline at Any Time Post-dose', 'description': 'Treatment-emergent clinical parameters were defined as the following: Treatment-emergent alanine transferase (ALT) \\> 3×upper limit of normal (ULN), \\> 5×ULN and \\> 8×ULN; Treatment-emergent aspartate aminotransferase (AST) \\> 3×ULN, \\> 5×ULN and \\> 8×ULN; Treatment-emergent ALT or AST \\> 3×ULN, \\> 5×ULN and \\> 8×ULN; Treatment-emergent ALT or AST \\> 3×ULN and either bilirubin \\> 2×ULN or international normalized ratio (INR) \\> 1.5.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose', 'description': 'Potentially clinically significant vital sign values of blood pressure (BP) were defined as sitting systolic BP (mmHg) change: \\< -20 or \\> 20 mmHg and sitting diastolic BP change: \\< -10 or \\> 10 mmHg. Vital sign measurements were taken in a sitting position at rest for 5 minutes. Blood pressure readings were recorded using the same arm throughout the trial, when possible.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE'}, {'measure': 'Number of Participants With Clinically Significant Changes in the Vital Sign Values of Pulse Rate From the Baseline at Any Time Post-dose', 'description': 'Potentially clinically significant vital sign values of pulse rate were defined as pulse rate change: \\< -10 or \\> 10 beats per minute. Vital sign measurements were taken in a sitting position at rest for 5 minutes.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE'}, {'measure': 'Number of Participants With Clinically Significant Percent Change in Body Weight From the Baseline at Any Time Post-dose', 'description': 'Clinically significant body weight changes were defined as the percent change in body weight (≤7% change or ≥7% change).', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With At Least One Post Open Label Extension Baseline Flagged ECG Result', 'description': 'Electrocardiogram assessments were performed for QTcB and QTcF \\>450 msec, \\>480 msec, and \\>500 msec. QTcB = corrected QT interval with Bazette correction. QTcF = QTc corrected by Fridericia.', 'timeFrame': 'Visit 4 (Day 29) up to Visit 15 (Day 739) in the OLE'}, {'measure': 'Number of Participants With Any Changes In Menstruation Cycle at Any Time Post-dose', 'description': 'Participants were evaluated for any changes to typical menstrual cycles, duration of menstrual cycles, and typical strength of the menstrual cycles during the study.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With Suicidal Ideation or Behavior at the Baseline and at Any Time Post-dose', 'description': 'Suicidal ideation and behavior was assessed by the investigator via a clinical interview with the caregiver. The questionnaire included following questions: Has the child expressed any wish to be dead?, Has the child made any suicide attempts?, Has the child shown any non-suicidal self-injurious behavior? The responses were recorded as Yes/No.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment', 'description': 'Blood samples were collected to assess changes in serum IGF-1 levels. A negative mean change from baseline indicates a reduction in IGF-1 levels.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With Changes in Tanner Staging at the Baseline and at End of Treatment', 'description': 'Pubic hair growth and breast development of all adolescents were assessed by the investigator or caregiver using Tanner Staging categorization from 1 to 5.\n\nStage 1- No glandular tissue; areola follows skin contours of chest; No pubic hair Stage 2- Breast bud forms; areola begins to widen; a small amount of long, downy hair with slight pigmentation on labia majora Stage 3- Breast begins to become more elevated and extends beyond borders of the areola, which continues to widen but remains in contour with surrounding breast; Hair becomes more coarse and curly and begins to extend laterally Stage 4- Increased breast size and elevation; areola and papilla form a secondary mound projecting from the contour of the surrounding breast; Adult-like hair quality, extending across pubis but sparing medial thighs Stage 5- Breast reaches final adult size; areola returns to the contour of the surrounding breast, with a projecting central papilla; Hair extends to medial surface of the thigh.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}]","[{'measure': 'Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment', 'description': 'RSBQ is a caregiver-completed questionnaire that assesses the overall condition (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is ""not true as far as you know,"" 1 indicating an item is ""somewhat or sometimes true,"" and 2 indicating an item that is ""very true or often true"". "" Item 31 (""Uses eye gaze to convey feelings, needs and wishes"") is reverse-scored (0 indicating ""very true or often true"", 1 indicating ""somewhat or sometimes true,"" and 2 indicating ""not true as far as you know""). The total summed score ranges from 0 to 90, with higher scores representing greater severity. A negative mean change from baseline indicates an improvement in overall condition.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment', 'description': ""CGI-I is a 7-point scale that requires the clinician to assess whether a patient's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. The mean continuous CGI-I score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher mean scores indicate worse condition."", 'timeFrame': 'Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment', 'description': ""CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This was rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 =severely ill; or 7 = extremely ill. The mean continuous CGI-S score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher scores indicate more severe disease."", 'timeFrame': 'Visit 14 (Day 729) in the OLE'}, {'measure': ""Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment"", 'description': 'CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales:bedtime resistance (score range 6-18), sleep onset delay (range 1-3), sleep duration (range 3-9), sleep anxiety (range 4-12), night wakings (range 3-9), parasomnias (range 7-21), sleep-disordered breathing (range 3-9), daytime sleepiness (range 8-24). The 33 items range from 1 to 3, where 3=""usually"" (≥5 times/week), 2=""sometimes"" (2-4 times/week), and 1=""rarely"" (≤1 time/week); for items 31 and 32, 3=fall asleep, 2=very sleepy, 1=not sleepy. A score of 3 indicates greater severity; however, 6 items (1-Goes to bed at same time; 3-Falls asleep in own bed; 26-Wakes by himself; 2-Falls asleep in 20 minutes; 10-Sleeps the right amount; 11-Sleeps same amount each day) are reverse scored. The total summed score ranges from 33 to 99, with higher scores indicating disturbed sleep behavior. A negative mean change from baseline indicates improvement in sleep.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment', 'description': 'MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. The MBA-9 includes 9 items (Regression of motor skills; Poor eye/social contact; Lack of sustained interest; Does not reach for objects or people; Chewing difficulties; Speech disturbance; Hand clumsiness; Dystonia; and Hypertonia/rigidity). For each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. A negative mean change from baseline indicates improvement in behavior.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}]",15.0,2 Years,18 Years,ALL,False,INDUSTRY,1.0,21.0,ACTUAL,v2_robust,True,False,True,True,Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).
NCT00745186,Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers,Glucagen,"['Mayne Glucagon', 'Glucagen']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hypoglycemia,"Hospira, now a wholly owned subsidiary of Pfizer",2025-09-01T16:18:07.028016,True,,,,,"A Randomized, Open Label, Four Way Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety After Intramuscular (IM) Administration of Mayne Glucagon for Injection With Glucagen® (Novo Nordisk) in Healthy Volunteers.",,['Hypoglycemia'],[],,2007-08,2008-03,"[{'measure': 'Area Under the Curve from Time 0 to the Last Time Point (AUC0-tlast) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Maximum Glucagon Concentration Observed (Cmax) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Maximum Blood Glucose Concentration Observed (BG Cmax) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20,25,30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}]","[{'measure': 'Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Time at which Cmax occurs (Tmax) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Elimination half life (T1/2) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20,25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Area Under the Curve from Time 0 to the Last Time Point (AUC0-tlast) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Maximum Glucagon Concentration Observed (Cmax) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Time at which Cmax occurs (Tmax) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Elimination half-life (T1/2) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Time at which Blood Glucose Cmax occurs (BG Tmax) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Area under the curve from time 0 to return to baseline (rtb) for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Maximum absolute Blood Glucose excursion (MAE) from baseline for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Area under the glucose excursion versus time curve from 0 to rtb for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'The earliest recorded time of the MAE for 1 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.'}, {'measure': 'Maximum Blood Glucose Concentration Observed (BG Cmax) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Time at which Blood Glucose Cmax occurs (BG Tmax) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Area under the curve from time 0 to return to baseline (rtb) for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Maximum absolute Blood Glucose excursion (MAE) from baseline for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'Area under the glucose excursion versus time curve from 0 to rtb for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}, {'measure': 'The earliest recorded time of the MAE for 0.2 mg Dose Level', 'timeFrame': 'Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.'}]",22.0,18 Years,50 Years,ALL,True,INDUSTRY,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,
NCT04630886,Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery,Tranexamic acid injection,"['Lidocaine Epinephrine', 'Tranexamic acid injection']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,TERMINATED,Skin Neoplasms,Riley McLean,2025-09-01T16:18:07.028052,True,,,,,"Local Injection of Tranexamic Acid May Reduce Bleeding, Injection Pain, and Other Post-op Complications During Mohs Micrographic Surgery",,['Skin Neoplasms'],[],Drug supply issues,2021-06-16,2024-01-16,"[{'measure': 'Postoperative Complications', 'description': 'Primary outcome measures will be the number of postoperative complications, including infection, bleeding (necessitating phone calls to providers or additional clinic visits), hematoma formation, and flap or graft failure.', 'timeFrame': 'From day of surgery to 12 weeks post-operation'}]","[{'measure': 'Hemostasis', 'description': 'The quality of intraoperative hemostasis will be measured on a 1-4 scale titled ""Quality of the Field"", with 1 being ""excellent, better than expected/predicted for this procedure"" and 4 being ""poor, oozing that required adding gauze dressing and local pressure"" (the higher the score, the worse the outcome)', 'timeFrame': 'during surgery'}, {'measure': 'Injection Pain', 'description': 'Injection pain will be measured via self reported pain intensity within the first 30 minutes of initial injection on the day of surgery. The pain scale is scored 0-10 (0 = no pain; 10 = unable to move). The higher the score, the worse the outcome.', 'timeFrame': '30 minutes post initial injection'}]",3.0,18 Years,99 Years,ALL,False,OTHER,0.0,34.0,ACTUAL,v2_robust,True,False,True,False,Drug supply issues
NCT01354470,"A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence",Modafinil,['Modafinil'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Methamphetamine Dependence,California Pacific Medical Center Research Institute,2025-09-01T16:18:07.028152,True,,,,,"A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence",,['Methamphetamine Dependence'],"['Meth', 'Methamphetamine Addiction', 'Methamphetamine Treatment', 'Modafinil']",,2011-10,,"[{'measure': 'Urine Samples Negative for Methamphetamine', 'timeFrame': 'Twice weekly for 4 weeks'}]",[],1.0,18 Years,50 Years,ALL,False,OTHER,0.0,72.0,ESTIMATED,v2_robust,True,True,False,False,
NCT05059470,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,Pembrolizumab,['Pembrolizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Thyroid,M.D. Anderson Cancer Center,2025-09-01T16:18:07.028160,True,,,,,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,,['Thyroid'],[],\<75% participant accrual,2022-02-11,2025-07-01,"[{'measure': 'To establish the median progression-free survival (PFS).', 'timeFrame': 'through study completion, an average of 1 year'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,6.0,ACTUAL,v2_robust,True,False,True,False,\<75% participant accrual
NCT00574470,Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD,"daclizumab, infliximab","['daclizumab, infliximab']",1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Graft vs Host Disease,University of Iowa,2025-09-01T16:18:07.028186,True,,,,,Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD,,['Graft vs Host Disease'],[],,2006-01,2008-08,"[{'measure': 'Complete or partial response of GVHD to treatment according to standard staging/grading scale', 'timeFrame': '28 days'}]","[{'measure': 'incidence of chronic GVHD and overall survival', 'timeFrame': '9 months'}]",2.0,18 Years,,ALL,False,OTHER,0.0,3.0,ACTUAL,v2_robust,True,True,False,False,
NCT00522470,Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels,rosiglitazone,['rosiglitazone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Type 2 Diabetes Mellitus,Baskent University,2025-09-01T16:18:07.028208,True,,,,,Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels in Diabetic Women,,"['Type 2 Diabetes Mellitus', 'Obesity']",[],,,,[],[],0.0,45 Years,65 Years,FEMALE,,OTHER,0.0,,,v2_robust,True,True,False,False,
NCT03257670,Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors,4% Topical Lidocaine Gel,['4% Topical Lidocaine Gel'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Dyspareunia,University of Cincinnati,2025-09-01T16:18:07.028221,True,,,,,Prospective Randomized Trial Comparing Treatment of Dyspareunia With Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel in the Setting of Breast Cancer Survivors.,,['Dyspareunia'],"['Dyspareunia', 'Laser', 'CO2', 'Breast Cancer', 'Vaginal Atrophy', 'Lidocaine']",,2018-03-20,2022-06-01,"[{'measure': 'Female Sexual Function Index (FSFI) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The Female Sexual Function Index (FSFI) is a survey instrument used to determine the level of sexual function or dysfunction in females. It is comprised of a 19 item questionnaire focused on sexual functioning. There are six domains assessed: desire, arousal, lubrication, orgasm, satisfaction, and pain. The subject is to consider each of the questions in the context of the previous 4 weeks. The scores of each of the domains are then calculated into a final score.\n\nInitial and follow-up assessments will allow comparisons across this instrument as well as all the secondary and other pre-specified outcome measures.', 'timeFrame': '9 months'}]","[{'measure': 'Numeric Pain Rating Scale (NPRS) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The Numeric Pain Rating Scale (NPRS) is a measure of pain intensity in adults.The NPRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain. The common format is a horizontal bar or line. Similar to the VAS, the NPRS is anchored by terms describing pain severity extremes. The 11-point numeric scale ranges from \'0\' representing one pain extreme (e.g. ""no pain"") to \'10\' representing the other pain extreme (e.g. ""pain as bad as you can imagine"" or ""worst pain imaginable"").The NPRS can be administered verbally (therefore also by telephone) or graphically for self-completion. Scores range from 0-10 with higher numbers representing higher pain intensity.', 'timeFrame': '9 months'}, {'measure': 'Incontinence Severity Index (ISI) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The Incontinence Severity Index (ISI) consists of two questions, regarding frequency and amount of leakage. It categorizes urinary incontinence (UI) into none, slight, moderate, severe, and very severe. It assess the frequency (from 0-4): (0-never, 1-less than once a month, 2-a few times a month, 3-a few times a week, 4-every day and/or night ), and amount (from 0-3) of urine leakage: 0-none, 1-drops, 2-small splashes, 3-more. The index value is from 0-12 obtained by multiplying the numbers responded in the two questions with categories of urinary incontinence severity of: None (0), Slight (1-2), Moderate (3-6), Severe (8-9), Very severe (12).', 'timeFrame': '9 months'}, {'measure': '3 Incontinence Questions (3-IQ) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The 3 Incontinence Questions (3-IQ) is a survey instrument that is used to determine if a patient has stress urinary incontinence (SUI), urge urinary incontinence (UUI), or mixed urinary incontinence (MUI). The subject is to consider each of the questions in the context of the previous 3 months.The first question asks if the patient has every leaked urine. The second question asks the patient to indicate if she has leaked urine with any of the following: activity, urge, or without activity or urge. The Third question asks which form of urinary leakage was most common. The response to question 3 is then used to determine if the patient has: 1) Stress only or mostly stress, 2) urge only or mostly urge, 3) other cause, or 4) mixed.', 'timeFrame': '9 months'}, {'measure': 'Colon Rectal Anal Distress Inventory (CRADI) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The Colon Rectal Anal Distress Inventory (CRADI) is a survey instrument used to determine the level and severity of bowel symptoms. It consists of 17 questions inquiring to specific questions regarding bowel symptoms. Total score out of 400, with higher scores indicating more bowel symptoms.', 'timeFrame': '9 months'}, {'measure': 'Patient Global Impression of Severity (PGI-S) score before treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The PGI-S are 1 question assessments of overall condition severity before implementation of therapy measured on a 7-point response scale.', 'timeFrame': '9 months'}, {'measure': 'Patient Global Impression of Improvement (PGI-I) score after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The Patient Global Impression of Improvement (PGI-I) is 1 question assessment of overall condition improvement since implementation of therapy measured on a 7-point response scale.', 'timeFrame': '9 months'}, {'measure': 'Satisfaction with Decision (SDS) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.', 'description': 'The Satisfaction with Decision (SDS) was developed to measure patient satisfaction with health care decisions. The SDS is a 6-item questionnaire with a 5-point response scale with higher scores indicating higher overall satisfaction.', 'timeFrame': '9 months'}]",8.0,18 Years,,FEMALE,True,OTHER,1.0,70.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00114270,Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density,letrozole,"['letrozole', 'zoledronic acid']",2,INTERVENTIONAL,['NA'],,COMPLETED,Breast Cancer,University of Virginia,2025-09-01T16:18:07.028330,True,,,,,Evaluating the Effect of Letrozole With or Without Concomitant Zoledronic Acid on Estrogen Responsive Targets in Postmenopausal Women,,"['Breast Cancer', 'Osteoporosis']","['breast cancer', 'osteoporosis']",,2004-05,2007-06,[],[],0.0,18 Years,,FEMALE,True,OTHER,1.0,,,v2_robust,True,True,False,False,
NCT00037570,Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage,Pantoprazole,['Pantoprazole'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Peptic Ulcer Hemorrhage,Wyeth is now a wholly owned subsidiary of Pfizer,2025-09-01T16:18:07.028341,True,,,,,A Randomized Study of the Effect of Intravenous Pantoprazole on Gastric pH After Successful Hemostasis in Patients With Bleeding Peptic Ulcer,,['Peptic Ulcer Hemorrhage'],"['Peptic', 'Ulcer', 'Hemorrhage']",,2000-11,2002-02,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,
NCT03459170,Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant,rimiducid,"['AP1903', 'rimiducid']",2,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Hematologic Malignancy,Bellicum Pharmaceuticals,2025-09-01T16:18:07.028347,True,,,,,"A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant",,['Hematologic Malignancy'],"['leukemia', 'myelodysplastic syndrome', 'lymphoma', 'minimal residual disease', 'BPX-501', 'AP1903', 'rimiducid']",,2018-02-01,2035-09,"[{'measure': 'BPX-501 Safety', 'description': 'Incidence of treatment emergent adverse events of 2 stratified dose levels of BPX-501 T cell infusions based on patient-donor match in pediatric subjects with hematologic malignancies', 'timeFrame': 'Month 24'}, {'measure': 'Mean plasma concentration', 'description': 'Measure plasma concentrations of rimiducid (AP1903) at two doses (Arm 1: 0.04mg/kg; Arm 2: 0.4mg/kg) in pediatric subjects, during and after a 2-hour infusion', 'timeFrame': 'pre-dose, 30 min, 2 hours and 8 hours after start of infusion'}]","[{'measure': 'Overall survival', 'description': 'Measure overall survival rates after BPX-501 infusion', 'timeFrame': 'Month 24'}, {'measure': 'Response Rate', 'description': 'Assess response rates after BPX-501 infusion', 'timeFrame': 'Month 24'}]",4.0,1 Year,18 Years,ALL,False,INDUSTRY,0.0,15.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03045770,mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA,Fluorouracil,"['Paclitaxel', 'Oxaliplatin', 'Irinotecan', '5-FU', 'CPT-11', 'Fluorouracil', 'PTX', 'calcium levofolinate', 'OXA']",9,INTERVENTIONAL,['NA'],,UNKNOWN,Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction,Fujian Cancer Hospital,2025-09-01T16:18:07.028470,True,,,,,"A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction",,['Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction'],[],,2017-02-10,2019-12-30,"[{'measure': 'Progression-Free Survival (PFS)', 'timeFrame': '24 months'}, {'measure': 'Adverse Event（AE）', 'description': 'NCI CTC 4.03', 'timeFrame': '35 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'timeFrame': '24 months'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': '24 months'}, {'measure': 'Overall Survival (OS)', 'timeFrame': '35 months'}, {'measure': 'Quality of Life (QoL)', 'description': 'Use the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 \\[EORTC QLQ-C30\\].', 'timeFrame': '35 months'}]",6.0,18 Years,70 Years,ALL,False,OTHER_GOV,0.0,150.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00592670,Hypoglycemia Associated Autonomic Failure in Type 1 DM,Fluoxetine,"['Placebo', 'Prozac', 'Fluoxetine']",3,INTERVENTIONAL,['NA'],,COMPLETED,Type 1 Diabetes,Vanderbilt University,2025-09-01T16:18:07.028480,True,,,,,"Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6",,['Type 1 Diabetes'],[],,2005-03,2008-10,"[{'measure': 'Catecholamine measures', 'timeFrame': '6 weeks'}]",[],1.0,18 Years,45 Years,ALL,True,OTHER,1.0,48.0,ACTUAL,v2_robust,True,True,False,False,
NCT04647773,To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain,HSK16149 20mg BID,"['HSK16149 40mg BID', 'HSK16149 80mg BID', 'Pregabalin 150mg BID', 'HSK16149 60mg BID', 'Placebo BID', 'HSK16149 20mg BID']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Diabetic Peripheral Neuropathic Pain,"Haisco Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:07.028488,True,,,,,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Pregabalin Capsule-Controlled, 13-Week, Adaptive-design Phase 2/3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Diabetic Peripheral Neuropathic Pain",,['Diabetic Peripheral Neuropathic Pain'],[],,2020-12-02,2022-11-16,"[{'measure': 'Compare the change from baseline in Average Daily Pain Score（ADPS） between HSK16149 and placebo at week 5.', 'description': ""The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \\[no pain\\] to 10 \\[worst possible pain\\]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries."", 'timeFrame': 'Baseline and week 5'}, {'measure': 'Compare the change from baseline in Average Daily Pain Score （ADPS） between HSK16149 and placebo at week 13.', 'description': ""The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \\[no pain\\] to 10 \\[worst possible pain\\]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries."", 'timeFrame': 'Baseline and week 13'}]","[{'measure': 'Compare the response rate between HSK16149 and placebo at week 5 (Proportion of subjects whose ADPS decreased by ≥30% and ≥50% from baseline ).', 'description': 'Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline. The ADPS is used to determine categorical response rates.', 'timeFrame': 'Baseline and week 5'}, {'measure': 'AE, laboratory tests, physical and neurological examination, vital signs and 12-lead ECG to evaluate the safety of HSK16149 in 5 weeks post treatment.', 'description': 'Number and severity of AEs, clinical laboratory abnormalities, physical examinations, 12-lead electrocardiograms (ECGs), and vital signs.', 'timeFrame': 'From week 1 to week 5'}, {'measure': 'Compare the response rate between HSK16149 and placebo at week 13 (Proportion of subjects whose ADPS decreased by ≥30% and ≥50% from baseline ).', 'description': 'Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline. The ADPS is used to determine categorical response rates.', 'timeFrame': 'Baseline and week 13'}, {'measure': 'Compare the change from baseline in ADPS between HSK16149 and placebo at week 1 to 13.', 'description': ""The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \\[no pain\\] to 10 \\[worst possible pain\\]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries."", 'timeFrame': 'From week 1 to week 13'}, {'measure': 'Compare the change from baseline in Visual Analog Scale （VAS） between HSK16149 and placebo at week 13.', 'description': 'VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain.', 'timeFrame': 'Baseline and week 13'}, {'measure': 'Compare the change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) between HSK16149 and placebo at week 13.', 'description': 'Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score:\n\nPart 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe)\n\nPart 2 - a visual analog scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain\n\nPart 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain)', 'timeFrame': 'Baseline and week 13'}, {'measure': 'Compare the Patient Global Impression of Change（PGIC） between HSK16149 and placebo at week 13.', 'description': 'Patient global impression of change (PGIC) on a 7-point categorical scale, where 1 = very much improved and 7 = very much worse.', 'timeFrame': 'Week 13'}, {'measure': 'Compare the change from baseline in Average Daily Sleep Interference score (ADSIS) between HSK16149 and placebo at week 13.', 'description': 'The sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores.', 'timeFrame': 'Baseline and week 13'}, {'measure': 'Compare the change from baseline in EuroQol-5-Domain-5-Level health questionnaire (EQ-5D-5L) between HSK16149 and placebo at week 13.', 'description': 'The change from baseline in total EuroQol-5-Domain-5-Level health questionnaire.', 'timeFrame': 'Baseline and week 13'}, {'measure': 'AE, laboratory tests, physical and neurological examination, vital signs and 12-lead ECG to evaluate the safety of HSK16149 during the trial.', 'description': 'Number and severity of AEs, clinical laboratory abnormalities, physical examinations, 12-lead electrocardiograms (ECGs), and vital signs.', 'timeFrame': 'From week 1 to week 14'}, {'measure': 'Pharmacokinetic (PK) characteristics of HSK16149 capsules in Chinese patients with diabetic peripheral neuropathic pain.', 'description': 'Pharmacokinetics will be determined by measuring serum concentration of HSK16149.', 'timeFrame': 'Week 1,week 5,week 11,week 13'}]",13.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,687.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00541073,"Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery",cisplatin,"['cisplatin', 'pemetrexed disodium']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Malignant Mesothelioma,Centre Oscar Lambret,2025-09-01T16:18:07.028538,True,,,,,Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma,,['Malignant Mesothelioma'],"['advanced malignant mesothelioma', 'recurrent malignant mesothelioma']",,2007-06,,[{'measure': 'Individual dosage-adapted protocol'}],"[{'measure': 'Relationship between pharmacokinetic and pharmacodynamic parameters'}, {'measure': 'Pharmacokinetics'}, {'measure': 'Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)'}]",4.0,18 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,True,False,False,
NCT04351373,Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560,Fluorescein Sodium,"['AK-Fluor®', 'Fluorescein Sodium']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Vestibular Schwannoma,Mayo Clinic,2025-09-01T16:18:07.028552,True,,,,,"Microscopic Fluorescence-guided Vestibular Schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma Resection Using Fluorescein Sodium and YELLOW 560",,['Vestibular Schwannoma'],"['Head and Neck Paraganglioma', 'Head and Neck Schwannoma']",,2021-10-06,2022-05-25,"[{'measure': 'Surgeon Predicted Use of Fluorescein Sodium in Future Cases', 'description': 'Physician response to surgeon survey question, ""Based on the use and performance of FS in this case alone, how likely are you to use FS in future cases (excluding the research trial) involving this tumor?"" using a Likert-style rating from 0-4 where 0=Unsure; 1= Plan to not use in any cases; 2= Plan to use in select cases; 3=Plan to use in the majority of cases; 4=Plan to use in all cases.', 'timeFrame': 'Approximately 3 months postoperatively'}, {'measure': ""Correlation of Fluorescein Sodium With Surgeons' Visual Assessment"", 'description': ""Fluorescence correlate with surgeons' visual assessment of the tumor and nerve tissue under normal microscopy without the Yellow 560 filter using a Likert-style rating from 1-4 where 1=No correlation; 2=Some correlation; 3=Good correlation; 4=Excellent correlation."", 'timeFrame': 'Intraoperatively, approximately 1 day'}, {'measure': 'Correlation of Fluorescein Sodium With Electrostimulation', 'description': 'Surgeons\' assessment of fluorescence correlate with electrostimulation (e.g. tissues with high fluorescence do not stimulate, whereas nerve tissues with low fluorescence do stimulate)"" using a Likert-style rating from 1-4 where 1=No correlation; 2=Some correlation; 3=Good correlation; 4=Excellent correlation.', 'timeFrame': 'Intraoperatively, approximately 1 day'}]","[{'measure': 'Time to Differential Visualization', 'description': 'The amount of time in minutes for differential visualization of the tumor and surrounding tissue after sodium fluorescein administration during surgery', 'timeFrame': 'Intraoperatively, approximately 1 day'}, {'measure': 'Average Dose of Sodium Fluorescein Administration', 'description': 'Average dose of sodium fluorescein administered during surgery to achieve differential fluorescence of the tumor and tissue reported in mg/kg', 'timeFrame': 'Intraoperatively, approximately 1 day'}, {'measure': 'Total Resection Rate', 'description': 'Number of subjects to have a gross total resection', 'timeFrame': 'Intraoperatively, approximately 1 day'}]",6.0,18 Years,,ALL,False,OTHER,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,
NCT04626973,Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial,Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin),"['Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)', 'Statin monotherapy (rosuvastatin or atorvastatin)']",2,INTERVENTIONAL,['NA'],,RECRUITING,Atherosclerotic Cardiovascular Disease,Yonsei University,2025-09-01T16:18:07.028578,True,,,,,Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial,,['Atherosclerotic Cardiovascular Disease'],"['Dyslipidemia', 'ASCVD', 'Coronary artery disease']",,2021-01-15,2025-09,"[{'measure': 'Clinical outcomes by different lipid-lowering therapy', 'description': 'Composite of cardiovascular death, non-fatal MI, non-fatal stroke, any revascularization, and hospitalization for unstable angina', 'timeFrame': 'Within 3 years after the enrollment'}]","[{'measure': 'Each component of primary endpoint within 3 years', 'description': '* A. Rate of Cardiovascular death\n* B. Rate of non-fatal MI\n* C. Rate of non-fatal stroke\n* D. Rate of any revascularization\n* E. Rate of hospitalization for unstable angina', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Various composite outcomes within 3 years', 'description': '* A. Rate of composite of cardiovascular death, non-fatal MI, and non-fatal stroke\n* B. Rate of composite of cardiovascular death, non-fatal MI, non-fatal stroke, and any revascularization\n* C. Rate pf composite of cardiovascular death, non-fatal MI, and any revascularization\n* D. Rate of composite of all-cause death, non-fatal MI, non-fatal stroke, any revascularization, and hospitalization for unstable angina', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Proportion of subjects achieving target LDL-cholesterol level', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Rate of cross-over into the non-allocated therapy regimen in order to achieve target LDL-cholesterol level', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Proportions of subjects requiring proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to achieve target LDL-cholesterol level', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Difference in rate of primary outcome according to sex', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Difference in rate of primary outcome according to body mass index', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Rate of New-onset diabetes mellitus', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Rate of worsening of glycemic control or homeostatic model assessment (HOMA)-index', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Occurrence of statin-associated muscle symptoms (SAMS) requiring change of therapy regimen or dosage', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Occurence of elevation of muscle enzymes (CPK > 4 x UNL)', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Occurence of elevation of hepatic enzymes (AST, ALT, or both ≥ 3 x UNL)', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Occurence of elevation of serum creatinine level (>50% from baseline)', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Change of proteinuria', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Rate of cancer diagnosis', 'timeFrame': 'Within 3 years after the enrollment'}, {'measure': 'Rate of operation due to cataract', 'timeFrame': 'Within 3 years after the enrollment'}]",17.0,19 Years,80 Years,ALL,False,OTHER,0.0,3048.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00443573,Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer,recombinant nematode anticoagulant protein c2 (rNAPc2),"['anticoagulant', 'recombinant nematode anticoagulant protein c2 (rNAPc2)']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,SUSPENDED,Colon Cancer,"ARCA Biopharma, Inc.",2025-09-01T16:18:07.028627,True,,,,,"Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2",,['Colon Cancer'],"['metastatic colorectal carcinoma (mCRC)', 'colorectal carcinoma (CRC)', 'tissue factor', 'factor VIIa', 'rNAPc2', 'adenocarcinoma', 'targeted therapy', 'coagulation-dependent', 'RECIST', '5-FU-based chemotherapy', 'FOLFOX', 'FOLFIRI', 'leucovorin', 'XELOX']",Company suspended development of product.,2006-12,,"[{'measure': 'Safety measured by major hemorrhage (NCI CTCAE v3.0 grade 3 or greater), during and up to 30 days after completion of study drug administration or, if treatment is ongoing, by 8 months after study enrollment (Stage I) or randomization (Stage II)', 'timeFrame': '30 days after study completion'}]","[{'measure': 'Safety measured by adverse events', 'timeFrame': '30 days after study completion'}, {'measure': 'Efficacy measured by new metastasis-free survival by 8 months', 'timeFrame': '8 months'}, {'measure': 'Survival by 8 months', 'timeFrame': '8 months'}, {'measure': 'Arterial or venous thrombosis', 'timeFrame': '8 months'}, {'measure': 'Tumor response rate, as assessed by RECIST criteria', 'timeFrame': '30 days after study completion'}]",6.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,100.0,ESTIMATED,v2_robust,True,False,True,True,Company suspended development of product.
NCT01750073,Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer,Cyclophosphamide,"['Fosfaseron', 'Claphene', 'Doxorubin', 'Taxol Konzentrat', 'Adriacin', 'Adriblastina', 'Carloxan', 'Cyclophosphan', 'Neosar', 'Adrimedac', 'Doxolem', 'Cytoxan', 'WR- 138719', 'Adriblastine', 'Bristaxol', 'hydroxydaunorubicin', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Genuxal', 'Paclitaxel', 'Asotax', 'Doxorubicin Hydrochloride', 'Revimmune', 'Adriamycin Hydrochloride', 'Adriamycine', 'Farmiblastina', 'Cycloblastine', 'Cicloxal', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cyclophosphamidum', 'Cycloblastin', 'Cyclophosphamide', 'Ledoxina', 'ADRIAMYCIN, HYDROCHLORIDE', 'Cyclostine', 'Taxol', 'Cyclophospham', 'Anzatax', 'Doxorubicin.HCl', 'CP monohydrate', '5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)', 'Adriamycin RDF', 'CTX', 'DOX', 'FI 106', 'Cytophosphan', 'Cyclophosphane', 'Clafen', 'Genoxal', 'Praxel', 'DOXO-CELL', 'Adriamycin', 'Rubex', 'Syklofosfamid', 'Cyclophosphanum', 'FI-106', 'Cytophosphane', 'Ciclofosfamida', 'Cyclophosphamid monohydrate', 'ADM', 'Chloridrato de Doxorrubicina', 'Adriamycin PFS', 'CYCLO-cell', 'Mitoxan']",65,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Estrogen Receptor Negative,University of Nebraska,2025-09-01T16:18:07.028724,True,,,,,A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast Cancer,,"['Estrogen Receptor Negative', 'Estrogen Receptor Positive', 'HER2/Neu Negative', 'HER2/Neu Positive', 'Invasive Breast Carcinoma', 'Progesterone Receptor Negative', 'Progesterone Receptor Positive', 'Stage IA Breast Cancer', 'Stage II Breast Cancer', 'Stage IIA Breast Cancer', 'Stage IIB Breast Cancer', 'Stage III Breast Cancer', 'Stage IIIA Breast Cancer', 'Stage IIIB Breast Cancer', 'Stage IIIC Breast Cancer', 'Triple-Negative Breast Carcinoma']",[],,2012-12-07,2026-06,"[{'measure': 'Overall Incidence of Toxicities, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0', 'description': 'Number of participants in each subset (Her2 positive and Her2 negative) who experience at least one adverse event \\[overall incidence of toxicities, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\\].', 'timeFrame': 'Up to 30 days after completion of study treatment, maximum of 114 days'}, {'measure': 'Overall Severity of Toxicities, Graded According to the NCI CTCAE Version 4.0', 'description': 'Results reported as total events per grade for human epidermal growth factor receptor 2 (HER2)negative and HER2 positive (Overall severity of toxicities, graded according to the NCI CTCAE version 4.0).', 'timeFrame': 'Up to 30 days after completion of study treatment, maximum of 114 days'}, {'measure': 'Number of Participants in the Subgroups Who Had a Pathologic Complete Response (pCR)', 'description': 'The number of participants in the subgroups who had a pathologic complete response (pCR) determined from the surgical specimen and defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ.', 'timeFrame': 'Up to 12 weeks (after the first 6 courses of treatment), maximum of 168 days'}]","[{'measure': 'Clinical Complete Response', 'description': 'The absence of all detectable cancer after treatment is complete.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Failure-free Survival (FFS)', 'description': 'The analysis will be based on Kaplan-Meier estimates. FFS will be summarized overall and for human epidermal growth factor receptor 2 (HER2)+ and HER- subsets.', 'timeFrame': 'The time from the date of administration of study drug to the date of first appearance of tumor lesions by imaging, or death, assessed up to 2 years'}, {'measure': 'Identification of Gene Expression Profile Signatures That Correlate With Clinical Response as Measured by pCR', 'description': 'The number of the identified mutated genes, the frequency of each gene being validated by reverse transcriptase-polymerase chain reaction (RT-PCR)/Sanger sequencing method, and the functions of these identified genes will be descriptively summarized.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall Survival (OAS)', 'description': 'The analysis will be based on Kaplan-Meier estimates. OAS will be summarized overall and for HER+ and HER- subsets.', 'timeFrame': 'The time from the date of the date of administration of study drug to the date of death from any cause, assessed up to 2 years'}]",7.0,19 Years,,FEMALE,False,OTHER,1.0,92.0,ACTUAL,v2_robust,True,False,False,True,
NCT00083473,A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia,Pivanex,['Pivanex'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,"Leukemia, Lymphocytic, Chronic",Titan Pharmaceuticals,2025-09-01T16:18:07.028768,True,,,,,"A Pilot Study of Pivanex, a Histone Deacetylase Inhibitor, in Patients With Chronic Lymphocytic Leukemia",,"['Leukemia, Lymphocytic, Chronic', 'Lymphoma, Small Lymphocytic']","['Leukemia Lymphocytic Chronic,', 'Pivanex,', 'Histone deacetylase inhibitor']",,2004-05,2005-04,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,28.0,,v2_robust,True,False,True,False,
NCT01236573,Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes,Fludarabine,"['Cyclophosphamide', 'Fludarabine']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Skin Cancer,National Institutes of Health Clinical Center (CC),2025-09-01T16:18:07.028831,True,,,,,Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12,,"['Skin Cancer', 'Metastatic Melanoma']","['Gene Therapy', 'Immunotherapy', 'Adoptive Cell Therapy', 'Metastatic Melanoma']","Unexpected toxicities, likely due to TIL/IL-12 \& low % of durable responses.",2010-10,2015-03,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'The MTD was determined by evaluating dose limiting toxicities (DLT) of participants that received increasing doses of intravenous infusion of IL-12 gene transduced tumor infiltrating lymphocytes (TIL) (i.e., 1x10\\^6, 3x10\\^6, 3x10\\^7, 1x10\\^7, 3x10\\^7, 1x10\\^8, 3x10\\^8, 1x10\\^9, and 3x10\\^9) in cohorts 1-10. Maximum tolerated cell dose is the highest dose at which \\</= 1 of 6 patients experienced a DLT (i.e. grade 2 or greater allergic reaction)).', 'timeFrame': '4 years'}, {'measure': 'Response (Complete Response (CR) + Partial Response (PR)) to Therapy', 'description': 'Response was determined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline um LD. Progressive disease (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions.', 'timeFrame': '4 years'}]","[{'measure': 'Number of Participants With Adverse Events', 'description': 'Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.', 'timeFrame': '49 months and 20 days'}]",3.0,18 Years,66 Years,ALL,False,NIH,1.0,34.0,ACTUAL,v2_robust,True,False,True,True,"Unexpected toxicities, likely due to TIL/IL-12 \& low % of durable responses."
NCT00201669,A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma,Clofarabine,"['Clofarabine', 'Clolar']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Non-Hodgkin's Lymphoma,Ohio State University Comprehensive Cancer Center,2025-09-01T16:18:07.028875,True,,,,,A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma,,"[""Non-Hodgkin's Lymphoma""]","['Aggressive', 'Clofarabine']",,2004-10,2006-06,"[{'measure': 'Response rate', 'timeFrame': 'up to two years'}]","[{'measure': 'Determine the toxicity of clofarabine administered in conjunction with growth factor support in patients with relapsed/refractory aggressive NHL.', 'timeFrame': 'up to two years'}, {'measure': 'determine the effect of clofarabine on T-, B-, and natural killer (NK)-cell subsets and quantitative immunoglobulin levels after prolonged administration of clofarabine in patients with NHL.', 'timeFrame': 'up to two years'}, {'measure': 'Assess cytokine (tumor necrosis factor [TNF]-alpha, interleukin [IL]-6, and IL-10) release following clofarabine therapy.', 'timeFrame': 'up to two years'}, {'measure': 'Assess the effect of pre-treatment prognostic factors (p53 mutational status, DNA methylation, and apoptotic protein levels) in patient-derived tumor tissue on response to clofarabine.', 'timeFrame': 'up to two years'}]",5.0,18 Years,,ALL,False,OTHER,0.0,6.0,ACTUAL,v2_robust,True,True,False,False,
NCT05400369,A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease,Sitafloxacin,"['Avelox', 'Sitafloxacin', 'Moxifloxacin Hydrochloride', 'Gracevit']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,COPD Exacerbation Acute,Daiichi Sankyo,2025-09-01T16:18:07.028890,True,,,,,"A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease",,['COPD Exacerbation Acute'],"['Chronic obstructive pulmonary disease', 'Exacerbation', 'Sitafloxacin']",,2022-08-10,2024-09-25,"[{'measure': 'Number of Participants Achieving Clinical Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease', 'description': 'Clinical efficacy is divided into clinical cure and clinical ineffective. Clinical cure is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that disappear or return to the baseline level of stable phase at the end of treatment/discontinuation and no additional systemic antibacterial therapy is required for the target indication.\n\nClinical ineffective is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that persist or incompletely disappear (do not return to the baseline level of stable phase).', 'timeFrame': 'End of treatment (approximately Day 10 post-dose)'}]","[{'measure': 'Number of Participants Achieving Clinical Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease', 'description': 'Clinical efficacy is divided into clinical cure and clinical ineffective. Clinical cure is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that disappear or return to the baseline level of stable phase at the end of treatment/discontinuation and no additional systemic antibacterial therapy is required for the target indication.\n\nClinical ineffective is defined as the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) that persist or incompletely disappear (do not return to the baseline level of stable phase).', 'timeFrame': '1 month post-dose'}, {'measure': 'Number of Participants Achieving Microbiological Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease', 'description': 'Microbiological efficacy is determined by bacterial clearance:\n\nClearance is defined as specimens from the original infection site after treatment do not culture pathogenic bacteria from the original infection.', 'timeFrame': 'End of treatment (approximately Day 10 post-dose)'}, {'measure': 'Number of Days With Symptom Relief in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease', 'description': 'The number of days with symptom relief of the three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence) will be assessed.', 'timeFrame': 'From the start of treatment up to relief of three main symptoms of AECOPD (worsening dyspnea, increased sputum volume and sputum purulence), up to 1 month post-dose'}, {'measure': 'Change from Baseline in Each Chronic Obstructive Pulmonary Disease Symptom Score in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease', 'description': 'Chronic obstructive pulmonary disease symptom scores include dyspnea (ranging from 0 \\[Dyspnea only with strenuous activity\\] to 4 \\[Unable to leave home due to severe respiratory distress, or dyspnea when wearing and undressing\\]), sputum volume (ranging from 0 \\[no sputum\\] to 3 \\[severe\\]), sputum purulence (ranging from 0 \\[myxoid sample\\] to 3 \\[severe purulent\\]), cough score (ranging from 0 \\[no cough\\] to 3 \\[severe cough\\]), fever (ranging from 0 \\[≤37.0°C\\] to 3 \\[\\>38.0°C\\], and COPD Assessment Test (CAT) (where questions 1-8, range from a score of 0 \\[no impact\\] to 5 \\[severely impacted\\]. For all assessments, higher scores indicate worse outcome.', 'timeFrame': 'End of treatment (approximately Day 10 post-dose)'}, {'measure': 'Change from Baseline in Inflammatory Biomarker C-reactive Protein in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease', 'timeFrame': 'End of treatment (approximately Day 10 post-dose)'}, {'measure': 'Recurrence Rate of Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease', 'description': 'Recurrence rate is defined as when the clinical outcome of the participant at the end/discontinuation of treatment is determined to be clinically cured, but AECOPD occurs again within 20 days after drug withdrawal due to incomplete anti-infective treatment, the participant develops one or more of the three main symptoms of worsening dyspnea, increased phlegm production, and sputum production, and also has relevant signs of AECOPD, with repeated blood routine, C-reactive protein and other inflammatory indicators, and needs to receive systemic antibacterial drug treatment again, and the pathogenic bacteria belonged to the same strain and serotype as the bacteria originally infected.', 'timeFrame': 'End of treatment (approximately Day 10 post-dose) up to 1 month post-dose'}]",7.0,40 Years,,ALL,False,INDUSTRY,0.0,140.0,ACTUAL,v2_robust,True,True,False,False,
NCT00231569,Dose-escalating Safety Study in Subjects on Stable Statin Therapy,ISIS 301012 or Placebo,['ISIS 301012 or Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hypercholesterolemia,"Kastle Therapeutics, LLC",2025-09-01T16:18:07.028969,True,,,,,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy",,['Hypercholesterolemia'],"['LDL-cholesterol', 'apoB-100', 'apoB-48']",,2005-09,2007-12,"[{'measure': 'Percent reduction in LDL-cholesterol from baseline', 'timeFrame': 'From baseline measurement'}]","[{'measure': 'Percent reduction in apoB-100', 'timeFrame': 'From baseline measurement'}, {'measure': 'Percent change in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL plus LDL-cholesterol and LDL-cholesterol particle size and concentration', 'timeFrame': 'From baseline measurement'}, {'measure': 'Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios', 'timeFrame': 'From baseline measurement'}, {'measure': 'AEs, SAEs, physical examination data, vital signs, and laboratory analyzes', 'timeFrame': 'Duration of study'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,1.0,74.0,ACTUAL,v2_robust,True,True,False,False,
NCT05001269,Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function,nedosiran,"['DCR-PHXC', 'nedosiran']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Primary Hyperoxaluria,"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",2025-09-01T16:18:07.028990,True,,,,,"A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function",,"['Primary Hyperoxaluria', 'Primary Hyperoxaluria Type 1', 'Primary Hyperoxaluria Type 2', 'Primary Hyperoxaluria Type 3']","['PH1', 'PH2', 'PH3', 'pediatric']",,2022-02-22,2025-02-05,"[{'measure': 'Efficacy: Percent change in urinary oxalate to creatinine ratio', 'description': 'Evaluate the effect of nedosiran on percent change in urinary oxalate-to-creatinine ratio', 'timeFrame': '180 days'}, {'measure': 'Efficacy: Absolute change in urinary oxalate to creatinine ratio', 'description': 'Evaluate the effect of nedosiran on absolute change in urinary oxalate-to-creatinine ratio', 'timeFrame': '180 days'}]","[{'measure': 'Safety: Incidence of Events', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger based on treatment emergent adverse events, and serious adverse events.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in ECG: Rhythm', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in ECG.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in ECG: Ventricular Rate', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in ECG.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in ECG: PR interval', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in ECG.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in ECG: QRS duration', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in ECG.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in ECG: QT interval', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in ECG.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Physical Exam', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in physical exam and physician review of systems based on CTCAE v5.0', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in Vitals: temperature', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in vital signs.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in Vitals: pulse rate', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in vital signs.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in Vitals: respiratory rate', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in vital signs.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline in Vitals: blood pressure', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in vital signs.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Labs - Hematology', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in clinical laboratory tests.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Labs - Clinical Chemistry', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in clinical laboratory tests.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Labs - Coagulation', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in clinical laboratory tests.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Labs - Antibody', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in clinical laboratory tests.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Labs - Plasma Oxalate', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in clinical laboratory tests.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Labs - Urinalysis', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in clinical laboratory tests.', 'timeFrame': '180 days'}, {'measure': 'Safety: Changes from baseline: Labs - Urine Oxalate', 'description': 'Characterize the safety of nedosiran in children 11 years of age and younger changes from baseline in clinical laboratory tests.', 'timeFrame': '180 days'}, {'measure': 'To characterize the PK of DCR PHXC in patients with PH by observing secondary parameters of the area under the curve.', 'description': 'Population and individual pharmacokinetic (PK) parameters for DCR PHXC, including secondary parameters of area under the curve (AUC)', 'timeFrame': '180 days'}, {'measure': 'To characterize the PK of DCR PHXC in patients with PH by observing maximum observed concentration (Cmax).', 'description': 'Population and individual pharmacokinetic (PK) parameters for DCR PHXC, including maximum observed concentration (Cmax)', 'timeFrame': '180 days'}, {'measure': 'To characterize the PK of DCR PHXC in patients with PH by observing minimum concentration (Cmin).', 'description': 'Population and individual pharmacokinetic (PK) parameters for DCR PHXC, including minimum observed concentration (Cmin)', 'timeFrame': '180 days'}, {'measure': 'To characterize the PK of DCR PHXC in patients with PH by observing maximum concentration (Tmax).', 'description': 'Population and individual pharmacokinetic (PK) parameters for DCR PHXC, including time to maximum concentration (Tmax)', 'timeFrame': '180 days'}, {'measure': 'To characterize the PK of DCR PHXC in patients with PH by observing terminal elimination half-life (t1/2).', 'description': 'Population and individual pharmacokinetic (PK) parameters for DCR PHXC, including terminal elimination half-life (t1/2)', 'timeFrame': '180 days'}, {'measure': 'Efficacy: eGFR changes', 'description': 'Evaluate the effect of nedosiran on eGFR from baseline', 'timeFrame': '180 days'}]",26.0,,11 Years,ALL,False,INDUSTRY,0.0,27.0,ACTUAL,v2_robust,True,True,False,True,
NCT00002269,"A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen",Ampligen,"['Zidovudine', 'Ampligen']",2,INTERVENTIONAL,['NA'],,COMPLETED,HIV Infections,HEM Research,2025-09-01T16:18:07.029009,True,,,,,"A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen",,['HIV Infections'],"['Acquired Immunodeficiency Syndrome', 'ampligen', 'AIDS-Related Complex', 'Zidovudine']",,,,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,,,v2_robust,True,True,False,False,
NCT04583969,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,Remdesivir,['Remdesivir'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,COVID-19,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:07.029029,True,,,,,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,,['COVID-19'],"['Adults', 'COVID-19', 'Multicenter', 'Putative', 'Therapeutics']",,2020-10-23,2022-04-22,"[{'measure': 'Proportion of Participants Alive and Without Mechanical Ventilation Through Day 29 in Participants With Baseline Ordinal Score of 5 or 6, C-reactive Protein (CRP)<150mg/L and Age <85 Years', 'description': 'Ordinal scale categories include 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) and 8) Death. Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO from Day 1 through Day 29. Estimates for the proportions are estimated from a logistic regression model adjusted for baseline dexamethasone, baseline ordinal score, age (continuous), and baseline CRP.', 'timeFrame': 'Day 1 through Day 29'}]","[{'measure': 'Proportion of Participants Alive and Without Mechanical Ventilation Through Day 29 in Participants With Any Baseline Ordinal Score', 'description': 'Mechanical ventilation-free survival was assessed through Day 29, defined as the proportion of participants who had not died nor were hospitalized on invasive mechanical ventilation or ECMO from Day 1 through Day 29. Estimates for the proportions are estimated from a logistic regression model adjusted for baseline dexamethasone, baseline ordinal score, age (continuous), and baseline CRP.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Time to Sustained Recovery in Participants With a Baseline Ordinal Score of 5 or 6, CRP<150mg/L and Age <85 Years', 'description': 'Day of sustained recovery is defined as the first day on which the participant satisfies 1 of the following 3 categories from the clinical status ordinal scale (and does not return to a score of = 4 up to and including Study Day 60): 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, Continuous Positive Airway Pressure (CPAP), or Bilevel Positive Airway Pressure (BiPAP); 3) Hospitalized, not requiring new or increased supplemental oxygen - no longer requires ongoing medical care.', 'timeFrame': 'Day 1 through Day 60'}, {'measure': 'Time to Sustained Recovery in Participants With Any Baseline Ordinal Score', 'description': 'Day of sustained recovery is defined as the first day on which the participant satisfies 1 of the following 3 categories from the clinical status ordinal scale (and does not return to a score of = 4 up to and including Study Day 60): 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, CPAP, or BiPAP; 3) Hospitalized, not requiring new or increased supplemental oxygen - no longer requires ongoing medical care.', 'timeFrame': 'Day 1 through Day 60'}, {'measure': 'Number of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories on Day 8', 'description': 'The ordinal scale categories are defined as: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, CPAP, or BiPAP; 3) Hospitalized, not requiring new or increased supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased non-invasive ventilation or highflow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death', 'timeFrame': 'Day 8'}, {'measure': 'Change From Baseline in C-Reactive Protein (CRP)', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in D-dimer', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Ferritin', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Fibrinogen', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Higher results are better, so a higher positive change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Alanine Aminotransferase (ALT)', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Aspartate Transaminase (AST)', 'description': 'Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Creatinine', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in International Normalized Ratio (INR)', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Hemoglobin', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Higher results are better, so a higher positive change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Platelets Count', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Higher results are better, so a higher positive change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Total Bilirubin', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in White Blood Cell (WBC) Count', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Higher results are better, so a higher positive change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Neutrophils', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Higher results are better, so a higher positive change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Eosinophils', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Basophils', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Lymphocytes', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Higher results are better, so a higher positive change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Change From Baseline in Monocytes', 'description': 'Blood was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. Lower results are better, so a higher negative change from baseline indicates a more favorable outcome.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 29'}, {'measure': 'Number of Participants Reporting Grade 3, 4, or 5 Clinical and/or Laboratory Adverse Events (AEs)', 'description': 'Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening while Grade 5 AEs are those that are fatal. Laboratory results were considered AEs if they were grade 3 or above according to the thresholds in the Division of AIDS (DAIDS) Table for Grading the Severity of Adverse Events.', 'timeFrame': 'Day 1 through Day 60'}, {'measure': 'Number of Participants Reporting Serious Adverse Events (SAEs)', 'description': 'An SAE is defined as an AE or suspected adverse reaction that is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.', 'timeFrame': 'Day 1 through Day 60'}, {'measure': 'Number of Participants Who Discontinued or Temporarily Suspended Study Treatment', 'description': 'Discontinuation or temporary suspension of study product is defined as any episode of early discontinuation or interruption of study product administration.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Duration of Hospitalization', 'description': 'Duration of hospitalization is defined first as the total number of days hospitalized for COVID-19, including readmissions for COVID-19-related reasons. It is also calculated as the total number of days hospitalized, including any readmissions for any reason.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Days of Invasive Mechanical Ventilation/Extracorporeal Membrane Oxygenation (ECMO) Use', 'description': 'Duration of invasive ventilation/ECMO was measured in days among participants who required invasive ventilation or died.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Days of New Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) Use', 'description': 'Duration of new invasive mechanical ventilation/ECMO use was measured in days among participants not on invasive ventilation/ECMO at baseline who progressed to invasive ventilation/ECMO or died.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Days of Non-invasive Ventilation/High Flow Oxygen Use', 'description': 'Duration of non-invasive ventilation or high flow oxygen use was measured in days among participants who required non-invasive ventilation/high flow oxygen, invasive ventilation/ECMO or died.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Days of New Non-invasive Ventilation/High Flow Oxygen Use', 'description': 'Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants not on non-invasive ventilation/high flow oxygen at baseline who progressed to non-invasive ventilation/high flow oxygen, invasive ventilation/ECMO or died.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Days of Supplemental Oxygen Use', 'description': 'Duration of supplemental oxygen use was measured in days among participants who required any supplemental oxygen, non-invasive ventilation/high flow oxygen, invasive ventilation/ECMO or died.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Number of Participants With New Invasive Mechanical Ventilation / Extracorporeal Membrane Oxygenation (ECMO) Use', 'description': 'New Invasive Mechanical Ventilation / Extracorporeal Membrane Oxygenation (ECMO) Use is defined as participants not on invasive ventilation/ECMO at baseline who progressed to invasive ventilation/ECMO or died during the study.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Number of Participants With New Non-invasive Ventilation/High Flow Oxygen Use', 'description': 'New Non-invasive Ventilation/High Flow Oxygen Use is defined as participants in the hospitalized requiring new or increased supplemental oxygen ordinal scale or below at baseline who progressed to noninvasive ventilation/high flow oxygen, invasive ventilation/ECMO or died during the study.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': 'Mean Change in Ordinal Scale', 'description': 'The ordinal scale categories are defined as: 1) Not hospitalized, no new or increased limitations on activities;2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, CPAP, or BiPAP; 3) Hospitalized, not requiring new or increased supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased non-invasive ventilation or highflow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death. A positive change indicates a worsening and a negative change is an improvement.', 'timeFrame': 'Days 1, 3, 5, 8, 11, 15, 22, 29'}, {'measure': '14-day Participant Mortality', 'description': 'The mortality rate was determined as the proportion of participants who died by study Day 15. The proportions reported are Kaplan-Meier estimates.', 'timeFrame': 'Day 1 through Day 15'}, {'measure': '28-day Participant Mortality', 'description': 'The mortality rate was determined as the proportion of participants who died by study Day 29. The proportions reported are Kaplan-Meier estimates.', 'timeFrame': 'Day 1 through Day 29'}, {'measure': '59-day Participant Mortality', 'description': 'The mortality rate was determined as the proportion of participants who died by study Day 60. The proportions reported are Kaplan-Meier estimates.', 'timeFrame': 'Day 1 through Day 60'}, {'measure': 'Proportion of Participants Not Meeting Criteria for One of Two Ordinal Scale Categories at Day 29', 'description': 'Ordinal scale categories include 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) and 8) Death. Defined as the proportion of participants who were alive and were not hospitalized on invasive mechanical ventilation or ECMO at the Day 29 visit.', 'timeFrame': 'Day 29'}, {'measure': 'Time to an Improvement of One Category From Baseline Using an Ordinal Scale', 'description': 'The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, CPAP, or BiPAP; 3) Hospitalized, not requiring new or increased supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased noninvasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.', 'timeFrame': 'Day 1 through Day 60'}, {'measure': 'Time to an Improvement of Two Categories From Baseline Using an Ordinal Scale', 'description': 'The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, CPAP, or BiPAP; 3) Hospitalized, not requiring new or increased supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased noninvasive ventilation or high-flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.', 'timeFrame': 'Day 1 through Day 60'}, {'measure': 'Time to Death', 'description': 'The time to death from study Day 1 to study Day 29, measured in days. The times reported are Kaplan-Meier estimates.', 'timeFrame': 'Day 1 through Day 29'}]",41.0,18 Years,99 Years,ALL,False,NIH,0.0,527.0,ACTUAL,v2_robust,True,True,False,True,
NCT05272683,Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects,GLPG3667,"['Itraconazole', 'GLPG3667']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Galapagos NV,2025-09-01T16:18:07.029157,True,,,,,"An Open-label, Fixed-sequence, Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of Itraconazole, a Strong CYP3A4 Inhibitor and Potent P-gp Inhibitor on the Pharmacokinetics of GLPG3667",,['Healthy'],[],,2022-02-28,2022-04-22,"[{'measure': 'Maximum observed plasma concentration (Cmax) of GLPG3667', 'description': 'To determine the effect of itraconazole on the pharmacokinetics (PK) of GLPG3667', 'timeFrame': 'From Day 1 pre-dose until Day 12'}, {'measure': 'Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of GLPG3667', 'description': 'To determine the effect of itraconazole on the PK of GLPG3667', 'timeFrame': 'From Day 1 pre-dose until Day 12'}]","[{'measure': 'Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation.', 'description': 'To evaluate the safety and tolerability of GLPG3667 alone or when co-administered with itraconazole', 'timeFrame': 'From Day 1 through study completion, an average of 2 months'}]",3.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,14.0,ACTUAL,v2_robust,True,True,False,True,
NCT04906083,Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia,Avatrombopag,"['transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.', 'Avatrombopag', 'Standard medical treatment']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Liver Failure,Tongji Hospital,2025-09-01T16:18:07.029169,True,,,,,"The Efficacy and Safety of Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia: A Multicenter, Prospective, Randomized Controlled Trial（EAST）",,"['Liver Failure', 'Thrombocytopenia', 'Decompensated Cirrhosis']","['end-stage liver disease', 'thrombocytopenia', 'avatrombopag', 'efficacy', 'safety']",,2021-02-01,2022-12-31,"[{'measure': 'Platelet count response time', 'description': 'Platelet count response time(PLT) refers to condition of PLT during 24 weeks between the Intervention group and Control group.', 'timeFrame': '24 weeks'}]","[{'measure': 'Adverse Event (thrombotic events, bleeding events, etc.) incidence;', 'description': 'Adverse Event refers to the incidence rate of adverse event between the two groups during 24 weeks', 'timeFrame': '24 weeks'}, {'measure': 'Incidence of complications of liver cirrhosis (infection, etc.)', 'description': 'Incidence of complications of liver cirrhosis refers to the incidence rate of complications between the two groups during 24 weeks', 'timeFrame': '24 weeks'}, {'measure': 'Patients without platelet transfusion or rescue due to bleeding', 'description': 'Patients without platelet transfusion or rescue due to bleeding refers to the patients rate without platelet transfusion or rescue due to bleeding between the two groups at 24 week', 'timeFrame': '24 weeks'}, {'measure': 'Proportion of patients readmitted', 'description': 'Proportion of patients readmitted refers to the readmission rate within 24 weeks between the Intervention group and Control group', 'timeFrame': '24 weeks'}, {'measure': 'Changes in total bilirubin level', 'description': 'Changes in total bilirubin level refers to the changes of total bilirubin at 24 week compared to baseline between the Intervention group and Control group.', 'timeFrame': '24 weeks'}, {'measure': 'Changes in alanine aminotransferase level', 'description': 'Changes in alanine aminotransferase level refers to the changes of alanine aminotransferase at 24 week compared to baseline between the Intervention group and Control group.', 'timeFrame': '24 weeks'}, {'measure': 'Changes in albumin level', 'description': 'Changes in albumin level refers to the changes of albumin at 24 week compared to baseline between the Intervention group and Control group.', 'timeFrame': '24 weeks'}, {'measure': 'Changes in prothrombin time level', 'description': 'Changes in prothrombin time level refers to the changes of prothrombin time at 24 week compared to baseline between the Intervention group and Control group.', 'timeFrame': '24 weeks'}, {'measure': 'Changes in international normalized ratio level', 'description': 'Changes in international normalized ratio level refers to the changes of international normalized ratio at 24 week compared to baseline between the Intervention group and Control group.', 'timeFrame': '24 weeks'}]",10.0,18 Years,,ALL,False,OTHER,4.0,150.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05322083,HIV A6 Genome In ART Unsuccessful Patients On DOR,Doravirine,"['DOR', 'Doravirine']",2,OBSERVATIONAL,[],,UNKNOWN,Virus-HIV,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",2025-09-01T16:18:07.029212,True,,,,,Analysis of HIV Subtype A6 Genome in Patients With Virological Failure After Switching to Doravirine (DOR),,['Virus-HIV'],"['HIV, mutation, resistance']",,2022-05,2024-01,"[{'measure': 'HIV viral load', 'description': 'The result of measuring the HIV viral load 8 weeks after the start of DOR-based treatment. The success of therapy will correspond to an undetectable level of viral load (less than 50 RNA copies/ml) or a decrease of two logarithms compared with the values before treatment start. Upon receipt of a detected viral load, treatment will be nevertheless continued up to 24 weeks.', 'timeFrame': 'Week 8'}, {'measure': 'HIV viral load', 'description': 'The result of measuring the HIV viral load 24 weeks after the start of DOR-based treatment. The success of therapy will correspond to an undetectable level of viral load (less than 50 RNA copies/ml). Upon receipt of any detected viral load, the treatment will be considered a failure and the reasons for the failure (lack of adherence, drug interactions, non-compliance with dietary requirements, etc.) will be analyzed. If these causes are excluded, the HIV genotype will be analyzed for the presence of drug resistance mutations (RT genome region).', 'timeFrame': 'Week 24'}]","[{'measure': 'HIV genotype', 'description': 'HIV genotype in patients experienced failure on DOR-based treatment regimen (RT genome region). The study of the genotype will make it possible to understand to which of the components of the therapy regimen the virus has developed resistance and which of the drugs needs to be replaced. If it turns out to be a drug from the basic regimen (not DOR but NRTIs), the regimen will be changed at the discretion of the attending physician (this decision is not within the scope of this project). If DOR resistance mutations are detected such as V106I or Y188L, their frequency will be estimated (the proportion of patients with such mutations ) and the spectrum of associated mutations will be analysed.', 'timeFrame': 'Week 24'}]",3.0,18 Years,,ALL,,OTHER,1.0,60.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01641783,Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients,nanoparticle Albumin-Bound paclitaxel,"['ABI-007', 'nanoparticle Albumin-Bound paclitaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Gastric Adenocarcinoma,Yanqiao Zhang,2025-09-01T16:18:07.029246,True,,,,,To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial,,['Gastric Adenocarcinoma'],"['advanced', 'paclitaxel', 'capecitabine', 'first line therapy']",,2012-07,2013-12,"[{'measure': 'progression free survival', 'description': 'the follow-up visit of PFS will be performed every 6 weeks', 'timeFrame': '1 year'}]","[{'measure': 'objective response rate', 'description': 'CT/MRI/Ultrasound will be performed every 2 cycles of treatment for efficacy evaluation', 'timeFrame': '6 weeks'}, {'measure': 'overall survival of participants', 'description': 'OS means that from the first dose of treatment drug to death or lost,the follow-up visit will be performed every 3 months till death or lost', 'timeFrame': '2 years'}, {'measure': 'biomarkers', 'description': 'To identify the molecular biomarkers(such as SPARK,β-Tubulin III,caveolin,etc)by immunohistochemical and western-bloting before and during therapy,to study the biomarkers correlations with clinical outcome and toxicity.', 'timeFrame': '6 weeks'}]",4.0,18 Years,75 Years,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00046683,"Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia",alemtuzumab,['alemtuzumab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,B Cell Chronic Lymphocytic Leukemia,"Genzyme, a Sanofi Company",2025-09-01T16:18:07.029263,True,,,,,"A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia",,['B Cell Chronic Lymphocytic Leukemia'],"['Adult acute leukemia', 'Adult chronic leukemia', 'Childhood leukemia', 'Campath', 'Alemtuzumab']",,2001-07,2006-06,[{'measure': 'Campath vs. chlorambucil'}],[{'measure': 'survival comparison'}],2.0,18 Years,,ALL,False,INDUSTRY,0.0,284.0,,v2_robust,True,True,False,False,
NCT02584283,Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation,Glutathione,['Glutathione'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Liver Failure,Robert J. Porte,2025-09-01T16:18:07.029332,True,,,,,A Multicenter Randomized Controlled Trial to Compare the Efficacy of End-ischemic Dual Hypothermic Oxygenated Perfusion With Standard Static Cold Storage of Liver Grafts Donated After Circulatory Death in Preventing Biliary Complications,,"['Liver Failure', 'End Stage Liver Disease', 'Biliary Tract Diseases']","['Liver Transplantation', 'Donation after Circulatory Death', 'Machine Perfusion']",,2016-01,2020-01,"[{'measure': 'The incidence of symptomatic non-anastomotic biliary strictures (NAS)', 'description': 'NAS is defined as all of the following criteria:\n\n* any irregularities or narrowing of the lumen of the intra- or extrahepatic donor bile ducts, but not at the anastomosis\n* which are diagnosed by cholangiogram (preferably by MRCP)\n* in the presence of a patent hepatic artery demonstrated by Doppler ultrasonography and if necessary, by computed tomography angiography\n* and as assessed by the Adjudication Committee\n* when imaging is indicated by clinical signs (i.e., jaundice, cholangitis) or elevation of cholestatic laboratory parameters in blood samples taken during follow-up', 'timeFrame': '6 months'}]","[{'measure': 'Asymptomatic NAS', 'description': 'Asymptomatic NAS is defined as all of the following:\n\n* irregularities or narrowing of the lumen of the intra- or extrahepatic donor bile ducts, but not at the anastomosis\n* which are diagnosed by cholangiogram (preferably by MRCP)\n* in the presence of a patent hepatic artery demonstrated by Doppler ultrasonography and if necessary, by computed tomography angiography\n* in the absence of clinical signs (i.e., jaundice, cholangitis) or elevation of cholestatic laboratory parameters in blood samples taken during follow-up', 'timeFrame': '6 months'}, {'measure': 'The severity of NAS', 'description': 'Severity and location of NAS is based on assessment of the images of the MRCP obtained in all patients at six months after transplantation (time window of 15 days) which will be performed based on a scoring system described by Buis et. al. And required treatment for NAS (i.e. ursodeoxycholic acid, ERCP, retransplantation)', 'timeFrame': '6 months'}, {'measure': 'The location of NAS', 'description': 'Assessment of the images of the MRCP obtained in all patients at six months after transplantation (time window of 15 days) which will be performed based on a scoring system described by Buis et. al.', 'timeFrame': '6 months'}, {'measure': 'Graft (censored and uncensored for patient death) survival', 'timeFrame': '7 days, 1, 3 , 6, and 12 months after transplantation'}, {'measure': 'Patient survival', 'timeFrame': '7 days, 1, 3 , 6, and 12 months after transplantation'}, {'measure': 'Primary non-function', 'description': 'Defined as liver failure requiring retransplantation or leading to death within seven days after transplantation without any identifiable cause such as surgical problems, hepatic artery thrombosis, portal vein thrombosis and acute rejection', 'timeFrame': '7 days'}, {'measure': 'Initial poor function', 'description': 'Defined as a modification of the Olthoff criteria: Prothrombin time/ international normalized ratio (INR) \\>1.6 and or serum total bilirubin \\>10 mg/dL on postoperative day 7', 'timeFrame': '7 days'}, {'measure': 'Biochemical analysis of graft function and ischemia-reperfusion injury', 'description': 'serum levels of alanine aminotransferase (ALT), AST, alkaline phosphatase (AlkP), gamma-glutamyl transferase (γGT), and total bilirubin', 'timeFrame': 'Postoperative day 0 - 7 and 1, 3, 6 months'}, {'measure': 'Blood pressure', 'description': 'mm Hg', 'timeFrame': '5 min before reperfusion, at reperfusion and after 10 and 20 minutes of reperfusion'}, {'measure': 'Heart rate', 'description': 'beats per minute', 'timeFrame': '5 min before reperfusion, at reperfusion and after 10 and 20 minutes of reperfusion'}, {'measure': 'Vasopressor dosage', 'description': 'microgram/kg/min', 'timeFrame': '5 min before reperfusion, at reperfusion and after 10 and 20 minutes of reperfusion'}, {'measure': 'Length of stay', 'description': 'Length of initial ICU and initial hospital stay is determined in days of admission following liver transplantation. Duration of follow-up hospital stay is determined in days of hospital admission after discharge and up to six months after liver transplantation', 'timeFrame': '6 months'}, {'measure': 'Postoperative complications', 'description': 'According to the comprehensive complication index (CCI)', 'timeFrame': '6 months'}, {'measure': 'Renal function', 'description': 'Estimated glomerular filtration rate (eGFR) according to the 4-variable Modification of Diet in Renal Disease (MDRD) equation', 'timeFrame': 'day 7, and 1, 3, 6 months'}, {'measure': 'Flow', 'description': 'ml/min', 'timeFrame': 'At 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes after start of perfusion'}, {'measure': 'Pressure', 'description': 'mm Hg', 'timeFrame': 'At 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes after start of perfusion'}, {'measure': 'Resistance', 'description': 'ml/min/mm Hg', 'timeFrame': 'At 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's pH"", 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's sodium"", 'description': 'mmol/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's potassium"", 'description': 'mmol/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's bicarbonate"", 'description': 'mmol/l', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's lactate"", 'description': 'mmol/l', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's alanine transaminase (ALT)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's aspartate transaminase (AST)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's alkaline phosphatase (AlkP)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's gamma glutamyltransferase (γGT)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's urea"", 'description': 'mmol/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's total bilirubin"", 'description': 'umol/l', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's thrombomodulin"", 'description': 'pg/dl', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's high mobility group box-1 (HMBG) protein"", 'description': 'μg/mL', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's cytochrome C"", 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA CDmiR-30e in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA CDmiR-222 in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA CDmiR-296 in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA HDmiR-122 in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA HDmiR-148a in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': 'Histopathological status liver and bile ducts (in selected centers)', 'timeFrame': 'Within 0 to 30 minutes before perfusion, at 2 hours of perfusion, and at 1 hour after reperfusion'}, {'measure': 'New onset diabetes after transplantation', 'description': '* Symptoms of diabetes and random plasma glucose ≥11.1 mmol/L. Symptoms include polyuria, polydipsia, and unexplained weight loss. OR\n* Fasting plasma glucose ≥7.0 mmol/L. Fasting is defined as no caloric intake for at least eight hours. OR\n* Two-hour plasma glucose ≥11.1 mmol/L during an oral glucose tolerance test. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.', 'timeFrame': '90 days'}, {'measure': 'Costs of treatment (in selected centers)', 'description': 'according to the Cost and Outcome analysis of Liver Transplantation (COLT) study', 'timeFrame': 'within 6 months after transplantation, including transplant operation'}, {'measure': 'Health related quality of life', 'description': 'EQ6D questionnaire', 'timeFrame': 'within 6 months before transplantation and 6 months after transplantation'}]",41.0,18 Years,100 Years,ALL,False,OTHER,5.0,157.0,ACTUAL,v2_robust,True,True,False,False,
NCT06079983,"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects",JSKN003,"['Capecitabine tablets', 'Eribulin mesylate injection', 'Vinorelbine tartrate injection', 'Docetaxel injection', 'Paclitaxel for injection (albumin-bound type)', 'JSKN003', 'Gemcitabine hydrochloride for injection']",7,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Breast Cancer,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",2025-09-01T16:18:07.029436,True,,,,,"A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects",,['Breast Cancer'],[],,2023-12-01,2029-03-01,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS evaluated by BICR according to RECIST v1.1 criteria is defined as the time from randomization to the first recorded disease progression or death from any cause as a result of BICR evaluation according to RECIST v1.1 criteria.', 'timeFrame': '16 months 、26 months after the first enrollment'}]","[{'measure': 'Overall survival（OS）', 'description': 'OS, defined as the time from randomization to death from any cause;', 'timeFrame': '16 months 、26months 、60 months after the first enrollment'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'BICR and investigators were judged according to RECIST v1.1 criteria ，objective response rate (ORR), defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RECIST v1.1 criteria;', 'timeFrame': '16 months 、26 months after the first enrollment'}, {'measure': 'Duration of Response (DOR)', 'description': 'BICR and investigators were judged according to RECIST v1.1 criteria，Duration of response (DoR), defined as the time from the first recorded response (CR/PR) to the first documented disease progression (PD) or death from any cause;', 'timeFrame': '16 months 、26 months after the first enrollment'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,400.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02040883,Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia,Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole,"['Tandospirone', 'Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole', 'Sediel', 'AAPD']",4,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Schizophrenia,Qingyun Yin,2025-09-01T16:18:07.029544,True,,,,,Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia,,['Schizophrenia'],"['Schizophrenia', 'Tandospirone', 'Cognitive Therapy']",,2014-02,2014-12,"[{'measure': 'Measurement and treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery(MCCB) total score', 'timeFrame': 'From baseline to 12 weeks of treatment'}]","[{'measure': 'MATRICS Consensus Cognitive Battery(MCCB) factor score', 'timeFrame': 'From baseline to 12 weeks of treatment'}, {'measure': 'Positive and Negative Syndrome Scale(PANSS) total score', 'timeFrame': 'From baseline to 12 weeks of treatment'}, {'measure': 'Positive and Negative Syndrome Scale(PANSS) factor score', 'timeFrame': 'From baseline to 12 weeks of treatment'}, {'measure': 'Personal and Social Performance Scale(PSP) total score', 'timeFrame': 'From baseline to 12 weeks of treatment'}, {'measure': 'Clinical Global Impression(CGI) factor score', 'timeFrame': 'From baseline to 12 weeks of treatment'}, {'measure': 'Treatment Emergent Symptom Scale(TESS) factor score', 'timeFrame': 'From baseline to 12 weeks of treatment'}, {'measure': 'Functional magnetic resonance imaging(FMRI)', 'timeFrame': 'From baseline to 12 weeks of treatment'}]",8.0,18 Years,65 Years,ALL,False,OTHER_GOV,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03288441,Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia,Hold,"['Change antithrombotic Drug', 'Hold', 'Full dose antithrombotics', 'Intermediate dose antithrombotic', 'Prophylactic dose antithrombotic']",5,OBSERVATIONAL,[],,UNKNOWN,Hematologic Neoplasms,Maastricht University Medical Center,2025-09-01T16:18:07.029607,True,,,,,Management Patterns of AntiThrombotics and Outcomes in Patients With Hematological Malignancy and ThrombocytopEnia: a Prospective Registry (MATTER Study),,"['Hematologic Neoplasms', 'Thrombocytopenia', 'Anticoagulants', 'Platelet Aggregation Inhibitors']","['Hematologic Neoplasms', 'Thrombocytopenia', 'Anticoagulants', 'Platelet Aggregation Inhibitors']",,2018-03-20,2021-12-31,"[{'measure': 'Composite of major bleeding or thrombosis', 'description': '1\\) ISTH-defined Major bleeding events defined as: Fatal bleeding; bleeding into a critical organ; clinically overt bleeding associated with a decrease in hemoglobin level of more than 2 g/dL or leading to the transfusion of two or more units of blood OR: 2) Thrombosis defined as: Any symptomatic deep or superficial venous or arterial thromboembolism demonstrated on objective imaging/laboratory tests. Ischemic strokes with no immediate imaging signs will also be considered events, provided this was diagnosed by a neurologist and that the patient had objective neurological signs.', 'timeFrame': '30 days (from study index) or until death (whichever first)'}]","[{'measure': 'Platelet transfusion related adverse effects', 'description': 'Number of adverse effects (all types and individually grouped) related to platelet/plasma transfusion, occurring within 24 hours of transfusion', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Clinically Relevant non-Major Bleeding', 'description': 'Defined according to the ISTH criteria published in the journal of thrombosis and Hemostasis by Kaatz et al in 2015', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Number of platelet tranfusions', 'description': 'Number of platelet transfusions', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Number of RBC tranfusions', 'description': 'Number of red blood cell transfusions', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Death', 'description': 'death from any cause', 'timeFrame': '30 days (from study index)'}, {'measure': 'Change in antithrombotic management', 'description': 'Change in dose/type of antiplatelet or anticoagulant medication OR change in platelet threshold, AFTER the initial intervention which was recorded at study index.', 'timeFrame': '30 days (from study index) or until death (whichever first)'}]",7.0,18 Years,,ALL,False,OTHER,0.0,300.0,ESTIMATED,v2_robust,False,False,False,True,
NCT01231841,Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia,cyclosporine,"['cyclosporin', 'ciclosporin', '27-400', 'cyclosporine', 'Sandimmune', 'CYSP', 'cyclosporin A']",7,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Aplastic Anemia,The Cleveland Clinic,2025-09-01T16:18:07.029653,True,,,,,Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA),,['Aplastic Anemia'],[],,2005-03,2010-12,"[{'measure': 'Patients Treated With Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) Achieving at Least a Partial Remission (PR) at 6 Months', 'description': 'Patients will be classified as responders if they have transfusion independence and meet two of the following three criteria: ANC greater than 500/mm3; platelet count greater than 20,000/mm3; and reticulocyte count greater than 40,000/mm3. Transfusion independence is defined as no need for transfusions for one month prior to response assessment.', 'timeFrame': 'At 6 months'}]",[],1.0,12 Years,,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT04669041,A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy,Rosuvastatin,"['Rosuvastatin active capsule', 'SPC ezetimibe/rosuvastatin', 'Placebo', 'Rosuvastatin', 'Crestor®']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hypercholesterolemia,Sanofi,2025-09-01T16:18:07.029688,True,,,,,"A Randomized Double-blinded, Double Dummy, Active-controlled, Parallel Design, Phase 3 Clinical Trial to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia, Not Adequately Controlled on Statin Therapy",,['Hypercholesterolemia'],[],,2020-12-08,2022-06-15,"[{'measure': 'Percent change in measured LDL-C from baseline (the last available measured LDL-C value obtained up to randomization) to Week 8', 'description': 'The percent change from baseline in measured LDL-C at Week 8 will be analyzed in the modified intent-to-treat (mITT) population using a mixed effect model with repeated measures (MMRM) approach.', 'timeFrame': 'Baseline to Week 8'}]","[{'measure': 'Proportion of patients who attain lipid goal (measured LDL-C <2.6 mmol/L [100 mg/dL]) at Week 8', 'timeFrame': 'Week 8'}, {'measure': 'Percent change in measured LDL-C plasma level from baseline to Week 4', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Percent change in total cholesterol (TC) from baseline to Week 8', 'timeFrame': 'Baseline to Week 8'}, {'measure': 'Percent change in TC from baseline to Week 4', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Percent change in triglyceride (TG) serum levels from baseline to Week 8', 'timeFrame': 'Baseline to Week 8'}, {'measure': 'Percent change in TG serum levels from baseline to Week 4', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Percent change in high density lipoprotein cholesterol (HDL-C) from baseline to Week 8', 'timeFrame': 'Baseline to Week 8'}, {'measure': 'Percent change in HDL-C from baseline to Week 4', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Number of patients with adverse events (AEs)', 'timeFrame': 'Up to 16 weeks (±3 days)'}]",10.0,18 Years,,ALL,False,INDUSTRY,0.0,305.0,ACTUAL,v2_robust,True,True,False,True,
NCT00406341,Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation,Difluprednate Ophthalmic Emulsion,['Difluprednate Ophthalmic Emulsion'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Inflammation,"Sirion Therapeutics, Inc.",2025-09-01T16:18:07.029710,True,,,,,Phase 3 Confimatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treament of Postoperative Inflammation,,['Inflammation'],[],,2004-04,2005-03,[{'measure': 'The changes in anterior chamber cell score at day 14 after start of instillation from the baseline level (differences from the baseline score) were compared between the 2 treatment groups.'}],"[{'measure': 'The changes in anterior chamber cell score at days 3 and 7 after start of instillation were compared between the 2 treatment groups.'}, {'measure': 'The numbers of patients showing an anterior chamber cell score of ""0"" at days 3, 7 and 14 after start of instillation were compared between the 2 treatment groups.'}, {'measure': 'The changes in anterior chamber flare score at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.'}, {'measure': 'The changes in the total scores of subjective symptoms and objective signs at days 3, 7 and 14 after start of instillation (difference from the baseline score) were compared between the 2 treatment groups.'}]",5.0,20 Years,,ALL,False,INDUSTRY,0.0,200.0,,v2_robust,True,True,False,False,
NCT00869141,Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma,"glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)","['glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)', 'Timolol, Brimonidine, Dorzolamide, Brinzolamide']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Glaucoma,"University of California, Los Angeles",2025-09-01T16:18:07.029723,True,,,,,Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma,,['Glaucoma'],['Glaucoma tube shunt procedure'],,2009-03,2013-03,"[{'measure': 'Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma', 'description': 'Intraocular pressure more than 21 mmHg during the first 6 months after Ahmed valve implantation after the pressure has been reduced to less than 22 mmHg in the first postoperative week', 'timeFrame': 'within 6 months after surgery'}, {'measure': 'Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma', 'description': 'intraocular pressure comparison between groups after the Ahmed valve implantation', 'timeFrame': '3 weeks after surgery'}, {'measure': 'Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase', 'description': 'intraocular pressure of eyes with hypertensive phase versus without hypertensive phase', 'timeFrame': '1 year after surgery'}]",[],3.0,18 Years,85 Years,ALL,False,OTHER,0.0,52.0,ACTUAL,v2_robust,True,True,False,False,
NCT05688241,EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases,Donor-derived ex-vivo expanded EBV Tscm CTL,['Donor-derived ex-vivo expanded EBV Tscm CTL'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,NOT_YET_RECRUITING,EBV Lymphoma,"University Hospital, Basel, Switzerland",2025-09-01T16:18:07.029753,True,,,,,Epstein-Barr Virus (EBV) -Specific T Memory Stem Cell (Tscm) Therapy to Treat EBV- Driven Lymphomas/ Diseases,,"['EBV Lymphoma', 'Post-transplant Lymphoproliferative Disease (PTLD)']","['EBV-driven Lymphomas', 'EBV disease', 'Epstein-Barr Virus (EBV)', 'Memory Stem Cell Therapy', 'Epstein-Barr Virus-specific T Memory Stem Cell Therapy (EBV-Tscm)', 'cytotoxic T-cell line (CTL)', 'T memory stem cells (Tscm)', 'T-cell receptor (TCR)', 'post-transplant lymphoproliferative disease (PTLD)', 'Wnt-β-catenin inhibition', 'hematopoietic cell transplantation (HCT)', 'Hematopoietic stem cell transplantation (HSCT)']",,2026-11,2031-12,"[{'measure': 'Assessment of feasibility to expand Tscm-enriched EBV CTLs', 'description': 'Feasibility is defined as meeting the release criteria of EBV Tscm-CTL endproduct.\n\nRelease criteria for the EBV Tscm-CTL follow Swissmedic Investigational Medicinal Product Dossier (IMPD). This includes viability of cluster of differentiation 3 (CD3)+ \\>70%, absolute CD3 count per kg of body weight per dose (≤2x10e6/kg), and a purity of CD3+ \\>90%. These criteria will be assessed before cryopreservation. A negative culture for bacteria and fungi for at least 7 days, endotoxin testing ≤5 EU/ml and negative result for Mycoplasma is required.', 'timeFrame': 'one time assessment on day 9-11 of expansion before cryopreservation (plus at least 7 days for microbiological culture)'}, {'measure': 'Safety of EBV Tscm-CTL infusion assessed by number of early infusion-related events', 'description': 'Number of early infusion-related events (early infusion-related events are clinically significant alterations of vital signs)', 'timeFrame': 'up to 12 hours after first dose of EBV Tscm-CTL infusion'}, {'measure': 'Safety of EBV Tscm-CTL infusion assessed by number of late clinical reaction to EBV Tscm-CTLs', 'description': 'Late clinical reaction to EBV Tscm-CTLs are signs of acute graft-versus-host disease (GvHD). Acute GVHD will be graded according to the modified Glucksberg criteria.', 'timeFrame': 'from 12 hours after first dose until 3 months after the last dose of EBV CTLs'}]",[],3.0,,,ALL,False,OTHER,0.0,10.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00667641,Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors,bortezomib,"['bortezomib', 'paclitaxel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Breast Cancer,University of Medicine and Dentistry of New Jersey,2025-09-01T16:18:07.030016,True,,,,,Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway,,"['Breast Cancer', 'Colorectal Cancer', 'Head and Neck Cancer', 'Lung Cancer', 'Melanoma (Skin)', 'Ovarian Cancer', 'Pancreatic Cancer', 'Prostate Cancer', 'Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific', 'recurrent breast cancer', 'stage IV breast cancer', 'recurrent prostate cancer', 'stage IV prostate cancer', 'recurrent colon cancer', 'stage IV colon cancer', 'recurrent pancreatic cancer', 'stage IV pancreatic cancer', 'recurrent ovarian epithelial cancer', 'stage IV ovarian epithelial cancer', 'recurrent ovarian germ cell tumor', 'stage IV ovarian germ cell tumor', 'recurrent non-small cell lung cancer', 'stage IV non-small cell lung cancer', 'recurrent melanoma', 'stage IV melanoma', 'stage IV papillary thyroid cancer', 'recurrent thyroid cancer']",,2007-03,2009-02,"[{'measure': 'Maximum tolerated dose of paclitaxel in combination with bortezomib', 'timeFrame': '2 years'}]",[],1.0,18 Years,,ALL,False,OTHER,1.0,16.0,ACTUAL,v2_robust,True,True,False,False,
NCT02802241,Effects of Open-label vs Double-blind Treatment in IBS,placebo,['placebo'],1,INTERVENTIONAL,['NA'],,COMPLETED,Irritable Bowel Syndrome,Beth Israel Deaconess Medical Center,2025-09-01T16:18:07.030023,True,,,,,Effects of Open-label vs Double-blind Treatment in IBS.,,"['Irritable Bowel Syndrome', 'Placebo Effect', 'Placebos', 'Peppermint Oil']",[],,2016-06,2019-01,"[{'measure': 'Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks.', 'description': 'Score ranges from 0-500, 0 indicates no symptoms, 500 indicates worst possible symptoms', 'timeFrame': '6 weeks'}]",[],1.0,18 Years,,ALL,False,OTHER,1.0,340.0,ACTUAL,v2_robust,True,True,False,False,
NCT03778541,HFSRT With Concurrent TMZ for Large BMs,Temozolomide,['Temozolomide'],1,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Brain Metastases,Chinese Academy of Medical Sciences,2025-09-01T16:18:07.030031,True,,,,,Hypofractionated Radiotherapy With Concurrent Temozolomide for Large Brain Metastases: a Multi-center Randomized Phase III Trial,,"['Brain Metastases', 'Chemotherapy', 'Radiotherapy']",[],,2018-12-03,2022-12-03,"[{'measure': 'intracranial progression free survival (IPFS) rate', 'description': 'IPFS was defined as the interval from the beginning of radiation to any intracranial progression', 'timeFrame': 'up to 2 years'}]","[{'measure': 'local control rate', 'description': 'the control rate of treated lesions', 'timeFrame': 'up to 2 years'}, {'measure': 'Brain metastasis-specific survival (BMSS) rate', 'description': 'BMSS was defined as the internal from the beginning of RT to death caused by BM', 'timeFrame': 'up to 2 years'}, {'measure': 'overall survival (OS) rate', 'description': 'OS was defined as the internal from the beginning of RT to death caused by any reason', 'timeFrame': 'up to 2 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 and NRG/RTOG CNS toxicities criteria', 'description': 'the toxicities caused by RT and (or) Chemotherapy', 'timeFrame': 'acute toxicities: up to 3 months after RT; Late toxicities: up to 2 years after RT'}]",5.0,18 Years,75 Years,ALL,False,OTHER,0.0,224.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03723941,Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma,Cisplatin plus Etoposide,"['Adjuvant Chemotherapy', 'Cisplatin plus Etoposide']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Adrenocortical Carcinoma,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,2025-09-01T16:18:07.030062,True,,,,,Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence,,['Adrenocortical Carcinoma'],"['Adrenocortical Carcinoma', 'Adjuvant Chemotherapy']",,2018-07-20,2024-05-30,"[{'measure': 'Comparison of the recurrence-free survival (RFS) status in patientis treated with adiuvant chemotherapy with or without mitotane (arm A) versus no treatment or adjuvant mitotane (arm B).', 'description': 'Evaluation of recurrence-free survival (RFS). Recurrence will be objectively assessed every 16 weeks by imaging the chest/abdomen/pelvis by either computed tomography (CT; with slice thickness of 5 mm or less) or magnetic resonance imaging (MRI). Suspected lesions will be accurately measured in at least one dimension (the longest diameter in the plane of measurement will be recorded). Soft tissue lesions must have a minimum size of 10 mm, and suspected malignant lymph nodes must be more than 15 mm (short axis) to be considered pathological.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months'}]","[{'measure': 'Assessment of overal survival', 'description': 'defined as the time interval between the date of randomization and the date of death from any cause.', 'timeFrame': 'From date of randomization until the date of death from any cause, assessed up to 36 months'}, {'measure': 'Assessment of toxicity and adverse events', 'description': 'Toxicity and adverse events will be graded according to the NCI-CTCAE (version 4.03).', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months'}, {'measure': 'Assessment of the predictive role of Ki67 expression for chemotherapy efficacy', 'description': 'Histological evaluation of KI67 expression on basal tumor tissue sections and correlation to chemotherapy efficacy', 'timeFrame': 'Ki67 expression evaluated at the screening phase'}, {'measure': 'Assessment of the predictive role of histopathologic characteristics (Weiss-score) for chemotherapy efficacy', 'description': 'Weiss score will be identified on basal tumor tissue resection based on the original Weiss criteria for malignancy (Am J Surg Pathol 1984;8:163), and will be correlated to chemotherapy efficacy. The Weiss scoring system is based on the recognition at light microscopy of nine morphological parameters: three of them are related to tumor structure, namely presence of eosinophilic (""dark"") cytoplasm in more than 75% of tumor cells, of a ""patternless"" diffuse architecture, and of necrosis; three others are related to cytological features, namely presence of nuclear atypia, of mitotic index above 5 per 50 high-power fields, and of atypical mitoses; the remaining three are related to invasive tumor properties, including sinusoidal, venous, and capsular invasion. A diagnosis of malignancy is achieved if at least three parameters are identified out of 9 (scale from 0 to 9).', 'timeFrame': 'Weiss score identified at the screening phase'}]",5.0,18 Years,,ALL,False,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,True,
NCT02942654,A Study of LY900014 Formulation in Healthy Participants,LY900014,"['Ultra-Rapid Lispro', 'LY900014', 'Insulin Lispro']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Eli Lilly and Company,2025-09-01T16:18:07.030080,True,,,,,Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro Following Single-Dose Administration in Healthy Subjects,,['Healthy'],[],,2016-11,2016-12,"[{'measure': 'Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 8 Hours (AUC[0-8 Hours])', 'description': 'Area Under the Concentration Versus Time Curve (AUC) was measured from time zero to 8 hours (AUC\\[0-8 Hours\\]).', 'timeFrame': 'Predose (0), 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 90, 120, 150, 180, 210, 240, 300, 330, 360, 420, and 480 minutes, post dose'}]","[{'measure': 'Glucodynamics (GD): Total Amount of Glucose Infused (Gtot)', 'description': 'Gtot is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY900014 or Insulin Lispro by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.', 'timeFrame': '2.5 minutes for the first 30 minutes, then every 5 minutes until 120 minutes postdose, and then every 10 minutes until 480 minutes postdose'}]",2.0,21 Years,70 Years,ALL,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT01616654,Dose Range Study of CD5789 in Acne Vulgaris,CD5789 25 µg/g cream,"['CD5789 50 µg/g cream', 'Tazarotene 0.1% gel', 'CD5789 100 µg/g cream', 'CD5789 25 µg/g cream', 'Vehicle cream']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acne Vulgaris,Galderma R&D,2025-09-01T16:18:07.030109,True,,,,,"A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris",,['Acne Vulgaris'],[],,2012-06-20,2014-06-12,"[{'measure': 'Percentage of Participants With Success Rate 1 (SR1)', 'description': 'Success Rate 1 was defined as percentage of participants who achieved at least a two-point reduction in the Investigator Global Assessment (IGA) scale from baseline at week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by last observation carried forward (LOCF).', 'timeFrame': 'From Baseline at Week 12'}, {'measure': 'Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Percentage of Participants With Success Rate 2 (SR2)', 'description': 'Success Rate 2 (SR2) was defined as the percentage of participants rated ""Clear"" (Grade 0) or ""Almost clear"" (Grade 1) with at least a two-point reduction on the IGA scale from Baseline to Week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by LOCF.', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Absolute Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percentage Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF. Percent changes in lesion counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100.', 'timeFrame': 'Baseline, Week 12'}]",6.0,12 Years,35 Years,ALL,False,INDUSTRY,0.0,304.0,ACTUAL,v2_robust,True,True,False,False,
NCT05549154,A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation,High-dose vitamin D2 softgels,"['High-dose vitamin D2 softgels', 'low-dose vitamin D2 softgels', 'placebo']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Chronic Kidney Disease 5D,First Affiliated Hospital Xi'an Jiaotong University,2025-09-01T16:18:07.030161,True,,,,,A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation,,"['Chronic Kidney Disease 5D', 'Secondary Hyperparathyroidism Due to Renal Causes', 'Vitamin D Deficiency']",[],,2022-12-05,2023-10-30,"[{'measure': 'Differences in changes in PTH levels from baseline to 6 months of intervention', 'timeFrame': 'baseline，at 6 months intervention'}]","[{'measure': 'Differences in changes in PTH levels from baseline to intervention at 1months、2months、3months、4months、5months', 'timeFrame': 'baseline，at 1，2，3，4，5 months intervention'}, {'measure': 'Proportion of 25(OH)D >30ng/ml at 3 months of intervention', 'timeFrame': 'at 3 months intervention'}, {'measure': 'Trends in changes in 25(OH)D levels from baseline to intervention at 1months、2months、3months、4months、5months、6months', 'timeFrame': 'baseline，at 1，2，3，4，5，6 months intervention'}, {'measure': 'Incidence of cardiovascular events after 6 months of intervention', 'timeFrame': 'baseline，at 6 months intervention'}, {'measure': 'Change in prevalence of vascular calcification at 6 months of intervention', 'description': 'We used cardiac ultrasound and lateral abdominal views to look for vascular calcification', 'timeFrame': 'baseline，at 6 months intervention'}, {'measure': 'Change in Montreal Cognitive Assessment Scale scores at 6 months of intervention', 'description': 'A total score of 30 on this scale, with a score of ≥26 indicating normal; a score of \\<26 indicates the presence of cognitive impairment: 18-26 for mild cognitive impairment, 10-17 for moderate cognitive impairment and \\<10 for severe cognitive impairment', 'timeFrame': 'baseline，at 6 months intervention'}, {'measure': 'Trends in blood calcium levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention', 'timeFrame': 'baseline，at 1，2，3，4，5，6 months intervention'}, {'measure': 'Trends in blood phosphorus levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention', 'timeFrame': 'baseline，at 1，2，3，4，5，6 months intervention'}, {'measure': 'Trends in FGF23 levels at 3 and 6 months of intervention', 'timeFrame': 'baseline，at 3，6 months intervention'}, {'measure': 'Trends in Osteocalcin(OC) levels at 3 and 6 months of intervention', 'timeFrame': 'baseline，at 3，6 months intervention'}, {'measure': 'Trends in Precollagen type I amino-terminal peptide(PINP) levels at 3 and 6 months of intervention', 'timeFrame': 'baseline，at 3，6 months intervention'}, {'measure': 'Trends in β specific collagen degradation products(β-CTX) levels at 3 and 6 months of intervention', 'timeFrame': 'baseline，at 3，6 months intervention'}, {'measure': 'Trends in ALP levels at 3 and 6 months of intervention', 'timeFrame': 'baseline，at 3，6 months intervention'}, {'measure': 'Incidence of fractures at 6 months of intervention', 'description': 'Ask if the patient had a fracture during the intervention, the site of the fracture and the type of fracture', 'timeFrame': 'baseline，at 6 months intervention'}, {'measure': 'Incidence of falls at 6 months of intervention', 'description': 'Ask if the patient has fallen during the intervention, the number of falls and the reasons for them', 'timeFrame': 'baseline，at 6 months intervention'}]",16.0,18 Years,90 Years,ALL,False,OTHER,0.0,372.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01918254,A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein,Paclitaxel,"['Paclitaxel', 'Lumretuzumab', 'Perjeta', 'RO5479599; RG7116', 'Pertuzumab']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Breast Cancer,Hoffmann-La Roche,2025-09-01T16:18:07.030346,True,,,,,"Phase IB, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered in Combination With Pertuzumab and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein",,['Breast Cancer'],[],,2013-08-06,2016-10-07,"[{'measure': 'Percentage of Participants With Dose-Limiting Toxicities (DLTs)', 'timeFrame': 'Day 1 up to Day 21'}, {'measure': 'Percentage of Participants With Adverse Events', 'timeFrame': 'Baseline up to approximately 39 months'}, {'measure': 'Percentage of Participants With Anti-Human Antibodies (HAHAs) to lumretuzumab [RO5479599]', 'timeFrame': 'Pre-infusion (Pr-I) (0 hour [h]) on Day 1 (D1) of each Cycle (Cy) up to approximately 39 months (assessed at Pr-I on D1 of each treatment Cy up to 28 and 42-45 days after last infusion [up to approximately 39 months overall]) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 Hr) & 3, 24, 72, 168, 264, 312, 432, & 480 Hr post D1 infusion (infusion duration = 1.5-2 hours) of Cy4, 8 & post D2 infusion of Cy1; D1 of all other cycles up to 28 and 42-45 days after last dose (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Maximum Serum Concentration (Cmax) of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 Hr) & 3, 24, 72, 168, 264, 312, 432, & 480 Hr post D1 infusion (infusion duration = 1.5-2 hours) of Cy4, 8 & post D2 infusion of Cy1; D1 of all other cycles up to 28 and 42-45 days after last dose (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Trough Serum Concentration (Ct) of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 h) on D1 of each cycles beginning from Cy 2 up to 28 and 42-45 days after last infusion (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Time to Reach Maximum Serum Concentration (tmax) of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 h) & 3, 24, 72, 168, 264, 312, 432, & 480 Hr post D1 infusion (infusion duration = 1.5-2 h) of Cy4, 8 & post D2 infusion of Cy1; D1 of all other cycles up to 28 and 42-45 days after last dose (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Clearance (CL) of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 h) & 3, 24, 72, 168, 264, 312, 432, & 480 h post D1 infusion (infusion duration = 1.5-2 h) of Cy4, 8 & post D2 infusion of Cy1; D1 of all other cycles up to 28 and 42-45 days after last dose (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Volume of distribution (V) of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 h) & 3, 24, 72, 168, 264, 312, 432, & 480 h post D1 infusion (infusion duration = 1.5-2 h) of Cy4, 8 & post D2 infusion of Cy1; D1 of all other cycles up to 28 and 42-45 days after last dose (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Accumulation Ratio of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 h) & 3, 24, 72, 168, 264, 312, 432, & 480 h post D1 infusion (infusion duration = 1.5-2 h) of Cy4, 8 & post D2 infusion of Cy1; D1 of all other cycles up to 28 and 42-45 days after last dose (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Elimination Half-Life (t1/2) of lumretuzumab [RO5479599]', 'timeFrame': 'Pr-I (0 h) & 3, 24, 72, 168, 264, 312, 432, & 480 h post D1 infusion (infusion duration = 1.5-2 h) of Cy4, 8 & post D2 infusion of Cy1; D1 of all other cycles up to 28 and 42-45 days after last dose (up to approximately 39 months) (1 Cy = 21 days)'}, {'measure': 'Pharmacokinetics: Serum Concentration at the Time of Tumor Progression (Cprog) of lumretuzumab [RO5479599]', 'timeFrame': 'At the time of tumor progression (up to approximately 39 months)'}, {'measure': 'Pharmacokinetics: Serum Concentration at the Time of Tumor Response (Complete response [CR]/Partial Response [PR]) of lumretuzumab [RO5479599]', 'timeFrame': 'At the time of tumor progression (up to approximately 39 months)'}, {'measure': 'Pharmacokinetics: Serum Concentration at the Time of DLT of lumretuzumab [RO5479599]', 'timeFrame': 'At the time of DLT (up to 21 days)'}, {'measure': 'Pharmacokinetics: Serum Concentration at the Time of Tumor and Skin Biopsy (Cb) of lumretuzumab [RO5479599]', 'timeFrame': 'At the time of tumor/skin biopsy (up to approximately 39 months)'}, {'measure': 'Pharmacokinetics: Serum Concentration at the Time of Infusion-Related Reactions (IRR) of lumretuzumab [RO5479599]', 'timeFrame': 'At the time of IRR (up to approximately 39 months)'}, {'measure': 'Recommended Phase II Dose of lumretuzumab [RO5479599]', 'timeFrame': 'Day 1 up to Day 21'}]","[{'measure': 'Percentage of Participants With Best Overall Response of CR or PR (Objective Response) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1) Criteria', 'timeFrame': 'Baseline up to documented disease progression (PD) or death, whichever occurs first up to approximately 39 months (assessed at baseline thereafter every 9 weeks up to 28 days after last infusion or early discontinuation)'}, {'measure': 'Percentage of Participants With Best Overall Response of CR or PR or SD (Disease Control), Assessed Using RECIST V1.1 Criteria', 'timeFrame': 'Baseline up to documented PD or death, whichever occurs first up to approximately 39 months (assessed at baseline thereafter every 9 weeks up to 28 days after last infusion or early discontinuation)'}, {'measure': 'Duration of Response, Assessed Using RECIST V1.1 Criteria', 'timeFrame': 'From first confirmed documented objective response (CR/PR) up to documented PD or death, whichever occurs first up to approximately 39 months (assessed at baseline thereafter every 9 weeks up to 28 days after last infusion or early discontinuation)'}, {'measure': 'Progression-Free Survival Assessed Using RECIST V1.1 Criteria', 'timeFrame': 'Baseline up to documented PD or death, whichever occurs first up to approximately 39 months (assessed at baseline thereafter every 9 weeks up to 28 days after last infusion or early discontinuation)'}, {'measure': 'Overall Survival', 'timeFrame': 'Baseline up to death (up to approximately 39 months)'}]",22.0,18 Years,,ALL,False,INDUSTRY,0.0,66.0,ACTUAL,v2_robust,True,True,False,True,
NCT03691454,Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.,Docetaxel,"['S-1', 'Docetaxel', 'Oxaliplatin', 'Herceptin']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Gastric Adenocarcinoma,Peking University,2025-09-01T16:18:07.030357,True,,,,,"A Randomized, Multicenter, Controlled, Adaptive II/III Study to Compare Neoadjuvant Chemotherapy of Docetaxel，Oxaliplatin Combined With S-1(DOS) Versus Oxaliplatin Combined With S-1(SOX)in Locally Advanced Gastric Adenocarcinoma (RESOLVE-2 Study)",,['Gastric Adenocarcinoma'],"['gastric adenocarcinoma', 'neoadjuvant chemotherapy', 'locally advanced', 'Oxaliplatin', 'S-1', 'Docetaxel']",,2018-06-28,2023-06-30,"[{'measure': 'The rate of pathologic complete response（pCR%）', 'description': 'Evaluation of pCR% of DOS regimen versus SOX regimen in locally advanced gastric adenocarcinoma', 'timeFrame': '1 year'}]","[{'measure': 'Overall Survival : From date of enrollment until the date of death', 'description': 'Evaluation of the Overall Survival of DOS regimen versus SOX regimen in locally advanced gastric adenocarcinoma', 'timeFrame': '5 years'}, {'measure': 'Progression-free Survival：From date of enrollment until the date of first documented progression or second gastric cancer or death from any cause, whichever came first.', 'description': 'Evaluation of the Progression-free Survival of DOS regimen versus SOX regimen in locally advanced gastric adenocarcinoma', 'timeFrame': '3 years'}]",3.0,18 Years,,ALL,False,OTHER,0.0,258.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06158854,A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion,ABBV-383 (Etentamig),"['ABBV-383 (Etentamig)', 'TNB-383B']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Immunoglobulin Light Chain (AL) Amyloidosis,AbbVie,2025-09-01T16:18:07.030408,True,,,,,An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis,,['Immunoglobulin Light Chain (AL) Amyloidosis'],"['Immunoglobulin Light Chain (AL) Amyloidosis', 'ABBV-383', 'TNB-383B']",,2024-04-01,2028-02,"[{'measure': 'Number of Participants with Dose-Limiting Toxicities (DLT)', 'description': 'DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.', 'timeFrame': 'Up to 28 Days'}]","[{'measure': 'Percentage of Participants who Achieve Hematologic Complete Response (CR)', 'description': 'Hematologic CR is defined as the percentage of participants who achieve normalization of free light chain levels, negative serum immunofixation, negative urine immunofixation as determined per the modified International Amyloidosis Consensus Criteria (IACC).', 'timeFrame': 'Up to 3 Years'}, {'measure': 'Overall Hematologic Response (OHR)', 'description': 'OHR is defined as partial response (PR) + very good partial response (VGPR) + complete remission (CR), proportion of participants who achieved a PR or better, per the modified IACC.', 'timeFrame': 'Up to 3 Years'}, {'measure': 'Time to Hematologic CR', 'description': 'Time to hematologic CR is defined as the time from first dose of study drug until CR, per the modified IACC.', 'timeFrame': 'Up to 3 Years'}, {'measure': 'Duration of Hematologic CR', 'description': 'Duration of hematologic CR is defined as the time from CR until disease progression, per the modified IACC.', 'timeFrame': 'Up to 3 Years'}, {'measure': 'Organ Response Rate (OrRR)', 'description': 'Organ response rate is defined as the time from first dose of study drug until to response in the heart kidney and liver, per the IACC.', 'timeFrame': 'Up to 3 Years'}, {'measure': 'Time to Organ Response', 'description': 'Time to organ response is defined as the time from first dose of study drug until organ response, per the IACC.', 'timeFrame': 'Up to 3 Years'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,76.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00001005,A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes,Zidovudine,"['Zidovudine', 'Aldesleukin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,HIV Infections,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:07.030474,True,,,,,Interleukin-2 Augmentation of Specific Anti-HIV Immune Responses: Phase I Trial of the Combination of 3'-Azido-3'-Deoxythymidine (Zidovudine) and Recombinant Interleukin-2 in Patients With Asymptomatic HIV Infection Associated With Lymphadenopathy (Walter Reed Stage II),,['HIV Infections'],"['Recombinant Proteins', 'HIV Seropositivity', 'Interleukin-2', 'Drug Evaluation', 'Drug Therapy, Combination', 'Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex', 'Zidovudine']",,,1995-02,[],[],0.0,18 Years,,ALL,False,NIH,0.0,30.0,,v2_robust,True,True,False,False,
NCT06839105,A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies,Taxol,"['Oxaliplatin', 'Renvastinib', 'AWT020', 'Capecitabine', 'Pemetrexed', 'Taxol', 'Cisplatin or Carboplatin', 'Bevacizumab']",8,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,"Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor","Shanghai Junshi Bioscience Co., Ltd.",2025-09-01T16:18:07.030529,True,,,,,"A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AWT020 Alone and in Combination With Other Antitumor Therapies in Patients With Advanced Malignancies",,"['Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor']",[],,2025-02-21,2028-04-30,"[{'measure': 'DLT rate', 'description': 'DLT rate', 'timeFrame': 'Up to approximately 12 months from first patient in'}, {'measure': 'AE', 'description': 'Safety endpoint: incidence and severity of AE, abnormal changes in clinically significant laboratory and other tests', 'timeFrame': 'Up to approximately 12 months from first patient in'}, {'measure': 'SAE', 'description': 'Safety endpoint: incidence and severity of SAE, abnormal changes in clinically significant laboratory and other tests', 'timeFrame': 'Up to approximately 12 months from first patient in'}, {'measure': 'MTD', 'description': 'Determine maximum tolerated dose', 'timeFrame': 'Up to approximately 12 months from first patient in'}, {'measure': 'RP2D', 'description': 'Recommended phase II dose (RP2D) for AWT020 monotherapy and combination therapy', 'timeFrame': 'Up to approximately 32 months from first patient in'}]","[{'measure': 'Drug concentrations', 'description': 'Drug concentrations in individual subjects at different time points after dosing', 'timeFrame': 'Up to approximately 24 months from first patient in'}, {'measure': 'Immunogenicity', 'description': 'Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (Nab), titer of ADA positive samples', 'timeFrame': 'Up to approximately 24 months from first patient in'}, {'measure': 'ORR', 'description': 'Efficacy endpoint: Objective response rate(ORR) per RECIST v1.1', 'timeFrame': 'Up to approximately 32 months from first patient in'}, {'measure': 'DOR', 'description': 'Efficacy endpoint: Duration of response (DOR) per RECISIT v1.1', 'timeFrame': 'Up to approximately 32 months from first patient in'}, {'measure': 'DCR', 'description': 'Efficacy endpoint: Disease control rate (DCR) per RECISIT v1.1', 'timeFrame': 'Up to approximately 32 months from first patient in'}, {'measure': 'PFS', 'description': 'Efficacy endpoint: Progress -free survival (PFS) per RECISIT v1.1', 'timeFrame': 'Up to approximately 32 months from first patient in'}, {'measure': 'OS', 'description': 'Efficacy endpoint: Overall survival (OS)', 'timeFrame': 'Up to approximately 32 months from first patient in'}]",12.0,18 Years,,ALL,False,OTHER,0.0,214.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03422705,A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation,Lisinopril,['Lisinopril'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,"Pacemakers, Heart Failure",University of Leeds,2025-09-01T16:18:07.030632,True,,,,,"A Randomised, Placebo-controlled Pilot Trial to Examine the Efficacy of Interventions to Prevent Left Ventricular Remodelling in Patients Receiving New Pacemaker Implantation (OPT-Prevent-pilot).",,"['Pacemakers, Heart Failure']",[],,2022-12-01,2022-12-01,"[{'measure': 'Change in left ventricular ejection fraction', 'description': 'Difference in change between the groups', 'timeFrame': '6 months'}]","[{'measure': 'Change in left ventricular end systolic diameter', 'description': 'Difference in change between the groups', 'timeFrame': '6 months'}, {'measure': 'Change in left ventricular end diastolic diameter', 'description': 'Difference in change between the groups', 'timeFrame': '6 months'}]",3.0,18 Years,,ALL,False,OTHER,0.0,75.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01719705,Effects of Pregabalin on Post-cesarean Pain,Placebo,"['Pregabalin 150 mg group', 'Pregabalin 300 mg group', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Uncomplicated Singleton Pregnancies,Mansoura University,2025-09-01T16:18:07.030648,True,,,,,Efficacy of Preoperative Pregabalin on the Post-caesarean Pain; a Dose-response Study,,['Uncomplicated Singleton Pregnancies'],"['caesarean delivery', 'spinal anesthesia', 'pregabalin', 'postoperative pain', 'morphine']",,2012-11,2015-06,"[{'measure': 'cumulative patient controlled morphine consumptions', 'description': 'cumulative patient controlled morphine consumptions 24 hours after delivery', 'timeFrame': '24 hours after delivery'}]","[{'measure': 'postoperative pain scores', 'description': 'visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and100 mm for worst imaginable pain) at rest and on movement', 'timeFrame': '1, 4, 6, 12, 24 and 48 hours after delivery'}, {'measure': 'neonatal Apgar scores', 'timeFrame': '1 and 5 min aftr delivery'}, {'measure': 'Neurologic and adaptive capacity scores', 'description': 'NACS gives a maximum of 40 with a score \\>35 denoting vigor.The percentage of infants scoring \\<35 will be determined.', 'timeFrame': 'at 15 min, 2h, 24 and 48 h after delivery'}, {'measure': 'Maternal sedation', 'description': 'sedation (0, alert; 1, somnolent easy to arouse; 2, somnolent difficult to arouse or asleep; 3, not arousable)', 'timeFrame': 'every two hours after delivery, for 48 hours after delivery'}, {'measure': 'Maternal nausea and vomiting', 'description': 'nausea and vomiting (0: no nausea; 1: nausea no vomiting; 2: nausea and vomiting),', 'timeFrame': 'at 24 hours after delivery'}]",6.0,18 Years,38 Years,FEMALE,False,OTHER,0.0,135.0,ACTUAL,v2_robust,True,True,False,False,
NCT03715205,Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593),Pembrolizumab,"['KEYTRUDA®', 'Pembrolizumab', 'MK-3475']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Carcinoma, Non-Small-Cell Lung",Merck Sharp & Dohme LLC,2025-09-01T16:18:07.030666,True,,,,,"A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)",,"['Carcinoma, Non-Small-Cell Lung', 'Melanoma']","['programmed cell death 1 (PD-1, PD1)', 'programmed cell death ligand 1 (PD-L1, PDL1)', 'programmed cell death ligand 2 (PD-L2, PDL2)']",,2019-01-31,2024-08-21,"[{'measure': 'Number of Participants With an Adverse Event (AE)', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. The number of participants with an AE was reported.', 'timeFrame': 'Up to approximately 66.5 months'}, {'measure': 'Number of Participants With a Serious Adverse Event (SAE)', 'description': ""An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. An SAE was any adverse event occurring at any dose or during any use of Sponsor's product that resulted in death; was life threatening; resulted in persistent or significant disability/incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly/birth defect; was another important medical event. The number of participants with an SAE was reported."", 'timeFrame': 'Up to approximately 66.5 months'}, {'measure': 'Number of Participants With a Drug-Related AE', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A drug-related AE was defined as an AE that was determined by the investigator to be possibly, probably, or definitely related to drug. The number of participants with a drug-related AE was reported.', 'timeFrame': 'Up to approximately 66.5 months'}, {'measure': 'Number of Participants With a Drug-Related SAE', 'description': ""An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An SAE was any AE occurring at any dose or during any use of Sponsor's product that resulted in death; was life threatening; resulted in persistent or significant disability/incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly/birth defect; was another important medical event. A drug-related SAE was defined as an SAE that was determined by the investigator to be possibly, probably, or definitely related to drug. The number of participants with a drug-related SAE was reported."", 'timeFrame': 'Up to approximately 66.5 months'}, {'measure': 'Number of Participants Who Discontinued Study Drug Due to an AE', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. The number of participants who discontinued study drug due to an AE was reported', 'timeFrame': 'Up to approximately 26 months'}]",[],5.0,18 Years,,ALL,False,INDUSTRY,0.0,150.0,ACTUAL,v2_robust,True,True,False,True,
NCT02753205,Dexmedetomidine on Optic Nerve Sheath Diameter,Dexmedetomidine,"['NS', 'dex', 'Dexmedetomidine', 'normal saline']",4,INTERVENTIONAL,['NA'],,WITHDRAWN,Intracranial Hypertension,Gachon University Gil Medical Center,2025-09-01T16:18:07.030693,True,,,,,Effect of Dexmedetomidine on Optic Nerve Sheath Diameter During Laparoscopic Anterior Resection,,['Intracranial Hypertension'],[],,2016-04,2018-04,"[{'measure': 'Optic nerve sheath diameter', 'description': 'mm', 'timeFrame': 'Change from Baseline optic nerve sheath diameter at pneumoperitoneum 30 min'}]","[{'measure': 'Respiratory and mean arterial pressure', 'description': 'mmHg', 'timeFrame': 'Change from Baseline Respiratory and mean arterial pressure at pneumoperitoneum 30 min'}]",2.0,20 Years,65 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,
NCT02520505,SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis,Supraovulation clomiphene citrate,"['Clomiphene citrate', 'Supraovulation clomiphene citrate']",2,INTERVENTIONAL,['NA'],,WITHDRAWN,Endometriosis,The Cleveland Clinic,2025-09-01T16:18:07.030710,True,,,,,Determining the Fertility Benefit of Immediate SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis,,"['Endometriosis', 'Infertility']",[],no participants enrolled,2015-04,2017-12,"[{'measure': 'Pregnancy rates in SO+IUI versus expectant management', 'description': 'The primary objective of this study is to determine whether or not immediate clomiphene citrate SO+IUI is more efficacious for improving pregnancy rates in patients with stage III/IV endometriosis after operative laparoscopy as compared expectant management.', 'timeFrame': 'Patients will participate in the study up to 6 months, starting from the first menstrual period after surgery until the completion of the second three month arm of the study.'}]","[{'measure': 'Post-operative fecundity rates in SO+IUI versus expectant management groups', 'description': 'A secondary objective is to determine the post-operative fecundity rates in women with stage III/IV endometriosis as compared to the timed intercourse group.', 'timeFrame': 'Patients will participate in the study up to 6 months, starting from the first menstrual period after surgery until the completion of the second three month arm of the study.'}, {'measure': 'Patient characteristics in SO+IUI versus expectant management groups', 'description': 'A secondary objective is to investigate patient characteristics that may affect pregnancy outcomes.', 'timeFrame': 'Patients will participate in the study up to 6 months, starting from the first menstrual period after surgery until the completion of the second three month arm of the study.'}, {'measure': 'Time to pregnancy in SO+IUI versus expectant management groups', 'description': 'A secondary objective is to estimate the time to pregnancy between SO+IUI and expectant management.', 'timeFrame': 'Patients will participate in the study up to 6 months, starting from the first menstrual period after surgery until the completion of the second three month arm of the study.'}, {'measure': 'Endometriosis fertility index in SO+IUI versus expectant management groups', 'description': 'A secondary objective is to determine whether or not the endometriosis fertility index has an impact on outcomes between SO+IUI and expectant management.', 'timeFrame': 'Patients will participate in the study up to 6 months, starting from the first menstrual period after surgery until the completion of the second three month arm of the study.'}]",5.0,18 Years,35 Years,FEMALE,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,no participants enrolled
NCT00951405,Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors,"activated recombinant human factor VII, long acting","['activated recombinant human factor VII, long acting', 'NN7128', 'LA-rFVIIa']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Congenital Bleeding Disorder,Novo Nordisk A/S,2025-09-01T16:18:07.030741,True,,,,,"An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of Prophylactic Administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients With Inhibitors",,"['Congenital Bleeding Disorder', 'Haemophilia A With Inhibitors', 'Haemophilia B With Inhibitors']",[],,2009-09-01,2011-03-29,"[{'measure': 'Thrombogenecity', 'timeFrame': 'at all scheduled visits (1 - 9)'}, {'measure': 'Immunogenecity: Neutralising Antibody Development', 'timeFrame': 'at all scheduled visits (1 - 9)'}]","[{'measure': 'AUC(0-48h) and AUC: Area under the FVIIa activity-time profile in the given time period, which is a measure of total blood exposure', 'timeFrame': 'at visit 2 and visit 7 until 48 hours after trial product administration'}, {'measure': 'Annualized bleeding rates', 'timeFrame': 'During observation period; from visit 1 until visit 2 and treatment period; from visit 2 until visit 7. In total a period of 6 to 8 months'}]",4.0,12 Years,65 Years,MALE,False,INDUSTRY,0.0,23.0,ACTUAL,v2_robust,True,True,False,False,
NCT02347605,Medicinal Nicotine for Preventing Cue Induced Craving,Nicotine lozenge 4 mg,"['Nicotine lozenge 4 mg', 'Placebo lozenge']",2,INTERVENTIONAL,['NA'],,COMPLETED,Tobacco Use Disorder,University of Minnesota,2025-09-01T16:18:07.030753,True,,,,,,,['Tobacco Use Disorder'],[],,2013-09,2015-01,"[{'measure': 'Craving Symptom Severity Score Assessed Via Questionnaire', 'description': 'Craving as assessed via the craving question on the Minnesota Nicotine Withdrawal Scale. The score range is from 0 (no craving) to 4 (severe craving). The outcome measure is the change in craving score from before cue exposure to craving score after cue exposure.', 'timeFrame': 'approximately 15 minutes'}, {'measure': 'Withdrawal Symptom Severity Score Assessed Via Questionnaire', 'description': 'Withdrawal as assessed via the Minnesota Nicotine Withdrawal Scale. The score range is from 0 to 28 with higher scores indicating more severe withdrawal symptoms. The outcome measure is the change in withdrawal score from before cue exposure to the withdrawal score after cue exposure.', 'timeFrame': 'approximately 15 minutes'}]",[],2.0,18 Years,64 Years,ALL,False,OTHER,0.0,56.0,ACTUAL,v2_robust,True,True,False,False,
NCT05771194,Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients,Routine preoperative and postoperative anti-infection therapy,"['Routine preoperative and postoperative anti-infection therapy', 'artificial tear therapy']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid",Tianjin Medical University Eye Hospital,2025-09-01T16:18:07.030862,True,,,,,Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients,,"['Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid']","['Meibomian gland dysfunction', 'Dry eye', 'Non-invasive ocular surface analyser', 'Pars plana vitrectomy', ',Meibomian gland massage']",,2021-02-01,2022-07-02,"[{'measure': 'The average non-invasive tear film break-up time', 'description': 'The NITBUT values were measured using a non-invasive ophthalmic analyser; the patients were instructed to blink 2 times after a normal blink, focus their eyes, and then refrain from blinking until the Placido ring projected onto the cornea was broken; the duration was recorded.', 'timeFrame': '5minutes to 10 minutes'}]","[{'measure': 'lipid layer thickness', 'description': 'The LipiView interferometer was used for examination under natural light. The patient was in a sitting position, and the mandible and forehead were against the jaw bracket and the forehead bracket, respectively. The aiming frame was aligned between the pupil and the lower eyelid margin; the position was adjusted until the reflection of the lower eyelashes was clear. Patients were asked to gaze at the light source for approximately 20 s and blink normally. The average LLT were recorded.', 'timeFrame': '1minutes to 5 minutes'}, {'measure': 'non-invasive measured tear meniscus height', 'description': 'The lacrimal river was imaged, and the height of the lacrimal river directly below the centre of the pupil was measured with the built-in measurement tool of the system. Each patient was examined by the same ophthalmologist three times, and the average of the three measurements was used as the final result.', 'timeFrame': '1minutes to 5 minutes'}, {'measure': 'meibomian gland loss', 'description': 'The Meibo-Scan mode was selected. Then, the upper and lower eyelids were turned outward, and morphological images of the meibomian glands were obtained under an infrared light source. The shortening and loss of meibomian glands were observed and recorded on the following scale: The absence of meibomian gland loss (MGL) corresponded to a score of 0 point, an MGL ratio of less than 1/3 was assigned 1 point, an MGL ratio of 1/3 to 2/3 received 2 points, and a ratio of \\>2/3 received 3 points.', 'timeFrame': '1minutes to 5 minutes'}]",4.0,50 Years,80 Years,ALL,True,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT01353794,Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer,"Sorafenib (Nexavar, BAY43-9006)","['Sorafenib (Nexavar, BAY43-9006)']",1,OBSERVATIONAL,[],,WITHDRAWN,"Carcinoma, Renal Cell",Bayer,2025-09-01T16:18:07.030905,True,,,,,"Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar® in Advanced Renal Cell Carcinoma",,"['Carcinoma, Renal Cell']","['SORAFENIB', 'RENAL CELL CARCINOMA', 'TYROSINE KINASE INHIBITOR', 'OBSERVATIONAL STUDY']",,2014-12,2018-04,"[{'measure': 'Efficacy related variables are status of tumor / metastases.', 'timeFrame': 'After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)'}, {'measure': ""Efficacy related variables are patient's performance status."", 'timeFrame': 'After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)'}, {'measure': 'Efficacy related variables are efficacy assessment by the physician.', 'timeFrame': 'After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)'}, {'measure': 'Efficacy related variable - Quality of Life (QOL) assessment by the patient', 'timeFrame': 'After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)'}]","[{'measure': 'General tolerability assessment by physician and reports of adverse events.', 'timeFrame': 'After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)'}]",5.0,,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,False,False,True,True,
NCT05691894,Tracer Targeting FAP PET Imaging in Patients,18F-FAPI,"['18F-FAPI', '68Ga-FAPI']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,Cancer,Affiliated Hospital of Jiangnan University,2025-09-01T16:18:07.030920,True,,,,,Tracer Targeting FAP PET Imaging in Patients,,['Cancer'],[],,2022-11-02,2023-11,"[{'measure': 'Evaluation of tissue distribution of 18F-FAPI', 'description': 'Biodistribution of 18F-FAPI evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 18F-PET scans will be reported.', 'timeFrame': '1 day'}, {'measure': 'Evaluation of tissue distribution of 68Ga-FAPI', 'description': 'Biodistribution of 68Ga-FAPI evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 68Ga-PET scans will be reported.', 'timeFrame': '1 day'}]",[],2.0,18 Years,75 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00183794,Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma,Docetaxel and Gemcitabine,['Docetaxel and Gemcitabine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Ovarian Carcinoma,University of Southern California,2025-09-01T16:18:07.030999,True,,,,,Phase II Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma,,"['Ovarian Carcinoma', 'Peritoneal Neoplasms']",['Primary Peritoneal'],,2002-11,2010-05,"[{'measure': 'Tumor Response Type: CR, PR, SD or PD', 'description': 'Tumor response will be based on the RECIST v1.0 criteria. CR (complete response)= disappearance of all target lesions, PR (partial response)= greater or equal to 30% decrease in sum of longest diameter of target lesions, SD (stable disease)= \\<30% decrease or \\<20% increase, PD (progressive disease)= greater or equal to 20% increase in longest diameter of target lesions. For patients with an elevated CA-125 as the only evidence of disease, a PR was defined as a decrease of 50% or more lasting at least 8 weeks (Rustin et al. JCO 14:1545-51, 1996). Disease assessment performed every 2 cycles (1 cycle = 21 days). Responders included CR and PR.', 'timeFrame': '6 months after enrollment of last participant'}]","[{'measure': 'Median Time to Progression (Months)', 'description': 'Defined as the time from first day of treatment to the first observation of disease progression or death due to any cause. If a patient has not progressed or died, progression-free survival is censored at the time of last follow-up. Progression based on RECIST v1.0 criteria for measurable disease, and on CA-125 for patients with an elevated CA-125 as the only evidence of disease (Rustin et al. JCO 14:1545-51, 1996)', 'timeFrame': '6 months after enrollment of last patient'}]",2.0,18 Years,,FEMALE,False,OTHER,2.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT06191094,Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy,Faricimab Injection,"['Faricimab Injection', 'Vabysmo', 'sham treatment']",3,INTERVENTIONAL,['PHASE4'],PHASE4,ENROLLING_BY_INVITATION,Diabetic Retinopathy,"University of Colorado, Denver",2025-09-01T16:18:07.031045,True,,,,,"A Randomized, Double-masked, Sham-controlled Study to Evaluate the Efficacy of Peri-operative Farcimab in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy",,"['Diabetic Retinopathy', 'Vitreous Hemorrhage Due to Diabetes Mellitus']",[],,2024-07-12,2027-01,"[{'measure': 'Rates of post-operative vitreous hemorrhage', 'description': 'Following treatment and surgery, the development of vitreous hemorrhage will be quantified and evaluated.', 'timeFrame': '6 months'}]","[{'measure': 'BCVA outcomes', 'description': 'Vision will be tested following treatment and surgery on the Snellen Chart, with or without correction as indicated.', 'timeFrame': '6 and 12 months'}, {'measure': 'Rates of re-operation for non-clearing vitreous hemorrhage', 'description': 'Following treatment and surgery, if re-operation for non-clearing vitreous hemorrhage is indicated, this will be track and quantified.', 'timeFrame': '6 and 12 months'}, {'measure': 'Rate of post-operative epiretinal membrane formation.', 'description': 'Following treatment and surgery, the duration of time if a patient was to develop an epiretinal membrane will be quantified and evaluated.', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Rate of post-operative rhegmatogenous or tractional retinal detachment.', 'description': 'Following treatment and surgery, the duration of time if a patient was to develop a rhegmatogenous or tractional retinal detachment will be quantified and evaluated.', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Duration of operative time.', 'description': 'The official duration of surgical time will be quantified and evaluated.', 'timeFrame': 'intra-operatively'}, {'measure': 'Number of endodiathermy use exchanges intra-operatively.', 'description': 'At the time of surgery, the number of endodiathermy use exchanges will be counted and evaluated.', 'timeFrame': 'intra-operatively'}, {'measure': 'Number of retinal breaks intra-operatively.', 'description': 'At the time of surgery, the number of retinal breaks intra-operatively will be counted and evaluated.', 'timeFrame': 'intra-operatively'}, {'measure': 'Number of patients with intra-operative bleeding', 'description': 'At the time of surgery, the number of patients who experience intra-operative bleeding will be counted and evaluated.', 'timeFrame': 'intra-operatively'}]",9.0,18 Years,,ALL,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00915694,"Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme",nelfinavir mesylate,"['temozolomide', 'nelfinavir mesylate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Brain and Central Nervous System Tumors,Abramson Cancer Center at Penn Medicine,2025-09-01T16:18:07.031070,True,,,,,A Phase I Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma,,['Brain and Central Nervous System Tumors'],"['adult giant cell glioblastoma', 'adult gliosarcoma', 'adult glioblastoma']",Insufficient accrual,2009-04,2015-12,"[{'measure': 'Maximum tolerated dose of nelfinavir mesylate', 'timeFrame': '90 days'}, {'measure': 'Dose-limiting toxicities as assessed by NCI CTC v3.0', 'timeFrame': '90 days'}]","[{'measure': 'Progression-free survival', 'timeFrame': 'One year'}, {'measure': 'Overall survival', 'timeFrame': '5 years'}]",4.0,18 Years,120 Years,ALL,False,OTHER,1.0,15.0,ACTUAL,v2_robust,True,False,True,False,Insufficient accrual
NCT02443194,"The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients",duloxetine,"['cymbalta', 'duloxetine', 'PLACEBO']",3,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Depression,michal roll,2025-09-01T16:18:07.031081,True,,,,,"The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients",,['Depression'],"['depression', 'glioblastoma']",principle investigator decision due to many adverse events in patients,2015-05,2015-11,"[{'measure': 'changes in patients mood and cognitive function according to the neuropsychological assessment', 'timeFrame': '3 months of treatment'}]",[],1.0,18 Years,80 Years,ALL,False,OTHER_GOV,0.0,50.0,ACTUAL,v2_robust,True,False,True,False,principle investigator decision due to many adverse events in patients
NCT05734794,Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial,Rituximab,"['Steroid', 'Rituximab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Nephrotic Syndrome in Children,The Children's Hospital of Zhejiang University School of Medicine,2025-09-01T16:18:07.031110,True,,,,,Study of Rituximab Monotherapy VS Steroid Therapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial,,"['Nephrotic Syndrome in Children', 'Rituximab']","['Rituximab', 'Glucocorticosteroids']",,2023-02-09,2026-07-30,"[{'measure': 'Recurrence-free survival time(day) after first complete remission', 'description': 'The time from complete remission to the first relapse during the whole 52-week follow-up in patients who achieve complete remission within 6 weeks. In order to evaluate the remission, all the participants will document their proteinuria. Relapse is defined by first-morning urine dipstick ≥3+ on three or more consecutive days, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg, with or without edema after complete remission(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases). Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).', 'timeFrame': 'From complete remission to 52 weeks'}]","[{'measure': 'Complete remission of nephrotic syndrome', 'description': 'Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions (KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases). It will be recorded as ""1"" when patients achieve complete remission, or as ""0"".', 'timeFrame': 'From admission day to 6 weeks'}, {'measure': 'Inefficiency of nephrotic syndrome', 'description': 'Inefficiency is defined as patients still have nephrotic-range proteinuria(first-morning urine dipstick ≥3+dipstick, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg) after 6-week treatment.', 'timeFrame': 'From admission day to 6 weeks'}, {'measure': 'The time(day) to first complete remission', 'description': 'The time(day) from the first medicine administration to complete remission within 6 weeks.Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions (KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).', 'timeFrame': 'From admission day to 6 weeks'}, {'measure': 'Relapse of nephrotic syndrome', 'description': 'Relapse is defined as patients who have first-morning urine dipstick ≥3+ on three or more consecutive days, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg, with or without edema after complete remission(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases). It will be recorded as ""1"" when patients have a relapse, or as ""0"".', 'timeFrame': 'From admission day to 52 weeks'}, {'measure': 'Cumulative prednisone dosage of each individual (milligrams per kilogram per year)', 'description': 'The total dosage of prednisone for each individual from the beginning to the end of the trial.', 'timeFrame': 'From admission day to 52 weeks'}]",6.0,2 Years,17 Years,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT07026994,Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage,Colchicine 0.5mg,"['Matching placebo', 'Colchicine 0.5mg']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Cerebral Amyloid Angiopathy,Huashan Hospital,2025-09-01T16:18:07.031162,True,,,,,Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage (CARE-ICH),,"['Cerebral Amyloid Angiopathy', 'Intracerebral Hemorrhage Lobar']","['Cerebral Amyloid Angiopathy', 'Intracerebral Hemorrhage', 'Colchicine', 'Recurrence']",,2025-06-18,2027-12,"[{'measure': 'Incidence of treatment emergent adverse events (TEAE)', 'description': 'Incidence of treatment emergent adverse events (TEAE)', 'timeFrame': 'Any time within 1 year'}, {'measure': 'Frequency of participants who are adherence to medicine without permanent discontinuation due to TEAE until the end of follow-up.', 'description': 'Frequency of participants who are adherence to medicine without permanent discontinuation due to TEAE until the end of follow-up', 'timeFrame': '1 year'}]","[{'measure': 'Safety-Treatment-related adverse events (TRAE)', 'description': 'An AE assessed as having a causal relationship to the study product, and be classified as definitely, probably or possibly related AEs', 'timeFrame': 'Any time within 1 year'}, {'measure': 'Safety-TEAE according to Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3', 'description': 'TEAE according to Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3', 'timeFrame': 'Any time within 1 year'}, {'measure': 'Feasibility-Recruitment rate', 'description': 'The mean number of participants randomized per site per year', 'timeFrame': '1 year'}, {'measure': 'Feasibility-Retention rate', 'description': 'Randomized participants who completed 1-year follow-up', 'timeFrame': '1 year'}, {'measure': 'Clinical efficacy-Recurrent symptomatic spontaneous lobar ICH', 'description': 'A new non-traumatic lobar ICH lesion confirmed on SWI or CT with corresponding symptoms', 'timeFrame': 'Any time within 1 year'}, {'measure': 'Clinical efficacy-Composite of major adverse cardiovascular events (MACE)', 'description': 'Stroke (ischemic, hemorrhagic or undefined), myocardial infarction, revascularization procedure for coronary, carotid or peripheral arterial disease, and vascular death', 'timeFrame': 'Any time within 1 year'}, {'measure': 'Clinical efficacy-Any individual MACE', 'description': 'Stroke (ischemic, hemorrhagic or undefined), myocardial infarction, revascularization procedure for coronary, carotid or peripheral arterial disease, and vascular death', 'timeFrame': 'Any time within 1 year'}, {'measure': 'Clinical efficacy-Cognitive outcome', 'description': 'Cognitive function assessed by the Montreal Cognitive Assessment (MoCA) (The total score ranges from 0 to 30, with higher scores indicating better cognitive function)', 'timeFrame': '1 year'}, {'measure': 'Clinical efficacy-Functional outcome', 'description': 'Functional outcome assessed by the modified Rankin scale (mRS) \\[mRS score ranges from 0 (no symptom) to 6 (death) and higher score means worse functional outcome\\]', 'timeFrame': '3-month, 6-month and 1-year'}, {'measure': 'Clinical efficacy-Quality of life', 'description': ""Quality of life assessed by the EuroQol Five-Dimension Five-Level (EQ-5D-5L) questionnaire, which consists of two parts. The descriptive system evaluates health across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on five levels of severity, where higher levels indicate more severe problems. The visual analogue scale is rated from 0 (worst imaginable health state) to 100 (best imaginable health state), representing the patient's self-rated overall health."", 'timeFrame': '1 year'}, {'measure': 'Clinical efficacy-Blood inflammatory markers', 'description': 'High-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).', 'timeFrame': '6 month and 1 year'}, {'measure': 'Radiological efficacy-New asymptomatic ICH lesion', 'description': 'A new hemorrhagic lesion confirmed on SWI at 1-year, which was absent on SWI at baseline and was not associated with any acute neurological deficit', 'timeFrame': '1 year'}, {'measure': 'Radiological efficacy-Severe cSS progression', 'description': '≥2 new cSS foci on 1-year SWI scan', 'timeFrame': '1 year'}, {'measure': 'Radiological efficacy-Any cSS progression', 'description': '≥1 new cSS foci on 1-year SWI scan', 'timeFrame': '1 year'}, {'measure': 'Radiological efficacy-CMB progression', 'description': '≥5 new CMBs on 1-year SWI scan', 'timeFrame': '1 year'}]",17.0,55 Years,,ALL,False,OTHER,2.0,80.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04569994,A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes,NNC0363-0845,"['Insulin degludec', 'Placebo (NNC0363-0845)', 'NNC0363-0845']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,Novo Nordisk A/S,2025-09-01T16:18:07.031187,True,,,,,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Healthy Subjects and in Subjects With Type 1 Diabetes",,"['Healthy Volunteers', 'Diabetes Mellitus, Type 1']",[],,2020-09-30,2021-06-23,"[{'measure': 'Number of treatment-emergent adverse events (AEs)', 'description': 'Number of events', 'timeFrame': 'Part 1 and 2: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10'}, {'measure': 'Number of treatment-emergent adverse events (AEs)', 'description': 'Number of events', 'timeFrame': 'Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1)'}]","[{'measure': 'Number of treatment-emergent hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'Part 1 and 2 From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10'}, {'measure': 'Number of treatment-emergent hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1)'}, {'measure': 'Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose', 'description': 'pmol\\*h/L', 'timeFrame': 'Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)'}, {'measure': 'Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose', 'description': 'pmol\\*h/L', 'timeFrame': 'Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)'}, {'measure': 'Maximum observed serum NNC0363-0845 concentration after a single dose', 'description': 'pmol/L', 'timeFrame': 'Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)'}, {'measure': 'Maximum observed serum NNC0363-0845 concentration after a single dose', 'description': 'pmol/L', 'timeFrame': 'Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)'}]",8.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,68.0,ACTUAL,v2_robust,True,True,False,True,
NCT04189094,Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC,Sintilimab,"['Etoposide', 'DDP', 'Cisplatin', 'Sintilimab', 'VP-16']",5,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Small Cell Lung Cancer Limited Stage,Zhejiang Cancer Hospital,2025-09-01T16:18:07.031198,True,,,,,Chemoradiotherapy With or Without Sintilimab in Limited-stage Small Cell Lung Cancer: a Multicenter Prospective Randomized Phase II Trial,,['Small Cell Lung Cancer Limited Stage'],"['radiotherapy', 'chemotherapy', 'immunotherapy', 'PD-1 inhibitor', 'lung cancer', 'small cell', 'limited-stage']",,2020-01-01,2023-07-01,"[{'measure': 'Progression-free survival', 'description': 'PFS, defined as the time from the date of randomization to the first date of documented objective progression disease or of death from any cause.', 'timeFrame': '2 years'}]","[{'measure': 'Overall survival', 'description': 'OS, measured from the date of randomization to the date of death from any cause.', 'timeFrame': '5 years'}, {'measure': 'Overall response rates', 'description': 'ORR, tumor response will be measured by using the RECIST 1.1.', 'timeFrame': '2 years'}]",3.0,18 Years,,ALL,False,OTHER,3.0,140.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03145194,TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI,Ticagrelor,['Ticagrelor'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,ST Elevation Myocardial Infarction,Papworth Hospital NHS Foundation Trust,2025-09-01T16:18:07.031209,True,,,,,A Randomised Mechanistic Study Comparing the Effects of Different Anti-platelet Combinations (Ticagrelor vs. Placebo/ Clopidogrel) With Aspirin in Patients Presenting With Anterior STEMI Treated With Primary PCI,,['ST Elevation Myocardial Infarction'],[],,2017-01-30,2019-11-30,"[{'measure': 'Index of Myocardial Resistance (IMR)', 'description': 'To compare final Index of Myocardial Resistance (IMR) at the end of the PPCI procedure between the two arms.', 'timeFrame': 'Baseline to end of PPCI procedure.'}]","[{'measure': 'Baseline IMR and change in IMR during PPCI', 'description': 'To compare between the two arms.', 'timeFrame': 'Baseline to end of PPCI procedure.'}, {'measure': 'ACF and AMR pre/post PPCI', 'description': 'To compare between the two arms.', 'timeFrame': 'Baseline to end of PPCI procedure.'}, {'measure': 'TIMI flow and TMBG pre/post PPCI', 'description': 'To compare between the two arms.', 'timeFrame': 'Baseline to end of PPCI procedure.'}, {'measure': 'ST segment resolution', 'description': 'To compare between the two arms.', 'timeFrame': 'Baseline to end of PPCI procedure.'}, {'measure': 'OCT quantified clot volume pre/post PPCI', 'description': 'To compare between the two arms.', 'timeFrame': 'Baseline to end of PPCI procedure.'}, {'measure': 'Cardiac troponin - I and CKMB levels at 0, 12 and 24 hours', 'description': 'To compare between the two arms.', 'timeFrame': 'Baseline to 24 hours.'}, {'measure': 'Cardiac MRI microvascular obstruction between 24-48 hours and infarct size at 3 months', 'description': 'To compare between the two arms.', 'timeFrame': 'Baseline to 3 months.'}]",8.0,18 Years,90 Years,ALL,False,OTHER_GOV,1.0,140.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00389194,PREventing Progression of Adipose Tissue Redistribution,continuing AZT+3TC or switching AZT+3TC to TDF+ FTC,['continuing AZT+3TC or switching AZT+3TC to TDF+ FTC'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,HIV Infections,International Antiviral Therapy Evaluation Center,2025-09-01T16:18:07.031287,True,,,,,"A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.",,['HIV Infections'],"['HIV-1 infection', 'fat distribution', 'lipodystrophy', 'lipids', 'kidney function', 'Treatment Experienced']",,2006-04,2008-10,[],"[{'measure': 'Difference between the continuation arm and the switch arm in:'}, {'measure': 'changes in subcutaneous and visceral abdominal fat by CT and truncal fat by whole body DEXA over 48 weeks'}, {'measure': 'changes in lipids (total-, HDL-, and LDL-cholesterol, total /HDL cholesterol ratio, triglycerides), and glucose-metabolism (glucose, insulin) and insulin resistance (HOMA-index1) over 48 weeks.'}, {'measure': 'incidence of new onset of lipodystrophy and changes in lipodystrophy severity according to the LDCD score.'}, {'measure': 'changes in bone mineral density by regional DEXA (vertebra L4 and femoral neck) over 48 weeks'}, {'measure': 'proportion of patients with plasma HIV-1 RNA concentrations < 50 copies/mL after 48 weeks and proportion of patients that developed new CDC-C events or increased in CDC classification.'}, {'measure': 'incidence and severity of adverse events (grade 3 and 4), and laboratory abnormalities (grade 1-4)'}, {'measure': 'A comparison between different GFR-estimations and the gold standard for GFR-measurement in HIV-1 infected patients on HAART.', 'description': 'Conclusions: Each eGFR estimation underestimated the mGFR. In patients with preserved renal function and suppressed HIV-infection, C\\&G, 24-hours urine clearance and MDRD-6 based eGFR reasonably estimated true GFR, but cysC-based eGFR did not.', 'timeFrame': 'baseline'}]",8.0,18 Years,,ALL,False,OTHER,1.0,120.0,ESTIMATED,v2_robust,True,True,False,True,
NCT05852366,Efficacy of Herbal Dentifrice for Management of Dentinal Hypersensitivity,Toothpaste Preparation,['Toothpaste Preparation'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Dentinal Hypersensitivity,Dr. D. Y. Patil Dental College & Hospital,2025-09-01T16:18:07.031333,True,,,,,Efficacy of Herbal Dentifrice for Management of Dentinal Hypersensitivity Post Scaling and Root Planning in Chronic Periodontitis: A Randomized Controlled Clinical Trial,,"['Dentinal Hypersensitivity', 'Chronic Periodontitis']",[],,2023-05-15,2023-12-15,"[{'measure': 'Change in dentinal hypersensitivity', 'description': 'Dentinal hypersensitivity score will be measured by Visual analogue scores on a scale of 0 to 10 using Air stimulus', 'timeFrame': 'Baseline to 8 weeks'}]",[],1.0,25 Years,60 Years,ALL,False,OTHER,1.0,75.0,ACTUAL,v2_robust,True,True,False,False,
NCT02057666,Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer,Tasquinimod,"['ABR-215050', 'Tasquinimod', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,"Prostatic Neoplasms, Castration-Resistant",Ipsen,2025-09-01T16:18:07.031354,True,,,,,"A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer",,"['Prostatic Neoplasms, Castration-Resistant']","['CRPC', 'Metastatic', 'Chemotherapy naïve', 'Chemo-naïve', 'Prostate cancer', 'mCRPC', 'Chemotherapy-naïve', 'Chemo naïve']",Development of tasquinimod in prostate cancer discontinued,2014-01,2015-05,"[{'measure': 'Time to Radiological Progression-Free Survival (PFS)', 'description': 'PFS was defined as the time from the date of randomisation to the date of radiological progression (confirmed by the central imaging assessment) or death due to any cause. Radiological progression was defined by any of the following criteria: progression of soft tissue lesions evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scan according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 criteria; progression of bone lesions detected with bone scan according to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria; or radiologically confirmed spinal cord compression or pathological fracture due to malignant progression.\n\nThe primary endpoint was centrally and independently evaluated.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years'}]","[{'measure': 'Overall Survival', 'description': 'An overall survival event was defined as death due to any cause. The number of participants with overall survival events is reported.', 'timeFrame': 'From randomisation up to 3 years'}, {'measure': 'Local Assessment of Radiological PFS', 'description': 'The Investigator was to evaluate radiological disease progression in accordance with the criteria defined for the primary endpoint.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years'}, {'measure': 'Time to Symptomatic PFS Based on Local Assessment', 'description': 'Symptomatic PFS, defined as the time from the date of randomisation to the date of appearance of pain (using pain visual analogue scale (VAS)) at a site with documented disease and analgesic use, or skeletal-related events, or death due to prostate cancer, whichever occurred first.', 'timeFrame': 'Every 3 months'}, {'measure': 'Time From Randomisation to Further Treatment for Prostate Cancer', 'description': 'The need for any anti-tumour prostate cancer treatments was to be recorded during the Follow-up Period, with the time to further treatment to subsequently be derived.', 'timeFrame': 'Every 6 months during the follow-up period'}, {'measure': 'Quality of Life (QoL)', 'description': 'QoL measured by the Functional Assessment of Cancer Therapy Prostate Module (FACT-P) questionnaire and by the EuroQol 5-Dimension QoL Instrument (EQ-5D).\n\nDue to the early termination of the study, a simplified data analysis (primary endpoint and overall survival) was performed to fulfil the requirement from regulatory authorities for early termination studies. Therefore, no analyses were performed on this secondary efficacy endpoint.', 'timeFrame': 'Every 3 months'}, {'measure': 'Tasquinimod Pharmacokinetic (PK) Profile', 'description': 'Tasquinimod PK profile:\n\n1. Following a single 1 mg dose of tasquinimod given to a subgroup of 12 Asian-Chinese patients (ancillary study).\n2. At steady state conditions based on limited sampling strategy.\n\nFollowing termination of the study the PK analyses were not performed.', 'timeFrame': 'Up to 216 hours after a single dose and during the double blind treatment period (Day 15, 29, 57 and 127)'}]",7.0,20 Years,,MALE,False,INDUSTRY,0.0,146.0,ACTUAL,v2_robust,True,False,True,False,Development of tasquinimod in prostate cancer discontinued
NCT01193166,Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital,paliperidone palmitate,"['risperidone', 'quetiapine', 'paliperidone', 'aripiprazole', 'haloperidole', 'paliperidone palmitate', 'perphenazine', 'olanzapine']",8,INTERVENTIONAL,['PHASE4'],PHASE4,WITHDRAWN,Schizophrenia,"Ortho-McNeil Janssen Scientific Affairs, LLC",2025-09-01T16:18:07.031393,True,,,,,"A Twelve-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital",,['Schizophrenia'],"['Schizophrenia', 'Risperidone', 'Risperdal', 'Paliperidone palmitate', 'Aripiprazole', 'Haloperidol', 'Olanzapine', 'Paliperidone', 'Perphenazine', 'Quetiapine']",This study was stopped due to an internal reconsideration of priorities of the product portfolio.,2010-08,2012-09,"[{'measure': 'Time to treatment failure defined as psychiatric hospitalization, suicide, discontinuation of treatment due to inadequate efficacy or safety/tolerability, treatment supplementation due to inadequate efficacy, or increase in psychiatric services', 'timeFrame': 'Up to 12 months'}]","[{'measure': 'Change in Clinical Global Impression-Severity score', 'timeFrame': 'Up to 12 months'}, {'measure': 'Change in Global Assessment of Functionality score', 'timeFrame': 'Up to 12 months'}, {'measure': 'Change in Medication Satisfaction Questionnaire score', 'timeFrame': 'Up to 12 months'}, {'measure': 'Proportion of subjects with at least one psychiatric hospitalization', 'timeFrame': 'Up to 12 months'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,This study was stopped due to an internal reconsideration of priorities of the product portfolio.
NCT01096966,Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain,Bupivacaine TTS (Bupivacaine Patch),"['Bupivacaine TTS (Bupivacaine Patch)', 'Placebo patch']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Chronic Low Back Pain,Durect,2025-09-01T16:18:07.031399,True,,,,,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Bupivacaine TTS (Bupivacaine Patch) in Patients With Chronic Low Back Pain",,['Chronic Low Back Pain'],['chronic low back pain'],,2010-03,2011-02,"[{'measure': 'Mean change from baseline to 12 weeks in pain in the last 24 hours (daily scores averaged over 14 days)', 'timeFrame': 'baseline to 12 weeks after baseline'}]","[{'measure': 'Subjects achieving 20% pain relief at 12 weeks compared to baseline', 'timeFrame': 'baseline to 12 weeks after baseline'}, {'measure': ""Subjects 'much improved' or 'very much improved' at 12 weeks"", 'timeFrame': '12 weeks after baseline'}]",3.0,18 Years,70 Years,ALL,False,INDUSTRY,1.0,263.0,ACTUAL,v2_robust,True,True,False,False,
NCT00947466,A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain,Buprenorphine,['Buprenorphine'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Chemotherapy Induced Mucositis,Mundipharma Research Limited,2025-09-01T16:18:07.031466,True,,,,,A Multi Centre Open Label Single Therapy Dose Ranging Study to Characterise the Pharmacokinetics & Tolerability of BTDS 5-20 ug/h in Children Who Require Opioid Analgesia for Moderate to Severe Mouth Pain Secondary to Chemotherapy Induced Mucositis.,,"['Chemotherapy Induced Mucositis', 'Mouth Pain']","['Buprenorphine transdermal patch (BTDS)', 'Moderate to severe mouth pain', 'Chemotherapy induced mucositis', 'Pharmacokinetic']",25 patients have been recruited and it was considered that further recruitment would add no extra PK information,2010-02,2012-11,"[{'measure': 'To characterise the pharmacokinetics of BTDS 5-20 ug/h in children weighing >15kg', 'timeFrame': ""PK's taken daily for 12 days""}]","[{'measure': 'safety & tolerability of BTDS 5-20ug/h in children', 'timeFrame': 'every 4 hours to day 5, day 12 and day 21'}]",2.0,2 Years,16 Years,ALL,False,INDUSTRY,0.0,25.0,ACTUAL,v2_robust,True,False,True,True,25 patients have been recruited and it was considered that further recruitment would add no extra PK information
NCT01449266,Safety and Dialysability of Dotarem® in Dialysed Patients,Dotarem® IV injection at 0.1 mmol/kg,"['Dotarem® IV injection at 0.1 mmol/kg', 'gadoterate meglumine', 'gadoteric acid']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,End-stage Renal Failure,Guerbet,2025-09-01T16:18:07.031489,True,,,,,Safety and Dialysability of Dotarem® in Dialysed Patients - Phase 1 Clinical Study,,['End-stage Renal Failure'],"['Dotarem', 'Dialyses', 'Dialysed', 'Safety', 'Safety and dialysability of Dotarem in dialysed patients']",,2011-11,2012-06,"[{'measure': 'Dialysability of Dotarem® in Dialysed Patients', 'description': 'To evaluate the decrease in seric concentration of gadolinium, after each hemodialysis session of patients injected with 0.1 mmol/kg of Dotarem® . The percent change of gadolinium concentration is calculated by estimating the amount of serum gadolinium before and after each hemodialysis session. Calculations are performed only for subjects with concentration above the lower limit of quantification (LLQ)', 'timeFrame': 'Dotarem® dialysability assessed up to 4 days after Dotarem® administration'}]","[{'measure': 'Safety of Dotarem® in Dialysed Patients Evaluated by the Number of Patients Experiencing Adverse Events.', 'description': 'To evaluate the biological and clinical safety of Dotarem® by assessing vital signs, biological parameters, injection-site tolerance, through a 4-day post injection follow-up, adverse events through a 3-week post injection period and serious adverse events through a 3-month post injection period.', 'timeFrame': 'Safety assessed from patients inclusion until the last follow-up visit 3 months after Dotarem® administration'}]",2.0,18 Years,95 Years,ALL,False,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,True,False,True,
NCT00472966,Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma,Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels,"['Tri-Luma® Cream', 'Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels', 'NeoStrata® Glycolic Acid Skin Renewal Peel']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Melasma,Galderma R&D,2025-09-01T16:18:07.031577,True,,,,,"Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma",,['Melasma'],[],,2006-11,2007-04,"[{'measure': ""Efficacy - Improvement in Investigator's global assessment of melasma"", 'timeFrame': '12 weeks'}]","[{'measure': 'Safety - Tolerability assessments and adverse event reporting', 'timeFrame': '12 weeks'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,
NCT04969666,"A Phase II, Repeat Single Oral Dose Study of IPED2015 in Healthy Male Subjects With Erectile Dysfunction",IPED2015,"['IPED2015', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Erectile Dysfunction,Initiator Pharma,2025-09-01T16:18:07.031726,True,,,,,"A Phase II, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Repeat Single Oral Dose Study of IPED2015 or Placebo in Otherwise Healthy Male Subjects With Erectile Dysfunction",,['Erectile Dysfunction'],[],,2021-08-04,2022-11-30,"[{'measure': 'International Index of Erectile Function (IIEF-15) scale', 'description': 'Erectile Dysfunction assessment', 'timeFrame': '4 weeks'}]","[{'measure': 'Rigiscan (diagnosis and assessment of male sexual impotence)', 'description': 'Device to assess erectile dysfunction', 'timeFrame': '4 weeks'}, {'measure': 'Semen analysis (check of quality of semen)', 'description': 'Analysis of tissue', 'timeFrame': '4 weeks'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'Assessment of patients health', 'timeFrame': '4 weeks'}]",4.0,18 Years,59 Years,MALE,False,INDUSTRY,0.0,120.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05082766,Improvement in the Appearance of Periorbital Wrinkles,enhanced DefenAge 8-in-1 BioSerum,['enhanced DefenAge 8-in-1 BioSerum'],1,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Periorbital Wrinkles,"Goldman, Butterwick, Fitzpatrick and Groff",2025-09-01T16:18:07.031737,True,,,,,Improvement in the Appearance of Periorbital Wrinkles With DefenAge 8-in-1 BioSerum Supplemented With Enhanced Concentration of Defensins,,['Periorbital Wrinkles'],"['wrinkles', ""crow's feet"", 'face wrinkles', 'face', 'cosmetic']",,2021-10-11,2022-12-01,"[{'measure': 'Clinician evaluator assessment of change using Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale', 'description': 'measurements will be completed based on images captured at baseline, Day 30, Day 60, and Day 90 and assessed by a blinded evaluator using the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale where wrinkling ranges from class 1 (fine wrinkles) to class 3 (Fine to deep wrinkles, numerous lines, with or without redundant skin folds) and Elastosis ranges from 1-3 (mild) to 7-9 (severe)', 'timeFrame': 'baseline, Day 30, Day 60, and Day 90'}, {'measure': 'Asses the change of Percent of improvement at different time points', 'description': 'Percent improvement in periorbital wrinkles, laxity, pigmentation, erythema, texture, and radiance conducted by an evaluator', 'timeFrame': 'Day 30, Day 60, and Day 90'}]","[{'measure': 'Investigator-assessed Global Aesthetic Improvement Score (I-GAIS)', 'description': 'Investigator-assessed Global Aesthetic Improvement Score based on photographs where scale is 1 (much improved) to 5 (much worse)', 'timeFrame': 'Day 30, 60 and 90'}, {'measure': 'Subject Global Aesthetic Improvement Score (S-GAIS)', 'description': 'Subject Global Aesthetic Improvement Score Day 30, 60 and 90 using photographs where scale is 1 (much improved) to 5 (much worse)', 'timeFrame': 'Day 30, 60 and 90'}, {'measure': 'Investigator assessment of tolerability of study drug including erythema, burning/stinging, dryness, peeling (desquamation), and tenderness', 'description': 'Investigator assessment of tolerability of study drug', 'timeFrame': 'Day 30, 60 and 90.'}, {'measure': 'Patient questionnaire', 'description': 'Self-Assessment questionnaire', 'timeFrame': 'Day 30, 60 and 90.'}]",6.0,31 Years,,ALL,True,OTHER,2.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00280566,Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed),Placebo,"['Ziprasidone Oral Capsule', 'Geodon, Zeldox', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bipolar Mania,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,2025-09-01T16:18:07.031759,True,,,,,"A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment With Both Agents",,"['Bipolar Mania', 'Bipolar Disorder']",[],,2005-12,2008-05,"[{'measure': 'Time to Intervention for a Mood Episode During Double Blind Period', 'description': 'Time to Intervention for Mood Episode (TIME) while on randomized drug after at least 8 weeks of symptom reduction on open-label ziprasidone plus mood stabilizer. Mood episode considered to have occurred and subject discontinued if one or more of the following: Investigator (INV) decides discontinuation is in best interest of subject; loss of effect and/or change to treatment regimen (INV judgment); subject hospitalized for disease under study; Mania Rating Scale (MRS) and/or Montgomery-Asberg Rating Scale (MADRS) rating is ≥18 for 2 consecutive visits scheduled no more than 10 days apart.', 'timeFrame': 'Period 2: 24 weeks or time of early termination'}]","[{'measure': 'Time to Discontinuation for Any Reason During Double Blind Period 2', 'description': 'Key Secondary endpoint is time to discontinuation for any reason. Profile of patients remaining in the trial over time.', 'timeFrame': 'Period 2: 24 weeks or time of early termination'}, {'measure': 'Modified Time to Intervention for a Mood Episode (TIME)', 'description': 'Time to intervention for a mood episode or time to discontinuation for treatment related adverse events, or death due to drug, or death due to disease. Mood episode considered to have occurred and subject discontinued if one or more of the following: Investigator (INV) decides discontinuation is in best interest of subject; loss of effect and/or change to treatment regimen (INV judgment); subject hospitalized for disease under study; Mania Rating Scale (MRS) and/or Montgomery-Asberg Rating Scale (MADRS) rating is ≥18 for 2 consecutive visits scheduled no more than 10 days apart.', 'timeFrame': 'Period 2: Week 24 or time of early termination'}, {'measure': 'Change From Baseline in Mania Rating Scale (MRS) by Visit During Double Blind Period', 'description': 'Period 2 Baseline = last observation in Period 1 to the start of Period 2. MRS is 11-item scale to measure mania; derived from Schedule for Affective Disorders and Schizophrenia-Change Behavior (SADS-CB). Subscales: Manic Syndrome (elevated mood, less need for sleep, excessive energy and activity, grandiosity), Behavior and Ideation (irritability, motor hyperactivity, accelerated speech, racing thoughts, poor judgment), and Impaired Insight. Racing thoughts range=0 to 2 (highest level of abnormal=2); all other items 0 to 5 (highest level of abnormal=5). Higher score = greater abnormality.', 'timeFrame': 'Period 2: Weeks 1 - 24 or time of early termination'}, {'measure': 'Change From Baseline in Clinical Global Impression Severity (CGI-S) Score by Visit During Double Blind Period', 'description': 'Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Clinical Global Impression Severity Score is 7-item scale rates severity of illness from 0=not assessed, 1= normal to 7=most extremely ill.', 'timeFrame': 'Period 2: Weeks 1 - 24 or time of early termination'}, {'measure': 'Clinical Global Impression - Improvement (CGI-I) Score by Visit During Double Blind Period', 'description': ""Clinical Global Impression measures 7 items in Global assessment of improvement in patient's condition; 0=not assessed, 1= very much improved to 7= very much worse."", 'timeFrame': 'Period 2: Weeks 1 - 24 or time of early termination'}, {'measure': 'Change From Baseline in Montgomery-Asberg Rating Scale (MADRS) Score by Visit During Double Blind Period', 'description': 'Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. MADRS is 10-item instrument measuring depression: scales from 0=Normal to 6 = most abnormal.', 'timeFrame': 'Period 2: Weeks 1 - 24 or time of early termination'}, {'measure': 'Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Visit During Double Blind Period', 'description': 'Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Positive and Negative Syndrome Scale Total Score is 30-item scale measuring severity of psychopathology (16 items), positive symptoms (7 items) and negative symptoms (7 items); scale from 1 (absent) to 7 (extreme)', 'timeFrame': 'Period 2: Weeks 4 - 24 or time of early termination'}, {'measure': 'Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Postive Scale by Visit During Double Blind Period', 'description': 'Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Positive Scale is 7-items derived from PANSS; 1 (absent), 2 (minimal) to 7 (extreme).', 'timeFrame': 'Period 2: Weeks 4 - 24 or time of early termination'}, {'measure': 'Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Scale by Visit During Double Blind Period', 'description': 'Baseline for Period 2 is the last observation in Period 1 to the start of Period 2. Negative Scale is 7 items derived from PANSS; scale is 1 (absent) to 7 (extreme).', 'timeFrame': 'Period 2: Weeks 4 - 24 or time of early termination'}]",10.0,18 Years,,ALL,False,INDUSTRY,0.0,584.0,ACTUAL,v2_robust,True,True,False,True,
NCT01343966,A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY),MABT5102A,"['MABT5102A', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Alzheimer's Disease,"Genentech, Inc.",2025-09-01T16:18:07.031824,True,,,,,"A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)",,"[""Alzheimer's Disease""]",[],,2011-04-30,2014-02-28,"[{'measure': ""Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score"", 'timeFrame': 'From baseline to Week 73'}, {'measure': 'Change in Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score', 'timeFrame': 'From baseline to Week 73'}]","[{'measure': ""Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score"", 'timeFrame': 'From baseline to Week 73'}]",3.0,50 Years,80 Years,ALL,False,INDUSTRY,0.0,448.0,ACTUAL,v2_robust,True,True,False,False,
NCT02056366,The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy,α-lipoic acid,"['α-lipoic acid', 'Neuropaid OD Tablet']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Type 2 Diabetes,The Catholic University of Korea,2025-09-01T16:18:07.031854,True,,,,,"The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study",,"['Type 2 Diabetes', 'Cardiac Autonomic Neuropathy']",['Cardiac Autonomic Neuropathy'],,2010-01,2013-09,"[{'measure': 'Primary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy', 'description': 'check the Heart rate variability(HRV) Index', 'timeFrame': 'up to 24weeks'}]","[{'measure': 'Secondary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy', 'description': 'Check the Autonomic Nerve System(ANS) function 5 test', 'timeFrame': 'up to 24weeks'}]",2.0,20 Years,80 Years,ALL,False,OTHER,0.0,91.0,ACTUAL,v2_robust,True,True,False,False,
NCT00002556,Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma,vincristine sulfate,"['Vincasar PFS', 'carmustine', 'L-PAM', 'L-phenylalanine mustard', 'Deltra', 'prednisone', 'Cytoxan', 'cyclophosphamide', 'Endoxan', 'DeCortin', 'CTX', 'BCNU', 'CPM', 'melphalan', 'Alkeran', 'BiCNU', 'VCR', 'L-Sarcolysin', 'vincristine sulfate', 'bis-chloronitrosourea', 'Endoxana', 'leurocristine sulfate', 'CB-3025']",23,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Stage I Multiple Myeloma,National Cancer Institute (NCI),2025-09-01T16:18:07.031908,True,,,,,The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma,,"['Stage I Multiple Myeloma', 'Stage II Multiple Myeloma', 'Stage III Multiple Myeloma']",[],,1994-07,,"[{'measure': 'Median survival', 'description': 'Detected using a one-sided log rank test at the .05 significance level.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Objective response, evaluated using the following ECOG Myeloma Response Criteria', 'description': 'Compared between treatment groups using a two-sided Fisher Exact Test at the .05 significance level. Response evaluation will be based on determination of reduction in serum and/or urine M-protein (monoclonal or myeloma protein) and on improvement in measurable soft tissue plasmacytomas when present.', 'timeFrame': 'Up to 1 year'}]",[],2.0,18 Years,,ALL,False,NIH,0.0,312.0,ACTUAL,v2_robust,True,True,False,False,
NCT03588156,Single-dose PK Study of Benapenem In Healthy Subjects,Benapenem,"['5081', 'Benapenem', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Subject,Sihuan Pharmaceutical Holdings Group Ltd.,2025-09-01T16:18:08.336253,True,,,,,Single-dose Tolerability Study of Benapenem for Injection in Phase I Clinical Healthy Subjects,,['Healthy Subject'],"['Healthy Subject', 'PK Study', 'Tolerability', 'Safety Evaluation']",,2015-03-11,2015-09-17,"[{'measure': 'Number of subjects with clinically significant findings in vital signs', 'description': 'Vitals signs such as systolic and diastolic blood pressure, heart rate, and pulse rate will be measured in a semi-supine position after 5 minutes of rest.', 'timeFrame': 'Change from Baseline at Day1, Day2, Day4 after dosing'}, {'measure': 'Number of subjects with clinically significant findings in laboratory parameters', 'description': 'Hematology and clinical chemistry and Urine Routine abnormalities will be monitored', 'timeFrame': 'Change from Baseline at Day1, Day2, Day4 after dosing'}, {'measure': 'Number of subjects with clinically significant 12-lead ECGs', 'description': 'Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals', 'timeFrame': 'Change from Baseline at Day1, Day2, Day4 after dosing'}]","[{'measure': 'AUC(0-24) of Benapenem', 'description': 'AUC(0-24) is the area under the curve from time 0 to 24 hour', 'timeFrame': 'In each group: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hour after dosing'}, {'measure': 'Maximum observed plasma concentration (Cmax) of Benepenem', 'timeFrame': 'In each group: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hour after dosing'}, {'measure': 'Time to maximum observed plasma concentration (tmax) of Benapenem', 'timeFrame': 'In each group: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hour after dosing'}]",6.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,98.0,ACTUAL,v2_robust,True,True,False,False,
NCT06920056,A Study of BGM0504 in Overweight or Obese Participants,Paracetamol,"['Paracetamol', 'BGM0504', 'Warfarin', 'Metformin Hydrochloride']",4,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Overweight or Obese,"BrightGene Bio-Medical Technology Co., Ltd.",2025-09-01T16:18:08.336279,True,,,,,"A Single Center, Open-label, Fixed Sequence Trial, Investigating the Influence of BGM0504 Injection on Gastric Emptying and Pharmacokinetics of Metformin and Warfarin in Overweight or Obese Participants",,['Overweight or Obese'],[],,2025-03-24,2025-06-28,"[{'measure': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t)of Paracetamol', 'description': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Paracetamol', 'timeFrame': 'From Day1 to Day72'}, {'measure': 'Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Paracetamol', 'description': 'Pharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax) of Paracetamol', 'timeFrame': 'From Day1 to Day72'}, {'measure': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Metformin', 'description': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t)of Metformin', 'timeFrame': 'From Day4 to Day76'}, {'measure': 'Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin', 'description': 'Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin', 'timeFrame': 'From Day4 to Day76'}, {'measure': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Warfarin', 'description': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Warfarin', 'timeFrame': 'From Day7 to Day84'}, {'measure': 'Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Warfarin', 'description': 'Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Warfarin', 'timeFrame': 'From Day7 to Day84'}]","[{'measure': 'Area Under the Stable-State Concentration Versus Time Curve (AUC0-∞,ss ) of BGM0504', 'description': 'Area Under the Stable-State Concentration Versus Time Curve (AUC0-∞,ss ) of BGM0504', 'timeFrame': 'From Day14 to Day69'}, {'measure': 'Time to Maximum Concentration (Tmax) of Metformin and Warfarin', 'description': 'Time to Maximum Concentration (Tmax) of Metformin and Warfarin', 'timeFrame': 'From Day1 to Day84'}, {'measure': 'Terminal Half-life (t1/2) of Paracetamol', 'description': 'Terminal Half-life (t1/2) of Paracetamol', 'timeFrame': 'From Day1 to Day72'}]",9.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,28.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00537056,Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI,F-18 Fluoro-deoxi-glucose,"['Fludeoxyglucose (18F)', 'Sutent', 'F-18 Fluoro-deoxi-glucose', 'FDG', '18F-FDG', 'Gadolinium-DTPA', 'fluorodeoxyglucose (18F)', 'Gd-DTPA', 'SU11248', 'gadopentetate dimeglumine', 'Gadopentetic acid', 'Berlex', 'Sunitinib']",13,INTERVENTIONAL,['NA'],,COMPLETED,Kidney Neoplasms,Stanford University,2025-09-01T16:18:08.336374,True,,,,,Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI,,"['Kidney Neoplasms', 'Carcinoma, Renal Cell', 'Kidney (Renal Cell) Cancer']",[],,2007-10,2012-04,"[{'measure': 'F-18 FDG Tumor Uptake (SUV Max)', 'description': 'The maximum standardized uptake value (SUVmax) is a measurement of tumor metabolism as determined by the PET scan before and after 12-weeks of sunitinib therapy. Decreased SUVmax correlates to a reduction of tumor metabolism. Increased SUVmax correlates to an increase in tumor metabolism.\n\nReduction or increased SUVmax will be determined as the change from baseline in uptake of F18 FDG.\n\nResults were based on the European Organization for Research and Treatment of Cancer (EORTC) for predicting progression free survival. EORTC criteria is a ± 25% change of SUVmax for assessment of progressive disease, stable disease and partial response.', 'timeFrame': '12 weeks minus baseline'}]","[{'measure': 'Histopathology', 'description': 'Histopathologic findings were correlated to the pre-treatment 18F-fluorodeoxyglucose positron emission tomography (F-18 FDG PET/CT) scan. Outcome is reported as the number of participants for whom both histopathology and F-18 FDG PET/CT indicated that active cancers was present.', 'timeFrame': '1 day'}, {'measure': 'Initial Comprehensive Metabolic Panel', 'description': 'A comprehensive metabolic panel is a blood test that measures sugar (glucose) level, electrolyte and fluid balance, kidney function, and liver function. It was performed prior to the administration of gadolinium contrast. For patients with normal renal function, approximately 90% of gadolinium contrast is excreted through the urinary system. These patients have known renal cell carcinoma, so it was important to perform a metabolic function panel prior to gadolinium injection, specifically to determine kidney function. Reported as the number of patients for whom the initial comprehensive metabolic panel was within institutional standards.', 'timeFrame': 'Prior to baseline DCE MRI'}, {'measure': 'Adverse Events', 'description': 'Adverse events were monitored for on F-18 FDG PET/CT and DCE MRI imaging days: baseline (n=17); interim (n=12); and post-sunitinib therapy (n=17). Reported as the overall number of adverse events experienced.', 'timeFrame': 'up to 12 months'}, {'measure': 'Tumor Necrosis', 'description': 'The degree of tumor necrosis was measured using values obtained from dynamic contrast enhanced magnetic resonance imaging (DCE MRI) pre- and post-sunitinib therapy. Gadolinium contrast material given intravenously during the DCE MRI scan is used to improve visualization of blood vessels, tumors, and/or organs.', 'timeFrame': '12 weeks'}, {'measure': 'Tumor Size by Computed Tomography (CT) Scan', 'description': 'Tumor size was measured based on computed tomography (CT) pre- and post-sunitinib therapy. CT was performed immediately prior to the PET scan and is used to determine both the PET scan imaging area and PET image attenuation correction (AC). F-18 FDG PET provides the metabolic and physiologic data while CT provides the anatomical data.', 'timeFrame': '12 weeks'}, {'measure': 'Tumor Size by DCE Magnetic Resonance Imaging (MRI) Scan', 'description': 'Tumor size was measured using values obtained from DCE MRI pre- and post-sunitinib therapy. Gadolinium contrast material given intravenously during the DCE MRI scan is used to improve visualization of blood vessels, tumors, and/or organs.', 'timeFrame': '12 weeks'}, {'measure': 'DCE MRI AUC Peak Flow', 'description': 'Area under the curve (AUC) was measured using receiver operating characteristic (ROC) curve analysis. ROC curve analysis measures sensitivity (true-positives, correctly diagnosed positive pathologies) against specificity (true-negatives, correctly diagnosed negative pathologies or free of disease) of the DCE MRI scan. An area of 1.0 under the curve would equal a perfect test (with 100% sensitivity; 100% specificity) while an area of 0.5 would equal a useless test (50% sensitivity; 50% specificity).', 'timeFrame': '12 weeks'}, {'measure': 'Initial Tumor Size', 'description': 'Initial tumor size was measured using values obtained from computed tomography (CT) pre-sunitinib therapy. CT is performed immediately prior to the PET scan and is used to determine both the PET scan imaging area and PET image attenuation correction (AC). F-18 FDG PET provides the metabolic and physiologic data while CT provides the anatomical data.', 'timeFrame': 'pre-sunitinib therapy'}]",9.0,18 Years,,ALL,False,OTHER,1.0,17.0,ACTUAL,v2_robust,True,True,False,True,
NCT01564056,Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment,HORMONOTHERAPY,"['CHEMOTHERAPY then HORMONOTHERAPY', 'HORMONOTHERAPY']",2,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Breast Cancer,UNICANCER,2025-09-01T16:18:08.336574,True,,,,,Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial,,['Breast Cancer'],"['Adjuvant systemic treatment', 'Breast cancer', 'Elderly patients']",,2012-04-12,2026-03,"[{'measure': 'Overall survival', 'description': 'The OS is defined as the interval between the date of randomization and the date of death from any cause.', 'timeFrame': 'Median follow-up = 4 years'}]","[{'measure': 'Specific overall survival', 'description': 'The specific OS is defined as the interval between the date of randomization and the date of death due to cancer. Alive patients or dead patients from another cause will be censored at the last follow-up', 'timeFrame': 'median follow-up = 4 years'}, {'measure': 'Disease-free survival (DFS)', 'description': 'The DFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or death from any cause, whichever occurs first.', 'timeFrame': 'median follow-up = 4 years'}, {'measure': 'Event-free survival (ESF)', 'description': 'The EFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or the date of second neoplasia, or the date of death from any cause, whichever occurs first.', 'timeFrame': 'median follow-up = 4 years'}, {'measure': 'Acute and late toxicity during the study', 'description': 'The National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = ""mild"", 2 = ""moderate"", 3 = ""severe"", 4 = ""life-threatening"", and 5 = ""death"") determined by the investigator, will make it possible to assess the severity of the disorders.', 'timeFrame': 'Throughout treatment completion, up to 4 years'}, {'measure': 'Geriatric Assessment', 'description': 'the geriatric questionnaires (CCI \\& listing comedications, G8, IADL or MMSE) will be completed by a geriatrician or a person trained to geriatric assessment before randomization, at the end of the chemotherapy in arm B or 16 weeks after the randomization in arm A (endocrine treatment only), and then each year during a 4-year follow-up period, for both arms.', 'timeFrame': 'at the end of the chemotherapy in arm B or 16 weeks after the randomization in arm A (endocrine treatment only), and then each year during a 4-year follow-up period, for both arms'}, {'measure': 'Four-Year Mortality Index for Older Adults(Lee Score)', 'description': 'A 4-year mortality score including items depicting functional status, nutritional status and comorbidities, three key issues in elderly, will be systematically calculated.', 'timeFrame': 'At the inclusion'}, {'measure': 'Quality of life questionnaire - Core 30 (QLQ-C30)', 'description': 'Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.\n\nThe questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.\n\nAll of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At baseline, week 16, 5 months, 6 months, 1 year, 2 years, 3 years, and 4 years'}, {'measure': 'Quality of life questionnaire - Elderly cancer patients (QLQ-ELD15)', 'description': 'The EORTC QLQ-ELD15, a validated HRQOL questionnaire for cancer patients aged greater than or equal to 70 years, is intended to supplement the QLQ-C30.\n\nThe QLQ-ELD15 contains 15 items incorporating five scales to assess mobility, family support, worries about future, autonomy and maintaining purpose, and burden of illness. All items are rated on a four-point Likert-type scale (1 = ""not at all"", 2 = ""a little"", 3 = ""quite a bit"", and 4 = ""very much""), and are linearly transformed to a 0-100 scale. High scores indicate poor mobility, good family support, less worried about the future, poor autonomy and maintaining purpose, and high burden of illness.', 'timeFrame': 'At baseline, week 16, 5 months, 6 months, 1 year, 2 years, 3 years, and 4 years'}, {'measure': 'Usefulness of GG by RT-PCR', 'description': 'The prognostic signature of the GG test will be evaluated in an elderly population by comparison to standardized routine histopathological criteria and to the results obtained in the general non elderly population. In the whole cohort (n=2000) results of the GG will be compared to routine histopathological characteristics (pN, histological grade, mitotic count, Ki67 index, determination of Elston and Ellis histological grade) as determined locally or centrally for assessment of patient prognosis.', 'timeFrame': 'two weeks after surgery (local histo. and GG test) then after inclusions are performed (central histo.)'}, {'measure': 'Cost-effectiveness analysis', 'description': 'In parallel with efficacy analysis, measured by an objective clinical result indicator of state of health, such as the number of year gained (overall survival), costs for the two treatment strategies (endocrine treatment only or endocrine treatment and chemotherapy) in adjuvant systematic treatment will be also estimated. This study should provide information for decision-makers about the incremental efficacy obtained in relation to the incremental cost.', 'timeFrame': 'at the end of the chemotherapy in arm B or 16 weeks after randomization in arm A, and then each year during a 4-year follow-up period, for both arms of the group I.'}]",11.0,70 Years,,FEMALE,False,OTHER,0.0,1989.0,ACTUAL,v2_robust,True,False,False,True,
NCT00030056,GM-CSF in Patients With Pulmonary Alveolar Proteinosis,"GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)","['GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)']",1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Pulmonary Alveolar Proteinosis,The Cleveland Clinic,2025-09-01T16:18:08.336634,True,,,,,Trial of GM-CSF for Alveolar Proteinosis,,['Pulmonary Alveolar Proteinosis'],"['Sargramostim', 'Injections, Subcutaneous']",,2001-09,2005-12,[],[],0.0,18 Years,70 Years,ALL,False,OTHER,0.0,48.0,ESTIMATED,v2_robust,True,False,True,False,
NCT04860856,Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial,0.5% ropivacaine,"['Normal Saline', '0.5% ropivacaine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Femur Fracture,University of Cincinnati,2025-09-01T16:18:08.336641,True,,,,,Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial,,['Femur Fracture'],"['Femoral Intramedullary Rod', 'Hematoma Block']",,2019-08-17,2023-02-07,"[{'measure': 'Change in postoperative pain at 72 hours', 'description': 'Postoperative pain will be assessed using a visual analog scale', 'timeFrame': 'Measured at 0, 8, 16, 24, 36, 48, and 72 hours postoperatively'}]","[{'measure': 'Narcotic usage', 'description': 'Oral morphine equivalents will be recorded', 'timeFrame': 'Narcotic usage will be assessed through 72 hours postoperatively'}]",2.0,18 Years,,ALL,False,OTHER,0.0,88.0,ACTUAL,v2_robust,True,True,False,False,
NCT00946556,Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix,Valacyclovir,"['Valacyclovir', 'Placebo']",2,INTERVENTIONAL,['NA'],,COMPLETED,Herpes Simplex Type Two Infection,University of Toronto,2025-09-01T16:18:08.336774,True,,,,,Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix.,,"['Herpes Simplex Type Two Infection', 'HIV Infections']","['herpes simplex virus type 2', 'HIV', 'genital immunology', 'CD4+ T cell', 'valacyclovir', 'HIV seronegativity']",,2010-04,2011-05,"[{'measure': 'Number of CD4+ T cells on a cervical cytobrush.', 'timeFrame': 'Monthly intervals for 5 months'}]","[{'measure': 'Number of immature dendritic cells on a cervical cytobrush', 'timeFrame': 'Monthly intervals for 5 months'}, {'measure': 'Proinflammatory cytokine/chemokine levels in cervicovaginal secretions', 'timeFrame': 'Monthly intervals for 5 months'}]",3.0,18 Years,,FEMALE,True,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT05334056,Drug Test Detection of Cocaine for Nasal Intubation,Cocaine Nasal,"['Cocaine 4%', 'Cocaine Nasal']",2,OBSERVATIONAL,[],,COMPLETED,Cocaine Adverse Reaction,"Rigshospitalet, Denmark",2025-09-01T16:18:08.336783,True,,,,,Drug Test Detection 24 Hours After Nasal Administration of Cocaine as a Local Vasoconstrictor Prior to Nasal Intubation,,['Cocaine Adverse Reaction'],[],,2023-03-22,2023-05-27,"[{'measure': 'Saliva analysis', 'description': ""Analysis of cocaine's main metabolite benzoylecgonine in saliva measured in nanograms per milliliter"", 'timeFrame': '24 hours after cocaine administration'}]","[{'measure': 'Whole blood toxicology', 'description': 'Analysis of cocaine in a whole blood sample measured in nanograms per milliliter', 'timeFrame': '1 hour and 24 hours after cocaine administration'}]",2.0,18 Years,,ALL,False,OTHER,0.0,27.0,ACTUAL,v2_robust,False,True,False,False,
NCT03394222,Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV,preoperative budesonide inhalation,"['preoperative budesonide inhalation', 'preoperative normal saline inhalation']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Lung Cancer,Fujian Medical University Union Hospital,2025-09-01T16:18:08.336856,True,,,,,Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt in Patients Received One-lung Ventilation,,['Lung Cancer'],[],,2016-07,2017-04,"[{'measure': 'Arterial blood oxygenation', 'description': 'Arterial blood oxygenation was assessed through blood gas analysis of sample taken from radial artery', 'timeFrame': 'Arterial blood oxygenation was assessed through blood gas analysis before intervention,before OLV ,10 min after OLV,30 min after OLV,60 min after OLV and 10min after two-lung ventilation.'}]","[{'measure': 'Intrapulmonary shunt', 'description': 'Intrapulmonary shunt was assessed through blood gas analysis of sample taken', 'timeFrame': 'Intrapulmonary shunt was assessed through blood gas analysis before intervention,before OLV ,10 min after OLV,30 min after OLV,60 min after OLV and 10min after two-lung ventilation'}]",2.0,45 Years,65 Years,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT05188222,Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery,Maltodextrin solution,"['Placebo solution', 'Intervention group', 'Maltodextrin solution', 'Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Left Ventricular Dysfunction,Jewish General Hospital,2025-09-01T16:18:08.336927,True,,,,,"The Effect of Preoperative Maltodextrin on Cardiac Function in Cardiac Surgery Patients with Reduced Left Ventricular Ejection Fraction: a Randomized, Controlled, Double-blind, Clinical Trial",,"['Left Ventricular Dysfunction', 'Quality of Recovery', 'Right Ventricular Dysfunction']","['Cardiac surgery', 'Insulin', 'Maltodextrin', 'Enhanced Recovery After Surgery', 'Quality of Recovery After Surgery']",,2025-12-01,2027-03-01,"[{'measure': 'Intraoperative three-dimensional left ventricular ejection fraction (3-D LVEF)', 'description': 'LVEF as measured from a 3-D dataset', 'timeFrame': 'After induction of anesthesia, prior to the start of surgery, and at the conclusion of surgery, just after chest closure'}]","[{'measure': 'Right Ventricular 3-D EF', 'description': 'Right ventricular ejection fraction as measured from a 3-D dataset', 'timeFrame': 'After induction of anesthesia, prior to the start of surgery, and at the conclusion of surgery, just after chest closure'}, {'measure': 'Left Ventricular Strain', 'description': 'Strain values obtain by left ventricular speckle tracking', 'timeFrame': 'After induction of anesthesia, prior to the start of surgery, and at the conclusion of surgery, just after chest closure'}, {'measure': ""E/e' ratio"", 'description': 'early diastolic mitral inflow velocity to early diastolic mitral annulus velocity', 'timeFrame': 'After induction of anesthesia, prior to the start of surgery, and at the conclusion of surgery, just after chest closure'}, {'measure': 'Cardiac Index', 'description': 'Cardiac index, defined as cardiac output / body surface area, as measured by pulmonary artery catheter', 'timeFrame': 'After induction of anesthesia, prior to the start of surgery, and at the conclusion of surgery, just after chest closure'}, {'measure': 'Vasopressors and Inotrope Use', 'description': 'Dose of vasopressors and inotropes used upon arrival to ICU, and the length of time that they were used', 'timeFrame': 'First 1-7 days after surgery'}, {'measure': 'Time to extubation', 'description': 'Time from ICU arrival to extubation', 'timeFrame': 'First 1-48 hours after surgery'}, {'measure': 'Hyperglycemia', 'description': 'Incidence of glucose levels greater than 10mmol/L', 'timeFrame': 'First 1-48 hours after surgery'}, {'measure': 'Insulin Requirements', 'description': 'Dose of insulin required after surgery', 'timeFrame': 'First 1-48 hours after surgery'}, {'measure': 'Length of ICU stay', 'description': 'Time from surgery to ICU discharge', 'timeFrame': 'First 1-7 days after surgery'}, {'measure': 'Hospital Length of Stay', 'description': 'Time from surgery to discharge from the hospital', 'timeFrame': '1-4 weeks after surgery'}, {'measure': 'Postoperative complications', 'description': 'as death, need for intra aortic balloon pump, dialysis, stroke, positive bacterial culture from the wound or blood', 'timeFrame': '1-4 weeks after surgery'}, {'measure': 'Quality of Recovery', 'description': 'Quality of Recovery after surgery as measured by the QoR-15 questionnaire', 'timeFrame': 'At 48 hours after surgery'}, {'measure': 'Hyperinsulinemic-normoglycemic clamp (HNC) details', 'description': 'Total dose of insulin and glucose needed, and the peak insulin dose required', 'timeFrame': 'During the surgery'}, {'measure': 'Myocardial glycogen content', 'description': 'Measurements of myocardial mitochondrial function', 'timeFrame': 'From biopsies optained intraoperatively, during cardiopulmonary bypass'}]",15.0,18 Years,,ALL,False,OTHER,0.0,70.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00183222,Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking,naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days,['naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Alcohol Dependence,Medical University of South Carolina,2025-09-01T16:18:08.337086,True,,,,,Alcohol Research Center Grant. Component #1. COMBINING MEDICATIONS: ALCOHOL REACTIVITY AND CONSUMPTION,,['Alcohol Dependence'],"['Alcohol dependence', 'Alcoholism', 'Craving']",,2005-05,2005-12,"[{'measure': '""Natural"" alcohol consumption period -- Total number of drinks consumed during the 5 day observation period'}, {'measure': 'Pharmacological effects of alcohol consumption -- Average BAES stimulation score'}, {'measure': 'Limited access alcohol consumption paradigm -- Total number of drinks consumed'}, {'measure': 'Cue induced brain imaging -- Alcohol beverage cue minus neutral beverage cue activity in nucleus accumbens and insula'}]","[{'measure': 'Change in craving as measured by the OCDS from pre-study to end of 5 day period'}, {'measure': 'Change in craving from pre to post-alcohol ingestion'}, {'measure': 'Change in craving during limited-access alcohol consumption'}, {'measure': 'Change in craving during cue-induced brain activity'}, {'measure': 'Side effects of medications'}]",9.0,21 Years,65 Years,ALL,True,OTHER,1.0,160.0,,v2_robust,True,True,False,False,
NCT00517322,Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan,ramipril,"['ramipril', 'irbesartan']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Left Atrial Volume,Università degli Studi dell'Insubria,2025-09-01T16:18:08.337140,True,,,,,Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan,,"['Left Atrial Volume', 'Hypertensive Heart Disease', 'Antihypertensive Drugs', 'Diastolic Function', 'Renin Angiotensin System']","['left atrial volume', 'hypertension', 'ramipril', 'irbesartan', 'diastolic function']",,2007-08,2010-08,"[{'measure': 'left atrial volume', 'timeFrame': 'one year'}, {'measure': 'diastolic function', 'timeFrame': 'one year'}]","[{'measure': 'systolic and diastolic blood pressure', 'timeFrame': 'one year'}]",3.0,40 Years,65 Years,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04492722,A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease,AZD5718,"['Dapagliflozin 10 mg', 'Placebo', 'AZD5718']",3,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Chronic Kidney Disease,AstraZeneca,2025-09-01T16:18:08.337184,True,,,,,"A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease",,['Chronic Kidney Disease'],"['Nephrology', 'Chronic kidney disease', 'Proteinuria', 'Diabetic kidney disease', 'Diabetes mellitus']",The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.,2020-10-01,2022-09-06,"[{'measure': 'Change From Baseline in Reduction of Urine Albumin to Creatinine Ratio (ACR) to Week 20', 'description': 'The dose response effect of AZD5718 on urine ACR at 20 weeks was evaluated. Values less than 1 indicate improvement from baseline.', 'timeFrame': 'Week 1 (Baseline) to Week 20'}]","[{'measure': 'Change From Baseline in Reduction of Urine ACR to Week 12', 'description': 'The dose response effect of AZD5718 on urine ACR at 12 weeks was evaluated. Values less than 1 indicate improvement from baseline.', 'timeFrame': 'Week 1 (Baseline) to Week 12'}, {'measure': 'Number of Participants With Adverse Events and Serious Adverse Events', 'description': 'The safety and tolerability profile of AZD5718 treatment was assessed', 'timeFrame': 'From Screening (Week -4 to 0) to Week 24'}, {'measure': 'Change From Baseline in 24-hours Mean Systolic Blood Pressure to Week 12', 'description': 'The effect of AZD5718 on ambulatory blood pressure was assessed', 'timeFrame': 'Week 1 (Baseline) to Week 12'}, {'measure': 'Plasma Concentrations of AZD5718', 'description': 'The PK of AZD5718 after repeated oral dosing for 20 weeks was evaluated', 'timeFrame': 'From Week 2 to Week 20'}, {'measure': 'Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) to Week 12', 'description': 'The effect of AZD5718 on renal function was evaluated', 'timeFrame': 'Week 1 (Baseline), Week 2, Week 4, Week 8, and Week 12'}]",6.0,18 Years,130 Years,ALL,False,INDUSTRY,2.0,613.0,ACTUAL,v2_robust,True,False,True,True,The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.
NCT02114151,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis,Simeprevir,"['Sofosbuvir', 'Simeprevir']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hepatitis C Virus Infection,Janssen Infectious Diseases BVBA,2025-09-01T16:18:08.337196,True,,,,,"A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis",,['Hepatitis C Virus Infection'],"['Hepatitis C Virus Infection', 'Simeprevir', 'Sofosbuvir', 'HCV', 'Cirrhosis']",,2014-04,2015-04,"[{'measure': 'Percentage of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Actual End of Treatment (EOT)', 'description': 'Participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\\<) 25 international unit per milliliter (IU/mL) (detectable or undetectable) at 12 weeks after the actual end of treatment.', 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Actual End of Treatment (EOT)', 'description': 'Participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\\<) 25 international unit per milliliter (IU/mL) (detectable or undetectable) at 4 weeks after the actual end of treatment.', 'timeFrame': 'Week 16'}, {'measure': 'Percentage of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Actual End of Treatment (EOT)', 'description': 'Participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (\\<) 25 international unit per milliliter (IU/mL) (detectable or undetectable) at 24 weeks after the actual end of treatment.', 'timeFrame': 'Week 36'}, {'measure': 'Percentage of Participants With On-treatment Virologic Response', 'description': 'On-treatment virologic response was determined by HCV RNA results satisfying a specified threshold. \\<LLOQ undetectable was considered as threshold at any time point. The LLOQ value is 25 IU/mL. EOT=End of Treatment.', 'timeFrame': 'Week 2, 4 and End of Treatment (Week 12)'}, {'measure': 'Percentage of Participants With On-treatment Failure', 'description': 'On-treatment failure is defined as participants who do not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of study drug treatment.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With Viral Breakthrough', 'description': 'Viral breakthrough was defined as confirmed greater than (\\>) 1 log10 increase in HCV RNA from nadir or confirmed HCV RNA \\>100 IU/mL in participants who had previously achieved HCV RNA \\< LLOQ (25 IU/mL).', 'timeFrame': 'Up to End of Treatment (Week 12)'}, {'measure': 'Percentage of Participants With Viral Relapse', 'description': 'Viral relapse was defined as participants who did not achieve SVR12 and had HCV RNA \\< LLOQ (25 IU/mL) undetectable at EOT and had HCV RNA \\>= LLOQ (25 IU/mL) during the follow-up period.', 'timeFrame': 'During the Follow-up (Week 24)'}, {'measure': 'Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Overall Body System Score (OBSS) up to Follow-up Week 12', 'description': 'The HCV-SIQv4 OBSS was a self-administered questionnaire that contained 33 items: 29 questions developed to assess severity or frequency of symptoms associated with HCV or its treatment, 3 questions regarding the impact of symptoms on work/school attendance, and 1 question regarding the impact of symptoms on daily activities. A symptom severity score (the mean of responses to the 29 symptom items); each symptom score was transformed to have a range from 0 to 100 (most severe). Higher HCV SIQv4 scores indicates worse symptom severity, more time missed from work/school, and more impairment in daily activities, respectively.', 'timeFrame': 'Baseline, Week 4, Week 12 and Follow-Up Week 12'}, {'measure': 'Change From Baseline in Fatigue Severity Score (FSS) up to Follow-up Week 24', 'description': 'The FSS was a self-administered questionnaire with 9 items developed to assess disabling fatigue that has been used extensively in studies of chronic HCV infection. Item responses were measured on a 7-point Likert scale ranging from strongly disagree (1 point) to strongly agree (7 points). The 9 items were averaged to produce a total score; a lower total score indicates less severe fatigue. FSS scores have a range from 1 to 7 where higher scores indicate more severe fatigue.', 'timeFrame': 'Baseline, Week 12, Follow-up Week 12 and 24'}, {'measure': 'Percentage of Participants With Depression by Using Center for Epidemiologic Studies Depression Scale (CES-D)', 'description': 'The CES-D Scale assessed how often during the past week participants experienced 20 symptoms commonly associated with major depression. The CES-D scores range from 0 (no symptoms) to 60 (all 20 symptoms most or all of the time during the past 5 to 7 days). The CES-D scores between 16 and 23 points indicate mild to moderate depressive illness while CES-D scores \\>=23 indicate probable major depressive illness.', 'timeFrame': 'Baseline, Week 12, Follow-up Week 12 and 24'}, {'measure': 'Change From Baseline in EuroQol 5 Dimension Questionnaire (EQ-5D) up to Follow-up Week 24', 'description': 'The EQ-5D questionnaire was a brief, generic health-related quality of life (HRQOL) assessment that could also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assessed HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a ""thermometer"" visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).', 'timeFrame': 'Baseline, Follow-up Week 12 and 24'}, {'measure': 'Number of Participants Not Achieving SVR Showing Emerging Mutation at Time of Failure in HCV NS3/4A Sequence and NS5B up to Follow-up Week 24', 'description': 'Sequencing of the HCV nonstructural protein 3/4A (NS3/4A) and nonstructural protein 5B (NS5B) genes was done to identify pre-existing sequence polymorphisms and characterize emerging HCV viral variants in participants not achieving SVR. Sequencing data is available for 16 participants.', 'timeFrame': 'Baseline, Day 3, Week 1, 2, 3, 4, 8, 12, Follow-up Week 4, 12 and 24'}]",12.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,103.0,ACTUAL,v2_robust,True,True,False,False,
NCT00762151,A Study to Investigate the Anti-Plaque Effect of AN0128 Toothpaste,Prototype (AN0128 Toothpaste),['Prototype (AN0128 Toothpaste)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Dental Plaque,Pfizer,2025-09-01T16:18:08.337251,True,,,,,Clinical Research Study to Investigate the Anti-Plaque Effect of a Prototype Toothpaste Containing an Anacor Material Via the MGMPI Method,,['Dental Plaque'],['Dental Plaque'],,2007-11,2008-01,"[{'measure': 'Reduction in the gingival margin plaque index in a 24-hour post-treatment (no brushing)', 'timeFrame': 'Baseline (time zero), 24 hour time point'}]",[],1.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT06467851,Effect of Suanzaoren Decoction and Huanglian Wendan Decoction on Biorhythm of Insomnia Patients,Suanzaoren Decoction and Huanglian Wenda Decoction,['Suanzaoren Decoction and Huanglian Wenda Decoction'],1,INTERVENTIONAL,['NA'],,COMPLETED,Chronic Insomnia,The First Affiliated Hospital with Nanjing Medical University,2025-09-01T16:18:08.337296,True,,,,,An Interventional Clinical Study to Investigate the Effect of Oral Administration of Suanzaoren Decoction and Huanglian Wendan Decoction on Human Biorhythms in Patients With Insomnia,,"['Chronic Insomnia', 'Melatonin', 'Circadian Rhythm', 'Suanzaoren Decoction and Huanglian Wendan']",[],,2023-08-31,2024-04-10,"[{'measure': 'Changes from Baseline in melatonin concentration at Week 4', 'description': 'The level of melatonin in the body', 'timeFrame': 'Baseline and Week 4'}]","[{'measure': 'Change from Baseline in the total score of the Pittsburgh sleep quality index (PSQI) at 4 weeks', 'description': 'The Pittsburgh sleep quality index (PSQI) is a validated,self-reported instrument assessing the sleep quality over the past 4 week period. Possible scores range from 0(the best sleep quality) to 21(the worst possible sleep) quality).The higher the score of PSQI, the worse the sleep quality. Change=(Month 1 Score-Baseline Score)', 'timeFrame': 'Baseline and Week 4'}, {'measure': 'Change from Baseline in the total score of Morning and Evening Questionnaire (MEQ) at 4 weeks', 'description': 'The Morning and Evening Questionnaire (MEQ) was used to evaluate the type of biological clock of subjects', 'timeFrame': 'Baseline and Week 4'}]",3.0,18 Years,55 Years,ALL,True,OTHER,0.0,19.0,ACTUAL,v2_robust,True,True,False,False,
NCT03659851,Levosimendan In Patients Undergoing LVAD Implantation,Levosimendan 2.5 MG/ML Injectable Solution,"['Simdax', 'Levosimendan 2.5 MG/ML Injectable Solution']",2,OBSERVATIONAL,[],,UNKNOWN,Left Ventricular Dysfunction,University Hospital Dubrava,2025-09-01T16:18:08.337375,True,,,,,Pretreatment With Levosimendan In Patients Undergoing Left Ventricular Assist Device Implantation,,"['Left Ventricular Dysfunction', 'Right Ventricular Dysfunction', 'Biventricular Failure']","['Heart failure', 'Left ventricular dysfunction']",,2009-06-01,2021-12-31,"[{'measure': 'Measurement of laboratory parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotropic day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, laboratory data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes and improvement/worsening of laboratory parameters depending of preoperative treatment.', 'timeFrame': '9 years'}, {'measure': 'Measurement of hemodynamic parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotrope day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, hemodynamic data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes in hemodynamic outcome depending of preoperative treatment. Hemodynamic parameter 1 and its changes is systemic vascular resistance index (SVRI); expressed by dyn·sec/cm5/m2', 'timeFrame': '9 years'}, {'measure': 'Measurement of hemodynamic parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotrope day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, hemodynamic data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes in hemodynamic outcome depending of preoperative treatment. Hemodynamic parameter 2 and its changes is pulmonary vascular resistance index (PVRI), expressed by dyn·sec/cm5/m2', 'timeFrame': '9 years'}, {'measure': 'Measurement of hemodynamic parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotrope day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, hemodynamic data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes in hemodynamic outcome depending of preoperative treatment. Hemodynamic parameter 3 and its changes is cardiac index (CI) expressed by L/min per m2', 'timeFrame': '9 years'}, {'measure': 'Measurement of hemodynamic parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotrope day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, hemodynamic data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes in hemodynamic outcome depending of preoperative treatment. Hemodynamic parameter 4 and its changes is right stroke work indexes (RVSWI) expressed by g·m/m2/beat', 'timeFrame': '9 years'}, {'measure': 'Measurement of hemodynamic parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotrope day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, hemodynamic data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes in hemodynamic outcome depending of preoperative treatment. Hemodynamic parameter 5 and its changes is left stroke work indexes (LVSWI) expressed by g·m/m2/beat', 'timeFrame': '9 years'}, {'measure': 'Measurement of hemodynamic parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotrope day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, hemodynamic data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes in hemodynamic outcome depending of preoperative treatment. Hemodynamic parameter 6 and its changes is stroke volume index (SVI) expressed by mL/m2', 'timeFrame': '9 years'}, {'measure': 'Measurement of hemodynamic parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotrope day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Further, hemodynamic data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes in hemodynamic outcome depending of preoperative treatment. Hemodynamic parameter 7 and its changes is right ventricular end-diastolic volume (RVEDV) expressed by mL.', 'timeFrame': '9 years'}, {'measure': 'Measurement of echocardiography parameters in patients who underwent LVAD implantation and pretreated with levosimendan or other inotropic day before surgery', 'description': 'Patients will be divided into two groups depending of administrated inotropic pretreatment (levosimendan or other inotropic medications) in preoperative period. Echocardiography data will be collected and analyzed three times in day before surgery and every four hours during first postoperative day after LVAD implantation to estimate changes and improvement/worsening of echocardiography parameters depending of preoperative treatment.', 'timeFrame': '9 years'}]",[],9.0,18 Years,70 Years,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,False,False,False,False,
NCT06358651,Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3),Fasedienol Nasal Spray,"['Fasedienol Nasal Spray', 'Placebo Nasal Spray']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Social Anxiety Disorder,"VistaGen Therapeutics, Inc.",2025-09-01T16:18:08.337505,True,,,,,"US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3)",,['Social Anxiety Disorder'],"['Fasedienol', 'PH94B', 'Social Anxiety Disorder', 'SAD', 'pherine', 'pherine nasal spray', 'acute treatment', 'anxiety treatment', 'acute anxiety treatment', 'anxiotlytic', 'mental health', 'anxiety', 'anxiety nasal spray', 'PSC', 'public speaking challenge', 'social phobia']",,2024-03-28,2026-06,"[{'measure': 'Subjective Units of Distress Scale (SUDS)', 'description': 'The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt).', 'timeFrame': '7 days (Visit 2 to Visit 3)'}]","[{'measure': 'Global Impression Scale of Improvement (CGI-I)', 'description': 'The CGI-I scale is a clinician-rated scale to assess illness improvement. The CGI-I scale includes one item being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change.', 'timeFrame': '7 days (Visit 2 to Visit 3)'}, {'measure': 'Patient Global Impression of Change (PGI-C)', 'description': 'The PGI-C is a patient self-rated scale to assess improvement. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change.', 'timeFrame': '7 days (Visit 2 to Visit 3)'}]",3.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,236.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02829151,Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study),"Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )","['Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )', 'Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol', 'Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Critical Limb Ischemia,Yonsei University,2025-09-01T16:18:08.337520,True,,,,,Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study),,['Critical Limb Ischemia'],"['Peripheral artery disease', 'Critical limb ischemia', 'Angioplasty', 'Antiplatelet therapy']",,2017-02-21,2021-10,"[{'measure': 'Major adverse events', 'description': 'A composition event of all-cause death, myocardial infarction, stroke, repeat revascularization of the target lesion, and unexpected amputation of the target limb between TAP group and DAP A group (aspirin \\& clopidogrel)', 'timeFrame': '12 months'}]","[{'measure': 'Major adverse event between TAP group and DAP B group', 'timeFrame': '12 months'}, {'measure': 'Adverse limb event among the 3 patient groups', 'timeFrame': '12 months'}, {'measure': 'Bleeding complications among the patient groups', 'timeFrame': '12 months'}]",4.0,19 Years,85 Years,ALL,False,OTHER,0.0,390.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00073151,A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer,ABT-751,['ABT-751'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Non-Small Cell Lung Cancer,Abbott,2025-09-01T16:18:08.337568,True,,,,,A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens,,['Non-Small Cell Lung Cancer'],[],,2003-09,2006-01,"[{'measure': 'Objective Response Rate in subjects with NSCLC', 'timeFrame': '1 year'}]","[{'measure': 'Time to Tumor Progression (TTP)', 'timeFrame': '1 year'}, {'measure': 'Survival', 'timeFrame': '2 years'}, {'measure': 'Toxicities associated with treatment administration', 'timeFrame': '1 year'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,30.0,ESTIMATED,v2_robust,True,True,False,False,
NCT00324051,Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet,olanzapine therapy,['olanzapine therapy'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Schizophrenia,Eli Lilly and Company,2025-09-01T16:18:08.337578,True,,,,,PREFERENCE: 12-Week Open Label Trial On Olanzapine Orodispersible Tablet Vs. Oral Olanzapine Preference Study,,['Schizophrenia'],[],,2006-05,2007-09,[{'measure': 'Patient preference measured by a simple preference question.'}],"[{'measure': 'Better treatment adherence as measured by DAI-10'}, {'measure': 'Safety and tolerability as measured by AMDP-5'}, {'measure': 'Determine the predictors of drug compliance'}, {'measure': 'Mean change from baseline to endpoint in body mass index (BMI)'}, {'measure': 'Compare serum ghrelin levels'}, {'measure': 'Differences in subjective appetite from baseline to endpoint using a visual analog scale (VAS)'}, {'measure': 'Effect on the medication compliance, level of medication supervision, and willingness to remain on medication, as measured by Medication Adherence Form (MAF)'}, {'measure': 'Patient preference of the paranoid sub population as measured by a simple preference question'}]",9.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,284.0,ACTUAL,v2_robust,True,True,False,True,
NCT01208051,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,Cediranib,"['Cediranib Maleate', 'Lenalidomide', 'CDC 501', 'AZD2171', 'Recentin', 'CC-5013', 'Cediranib', 'AZD2171 Maleate', 'Revlimid', 'CC5013']",10,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Refractory Differentiated Thyroid Gland Carcinoma,National Cancer Institute (NCI),2025-09-01T16:18:08.337600,True,,,,,Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer,,"['Refractory Differentiated Thyroid Gland Carcinoma', 'Refractory Thyroid Gland Follicular Carcinoma', 'Refractory Thyroid Gland Hurthle Cell Carcinoma', 'Refractory Thyroid Gland Papillary Carcinoma', 'Unresectable Thyroid Gland Carcinoma']",[],,2010-09-09,2020-02-01,"[{'measure': 'Dose Limiting Toxicity', 'description': 'Dose limiting toxicity was defined as any of the following occurring during the first cycle (28 days) of therapy:\n\nHematological toxicities:\n\n* Any grade 4 neutropenia (ANC \\< 500) lasting more than 5 days\n* Any grade 4 neutropenia with concomitant fever (temperature \\> 38.5)\n* Any grade 4 neutropenia and sepsis or other severe infection\n* Any grade 4 thrombocytopenia\n\nAny other grade 3-4 non-hematological adverse drug reactions, except untreated nausea/vomiting, or hypersensitivity reactions.\n\nGrade 4 hypertension\n\nGrade 4 proteinuria Delay in the administration of a subsequent dose of cediranib and lenalidomide exceeding 2 weeks, due to an adverse drug reaction', 'timeFrame': '28 days'}, {'measure': 'Progression-free Survival (Phase II Futility Analysis)', 'description': 'Time from enrollment on study to disease progression or death from any cause. Surviving patients without progression are censored as of the date of the last negative examination. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. This analysis corresponds to the planned futility analysis after 40 events.', 'timeFrame': 'Assessed up to 3 years'}, {'measure': 'Progression-free Survival (Final Results After Crossover)', 'description': 'Time from study enrollment until disease progression or death from any cause. Surviving patients without progression are censored as of the date of the last negative examination. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': 'Assessed up to 3 years'}]","[{'measure': 'Objective Response Rate', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': 'Assessed up to 3 years'}, {'measure': 'Overall Survival (Final Results After Crossover)', 'description': 'Time from randomization to death from any cause. Patients who have not died are censored as of the date last known alive.', 'timeFrame': '24 months'}, {'measure': 'Percent Change in Tumor Size (Phase II)', 'description': 'The percent change in tumor size from baseline to the end of cycle 2 (two months). The post-treatment total sum of lengths for a patient with a new lesion at cycle 2 will be scored as 1.2\\*max(pre-sum, post-sum) to ensure that the appearance of new lesions corresponds to a disease progression per Response Evaluation Criteria in Solid Tumors criteria. In the event of any early deaths prior to cycle 2, a nonparametric rank sum test will be used with deaths ranked at the extreme end of the distribution.', 'timeFrame': 'From baseline to 2 months'}, {'measure': 'Serial Measurements of Thyroid Stimulating Hormone and Thyroglobulin', 'description': 'Thyroid stimulating hormone and thyroglobulin levels', 'timeFrame': 'Up to 3 years'}, {'measure': 'Presence or Absence of B-RAF and RAS Mutations and Outcomes', 'description': 'Presence or absence of B-RAF and RAS mutations at baseline--to be correlated with response rates, progression-free survival, and overall survival.', 'timeFrame': 'Up to 3 years'}]",8.0,18 Years,,ALL,False,NIH,0.0,127.0,ACTUAL,v2_robust,True,True,False,True,
NCT03403751,Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury,Reltecimod 0.5 mg/kg,"['AB103 0.5 mg/kg', 'Reltecimod 0.5 mg/kg', '0.9% Sodium Chloride Injection (Normal saline)', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Acute Kidney Injury,Atox Bio Ltd,2025-09-01T16:18:08.337615,True,,,,,"Phase 3 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)",,"['Acute Kidney Injury', 'Peritonitis', 'Necrotizing Soft Tissue Infection']","['Abdominal sepsis', 'AKI', 'NSTI']",Very slow enrollment of target patient population,2018-05-24,2019-12-14,"[{'measure': 'Freedom From Durable Loss of Renal Function at Day 28', 'description': 'Freedom from durable loss of renal function at Day 28 required all of the following 3 components: alive at Day 28, free of dialysis at Day 28, and less than 37% loss of estimated glomerular filtration rate (eGFR) at Day 28 from patient reference eGFR (measured by Modification of Diet in Renal Disease \\[MDRD\\] formula).', 'timeFrame': '28 Days'}, {'measure': 'Serious Adverse Events (SAEs)', 'description': 'Number of patients experiencing at least one SAE', 'timeFrame': '28 Days'}, {'measure': 'Adverse Events (AEs)', 'description': 'The number of patients experiencing at least one AE.', 'timeFrame': '28 Days'}]","[{'measure': 'Freedom From Durable Loss of Renal Function at Day 14', 'description': 'Freedom from durable loss of renal function at Day 14 required all of the following 3 components: alive at Day 14, free of dialysis at Day 14, and less than 37% loss of estimated glomerular filtration rate (eGFR) at Day 14 from patient reference eGFR (measured by Modification of Diet in Renal Disease \\[MDRD\\] formula).', 'timeFrame': '14 Days'}, {'measure': 'Intensive Care Unit (ICU)-Free Days', 'description': 'ICU-free days refers to the number of days a patient did not spend time in the ICU through Day 28.', 'timeFrame': '28 Days'}, {'measure': 'Ventilator-free Days', 'description': 'Ventilator-free days refers to the number of days a patient was not on a ventilator through Day 28.', 'timeFrame': '28 Days'}, {'measure': 'Vasopressor-free Days', 'description': 'Vasopressor-free days refers to the number of days a patient did not receive a vasopressor through Day 28.', 'timeFrame': '28 Days'}, {'measure': 'Hospital Days', 'description': 'Hospital days refers to the number of days a patient spent time in the hospital.', 'timeFrame': '90 Days'}, {'measure': 'Cumulative Number of Deaths', 'description': 'The number of deaths occurring through Day 90', 'timeFrame': '90 Days'}, {'measure': 'Secondary Infections', 'description': 'Number of patients experiencing at least one secondary infection', 'timeFrame': '28 Days'}, {'measure': 'ICU-free Days by Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Category', 'description': 'The number of days a patient did not spend in the ICU through Day 28, by mSOFA category (mSOFA total score of 1 or less; mSOFA total score of 2 or more). Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.', 'timeFrame': '28 Days'}, {'measure': 'Ventilator-free Days by Day 14 mSOFA Category', 'description': 'The number of days a patient was not on a ventilator through Day 28, by mSOFA category', 'timeFrame': '28 Days'}, {'measure': 'Vasopressor-free Days by Day 14 mSOFA Category', 'description': 'The number of days a patient was not receiving a vasopressor through Day 28, by mSOFA category', 'timeFrame': '28 Days'}, {'measure': 'Hospital Days by Day 14 mSOFA Category', 'description': 'The number of days a patient was in the hospital.', 'timeFrame': '90 Days'}, {'measure': 'Hospital Discharge Location by Day 14 mSOFA Category', 'description': 'Number of patients with more favorable discharge location (home or rehabilitation facility) or less favorable discharge location (skilled nursing facility, another acute care facility, death, other) among patients alive at Day 14.', 'timeFrame': '90 Days'}]",15.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,58.0,ACTUAL,v2_robust,True,False,True,True,Very slow enrollment of target patient population
NCT06512051,A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer,SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin,['SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Advanced or Metastatic Non-small Cell Lung Cancer,"Shanghai Hengrui Pharmaceutical Co., Ltd.",2025-09-01T16:18:08.337627,True,,,,,"A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer",,['Advanced or Metastatic Non-small Cell Lung Cancer'],[],,2024-07-30,2026-10,"[{'measure': 'RP2D', 'description': 'RP2D will be determined on the basis of evaluation on safety, PK, efficacy data in Phase IB stages；', 'timeFrame': 'through phase IB completion, an average of 1 years'}, {'measure': 'Incidence and severity of AE(DLT)', 'description': 'According to NCI-CTCAE v5.0 evaluation criteria from Day 1 to 90 days after last dose；', 'timeFrame': 'from Day1 to 90 days after last dose'}, {'measure': 'ORR', 'description': 'efficacy was assessed every 6 weeks within 48 weeks and every 9 weeks after 48 weeks s as determined by RECIST1.1', 'timeFrame': '18 months after the last subject was enrolled in the group'}]","[{'measure': 'DCR', 'description': 'Since C1D1 every 6 weeks within 48 weeks and every 9 weeks after 48 weeks, and the proportion of subjects whose best response was PR or CR or SD as determined by RECIST1.1；', 'timeFrame': '18 months after the last subject was enrolled in the group'}, {'measure': 'DOR', 'description': 'Since C1D1 every 6 weeks within 48 weeks and every 9 weeks after 48 weeks, and the proportion of subjects whose best response was PR or CR or SD as determined by RECIST1.1；', 'timeFrame': '18 months after the last subject was enrolled in the group'}, {'measure': 'PFS(Investigator evaluation)', 'description': 'Since C1D1 every 6 weeks within 48 weeks and every 9 weeks after 48 weeks, and the proportion of subjects whose best response was PR or CR or SD as determined by RECIST1.1；', 'timeFrame': '18 months after the last subject was enrolled in the group'}, {'measure': 'OS(Investigator evaluation)', 'description': 'Since C1D1 and death from any cause；', 'timeFrame': '18 months after the last subject was enrolled in the group'}]",7.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,248.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00580151,The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children,clonidine,"['clonidine', 'placebo']",2,INTERVENTIONAL,['NA'],,TERMINATED,Pain,"The University of Texas Medical Branch, Galveston",2025-09-01T16:18:08.337637,True,,,,,The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children,,"['Pain', 'Anxiety']","['Pain not controled by morphine', 'Anxiety not controled by lorazepam']",Closed due to no response from PI to IRB,2004-06,2014-06,"[{'measure': 'Pain Reduction', 'description': 'The scale name is ""FACES"" (Faces Pain Rating Scale). Subjects were asked ""rate your WORST PAIN today"" (0 = no pain at all, 1-4 = mild pain, 5-6 = moderate pain, 7-9 = severe pain, 10 = excruciating pain). The Faces Pain Rating Scale should be collected every day and then averaged.', 'timeFrame': 'Average of the 10 days'}]","[{'measure': 'Anxiety Reduction', 'description': 'The ""Fear Thermometer"" measures how much fear subject is currently having. (0=None, 1= A little bit, 2= Some, 3= A lot, 4= Very, very much). The average of daily Value for 10 days.', 'timeFrame': 'Average of the 10 days'}]",2.0,4 Years,20 Years,ALL,False,OTHER,0.0,9.0,ACTUAL,v2_robust,True,False,True,False,Closed due to no response from PI to IRB
NCT04469829,Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome,Secukinumab,"['Secukinumab', 'Methotrexate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Psoriasis,Universita di Verona,2025-09-01T16:18:08.337695,True,,,,,Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome,,"['Psoriasis', 'Metabolic Syndrome']","['psoriasis', 'methotrexate', 'secukinumab', 'metabolic syndrome', 'safety']",,2020-08-01,2022-12-31,"[{'measure': 'Changes in waist circumference at month 12', 'description': 'Changes in waist circumference at month 12', 'timeFrame': '12 month'}, {'measure': 'Changes in BMI at month 12', 'description': 'Changes in BMI at month 12', 'timeFrame': '12 month'}, {'measure': 'Changes in blood pressure at month 12', 'description': 'Changes in blood pressure at month 12', 'timeFrame': '12 month'}, {'measure': 'Changes in fasting glucose at month 12', 'description': 'Changes in fasting glucose at month 12', 'timeFrame': '12 month'}, {'measure': 'Changes in total cholesterol at month 12', 'description': 'Changes in total cholesterol at month 12', 'timeFrame': '12 month'}, {'measure': 'Changes in LDL cholesterol at month 12', 'description': 'Changes in LDL cholesterol at month 12', 'timeFrame': '12 month'}, {'measure': 'changes in (HDL)-cholesterol at month 12', 'description': 'changes in (HDL)-cholesterol at month 12', 'timeFrame': '12 month'}, {'measure': 'Changes in triglycerides at month 12', 'description': 'Changes in triglycerides at month 12', 'timeFrame': '12 month'}, {'measure': 'Changes in AST at month 12', 'description': 'Changes in AST at month 12', 'timeFrame': 'month 12'}, {'measure': 'Changes in ALT at month 12', 'description': 'Changes in ALT at month 12', 'timeFrame': 'month 12'}]","[{'measure': 'PASI75 and PASI90', 'description': 'assessing the PASI 75 and PASI 90 proportion of responders in the two groups at 6 and 12 months follow-up', 'timeFrame': '6 and 12 months'}]",11.0,18 Years,,ALL,True,OTHER,0.0,70.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03277729,A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas,Cyclophosphamide,"['Fosfaseron', 'Claphene', 'Carloxan', 'Cyclophosphan', 'Neosar', 'Cytoxan', 'WR- 138719', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Genuxal', 'Fludara', 'Revimmune', 'Cycloblastine', 'Cicloxal', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cyclophosphamidum', 'Cycloblastin', 'Cyclophosphamide', 'Ledoxina', 'SH T 586', 'Cyclostine', 'Cyclophospham', '2-F-ara-AMP', 'CP monohydrate', 'CTX', 'Beneflur', 'Cytophosphan', 'Cyclophosphane', 'Clafen', 'Genoxal', 'Syklofosfamid', 'Fludarabine Phosphate', ""Fludarabine-5''-Monophosphate"", 'Cyclophosphanum', 'Cytophosphane', 'Ciclofosfamida', 'Cyclophosphamid monohydrate', 'CYCLO-cell', 'Mitoxan']",40,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,ACTIVE_NOT_RECRUITING,Recurrent B-Cell Non-Hodgkin Lymphoma,Fred Hutchinson Cancer Center,2025-09-01T16:18:08.337722,True,,,,,A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas,,"['Recurrent B-Cell Non-Hodgkin Lymphoma', 'Recurrent Chronic Lymphocytic Leukemia', 'Recurrent Diffuse Large B-Cell Lymphoma', 'Recurrent Follicular Lymphoma', 'Recurrent Lymphoplasmacytic Lymphoma', 'Recurrent Mantle Cell Lymphoma', 'Recurrent Marginal Zone Lymphoma', 'Refractory B-Cell Non-Hodgkin Lymphoma', 'Refractory Diffuse Large B-Cell Lymphoma', 'Refractory Follicular Lymphoma', 'Refractory Lymphoplasmacytic Lymphoma', 'Refractory Mantle Cell Lymphoma', 'Refractory Transformed Non-Hodgkin Lymphoma', 'Recurrent Transformed B-Cell Non-Hodgkin Lymphoma', 'Recurrent Transformed Chronic Lymphocytic Leukemia', 'Refractory Marginal Zone Lymphoma', 'Refractory Transformed B-Cell Non-Hodgkin Lymphoma', 'Refractory Transformed Chronic Lymphocytic Leukemia', 'Recurrent Small Lymphocytic Lymphoma', 'Refractory Chronic Lymphocytic Leukemia', 'Refractory Small Lymphocytic Lymphoma', 'Recurrent Central Nervous System Lymphoma', 'Refractory Central Nervous System Lymphoma']","['Lymphoid Leukemia', ""Non-Hodgkin's Lymphoma""]",,2017-12-05,2037-11-16,"[{'measure': 'Dose-limiting Toxicities (DLT) Rate', 'description': 'Will be graded by Common Terminology Criteria for Adverse Events version 4.0. Observed DLT rates will be summarized based on the DLT-Evaluable analysis set. Outcome reported as count of participants in each arm who experienced a DLT.', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Complete Remission', 'description': 'Will be assessed based on the Lugano criteria.', 'timeFrame': 'Up to 15 years'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'A Cox proportional hazards model will be used to evaluate PFS.', 'timeFrame': 'Duration from study enrollment to progression or death due to any cause (whichever comes first), assessed up to 15 years'}, {'measure': 'Overall Survival (OS)', 'description': 'A Cox proportional hazards model will be used to evaluate OS.', 'timeFrame': 'Duration from study enrollment to death due to any cause, assessed up to 15 years'}, {'measure': 'Incidence of Adverse Events', 'description': 'Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.', 'timeFrame': 'Up to 15 years'}]",5.0,18 Years,,ALL,False,OTHER,1.0,53.0,ACTUAL,v2_robust,True,False,False,True,
NCT03797729,Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.,Tirofiban,"['Normal saline', 'Sodium Chloride Injection', 'Tirofiban']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,ST Elevation Myocardial Infarction,Shanghai Zhongshan Hospital,2025-09-01T16:18:08.337741,True,,,,,Early Initiation of Low Dose Tirofiban for Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction.,,['ST Elevation Myocardial Infarction'],"['ST Elevation Myocardial Infarction', 'Tirofiban', 'Percutaneous Coronary Intervention']",,2019-05-14,2021-12,"[{'measure': 'TFG(TIMI flow grades) grade III: complete myocardial perfusion immediately after primary percutaneous coronary intervention detected by DSA(Digital Substraction Angiography).', 'description': 'TIMI flow grades: grade III.', 'timeFrame': 'Immediately after primary percutaneous coronary intervention.'}, {'measure': 'TMP(TIMI myocardial perfusion grades) grade III: complete myocardial perfusion immediately after primary percutaneous coronary intervention detected by DSA(Digital Substraction Angiography).', 'description': 'TIMI myocardial perfusion grades: grade III.', 'timeFrame': 'Immediately after primary percutaneous coronary intervention.'}]","[{'measure': 'Remedial Tirofiban intravenous use during primary percutaneous coronary intervention procedure.', 'description': 'Remedial Tirofiban use during primary percutaneous coronary intervention.', 'timeFrame': 'During the process of primary percutaneous coronary intervention.'}, {'measure': 'ST segment', 'description': 'The sum of the initial ST segment elevation drops 70% or more.', 'timeFrame': '90 minutes after primary percutaneous coronary intervention.'}, {'measure': 'Myocardial microcirculation perfusion estimated by cardiac magnetic (CMR).', 'description': 'Myocardial microcirculation perfusion estimated by cardiac magnetic resonance imaging.', 'timeFrame': '7 days after primary percutaneous coronary intervention.'}, {'measure': 'Major adverse cardiovascular events(MACE), including a composite of all-cause death, nonfatal myocardial infarction, stroke, target vessel revascularization.', 'description': 'Major adverse cardiovascular events, including a composite of all-cause death, nonfatal myocardial infarction, stroke, target vessel revascularization.', 'timeFrame': '30 days after primary percutaneous coronary intervention.'}]",6.0,18 Years,85 Years,ALL,False,OTHER,0.0,500.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01591629,The Effects of ∆-9-THC and Naloxone in Humans,Naloxone,"['Delta-9-THC', 'Placebo', 'Naloxone']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Healthy,Yale University,2025-09-01T16:18:08.337761,True,,,,,Assessment of Cannabinoid-opiate Interactions in Humans With a Cannabis Use Disorder and Healthy Subjects,,['Healthy'],"['Cannabis', 'Marijuana', 'Naloxone', 'THC', 'Psychotic Disorders']",,2011-11-04,2012-06-01,"[{'measure': 'Behavioral Measures', 'description': 'Subjective effects and perceptual alterations will be assessed using the Positive and Negative Symptom Subscale (PANNS).', 'timeFrame': '4 test days'}]","[{'measure': 'Visual analog scales', 'description': 'Will assess subjective effects, perceptual alterations, and cognitive effects.', 'timeFrame': '4 test days'}, {'measure': 'Clinician Administered Dissociative States Scales (CADSS)', 'description': 'Will measure subjective effects, perceptual alterations, and cognitive effects.', 'timeFrame': '4 test days'}, {'measure': 'Psychotomimetic States Inventory (PSI)', 'description': 'Will assess subjective effects, perceptual alterations, and cognitive effects.', 'timeFrame': '4 test days'}, {'measure': 'Marijuana Withdrawal Scale', 'description': 'Will assess subjective effects, perceptual alterations, and cognitive effects.', 'timeFrame': '4 test days'}, {'measure': 'Clinical Opiate Withdrawal Scale', 'description': 'Will assess subjective effects, perceptual alterations, and cognitive effects.', 'timeFrame': '4 test days'}, {'measure': 'Marijuana Craving Scale', 'description': 'Will assess subjective effects, perceptual alterations, and cognitive effects.', 'timeFrame': '4 test days'}, {'measure': 'Neuro cognitive battery', 'description': 'Will assess cognitive effects.', 'timeFrame': '4 test days'}]",8.0,18 Years,55 Years,ALL,True,OTHER,0.0,6.0,ACTUAL,v2_robust,True,True,False,False,
NCT06995729,A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine,Zavegepant,['Zavegepant'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Acute Treatment of Migraine,Pfizer,2025-09-01T16:18:08.337786,True,,,,,"A PHASE 1, MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE",,['Acute Treatment of Migraine'],"['migraine', 'zavegepant', 'pediatric']",,2025-05-16,2027-08-12,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'Cmax is defined as the maximum observed plasma concentration of zavegepant after administration of a single dose', 'timeFrame': 'Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'description': 'Tmax is defined as the time to reach maximum observed plasma concentration', 'timeFrame': 'Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours'}, {'measure': 'Area Under the Curve From Time Zero to infinity.', 'description': 'AUC (0 - inf) is defined as area under the concentration-time curve from time 0 to infinity.', 'timeFrame': 'Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours'}]","[{'measure': 'Number of Participants with All-Causality Treatment-emergent Adverse Events (TEAEs)', 'description': 'An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.', 'timeFrame': 'TEAE is reported from informed consent up to 28 days after administration of study drug.'}, {'measure': 'Number of participants with clinically significant abnormal vital signs', 'description': 'Vital sign measurements include temperature, respiratory rate, pulse rate, and blood pressure.', 'timeFrame': 'Assessed from screening up to 6 days after administration of study drug'}, {'measure': 'Number of participants with clinically significant abnormal laboratory findings', 'description': 'Laboratory assessment includes hematology, chemistry and urinalysis. Clinical significance of laboratory abnormalities was judged by investigator.', 'timeFrame': 'Assessed from screening up to 6 days after administration of study drug'}, {'measure': 'Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. The C-SSRS assessment MUST be performed by an adequately trained, certified, and delegated rater. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of ""yes"" on ""actual attempt""), 3: preparatory acts toward imminent suicidal behavior (""yes"" on ""aborted attempt"", ""interrupted attempt"", ""preparatory acts or behavior""), 4: any suicidal behavior or ideation, suicidal ideation (""yes"" on ""wish to be dead"", ""non-specific active suicidal thoughts"", ""active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent""), 7: self-injurious behavior, no suicidal intent (""yes"" on ""has participant engaged in non-suicidal self-injurious behavior"").', 'timeFrame': 'Assessed from screening up to 6 days after administration of study drug'}]",7.0,6 Years,11 Years,ALL,False,INDUSTRY,0.0,16.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01146431,Memory During Inhalation Anesthesia Performed With or Without Bispectral Index (BIS) in Patients Undergoing Thyroidectomy,Inhaled anesthetics,['Inhaled anesthetics'],1,OBSERVATIONAL,[],,UNKNOWN,Thyroidectomy,Catholic University of the Sacred Heart,2025-09-01T16:18:08.337852,True,,,,,,,['Thyroidectomy'],[],,2010-06,,"[{'measure': 'Implicit memory', 'description': 'Implicit memory will be investigated using free association test: patients, during maintenance of anesthesia, will listen a piece of one of two stories, ""Puss in Boots"" or ""Pinocchio"", each followed by four keywords. Approximately 24 hours after surgery, patients will be asked to associate the first thing that comes to mind with these keywords in order to highlight the presence of implicit memory. The test will be repeated twice and will be positive if the patient will reply with the title of the story or a word of it.', 'timeFrame': 'Approximately 24 hours after surgery'}]","[{'measure': 'Dreams recall', 'description': 'A first interview about dreams recall will be carried out 5 minutes after awakening from anesthesia. Patients will be asked about dream content.', 'timeFrame': 'Approximately 5 minutes after awakening from anesthesia'}, {'measure': 'Explicit memory', 'description': 'Patients will be asked about the last thing they remembered before going to sleep; the first thing they remember when they woke up; and anything which happen in between, including sounds, dreams and imagination.', 'timeFrame': 'Approximately 24 hours after surgery'}, {'measure': 'Dreams recall', 'description': 'Patients will be asked again about dreams recall. The content of dreams will be analyzed using the 5-point Likert scales which contains the following dreams characteristics: memory content, emotional content, emotional intensity, vivid description, amount of sounds, meaning, how much movement, strange, episodic content, references to episodes of life.', 'timeFrame': 'Approximately 24 hours after anaesthesia'}]",4.0,18 Years,70 Years,ALL,False,OTHER,0.0,130.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01688531,A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients,CD0271 0.1%/CD1579 2.5% gel,"['CD0271 0.1%/CD1579 2.5% gel vehicle', 'CD0271 0.1%/CD1579 2.5% gel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Acne,Galderma R&D,2025-09-01T16:18:08.337905,True,,,,,A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients,,['Acne'],[],,2012-08,2013-09,"[{'measure': 'Description and documentation of acne lesions', 'timeFrame': 'over 6 months'}]","[{'measure': 'Treatment effect on acne lesions', 'timeFrame': 'over 6 months'}]",2.0,18 Years,35 Years,ALL,False,INDUSTRY,0.0,38.0,ACTUAL,v2_robust,True,True,False,False,
NCT00378131,"Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia",RC-1291,"['placebo', 'RC-1291']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cancer Cachexia,"Helsinn Therapeutics (U.S.), Inc",2025-09-01T16:18:08.337921,True,,,,,"A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of RC-1291 and Placebo in Patients With Cancer Anorexia/Cachexia",,['Cancer Cachexia'],[],,2006-09,2007-04,"[{'measure': 'Body weight; Lean body mass; Functional performance', 'timeFrame': '4 weeks'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,51.0,ACTUAL,v2_robust,True,True,False,False,
NCT04857931,Colchicine in HFpEF,Colchicine,"['Colchicine', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Heart Failure,Montreal Heart Institute,2025-09-01T16:18:08.337979,True,,,,,A Biomarker Study Assessing the Effects of Colchicine on Inflammation and Extra-Cellular Matrix Turnover in Patients With Heart Failure and Preserved Ejection Fraction.,,"['Heart Failure', 'Inflammation', 'Colchicine']",[],"Lack of funds to support opening of new sites to help patient recruitment, which was found to be more challenging than initially expected.",2022-06-17,2023-03-07,"[{'measure': 'Change in hs-CRP (C reactive protein)', 'description': 'The primary endpoint will be the change from baseline to 6 months in hs-CRP (mg/L), a circulating biomarker of inflammation.', 'timeFrame': 'Change from baseline to 6 months in hs-CRP'}]","[{'measure': 'Change in circulating biomarkers of hemodynamic stress', 'description': 'Change in circulating biomarkers of hemodynamic stress (N-terminal pro-brain natriuretic peptide (NT-proBNP, in pg/mL))', 'timeFrame': 'Change from baseline to 6 months in other biomarkers'}, {'measure': 'Change in circulating biomarkers of myocardial injury', 'description': 'Change in circulating biomarkers of myocardial injury (hs-TnT, Troponin, in ng/L)', 'timeFrame': 'Change from baseline to 6 months in other biomarkers'}, {'measure': 'Change in left ventricular (LV) diastolic function', 'description': 'Change in a combination of echocardiography-based measures assessing left ventricular (LV) diastolic function', 'timeFrame': 'Change from baseline to 6 months in LV diastolic function'}, {'measure': 'Change in functional status and symptoms', 'description': 'Change in functional status and New York Heart Association (NYHA) class', 'timeFrame': 'Change from baseline to 6 months in functional status and symptoms'}]",5.0,40 Years,,ALL,False,OTHER,0.0,14.0,ACTUAL,v2_robust,True,False,True,False,"Lack of funds to support opening of new sites to help patient recruitment, which was found to be more challenging than initially expected."
NCT00505531,Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics,Tramadol Extended Release Oral Capsule,"['Ultram ER', 'Benadryl', 'Diphenhydramine', 'Tramadol Extended Release Oral Capsule']",4,OBSERVATIONAL,[],,TERMINATED,Chronic Pain,Massachusetts General Hospital,2025-09-01T16:18:08.337997,True,,,,,Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics,,['Chronic Pain'],['Pain'],Not enough data to analyze the results.,2007-06,2007-12,"[{'measure': 'Tramadol ER reduces VAS for patients with OIH', 'description': 'VAS will be recorded at each visit and then analyzed', 'timeFrame': '6 weeks'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,1.0,7.0,ACTUAL,v2_robust,False,False,True,False,Not enough data to analyze the results.
NCT01370031,Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices,Clenil® Modulite® via AeroChamber Plus™,"['Clenil® Modulite® via AeroChamber Plus™ plus charcoal block', 'Clenil® Modulite® via AeroChamber Plus™', 'Clenil® Modulite® via Volumatic™ spacer', 'Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Asthma,Chiesi Farmaceutici S.p.A.,2025-09-01T16:18:08.338014,True,,,,,"Pilot, Open-Label, Randomized, Repeated Dose, 4-Way Cross-Over, Clinical Pharmacology Study of Beclomethasone Dipropionate (Clenil® Modulite®) 250 µg HFA pMDI Using the Aerochamber Plus™ Spacer Device Versus the Volumatic™ Spacer Device Without or With Charcoal Block in Asthmatic Adults Patients",,['Asthma'],"['Asthma', 'PK', 'Adults']",,2011-04,2011-06,"[{'measure': 'Systemic exposure to B17MP (active metabolite of BDP) at steady state after repeated dose of Clenil® Modulite®', 'description': 'Plasma AUC0-12h,ss for B17MP', 'timeFrame': '0-12 hours'}, {'measure': 'Systemic exposure to B17MP (active metabolite of BDP) at steady state after repeated dose of Clenil® Modulite®', 'description': 'Plasma Cmax,ss for B17MP', 'timeFrame': '0-12 hours'}]","[{'measure': 'evaluation of the pharmacokinetic profile of BDP', 'description': 'AUC and Cmax for BDP', 'timeFrame': '0-12 hours'}, {'measure': 'Vital signs assessment', 'description': 'Heart rate and Blood pressure assessment', 'timeFrame': 'from screening (week -1) to week 8'}, {'measure': 'haematology and blood chemistry assessment', 'description': 'haematology and blood chemistry assessment', 'timeFrame': 'at screening (week - 1) and week 8'}, {'measure': 'Number of patients with Adverse events', 'description': 'Adverse events', 'timeFrame': 'during the 11 weeks of study'}, {'measure': 'FEV1 predose assessment', 'description': 'FEV1 predose assessment as lung function parameter', 'timeFrame': 'from screening (week-1) to week 8'}]",7.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT02352831,Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma,Tosedostat,"['Xeloda', 'Capecitabine', 'Tosedostat']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Pancreatic Cancer,Washington University School of Medicine,2025-09-01T16:18:08.338069,True,,,,,Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma,,"['Pancreatic Cancer', 'Cancer of Pancreas', 'Cancer of the Pancreas', 'Pancreas Cancer']",[],Insufficient funding and drug supply from manufacturer,2015-08-31,2018-10-19,"[{'measure': 'Phase I Only: Recommended Phase II Dose of Tosedostat', 'description': 'The recommended phase 2 dose (RP2D) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle. If 0 or 1 of 6 patients in Dose Level 1 experience DLT during the first cycle, Dose Level 1 will be presumed to be the RP2D.\n\nDLTs are followed through completion of the first cycle.', 'timeFrame': 'Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)'}, {'measure': 'Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLTs)', 'description': '* Possibly/probably/definitely related to study treatment in 1st cycle (cyc)\n\n  \\*Grade (Gr) 4 neutropenia \\>7 day, Febrile neutropenia of any duration with temperature ≥ 38.5 °C, Gr 4 anemia requires transfusion therapy on more than 2 occasions in 7 days, Gr 4 thrombocytopenia\n* Possibly/probably/definitely related gr. 3/4 non-hematologic toxicity that occurs 1st cyc with the following EXCEPTIONS:\n\n  * Gr 3 nausea/vomiting/diarrhea/anorexia \\<72 hours that returns to Gr 1 prior to the start of cyc 2, Gr 3 hand-foot syndrome will only be considered a DLT for patients who have received 1 week of supportive care treatment with no improvement, Gr 3 fatigue that returns to Gr 1 prior to the start of cyc 2, Gr 3 flu-like symptoms \\<72 hours that returns to Gr 1 prior to start of cyc 2, Gr 3 arthralgia or myalgias \\<72 hours that return to Gr 1 prior to the start of cyc 2, Gr 3 potassium/phosphorus/magnesium that is asymptomatic or of non-clinical significance \\<72 hours, Gr 3 hypoalbuminemia', 'timeFrame': 'Completion of cycle 1 of all participants in Phase I portion of study (approximately 14 months)'}, {'measure': 'Progression-free Survival (PFS) Rate', 'description': '* PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.\n* Progressive disease (PD)\n\n  * Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).\n  * Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.', 'timeFrame': '3 months'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': '* ORR = Complete response + partial response\n* Target lesions\n\n  * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.\n  * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.\n* Non target lesions \\*Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\\<10 mm short axis).', 'timeFrame': 'Up to 18 months'}, {'measure': 'Time-to-progression (TTP)', 'description': '-Progressive disease (PD)\n\n* Target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).\n* Non target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase', 'timeFrame': 'Up to 24 months'}, {'measure': 'Overall Survival Rate (OS)', 'timeFrame': 'Up to 1 year from completion of treatment (median treatment length 81.50 days (28.00-346.00)'}, {'measure': 'Number of Participants With a CA19-9 Response', 'description': '* CA19-9 is a tumor marker that is used in the management of pancreatic cancer. Rising CA19-9 levels may mean the tumor is growing and decreasing CA19-9 levels may mean the tumor is shrinking or the amount of cancer in the body is decreasing\n* A CA19-9 response means that the tumor marker has decreased over baseline (before treatment started) levels', 'timeFrame': 'Completion of treatment (median treatment length 81.50 days (28.00-346.00)'}]",7.0,18 Years,,ALL,False,OTHER,0.0,16.0,ACTUAL,v2_robust,True,False,True,False,Insufficient funding and drug supply from manufacturer
NCT00772031,NINDS CRC Chronic Migraine Treatment Trial,propranolol LA,"['placebo', 'Inderal LA', 'propranolol LA', 'topiramate']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Migraine,Anne Lindblad,2025-09-01T16:18:08.338148,True,,,,,NINDS Clinical Research Collaboration Chronic Migraine Treatment Trial,,['Chronic Migraine'],"['chronic migraine, migraine prevention, chronic headache']",,2008-10,2010-09,"[{'measure': 'Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline', 'description': '(Number of moderate to severe headache days (as defined by the International Headache Society Guidelines (2006)) counted over a 28 day diary period at baseline (before treatment with propranolol or placebo)) minus (the number of moderate to severe headache days counted over a 56 day diary period (weeks 16-24 post treatment) divided by 2).', 'timeFrame': 'Baseline (pre-randomization), months 5 and 6 post randomization'}]","[{'measure': 'Number of Subjects Experiencing at Least a 30% Reduction in 28-day Moderate to Severe Headache Days', 'timeFrame': '6 months post randomization'}, {'measure': 'Number of Subjects Experiencing at Least a 50% Reduction in 28-day Moderate to Severe Headache Days', 'timeFrame': '6 months'}, {'measure': ""Change From Baseline in Beck's Depression Inventory FastScreen Score at 6 Months"", 'description': ""Total score from Beck's Depression Inventory FastScreen at 6 months minus total score from Beck's Depression Inventory FastScreen at baseline. Scale scores range from 0 to 21 with higher values indicating worsening depression. the following categories separate participants into groups of depression levels: Minimal (Score 0-3), Mild (Score 4-8),Moderate (Score 9-12),Severe (Score 13-21)."", 'timeFrame': 'Baseline and 6 months'}, {'measure': 'Change From Baseline in Migraine Disability Assessment (MIDAS) Score at 6 Months', 'description': 'MIDAS scoring ranges from 0 to 270. The scores are divided into ranges of disability with higher scores indicating increased disability as follows: 0-5 (Grade I - Minimal or infrequent disability); 6-10 (Grade II - Mild or infrequent disability); 11-20 (Grade III - Moderate disability); and 21+ (Grade IV - Severe disability).', 'timeFrame': 'Baseline and 6 months'}, {'measure': 'Change From Baseline in Migraine Specific Quality of Life (MSQ)-Role Restrictive Score at 6 Months', 'description': 'The MSQ (version 2.1 copyrighted 1992, 1996, 1998 by Glaxo Wellcome Inc., Research Triangle Park, North Carolina) is a 14 item questionnaire. Item responses are summed and scored as a total score and three domains: Role Preventive, Role Restrictive, Emotional Function. Scores within each domain are rescaled to range from 0 to 100. A lower score indicates a poorer quality of life associated with that domain or in total. Because of the observed interaction within a domain, only domain scores were used as outcome measures for this study.', 'timeFrame': 'baseline and 6 months post randomization'}, {'measure': 'Change From Baseline in Migraine-Specific Quality of Life (MSQ)-Role Preventive at 6 Months', 'description': 'The MSQ (version 2.1 copyrighted 1992, 1996, 1998 by Glaxo Wellcome Inc., Research Triangle Park, North Carolina) is a 14 item questionnaire. Item responses are summed and scored as a total score and three domains: Role Preventive, Role Restrictive, Emotional Function. Scores within each domain are rescaled to range from 0 to 100. A lower score indicates a poorer quality of life associated with that domain or in total. Because of the observed interaction within a domain, only domain scores were used as outcome measures for this study.', 'timeFrame': 'Baseline and 6 months'}, {'measure': 'Change From Baseline in Migraine-Specific Quality of Life (MSQ) - Emotional Function at 6 Months', 'description': 'The MSQ (version 2.1 copyrighted 1992, 1996, 1998 by Glaxo Wellcome Inc., Research Triangle Park, North Carolina) is a 14 item questionnaire. Item responses are summed and scored as a total score and three domains: Role Preventive, Role Restrictive, Emotional Function. Scores within each domain are rescaled to range from 0 to 100. A lower score indicates a poorer quality of life associated with that domain or in total. Because of the observed interaction within a domain, only domain scores were used as outcome measures for this study.', 'timeFrame': 'Baseline and 6 Months'}]",8.0,18 Years,,ALL,True,INDUSTRY,2.0,191.0,ACTUAL,v2_robust,True,True,False,False,
NCT03198702,Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy,Botulinum toxin type A injection,['Botulinum toxin type A injection'],1,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Obstetrical Brachial Plexus Palsy,"University Hospital, Brest",2025-09-01T16:18:08.338202,True,,,,,Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy,,['Obstetrical Brachial Plexus Palsy'],"['physiotherapy', 'children', 'shoulder deformation', 'obstetrical brachial plexus palsy']",,2018-05-17,2025-04,"[{'measure': 'Change in the percentage posterior migration of the humeral head measured on axial MRI slices between 11 (before the BTI carried out at 12 months) and 18 months of age (6 months post BTI).', 'timeFrame': 'At 18 month age'}]","[{'measure': 'compare the effectiveness of BTI with Sham procedure in preventing an increase in glenoid retroversion and three-dimensional deformity', 'description': 'With 2D glenoid changes measured on axial MRI and 3D glenoid version and migration of the humeral head measured on MRI', 'timeFrame': 'At 18 month age'}, {'measure': 'compare the effectiveness of BTI with Sham procedure in the improvement of active and passive joint range of motion and upper limb function', 'description': 'By measurement of passive range of motion, Active Movement Scale and Assistive Hand Assessment.', 'timeFrame': 'At 18 month age'}, {'measure': 'confirm good clinical tolerance of BTI treatment', 'description': 'By measurement of the number of serious and non-serious adverse events', 'timeFrame': 'At 18 month age'}, {'measure': 'evaluate the effects of BTI on trophicity, fibrosis and fatty infiltration of the injected muscles as well as muscle balance of the OBPP shoulder', 'description': 'Bu measurement of the degree of trophicity, fibrosis and fatty infiltration of the injected muscles (supraspinous, infraspinous, teres minor, subscapularis, teres major, pectoralis major, deltoid and latissimus dorsi)', 'timeFrame': 'At 18 month age'}, {'measure': 'determine if the treatment changes the frequency and type of surgical interventions in the long term', 'description': ""the number and type of surgical interventions undergone by the children in each group will be recorded during routine medical follow-up (as in usual practice) until the child's 10th birthday following unblinding (9 years and 6 months after the BTI)."", 'timeFrame': 'every years on 2 years old to 10 years old'}]",6.0,10 Months,11 Months,ALL,False,OTHER,0.0,62.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00952302,Study of the Effects of Iron Levels on the Lungs at High Altitude,Iron sucrose,"['Venofer', 'Iron sucrose', 'Normal saline']",3,INTERVENTIONAL,['NA'],,COMPLETED,Pulmonary Hypertension,University of Oxford,2025-09-01T16:18:08.338236,True,,,,,Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension,,"['Pulmonary Hypertension', 'Mountain Sickness']","['Hypoxia', 'Iron', 'Hypoxia-Inducible Factor 1', 'Chronic mountain sickness']",,2008-10,2008-11,"[{'measure': 'Change in pulmonary artery systolic pressure', 'timeFrame': 'One week (SLR arm) and one month (CMS arm)'}]",[],1.0,18 Years,60 Years,MALE,True,OTHER,1.0,33.0,ACTUAL,v2_robust,True,True,False,False,
NCT03180502,Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma,Temozolomide,"['M and B 39831', 'Methazolastone', 'M & B 39831', 'TMZ', 'Temodal', 'Temcad', 'SCH 52365', 'Temizole', 'RP-46161', 'Temodar', 'Temomedac', 'Temozolomide', 'Gliotem', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045']",15,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Anaplastic Astrocytoma,NRG Oncology,2025-09-01T16:18:08.338257,True,,,,,"A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas",,"['Anaplastic Astrocytoma', 'Anaplastic Oligoastrocytoma', 'Anaplastic Oligodendroglioma', 'Diffuse Astrocytoma', 'Glioma', 'Oligoastrocytoma', 'Oligodendroglioma', 'WHO Grade 3 Glioma']",[],,2018-01-23,2027-06-01,"[{'measure': 'Change in cognition as measured by the Clinical Trial Battery Composite (CTB COMP) score', 'description': 'Assessed with a general linear model with maximum likelihood estimation. Three models will be conducted. Baseline CTB COMP score, treatment arm, time, treatment by time interaction (if significant) and stratification factors will be included in the model for the primary endpoint. A second model will be built with these same variables and relevant covariates, such as total volume of intracranial disease, gross tumor volume (GTV) and clinical tumor volume (CTV) size, histology, anti-epileptic use, and disease response to therapy (as measured by Response Assessment in Neuro-Oncology \\[RANO\\] criteria). Other than baseline score CTB COMP, treatment arm, and time, only covariates with a p-value \\< 0.10 will be retained in the model. A third model will be conducted at 10 years using the additional time points of neurocognitive assessments.', 'timeFrame': 'Baseline to up to 10 years'}]","[{'measure': 'Cognition as measured individually by Hopkins Verbal Learning Test Revised (HVLT-R), Trail Making Test (TMT) parts A and B, and Controlled Oral Word Association (COWA)', 'description': 'The HVLT-R, TMT parts A \\& B, and COWA will be analyzed independently using a general linear model with maximum likelihood estimation. Standardized scores will be used.', 'timeFrame': 'Up to 10 years'}, {'measure': 'Change in symptoms as measured by M.D. Anderson Symptom Inventory Brain Tumor (MDASI-BT)', 'description': 'The change from baseline to each follow-up time point (calculated as baseline score subtracted from follow-up score) will be compared between treatment arms using a t-test, or Wilcoxon test if the data is not normally distributed. A reduced one-sided significance level will be used for the multiple comparisons in the MDASI-BT using the Bonferroni adjustment (alpha=0.017 for disease related factors and alpha=0.025 for treatment related symptoms and overall impact). A general linear model with maximum likelihood estimation will be used to assess symptom trends across time. Baseline score, treatment arm, time, treatment by time interaction (if significant), stratification factors, and relevant covariates, such as total volume of, GTV and CTV size, histology, anti-epileptic use, and disease response to therapy (as measured by RANO criteria) will be included as covariates in each model.', 'timeFrame': 'Baseline to up to 10 years'}, {'measure': 'Change in quality of life as measured by the Linear Analog Scale Assessment (LASA) scale', 'description': 'The change from baseline to each follow-up time point (calculated as baseline score subtracted from follow-up score) will be compared between treatment arms using a t-test, or Wilcoxon test if the data is not normally distributed. A one-sided alpha=0.05 will be used for the LASA. A general linear model with maximum likelihood estimation will be used to assess symptom and QOL trends across time. Baseline score, treatment arm, time, treatment by time interaction (if significant), stratification factors, and relevant covariates, such as total volume of, GTV and CTV size, histology, anti-epileptic use, and disease response to therapy (as measured by RANO criteria) will be included as covariates in each model. Other than baseline score, treatment arm, and time, only covariates with a p-value \\< 0.10 will be retained in the model.', 'timeFrame': 'Up to 10 years'}, {'measure': 'Overall survival (OS)', 'description': 'OS will be estimated using the Kaplan-Meier method and compared between arms using the log rank test. Cox proportional hazards models will be used for OS adjusting for treatment arm and stratification factors.', 'timeFrame': 'From randomization to the date of death, assessed up to 10 years'}, {'measure': 'Local control as assessed by Response Assessment in Neuro-Oncology (RANO) criteria', 'description': ""Local control will be estimated using cumulative incidence, treating death prior to an event as a competing risk. Gray's test will be used to compare local control rates between arms. Cause-specific Cox proportional hazards models will be used for local control, adjusting for treatment arm and stratification factors. A two-sided significance level of 0.05 will be used for comparisons between arms."", 'timeFrame': 'Up to 10 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'A confidence interval will be used to determine if the PFS rate in the proton arm is greater than that in the photon at 1 year. PFS will be estimated using the Kaplan-Meier method and compared between arms using the log rank test. Cox proportional hazards models will be used for PFS adjusting for treatment arm and stratification factors.', 'timeFrame': 'From date of randomization to date of progression or death, whichever occurs first, assessed up to 10 years'}, {'measure': ""Incidence of adverse events (AEs) graded according to the National Cancer Institute's Common Terminology for Adverse Events version 5.0"", 'description': ""Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. Grade 3+ treatment related AEs will be compared between arms using a chi-square test, or Fisher's exact test if cell frequencies are \\< 5, at the one-sided 0.05 significance level."", 'timeFrame': 'Up to 10 years'}, {'measure': 'IDH mutation as assessed by sequencing and 1p19q status as assessed by fluorescence in situ hybridization', 'description': 'A single test will be done for both IDH and 1p19q testing centrally while sites will perform a separate test for IDH and 1p19q. The results from the central and site testing will be compared using the kappa statistic. The asymptotic test of H0: k=0 will be performed using the Z-statistic to determine the strength of agreement. Concordance and discordance rates will be tabulated.', 'timeFrame': 'Baseline'}]",9.0,18 Years,,ALL,False,OTHER,1.0,120.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02773602,Dexamethasone or Clonidine as Adjuncts to Ropivacaine for Caudal Analgesia on Analgesia Duration in Children,Dexamethasone,"['Normal Saline', 'Clonidine', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Postoperative Pain,"The University of Texas Health Science Center, Houston",2025-09-01T16:18:08.338361,True,,,,,Effect of Dexamethasone or Clonidine When Given as Adjuncts to Ropivacaine for Caudal Analgesia on Duration of Analgesia Compared to Placebo in Children,,['Postoperative Pain'],"['Analgesia', 'caudal analgesia', 'ropivacaine', 'clonidine', 'dexamethasone']",,2011-05,2017-12,"[{'measure': 'Duration of block', 'description': 'Duration of block is calculated from time of first pain medication minus time of caudal placement. Caudal placement occurs before pain medication is administered.', 'timeFrame': 'Within 24 hours after surgery'}]","[{'measure': 'Number of children between the groups who received pain medication in the PACU', 'timeFrame': 'Within 24 hours after surgery'}, {'measure': 'Number of children between the groups who received pain medication after hospital discharge', 'timeFrame': 'Within 24 hours after surgery'}, {'measure': 'number of children group between the groups who required pain medication in first 24 h after surgery', 'timeFrame': 'Within 24 hours after surgery'}, {'measure': 'Awakening time', 'description': 'Awakening time is calculated from the end of anesthesia to time to reach Steward Score of 6. Patients who are awake, coughing/crying, and have purposeful movements are assigned a Steward Score of 6.', 'timeFrame': 'Within 24 hours after surgery'}]",5.0,6 Months,6 Years,ALL,True,OTHER,0.0,155.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05913102,"A Prospective, Split-face, Randomized Study of the Poly-D, L Lactic Acid (PDLLA) for Photoaged Skin",PDLLA,['PDLLA'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Pigmentation,Jin Cheol Kim,2025-09-01T16:18:08.338762,True,,,,,"A Prospective, Split-face, Randomized Study of the Poly-D, L Lactic Acid (PDLLA) for Photoaged Skin",,"['Pigmentation', 'Pigmentation Disorder']",[],,2022-09-28,2023-12-31,"[{'measure': 'change of lightness value', 'description': 'change of lightness value by a chromometer', 'timeFrame': 'Chromometer will be taken before treatment and 4,8,12 weeks after last treatment.'}]","[{'measure': 'patinent global assessment for skin condition', 'description': 'patinent global assessment for skin condition by a self-questionnaire', 'timeFrame': 'Questionnaire will be taken before treatment and 4,8,12 weeks after last treatment.'}, {'measure': 'investigator global assessment score for pigmentation', 'description': 'investigator global assessment score for pigmentation by clinical photos', 'timeFrame': 'Photos will be taken before each treatment and 4,8,12 weeks after the final treatment.'}, {'measure': 'Fitzpatrick wrinkle and elastosis scale', 'description': 'Fitzpatrick wrinkle and elastosis scale by clinical photos', 'timeFrame': 'Photos will be taken before each treatment and 4,8,12 weeks after the final treatment'}]",4.0,30 Years,,FEMALE,True,OTHER,0.0,40.0,ACTUAL,v2_robust,True,False,False,False,
NCT04229602,Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers,Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg,"['EFEXOR® XR', 'Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Bioequivalence Study,Beijing Tongren Hospital,2025-09-01T16:18:08.338777,True,,,,,Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules and EFEXOR® XR Under Fed Conditions in Chinese Healthy Volunteers,,['Bioequivalence Study'],[],,2020-01-02,2020-07-02,"[{'measure': 'Bioequivalence based on Cmax', 'description': 'Cmax - Maximum Observed Concentration (of Venlafaxine in Plasma)', 'timeFrame': 'Blood samples collected over 72 hour period'}, {'measure': 'Bioequivalence based on AUC0-t', 'description': 'AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)', 'timeFrame': 'Blood samples collected over 72 hour period'}, {'measure': 'Bioequivalence based on AUC0-∞', 'description': 'AUC0-∞- Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)', 'timeFrame': 'Blood samples collected over 72 hour period'}]",[],3.0,18 Years,65 Years,ALL,True,OTHER,0.0,28.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02799602,Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer,BAY1841788 / darolutamide (ODM-201),"['BAY1841788 / darolutamide (ODM-201)', 'Standard ADT (androgen deprivation therapy)', 'Docetaxel', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Metastatic Hormone-sensitive Prostate Cancer,Bayer,2025-09-01T16:18:08.338843,True,,,,,"A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer",,['Metastatic Hormone-sensitive Prostate Cancer'],[],,2016-11-30,2023-04-11,"[{'measure': 'OS From Date of Randomization Until Death From Any Cause - Number of Events', 'description': 'Overall survival (OS) was defined as the time from the date of randomization until death from any cause.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nLong-term (Survival) follow-up period: After Active follow-up, patients continued to be contacted approximately every 12 weeks by phone. The end of the Survival follow-up period was defined as when the patient died, was lost to follow-up, withdrew consent, or at the end-of-study.', 'timeFrame': 'From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)'}, {'measure': 'OS From Date of Randomization Until Death From Any Cause - Month', 'description': 'Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nLong-term (Survival) follow-up period: After Active follow-up, patients continued to be contacted approximately every 12 weeks by phone. The end of the Survival follow-up period was defined as when the patient died, was lost to follow-up, withdrew consent, or at the end-of-study.\n\nMedian, percentile and other 95% CIs were computed using Kaplan-Meier estimates.\n\nNA = Value cannot be estimated due to censored data', 'timeFrame': 'From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)'}]","[{'measure': 'Number of Participants With TEAEs', 'description': 'TEAEs = Treatment-emergent adverse events, were defined as any event(s) arising or worsening after the first dose of darolutamide or placebo, until 30 days after the last dose of darolutamide or placebo administration.', 'timeFrame': 'From the first dose of darolutamide or placebo until 30 days after the last dose of darolutamide or placebo administration up to cut-off date for the final completion analysis 11 APR 2023 (approximately 77 months)'}, {'measure': 'Time to Castration-Resistant Prostate Cancer (CRPC) - Number of Events', 'description': 'Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of one of the following events: PSA progression, Radiological progression by bone lesions, or Radiological progression by soft tissue and visceral lesions.\n\nTreatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the first occurrence of an CRPC event up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Castration-Resistant Prostate Cancer (CRPC) - Month', 'description': 'Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of one of the following events: PSA progression, Radiological progression by bone lesions, or Radiological progression by soft tissue and visceral lesions.\n\nTreatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nNA = Value cannot be estimated due to censored data', 'timeFrame': 'From randomization of the first participant to the first occurrence of an CRPC event up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Pain Progression - Number of Events', 'description': 'Time to pain progression was defined as the time from randomization to the first date a patient experienced pain progression.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the first occurrence of a pain progression event up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Pain Progression - Month', 'description': 'Time to pain progression was defined as the time from randomization to the first date a patient experienced pain progression.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nNA = Value cannot be estimated due to censored data', 'timeFrame': 'From randomization of the first participant to the first occurrence of a pain progression event up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Symptomatic Skeletal Event Free Survival (SSE-FS) - Number of Events', 'description': 'Symptomatic skeletal event-free survival (SSE-FS) was defined as the time from randomization to the first occurrence of an SSE or death from any cause, whichever occurred first.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the first occurrence of an SSE event or death from any cause, whichever occurred first up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Symptomatic Skeletal Event Free Survival (SSE-FS) - Month', 'description': 'Symptomatic skeletal event-free survival (SSE-FS) was defined as the time from randomization to the first occurrence of an SSE or death from any cause, whichever occurred first.\n\nTreatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nNA = Value cannot be estimated due to censored data', 'timeFrame': 'From randomization of the first participant to the first occurrence of an SSE event or death from any cause, whichever occurred first up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to First Symptomatic Skeletal Event (SSE) - Number of Events', 'description': 'Time to the first SSE was defined as the time from randomization to the first occurrence of an SSE. Identical to the definition used for SSE-FS. Death was not considered as an event in this endpoint.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the first occurrence of an SSE event up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to First Symptomatic Skeletal Event (SSE) - Month', 'description': 'Time to the first SSE was defined as the time from randomization to the first occurrence of an SSE. Identical to the definition used for SSE-FS. Death was not considered as an event in this endpoint.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nNA = Value cannot be estimated due to censored data', 'timeFrame': 'From randomization of the first participant to the first occurrence of an SSE event up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Initiation of Subsequent Antineoplastic Therapy - Number of Events', 'description': 'Time to initiation of subsequent systemic antineoplastic therapy was defined as the time from randomization to the initiation of first subsequent systemic antineoplastic therapy.\n\nTreatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the initiation of first subsequent systemic antineoplastic therapy up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Initiation of Subsequent Antineoplastic Therapy - Month', 'description': 'Time to initiation of subsequent systemic antineoplastic therapy was defined as the time from randomization to the initiation of first subsequent systemic antineoplastic therapy.\n\nTreatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nNA = Value cannot be estimated due to censored data', 'timeFrame': 'From randomization of the first participant to the initiation of first subsequent systemic antineoplastic therapy up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Worsening of Disease-Related Physical Symptoms - Number of Events', 'description': 'Time to worsening of disease-related physical symptoms was defined as the time from randomization to the first date a patient experienced an increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the first increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Worsening of Disease-Related Physical Symptoms - Month', 'description': 'Time to worsening of disease-related physical symptoms was defined as the time from randomization to the first date a patient experienced an increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire.\n\nTreatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the first increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Initiation of Opioid Use for ≥7 Consecutive Days - Number of Events', 'description': 'Time to the initiation of opioid use for ≥7 consecutive days was defined as the time from randomization to the date of the first opioid use for ≥7 consecutive days. Data of opioid use related to cancer pain was included in the analysis, and opioid use for non-malignant causes was excluded.\n\nTreatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.', 'timeFrame': 'From randomization of the first participant to the first opioid use for ≥7 consecutive days up to 25 OCT 2021 cut-off date approximately 59 months'}, {'measure': 'Time to Initiation of Opioid Use for ≥7 Consecutive Days - Month', 'description': 'Time to the initiation of opioid use for ≥7 consecutive days was defined as the time from randomization to the date of the first opioid use for ≥7 consecutive days. Data of opioid use related to cancer pain was included in the analysis, and opioid use for non-malignant causes was excluded.\n\nTreatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance.\n\nActive follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.\n\nNA = Value cannot be estimated due to censored data', 'timeFrame': 'From randomization of the first participant to the first opioid use for ≥7 consecutive days up to 25 OCT 2021 cut-off date approximately 59 months'}]",17.0,18 Years,,MALE,False,INDUSTRY,1.0,1306.0,ACTUAL,v2_robust,True,True,False,True,
NCT05028153,Azithromycin Treatment of Hospitalized Children With Asthmatic Symptoms,Azithromycin Oral Liquid Product,['Azithromycin Oral Liquid Product'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Childhood Asthma With Acute Exacerbation,Copenhagen Studies on Asthma in Childhood,2025-09-01T16:18:08.338875,True,,,,,"Azithromycin Treatment of Hospitalized Children With Asthmatic Symptoms: A Double-blinded, Randomized, Controlled Study",,['Childhood Asthma With Acute Exacerbation'],"['Asthma', 'Infections', 'Wheeze', 'Antibiotics']",,2022-11-14,2032-11-13,"[{'measure': 'Duration in days of the asthma-like episode from the start of randomization.', 'description': 'Number of days based on a diary.', 'timeFrame': '1-30 days'}]","[{'measure': 'Change in symptom score.', 'description': 'Using a previously validated symptom scoring model based on a diary. The score range is from 0 (no symptoms) and up to 3 (depending on presence of one or more of the followings symptoms: Cough, breathlessness and wheezing).', 'timeFrame': 'From day 1 after randomization to completion of each randomized asthmatic episode aged 1-5 years.'}, {'measure': ""Effect modification in relation to the child's respiratory microbiota profile."", 'description': 'Airway microbiota, pathogenic bacteria and vira as measured by 16S-rRNA and whole genome sequencing.', 'timeFrame': 'Sample time, day 1'}, {'measure': ""Effect modification in relation to the child's respiratory immunological profile."", 'description': 'Evaluation of immune mediator profiles (cytokine and chemokine levels) in the upper airway epithelial lining fluid.', 'timeFrame': 'Sample time, day 1'}, {'measure': 'The length of hospitalization (days)', 'description': 'Determined by participants medical record.', 'timeFrame': '1-30 days'}, {'measure': 'Need for SABA during the asthma-like episode', 'description': 'Number of days based on a diary.', 'timeFrame': '1-30 days'}, {'measure': 'Need for oral corticosteroids (OCS) during the asthma-like episode.', 'description': 'Number of days based on a diary.', 'timeFrame': '1-30 days'}, {'measure': 'Stratification of the above analyzes.', 'description': 'On the basis of the presence or absence of bacteria/microbiota in the respiratory tract, based on outcomes 3, 4 and 5.', 'timeFrame': 'Sample time, day 1'}, {'measure': 'Number of days away from daycare offers.', 'description': 'Number of days based on a diary.', 'timeFrame': '1-30 days'}, {'measure': 'Health economic gain based on treatment costs and lost earnings. lost earnings for parent / guardian (s)', 'description': 'The number of days home from daycare causing parent absenteeism due to illness based on this diary registration.', 'timeFrame': '1-30 days'}, {'measure': 'Gut microbiome profile', 'description': 'Occurrence, diversity and abundance of gut microbiota using 16S rRNA sequencing and whole genome sequencing.', 'timeFrame': '1-30 days'}, {'measure': 'Resistance profiles', 'description': 'Occurrence, diversity and abundance of antibiotic resistance genes as assessed by metagenome sequencing.', 'timeFrame': '1-30 days'}, {'measure': 'Adverse Event (AE) registration', 'description': 'Number of events and type of event based on a diary.', 'timeFrame': '1-30 days'}]",13.0,12 Months,71 Months,ALL,False,OTHER,0.0,320.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02329353,Effect of Probiotics on Chronic Periodontitis in Smoker and Non- Smokers,Lactobacillus brevis CD2 Lozenges,"['Probiotics', 'Lactobacillus brevis CD2 Lozenges']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Periodontitis,Next Gen Pharma India Pvt. Ltd.,2025-09-01T16:18:08.338970,True,,,,,Clinical And Microbiological Analysis Of Orally Administered Lactobacillus Probiotic Lozenges In Chronic Periodontitis Patients Among Smokers And Non-smokers And Its Correlation With Clinical Parameters - A Clinico-Microbiological Study,,['Chronic Periodontitis'],[],,2015-02,2016-12,"[{'measure': 'Improvement in Clinical Periodontal Indices', 'description': 'Improvement in clinical periodontal indices, namely, Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD)', 'timeFrame': '8 weeks'}]","[{'measure': 'Change in microbiological indices', 'description': 'Porphyromonas gingivalis, Tanerella forsythus', 'timeFrame': '8 weeks'}]",2.0,30 Years,55 Years,ALL,False,INDUSTRY,1.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT00194753,Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12,Paclitaxel,"['Paclitaxel', 'G-CSF', 'Cyclophosphamide', 'Doxorubicin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Breast Neoplasm,University of Washington,2025-09-01T16:18:08.338981,True,,,,,"Adjuvant Therapy for High-Risk Localized Breast Cancer With Weekly Adriamycin +/- Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Taxol for 12 Weeks, Phase II",,['Breast Neoplasm'],['Breast cancer'],,2001-12,2011-03,"[{'measure': 'Delivered dose intensity', 'timeFrame': '24 weeks'}, {'measure': 'Toxicity', 'timeFrame': '24 weeks'}]","[{'measure': 'Time to treatment failure', 'timeFrame': '7 years'}, {'measure': 'Overall survival', 'timeFrame': '7 years'}]",4.0,18 Years,,ALL,False,OTHER,2.0,80.0,ACTUAL,v2_robust,True,True,False,False,
NCT06490653,Tranexamic Acid Versus Blood Stopper Treatments in Epistaxis Management,Blood Stopper (Ankaferd),['Blood Stopper (Ankaferd)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Epistaxis Nosebleed,Ankara Ataturk Sanatorium Training and Research Hospital,2025-09-01T16:18:08.339142,True,,,,,Comparison of the Efficacy of Tranexamic Acid and Blood Stopper Treatments in Bleeding Control in Patients With Epistaxis: A Randomized Controlled Trial,,['Epistaxis Nosebleed'],"['Epistaxis', 'Nosebleed', 'Ankaferd', 'Tranexamic acid']",,2024-10,2025-12,"[{'measure': 'Cessation of bleeding', 'description': 'Primary outcome was definition cessation in bleeding at 10-minutes after performing local drug interventions.', 'timeFrame': '10-minutes after performing local drug interventions.'}]","[{'measure': 'Re-bleeding', 'description': 'The secondary outcome was a comparison of the re-bleeding rate within 24 hours in the two treatments groups.', 'timeFrame': 'From cessation of bleeding to re-bleeding within 24-hours.'}]",2.0,18 Years,,ALL,False,OTHER_GOV,0.0,186.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00311753,Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients,Certoparin,"['Certoparin', 'Heparin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Embolism,Novartis Pharmaceuticals,2025-09-01T16:18:08.339154,True,,,,,An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients,,['Embolism'],"['heparin, thromboprophylaxis, medical patients, acutely ill', 'Acutely ill non surgical patients', 'Immobilization']",,2006-02,,"[{'measure': 'The occurrence of thromboembolic events (proximal or distal DVT, PE or VTE related death) during treatment', 'timeFrame': '10 ± 2 days'}]","[{'measure': 'Thromboembolic events during follow-up period of 3 months', 'timeFrame': '90 days (± 7 days) after the end of the treatment'}, {'measure': 'Safety endpoints occurring during the treatment period: Hemorrhage (major or minor), Thrombocytopenia, Symptomatic HIT type II, Induction of HIT-II specific antibodies', 'timeFrame': '10 ± 2 days'}]",3.0,40 Years,,ALL,,INDUSTRY,0.0,342.0,ACTUAL,v2_robust,True,True,False,True,
NCT01212653,Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS),Simponi,"['Golimumab', 'Simponi']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Ankylosing Spondylitis(AS),Chinese University of Hong Kong,2025-09-01T16:18:08.339176,True,,,,,Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS,,['Ankylosing Spondylitis(AS)'],"['Ankylosing Spondylitis', 'Golimumab', 'Simponi', 'Anti-TNF alpha', 'EPCs', 'Vascular stiffness']",,2010-10,2013-05,"[{'measure': 'Effect of Golimumab treatment on the progression of subclinical atherosclerosis', 'description': 'Effect of Golimumab treatment on the progression of subclinical atherosclerosis at 12 months compared with baseline as evaluated by Intima-Media Thickness (IMT).', 'timeFrame': 'Month 12'}]","[{'measure': 'Effect of Golimumab treatment on the changes in arterial stiffness', 'description': 'Effect of Golimumab on changes in arterial stiffness at 12 months compared with baseline as evaluated by Pulse Wave Velocity and Augmentation Index.', 'timeFrame': 'Month 12'}, {'measure': 'Changes on the number and function of Endothelial Progenitor Cells in Ankylosing Spondylitis before and after 1 year of Golimumab compared with baseline.', 'description': 'The number and function of EPCs before and after golimumab will be assessed using Wilcoxin-sign rank test', 'timeFrame': 'Month 12'}, {'measure': 'To correlate the changes in Intima-Media Thickening, Pulse Wave Velocity, Augmentation Index and Endothelial Progenitor Cells with the changes in markers of disease activity.', 'description': ""Correlation between the change in disease activity markers (BASDAI, ESR, CRP, and MRI global activity score) and the change in IMT, PWV and AIx and EPC number will be assessed using Spearman's test"", 'timeFrame': 'Month 12'}, {'measure': 'Incremental cost-utility ratio of the treatment of Golimumab.', 'description': 'Utility will be assessed using the EuroQol 5D (EQ5D) and the Short-Form 36 (SF-36), at baseline and every visit.Utility is used to calculate quality-adjusted life years (QALYs). The incremental cost-utility ratio expressed as ""(annual costs of golimumab treatment - annual costs of placebo treatment) / additional QALY gain by golimumab treatment"" is calculated.', 'timeFrame': 'Month 12'}]",5.0,18 Years,75 Years,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT05539053,"Efficacy of NAC for the Prevention and Relief of PIPN in Women With Ovarian, Tubal, and Peritoneal Cancer",N Acetylcysteine A,"['N Acetylcysteine B', 'N Acetylcysteine A']",2,INTERVENTIONAL,['NA'],,COMPLETED,Chemotherapy-induced Peripheral Neuropathy,Department of Medical Services Ministry of Public Health of Thailand,2025-09-01T16:18:08.339247,True,,,,,"Efficacy of N-acetylcysteine for the Prevention and Relief of Paclitaxel-induced Peripheral Neuropathy in Women With Ovarian, Tubal, and Peritoneal Cancer: an Open-label, Randomized Controlled Trial",,['Chemotherapy-induced Peripheral Neuropathy'],[],,2022-11-01,2023-12-30,"[{'measure': 'Paclitaxel-induce peripheral neuropathy', 'description': 'Assessment of grade of peripheral neuropathy by CTCAE v.5.0', 'timeFrame': 'Day 0 (before chemotherapy administration), at the end of cycle 1, at the end of cycle 2, and at the end of cycle 3 (each cycle is 21 days)'}]","[{'measure': 'Severity of paclitaxel-induce peripheral neuropathy', 'description': 'Assessment of severity of peripheral neuropathy by Patient Neurotoxicity Questionnaire (PNQ)', 'timeFrame': 'Day 0 (before chemotherapy administration), at the end of cycle 1, at the end of cycle 2, and at the end of cycle 3 (each cycle is 21 days)'}, {'measure': 'Quality of life associated paclitaxel-induce peripheral neuropathy', 'description': 'Assessment of quality of life using FACT/GOG-Ntx', 'timeFrame': 'Day 0 (before chemotherapy administration), at the end of cycle 1, at the end of cycle 2, and at the end of cycle 3 (each cycle is 21 days)'}]",3.0,18 Years,,FEMALE,True,OTHER_GOV,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT03977753,"Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts",2LVERU® or 2LVERU® JUNIOR,"['2LVERU® or 2LVERU® JUNIOR', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Common Wart,Labo'Life,2025-09-01T16:18:08.339375,True,,,,,Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.,,"['Common Wart', 'Flat Wart', 'Plantar Wart']",[],,2020-02-17,2027-03-16,"[{'measure': 'Disappearance of warts at the end of treatment (6-month visit)', 'description': 'A wart will be considered as disappeared if the colour and texture of the skin has returned to normal and can no longer be felt to the touch.', 'timeFrame': '6 months'}]","[{'measure': 'Disappearance of warts at 4 months.', 'timeFrame': '4 months'}, {'measure': 'Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 4 months', 'timeFrame': '4 months'}, {'measure': 'Warts recurrence at 9 months', 'timeFrame': '9 months'}, {'measure': 'Pain evaluation during the study by visual analogic scale and consumption of antalgic medication.', 'description': 'Minimum value: 0 (better outcome) Maximum Value: 10 (worse outcome)', 'timeFrame': '6 months'}, {'measure': 'Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug.', 'timeFrame': '6 months'}, {'measure': 'Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 6 months', 'timeFrame': '6 months'}]",7.0,3 Years,,ALL,False,INDUSTRY,0.0,162.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02134353,A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects,Inhaled mannitol,"['Inhaled mannitol', 'Placebo Comparator: Arm B - Control']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Cystic Fibrosis,Syntara,2025-09-01T16:18:08.339389,True,,,,,Long Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects,,['Cystic Fibrosis'],[],,2014-09,2017-02,"[{'measure': 'Mean Change in FEV1 (mL) From Baseline (Visit 1) Over the 26-week Treatment Period (to Visit 4).', 'description': 'The mean absolute change from baseline FEV1 (mL) over 26 weeks (measured at week 6, 14 and 26) will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach.\n\nLeast square means presented are for the average change over the 6, 14, and 26 week visits.\n\nMissing values due to withdrawal for reasons related to safety or efficacy were imputed using a baseline observation carried forward approach (BOCF).', 'timeFrame': '26 weeks'}]","[{'measure': 'Mean Change From Baseline FVC (mL) Over the 26-week Treatment Period', 'description': 'To determine whether inhaled mannitol (400 mg b.i.d.) is superior to control for improving lung function as measured by mean change from baseline forced vital capacity (FVC) (mL) over the 26-week treatment period in adult subjects with cystic fibrosis (CF).\n\nThe mean absolute change from baseline FVC (mL) over 26 weeks will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach.\n\nLeast square means presented are for the change from baseline averaged over the treatment period (ie the average of the changes at 6 weeks, 14 weeks and 26 weeks).\n\nMissing values due to withdrawal for reasons related to safety or efficacy were imputed using a baseline observation carried forward approach (BOCF).', 'timeFrame': '26 weeks'}]",2.0,18 Years,99 Years,ALL,False,INDUSTRY,0.0,423.0,ACTUAL,v2_robust,True,True,False,True,
NCT00541853,CCB Safety Study in Treatment of Hypertension of ADPKD,Candesartan,"['Candesartan and Cilnidipine', 'Candesartan', 'Candesartan plus non-CCB agents']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,"Kidney, Polycystic, Autosomal Dominant",Kyorin University,2025-09-01T16:18:08.339414,True,,,,,Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients,,"['Kidney, Polycystic, Autosomal Dominant']","['Autosomal Dominant Polycystic Kidney Disease', 'Hypertension', 'Angiotensin-2 Receptor Blocker', 'Calcium Channel Blocker', 'Kidney Volume']",,2007-12,2012-11,"[{'measure': 'Kidney Volume measured by MRI.', 'timeFrame': 'Every year'}]","[{'measure': 'Serum creatinine, hemodialysis, cardiovascular events and central nervous vascular events', 'timeFrame': 'any time during study period'}]",2.0,20 Years,60 Years,ALL,False,OTHER,1.0,150.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03527537,Gestational Diabetes and Pharmacotherapy (GAP),Insulin,['Insulin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Gestational Diabetes,Medical College of Wisconsin,2025-09-01T16:18:08.339509,True,,,,,Gestational Diabetes and Pharmacotherapy (GAP) - a Randomized Controlled Trial Investigating Timing of Pharmacotherapy Initiation for Patients with Gestational Diabetes,,['Gestational Diabetes'],[],,2021-05-04,2026-10-01,"[{'measure': 'Composite Neonatal Outcome', 'description': 'Our primary outcome will be a composite adverse neonatal outcome associated with gestational diabetes:\n\nlarge-for-gestational age macrosomia birth trauma preterm birth neonatal hypoglycemia hyperbilirubinemia', 'timeFrame': 'The data will be collected up to 6 weeks of life'}]","[{'measure': 'Cesarean Delivery Rate', 'description': 'Our secondary outcome will be to compare the rates of cesarean delivery between two thresholds for medical treatment initiation for GDM.', 'timeFrame': 'The data will be collected up to 6 weeks postpartum'}, {'measure': 'Preeclampsia', 'timeFrame': 'The data will be collected up to 6 weeks postpartum'}]",3.0,18 Years,45 Years,FEMALE,False,OTHER,1.0,416.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06017037,REward Processing And Citalopram Study,Citalopram 20mg,"['Citalopram 20mg', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Anhedonia,University of Oxford,2025-09-01T16:18:08.339598,True,,,,,REward Processing And Citalopram Study,,['Anhedonia'],[],,2023-05-19,2024-05-01,"[{'measure': 'Reward & aversive learning: behavioural correlates', 'description': 'Optimal choice learning rate of conditioned stimuli to win and loss outcomes.\n\nDuring an instrumental reinforcement learning task participant will complete trials with a pair of symbols (the valence will either be loss or win, which is implicit).\n\nOne symbol will be high chance of that outcome (either win or loss depending on the valence of the pair) and the other low chance of the outcome.\n\nIn the win pair the optimal choice is the high chance symbol (i.e. to win), in the loss pair the optimal choice is the low chance option (i.e. avoid loss).\n\nIn each allocation group the proportion of participants making an optimal choice will be calculated on a trial-by-trial basis. This provide the learning rate outcome.', 'timeFrame': 'Day 7-9 of treatment'}, {'measure': 'Reward & aversive learning: neural correlates', 'description': 'Activity of a network of brain regions associated with reward learning (during anticipation and outcome), in response to a positive \\& negative outcomes in reward learning task.\n\nThis will be the difference in BOLD activation in certain brain regions (pertinent to reward processing) between allocation groups during the anticipation stage and the outcome stage of the instrumental learning task.', 'timeFrame': 'Day 7-9 of treatment'}]","[{'measure': 'Resting state', 'description': 'Resting state fMRI activation', 'timeFrame': 'Day 7-9 of treatment'}, {'measure': 'Subjective rating of primary reward', 'description': 'Subjective rating of four tastes (sweet, salt, sour \\& bitter) in terms of intensity, anticipation of pleasurableness and actual pleasurableness.', 'timeFrame': 'Day 0 and day 7-9 of treatment'}, {'measure': 'Reward & aversive learning: behavioural volatile reward learning task: total money won', 'description': 'Amount of money won/lost \\& total amount of money received.', 'timeFrame': 'day 7-9 of treatment'}, {'measure': 'Motivational reward task', 'description': 'Participants are asked to accept or decline hypothetical offers made of various combinations of reward and physical effort (grip strength). For a limited number of offers participants are asked to actually expend effort for offers too. The investigators will examine\n\n1. Proportion of offer acceptance for various levels of reward and effort\n2. proportion of accepted offers successfully obtained', 'timeFrame': 'day 7-9 of treatment'}, {'measure': 'Reward & aversive learning: behavioural volatile reward learning task: learning rate', 'description': 'Learning rate of optimal choices changes during the task. Proportion of participants in each allocation arm making an optimal choice on a trial-by-trial basis will provide the learning rate for each group.\n\nProvides sensitive measure of reward and aversive learning rates.', 'timeFrame': 'day 7-9 of treatment'}]",7.0,18 Years,65 Years,ALL,True,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06214637,Effectiveness of Melissa Officinalis for the Treatment of Probable Sleep Bruxism in Children and Adolescents,Melissa,"['Melissa', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Sleep Bruxism,Universidade Federal do Rio de Janeiro,2025-09-01T16:18:08.339636,True,,,,,Effectiveness of Melissa Officinalis in Various Concentrations for the Treatment of Probable Sleep Bruxism in Children and Adolescents: Controlled and Randomized Clinical Trial,,"['Sleep Bruxism', 'Adolescent', 'Children', 'Temporomandibular Joint Disorders']","['Sleep bruxism', 'Homeopathy', 'Adolescent', 'Children']",,2023-08-01,2024-09-30,"[{'measure': 'General objective', 'description': 'Number of participants who had a positive response to the proposed treatment, that is a reduction in bruxism episodes during the sleep period.', 'timeFrame': 'Twice a month'}]",[],1.0,5 Years,16 Years,ALL,True,OTHER,0.0,42.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00679237,Risk Reduction in Coronary Heart Disease,"betablocker, diuretics, ACEI, ARB,","['betablocker, diuretics, ACEI, ARB,', 'statins, ezetimibe', 'metformin, glimepiride, insulin']",3,INTERVENTIONAL,['NA'],,COMPLETED,Coronary Heart Disease,Sorlandet Hospital HF,2025-09-01T16:18:08.339645,True,,,,,Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study,,['Coronary Heart Disease'],[],,2007-09,2019-12,"[{'measure': 'New cardiovascular events (MACE)', 'timeFrame': '3 years'}]",[],1.0,18 Years,79 Years,ALL,False,OTHER_GOV,1.0,1600.0,ACTUAL,v2_robust,True,True,False,False,
NCT00287937,"Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors",vorinostat,"['L-001079038', 'Anzatax', 'JM-8', 'SAHA', 'Zolinza', 'paclitaxel', 'Asotax', 'Carboplat', 'vorinostat', 'CBDCA', 'Paraplatin', 'carboplatin', 'Taxol', 'suberoylanilide hydroxamic acid', 'TAX', 'Paraplat']",16,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Unspecified Adult Solid Tumor, Protocol Specific",National Cancer Institute (NCI),2025-09-01T16:18:08.339679,True,,,,,Phase I Study Of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) in Combination With Paclitaxel /Carboplatin for Advanced and Refractory Solid Malignancies,,"['Unspecified Adult Solid Tumor, Protocol Specific']",[],,2005-07,,"[{'measure': 'MTD of vorinostat defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT', 'timeFrame': '21 days'}]","[{'measure': 'Toxicity graded using the CTC version 2.0', 'description': 'Tables will be created to summarize these toxicities by dose and by course.', 'timeFrame': 'Up to 1 month after completion of study treatment'}, {'measure': 'Overall survival', 'description': 'Summarized with Kaplan-Meier plots.', 'timeFrame': 'Up to 1 month after completion of study treatment'}, {'measure': 'Time to failure', 'description': 'Summarized with Kaplan-Meier plots.', 'timeFrame': 'Up to 1 month after completion of study treatment'}, {'measure': 'Response defined using the RECIST criteria', 'timeFrame': 'Up to 1 month after completion of study treatment'}]",5.0,18 Years,,ALL,False,NIH,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT02637037,A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects,dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon),"['dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)', 'dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)', 'dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)', 'dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Bioequivalence,AstraZeneca,2025-09-01T16:18:08.339807,True,,,,,A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants in Healthy Subjects Under Fasting and Fed Conditions,,"['Bioequivalence', 'Fixed Dose Combination Tablets', 'Healthy Male and Female Subjects']","['dapagliflozin/metformin XR 5/500 mg', 'dapagliflozin/metformin XR10/1000 mg', 'bioequivalence', 'fixed dose combination tablets', 'pharmacokinetic', 'type 2 Diabetes Mellitus (T2DM)', 'safety']",,2015-12-21,2016-04-07,"[{'measure': 'Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State', 'description': 'To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state.', 'timeFrame': 'Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period'}, {'measure': 'AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.', 'description': 'To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state', 'timeFrame': 'Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period'}, {'measure': 'Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State', 'description': 'To evaluate the Bioequivalence for Dapagliflozin and Metformin following administration Dapagliflozin/Metformin XR 5/500 mg and 10/1000 mg Manufactured at Mt. Vernon plant, US, Compared to Humacao plant, Puerto Rico, in the Fasted or Fed state', 'timeFrame': 'Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period'}]","[{'measure': 'Time to Reach Maximum Plasma Concentration (t Max)', 'description': 'To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.', 'timeFrame': 'Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period'}, {'measure': 'Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]', 'description': 'To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.', 'timeFrame': 'Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period'}, {'measure': 'Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]', 'description': 'To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.', 'timeFrame': 'Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period'}, {'measure': 'Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]', 'description': 'To characterize and compare the pharmacokinetic profiles of dapagliflozin and metformin when administered as the 2 fixed-dose combination formulations and in the fed and fasted states.', 'timeFrame': 'Days 1 to 3: pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose for each treatment period'}]",7.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,80.0,ACTUAL,v2_robust,True,True,False,False,
NCT05547737,"Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer",Camrelizumab,['Camrelizumab'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,NSCLC,Henan Cancer Hospital,2025-09-01T16:18:08.339905,True,,,,,"Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer",,['NSCLC'],[],,2022-09-21,2025-09-21,"[{'measure': 'Objective Response Rate (ORR) in second-line treatment of patients with non-small cell lung cancer based on Camrelizumab regimen', 'description': 'CR+PR', 'timeFrame': 'Up to 12 months'}]","[{'measure': 'Evaluation of Progression Free survival (PFS) in patients with non-small cell lung cancer based on first-line/second-line treatment with Camrelizumab', 'description': 'Progression free survival (PFS) according to RECIST 1.1', 'timeFrame': 'Up to 36 months'}, {'measure': 'Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen', 'description': 'Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen', 'timeFrame': 'Up to 12 months'}, {'measure': 'OS', 'description': 'Overall survival', 'timeFrame': 'Up to 12 months'}, {'measure': 'To evaluate the safety of Camrelizumab based first/second line therapy in patients with non-small cell lung cancer', 'description': 'according to NCI-CTCAE version 5.0', 'timeFrame': 'Up to 12 months'}]",5.0,18 Years,75 Years,ALL,,OTHER_GOV,1.0,500.0,ESTIMATED,v2_robust,False,False,False,True,
NCT03606837,68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging,68Ga-PSMA-617 PET/CT,"['68Ga-PSMA-617 PET/CT', '68Ga-RM2 PET/CT']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Prostate Cancer,"University Hospital, Bordeaux",2025-09-01T16:18:08.339959,True,,,,,"Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Intermediate Risk Prostate Cancer Candidates for Radical Prostatectomy",,['Prostate Cancer'],"['Prostate Cancer', '68Ga-RM2', '68Ga-Prostate Specific Membrane Antigen', 'PET/CT', 'Prostate cancer imaging']",,2019-07-11,2023-07-11,"[{'measure': 'Median Standardized Uptake Value (SUV)', 'description': 'Uptake intensity of 68Ga-PSMA-617', 'timeFrame': 'Day 0 (inclusion) or Day 2 to 21 (Visit 2)'}]","[{'measure': 'Gleason score', 'timeFrame': 'Day 3 to 60 (Last visit)'}, {'measure': 'Receptor density Bmax', 'timeFrame': 'Day 0 (inclusion) or Day 2 to 21 (Visit 2)'}, {'measure': 'Local radioactive concentration (cpm)', 'timeFrame': 'Day 0 (inclusion) or Day 2 to 21 (Visit 2)'}, {'measure': 'Immunoreactive score (IRS)', 'timeFrame': 'Day 3 to 60 (Last visit)'}, {'measure': 'New World Health Organization 2016 classification', 'timeFrame': 'Day 3 to 60 (Last visit)'}]",6.0,18 Years,,MALE,False,OTHER,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,
NCT00488137,Efficacy and Safety Study of Prucalopride to Treat Chronic Constipation,Prucalopride,"['Resolor', 'Prucalopride']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Constipation,Movetis,2025-09-01T16:18:08.339973,True,,,,,"A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation",,['Constipation'],"['constipation', 'prucalopride', 'QOL', 'SCBM', 'PAC-SYM']",,1998-03,1999-07,"[{'measure': 'Proportion of subjects with an average of 3 or more SCBM per week', 'timeFrame': '12 weeks'}]","[{'measure': 'Secondary efficacy variables: 1) Symptom variables 2) QOL variables', 'timeFrame': '12 weeks'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,716.0,ACTUAL,v2_robust,True,True,False,False,
NCT06423937,Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer,combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab,['combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Colorectal Cancer,Fudan University,2025-09-01T16:18:08.340039,True,,,,,"A Single-center, Open-label, Double-cohort Clinical Study of Fruquintinib Plus Camrelizumab Plus HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer Patients With Liver Metastasis After the Failure of First-line Treatment",,['Colorectal Cancer'],[],,2024-05,2027-07,"[{'measure': 'objective response rate (ORR)', 'description': 'Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1.', 'timeFrame': '24 months'}]","[{'measure': 'disease control rate (DCR)', 'description': 'DCR was defined as the percentage of participants who have a confirmed complete response#CR# or partial response#PR# or stable disease#SD# per RECIST 1.1 as assessed by investigator', 'timeFrame': '24 months'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator', 'timeFrame': '24 months'}, {'measure': 'Progression-Free Survival rate at 6 months', 'description': 'The proportion of patients who did not experience disease progression or death from treatment initiation to 6 months', 'timeFrame': '6 months'}, {'measure': 'overall survival (OS)', 'description': 'OS is the time from enrollment to death due to any cause.', 'timeFrame': '24 months'}, {'measure': 'Adverse events as assessed by NCI CTCAE v5.0', 'description': 'overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use', 'timeFrame': '24 months'}]",6.0,18 Years,75 Years,ALL,False,OTHER,0.0,129.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02367937,PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study,PRC-4016 (icosabutate),"['PRC-4016 (icosabutate)', 'Midazolam, omeprazole, flurbiprofen and simvastatin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Pronova BioPharma,2025-09-01T16:18:08.340060,True,,,,,"A Phase I, Open-Label Study to Assess the Effects of PRC-4016 (Icosabutate) on the Pharmacokinetics of Midazolam, Omeprazole, Flurbiprofen and Simvastatin in Healthy Male/Female Subjects",,['Healthy'],['Phase I drug-drug interaction'],,2014-08,2014-10,"[{'measure': 'Area under curve for effect of PRC-4016 at steady state on the PK of CYP3A substrates (midazolam, simvastatin), a CYP2C9 substrate (omeprazole) and a CYP2C19 substrate (flurbiprofen) in healthy male/female subjects.', 'description': 'Blood-sampling', 'timeFrame': '24 h postdose'}, {'measure': 'Peak plasma concentration for effect of PRC-4016 at steady state on the PK of CYP3A substrates (midazolam, simvastatin), a CYP2C9 substrate (omeprazole) and a CYP2C19 substrate (flurbiprofen) in healthy male/female subjects.', 'description': 'Blood-sampling', 'timeFrame': '24 hours post-dose'}]","[{'measure': 'Number of participants with adverse events as a measure of safety and tolerability of PRC-4016 co-administered with midazolam, omeprazole, flurbiprofen and simvastatin in healthy male/female subjects.', 'description': 'Adverse event recording', 'timeFrame': '24 h postdose'}]",3.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT02599337,Bioequivalence Study of Sorafenib Tablet and Nexavar,Nexavar,"['Sorafenib', 'sarafenib', 'Nexavar']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Fasting,Yabao Pharmaceutical Group,2025-09-01T16:18:08.340072,True,,,,,"Randomized, Open-label, 3-way Reference Replicated Crossover Bioequivalence Study of Sorafenib 200 mg Tablet and Nexavar (Reference) Following a 200 mg Dose in Healthy Subjects Under Fasting Conditions",,['Fasting'],['bioequivalence'],,2015-07,2015-10,"[{'measure': 'Assessment of the bioequivalence of sorafenib tablet (Test)and Nexavar(Reference), on day 4.', 'description': 'Compare the rate and extent of absorption of sorafenib 200 mg tablet (Test) versus Nexavar (Reference), administered as 1 x 200 mg tablet under fasting conditions. Evaluate whether has the bioequivalence between the Test and the Reference.Criteria as follows: for a primary parameter (AUC0-t, AUC0-inf, or Cmax), if\n\n1. the point estimate of the Test-to-Reference ratio must be within 80.00% 125.00%, and\n2. the 95% upper confidence bound for the scaled average bioequivalence criterion must be equal to or less than zero (≤0) to conclude in favor of BE for that parameter.', 'timeFrame': '96 hours'}]","[{'measure': 'safety: number TEAEs, deaths, SAEs and other significant adverse events', 'description': 'Number of Treatment-Emergent Adverse Events(TEAEs). Number of deaths. Number of SAEs. Number of other significant adverse events.', 'timeFrame': '96 hours'}]",2.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,
NCT05862337,Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.,"Anlotinib hydrochloride capsules, Penpulimab injection","['Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo', 'Anlotinib hydrochloride capsules, Penpulimab injection']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Hepatocellular Carcinoma,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:08.340101,True,,,,,"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study of Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection in Patients With High Risk of Relapse After Radical Surgery or Ablation of Hepatocellular Carcinoma (HCC).",,['Hepatocellular Carcinoma'],[],,2023-05-10,2026-12,"[{'measure': 'Recurrence-free survival (RFS)', 'description': 'RFS assessed by the Blinded Independent Image Review Committee and the investigator is the time from randomization to the first local, regional recurrence or distant metastasis, or death from any cause, whichever occurred first.', 'timeFrame': 'Baseline up to 3 years.'}]","[{'measure': 'Time to recurrence(TTR)', 'description': 'TTR assessed by the Blinded Independent Image Review Committee and the investigator is the time from randomization to the first local, regional recurrence or distant metastasis, whichever occurred first.', 'timeFrame': 'Baseline up to 3 years.'}, {'measure': 'Time to extrahepatic metastasis or macrovascular invasion', 'description': 'Time to extrahepatic metastasis or macrovascular invasion as assessed by the investigator.', 'timeFrame': 'Baseline up to 3 years.'}, {'measure': 'Overall survival (OS)', 'description': 'OS defined as the time from the date of randomization until the date of death due to any cause.', 'timeFrame': 'Baseline up to 3 years.'}, {'measure': 'Objective response rate (ORR) after first recurrence', 'description': 'subjects with evaluable tumor lesion status who were cross-treated with Anlotinib hydrochloride capsules combined with Penpulimab injection developed complete response or partial response after a first HCC relapse as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.', 'timeFrame': 'Baseline up to 3 years.'}]",5.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,480.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06785337,"""The Effect of Inhaled Nitroglycerin for COPD Patients",Inhaled nitroglycerin,['Inhaled nitroglycerin'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,RECRUITING,COPD,Beni-Suef University,2025-09-01T16:18:08.340121,True,,,,,"""The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit""",,"['COPD', 'COPD III/IV']","['Inhaled', 'nitroglycerin']",,2025-02-01,2025-12-01,"[{'measure': 'Change in pulmonary functions', 'description': 'Change in pulmonary functions Defined as:\n\n* Reduction of PaCO2 in arterial blood gases from admission value.\n* increase in Pao2 from admission value.', 'timeFrame': '5 days after start of nebulized nitroglycerin'}]","[{'measure': 'Number of days on mechanical ventilation', 'timeFrame': '5 days after start of nebulized nitroglycerin'}, {'measure': 'Dose of vasopressor therapy', 'timeFrame': '5 days after start of nebulized nitroglycerin'}, {'measure': 'Reduction of WBC count', 'timeFrame': '10 days after start of nebulized nitroglycerin'}, {'measure': 'Mortality rate', 'timeFrame': '10 days after start of nebulized nitroglycerin'}]",5.0,18 Years,,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01827137,WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation,lenalidomide,"['bortezomib', 'immunomodulatory drugs', 'lenalidomide', 'proteasome inhibitor']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Multiple Myeloma,Sellas Life Sciences Group,2025-09-01T16:18:08.340136,True,,,,,A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,,['Multiple Myeloma'],"['WT1 Analog Peptide Vaccine', '12-288', 'Galinpepimut-S', 'GPS', 'Maintenance therapy', 'Autologous Stem Cell Transplant (ASCT)', 'Wilms Tumor 1', 'Immunotherapeutic Agent', 'Post-ASCT maintenance', 'SLS-001']",,2013-04,2017-11-06,"[{'measure': 'WT1 T-cell Immune Response (IR) 12-14 Weeks After First GPS Administration (6 x Administrations)', 'description': 'Number and percentage of participants with CD4 and/or CD8 immune responses against WT1m measured 12-14 weeks after first GPS administration (6 x administrations)', 'timeFrame': '12 weeks after the initial GPS vaccine (end of first series [GPS x 6 administrations])'}]","[{'measure': 'Progression-free Survival (PFS) From Autologous Stem Cell Transplant (ASCT)', 'description': 'PFS measured from ASCT to time of myeloma progression (as defined by the International Myeloma Working Group \\[IMW\\] consensus criteria or subject death.', 'timeFrame': '3 years and 8 months'}, {'measure': 'Overall Survival (OS) From Autologous Stem Cell Transplant (ASCT)', 'description': 'OS measured from time of autologous stem cell transplant (ASCT) to the time of subject death', 'timeFrame': '3 years and 8 months'}]",3.0,18 Years,,ALL,False,INDUSTRY,1.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT00537537,To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB),Telbivudine,['Telbivudine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Hepatitis B, Chronic",Novartis Pharmaceuticals,2025-09-01T16:18:08.340150,True,,,,,"An Open Label, Response Adaptive Study of Telbivudine in Adults With HBeAg Positive Compensated CHB",,"['Hepatitis B, Chronic']","['Hepatitis B, Chronic, Hepatitis B e Antigen positive, Adults, Telbivudine, Adefovir']",,2007-08,,[{'measure': 'Antiviral efficacy with adefovir combination assessed by HBV DNA non-detectability (PCR <300 copies/ml) by week 104.'}],"[{'measure': 'Antiviral efficacy with telbivudine alone assessed by HBV DNA non-detectability (PCR <300 copies/ml) at week 24 and 36.'}, {'measure': 'HBeAg loss & HBeAg seroconversion (defined as a loss of HBeAg and a gain of detectable level of HBeAb).'}, {'measure': 'Alanine Transaminase (ALT) normalization, in patients with raised levels at baseline.'}, {'measure': 'Change in HBV DNA level (log10 copies/ml) from baseline to week 4, 8, 12, 24, 36, 52, 76 and 104.'}, {'measure': 'Viral breakthrough, defined as increase of HBV DNA by 1 log10 copies/ml from treatment nadir, at any point after week 24.'}]",6.0,18 Years,,ALL,,INDUSTRY,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,
NCT00150345,Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients,voriconazole (Vfend),['voriconazole (Vfend)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Possible Fungal Infection,Pfizer,2025-09-01T16:18:08.340186,True,,,,,Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In High-Risk Neutropenic Patients With Fever And A Positive Panfungal Polymerase Chain Reaction Assay (IDEA Study),,['Possible Fungal Infection'],"['Neutropenia', 'Fever of unknown origin', 'Empirical treatment', 'Voriconazole']",,2005-01,2009-04,"[{'measure': 'Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis', 'description': 'Number of participants with proven (deep tissue infection, fungemia, or endemic fungal infections) or probable IFI (at least 1 host criterion \\[fever, body temperature \\<36 or \\>38 degrees Celsius, graft-versus-host disease, use of corticosteroids\\]; and 1 microbiological criterion \\[fungal or yeasts\\]; or clinical criteria \\[abnormal site consistent with infection\\]) as defined by European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) criteria. Complete case analysis: must be evaluable until Day 28 or had developed a proven or probable IFI by the final visit.', 'timeFrame': 'Day 2 through Day 28'}]","[{'measure': 'Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment)', 'description': ""Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participants's body temperatures within 24 hours of evaluation time were \\<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol)."", 'timeFrame': 'Day 5 (96 hours through 120 hours after start of study treatment)'}, {'measure': 'Number of Participants With Defervescence Day 9 (8 Days After Initiation of Study Treatment)', 'description': ""Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participant's body temperatures within 24 hours of evaluation time were \\<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol)."", 'timeFrame': 'Day 9 (192 hours through 216 hours after start of study treatment)'}, {'measure': 'Time to Continuous Defervescence', 'description': 'Time (in days) from start of study medication to continuous defervescence. Continuous defervescence stated if participant maintains a body temperature of \\<38.0 degrees C for at least 96 hours.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Number of Participants Per Reason for Lack of Defervescence', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Number of Participants That Died on or Before Day 28 (Mortality)', 'description': 'Number of participants that died on or before Day 28 after start of study treatment. A participant must be evaluable until Day 28 (final visit) or have died before the final visit.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Time to Negative Panfungal Polymerase Chain Reaction (PCR)', 'description': 'Time (in days) from start of study medication to negative panfungal PCR; assessed for participants whose most recent panfungal PCR result prior to start of study medication was positive. Defined as negative if at least 2 successive and all following panfungal PCR assessments from start of study medication until 24 hours after end of treatment are negative. Measured as first quartile of time (point in time measurement; no median or measure of dispersion calculated); median time was not estimable for deferred voriconazole treatment group.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=Yes). Continuous defervescence stated if participant maintains a body temperature of \\<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=No). Continuous defervescence stated if participant maintains a body temperature of \\<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Age', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with age for participants who completed the study and have a non-missing value for percent of positive panfungal PCR.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Gender', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with gender (Female or Male). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Primary Underlying Neoplastic Disease', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with primary underlying neoplastic disease. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Planned Allogeneic Transplants', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with allogeneic bone marrow transplant or allogeneic peripheral stem cell transplant (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Concomitant Fluconazole', 'description': 'Percent positive panfungal PCR assessments during treatment phase of study in association with use of concomitant (prophylaxis) fluconazole (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Neutrophil Count >500 uL', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with neutrophil count \\>500 uL (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With C-reactive Protein Level >1.25 Times the Upper Limit of Normal (x ULN)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with c-reactive protein level (measured in milligrams per liter \\[mg/L\\]) \\>1.25 x ULN (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \\[one species\\]=sp; plural \\[many species\\]=spp) identified (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \\[one species\\]=sp; plural \\[many species\\]=spp) identified (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Proven or Probable IFI (Complete Cases) Between Day 2 and Day 28', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with proven or probable IFI (complete cases) between Day 2 and Day 28 (Yes or No). Complete case analysis: participant must be evaluable until Day 28 (final visit) or have developed a proven or probable IFI by the final visit. Participant considered evaluable until Day 28 if participant completed the study and completed an assessment of IFI at Day 28 or final visit. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence Day 5 (4 Days After Initiation of Study Treatment)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 5 (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 5 (96 hours through 120 hours after start of study treatment)'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Time to Defervescence', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with time to defervescence. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence (No)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Alive). A participant must be evaluable until Day 28 (final visit).', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Died)', 'description': 'Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Died). A participant must have died before Day 28 (final visit).', 'timeFrame': 'Day 2 through Day 28'}, {'measure': 'Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned', 'timeFrame': 'Day 28'}, {'measure': 'Number of Participants With Reasons Why Antineoplastic Therapy Not Continued as Planned', 'timeFrame': 'Day 28'}]",29.0,18 Years,,ALL,False,INDUSTRY,1.0,147.0,ACTUAL,v2_robust,True,True,False,False,
NCT01771445,Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise,IL-1Ra,"['Placebo', 'IL-1Ra']",2,INTERVENTIONAL,['NA'],,COMPLETED,Type 2 Diabetes,Marc Y.Donath,2025-09-01T16:18:08.340373,True,,,,,Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise,,['Type 2 Diabetes'],"['IL-1', 'IL-6', 'Inflammation']",,2011-12,2013-10,"[{'measure': 'IL6', 'timeFrame': 'Change of IL6 during exercise stimulation at baseline compared to change of IL6 during exercise stimulation at day 7'}]","[{'measure': 'change of inflammatory markers (CRP, Tumor Necrosis Factor alpha, IL-1Ra)', 'timeFrame': 'Change of inflammatory markers during exercise stimulation at baseline compared to change of inflammatory markers during exercise stimulation at day 7'}, {'measure': 'Muscle soreness', 'timeFrame': 'Change in muscle soreness before and after exercise stimulation at baseline compared to change in muscle soreness before and after exercise stimulation at day 7'}, {'measure': 'Activity induced Fatigue (ACTIF) Scale', 'timeFrame': 'Change in ACTIF before and after exercise stimulation at baseline compared to change in ACTIF before and after exercise stimulation at day 7'}, {'measure': 'Depression', 'timeFrame': 'Change in depression during exercise stimulation at baseline compared to change in depression at day 7'}, {'measure': 'Change of vascular function (CAVI, pulse wave velocity, AVR)', 'timeFrame': 'Change in vascular function during exercise stimulation at baseline compared to change of vascular function at day 7'}, {'measure': 'glucose metabolism', 'timeFrame': 'Change glucose metabolism during exercise stimulation at basleine compared to change in glucose metabolism during exercise stimulation at day 7'}, {'measure': 'Cognition', 'timeFrame': 'Change in cognition during exercise stimulation at baseline compared to change in cognition at day 7'}, {'measure': 'Motor strength', 'timeFrame': 'Change in motor strength during exercise stimulation at baseline compared to change in motor stength at day 7'}, {'measure': 'Insulin', 'timeFrame': 'Change in insulin during exercise stimulation at baseline compared to change in insulin at day 7'}, {'measure': 'Glucagon', 'timeFrame': 'Change in glucagon during exercise stimulation at baseline compared to change in glucagon at day 7'}, {'measure': 'GLP-1', 'timeFrame': 'Change in GLP-1 during exercise stimulation at baseline compared to change in GLP-1 at day 7'}, {'measure': 'Cortisol', 'timeFrame': 'Change in cortisol during exercise stimulation at baseline compared to change in cortisol at day 7'}, {'measure': 'Creatinkinase', 'timeFrame': 'Change in creatinkinase during exercise stimulation at baseline compared to change in creatinkinase at day 7'}, {'measure': 'Growth hormone', 'timeFrame': 'Change of growth hormone during exercise stimulation at baseline compared to change of growth hormone during exercise stimulation at day 7'}, {'measure': 'Copeptin', 'timeFrame': 'Change of copeptin during exercise stimulation at baseline compared to change of copeptin during exercise stimulation at day 7'}]",16.0,20 Years,50 Years,MALE,True,OTHER,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT00393445,Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans,GLP-1 control,"['GLP-1 control', 'saline control', 'GLP-1 and Exendin(9-39) 300', 'GLP-1 and Exendin(9-39) 900', 'GLP-1 and Exendin(9-39) 600', 'GLP-1 and Exendin(9-39) 1200', 'GLP-1(7-36)amide']",7,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hyperglycemia,Ludwig-Maximilians - University of Munich,2025-09-01T16:18:08.340405,True,,,,,Effect of GLP-1 on Glucose Metabolism in Healthy Subjects and Patients With T2DM. Part 1: A Pilot Study to Assess the Efficacy of Exendin(9-39)Amide as a GLP-1 Receptor Antagonist in Healthy Subjects,,['Hyperglycemia'],"['GLP-1', 'Exendin(9-39)', 'Insulin', 'Glucagon', 'Human physiology']",,2006-11,2007-05,"[{'measure': 'To assess the effect of increasing doses of exendin(9-39) on first and second phase insulin secretion stimulated by intravenous GLP-1 during hyperglycemia', 'timeFrame': 'within the actual study period'}]","[{'measure': 'To assess the effect of increasing doses of exendin(9-39) on plasma glucagon levels decreased by intravenous GLP-1 during hyperglycemia', 'timeFrame': 'within the actual study period'}]",2.0,18 Years,65 Years,ALL,True,OTHER,2.0,6.0,ACTUAL,v2_robust,True,True,False,False,
NCT00279045,Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide,Rosiglitazone,"['metformin', 'Rosiglitazone', 'glyburide']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Diabetes Mellitus, Type 2",GlaxoSmithKline,2025-09-01T16:18:08.340416,True,,,,,"A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus",,"['Diabetes Mellitus, Type 2']",['type 2 diabetes monotherapy treatment naive'],,2000-01-03,2006-06-19,[{'measure': 'Time from randomization to the primary action point (monotherapy failure).'}],"[{'measure': 'Comparison of effects of long-term treatment with Rosiglitazone, Metformin, Glyburide: - maintenance/restoration of beta-cell function: HOMA IS, progression of microalbuminuria, fibrinolytic markers (PAI-1,fibrinogen, CRP).'}]",2.0,30 Years,75 Years,ALL,False,INDUSTRY,0.0,4426.0,ACTUAL,v2_robust,True,True,False,False,
NCT04762745,The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma,Pomalidomide,"['Pomalidomide', 'Bendamustine( Leweixin®, Chia Tai TIANQING, China)', 'Pomalidomide( Anyue®, Chia Tai TIANQING, China)', 'Dexamethasone', 'Bendamustine']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,"Relapsed, Refractory, Multiple Myeloma",Sun Yat-sen University,2025-09-01T16:18:08.340483,True,,,,,"Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China",,"['Relapsed, Refractory, Multiple Myeloma']","['pomalidomide, bendamustine, multiple myeloma']",,2021-02,2023-02,"[{'measure': 'Overall response rate', 'description': 'The number of patients achieving partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) after 8 cycles in phase II.\n\nsCR = CR as defined in Primary Outcome measure 2 plus normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.\n\nCR- Negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow.\n\nVGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\> 90% reduction in serum M-protein plus urine M-protein level \\< 100 mg/24 h.\n\nPR- \\> 50% reduction of serum M-protein and urine M-protein by \\>90% or to \\< 200 mg/24 h In addition, if present at baseline, a \\> 50% reduction in the size of soft tissue plasmacytomas is also required.', 'timeFrame': 'At the end of Cycle 8 in Phase II (each cycle is 28 days)'}]","[{'measure': 'Complete response(CR) and stringent complete response(sCR) rate', 'description': 'The CR and sCR rate after 8 cycles in phase II.\n\nCR- Negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow.\n\nsCR = CR as defined in Primary Outcome measure 2 plus normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.', 'timeFrame': 'At the end of Cycle 8 in Phase II (each cycle is 28 days)'}, {'measure': 'Progression free survival(PFS)', 'description': 'The time relapsed for patients between initiation of study therapy and either disease progression or death', 'timeFrame': 'Through study completion, up to 2 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'Number of participants with treatment-related adverse events during the study period as assessed by CTCAE v4.0', 'timeFrame': 'Through study completion, up to 2 years'}]",4.0,18 Years,75 Years,ALL,False,OTHER,0.0,56.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06790745,Plasma Rich Fibrin Epidural Injection by Racz Catheter Versus Epidural Blood Patch in Postdural Puncture Headache,Plasma rich fibrin epidural injection by Racz catheter,['Plasma rich fibrin epidural injection by Racz catheter'],1,INTERVENTIONAL,['NA'],,RECRUITING,Plasma Rich Fibrin,Tanta University,2025-09-01T16:18:08.340511,True,,,,,Plasma Rich Fibrin Epidural Injection by Racz Catheter Versus Epidural Blood Patch in Postdural Puncture Headache,,"['Plasma Rich Fibrin', 'Epidural', 'Racz Catheter', 'Epidural Blood Patch', 'Postdural Puncture Headache']",[],,2025-01-25,2026-10-01,"[{'measure': 'Success rate of the procedures', 'description': 'The success rate of techniques for the treatment of headaches and associated symptoms on a 4-point rating scale (0 = none, 1 = slight, 2 = marked, 3 = complete relief) will be recorded.', 'timeFrame': '24 hours postoperatively'}]","[{'measure': 'Degree of pain', 'description': 'The degree of pain will be assessed using the Numeric Rating Scale (NRS). NRS (0 represents ""no pain"" while 10 represents ""the worst pain imaginable""). NRS will be assessed at (0, 6, 12, 24, 48) h, 3, 4, 5, 6, 7, 8 days postoperatively.', 'timeFrame': '8 days postoperatively'}, {'measure': 'Length of bed rest', 'description': 'Length of bed rest after techniques and the efﬁcacy of techniques for the treatment of headaches and associated symptoms on a 4-point rating scale (0 = none, 1 = slight, 2 = marked, 3 = complete relief) will be recorded.', 'timeFrame': '8 days postoperatively'}, {'measure': 'Change in optic nerve sheath diameter (ONSD)', 'description': 'Optic nerve sheath diameter (ONSD) will be measured before and after 6 hours of the procedure.', 'timeFrame': '6 hours the procedure'}, {'measure': 'Incidence of complications', 'description': 'Incidence of complications that may occur during the technique such as (bending of the tip of the needle, shearing of the catheter, misplacement of the catheter, blocking of the catheter, blood aspiration and bleeding in the epidural space, hypotension, migration of the catheter, paresthesia, headache and infection) will be recorded.', 'timeFrame': '8 days postoperatively'}]",5.0,18 Years,65 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04136145,Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects,Belimumab for IV,"['Belimumab for IV', 'Belimumab for SC']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Systemic Lupus Erythematosus,GlaxoSmithKline,2025-09-01T16:18:08.340566,True,,,,,"An Open-label, Randomized, Parallel Group, Single Dose Study to Investigate the PK and Safety of Belimumab 200 mg Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Participants",,['Systemic Lupus Erythematosus'],"['belimumab', 'Chinese', 'intravenous', 'subcutaneous', 'auto-injector']",,2019-10-28,2020-01-14,"[{'measure': 'Serum Concentration of Belimumab Following Intravenous Administration', 'description': 'Blood samples were collected at indicated time points for measurement of serum concentrations of belimumab following intravenous administration. Pharmacokinetic Population comprised of all safety participants (all randomized participants who received at least one dose of study treatment) for whom at least one evaluable pharmacokinetic sample was obtained and analyzed.', 'timeFrame': 'Pre-dose (prior to start of belimumab IV infusion), 30 minutes (after the start of infusion), 0 hour (end of infusion); at 1, 6, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344 and 1680 hours after end of infusion'}, {'measure': 'Serum Concentration of Belimumab Following Subcutaneous Administration', 'description': 'Blood samples were collected at indicated time points for measurement of serum concentrations of belimumab following subcutaneous administration.', 'timeFrame': 'Pre-dose and at 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 240 hours, 336 hours, 504 hours, 672 hours, 1008 hours, 1344 hours and 1680 hours post-dose'}]","[{'measure': 'Number of Participants With Abnormal Vital Signs', 'description': 'Vital signs were measured in a semi-supine position after five minutes of rest and included tympanic temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. The normal ranges were: temperature (35.0-38.0 degrees celsius), SBP (85-160 millimeters of mercury \\[mmHg\\]), DBP (45-100 mmHg), heart rate (60-90 beats per minute). Number of participants with abnormality in any vital signs are presented. Safety Population comprised of all randomized participants who received at least one dose of study treatment.', 'timeFrame': 'Up to Day 71'}, {'measure': 'Number of Participants With Abnormal Electrocardiogram (ECG) Findings', 'description': ""Twelve-lead ECGs were recorded with the participants in a semi-supine position, after 5 minutes of rest using an ECG machine. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with clinically significant and not clinically significant abnormal ECG findings have been presented."", 'timeFrame': 'Up to Day 71'}, {'measure': 'Number of Participants With Abnormal Clinical Chemistry Parameters', 'description': 'Blood samples were collected for the assessment of clinical chemistry parameters. The normal ranges were: alanine aminotransferase(7-40 international units per liter\\[IU/L\\]), albumin(40-55 grams per liter\\[g/L\\]), alkaline phosphatase(35-100 IU/L), amylase(25-125 units per liter), aspartate aminotransferase(13-35 IU/L), bilirubin(Bil.)(3.4-20.5 micromoles per liter \\[µmol/L\\]), calcium(2.1-2.55 millimoles per liter\\[mmol/L\\]), chloride(99-110 mmol/L), cholesterol(Chol.)(0-5.17 mmol/L), creatine kinase(29-168 IU/L), creatinine(41-73 µmol/L), direct Bil.(0-8.6 µmol/L), gamma glutamyl transferase(7-45 IU/L), glucose(3.9-6.1 mmol/L), high density Chol.(1.04-1.55 mmol/L), low density Chol.(2.59-4.11 mmol/L), lactate dehydrogenase(120-250 IU/L), phosphate(0.74-1.52 mmol/L), potassium(3.5-5.3 mmol/L), protein(65-85 g/L), sodium(137-147 mmol/L), triglycerides(0-1.69 mmol/L), urate(150-350 µmol/L), urea(2.6-7.5 mmol/L). Number of participants with abnormal clinical chemistry parameters are presented.', 'timeFrame': 'Up to Day 71'}, {'measure': 'Number of Participants With Abnormal Hematology Parameters', 'description': 'Blood samples were collected for the assessment of hematology parameters. The normal ranges for the parameters were: basophil count (\\[0.00-0.06\\]\\*10\\^9 cells per liter \\[cells/L\\]), eosinophil count (\\[0.02-0.52\\]\\*10\\^9 cells/L), erythrocyte count (\\[3.8-5.1\\]\\*10\\^12 cells/L), hematocrit (0.35-0.45 proportion of red blood cells in blood), hemoglobin (115-150 g/L), leukocyte count (\\[3.5-9.5\\]\\*10\\^9 cells/L), lymphocyte count (\\[1.1-3.2\\]\\*10\\^9 cells/L), monocyte count (\\[0.1-0.6\\]\\*10\\^9 cells/L), neutrophil count (\\[1.8-6.3\\]\\*10\\^9 cells/L), platelet count (\\[125-350\\]\\*10\\^9 cells/L). Number of participants with abnormal hematology parameters are presented.', 'timeFrame': 'Up to Day 71'}, {'measure': 'Number of Participants With Abnormal Urinalysis Parameters', 'description': ""Urine samples were analyzed for glucose, ketones, occult blood and protein by dipstick method. The dipstick test results are read as Negative, Trace, 1+, 2+, 3+, 4+ indicating proportional concentrations in the urine sample. Normal range for dipstick test results are 'negative' results. Urine potential of hydrogen (pH) and specific gravity were also analyzed. pH is measured on a numeric scale of 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Urine specific gravity is a measure of the concentration of solutes in the urine and indicated as ratio of urine density to water density. The normal ranges for pH: 4.8 to 7.4; and for specific gravity: 1.003 to 1.03. Number of participants with abnormal results in any urinalysis parameters are presented."", 'timeFrame': 'Up to Day 71'}, {'measure': 'Number of Participants With Injection Site Reaction', 'description': 'Local tolerability as measured by injection site reaction example: induration, erythema, edema, rash, pruritis or pain. Number of participants with any injection site reaction are presented.', 'timeFrame': 'Up to Day 71'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations as judged by physician. Number of participants who had SAEs and non-SAEs are presented.', 'timeFrame': 'Up to Day 71'}]",9.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,
NCT03774472,"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer",Hydroxychloroquine,"['Palbociclib', 'PD 0332991', 'Hydroxychloroquine', 'PD 332991', 'CGS 20267', 'PD 991', 'PD-0332991', '6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one', 'Ibrance', 'Femara', 'Letrozole']",11,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Anatomic Stage I Breast Cancer AJCC v8,M.D. Anderson Cancer Center,2025-09-01T16:18:08.340587,True,,,,,Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer,,"['Anatomic Stage I Breast Cancer AJCC v8', 'Anatomic Stage IA Breast Cancer AJCC v8', 'Anatomic Stage IB Breast Cancer AJCC v8', 'Anatomic Stage II Breast Cancer AJCC v8', 'Anatomic Stage IIA Breast Cancer AJCC v8', 'Anatomic Stage IIB Breast Cancer AJCC v8', 'Anatomic Stage III Breast Cancer AJCC v8', 'Anatomic Stage IIIA Breast Cancer AJCC v8', 'Anatomic Stage IIIB Breast Cancer AJCC v8', 'Anatomic Stage IIIC Breast Cancer AJCC v8', 'Anatomic Stage IV Breast Cancer AJCC v8', 'Prognostic Stage I Breast Cancer AJCC v8', 'Prognostic Stage IA Breast Cancer AJCC v8', 'Prognostic Stage IB Breast Cancer AJCC v8', 'Prognostic Stage IIA Breast Cancer AJCC v8', 'Prognostic Stage IIB Breast Cancer AJCC v8', 'Prognostic Stage III Breast Cancer AJCC v8', 'Prognostic Stage IIIA Breast Cancer AJCC v8', 'Prognostic Stage IIIB Breast Cancer AJCC v8', 'Prognostic Stage IIIC Breast Cancer AJCC v8', 'Prognostic Stage IV Breast Cancer AJCC v8']",[],,2018-08-20,2024-04-17,"[{'measure': 'Incidence of Adverse Events (Phase I)', 'description': 'Incidence of adverse events (Phase I) \\[Time Frame: Up to 30 days post-treatment\\] Assessed continuously using Common Terminology Criteria for Adverse Events version 4.03, with physical examination and laboratory assessments.', 'timeFrame': 'Up to 5 years and 4 months'}]","[{'measure': 'Recommended Phase II Dose for HCQ', 'description': 'Phase I portion in the metastatic setting is to determine the safety of adding HCQ to continuous low dose palbociclib and letrozole and to determine the recommended phase II dose for HCQ for the subsequent Phase II study.', 'timeFrame': 'Up to 5 years and 4 months'}, {'measure': 'Clinical Benefit Rate at 8 Weeks', 'description': 'The secondary objective is to determine the response rate and clinical benefit rate at 8 weeks of the assigned HCQ dose plus continuous low dose palbociclib and letrozole.', 'timeFrame': 'Up to 5 years and 4 months'}]",3.0,18 Years,,FEMALE,False,OTHER,0.0,15.0,ACTUAL,v2_robust,True,True,False,True,
NCT06717672,Effect of Lidocaine in Reducing Opioids Requirement in Day Care Surgery,Lidocaine 2% without vessel constrictor,"['Normal Saline', 'Lidocaine 2% without vessel constrictor']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Pain,Liaquat National Hospital & Medical College,2025-09-01T16:18:08.340597,True,,,,,Efficacy of Lidocaine in Decreasing Perioperative Analgesic Opioids Requirement After Ambulatory Surgery,,"['Pain', 'Post-operative Pain Control', 'Post-operative Pain']","['Lidocaine', 'Opiods', 'Peri-operative pain', 'Decrease Opioid requirement', 'Ambulatory surgeries']",,2023-11-05,2024-05-10,"[{'measure': 'Peri-operative pain', 'description': 'Visual Analog pain scale to rate pain scale comprises 0 to 10 score 0 minimum to 10 Maximum', 'timeFrame': 'at 2 hours, 4 hours, 6 hours'}]",[],1.0,18 Years,65 Years,ALL,True,OTHER,0.0,80.0,ACTUAL,v2_robust,True,True,False,False,
NCT06148272,A Study of LY3971297 in Healthy Participants,LY3971297,"['LY3971297 IV', 'LY3971297', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Healthy,Eli Lilly and Company,2025-09-01T16:18:08.340639,True,,,,,A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate,,"['Healthy', 'Obesity', 'Hypertension']",[],,2023-12-07,2025-12,"[{'measure': 'Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'description': 'Part A and F: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module', 'timeFrame': 'Baseline (Day of Exposure) to Day 29 post-dose'}, {'measure': 'Part B, C, D, E, & G: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'description': 'Part B, C, D, E, \\& G: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module', 'timeFrame': 'Baseline (Day of Exposure) to Day 57 post-dose'}, {'measure': 'Part F: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297', 'description': 'Part F: PK: AUC of LY3971297', 'timeFrame': 'Baseline Up to Day 29 post-dose for Part F'}, {'measure': 'Part F: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297', 'description': 'Part F: PK: Cmax of LY3971297', 'timeFrame': 'Baseline Up to Day 29 post-dose for Part F'}]","[{'measure': 'Part B, C, D, E, and G: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297', 'description': 'Part B, C, D, E, and G: PK: AUC of LY3971297', 'timeFrame': 'Predose on day 1 up to 29 days post-dose for Part A and pre-dose on day 1 up to 57 days post-dose for Part B, C, D, E, and G'}, {'measure': 'Part B, C, D, E, and G: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297', 'description': 'Part B, C, D, E, and G: PK: Cmax of LY3971297', 'timeFrame': 'Predose on day 1 up to 29 days post-dose for Part A and pre-dose on day 1 up to 57 days post-dose for Part B, C, D, E, and G'}]",6.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,225.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05897372,Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study,"ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib","['ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib']",1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Diabetic Kidney Disease,Iain Bressendorff,2025-09-01T16:18:08.340648,True,,,,,Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study,,['Diabetic Kidney Disease'],[],Slow recruitment,2023-08-01,2024-09-23,"[{'measure': 'urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline', 'description': 'number of subjects achieving this endpoint', 'timeFrame': 'after 9 months of treatment'}]","[{'measure': 'UACR reduction to less than 70% of baseline', 'description': 'number of subjects achieving this endpoint', 'timeFrame': 'after 9 months of treatment'}, {'measure': 'UACR less than 300', 'description': 'number of subjects achieving this endpoint', 'timeFrame': 'after 9 months of treatment'}, {'measure': 'difference in UACR', 'description': 'between-groups difference in UACR', 'timeFrame': 'after 9 months of treatment'}, {'measure': 'difference in UACR', 'description': 'between-groups difference in UACR', 'timeFrame': 'after 10 months of treatment (1 month off study drugs)'}, {'measure': 'difference in eGFR', 'description': 'between-groups difference in eGFR', 'timeFrame': 'after 9 months of treatment'}, {'measure': 'difference in eGFR', 'description': 'between-groups difference in eGFR', 'timeFrame': 'after 10 months of treatment (1 month off study drugs)'}, {'measure': 'difference in systolic and diastolic blood pressure', 'description': 'between-groups difference in blood pressure', 'timeFrame': 'after 9 months of treatment'}, {'measure': 'difference in systolic and diastolic blood pressure', 'description': 'between-groups difference in blood pressure', 'timeFrame': 'after 10 months of treatment (1 month off study drugs)'}, {'measure': 'incidence of plasma potassium >5.5 mmol/L', 'description': 'number of subjects achieving this endpoint', 'timeFrame': 'after 9 months of treatment'}, {'measure': 'incidence of plasma potassium >6.0 mmol/L', 'description': 'number of subjects achieving this endpoint', 'timeFrame': 'after 9 months of treatment'}, {'measure': 'incidence of symptomatic hypotension', 'description': 'number of subjects achieving this endpoint', 'timeFrame': 'after 9 months of treatment'}]",12.0,18 Years,,ALL,False,OTHER,0.0,1.0,ACTUAL,v2_robust,True,False,True,False,Slow recruitment
NCT00053872,Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma,cisplatin,"['lomustine', 'cisplatin', 'vincristine sulfate']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Brain and Central Nervous System Tumors,University of Leicester,2025-09-01T16:18:08.340695,True,,,,,A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma,,['Brain and Central Nervous System Tumors'],['untreated childhood medulloblastoma'],,2003-02,,[{'measure': 'Comparison of event-free survival at 3 years'}],"[{'measure': 'Comparison of overall survival'}, {'measure': 'Comparison of the pattern of relapse (i.e., local relapse [tumor bed and posterior fossa outside tumor bed])'}, {'measure': 'Comparison of late sequelae, in terms of health status, quality of life, hearing loss, and endocrine deficiencies'}, {'measure': 'Toxicity of neurosurgery'}]",5.0,3 Years,21 Years,ALL,False,OTHER,0.0,316.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04303572,The Hemophilia Inhibitor Eradication Trial,Eloctate ITI,"['Eloctate ITI', 'rFVIIIFc', 'Hemlibra', 'Emicizumab']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Hemophilia A With Inhibitor,Margaret Ragni,2025-09-01T16:18:08.340720,True,,,,,"Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A",,['Hemophilia A With Inhibitor'],"['hemophilia', 'inhibitor formation', 'Eloctate', 'Emicizumab']","The INHIBIT Trials IDSMB, in a letter dated 05-18-22, recommended, given the slow enrollment, that the INHIBIT Trials be discontinued due to futility.",2021-11-01,2022-06-27,"[{'measure': 'Inhibitor Eradication', 'description': 'The proportion eradicating anti-FVIII inhibitors', 'timeFrame': '48 weeks'}]","[{'measure': 'Number of Bleeding Events', 'description': 'The number of bleeding events: hematoma, joint, central nervous system, other bleeds.', 'timeFrame': '48 weeks'}, {'measure': 'FVIII Trough Level', 'description': 'The FVIII trough activity by chromogenic assay.', 'timeFrame': '48 weeks'}, {'measure': 'Human Leukocyte Antigen (HLA) Haplotype', 'description': 'The number of HLA haplotype variants.', 'timeFrame': '48 weeks'}, {'measure': 'FVIII Mutation', 'description': 'The number of FVIII mutation variants.', 'timeFrame': '48 weeks'}]",5.0,,,MALE,False,OTHER,1.0,1.0,ACTUAL,v2_robust,True,False,True,False,"The INHIBIT Trials IDSMB, in a letter dated 05-18-22, recommended, given the slow enrollment, that the INHIBIT Trials be discontinued due to futility."
NCT06487572,A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants,Risankizumab,"['SKYRIZI', 'ABBV-066', 'Risankizumab']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,AbbVie,2025-09-01T16:18:08.340744,True,,,,,"A Phase 1, Open-label Study to Assess PK Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects",,['Healthy Volunteers'],"['Healthy Volunteers', 'Risankizumab', 'ABBV-066']",,2024-07-23,2025-02-07,"[{'measure': 'Number of Participants Experiencing Adverse Events', 'description': 'An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'Up to approximately 140 days'}, {'measure': 'Maximum Observed Serum Concentration (Cmax) of Risankizumab', 'description': 'Cmax of Risankizumab.', 'timeFrame': 'Up to approximately 140 days'}, {'measure': 'Time to Cmax (Tmax) of Risankizumab', 'description': 'Tmax of Risankizumab.', 'timeFrame': 'Up to approximately 140 days'}, {'measure': 'Area Under the Serum Concentration-Time Curve (AUC) of Risankizumab', 'description': 'AUCt of Risankizumab.', 'timeFrame': 'Up to approximately Week 4'}]",[],4.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,60.0,ACTUAL,v2_robust,True,True,False,True,
NCT03851172,Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery,Ketorolac Ophthalmic,"['Nepafenac Ophthalmic', 'Ketorolac Ophthalmic', 'Cyclopentolate Ophthalmic']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Cataract,Assiut University,2025-09-01T16:18:08.340886,True,,,,,Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery,,"['Cataract', 'Miosis']","['Cataract surgery', 'Intraoperative Miosis', 'Ketorolac eye drops', 'Nepafenac eye drops']",,2019-03-01,2020-03-30,"[{'measure': 'Prevention of miosis during cataract surgery', 'description': 'The prevention of intraoperative miosis during cataract surgery after preparation by the different eye drops and cyclopentolate', 'timeFrame': '30 minutes'}]",[],1.0,2 Days,80 Years,ALL,True,OTHER,0.0,75.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00937872,A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects,250 mg SRT2104 Suspension,"['250 mg SRT2104 Suspension', 'Carbon-14 radio-labeled SRT2104']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 2","Sirtris, a GSK Company",2025-09-01T16:18:08.340903,True,,,,,A Phase I Study to Evaluate the Intravenous Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension in Healthy Subjects,,"['Diabetes Mellitus, Type 2']",[],,2008-11-22,2008-12-22,"[{'measure': 'Absolute bioavailability of SRT2104 250 mg suspension.', 'timeFrame': 'Time points to measure the bioavailability of SRT2104 oral 250 mg suspension: 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72 hrs following administration.'}, {'measure': 'Define the intravenous pharmacokinetics of SRT2104.', 'timeFrame': 'Time points to define the IV PK of SRT2104: Just before infusion (0); During infusion (5, 10 min); Post infusion (5, 10, 20, 30, 45 min and 1, 2, 3, 4, 6, 8, 10, 12, 15, 21, 45, 69 hours).'}]","[{'measure': 'Potential systemic metabolite burden of SRT2104 following administration.', 'timeFrame': 'At time points: Pre-dose; 0-12 hrs post dose; 12-24 hrs post dose).'}]",3.0,18 Years,65 Years,MALE,True,INDUSTRY,1.0,9.0,ACTUAL,v2_robust,True,True,False,False,
NCT04551495,Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE),Entrectinib,"['Goserelin', 'Entrectinib', 'Letrozole']",3,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Invasive Lobular Breast Carcinoma,Jules Bordet Institute,2025-09-01T16:18:08.340994,True,,,,,Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast,,"['Invasive Lobular Breast Carcinoma', 'ER+ Breast Cancer', 'HER2-negative Breast Cancer']",[],,2021-01-14,2025-01,"[{'measure': 'Evaluation of the efficacy of endocrine therapy + entrectinib in women with ER+/HER2- early breast cancer of the lobular subtype:Residual Cancer Burden (RCB)', 'description': 'Residual Cancer Burden (RCB) 0/1 by local evaluation in all enrolled subjects.', 'timeFrame': 'At surgery'}]","[{'measure': 'Evaluation of the efficacy of the combination by pathology: Pathologic complete response (pCR) rate', 'description': 'Pathologic complete response (pCR) rate in breast and axilla (ypT0/Tis ypN0) by local evaluation', 'timeFrame': 'At surgery'}]",2.0,18 Years,,FEMALE,False,OTHER,1.0,65.0,ESTIMATED,v2_robust,True,False,False,False,
NCT07077395,Finding Links Between Hot flASHes and CardioVascular Disease,fezolinetant - reference formulation,"['fezolinetant - reference formulation', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Menopause-related Hot Flashes,Massachusetts General Hospital,2025-09-01T16:18:08.341184,True,,,,,Finding Links Between Hot flASHes and CardioVascular Disease,,['Menopause-related Hot Flashes'],"['menopause', 'hot flashes', 'heart health']",,2025-10,2030-10,"[{'measure': 'brachial artery flow mediated dilation', 'timeFrame': '12 weeks'}]","[{'measure': 'concentration of eicosanoid metabolites', 'timeFrame': '12 weeks'}]",2.0,40 Years,65 Years,FEMALE,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01120795,Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy,Pegylated interferon and ribavirin,"['Pegylated interferon and ribavirin', 'Pegasys and Copegus']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Hepatitis C,Melbourne Health,2025-09-01T16:18:08.341257,True,,,,,Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes,,['Chronic Hepatitis C'],[],,2004-02,2006-07,"[{'measure': 'Sustained virological response', 'timeFrame': '24 weeks post cessation of HCV therapy'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,5.0,55.0,ACTUAL,v2_robust,True,True,False,False,
NCT03684395,Accessibility to New Drugs Versus SOC in Sweden,"DOACs: Rivaroxaban, Dabigatran, Apixaban","['Standard of care (Warfarin)', 'DOACs: Rivaroxaban, Dabigatran, Apixaban']",2,OBSERVATIONAL,[],,COMPLETED,Anticoagulation,Bayer,2025-09-01T16:18:08.341264,True,,,,,Association Between Socioeconomic Factors and Use of Direct Oral Anticoagulants Versus Standard of Care (Warfarin) in Patients With Non-valvular Atrial Fibrillation in Sweden,,['Anticoagulation'],[],,2016-06-15,2017-06-30,"[{'measure': 'Correlation between socioeconomic factors and use of DOACs vs. Warfarin (as identified from the LISA database before the index date)', 'description': 'Between 1 December 2011 and 31 December 2014;\n\nSocioeconomic factors:\n\n* Occupation\n* Education\n* Income\n* Family status\n* Immigrant status', 'timeFrame': 'approximately 3 years'}]","[{'measure': 'Secular trends in the correlation between socioeconomic factors and use of DOACs (vs. warfarin) - Trends based on the date of prescription by year', 'description': 'Between 1 December 2011 and 31 December 2014; Relationship between socioeconomic factors and access to newly marketed drugs (DOACs as one class which includes Rivaroxaban, Dabigatran and Apixaban) versus standard of care (warfarin) for different calender period.', 'timeFrame': 'approximately 3 years'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,68056.0,ACTUAL,v2_robust,False,True,False,False,
NCT01184495,Efficacy Study of Two Formulations of Erythropoietin,Epoetin Alfa-BioManguinhos,"['Epoetin Alfa-BioManguinhos', 'Epoetin Alfa-BioSimilar']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Comparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis,Hospital de Clinicas de Porto Alegre,2025-09-01T16:18:08.341289,True,,,,,Comparison of the Efficacy of Erythropoietin Produced in the Institute of Technology in Immunobiology of the Oswald Cruz Foundation (BioMaguinhos/FioCruz/MS) and Erythropoietin Industrialized in Patients With Chronic Renal Failure,,['Comparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis'],"['Erythropoietin', 'Chronic renal failure', 'Hemodialysis', 'Anemia']",,2008-04,2009-01,"[{'measure': 'Hemoglobin Level in blood', 'description': 'The evaluation of the efficacy between different formulations of recombinant EPO: the one produced by Bio-Manguinhos and produced by private industry was observed in response to EPO as measured by levels of hemoglobin (Hb) results. The mean Hb of the two groups were compared, as well as the variation observed in both groups over time follow-up (six months).', 'timeFrame': 'Monthly assessment of the levels of hemoglobin in blood at baseline and monthly for six months'}]","[{'measure': 'Safety', 'description': 'Assessing the safety of the formulation produced by Bio-Manguinhos was performed by comparing the rate of adverse events related to the use of recombinant EPO in the two study groups', 'timeFrame': 'Monthly assessment of adverse events'}]",2.0,18 Years,,ALL,False,OTHER,2.0,74.0,ACTUAL,v2_robust,True,True,False,True,
NCT00540995,"Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer",busulfan,"['busulfan', 'epipodophyllotoxin', 'BSF', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'BU', 'Myelosan', 'VP-16-213', 'Myeloleukon', 'etoposide', 'Misulfan', 'Mitosan', 'VePesid', 'VP-16', 'EPEG']",14,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Adult Acute Myeloid Leukemia in Remission,City of Hope Medical Center,2025-09-01T16:18:08.341310,True,,,,,Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Advanced Myeloid Malignancies,,"['Adult Acute Myeloid Leukemia in Remission', 'Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities', 'Adult Acute Myeloid Leukemia With Del(5q)', 'Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)', 'Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)', 'Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)', 'Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)', 'Blastic Phase Chronic Myelogenous Leukemia', 'Childhood Acute Myeloid Leukemia in Remission', 'Childhood Chronic Myelogenous Leukemia', 'Childhood Myelodysplastic Syndromes', 'Previously Treated Myelodysplastic Syndromes', 'Recurrent Adult Acute Myeloid Leukemia', 'Recurrent Childhood Acute Myeloid Leukemia', 'Refractory Anemia With Excess Blasts']",[],"Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than FTBI. Likely due to the giving of Busulfan prior to radiation delivery. Therefore, the study was abandoned and no further patients were accrued.",2007-06-11,2011-08-09,"[{'measure': 'Maximum Tolerated Dose (MTD) of Intensity-modulated Radiation Therapy (Phase I)', 'description': 'The highest dose tested in which fewer than 33% of patients experienced DLT attributable to the study treatment when at least six patients were treated at the dose and are evaluable for toxicity. The MDT is one dose level below the DLT level. At least six patients will be treated at the MTD.', 'timeFrame': 'from initial treatment date to Day 30 post-transplant'}]",[],1.0,6 Years,55 Years,ALL,False,OTHER,0.0,25.0,ACTUAL,v2_robust,True,False,True,False,"Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than FTBI. Likely due to the giving of Busulfan prior to radiation delivery. Therefore, the study was abandoned and no further patients were accrued."
NCT01796795,Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients,Vehicle gel,"['SR-T100 gel with 2.3% of SM', 'SR-T100 gel with 1.0% of SM', 'Vehicle gel']",3,INTERVENTIONAL,['PHASE2'],PHASE2,SUSPENDED,Common Wart,"G&E Herbal Biotechnology Co., LTD",2025-09-01T16:18:08.341321,True,,,,,"A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.",,['Common Wart'],"['common wart', 'verruca vulgaris']",Budget issue.,2030-09,2033-08,"[{'measure': 'Total clearance rate of treated CW', 'timeFrame': '16 weeks'}]","[{'measure': 'Proportion of patient with at least 75% reduction in CW lesion counts', 'timeFrame': '16 weeks'}, {'measure': 'Proportion of patient with at least 50% reduction in lesion size (volume)', 'timeFrame': '16 weeks'}, {'measure': 'Mean of percent reduction in CW lesion counts from individual patient by visit', 'timeFrame': '16 weeks'}, {'measure': 'Mean of percent reduction in CW lesion size from individual patient by visit', 'timeFrame': '16 weeks'}, {'measure': 'CW recurrence rate', 'timeFrame': '28 weeks'}, {'measure': 'Time to complete clearance', 'timeFrame': '16 weeks'}, {'measure': 'Percent reduction for pooled lesion counts by visit', 'timeFrame': '16 weeks'}, {'measure': 'Safety: evaluate the changes occurring from baseline (Randomization visit) to EOT visit.', 'description': 'including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.', 'timeFrame': '28 weeks'}]",9.0,17 Years,,ALL,False,INDUSTRY,0.0,102.0,ESTIMATED,v2_robust,True,False,True,True,Budget issue.
NCT05704439,Cardiovascular Risk Reduction in Epilepsy,Neurologist Initiated Treatment,"['antihypertensive agent or Hyperlipidemia agent', 'Neurologist Initiated Treatment']",2,INTERVENTIONAL,['NA'],,WITHDRAWN,Epilepsy,"University of California, Los Angeles",2025-09-01T16:18:08.341383,True,,,,,Cardiovascular Risk in Epilepsy: Pilot Feasibility and Efficacy Study of Neurologist-Initiated Treatment of Hypertension and Hyperlipidemia in an Underserved Minority Population in Los Angeles,,"['Epilepsy', 'Hypertension', 'Hyperlipidemia (E.G., Hypercholesterolemia)']","['Epilepsy', 'Hyperlipidemia', 'Hypertension', 'Underserved']",not funded,2024-01,2027-01,"[{'measure': 'Change in ACC-ASCVD score from baseline', 'description': 'Percent change in ACC-ASCVD score (ACC-ASCVD) compared with baseline', 'timeFrame': '3-months'}]","[{'measure': 'Systolic blood pressure', 'description': 'change in blood pressure (mmHg)', 'timeFrame': '3 months'}, {'measure': 'Total Cholesterol', 'description': 'change in total cholesterol (mg/dl) from baseline', 'timeFrame': '3 months'}, {'measure': 'LDL-low density lipoprotein', 'description': 'change in low density lipoprotein (mg/dl) from baseline', 'timeFrame': '3 months'}, {'measure': 'Compliance', 'description': 'Percent of enrolled subjects who complete visit three', 'timeFrame': '3 months'}, {'measure': 'Acceptability Rate', 'description': 'Rate: Number of medication proposals accepted by primary care physicians/number of medication proposals submitted to primary care physicians', 'timeFrame': '3 months'}]",6.0,40 Years,79 Years,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,not funded
NCT02945839,Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department,Preventative Medication (PM),"['Topiramate', 'Preventative Medication (PM)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,WITHDRAWN,Migraine,NYU Langone Health,2025-09-01T16:18:08.341430,True,,,,,Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department,,['Migraine'],"['Migraine', 'emergency department']",Significant changes have been made to the protocol.,2016-12-28,2019-12,"[{'measure': 'Migraine Disability Assessment Scale (MIDAS) at 3 Months and Baseline', 'description': 'A decrease of 3 points in the MIDAS score corresponds to a one day reduction in headache related disability per month, a clinically meaningful difference.', 'timeFrame': '12 Weeks'}]","[{'measure': 'Perceived Stress Scale (PSS)', 'description': 'PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \\& 4 = 0) to the four positively stated items (items 4, 5, 7, \\& 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale.', 'timeFrame': '12 Weeks'}, {'measure': 'Number of days/week treated with acute medications', 'timeFrame': '12 Weeks'}, {'measure': 'Number of drug administrations/week for acute medications', 'timeFrame': '12 Weeks'}]",4.0,18 Years,64 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Significant changes have been made to the protocol.
NCT03170739,Effects of Dexmedetomidine and Dopamine on Renal Function After Major Surgery,Dexmedetomidine,"['Dopamine', 'Dexmedetomidine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Renal Function,Tao Zhang,2025-09-01T16:18:08.341444,True,,,,,Effects of Dexmedetomidine and Dopamine on Renal Function After Selective Major Surgery in Adult Patients,,['Renal Function'],"['dexmedetomidine', 'dopamine', 'surgery']",,2017-06-06,2019-12,"[{'measure': 'Postoperative renal function', 'description': 'Serum Cr and Cys-c', 'timeFrame': 'Change from baseline to the 5th day after surgery'}, {'measure': 'Mortality', 'timeFrame': '30 days'}, {'measure': 'Postoperative complications', 'timeFrame': '2 weeks'}]",[],3.0,18 Years,80 Years,ALL,False,OTHER,0.0,180.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05674539,Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome,Fludarabine and Busulfan,"['Fludara and Busulfex', 'Fludarabine and Melphalan', 'Busulfex and Fludara', 'Fludarabine and Busulfan']",4,INTERVENTIONAL,['PHASE3'],PHASE3,ENROLLING_BY_INVITATION,"Acute Myeloid Leukemia, Adult","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2025-09-01T16:18:08.341505,True,,,,,"Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Multi-Center, Phase III Study",,"['Acute Myeloid Leukemia, Adult', 'Myelodysplastic Syndrome(MDS)', 'Allogeneic Hematopoietic Stem Cell Transplantation']","['hematopoietic stem cell transplantation (HSCT)', 'reduced intensity conditioning (RIC)', 'Acute Myeloid Leukemia(AML)', 'Myelodysplastic Syndrome(MDS)']",,2023-02-15,2025-12-30,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Survival without relapse or progression of the primary disease. Kaplan-Meier (KM) method was used to estimate median PFS.', 'timeFrame': '18 months post-randomization'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Overall survival is defined as survival duration from the date of randomization to the date of death from any cause. Kaplan-Meier (KM) method was used to estimate median OS', 'timeFrame': '18 months post-randomization'}, {'measure': 'Non-Relapse Mortality (NRM)', 'description': 'Death not due to recurrence or progression of the primary disease. Recurrence was considered as a competing risk event, and the Gray test was used for statistical analysis.', 'timeFrame': '18 months post-randomization'}, {'measure': 'Disease Relapse', 'description': ""Relapse of the primary disease. Non-relapse mortality (TRM) was considered as a competing risk event, and Gray's test was used for statistical analysis."", 'timeFrame': '18 months post-randomization'}, {'measure': 'Percentage of Participants With Severe Acute Graft-versus-host Disease (GVHD)', 'description': 'Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:\n\nSkin stage:\n\n0: No rash\n\nRash \\<25% of body surface area Rash on 25-50% of body surface area Rash on \\> 50% of body surface area Generalized erythroderma with bullous formation\n\nLiver stage (based on bilirubin level)\\*:\n\n0: \\<2 mg/dL\n\n2-3 mg/dL 3.01-6 mg/dL 6.01-15.0 mg/dL \\>15 mg/dL\n\nGI stage\\*:\n\n0: No diarrhea or diarrhea \\<500 mL/day\n\nDiarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD Diarrhea 1000-1499 mL/day Diarrhea \\>1500 mL/day Severe abdominal pain with or without ileus \\* If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.\n\nGVHD grade:\n\n0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4', 'timeFrame': 'Day 100 post-transplant'}, {'measure': 'Percentage of Participants With Chronic GVHD', 'description': 'Chronic GVHD is classified as the occurrence of mild, moderate, or severe chronic GVHD per 2005 NIH Consensus Criteria (Filipovich et al. 2005)', 'timeFrame': '18 months post-transplant'}]",6.0,18 Years,,ALL,False,OTHER,0.0,200.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,Vemurafenib and Cobimetinib,"['Vemurafenib and Cobimetinib', 'Zelboraf for vemurafenib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Stage IIIB-C Melanoma,Inova Health Care Services,2025-09-01T16:18:08.341595,True,,,,,Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma,,['Stage IIIB-C Melanoma'],[],Sponsor has decided to close study.,2017-06-01,2018-02-24,"[{'measure': 'Radiologic Complete Response Rate', 'description': 'Radiologic complete response rate will be the primary endpoint. This will be assessed after completion of the 8-week treatment of vemurafenib and cobimetinib by CT measurements of tumor diameter pre-treatment and at day 56 (± 3 days) using RECIST 1.1. Complete response (CR) is defined by a reduction in the short-axis diameter of any pathologic lymph node to less than 10 mm, whereas partial response (PR) is defined as 30% or more decrease in the short axis. The analysis of response rate is based on the efficacy evaluable patients who has post-treatment CT scan at Day 43. Patients who discontinued study drug or withdraw from the study will be included only if they had post-treatment CT scan. We will calculate radiologic complete response rate with 95% confidence interval.', 'timeFrame': 'Day 56 (+/- 3 days)'}]","[{'measure': 'Overall response rate, pathologic complete response rate', 'description': 'Overall response rate is defined as the proportion of the patients in the analysis population who have a CR or PR. Pathologic complete response is defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of all sampled lymph nodes +/- primary melanoma specimen following completion of neoadjuvant systemic therapy (ypT0ypN0 in the current AJCC staging system). The analysis of pathologic response is based on the efficacy evaluable patients who underwent therapeutic lymph node dissection. Patients who discontinued study drug or withdraw from the study will be included only if they underwent therapeutic lymph node dissection. We will calculate the pathological complete response rate with 95% confidence interval.', 'timeFrame': 'Day 56 (+/- 3 days)'}]",2.0,18 Years,,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Sponsor has decided to close study.
NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gilteritinib,"['Azacitidine', 'ASP2215', 'gilteritinib', 'XOSPATA®', 'LoDAC (Low Dose Cytarabine)', 'MEC (Mitoxantrone, Etoposide, Cytarabine)', 'FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Leukemia, Acute Myeloid (AML)","Astellas Pharma Global Development, Inc.",2025-09-01T16:18:08.341638,True,,,,,"A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation",,"['Leukemia, Acute Myeloid (AML)']","['ASP2215', 'Relapsed Acute Myeloid Leukemia', 'FLT3 Mutation', 'gilteritinib', 'Refractory Acute Myeloid Leukemia', 'Acute Myeloid Leukemia (AML)', 'XOSPATA®']",,2015-10-20,2025-02-25,"[{'measure': 'Duration of Overall Survival (OS)', 'description': 'Overall survival was defined as the time from the date of randomization until the date of death from any cause (death date - randomization date + 1). For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - randomized date + 1). The date of last contact was the latest date that the participant was known to be alive. The last contact date was derived for participants alive at the analysis cutoff date. Survival rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula.', 'timeFrame': 'From randomization to until the date of death from any cause (median time of follow-up for OS was 17.8 months)'}, {'measure': 'Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm', 'description': 'The CR/CRh rate was defined as the number of participants who achieved either CR or CRh divided by the number of participants in the analysis population.\n\nCR: For participants to be classified as being in CR at, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\\^9/L and platelet count ≥ 100 x 10\\^9/L and normal marrow differential with \\< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia.\n\nCRh: Participants were classified as CRh if they had marrow blasts \\< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\\^9/L and platelets ≥ 50 x 10\\^9/L, no evidence of extramedullary leukemia and could not be classified as CR.', 'timeFrame': 'From the date of randomization up to at least 112 days'}]","[{'measure': 'Duration of Event-Free Survival (EFS)', 'description': 'EFS: time from randomization date up to date of documented relapse (excluding relapse after PR)/ treatment failure (failure to achieve CR, CRp, CRi /PR) /death, whichever occurred first. Relapse: leukemic blasts in peripheral blood 5/ ≥ 25% blasts in bone marrow (BM) aspirate due to no other cause/reappearance/new appearance of extramedullary leukemia. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥1x10\\^9/L, platelet count ≥100x10\\^9/L, normal marrow differential with \\<5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\\<100x 0\\^9/L). CRi: criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \\<1x10\\^9/L with /without complete platelet recovery. PR: BM regenerating normal hematopoietic cells, peripheral recovery, no circulating blasts and decrease of 50% blasts in with total blasts between 5% -25% or, 5% if Auer rods present.', 'timeFrame': 'From the date of randomization until the date of documented relapse, treatment failure or death from any cause (median time of follow-up was 17.8 months)'}, {'measure': 'Percentage of Participants With Complete Remission (CR) Rate', 'description': 'The CR rate was defined as the number of participants who achieved the best response of CR divided by the number of participants in the analysis population. CR: For participants to be classified as being in CR, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\\^9/L and platelet count ≥ 100 x 10\\^9/L and normal marrow differential with \\< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia.', 'timeFrame': 'From the date of randomization up to at least 6 months'}, {'measure': 'Duration of Leukemia-Free Survival (LFS)', 'description': 'LFS: time from the date of first CRc until the date of documented relapse or death for subjects who achieve CRc. For a subject who is not known to have relapsed or died, LFS is censored on the date of last relapse-free disease assessment date. CRc: achieved CR, CRp or CRi. Relapse: leukemic blasts in peripheral blood/ ≥ 25% blasts in bone marrow (BM) aspirate not due to any other cause/reappearance/new appearance of extramedullary leukemia. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥ 1 x 10\\^9/L, platelet count ≥ 100 x 10\\^9/L, normal marrow differential with \\< 5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\\< 100 x 10\\^9/L). CRi : criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \\< 1 x 10\\^9/L with /without complete platelet recovery..', 'timeFrame': 'From the date of first CRc until the date of documented relapse or death for participants who achieved CRc (median time of follow-up was 17.8 months)'}, {'measure': 'Duration of Remission', 'description': 'Duration of remission included duration of CRc, CR/CRh, CRh, CR, CRi, CRp (defined as the time from the date of first CRc until the date of first documented relapse for participants who achieved CRc, CR/CRh, CRh, CR, CRi, CRp respectively) and duration of response (CRc + PR). CRc: achieved CR, CRp or CRi at the visit. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥1x10\\^9/L, platelet count ≥100x10\\^9/L, normal marrow differential with \\<5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\\<100x 0\\^9/L). CRi: criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \\<1x10\\^9/L with /without complete platelet recovery. PR: BM regenerating normal hematopoietic cells, peripheral recovery, no circulating blasts and decrease of 50% blasts in with total blasts between 5% -25% or, 5% if Auer rods present.', 'timeFrame': 'From the date of first response until the date of documented relapse for participants who achieved CRc or PR (median time of follow-up was 17.8 months)'}, {'measure': 'Percentage of Participants With Composite Complete Remission (CRc Rate)', 'description': 'CRc rate: Number of participants with best response of CRc (CR,complete remission with incomplete platelet recovery \\[CRp\\] or complete remission with incomplete hematologic recovery \\[CRi\\]) divided by number of participants in the analysis population. CRc : Participants who achieved CR, CRp or CRi at a post-baseline visit. CR: Participants having bone marrow regenerating normal hematopoietic cells, a morphologic leukemia-free state, an ANC ≥ 1 x 10\\^9/L and platelet count ≥ 100 x 10\\^9/L, normal marrow differential with \\< 5% blasts, and being RBC and platelet transfusion independent with no evidence of extramedullary leukemia at a post-baseline visit. CRp: Participants achieving CR except for incomplete platelet recovery (\\< 100 x 10\\^9/L) at a post-baseline visit. CRi : Participants, who fulfilled all criteria for CR except incomplete hematological recovery with residual neutropenia \\< 1 x 10\\^9/L with or without complete platelet recovery at a post-baseline visit.', 'timeFrame': 'From the date of randomization up to at least 6 months'}, {'measure': 'Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant', 'description': 'Transplantation rate is defined as the percentage of participants undergoing Hematopoietic stem cell transplant (HSCT) during the study period.', 'timeFrame': 'From the date of randomization until end of study (median time of follow-up was 17.8 months)'}, {'measure': 'Change From Baseline in Brief Fatigue Inventory (BFI)', 'description': 'The Brief Fatigue Inventory (BFI) was a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions asked participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions asked participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A global fatigue score can be obtained by averaging all the items on the BFI. The total score range is 0-10 with a higher BFI fatigue score indicates worse outcome. The global BFI score was calculated only if at least 5 of the 9 items are answered.', 'timeFrame': 'Baseline, Cycle 1 Day 8 and Cycle 2 Day 1'}, {'measure': 'Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)', 'description': 'CRh rate was defined as the number of participants who achieved CRh at any of the postbaseline visits and did not have a best response of CR divided by the number of participants in the analysis population.\n\nCR: For participants to be classified as being in CR at a post-baseline visit, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\\^9/L and platelet count ≥ 100 x 10\\^9/L and normal marrow differential with \\< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia.\n\nCRh: At a post baseline visit, participantss were classified as CRh if they had marrow blasts \\< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\\^9/L and platelets ≥ 50 x 10\\^9/L, no evidence of extramedullary leukemia and could not be classified as CR.', 'timeFrame': 'From the date of randomization up to at least 6 months'}, {'measure': 'Percentage of Participants Who Achieved Transfusion Conversion and Maintenance', 'description': 'Transfusion conversion \\& maintenance rate was defined for gilteritinib arm. Participants were classified as transfusion independent if there were no RBC or platelet transfusions within 28 days prior to the first dose to 28 days after the first dose; otherwise they were classified as transfusion dependent at baseline. Participants were considered independent postbaseline if they had 1 consecutive 8 week period without any RBC or platelet transfusion from 29 days after the first dose until the last dose date. For participants who were on treatment ≤ 4 weeks or \\> 4 weeks but \\< 12 weeks and there was no RBC or platelet transfusion within postbaseline period, they were considered not evaluable; otherwise, they were considered postbaseline transfusion dependent. Transfusion conversion rate was defined for participants who had evaluable postbaseline transfusion status. Transfusion status (independent vs. dependent) at baseline and postbaseline was reported in a 2 by 2 contingency table.', 'timeFrame': 'From 29 days post first dose of study drug until last dose(median treatment duration was (126.00 [4.0, 885.0])'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events', 'description': 'An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not related to it. It could be any unfavorable/unintended sign (including abnormal laboratory finding), symptom, or disease (new/exacerbated) temporally associated with use of the study drug. A treatment-emergent adverse event (TEAE) : AEs observed after starting administration of study drug (gilteritinib or salvage chemotherapy). Serious AEs (SAEs): AEs which caused death, were life-threatening, resulted in persistent/significant disability/incapacity or disruption of the ability to conduct normal life functions, congenital anomaly, birth defect, required inpatient hospitalization/led to prolongation of hospitalization. Based on national cancer institute common terminology criteria (NCI-CTCAE), AEs were graded as grade 1=mild, grade 2=moderate, grade 3 =severe or medically significant, grade 4 =life threatening, grade 5 =death related to AE', 'timeFrame': 'From first dose of study drug up to 30 days after the last dose of study drug (median treatment duration for gilteritinib was (126.00 [4.0, 885.0]) days versus salvage chemotherapy 28.0 [5.0, 217.0] days)'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,371.0,ACTUAL,v2_robust,True,True,False,True,
NCT06909877,Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma,HH2853 Tablets,"['HH2853 Tablets', 'HH2853']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL),"Haihe Biopharma Co., Ltd.",2025-09-01T16:18:08.341913,True,,,,,"An Open-label, Multinational, Multicenter, Single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853, a Selective EZH1/2 Inhibitor, in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma",,['Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)'],"['Relapsed/Refractory', 'Peripheral T-cell Lymphoma']",,2022-07-27,2027-07-30,"[{'measure': 'Phase Ib: To determine the RP2D of HH2853 in PTCL patients', 'description': 'Determine RP2D of HH2853', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: To evaluate the efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug', 'description': 'ORR will be based on the blinded independent review committee (BIRC). Assessment of oncologic response will be performed according to the 2014 edition of the Lugano Criteria for Efficacy \\[Lugano\\]', 'timeFrame': '28-day treatment cycles'}]","[{'measure': 'Phase Ib: 1. Preliminary efficacy of HH2853 in R/R PTCL patients;', 'description': 'Investigator assessed: complete response rate (CRR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 1. Preliminary efficacy of HH2853 in R/R PTCL patients;', 'description': 'Duration of response (DoR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 1. Preliminary efficacy of HH2853 in R/R PTCL patients;', 'description': 'Disease control rate (DCR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 1. Preliminary efficacy of HH2853 in R/R PTCL patients;', 'description': 'Time to response (TTR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 2.To characterize the pharmacokinetic profile of HH2853', 'description': 'Area under the concentration-time curve (AUC)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 2.To characterize the pharmacokinetic profile of HH2853', 'description': 'Maximum plasma concentration (Cmax)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 2.To characterize the pharmacokinetic profile of HH2853', 'description': 'Trough concentration (Cmin)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 2.To characterize the pharmacokinetic profile of HH2853', 'description': 'Time to maximum plasma concentration (Tmax)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 2.To characterize the pharmacokinetic profile of HH2853', 'description': 'Apparent clearance (CL/F)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase Ib: 2.To characterize the pharmacokinetic profile of HH2853', 'description': 'Terminal half-life (t1/2)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'ORR assessed by investigator', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'Complete response rate (CRR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'Progression-free survival (PFS)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'Duration of response (DoR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'Disease control rate (DCR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'Time to response (TTR)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'Overall survival (OS) by BIRC', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 1.To further assess the other efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug (such as Chidamide, Pralatrexate and Brentuximab vedotin, et al.) therapy', 'description': 'Overall survival (OS) by investigator', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 2. To evaluate the safety and tolerability of HH2853', 'description': 'Duration and severity of adverse events (AEs)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 3. To characterize the population pharmacokinetic profile of HH2853', 'description': 'Area under the concentration-time curve (AUC)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 3. To characterize the population pharmacokinetic profile of HH2853', 'description': 'Maximum plasma concentration (Cmax)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 3. To characterize the population pharmacokinetic profile of HH2853', 'description': 'Steady-state trough concentration (Cmin)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 3. To characterize the population pharmacokinetic profile of HH2853', 'description': 'Time to maximum plasma concentration (Tmax)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 3. To characterize the population pharmacokinetic profile of HH2853', 'description': 'Apparent clearance (CL/F)', 'timeFrame': '28-day treatment cycles'}, {'measure': 'Phase II: 3. To characterize the population pharmacokinetic profile of HH2853', 'description': 'Half life (t1/2)', 'timeFrame': '28-day treatment cycles'}]",27.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,100.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02066077,The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy,Etomidate,"['Propofol', 'Etomidate']",2,INTERVENTIONAL,['NA'],,COMPLETED,Major Depressive Disorder,Shanghai Mental Health Center,2025-09-01T16:18:08.341955,True,,,,,The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy: A Randomized Clinical Trial And Its Standard Technology Promotion Research,,['Major Depressive Disorder'],"['Major Depressive Disorder', 'Modified Electroconvulsive Therapy', 'Cognition', 'Memory']",,2013-01-01,2017-12-31,"[{'measure': 'Change in Hamilton Depression Scale(HAMD) Scores', 'timeFrame': 'Change from Baseline in Hamilton Depression Scale scores at 7d, 14d, 21d, 28d, 35d, 42d and 180d after the last MECT session'}, {'measure': 'Change in Wechsler Memory Scale (WMS) Scores as a Measure of Safety', 'timeFrame': 'Change from Baseline in Wechsler Memory Scale (WMS) Scores at 42d and 180d after the last MECT session'}]","[{'measure': 'Young Manic Rating Scale(MMSE) as a Measure for Evaluation of Mania State', 'timeFrame': '42d and 180d after the last MECT session'}, {'measure': 'Resting-state/Task-state functional magnetic resonance imaging (fMRI)', 'timeFrame': 'Change form Baseline in Resting-state/Task-state fMRI Imging Results at 42d and 180d after the last MECT session'}, {'measure': 'Change in Hamilton Anxiety Scale(HAMA) Scores', 'timeFrame': 'Change from Baseline in Hamilton Anxiety Scale Scores at 7d, 14d, 21d, 28d, 35d, 42d and 180d after the last MECT session'}, {'measure': 'Change in Clinical Global Impression-severity of illness(CGI-SI) Scores as a Measure of Efficacy', 'timeFrame': 'Change from Baseline in CGI-SI Scores at 7d, 14d, 21d, 28d, 35d, 42d and 180d after the last MECT session'}, {'measure': 'Change in Wisconsin Card Sorting Test(WCST) Scores as a Measure of Safety', 'timeFrame': 'Change from Baseline in Wisconsin Card Sorting Test(WCST) Scores at 42d and 180d after the last MECT session'}, {'measure': 'Change in P300/P50 Event-Related Potentials(ERP)', 'timeFrame': 'Change from Baseline in P300/P50 Event-Related Potentials(ERP) at 42d and 180d after after the last MECT session'}]",8.0,18 Years,,ALL,False,OTHER,2.0,280.0,ACTUAL,v2_robust,True,True,False,True,
NCT00495677,A Phase 2 Study Of PF-00232798 In HIV Positive Patients,PF-00232798,['PF-00232798'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV,Pfizer,2025-09-01T16:18:08.341965,True,,,,,"A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798",,['HIV'],"['Treatment Experienced', 'Treatment Naive']",,2007-06,2008-09,"[{'measure': 'Change From Baseline in Log 10-transformed Human Immunodeficiency Virus (HIV) Viral Load at Day 11', 'description': 'Viral load was determined using the Roche COBAS Taqman HIV-1 assay with a lower limit of detection of 40 copies per milliliter (copies/mL). Samples with an initial reading of less than 1,000,000 copies/mL were diluted into range and re-assayed.', 'timeFrame': 'Baseline, Day 11'}]","[{'measure': 'Number of Participants With Time to Rebound of Human Immunodeficiency Virus (HIV) Viral Load', 'description': 'The time to rebound of viral load was calculated as the time from the last dose to the time of the first occasion at which the viral load was greater than the baseline value. Results are reported for number of participants who rebound within specified days from last dose and who did not rebound up to Day 25.', 'timeFrame': 'Day 1 up to Day 25'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': '0 hour (pre-dose) on Day 1 to 9; 0 hour (pre-dose), 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 10; Day 12, 13, 15 morning'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': '0 hour (pre-dose) on Day 1 to 9; 0 hour (pre-dose), 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 10; Day 12, 13, 15 morning'}, {'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)', 'description': 'AUCtau= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to the time end of dosing interval (24 hours post-dose).', 'timeFrame': '0 hour (pre-dose), 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 10'}]",5.0,18 Years,55 Years,MALE,False,INDUSTRY,0.0,43.0,ACTUAL,v2_robust,True,True,False,False,
NCT02901977,Doxazosin and Ramipril in Hypertension,Ramipril,"['Ramipril', 'Alfadil ,Cardura', 'Doxazosin', 'Tiratec']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hypertension,Karolinska Institutet,2025-09-01T16:18:08.341984,True,,,,,On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension,,['Hypertension'],"['Hypertension', 'Blood pressure', 'Hemostasis', 'Endothelial function']",,2011-03,2015-04,"[{'measure': 'Thrombin generation', 'description': 'Thrombin-Antithrombin complex (TAT)', 'timeFrame': '12 weeks'}, {'measure': 'Endothelial function', 'description': 'Forearm post-ischemic flow mediated dilatation', 'timeFrame': '12 weeks'}]",[],2.0,18 Years,100 Years,ALL,False,OTHER,0.0,71.0,ACTUAL,v2_robust,True,True,False,False,
NCT02790177,Role of Hyaluronic Acid in the Prevention of Post-operative Adhesions: a RCT,Hyaluronic Acid,"['NORMAL SALINE', 'Hyaluronic Acid']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Post Operative Adhesions,"Services Institute of Medical Sciences, Pakistan",2025-09-01T16:18:08.341993,True,,,,,Is Hyaluronic Acid Effective in the Prevention of Post-operative Adhesion?,,['Post Operative Adhesions'],[],,2016-06,2017-12,"[{'measure': 'POST OPERATIVE ADHESIONS TO BE EVALUATED BY LAPAROSCOPY AT THREE MONTHS INTERVAL', 'timeFrame': '3 months'}]",[],1.0,12 Years,,ALL,False,OTHER_GOV,0.0,150.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05364177,68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma,68Ga-Pentixather,"['68Ga-Pentixather', '68Ga-Pentixather injection', '68Ga-Pentixafor', '68Ga-Pentixafor injection']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,Multiple Myeloma,Peking Union Medical College Hospital,2025-09-01T16:18:08.342022,True,,,,,Comparison of 68Ga-pentixather and 68Ga-pentixafor PET/CT in Patients With Multiple Myeloma,,['Multiple Myeloma'],"['multiple myeloma', 'CXCR4', '68Ga-pentixather', 'PET/CT', '68Ga-pentixafor']",,2021-08-11,2024-08,"[{'measure': 'Metabolic parameter', 'description': 'Comparison of metabolic parameter (SUVmax) between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'PET-positive diffuse bone marrow involvement', 'description': 'Comparison of the number of diffuse bone marrow involvement between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'PET-positive focal bone marrow lesions', 'description': 'Comparison of the number of focal bone marrow lesions between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'PET-positive extramedullary lesions', 'description': 'Comparison of the number of extramedullary lesions between 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT.', 'timeFrame': 'through study completion, an average of 2 years'}]","[{'measure': 'Adverse effects', 'description': 'Types of adverse events.', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Tumor burden assessment', 'description': 'The correlation between metabolic parameter (SUVmax) in 68Ga-pentixather PET/CT and clinical staging', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Follow-up assessment', 'description': 'The correlation between metabolic parameter (SUVmax) in 68Ga-pentixather PET/CT and follow-up parameter (PFS).', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'CXCR4 expression in biopsies and metabolic parameters in PET', 'description': 'The correlation between CXCR4 expression in biopsies and metabolic parameter (SUVmax) in PET.', 'timeFrame': 'through study completion, an average of 2 years'}]",8.0,18 Years,,ALL,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05400577,"Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC","Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)","['Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)']",1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Non-Small Cell Lung Cancer,Fox Chase Cancer Center,2025-09-01T16:18:08.342064,True,,,,,"Neoadjuvant Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA Non-Small Cell Lung Cancer (NSCLC)",,['Non-Small Cell Lung Cancer'],[],Grantor withdrew support due to slow accrual,2022-07-13,2024-02-01,"[{'measure': 'Major pathologic response', 'description': 'Major pathologic response is defined as a resection specimen with \\< or = to 10% viable tumor cells in patients treated with neoadjuvant sotorasib for KRAS G12C mutated, stage Ib-IIIa NSCLC', 'timeFrame': '2 months'}]","[{'measure': 'Determine the safety, feasibility and tolerability of neoadjuvant sotorasib therapy in patients with surgically resectable KRAS G12C mutant NSCLC', 'description': 'Safety is assessed by all treatment-emergent adverse events and treatment-related adverse events. All adverse events will be assessed by the NCI CTCAE v5.0.', 'timeFrame': '1 months'}]",2.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Grantor withdrew support due to slow accrual
NCT00065377,Effects of Oral Glucosamine on Insulin and Blood Vessel Activity in Normal and Obese People,Glucosamine Hydrochloride,['Glucosamine Hydrochloride'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Obesity,National Center for Complementary and Integrative Health (NCCIH),2025-09-01T16:18:08.342075,True,,,,,An Exploratory Study of the Effects of Oral Glucosamine Administration on Insulin Sensitivity and Capillary Recruitment in Normal and Obese Subjects,,"['Obesity', 'Insulin Resistance']","['Diabetes', 'Insulin Resistance', 'Capillary Blood Flow', 'Osteoarthritis', 'Endothelial Dysfunction', 'Obesity', 'Healthy Volunteer', 'HV']",,2003-07,2006-06,[],[],0.0,21 Years,65 Years,ALL,True,NIH,0.0,60.0,,v2_robust,True,True,False,False,
NCT00164775,The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia,Imipramine,"['Imipramine', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Functional Gastrointestinal Disorder,Chinese University of Hong Kong,2025-09-01T16:18:08.342147,True,,,,,The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial,,['Functional Gastrointestinal Disorder'],"['Functional dyspepsia, refractory, antidepressant']",,2005-06,2010-08,"[{'measure': 'Overall satisfactory relief (Global Symptom Assessment) at 12 weeks', 'description': 'It is defined as a response of ""Yes"" to the question: ""Do you experience overall satisfactory relief of dyspeptic symptom with the current treatment?"" by global symptom assessment.', 'timeFrame': '12 weeks'}]","[{'measure': 'Individual dyspeptic symptom scores', 'description': '8-item dyspepsia symptom score questionnaire assessing epigastric pain, epigastric burning, postprandial fullness, early satiety, belching, bloating, nausea, and vomiting on a scale of 0-3 over the last 7 days', 'timeFrame': '12 weeks'}, {'measure': 'Days of sleep disturbance', 'description': 'Effect on sleep will be assessed by asking patients if they had insomnia on ≥1 day per week', 'timeFrame': '12 weeks'}, {'measure': 'Mood assessment', 'description': 'Effect on mood will be assessed using the hospital anxiety and depression scale (HADS)', 'timeFrame': '12 weeks'}]",4.0,18 Years,,ALL,False,OTHER,0.0,107.0,ACTUAL,v2_robust,True,True,False,False,
NCT02529475,Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS),Gadoteric acid,['Gadoteric acid'],1,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Meniere Disease,"University Hospital, Grenoble",2025-09-01T16:18:08.342204,True,,,,,Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS),,['Meniere Disease'],[],recruitment problem-covid-,2016-02-01,2020-09,"[{'measure': 'Gadolinium enhancement in inner ear structures as measured by MR T1 Weighted Imaging', 'timeFrame': 'One MR scan (4 hours)'}]",[],1.0,40 Years,,ALL,True,OTHER,0.0,25.0,ACTUAL,v2_robust,True,False,True,False,recruitment problem-covid-
NCT06259175,"Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)",Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg,"['Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg', 'Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg', 'Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg']",3,OBSERVATIONAL,[],,COMPLETED,Arterial Hypertension,Servier Russia,2025-09-01T16:18:08.342213,True,,,,,"Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)",,"['Arterial Hypertension', 'HTN']",[],,2024-05-01,2025-06-01,"[{'measure': 'To describe antihypertensive effectiveness of the triple single-pill combination (SPC) of amlodipine, indapamide and perindopril in outpatients with arterial hypertension (HTN) who do not receive any other concomitant antihypertensive medicines within 12', 'description': 'Mean changes from baseline (BL) in SBP (systolic blood pressure) assessed at V3 (12+1 weeks after the SPC initiation).', 'timeFrame': '12 weeks'}, {'measure': 'To describe antihypertensive effectiveness of the triple single-pill combination (SPC) of amlodipine, indapamide and perindopril in outpatients with arterial hypertension (HTN) who do not receive any other concomitant antihypertensive medicines within 12', 'description': 'Mean changes from baseline (BL) in DBP (diastolic blood pressure) assessed at V3 (12+1 weeks after the SPC initiation).', 'timeFrame': '12 weeks'}]","[{'measure': 'To describe changes in systolic blood pressure (SBP) from baseline to weeks 4 and 8 from the SPC initiation.', 'description': 'Mean change from BL in SBP assessed at V1 (4+1 weeks after the SPC initiation)', 'timeFrame': '4 weeks'}, {'measure': 'To describe changes in diastolic blood pressure (DBP) from baseline to weeks 4 and 8 from the SPC initiation.', 'description': 'Mean change from BL in DBP assessed at V1 (4+1 weeks after the SPC initiation)', 'timeFrame': '4 weeks'}, {'measure': 'To describe changes in systolic blood pressure (SBP) from baseline to weeks 4 and 8 from the SPC initiation.', 'description': 'Mean change from BL in SBP assessed at V2 (8+1 weeks after the SPC initiation).', 'timeFrame': '8 weeks'}, {'measure': 'To describe changes in diastolic blood pressure (DBP) from baseline to weeks 4 and 8 from the SPC initiation.', 'description': 'Mean change from BL in SBP and DBP assessed at V2 (8+1 weeks after the SPC initiation).', 'timeFrame': '8 weeks'}, {'measure': 'To describe a proportion of patients who reached SBP target goals at week 12 from the SPC initiation.', 'description': 'Proportion of patients who reached SBP ≤130 mm Hg at V3 (12+1 weeks after the SPC initiation).', 'timeFrame': '12 weeks'}, {'measure': 'To describe a proportion of patients who reached DBP target goals at week 12 from the SPC initiation.', 'description': 'Prortion of patients who reached DBP \\<80 mm Hg at V3 (12+1 weeks after the SPC initiation).', 'timeFrame': '12 weeks'}, {'measure': ""To describe changes in patients' quality-of-life throughout the observational period of the study."", 'description': 'Mean changes in scores of the Health-related quality of life Questionnaire for Patients with Hypertension (HRQoL) assessed at V3 (12+1 weeks after the SPC initiation).', 'timeFrame': '12 weeks'}]",9.0,18 Years,,ALL,False,INDUSTRY,0.0,396.0,ACTUAL,v2_robust,False,True,False,False,
NCT04760275,Fluoxetine vs CBT in Childhood Anxiety Disorders,Fluoxetine,['Fluoxetine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Anxiety Disorders,Children's Hospital Los Angeles,2025-09-01T16:18:08.342241,True,,,,,"A Sequential Multiple Assignment Randomized Trial (SMART) Assessing Medication and CBT Sequencing Strategies in the Treatment of Predominantly Ethnic Minority, Underserved Youth With Anxiety Disorders",,['Anxiety Disorders'],[],,2021-02-10,2026-07,"[{'measure': 'Youth - SCARED (Screen for Child Anxiety Related Disorders)', 'description': 'Patient ratings of anxiety symptom severity. Possible range of scores is 0-82, with higher scores indicating greater severity.', 'timeFrame': 'Week 24'}]","[{'measure': 'Parent - SCARED (Screen for Child Anxiety Related Disorders)', 'description': 'Parent ratings of anxiety symptom severity. Possible range of scores is 0-82, with higher scores indicating greater severity.', 'timeFrame': 'Week 24'}, {'measure': 'Youth - Child Anxiety Impact Scale (CAIS)', 'description': 'Patient ratings of anxiety functional impairment. Possible range of scores is 0-81, with higher scores indicating greater impact.', 'timeFrame': 'Week 24'}, {'measure': 'Parent - Child Anxiety Impact Scale (CAIS)', 'description': 'Parent ratings of anxiety functional impairment. Possible range of scores is 0-81, with higher scores indicating greater impact.', 'timeFrame': 'Week 24'}]",4.0,8 Years,17 Years,ALL,False,OTHER,1.0,316.0,ACTUAL,v2_robust,True,False,False,False,
NCT04758975,"Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)",Venetoclax,"['Venetoclax', 'Ibrutinib', 'Rituximab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Chronic Lymphocytic Leukemia (CLL),Paolo Ghia,2025-09-01T16:18:08.342384,True,,,,,Venetoclax and Delayed Rituximab With Ibrutinib Consolidation Aiming at Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL),,['Chronic Lymphocytic Leukemia (CLL)'],[],,2022-09-19,2027-12-30,"[{'measure': 'uMRD (<10-4) by 6-color flow cytometry in the bone marrow', 'description': 'uMRD (\\<10-4) by 6-color flow cytometry in the bone marrow as best response at any time during treatment for up to 3 months after completion of combined therapy (VR or VR followed by VI)', 'timeFrame': '27 months'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,55.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04179175,Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa,secukinumab,"['AIN457', 'secukinumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Hidradenitis Suppurativa,Novartis Pharmaceuticals,2025-09-01T16:18:08.342394,True,,,,,"A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa",,['Hidradenitis Suppurativa'],"['acne inversa', 'Hidradenitis suppurativa (HS)', 'maladie de Verneuil', 'inflammatory disease', 'AIN457', 'AIN457M', 'Secukinumab', 'Loss of Response (LOR)', 'Hidradenitis Suppurativa Clinical Response (HiSCR)', 'interleukin-17A (IL-17A)']",,2020-03-18,2026-07-15,"[{'measure': 'Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders', 'description': 'Loss of response was defined as:\n\n* at least a 50% increase in abscess and/or nodules (AN) count compared to the average AN count from the 3 previous visits or at Week 52, whichever is lower and the increase was at least of 3 AN.\n* at least a 30% increase in AN compared to the average AN count from the 3 previous visits or Week 52, whichever is lower, with an increase of at least 2 AN and a further increase in the AN count of at least 2 AN at a re-assessment visit within 2-4 weeks', 'timeFrame': 'Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.'}, {'measure': 'Incidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders', 'description': 'The incidence rate of participants achieving Loss of Response (LOR) was based on the primary estimand.\n\n* Day 1 = Date of 1st dose intake in the extension study.\n* Subjects at risk = Subjects who did not have LOR and were not censored before or at the start of the specified time interval.\n* Incidence rate (%) = (number of subjects with LOR / number of subjects at risk) x 100.', 'timeFrame': 'Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.'}]","[{'measure': 'Number of Participants With Treatment Emergent Adverse Events', 'description': 'To assess the long-term safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa (HS)', 'timeFrame': 'Up to 216 weeks: from randomization at the extension study (Week 52) up to Week 268. Study day is defined with respect to the core studies.'}]",3.0,18 Years,100 Years,ALL,False,INDUSTRY,0.0,703.0,ACTUAL,v2_robust,True,False,False,True,
NCT01105975,A Study of LY2484595 in Patients With High LDL-C or Low HDL-C,LY2484595,"['Placebo for LY2484595', 'Atorvastatin', 'Simvastatin', 'Placebo for Statins', 'Rosuvastatin', 'LY2484595']",6,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Dyslipidemia,Eli Lilly and Company,2025-09-01T16:18:08.342446,True,,,,,"A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C",,['Dyslipidemia'],"['Dyslipidemias', 'Mixed dyslipidemia', 'Hypercholesterolemia', 'Atherosclerosis', 'Atorvastatin', 'Simvastatin', 'Rosuvastatin', 'Metabolic Diseases', 'Antilipemic Agents', 'Enzyme Inhibitors', 'Anticholesteremic Agents', 'Cholesteryl Ester Transfer Protein Inhibitors', 'Cholesteryl Ester', 'Lipid Metabolism Disorders']",,2010-04,2011-06,"[{'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 and Placebo', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Pharmacokinetics - LY2484595 Area Under the Concentration-Time Curve (AUC) at Steady-State', 'timeFrame': 'Baseline up to 12 weeks'}, {'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Mass', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'The Number of Episodes of Rashes at Any Time From Baseline Through Week 12', 'description': 'All rash cases were adjudicated by a central dermatologist blinded to treatment assignment according to a study-specific Clinical Events Committee (CEC) charter. Rash events were assessed according to clinical relevance (high risk, low risk, not a relevant dermatosis, or insufficient documentation for determination). A participant could be reported in multiple categories.', 'timeFrame': 'Baseline through Week 12'}, {'measure': 'Change From Baseline to 12 Weeks Endpoint in Blood Pressure (BP)', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Weeks Endpoint in Serum Aldosterone', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Weeks Endpoint in Plasma Renin Activity', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Weeks Endpoint in Serum Potassium', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Weeks Endpoint in Serum Sodium', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Weeks Endpoint in Serum Bicarbonate', 'description': 'Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 18 Weeks Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) Score', 'description': 'EQ-5D is a health-related, quality-of-life instrument. It allows participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score 1 -3 is generated for each domain, with 1=no problem and 3= extreme problems. The outcome ratings on the 5 domains are mapped to a single index through an algorithm. The index ranges 0-1, with the higher score indicating a better health state perceived by the participants. LS Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.', 'timeFrame': 'Baseline up to Week 18'}]",17.0,18 Years,,ALL,False,INDUSTRY,0.0,398.0,ACTUAL,v2_robust,True,True,False,False,
NCT04183257,Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics,oral vitamin D,"['oral vitamin D', 'oral vitamin D 400IU']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Vitamin D Deficiency,King Edward Medical University,2025-09-01T16:18:08.342501,True,,,,,Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics,,"['Vitamin D Deficiency', 'Insulin Resistance', 'Diabetes Mellitus, Type 2']","['Vitamin D', 'T2DM', 'Insulin Resistance']",,2016-09-30,2017-07-30,"[{'measure': 'Homeostatic Model Assessment of Insulin Resistance', 'description': 'insulin resistance reduction to \\<2.5', 'timeFrame': '3 months'}]","[{'measure': 'Glycated Hemoglobin (HbA1C)', 'description': 'Reduction by 0.5%', 'timeFrame': '3 months'}]",2.0,25 Years,50 Years,ALL,False,OTHER,0.0,106.0,ACTUAL,v2_robust,True,True,False,False,
NCT00834457,A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe,abacavir/3TC/zidovudine,"['Kivexa or Epzicom', 'abacavir /3TC plus ritonavir boosted lopinavir', 'Trizivir', 'abacavir/3TC/zidovudine', 'Aluvia']",5,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,AIDS-related Kaposi's Sarcoma,Parirenyatwa Hospital,2025-09-01T16:18:08.342533,True,,,,,A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe,,"[""AIDS-related Kaposi's Sarcoma""]","[""AIDS-related Kaposi's sarcoma"", 'antiretroviral therapy']",,2007-06,2009-07,"[{'measure': 'Compare effects of twice-daily all-(NRTI) antiretroviral regimen to a once-daily regimen of 2 NRTIs plus a protease inhibitor AIDS-KS subjects with good virologic suppression on all-NRTI regimen.', 'timeFrame': '96 weeks'}]",[],1.0,18 Years,,ALL,False,OTHER,3.0,49.0,ACTUAL,v2_robust,True,True,False,False,
NCT04465357,Efficacy of Erenumab on Functional Impact of Migraine,Erenumab-Aooe 140 MG/ML [Aimovig],"['Erenumab-Aooe 140 MG/ML [Aimovig]', 'Aimovig', 'Erenumab']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Migraine,Merle Diamond,2025-09-01T16:18:08.342564,True,,,,,"A Multicenter, Open Label Study Assessing the Efficacy of Erenumab on Functional Impact of Migraine",,['Migraine'],[],,2020-10-22,2022-06-03,"[{'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Overall Impact on Usual Activities"" Scores at Baseline and at End of Treatment (Treatment Month 3).', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the single MFIQ Global Item Overall Impact on Usual Activities (item # 16). The item's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Month 3'}]","[{'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Physical Function"" Domain Scores at Baseline and at the End of Treatment (Treatment Month 3).', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Physical Function. The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Month 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Usual Activities"" Scores at Baseline and at the End of Treatment (Treatment Month 3).', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Usual Activities. The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Month 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Emotional Function"" Scores at Baseline and at the End of Treatment (Treatment Month 3).', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Emotional Function. The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Month 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Social Function"" Scores at Baseline and at the End of Treatment (Treatment Month 3).', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Social Function. The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Month 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Overall Impact on Usual Activities"" Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the single MFIQ Global Item Overall Impact on Usual Activities (item # 16). The item's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Physical Function"" Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Physical Function The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Usual Activities"" Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Usual Activities. The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Emotional Function"" Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Emotional Function. The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Migraine Functional Impact Questionnaire (MFIQ) - ""Impact on Social Function"" Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': ""The Migraine Functional Impact Questionnaire (MFIQ) is a 26-item self-report questionnaire. It is designed to measure the impact of migraine on physical, social, and emotional functioning over 5 domains: Physical Function (PF), Usual Activities (UA), Overall impact on Usual Activities, Social Function (SF), and Emotional Function (EF). Final transformed scores range from 0-100, with higher scores indicating more impact on the participant. For this endpoint we will be measuring changes in participant's response on the MFIQ domain, Social Function. The domain's transformed score can range from 0-100, with higher scores indicating more impact on the participant."", 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Migraine Interictal Burden Scale (MIBS-4) Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'The Migraine Interictal Burden Scale (MIBS-4) is a 4-item, self-administered questionnaire which measures interictal migraine-related burden in 4 domains: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Possible scores range from 0 (No interictal burden) to 12 (Severe interictal burden). Higher scores indicate worse interictal burden.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Number of Migraine Days at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'Comparison of the mean change from baseline in the frequency of migraine headache days per 28-day period ending with the cessation of treatment month 3. A migraine headache day will be defined as a calendar day (00:00 to 23:59) with 4 or more hours of migraine headache, fulfilling International Classification of Headache Disorders-3 criteria, and/or any headache of any duration with the use of migraine-specific acute medications(s) (i.e. ergot alkaloids, ergot combinations, opioids, triptans, combination analgesics \\[simple analgesics combined with opioids or barbiturate with or without caffeine\\]).', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Work Productivity and Activity Impairment- Migraine (WPAI-M): Absenteeism Domain Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'The Work Productivity and Activity Impairment- Migraine (WPAI-M) is a 6-item self-administered questionnaire that measures work productivity and the amount of time missed from work due to migraine. Domain scores are expressed as a percentage, with a range of scores form 0-100%, with higher scores indicating greater impairment and less productivity.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Work Productivity and Activity Impairment- Migraine (WPAI-M): Activity Impairment Domain Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'The Work Productivity and Activity Impairment- Migraine (WPAI-M) is a 6-item self-administered questionnaire that measures work productivity and the amount of time missed from work due to migraine. Domain scores are expressed as a percentage, with a range of scores form 0-100%, with higher scores indicating greater impairment and less productivity.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Work Productivity and Activity Impairment- Migraine (WPAI-M): Work Productivity Loss Domain Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'The Work Productivity and Activity Impairment- Migraine (WPAI-M) is a 6-item self-administered questionnaire that measures work productivity and the amount of time missed from work due to migraine. Domain scores are expressed as a percentage, with a range of scores form 0-100%, with higher scores indicating greater impairment and less productivity.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Work Productivity and Activity Impairment- Migraine (WPAI-M): Presenteeism Domain Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'The Work Productivity and Activity Impairment- Migraine (WPAI-M) is a 6-item self-administered questionnaire that measures work productivity and the amount of time missed from work due to migraine. Domain scores are expressed as a percentage, with a range of scores form 0-100%, with higher scores indicating greater impairment and less productivity.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Neuro-QoL Sleep Disturbance Short Form (SDSF) Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'The Neuro-QoL Sleep Disturbance Short Form (SDSF) is an 8-item, self-administered questionnaire which measures quality of sleep including difficulties and perception of sleep satisfaction. Possible transformed t-scores ranging from 32 to 84.20, with higher scores indicating worse sleep habits.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'General Self-Efficacy Severity Scale (GSESS) Scores at Baseline and at Treatment Months 1, 2, and 3.', 'description': 'The General Self-Efficacy Severity Scale (GSESS) is a 4 item, self-administered questionnaire where the participant is asked to rate their confidence in managing situations, problems, and events. Final scores range from 18.60 to 64.70 and are represented by the T-score, a standardized score with a mean of 50 and a standard deviation (SD) of 10. Higher scores indicate the participant has more self-efficacy managing difficult situations.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}, {'measure': 'Brief Measure of Worry Severity (BMWS) Scores at Baseline and at Treatment Months 1, 2, and 3', 'description': 'The Brief Measure of Worry Severity (BMWS) is a 8-item, self-administered questionnaire that measures various components of dysfunctional worry. Score range from 0-24 with higher scores indicating more worry within the participant.', 'timeFrame': 'Baseline and Treatment Months 1, 2, and 3'}]",19.0,18 Years,65 Years,ALL,False,OTHER,2.0,55.0,ACTUAL,v2_robust,True,True,False,False,
NCT04081857,A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects,HGP1810,"['HCP1704', 'HGP1810']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Health, Subjective",Hanmi Pharmaceutical Company Limited,2025-09-01T16:18:08.342671,True,,,,,"A Randomized, Open-Label, Single-Dose, Crossover Study to Compare Pharmacokinetic Properties and Safety of HCP1704 and HGP1810 in Healthy Adults",,"['Health, Subjective']",[],,2019-06-03,2019-08-05,"[{'measure': 'Cmax of Vildagliptin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'AUClast of Vildagliptin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'Cmax of Metformin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'AUClast of Metformin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}]","[{'measure': 'AUCinf of Vildagliptin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'Tmax of Vildagliptin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 't1/2 of Vildagliptin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'CL/F of Vildagliptin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'Vd/F of Vildagliptin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'AUCinf of Metformin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'Tmax of Metformin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 't1/2 of Metformin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'CL/F of Metformin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}, {'measure': 'Vd/F of Metformin', 'description': 'pharmacokinetic evaluation', 'timeFrame': 'pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hour'}]",14.0,19 Years,55 Years,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,False,
NCT05904457,A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer,bevacizumab,"['bevacizumab', 'eltinib', 'erlotinib', 'onbevzi']",4,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Solid Tumors,Asan Medical Center,2025-09-01T16:18:08.342712,True,,,,,"A Phase II Clinical Trial of Bevacizumab Plus eRlotinIb in patientS With Advanced Cancer Having Genetic Alterations in Krebs Cycle (BRISK, KCSG AL22-16)",,"['Solid Tumors', 'Advanced Solid Tumors', 'Metastatic Cancer']","['Krebs cycle', 'FH', 'IDH', 'SDH', 'bevacizumab', 'erlotinib', 'cancer', 'aerobic glycolysis', 'brisk']",,2023-01-02,2026-01-31,"[{'measure': 'Objective response rate', 'description': 'Defined as a proportion of complete response (CR) + partial response (PR) according to RECIST v1.1, the fraction with a response (CR+PR) will be reported separately by cohort, along with a 95% confidence interval', 'timeFrame': '12 months after treatment initiation (estimated average)'}]","[{'measure': 'Progression-free survival', 'description': 'Assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, PFS will be determined using the Kaplan-Meier method, and the curves presented along with a 95% confidence interval on the median PFS', 'timeFrame': 'Time from study treatment initiation until disease progression or death, assessed up to 1 years from study enrollment (estimated average)12 months after treatment initiation (estimated average)'}, {'measure': 'Overall survival (OS)', 'description': 'The Kaplan-Meier method will be used and the curves presented along with a 95% confidence interval on the median OS', 'timeFrame': 'Time from study treatment initiation until death from any cause, assessed up to 2 years from study enrollment (estimated average)'}, {'measure': 'Incidence of adverse events', 'description': 'Severity of adverse events will be graded by NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) v5.0', 'timeFrame': 'Time from study treatment initiation up to 30 days after last treatment, 12 months after treatment initiation (estimated average)'}]",4.0,19 Years,,ALL,False,OTHER,2.0,32.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02848157,Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery,Dexmedetomidine,"['plain ropivacaine', 'Ropivacaine', 'Dexmedetomidine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Elective Penile Surgeries,Yonsei University,2025-09-01T16:18:08.342777,True,,,,,,,"['Elective Penile Surgeries', 'Hypospadias', 'Urethral Fistula or Stricture After Hypospadias Repair', 'Penile Curvature']","['dexmedetomidine', 'pudendal block', 'hypospadias']",,2016-06-17,2017-03-24,"[{'measure': '1st analgesic request time', 'description': 'time to first rescue medication, assessed up to 24 h (time frame: from the administration of the pudendal block to the first registration of a FLACC≥4) (FLACC: face, legs, activity, cry, consolability)', 'timeFrame': 'until 24 hours after surgery'}]","[{'measure': 'Postoperative pain evaluated by the FLACC scale', 'description': 'Postoperative pain is evaluated by the FLACC scale', 'timeFrame': 'The time of arrival in the recovery room, 10, 20, 30 min after arrival of the recovery room, and 4, 8, 12, 24 h after the surgery.'}, {'measure': 'Emergence delirium evaluated by the pediatric anesthesia emergence delirium scale', 'description': 'emergence delirium is evaluated by the pediatric anesthesia emergence delirium scale', 'timeFrame': 'The time of arrival in the recovery room, 10, 20, 30 min after arrival of the recovery room, and through the time of discharge from the PACU, an average of 30 minutes'}]",3.0,,6 Years,MALE,True,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT00271401,"A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab",Abxicimab,"['Abxicimab', 'Heparin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Angioplasty, Transluminal, Percutaneous Coronary","Centocor, Inc.",2025-09-01T16:18:08.343028,True,,,,,"A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percutaneous Coronary Intervention",,"['Angioplasty, Transluminal, Percutaneous Coronary']","['Stents', 'Angioplasty, Transluminal, Percutaneous Coronary']",,1996-07,1997-09,"[{'measure': 'Number of Participants With any one of these: Deaths, Myocardial Infarctions, or Urgent Repeat Revascularizations', 'timeFrame': 'Up to 30 days'}]","[{'measure': 'Number of Particpants with Angiographic Outcome, Death or Myocardial Infraction and Cardiovascular Functional Status', 'timeFrame': 'Up to 6 months'}]",2.0,21 Years,,ALL,False,INDUSTRY,0.0,2399.0,ACTUAL,v2_robust,True,True,False,False,
NCT01761201,"""Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients"".",Levofloxacin,"['Isoniazid', 'Generic name: Levofloxacin', 'Levofloxacin', 'Generic name: Isoniazid.', 'Pharmaceutical form: tablets.', 'ATC Code: J01MA.', 'Pharmaceutical form: Levofloxacin 500 mg film-coated tablets', 'ATC Code: J04AC']",8,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Latent Tuberculosis Infection,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,2025-09-01T16:18:08.343054,True,,,,,"""A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients"".",,"['Latent Tuberculosis Infection', 'Infection in Solid Organ Transplant Recipients']","['Prophylaxis', 'Tuberculosis', 'Transplant recipients', 'Transplant waiting list']",Recruitment rythm not sufficent to reach the simple size needed.,2012-01,2014-02,"[{'measure': 'Difference in incidence of tuberculosis disease', 'description': 'A patient will be considered as having tuberculosis when Mycobacterium tuberculosis is isolated by culture or M. Tuberculosis DNA is isolated from a representative clinical sample, organ fluid or tissue by polymerase chain reaction. Also cases of histopathologically confirmed tuberculosis (caseating granulomas with/without demonstration of acid-alcohol resistant bacillus \\[BAAR\\]) and clinically compatible presentation will be accepted. Tuberculosis will be classified as pulmonary (pulmonary parenchymal involvement), extrapulmonary (involvement of different organs to the lung) or disseminated (involvement of at least two non-contiguous organs). Cases where tuberculosis is diagnosed on the basis of clinical and/or radiology suspicion and for whom the corresponding physician has prescribed a specific treatment will not be accepted.', 'timeFrame': '18 months of follow-up'}]","[{'measure': 'Mortality', 'description': 'Number of deaths of any cause', 'timeFrame': '18 months'}, {'measure': 'Toxicity', 'description': 'Occurrence of grade 3 or 4 toxicities according to the grading (severity) scale of the National Cancer Institute Common Toxicity Criteria Version 4.0, NCI-CTC-AE v 4.0.', 'timeFrame': 'During all the 18 months of follow-up'}, {'measure': 'Retransplantation', 'description': 'A new liver transplantation during the follow-up', 'timeFrame': '18 months'}, {'measure': 'Graft dysfunction', 'description': 'Development of advanced graft fibrosis stages 3 and 4', 'timeFrame': '18 months'}, {'measure': 'Transplant rejection', 'description': 'The occurrence of acute rejection or chronic rejection as per conventional definitions during the follow-up.', 'timeFrame': '18 months'}]",6.0,18 Years,,ALL,False,OTHER,1.0,68.0,ACTUAL,v2_robust,True,False,True,False,Recruitment rythm not sufficent to reach the simple size needed.
NCT04985201,Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy,Irinotecan,"['Irinotecan', 'Simvastatin', 'Simvastatin 40mg', 'Irinotecan injection']",4,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Small Cell Lung Cancer,"Shanghai Pulmonary Hospital, Shanghai, China",2025-09-01T16:18:08.343126,True,,,,,Clinical Study of Irinotecan With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy,,['Small Cell Lung Cancer'],"['ES-SCLC', 'Chemo-resistance', 'Simvastatin']",,2021-11-01,2023-08-01,"[{'measure': 'Progression-free survival (PFS)', 'description': 'To evaluate the progression-free survival (PFS) of patients.', 'timeFrame': '12 weeks'}]","[{'measure': 'Disease control rate (DCR)', 'description': 'To assess disease control rate (DCR) after treatment.', 'timeFrame': '6 weeks'}, {'measure': 'Overall response rate (ORR)', 'description': 'To assess best overall response rate (ORR) after treatment.', 'timeFrame': '6 weeks'}, {'measure': 'Overall survival (OS)', 'description': 'To estimate overall survival (OS) of patients with ES-SCLC.', 'timeFrame': '24 weeks'}, {'measure': 'Number of participants with treatment-related adverse events (AE) as assessed by CTCAE v4.0', 'description': 'To evaluate the toxicity profile.', 'timeFrame': '24 weeks'}]",5.0,18 Years,75 Years,ALL,False,OTHER,1.0,40.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03132701,The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children,Magnesium,"['Magnesium sulfate', 'Saline', 'Normal saline', 'Magnesium']",4,INTERVENTIONAL,['NA'],,COMPLETED,Emergence Delirium,Seoul National University Hospital,2025-09-01T16:18:08.343177,True,,,,,The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children,,['Emergence Delirium'],[],,2017-06-08,2017-12-12,"[{'measure': 'Emergence delirium', 'description': 'Pediatric Anesthesia Emergence Delirium (PAED) scale', 'timeFrame': '30 minutes after anesthesia'}]","[{'measure': 'Pain score', 'description': ""Modified Children's Hospital of Eastern Ontario Pain Scale, CHEOPS)"", 'timeFrame': 'At each two points: during emergence in operating room and 30 minutes after surgery ends'}, {'measure': 'Nausea', 'description': 'visual analogue scale', 'timeFrame': 'At each two points: during emergence in operating room and 30 minutes after surgery ends'}, {'measure': 'vomiting', 'description': 'number', 'timeFrame': 'At each two points: during emergence in operating room and 30 minutes after surgery ends'}, {'measure': 'Duration of post-anesthetic care unit (PACU) stay', 'description': 'Duration of post-anesthetic care unit (PACU) stay', 'timeFrame': 'During 1 hour after surgery at PACU'}]",5.0,2 Years,7 Years,ALL,True,OTHER,0.0,66.0,ACTUAL,v2_robust,True,True,False,False,
NCT06081101,Ketorolac Versus Corticosteroid Injections for Sacroiliac Joint Pain,Methylprednisolone Injection,"['Methylprednisolone Injection', 'Ketorolac Injection']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,NOT_YET_RECRUITING,Sacro-iliac Joint Pain,McMaster University,2025-09-01T16:18:08.343192,True,,,,,Ultrasound Guided Sacroiliac Joint Injections With Ketorolac Versus Corticosteroid: A Prospective Non-inferiority Study,,['Sacro-iliac Joint Pain'],[],,2025-01,2026-06,"[{'measure': 'Sacroiliac (SI) joint pain', 'description': 'SI joint pain at 2, 6 and 12 week marks post SI joint injection measured on visual analogue scale. Higher numbers equate to worse pain and worse outcomes.', 'timeFrame': '3 months following SI joint injection'}]",[],1.0,18 Years,,ALL,True,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02918812,Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief in HSG in a Tertiary Hospital in Kano,Intracervical lidocaine,"['Intracervical lidocaine', 'lignocaine', 'Intramuscular Diclofenac', 'Diclofenac sodium', 'Voltaren']",5,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Female Infertility of Tubal Origin,"Bayero University Kano, Nigeria",2025-09-01T16:18:08.343201,True,,,,,The Effect of Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief During Hysterosalpingography Among Infertile Women In A Tertiary Hospital In Kano: A Randomized Controlled Trial,,['Female Infertility of Tubal Origin'],"['Hysterosalpingography', 'Pain relief', 'Infertility', 'Intracervical block', 'Diclofenac']",,2016-09,2017-03,"[{'measure': 'Change in Visual Analogue Score', 'description': ""A detailed description of the visual analogue scale (VAS) will be given personally to each woman prior to the procedure. The VAS included a 10 cm linear scale on which 0 represents 'no pain' and 10 represents 'worst pain imaginable'. All patients will be asked to grade their perceived lower abdominal pain levels during specified stages of HSG using the VAS as explained to them. The scale will be used at different stages of the procedure: (1) before beginning the procedure; (2) after speculum application but before instrumentation; (3) after the application of the tenaculum and metal cannula and just before the injection of contrast medium; (4) at the end of uterine filling with contrast medium;"", 'timeFrame': 'Preprocedure and procedure time 0'}]","[{'measure': ""patient's satisfaction with pain relief in the two groups using Likert scale"", 'timeFrame': 'Time Frame: 30 minutes post procedure and 24 hours post procedure'}, {'measure': 'Change in pain score from pre-procedure to 5 and 30 minutes post procedure', 'timeFrame': '5 minutes and 30 minutes'}, {'measure': 'Change in pain score from pre-procedure to 5 and 24 hours post procedure', 'timeFrame': '5 minutes and 24 hours'}]",4.0,18 Years,49 Years,FEMALE,True,OTHER,0.0,140.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00756912,A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors,E5564,"['E5564', 'Eritoran']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Leukemia,Eisai Inc.,2025-09-01T16:18:08.343220,True,,,,,"A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors",,['Leukemia'],"['ANC', 'BMT', 'graft versus leukemia', 'graft vs. host disease', 'MD2 (endotoxin binding-protein)', 'undergo allogeneic BMT', 'myeloablative', 'conditioning', 'therapy']","This study was terminated in November 2008 due to ""a business decision (resources)"".",2008-09,,"[{'measure': 'Safety and assessments will be done daily.', 'timeFrame': 'Performed daily through Day 28, with follow-up every other week to Day 100 and at 1 year post-transplant.'}]",[],1.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,False,True,True,"This study was terminated in November 2008 due to ""a business decision (resources)""."
NCT00282412,Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism,Fludarabine,"['Fludara', 'Mycophenolate Mofetil', 'Campath 1H', 'Alemtuzumab', 'Cyclosporins', 'Cyclophosphamide', 'Neupogen', 'Cellcept', 'GCSF', 'CSA', 'Fludarabine', 'Cytoxan, Neosar']",12,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Rheumatoid Arthritis,Northwestern University,2025-09-01T16:18:08.343268,True,,,,,Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism,,['Rheumatoid Arthritis'],[],No participant enrolled for three years. No plan to continue study.,2002-09,2016-06,"[{'measure': 'Survival', 'description': 'The number of participants who survived treatment', 'timeFrame': 'up to 5 years'}]",[],1.0,18 Years,60 Years,ALL,False,OTHER,0.0,4.0,ACTUAL,v2_robust,True,False,True,False,No participant enrolled for three years. No plan to continue study.
NCT01718912,Periodontal Disease Treatment of a Physically Challenged Population,metronidazole-nystatin oral rinse,['metronidazole-nystatin oral rinse'],1,INTERVENTIONAL,['NA'],,COMPLETED,Periodontal Disease,Oravital Inc,2025-09-01T16:18:08.343277,True,,,,,The Effect of an Antibiotic-antifungal Rinse on Periodontal Disease,,['Periodontal Disease'],"['periodontal disease', 'bleeding on probing', 'periodontal pockets', 'disabled']",,2013-11,2014-10,"[{'measure': 'Evidence of healing of periodontal tissues as shown by a reduction of bleeding', 'description': 'Evidence of healing of periodontal tissues is assessed by measuring bleeding points and periodontal pocket depth using a dental probe.', 'timeFrame': 'two weeks'}]",[],1.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,11.0,ACTUAL,v2_robust,True,True,False,False,
NCT01465412,A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513),Preladenant,"['Preladenant', 'SCH 420814', 'Adenosine 2a Antagonist', 'MK-3814']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Chronic Hepatic Impairment,Merck Sharp & Dohme LLC,2025-09-01T16:18:08.343328,True,,,,,"An Open-label, Single Dose, Oral Administration, Sequential Two Parts Study to Compare the Pharmacokinetics of SCH 420814 / MK-3814 in Subjects With Mild and Moderate Chronic Hepatic Impairment With Their Respectively Matching Healthy Volunteers",,['Chronic Hepatic Impairment'],['Parkinson disease'],,2011-11-10,2012-06-14,"[{'measure': 'Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the AUC 0-t of preladenant.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Preladenant After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the Cmax of preladenant.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}]","[{'measure': 'AUC 0-t of Preladenant Metabolite SCH 434748 After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the AUC 0-t of SCH 434748.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}, {'measure': 'Cmax of Preladenant Metabolite SCH 434748 After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the Cmax of SCH 434748.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}, {'measure': 'AUC 0-t of Preladenant Metabolite SCH 446637 After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the AUC 0-t of SCH 446637.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}, {'measure': 'Cmax of Preladenant Metabolite SCH 446637 After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the Cmax of SCH 446637.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}, {'measure': 'AUC 0-t of Preladenant Calculated Using Free Drug Concentration After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the AUC 0-t of preladenant calculated using free drug concentration.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}, {'measure': 'Cmax of Preladenant Calculated Using Free Drug Concentration After a Single Dose of Preladenant', 'description': 'For healthy and HI participants blood samples were collected at pre-dose (0 hour) and at 0.50, 1, 2, 4, 6, 12, 16, 24, 30, 36, and 48 hours postdose. Blood samples were also collected for HI participants only at 60 and 72 hours postdose in order to determine the Cmax of preladenant calculated using free drug concentration.', 'timeFrame': 'Pre-dose up to 72 hours postdose'}]",8.0,18 Years,70 Years,ALL,True,INDUSTRY,0.0,42.0,ACTUAL,v2_robust,True,True,False,False,
NCT01208012,Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus,Victoza®,"['Victoza®', 'Victoza®, Liraglutide']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Diabetes Mellitus, Type 2",ikfe-CRO GmbH,2025-09-01T16:18:08.343360,True,,,,,Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus,,"['Diabetes Mellitus, Type 2']",['Diabetes Mellitus treatment Metformin'],,2010-04,2010-11,"[{'measure': 'The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells', 'description': 'Retinal capillary blood flow will be assessed using scanner laser doppler flowmetry.', 'timeFrame': 'timepoint 0 and after 6 and 12 weeks'}]","[{'measure': 'Central vascular elasticity', 'description': 'Central arterial elasticity will be measured by Pulse wave velocity.', 'timeFrame': 'timepoint 0 and after 6 and 12 weeks'}, {'measure': 'Skin endothelial function and Skin oxygenation', 'description': 'Microvascular skin blood flow and postcapillary tissue oxygenation (sO2)will be measured.', 'timeFrame': 'timepoint 0 and after 6 and 12 weeks'}, {'measure': 'Blood glucose control', 'description': 'Fasting plasma glucose will be measured.', 'timeFrame': 'timepoint 0 and after 6 and 12 weeks'}, {'measure': 'Blood glucose control', 'description': 'HbA1c will be maesured.', 'timeFrame': 'up to 2 weeks before baseline and after 6 and 12 weeks after baseline'}, {'measure': 'Change of biomarkers of sub-clinical inflammation and cardiovascular risk', 'description': 'Biomarkers PAI-1, hsCRP, VCAM, E-selectin and ADMA will be measured.', 'timeFrame': 'timepoint 0 and after 6 and 12 weeks'}, {'measure': 'Change of biomarker of heart failure', 'description': 'NT-pro BNP will be measured.', 'timeFrame': 'timepoint 0 and after 6 and 12 weeks'}, {'measure': 'Insulin/ intact Proinsulin ratio, C-peptide', 'description': 'Insulin Intact Proinsulin and C-peptide will be maesured.', 'timeFrame': 'timepoint 0 and after 6 and 12 weeks'}, {'measure': 'Change of body weight', 'description': 'Body weight will be measured.', 'timeFrame': 'up to 2 weeks before baseline and after 6 and 12 weeks after baseline'}, {'measure': 'Safety evaluation', 'description': 'The safety evaluation includes:\n\n* Metabolic parameters indicating hepatic function (ALAT, ASAT, γ-GT)\n* Blood analysis (Alkaline Phosphatase, Blood cell count)\n* Change in pancreas function (Amylase, Lipase)\n* Change in renal function (Creatinine, Potassium)\n* Change in thyroid function (Calcitonin)\n* Vital signs (Blood Pressure, Radial Pulse, ECG)\n* β-HCG (only female patients of childbearing potential)\n* Adverse Events\n* Adverse Drug Reactions', 'timeFrame': 'up to 2 weeks before baseline and after 12 weeks post baseline'}]",10.0,30 Years,65 Years,ALL,False,INDUSTRY,2.0,44.0,ACTUAL,v2_robust,True,True,False,True,
NCT04581512,Study to Evaluate the Safety and Tolerability of EP0042,EP0042,['EP0042'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Acute Myeloid Leukemia,Ellipses Pharma,2025-09-01T16:18:08.343561,True,,,,,"A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies",,"['Acute Myeloid Leukemia', 'Chronic Myelomonocytic Leukemia', 'Myelodysplastic Syndromes']",[],,2020-11-02,2025-12,"[{'measure': 'Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period.', 'description': 'Incidence of dose-limiting toxicities (DLT)', 'timeFrame': 'First cycle of treatment (28 Days)'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,70.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02368912,"A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects",ASP1707 single dose of dose levels 1 -7,"['ASP1707 multiple dose of dose levels 1-4', 'Placebo multiple dose of dose levels 1-4', 'ASP1707 single dose of dose levels 1 -7', 'Placebo multiple dose of dose levels 1-2', 'ASP1707 parallel multiple dose of dose levels 1-3', 'Placebo parallel multiple dose', 'Placebo single dose of dose levels 1-7', 'ASP1707 multiple dose of dose levels 1-2', 'ASP1707 single dose fasted', 'ASP1707 single dose fed']",10,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pharmacokinetics of ASP1707,Astellas Pharma Europe B.V.,2025-09-01T16:18:08.343595,True,,,,,"A Double Blind, Randomized, Placebo-controlled, Ascending Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1707 in Healthy Young and Elderly Male Subjects and in Healthy Pre-menopausal Female Subjects Including an Open-label Comparison of Pharmacokinetics Under Fasted and Fed Conditions in Healthy Young Male Subjects",,"['Pharmacokinetics of ASP1707', 'Pharmacodynamics of ASP1707']","['Phase 1', 'ASP1707', 'Dose escalation', 'Food effect', 'Maximum tolerated dose (MTD)', 'Healthy subjects', 'Single ascending dose', 'Multiple ascending dose']",,2010-06,2011-08,"[{'measure': 'Safety assessed by nature, frequency and severity of adverse events', 'description': 'Respectively Part 1 and Part 3', 'timeFrame': 'Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)'}, {'measure': 'Safety assessed by physical examination', 'description': 'Respectively Part 1 and Part 3', 'timeFrame': 'Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)'}, {'measure': 'Safety assessed by vital signs', 'description': 'Respectively Part 1 and Part 3. Vital signs include blood pressure and pulse.', 'timeFrame': 'Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)'}, {'measure': 'Safety assessed by safety laboratory tests', 'description': 'Respectively Part 1 and Part 3, Biochemistry, hematology, and urinalysis', 'timeFrame': 'Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)'}, {'measure': 'Safety assessed by 12 lead electrocardiogram (ECG)', 'description': 'Respectively Part 1 and Part 3', 'timeFrame': 'Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)'}, {'measure': 'Safety assessed by continuous cardiac monitoring (Holter)', 'description': 'Part 3', 'timeFrame': 'Days -1 and 21'}, {'measure': 'Pharmacokinetics (PK) of ASP1707 measured by area under the plasma concentration - time curve (AUC) extrapolated to time = infinity (AUCinf) in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by area under the plasma concentration-time curve (AUC) to time from the time of dosing to the last measurable concentration (AUClast) in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by time to reach quantifiable concentrations (tlag) in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by time to attain maximum concentration (tmax) in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by Cmax in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by terminal elimination half-life (t1/2) in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by apparent volume of distribution (Vz/F) in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by apparent clearance (CL/F) in plasma', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by amount excreted unchanged into urine (Ae) from time of dosing until last measurable concentration (Aelast) in urine', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by Ae extrapolated to time = infinity (Aeinf) in urine', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by Ae in % up to the collection time of the last measurable concentration (Aelast%) in urine', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by Ae in % extrapolated to time infinity (Aeinf%) in urine', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'PK of ASP1707 measured by renal clearance (CLR) in urine', 'description': 'Part 2', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'Pharmacodynamics (PD) of ASP1707 measured by Cmax in plasma', 'description': 'Part 4, period 1, 2 and 3. Estradiol (E2), Follicle-stimulating hormone (FSH) and Luteinizing Hormone (LH) levels', 'timeFrame': 'Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3'}, {'measure': 'PD of ASP1707 measured by tmax in plasma', 'description': 'Part 4, period 1, 2 and 3. E2, FSH and LH levels', 'timeFrame': 'Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3'}, {'measure': 'PD of ASP1707 measured by average concentration (Cavg, day 7-15) in plasma', 'description': 'Part 4, period 1, 2 and 3. E2, FSH and LH levels', 'timeFrame': 'Pre-dose to Day 26'}, {'measure': 'PD of ASP1707 measured by average concentration (Cavg, day 5-19) in plasma', 'description': 'Part 4, period 3. E2, FSH and LH levels', 'timeFrame': 'Pre-dose to Day 26'}, {'measure': 'PD of ASP1707 measured by average concentration (Cavg, day 23-26) in plasma', 'description': 'Part 4, period 2. E2, FSH and LH levels', 'timeFrame': 'Pre-dose to Day 26'}, {'measure': 'PD of ASP1707 - maximal duration within therapeutic range', 'description': 'Part 4, period 2. E2 levels', 'timeFrame': 'Pre-dose to Day 26'}, {'measure': 'PD of ASP1707 - total duration within therapeutic range (20-50 pg/mL)', 'description': 'Part 4, period 2. E2 levels', 'timeFrame': 'Pre-dose to Day 26'}, {'measure': 'PD of ASP1707 - Time of onset therapeutic range', 'description': 'Part 4, period 2. E2 levels', 'timeFrame': 'Pre-dose to Day 26'}, {'measure': 'PD of ASP1707 - Time of offset therapeutic range', 'description': 'Part 4, period 2. E2 levels', 'timeFrame': 'Pre-dose to Day 26'}, {'measure': 'PD of ASP1707 - Time of start menstruation after last dose of study drug', 'description': 'Part 4, period 3', 'timeFrame': 'Pre-dose to Day 26'}]","[{'measure': 'PK profile of ASP1707 in plasma and urine for Part 1', 'description': 'AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR', 'timeFrame': 'Pre-dose (Day 1) to Day 5'}, {'measure': 'Safety profile assessed by nature, frequency and severity of adverse events, physical examination, vital signs, safety laboratory tests and 12 lead ECG', 'description': 'Respectively Part 2 and Part 4', 'timeFrame': 'Screening to End of Study Visit (ESV) (Up to 31 days and up to 62 days)'}, {'measure': 'PD profile of ASP1707 for Part 1 and Part 2', 'description': 'Testosterone (T), LH and FSH levels: Cmin, tmin, maximal %Reduction and T only: Number and percentage of subjects with T castration level (= T \\< 0.5 ng/mL) after single dose, Time of onset of T \\< 0.5 ng/mL after single dose, Duration of T \\<0.5 ng/mL after single dose', 'timeFrame': 'Pre-dose (Day 1) to Day 12-19'}, {'measure': 'PD profile of ASP1707 for Part 3', 'description': 'T, LH and FSH levels: Cmin, tmin, maximal %Reduction T only: Number and percentage of subjects with T \\< 0.5 ng/mL at any time post-first dose, Number and percentage of subjects with T \\< 0.5 ng/mL after last dose, Number of subjects reaching T\\<0.5 ng/mL for ≥14 days, Day of onset of T \\< 0.5 ng/mL after multiple doses of ASP1707 (T \\< 0.5 ng/mL for the first time), Time of onset of T \\< 0.5 ng/mL after first dose, Duration of T \\< 0.5 ng/mL after single dose and during multiple dosing, Total duration, Maximal duration:Time from last dose to return to baseline levels for T, LH and FSH, Duration of T \\< 0.5 ng/mL after last dose', 'timeFrame': 'Pre-dose (Day 1) to Day 39'}, {'measure': 'PK profile of ASP1707 in plasma and urine for Part 3', 'description': 'AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR, Ctrough, AUC during the time interval between consecutive dosing (AUCtau), Accumulation Ratio (Rac), Peak Trough Ratio (PTR), Ae during the time interval between consecutive dosing (Aetau), Aetau as percentage of total dose (Aetau%), Ae during the time interval between consecutive dosing (AUCtau), (AUC0-24h), Ae0-24h, Ae0-24h%', 'timeFrame': 'Pre-dose (Day 1) to Day 25'}, {'measure': 'PK profile of ASP1707 in plasma and urine for Part 4', 'description': 'AUCtau, tmax, Cmax, t1/2, Vz/F, CL/F, CLR, Ctrough, PTR, Aetau, Aetau%,', 'timeFrame': 'Pre-dose (Day 23) to Day 25'}]",35.0,18 Years,,ALL,True,INDUSTRY,0.0,176.0,ACTUAL,v2_robust,True,True,False,True,
NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,natalizumab,"['BG00002', 'Tysabri', 'natalizumab', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Secondary Progressive Multiple Sclerosis,Biogen,2025-09-01T16:18:08.343685,True,,,,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension",,['Secondary Progressive Multiple Sclerosis'],"['Natalizumab', 'secondary', 'multiple sclerosis', 'MS', 'SPMS', 'Tysabri']",The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.,2011-09-13,2016-04-13,"[{'measure': 'Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)', 'description': 'Confirmed disability progression, defined as ≥1 of the following criteria (confirmed at a second visit ≥6 months later and at Week 96):\n\n* Confirmed progression in EDSS (EDSS score increased from baseline \\[BL\\] by ≥1 point if BL EDSS ≤5.5 or by ≥0.5 points if BL EDSS ≥6);\n* Confirmed progression in T25FW (T25FW increased by ≥20% of the BL walk);\n* Confirmed progression in 9HPT (9HPT increased by ≥20% of the time taken at BL on either hand and confirmed on the same hand).\n\nThe EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation.', 'timeFrame': 'Up to 96 weeks (2 years)'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator.', 'timeFrame': '218 weeks'}]","[{'measure': 'Part 1: Percentage of Participants With a T25FW Response', 'description': 'T25FW response is defined as any improvement from the best pre-dose T25FW in at least 75% of the scheduled on-treatment visits through Week 96. The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score for the T25FW is the average of the 2 completed trials. The 95% CI of the percentage is based on normal approximation.', 'timeFrame': 'Up to 96 weeks'}, {'measure': 'Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)', 'description': 'MSWS-12 is a participant self-assessment of the walking limitations due to MS during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where higher scores indicate greater impact on walking. A negative number on change from BL value indicates an improvement in MSWS-12.', 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire', 'description': ""The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. The participant completes a 56-item questionnaire by estimating their own difficulty or ease in performing each of 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability. A positive number on change from baseline value indicates an improvement in ABILHAND."", 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score', 'description': ""The 29-item MSIS-29 is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29."", 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96', 'description': 'Whole brain volume as measured by MRI.', 'timeFrame': 'Week 24 and Week 96'}, {'measure': 'Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores', 'description': 'The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who met one of the following criteria:\n\n* an increase of ≥ 1 point from baseline system score of ≥ 1 or an increase of ≥ 2 points from baseline system score of 0 in at least 2 physical functional systems, or\n* an increase of ≥ 2 points from baseline system score of ≥ 1 or an increase of ≥ 3 points from baseline system score of 0 in any 1 physical functional system.\n\nA confirmed progressor was defined as a participant who met the criteria for disability progression at any given visit and at the 6-Month Confirmation Visit. The 95% CIs are based on normal approximation.', 'timeFrame': 'Up to 96 weeks'}, {'measure': 'Part 2: Percentage of Participants With Disability Worsening at 156 Weeks', 'description': 'Percentage of participants with disability worsening at each scheduled efficacy visit in Part 2, defined as one or more of the following: • ≥ 20% worsening from Part 1 baseline in T25FW; • ≥ 20% worsening from Part 1 baseline in 9HPT; • Worsening from Part 1 baseline in EDSS (≥ 1 point increase if Part 1 baseline EDSS ≤ 5.5 or ≥ 0.5 point increase if Part 1 baseline EDSS \\> 5.5). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. 95% CIs of percentages are based on normal approximation.', 'timeFrame': 'Week 156'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in T25FW', 'description': 'The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Lower scores on time taken to reach 25 foot mark reflect a better outcome. Values are presented for the overall group, as well as the Confirmed Progressor (CP, defined in the primary outcome measure description above) and Non-Progressor (NP) subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in T25FW', 'description': 'The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in EDSS', 'description': 'The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in EDSS', 'description': 'The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)', 'description': 'The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.', 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in the 6MWT', 'description': 'The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score', 'description': ""The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29."", 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score', 'description': ""The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29."", 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)', 'description': 'SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).', 'timeFrame': 'Baseline (Part 1) and every 4 weeks from Week 108 to Week 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in the SDMT', 'description': 'SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).', 'timeFrame': 'Baseline (Part 1) and every 4 weeks from Week 108 to Week 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment - Multiple Sclerosis (WPAI-MS) Questionnaire', 'description': 'The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (percentage of overall work impairment \\[absenteeism plus presenteeism\\]) 4. Activity Impairment (percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.', 'timeFrame': 'Part 2 Baseline (Week 108) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire', 'description': 'The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (WPL; percentage of overall work impairment \\[absenteeism plus presenteeism\\]) 4. Activity Impairment (AI; percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.', 'timeFrame': 'Part 2 Baseline (Week 108) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume', 'description': 'Whole brain volume as measured by MRI.', 'timeFrame': 'Week 24 (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume', 'description': 'Whole grey matter brain volume as measured by MRI.', 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Summary of New/Enlarging T2 Lesion Counts', 'description': 'New or enlarging T2 lesions as measured by MRI.', 'timeFrame': 'Baseline (Part 1) up to Week 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions', 'description': 'New or enlarging T2 lesions as measured by MRI.', 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}]",29.0,18 Years,58 Years,ALL,False,INDUSTRY,0.0,889.0,ACTUAL,v2_robust,True,False,True,True,The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.
NCT00003981,E7070 in Treating Patients With Solid Tumors,indisulam,['indisulam'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Unspecified Adult Solid Tumor, Protocol Specific",European Organisation for Research and Treatment of Cancer - EORTC,2025-09-01T16:18:08.343722,True,,,,,"Phase I Study to Determine the Safety of E7070 in Patients With a Solid Tumor as a Single IV Infusion Weekly X 4, Repeated Every 6 Weeks",,"['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",,1998-04,,[],[],0.0,18 Years,,ALL,False,NETWORK,0.0,30.0,ESTIMATED,v2_robust,True,True,False,False,
NCT01729481,Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer,Gemcitabine,"['Gemzar', 'Leucovorin', 'Oxaliplatin', 'Erlotinib', 'Folinic Acid', 'Irinotecan', 'Eloxatin', 'Gemcitabine', 'Tarceva', 'Campto', '5-Flourouracil', '5-FU']",12,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Metastatic Pancreatic Adenocarcinoma,Ludwig-Maximilians - University of Munich,2025-09-01T16:18:08.343742,True,,,,,Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances,,['Metastatic Pancreatic Adenocarcinoma'],[],,2012-07,2017-12,"[{'measure': '1-year Survial rate of ""good-risk"" patients', 'description': '1-year Survial rate of ""good-risk"" patients of patients under gemcitabine plus erlotinib with RASH', 'timeFrame': 'Follow-Up Phase (1.5 years)'}]","[{'measure': 'Evalutation of overall response rate, disease control rate and progression free survival', 'description': 'Evaluation of Parameters by RASH positve and negative patients:\n\n* ORR\n* DCR\n* PFS\n* OS', 'timeFrame': 'Approximately 12 months'}, {'measure': 'Evaluation of adverse events', 'description': 'Assesment with NCI-CTCAE V4.0 Evalutation of side effects including picture documentation of skin-rash', 'timeFrame': 'Treatment Phase (1.5 Years)'}, {'measure': 'Translational Projects', 'description': '* Evaluation of Parameters for EGFR signal transduction\n* Evaluation Molecularbiological Parametrs of RASH\n* Picture Documentation of RASH. Corellation with clinical and molecularbiological Parameters', 'timeFrame': 'Approximately 24 months'}]",4.0,18 Years,75 Years,ALL,False,OTHER,1.0,150.0,ACTUAL,v2_robust,True,False,False,True,
NCT03240081,Treating Postmenopausal Dyspareunia Where it Hurts,50mcg estradiol cream,"['50mcg estradiol cream', '100mcg estradiol cream']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Dyspareunia,Oregon Health and Science University,2025-09-01T16:18:08.343845,True,,,,,Treating Where it Hurts: A Randomized Blinded Clinical Trial of Local Estrogen to the Vulvar Vestibule for Dyspareunia in Postmenopausal Women,,['Dyspareunia'],"['Post-menopause dyspareunia', 'Vulvar vestibular pain', 'Genitourinary syndrome of menopause', 'Sexual pain']",,2017-06-20,2019-11-21,"[{'measure': 'Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug', 'description': 'Change in median dyspareunia pain scores between baseline and 4 weeks of use of nightly use of study medication. Pain will be assessed using 11-point Numerical Rating Scale (NRS) where 0 = no pain and 10 = worst possible pain.', 'timeFrame': 'Baseline to 4 weeks'}, {'measure': 'Change in Median Pain Scores for Intercourse After 12 Weeks Using Study Drug', 'description': 'Difference in median dyspareunia pain scores between arms for intercourse at 12 weeks after use of nightly study medication for 90d. Pain will be assessed using 11-point Numerical Rating Scale (NRS) where 0 = no pain and 10 = worst possible pain.', 'timeFrame': 'Baseline and 12 weeks'}]",[],2.0,40 Years,70 Years,FEMALE,True,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT02369081,Optimum Treatment for Drug-Resistant Hypertension,Spironolactone,"['Doxazosin', 'Placebo', 'Bisoprolol', 'Spironolactone']",4,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,"Hypertension, Resistant to Conventional Therapy",University of Cambridge,2025-09-01T16:18:08.343858,True,,,,,Optimum Treatment for Drug-Resistant Hypertension,,"['Hypertension, Resistant to Conventional Therapy']",['Hypertension'],,2009-05,2015-08,"[{'measure': 'Treatment arm comparison according to home blood pressure measurement', 'description': 'We will adopt a hierarchical procedure to test, in order, the differences in home systolic BP between spironolactone and\n\n1. placebo\n2. the average of the other two active drugs\n3. each of the other two drugs. The second and third tests will be carried out if and only if the preceding test(s) are significant (P\\<0.05).\n\nWe shall use a mixed model to analyse home BP, with unstructured covariances for the repeated measures across the two doses for each treatment within a patient. The model will include terms for gender, age, height, weight, smoking history and a diagnosis of diabetes at baseline. We will also adjust for baseline BP.', 'timeFrame': '48 weeks'}]","[{'measure': 'Measurement of plasma renin as predictor of effective treatment', 'description': ""The difference in home systolic BP averages between the best drug predicted by the patient's plasma renin (according to the 'α, β, ∆' rule cited above) and further diuretic therapy;ie with spironolactone, which we have predicted will be the most effective treatment on average."", 'timeFrame': '48 weeks'}]",2.0,18 Years,79 Years,ALL,False,OTHER,1.0,348.0,ACTUAL,v2_robust,True,False,False,False,
NCT00376181,"Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus",Pioglitazone and Azilsartan,"['TAK-536', 'Pioglitazone', 'Pioglitazone and Azilsartan', 'AD-4833', 'Actos']",5,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Type 2 Diabetes,Takeda,2025-09-01T16:18:08.343913,True,,,,,"A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes",,['Type 2 Diabetes'],"['type 2 diabetes', 'hypertension', 'blood pressure', 'diastolic blood pressure']",Combination formulation concerns,2006-06,2007-05,"[{'measure': 'Change from Baseline in Glycosylated Hemoglobin.', 'description': 'The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or including final visit, and Glycosylated Hemoglobin collected at baseline.', 'timeFrame': 'Baseline and Week 24'}]","[{'measure': 'Change from Baseline in Diastolic Blood Pressure', 'description': 'The change between Diastolic Blood Pressure measured at each week indicated including final visit and Diastolic Blood Pressure measured at baseline.', 'timeFrame': 'Baseline and Weeks 4, 8, 12, 16, 20, and 24.'}, {'measure': 'Change from Baseline in Systolic Blood Pressure', 'description': 'The change between Systolic Blood Pressure measured at each week indicated including final visit and Systolic Blood Pressure measured at baseline.', 'timeFrame': 'Baseline and Weeks 4, 8, 12, 16, 20, and 24'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,96.0,ACTUAL,v2_robust,True,False,True,False,Combination formulation concerns
NCT07118319,"The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis",Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN),['Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,NOT_YET_RECRUITING,Amyotrophic Lateral Sclerosis (ALS),"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.",2025-09-01T16:18:08.343927,True,,,,,"A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis",,['Amyotrophic Lateral Sclerosis (ALS)'],[],,2025-08-04,2028-09-30,"[{'measure': 'The incidence of XS228CN-related adverse events (AEs) and serious adverse events (SAEs) within 28 days after the last administration in ALS patients', 'timeFrame': 'within 28 days after the last administration'}]",[],1.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,12.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05437419,"A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis",TCK-276,"['Cyclin Dependent Kinase 4/6 (CDK 4/6) Inhibitor', 'Placebo', 'TCK-276 Placebo', 'TEI-T01276', 'TCK-276']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Rheumatoid Arthritis,"Teijin America, Inc.",2025-09-01T16:18:08.343980,True,,,,,"A Phase 1, Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis",,['Rheumatoid Arthritis'],"['Multiple Ascending Dose', 'autoimmune disease', 'Disease modifying antirheumatic drugs (DMARD)']",,2022-08-10,2023-07-27,"[{'measure': 'Number ot Participants With Treatment Emergent Adverse Events', 'description': 'To evaluate the safety and tolerability of multiple oral doses of TCK-276 or placebo in patients with rheumatoid arthritis (RA)', 'timeFrame': '42 days (duration of study)'}]","[{'measure': 'Cmax: Plasma Concentrations of TCK-276 and TEI-W00595 (Metabolite)', 'description': 'Cmax: Plasma Concentrations of TCK-276 and TEI-W00595 with time-concentration profile', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Tmax: Time of Maximum Plasma Concentration Determined Directly From the Concentration-time Profile', 'description': 'To evaluate tmax as pharmacokinetic (PK) variables of TCK-276 and its metabolite in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 't½: Terminal Elimination Half-life', 'description': 'To evaluate t½ as PK variables of TCK-276 and its metabolite in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'AUCtau: Area Under the Plasma Concentration-time Curve Over a Dosing Interval, Tau = 24 Hours', 'description': 'To evaluate AUCtau as PK variables of TCK-276 and its metabolite in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'AUC0-inf: Area Under the Plasma Concentration Time Curve From Pre-dose (Time 0) Extrapolated to Infinite Time', 'description': 'AUC0-inf:Area under the plasma concentration time curve from pre-dose (time 0) extrapolated to infinite time (Days 1 and 7)', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Clearance (CL)/F: Apparent Total Body Clearance (Parent Only)', 'description': 'To evaluate CL/F as PK variables of TCK-276 in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Vz/F: Apparent Volume of Distribution Based on Terminal Phase (Parent Only)', 'description': 'To evaluate Vz/F as PK variables of TCK-276 in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'MRT0-inf: Mean Residence Time Extrapolated to Infinity', 'description': 'To evaluate MRT0-inf as PK variables of TCK-276 and its metabolite in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Racc (Cmax): Accumulation Ratio Based on Cmax', 'description': 'Racc (Cmax) calculated as Cmax on Day 7/Cmax on Day 1.', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Racc (AUCtau): Accumulation Ratio Based on AUCtau', 'description': 'Racc (AUCtau) calculated as AUCtau on Day 7/AUCtau on Day 1. To evaluate Racc (AUCtau) as PK variables of TCK-276 and its metabolite in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Metabolic Ratio (MR) for Cmax', 'description': 'Molar metabolic ratio of Cmax calculated as (Cmax \\[metabolite\\] × molecular weight of parent)/(Cmax \\[parent\\] × molecular weight of metabolite).', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'MR for Area Under the Plasma Concentration-time Curve (AUC)Tau', 'description': 'Molar metabolic ratio of AUC calculated as (AUC \\[metabolite\\] × molecular weight of parent)/(AUC \\[parent\\] × molecular weight of metabolite). To evaluate MR AUC as PK variables of TCK-276 and its metabolite in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'MR for Area Under the Plasma Concentration-time Curve (AUC)0-inf', 'description': 'Molar metabolic ratio of AUC calculated as (AUC \\[metabolite\\] × molecular weight of parent)/(AUC \\[parent\\] × molecular weight of metabolite) 0-inf. To evaluate MR AUC 0-inf as PK variables of TCK-276 and its metabolite in patients with RA after multiple ascending dose (MAD) administration', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Ae 0-24: Amount of Study Drug Excreted Unchanged in the Urine (Days 1 and 7)', 'description': 'Ae 0-24: Amount of study drug excreted unchanged in the urine (Days 1 and 7) over 24 hours', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Fe 0-24: Percentage of Study Drug Excreted Unchanged in the Urine (Days 1 and 7)', 'description': 'Fe 0-24: Percentage of study drug excreted unchanged in the urine (Days 1 and 7) over 24 hours', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Clearance Renal (CLr): Renal Clearance (Days 1 and 7)', 'description': 'CLr: Renal clearance Day 1 and Day 7 (24 hours)', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Ae 0-72: Amount of Study Drug Excreted Unchanged in the Urine (Day 7)', 'description': 'Ae 0-72: Amount of study drug excreted unchanged in the urine (Day 7) over a 72 hour period', 'timeFrame': 'Day 7 0-72 hours'}, {'measure': 'Fe 0-72: Percentage of Study Drug Excreted Unchanged in the Urine', 'description': 'Fe 0-72: Percentage of study drug excreted unchanged in the urine on Day 7 (72 hours)', 'timeFrame': 'Day 7 0-72 hours'}]",19.0,18 Years,64 Years,ALL,False,INDUSTRY,1.0,32.0,ACTUAL,v2_robust,True,True,False,True,
NCT03244319,Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial),Edoxaban,"['Warfarin', 'parenteral anti-coagulant (UFH)', 'Edoxaban']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,MV(Mitral Valve) Repair,Yonsei University,2025-09-01T16:18:08.344050,True,,,,,Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial),,['MV(Mitral Valve) Repair'],[],,2017-12-01,2019-09-30,"[{'measure': 'Occurrence of thromboembolic event', 'description': 'Occurrence of thromboembolic events and any thrombus at repaired ring or bioprosthetic valves detected by follow up echocardiography or 3D CT scan', 'timeFrame': '12 weeks'}]","[{'measure': 'Dysfunction of treated valve', 'description': 'Dysfunction of treated valve caused by thrombosis on echocardiography or 3D CT scan', 'timeFrame': '12 weeks'}]",2.0,20 Years,85 Years,ALL,False,OTHER,0.0,220.0,ACTUAL,v2_robust,True,True,False,False,
NCT00145730,Prevention of Ectopic Bone Related Pain and Disability After Hip Replacement Surgery With Peri-Operative Ibuprofen,Ibuprofen,['Ibuprofen'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Osteoarthritis, Hip",The George Institute,2025-09-01T16:18:08.344123,True,,,,,A Multicentre Randomised Placebo-Controlled Trail of Ibuprofen for the Prevention of Ectopic Bone-Related Pain and Disability After Elective Hip Replacement Surgery (HIPAID),,"['Osteoarthritis, Hip', 'Arthroplasty, Replacement, Hip', 'Arthritis, Rheumatoid']","['osteoarthritis hip', 'arthroplasty', 'ectopic bone formation', 'non-steroidal anti-inflammatory drugs', 'disability']",,2002-02,2004-05,[{'measure': 'Self-reported pain and physical function (WOMAC)'}],"[{'measure': 'Health-related quality of life (SF36v2)'}, {'measure': ""Patients' global assessment""}, {'measure': 'Physical performance measures: hip flexion, 50ft walk time, up and go.'}, {'measure': 'Major bleeding events: bleeding from wound > 3 days, evacuation of wound hematoma, hematemesis, melaena, other.'}]",5.0,,,ALL,False,OTHER,2.0,1000.0,,v2_robust,True,True,False,False,
NCT03043430,Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients,Ketamine 100 MG/ML,"['Ketamine 100 MG/ML', 'Midazolam 5 MG/ML']",2,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Anxiety,Brooke Army Medical Center,2025-09-01T16:18:08.344135,True,,,,,Anxiolysis for Emergency Department Procedures in Pediatric Patients Using Intranasal Ketamine Compared With Intranasal Midazolam: A Randomized Controlled Trial,,"['Anxiety', 'Pediatric ALL', 'Procedural Anxiety']",[],Research manpower shortage,2016-05,2023-04,"[{'measure': 'Change in mYPAS', 'description': 'Modified Yale preoperative anxiety scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre-procedure'}]","[{'measure': 'Change in sedation scale', 'description': 'University of Michigan sedation scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre procedure, 5 minutes post procedure, and 5 minutes pre-discharge'}, {'measure': 'Change in pain rating (Wong-Baker Pain Faces Rating Scale)', 'description': 'Wong-Baker Pain Faces Rating Scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre procedure, 5 minutes post procedure, and 5 minutes pre-discharge'}, {'measure': 'Change in anxiety score (Visual analogue scale)', 'description': 'Visual analogue scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre procedure, 5 minutes post procedure, and 5 minutes pre-discharge'}]",4.0,2 Years,12 Years,ALL,False,FED,0.0,10.0,ACTUAL,v2_robust,True,False,True,False,Research manpower shortage
NCT06332430,Intratumoral CAN2109 in Subjects With Solid Tumors,CAN2109,['CAN2109'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Solid Tumor,Canwell Biotech Limited,2025-09-01T16:18:08.344397,True,,,,,"A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.",,"['Solid Tumor', 'Lymphoma']",[],,2024-05-28,2026-05-30,"[{'measure': 'Safety', 'description': 'determined by assessment of dose limiting toxicities per protocol of CAN2109 with cancers.', 'timeFrame': '12 months'}, {'measure': 'Recommended Phase 2 Dose (RP2D)', 'description': 'To determine a recommended phase 2 dose of CAN21909 for further development by evaluating number of patients with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).', 'timeFrame': '12 months'}, {'measure': 'tolerability', 'description': 'determined by assessment of the maximum tolerated dose or maximal assessed dose per protocol of CAN2109 with cancers.', 'timeFrame': '12 months'}]","[{'measure': 'To determine the efficacy of CAN2109', 'description': 'Proportion of patients experiencing a tumor response or a stable disease according to RECIST 1.1 or iRECIST 1.1 as appropriate.', 'timeFrame': '12 months'}, {'measure': 'To evaluate the pharmacodynamics of CAN2109', 'description': 'Maximum observed plasma and tumor concentration of CAN2109 after IT administration.', 'timeFrame': '12 months'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,27.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02619630,Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old),nelarabine,['nelarabine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,T-cell Adult Acute Lymphoblastic Leukemia,Assistance Publique - Hôpitaux de Paris,2025-09-01T16:18:08.344404,True,,,,,Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients,,['T-cell Adult Acute Lymphoblastic Leukemia'],[],,2015-12,2025-12,"[{'measure': 'Disease free survival (DFS)', 'timeFrame': '4 years'}]","[{'measure': 'Overall survival', 'timeFrame': '4 years'}, {'measure': 'Cumulative incidence of relapse', 'timeFrame': '4 years'}, {'measure': 'Non relapse mortality (NRM)', 'timeFrame': '4 years'}, {'measure': 'Disease free survival censored at allograft in first complete remission (CR)', 'timeFrame': '4 years'}, {'measure': 'Cumulative incidence of relapse censored at allograft in first complete remission (CR)', 'timeFrame': '4 years'}, {'measure': 'Overall survival censored at allograft in first complete remission (CR)', 'timeFrame': '4 years'}, {'measure': 'Non relapse mortality (NRM) censored at allograft in first complete remission (CR)', 'timeFrame': '4 years'}, {'measure': 'Minimal residual disease (MRD)', 'timeFrame': 'within 1 year'}, {'measure': 'Proportion of patients having received the 5 cycles of nelarabine', 'timeFrame': '3 years'}]",10.0,18 Years,59 Years,ALL,False,OTHER,0.0,275.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02622230,"Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult Subjects",Mianhuahua Flavonoids Tablets,"['Mianhuahua Flavonoids Tablets', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Healthy,"Xinjiang Uygur Pharmaceutical Co., Ltd.",2025-09-01T16:18:08.344420,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics of Mianhuahua Flavonoids Tablets After Oral Administration In Healthy Adult Subjects",,['Healthy'],['Uygur Medicine'],,2015-12,2016-11,"[{'measure': 'Safety and tolerability of single and repeated oral administration of Mianhuahua Flavonoids Tablets as measured by the frequency of drug-related clinical adverse events in healthy adults.', 'description': 'Safety and tolerability will be evaluated through Composite Metrics：adverse events, vital signs, electrocardiograms, physical exams, and clinical laboratory assessments.', 'timeFrame': 'Period I: single dose,up to 7 Days;Period II: repeated dose,up to 36 Days'}]","[{'measure': 'Cmax of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 24h'}, {'measure': 'Tmax of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 24h'}, {'measure': 'area under curve(AUC) of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 24h'}, {'measure': 't1/2 of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 24h'}, {'measure': 'Vd of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 24h'}, {'measure': 'Cls of single oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 24h'}, {'measure': 'Css_max of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 29 days'}, {'measure': 'Css_min of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 29 days'}, {'measure': 'Tss_max of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 29 days'}, {'measure': 'area under curve of steady state(AUCss) of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 29 days'}, {'measure': 'Degree of fluctuation（DF） of repeated oral administration of Mianhuahua Flavonoids Tablets in healthy adults.', 'timeFrame': 'up to 29 days'}]",12.0,18 Years,45 Years,ALL,True,INDUSTRY,1.0,60.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00278330,Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia,alvocidib,"['L-001079038', 'SAHA', 'FLAVO', 'Zolinza', 'vorinostat', 'flavopiridol', 'HMR 1275', 'L-868275', 'suberoylanilide hydroxamic acid', 'alvocidib']",10,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Blastic Phase Chronic Myelogenous Leukemia,National Cancer Institute (NCI),2025-09-01T16:18:08.344490,True,,,,,"Phase I Trial of Vorinostat (SAHA) in Combination With Alvocidib (Flavopiridol) in Patients With Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia With Excess Blasts-2",,"['Blastic Phase Chronic Myelogenous Leukemia', 'Recurrent Adult Acute Lymphoblastic Leukemia', 'Recurrent Adult Acute Myeloid Leukemia', 'Refractory Anemia With Excess Blasts', 'Relapsing Chronic Myelogenous Leukemia', 'Untreated Adult Acute Lymphoblastic Leukemia', 'Untreated Adult Acute Myeloid Leukemia']",[],,2006-01,,"[{'measure': 'MTD for the combination of alvocidib and vorinostat, assessed by Common Toxicity Criteria version 3.0', 'timeFrame': '21 days'}]",[],1.0,18 Years,,ALL,False,NIH,0.0,24.0,ACTUAL,v2_robust,True,True,False,False,
NCT00003930,Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer,cisplatin,"['cisplatin', 'paclitaxel', 'gemcitabine hydrochloride']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Bladder Cancer,Radiation Therapy Oncology Group,2025-09-01T16:18:08.344557,True,,,,,"A Phase I/II Trial in Patients With Muscle-Invading Bladder Cancer of Transurethral Surgery Plus Taxol, Cisplatin and Bid Irradiation Followed by Either Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy",,['Bladder Cancer'],"['stage II bladder cancer', 'stage III bladder cancer']",,1999-09,2013-11,"[{'measure': 'Completion and safety of induction chemo-radiotherapy followed by definitive local therapy of either radical cystectomy or consolidation TCI, followed by four cycles of outpatient adjuvant gemcitabine-cisplatin chemotherapy.', 'description': 'Completion and safety of induction chemo-radiotherapy (cisplatin, paclitaxel and irradiation \\[TCI\\]) followed by definitive local therapy of either radical cystectomy (for patients for whom the initial tumor is not a complete response) or consolidation TCI (for patients for whom the initial tumor has cleared), followed by four cycles of outpatient adjuvant gemcitabine-cisplatin chemotherapy.', 'timeFrame': 'From start to end of all protocol therapy'}]","[{'measure': 'Complete response after TCI induction', 'timeFrame': 'From start to end of all protocol therapy'}, {'measure': 'Completion and safety of the four cycles of gemcitabine-cisplatin chemotherapy', 'timeFrame': 'From start to end of all protocol therapy'}, {'measure': 'Invasive local treatment failure', 'timeFrame': 'From start of protocol treatment to date of local failure. Analysis occurs after all patients have copmleted treatment.'}, {'measure': 'Distant metastasis', 'timeFrame': 'From start of protocol treatment to date of distant metastasis'}, {'measure': 'To examine the value of tumor histopathology, molecular genetics and DNA flow cytometric parameters as possible significant prognostic factors for initial tumor response and recurrence-free survival.', 'timeFrame': 'From the start of protocol treatment to the date the last patient has completed treatment. Analysis occurs after all patients have completed treatment.'}]",6.0,18 Years,,ALL,False,NETWORK,1.0,84.0,ACTUAL,v2_robust,True,True,False,True,
NCT00528528,An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants,Telaprevir,"['Ribavirin (RBV) tablet', 'Telaprevir', 'Ribavirin (RBV) capsule', 'Peg-IFN-alfa-2b', 'Peg-IFN-alfa-2a']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Chronic Hepatitis C,Tibotec BVBA,2025-09-01T16:18:08.344610,True,,,,,"A Phase IIa Randomized, Open-Label Study of Telaprevir (VX-950) Administered Every 12 or Every 8 Hours in Combination With Either Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol) in Treatment-Naive Subjects With Chronic Genotype 1 Hepatitis C Infection",,['Chronic Hepatitis C'],"['Chronic Hepatitis C', 'Genotype 1', 'Telaprevir', 'Treatment-naïve', 'VX-950-C208', 'VX-950-TiDP24-C208']",,2007-10,2009-08,"[{'measure': 'Percentage of Participants With Virologic Response at Week 12', 'description': ""Virologic response was either defined as having undetectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) (i.e., no HCV RNA was detected in the participants' plasma samples) or less than 25 international units/milliliter (IU/mL) HCV RNA (i.e., the participants' plasma samples contained traces of HCV RNA at a concentration below the limit of quantification of the viral load assay or no HCV RNA was detected in the samples)."", 'timeFrame': 'End of treatment (EOT) (up to Week 48)'}]","[{'measure': 'Time to First Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level', 'description': ""Virologic response was either defined as having undetectable HCV RNA (i.e., no HCV RNA was detected in the participants' plasma samples) or less than 25 IU/mL HCV RNA (i.e., the participants' plasma samples contained traces of HCV RNA at a concentration below the limit of quantification of the viral load assay or no HCV RNA was detected in the samples)."", 'timeFrame': 'Baseline (Day 1) up to EOT (up to Week 48)'}, {'measure': 'Number of Participants With Viral Breakthrough at End of Treatment (EOT)', 'description': 'Viral breakthrough was defined as a confirmed increase of more than 1 log 10 in HCV RNA level from the lowest level reached or a confirmed value of HCV RNA more than 100 IU/mL in participants whose HCV RNA was previously less than 25 IU/mL.', 'timeFrame': 'EOT (up to Week 48)'}, {'measure': 'Percentage of Participants With Partial Response', 'description': ""Partial response was defined as having at least 2 log drop in HCV RNA from Baseline, but not having undetectable HCV RNA (i.e., no HCV RNA is detected in the participants' plasma samples)."", 'timeFrame': 'Baseline (Day 1) up to EOT (up to Week 48)'}, {'measure': 'Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Week 12', 'description': 'Change from baseline in log 10 of Plasma HCV RNA levels were measured using the COBAS TaqMan HCV test (lower limit of quantification 25 IU/mL). The assay used real-time reverse transcription - polymerase chain reaction (RT-PCR) methodology. HCV RNA samples were taken pre-dose of Peg-IFN administration.', 'timeFrame': 'Baseline (pre-dose), Week 12'}, {'measure': 'Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at End of Treatment (EOT)', 'description': 'Change from baseline in log 10 of Plasma HCV RNA levels were measured using the COBAS TaqMan HCV test (lower limit of quantification 25 IU/mL). The assay used real-time reverse transcription - polymerase chain reaction (RT-PCR) methodology.', 'timeFrame': 'Baseline (pre-dose), EOT (up to Week 48)'}, {'measure': 'Percentage of Participants With Sustained Viral Response 24 Weeks After End of Treatment (SVR24)', 'description': ""SVR24 was defined as having undetectable HCV RNA (i.e., no HCV RNA is detected in the participants' plasma samples) at EOT and no confirmed detectable HCV RNA levels between EOT and 24 weeks after the last dose of study medication."", 'timeFrame': 'EOT (up to Week 48) and up to 24 weeks after EOT'}]",7.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,166.0,ACTUAL,v2_robust,True,True,False,False,
NCT00074828,New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery,LY517717,"['enoxaparin', 'LY517717']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Total Knee Replacement,Eli Lilly and Company,2025-09-01T16:18:08.344660,True,,,,,A Comparison of the Oral Anticoagulant LY517717 Difumarate to Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolic Events (VTE) Post-Total Hip Replacement (THR) and Post-Total Knee Replacement (TKR) Surgery,,"['Total Knee Replacement', 'Total Hip Replacement']","['elective', 'primary unilateral']",,2003-12,2005-05,"[{'measure': 'Efficacy of LY517717 to enoxaparin in the prevention of VTEs measured by the proportion of patients with VTE event (DVT and/or PE) as confirmed by bilateral venography or on clinical assessment', 'timeFrame': 'end of study drug administration'}]","[{'measure': 'Safety and tolerability, major and minor bleeding, death due to VTE, effect on QTc duration, AEs and SAEs, hepatobiliary and other safety lab parameters', 'timeFrame': 'baseline, daily during therapy, at follow up visit'}, {'measure': 'Pharmacokinetics and pharmacodynamics', 'timeFrame': 'predose, daily during therapy'}, {'measure': 'Compare the effect of LY517717 versus enoxaparin measured by DVT, Proximal DVT, Distal DVT and PE', 'timeFrame': 'end of study drug administration'}, {'measure': 'Compare the effect of LY517717 versus enoxaparin with confirmed VTE', 'timeFrame': 'end of study drug administration'}, {'measure': 'Compare the effect of LY517717 versus enoxaparin measured by all confirmed VTEs and /or clinically suspected and confirmed VTE', 'timeFrame': 'through follow up'}]",6.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,511.0,ACTUAL,v2_robust,True,True,False,True,
NCT05584228,Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease,Azathioprine + infliximab,"['Azathioprine + infliximab', 'Imurel, Remsima']",2,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Crohn Disease,Nantes University Hospital,2025-09-01T16:18:08.344687,True,,,,,"SyMptomAtic Stricturing Small Bowel CRohn's Disease - Medical Treatment Versus Surgery, a Prospective, Multi-centre, Randomized, Non-inferiority Trial",,['Crohn Disease'],"[""Crohn's disease"", 'stricture', 'resection', 'infliximab', 'azathioprine']",,2023-04-01,2027-10-01,"[{'measure': 'IBD (inflammatory bowel disease) - related quality of life', 'description': 'Mean total inflammatory bowel disease questionnaire (IBDQ - Inflammatory Bowel Disease Questionnaire ) score.\n\nThe total score ranges from 32 to 224, the higher the score the better the quality of life.', 'timeFrame': '12 months'}]","[{'measure': 'IBD (inflammatory bowel disease) -related quality of life', 'description': 'Mean total inflammatory bowel disease questionnaire (IBDQ - Inflammatory Bowel Disease Questionnaire ) score.\n\nThe total score ranges from 32 to 224, the higher the score the better the quality of life.', 'timeFrame': '1, 3, 6, 9, 18 and 24 months'}, {'measure': 'Endoscopic remission', 'description': 'Proportion of patients achieving endoscopic remission at month 6 (SES-CD \\< 2 in case of medical treatment or Rutgeerts score \\< i,2 in case of resection)', 'timeFrame': '6 months'}, {'measure': 'Obstructive symptoms', 'description': ""Mean total score of CDOS (CROHN'S DISEASE OBSTRUCTIVE SCORE ) Scale frome 0 to 6. 0 is the best outcome."", 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': 'Clinical activity', 'description': ""Mean total score of CDAI (CROHN'S DISEASE ACTIVITY INDEX ) Scale from 0 to 1100. 0 is the best outcome."", 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': 'inflammatory biomarkers (fecal calprotectin)', 'description': 'Mean values of fecal calprotectin', 'timeFrame': '1, 6, 12, 18 and 24 months'}, {'measure': 'inflammatory biomarkers ( C-reactive protein [CRP])', 'description': 'Mean values of CRP', 'timeFrame': '1, 6, 12, 18 and 24 months'}, {'measure': 'imaging parameters', 'description': 'Proportion of patients with an improvement in wall thickening, contrast enhancement, T2-signal increase, diffusion weighted-signal increase and length of pathological segment at month 12 as compared to screening imaging (MRI) by physician global assessment', 'timeFrame': '12 months'}, {'measure': 'treatment failures', 'description': 'Proportion of patients without any treatment failures', 'timeFrame': '12 and 24 months'}, {'measure': 'patient-reported outcomes (disability)', 'description': 'Mean total score of IBD-DI (INFLAMMATORY BOWEL DISEASE DISABILITY INDEX ) Score from 0 to 100. 0 is the best outcome (no disability)', 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': 'patient-reported outcomes (work productivity)', 'description': 'Mean total score of WPAI (WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE) In percentage from 0 to 100.', 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': 'patient-reported outcomes (fatigue)', 'description': 'Mean total score of FACIT-F (Functional Assessment of Chronic Illness Therapy ) scores from 0 to 52, with higher scores corresponding to less fatigue', 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': 'patient-reported outcomes (body image)', 'description': 'Mean total score of body image questionnaire Ranges from 0 to 30 and can be calculated by summing up the 10 items. A higher score means a higher level of body image disturbance', 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': 'patient-reported outcomes (generic quality-of-life)', 'description': 'Mean total score of SF-36 (QUESTIONNAIRE SHORT FORM 36 HEALTH SURVEY ) Score ranging from 0 to 100. A low score reflects a perception of poor health, loss of function, presence of pain. A high score reflects a perception of good health, absence of functional deficit and pain', 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': 'patient-reported outcomes (anxiety/depression)', 'description': 'Mean total score of HAD (Hospital Anxiety and Depression scale) 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores (maximum score for each score = 21). Minimum : 0. The best outcome is 0.', 'timeFrame': '1, 3, 6, 9, 12, 18 and 24 months'}, {'measure': ""Patient's acceptability -patients refusing to be included"", 'description': 'Number of screened patients refusing to be included', 'timeFrame': '24 months'}, {'measure': ""patient's acceptability - The reason"", 'description': 'The reason for refusing', 'timeFrame': '24 months'}, {'measure': 'intervention-related adverse events', 'description': 'Proportion of patients with intervention (drug or surgery) -related adverse events during the study', 'timeFrame': '24 months'}, {'measure': 'efficiency of medical treatment compared to surgery as assessed by a cost-utility analysis performed from a collective perspective', 'description': 'Incremental cost-utility ratio (cost per Quality-Adjusted Life-Years, QALYs) from a collective perspective', 'timeFrame': '24 months'}]",19.0,18 Years,70 Years,ALL,False,OTHER,1.0,150.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06066528,A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight,Survodutide,"['Survodutide', 'BI 456906', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Obesity,Boehringer Ingelheim,2025-09-01T16:18:08.344737,True,,,,,"A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus",,"['Obesity', 'Diabetes Mellitus, Type 2']",[],,2023-11-27,2026-04-03,"[{'measure': 'Percentage change in body weight from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}]","[{'measure': 'Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in body weight (kg)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in waist circumference (cm)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in ""Capacity to Resist"" domain score of Eating Behaviour patient reported outcome (PRO)', 'description': '""Capacity to Resist"" domain score of the Eating Behaviour PRO is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Key secondary endpoint: Absolute change from baseline to Week 76 in Eating Behaviour PRO total score', 'description': 'Eating Behaviour PRO total score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in HbA1c (mmol/mol)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in total cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in high density lipoprotein (HDL) cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in low density lipoprotein (LDL) cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in triglycerides (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in free fatty acids (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)', 'timeFrame': 'Baseline and at Week 76'}]",24.0,18 Years,,ALL,False,INDUSTRY,0.0,756.0,ACTUAL,v2_robust,True,False,False,False,
NCT01231828,Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.,L-carnitine,"['Duphalac.', 'Lactulose', 'Levocarnil.', 'L-carnitine']",4,INTERVENTIONAL,['NA'],,COMPLETED,Cirrhosis,"University Hospital, Caen",2025-09-01T16:18:08.344807,True,,,,,Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. Impact of Lactulose and Carnitine Treatment.,,['Cirrhosis'],"['sleep', 'cirrhosis', 'encephalopathy', 'simulated driving', 'sleep disorders']",,2009-09,2012-12,"[{'measure': 'Sleep latency during Maintenance of Wakefulness Test (MWT)', 'timeFrame': '40 min'}]","[{'measure': 'Nocturnal sleep quality and quantity will be measured by Polysomnography (PSG).', 'timeFrame': '1 night'}, {'measure': 'Nocturnal sleep quality and quantity measured by Actimetry.', 'timeFrame': 'during 3 days'}]",3.0,18 Years,80 Years,ALL,False,OTHER,0.0,55.0,ACTUAL,v2_robust,True,True,False,False,
NCT03248128,Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma,FF/VI via ELLIPTA DPI,"['FF/VI via ELLIPTA DPI', 'FF via ELLIPTA DPI']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Asthma,GlaxoSmithKline,2025-09-01T16:18:08.344832,True,,,,,"A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids",,['Asthma'],"['Fluticasone furoate', 'Efficacy', 'Vilanterol', 'Asthma', 'Safety', 'GW642444', 'GW685698']",,2017-10-20,2022-03-21,"[{'measure': 'Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population', 'description': 'Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second using a standardized calibrated spirometer. Weighted mean FEV1 was derived using the post-dose assessments (after 30 minutes and 1, 2, 3, 4 hours) with their actual times and using the pre-dose assessment as the 0 hour measurement.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Mean Pre-dose Morning Peak Expiratory Flow (AM PEF) in 5-11 Year Old Population', 'description': 'PEF was defined as the maximum speed of expiration of a participant. PEF was measured using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three measurements were recorded in the electronic patient diary. The mean morning PEF was calculated for each participant as an averaged mean over weeks 1-12 of the treatment period. Baseline was defined as the average of measurements with a non-missing value from Day -6 to Day 1 of pre-dose.', 'timeFrame': 'Baseline and Week 1-12'}]","[{'measure': 'Change From Baseline in Mean Pre-dose AM PEF Period in 5-17 Year Old Population', 'description': 'PEF was defined as the maximum speed of expiration of a participant. PEF was measured using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three measurements were recorded in the daily diary. The mean morning PEF was calculated for each participant as an averaged mean over weeks 1-12 of the treatment period. Baseline was defined as the average of measurements with a non-missing value from Day -6 to Day 1 of pre-dose.', 'timeFrame': 'Baseline and Week 1-12'}, {'measure': 'Absolute Weighted Mean of FEV1 (0-4 Hours) at Week 12 in 5-11 Year Old Population', 'description': 'Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second using a standardized calibrated spirometer. Weighted mean FEV1 was derived using the post-dose assessments (after 30 minutes and 1, 2, 3, 4 hours) with their actual times and using the pre-dose assessment as the 0 hour measurement.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in the Percentage of Rescue-free 24-hour Periods Over Weeks 1-12 of the Treatment Period in 5-17 Year Old Population', 'description': 'The number of inhalations of rescue albuterol/salbutamol aerosol used during the day and night were recorded in a daily electronic diary. Percentages of rescue-free 24-hour periods was calculated based on the number of 24-hour periods on which a participant recorded no use of albuterol/salbutamol divided by the length of the time period being assessed (with non-missing values of rescue medication recorded, respectively). A 24-hour period in which the response of participants to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Baseline was calculated from the evening (Day -7 to Day -1) and morning (Day -6 to Day 1) measurements. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value.', 'timeFrame': 'Baseline and Week 1-12'}, {'measure': 'Change From Baseline in the Percentage of Symptom-free 24-hour Periods Over Weeks 1-12 of the Treatment Period in 5-17 Year Old Population', 'description': 'The symptom-free days were recorded in a daily electronic diary every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. Percentages of symptom-free 24-hour periods was calculated based on the number of 24-hour periods on which a participant recorded no symptoms divided by the length of the time period being assessed (with non-missing values of rescue medication recorded, respectively). A 24-hour period in which the response of participants to both the morning and evening assessments indicated no symptoms was considered as symptom free. Baseline was calculated from evening (Day -7 to Day -1) and morning (Day -6 to Day 1) measurements. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value.', 'timeFrame': 'Baseline and Week 1-12'}, {'measure': 'Change From Baseline in Morning (AM) FEV1 at Week 12 in 5-17 Year Old Population', 'description': 'Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Morning FEV1 was measured using the pre-dose serial spirometry assessment at the Week 12. Baseline was defined as the pre-dose assessment with a non missing value on Visit 2 (Day -5).', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 24 in 5-17 Year Old Population', 'description': 'Asthma control as measured by improvements in ACQ-5, a five-item questionnaire with response options for each question rated from 0 to 6 scale. A score of 0 indicates well controlled asthma and a score of 6 indicates extremely poorly controlled asthma. Individual questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) are equally weighted and the ACQ-5 score is calculated as the mean of these 5 item responses. A lower mean score indicates greater asthma control and higher mean score indicates lesser asthma control. Baseline was defined as the pre-dose assessment with a non-missing value on Visit 3 (Day 1).', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Change From Baseline in the Percentage of Rescue-free 24-hour Periods Over Weeks 1-12 of the Treatment Period in 5-11 Year Old Population', 'description': 'The number of inhalations of rescue albuterol/salbutamol aerosol used during the day and night were recorded in a daily electronic diary. Percentages of rescue-free 24-hour periods was calculated based on the number of 24-hour periods on which a participant recorded no use of albuterol/salbutamol divided by the length of the time period being assessed (with non-missing values of rescue medication recorded, respectively). A 24-hour period in which the response of participants to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. Baseline was calculated from the evening (Day -7 to Day -1) and morning (Day -6 to Day 1) measurements. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value.', 'timeFrame': 'Baseline and Week 1-12'}, {'measure': 'Change From Baseline in the Percentage of Symptom-free 24-hour Periods Over Weeks 1-12 of the Treatment Period in 5-11 Year Old Population', 'description': 'The symptom-free days were recorded in a daily electronic diary every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. Percentages of symptom-free 24-hour periods was calculated based on the number of 24-hour periods on which a participant recorded no symptoms divided by the length of the time period being assessed (with non-missing values of rescue medication recorded, respectively). A 24-hour period in which the response of participants to both the morning and evening assessments indicated no symptoms was considered as symptom free. Baseline was calculated from evening (Day -7 to Day -1) and morning (Day -6 to Day 1) measurements. Change from Baseline was calculated as the averaged value during the 12-week treatment period minus the Baseline value.', 'timeFrame': 'Baseline and Week 1-12'}, {'measure': 'Change From Baseline in Morning (AM) FEV1 at Week 12 in 5-11 Year Old Population', 'description': 'Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Morning FEV1 was measured using the pre-dose serial spirometry assessment at the Week 12. Baseline was defined as the pre-dose assessment with a non-missing value on Visit 2 (Day -5).', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline ACQ-5 Score at Week 24 in 5-11 Year Old Population', 'description': 'Asthma control as measured by improvements in ACQ-5, a five-item questionnaire with response options for each question rated from 0 to 6 scale. A score of 0 indicates well controlled asthma and a score of 6 indicates extremely poorly controlled asthma. Individual questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) are equally weighted and the ACQ-5 score is calculated as the mean of these 5 item responses. A lower mean score indicates greater asthma control and higher mean score indicates lesser asthma control. Baseline was defined as the pre-dose assessment with a non-missing value on Visit 3 (Day 1).', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in 5-17 Year Old Population', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before.', 'timeFrame': 'Up to week 25'}, {'measure': 'Number of Participants With Abnormal Electrocardiogram (ECG) Findings in 5-17 Year Old Population', 'description': 'A single 12-lead ECG was obtained using an ECG machine that automatically calculates the heartrate and measures PR, QRS, QT, and QT interval corrected (QTc).', 'timeFrame': 'Week 24'}, {'measure': 'Change From Baseline in Fasting Glucose in 5-17 Year Old Population', 'description': 'Blood samples were collected for evaluation of fasting blood glucose pre and post-treatment. Baseline was defined as Visit 1 (Screening).', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Number of Participants With Any Incidence of Asthma Exacerbation Over the 24-week Treatment Period in 5-17 Year Old Population', 'description': 'Asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension or injection) for at least three days or a single depot corticosteroid injection or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.', 'timeFrame': 'Up to week 24'}, {'measure': 'Number of Participants With AEs and SAEs in 5-11 Year Old Population', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the participant or may require medical or surgical intervention/Standard of care (SOC) to prevent one of the other outcomes mentioned before.', 'timeFrame': 'Up to week 25'}, {'measure': 'Number of Participants With Abnormal ECG Findings in 5-11 Year Old Population', 'description': 'A single 12-lead ECG was obtained using an ECG machine that automatically calculates the heartrate and measures PR, QRS, QT, and QTc.', 'timeFrame': 'Week 24'}, {'measure': 'Change From Baseline in Fasting Glucose in 5-11 Year Old Population', 'description': 'Blood samples were collected for evaluation of fasting blood glucose pre and post-treatment. Baseline was defined as Visit 1 (Screening).', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Number of Participants With Any Incidence of Asthma Exacerbation Over the 24-week Treatment Period in 5-11 Year Old Population', 'description': 'Asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension or injection) for at least three days or a single depot corticosteroid injection or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.', 'timeFrame': 'Up to week 24'}]",20.0,5 Years,17 Years,ALL,False,INDUSTRY,0.0,906.0,ACTUAL,v2_robust,True,True,False,True,
NCT00427128,Prozac Treatment of Major Depression: Discontinuation Study,fluoxetine,"['fluoxetine', 'Prozac', 'placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Major Depression,New York State Psychiatric Institute,2025-09-01T16:18:08.344952,True,,,,,Prozac Treatment of Major Depression: Discontinuation Study,,['Major Depression'],"['Major Depression', '""true drug"" response', '""placebo response"" pattern', 'continuation treatment outcomes']",,1995-11,2003-03,"[{'measure': 'MDD section of Mood Disorders Module of Structured Clinical Interview for DSM-IV (SCID)', 'timeFrame': 'up to 9 mos.'}, {'measure': 'Ham-D', 'timeFrame': 'up to 9 mos.'}, {'measure': 'CGI', 'timeFrame': 'up to 9 mos.'}]",[],3.0,18 Years,65 Years,ALL,False,OTHER,1.0,627.0,ACTUAL,v2_robust,True,True,False,False,
NCT04494828,Impact Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor,Dexmedetomidine,"['Dexmedetomidine hydrochloride', 'Normal saline group', 'Dexmedetomidine', '0.9% Sodium Chloride']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Central Nervous System Diseases,Capital Medical University,2025-09-01T16:18:08.345001,True,,,,,Impact of Prophylactic Use of Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Pilot Randomized Controlled Trial,,['Central Nervous System Diseases'],"['delirium', 'postoperative', 'dexmedetomidine', 'intracranial operation', 'prevention']",,2020-08-10,2020-12-21,"[{'measure': 'Incidence of study agent interruption during the study', 'description': 'Predicted adverse events in the present study included bradycardia (defined as heart rate lower than 50 beats/min), hypotension (defined as systolic blood pressure lower than 90 mmHg), tachycardia (defined as heart rate greater than 100 beats/min), hypertension (defined as systolic blood pressure greater than 160 mmHg) and hypoxemia (defined as pulse oxygen saturation lower than 90%). The treatment of adverse events was determined by the responsible attending ICU physicians, who could stop the study agent infusion when the treatment failure or other conditions deemed necessary.', 'timeFrame': 'From the start of study agent infusion to postoperative day 1'}]","[{'measure': 'Time from the end of operation to randomization', 'description': 'Time from the end of operation to randomization', 'timeFrame': 'From the end of operation until the randomization, assessed up to 24 hours'}, {'measure': 'Duration of study agent infusion', 'description': 'Duration of study agent infusion', 'timeFrame': 'From the start of study agent infusion to postoperative day 1'}, {'measure': 'Incidence of adverse events from the start of study agent infusion until 24 hours or until ICU discharge', 'description': 'Include bradycardia (defined as heart rate lower than 55 beats/min), hypotension (defined as systolic blood pressure lower than 90 mmHg), and hypoxemia (defined as pulse oxygen saturation lower than 90%)', 'timeFrame': 'From the start of study agent infusion to postoperative day 1'}, {'measure': 'Non-delirium complications', 'description': 'Include airway obstruction and apnea, respiratory failure, cardiac events, coma, epilepsy, cerebral hemorrhage or infarction, renal injury and infection', 'timeFrame': 'From the start of study agent infusion to postoperative day 28'}]",5.0,18 Years,,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,True,
NCT07052565,CAR-T Cells Therapy for Patients With Autoimmune Diseases,Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis,['Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis'],1,INTERVENTIONAL,['NA'],,RECRUITING,Autoimmune Diseases,Anhui Provincial Hospital,2025-09-01T16:18:08.345045,True,,,,,An Exploratory Clinical Study of Enhanced Autologous CAR-T Cell Injection (ECAR01) Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases,,['Autoimmune Diseases'],"['systemic sclerosis', 'dry syndrome', 'rheumatoid arthritis', 'systemic lupus erythematosus']",,2025-07-20,2028-11-01,"[{'measure': 'Adverse events', 'description': 'Total number, incidence and severity of adverse events (AEs) in patients of SCAR02 infusion. The AEs will be assessed according to the 2019 Consensus on Cytokine Release Syndrome and Immune-cell-associated Neurotoxicity published by the American Society of Transplantation and Cell Therapy (ASTCT), the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and EBMT 2019 consensus.', 'timeFrame': 'up to 1 years'}]","[{'measure': 'The change of CAR copy number in peripheral blood was investigated by comparison with baseline', 'description': 'Peripheral blood CAR copy concentrations (copies/µL) will be detected using QPCR', 'timeFrame': 'up to 1 years'}, {'measure': 'Disease activity was assessed by DAS28', 'description': 'DAS28 was used to assess disease activity, and the number of swelling and tenderness in 28 joints was examined, Min/Max Value: Not specified,with higher scores representing worse disease status.', 'timeFrame': 'up to 1 years'}, {'measure': 'Modified Rodnan Skin Score assesses disease activity in patients', 'description': ""Disease activity was assessed by Modified Rodnan Skin Score Modified Rodnan Skin Score: The modified Rodnan Skin Score was used to assess the degree of skin involvement in patients with systemic sclerosis, and the thickness and hardness of the skin on the patient's head and neck, upper limbs, fingers, chest, abdomen, lower limbs, feet, etc., each part was divided into 0 (normal), 1 (mild thickening), 2 (moderate thickening), and 3 (severe thickening) according to the skin involvement, and the scores of each part were added together to obtain a total score, The higher the score, the worse the skin lesion status in patients with systemic sclerosis."", 'timeFrame': 'up to 1 years'}, {'measure': 'SLEDAI assesses disease activity in patients', 'description': 'SLEDAI was used to evaluate the disease activity of patients with systemic lupus erythematosus, and the clinical symptoms and laboratory examination indicators of the patients were quantitatively scored.The SLEDAI score ranges from 0\\~105 points, and the higher the score, and the higher the score, the worse the disease status of systemic lupus erythematosus.', 'timeFrame': 'up to 1 years'}, {'measure': 'BILAG-2004 assesses disease activity in patients', 'description': 'BILAG-2004 score: BILAG-2004 was used to evaluate the disease activity of patients with systemic lupus erythematosus, and the clinical manifestations of patients in 10 systemic domains were scored according to the involvement of each domain according to the five grades of A (very severe), B (moderately severe), C (mild), D (in the past, now none), and E (never), and the scores in each domain were comprehensively weighted, and the higher the score, the worse the disease status of systemic lupus erythematosus.', 'timeFrame': 'up to 1 years'}, {'measure': ""Change from baseline in Physician's Global Assessment of Arthritis (PGA) (VAS)"", 'description': ""The investigator/sub-investigator assesses the participant's disease activity on a VAS of 0 - 3 mm on the physician assessment table"", 'timeFrame': 'up to 1 years'}, {'measure': 'Change from baseline in ESR', 'description': 'ESR will be measured with blood samples', 'timeFrame': 'up to 1 years'}, {'measure': 'ACR70 response rate', 'description': 'The ACR70 response indicates a 70% improvement in all criteria used in the ACR70 assessment', 'timeFrame': 'up to 1 years'}, {'measure': ""Clinical response for Sjögren's Syndrome"", 'description': ""Sjögren's tool for assessing response (STAR): Min/Max Value: Not specified; a decrease in score indicates improvement; higher scores indicate worse outcome"", 'timeFrame': 'up to 1 years'}, {'measure': ""Change from baseline in participant's assessment of pain (VAS)"", 'description': ""Using the VAS pain visual analog scale to visually display the patient's pain level, using a 10cm long scale, there are 10 scales from 0 to 10, 0 represents no pain, 10 represents severe pain, and let the patient choose a scale that meets his pain feelings"", 'timeFrame': 'up to 1 years'}, {'measure': 'HAQ health assessment', 'description': ""The HAQ health assessment questionnaire was used to assess disease activity, and 8 questions of daily activities were set up for patients to answer, with each question scoring 0-3, 0 points indicating no difficulty, 1 point being somewhat difficult, 2 points being difficult or needing help, and 3 points being unable to complete. The higher the patient's score, the worse the function"", 'timeFrame': 'up to 1 years'}, {'measure': 'Change from baseline in CRP', 'description': 'CRP will be measured with blood samples', 'timeFrame': 'up to 1 years'}]",13.0,18 Years,,ALL,False,OTHER_GOV,0.0,18.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04531865,Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment,Rituximab,"['Mycophenolate Mofetil', 'Rituximab Biosimilar HLX01', 'Mycophenolate Mofetil Dispersible tablets（CYCOPIN®）', 'Rituximab', 'Placebo tablets matching Mycophenolate Mofetil']",5,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Frequently Relapsing Nephrotic Syndrome,Children's Hospital of Fudan University,2025-09-01T16:18:08.345082,True,,,,,"Efficacy and Safety of Mycophenolate Mofetil as Maintenance Therapy After Rituximab Treatment in Childhood-onset, Frequently-relapsing or Steroid-dependent Nephrotic Syndrome: a Multicenter Double-blind, Randomized, Placebo-controlled Trial",,"['Frequently Relapsing Nephrotic Syndrome', 'Steroid-Dependent Nephrotic Syndrome']",[],lack of funding,2021-01-01,2022-10-01,"[{'measure': '1-year relapse-free survival rate', 'description': 'The rate of no relapse within 1 year', 'timeFrame': '1-year period after randomization'}]","[{'measure': 'The concentration for MPA-area under curve(AUC)', 'description': 'Blood concentrations of mycophenolic acid (MPA)', 'timeFrame': 'At 48 weeks'}, {'measure': 'Proportion of patients with a relapse', 'description': 'The proportion of patients with relapse', 'timeFrame': '6 months period after randomization'}, {'measure': 'Time to relapse (days)', 'description': 'Number of days from randomization to occurrence of first relapse', 'timeFrame': '1-year period after randomization'}, {'measure': 'B-Cell Recovery Time', 'description': 'Time to the first detection of CD19+ cells above 1% of total CD45+ lymphocytes after CD19+ cell depletion', 'timeFrame': '1-year period after randomization'}, {'measure': 'Change in growth velocity', 'description': 'The standard deviation scores (SDS) for height at 12th month minus that of randomization.', 'timeFrame': '1-year period after randomization'}, {'measure': 'adverse events', 'description': 'It is a binary variable (1/0). The varibale would be setted as ""1"" if any adverse events occours including early infusion termination, acute infusion reaction Infection, pulmonary fibrosis, encephalopathy, neutropenia. Adverse events graded according to Common Terminology Criteria For Adverse Events (NCI-CTCAE v4.03)', 'timeFrame': '1-year period after randomization'}]",7.0,1 Year,16 Years,ALL,False,OTHER,3.0,0.0,ACTUAL,v2_robust,True,False,True,True,lack of funding
NCT02334865,SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy,Lenalidomide,"['CDC 501', 'CC-5013', 'Lenalidomide', 'Revlimid', 'CC5013']",5,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Partial Response of Multiple Myeloma or Plasma Cell Leukemia,Roswell Park Cancer Institute,2025-09-01T16:18:08.345107,True,,,,,"A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy",,"['Partial Response of Multiple Myeloma or Plasma Cell Leukemia', 'Plasma Cell Myeloma']",[],,2017-04-13,2026-05-19,"[{'measure': ""Toxicity profile of the SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant plus sargramostim, given before or after the start of lenalidomide maintenance"", 'description': 'The National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 will be used to evaluate toxicity. The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category and grade. The frequency of toxicities will also be tabulated for the regimen estimated to be the regimen-limiting toxicity.', 'timeFrame': 'Up to 24 weeks'}]","[{'measure': 'Immune response using interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and multimer assays', 'description': ""A responder is defined as a patient who has responded in either IFN-gamma ELISPOT or multimer assays. For both the ELISPOT and multimer assays, time course and magnitude of responses will be plotted and data will be treated using mixed-effect modeling. In addition, Kendall's tau-b will be used to determine whether ELISPOT and multimer responses are associated."", 'timeFrame': 'Up to 24 weeks'}]",2.0,18 Years,,ALL,False,OTHER,1.0,18.0,ACTUAL,v2_robust,True,False,False,True,
NCT01462565,Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH),current marketed FLOLAN (epoprostenol sodium),"['current marketed FLOLAN (epoprostenol sodium)', 'new thermo stable formulation of epoprostenol sodium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Hypertension, Pulmonary",GlaxoSmithKline,2025-09-01T16:18:08.345153,True,,,,,"A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.)",,"['Hypertension, Pulmonary']","['flolan', 'pulmonary arterial hypertension', 'thermo stable formulation', 'epoprostenol sodium', 'modified sterile diluent']",,2011-11-01,2012-11-08,"[{'measure': 'Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36)', 'description': 'Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores was considered as better health status. Change from Baseline was calculated as score at observation minus score at baseline. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3)'}, {'measure': 'Change From Baseline in Study Specific Participant Acceptance Survey', 'description': 'Study-specific questionnaire comprised the pre-defined15 questions which included activities of daily living assessment. Participants rated the question on a scale of 1 to 10, where 1 was do not agree and 10 was strongly agree. Change from Baseline was calculated as score at observation minus score at Baseline. Changes from Baseline was assessed for Questions 2 to 12. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3).'}, {'measure': 'Change From Baseline in Dose of Thermo Stable Epoprostenol Sodium at Week 4', 'description': 'Dose titration requirement was assessed at the time of discharge. Change from Baseline was calculated as score at observation minus score at Baseline. Units- nanogram per kilogram per minute (ng/kg/min). Baseline was Visit 2 i.e . Day-14 (+ or - 7 days).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4'}]","[{'measure': 'Number of Participants With Any Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events(SAEs)', 'description': 'An AE was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, congenital anomaly/birth defect and medically significant and all events of possible drug-induced liver injury with hyperbilirubinaemia. Only treatment emergent AEs and SAEs were reported in this outcome measure. Specifically, this study reported 2 SAEs, but only 1 was categorized as treatment emergent.', 'timeFrame': 'Up to visit 3 (Week 4)'}, {'measure': 'Number of Participants With Infusion Site Reactions During Treatment Period', 'description': 'Infusion site reactions were reported during the treatment period. Infusion site was inspected for erythema, excoriation, induration, skin necrosis or signs of local sepsis.', 'timeFrame': 'Baseline visit (Visit 2) to Week 4 (Visit 3)'}, {'measure': 'Change From Baseline in Vital Signs at Week 4 : Systolic and Diastolic Blood Pressure', 'description': 'Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Change from Baseline was calculated as the value at the indicated time points minus the value at Baseline. Baseline was Visit 2 i.e. Day-14 (+ or - 7 days).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4(Visit 3)'}, {'measure': 'Change From Baseline in Vital Signs at Week 4: Heart Rate', 'description': 'Summary mean change in heart rate measured in beats per minute (beats/min or BPM). Change from Baseline was calculated as the value at the indicated time points minus the value at Baseline. Baseline was Visit 2 i.e. Day-14 (+ or - 7 days).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) to Week 4'}, {'measure': 'Number of Participants With Abnormal Clinical Chemistry', 'description': 'Abnormal clinical chemistry was analyzed as follows: serum alanine aminotransferase (ALT/SGPT) \\>= 3 x upper limit of normal (ULN) , aspartate aminotransferase (AST/SGOT) \\>= 3 x ULN , total bilirubin \\>= 34.2, creatinine \\>= 176.8.', 'timeFrame': 'Up to 1 week after Week 4 (Follow-up)'}, {'measure': 'Number of Participants With Abnormal Hematology', 'description': 'Values for hemoglobin, hematocrit, and platelet count were analyzed. Participants with abnormal values have been reported. The low and high value concern were as follows: hemoglobin (Males \\< 98, \\>180.0) (females \\<91, \\>161.0)grams per litre (g/L); hematocrit (Males \\< 32.0, \\>54.0) (females \\<29.0, \\>50.6) fraction (1); platelet count (\\< 100, \\> 500) gram international units per litre (gI/L).', 'timeFrame': 'Up to 1 week after Week 4 (Follow-up)'}, {'measure': 'Number of Participants With Abnormal Urinalysis', 'description': 'Dipstick method was used to measure blood, glucose and protein. Data was analyzed up to 1 week after Week 4 (Follow-up visit).', 'timeFrame': 'Up to 1 week after Week 4 (Follow-up)'}, {'measure': 'Change From Baseline in Six Minute Walk Distance Test (6MWD) After 4-weeks of Treatment', 'description': 'This assessment was a non-encouraged test that measures the distance walked for a duration of 6 minutes. Change from Baseline was calculated as value at observation minus value at Baseline. Baseline visit was Visit 2 i.e. Day-14 (+ or - 7 days).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4'}, {'measure': 'Breathlessness After 6MWD - Borg Dyspnoea Index (BDI)', 'description': 'The BDI was calculated by using a 10-point scale (0 = None, 10 = Maximum) and indicates the degree of breathlessness after completion of the 6-minute walk test. The BDI scale was assessed by each participant. Change from Baseline = score at observation minus score at Baseline. Baseline visit was Visit 2 i.e. Day-14 (+ or - 7 days).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) to Week 4'}, {'measure': 'World Health Organization [WHO] Functional Class at Baseline and After 4- Weeks of Treatment', 'description': 'World Health Organization functional class was analyzed as class I, class II, class III and class IV. World Health Organization functional class was analyzed at Baseline (Visit 2 i.e. Day-14 \\[+ or - 7 days\\]) and Week 4. The classed were defined as Class I: No symptoms of pulmonary arterial hypertension with exercise or at rest, Class II: No symptoms at rest but uncomfortable and short of breath with normal activity, Class III: May not have symptoms at rest but activities greatly limited by shortness of breath, fatigue, or near fainting and Class IV: Symptoms at rest and severe symptoms with any activity. Hence the severity increased from class I (better) to Class IV (worse).', 'timeFrame': 'Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4'}, {'measure': 'Mean Oxygen Saturation in Blood Over Time', 'description': 'Pulse oximetry (oxygen saturation) was analyzed. Data for Pulse oximetry (oxygen saturation) was analyzed up to the treatment follow up (1 week after Visit 3 \\[Week 4\\]).', 'timeFrame': 'up to the treatment follow up (1 week after Visit 3 [Week 4])'}, {'measure': 'Number of Participants With Urine Pregnancy Test Positive', 'description': 'Urine samples were collected for urine pregnancy test. Urine samples were collected at up to the treatment follow up (1 week after Visit 3 \\[Week 4\\]). Number of participants with urine pregnancy test positive has been reported.', 'timeFrame': 'up to the treatment follow up (1 week after Visit 3 [Week 4])'}]",15.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT01924065,Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation,Oral Anticoagulant,['Oral Anticoagulant'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Atrial Fibrillation,Suleyman Demirel University,2025-09-01T16:18:08.345202,True,,,,,Does Cardioversion of Atrial Fibrillation Increase the Risk of Stroke and Silent Cerebrovascular Thromboembolism? Comparison of the Two Cardioversion Methods,,"['Atrial Fibrillation', 'Cardioversion', 'Cerebrovascular Stroke']","['Atrial fibrillation, conversion, stroke']",,2013-08,2024-10-29,"[{'measure': 'Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli', 'description': 'Clinical events during 2 years follow-up or silent cerebral thromboemboli detected by diffusion magnetic resonance imaging at 1 week post-cardioversion', 'timeFrame': '2 years'}, {'measure': 'Efficacy Clinical End-point', 'description': 'Any Clinical Thromboembolic Event, Death or Silent Cerebral Thromboemboli', 'timeFrame': '2 years'}, {'measure': 'Ischemic Stroke/Transient Ischemic Attack', 'timeFrame': '2 years'}, {'measure': 'Acute Ischemia in MRI', 'description': 'Development of acute silent cerebral ischemia detected by MRI', 'timeFrame': '1 week'}, {'measure': 'Mortality', 'timeFrame': '2 years'}, {'measure': 'Hemorrhagic Stroke', 'timeFrame': '2 years'}, {'measure': 'Gastrointestinal Bleeding', 'timeFrame': '2 years'}]",[],7.0,18 Years,85 Years,ALL,False,OTHER,0.0,112.0,ACTUAL,v2_robust,True,True,False,False,
NCT01134965,"to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers",Flibanserin plus Digoxin,"['Digoxin', 'Flibanserin plus Digoxin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:08.345296,True,,,,,An Open Two-way Cross-over Study to Evaluate the Effect of Multiple Doses of Flibanserin 100 mg Film-coated Tablets Given Once Daily on the Single Dose Pharmacokinetics of Digoxin 0.5 mg in Healthy Male and Female Volunteers,,['Healthy'],[],,2010-06,,"[{'measure': 'Maximum concentration of digoxin in plasma after single dose (Cmax)', 'timeFrame': '72 hours'}, {'measure': 'Area under the concentration-time curve of digoxin in plasma over the time interval 0 to infinity (AUC0-inf)', 'timeFrame': '72 hours'}]","[{'measure': 'Renal clearance of digoxin from time 0 to 24 hours after drug administration (CLR,0-24)', 'timeFrame': '72 hours'}]",3.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,False,
NCT06896565,Effect of Nano Hydroxy Apatite Varnish and Potassium Nitrate Gel on the MIH-affected Permanent Teeth,nano hydroxy apatite varnish,"['Potassium Nitrate Gel', 'Ultradent UltraEZ Desensitizing Gel, Ultradent Inc., USA', ""Fygg's professional strength, Fygg, USA"", 'DentKist Charm Varnish 5% Sodium Fluoride Varnish', 'nano hydroxy apatite varnish', 'Varnishes, Fluoride']",6,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Molar Incisor Hypomineralisation,Cairo University,2025-09-01T16:18:08.345370,True,,,,,Comparative Evaluation of Three Different Topically Applied Materials as Non-invasive Treatment of Permanent Teeth With Molar Incisor Hypo-mineralization: Randomized Clinical Trial,,['Molar Incisor Hypomineralisation'],[],,2025-06-01,2026-08-01,"[{'measure': 'Dentin Hypersensitivity', 'description': 'Measured by:\n\nFace scale: scores from 0-4. the higher the score the worse the sensitivity.', 'timeFrame': 'Baseline, 15 miutes pot-op, 2 weeks post-op, and 4 weeks post op.'}, {'measure': 'Dentin Hypersensitivity', 'description': 'Measured by:\n\nSchiff Cold Air Blasting Sensitivity Scale: scores from 0-3. The higher the score the worse the sensitivity.', 'timeFrame': 'Baseline, 15 miutes pot-op, 2 weeks post-op, and 4 weeks post op.'}]","[{'measure': 'Post-eruptive enamel breakdown', 'description': 'Measured by Wurzburg Molar Incisor Hypomineralization - Treatment Need Index (MIH-TNI): ordinal scores: 1,2,3, 4a, 4b, 4c.', 'timeFrame': ': baseline, 3-, 6-, 9-, and 12- month post-op.'}, {'measure': 'Caries incidence', 'description': 'Measured by International Caries Detection and Assessment System (ICDAS II) criteria: scores from 0-6.\n\nThe higher the score the worse the caries.', 'timeFrame': 'baseline, 3-, 6-, 9-, and 12- month post-op.'}, {'measure': 'Oral hygiene', 'description': 'Measured by Plaque Control Record: Percentage.', 'timeFrame': 'baseline, 2-, and 4- week post-op.'}, {'measure': 'Oral health-related quality of life', 'description': 'Measured by: Short form Parental-Caregiver Perceptions Questionnaire (P-CPQ): from 0 -32.\n\nThe higher the score the worse the Oral Health Related Quality of Life.', 'timeFrame': 'baseline, 6-, and 12- month post-op.'}, {'measure': 'Cost Effectiveness Ratio (CER) and Incremental Cost Effectiveness Ratio (ICER', 'description': 'Measured by: Equation : CER = C / E, where C is the average direct medical cost calculated for the group, and E is the health effectiveness measure for the same group (change in hypersensitivity score).\n\nICER = (CI - CC) / (EI - EC), where CI is the average direct medical cost of the intervention group CC is the average direct medical cost in the control group, EI is the health effectiveness measure (change in hypersensitivity score) in the intervention group, and EC is the health effectiveness measure in the control group', 'timeFrame': '12-month- post-op.'}]",7.0,6 Years,10 Years,ALL,False,OTHER,0.0,48.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05575167,Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study),Zoledronate or Alendronate,"['Calcium and vitamin D supplementation', 'Zoledronate or Alendronate']",2,OBSERVATIONAL,[],,RECRUITING,"Osteoporosis, Postmenopausal",424 General Military Hospital,2025-09-01T16:18:08.345407,True,,,,,The Effectiveness of Single or Repeat Zoledronate Infusion Versus Oral Alendronate in Consolidating the Bone Accrual Achieved With Denosumab: a Study Organised by the European Calcified Tissue Society,,"['Osteoporosis, Postmenopausal']",[],,2023-11-28,2027-11,"[{'measure': 'lumbar spine BMD', 'description': 'BMD changes at the lumbar spine at 12 and 24 months', 'timeFrame': '24 months'}]","[{'measure': 'femoral neck BMD', 'description': 'BMD changes at the non-dominant femoral neck and total hip at 12 and 24 months', 'timeFrame': '24 months'}, {'measure': 'P1NP', 'description': 'bone turnover (formation) marker', 'timeFrame': 'baseline, 3 months, 6 months, 12 months, 18 months, 24 months'}, {'measure': 'CTx', 'description': 'bone turnover (resorption) marker', 'timeFrame': '24 months'}, {'measure': 'fracture', 'description': 'incident fractures: vertebral (clinical and morphometric identified on VFA scans) and non-vertebral', 'timeFrame': '24 months'}, {'measure': 'height', 'description': 'loss of height', 'timeFrame': '24 months'}]",6.0,50 Years,85 Years,FEMALE,False,OTHER,0.0,125.0,ESTIMATED,v2_robust,False,False,False,False,
NCT02171767,Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers,BIBW 2992 MA2 - single rising dose,['BIBW 2992 MA2 - single rising dose'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:08.345528,True,,,,,"Pharmacokinetics, Safety and Tolerability of BIBW 2992 Administered Orally as 20 mg, 30 mg, 40 mg, and 50 mg Tablets (Final Formulation) to Healthy Male Volunteers in an Open-label, Single Rising Dose, Phase I Trial",,['Healthy'],[],,2009-08,,"[{'measure': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': 'predose, up to120 h after drug administration'}, {'measure': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'predose, up to 120 h after drug administration'}]","[{'measure': '%AUCtz-∞ (percentage of the AUCtz-∞ obtained by extrapolation from the last quantifiable data point to infinity)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 'AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 [predose] to 24 h)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 'tmax (time from dosing to the maximum concentration of the analyte in plasma)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 'λz (terminal rate constant of the analyte in plasma)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 't1/2 (terminal half-life of the analyte in plasma)', 'timeFrame': 'predose, up to 120 h days after drug administration'}, {'measure': 'MRTpo (mean residence time of the analyte in the body after oral administration)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 'CL/F (apparent clearance of the analyte in plasma after extravascular administration)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 'Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)', 'timeFrame': 'predose, up to 120 h after drug administration'}, {'measure': 'Number of patients with abnormal findings in physical examination', 'timeFrame': 'Screening, up to 20 days after drug administration'}, {'measure': 'Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)', 'timeFrame': 'Screening, up to 20 days after drug administration'}, {'measure': 'Number of patients with abnormal changes in laboratory parameters', 'timeFrame': 'Screening, up to 20 days after drug administration'}, {'measure': 'Number of patients with adverse events', 'timeFrame': 'up to 41 days'}, {'measure': 'Assessment of tolerability by investigator on a 4-point scale', 'timeFrame': 'up to 20 days after drug administration'}, {'measure': 'Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)', 'timeFrame': 'Screening, up to 20 days after drug administration'}]",17.0,21 Years,55 Years,MALE,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,
NCT06260267,A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis,Microbiota suspension,"['Microbiota suspension', 'Placebo capsule', 'Microbiota capsule', 'Placebo suspension']",4,INTERVENTIONAL,['PHASE1'],PHASE1,WITHDRAWN,Ulcerative Colitis,Ferring Pharmaceuticals,2025-09-01T16:18:08.345565,True,,,,,A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis,,['Ulcerative Colitis'],[],"Not due to safety concerns, but changes in strategy which this trial no longer fulfills.",2024-03-12,2026-01-15,"[{'measure': 'Treatment-emergent adverse events from baseline to week 52', 'timeFrame': 'From baseline to week 52'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,"Not due to safety concerns, but changes in strategy which this trial no longer fulfills."
NCT02264067,Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers,Talsaclidine,"['Talsaclidine', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:08.345572,True,,,,,Phase I Clinical Study of WAL2014 (Talsaclidine) Capsule: A Single Oral Dose Study,,['Healthy'],[],,1998-07,,"[{'measure': 'Maximum concentration of the analyte in plasma (Cmax)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Time to reach maximum plasma concentration (tmax)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Area under the plasma concentration-time curve (AUC)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Distribution volume', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Total clearance', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Mean residence time (MRT)', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Urinary excretion rate', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Number of subjects with adverse events', 'timeFrame': 'up to 8 days after administration'}]",[],8.0,20 Years,30 Years,MALE,True,INDUSTRY,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,
NCT02863367,A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer,Apatinib,"['YN968D1', 'Apatinib', 'Gemcitabine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Metastatic Pancreatic Cancer,Tianjin Medical University Cancer Institute and Hospital,2025-09-01T16:18:08.345587,True,,,,,A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer,,['Metastatic Pancreatic Cancer'],[],,2016-08,2017-12,"[{'measure': 'Objective Response Rate (ORR)', 'timeFrame': '1 years'}]","[{'measure': 'progression-free survival (PFS)', 'timeFrame': '1 years'}, {'measure': 'Overall Survival (OS)', 'timeFrame': '1 years'}, {'measure': 'Life Quality Score (QoL)', 'timeFrame': '1 years'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': '1 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '1 years'}]",6.0,18 Years,75 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06687967,A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1),Dupilumab,"['Dupilumab', 'SAR231893', 'Dupixent', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Lichen Simplex Chronicus,Sanofi,2025-09-01T16:18:08.345649,True,,,,,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults",,['Lichen Simplex Chronicus'],[],,2024-11-28,2027-07-05,"[{'measure': 'Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24', 'description': 'Worst-Itch numerical rating score (WI-NRS) is a patient report outcome (PRO) comprised of a single item rated on a scale from 0 (""No itch"") to 10 (""Worst imaginable itch"").', 'timeFrame': 'Week 24'}]","[{'measure': 'Change in weekly average of daily WI-NRS from baseline to Week 24', 'description': 'WI-NRS is a PRO comprised of a single item rated on a scale from 0 (""No itch"") to 10 (""Worst imaginable itch"").', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change in weekly average of daily Itch-related Sleep Disturbance NRS from baseline to Week 24', 'description': 'The Itch-related Sleep Disturbance NRS is a single-item PRO to report the degree of sleep loss related to itch over the past 24 hours, from 0 (""no sleep loss related to itch"") to 10 (""I cannot sleep at all due to itch"").', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change in ItchyQoL score from baseline to Week 24', 'description': 'Itchy quality of life survey (ItchyQoL) is a pruritus-specific QoL instrument to measure dermatology-specific QoL in patients aged 16 years and older. The overall score ranging from 1 to 5. A higher score corresponds to a more adverse impact on health-related QoL', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change in DLQI total score from baseline to Week 24', 'description': 'Dermatology life quality index (DLQI) is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer health-related QoL.', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 12', 'description': 'WI-NRS is a PRO comprised of a single item rated on a scale from 0 (""No itch"") to 10 (""Worst imaginable itch"").', 'timeFrame': 'Week 12'}, {'measure': 'Incidence of treatment-emergent anti-drug antibody (ADA) against dupilumab', 'timeFrame': 'Baseline through Week 36'}, {'measure': 'Percentage of participants experiencing treatment-emergent adverse event (TEAEs) or serious adverse event (SAEs)', 'timeFrame': 'Baseline through Week 36'}]",8.0,18 Years,,ALL,False,INDUSTRY,1.0,136.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00001567,A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia,Roferon-A,['Roferon-A'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hairy Cell Leukemia,National Cancer Institute (NCI),2025-09-01T16:18:08.345696,True,,,,,A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia,,['Hairy Cell Leukemia'],"['Follow-Up Study', 'Relapse-Free Survival', 'Serum Soluble IL-2 Receptor', 'Hematologic Malignancy', 'Chronic Therapy']",,1997-01,2002-04,[],[],0.0,,,ALL,False,NIH,0.0,56.0,,v2_robust,True,True,False,False,
NCT03411967,Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC,Apatinib,"['Apatinib', 'Aitan', 'Docetaxel']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Lung Cancer,Zigong No.1 Peoples Hospital,2025-09-01T16:18:08.345721,True,,,,,Clinical Study of Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC After Failure of Platinum-based Double-drug Therapy,,['Lung Cancer'],[],,2018-02-01,2021-12-01,"[{'measure': 'ORR', 'description': 'Objective Response Rate', 'timeFrame': '6 month'}]","[{'measure': 'PFS', 'description': 'Progress-Free Survival', 'timeFrame': '12 month'}]",2.0,18 Years,,ALL,False,OTHER,1.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01142700,A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I,BMS-824393,"['Pegasys', 'Copegus', 'Peginterferon Alpha-2a', 'Placebo', 'Ribavirin', 'BMS-824393']",6,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Chronic Hepatitis C Virus Genotype 1,Bristol-Myers Squibb,2025-09-01T16:18:08.345759,True,,,,,"A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I",,['Chronic Hepatitis C Virus Genotype 1'],[],,2010-07,2010-12,"[{'measure': 'Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)', 'timeFrame': 'Week 4'}, {'measure': 'Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)', 'timeFrame': 'Week 12'}, {'measure': 'Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)', 'timeFrame': 'Week 24'}, {'measure': 'Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)', 'timeFrame': 'Week 48'}, {'measure': 'Antiviral activity as determined by the proportion of subjects with extended rapid virologic response (eRVR) defined as undetectable HCV RNA', 'timeFrame': 'Week 4'}, {'measure': 'Antiviral activity as determined by the proportion of subjects with extended rapid virologic response (eRVR) defined as undetectable HCV RNA', 'timeFrame': 'Week 12'}]","[{'measure': 'Proportion of subjects with rapid virologic response (RVR), defined as undetectable RNA', 'timeFrame': 'Week 4'}, {'measure': 'Proportion of subjects with complete early virologic response (cEVR), defined as undetectable HCV RNA', 'timeFrame': 'Week 12'}, {'measure': 'Proportion of subjects with a sustained virologic response (SVR), defined as HCV RNA undetectable', 'timeFrame': 'Week 12 (SVR12)'}, {'measure': 'Proportion of subjects with a sustained virologic response (SVR), defined as HCV RNA undetectable', 'timeFrame': 'Week 24 (SVR24)'}, {'measure': 'Resistant variants associated with virologic failure', 'timeFrame': 'Week 4'}, {'measure': 'Resistant variants associated with virologic failure', 'timeFrame': 'Week 12'}, {'measure': 'Resistant variants associated with virologic failure', 'timeFrame': 'Follow up Week 12'}, {'measure': 'Resistant variants associated with virologic failure', 'timeFrame': 'Week 24'}]",14.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,
NCT04329000,On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.,Esomeprazole 40mg,"['Esomeprazole 40mg', 'nexium 40 mg', 'Esomeprazole']",3,INTERVENTIONAL,['NA'],,COMPLETED,Barrett Esophagus,Kaohsiung Veterans General Hospital.,2025-09-01T16:18:08.345990,True,,,,,The Impacts of On-demand Versus Continuous Esomeprazole Therapy on the Symptom Control and Histological Changes of Metaplastic Esophageal Epithelium in Patients With Barrett's Esophagus (EsoBE) - a Multicentre Randomized Controlled Trial,,"['Barrett Esophagus', 'Proton Pump Inhibitor', 'Symptom', 'Reflux']","[""Barrett's Esophagus"", 'Erosive esophagitis', 'Proton pump inhibitor', 'On-demand therapy', 'Continuous therapy']",,2010-02-02,2019-12-08,"[{'measure': 'Rates of progression, remaining unchanged, or regression of the distal esophageal metaplastic mucosa in both groups after 48 weeks', 'description': 'Progression, stationary, regression', 'timeFrame': '48 weeks.'}, {'measure': 'Total symptom day', 'description': 'Days with reflux symptoms', 'timeFrame': '48 weeks'}, {'measure': 'Number of tablets consumed', 'description': 'PPI tablets consumed during follow-up', 'timeFrame': '48 weeks'}]",[],3.0,20 Years,80 Years,ALL,False,OTHER,0.0,218.0,ACTUAL,v2_robust,True,True,False,False,
NCT04817800,"To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray",140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate),"['RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)', '140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)', '100 μg Beclomethasone dipropionate, Nasal Spray']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Seasonal Allergic Rhinitis,Humanis Saglık Anonim Sirketi,2025-09-01T16:18:08.346001,True,,,,,"An Open Label, Randomized, Three-treatment, Three-period, Crossover, Single Dose Study, to Investigate Drug-drug Interaction and Relative Bioavailability Between the Fixed Dose Combination Azelastine Hydrochloride / Beclomethasone Dipropionate (140/100 μg Azelastine Hydrochloride / Beclomethasone Dipropionate) Nasal Spray, and Beclomethasone Dipropionate Nasal Spray (100 μg Beclomethasone Dipropionate) in the Test Vehicle, and the Commercially Available Product, RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate), in Healthy Subjects Under Fasting Conditions",,['Seasonal Allergic Rhinitis'],[],,2021-03-25,2021-04-10,"[{'measure': 'Maximum observed plasma concentration (Cmax) of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate', 'description': 'For the assessment of a potential drug-drug interaction, no effect of Azelastine on the pharmacokinetics of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate will be concluded if the fixed dose combination Test-to-mono test GMR and the corresponding 90% CI of the ln-transformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.\n\nFor the assessment of the relative bioavailability, bioequivalence between Beclomethasone dipropionate drug products will be concluded if the fixed dose combination test-to-mono reference GMR and the corresponding 90% CI of the Lntransformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.', 'timeFrame': '23 hours'}, {'measure': 'area under the plasma concentration versus time curve (AUC) from pre-dose (time zero) to the last sampling time with quantifiable concentrations (AUC0-t) of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate', 'description': 'For the assessment of a potential drug-drug interaction, no effect of Azelastine on the pharmacokinetics of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate will be concluded if the fixed dose combination Test-to-mono test GMR and the corresponding 90% CI of the ln-transformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.\n\nFor the assessment of the relative bioavailability, bioequivalence between Beclomethasone dipropionate drug products will be concluded if the fixed dose combination test-to-mono reference GMR and the corresponding 90% CI of the Lntransformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.', 'timeFrame': '23 hours'}, {'measure': 'AUC from time zero to infinity (AUC0-∞) of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate', 'description': 'For the assessment of a potential drug-drug interaction, no effect of Azelastine on the pharmacokinetics of Beclomethasone dipropionate and its active metabolite Beclomethasone 17-monopropionate will be concluded if the fixed dose combination Test-to-mono test GMR and the corresponding 90% CI of the ln-transformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.\n\nFor the assessment of the relative bioavailability, bioequivalence between Beclomethasone dipropionate drug products will be concluded if the fixed dose combination test-to-mono reference GMR and the corresponding 90% CI of the Lntransformed primary pharmacokinetic parameters are within the 80.00% to 125.00% acceptance interval.', 'timeFrame': '23 hours'}]","[{'measure': 'Obtaining the Tmax (Time to reach maximum concentration)', 'description': 'The descriptive statistics including Maximum, Minimum and Median values will be measured for Tmax.', 'timeFrame': '23 hours'}, {'measure': 'Blood pressure (safety and tolerability)', 'description': 'Clinically significant abnormal deviations. Normal range of blood pressure \\> 90/60 and \\<140/90 mmHg. Treatment will be offered to those subjects whom blood pressure drops to 90/60 mm Hg or less and the subject will be excluded in case of not responding to treatment.', 'timeFrame': 'At 1 hour pre-dosing and 2, 4, 6, 8, 12, and 23 hours post dosing,'}, {'measure': 'Pulse (safety and tolerability)', 'description': 'Clinically significant abnormal deviations. Normal range of Pulse 60-100 Bpm.', 'timeFrame': 'At 1 hour pre-dosing and 2, 4, 6, 8, 12, and 23 hours post dosing,'}, {'measure': 'Temperature (safety and tolerability)', 'description': 'Clinically significant abnormal deviations. The temperature will be measured axillary, orally or using infrared thermometer, standardized across all subjects. Normal range of temperature 36.5-37.5 ºC.', 'timeFrame': 'At 1 hour pre-dosing and 2, 6, 10, 14, 18, 22 and 23 hours post dosing,'}]",7.0,18 Years,50 Years,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,
NCT04256200,Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis,Dienogest 2 MG Oral Tablet,"['combined oral contraceptive', 'Visanne', 'Dienogest 2 MG Oral Tablet', 'Yasmin']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Endometriosis,American University of Beirut Medical Center,2025-09-01T16:18:08.346059,True,,,,,Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis,,['Endometriosis'],"['endometriosis', 'oral contraceptive pills', 'progestin']",,2017-02-07,2021-12,"[{'measure': 'Endometriosis-associated pelvic pain', 'description': 'be the absolute change in endometriosis -associated pelvic pain from baseline to end of treatment, assessed by the Visual Analogue Scale (VAS): with ""absence of pain"" corresponding to the value ""0"" and ""unbearable pain"" corresponding to the value ""10""', 'timeFrame': '6 months'}]","[{'measure': 'Impact on Quality of life', 'description': 'Outcome quality of life will be assessed using Endometriosis Health Profile 30 (EHP30) with each item of this questionnaire can be answered by choosing one of the following (Never, rarely,sometimes, often and always). The endometriosis health profile is a patient-generated questionnaire in which the items were developed from interviews with women with the condition ( Obtained from Oxford University Press) .', 'timeFrame': '6 months'}, {'measure': 'incidence of side effects', 'description': 'Incidence of possible side effects including headache, migraine,nausea, vomiting, abdominal pain/discomfort, breast pain or tenderness, mood swings, premenstrual syndrome, decreased libido, fatigue, weight changes and menstrual irregularities', 'timeFrame': '6 months'}, {'measure': 'Patient Tolerability', 'description': 'Assessing tolerability to side effects via numerical scale from zero to ten ( zero not bothersome at all , ten maximum possible)', 'timeFrame': '6 months'}]",4.0,20 Years,45 Years,FEMALE,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05395507,Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia,Recombinant Interferon Alpha,"['Pegylated interferon alfa-2b', 'Recombinant Interferon Alpha']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Essential Thrombocytopenia,"Institute of Hematology & Blood Diseases Hospital, China",2025-09-01T16:18:08.346278,True,,,,,"A Prospective, Multicenter, Randomized Controlled Clinical Trial of Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Adult Essential Thrombocythemia",,['Essential Thrombocytopenia'],"['Essential Thrombocytopenia', 'Interferon Alfa', 'Pegylated Interferon Alfa-2b', 'Efficacy', 'Safety']",,2022-06-01,2025-06-30,"[{'measure': 'Complete hematological remission (CHR) rates', 'description': 'The CHR rates defined as European Leukemia Net will be compared between the two groups.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52'}]","[{'measure': 'CHR rates at week 24 and 36', 'description': 'The CHR rates at week 24 and 36 will be compared between the two groups', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 24 and Week 36, respectively'}, {'measure': 'Time to CHR', 'description': 'The time of reaching CHR will be compared between the two groups', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'The proportion of patients crossed to the contralateral group', 'description': 'The proportion of patients crossed to the contralateral group will be compared between the two groups', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'The CHR rates after crossover', 'description': 'The CHR rates within 52 weeks after crossover', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Impact of therapy on driver mutations', 'description': 'To compare the proportion of subjects that display change on key biomarkers of the disease- JAK2V617F, CALR, MPL mutations.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Impact of therapy on non-driver mutations', 'description': 'To compare the proportion of subjects that display change on key non-driver biomarkers of the disease-DNMT3A, ASXL1, TET2 or other mutations.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Change of splenomegaly', 'description': 'To compare the proportion of subject with improvement and no progress rate of splenomegaly between the two groups.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Change of bone marrow pathology', 'description': 'To compare the rate of patients with improvement and no progress rate of bone marrow pathology between the two groups', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'The incidence of major thrombotic events', 'description': 'To compare the incidence of major thrombotic events between the two groups.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'The incidence of major bleeding events', 'description': 'To compare the incidence of major bleeding events between the two groups.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'The incidence of progressing to bone marrow fibrosis', 'description': 'The incidence of progressing to bone marrow fibrosis will be compared between the two groups', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'The incidence of progressing to acute leukemia', 'description': 'The incidence of progressing to acute leukemia will be compared between the two groups', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score', 'description': 'To compare the proportion of subjects that display change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (0-100 scores, higher scores mean a worse outcome) between different treatment groups.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Change of quality of life', 'description': 'Compare the rate of patients with improvement in quality of life between the two groups (assessed by EORTC quality of life scale QLQ-C30 V3.0 questionnaire).', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Change of microcirculation disturbance', 'description': 'The rate of patients with improvement in microcirculation disturbance (such as pruritus, headache, dizziness, chest tightness, erythematous limb pain and limb paresthesia) will be compared between the two groups', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}, {'measure': 'Specific pre-defined toxicity', 'description': 'To compare incidence of specific pre-defined toxicity including fatigue, flu-like symptoms, dizziness, injection site necrosis, dyspnea, pain, depression, blurred Vision, insomnia, anorexia, weight Loss, weakness, pruritis, sweating, fever, decreased Libido, hot Flashes, flushing.', 'timeFrame': 'From the start of study treatment (Week 0) up to the end of Week 52.'}]",17.0,18 Years,,ALL,False,OTHER,0.0,194.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01654107,Persistence-Targeted Smoking Cessation,Nicotine lozenge,['Nicotine lozenge'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Tobacco Use Disorder,"Rutgers, The State University of New Jersey",2025-09-01T16:18:08.346348,True,,,,,Persistence-Targeted Smoking Cessation,,['Tobacco Use Disorder'],"['tobacco', 'smoking cessation', 'nicotine dependence']",,2012-07,2014-09,"[{'measure': '7-day Point Prevalence Abstinence', 'description': '3-months after the Quit Date', 'timeFrame': '3-months'}]",[],1.0,18 Years,64 Years,ALL,True,OTHER,1.0,58.0,ACTUAL,v2_robust,True,True,False,False,
NCT01866007,A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants,Guselkumab (lyophilized formulation),"['Guselkumab (liquid formulation with PFS-U)', 'Guselkumab (liquid formulation with PFS FID)', 'CNTO1959', 'Guselkumab (liquid formulation)', 'Guselkumab (lyophilized formulation)']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Janssen Research & Development, LLC",2025-09-01T16:18:08.346365,True,,,,,"Phase 1, Open-label, Randomized, Parallel Study to Assess the Pharmacokinetic Comparability of 2 Formulations and to Evaluate Pharmacokinetic Comparability of Guselkumab (CNTO1959) Delivered by 2 Different Devices in Healthy Subjects",,['Healthy'],"['Healthy', 'Guselkumab', 'CNTO1959', 'Pharmacokinetics', 'UltraSafe Passive Delivery System (PFS-U)', 'Prefilled syringe facilitated injection device (PFS FID)']",,2013-05-09,2013-10-09,"[{'measure': 'Maximum observed serum concentration (Cmax) of guselkumab', 'timeFrame': 'Day 1 through Week 12'}, {'measure': 'Area under the curve (AUC) from time 0 to 70 days of guselkumab', 'timeFrame': 'Day 1 through Week 12'}]","[{'measure': 'Absolute bioavailability of guselkumab', 'description': 'Bioavailability will be evaluated by using formula: AUC from time zero to infinity with extrapolation of the terminal phase of SC injection divided by AUC from time zero to infinity with extrapolation of the terminal phase of IV infusion of guselkumab and multiplied by 100.', 'timeFrame': 'Day 1 through Week 12'}, {'measure': 'Immunogenicity of guselkumab', 'description': 'Plasma levels of antibodies to guselkumab for evaluation of potential immunogenicity.', 'timeFrame': 'Day 1 through Week 12'}, {'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': 'Up to 12 weeks'}]",5.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,141.0,ACTUAL,v2_robust,True,True,False,True,
NCT01286207,"Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)",Rizatriptan 5 mg,"['Rizatriptan 5 mg', 'Standard Care', 'Rizatriptan 10 mg', 'MK-0462, Maxalt']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Migraine Disorders,Organon and Co,2025-09-01T16:18:08.346522,True,,,,,"Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029)",,['Migraine Disorders'],['Migraine headache'],,1995-03,1997-05,"[{'measure': ""Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug"", 'description': 'Headache severity was rated on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain) immediately before initial dose and at 2 hours thereafter. Pain relief was defined as a reduction of headache severity from grades 2/3 at baseline to 0/1.', 'timeFrame': '2 hours after initial dose of test drug'}, {'measure': 'Number of Participants With Serious Clinical Adverse Experiences', 'description': 'Serious clinical adverse experiences (CAEs) are any adverse events (AEs) occurring at any dose that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of Participants With Drug-related Clinical Adverse Experiences', 'description': 'Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of Participants Who Discontinued Due to Clinical Adverse Experiences', 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of Participants With Drug-related Lab Adverse Experiences', 'description': ""Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) laboratory adverse experience (LAE).\n\nA LAE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product."", 'timeFrame': 'Up to 12 weeks'}]",[],5.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,1959.0,ACTUAL,v2_robust,True,True,False,True,
NCT00545207,A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.,ibandronate [Bonviva/Boniva],"['Placebo', 'ibandronate [Bonviva/Boniva]']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Post-Menopausal Osteopenia,Hoffmann-La Roche,2025-09-01T16:18:08.346537,True,,,,,"A Randomized, Double-blind Study of the Effect of Oral Monthly Bonviva on in Vivo Bone Micro-architecture Parameters in Post-menopausal Women With Osteopenia",,['Post-Menopausal Osteopenia'],[],,,2010-09,"[{'measure': 'Trabecular BV/TV at distal radius of non-dominant arm', 'timeFrame': '12 arms'}]","[{'measure': 'Trabecular BV/TV at distal radius of non-dominant arm', 'timeFrame': '6 months and 2 years'}, {'measure': 'Bone density, trabecular BV/TV at distal tibia', 'timeFrame': '6 months, 1 and 2 years'}, {'measure': 'Serum CTX', 'timeFrame': 'Intervals throughout study'}, {'measure': 'Lumbar hip and wrist BMD', 'timeFrame': '1 and 2 years'}, {'measure': 'AEs and laboratory parameters', 'timeFrame': 'Throughout study'}]",6.0,55 Years,75 Years,FEMALE,False,INDUSTRY,0.0,150.0,ACTUAL,v2_robust,True,True,False,False,
NCT01302392,A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma,Carfilzomib,"['PR-171', 'Best Supportive Care', 'Carfilzomib']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Multiple Myeloma,Amgen,2025-09-01T16:18:08.346767,True,,,,,"A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma",,['Multiple Myeloma'],[],,2010-09,2015-09,"[{'measure': 'Overall Survival', 'description': 'Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at date when the subject is last known alive or the data cutoff date, whichever occurs earlier.', 'timeFrame': 'From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.'}]","[{'measure': 'Progression-free Survival', 'description': 'Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). 1 or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).', 'timeFrame': 'From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.'}, {'measure': 'Overall Response', 'description': 'Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).', 'timeFrame': 'From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.'}, {'measure': 'Duration of Response', 'description': 'Duration of response (DOR) was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.', 'timeFrame': 'From the time achieving response through the final analysis data cutoff with longest follow-up time of approximately 29 months.'}, {'measure': 'Clinical Benefit Response', 'description': 'Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (MR was determined using European Group for Blood and Marrow Transplantation criteria)', 'timeFrame': 'From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.'}, {'measure': 'Duration of Clinical Benefit', 'description': 'Duration of Clinical Benefit was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR) or minimal response (MR). Duration of Clinical Benefit was defined as the time in months from the initial start of response (MR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.', 'timeFrame': 'From time of achieving clinical benefit through the final analysis data cutoff with longest follow-up time of approximately 30 months.'}, {'measure': 'Disease Control', 'description': 'Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (MR was determined using European Group for Blood and Marrow Transplantation criteria)', 'timeFrame': 'From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.'}, {'measure': 'Duration of Disease Control', 'description': 'Duration of Disease Control was calculated for subjects who achieved disease control. Duration of Disease Control was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.', 'timeFrame': 'From time of achieving disease control through the final analysis data cutoff with longest follow-up time of approximately 31 months.'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,315.0,ACTUAL,v2_robust,True,True,False,False,
NCT00149292,"Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo",LY2140023,"['LY2140023', 'placebo', 'olanzapine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Schizophrenia,Denovo Biopharma LLC,2025-09-01T16:18:08.346844,True,,,,,"A Randomized, Double-Blind Comparison of LY2140023, Olanzapine, and Placebo in the Treatment of Patients With Schizophrenia",,['Schizophrenia'],[],,2005-08-23,2006-07-17,"[{'measure': 'To determine if a mGlu2/3 agonist (LY2140023) dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score', 'description': 'The primary objective of this study was to determine if LY2140023 dosed at 40 mg twice daily (BID) for 28 days was superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scale (PANSS) total score.', 'timeFrame': '28 days'}]","[{'measure': 'Safety and tolerability of LY2140023 compared with placebo and olanzapine', 'description': 'Safety parameters evaluated included physical and neurological examinations, vital signs, body weight, 12-lead electrocardiograms (ECGs), clinical laboratory tests, prolactin levels, and the record of symptoms. Other safety measures included the Barnes Akathisia Scale (BAS), Simpson- Angus Scale (SAS), and the Abnormal Involuntary Movement Scale (AIMS).', 'timeFrame': '28 days'}, {'measure': 'Efficacy of LY2140023 compared with placebo in change from baseline to Visit 8 in the PANSS positive symptom subset score', 'description': 'The secondary efficacy variables include the change from baseline in the PANSS positive symptoms subset score, the PANSS negative symptom subset score, CGI-S score, and HAMA total score. A patient will be included in the analysis if he or she has a baseline and at least one post-baseline measure.', 'timeFrame': '28 days'}, {'measure': 'Efficacy of LY2140023 compared with placebo in the responder rate in the PANSS total score', 'description': 'Efficacy of LY2140023 compared with placebo in the responder rate (defined as 25% or more decrease from baseline to Visit 8) in the PANSS total score', 'timeFrame': '28 days'}, {'measure': 'Efficacy of LY2140023 compared with placebo in responder rate in the PANSS positive and negative symptom subset score', 'description': 'Efficacy of LY2140023 compared with placebo in responder rate (defined as 25% or more decrease from baseline to Visit 8) in the PANSS positive and negative symptom subset score', 'timeFrame': '28 days'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,195.0,ACTUAL,v2_robust,True,True,False,True,
NCT02260492,Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma,OT329 (combination of fluticasone propionate and salmeterol xinafoate),"['Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)', 'OT329 (combination of fluticasone propionate and salmeterol xinafoate)', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Asthma,Oriel Therapeutics,2025-09-01T16:18:08.346933,True,,,,,Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma,,['Asthma'],[],,2014-09,2015-07,"[{'measure': 'Area Under the Serial FEV1-time Curve (AUC 0-12h)', 'description': 'Bioequivalence comparison of lung function (FEV1) for 12 hours after the first dose on Day 1 following OT329 Solis and Advair Diskus treatment. Serial lung function measurements were made pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose.', 'timeFrame': '0-12 hours after dosing on Day 1'}, {'measure': 'FEV1 Trough', 'description': 'Bioequivalence comparison of trough lung function (FEV1) after 4 weeks of treatment with OT329 SOLIS or ADVAIR DISKUS.', 'timeFrame': 'Post-4 weeks of treatment'}]","[{'measure': 'Number of Participants With Adverse Events', 'timeFrame': 'From Screen (Day -28) until 1 week post last treatment'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,879.0,ACTUAL,v2_robust,True,True,False,True,
NCT06138236,Plantar Fascitiis: Comparison of ESWT and Collagen Hydrolyzed Peptides,Collagen hydrolyzed peptides,"['ESWT', 'Collagen hydrolyzed peptides']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,Plantar Fascitis,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,2025-09-01T16:18:08.347069,True,,,,,Comparison of ESWT and Collagen Hydrolyzed Peptides in the Treatment of Plantar Fascitiis,,['Plantar Fascitis'],[],,2023-07-01,2024-12-31,"[{'measure': 'VAS (Visuoanalogic scale)', 'description': 'Visuoanalogic Scale during walking. Range 0 (No pain) -10 (maximum pain)', 'timeFrame': 'Between recruitment and 30 days'}, {'measure': 'AFAS (American Foot and Ankle Score) is the American Foot and Ankle Scale', 'description': 'It is a measurement of active ROM and deambulation of the patient. Range 0 (no function) -100 (perfect function)', 'timeFrame': 'Between Recruitment and 15 days'}, {'measure': 'AFAS is American Foot and Ankle Scale', 'description': 'It is a measurement of active ROM and deambulation of the patient (Range 0-100)', 'timeFrame': 'Between Recruitment and 30 days'}, {'measure': 'AFAS is American Foot and Ankle Scale', 'description': 'It is a measurement of active ROM and deambulation of the patient (Range 0-100)', 'timeFrame': 'Between Recruitment and 60 days'}]",[],4.0,18 Years,80 Years,ALL,False,OTHER,0.0,84.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01141036,Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients,propofol,"['Midazolam', 'propofol']",2,INTERVENTIONAL,['NA'],,COMPLETED,Cirrhosis,Ziv Hospital,2025-09-01T16:18:08.347082,True,,,,,Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients,,['Cirrhosis'],"['Propofol', 'Midazolam', 'sedation', 'cirrhosis', 'endoscopy', 'recovery time', 'efficacy and safety of sedation', 'patient satisfaction', 'return to baseline function', 'saturation of oxygen']",,2008-07,2009-02,[{'measure': 'Exacerbation of hepatic encephalopathy'}],"[{'measure': 'Recovery time, time to discharge'}]",2.0,18 Years,,ALL,False,OTHER_GOV,0.0,60.0,ESTIMATED,v2_robust,True,True,False,False,
NCT00526136,Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study,Placebo,"['Vernakalant (oral)', 'RSD1235-SR', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Atrial Fibrillation,Advanz Pharma,2025-09-01T16:18:08.347128,True,,,,,Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study,,['Atrial Fibrillation'],['Atrial Fibrillation'],,2007-03,2008-07,"[{'measure': 'Time to first documented recurrence of symptomatic sustained AF.', 'timeFrame': 'Time to first documented recurrence of symptomatic sustained AF within Day 90 of dosing'}, {'measure': 'Safety assessments- Vital signs, safety laboratory assays, ECG parameters, physical examinations, and frequency of adverse events', 'timeFrame': 'Safety assessments within Day 120 of dosing'}]","[{'measure': 'Time to first documented recurrence of symptomatic or asymptomatic sustained AF', 'timeFrame': 'Time to first documented recurrence of symptomatic or asymptomatic sustained AF within 90 days of dosing'}, {'measure': 'Time to first documented recurrence of symptomatic AF', 'timeFrame': 'Time to first documented recurrence of symptomatic AF within 90 days of dosing'}, {'measure': 'Time to first documented recurrence of symptomatic or asymptomatic AF', 'timeFrame': 'Time to first documented recurrence of symptomatic or asymptomatic AF within 90 days of dosing'}, {'measure': 'Proportion of subjects in sinus rhythm on Day 90.', 'timeFrame': 'Proportion of subjects in sinus rhythm on Day 90 of dosing'}, {'measure': 'Improvement in AF symptoms as assessed by an AF symptom checklist.', 'timeFrame': 'Improvement in AF symptoms as assessed by an AF symptom checklist within Day 90 of dosing'}, {'measure': 'Improvement in QOL as measured by SF-36', 'timeFrame': 'Improvement in QOL as measured by SF-36 within Day 90 of dosing'}]",8.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,735.0,ACTUAL,v2_robust,True,True,False,True,
NCT00000736,Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals,Zidovudine,['Zidovudine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,HIV Infections,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:08.347153,True,,,,,Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals,,['HIV Infections'],"['Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex', 'Zidovudine']",,,1995-02,[],[],0.0,18 Years,,ALL,False,NIH,0.0,3200.0,,v2_robust,True,True,False,False,
NCT03410836,Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions,intravenous lidocaine (IVL),['intravenous lidocaine (IVL)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Intravenous Lidocaine and Immunity,Ciusss de L'Est de l'Île de Montréal,2025-09-01T16:18:08.347367,True,,,,,"Impact of Intraoperative Intravenous Lidocaine Administered During Laparoscopic Colorectal Surgery on Remifentanil Consumption, Postoperative Pain and Immune Cell Activity: A Pilot Study",,['Intravenous Lidocaine and Immunity'],"['lidocaine', 'colorectal cancer', 'laparoscopy surgery', 'anesthesia', 'inflammation', 'cytokine', 'post-operative immunosuppression']",,2019-04-29,2025-06,"[{'measure': 'Reduction of total intraoperative remifentanil consumption by 30% in the intravenous lidocaine (""IVL"") group compared with the control group (""C""). Total consumption of remifentanil in mcg.', 'description': 'Reduction of total intraoperative remifentanil consumption by 30% in the intravenous lidocaine group compared with the control group.', 'timeFrame': 'Intra-operative, 5 hours'}]","[{'measure': 'Evaluation of the number of remifentanil boluses given intraoperatively (n)', 'description': 'Evaluation of the number of remifentanil boluses given intraoperatively, based on the intraoperative NOL index from T0 which is the time of the incision', 'timeFrame': 'T0 to end of surgery, 5 hours'}, {'measure': 'Assessment of total consumption of inhaled anesthetic desflurane in ml', 'description': 'The Dräger Perseus A500 that we have in each anesthesia room offers the opportunity to get the ml of halogenous gas consumed precisely, and our electronic extraction database will allow to have this data in ml per second and the total at the end of surgery', 'timeFrame': 'intra-operative'}, {'measure': 'Evaluation of time for extubation', 'description': 'Evaluation of time for extubation after surgery in the operating room', 'timeFrame': 'post-operative 1 hour'}, {'measure': 'Evaluation of the hydromorphone dose in mg used in the post-operative care unit (PACU) titration', 'description': 'Evaluation of the hydromorphone dose in mg used as post-operative titration immediately in the recovery room (PACU) to obtain NRS pain scores \\< 3/10', 'timeFrame': 'in recovery room, 3 hours'}, {'measure': 'Evaluation of the nausea and vomiting scores, 0 to 3 scale', 'description': 'Evaluation of the nausea and vomiting scores (0 to 3) for the first 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Evaluation of the length of stay in the recovery room based on the Aldrete scores (Score from 0 to 9)', 'description': 'Evaluation of the length of stay in the recovery room based on the Aldrete scores (time to be ready to leave the recovery room)', 'timeFrame': 'in recovery room, 3 hours'}, {'measure': 'total hydromorphone consumption (mg) after PACU, on wards', 'description': 'total hydromorphone consumption (mg given by Patient Controlled Analgesia) on wards for 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Evaluation of the satisfaction of the patient scale 0 to 100 (%)', 'description': 'Evaluation of the satisfaction of the patient as for the management of his pain for 48 hours', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Assessment of total hospital duration of stay in hours', 'description': 'Assessment of total hospital stay in hours', 'timeFrame': '7 days postoperatively'}, {'measure': 'Evaluation of the time in hours required for the emission of a first gas in hours', 'description': 'Evaluation of the time in hours required for the emission of a first gas, a sign of resumption of normal intestinal function', 'timeFrame': '5 days postoperatively'}, {'measure': 'Assessment of rehabilitation scores and cognitive functions', 'description': 'Assessment of rehabilitation scores and cognitive functions at 48h after surgery', 'timeFrame': '2 days'}, {'measure': 'Assessment of cytokines in plasma', 'description': 'Assessment of inflammation parameters by blood sample for 48 hours', 'timeFrame': '48 hours'}]",13.0,18 Years,,ALL,False,OTHER,1.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04736836,Microbial Resistance of Rifaximin in Hepatic Encephalopathy,Rifaximin,['Rifaximin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hepatic Encephalopathy,National Hepatology & Tropical Medicine Research Institute,2025-09-01T16:18:08.347512,True,,,,,Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis,,['Hepatic Encephalopathy'],[],,2015-01,2019-06,"[{'measure': 'the time to the first breakthrough episode of OHE the time to the first breakthrough episode of OHE (overt hepatic encephalopathy)', 'description': '(defined as the time from the first dose of the study drug to an increase from a baseline Conn score of 0 or 1 to a score of 2 or more or from a baseline Conn score of 0 to a Conn score of 1 plus a 1-unit increase in the asterixis grade.', 'timeFrame': '6 months'}]",[],1.0,18 Years,75 Years,ALL,False,OTHER_GOV,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,
NCT00649636,Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg,Fluoxetine Capsules 40 mg,"['Prozac Pulvules 40 mg', 'Fluoxetine Capsules 40 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Mylan Pharmaceuticals Inc,2025-09-01T16:18:08.347591,True,,,,,Single-Dose Fasting Bioequivalence Study of Fluoxetine Capsules (40 mg; Mylan) and Prozac Pulvules (40 mg; Dista) in Healthy Adult Volunteers,,['Healthy'],[],,2006-02,2006-04,"[{'measure': 'Bioequivalence', 'timeFrame': 'within 30 days'}]",[],1.0,18 Years,,ALL,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT01303536,Ondansetron Augmentation in Treatment-resistant OCD,Ondansetron,['Ondansetron'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Obsessive Compulsive Disorder,"Institute of Neuroscience, Florence, Italy",2025-09-01T16:18:08.347598,True,,,,,Ondansetron Augmentation in Treatment-resistant OCD,,['Obsessive Compulsive Disorder'],[],,2009-12,2010-03,"[{'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'baseline'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 2'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 4'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 6'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 8'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 10'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 12'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 14'}, {'measure': 'Yale Brown Obsessive Compulsive Scale', 'timeFrame': 'week 16'}]","[{'measure': 'The Drug Effect scale', 'timeFrame': 'week 0'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 2'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 4'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 6'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 8'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 10'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 12'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 14'}, {'measure': 'The Drug Effect scale', 'timeFrame': 'week 16'}]",18.0,18 Years,60 Years,ALL,False,OTHER,0.0,21.0,ACTUAL,v2_robust,True,True,False,False,
NCT06981936,This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control,Balance Tablet,"['Balance Tablet', 'Control (placebo)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Micronutrient Deficiencies,"General Committee of Teaching Hospitals and Institutes, Egypt",2025-09-01T16:18:08.347644,True,,,,,Evaluation of Balance Tablets in Reducing Vitamin and Mineral Deficiencies in Patients Using GLP-1 Receptor Agonists for Weight Loss,,['Micronutrient Deficiencies'],"['Balance Tablets', 'Vitamin and Mineral Deficiencies', 'GLP-1 Receptor Agonists for Weight Loss', 'Weight Loss', 'Micronutrient Deficiencies']",,2025-05,2026-05,"[{'measure': 'Incidence of vitamin and mineral deficiencies at 12 months, comparing the proportion of participants in each group who develop one or more deficiencies.', 'description': 'Deficiency is defined for each nutrient as a serum concentration below the lower limit of the normal reference range (see Definitions below). The incidence of deficiencies will also be measured at interim time points (3, 6, and 9 months) to observe the trajectory over time, but the comparison at 12 months is the primary endpoint for efficacy.', 'timeFrame': 'From enrollment to the end of treatment at 12 months'}]","[{'measure': 'Serum nutrient levels', 'description': 'Changes in specific vitamin and mineral concentrations from baseline at 3, 6, 9, and 12 months. This includes vitamins B\\_12, B\\_1 (thiamine), B\\_6 (pyridoxine), folic acid, 25-hydroxyvitamin D (25-OHD), and minerals such as iron stores (ferritin), calcium (albumin-corrected), magnesium, phosphate, zinc, as well as parathyroid hormone (PTH) and albumin (as a marker of nutritional status). For each of these analytes, the mean (or median) change over 12 months and the proportion of patients below normal range at each time point will be compared between groups.', 'timeFrame': 'From enrollment to the end of treatment at 12 months'}, {'measure': 'Incidence of hypervitaminosis', 'description': 'Number and proportion of participants in each group who develop hypervitaminosis (excess levels of any vitamin above the normal reference range) during the 12-month period. This will be assessed at the same blood sampling intervals. Particularly, fat-soluble vitamin levels (e.g., vitamins A, D, B\\_12) will be monitored for any values above the upper limit of normal.', 'timeFrame': 'From enrollment to the end of treatment at 12 months'}, {'measure': 'Compliance with supplementation', 'description': ""Adherence to the prescribed daily tablet regimen will be evaluated utilizing the 5-item Medication Adherence Report Scale (MARS-5), a validated instrument that identifies prevalent non-adherence patterns. Each of the five items will be rated on a 5-point Likert scale from 1 (indicating 'always') to 5 (indicating 'never'), yielding a cumulative score ranging from 5 to 25, where higher scores reflect improved adherence. At each designated follow-up interval (3, 6, 9, and 12 months), a bilingual study specialist will administer the MARS-5 questionnaire orally in the participant's preferred language, either Arabic or English, and meticulously document the responses. Comparative analyses of average adherence scores will be conducted between the Balance and placebo cohorts, and we will also assess the correlation between adherence levels and the occurrence of vitamin and mineral deficiencies."", 'timeFrame': 'From enrollment to the end of treatment at 12 months'}, {'measure': 'Anthropometric outcome', 'description': 'Changes in body weight and adiposity measure including BMI (weight and height will be combined to report BMI in kg/m\\^2) at 3, 6, 9, and 12 months. That outcome will indicate the degree of weight loss and will be tracked to ensure both groups have similar weight loss (since all are on GLP-1 therapy) and to explore if improved micronutrient status correlates with better weight outcomes or vice versa. (weight in kilograms, height in meters)', 'timeFrame': 'From enrollment to the end of treatment at 12 months'}, {'measure': 'Anthropometric outcome', 'description': 'Changes in body weight and adiposity measure including %EWL (weight in kilograms) at 3, 6, 9, and 12 months. %EWL is defined as the percentage of above-ideal body weight lost. That outcome will indicate the degree of weight loss and will be tracked to ensure both groups have similar weight loss (since all are on GLP-1 therapy) and to explore if improved micronutrient status correlates with better weight outcomes or vice versa.', 'timeFrame': 'From enrollment to the end of treatment at 12 months'}, {'measure': 'Anthropometric outcome', 'description': 'Changes in body weight and adiposity measure including %TWL (weight in kilograms) at 3, 6, 9, and 12 months. %TWL is the percentage of total body weight lost from baseline. These outcomes will indicate the degree of weight loss and will be tracked to ensure both groups have similar weight loss (since all are on GLP-1 therapy) and to explore if improved micronutrient status correlates with better weight outcomes or vice versa.', 'timeFrame': 'From enrollment to the end of treatment at 12 months'}]",7.0,18 Years,65 Years,ALL,True,OTHER_GOV,0.0,150.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00622336,"A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma",CC-5013,"['Lenalidomide', 'lenalidomide', 'Revlimid', 'CC-5013']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Multiple Myeloma,Celgene,2025-09-01T16:18:08.347688,True,,,,,"Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 Monotherapy for Subjects With Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010",,['Multiple Myeloma'],"['Multiple Myeloma', 'Revlimid']",,2003-04-01,2013-11-25,"[{'measure': 'Number of Participants With Adverse Events (AE) During the Treatment Phase', 'description': 'An AE is any sign, symptom, illness, or diagnosis (either observed or volunteered) that appears or worsens during the course of the study Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event. A treatment emergent AE is defined as any AE occurring or worsening on or after the first dose of study drug and within 30 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 2.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;', 'timeFrame': 'Until data cut-off of 22 Oct 2009; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Maximum exposure to Lenalidomide treatment was 1260 days.'}, {'measure': 'Number of Participants With Adverse Events (AE) During the Extension Phase', 'description': 'An AE is any sign, symptom, illness, or diagnosis (either observed or volunteered) that appears or worsens during the course of the study Serious adverse event (SAE) = any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event. A treatment emergent AE is defined as any AE occurring or worsening on or after the first dose of study drug and within 30 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 2.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;', 'timeFrame': 'From 22 Oct 2009 to November 2013; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit.'}]","[{'measure': 'Time to Progression', 'description': 'Time to progression based on the myeloma response determination criteria developed by Bladé et al 1998 and is defined as the time from registration to the first documented progression. The progressive disease criteria included increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.', 'timeFrame': 'Up to 70 months'}, {'measure': 'Myeloma Response Rate', 'description': 'Myeloma response determination criteria developed by Bladé et al 1998. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.', 'timeFrame': 'Up to 70 months'}, {'measure': 'Duration of Response', 'description': 'Duration of response based on the Myeloma response determination criteria developed by Bladé et al 1998 and defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on International Myeloma Working Group (IMWG) criteria.', 'timeFrame': 'Up to 70 months'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,330.0,ACTUAL,v2_robust,True,True,False,True,
NCT03374111,Colla Corii Asini Treating Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency),Colla corii asini,"['Colla corii asini', 'a Simulate Agent of Colla corii asini granule', 'Placebo of Colla corii asini granule', 'donkey-hide gelatin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Thalassemia,"The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine",2025-09-01T16:18:08.347699,True,,,,,"A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency)",,['Thalassemia'],"['Thalassemia;', 'the Syndrome of Blood Deficiency', 'Anemia', 'Colla Corii Asini']",,2018-03-01,2019-12-30,"[{'measure': 'Hemoglobin(Hb)', 'description': 'the change of hemoglobin(g/L)', 'timeFrame': 'baseline, week 4 and week 8'}]","[{'measure': 'reticulocyte (RET)', 'description': 'the change of reticulocyte (RET)count（×10\\^9/L）', 'timeFrame': 'baseline, week 4 and week 8'}, {'measure': 'immature reticulocyte fraction（IRF）', 'description': 'the change of immature reticulocyte fraction(%)', 'timeFrame': 'baseline, week 4 and week 8'}, {'measure': 'adverse event', 'description': 'undesirable pregnancy outcomes', 'timeFrame': 'tracked for 42 days after giving birth'}, {'measure': 'indirect bilirubin(IBIL)', 'description': 'the change of indirect bilirubin(IBIL)(μmol/L)', 'timeFrame': 'baseline, week 4 and week 8'}, {'measure': 'total bilirubin(TBIL)', 'description': 'the change of total bilirubin(TBIL) (μmol/L)', 'timeFrame': 'baseline, week 4 and week 8'}, {'measure': 'lactic dehydrogenase(LDH)', 'description': 'the change of lactic dehydrogenase(LDH)(U/L)', 'timeFrame': 'baseline, week 4 and week 8'}, {'measure': 'anaemia cure rates', 'description': 'anaemia cure rates(%):The concentration of hemoglobin was higher than baseline \\> 5g/L;The improvement rate = improved cases/the total number of cases \\* 100%', 'timeFrame': 'week 8'}, {'measure': 'The curative effect of TCM Syndrome', 'description': 'the change of the TCM syndrome scores of two groups before and after treatment（%）', 'timeFrame': 'week 8'}]",9.0,20 Years,50 Years,FEMALE,False,OTHER,0.0,480.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05442411,Regional Scalp Block Versus IV Parecoxib for Post-operative Cranioplasty Surgery Pain: A Comparison of Pain Score.,Ropivacaine 0.75% Injectable Solution,"['Ropivacaine 0.75% Injectable Solution', 'parecoxib 40mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Postoperative Pain,Universiti Sains Malaysia,2025-09-01T16:18:08.347717,True,,,,,Regional Scalp Block Versus IV Parecoxib for Post-operative Cranioplasty Surgery Pain: A Comparison of Pain Score.,,['Postoperative Pain'],[],,2021-03-09,2022-03-30,"[{'measure': 'pain score', 'description': 'visual analog score', 'timeFrame': '12 hours'}]","[{'measure': 'total morpine requirement', 'description': 'PCA post operatively', 'timeFrame': '12 hours'}]",2.0,18 Years,60 Years,ALL,True,OTHER,0.0,58.0,ACTUAL,v2_robust,True,True,False,False,
NCT03240211,Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL,Pembrolizumab,"['Dacogen', 'Pembrolizumab', 'Keytruda', 'Decitabine', 'Folotyn', 'Pralatrexate']",6,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,PTCL,University of Virginia,2025-09-01T16:18:08.347735,True,,,,,Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate,,"['PTCL', 'CTCL']","['Pembrolizumab', 'Decitabine', 'Pralatrexate', 'T-cell lymphoma']",,2022-02-02,2026-05-25,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'The study dose level that is recommended after the maximum target sample size of 10 participants are accrued to each arm', 'timeFrame': '1-2 years'}, {'measure': 'Dose Limiting Toxicity (DLT)', 'description': ""Only DLT's that occur prior to the initiation of cycle 2 will be used to determine dose escalation/de-escalation decisions. DLT criteria are defined as any non-hematologic toxicity greater and/or equal to grade 3 except for exceptions outlined in the protocol."", 'timeFrame': '1-2 years'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'Evaluate the efficacy, as determined by the ORR (complete + partial response) for each Arm', 'timeFrame': '1-2 years'}]","[{'measure': 'Anti-tumor activity', 'description': 'Describe the anti-tumor activity of the combinations in each Arm.', 'timeFrame': '1-2 years'}, {'measure': 'ORR, PFS, DOR', 'description': 'Evaluate the efficacy, as determined by the overall response rate (ORR), progression free survival (PFS), and duration of response (DOR) for each Arm.', 'timeFrame': '1-2 years'}, {'measure': 'Pharmacodynamic markers', 'description': 'Evaluate pharmacodynamic markers of drug effect in paired tissue biopsies (pre- and post-treatment).', 'timeFrame': '1-2 years'}, {'measure': 'Pharmacokinetic Profile', 'description': 'Establish pharmacokinetic profile for pembrolizumab when administered with pralatrexate (Arm A), with decitabine (Arm C) and when given as a combination (Arm B) during cycle 1 only.', 'timeFrame': '1-2 years'}]",7.0,18 Years,90 Years,ALL,False,OTHER,2.0,37.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00696111,Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea,Depot Lupron followed by estrogen plus placebo,"['Arm 1', 'Depot Lupron followed by estrogen plus placebo']",2,INTERVENTIONAL,['NA'],,COMPLETED,Polycystic Ovary Syndrome,University of Chicago,2025-09-01T16:18:08.347835,True,,,,,"PCOS, Sleep Apnea and Metabolic Risk in Women",,"['Polycystic Ovary Syndrome', 'Obstructive Sleep Apnea']","['PCOS', 'OSA', 'Metabolism', 'Diabetes']",,2007-12,2022-06-30,"[{'measure': 'Estrogen Levels', 'description': 'Estrogen levels measured every 20 minutes for 24 hours and the the average of those values are presented. The units of measurement are picograms per milliter (pg/ml).', 'timeFrame': 'Baseline'}, {'measure': 'Sleep Efficiency Measured at Baseline', 'description': 'Sleep efficiency recorded with polysomnography minimum value = 0%, maximum value = 100%, higher values are a better outcome.', 'timeFrame': 'Baseline'}, {'measure': 'Total Testosterone', 'description': 'Total Testosterone levels measured every 20 minutes for 24 hours and the average of those values are presented. The units of measurement are picograms per milliter (pg/ml).', 'timeFrame': 'Baseline'}]","[{'measure': 'Intravenous Glucose Tolerance Test', 'description': 'Acute Insulin Response measured by the intravenous glucose tolerance test measured during baseline. The unit of measurement is mg/dl.', 'timeFrame': 'Baseline'}]",4.0,18 Years,40 Years,FEMALE,False,OTHER,2.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT06777511,Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients,5-aminolevulinic acid (5-ALA),['5-aminolevulinic acid (5-ALA)'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Amputation,Dartmouth-Hitchcock Medical Center,2025-09-01T16:18:08.347887,True,,,,,Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients,,"['Amputation', 'Osseointegration']",[],,2025-08-01,2026-08-30,"[{'measure': 'Feasibility', 'description': 'Feasibility will be defined as 80% of patients successfully completing the administration protocol as well as 1 week/2-week follow-up.', 'timeFrame': '2 weeks'}]","[{'measure': 'Treatment Evaluation Inventory-Short Form (TEI-SF)', 'description': 'The TEI-sf is a 9-item questionnaire used to measure intervention acceptability from the participants point of view. Scores range from 9 to 45, and scores above 27 are considered acceptable.', 'timeFrame': '2 weeks'}, {'measure': 'System Usability Scale (SUS)', 'description': 'The SUS is a reliable 10-item usability measure with scores that range from 0 to 100 (an above average score is 68 or higher.', 'timeFrame': '2 weeks'}, {'measure': 'Bioburden quantification (16S rRNA sequencing)', 'description': 'Bioburden will be quantified using quantitative PCR-based assays as well as addition of a ""spikein"" of a defined quantity of bacterial cells derived from halophilic organism Salnibacter ruber.', 'timeFrame': '2 weeks'}, {'measure': 'Bioburden quantification (Optical Coherence Tomography (OCT)', 'description': 'Biofilm will be imaged and quantified on the metal abutment', 'timeFrame': '2 weeks'}, {'measure': 'OCT ""virtual biopsy""', 'description': 'Presence of inflammation, hypergranulation, and any resulting changes (e.g., the degree of epidermal regression, dermal attachment to the implant, and epithelial layer thickness) can be quantified through morphologic analysis of the OCT B-scans. Scars are characterized by excessive collagen deposition, increased blood vessel density, and parallel blood vessel organization compared with normal skin.', 'timeFrame': '2 weeks'}, {'measure': 'Scar thickness', 'description': 'Scar thickness measured using OCT', 'timeFrame': '2 weeks'}, {'measure': 'Blood vessel density', 'description': 'Blood vessel density measuring using OCT', 'timeFrame': '2 weeks'}, {'measure': 'Presence of hypergranulation', 'description': 'Hypergranulation measured using OCT', 'timeFrame': '2 weeks'}, {'measure': 'Pain during light exposure', 'description': 'Patient reported pain during light exposure', 'timeFrame': '2 weeks'}, {'measure': 'Discomfort, burning, itchiness, or redness', 'description': 'Patient reported discomfort, burning, itchiness or redness', 'timeFrame': '2 weeks'}]",11.0,18 Years,,ALL,False,OTHER,1.0,10.0,ESTIMATED,v2_robust,False,False,False,False,
NCT00716911,Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant,ganciclovir,['ganciclovir'],1,INTERVENTIONAL,['NA'],,COMPLETED,Chronic Myeloproliferative Disorders,City of Hope Medical Center,2025-09-01T16:18:08.347921,True,,,,,"CMV Specific Cellular Immunity in Recipients of Allogeneic Bone Marrow Transplantation: Association of CMV-Specific HLA-Peptide Tetramer Binding With Cytotoxic T-Cell Function, CMV Infection and Other Clinical Events",,"['Chronic Myeloproliferative Disorders', 'Leukemia', 'Lymphoma', 'Multiple Myeloma and Plasma Cell Neoplasm', 'Myelodysplastic Syndromes', 'Myelodysplastic/Myeloproliferative Neoplasms', 'Nonneoplastic Condition']","['cytomegalovirus infection', 'accelerated phase chronic myelogenous leukemia', 'atypical chronic myeloid leukemia, BCR-ABL negative', 'blastic phase chronic myelogenous leukemia', 'chronic myelomonocytic leukemia', 'chronic phase chronic myelogenous leukemia', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'refractory chronic lymphocytic leukemia', 'refractory hairy cell leukemia', 'relapsing chronic myelogenous leukemia', 'secondary acute myeloid leukemia', 'stage III chronic lymphocytic leukemia', 'stage IV chronic lymphocytic leukemia', 'splenic marginal zone lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'stage III adult Burkitt lymphoma', 'stage III adult diffuse large cell lymphoma', 'stage III adult diffuse mixed cell lymphoma', 'stage III adult diffuse small cleaved cell lymphoma', 'stage III adult immunoblastic large cell lymphoma', 'stage III adult lymphoblastic lymphoma', 'stage III grade 1 follicular lymphoma', 'stage III grade 2 follicular lymphoma', 'stage III grade 3 follicular lymphoma', 'stage III mantle cell lymphoma', 'stage III marginal zone lymphoma', 'stage III small lymphocytic lymphoma', 'stage IV adult Burkitt lymphoma', 'stage IV adult diffuse large cell lymphoma', 'stage IV adult diffuse mixed cell lymphoma', 'stage IV adult diffuse small cleaved cell lymphoma', 'stage IV adult immunoblastic large cell lymphoma', 'stage IV adult lymphoblastic lymphoma', 'stage IV grade 1 follicular lymphoma', 'stage IV grade 2 follicular lymphoma', 'stage IV grade 3 follicular lymphoma', 'stage IV mantle cell lymphoma', 'stage IV marginal zone lymphoma', 'stage IV small lymphocytic lymphoma', 'recurrent adult Hodgkin lymphoma', 'recurrent adult Burkitt lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent adult lymphoblastic lymphoma', 'recurrent cutaneous T-cell non-Hodgkin lymphoma', 'recurrent mycosis fungoides/Sezary syndrome', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent mantle cell lymphoma', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'chronic eosinophilic leukemia', 'chronic neutrophilic leukemia', 'primary myelofibrosis', 'stage II multiple myeloma', 'stage III multiple myeloma', 'refractory multiple myeloma', 'de novo myelodysplastic syndromes', 'previously treated myelodysplastic syndromes', 'secondary myelodysplastic syndromes', 'myelodysplastic/myeloproliferative neoplasm, unclassifiable', 'stage I multiple myeloma']",,2000-01,2007-07,"[{'measure': 'Quantitative determination of HLA-peptide tetramer-binding assay (TBA) pp65 on days 40 and 90 after stem cell transplantation, with and without in vitro stimulation'}, {'measure': 'Comparison of quantitative determination of TBApp65 with concomitant determination of in vitro CMV-specific cytotoxic T-lymphocyte function on days 40 and 90 after stem cell transplantation'}, {'measure': 'Correlation of TBApp65 results with CMV viral loads'}, {'measure': 'Correlation of TBApp65 results with CMV-associated complications'}]","[{'measure': 'Correlation of TBApp65 results with clinical events, including acute graft-versus-host-disease (GVHD), chronic GVHD, ganciclovir exposure, and survival'}]",5.0,18 Years,,ALL,True,OTHER,2.0,100.0,ESTIMATED,v2_robust,True,True,False,False,
NCT01139671,Comparison of Sufentanil and Remifentanil Infusion During General Anaesthesia for Removal of Wisdom Teeth in Ambulatory Surgery,Remifentanil,['Remifentanil'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Tooth Extractions,"University Hospital, Clermont-Ferrand",2025-09-01T16:18:08.347951,True,,,,,Comparison of Sufentanil and Remifentanil Infusion During General Anaesthesia for Removal of Wisdom Teeth in Ambulatory Surgery,,['Tooth Extractions'],"['Remifentanil', 'Sufentanil', 'Surgical removal of three to four wisdom teeth', 'General anaesthesia', 'Ambulatory oral surgery', 'Target Controlled Infusion (TCI)', 'Opioid induced hyperalgesia', 'Postoperative nausea and vomiting', 'Postoperative Morphine consumption', 'Under General anaesthesia', 'In Ambulatory surgery']",,2010-06,2011-07,"[{'measure': 'Morphine consumption in Post Anaesthesia Care Unit ( with intravenous titration given by nurse)', 'timeFrame': '48 h after the surgery'}]","[{'measure': '- Postoperative pain (measured by the numeric pain intensity scale)', 'timeFrame': '48 h after the surgery'}, {'measure': ""patient's satisfaction"", 'timeFrame': '48 h after the surgery'}, {'measure': 'Length of stay in Post Anaesthesia Care Unit and in ambulatory surgery unit', 'timeFrame': '48 h after the surgery'}, {'measure': '- Occurrence of postoperative nausea and vomiting', 'timeFrame': '48 h after the surgery'}, {'measure': 'additional workload for nurses', 'timeFrame': '48 h after the surgery'}, {'measure': 'postoperative analgesic requirement in the first 48 hours after surgery', 'timeFrame': '48 h after the surgery'}, {'measure': 'percentage of Glottic opening (POGO) score, Cormack-Lehane grading', 'timeFrame': '48 h after the surgery'}, {'measure': 'tolerance of the procedure', 'timeFrame': '48 h after the surgery'}]",9.0,15 Years,35 Years,ALL,False,OTHER,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT03724071,Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.,"Flucytosine (5-FC, Ancotil)","['Flucytosine (5-FC, Ancotil)']",1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Colorectal Neoplasm,Transgene,2025-09-01T16:18:08.348022,True,,,,,A Phase I/IIa Study of TG6002 (VV TK-RR-FCU1) Administered by Intravenous (IV) Infusions in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Gastro-intestinal (GI) Tumors.,,"['Colorectal Neoplasm', 'Digestive System Neoplasm']",[],Study has been terminated after Phase I part on 23 February 2023,2018-10-16,2023-02-23,"[{'measure': 'Phase I part - Dose-limiting toxicities', 'description': 'Dose-limiting toxicities', 'timeFrame': 'Day 28'}, {'measure': 'Phase II part - Overall response rate', 'description': 'Overall response rate according to Recist v1.1', 'timeFrame': 'Day 43'}]",[],2.0,18 Years,,ALL,False,INDUSTRY,0.0,51.0,ACTUAL,v2_robust,True,False,True,False,Study has been terminated after Phase I part on 23 February 2023
NCT03994471,Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.,"XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght","['Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance', '1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution', 'XyloCore 0.7 or 1.5 or 2.0', 'XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,End Stage Renal Disease,Iperboreal Pharma Srl,2025-09-01T16:18:08.348031,True,,,,,"A Study to EvaLuate the EffIcacy and Safety of XyloCore, a Glucose SparIng ExpeRimental Solution, for Peritoneal Dialysis",,['End Stage Renal Disease'],"['peritoneal dialysis', 'ESRD']",,2022-12-14,2026-04,"[{'measure': 'Total weekly Kt/Vurea', 'description': 'To measure solutes and calculate peritoneal and renal Kt/V (summing up to total Kt/V), dialysate outflow and urine covering 24 hours will be collected, the volumes will be determined, and a blood sample will be taken', 'timeFrame': '24-week'}]","[{'measure': 'Changes in HbA1c (glycated haemoglobin)', 'description': 'Change from baseline value', 'timeFrame': '6 months'}, {'measure': 'Insulin', 'description': 'Changes from the baseline value', 'timeFrame': '6 months'}, {'measure': 'LDL cholesterol', 'description': 'Changes from the baseline value', 'timeFrame': '6 months'}, {'measure': 'HDL cholesterol', 'description': 'Change from the baseline value', 'timeFrame': '6 months'}, {'measure': 'Serum triglycerides', 'description': 'Change from the baseline value', 'timeFrame': '6 months'}, {'measure': 'Total cholesterol', 'description': 'Changes from the baseline', 'timeFrame': '6 months'}, {'measure': 'Hemoglobin', 'description': 'Changes from the baseline value', 'timeFrame': '6 months'}, {'measure': 'EPO requirements', 'description': 'Change from the baseline', 'timeFrame': '6 months'}, {'measure': 'Fatigue measured through a validated instrument', 'description': 'Changes from the baseline', 'timeFrame': '6 months'}, {'measure': 'Peritoneal ultrafiltration', 'description': 'Changes from baseline', 'timeFrame': '6 months'}, {'measure': 'Diuresis (or 24 hours urinary volume)', 'description': 'Changes from baseline', 'timeFrame': '6 months'}, {'measure': 'Residual renal function', 'description': 'Changes from baseline - measured as the arithmetic mean of urinary urea and creatinine clearance', 'timeFrame': '6 months'}, {'measure': 'Adverse Events', 'description': 'Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected, recorded and followed as appropriate.', 'timeFrame': '6 months'}]",14.0,18 Years,,ALL,False,INDUSTRY,0.0,170.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01770171,Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer,Bevacizumab,"['Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles', 'Bevacizumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Stage III-IV or Recurrent Endometrial Cancer,Catholic University of the Sacred Heart,2025-09-01T16:18:08.348147,True,,,,,A Randomized Phase II Trial of Carboplatin-Paclitaxel Compared to Carboplatin-Paclitaxel-Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer,,['Stage III-IV or Recurrent Endometrial Cancer'],"['endometrial cancer', 'recurrent endometrial cancer', 'bevacizumab']",,2012-04,2017-12,"[{'measure': 'Progression-free survival', 'description': '• Progression-free survival, defined as the time from the date of randomization to the date of documented progressive disease, recurrence or death (whichever occurs first)', 'timeFrame': '3 months'}]","[{'measure': 'Overall survival', 'description': '• Overall survival defined as the time from the date of randomization to the date of death', 'timeFrame': '3 months'}, {'measure': 'Best target lesion response', 'description': 'Best target lesion response, defined as best change in sum of the target lesions from baseline to disease progression.', 'timeFrame': '6 months'}, {'measure': 'Duartion of Response', 'description': 'Duration of response Safety and tolerability', 'timeFrame': '3 months'}, {'measure': 'Quality of life', 'description': 'Changes Quality of Life parameters as measured using EORTC QLQ-30 \\& EORTC-QLQ-EN-24', 'timeFrame': '3 cycle'}]",5.0,18 Years,,FEMALE,False,OTHER,0.0,108.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01607671,Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%,Timolol maleate,"['Timoptic.', 'Timolol.', 'Timolol maleate.', 'Timolol maleate']",4,INTERVENTIONAL,['PHASE1'],PHASE1,WITHDRAWN,"Optic Neuropathy, Ischemic",Fraser Health,2025-09-01T16:18:08.348175,True,,,,,Can Urgent Reduction of Intraocular Pressure With Ophthalmic Timolol Improve Recovery From Non-arteritic Anterior Ischemic Optic Neuropathy (NAION): a Randomized Study.,,"['Optic Neuropathy, Ischemic', 'Anterior Ischemic Optic Neuropathy', 'Ischemic Optic Neuropathy', 'Optic Neuropathy, Anterior Ischemic']","['Ischemic', 'Optic Neuropathy', 'Non-Arteritic Anterior Ischemic Optic Neuropathy', 'NAION', 'Ischemic Optic Neuropathy', 'Intraocular Pressure']",Unable to recruit participants from recruiting sites.,2012-06,2013-11,"[{'measure': 'Recruitment Rate of patients during the one year study to assess feasibility of a larger study', 'description': 'This is to define the feasabilty of the study design for a larger study.', 'timeFrame': '12 months'}, {'measure': 'Number of patients with adverse events', 'timeFrame': '12 months'}]","[{'measure': 'Change in visual acuity at enrollment and three month follow up using a logMAR scale.', 'description': 'This will evaluate the change in visual acuity as a measure of visual function.', 'timeFrame': 'Enrolment, Within 48 hours of enrollment , 1 month, 3 months.'}, {'measure': 'Change in the mean deviation of actual versus predicted sensitivity of the visual field.', 'description': 'Using a a Haag-Streit Octopus 900 with white on white TOP 30-2 visual field program, the mean deviation will be compared at various time points to assess for improving visual function as it relates to the field of vision.', 'timeFrame': '48 hours after enrollment, 1 month, 3 months'}, {'measure': 'Change in Colour vision as measured by HRR colour plates.', 'description': 'The total number of colour plates seen will be counted and compared to baseline as a measure of visual recovery as it effects colour vision.', 'timeFrame': 'Within 48 hours of enrollment, 1 month, 3 months'}, {'measure': 'Change in contrast sensitivity will be measured using the Pelli-Robson contrast sensitivity chart.', 'description': 'The Pelli-Robson contrast sensitivity chart is another method to assess visual function. The change in total number of plates seen will be compared at the various time points.', 'timeFrame': '48 hours from enrollment, 1 month, 3 months.'}]",6.0,41 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Unable to recruit participants from recruiting sites.
NCT04379271,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",IMU-838,"['vidofludimus calcium', 'IMU-838']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,COVID-19,Immunic AG,2025-09-01T16:18:08.348184,True,,,,,"A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19",,['COVID-19'],[],,2020-06-11,2021-02-23,"[{'measure': 'Proportion of Patients Without Any Need for INV Until EoS', 'description': 'Number of Participants Stratified as those With and Without the Need for INV Until End-of-study (EoS). For this outcome a worst case approach was used in which patients who were lost to follow-up or who discontinued the trial on or before Day 13 due to any other reason than death and discontinued with a last observed WHO clinical status no lower than that at Screening, and patients who died were considered as patients requiring INV.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}]","[{'measure': 'Days in ICU Department', 'description': 'Duration of ICU Treatment Until EoS for Only Patients Who Were Admitted to the ICU During the Trial.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'All Cause Mortality (ITT Approach)', 'description': ""28-day All-cause Mortality (including lost to follow-up): 'all-cause-mortality' includes all confirmed deaths and patients who discontinued the trial before Day 28 and for whom no outcome (alive or dead) could be determined at EoS; 'actual death' includes only those patients for which a fatal outcome was confirmed by Day 28."", 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Time to Clinical Improvement', 'description': 'Defined as the time from first dose of investigational medicinal product (IMP) to an improvement of at least 2 points on the Modified WHO Ordinal Scale for Clinical Status (Modified WHO Ordinal Scale for Clinical Status), or live discharge from hospital without oxygen supplementation, whichever comes first. The 50% Kaplan-Meier quartile (median) of actual values per treatment arm is provided as outcome of this variable below.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days of Hospitalization', 'description': 'Duration of hospitalization (for US sites only: or treatment in special outpatient setting in lieu of hospitalization due to resource restraints)cacy:', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Patients Free of Renal-replacement Therapy (RRT)* Until EoS', 'description': 'Number of Patients Both for All Patients and Surviving Patients Free of Renal-replacement Therapy (RRT)\\* Until EoS', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Patients Required ECMO Until EoS', 'description': 'Number and Percentage of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)\\* until EoS.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Patients Free of INV Until Day 14*', 'description': 'Number and persentage of patients free of INV until Day 14\\*', 'timeFrame': 'Throughout the Study (Day 0 to Day 14 )'}, {'measure': 'Patients Free of RRT', 'description': 'Percentage of patients free of RRT until Day 14\\*', 'timeFrame': 'Day 0 to Day 14'}, {'measure': 'Number of Patients Free of ECMO', 'description': 'Number of patients free of ECMO until Day 14.', 'timeFrame': 'Day 0 to Day 14'}, {'measure': 'Patients With Improvement of at Least 2 Points (From Randomization) on the 9-category WHO Ordinal scale1', 'description': 'Numbers of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1( Modified WHO Ordinal Scale for Clinical Status)on Days 6, 14, and 28, where score 0 means no clinical or virological evidence of infection and score 8 is the worth outcome ( mens death).', 'timeFrame': 'on Days 6, 14, and 28'}, {'measure': 'Patients With Auxiliary Oxygen Therapy (Including All Types of Oxygen Therapy)', 'description': 'Percentage of Patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28.', 'timeFrame': 'on Days 6, 14, and 28'}, {'measure': 'Patients With Clinical Recovery', 'description': 'Percentage of Patients With Clinical Recovery: Axillary Temp \\<= 36.6 °C, or Oral Temp \\<= 37.2 °C, or Rectal or Tympanic Temp \\<= 37.8 °C and Respiratory Frequency \\<= 24 Times/Min Without O2 Inhalation and O2 Saturation \\>= 98% Without O2 Inhalation', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Patients With Clinical Recovery', 'description': 'Percentage of Patients With Clinical Recovery Oxygen Saturation ≥98% Without Oxygen Inhalation', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Patients With Clinical Improvement or Live Discharge From Hospital Without Oxygen Supplementation', 'description': 'Percentage of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first (Modified WHO Ordinal Scale for Clinical Status, where score 0 - for patient with no clinical or virological evidence of infections, score 9 - the worth scenario- death)', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Percentage of Participants With WHO Status<=2', 'description': 'Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28', 'timeFrame': 'on Days 6, 14, and 28'}, {'measure': 'Duration of INV', 'description': 'Duration of INV throughout the study. If no entry on the respective CRF page exists, the duration is set to 0 days for patients who performed Day 28 visit. Patients without Day 28 visit and without any entry on the respective CRF page are excluded from analysis.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28 )'}, {'measure': 'Days on ECMO', 'description': 'Duration of ECMO in days (duration set to 0 for those who did not require ECMO). No participants required ECMO.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days on RRT', 'description': 'Duration of RRT in days (duration set to 0 for those who did not require RRT).No participants required RRT.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days of Auxiliary Oxygen Therapy', 'description': 'Duration of auxiliary oxygen therapy (including all types of oxygen therapy)', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days of Hospitalization', 'description': 'Duration of hospitalization for survivors', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Participants With ICU Admission', 'description': 'Percentage of Participants with ICU Admission at different time point', 'timeFrame': 'on Days 6, 14, and 28'}, {'measure': 'Probability of Death', 'description': 'Probability of death derived from Kaplan Meier analyses', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days to INV', 'description': 'Time to first prescription of invasive ventilation (INV). The time to first prescription of INV, only patients with actual INV or prescription for INV are considered.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days to RRT', 'description': 'Time to first prescription of RRT', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days to ECMO', 'description': 'Time to first prescription of ECMO', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Days to INV, RRT and ECMO', 'description': 'Time to first prescription of INV, RRT, and ECMO. The time to first prescription of INV, only patients with actual INV or prescription for INV are considered.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Probability of ICU Admission', 'description': 'Overall probability of ICU admission derived from Kaplan Meier analyses.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Cumulative Dose', 'description': 'Cumulative Dose of Vasoactive Therapies and Days With Vasoactive Therapies (Daily Until Day 14)', 'timeFrame': 'Day 0 to day 14'}, {'measure': 'Time to Clinical Recovery', 'description': 'Time of first assessments of parameters contributing to clinical recovery', 'timeFrame': 'Throughout the Study (Day 0 to EoS [Day 27 up to Day 42])'}, {'measure': 'Plasma Levels of IMU-838', 'description': 'Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28', 'timeFrame': 'on Days 0, 1, 2, 3, 6, 14, and 28'}, {'measure': 'Correlation of Trough Levels (Quartiles) to Selected Clinical Outcomes', 'description': 'Kaplan-Meier analyses were used to investigate a potential relationship between trough plasma levels of IMU-838 and time to clinical improvement and time to clinical recovery. Estimates of the clinical outcomes were evaluated separately for patients within each of the four quartiles of IMU-838 trough levels at Day 14.', 'timeFrame': 'Trough levels at Day 14; Clinical outcome: Day 0 to EoS (EoS = Day 27 up to Day 42)'}, {'measure': 'Number of Participants With Adverse Events (AEs) and Serious AEs', 'description': 'Adverse events (AEs) and serious AEs. AEs-Hypertriglyceridemia,Increased glycosylated hemoglobin, Headache, Thrombocytosis, Hyperglycemia, AEs reported in ≥ 2.0% of patients in any treatment group included anemia, bradycardia, sinus bradycardia, tachycardia, pyrexia, hepatocellular injury, hematuria, hypertension and hypertensive crisis. SAEs- deep vein thrombosis,COVID-19 pneumonia, patient death.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Vital Signs: Height', 'description': 'Safety Height in centimeters will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.', 'timeFrame': 'at Baseline'}, {'measure': 'Vital Signs: Weight', 'description': 'Safety Weight in kilograms will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.', 'timeFrame': 'at Baseline'}, {'measure': 'Vital Signs: Body Temperature (ºC)', 'description': 'Safety Body temperature can be measured axillary, oral, rectal or tympanic, but should be always measured by the same method for a patient. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.', 'timeFrame': 'at Baseline'}, {'measure': 'Albumin Concentration at Various Time Points', 'description': 'Clinical laboratory parameters: blood chemistry (Albumin concentration at various time points)', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Hematocrit Ratio at Various Time Points', 'description': 'Clinical laboratory parameters: hematology- Hematocrit ratio at various time points', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Urine Creatinine at Various Time Points', 'description': 'Clinical laboratory parameters: urinalysis- Urine creatinine at various time points', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Temperature', 'description': 'Temperature data at different time point.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'D-dimer', 'description': 'Disease markers', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Lactate Dehydrogenase (LDH)', 'description': 'Blood levels of disease markers', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'C-reactive Protein', 'description': 'Blood levels of disease markers', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Troponin I', 'description': 'Bood levels of disease markers', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Procalcitonin', 'description': 'Blood levels of disease markers', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Correlation of Time to Clinical Improvement With Quartiles of D-Dimer Blood Levels at Day 6', 'description': 'Kaplan-Meier analyses were used to investigate a potential relationship between blood levels of D-Dimer and time to clinical improvement. Estimates of the clinical outcome were evaluated separately for patients within each of the four quartiles of D-Dimer levels at Day 6.', 'timeFrame': 'D-Dimer levels at Day 6; Clinical outcome: Day 0 to EoS (EoS = Day 27 up to Day 42)'}, {'measure': 'Changing in Log 10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples at Various Time Points', 'description': 'Virologic markers: Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) Mean Viral Load - log10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples: changing of SARS-CoV-2 Viral Load in patients on Days 6,14,28', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Mean Viral Load - log10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples', 'description': 'Virologic markers :Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples:\n\nTime course of SARS-CoV-2 viral load', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Number of Participants With 2 Consecutive Negative SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction Tests at Least 24 Hours Apart', 'description': 'Virologic markers: Qualitative Virologic Clearance in Spontaneous Sputum and Nasopharyngeal Swab Samples (= 2 Consecutive Negative SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction Tests at Least 24 Hours Apart)', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Rate of Conversion to a Negative SARS-CoV-2 (Qualitative) Test', 'description': 'Virologic markers: conversion to a negative SARS-CoV-2 (qualitative) test on Day 28.', 'timeFrame': 'on Day 28'}, {'measure': 'Time to Conversion to a Negative SARS-CoV-2 (Qualitative) Test', 'description': 'Virologic markers : Time to Conversion to a Negative SARS-CoV-2 (Qualitative) Test Throughout the study. Only patients with viral load measured from nasopharyngeal swab and results provided by the central laboratory (Covance) were included.Conversion to a negative SARS-CoV-2 status is only assumed if a negative test is confirmed by all available subsequent assessments. This means for Day 28/early termination visit no confirmation is needed.\n\nIf no conversion to a negative status is documented, patients will be censored for survival analysis at the time of the last documented positive test result.', 'timeFrame': 'Throughout the Study (Day 0 to Day 28)'}, {'measure': 'Interleukin (IL)-17', 'description': 'The profiles of immune system biomarkers', 'timeFrame': 'Day 0, 6, 14 and Day 28'}, {'measure': 'Interleukin (IL)-1ß', 'description': 'The profiles of immune system biomarkers', 'timeFrame': 'Day 0, 6, 14 and Day 28'}, {'measure': 'Interleukin (IL)-6', 'description': 'The profiles of immune system biomarkers', 'timeFrame': 'Day 0, 6, 14 and 28'}, {'measure': 'Interferon Gamma (IFNγ)', 'description': 'The profiles of immune system biomarkers', 'timeFrame': 'Day 0, 6, 14 and 28'}, {'measure': 'Tumor Necrosis Factor Alpha', 'description': 'The profiles of immune system biomarkers', 'timeFrame': 'Day 0, 6, 14 and 28'}, {'measure': 'Immunoglobulin (Ig)A and/or IgG Antibodies Against SARS-CoV-2', 'description': 'Proportion of patients with IgA and/or IgG antibodies against SARS-CoV-2on at different time point', 'timeFrame': 'Day 6, 14 and 28'}]",57.0,18 Years,,ALL,False,INDUSTRY,1.0,234.0,ACTUAL,v2_robust,True,True,False,True,
NCT00130871,Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass,levosimendan,['levosimendan'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Coronary Heart Disease,"Orion Corporation, Orion Pharma",2025-09-01T16:18:08.348328,True,,,,,Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG),,['Coronary Heart Disease'],"['levosimendan', 'weaning', 'cardio-pulmonary bypass']",,2004-01,2006-01,[{'measure': 'Proportion of successful primary weanings'}],[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,,v2_robust,True,True,False,False,
NCT06201871,Effect of Alcohol Consumption on the Success Rates,Lidocaine Hydrochloride,['Lidocaine Hydrochloride'],1,INTERVENTIONAL,['NA'],,RECRUITING,Pulpitis - Irreversible,Jamia Millia Islamia,2025-09-01T16:18:08.348417,True,,,,,Effect of Alcohol Consumption on the Success Rates of Local Anesthesia in Patients With Symptomatic Irreversible Pulpitis,,['Pulpitis - Irreversible'],[],,2024-01-02,2024-03-02,"[{'measure': 'Anesthetic success', 'description': 'The injection shall be considered as successful if the patient reports pain scores less than 55 on the visual analouge scale. The scale is 170mm long, with 0 marked as no pain and 170 marked as the maximum pain.', 'timeFrame': '15 minutes following the injection'}]",[],1.0,18 Years,50 Years,ALL,True,OTHER,0.0,70.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04692844,Pathophysiology of Tremor-modulating Mechanisms of Propranolol and Primidone in Essential Tremor,Propranolol,"['Propranolol', 'Primidone']",2,OBSERVATIONAL,[],,COMPLETED,Essential Tremor,University Medical Centre Ljubljana,2025-09-01T16:18:08.348435,True,,,,,The Mechanism of Tremor Modulating Properties of Propranolol and Primidone in Essential Tremor: A Study With Transcranial Magnetic Stimulation and Eye Blink Classical Conditioning Paradigm,,['Essential Tremor'],"['Essential tremor', 'Primidone', 'Propranolol']",,2017-08-28,2022-12-31,"[{'measure': 'Electrophysiological correlations of clinical effect', 'description': 'Comparison of TMS and clinical measures before and after treatment, comparison of cerebellar dysfunction with response to treatment', 'timeFrame': '3-6 months'}, {'measure': 'Effect of cerebellar function assessed by eye blink classical conditioning on drug effectiveness', 'description': 'Comparison of cerebellar function of responders and non-responders', 'timeFrame': '3-6 months'}]",[],2.0,15 Years,,ALL,True,OTHER,0.0,61.0,ACTUAL,v2_robust,False,True,False,False,
NCT01815944,Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose,0.75% Ropivacaine,"['Dextrose 5%', 'Naropin', '0.75% Ropivacaine', 'Normal saline']",4,INTERVENTIONAL,['NA'],,COMPLETED,Comparison of Onset Time,University of Malaya,2025-09-01T16:18:08.348458,True,,,,,Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose,,['Comparison of Onset Time'],"['onset time', 'ultrasound-guided supraclavicular block', 'ropivacaine', 'normal saline', 'dextrose 5%']",,2011-12,2012-10,"[{'measure': 'Onset time for sensory blockade', 'timeFrame': '60 minutes'}]","[{'measure': 'Duration of sensory blockade', 'timeFrame': '12 hours'}]",2.0,18 Years,85 Years,ALL,False,OTHER,0.0,55.0,ACTUAL,v2_robust,True,True,False,False,
NCT04270344,The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment,Pitavastatin 4mg,"['Pitavastatin 4mg', 'valsartan']",2,OBSERVATIONAL,[],,UNKNOWN,Hypercholesterolemia,JW Pharmaceutical,2025-09-01T16:18:08.348466,True,,,,,"A 12-month Open-label, Multicenter Observation Study on the Occurrence of Major Adverse Cardiac Events (MACE) in Patients With Acute Myocardial Infarction (AMI) Receiving Pitavastatin/Valsartan Treatment",,['Hypercholesterolemia'],[],,2018-07-01,2022-06-30,"[{'measure': 'all-cause mortality, non-fatal MI, repeat re-vascularization', 'description': 'MACE', 'timeFrame': '12 months'}]","[{'measure': 'The rate of mortality', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of cardiac death', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of nonfatal MI', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of hospitalization due to heart failure', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of Coronary artery bypass graft(CABG)', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of target lesion re-vascularization', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of target vessel re-vascularization', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of cerebrovascular disease', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The change of SBP, DBP', 'description': 'Hypertensive parameters', 'timeFrame': '6 and 12 months'}, {'measure': 'The change of TC, TG, HDL-C, LDL-C, hsCRP', 'description': 'Lipid parameters', 'timeFrame': '6 and 12 months'}, {'measure': 'The change of HbA1c, FBS', 'description': 'No Onset of Diabetes', 'timeFrame': '6 and 12 months'}]",12.0,19 Years,,ALL,True,INDUSTRY,0.0,905.0,ESTIMATED,v2_robust,False,False,False,False,
NCT05032144,The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects,STSA-1002 injection,"['STSA-1002 injection', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",2025-09-01T16:18:08.348489,True,,,,,"A Randomized,Double-blind,Placebo-controlled,Single-ascending Dose Phase Ⅰa Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of STSA-1002 Following Intravenous Infusion in Healthy Subjects",,['Healthy'],[],,2021-09-28,2022-03-31,"[{'measure': 'Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities,Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination Abnormalities', 'timeFrame': 'Day 1 through Day 51'}, {'measure': 'Maximum plasma concentration(Cmax)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to the collection time point of the last measurable concentration(AUC 0-t)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Time of maximum concentration(Tmax)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Elimination half-life(t1/2)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Elimination rate constant of plasma drug concentration in terminal phase(λz)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Last measurable concentration(Clast)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Mean residence time(MRT)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Clearance(CL)', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Apparent volume of distribution(Vz)', 'timeFrame': 'Up to 1200 hours postdose'}]","[{'measure': 'Change from baseline in concentration of free C5a and anti-drug antibody', 'description': 'To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 in healthy subjects', 'timeFrame': 'Up to 1200 hours postdose'}, {'measure': 'Change from baseline in concentration of CH50,IL-6,IL-8,TNF-α,IFN-γ', 'description': 'To evaluate the effect of STSA-1002 on CH50, IL-6, IL-8, TNF-α, IFN-γ', 'timeFrame': 'Up to 1200 hours postdose'}]",13.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,40.0,ACTUAL,v2_robust,True,True,False,True,
NCT06199544,Effect of Unani Medicine for the Management of Anomalies Associated With Polycystic Ovarian Syndrome,Metformin,"['Rasoline', 'Picolin', 'Metformin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Comparative Study,Hamdard University,2025-09-01T16:18:08.348539,True,,,,,Effect of Unani Medicine Coded Formulations for the Management of Anomalies Associated With Polycystic Ovarian Syndrome,,['Comparative Study'],[],,2022-10-01,2024-12-01,"[{'measure': 'Improvement in the menstrual regularity of the patient', 'description': 'The lengths and duration of menstrual cycle of patients will be measured', 'timeFrame': '1 year'}]",[],1.0,18 Years,38 Years,FEMALE,False,OTHER,0.0,150.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03442244,Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects,LEO 90100 foam,"['LEO 90100 foam', 'Vehicle of LEO 90100 foam']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Psoriasis Vulgaris,LEO Pharma,2025-09-01T16:18:08.348672,True,,,,,Skin Irritation Trial of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects,,['Psoriasis Vulgaris'],[],,2018-01-30,2018-02-20,"[{'measure': 'Skin irritation', 'description': 'Skin irritation measured as skin irritation index (summation of clinical scores \\[ranging from no reaction to blisters\\] from 49 hrs to 72 hrs after aplication) divided by total number of skin irritation assessments', 'timeFrame': 'Up to Day 4'}, {'measure': 'Photo irritation', 'description': 'Positive ratios calculated from the photo irritation scores', 'timeFrame': 'Up to Day 4'}]",[],2.0,20 Years,40 Years,MALE,True,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT04544644,A Study of Combination Therapy in NSCLC,AK104+anlotinib,['AK104+anlotinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Non-small Cell Lung Cancer,Chinese PLA General Hospital,2025-09-01T16:18:08.348763,True,,,,,A Phase II Study of AK104 (Binding Kenetics to PD-1 and CTLA-4) in Combination With Anlotinib in Patients With Advanced NSCLC,,['Non-small Cell Lung Cancer'],[],,2020-09,2023-09,"[{'measure': 'ORR', 'description': 'objective response rate per RECIST1.1', 'timeFrame': 'through study completion, an average of 1 year'}]","[{'measure': 'PFS and OS', 'description': 'progression-free survival and overall survival', 'timeFrame': 'through study completion, an average of 2 years'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01952444,"Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers",Ciprofloxacin,['Ciprofloxacin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Inhalational Anthrax,Elusys Therapeutics,2025-09-01T16:18:08.348908,True,,,,,"An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers",,['Inhalational Anthrax'],"['monoclonal antibody, ETI-204, ciprofloxacin, safety, PK']",,2013-10-29,2014-04-09,"[{'measure': 'Number of Participants Who Experienced Adverse Events', 'description': 'Safety was assessed for all subjects in the Safety Population by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical assessments, skin assessments, infusion site assessments, and adverse events (AEs).', 'timeFrame': 'Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.'}]","[{'measure': 'Maximum Observed Plasma Concentration of ETI-204 (Cmax)', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Time to Maximum Observed Plasma Concentration of ETI-204 (Tmax)', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last))', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Terminal Half-life (t1/2)', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Systemic Clearance (CL)', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Volume of Distribution (Vd)', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Volume of Distribution at Steady State (Vss)', 'description': 'Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.', 'timeFrame': 'On Day 1 at predose, at the end of ETI-204 infusion, 2.5, 4.5 and 7.5 hours after the start of the ETI-204 infusion, and on Days 2 (24 hours), 9, 16, 29, 43, and 71.'}, {'measure': 'Number of Participants With Anti-ETI-204 Antibodies', 'description': 'Serum anti-ETI-204 antibody titers were determined for all subjects in the Safety Population. Blood samples were collected and serum samples were assayed at an initial dilution of 1:10. Samples that were positive at the 1:10 dilution were serially diluted 1:2 and assayed until a negative result was attained. The titer of the most dilute sample yielding a positive result was recorded as the titer for that time point. Immunogenicity was measured by the number of participants in each study arm with anti-ETI-204 antibody values post-treatment ≥ 4-times higher than baseline at Day 8, 43 or 71, or if the titer was negative at baseline, the post-treatment sample(s) required a titer of at least 1:20 for it to be considered positive.', 'timeFrame': 'On Day 1 at predose and on Days 9, 29, 43, and 71.'}]",10.0,18 Years,60 Years,ALL,True,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,True,
NCT01859234,89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma,89Zr-bevacizumab,"['Bevacizumab Roche registration limited eu/1/04/300/001', '89Zr-bevacizumab ATC code L01XC07', '89Zr-bevacizumab']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Multiple Myeloma,University Medical Center Groningen,2025-09-01T16:18:08.349007,True,,,,,Evaluation of VEGF Expression With 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma; a Feasibility Study,,['Multiple Myeloma'],"['multiple myeloma', 'PET scan']",,2013-05,,"[{'measure': 'Focal lesion of 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma', 'description': 'We assume focal lesion will be feasible with 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma. For each 89Zr-bevacizumab PET scan the amount of focal lesion and the localisation will be reported. When there is diffuse bone marrow uptake this will also be reported. The focal lesion found on the 89Zr-bevacizumab PET scan will be compared with focal lesions found on the FDG-PET scan. Furthermore the amount of focal lesion will be compared with the expression of VEGF, MVD, HIF 1 alpha and 2 alpha and GLUT 1 and 3.', 'timeFrame': 'during scanning'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01297634,Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle,Botulinum Toxin Type-A (day 0),['Botulinum Toxin Type-A (day 0)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Wrinkles,Ivo Pitanguy Institute,2025-09-01T16:18:08.349053,True,,,,,Phase IV Study of Radial Diffusion of the Botulinum Toxin Type A: Electromyographic Evaluation of the Frontal Muscle.,,['Wrinkles'],"['Botulinum toxin type A', 'Hyperfunctional forehead lines', 'Randomized controlled trial', 'Double-blinded trial', 'Electromyogram (EMG)', 'Electromyographic activity', 'Frontal Area']",,2011-05,2011-11,"[{'measure': 'Treatment Area', 'description': 'Radial area (cephalic, lateral, medial and caudal points) of physioelectric activity of the frontal muscle, measured with electromyography (EMG).\n\nClinical and Photographical register evaluation of the dynamical wrinkles in the treatment area.', 'timeFrame': 'Change from baseline at day 30'}]","[{'measure': 'Complete Treatment Phase', 'description': 'Quantity of Botulinum Toxin used in every subject to aim to complete the treatment to the rest of the frontal area, based on the results of the primary outcomes.', 'timeFrame': 'Day 30'}]",2.0,30 Years,60 Years,FEMALE,True,OTHER,1.0,64.0,ACTUAL,v2_robust,True,True,False,False,
NCT06184334,Management of OAB in Female Patients .,Solfenacin,"['Tadalafil 5mg', 'Mirabegron', 'Solfenacin']",3,INTERVENTIONAL,['NA'],,COMPLETED,Overactive Bladder,Elsayed Abdelhalim Elsayed,2025-09-01T16:18:08.349112,True,,,,,"Assessment of Efficacy of Mirabegron, Solifenacin, Tadalafil 5mg and Combination Therapy in Female Patients With Overactive Bladder: A Double Blinded Prospective Randomized Placebo -Controlled Trial",,['Overactive Bladder'],[],,2022-09-14,2023-12-01,"[{'measure': 'overactive bladder symptoms score (OABSS)', 'description': 'OABSS is a symptom assessment questionnaire designed to quantify OAB symptoms into a single score The questionnaire consists of 4 questions on OAB symptoms with maximum scores ranging from 2 to 5: daytime frequency (2 points), night-time frequency (3 points), urgency (5 points), and UUI (5 points). The total score ranges from 0 to 15 points, with higher scores indicating higher symptom severity.', 'timeFrame': 'three months'}]",[],1.0,18 Years,65 Years,FEMALE,True,OTHER,0.0,300.0,ACTUAL,v2_robust,True,True,False,False,
NCT00255034,"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)",Ribavirin,"['SCH 18908 Rebetol', 'Ribavirin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,"Hepatitis C, Chronic",Merck Sharp & Dohme LLC,2025-09-01T16:18:08.349215,True,,,,,Phase IV Study of Tailored Therapy With Peg Interferon Alfa 2b and Ribavirin for Patients With Genotype 3 and High Viral Load. Genotype 3 Extended Treatment for HCV (GET-C Study),,"['Hepatitis C, Chronic']","['chronic hepatitis C', 'pegylated interferon alfa-2b', 'ribavirin', 'Australia']",Recruitment targets were unachievable in the currently available population.,2005-02,2008-06,"[{'measure': 'Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy', 'description': 'No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfill the recruitment target.', 'timeFrame': '24 weeks after completion of either up to 24 or 48 weeks of therapy'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,146.0,ACTUAL,v2_robust,True,False,True,False,Recruitment targets were unachievable in the currently available population.
NCT03082534,Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,"Pembrolizumab, Cetuximab","['Pembrolizumab, Cetuximab', 'Keytruda®, Erbitux®']",2,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,HNSCC,"University of California, San Diego",2025-09-01T16:18:08.349241,True,,,,,"An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",,"['HNSCC', 'Lip SCC', 'Oral Cavity Cancer', 'Oropharynx Cancer', 'Larynx Cancer', 'Hypopharynx Cancer', 'Nasopharynx Cancer', 'Sinonasal Carcinoma', 'Cutaneous Squamous Cell Carcinoma', 'Head and Neck Neoplasms', 'Head and Neck Cancer', 'Head and Neck Squamous Cell Carcinoma']","['Head and Neck Cancer', 'Pembrolizumab', 'Keytruda®', 'Cetuximab', 'Erbitux®', 'Recurrent', 'Metastatic', 'PD-1', 'PD-L1', 'non-EBV related Nasopharynx']",,2017-03-28,2026-05,"[{'measure': 'Overall Response Rate', 'description': 'Proportion of patients with partial or complete response in tumor burden as defined by RECIST', 'timeFrame': '6 months from the time of study enrollment'}]","[{'measure': 'Progression Free Survival Probability', 'description': 'Probability of no disease progression or death from any cause at 12 months from the time of study enrollment', 'timeFrame': '12 months from the time of study enrollment'}, {'measure': 'Overall Survival', 'description': 'Time from study enrollment to death from any cause', 'timeFrame': 'From the time of study enrollment until the date of death from any cause or completion of study, whichever came first, assessed up to 36 months'}, {'measure': 'Duration of Response', 'description': 'Time from documentation of tumor response to disease progression', 'timeFrame': 'Every 9 weeks from first on-treatment scan until disease progression or patient withdrawal from study or date of death from any cause, whichever came first, assessed up to 36 months'}, {'measure': 'Number of patients with grade 3 through grade 5 adverse events that are related to pembrolizumab and cetuximab, graded according to NCI CTCAE v4.03', 'description': 'Description, grade (per CTCAE v4.03), seriousness and relatedness', 'timeFrame': 'Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months'}, {'measure': 'Correlative analyses', 'description': 'Tumor tissue biomarkers correlated with outcome to pembrolizumab or cetuximab, such as PD-L1 expression, EGFR expression, p16 status, and immunophenotyping', 'timeFrame': 'Tumor specimens (archival or new specimen) should be obtained within 42 days of screening'}, {'measure': 'Correlative analyses', 'description': 'Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including T cell receptor (TCR) sequencing', 'timeFrame': 'Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months'}, {'measure': 'Correlative analyses', 'description': 'Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including Epstein-Barr virus plasma DNA titers', 'timeFrame': 'Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months'}, {'measure': 'Correlative analyses', 'description': 'Whole exome sequencing for neoantigen discovery', 'timeFrame': 'Newly obtained tumor specimen within 42 days of screening (when feasible)'}]",9.0,18 Years,,ALL,False,OTHER,1.0,78.0,ACTUAL,v2_robust,True,False,False,True,
NCT00867334,New Individualized Therapy Trial for Metastatic Colorectal Cancer,Imatinib mesylate and panitumumab,"['Vectibix', 'ABX-EGF monoclonal antibody', 'Imatinib mesylate and panitumumab', 'Gleevec', 'Standard-of-care treatment with panitumumab', 'ST1571']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Colorectal Neoplasm,Inova Health Care Services,2025-09-01T16:18:08.349262,True,,,,,A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay,,"['Colorectal Neoplasm', 'Colorectal Cancer']","['colorectal neoplasm', 'colorectal cancer', 'imatinib mesylate', 'Gleevec', 'Physiological Effects of Drugs', 'panitumumab', 'Vectibix', 'c-kit receptor', 'Receptor', 'Platelet-Derived Growth Factor alpha']",,2009-06,2011-08,"[{'measure': 'Number of Patients With Adverse Events', 'description': 'Information about all adverse events, whether volunteered by the subject, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected and recorded.', 'timeFrame': 'From consent up until 4 weeks after patient has stopped study participation'}]","[{'measure': 'Number of Participants With Stabilization or Reduction in Tumor Size', 'description': 'Results reported as number of patients with stabilization or reduction in tumor size. Tumor response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) solid tumor response criteria, evaluated by CT.', 'timeFrame': '8 weeks after baseline'}]",2.0,18 Years,,ALL,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,True,
NCT06222034,Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA),Filgotinib,"['GS-6034', 'Filgotinib', 'GLPG0634', 'Jyseleca']",4,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Juvenile Idiopathic Arthritis,Alfasigma S.p.A.,2025-09-01T16:18:08.349374,True,,,,,"An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis",,['Juvenile Idiopathic Arthritis'],[],,2024-05-13,2026-08,"[{'measure': 'Maximum observed plasma concentration at steady state of filgotinib (Cmax,ss)', 'timeFrame': 'Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10'}, {'measure': 'Cmax,ss of GS-829845, major active metabolite', 'timeFrame': 'Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10'}, {'measure': 'Area under the plasma concentration-time curve over the dosing interval at steady state of filgotinib (AUC0-24,ss)', 'timeFrame': 'Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10'}, {'measure': 'AUC0-24,ss of GS-829845, major active metabolite', 'timeFrame': 'Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10'}, {'measure': 'Area under the plasma concentration time curve over the dosing interval at steady state or the effective exposure of filgotinib (AUCeff,ss)', 'timeFrame': 'Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10'}, {'measure': 'AUCeff,ss of GS-829845, major active metabolite', 'timeFrame': 'Pre-dose on Day 10, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours post-dose on Day 10'}]","[{'measure': 'Number of participants with treatment-emergent adverse events (TEAEs), TEAEs of interest, serious TEAEs, and TEAEs leading to treatment discontinuation.', 'timeFrame': 'Baseline (Day 1) up to week 96'}, {'measure': 'Acceptability of the commercially developed film-coated tablets and of the minitablets as measured by the Pediatric Oral Medicine Acceptability Questionnaire for Patients (POMAQ-P).', 'timeFrame': 'Week 4 and week 12'}]",8.0,8 Years,18 Years,ALL,False,INDUSTRY,0.0,10.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00609934,Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone,Sorafenib,"['NSC 724772', 'Sorafenib', 'BAY 43-9006']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Renal Cell Carcinoma,"University Health Network, Toronto",2025-09-01T16:18:08.349485,True,,,,,A Phase I/II Study of Sorafenib and Palliative Radiotherapy in Patients With Advanced Renal Cell Carcinoma and Symptomatic Bony Metastases,,['Renal Cell Carcinoma'],"['renal cell carcinoma', 'kidney cancer', 'bone metastases', 'RCC', 'bone pain', 'palliative radiotherapy', 'sorafenib', 'radiation', 'renal cell']",,2007-12,2014-10,"[{'measure': 'Reduction in pain from index lesion 4 weeks following the completion of radiotherapy, assessed using Brief Pain Inventory.', 'timeFrame': '7 weeks'}]","[{'measure': 'reduction in pain in index lesion at study termination assessed using Brief Pain Inventory', 'timeFrame': '12 weeks'}, {'measure': 'acute toxicity of palliative radiotherapy and sorafenib together', 'timeFrame': '12 weeks'}, {'measure': 'acute toxicity of sorafenib alone', 'timeFrame': '1 week'}, {'measure': 'biologic response of the index lesion to radiotherapy and sorafenib assessed using FDG-PET-CT', 'timeFrame': '7 weeks'}, {'measure': 'disease-free survival', 'timeFrame': 'greater than 3 months'}]",6.0,18 Years,,ALL,False,OTHER,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,
NCT00884234,Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines,RT001 (Botulinum Toxin Type A Topical Gel),['RT001 (Botulinum Toxin Type A Topical Gel)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Lateral Canthal Lines,"Revance Therapeutics, Inc.",2025-09-01T16:18:08.349498,True,,,,,"A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Repeat Dose, Single Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines In Adults",,['Lateral Canthal Lines'],"['Lateral Canthal Lines', ""Crow's Feet"", 'Facial Wrinkles', 'Lateral Canthal Area']",,2009-02,2009-06,"[{'measure': 'The number of subjects classified as exhibiting improvement via the Investigator Global Assessment from Baseline (Day 0) to End of Study (Week 6).', 'timeFrame': 'Baseline (Day 0) and Week 6'}, {'measure': 'Incidence of treatment emergent AEs.', 'timeFrame': 'Baseline (Day 0) and Week 6'}]",[],2.0,30 Years,55 Years,ALL,True,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT01120964,Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol,Intravenous L-Citrulline,"['Intravenous L-Citrulline', 'Placebo of Intravenous L-Citrulline']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Atrial Septal Defect,"Asklepion Pharmaceuticals, LLC",2025-09-01T16:18:08.349517,True,,,,,"Phase IB Double Blind, Randomized, Placebo Controlled Clinical Trial to Determine the Pharmacokinetics and Safety of a Revised Protocol of Intravenous L-Citrulline (Citrupress®) Versus Placebo in Children Undergoing Cardiopulmonary Bypass",,"['Atrial Septal Defect', 'Ventricular Septal Defect', 'Atrioventricular Septal Defect']",[],,2010-09,2012-04,"[{'measure': 'L-citrulline Plasma Levels', 'description': 'Citrulline Blood Levels: 1. Baseline sample in OR prior to Cardiopulmonary Bypass prior to administration of first bolus of Citrulline or Placebo 2. Immediately after Bolus 1 administered in Operating Room. 3. 30 minutes after separation from Cardiopulmonary Bypass; immediately prior to administration of Bolus 2 and start of continuous infusion of Citrulline or Placebo. 4. Six hours after after start of infusion. 5. 12 hours after start of infusion. 6. 24 hours after start of infusion. 7. 48 hours after start of infusion; or whenever infusion is discontinued if prior to 48 hours.', 'timeFrame': 'Measured in seven blood sample time points from the beginning of surgery until end of IV Citrulline Infusion; at either 48 hours postoperatively or at extubation, whichever comes first.'}]","[{'measure': 'Postoperative Invasive Mechanical Ventilation (Mean and SD)', 'description': 'Duration of postoperative invasive mechanical ventilation was derived as the time in hours from separation from cardiopulmonary bypass until endotracheal extubation. If a patient required reintubation within 24 hours after extubation, the reintubation time was added in the main analysis. In a second analysis, the reintubation time was not included.', 'timeFrame': 'Measured in hours from the end of surgery until extubation, or Day 30, whichever occurs first'}, {'measure': 'Postoperative Invasive Mechanical Ventilation (Median and Range)', 'description': 'Duration of postoperative invasive mechanical ventilation was derived as the time in hours from separation from cardiopulmonary bypass until endotracheal extubation. If a patient required reintubation within 24 hours after extubation, the reintubation time was added in the main analysis. In a second analysis, the reintubation time was not included.', 'timeFrame': 'Measured in hours from the end of surgery until extubation or Day 30, whichever occurred first'}, {'measure': 'Total Duration of Respiratory Support', 'description': 'Analysis included any invasive and non-invasive respiratory support required during the study period', 'timeFrame': 'Baseline to discharge or Day 30, whichever occurs first'}, {'measure': 'Postoperative Intravenous Inotrope Duration', 'description': 'The length of time on IV inotropes was documented from the time of first use after surgery until completion of the study medication at Hour 48 (i.e., duration of inotrope use was maximally 48 hours). Patients still receiving inotropes at Hour 48 were censored.', 'timeFrame': 'Measured at 48 hours'}, {'measure': 'Total Inotrope Score', 'description': 'The inotrope dose was calculated each hour postoperatively from the time of PICU admission until the completion of study drug using the following scoring system:\n\nDopamine (μg/kg/min) x 1 plus Dobutamine (μg/kg/min) x 1 plus Milrinone (μg/kg/min) x10 plus Epinephrine (Adrenaline) (μg/kg/min) x 100 plus Phenylephrine (μg/kg/min) x 100 plus Norepinephrine (Noradrenaline) (μg/kg/min) x 100\n\n= Total inotrope score\n\nAn ANOVA was performed. Additionally a repeated measures analysis of variance was used to compare total inotrope score between placebo and citrulline.', 'timeFrame': 'PICU admission until Hour 48'}, {'measure': 'Time on Vasoactive Medications', 'description': 'The total number of hours on vasoactive medications, including nitroglycerin, nitroprusside and vasopressin, was calculated from the end of surgery until the discontinuation of vasoactive medications or end of study medication (Hour 48), whichever occurred first', 'timeFrame': 'Hour 0 to Hour 48'}, {'measure': 'Total Vasoactive Score', 'description': 'Vasoactive score is reflective of the pharmacological support required by the cardiovascular system and is a good predictor of mortality and morbidity in patients undergoing bypass surgery. A lower vasoactive score represents less pharmacological support and would indicate a lower risk for a poor clinical outcome. Therefore, any treatment effect would be indicated by a lower score in the citrulline group when compared to the placebo group.\n\nIn this study, the score was calculated post-operatively from the time of separation from bypass until the completion of study drug. Vasoactive score was calculated using the following formula:\n\nTotal Vasoactive Score = nitroglycerin dose + nitroprusside dose + vasopressin dose\n\nThe minimum value is zero (i.e., no vasoactive drugs administered), but it is not possible to define a maximum as this is wholly dependent upon the dose of each vasoactive drug administered.', 'timeFrame': 'Hour 0 to Hour 48'}, {'measure': 'Length of ICU Stay', 'description': 'Duration of ICU stay was analyzed once as the total number of postoperative hours spent in the ICU and once as the total number of postoperative hours that a patient required postoperative mechanical ventilator or continuous intravenous inotrope or vasodilator support. The latter combination of parameters represents another surrogate endpoint for ICU stay', 'timeFrame': 'Measured in hours from the end of surgery to discharge from ICU or Day 30, whichever occurred first'}, {'measure': 'Composite Endpoint: Cessation of Positive Pressure Ventilation and of Inotrope Therapy', 'description': 'The composite endpoint comprised the longer of the duration of positive pressure ventilatory support or of inotrope therapy. Since inotrope use was only documented until Hour 48 after surgery (end of study medication treatment), patients with inotrope use continuing until Hour 48 and with mechanical ventilation duration of ≤48 h were censored at this time point. If mechanical ventilation was continued beyond the 48-hour time point, the duration of mechanical ventilation was used in the analysis.', 'timeFrame': 'Until cessation of positive pressure ventilation and of inotrope therapy or Day 30, whichever occurred first'}, {'measure': 'Length of Hospitalization', 'timeFrame': 'Measured from the day of surgery until discharge from hospital or Day 30, whichever occurred first'}, {'measure': 'Incidence of Increased PVT (Defined as a Sustained Mean Pulmonary Artery Pressure Greater Than 20 mm Hg for at Least 2 Hours, Measured During the First 48 Hours', 'description': 'There were insufficient data to analyze ECHO measurements in summary statistics. Additionally, most images were of very low quality and the data from ECHO evaluations were insufficient to determine whether the affected patients had pulmonary hypertension.', 'timeFrame': 'Measured in hours from the end of surgery until extubation or Day 30, whichever occurred first'}, {'measure': 'Duration of Chest Tube Drainage', 'timeFrame': 'Measured in hours from the end of surgery until removal of chest tubes or Day 30, whichever occurred first'}, {'measure': 'Volume of Chest Tube Drainage', 'timeFrame': 'Measured in milliliters from the end of surgery until removal of chest tubes or Day 30, whichever occurred first'}, {'measure': 'Survival', 'description': '28-day postoperative survival and survival to discharge', 'timeFrame': 'Measured at 28 days post surgical repair'}, {'measure': 'Number of Patients With Clinically Significant Hypotension.', 'description': 'Age specific mean arterial blood pressure (MAP) limits compared between the citrulline and placebo groups will be used to determine significant hypotension.\n\nDefined as MAP below a specific age-based value (infants and age 1 year, 40; ; age 2 years, 44; age 3 years, 47; age 4 years, 50; age 5 years, 52; age 6 years, 53), that lasted greater than 30 minutes and was unresponsive to therapeutic interventions such as fluid administration (volume bolus) and increasing inotropic support.', 'timeFrame': 'Mean Arterial Blood pressure as continuously monitored postoperatively in the PCCU (Hour 0 to Hour 24) during Citrulline or Placebo infusion.'}]",16.0,,6 Years,ALL,False,INDUSTRY,0.0,22.0,ACTUAL,v2_robust,True,True,False,False,
NCT05261464,Heart Rate Controller in Computed Tomography Coronary Angiography,Metoprolol tartrate,"['Metoprolol tartrate', 'Ivabradine', 'Diltiazem']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Heart Rate,Mahidol University,2025-09-01T16:18:08.349624,True,,,,,"Heart Rate Controller in Computed Tomography Coronary Angiography: A Randomized Controlled Trial of Metoprolol, Diltiazem and Ivabradine",,"['Heart Rate', 'Coronary Computed Tomography Angiography']","['coronary computed tomography angiography (CCTA)', 'Target Heart rate']",,2021-01-30,2022-06-30,"[{'measure': 'Percent of patient achieving target heart rate (HR)', 'description': 'To compare percentage of patient in achieving adequate HR control (defined as target HR of 60 bpm) among oral Ivabradine, metoprolol and diltiazem during CCTA', 'timeFrame': '3 hours'}]","[{'measure': 'Side effects', 'description': 'To compare side effects between oral Ivabradine, metoprolol and diltiazem during CCTA', 'timeFrame': '3 hours'}, {'measure': 'Time to achieve target HR', 'description': 'To compare time to achieve target HR of less than 60 bpm', 'timeFrame': '3 hours'}, {'measure': 'Image quality', 'description': 'To compare image quality using 5 point grade scale and modified 15-segment American College of Cardiology and American Heart Association (AHA)', 'timeFrame': '1 week'}]",4.0,18 Years,,ALL,False,OTHER,0.0,246.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02259764,"Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers",KUC 7483 CL - single rising dose,"['KUC 7483 CL - single rising dose', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:08.349774,True,,,,,"Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400, 440 and 480 mg) of KUC 7483 CL Tablets in Healthy Male Volunteers. A Double-blind at Each Dose Level, Randomised, Placebo Controlled Study",,['Healthy'],[],,2004-08,,"[{'measure': 'Number of subjects with abnormal findings in physical examination', 'timeFrame': 'up to 8 days after last drug administration'}, {'measure': 'Number of subjects with abnormal changes in laboratory parameters', 'description': 'special parameters, Tropanin I, insulin, C-Peptide, glucagon, free fatty acids, lactate, potassium, cAMP and faecal occult blood testing', 'timeFrame': 'up to 8 days after last drug administration'}, {'measure': 'Number of subjects with clinically significant changes in vital signs', 'description': 'Blood Pressure, Pulse Rate, Respiratory Rate, body temperature, orthostatic testing', 'timeFrame': 'up to 8 days after last drug administration'}, {'measure': 'Number of subjects with clinically significant changes in 12-lead ECG (electrocardiogram)', 'timeFrame': 'up to 8 days after last drug administration'}, {'measure': 'Number of subjects with adverse events', 'timeFrame': 'up to 8 days after last drug administration'}, {'measure': 'Assessment of tolerability by investigator on a 4-point scale', 'timeFrame': '8 days after last drug administration'}]","[{'measure': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'tmax (time from dosing to the maximum concentration of the analyte in plasma)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'λ z (terminal rate constant of the analyte in plasma)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 't1/2 (terminal half-life of the analyte in plasma)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'MRTpo (mean residence time of the analyte in the body after oral administration)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'CL/F (apparent clearance of the analyte in the plasma after extravascular administration)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'Aet1-t2 (amount of the analyte that is eliminated in urine from the time point t1 until time point t2)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'fet1-t2 (fraction of administered drug excreted unchanged in urine from the time point t1 until time point t2)', 'timeFrame': 'up to 48 hours after drug administration'}, {'measure': 'CLR,t1-t2 (renal clearance of the analyte determined from the time point t1 until time point t2)', 'timeFrame': 'up to 48 hours after drug administration'}]",18.0,30 Years,60 Years,MALE,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,
NCT01136564,Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease,Zemplar,"['Zemplar', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Chronic Kidney Disease,Erling Bjerregaard Pedersen,2025-09-01T16:18:08.349789,True,,,,,Reno- and Vascular Protective Effect of a Low-calcemic Vitamin-D-analogue (Paricalcitol) in Stage III-IV Chronic Kidney Disease,,['Chronic Kidney Disease'],"['paricalcitol', 'vitamin d', 'kidney disease', 'renin', 'proteinuria']",,2010-07,2011-12,"[{'measure': 'plasma renin concentration', 'timeFrame': '6 weeks'}]","[{'measure': 'Urinary albumin excretion', 'timeFrame': '6 weeks'}, {'measure': 'GFR', 'timeFrame': '6 weeks'}, {'measure': 'Fractional excretion of sodium', 'timeFrame': '6 weeks'}, {'measure': 'Urinary excretion of aquaporin-2', 'timeFrame': '6 weeks'}, {'measure': 'Urinary excretion of ENaC-beta', 'timeFrame': '6 weeks'}, {'measure': 'Urinary excretion of NCC', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of aldosterone', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of angiotensin-II', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of ADH', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of atrial natriuretic peptide', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of brain natriuretic peptide', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of endothelin', 'timeFrame': '6 weeks'}, {'measure': '24-hr ambulatory blood pressure', 'timeFrame': '6 weeks'}, {'measure': 'Central blood pressure', 'timeFrame': '6 weeks'}, {'measure': 'Pulse wave velocity', 'timeFrame': '6 weeks'}, {'measure': 'augmentation index', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of ionized calcium', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of phosphate', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of alkaline phosphatase', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of Parathyroid hormon', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of 25-hydroxy-vitamin D', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of ultrasensitive CRP', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of TNF-alpha', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of TGF-beta', 'timeFrame': '6 weeks'}, {'measure': 'Urinary excretion of calcium', 'timeFrame': '6 weeks'}, {'measure': 'Plasma concentration of ADMA', 'timeFrame': '6 weeks'}]",27.0,18 Years,,ALL,False,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT00617864,The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome,Human Albumin Infusion,"['Human Albumin Infusion', 'Saline Infusion']",2,INTERVENTIONAL,['NA'],,WITHDRAWN,Ovarian Hyperstimulation Syndrome,Yale University,2025-09-01T16:18:08.349852,True,,,,,The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome.,,['Ovarian Hyperstimulation Syndrome'],[],The syndrome of hyperstimulation is so rare that after one year no patients were eligible.The study was withdrawn and never started.,2007-09,,"[{'measure': 'Serum VEGF levels', 'timeFrame': 'Time surrounding egg retrieval'}]","[{'measure': 'Urine VEGF levels', 'timeFrame': 'Time surrounding egg retrieval'}, {'measure': 'Pregnancy', 'timeFrame': 'Time surrounding egg retrieval'}]",3.0,18 Years,42 Years,FEMALE,True,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,The syndrome of hyperstimulation is so rare that after one year no patients were eligible.The study was withdrawn and never started.
NCT01710709,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Aripiprazole,['Aripiprazole'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bipolar I,"Otsuka Pharmaceutical Development & Commercialization, Inc.",2025-09-01T16:18:08.349917,True,,,,,"A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder",,['Bipolar I'],"['Aripiprazole, Intramuscular (IM) Depot, Bipolar']",,2012-11,2016-12,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or participant enrolled in the clinical trial and which does not necessarily have to have a causal relationship with the investigational medicinal product (IMP). AEs were assessed as a criteria for safety and tolerability.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Injection Site Pain Measured by the Visual Analog Scale (VAS)', 'description': 'Injection-site pain was evaluated by mean visual analog scale (VAS) scores as reported by the participant after each injection at visits where an injection occurred. Ratings ranged from 0 (no pain) to 100 (unbearably painful).', 'timeFrame': 'Up to Week 52'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Laboratory Test Results', 'description': 'Standard safety variables to be analyzed included clinical laboratory tests. Incidence of treatment emergent adverse events (TEAEs) of potential clinical relevance included abnormal values in serum chemistry, hematology, urinalysis, and other laboratory test that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as serious adverse event/adverse events (SAE/AEs) and are reported in the SAE/other AE section of this report.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Vital Signs', 'description': 'TEAEs of potential clinical relevance included abnormal values in body weight, systolic and diastolic blood pressure, heart rate, and body temperature that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECGs)', 'description': ""Twelve-lead ECGs were recorded at specified visits. For each time point, three 12-lead ECG recordings were obtained approximately 5 minutes apart. Additional 12-lead ECGs were permitted to be obtained at the investigator's discretion and were to always be obtained in the event of an early termination. The ECGs were evaluated at the investigational site to determine the participant's eligibility and to monitor safety during the trial."", 'timeFrame': 'Up to Week 52'}, {'measure': 'Extrapyramidal Symptoms Will be Assessed by Mean Change From Baseline on Abnormal Involuntary Movement Scale(AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS Only Used in Japan) and Barnes Akathisia Rating Scale (BARS)', 'description': 'AIMS: 10 items described dyskinesia signs; 0-absence/no awareness; 4-severe condition/severe distress. Total score for Items 1-10 ranges from 0 to 40; a higher score reflects severe condition. SAS:Consisted of 10 parkinsonism signs;1-no symptoms;5-severe.Total score for Items 1-10 ranges from 1 to 50;a higher score reflects severe condition.DIEPSS:A 9-item rating scale (8 assessed individual symptoms \\[4 categories of parkinsonism, akathisia, dystonia \\& dyskinesia\\]+1 assessed general severity) was used;0-no symptoms/normal, 4-severe.Total score (8 individual symptom items) was in range of 0 to 32 (a higher score reflects severe condition).BARS:Consisted of 4 items related to akathisia:objective observation, subjective feelings of restlessness, distress, global clinical evaluation.Only BARS global clinical assessment score has been presented and rated using scale:0-absence of symptoms;5-severe akathisia.Total BARS global score ranges from 0 to 5,a higher score reflects severe condition.', 'timeFrame': 'Baseline, Week 28, and Week 52'}, {'measure': 'Number of Participants Experiencing Suicidal Events and Their Classification According to the Completion of Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'Suicidality was monitored throughout the trial using the C-SSRS at every visit. The C-SSRS scale consisted of a screening/baseline evaluation that assessed the participant\'s lifetime experience and experience over the last 90 days with suicide events and suicidal ideation and a post-baseline/ ""Since Last Visit"" evaluation that focused on suicidality since the last trial visit.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating', 'description': 'Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe) . The participant indicated the degree of pain at the most recent injection site using a VAS. Ratings ranged from 0 (no pain) to 100 (unbearably painful). Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. These assessments occurred at trial visits where injections occurred (scheduled and unscheduled), beginning with the first dose of open-label aripiprazole IM depot administered at the final visit of the Oral Stabilization Phase and continued through the last injection prior to the end of the IM Depot Maintenance Phase/Early termination (ET) visit (ie, evaluations were not done at end of the IM Depot Maintenance Phase/ET visit).', 'timeFrame': 'Up to Week 52'}]","[{'measure': 'Percentage of Participants Who Remained Stable at End of Treatment in Phase C', 'description': 'The secondary objective was to evaluate the efficacy, as measured by the percentage of stable participants at baseline who remained stable at the end of treatment in the IM depot maintenance phase, of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to subjects with bipolar I disorder.', 'timeFrame': 'Up to Week 52'}]",9.0,18 Years,65 Years,ALL,False,INDUSTRY,1.0,748.0,ACTUAL,v2_robust,True,True,False,True,
NCT02844309,The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM,Thalidomide,"['Thal', 'Thalidomide']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Waldenström Macroglobulinemia,"Institute of Hematology & Blood Diseases Hospital, China",2025-09-01T16:18:08.349925,True,,,,,The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China,,['Waldenström Macroglobulinemia'],[],,2016-05,2020-05,"[{'measure': 'Overall response rate', 'timeFrame': 'up to 12 months'}]","[{'measure': 'progress-free survival', 'timeFrame': 'up to 36 months'}]",2.0,18 Years,85 Years,ALL,False,OTHER,0.0,44.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03616509,"GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition",Growth hormone,"['Genotonorm Miniquick', 'Growth hormone', 'Physiological serum (sodium chloride 0,9%)', 'Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Prader-Willi Syndrome,Corporacion Parc Tauli,2025-09-01T16:18:08.349941,True,,,,,"Treatment With Growth Hormone in Adults With PWS, Effect on Muscular Tone Evaluated by Functional MRI, Relationship With Strength and Body Composition",,['Prader-Willi Syndrome'],"['Growth Hormone', 'Functional Magnetic Resonance', 'Strength', 'Body composition']",,2017-06-19,2019-07-26,"[{'measure': 'Examine brain connectivity areas related with muscle tone maintenance', 'description': 'Examine brain connectivity areas related with muscle tone maintenance making a functional MRI while the subject is making motor maneuvers, before anf after 12 months on GH treatment.', 'timeFrame': '24 months'}]","[{'measure': 'Evaluation of strength', 'description': 'Evaluation of strength before and after 12 months on GH treatment', 'timeFrame': '24 months'}, {'measure': 'Evaluation of body composition', 'description': 'Evaluation of body composition by Dual energy x-ray absorptiometry (DEXA) before and after 12 months on GH treatment', 'timeFrame': '24 months'}]",3.0,18 Years,,ALL,True,OTHER,1.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT05835609,PM534 Administered Intravenously to Patients With Advanced Solid Tumors,PM534,['PM534'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Patients With Advanced Solid Tumors,PharmaMar,2025-09-01T16:18:08.350030,True,,,,,"Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid Tumors",,['Patients With Advanced Solid Tumors'],[],,2022-12-23,2026-10,"[{'measure': 'Determination of the Maximum Tolerated Dose and the Recommended Dose', 'description': 'A fully evaluable patient is a patient evaluable for the primary objective (i.e., determination of the MTD and the RD).', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}]","[{'measure': 'Safety AEs of PM534', 'description': 'AEs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'Safety Hb of PM534', 'description': 'Parameters Labs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'Safety neutrophils of PM534', 'description': 'Parameters Labs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'Safety platelets of PM534', 'description': 'Parameters Labs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'Safety BT of PM534', 'description': 'Parameters Labs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'Safety ALT/AST of PM534', 'description': 'Parameters Labs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'Safety ALK of PM534', 'description': 'Parameters Labs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'Safety creatinine of PM534', 'description': 'Parameters Labs will be graded according to the NCI-CTCAE v.5.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}, {'measure': 'QT Assessment', 'description': ""The direct relationship between PM534 plasma concentration C and the change from baseline in QT corrected according to Fridericia's formula (ΔQTcF) will be assessed using linear mixed effects (LME) models."", 'timeFrame': 'During Day of Cycle 1 (each cycle lasts 21 days)'}, {'measure': 'Pharmacokinetics Cmax of PM534', 'description': 'Maximum Plasma Concentration (Cmax). Pharmacokinetic analyses will be evaluated in plasma and urine by standard noncompartmental analysis. Compartmental modeling may be performed if appropriate.', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from treated patients once the MTD has been determined(each cycle is 21 days).'}, {'measure': 'Pharmacokinetics AUC of PM534', 'description': 'Area Under The Concentration-time Curve (AUC). Pharmacokinetic analyses will be evaluated in plasma and urine by standard noncompartmental analysis. Compartmental modeling may be performed if appropriate.', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from treated patients once the MTD has been determined(each cycle is 21 days).'}, {'measure': 'Pharmacogenomics Plasma AUC(0-t) of PM534', 'description': 'To analyze the expression levels of Plasma AUC(0-t) of response and/or resistance to treatment with PM534', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days)'}, {'measure': 'Pharmacogenomics Plasma Cmax of PM534', 'description': 'To analyze the expression levels of Plasma Cmax of response and/or resistance to treatment with PM534', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days)'}, {'measure': 'Pharmacogenomics Plasma half life of PM534', 'description': 'To analyze the expression levels of Plasma half life of response and/or resistance to treatment with PM534', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days)'}, {'measure': 'Pharmacogenomics Total body plasma clearance of PM534', 'description': 'To analyze the expression levels of Total body plasma clearance of response and/or resistance to treatment with PM534', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days)'}, {'measure': 'Pharmacogenomics Volume of distribution of PM534', 'description': 'To analyze the expression levels of Volume of distribution of response and/or resistance to treatment with PM534', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days)'}, {'measure': 'Pharmacogenomics Percentage of dose recovered in urine of PM534', 'description': 'To analyze the expression levels of Percentage of dose recovered in urine of response and/or resistance to treatment with PM534', 'timeFrame': 'Cycle 1 from all patients, and also in Cycle 2 from patients treated once the MTD has been determined) (each cycle is 21 days)'}, {'measure': 'Efficacy of PM534', 'description': 'To analyze the response rates will be determined in patients with measurable or evaluable disease specific tumor types, time-to-event parameter will also be analyzed ORR.', 'timeFrame': 'From the date of first infusion of PM534 to the date of study termination, up to 46 months'}]",19.0,18 Years,,ALL,False,INDUSTRY,0.0,30.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03642509,Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation,NOAC,"['Apixaban', 'Rivaroxaban', 'Dabigatran', 'NOAC', 'Edoxaban']",5,INTERVENTIONAL,['NA'],,RECRUITING,Atrial Fibrillation,University of Aarhus,2025-09-01T16:18:08.350071,True,,,,,Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation. A Multicenter Randomized Clinical Trial. (Occlusion-AF),,"['Atrial Fibrillation', 'Stroke']","['Left atrial appendage occlusion', 'Novel oral anticoagulation']",,2019-01-01,2030-10-01,"[{'measure': 'Composite endpoint of stroke (ischemic and hemorrhagic), systemic embolism, major bleeding and all-cause mortality.', 'description': 'The primary endpoint is the combined rate of stroke, systemic embolism, major bleeding and all-cause mortality.', 'timeFrame': 'Up to 5-years from randomization'}]","[{'measure': 'Incidence of ischemic stroke', 'description': 'The occurrence of an acute onset of a focal neurological deficit of presumed vascular origin lasting for ≥ 24 hours or resulting in death. Stroke is categorized as ischemic based on computed tomography (CT) or magnetic resonance imaging (MRI) of the brain or autopsy.', 'timeFrame': '2-, 3-, 5- and 10-years'}, {'measure': 'Incidence of hemorrhagic stroke', 'description': 'The occurrence of an acute onset of a focal neurological deficit of presumed vascular origin lasting for ≥ 24 hours or resulting in death. Stroke is categorized as hemorrhagic based on computed tomography (CT) or magnetic resonance imaging (MRI) of the brain or autopsy.', 'timeFrame': '2-, 3-, 5- and 10-years'}, {'measure': 'Incidence of systemic embolism', 'description': 'The occurrence of an acute vascular insufficiency or occlusion of the extremities or any non-CNS organ associated with clinical, imaging, surgical or autopsy evidence of arterial occlusion in the absence of other likely mechanism (e.g. trauma, atherosclerosis, or instrumentation).', 'timeFrame': '2-, 3-, 5- and 10-years'}, {'measure': 'Incidence of major or life-threatening bleeding', 'description': 'The occurrence of an overt bleeding associated with one or more of the following: decrease in hemoglobin of at least 3.0 g/dL, transfusion of 2 or more units of blood, causing hospitalization, requiring surgery, causing discontinuation of all antithrombotic therapy or pericardial bleeding with/without tamponade or occurring during the index LAAO procedure or during hospitalization for the index procedure (major bleeding). Life-threatening bleeding is defined as fatal bleeding, causing hypovolaemic shock or severe hypotension requiring vasopressor therapy or intervention, symptomatic bleeding in a critical organ (intracranial, intraspinal, intraocular, intramuscular with compartment syndrome, pericardial bleeding after hospitalization for the index LAAO) or overt bleeding with decrease in hemoglobin ≥ 5 g/dL or requiring transfusion of ≥ 4 units of blood.', 'timeFrame': '2-, 3-, 5- and 10-years'}, {'measure': 'Incidence of all-cause mortality', 'description': 'The occurrence of death from any cause', 'timeFrame': '2-, 3-, 5- and 10-years'}, {'measure': 'Incidence of Transient ischemic attack (TIA)', 'description': 'an episode of neurological dysfunction caused by focal brain, spinal cord or retinal ischemia leading to symptoms lasting less than 24 hours, without acute infarction based on neuroimaging.', 'timeFrame': '2-, 3-, 5- and 10-years'}, {'measure': 'Number of patients with a device-related complication', 'description': 'A complication related to the presence of the device. Device-related complications include:\n\n* Device embolization\n* Device erosion\n* Clinically significant device interference with surrounding structures. This includes structures at the implant location (circumflex coronary artery, mitral valve, pulmonary artery, pulmonary vein) or cardiovascular structures in the vicinity of the location to which the device migrated (if applicable).\n* Device thrombus\n* Device fracture\n* Device infection/endocarditis/pericarditis\n* Device perforation/laceration\n* Device allergy', 'timeFrame': '2 months'}, {'measure': 'Number of patients with a procedure-related complication', 'description': 'All complications related to the LAAO-procedure will be assessed.', 'timeFrame': '2 months'}, {'measure': 'Number of patients with a device success', 'description': 'Device deployed and implanted in correct position', 'timeFrame': '2 months'}, {'measure': 'Number of patients with technical success', 'description': 'Exclusion of the left atrial appendage (LAA) achieved without device-related complications and no leak \\>5 mm on color Doppler TEE.', 'timeFrame': '2 Months'}, {'measure': 'Number of patients with procedural success', 'description': 'Technical success and no procedure-related complications, except uncomplicated device embolization (i.e. device embolization resolved by percutaneous retrieval during the procedure without surgical intervention or damage to surrounding cardiovascular structures).', 'timeFrame': '2 months'}, {'measure': 'Number of patients with peri-device leaks at follow-up imaging', 'description': 'Detection of any peri-device flow/gap at follow-up cardiac CT/TEE.', 'timeFrame': '2 months'}, {'measure': 'Changes in functional status based on Modified Rankin Scale', 'description': 'The Modified Rankin scale is used to measure the degree of disability or dependence in daily activities caused by a stroke. The scale runs from 0-6, from no symptoms (0) to death (6).', 'timeFrame': '24 months'}, {'measure': 'Changes in Quality of life', 'description': 'Based on patient self-reported EuroQol-5D questionnaires. The EuroQol-5D is a standardized instrument to measure health-related quality of life. It includes five self-rated dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The questionnaire have 3 levels of severity for each of the five dimensions. It also includes a visual scale from 0 (worst thinkable health condition) to 100 (best thinkable health condition) to report an overall measure.', 'timeFrame': '12 months'}, {'measure': 'Compliance to NOAC', 'description': 'Adherence to assigned NOAC therapy will be assessed through the National Prescription Registries.', 'timeFrame': '2-, 3-, 5-, and 10-years'}, {'measure': 'Changes in neurological status based on National Institute of Health (NIH) Stroke scale score', 'description': 'Assessed by the NIH stroke scale at baseline and 12 month follow-up. A scale to quantify the neurological impairment caused by a stroke. It includes 11 items, each of which scores a specific ability between 0 to 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores are summed to calculate the total NIH Stroke Scale score, that can range from 0 to 42, with 0 being no symptoms.\n\n* Score 0: No stroke symptoms\n* Score 1-4: Minor stroke\n* Score 5-15: Moderate stroke\n* Score 16-20: Moderate to severe stroke\n* Score 21-42: Severe stroke', 'timeFrame': '12 months'}]",17.0,18 Years,,ALL,False,OTHER,13.0,750.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00472199,"Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",Pramipexole,"['Pramipexole', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Restless Legs Syndrome,Boehringer Ingelheim,2025-09-01T16:18:08.350400,True,,,,,"A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period",,['Restless Legs Syndrome'],[],,2007-05,,"[{'measure': 'Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks', 'description': 'IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe RLS symptoms)', 'timeFrame': 'Baseline and 26 weeks'}]","[{'measure': 'Clinical Global Impression - Global Improvement (CGI-I) Responder Rate', 'description': ""CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring 1 or 2 (at least much improved)"", 'timeFrame': 'after 26 weeks of treatment'}, {'measure': 'International Restless Legs Syndrome (IRLS) Study Group Rating Scale Responder Rate', 'description': 'IRLS response was defined as at least 50% reduction in IRLS total score from baseline. IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe symptoms)', 'timeFrame': 'after 26 weeks of treatment'}, {'measure': 'Patient Global Impression (PGI) Responder Rate', 'description': ""PGI scores ranging from '1' (very much better) to '7' (very much worse), PGI responder have scoring 1 or 2 (at least much better)"", 'timeFrame': 'after 26 weeks of treatment'}, {'measure': 'Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score ""Satisfaction With Sleep"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Severity Falling Asleep"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Severity During the Night"" After 26 Weeks', 'description': 'The question was rated on an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Severity During the Day When at Rest"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline RLS-6 Score ""Severity During the Day Engaged in Activities"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Tired or Sleepy During the Day"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks', 'description': 'Mood disturbance associated with RLS symptoms ranging from 0 (none) to 4 (very severe)', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks', 'description': 'The scale measures pain on a continuous 100 mm axis ranging from no pain (0 mm) to unbearable pain (100 mm)', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks', 'description': 'RLS QoL total score ranging from 0 to 100 with higher values indicating better quality of life', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating less bodily pain', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension General Health After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better health status', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better mental health', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better physical functioning', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating less limitations due to emotional problems', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating less limitations due to physical problems', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better social functioning', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Vitality After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better vitality', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better health', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better health', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Diagnosis of Classified Augmentation According to Independent Expert Panel', 'description': 'Augmentation is a worsening of RLS symptoms and may manifest as increased severity and the involvement of other extremities or as a shift of RLS symptoms to a time period that is 2 or more hours earlier than was typical of the time of symptom onset during the initial course of beneficial stable treatment or the state before recently starting treatment.', 'timeFrame': 'after at least 4 weeks of treatment'}, {'measure': 'Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation', 'description': 'Worsening of RLS symptoms, in comparison to baseline, following abrupt treatment discontinuation (for patients with no added RLS therapy after study drug discontinuation).\n\nAssessment of worsening of RLS was based on the IRLS total score assessed 7 ± 1 days after treatment discontinuation (the end of the study or premature discontinuation) compared with that at baseline. Analysis considered the number of patients experiencing a clinically relevant deterioration of ≥4 points in total IRLS score 7 ± 1 days after discontinuation of trial medication compared with baseline.', 'timeFrame': 'after at least 1 week of treatment discontinuation'}, {'measure': 'Baseline, Week 26 Mean Supine Systolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Standing Systolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Supine Diastolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Standing Diastolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Supine Pulse Rate', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Standing Pulse Rate', 'timeFrame': 'Baseline, Week 26'}]",31.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,331.0,ACTUAL,v2_robust,True,True,False,False,
NCT02015299,Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes,Linagliptin,"['DPP-4 inhibitor', 'placebo', 'Trajenta', 'Linagliptin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 2 Diabetes Mellitus,dr. DJ Mulder,2025-09-01T16:18:08.350483,True,,,,,Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes,,['Type 2 Diabetes Mellitus'],"['Diabetes', 'Pulse Wave Velocity', 'Dipeptidyl peptidase (DPP)-4 inhibitors', 'Linagliptin', 'Arterial Stiffness', 'Subclinical arterial inflammation']",,2014-03,2016-03,"[{'measure': 'change from baseline carotid-(right) femoral arterial Pulse Wave Velocity (PWV) at 26 weeks', 'timeFrame': 'baseline, week 26'}]","[{'measure': 'Secondary vascular study parameters', 'description': '* Central Blood Pressure (CBP) and Augmentation Index (AI) obtained from pulse wave analysis, using Sphygmocor\n* Carotid-(left) radial arterial PWV, using Sphygmocor', 'timeFrame': 'baseline, week 4, week 26, and 4 weeks after treatment discontinuation (week 30)'}, {'measure': 'Subclinical vascular inflammation (FDG PET-CT)', 'description': 'Target-to-background ratios (TBRs) (18)F-fluorodeoxyglucose positron emission tomography computed tomography coregistration (FDG PET-CT)', 'timeFrame': '26 weeks'}]",3.0,30 Years,70 Years,ALL,False,OTHER,1.0,45.0,ACTUAL,v2_robust,True,True,False,False,
NCT00434499,Effect of EGCG on the Body's Response to Insulin,EGCG,['EGCG'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Hypertension,"University of Maryland, Baltimore",2025-09-01T16:18:08.350606,True,,,,,An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects,,"['Hypertension', 'Obesity', 'Type 2 Diabetes', 'Insulin Resistance']","['Green Tea', 'Insulin Resistance', 'Endothelial Dysfunction', 'Nitric Oxide', 'Inflammation', 'Obesity', 'Overweight', 'Diabetes Type 2', 'High Blood Pressure', 'Healthy Volunteer', 'HV']",Not funded,2007-02,2015-12,"[{'measure': 'Improvement in insulin resistance', 'description': 'measurements of insulin resistance prior to study drug, after 4 weeks of EGCG or placebo and at end of study', 'timeFrame': '14 weeks'}]","[{'measure': 'Improvement in endothelial dysfunction', 'description': 'measurements of endothelial function prior to study drug, after 4 weeks of EGCG or placebo and at end of study', 'timeFrame': '14 weeks'}]",2.0,21 Years,65 Years,ALL,True,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Not funded
NCT02609399,ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir,Oseltamivir,"['Peramivir', 'Rapivab', 'Oseltamivir', 'Tamiflu']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Influenza,Johns Hopkins University,2025-09-01T16:18:08.350627,True,,,,,Influenza Therapeutic Trial: A Pilot Randomized Controlled Trial for Feasibility of Enrolling Subjects for Influenza Therapeutic Trials and Administering Influenza Antivirals in the Emergency Department to High Risk Subjects,,['Influenza'],"['Influenza', 'Antiviral treatment', 'Emergency department', 'Influenza therapeutics', 'Rapid influenza testing']",,2015-11-01,2018-05-31,"[{'measure': 'Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire', 'description': 'Symptom evaluation during the 2015-2016 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.\n\nItem responses:\n\n1. Not at all\n2. A little bit\n3. Somewhat\n4. Quite a bit\n5. Very much', 'timeFrame': 'ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)'}, {'measure': 'Mean Symptom Severity Score During the 2016-2017 Influenza Season for Symptom Domains as Assessed Using the FLU-PRO™ Questionnaire', 'description': 'Symptom evaluation during the 2016-2017 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.\n\nItem responses:\n\n1. Not at all\n2. A little bit\n3. Somewhat\n4. Quite a bit\n5. Very much', 'timeFrame': 'ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)'}, {'measure': 'Mean Karnofsky Performance Scale Score During the 2015-2016 Influenza Season', 'description': 'The Karnofsky Performance Scale is a tool for assessing subject functional impairment.\n\nSubjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2015-2016 influenza season.', 'timeFrame': 'ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)'}, {'measure': 'Mean Karnofsky Performance Scale Score During the 2016-2017 Influenza Season', 'description': 'The Karnofsky Performance Scale is a tool for assessing subject functional impairment.\n\nSubjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2016-2017 influenza season.', 'timeFrame': 'ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)'}]",[],4.0,18 Years,100 Years,ALL,False,OTHER,1.0,180.0,ACTUAL,v2_robust,True,True,False,False,
NCT01928199,Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant,Sitagliptin,"['Sitagliptin', 'Januvia', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Posttransplant Diabetes Mellitus,Washington University School of Medicine,2025-09-01T16:18:08.350679,True,,,,,"A Single Center, Randomized, Double-blind Controlled Trial of Sitagliptin Versus Placebo to Reduce the Incidence and Severity of New-onset Diabetes After Kidney Transplant",,['Posttransplant Diabetes Mellitus'],"['diabetes', 'transplant', 'kidney']",,2013-09,2020-10,"[{'measure': '2-hour Oral Glucose Tolerance Test-derived Blood Sugar', 'description': 'Change in 2-hour OGTT-derived blood sugar will be measured at three months and again at six months. These are 3 month OGTT results', 'timeFrame': '3 months'}]","[{'measure': 'Normal 2-hour Oral Glucose Tolerance Test-derived Blood Sugar', 'description': 'Number of subjects who have normal 2-hour oral glucose tolerance test-derived blood sugar will be measured at 3 months', 'timeFrame': '3 months'}, {'measure': '6 Month OGTT Result (Completion of Washout From Study Drug)', 'description': 'We tested another OGTT at 6 months into study, after a 3 month washout from the study drug. Study drug was discontinued after the 3 month OGTT was completed.', 'timeFrame': '6 months'}]",3.0,18 Years,,ALL,False,OTHER,1.0,61.0,ACTUAL,v2_robust,True,True,False,False,
NCT02562599,Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin,raltitrexed-cisplatin,"['raltitrexed-cisplatin', 'Tomudex']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Nasopharyngeal Carcinoma,Hubei Cancer Hospital,2025-09-01T16:18:08.350710,True,,,,,Study Of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Raltitrexed-Cisplatin for Patients With Locally Advanced Nasopharyngeal Carcinoma,,['Nasopharyngeal Carcinoma'],"['Induction Chemotherapy', 'Concurrent Chemoradiotherapy']",,2015-08,2018-08,"[{'measure': 'ORR (Objective Response Rate)', 'timeFrame': 'up to 12 weeks'}]","[{'measure': 'OS(Overall Survival)', 'timeFrame': '2 years'}, {'measure': 'TTP（Time To Progression）', 'timeFrame': '2 years'}, {'measure': 'DCR (Disease Control Rate)', 'timeFrame': '6 weeks after induction chemotherapy; 4 weeks and 12 weeks after radiotherapy.'}, {'measure': 'QOL（Quality Of Life）', 'timeFrame': '2 years'}]",5.0,18 Years,70 Years,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT02463032,Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer,GTx-024,['GTx-024'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,ER+ and AR+ Breast Cancer,GTx,2025-09-01T16:18:08.350811,True,,,,,"A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women",,['ER+ and AR+ Breast Cancer'],[],,2015-08,2019-03,"[{'measure': 'Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects', 'description': 'To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.', 'timeFrame': '24 weeks'}]","[{'measure': 'Clinical Benefit Rate, in Full Analysis Set', 'description': 'To estimate the clinical benefit response rate in all subjects randomized who receive at least one dose of study medication (the FAS) regardless of AR status as determined by the central laboratory. o estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.', 'timeFrame': '24 weeks'}, {'measure': 'Objective Response (CR + PR) in AR+ Patients', 'description': 'To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.', 'timeFrame': '24 weeks'}, {'measure': 'Best Overall Response in AR+ Patients', 'description': 'To estimate the best overall response of GTx-024 9 mg and 18 mg', 'timeFrame': 'From treatment initiation to end of treatment'}, {'measure': 'Progression Free Survival in All Subjects', 'description': 'To estimate the progression free survival of subjects receiving Gtx-024 9 mg and 18 mg. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Subjects were assessed up through 24 months.', 'timeFrame': 'From randomization to tumor progression or death'}, {'measure': 'Time to Progression in All Subjects', 'description': 'To estimate the time to progression in subjects receiving Gtx-024 9 mg and 18 mg in all subjects. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression was assessed up through 24 months.', 'timeFrame': 'From randomization to tumor progression or death'}]",6.0,18 Years,,FEMALE,False,INDUSTRY,0.0,136.0,ACTUAL,v2_robust,True,True,False,False,
NCT00139932,Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272),formoterol fumarate,['formoterol fumarate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Pulmonary Disease, Chronic Obstructive",Merck Sharp & Dohme LLC,2025-09-01T16:18:08.350857,True,,,,,"A Double-Blind Randomized, Parallel-Group, Multicenter Clinical Study to Compare the Efficacy and Tolerability of Tiotropium Bromide Alone vs. the Co-Administration of Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD",,"['Pulmonary Disease, Chronic Obstructive']",[],,2005-09-01,2006-11-21,"[{'measure': 'effects of tiotropium bromide alone vs.the effect of tiotropium bromide and formoterol fumarate', 'description': 'To compare the effects of tiotropium bromide alone vs. the effects of co-administration of tiotropium bromide and formoterol fumarate on the change from baseline of the normalized area under the time curve (AUC) for FEV1 for the 0 hour to 4 hours post-morning dose at the last study visit.', 'timeFrame': '12 weeks'}]",[],1.0,40 Years,,ALL,False,INDUSTRY,2.0,255.0,ACTUAL,v2_robust,True,True,False,False,
NCT05919732,Awake Caudal Catheter vs General Anesthesia,"Bupivacaine, Dexmedetomidine, Caffeine, Tylenol","['Propofol, rocuronium, caffeine, Tylenol, bupivacaine', 'Bupivacaine, Dexmedetomidine, Caffeine, Tylenol']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Inguinal Hernia,Nemours Children's Clinic,2025-09-01T16:18:08.350867,True,,,,,Awake Caudal Catheter Infusion Versus General Anesthesia and Single-dose Caudal Injection for Preterm Neonatal Intensive Care Unit (NICU) Patients Undergoing Inguinal Herniorrhaphy.,,['Inguinal Hernia'],[],,2016-03-08,2018-03-08,"[{'measure': 'Number of Participants With Return to Baseline Respiratory Function.', 'timeFrame': 'Within 24 hours post operative'}, {'measure': 'Surgical Completion.', 'timeFrame': 'Within 24 hours'}, {'measure': 'Number of Apneic Episodes.', 'description': 'Cessation of breathing by a premature infant that lasts for more than 20 seconds and/or is accompanied by hypoxia or bradycardia.', 'timeFrame': '24 hours post operative'}, {'measure': 'Number of Bradycardia Events.', 'description': 'heart rate \\<90.', 'timeFrame': '24 hours post operative'}]","[{'measure': 'Days to Hospital Discharge From Surgery', 'timeFrame': 'up to 10 days'}, {'measure': 'Number of Episodes Requiring Post-operative Narcotics Usage.', 'timeFrame': '24 hours post operative'}, {'measure': 'Operative Time.', 'timeFrame': 'Intraoperative, up to 100 minutes.'}, {'measure': 'Participants Requiring Mechanical Ventilation.', 'timeFrame': 'After 24 hours post operative'}, {'measure': 'Number of Participants Returning to Full Feeds.', 'timeFrame': 'Within 24 hours post operative'}]",9.0,23 Weeks,60 Weeks,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT01445132,Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation,Allogeneic Cell Therapy w/ Tumor-derived Lypho,['Allogeneic Cell Therapy w/ Tumor-derived Lypho'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Chronic Lymphocytic Leukemia,National Cancer Institute (NCI),2025-09-01T16:18:08.350886,True,,,,,"Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes",,['Chronic Lymphocytic Leukemia'],"['Adoptive Immunotherapy', 'Tumor Infiltrating Lymphocytes', 'Refractory Tumor', 'Resection', 'B-Cell Malignancies', 'Chronic Lymphocytic Leukemia', 'BCL', 'B-Cell Lymphoid Malignancy']",,2007-01-11,2013-04-24,[{'measure': 'To evaluate the feasibility of administering ex-vivo costimulated/expanded tumor-derived lymphocytes (TDL) in patients with persistent or recurrent B-cell lymphoid malignancies (BCL) following treatment with allogeneic hematopoietic stem cell tr...'}],[{'measure': 'To determine the safety of administering TDL in patients with persistent/recurrent BCL following alloHSCT.'}],2.0,18 Years,75 Years,ALL,False,NIH,0.0,11.0,ACTUAL,v2_robust,True,True,False,True,
NCT01451632,A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers,MM-121,"['Erbitux', 'Irinotecan', 'Camptosar', 'Cetuximab', 'Seribantumab, SAR256212', 'MM-121']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Colorectal Cancer,Merrimack Pharmaceuticals,2025-09-01T16:18:08.350916,True,,,,,A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers,,"['Colorectal Cancer', 'Squamous Cell Head and Neck Cancer', 'Non-small Cell Lung Cancer', 'Triple Negative Breast Cancer', 'Other Tumors With EGFR Dependence']","['Metastatic Colorectal cancer', 'Kras wild-type', 'Squamous cell head and neck cancer', 'Non-small cell lung cancer', 'Triple negative breast cancer', 'EGFR', 'ErbB3', 'MM-121', 'Cetuximab', 'Irinotecan']",,2011-10,2014-06,"[{'measure': 'Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination', 'description': 'To establish the safety of escalating doses of MM-121 in combination with cetuximab or in combination with cetuximab and irinotecan in order to determine the recommended phase 2 dose.. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.', 'timeFrame': 'From date of first dose to 30 days after termination, the longest 48.1 weeks'}, {'measure': 'To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s) (Via Recording of Maximum Tolerated Dose (MTD)): MM-121 Doses', 'description': 'Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD\n\nPart 1:\n\nCohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW\n\nPart 2:\n\nCohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2', 'timeFrame': 'From date of first dose to 30 days after termination, the longest 48.1 weeks'}, {'measure': 'To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan', 'description': 'Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD\n\nPart 1:\n\nCohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW\n\nPart 2:\n\nCohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2', 'timeFrame': 'From date of first dose to 30 days after termination, the longest 48.1 weeks'}]","[{'measure': 'Objective Response Rate', 'description': 'To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \\>20% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline. Objective Response is presented as the total # patients with PR or CR.', 'timeFrame': 'Patients were assessed for objective response from time of first dose through treatment termination, the longest treatment duration being 48.1 weeks'}, {'measure': 'Pharmacokinetics', 'description': 'Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the maximum observed concentration (Cmax). Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)', 'timeFrame': 'Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121'}, {'measure': 'Pharmacokinetic Parameters of MM-121', 'description': 'Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the AUClast. Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)', 'timeFrame': 'Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121'}, {'measure': 'Immunogenicity', 'description': 'Samples were collected to determine the presence of an immunologic reaction to MM-121 (i.e. human anti-human antibodies).', 'timeFrame': 'Samples were collected for all patients pre-dose on all cycles for duration of treatment, the longest of which was 48.1 weeks, and a collection was made post-infusion in any case of infusion reaction'}]",7.0,18 Years,,ALL,False,INDUSTRY,1.0,48.0,ACTUAL,v2_robust,True,True,False,True,
NCT00063232,Treating Nonalcoholic Steatohepatitis (NASH) With Metformin,Metformin,['Metformin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hepatitis,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),2025-09-01T16:18:08.350926,True,,,,,Treatment of Nonalcoholic Steatohepatitis With Metformin,,['Hepatitis'],"['Insulin', 'Obesity', 'Fatty Liver', 'Diabetes', 'Cirrhosis', 'Metformin', 'Insulin Resistance', 'Nonalcoholic Steatohepatitis', 'Hepatitis', 'NASH']",,2003-06,2008-03,"[{'measure': 'Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category)', 'description': 'Patients under went liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint is a three point improvement in the histological NASH activity index with a decrease in at least two of the component scores and no worsening of fibrosis or increase in Mallory bodies.', 'timeFrame': 'from baseline to 48 Weeks'}]","[{'measure': 'Change in Serum Alanine Aminotransferase (ALT) Levels From Baseline (Number of Participants in Each Change Category)', 'description': 'Alanine transaminase \\<42 U/L is considered normal', 'timeFrame': 'from baseline to 48 weeks'}, {'measure': 'Change in Insulin Sensitivity (Glucose Tolerance, Homeostatic Model Assessment of Insulin Resistence (HOMA-IR)) From Baseline', 'description': 'HOMA-IR is calculated from Fasting Glucose and Fasting Insulin', 'timeFrame': 'from baseline to 48 weeks'}]",3.0,18 Years,,ALL,False,NIH,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,
NCT01711632,"BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",Vemurafenib,"['Vemurafenib', 'Zelboraf™']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hairy Cell Leukemia,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:08.350963,True,,,,,"A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",,['Hairy Cell Leukemia'],"['VEMURAFENIB', 'BRAF Inhibitor', '12-200', 'Zelboraf™']",,2012-10,2024-08-16,"[{'measure': 'efficacy of vemurafenib', 'description': 'as assessed by overall response rates after three months of treatment in patients with relapsed or refractory HCL.', 'timeFrame': '3 months'}]","[{'measure': 'Toxicity (safety and tolerability)', 'description': 'Toxicity will be graded and recorded using the NCI Common Toxicology Criteria version 4.0.', 'timeFrame': '2 years'}, {'measure': 'To assess the pharmacodynamics', 'description': 'Peripheral blood and/or bone marrow aspirate samples from pretreatment and post-treatment at specified time points will be assessed by Western Blot or by phospho-flow for the downstream targets of BRAF (MEK, pMEK, ERK, pERK) to assess the ontarget effect of the Vemurafenib.', 'timeFrame': '2 years'}, {'measure': 'evaluate biomarkers', 'description': 'Reactivation of MAPK pathways: Increased expression of the other RAF isoforms CRAF and ARAF), and MAPK (MAPK8 or COT) will be analyzed by Western Blot and/or real-time PCR39,40. Secondary BRAF mutations (all 18 BRAF exons) and RAS mutations40 will be analyzed by bidirectional Sanger sequencing and by Raindance multiplex PCR and Illumina next generation sequencing, respectively. Activation of RTKs (i.e. PDGFRβ and IGF-IR) will be assessed by Western Blot. Cell Biosciences NanoPro 1000 technology will be used to examine quantitative signaling on the entire MAPK, PI3K and JAK-STAT pathways41.', 'timeFrame': '2 years'}]",4.0,18 Years,,ALL,False,OTHER,6.0,36.0,ACTUAL,v2_robust,True,True,False,True,
NCT02677532,Epidural Versus Wound Infusion Plus Morphine Bolus in Open Abdominal Aortic Aneurysm Repair,Paracetamol,"['Levobupivacaine epidural bolus', 'Paracetamol', 'Sufentanil epidural bolus', 'Levobupivacaine wound infiltration', 'Levobupivacaine plus sufentanil epidural infusion', 'Morphine', 'Levobupivacaine wound infusion']",7,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postoperative Pain,University of Genova,2025-09-01T16:18:08.351186,True,,,,,Analgesia Postoperatoria Mediante Catetere Perdurare e Analgesia Postoperatoria Mediante Infusione Continua Periferia Nell'Intervento Chirurgico Per Riparazione Chirurgica di Aneurismi Dell'Aorta Addominale: Tecniche a Confronto,,['Postoperative Pain'],[],,2011-12,2014-01,"[{'measure': 'Average postoperative pain assessed with numeric rating scale (NRS) in the first 48 hours', 'timeFrame': 'Average of the NRS recorded at the different time-points (up to 48 hours after emergence from general anaesthesia)'}]","[{'measure': 'Need for rescue doses of morphine at each time-point', 'description': 'Need for a bolus of 5 mg intravenous morphine to relief pain', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}, {'measure': 'Number of patients requiring oxygen administration at each time-point', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}, {'measure': 'Number of patients that have restored bowel function at each time-point', 'description': 'Time to first stool analysis', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}, {'measure': 'Number of patients whose urinary catheter was removed at each time-point', 'description': 'Time to catheter removal analysis', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}, {'measure': 'Number of patients that have restored ability to walk at each time-point', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}, {'measure': 'Non-invasive blood pressure (mmHg) at each time-point', 'description': 'Blood pressure (systolic, diastolic, mean in mmHg)', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}, {'measure': 'Length of hospital stay', 'timeFrame': 'Follow-up of up to 3 months after surgery'}, {'measure': 'Heart rate (bpm) at each time-point', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}, {'measure': 'Incidence of postoperative nausea and vomiting', 'timeFrame': '0, 4, 8, 12, 24, 36, 48 hours after emergence from general anaesthesia'}]",10.0,18 Years,,ALL,False,OTHER,0.0,51.0,ACTUAL,v2_robust,True,True,False,False,
NCT06600698,Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA,INM176,['INM176'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Prostate Cancer,Milton S. Hershey Medical Center,2025-09-01T16:18:08.351242,True,,,,,Evaluate Safety and Efficacy of Daily Oral Angelica Gigas Nakai (AGN)-INM176 in Prostate Patients With Rising Plasma PSA (Phase I/II Trial),,['Prostate Cancer'],"['Angelica gigas Nakai', 'INM 176', 'Pharmacokinetics', 'Decursin', 'decursinol', 'prostate specific antigen (PSA)']",,2025-05-07,2028-05-01,"[{'measure': 'Safety of INM176 after 1, 3 and 6 cycles of exposure at RP2D', 'description': 'Safety will be assessed as the combined incidence of adverse events, abnormal safety blood tests, and abnormal ECG readings, expressed as the proportion of participants showing any of these safety concerns following 1, 3, and 6 treatment cycles.', 'timeFrame': '10 months'}, {'measure': 'Efficacy of INM176 by Measuring PSA Level Changes After 6 Cycles of Treatment at the Recommended Phase II Dose (RP2D)', 'description': ""This outcome will assess the efficacy of INM176 by measuring changes in Prostate-Specific Antigen (PSA) levels from baseline to after 6 cycles of treatment at the Recommended Phase II Dose (RP2D). PSA levels will be monitored at baseline and following each treatment cycle, with a primary focus on the change observed after 6 cycles. The degree of PSA reduction will serve as an indicator of INM176's effectiveness in controlling or reducing prostate cancer activity."", 'timeFrame': '10 months'}, {'measure': 'Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D)', 'description': 'The Maximum Tolerated Dose (MTD) will be defined as the highest dose at which ≤ 1 out of 6 participants experience a dose-limiting toxicity (DLT) during the first cycle of treatment. Dose-limiting toxicities will be monitored and assessed based on predefined criteria CTCAE version 5.0. The Recommended Phase II Dose (RP2D) will be established based on safety, tolerability, and any observed efficacy at or below the MTD. RP2D will also take into consideration pharmacokinetics, pharmacodynamics, and other relevant biomarkers if applicable. Dose escalation will follow a 3+3 design to identify the MTD and RP2D.', 'timeFrame': '1 month'}, {'measure': 'Dose-Limiting Toxicities (DLTs)', 'description': 'Dose-Limiting Toxicities (DLTs) are defined as adverse events or laboratory abnormalities that are considered to be related to the study treatment and occur during the first treatment cycle (e.g., 28 days). DLTs will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The occurrence of DLTs will guide dose escalation decisions and help identify the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D).', 'timeFrame': '1 month'}]",[],4.0,40 Years,,MALE,False,OTHER,0.0,45.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01375998,YAZ Post-marketing Surveillance in Japan,"EE20/DRSP(YAZ, BAY86-5300)","['EE20/DRSP(YAZ, BAY86-5300)']",1,OBSERVATIONAL,[],,COMPLETED,Dysmenorrhea,Bayer,2025-09-01T16:18:08.351250,True,,,,,Drug Use Investigation of YAZ,,['Dysmenorrhea'],"['YAZ', 'Dysmenorrhea']",,2011-06-09,2018-03-08,"[{'measure': 'Incidence of adverse drug reactions and sever adverse events', 'timeFrame': 'During YAZ administration, up to 3 years'}, {'measure': 'Change from baseline in severity of dysmenorrhea at 6th cycles (28 days per cycle)', 'timeFrame': 'Baseline and during YAZ administration, up to 3 years'}]","[{'measure': 'Incidence of adverse events', 'timeFrame': 'During YAZ administration, up to 3 years'}, {'measure': 'Unpleasant physical symptoms collection', 'timeFrame': 'Baseline and during YAZ administration, up to 3 years'}, {'measure': 'Unpleasant psychological symptoms collection', 'timeFrame': 'Baseline and during YAZ administration, up to 3 years'}, {'measure': 'Analgesic drug for dysmenorrhea', 'timeFrame': 'During YAZ administration, up to 3 years'}, {'measure': 'QOL survey using Short-Form 36-Item Health Survey (SF-36)', 'timeFrame': 'Baseline and at 6th - 8th cycles (28 datys per cycle)'}]",7.0,,,FEMALE,False,INDUSTRY,0.0,3273.0,ACTUAL,v2_robust,False,True,False,True,
NCT03019198,TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL,Tranexamic Acid Injectable Solution,"['Tranexamic Acid Injectable Solution', 'Placebo - Concentrate', 'Lysteda', 'Transamin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Blood Loss, Surgical",Instituto Nacional de Traumatologia e Ortopedia,2025-09-01T16:18:08.351286,True,,,,,TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL,,"['Blood Loss, Surgical', 'Tranexamic Acid Adverse Reaction', 'Hip Replacement']","['Tranexamic Acid', 'Blood loss', 'Tranfusion']",,2013-12,2016-03,"[{'measure': 'Hemoglobin drop', 'timeFrame': '24 hours post operative'}, {'measure': 'Hematocrit drop', 'timeFrame': '24 hours post operative'}, {'measure': 'Blood transfusion rate', 'timeFrame': '5 days'}, {'measure': 'Operative blood loss', 'timeFrame': '24 hours post operative'}]","[{'measure': 'Length of stay in hospital', 'timeFrame': '7 days'}, {'measure': 'Systemic adverse events', 'timeFrame': '1 year'}, {'measure': 'Thromboembolic efects', 'timeFrame': '1 year'}]",7.0,,,ALL,True,OTHER_GOV,0.0,256.0,ACTUAL,v2_robust,True,True,False,True,
NCT04765098,Tamoxifen Versus Etoposide After First Recurrence in GBM Patients,Tamoxifen,"['Etoposide', 'Tamoxifen']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Glioblastoma Multiforme,AHS Cancer Control Alberta,2025-09-01T16:18:08.351298,True,,,,,A Randomized Controlled Trial of Tamoxifen Versus Etoposide for Patients With First Recurrence of Glioblastoma Multiforme,,['Glioblastoma Multiforme'],[],,2022-01-28,2027-07,"[{'measure': '3 month progression-free survival', 'description': 'Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.', 'timeFrame': '3 months'}]","[{'measure': 'One-year progression-free survival', 'description': 'Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.', 'timeFrame': '12 months'}, {'measure': 'Overall survival', 'description': 'Time between randomization and death due to any cause. Patients without an event will be censored the last time they were known to be alive.', 'timeFrame': 'Median, 6-month, 1-year, and 2-year OS rates will be measured'}, {'measure': 'Health-related quality-of-life status', 'description': 'Health-related quality-of-life will be assessed using the EORTC QLQ-BN20 brain tumor module questionnaire. This is a self-report questionnaire consisting of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit in brain tumor patients', 'timeFrame': 'Throughout study completion, up to 5 years.'}, {'measure': 'Adverse events', 'description': 'This includes fatigue, hematologic toxicities (neutropenia, thrombocytopenia, leukopenia, anemia), liver toxicities, hypertension, diarrhea, seizures and thrombosis and will all be recorded.', 'timeFrame': 'Throughout the whole duration of the trial, up to 5 years'}]",5.0,18 Years,65 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05439798,"Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting",Ondansetron+Dexamethasone,"['Ondansetron+Dexamethasone', 'Palonosetron+Dexamethasone', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Laparoscopic Surgery,Selcuk University,2025-09-01T16:18:08.351917,True,,,,,"Comparison of the Effects of Palonosetron + Dexamethazone, Ondansetron + Dexamethazone and Dexametazone Alone Against Postoperative Nausea and Vomiting in Pediatric Patients Undergoing Laparoscopic Surgery",,"['Laparoscopic Surgery', 'Pediatrics', 'Nausea and Vomiting, Postoperative', 'Antiemetics', 'Therapeutic Use']",[],,2022-06-01,2023-05-31,"[{'measure': 'Incidence of palonosetron, ondansetron and dexamethasone in postoperative nausea and vomiting', 'description': 'The primary endpoint of this study was to find the incidence of PONV among the three groups.', 'timeFrame': '72 hours'}]","[{'measure': 'The time to first rescue antiemetic intake', 'description': 'The Secondary endpoints were the time to first rescue antiemetic intake', 'timeFrame': '72 hours'}, {'measure': 'The total amount of antiemetic use', 'description': 'the total amount of antiemetic use', 'timeFrame': '72 hours'}, {'measure': 'The complications', 'timeFrame': '72 hours'}]",4.0,7 Years,18 Years,ALL,False,OTHER,0.0,66.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04091698,Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial,Co-Enzyme Q10 mucoadhesive tablets,"['Q10 mucoadhesive tablets -ubiquinol', 'Co-Enzyme Q10 mucoadhesive tablets']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Oral Lichen Planus,Cairo University,2025-09-01T16:18:08.351989,True,,,,,11 El-Saraya St. - Manial - Cairo,,['Oral Lichen Planus'],['co enzymeQ10 - Antioxidant- Corticosteroids'],,2019-10-01,2021-11,"[{'measure': 'pain score', 'description': 'visual analogue scale scoring system', 'timeFrame': '3months'}, {'measure': 'clinical size of lesion', 'description': 'Thongprasom score system', 'timeFrame': '3months'}]","[{'measure': 'Salivary level of Malondialdehyde', 'description': 'detect by ELISA', 'timeFrame': '3months'}]",3.0,15 Years,70 Years,ALL,True,OTHER,0.0,34.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05105698,Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg,gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting),"['gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)', 'gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)', 'DPP-4 inhibitor and SGLT-2 inhibitor combination']",3,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Healthy Volunteers,LG Chem,2025-09-01T16:18:08.352015,True,,,,,Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg Fixed Dose Combination Film-coated Tablet Under Fed and Fasting Conditions in Healthy Volunteers,,['Healthy Volunteers'],[],,2022-01-01,2022-09-30,"[{'measure': 'Peak Plasma Concentration (Cmax)', 'description': 'Cmax will be determined from the plasma concentration data of gemigliptin, LC15-0636 and dapagliflozin', 'timeFrame': 'Blood samples will be collected at time 0.00 and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00,12.00, 24.00, 48.00'}, {'measure': 'Area under the plasma concentrationup up to the last measurable concentration (AUC0-tlast)', 'description': 'AUC0-tlast will be determined from the plasma concentration data of gemigliptin, LC15-0636 and dapagliflozin', 'timeFrame': 'Blood samples will be collected at time 0.00 and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00,12.00, 24.00, 48.00'}, {'measure': 'Area under the plasma concentration-time curve to from time 0 to infinite(AUC0-∞)', 'description': 'AUC0-∞ will be determined from the plasma concentration data of gemigliptin, LC15-0636 and dapagliflozin', 'timeFrame': 'Blood samples will be collected at time 0.00 and at 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00,12.00, 24.00, 48.00'}]",[],3.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,28.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00003998,Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer,carboplatin,"['paclitaxel', 'carboplatin', 'docetaxel']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Ovarian Cancer,University of Glasgow,2025-09-01T16:18:08.352034,True,,,,,"A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer",,"['Ovarian Cancer', 'Primary Peritoneal Cavity Cancer']","['stage I ovarian epithelial cancer', 'stage II ovarian epithelial cancer', 'stage III ovarian epithelial cancer', 'stage IV ovarian epithelial cancer', 'primary peritoneal cavity cancer']",,1998-10,2004-12,[],[],0.0,18 Years,,FEMALE,False,OTHER,0.0,1050.0,ESTIMATED,v2_robust,True,True,False,False,
NCT00309998,Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,vinorelbine tartrate,['vinorelbine tartrate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Lung Cancer,University of Rochester,2025-09-01T16:18:08.352139,True,,,,,"Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer",,['Lung Cancer'],"['stage IIIB non-small cell lung cancer', 'stage IV non-small cell lung cancer', 'adenocarcinoma of the lung', 'bronchoalveolar cell lung cancer', 'large cell lung cancer', 'recurrent non-small cell lung cancer']",,2005-09,,[{'measure': 'Median time to disease progression by imaging study every 6 weeks'}],"[{'measure': 'Response rate by imaging study every 6 weeks'}, {'measure': 'Median survival'}, {'measure': 'Safety as measured by toxicity (e.g thromboembolism, bleeding, or bowel perforation) every three weeks or as required'}]",4.0,70 Years,120 Years,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,True,False,True,
NCT00911898,"A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers",MM-111,['MM-111'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Her2 Amplified Solid Tumors,Merrimack Pharmaceuticals,2025-09-01T16:18:08.352149,True,,,,,"A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers",,"['Her2 Amplified Solid Tumors', 'Metastatic Breast Cancer']","['Her2 amplified solid tumors', 'Breast Cancer', 'Her3/ErbB3', 'Bispecific Antibody']",,2009-06,2012-03,"[{'measure': 'Maximum Tolerated Dose (MTD) or Maximum Feasible Dose', 'description': 'The Maximum Tolerated Dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. If a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded and an additional three patients (up to a total of six) are to be treated at the next lower dose level.', 'timeFrame': '28 days'}]","[{'measure': 'To Determine the Clinical Activity of MM-111 in Patients Based on Objective Response Rate (ORR), Duration of Response (DoR), Progression Free Survival (PFS), and 16 & 24-week Clinical Benefit Rate (CBR)', 'timeFrame': 'December 2011'}, {'measure': 'To Explore the Role Functional Imagining (FDG-PET CT Scan), as a Predictor of Clinical Activity', 'timeFrame': 'December 2011'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT02322463,Ethnicity and Analgesic Practice in a Pediatric Emergency Department,Arab children,"['Arab children', 'Arabs']",2,OBSERVATIONAL,[],,UNKNOWN,Limb Fracture,Rambam Health Care Campus,2025-09-01T16:18:08.352164,True,,,,,Ethnicity and Analgesic Practice in a Pediatric Emergency Department,,['Limb Fracture'],['patients who were admitted to the pediatric ED'],,2014-12,2015-10,"[{'measure': 'Rate of oxycodone treatment by the nursing staff', 'timeFrame': 'At triage up to 1 hour after admission at the recpetion desk'}]",[],1.0,,18 Years,ALL,False,OTHER,0.0,5000.0,ESTIMATED,v2_robust,False,False,False,False,
NCT04337463,ATG-008 Combined With Toripalimab in Advanced Solid Tumors,ATG-008,"['Toripalimab', 'ATG-008']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Advanced Solid Tumor,Sichuan University,2025-09-01T16:18:08.352183,True,,,,,"An Open, Dose-escalation and Expansion Study With a Dual TORC1/2 Inhibitor of ATG-008 Combined With PD-1 Antibody of Toripalimab in Advanced Solid Tumors",,['Advanced Solid Tumor'],[],,2020-04-23,2022-12-01,"[{'measure': 'MTD', 'description': 'Maximum Tolerated Dose', 'timeFrame': 'Within 21 days after dosing'}, {'measure': 'RP2D', 'description': 'Recommended phase 2 dose', 'timeFrame': 'Within 21 days after dosing'}, {'measure': 'ORR', 'description': 'Overall Response Rate', 'timeFrame': 'Through study completion (approximately 2 years)'}]","[{'measure': 'Cmax', 'description': 'Peak Plasma Concentration (Cmax)', 'timeFrame': 'Day 1 - Day 15'}, {'measure': 'AUC', 'description': 'Area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Day 1 - Day 15'}, {'measure': 'DOR', 'description': 'Duration from the first observation of at least PR to time of disease progression, or deaths due to disease progression, whichever occurs first.', 'timeFrame': '12 months'}, {'measure': 'DCR', 'description': 'Disease Control Rate (DCR=CBR+Stable Disease\\[SD; for a minimum of 12 weeks\\])', 'timeFrame': '12 months'}, {'measure': 'PFS', 'description': 'Duration from start of study treatment to PD or death (regardless of cause), whichever comes first', 'timeFrame': '12 months'}, {'measure': 'OS', 'description': 'The estimates of Kaplan-Meier', 'timeFrame': '12 months'}]",9.0,18 Years,70 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00697463,Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women,Teriparatide (PTH 1-34),"['Teriparatide (PTH 1-34)', 'Forteo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Menopause,Columbia University,2025-09-01T16:18:08.352238,True,,,,,Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women,,"['Menopause', 'Fracture', 'Osteoporosis']","['Teriparatide', 'Forteo', 'Osteopenia', 'Osteoporosis', 'Fracture', 'Low Bone Density', 'Premenopausal women']",,2008-08-20,2012-01-03,"[{'measure': 'Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA)', 'description': 'Areal BMD at the lumbar spine was measured by dual energy x-ray absorptiometry (DXA) at baseline and at 6, 12, 18, and 24 months, if possible.', 'timeFrame': 'Baseline, Month 18 or 24 reported'}]",[],1.0,20 Years,48 Years,FEMALE,True,OTHER,1.0,22.0,ACTUAL,v2_robust,True,True,False,False,
NCT03687463,Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia,Decitabine,"['Dacogen', 'Decitabine']",2,OBSERVATIONAL,[],,UNKNOWN,Hematopoietic System--Cancer,Capital Research Institute of Pediatrics,2025-09-01T16:18:08.352247,True,,,,,"Modified Post-Transplant Cyclophosphamide Combined With DCAG as a Bridge Followed by Busulfan, Fludarabine and Melphalan Based Conditioning Regimen for Children With Juvenile Myelomonocytic Leukemia",,['Hematopoietic System--Cancer'],"['HSCT', 'PT/Cy', 'Decitabine', 'JMML']",,2015-04-10,2020-04-10,"[{'measure': 'disease statue', 'description': 'Disease status can be measured by test the of (minimal residual disease) MRD, MRD\\<0,01% as negative. The quantitative of gene mutation is ""0"" as negative.', 'timeFrame': 'one months'}]",[],1.0,1 Year,18 Years,ALL,,OTHER_GOV,0.0,6.0,ACTUAL,v2_robust,False,False,False,False,
NCT04324463,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,Colchicine,"['Aspirin', 'Rivaroxaban', 'Interferon-Beta', 'Colchicine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Coronavirus,Population Health Research Institute,2025-09-01T16:18:08.352256,True,,,,,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",,"['Coronavirus', 'Severe Acute Respiratory Syndrome']","['COVID-19', 'coronavirus', 'interferon', 'colchicine', 'aspirin', 'rivaroxaban', 'anti-inflammatory', 'antithrombotic', 'anti-viral']",,2020-04-21,2022-12-30,"[{'measure': 'Outpatient trial - Colchicine vs. control: Time from randomization to first occurrence of the composite of hospitalization or death', 'timeFrame': '45 days post randomization'}, {'measure': 'Outpatient trial - Aspirin vs. control: Time from randomization to first occurrence of the composite of hospitalization, death or major thrombosis (MI, stroke, ALI, or PE)', 'timeFrame': '45 days post randomization'}, {'measure': 'Inpatient trial - Colchicine vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, or death', 'timeFrame': '45 days post randomization'}, {'measure': 'Inpatient trial - Aspirin and Rivaroxaban vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, death or major thrombosis (MI, stroke, ALI, or PE)', 'timeFrame': '45 days post randomization'}]","[{'measure': 'Outpatient trial - Aspirin vs. control: Time from randomization to first occurrence of any thrombosis (MI, stroke, ALI, PE, or DVT)', 'timeFrame': '45 days post randomization'}, {'measure': 'Inpatient trial - Colchicine vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, or respiratory death', 'timeFrame': '45 days post randomization'}, {'measure': 'Inpatient trial - Aspirin vs. control: Time from randomization to first occurrence of the composite of high flow oxygen, mechanical ventilation, or respiratory death', 'timeFrame': '45 days post randomization'}, {'measure': 'Inpatient trial - Aspirin vs. control: Time from randomization to first occurrence of any thrombosis (MI, stroke, ALI, PE, or DVT)', 'timeFrame': '45 days post randomization'}]",8.0,18 Years,,ALL,False,OTHER,1.0,6667.0,ACTUAL,v2_robust,True,True,False,False,
NCT00576563,Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer,FDG,"['Omnipaque 350/ 18 Fluor FDG', 'FDG']",2,INTERVENTIONAL,['NA'],,COMPLETED,Rectum Cancer,Maastricht Radiation Oncology,2025-09-01T16:18:08.352274,True,,,,,Rectal Cancer: Determination of the Predictive Value by Use of FDG-PET-CT Scans and Blood Proteins for the Prognosis of Patients With Rectal Cancer,,['Rectum Cancer'],"['rectal cancer', 'blood proteins', 'irradiation', 'FDG-PET-CT']",,2007-03,2015-12,"[{'measure': 'The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63', 'timeFrame': '5 years'}]","[{'measure': 'Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)', 'timeFrame': '5 years'}]",2.0,18 Years,,ALL,False,OTHER,0.0,103.0,ACTUAL,v2_robust,True,True,False,False,
NCT03636763,"Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?",data report,"['gliptin', 'data report']",2,OBSERVATIONAL,[],,UNKNOWN,Bullous Pemphigoid,Assistance Publique Hopitaux De Marseille,2025-09-01T16:18:08.352284,True,,,,,"Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland",,['Bullous Pemphigoid'],[],,2018-09,2019-12,"[{'measure': 'numbers of patients exposed to gliptin', 'description': 'numbers of patients exposed to gliptin developing a Bullous pemphigoid', 'timeFrame': '3 years'}]",[],1.0,,,ALL,False,OTHER,0.0,183.0,ESTIMATED,v2_robust,False,False,False,False,
NCT06201663,Romiplostim in Chemotherapy-Induced Thrombocytopenia,Romiplostim,"['TPO-RA', 'Romiplostim']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Chemotherapy-induced Thrombocytopenia,Ain Shams University,2025-09-01T16:18:08.352299,True,,,,,Safety and Efficacy of Romiplostim in Chemotherapy-Induced Thrombocytopenia in Children and Adolescents With Solid Malignancy,,"['Chemotherapy-induced Thrombocytopenia', 'Solid Malignancy']",[],,2023-12-17,2025-12,"[{'measure': 'Hematologic response', 'description': 'Platelet count increase to \\> 75 x 10e9/L, as well as toleration of chemotherapy resumption for at least 8 weeks or two cycles without subsequent chemotherapy dose reduction or dose delay because of recurrent CIT', 'timeFrame': '12 weeks'}]",[],1.0,1 Year,18 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04531163,Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy,N Acetylcysteine,"['Fluimucil', '(NAC)', 'N Acetylcysteine']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Diabetic Kidney Disease,Al-Azhar University,2025-09-01T16:18:08.352314,True,,,,,Possible Ameliorating Effect of N- Acetylcysteine on Type-II Diabetes Induced Nephropathy,,"['Diabetic Kidney Disease', 'Diabetes Mellitus, Type 2', 'Diabetic Nephropathies']","['N-Acetyl cysteine', 'Lipoprotein a', 'Triglycerides', 'Total cholesterol', 'Glycated Haemoglobin', 'Fasting blood sugar', 'Serum creatinine', 'Blood urea nitrogen', 'Urine analysis', 'High density lipoprotein', 'Low density lipoprotein']",,2019-10-01,2020-12-01,"[{'measure': 'Lipoprotein (a)', 'description': 'unique lipoprotein that has emerged as an independent risk factor for developing vascular disease.', 'timeFrame': '2 months'}, {'measure': 'Triglycerides', 'description': 'Triglycerides are a type of fat (lipid) found in our blood. It is one of the lipid panel used to determine atherosclerotic risk that contributes to vascular diseases.', 'timeFrame': '2 months'}, {'measure': 'Systolic blood pressure', 'description': 'The first number of blood pressure reading and it indicates how much pressure our blood is exerting against our artery walls when the heart beats. It is a major risk factor for cardiovascular disease.', 'timeFrame': '2 months'}]",[],3.0,20 Years,,ALL,True,OTHER,0.0,60.0,ACTUAL,v2_robust,True,False,False,False,
NCT00122863,Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder,Duloxetine Hydrochloride,"['Duloxetine Hydrochloride', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Anxiety Disorders,Eli Lilly and Company,2025-09-01T16:18:08.352371,True,,,,,Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder,,['Anxiety Disorders'],[],,2005-01,2007-03,[{'measure': 'Assess the long-term maintenance of efficacy of duloxetine 60 to 120 mg QD compared with placebo by a comparison of the time to relapse among patients with GAD who responded to duloxetine during the open-label acute therapy phase after 22 to 26 weeks.'}],"[{'measure': 'Self-reported anxiety symptomatology'}, {'measure': 'Pain'}, {'measure': 'Quality of Life'}, {'measure': 'Clinical Global Improvement and HAMA Factor scores'}, {'measure': 'Maintenance of Effect'}]",6.0,18 Years,,ALL,False,INDUSTRY,1.0,380.0,,v2_robust,True,True,False,False,
NCT02137863,Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy,Dexmedetomidine,"['Normal Saline', 'Precedex', 'Dexmedetomidine', '0.9 % NaCl']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Radiographic Contrast Agent Nephropathy,TC Erciyes University,2025-09-01T16:18:08.352401,True,,,,,Phase 4 Study of Dexmedetomidine Effects on Preventing Contrast Induced Nephropathy,,['Radiographic Contrast Agent Nephropathy'],"['Contrast induced nephropathy', 'Diabetes Mellitus', 'Dexmedetomidine']",,2011-06,2012-07,"[{'measure': 'Changes in glomerular renal function after percutaneous coronary angiography as measured by neutrophil gelatinase-associated lipocalin, cystatin c, blood urea nitrogen, creatinin', 'timeFrame': '1 day (from start of angioplasty till discharge from the hospital)'}]","[{'measure': 'blood pressure', 'timeFrame': '1 day (from start of angiography till discharge from the hospital)'}, {'measure': 'Heart rate', 'timeFrame': '1 day (from start of angiography till discharge from the hospital)'}, {'measure': 'Blood electrolyte levels ( sodium, potassium, chloride)', 'timeFrame': 'before the angiography and just before the discharge from hospital'}, {'measure': 'complete blood count', 'timeFrame': 'before the angiography and just before the discharge from hospital'}]",5.0,18 Years,,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT00835263,Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions,Lamotrigine,"['Lamictal®', 'Lamotrigine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Teva Pharmaceuticals USA,2025-09-01T16:18:08.352415,True,,,,,"Randomized, 2-Way, Crossover, Bioequivalence Study of Lamotrigine 200 mg Tablets and Lamictal® 200 mg Tablets Administered as 1 x 200 mg Tablet in Healthy Subjects Under Fed Conditions",,['Healthy'],"['Bioequivalence', 'Healthy Subjects']",,2002-01,2002-02,"[{'measure': 'Cmax - Maximum Observed Concentration', 'description': 'Bioequivalence based on Cmax', 'timeFrame': 'Blood samples collected over 120 hour period'}, {'measure': 'AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)', 'description': 'Bioequivalence based on AUC0-inf', 'timeFrame': 'Blood samples collected over 120 hour period'}, {'measure': 'AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)', 'description': 'Bioequivalence based on AUC0-t', 'timeFrame': 'Blood samples collected over 120 hour period'}]",[],3.0,18 Years,,ALL,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT04568863,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,Melatonin intravenous,"['Melatonin intravenous', 'Placebo intravenous']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,COVID-19,Pharmamel S.L.,2025-09-01T16:18:08.352592,True,,,,,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)",,"['COVID-19', 'SARS-CoV 2', 'Coronavirus Infection']","['Melatonin intravenous', 'Placebo intravenous', 'ICU patients', 'COVID-19']",,2020-06-20,2020-11-30,"[{'measure': 'Mortality', 'description': 'Mortality in each study group represented in frequency and time-to-event at day 28 after randomization', 'timeFrame': 'one month'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,2.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT07086287,Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery,rhBNP and standard basic treatment,['rhBNP and standard basic treatment'],1,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,After Cardiac Surgery,The First Affiliated Hospital of Anhui Medical University,2025-09-01T16:18:08.352802,True,,,,,Evaluation of the Efficacy of Recombinant Human Brain Natriuretic Peptide in Patients With Diuretic Resistance After Cardiac Surgery: a Prospective Single-center Single-blind Randomized Controlled Study,,"['After Cardiac Surgery', 'Diuretic Resistance']","['recombinant human brain natriuretic peptide', 'diuretic resistance', 'after cardiac surgery', 'the incidence of renal replacement therapy']",,2025-08-01,2028-06-30,"[{'measure': 'the incidence of renal replacement therapy', 'description': 'Indications for initiating renal replacement therapy (RRT): (1) Severe electrolyte disturbances, such as blood potassium \\>6.5 mmol/L with ECG abnormalities, or ineffective drug treatment; (2) Metabolic acidosis, pH \\<7.15 and HCO₃-\\<12 mmol/L, excluding respiratory factors; (3) Volume overload, pulmonary edema/persistent heart failure, and unresponsive to diuretics (e.g., urine output \\<200ml/2h during furosemide stress test positive); (4) Toxin removal, rhabdomyolysis (creatine kinase (CK) \\> 5000 U/L with acute kidney injury).', 'timeFrame': 'From enrollment to discharge: at enrollment, the maintenance dose of rhBNP is 0.0075-0.01ug/kg/min, after 1 hour, 24 hours, 48 hours, and 72 hours post-medication.'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,120.0,ESTIMATED,v2_robust,True,False,False,False,
NCT07004387,Perioperative Use of Amino Acids in Recipients of Orthotopic Liver Transplantation as a Renal Protective Factor,Amino acid solution,"['Amino Acid infusion', 'Amino acid solution', 'l arginina', 'l arginine']",4,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Hepatic Failure,Hospital Dr Sotero del Rio,2025-09-01T16:18:08.352853,True,,,,,Perioperative Use of Amino Acids in Recipients of Orthotopic Liver Transplantation as a Renal Protective Factor,,"['Hepatic Failure', 'Liver Transplant', 'Renal Failure, Acute']","['liver transplant', 'renal failiure', 'amino acids', 'surguery', 'ICU']",,2025-05-27,2026-09-30,"[{'measure': 'acute kidney failiure', 'description': 'measure the incidence of renal failure in the postoperative period of liver transplantation', 'timeFrame': 'During the first 10 days of the postoperative period'}]","[{'measure': 'liver function post Liver Transplant', 'description': 'serial measurement of liver enzymes and bilirubin, lactate.', 'timeFrame': 'For ten days after the postoperative period'}, {'measure': 'Need for vasopressors', 'description': 'Doses of noradrenaline, adrenaline, and/or vasopressin', 'timeFrame': 'For ten days postoperatively.'}, {'measure': 'Mortality from all causes.', 'description': 'Mortality from all causes.', 'timeFrame': 'At 28 days'}]",4.0,18 Years,,ALL,False,OTHER,0.0,90.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00973687,Dexamethasone Tolerability in the Treatment of Acute Asthma in Children,Ora Sweet,"['Ora Sweet', 'Dexamethasone']",2,INTERVENTIONAL,['NA'],,COMPLETED,Asthma,IWK Health Centre,2025-09-01T16:18:08.352866,True,,,,,Dexamethasone Tolerability in the Treatment of Acute Asthma in Children,,['Asthma'],"['pediatric', 'dexamethasone', 'management', 'corticosteroids', 'asthma']",,2004-09,2006-05,"[{'measure': 'The primary objective of this study was to assess whether smaller volumes of oral dexamethasone resulted in better tolerability, specifically less vomiting, in pediatric patients with an acute exacerbation of asthma.', 'timeFrame': 'During Emergency Department visit'}]","[{'measure': 'To evaluate asthma symptom control post emergency room visit for acute asthma exacerbation.', 'timeFrame': '7-14 days following emergency dept visit'}]",2.0,2 Years,14 Years,ALL,False,OTHER,1.0,430.0,ACTUAL,v2_robust,True,True,False,False,
NCT01722487,Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL,Ibrutinib,"['Ibrutinib', 'Chlorambucil']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Lymphocytic Leukemia,Pharmacyclics LLC.,2025-09-01T16:18:08.352876,True,,,,,"Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"['Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma']","['CLL, SLL']",,2013-03,2015-05,"[{'measure': 'PFS (Progression Free Survival)', 'description': 'The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS\n\nProgressive disease according to 2008 IWCLL guidelines was defined as:\n\n* Group A\n\n  * Lymphadenopathy, increase ≥50%\n  * Hepatomegaly, increase ≥50%\n  * Splenomegaly, increase ≥50%\n  * Blood lymphocytes, increase ≥ 50% over baseline\n* Group B\n\n  * Platelets counts, decrease of ≥ 50% from baseline secondary to CLL\n  * Hemoglobin, decrease of \\> 2 g/dL from baseline secondary to CLL', 'timeFrame': 'Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.'}]","[{'measure': 'Overall Survival (OS)', 'description': 'OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure.', 'timeFrame': 'Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.'}, {'measure': 'ORR (Overall Response Rate)', 'description': 'ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy.', 'timeFrame': 'Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.'}, {'measure': 'Proportion of Sustained Hemoglobin Improvement', 'description': 'The proportion of subjects who achieved Hemoglobin \\>11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.', 'timeFrame': 'Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.'}, {'measure': 'Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia', 'description': 'In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin \\>11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.', 'timeFrame': 'Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.'}, {'measure': 'Proportion of Sustained Platelet Improvement', 'description': 'The proportion of subjects who achieved platelet \\>100 x 10\\^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.', 'timeFrame': 'Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.'}, {'measure': 'Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia', 'description': 'In randomized subjects with baseline platelet ≤ 100 x 10\\^9/L, the proportion of subjects who achieved platelet \\>100 x 10\\^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors.', 'timeFrame': 'Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.'}]",7.0,65 Years,,ALL,False,INDUSTRY,1.0,269.0,ACTUAL,v2_robust,True,True,False,False,
NCT00553787,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,VI-0521,['VI-0521'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Obesity,VIVUS LLC,2025-09-01T16:18:08.352941,True,,,,,"A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions",,"['Obesity', 'Type 2 Diabetes']","['Obesity, Type 2 diabetes']",,2007-11,2009-06,"[{'measure': 'Percent Weight Loss From Baseline to Week 56', 'timeFrame': 'Baseline to 56 weeks'}, {'measure': 'Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF', 'timeFrame': 'Baseline to 56 weeks'}]",[],2.0,18 Years,70 Years,ALL,False,INDUSTRY,1.0,2487.0,ACTUAL,v2_robust,True,True,False,False,
NCT05957887,Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients,Dapagliflozin,['Dapagliflozin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,STEMI,Mohamed Nabil Elkholy,2025-09-01T16:18:08.352978,True,,,,,Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients,,['STEMI'],[],,2022-04-15,2025-04-15,"[{'measure': 'number of patients with acute ST elevation anterior myocardial infarction who took Dapagliflozin who shows improvement in cardiac remodeling (assessed by 2D echocardiogram (by measuring GLS)', 'description': 'GLS is global longitudinal strain which is measured by 2D echocardiogram (normal GLS \\> -20) the absolute value of GLS is decreased in impaired LV systolic function', 'timeFrame': '18 months'}]","[{'measure': 'Assess of cardiac toxicity in patients presented with acute ST elevation anterior myocardial infarction', 'description': 'Cardiac toxicity was defined as a decrease in the left ventricular ejection fraction by 10% or occurrence of arrhythmia', 'timeFrame': '18 months'}]",2.0,18 Years,75 Years,ALL,True,OTHER,0.0,120.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05207787,Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors,HS-10365,['HS-10365'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Solid Tumor,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",2025-09-01T16:18:08.352990,True,,,,,"A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10365 in Patients With Locally Advanced or Metastatic Solid Tumors",,['Solid Tumor'],"['Advanced solid tumor', 'RET gene activation']",,2021-11-09,2025-12-31,"[{'measure': 'Phase 1: To determine the maximum tolerated dose (MTD) or maximum administrated dose(MAD)', 'description': 'MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a dose limiting toxicity (DLT).', 'timeFrame': 'Up to 28 days.'}, {'measure': 'Phase 2: Response Rate (ORR) assessed by independent review committee (IRC)', 'description': 'anti-tumor efficacy will be assessed by best radiographic response based on response evaluation criteria in solid tumors at baseline (Day -28 to -1). For patients that continue on repeating 28-Day cycles after the primary evaluation period, progression will be assessed after each 6 weeks before 18 weeks of therapy and then each 12 weeks. ORR is defined as the percentage of patients with a CR or PR that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.', 'timeFrame': 'From the date of first occurrence of complete response (CR) or partial response (PR) on 2 consecutive occasions (≥4 weeks), until the date of disease progression or withdrawal from study, whichever came first, up to 24 months.'}]","[{'measure': 'Incidence and severity of treatment-emergent adverse events', 'description': 'Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, and NCI CTCAE v5.0.', 'timeFrame': 'From baseline until 28 days after the last dose'}, {'measure': 'Observed maximum plasma concentration (Cmax) after single dose of HS-10365', 'description': 'n the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10365 on Day 1 to Day 6.', 'timeFrame': 'From pre-dose to 120 hours after single dose on Day 1'}, {'measure': 'Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-10365', 'description': 'At multiple-dose, Cmax ss will be obtained on Day 1 of dosing in the following 21-Day cycles of therapy.', 'timeFrame': 'From pre-dose to 24 hours after the first dose of multiple dosing on Day 1 of the following 21-Day cycles of therapy'}, {'measure': 'Time to reach maximum plasma concentration (Tmax) after single dose of HS-10365', 'description': 'In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10365 on Day 1 to Day 6.', 'timeFrame': 'From pre-dose to 120 hours after single dose on Day 1'}, {'measure': 'Apparent terminal half-life (T1/2) after single dose of HS-10365', 'description': 'Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.', 'timeFrame': 'From pre-dose to 120 hours after single dose on Day 1'}, {'measure': 'Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10365', 'description': 'Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.', 'timeFrame': 'From pre-dose to 120 hours after single dose on Day 1'}, {'measure': 'ORR of HS-10365', 'description': 'Anti-tumor efficacy will be assessed by best radiographic response based on response evaluation criteria in solid tumors at baseline (Day -28 to -1). For patients that continue on repeating 28-Day cycles after the primary evaluation period, progression will be assessed after each 6 weeks before 18 weeks of therapy and then each 12 weeks. ORR is defined as the percentage of patients with a CR or PR that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.', 'timeFrame': 'From the date of first occurrence of CR or PR on 2 consecutive occasions (≥4 weeks), until the date of disease progression or withdrawal from study, whichever came first, up to 24 months]（Only phase 1）'}, {'measure': 'Disease control rate of HS-10365 (DCR)', 'description': 'Objective response was assessed by RECIST 1.1 thereby to evaluate disease control rate. Disease control was deﬁned as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks).', 'timeFrame': 'From the first occurrence of confirmed CR or PR or SD until the date of disease progression or withdrawal from study, whichever came first, up to 24 months.'}, {'measure': 'Duration of response of HS-10365 (DoR)', 'description': 'Duration of response assessed by RECIST 1.1. Duration of response was defined as the time from when the criteria for CR or PR were first met to the occurrence of a objective disease progression (PD) or death.', 'timeFrame': 'From the date of the first dose to disease progression or death in patients who achieve CR or PR, whichever came first, up to 24 months.'}, {'measure': 'Progression-free survival of HS-10365 (PFS)', 'description': 'Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was deﬁned as the time from date of ﬁrst dose until the documentation of objective PD or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.', 'timeFrame': 'From the date of the first dose until the date of disease progression or death from any cause, whichever came first, up to 24 months.'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS)', 'timeFrame': 'The time from initial administration to death from any cause, up to 4 years'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,306.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02111187,A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer,LDE225,"['Sonidegib', 'LDE225']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Prostate Cancer,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2025-09-01T16:18:08.353110,True,,,,,A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.,,['Prostate Cancer'],"['LDE225', 'High risk localized prostate cancer', 'Pre-surgical']",,2014-04,2017-01-18,"[{'measure': 'Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation)', 'description': 'This was defined as the number of patients who achieved at least a two-fold reduction in GLI1 expression in post-treatment vs. pre-treatment tumor tissues.', 'timeFrame': 'Up to 3 Years'}]","[{'measure': 'Percentage of Participants With a Pathological Effect of Presurgical Treatment With LDE225', 'description': 'To determine whether presurgical treatment with LDE225 can exert a pathological effect on high-risk tumors (i.e. increase apoptosis, decrease proliferation).', 'timeFrame': 'Up to 3 years'}, {'measure': 'Effect of LDE225 on PSA Recurrence Following Prostatectomy', 'description': 'To evaluate whether presurgical treatment with LDE225 diminishes the risk of PSA recurrence following prostatectomy.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Adverse Events in Each Group (LDE225 and Observation)', 'description': 'Safety and tolerability, including any drug-related toxicities of Sonidegib, were reported via CTCAE version 4.0.', 'timeFrame': 'Up to 3 years'}]",4.0,18 Years,100 Years,MALE,False,OTHER,0.0,14.0,ACTUAL,v2_robust,True,True,False,True,
NCT02609087,Effect on Cerebral Oxygenation by Sevoflurane or Propofol Using Near-infrared Spectroscopy in Carotid Endarterectomy,Sevoflurane,"['Propofol', 'Sevoflurane']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Carotid Stenosis,Chonnam National University Hospital,2025-09-01T16:18:08.353125,True,,,,,Comparison the Effect on Cerebral Oxygenation by Sevoflurane-remifentanil or Propofol-remifentanil Anesthesia Using Near-infrared Spectroscopy in Patients Undergoing Carotid Endarterectomy),,['Carotid Stenosis'],[],,2015-08,2016-12,"[{'measure': 'cerebral oxygenation measured by near-infrared spectroscopy', 'timeFrame': 'one year'}]",[],1.0,18 Years,70 Years,ALL,False,OTHER,0.0,69.0,ACTUAL,v2_robust,True,True,False,False,
NCT03436693,Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy,Canagliflozin,"['TA-7284, Canaglu', 'Canagliflozin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Diabetic Nephropathy,Mitsubishi Tanabe Pharma Corporation,2025-09-01T16:18:08.353144,True,,,,,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy",,['Diabetic Nephropathy'],"['Diabetic Nephropathy', 'Canagliflozin', 'Canaglu', 'Diabetes Mellitus, Type 2']",,2018-02-15,2021-01-21,"[{'measure': 'Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104', 'description': 'Percentage of participants with 30% decline in eGFR was calculated by multiple imputation method for missing data.', 'timeFrame': 'Week 104'}]","[{'measure': 'Percentage of Participants With 40% Decline in eGFR From Baseline at Week 104', 'description': 'Percentage of participants with 40% decline in eGFR was calculated by multiple imputation method for missing data.', 'timeFrame': 'Week 104'}, {'measure': 'Change From Baseline in eGFR at Week 104', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Composite Endpoint of End-stage Renal Disease (ESRD), Doubling of Serum Creatinine, Renal Death, and Cardiovascular (CV) Death', 'timeFrame': 'up to approximately 108 weeks'}, {'measure': 'Change From Baseline in Percentage of Urine Albumin-to -Creatinine Ratio (UACR) at Week 104', 'timeFrame': 'Baseline and Week 104'}]",5.0,30 Years,,ALL,False,INDUSTRY,0.0,308.0,ACTUAL,v2_robust,True,True,False,False,
NCT06170593,Intralesional Injections of Triamcinolone for Acne Vulgaris,Triamcinolone Injection,['Triamcinolone Injection'],1,INTERVENTIONAL,['NA'],,COMPLETED,Acne Vulgaris,ACOM Labs,2025-09-01T16:18:08.353159,True,,,,,Intralesional Injections of Triamcinolone for Acne Vulgaris,,['Acne Vulgaris'],[],,2022-11-15,2023-02-14,"[{'measure': 'Safety of intralesional triamcinolone injection', 'description': 'Adverse events and changes in concomitant medications', 'timeFrame': '14 days'}]","[{'measure': 'Target Lesion Erythema', 'description': 'A 5-point scale ranging from 0 (No Erythema) to 4 (Very Severe Erythema).', 'timeFrame': '14 days'}, {'measure': 'Target Lesion Severity', 'description': 'A 5-point scale ranging from 0 (None) to 4 (Very Severe)', 'timeFrame': '14 days'}, {'measure': 'Target Lesion Improvement', 'description': 'A 7-point scale ranging from 1 (Clear; 100%) to 7 (Worse)', 'timeFrame': '14 days'}, {'measure': 'Target Lesion Pain', 'description': '0-10 Visual Analog Scale', 'timeFrame': '14 days'}, {'measure': 'Target Lesion Injection Pain', 'description': '0-10 Visual Analog Scale', 'timeFrame': 'Immediately after the injection of the first target lesion and at 5 minutes post-injection'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,
NCT04854993,Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy,Sugammadex 6 mg/kg,"['MK-8616', 'Sugammadex 6 mg/kg', 'Sugammadex 4 mg/kg']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Prostate Cancer,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,2025-09-01T16:18:08.353172,True,,,,,"Recovery From Deep Neuromuscular Blockade Using Different Sugammadex Doses in Elderly Patients Undergoing Laparoscopic Robot-assisted Prostatectomy: a Prospective, Randomized, Double-blind Clinical Trial",,"['Prostate Cancer', 'Neuromuscular Blockade']","['sugammadex', 'elderly', 'recovery time', 'robotic surgery']",,2021-07-13,2022-09-23,"[{'measure': 'Neuromuscular recovery time', 'description': 'Time from the end of sugammadex administration to train-of-four (TOF)=1', 'timeFrame': '5 minutes'}]","[{'measure': 'Time to extubation', 'description': 'Time from neuromuscular reversal (TOF=1) to extubation', 'timeFrame': '10 minutes'}, {'measure': 'Time to OR exit', 'description': 'Time from neuromuscular reversal (TOF=1) to exit from the operating room', 'timeFrame': '30 minutes'}, {'measure': 'PACU length of stay', 'description': 'Duration of stay in the post-anaesthesia care unit', 'timeFrame': '2 hours'}, {'measure': 'Hemodynamic parameters', 'description': 'Non-invasive blood pressure (mmHg) and heart rate (beats per minute) after sugammadex administration', 'timeFrame': 'up to discharge from post-anaesthesia care unit, an average of 2 hours'}, {'measure': 'Respiratory function', 'description': 'Peripheral oxygen saturation (percentage) and respiratory rate (breaths per minute) after sugammadex administration', 'timeFrame': 'up to discarge from post-anaesthesia care unit, an average of 2 hours'}]",6.0,65 Years,,MALE,False,OTHER,0.0,34.0,ACTUAL,v2_robust,True,True,False,False,
NCT00691093,Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy,fesoterodine,"['fesoterodine', 'TOVIAZ']",2,OBSERVATIONAL,[],,COMPLETED,Overactive Bladder,Pfizer,2025-09-01T16:18:08.353214,True,,,,,Observational Study In Patients With Overactive Bladder (OAB) Treated With Toviaz® After Failure Of Previous Antimuscarinic Therapy Due To Ineffectivity Or Intolerance.,,"['Overactive Bladder', 'Urinary Incontinence']",['observational'],,2008-07,2009-06,"[{'measure': 'Change From Baseline in Micturition Frequency Per 24 Hours at Each Visit', 'description': ""Micturition frequency: mean number of 'day time' (i.e., the time the participant was awake) micturitions per 24 hours and calculated as the total number of 'day time' urinations, divided by the total diary days collected at that visit."", 'timeFrame': 'Baseline, Month 1, Month 2, Month 3 or Early Termination (ET)'}, {'measure': 'Change From Baseline in Nocturnal Micturition Frequency Per 24 Hours at Visit 2, Visit 3, and Visit 4', 'description': ""Nocturnal frequency: mean number of 'night time' (the time the participant was asleep and the urge to urinate woke him/her up) micturitions and calculated as the total number of 'night time' urinations, divided by the total diary days collected at that visit."", 'timeFrame': 'Baseline, Month 1, Month 2, Month 3 or ET'}, {'measure': 'Change From Baseline in Urgency Episode Frequency (UEF) Per 24 Hours at Visit 2, Visit 3, and Visit 4', 'description': ""UEF: mean number of micturition related urgency episodes per 24 hours and calculated as the total number of 'urgency' urinations (i.e., sudden urges to urinate and problems to delay micturition) divided by 3 (or if data for 3 days were not available, over the total number of diary days collected at that visit)."", 'timeFrame': 'Baseline, Month 1, Month 2, Month 3 or ET'}, {'measure': 'Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Visit 2, Visit 3, and Visit 4', 'description': 'The mean number of UUI episodes: total number of UUI episodes, divided by the total diary days collected at that visit.', 'timeFrame': 'Baseline, Month 1, Month 2, Month 3 or ET'}]","[{'measure': 'Change From Baseline in Post Void Residual (PVR) Urine Volume at Visit 2, Visit 3, and Visit 4', 'description': 'The PVR urine volume: measured by an ultrasound scan.', 'timeFrame': 'Baseline, Month 1, Month 2, Month 3 or ET'}, {'measure': ""Patient's Global Evaluation of Fesoterodine"", 'description': ""The patients global evaluation of study medication was assessed via the question 'how would you rate your overall response to the study medication?' and was assessed on the four point categorical scale, ranging from 'Poor' to 'Excellent'."", 'timeFrame': 'Baseline, Month 3 or ET'}, {'measure': 'Clinical Global Evaluation of Fesoterodine', 'description': ""Clinical global evaluation of study medication was assessed via the question 'how would you rate the study medication the patient received for overactive bladder?,' and was assessed on the four point categorical scale, ranging from 'Poor' to 'Excellent.'"", 'timeFrame': '12 weeks'}, {'measure': 'Efficacy and Tolerability Compared to Previous Medication (Overall Treatment Effect Scale) at Visit 4', 'description': ""Overall Treatment Effect Scale: 3 questions from which a numeric score was derived. If a subject answered '(2) About the same' to question 1 then a score of 0 was given. If a subject answered '(1) Worse' to question 1, then a score between -7=a very great deal worse to -1=Almost the same, hardly worse at all was given depending on severity of their symptoms (determined from answer to question 2). If a subject answered '(3) Better' to question 1, then a score ranging from 1=Almost the same, hardly better at all to 7=A very great deal better, depending on their answer to question 3, was given."", 'timeFrame': 'Month 3 or ET'}, {'measure': 'Overactive Bladder Questionnaire (OAB-q): Symptom Severity/Bother Scale', 'description': 'Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=\\[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range\\] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.', 'timeFrame': 'Baseline, Month 3 or ET'}, {'measure': 'Change From Baseline in Total Scores of OAB-q at Visit 4', 'description': 'Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=\\[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range\\] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.', 'timeFrame': 'Baseline, Month 3 or ET'}, {'measure': 'Time To Onset Of Treatment Response', 'description': ""Participant's perception of treatment response assessment since the previous visit was noted at each visit. Time to onset of response was calculated in weeks from start of treatment."", 'timeFrame': 'Month 1, Month 2, Month 3 or ET'}, {'measure': 'Study Doses', 'description': 'Number of subjects that changed doses throughout the study period.', 'timeFrame': 'Month 3 or ET'}, {'measure': 'Reasons for Study Treatment Dose Changes', 'description': 'Possible change in the dose and the reasons for the change were collected and documented.', 'timeFrame': 'Month 3 or ET'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,823.0,ACTUAL,v2_robust,False,True,False,False,
NCT06990893,Comparison of the Analgesic Effect of Oliceridine Versus Morphine or Sufentanil for Postoperative Analgesia in Lumbar Surgeries: a Randomized Control Trial,Oliceridine,"['Oliceridine', 'Sufentanil', 'Morphine']",3,INTERVENTIONAL,['NA'],,RECRUITING,Sufentanil,Anqing Municipal Hospital,2025-09-01T16:18:08.353270,True,,,,,Comparison of the Analgesic Effect of Oliceridine Versus Morphine or Sufentanil for Postoperative Analgesia in Lumbar Surgeries: a Randomized Control Trial,,"['Sufentanil', 'Morphine', 'Validity', 'Safety', 'Oliceridine']","['Sufentanil', 'Safety', 'Morphine', 'oliceridine']",,2024-11-11,2026-10-01,"[{'measure': 'The VAS pain scores at rest and during exercise of the three groups of patients after the operation', 'timeFrame': 'at 30 minutes, 2 hours, 6 hours, 12 hours, 24 hours and 48 hours after the operation'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,90.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01214993,"A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects",GSK1349572,"['GSK1349572', 'OMNIPAQUE', 'Iohexol Injection', 'Placebo', 'Para-aminohippurate infusion']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Infections, Human Immunodeficiency Virus and Tuberculosis",ViiV Healthcare,2025-09-01T16:18:08.353304,True,,,,,"A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects",,"['Infections, Human Immunodeficiency Virus and Tuberculosis']","['GSK1349572', 'para-aminohippurate', 'iohexol']",,2010-10,2010-11,"[{'measure': 'Glomerular Filtration Rate (GFR) as measured by iohexol plasma clearance at days -1, 7 and 14', 'timeFrame': '14 days'}]","[{'measure': 'Serum creatinine, creatinine clearance (CrCL) as measured by 24-hour urine collection, and extra-glomerular creatinine excretion (EGCE) at days -1, 7, 14 and follow-up', 'timeFrame': '24 days'}, {'measure': 'Serum concentrations of Cystatin-C, 24-hour urinary excretions of albumin, total protein, beta2-microblobulin, N-acetyl-beta-d-glucosaminidase (NAG) and retinol binding protein at days -1, 7, 14 and at follow-up', 'timeFrame': '24 days'}, {'measure': 'Effective renal plasma flow (ERPF) as measured by plasma clearance of Para Aminohippurate (PAH) at days -1, 7 and 14', 'timeFrame': '14 days'}, {'measure': 'Safety and tolerability parameters, including adverse event, concurrent medication, clinical laboratory and vital signs assessments.', 'timeFrame': '24 days'}, {'measure': 'Day 14 GSK1349572 PK parameters including area under the concentration curve (AUC)(0-tau), AUC(0-24), concentration (C)max, C0, and Ctau.', 'timeFrame': 'day 14'}]",6.0,18 Years,65 Years,ALL,True,INDUSTRY,2.0,38.0,ACTUAL,v2_robust,True,True,False,True,
NCT01421693,Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever,Ceftriaxone,"['Ceftriaxone', 'Gatifloxacin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Enteric Fever,"Oxford University Clinical Research Unit, Vietnam",2025-09-01T16:18:08.353317,True,,,,,"Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever.",,"['Enteric Fever', 'Typhoid Fever']","['Gatifloxacin', 'Ceftriaxone', 'Enteric fever', 'Typhoid fever']",,2011-09,2015-01,"[{'measure': 'Rate of treatment failure', 'description': 'Any one (1) of the following defines treatment failure:\n\n* Fever clearance time \\>7 x 24hours post treatment initiation\n* Blood culture positive at Day 8 of treatment (microbiological failure)\n* Requirement of rescue treatment\n* Culture confirmed or syndromic relapse within 28 days of initiation of treatment\n* The development on treatment of any enteric fever related complication within 28 days of initiation of treatment including, clinically significant bleeding, fall in the Glasgow Coma Score, perforation of the gastrointestinal tract or admission to hospital Both the absolute risk of treatment failure and the time to treatment failure will be analyzed', 'timeFrame': 'upon occurance, within 28 days'}]","[{'measure': 'S.typhi or S.paratyphi carriage', 'description': 'Stool culture positive for S.typhi or S.paratyphi carriage', 'timeFrame': '1 month, 3 months and 6 months'}, {'measure': 'Number of adverse events', 'description': 'Treatment tolerance as defined by the number of adverse events, serious adverse events and disease complications', 'timeFrame': 'within 6 months'}, {'measure': 'Household transmission', 'description': 'Total number of febrile episodes, hospital visits and hospital admissions within household members', 'timeFrame': 'within 6 months'}, {'measure': 'Time to fever clearance', 'description': 'Time from first dose of treatment until a temperature which is ≤37•5°C for a 48 hour period is first recorded.', 'timeFrame': 'upon occurance, within 7 days'}, {'measure': 'Rate of culture-positive and syndromic clinical relapses', 'timeFrame': 'within 28 days of starting therapy'}, {'measure': 'Rate of relapses confirmed using additional diagnostic techniques', 'description': 'Additional techniques will include culture-PCR and gene expression profiling.', 'timeFrame': 'within 28 days of starting therapy'}]",7.0,2 Years,45 Years,ALL,False,OTHER,4.0,300.0,ACTUAL,v2_robust,True,True,False,True,
NCT03742193,Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy,Apatinib,"['VEGFR Inhibitor', 'Apatinib', 'Chemotherapy', 'GD regimen']",4,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Osteosarcoma,Ruijin Hospital,2025-09-01T16:18:08.353334,True,,,,,A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of Osteosarcoma,,"['Osteosarcoma', 'Pulmonary Metastases', 'Apatinib']",[],,2019-08-11,2023-12-30,"[{'measure': '12 months Progression-free survival rate(12mPFR)', 'description': 'The proportion of patients with progression-free survival at 12 months according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). A 12mPFR of 30% or less is considered inactive, while a 12mPFR of 50% or greater is regarded as of interest for additional development', 'timeFrame': '12 months from the recruitment of the study'}]","[{'measure': 'Overall survival (OS)', 'description': 'calculated from the date of treatment start until last follow-up or death, whichever comes first.', 'timeFrame': 'Baseline until death, followed through study completion, an average of 2 years'}, {'measure': 'Total resectability', 'description': 'The number of patients undergoing pre-planned metastasectomy divided by the number of patients considered resectable at baseline', 'timeFrame': 'after neoadjuvant systemic therapy, an average of 8~9 weeks'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'The occurrence of each adverse events(AEs), severe AEs(SAEs) and death according the CTCAE\\_5.0', 'timeFrame': 'through study completion, an average of 1 years'}, {'measure': 'Objective response rate (ORR)', 'description': 'Complete Response(CR)+Partial Response(PR) after neoadjuvant systemic therapy', 'timeFrame': 'after neoadjuvant systemic therapy, an average of 8~9 weeks'}, {'measure': 'Clinical benefit rate (CBR)', 'description': 'CR+PR+stable disease (SD) after neoadjuvant systemic therapy', 'timeFrame': 'after neoadjuvant systemic therapy, an average of 8~9 weeks'}, {'measure': 'Progression free survival (PFS)', 'description': 'Progression free survival according to RECIST 1.1', 'timeFrame': 'Baseline until disease progression or death, whichever occurs first (followed through study completion, an average of 1.5 years)'}, {'measure': 'OS rate', 'description': 'the proportion of OS at 12, 24 months', 'timeFrame': '12 and 24 months from baseline'}]",8.0,10 Years,50 Years,ALL,False,OTHER,0.0,43.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03357393,Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy,Midazolam,"['Midazolam', 'morphine-scopolamine', 'Propofol-Lipuro', 'Glycopyrrolate']",4,INTERVENTIONAL,['NA'],,COMPLETED,"Sedation, Bronchoscopy",Lena Nilsson,2025-09-01T16:18:08.353359,True,,,,,Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy - a Randomized Controlled Trial,,"['Sedation, Bronchoscopy']",[],,2016-04-04,2017-05-09,"[{'measure': 'Discharge Assessment Using PADSS After 2 Hours Number of Patients Reaching PADSS Score 10 After 2 Hours', 'description': 'Post Anaesthetic Discharge Scoring System (PADSS).A measurement of the PADSS score is done by pulmonary nurse every 15 min after bronchoscopy is finished (when bronchoscope is removed) for 2 hours. The PADSS is used to clinically assess if the patient is ready to be discharged after anaesthesia/sedation and consist of five criteria: vital signs, ambulation, nausea and/or vomiting, pain and surgical bleeding. Each criterion is given a score ranging from 0 to 2. Only patients who achieve a total score of 10 are considered ready for discharge after 2 hours.', 'timeFrame': '2 hours after bronchoscopy is finished'}]","[{'measure': ""Assessment of Self-rated Patient Questionaries' Using S-PSR"", 'description': 'Post-discharge Surgical Recovery Scale (S-PSR) The modified Swedish version S-PSR is based on the ""Post-discharge Surgical Recovery Scale"" and is a 14-item questionnaire to assess the recovery post-discharge regarding the patients\' health status and activity (see further appendix 2). Each item is rated using a semantic differential scale and the total sum is multiplied by 100. The possible range is 10-100, with higher score indicating a more favourable postoperative recovery.', 'timeFrame': 'The assessment is done by the patient at home (or at ward if pro-longed hospital stay is necessary) in the evening on the day of bronchoscopy. It takes approximately 2 minutes to complete the questionnaire.'}, {'measure': 'Quality of Recovery (QoR-23)', 'description': 'Modified version of Quality of Recovery (QoR-23) Minimum value 23. Maximum value 115. A higher score indicate a better quality of recovery.\n\nThe questionnaire ""Quality of Recovery"" (QoR-23) is a 23 item questionnaire to assess recovery after day surgery regarding the patients\' emotional state, physical comfort and physical independence (see further appendix 4). Each item is rated on a five-point scale (1-5) and the scores are summed.', 'timeFrame': 'The assessment is done by the patient at home (or at ward if pro-longed hospital stay is necessary) in the morning the day after bronchoscopy. It takes less than 1 minute to complete the assessment.'}, {'measure': ""Patients' Satisfaction Using a Likert-type Scale"", 'description': 'overall satisfaction with the procedure using the Likert-type scale (1. Very dissatisfied, 2. Dissatisfied, 3. Neither satisfied nor dissatisfied, 4. Satisfied, 5. Very satisfied). The patient may comment any cause which made the satisfaction score high or low and if the patient would like to receive the same method of sedation during a future bronchoscopy.', 'timeFrame': 'After patient has recovered after bronchoscopy and before discharge home, estimated period of time 0-24 hours.'}, {'measure': 'Bronchoscopist Evaluation Using a Likert-type Scale', 'description': 'the bronchoscopist assess their perception of cough, bronchial secretion respectively circumstances for a smooth performance of the bronchoscopy of procedure using the Likert-type scale (1. Very dissatisfied, 2. Dissatisfied, 3. Neither satisfied nor dissatisfied, 4. Satisfied, 5. Very satisfied).', 'timeFrame': 'Directly after completion of the procedure.'}]",5.0,18 Years,,ALL,True,OTHER,0.0,150.0,ACTUAL,v2_robust,True,True,False,False,
NCT00334893,"Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",eribulin mesylate,"['ER-086526', 'halichrondrin B analog', 'eribulin mesylate', 'E7389', 'B1939']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Fallopian Tube Cancer,National Cancer Institute (NCI),2025-09-01T16:18:08.353496,True,,,,,"A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer",,"['Fallopian Tube Cancer', 'Primary Peritoneal Cavity Cancer', 'Recurrent Ovarian Epithelial Cancer']",[],,2006-04,2012-03,"[{'measure': 'Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer.', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': 'up to a total of a year'}]","[{'measure': 'Toxicity Profile of Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer', 'description': 'Measured by NCI CTCAE Version 4.0. The 95% confidence intervals should be provided. Please see adverse events.', 'timeFrame': 'From the time of their first treatment with eribulin mesylate'}]",2.0,18 Years,,FEMALE,False,NIH,0.0,74.0,ACTUAL,v2_robust,True,True,False,True,
NCT00836693,Effect of Tadalafil Once a Day in Men With Erectile Dysfunction,tadalafil,"['tadalafil', 'placebo', 'Cialis', 'LY450190']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Erectile Dysfunction,Eli Lilly and Company,2025-09-01T16:18:08.353510,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors",,['Erectile Dysfunction'],['Erectile Dysfunction'],,2009-01,2010-01,"[{'measure': 'Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12', 'description': 'Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. ""Were you able to insert your penis into your partner\'s vagina?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Sexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 12 in Percentage of Yes Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. ""Did your erection last long enough for you to have successful intercourse?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}]","[{'measure': 'Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Number of Erectile Events Per Night', 'description': ""NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The man wears the device for three nights prior to visit 2 (baseline), visit 5 (end of randomised treatment) and visit 6 (end of follow-up). Data are entered for the 2 nights prior to the visit. During the night the man may have multiple erections. The number of erections is recorded."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Duration of Erectile Events Per Night', 'description': ""NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The duration of erections are measured and recorded. Data presented are the duration of erectile events at baseline and the change from baseline to Week 12."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change', 'description': ""NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The percent of volume change of the penis during erections is measured and recorded for each erection. Data presented are mean percentage of volumetric change from baseline to Week 12."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in the Frequency of Spontaneous Morning Erections Captured by Patient Diary', 'description': 'The morning erection diary allows the participant to record whether he experienced an erection on waking. The participant is to complete the morning erection diary every morning during the run-in, treatment and follow-up periods. The percentage of mornings the participant reported an erection is analysed.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint', 'description': 'The subject questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score will be obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), and multiplying by 25, thus obtaining a score that ranges from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction).', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Total and Subdomain Scores of the Self-Esteem and Relationship (SEAR) Questionnaire', 'description': 'SEAR measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). All questions except negatively worded questions 8 and 11 are scored from 1=almost never/never to 5=almost always/always. Questions 8 and 11 were reverse scored, thus a higher score signifies a more favorable response for all 14 items. Overall score is transformed into a 0 (least favorable) to 100 (most favorable) scale.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Orgasmic Functions (OF)', 'description': 'Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 2 questions of the IIEF-OF domain range from 0 to 10.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Sexual Desire (SD)', 'description': 'Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-SD domain range from 0 to 10.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Intercourse Satisfaction (IS)', 'description': 'Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction (OS)', 'description': 'Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 1 Percentage of ""Yes"" Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 1. ""Were you able to achieve at least some erection (some enlargement of the penis)? "" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 4 Percentage of ""Yes"" Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4. ""Were you satisfied with the hardness of your erection?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 5 Percentage of ""Yes"" Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5. ""Were you satisfied overall with this sexual experience?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Global Assessment Question (GAQ) Question 1 at 12 Week Endpoint', 'description': 'GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.', 'timeFrame': 'Week 12'}, {'measure': 'Global Assessment Question (GAQ) Question 2 at 12 Week Endpoint', 'description': 'GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.', 'timeFrame': 'Week 12'}]",18.0,18 Years,,MALE,False,INDUSTRY,0.0,217.0,ACTUAL,v2_robust,True,True,False,False,
NCT02038621,The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer,Paclitaxel,"['Paclitaxel', 'Oxaliplatin and Capecitabine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Advanced Gastric Cancer,The Second People's Hospital of Sichuan,2025-09-01T16:18:08.353578,True,,,,,Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer,,['Advanced Gastric Cancer'],[],,2014-01,2017-12,"[{'measure': 'Progression Free Survival (PFS)', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}]","[{'measure': 'overall survival (OS)', 'timeFrame': 'from the date of randomization until death from any cause or up to 1 year'}, {'measure': 'adverse events (AE)', 'timeFrame': 'from date of randomization to 28 days after the last chemo dosage'}, {'measure': 'health-related quality of life (HRQOL', 'timeFrame': 'evaluate every 6 weeks from the date of randomization until 28 days after the last chemo dosage'}]",4.0,18 Years,,ALL,False,OTHER,0.0,224.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00283621,Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide,Aranesp (darbepoetin alfa),"['Ifosfamide', 'Adriamycin', 'Adriamycin RDF', 'Doxorubicin Hydrocholoride', 'Aranesp (darbepoetin alfa)', 'Ifex', 'Neulasta (pegfilgrastim)', 'Adriamycin PFS']",8,INTERVENTIONAL,['NA'],,COMPLETED,Sarcoma,M.D. Anderson Cancer Center,2025-09-01T16:18:08.353596,True,,,,,A Pilot Study of Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta) in Patients With Sarcoma Receiving Adriamycin and Ifosfamide,,['Sarcoma'],"['Aranesp', 'Darbepoetin Alfa', 'Pegfilgrastim', 'Neulasta', 'Sarcoma', 'Adriamycin', 'Doxorubicin Hydrocholoride', 'Adriamycin PFS', 'Adriamycin RDF', 'Ifosfamide']",,2003-06-02,2006-04-12,"[{'measure': 'CBC diff/platelet counts', 'timeFrame': 'Monitored at least twice a week and daily during severe myelosuppression.'}, {'measure': 'Iron Stores', 'timeFrame': 'Blood drawn at baseline during cycle 3 and at the end of study.'}, {'measure': 'Peripheral blood and bone marrows', 'timeFrame': 'Performed at baseline and post treatment.'}]","[{'measure': 'Neurocognitive functions and Symptom burden assessment', 'timeFrame': 'Assessed at baseline, after 3 cycles of treatment and at the end of the study.'}]",4.0,18 Years,65 Years,ALL,True,OTHER,1.0,51.0,ACTUAL,v2_robust,True,True,False,False,
NCT00992121,An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma,Bevacizumab,"['Pazopanib 2 week', 'Pazopanib 3 week', 'Bevacizumab']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Carcinoma, Renal Cell",GlaxoSmithKline,2025-09-01T16:18:08.353629,True,,,,,An Open-Label Study to Investigate the Pharmacodynamics of a Repeat Dose Regimen of Bevacizumab (10 mg/kg q2w) and Escalating Repeat Doses of Pazopanib in Renal Cell Carcinoma,,"['Carcinoma, Renal Cell']","['pazopanib', 'Renal Cell Carcinoma', 'Kidney', 'cancer', 'bevacizumab']",,2009-11-18,2013-11-01,"[{'measure': 'Tumour size, as measured by the sum of the longest diameters of all target lesions on CT', 'timeFrame': '6 weeks'}]","[{'measure': 'Plasma levels of pharmacodynamic markers of study drug effect', 'timeFrame': '6 weeks Part I; 15 weeks Part II; 6 weeks during maintenance therapy'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,11.0,ACTUAL,v2_robust,True,True,False,False,
NCT06164821,Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia,luspatercept,['luspatercept'],1,INTERVENTIONAL,['NA'],,RECRUITING,Effect of Drug,Hematology department of the 920th hospital,2025-09-01T16:18:08.353638,True,,,,,Efficary and Safety of Luspatercept for Treatment of Anaemia in Transfusion-dependent β-thalassaemia in Southwest China,,['Effect of Drug'],"['luspatercept', 'β-Thalassemia']",,2024-01-01,2024-11-30,"[{'measure': 'Number of units in cumulative transfusion volume', 'description': 'The decrease of cumulative blood transfusion volume in low transfusion burden group (\\<7.5 units /24 weeks) and high transfusion burden group (7.5-15 units /24 weeks) after 24 weeks of treatment;', 'timeFrame': 'Within 24 weeks'}, {'measure': 'Proportion of patients with a 33% reduction in transfusion burden', 'description': '33% reduction in blood transfusion burden at week 24 in low transfusion burden group (\\<7.5 units /24 weeks) and high transfusion burden group (7.5-15 units /24 weeks);', 'timeFrame': 'Within 24 weeks'}]","[{'measure': 'Blood transfusion burden reduction ratio', 'description': 'The proportion of RBC transfusion burden reduced by 50% at any 12 weeks;\n\n(2) transfusion independence (TI) rates at any 8-week and any 12-week in the whole study population;', 'timeFrame': 'Within 24 weeks'}, {'measure': 'Ratio of TI', 'description': 'Transfusion independence (TI) rates at any 8 weeks and at any 12 weeks in the entire study population；', 'timeFrame': 'Within 24 weeks'}]",4.0,18 Years,,ALL,False,OTHER,0.0,10.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00953121,Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG),bevacizumab and CPT-11 and Carboplatin,"['bevacizumab', 'Irinotecan', 'Carboplatin', 'bevacizumab and CPT-11 and Carboplatin', 'CPT-11', 'Paraplatin', 'Camptosar', 'Avastin']",8,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Malignant Glioma,Annick Desjardins,2025-09-01T16:18:08.353855,True,,,,,Phase II Study of Bevacizumab Plus Irinotecan and Carboplatin for Recurrent Malignant Glioma Patients,,['Malignant Glioma'],"['irinotecan', 'carboplatin', 'bevacizumab', 'Avastin']",,2009-09,2013-01,"[{'measure': '6 Month Progression-free Survival', 'description': 'Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Response Assessment in Neuro-Oncology (RANO) criteria, or to death due to any cause. Progression is defined as greater than or equal to a 25% increase in the product of the largest perpendicular diameters of any enhancing lesion or any new enhancing tumor on MRI scans. Patients may also be classified as progressive disease with significant neurologic decline felt to be due to underlying tumor and not attributable to co-morbid event or concurrent medication regardless of MRI findings.', 'timeFrame': '6 months'}]","[{'measure': 'Objective Response Rate', 'description': 'Percentage of participants with an objective response (complete response or partial response) based on Response Assessment in Neuro-Oncology (RANO) criteria. A complete response is defined as disappearance of all enhancing tumor on contrast enhanced MRI scan. Patient must be off steroids or only on adrenal maintenance doses. A partial response is defined as greater than or equal to a 50% reduction in the size (products of the largest perpendicular diameters) for all enhancing lesions. No new lesions may arise. Steroids must be stable or decreasing dose.', 'timeFrame': '34 months'}, {'measure': 'Median Progression Free Survival (PFS)', 'description': 'Time in months from the start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve.', 'timeFrame': '40 months'}, {'measure': 'Median Overall Survival (OS)', 'description': 'Time in months from the start of study treatment to date of death due to any cause. Patients alive as of the last follow-up had OS censored at the last follow-up date. Median OS was estimated using a Kaplan-Meier curve.', 'timeFrame': '40 months'}, {'measure': 'Safety of Bevacizumab (Avastin) in Combination With Irinotecan and Carboplatin', 'description': 'Number of patients experiencing a toxicity greater than or equal to grade 2 treatment-related toxicity', 'timeFrame': '34 months'}]",5.0,18 Years,,ALL,False,OTHER,0.0,104.0,ACTUAL,v2_robust,True,True,False,True,
NCT01835314,Compassionate Use of Stiripentol in Dravet Syndrome,Stiripentol,['Stiripentol'],1,EXPANDED_ACCESS,[],,NO_LONGER_AVAILABLE,Dravet Syndrome,"University of Colorado, Denver",2025-09-01T16:18:08.353963,True,,,,,Compassionate Use of Stiripentol in Dravet Syndrome,,['Dravet Syndrome'],[],,,,[],[],0.0,1 Year,21 Years,ALL,,OTHER,0.0,,,v2_robust,False,False,False,False,
NCT03070314,Echinaforce Junior Bioavailability Trial,Echinaforce junior,['Echinaforce junior'],1,INTERVENTIONAL,['PHASE4'],PHASE4,WITHDRAWN,Common Cold,A. Vogel AG,2025-09-01T16:18:08.353970,True,,,,,"Bioavailability of an Echinacea Product (Echinaforce® Junior) in Children With a Common Cold, Aged 4-12 Years After Intake of a Daily Dosage",,['Common Cold'],"['Echinacea', 'bioavailability', 'children']",no participants could be recruited who were eager to donate blood for bioavailability despite prolongation of the study period.,2017-02-20,2018-06-30,"[{'measure': 'Peak Plasma Concentration (Cmax)', 'description': 'Peak concentration of tetraen', 'timeFrame': '270 minutes measurement'}]","[{'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'Area of tetraen in plasma versus time curve', 'timeFrame': '270 minutes measurement'}, {'measure': 'Timepoint when Cmax is reached (tmax)', 'description': 'timepoint when maximum tetraen concentration is reached', 'timeFrame': '270 minutes measurement'}]",3.0,4 Years,12 Years,ALL,False,INDUSTRY,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,no participants could be recruited who were eager to donate blood for bioavailability despite prolongation of the study period.
NCT00002214,Phase I Trial of S-1153 in Patients With HIV Infection,Capravirine,['Capravirine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,HIV Infections,Lexigen Pharmaceuticals,2025-09-01T16:18:08.354036,True,,,,,Phase I Trial of S-1153 in Patients With HIV Infection,,['HIV Infections'],"['Dose-Response Relationship, Drug', 'Reverse Transcriptase Inhibitors']",,,,[],[],0.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,40.0,,v2_robust,True,True,False,False,
NCT04135014,Combination With Intranasal Dexmedetomidine and Oral Midazolam for Premedication in Pediatric Patients,Midazolam,"['combination with intranasal dexmedetomidine and oral midazolam', 'Midazolam and Dexmedetomidine', 'Midazolam', 'Dexmedetomidine', 'intranasal dexmedetomidine', 'oral midazolam']",6,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Anxiety,Second Affiliated Hospital of Wenzhou Medical University,2025-09-01T16:18:08.354096,True,,,,,Intranasal Dexmedetomidine or Oral Midazolam Alone Versus Combination With Intranasal Dexmedetomidine and Oral Midazolam for Premedication in Pediatric Patients Undergoing Minor Surgery,,['Anxiety'],[],,2019-10-25,2020-10,"[{'measure': 'The degree of cooperation during inhalation anesthesia induction', 'description': 'Induction Compliance Checklist range from 0 through 10,and lower scores indicate the higher degree of cooperation during inhalation anesthesia induction', 'timeFrame': 'During inhalation anesthesia induction'}]","[{'measure': 'Anxiety before induction of anesthesia', 'description': 'The Modified Yale Preoperative Anxiety Scale:\n\nThe 22-item measure has five behavioural categories: activity, emotional expressivity, alertness and arousal, vocalizations, and interaction with parents. Total scores range from 23.33 through 100 with higher scores indicating greater anxiety.', 'timeFrame': 'Before preoperative medication'}, {'measure': 'The level of sedation', 'description': 'University of Michigan Sedation Scale:\n\n0 -Awake/Alert\n\n1 -Minimally Sedated: Tired/sleepy, appropriate response to verbal conversation and/or sounds.\n\n2- Moderately Sedated: Somnolent/sleeping, easily aroused with light tactile stimulation.\n\n3 - Deeply Sedated: Deep sleep, arousable only with significant physical stimulation.\n\n4 - Unarousable.\n\nhigher scores mean a higher levels of sedation.', 'timeFrame': 'Each 10 minutes during the preoperative period'}, {'measure': 'The onset time of satisfactory sedation', 'description': 'The onset time of satisfactory sedation, defined as the time from drug administration to the time when the University of Michigan Sedation Scale reached two points.\n\nUniversity of Michigan Sedation Scale:\n\n0 -Awake/Alert\n\n1 -Minimally Sedated: Tired/sleepy, appropriate response to verbal conversation and/or sounds.\n\n2- Moderately Sedated: Somnolent/sleeping, easily aroused with light tactile stimulation.\n\n3 - Deeply Sedated: Deep sleep, arousable only with significant physical stimulation.\n\n4 - Unarousable.\n\nhigher scores mean a higher levels of sedation.', 'timeFrame': 'During the preoperative period'}, {'measure': 'Parental separation anxiety scale', 'description': 'A four-point parental separation anxiety scale as follows:\n\n1. -Easy separation,\n2. -Whimpers, but is easily reassured, not clinging,\n3. \\- Cries and cannot be easily reassured, but not clinging to parents,\n4. \\- Crying and clinging to parents.\n\nThe scores of 1 and 2 signified acceptable separation whereas scores of 3 and 4 were classified as difficult separation.', 'timeFrame': 'During the preoperative period'}, {'measure': 'Recovery times', 'description': 'The time from discontinuation of sevoflurane to the first open eye of the children and to achieve aldrete≥9', 'timeFrame': ""Within up to 30 minutes after child's first eye opening in the postoperative period""}, {'measure': 'Pediatric anesthesia emergence delirium', 'description': 'The pediatric anesthesia emergence delirium scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20.\n\nThe degree of emergence delirium increased directly with the total score.pediatric anesthesia emergence delirium scale ≥12 at any time indicates presence of emergence delirium.', 'timeFrame': ""Within up to 15-30 minutes after child's first eye opening in the postoperative period""}, {'measure': 'Number of children with adverse effects', 'description': 'Number of children with adverse effects\n\n1. Bradycardia and/or hypotension need for hemodynamic support\n2. Desaturation is defined as Oxygen desaturation \\<90%\n3. Salivation\n4. Any adverse effects requiring interventions', 'timeFrame': 'Up to 24 hours including preoperative, intraoperative, and postoperative periods'}]",8.0,2 Years,6 Years,ALL,True,OTHER,0.0,138.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05176314,A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants,Rosuvastatin,"['Pirtobrutinib', 'LY3527727', 'Rosuvastatin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Loxo Oncology, Inc.",2025-09-01T16:18:08.354179,True,,,,,"A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Single and Multiple Doses of Pirtobrutinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants",,['Healthy'],[],,2022-01-11,2022-04-20,"[{'measure': 'Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin', 'description': 'PK: Cmax of Rosuvastatin', 'timeFrame': 'Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Rosuvastatin', 'description': 'PK: AUC(0-inf) of Rosuvastatin', 'timeFrame': 'Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.'}]",[],2.0,18 Years,64 Years,ALL,True,INDUSTRY,1.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT03334214,"Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes",IONIS DGAT2Rx,"['IONIS DGAT2Rx', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hepatic Steatosis,"Ionis Pharmaceuticals, Inc.",2025-09-01T16:18:08.354200,True,,,,,"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (IONIS-DGAT2Rx, an Antisense Inhibitor of Diacylglycerol Acyltransferase 2) Administered Once-Weekly for 13 Weeks in Adult Patients With Type 2 Diabetes",,['Hepatic Steatosis'],"['Hepatic Steatosis', 'IONIS-DGAT2Rx', 'Type 2 Diabetes']",,2017-11-03,2018-11-28,"[{'measure': 'Absolute Change in Liver Fat Percentage (Randomized Population)', 'description': 'Absolute change in liver fat percentage as quantified by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) from baseline to post-treatment MRI.', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Absolute Change in Liver Fat Percentage (Per Protocol Population)', 'description': 'Absolute change in liver fat percentage as quantified by MRI-PDFF from baseline to post-treatment MRI.', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Percentage of Participants With Adverse Events That Were Related to Treatment With IONIS DGAT2Rx', 'description': 'An adverse event (AE) is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product.', 'timeFrame': 'Up to 176 days'}, {'measure': 'Percentage of Participants With Adverse Events, Graded by Severity, That Were Related to Treatment With IONIS DGAT2Rx', 'description': ""AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010. Grades: mild - the event is easily tolerated by the participant and does not affect the participant's usual daily activities; moderate - the event causes the participant more discomfort and interrupts the participant's usual daily activities; severe - the event is incapacitating and causes considerable interference with the participant's usual daily activities."", 'timeFrame': 'Up to 176 days'}]","[{'measure': 'Percent Change in Liver Fat Percentage', 'description': 'Relative percent change in liver fat percentage from baseline to post-treatment MRI.', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Percentage of Participants With ≥ 30% Relative Reduction in Liver Fat Percentage', 'description': 'Percentage of participants with ≥ 30% relative reduction in liver fat percentage from baseline to post-treatment.', 'timeFrame': 'Week 15'}, {'measure': 'Percent Change in Liver Volume', 'description': 'Assessed from Baseline MRI to Post-Treatment MRI.', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Percent Change in Plasma Lipoprotein Profile', 'description': 'Percent change in plasma lipoprotein profile (total cholesterol, apolipoprotein B \\[ApoB\\], high density lipoprotein (HDL), low density lipoprotein cholesterol \\[LDL-C\\], non-HDL, triglycerides, and very low density lipoproteins \\[VLDL\\]) from baseline to the average of the post-treatment values assessed 1 and 2 weeks after the last dose (Post-Treatment 1 and Post-Treatment 2 visits).', 'timeFrame': 'Week 15'}, {'measure': 'Percent Change in Parameters of Insulin Resistance (IR)', 'description': 'Percent change in parameters of IR (fasting plasma glucose \\[FPG\\], homeostatic model assessment - insulin resistance \\[HOMA-IR\\], and insulin) from baseline to post-treatment.', 'timeFrame': 'Week 14'}, {'measure': 'Absolute Change in Hemoglobin A1C (HbA1C)', 'description': 'Absolute change in HbA1C from baseline to post-treatment.', 'timeFrame': 'Week 14'}]",10.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,44.0,ACTUAL,v2_robust,True,True,False,True,
NCT06933914,Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria,MY008211A tablets,['MY008211A tablets'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,RECRUITING,Paroxysmal Nocturnal Hemoglobinuria (PNH),"Wuhan Createrna Science and Technology Co., Ltd",2025-09-01T16:18:08.354214,True,,,,,"An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of MY008211A Tablets in Patients With PNH Paroxysmal Nocturnal Hemoglobinuria (PNH)",,['Paroxysmal Nocturnal Hemoglobinuria (PNH)'],[],,2024-11-30,2026-12-30,"[{'measure': 'Proportion of participants with adverse events, safety laboratory parameters, vital signs, ECG.', 'description': 'Safety evaluations including but not limited to adverse events, laboratory parameters, vital signs, ECG through End of Study visit every 12 weeks.', 'timeFrame': 'About 100 weeks'}]","[{'measure': 'Proportion of participants achieving sustained hemoglobin levels ≥ 120 g/L in the absence of red blood cell transfusions', 'description': 'Proportion of participants achieving sustained hemoglobin levels ≥ 120 g/L in the absence of red blood cell transfusions evaluated every 12 weeks.', 'timeFrame': 'About 100 weeks'}, {'measure': 'Change From Baseline in Hemoglobin', 'description': 'Change in hemoglobin concentration from baseline in patients without RBC transfusion every 12 weeks.', 'timeFrame': 'About 100 weeks'}, {'measure': 'The proportion of patients without RBC transfusion.', 'description': 'The proportion of patients without RBC transfusion.', 'timeFrame': 'About 100 weeks'}, {'measure': 'The Clinical BTH Rate', 'description': 'The Clinical BTH Rate', 'timeFrame': 'About 100 weeks'}, {'measure': 'The Major Adverse Vascular Events Rate', 'description': 'The Major Adverse Vascular Events Rate', 'timeFrame': 'About 100 weeks'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,120.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04049916,Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission,Pyronaridine Tetraphosphate/Artesunate,"['Primaquine', 'Pyronaridine Tetraphosphate/Artesunate', 'Euartesim', 'Primaquine Diphosphate', 'Dihydroartemisinin/Piperaquine', 'Pyramax']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,"Malaria,Falciparum",London School of Hygiene and Tropical Medicine,2025-09-01T16:18:08.354239,True,,,,,The Efficacy and Safety of Pyronaridine-artesunate Combined With Low Dose Primaquine for Preventing Transmission of P. Falciparum Gametocytes in Sub-Saharan Africa,,"['Malaria,Falciparum']","['Primaquine', 'Pyramax', 'Euartesim', 'Dihydroartemisinin-piperaquine', 'Pyronaridine-artesunate']",,2019-09-12,2020-01-07,"[{'measure': 'Change in mosquito infectivity assessed through membrane feeding assays (day 2)', 'description': 'The proportion of mosquitoes infected, assessed through membrane feeding and measured as oocyst prevalence in mosquitoes dissected on day 2 post feed, compared to baseline', 'timeFrame': '2 days (day 0 & 2)'}]","[{'measure': 'Change in mosquito infectivity assessed through membrane feeding assays (day 7)', 'description': 'The proportion of mosquitoes infected, assessed through membrane feeding and measured as oocyst prevalence in mosquitoes dissected on day 7 post feed, compared to baseline', 'timeFrame': '2 days (day 0 & 7)'}, {'measure': 'Mosquito infectivity assessed through membrane feeding assays - inter arm', 'description': 'Mosquito infection prevalence and density, assessed through membrane feeding and measured as oocyst prevalence/density in mosquitoes dissected on day 2 and 7 post feed, compared between study arms', 'timeFrame': '3 days (day 0, 2 & 7)'}, {'measure': 'Duration of infectivity', 'description': 'Non PQ arms only: Duration of infectivity will be determined from measures of mosquito infection prevalence, assessed through membrane feeding and measured as oocyst prevalence in mosquitoes dissected on day 0, 2, 7, 10 and 14 post treatment, and then weekly until 2 sequential negative feeds or until day 49.', 'timeFrame': '5-10 days (as described)'}, {'measure': 'Area under the curve (AUC) of infectivity/time', 'description': 'Non PQ arms only: AUC will be determined from measures of mosquito infection prevalence and density, assessed through membrane feeding and measured as oocyst prevalence/density in mosquitoes dissected on day 0, 2, 7, 10 and 14 post treatment, and then weekly until 2 sequential negative feeds or until day 49.', 'timeFrame': '5-10 days (as described)'}, {'measure': 'Haemoglobin level', 'description': 'Haemolysis will be monitored by measuring haemoglobin levels (g/dL) on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment.', 'timeFrame': '11 days'}, {'measure': 'Histidine rich protein 2 (HRP2) concentration', 'description': 'Histidine rich protein 2 (HRP2) protein concentration in plasma will be determined in subsequent lab analysis from samples collected on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment.', 'timeFrame': '11 days'}, {'measure': 'Histidine rich protein 2 (HRP2) circulation time', 'description': 'Histidine rich protein 2 (HRP2) protein circulation time will be compared between methods of detection', 'timeFrame': '11 days'}, {'measure': 'Histidine rich protein 2 (HRP2) area under the curve (AUC)', 'description': 'Histidine rich protein 2 (HRP2) area under the curve (AUC) will be determined from measures of HRP2 concentration', 'timeFrame': '11 days'}, {'measure': 'Rapid diagnostic test result', 'description': 'Varied rapid diagnostic tests based on the detection of HRP2 will be used on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment to determine infection prevalence, for comparison between study arms.', 'timeFrame': '11 days'}, {'measure': 'Gametocyte density', 'description': 'Gametocyte density (parasites/microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment.', 'timeFrame': '11 days'}, {'measure': 'Gametocyte under the curve (AUC)', 'description': 'Gametocyte area under the curve (AUC) will be determined from measures of density.', 'timeFrame': '11 days'}, {'measure': 'Gametocyte prevalence', 'description': 'Gametocyte prevalence (parasites/microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment.', 'timeFrame': '11 days'}, {'measure': 'Gametocyte circulation time', 'description': 'Gametocyte circulation time (days) will be determined from measures of prevalence.', 'timeFrame': '11 days'}, {'measure': 'Gametocyte sex ratio', 'description': 'Gametocyte density will be determined by molecular methods for males and females separately, allowing analysis of sex ratio (proportion of total that is male) on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment.', 'timeFrame': '11 days'}, {'measure': 'Asexual parasite density', 'description': 'Asexual parasite density (parasites/microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment.', 'timeFrame': '11 days'}, {'measure': 'Asexual parasite area under the curve (AUC)', 'description': 'Asexual parasite area under the curve (AUC) will be determined from measures of density.', 'timeFrame': '11 days'}, {'measure': 'Asexual parasite prevalence', 'description': 'Asexual parasite prevalence (parasites/microlitre) will be measured by microscopy and by molecular methods on days 0, 1, 2, 7, 10, 14, 21, 38, 35, 42 and 49 post treatment.', 'timeFrame': '11 days'}, {'measure': 'Asexual parasite circulation time', 'description': 'Asexual parasite circulation time (days) will be determined from measures of prevalence.', 'timeFrame': '11 days'}, {'measure': 'Parasite genotype', 'description': 'Parasite merozoite surface protein 2 (MSP2) allelic diversity (presence of distinct alleles) will be determined in subsequent lab analysis from whole blood samples collected at baseline.', 'timeFrame': '1 day'}, {'measure': 'Histidine rich protein gene deletion', 'description': 'Deletion (presence/absence) of the HRP2/3 genes will be determined from whole blood samples collected at baseline.', 'timeFrame': '1 day'}]",21.0,5 Years,50 Years,ALL,True,OTHER,2.0,100.0,ACTUAL,v2_robust,True,True,False,False,
NCT00689416,Effects of Crestor on Inflammation of Atherosclerotic Plaques,rosuvastatin,"['rosuvastatin', 'Crestor', 'placebo']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Atherosclerosis,AstraZeneca,2025-09-01T16:18:08.354306,True,,,,,Exploratory Study of New Imaging Biomarkers for Measurement of Carotid Plaque Inflammation,,"['Atherosclerosis', 'Inflammatory Activity in Carotid Arteries']","['imaging biomarkers', 'MRI', 'FDG-PET/CT scanning', 'Crestor']",,2007-12,2009-06,"[{'measure': 'Comparison between the active and the placebo group regarding changes in MRI contrast enhancement in terms of the transfer constant (Ktrans) for the carotid region', 'timeFrame': 'MRI scan at enrolment visit and within group after 3 months.'}]","[{'measure': 'Comparison between the active and the placebo group regarding changes in MRI contrast enhancement measured as fractional plasma volume (Vp) and changes in 18FDG uptake in terms of standardised uptake value (SUV), respectively', 'timeFrame': 'MRI scan at enrolment visit and within group after 3 months. 18FDG at randomisation visit (baseline) and within group after 3 months treatment.'}, {'measure': 'Change in carotid MRI contrast enhancement in terms of Ktrans and Vp.', 'timeFrame': 'At enrolment visit and within group after 3 months treatment.'}, {'measure': 'Change in 18FDG uptake in terms of SUV.', 'timeFrame': 'At randomisation visit (baseline) and within group after 3 months treatment.'}]",4.0,18 Years,70 Years,ALL,True,INDUSTRY,0.0,74.0,ESTIMATED,v2_robust,True,True,False,False,
NCT04176016,Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma,OTSA101-DTPA-111In,"['OTSA101-DTPA-111In', 'OTSA101-DTPA-90Y']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Relapsed or Refractory Synovial Sarcoma,"OncoTherapy Science, Inc.",2025-09-01T16:18:08.354362,True,,,,,"Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma",,['Relapsed or Refractory Synovial Sarcoma'],[],Some of the raw materials for the investigational drug are difficult to obtain and expensive.,2020-01-10,2024-01-11,"[{'measure': 'Pharmacokinetic (PK) and Biodistribution of OTSA101-DTPA-111In', 'description': 'Concentration of OTSA101-DTPA in plasma and the distribution of OTSA101-DTPA in the body by imaging scan will be assessed.', 'timeFrame': 'up to 72 hours post dosing'}, {'measure': 'Safety of OTSA101-DTPA-111In', 'description': 'This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria.', 'timeFrame': 'up to 10 days post dosing'}, {'measure': 'Safety of OTSA101-DTPA-90Y', 'description': 'This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria.', 'timeFrame': 'up to 6 weeks post dosing'}]",[],3.0,18 Years,,ALL,False,INDUSTRY,0.0,12.0,ACTUAL,v2_robust,True,False,True,True,Some of the raw materials for the investigational drug are difficult to obtain and expensive.
NCT01314716,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,AZLI,"['AZLI', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bronchiectasis,Gilead Sciences,2025-09-01T16:18:08.354382,True,,,,,"A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)",,['Bronchiectasis'],[],,2011-04,2013-07,"[{'measure': 'Change in QOL-B Respiratory Symptoms Score at Day 28', 'description': 'The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.', 'timeFrame': 'Baseline to Day 28'}]","[{'measure': 'Change in QOL-B Respiratory Symptoms Score at Day 84', 'description': 'The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.', 'timeFrame': 'Baseline to Day 84'}, {'measure': 'Time to Protocol-Defined Exacerbation (PDE)', 'description': 'Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.\n\n* Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough\n* Minor Criteria: fever (\\> 38º C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased \\> 10% from baseline; new or increased hemoptysis', 'timeFrame': 'Baseline to Day 112'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,274.0,ACTUAL,v2_robust,True,True,False,False,
NCT00836316,Levobupivacaine During Cholecystectomy,levobupivacaine,['levobupivacaine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Cholelithiasis,Ege University,2025-09-01T16:18:08.354427,True,,,,,"Effects of Intraperitoneal Levobupivacaine on Pain After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-Blinded Study",,"['Cholelithiasis', 'Pain']",['laparoscopic cholecystectomy'],,,,[],[],0.0,18 Years,50 Years,ALL,True,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT00047216,Tipifarnib in Treating Patients With Recurrent Bladder Cancer,tipifarnib,['tipifarnib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Bladder Cancer,"University Health Network, Toronto",2025-09-01T16:18:08.354433,True,,,,,A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder,,['Bladder Cancer'],"['recurrent bladder cancer', 'stage 0 bladder cancer', 'stage I bladder cancer', 'transitional cell carcinoma of the bladder']",,2002-11,,[{'measure': '1-year recurrence-free survival'}],"[{'measure': 'Recurrence rate at 3, 6, 9, and 12 months'}, {'measure': 'Progression rate at 3, 6, 9, and 12 months'}, {'measure': 'Survival rate'}, {'measure': 'Time to treatment failure'}, {'measure': 'Molecular changes in the host tissue'}]",6.0,18 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,True,False,False,
NCT00779116,"Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)",Desloratadine,"['Desloratadine', 'Zyrtec® (cetirizine)', 'Clarinex, SCH 034117']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Allergies,Organon and Co,2025-09-01T16:18:08.354445,True,,,,,"A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications",,['Allergies'],[],,2005-09,2005-10,"[{'measure': 'Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.', 'description': 'A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject ""now that you have tasted the two tablets, show us which tablet you like more"" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.', 'timeFrame': 'Following the second dose (8-10 minutes after the first dose)'}]",[],1.0,6 Years,11 Years,ALL,True,INDUSTRY,0.0,217.0,ACTUAL,v2_robust,True,True,False,False,
NCT04989816,Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens,Trastuzumab Deruxtecan,"['DS8201a; AZD4552; T-DXd', 'Trastuzumab Deruxtecan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,AstraZeneca,2025-09-01T16:18:08.354456,True,,,,,A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06),,['Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma'],"['Gastric Cancer', 'Gastroesophageal Junction Adenocarcinoma', 'HER2', 'Trastuzumab', 'Deruxtecan', 'T-DXd', 'DS-8201a', 'ERBB2']",,2021-08-20,2024-02-28,"[{'measure': 'Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)', 'description': 'Confirmed ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months'}, {'measure': 'Best Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)', 'description': 'The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months'}]","[{'measure': 'Progression-free Survival (PFS) Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}, {'measure': 'Progression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 3 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 6 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 9 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 12 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 15 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 18 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 21 months using the Kaplan-Meier technique'}, {'measure': 'Disease Control Rate (DCR) Based on Independent Central Review (ICR)', 'description': 'Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD)', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}, {'measure': 'Disease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 12', 'description': 'Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD) for at least 11 weeks (ie 12 weeks - 1 week to allow for an early assessment within the assessment window)', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. DCR assessed at Week 12'}, {'measure': 'Duration of Response (DoR) Based on Independent Central Review (ICR)', 'description': 'DoR defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) or death in the absence of progression based on investigator assessments by using RECIST version 1.1', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}, {'measure': 'Overall Survival (OS) Based on Independent Central Review (ICR)', 'description': 'OS based on ICR is defined as the time from date of enrolment until the date of death due to any cause', 'timeFrame': 'From date of enrolment until death due to any cause. Assessed up to approximately 30 months (from date of first subject in to data cut-off 28February2024)'}, {'measure': 'Best Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR)', 'description': 'Best percentage change based on ICR is defined as the best change in target lesion tumour size from baseline (maximum reduction or minimum increase from baseline in the absence of a reduction)', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}]",15.0,18 Years,,ALL,False,INDUSTRY,1.0,95.0,ACTUAL,v2_robust,True,True,False,False,
NCT05944016,Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients,Dapagliflozin,"['Placebo', 'Dapagliflozin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Chronic Kidney Failure in Children and Young Adults,University Hospital Goettingen,2025-09-01T16:18:08.354519,True,,,,,"DOUBLE PRO-TECT Alport: a Confirmatory, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Dapagliflozin on the Progression of Chronic Kidney Disease in Adolescents and Young Adult Patients with Alport Syndrome",,['Chronic Kidney Failure in Children and Young Adults'],"['chronic kidney disease in children', 'pediatric population', 'nephroprotective therapy in children', 'Alport syndrome', 'type IV collagen disease']",,2024-03-25,2026-12,"[{'measure': 'Primary endpoint', 'description': 'Change from baseline urine albumin to creatinine ratio (UACR) after 48 weeks', 'timeFrame': '48 weeks'}]","[{'measure': 'Key secondary efficacy endpoint', 'description': 'Change from baseline estimated glomerular filtration rate (eGFR) after 52 weeks (4 weeks off treatment)', 'timeFrame': '52 weeks'}, {'measure': 'Key secondary safety endpoint', 'description': 'Adverse events (including serious adverse events)', 'timeFrame': '52 weeks'}, {'measure': 'Adverse events (AE) of special interest', 'description': '(a) Ketoacidosis or symptomatic hypoglycemic event.', 'timeFrame': '52 weeks'}, {'measure': 'Adverse events (AE) of special interest', 'description': '(b) Hyperkalemia (potassium levels ≥15% of the upper normal limit)', 'timeFrame': '52 weeks'}, {'measure': 'Adverse events (AE) of special interest', 'description': '(c) Decline in eGFR of ≥ 30% relative from baseline eGFR.', 'timeFrame': '52 weeks'}]",6.0,10 Years,39 Years,ALL,False,OTHER,1.0,102.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00933816,Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy,"sorafenib, cisplatin, fluorouracil","['sorafenib with hepatic arterial infusion of low dose FP', 'sorafenib, cisplatin, fluorouracil']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Hepatocellular Carcinoma,Kindai University,2025-09-01T16:18:08.354545,True,,,,,Phase I/II Study of Sorafenib In Combination With Low-dose FP Intraarterial Infusion Chemotherapy,,['Hepatocellular Carcinoma'],"['sorafenib', 'intraarterial infusion chemotherapy', 'Low dose FP', 'cisplatin', 'fluorouracil']",,2009-07,2010-10,"[{'measure': 'Dose limiting toxicity in phase I and Time to progression in Phase II', 'timeFrame': 'Every 4 weeks'}]","[{'measure': 'Phase I and II: Overall survival (OS)', 'timeFrame': 'Every day'}, {'measure': 'Phase I and II: Progression free survival (PFS)', 'timeFrame': 'Every four weeks'}, {'measure': 'Phase I: Time to progression (TTP)', 'timeFrame': 'Every four weeks'}, {'measure': 'Phase I and II: Response Rate (RR)', 'timeFrame': 'Every four weeks'}, {'measure': 'Phase I and II: Adverse effect (AE)', 'timeFrame': 'Every four weeks'}]",6.0,20 Years,,ALL,False,OTHER,0.0,37.0,ESTIMATED,v2_robust,True,True,False,True,
NCT01035216,A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL),GNKG168,"['CpG ODN', 'GNKG168']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Leukemia,"SBI Biotech Co., Ltd.",2025-09-01T16:18:08.354558,True,,,,,A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL),,['Leukemia'],['Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)'],This study has been terminated.,2009-09,2013-11,[{'measure': 'To determine the dose limiting toxicity (DLT) and recommended phase 2 dose'}],[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,18.0,ACTUAL,v2_robust,True,False,True,False,This study has been terminated.
NCT05734716,Colorado-Oregon Altitude Study,Erythropoietin,"['Sterile Sodium Chloride', 'Iron sucrose (Venofer)', 'Erythropoietin']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Acute Mountain Sickness,University of Oregon,2025-09-01T16:18:08.354589,True,,,,,Colorado-Oregon Altitude Study,,['Acute Mountain Sickness'],[],,2021-02-17,2023-01-01,"[{'measure': 'Lake Louise Score', 'description': 'Lake Louise Score of Acute Mountain Sickness symptoms', 'timeFrame': 'Pre-ascension to altitude'}, {'measure': 'Lake Louise Score', 'description': 'Lake Louise Score of Acute Mountain Sickness symptoms', 'timeFrame': 'Day 1 ascent to altitude'}, {'measure': 'Lake Louise Score', 'description': 'Lake Louise Score of Acute Mountain Sickness symptoms', 'timeFrame': '24 hours after ascent to altitude'}, {'measure': 'Hemoglobin Mass', 'description': 'total mass of hemoglobin in body', 'timeFrame': 'Pre-ascent to altitude'}, {'measure': 'Hemoglobin Mass', 'description': 'total mass of hemoglobin in body', 'timeFrame': 'Day 1 of Altitude'}, {'measure': 'Hemoglobin Mass', 'description': 'total mass of hemoglobin in body', 'timeFrame': 'Day 7 of Altitude'}, {'measure': 'Hemoglobin Mass', 'description': 'total mass of hemoglobin in body', 'timeFrame': 'Day 13 of Altitude'}, {'measure': 'five kilometer run time trial', 'description': 'time to cover 5 kilometers', 'timeFrame': 'Pre-ascension to altitude'}, {'measure': 'five kilometer run time trial', 'description': 'time to cover 5 kilometers', 'timeFrame': 'Day 1 of Altitude'}, {'measure': 'five kilometer run time trial', 'description': 'time to cover 5 kilometers', 'timeFrame': 'Day 7 of Altitude'}, {'measure': 'five kilometer run time trial', 'description': 'time to cover 5 kilometers', 'timeFrame': 'Day 13 of Altitude'}, {'measure': 'p50', 'description': 'oxygen partial pressure point at which hemoglobin is 50% saturated with oxygen', 'timeFrame': 'Pre-ascension to altitude'}, {'measure': 'p50', 'description': 'oxygen partial pressure point at which hemoglobin is 50% saturated with oxygen', 'timeFrame': 'Day 1 of Altitude'}, {'measure': 'p50', 'description': 'oxygen partial pressure point at which hemoglobin is 50% saturated with oxygen', 'timeFrame': 'Day 7 of Altitude'}, {'measure': 'p50', 'description': 'oxygen partial pressure point at which hemoglobin is 50% saturated with oxygen', 'timeFrame': 'Day 13 of Altitude'}, {'measure': 'rucksack carry', 'description': 'time to complete rucksack (35 pounds) course', 'timeFrame': 'Pre-ascent to altitude'}, {'measure': 'rucksack carry', 'description': 'time to complete rucksack (35 pounds) course', 'timeFrame': 'Day 2 of altitude'}, {'measure': 'rucksack carry', 'description': 'time to complete rucksack (35 pounds) course', 'timeFrame': 'Day 14 of altitude'}, {'measure': 'pulmonary arterial systolic pressure', 'description': 'highest pressure experienced in pulmonary vasculature during cardiac cycle', 'timeFrame': 'Pre-ascent to altitude'}, {'measure': 'pulmonary arterial systolic pressure', 'description': 'highest pressure experienced in pulmonary vasculature during cardiac cycle', 'timeFrame': 'day 1 ascent to altitude'}, {'measure': 'pulmonary arterial systolic pressure', 'description': 'highest pressure experienced in pulmonary vasculature during cardiac cycle', 'timeFrame': 'day 7 ascent to altitude'}, {'measure': 'pulmonary arterial systolic pressure', 'description': 'highest pressure experienced in pulmonary vasculature during cardiac cycle', 'timeFrame': 'day 13 ascent to altitude'}, {'measure': 'hypercapnic ventilatory response', 'description': 'level of end-tidal carbon dioxide which stimulates a ventilatory response', 'timeFrame': 'Pre-ascent to altitude'}, {'measure': 'hypercapnic ventilatory response', 'description': 'level of end-tidal carbon dioxide which stimulates a ventilatory response', 'timeFrame': 'Day 1 of Altitude'}, {'measure': 'hypercapnic ventilatory response', 'description': 'level of end-tidal carbon dioxide which stimulates a ventilatory response', 'timeFrame': 'Day 7 of Altitude'}, {'measure': 'hypercapnic ventilatory response', 'description': 'level of end-tidal carbon dioxide which stimulates a ventilatory response', 'timeFrame': 'Day 13 of Altitude'}, {'measure': 'body core temperature', 'description': 'body core temperature as measured by telemetric pill', 'timeFrame': 'during 5k time trial pre-ascent to altitude'}, {'measure': 'body core temperature', 'description': 'body core temperature as measured by telemetric pill', 'timeFrame': 'during 5k time trial day 1 of Altitude'}, {'measure': 'body core temperature', 'description': 'body core temperature as measured by telemetric pill', 'timeFrame': 'during 5k time trial day 7 of Altitude'}, {'measure': 'body core temperature', 'description': 'body core temperature as measured by telemetric pill', 'timeFrame': 'during 5k time trial day 13 of Altitude'}]",[],30.0,18 Years,40 Years,ALL,True,OTHER,0.0,121.0,ACTUAL,v2_robust,True,True,False,False,
NCT01342016,A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients,tacrolimus capsule,"['prograf', 'airuohua', 'FK506', 'tacrolimus placebo', 'prednisone', 'leflunomide placebo', 'leflunomide tablet', 'tacrolimus capsule']",8,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Lupus Nephritis,Astellas Pharma Inc,2025-09-01T16:18:08.354635,True,,,,,"A Randomized, Double-blind Double Dummy, Parallel Control and Multi-center Clinical Trial to Compare the Efficacy and Safety of Tacrolimus Capsules in Treatment of Lupus Nephritis With Leflunomide Tablets",,['Lupus Nephritis'],"['prograf', 'nephritis', 'leflunomide', 'immunosuppressant']",Due to safety concern of active control drug,2011-04,2013-05,"[{'measure': 'remission rate (partial remission + complete remission)', 'timeFrame': 'at 6 months after treatment'}]","[{'measure': 'urinary protein excretion for 24 hrs (24hr proteinuria)', 'timeFrame': 'at 12 weeks and 24 weeks'}, {'measure': 'serum albumin level', 'timeFrame': 'at 12 weeks and 24 weeks'}, {'measure': 'serum creatinine level', 'timeFrame': 'at 12 weeks and 24 weeks'}, {'measure': 'estimated glomerular filtration rate (eGFR)', 'timeFrame': 'at 12 weeks and 24 weeks'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,1.0,84.0,ACTUAL,v2_robust,True,False,True,False,Due to safety concern of active control drug
NCT00495716,Effect of HSV-2 Suppressive Therapy on Sexual Behavior,acyclovir,['acyclovir'],1,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Genital Herpes,University of Washington,2025-09-01T16:18:08.354665,True,,,,,Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission,,['Genital Herpes'],[],Investigator relocated and study funding ended.,2008-01,2010-06,"[{'measure': 'The Effect of Suppressive Antiviral Therapy on Sexual Behavior Among HSV-2 Seropositive Persons With Multiple Sexual Partners.', 'timeFrame': '1 year'}]",[],1.0,18 Years,,ALL,False,OTHER,1.0,72.0,ACTUAL,v2_robust,True,False,True,False,Investigator relocated and study funding ended.
NCT01028716,Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies,Cyclophosphamide,"['Fosfaseron', 'Claphene', 'Carloxan', 'Cyclophosphan', 'Neosar', 'Fujimycin', 'Prograf', 'Cytoxan', 'WR- 138719', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Genuxal', 'Fludara', 'Revimmune', 'Protopic', 'Cycloblastine', 'Cicloxal', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cyclophosphamidum', 'Cycloblastin', 'Cyclophosphamide', 'Ledoxina', 'SH T 586', 'Cyclostine', 'Cellcept', 'Tacrolimus', 'Cyclophospham', '2-F-ara-AMP', 'CP monohydrate', 'CTX', 'Beneflur', 'Cytophosphan', 'Cyclophosphane', 'Clafen', 'Genoxal', 'Hecoria', 'Mycophenolate Mofetil', 'Syklofosfamid', 'Fludarabine Phosphate', 'Cyclophosphanum', 'MMF', '9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-', 'Cytophosphane', 'Ciclofosfamida', 'Cyclophosphamid monohydrate', 'FK 506', 'CYCLO-cell', 'Mitoxan']",49,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Acute Biphenotypic Leukemia,Fred Hutchinson Cancer Center,2025-09-01T16:18:08.354679,True,,,,,"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source",,"['Acute Biphenotypic Leukemia', 'Acute Erythroid Leukemia in Remission', 'Acute Leukemia in Remission', 'Acute Lymphoblastic Leukemia in Remission', 'Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome', 'Acute Myeloid Leukemia in Remission', 'Acute Myeloid Leukemia With FLT3/ITD Mutation', 'Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1', 'Acute Myeloid Leukemia With Multilineage Dysplasia', 'Acute Myeloid Leukemia With t(6;9)', 'Acute Undifferentiated Leukemia', 'Adult Acute Lymphoblastic Leukemia in Complete Remission', 'B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1)', 'Ph+ ALL', 'Burkitt Lymphoma', 'Childhood Acute Lymphoblastic Leukemia in Complete Remission', 'DS Stage II Plasma Cell Myeloma', 'DS Stage III Plasma Cell Myeloma', 'Myelodysplastic Syndrome', 'Recurrent Anaplastic Large Cell Lymphoma', 'Blasts Under 5 Percent of Bone Marrow Nucleated Cells', 'Recurrent Follicular Lymphoma', 'Recurrent Hodgkin Lymphoma', 'Recurrent Mantle Cell Lymphoma', 'Recurrent Marginal Zone Lymphoma', 'Recurrent Plasma Cell Myeloma', 'Refractory Plasma Cell Myeloma', 'Secondary Acute Myeloid Leukemia', 'T Lymphoblastic Lymphoma', 'Hematopoietic Cell Transplant Recipient']",[],The study experienced lower accrual rates after the onset of COVID. Upon review of the collected data it was deemed that an adequate amount of subjects has been enrolled to date to assess study aims.,2010-05-19,2021-10-07,"[{'measure': 'Non-relapse Mortality at 1 Year', 'description': 'Cumulative incidence of death without evidence of disease progression at 1 year', 'timeFrame': 'Up to 1 year'}, {'measure': 'Percentage of Participants With Chronic Graft Versus Host Disease', 'description': 'Scored according to the National Cancer Institute criteria. Mild-to-severe chronic GVHD at 2 years.', 'timeFrame': 'Up to 2 years post-transplant'}, {'measure': 'Incidence of Grades III/IV Acute Graft Versus Host Disease', 'description': 'Grading determined by organ system stages. Grade III/IV acute graft versus host disease is defined as skin: stage IV, liver: stages II-IV, and/or gastrointestinal tract: stages II-IV.', 'timeFrame': 'At day 84'}, {'measure': 'Relapse of Malignancy After Transplantation', 'description': 'Defined by either morphological or cytogenetic evidence of acute leukemia consistent with pre-transplant features, or radiologic evidence of lymphoma progression. When in doubt, the diagnosis of recurrent or progressive lymphoma should be documented by tissue biopsy.', 'timeFrame': 'Up to 7 years'}]","[{'measure': 'Time to Neutrophil Recovery', 'description': 'Achievement of an absolute neutrophil count greater or equal to 500/mm\\^3 for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil recovery.', 'timeFrame': 'Up to day 84 post-transplant'}, {'measure': 'Time to Platelet Recovery', 'description': 'The first day of a sustained platelet count \\> 20,000/mm\\^3 with no platelet transfusions in the preceding seven days.', 'timeFrame': 'Up to day 84 post-transplant'}, {'measure': 'Incidence of Primary Graft Failure', 'description': 'Defined as \\< 5% donor CD3 chimerism. Chimerism will be measured by short tandem repeat-polymerase chain reaction on peripheral blood sorted into CD3 and CD33 cell fractions.', 'timeFrame': 'At day 84'}, {'measure': 'Disease-free Survival', 'description': 'Defined as being alive and in remission by \\< 5% blasts by bone marrow morphology for patients with myeloid malignancies and CT or PET imaging for patients with lymphoid malignancies at the time of the assessment', 'timeFrame': '3 years from the date of transplant'}, {'measure': 'Toxicity of Treatment Regimen Determined by Number of Adverse Events Per Organ System', 'description': 'Assessed by Common Terminology Criteria for Adverse Events version 3.0. The incidence of all adverse events greater or equal to grade 3 was determined.', 'timeFrame': 'Up to day 90'}, {'measure': 'Number of Red Blood Cell Transfusions', 'description': 'Number of units of RBCs given to the patient between day 0 and day 100 post transplant', 'timeFrame': 'Day 0-100'}, {'measure': 'Number of Platelet Transfusions', 'description': 'Number platelet transfusions given to the patient between day 0 and day 100 post transplant', 'timeFrame': 'Day 0-100'}, {'measure': 'Point Estimate of Overall Survival at 3 Years', 'description': 'Kaplan Meier estimate of the percentage of participants with overall survival at 3 years', 'timeFrame': '3 years'}]",12.0,,,ALL,False,OTHER,0.0,46.0,ACTUAL,v2_robust,True,False,True,True,The study experienced lower accrual rates after the onset of COVID. Upon review of the collected data it was deemed that an adequate amount of subjects has been enrolled to date to assess study aims.
NCT00831506,Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects,digoxin,"['digoxin', 'dimebon']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Alzheimer Disease,Pfizer,2025-09-01T16:18:08.354709,True,,,,,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects",,"['Alzheimer Disease', 'Huntington Disease']",['digoxin dimebon drug-drug interaction study'],,2009-02,2009-05,"[{'measure': 'AUC24 and Cmin of digoxin on Day 14', 'timeFrame': 'Day 14'}]","[{'measure': 'Cmax, Tmax, Ae, and renal clearance of digoxin on Day 14', 'timeFrame': 'Day 14'}, {'measure': 'Adverse event monitoring through Day 14 including physical/neurological examination findings', 'timeFrame': 'Day 14'}, {'measure': 'Clinical safety assessments through Day 14 including chemistry, hematology, and vital signs', 'timeFrame': 'Day 14'}, {'measure': '12-lead ECGs through Day 14', 'timeFrame': 'Day 14'}]",5.0,18 Years,55 Years,ALL,True,INDUSTRY,1.0,12.0,ACTUAL,v2_robust,True,True,False,True,
NCT01486706,Efficacy and Safety of Gabapentin in Treating Overactive Bladder,Gabapentin,"['Gabapentin', 'Solifenacin Succinate', 'Placebo drugs']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Urinary Urgency,Michael E. Chua,2025-09-01T16:18:08.354719,True,,,,,Efficacy and Safety of Gabapentin in Treating Overactive Bladder,,"['Urinary Urgency', 'Urinary Frequency', 'Nocturia', 'Incontinence', 'Detrusor Uninhibited Activity', 'Quality of Life']","['Overactive Bladder', 'Gabapentin', 'Quality of Life', 'Urodynamic', 'safety', 'Efficacy']",,2010-10,2015-01,"[{'measure': 'improvement of symptom domain means decreased frequency to less than 8 micturitions per 24 hours, no urgency noted per 24 hrs and less that 3 wakening at bedtime for micturation.', 'description': 'Mean number of Micturations per 24 hrs, Mean number of urgency episodes pe 24 hrs, mean urgency incontinence episodes per 24hrs and mean nocturia episodes per 24hrs', 'timeFrame': '12 weeks'}]","[{'measure': 'Improvement of bladder function domain means increased bladder capacity (MVV)', 'timeFrame': '12 weeks'}, {'measure': 'Improvement in quality of life domain means increased overall quality of life as perceived and result in OAB-q', 'timeFrame': '12 weeks'}]",3.0,18 Years,75 Years,ALL,False,OTHER,1.0,94.0,ACTUAL,v2_robust,True,True,False,False,
NCT03419806,Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease,Infudopa i.v.,"['LCIG (Duodopa)', 'Infudopa IntraV', 'Infudopa SubC', 'Infudopa s.c.', 'Infudopa i.v.']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Parkinson Disease,Vastra Gotaland Region,2025-09-01T16:18:08.354731,True,,,,,"Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa",,['Parkinson Disease'],[],,2018-02-16,2020-04-20,"[{'measure': 'Steady state plasma concentration - levodopa', 'description': 'To demonstrate that Infudopa i.v. and s.c. yield steady state plasma concentration of levodopa that is equivalent with that of Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Area under plasma concentration versus time curve (AUC) - levodopa', 'description': 'AUC of levodopa plasma concentrations during the dosage interval with Infudopa i.v. and s.c. will be compared to Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Coefficient of variation (COV) for plasma levodopa concentrations', 'description': 'COV for plasma levodopa concentrations during the dosage interval with Infudopa i.v. and s.c. will be compared to Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}]","[{'measure': 'Local skin tolerability to the investigated products, Draize score', 'description': 'The number of participants with treatment-related local skin reactions during or following s.c and i.v. infusion of the IMP will be assessed. Local skin reactions will be rated by a dermatologist using Draize scoring.', 'timeFrame': 'For each treatment visit - Baseline: Day -1; Post infusion: t=24h, day 30±5 (only s.c. infusion), 30+/-5 days after last treatment visit.'}, {'measure': 'Local skin tolerability to the investigated products, subjective symptom ratings', 'description': 'In participants with skin reactions the skin symptoms tenderness and itching will be rated by the participants using a horizontal 10 cm visual analogue scale graded 0-100 where 0 represents no symptom and 100 worst possible.', 'timeFrame': 'For each treatment visit: Day 1 during infusion: t=2h, t=8h, t=16h after infusion start; Day 2 post infusion: t=24h after infusion start, day 30±5 (only s.c. infusion), 30+/-5 days after last treatment visit.'}, {'measure': 'Bioavailability - levodopa', 'description': 'To establish the bioavailability of levodopa given s.c. and as Duodopa compared to the i.v. administration', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Bioavailability - carbidopa', 'description': 'To establish the bioavailability of carbidopa given s.c. and as Duodopa compared to the i.v. administration', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Maximum plasma concentration (Cmax) - levodopa', 'description': 'Compare maximum plasma concentration (Cmax) of levodopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Maximum plasma concentration (Cmax) - carbidopa', 'description': 'Compare maximum plasma concentration (Cmax) of carbidopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Time of the maximum plasma concentration (tmax) - levodopa', 'description': 'Compare time of the maximum plasma concentration (tmax) of levodopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Time of the maximum plasma concentration (tmax) - carbidopa', 'description': 'Compare time of the maximum plasma concentration (tmax) of carbidopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Area under the curve (AUC) - levodopa', 'description': 'Compare area under the curve (AUC) of levodopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Area under the curve (AUC) - carbidopa', 'description': 'Compare area under the curve (AUC) of carbidopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Elimination half-life (t½) - levodopa', 'description': 'Compare elimination half-life (t½) of levodopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': 'Elimination half-life (t½) - carbidopa', 'description': 'Compare elimination half-life (t½) of carbidopa during treatment with s.c and i.v Infudopa versus Duodopa.', 'timeFrame': 'For each treatment visit: Pre-dose, t=15 min, t=30 min, t=1h, t=1.5h, t=2h, t=2.5h, t=3h, t=3.5h, t=4h, t=5h, t=6h, t=7h, t=8h, t=10h, t=12h, t=14h, t=16h, t=16.5h, t=17h, t=17.5h, t=18h, t=23h, and t=24h from infusion start.'}, {'measure': ""Parkinson's disease motor symptom ratings"", 'description': 'Bradykinesia and dyskinesia will be assessed using the Treatment Response Scale, TRS (Nyholm et al, 2005). For this assessment the following items from the UPDRS will be performed: Finger tapping (item 23), Rapid alternating hand movements (item 25), eg agility (item 26), arising from chair (item 27), gait (item 29), and global bradykinesia (item 31). The occurrence of dyskinesia during these items will be assessed according to the definitions of the Modified Dyskinesia Scale (Goetz et al. 1994). The TRS outcome measure is a Likert scale that ranges from -3 to +3 (severely bradykinetic to severely dyskinetic).', 'timeFrame': 'For each treatment visit: pre-dose, t=1,5h, t=5h, t=6h, t=7h, t=16h and t=24h from infusion start.'}, {'measure': 'Parkinson Kinetigraph objective bradykinesia measurement (BK score)', 'description': 'The 25th, 50th and 75th percentiles of the BK scores from a 24h recording will be determined.', 'timeFrame': 'For each treatment visit: Between 9-18 as well as +1h to +16h after infusion start.'}, {'measure': 'Parkinson Kinetigraph objective dyskinesia measurement (DK score)', 'description': 'The 25th, 50th and 75th percentiles of the DK scores from a 24h recording will be determined.', 'timeFrame': 'For each treatment visit: Day 1: Between 9-18 as well as +1h to +16h after infusion start.'}, {'measure': 'Parkinson Kinetigraph objective tremor episodes', 'description': 'The percent of time with ongoing tremor consisting of at least 10 seconds meeting the operational tremor criteria defined by Braybrook et al (2016) will be measured.', 'timeFrame': 'For each treatment visit: Day 1: Between 9-18 as well as +1h to +16h after infusion start.'}, {'measure': 'Parkinson Kinetigraph objective Fluctuation dyskinesia score (FDS)', 'description': 'The fluctuation dyskinesia score will be calculated from the interquartile range of BK and DK scores.', 'timeFrame': 'For each treatment visit: Day 1: Between 9-18 as well as +1h to +16h after infusion start.'}]",20.0,30 Years,,ALL,False,OTHER_GOV,3.0,25.0,ACTUAL,v2_robust,True,True,False,False,
NCT01998906,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer,Trastuzumab,"['Paclitaxel', 'Doxorubicin', 'CMF', 'Herceptin', 'Trastuzumab']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Breast Cancer,Hoffmann-La Roche,2025-09-01T16:18:08.354862,True,,,,,"A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer",,['Breast Cancer'],[],,2002-05,2012-07,"[{'measure': 'Event-Free Survival (EFS) - Percentage of Participants With an Event', 'description': 'EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.', 'timeFrame': 'Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Event-Free Survival', 'description': 'The median time, in months, between randomization and date of documented occurrence of an EFS event.', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Event Free at 1 Year', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Event Free at 2 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Event Free at 3 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}]","[{'measure': 'Percentage of Participants With Breast Pathological Complete Response (bpCR)', 'description': 'bpCR was defined as an absence of any invasive cancer cell of the primary tumor at the time of major surgery after neoadjuvant chemotherapy with and without trastuzumab.', 'timeFrame': 'BL, Day 1 of Cycles 1-10 (pre-surgery)'}, {'measure': 'Percentage of Participants With Total Pathological Complete Response (tpCR)', 'description': 'tpCR was defined as a determination of bpCR and an absence of positive axillary nodes on pathology.', 'timeFrame': 'BL, Day 1 of Cycles 1-10 (pre-surgery)'}, {'measure': 'Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria', 'description': 'Assessments were made based on objective tumor measurements of the lesions as recorded in the case report form. In inflammatory cancer, progressive disease (PD) was defined as progression of any of the 2 signs of breast edema and erythema. In non-inflammatory cancer, PD was concluded if either the investigator judged the participant as having progressed at any time prior to surgery, or there was at least a 20% increase in the sum of target lesions (TLs), any new lesion, or clear progression of any nontarget lesion (NTLs). Clear progression of any NTL was defined as at least a 20% increase in the sum of NTLs compared to BL. PR was defined as at least a 30% decrease from BL in the sum of the longest diameter of TLs. CR was defined as no PD as assessed by the investigator and complete disappearance of all lesions.', 'timeFrame': 'BL, Presurgery: Day 1 of Cycles 1-10'}, {'measure': 'Overall Survival (OS) - Percentage of Participants With an Event', 'description': 'OS was defined as the time from the date of randomization to the date of the death due to any cause.', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Overall Survival', 'description': 'OS was defined as the time from the date of randomization to the date of the death due to any cause.', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Surviving at 1 Year', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Surviving at 2 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Surviving at 3 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}]",13.0,18 Years,,FEMALE,False,INDUSTRY,0.0,330.0,ACTUAL,v2_robust,True,True,False,False,
NCT01913106,HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer,HSV-tk +Valacyclovir in Combination with Brachytherapy,"['HSV-tk +Valacyclovir in Combination with Brachytherapy', 'IND 13567']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Prostatic Neoplasms,The Methodist Hospital Research Institute,2025-09-01T16:18:08.355010,True,,,,,Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease,,['Prostatic Neoplasms'],[],,2007-06,2028-12,"[{'measure': '1. Safety based on standard laboratory and clinical adverse event monitoring', 'timeFrame': '5-year biochemical disease free survival rate'}]","[{'measure': 'Local control survival (measured by PSA and biopsy)', 'timeFrame': '5-year biochemical disease free survival rate'}, {'measure': 'Evaluate immunological markers', 'timeFrame': '5-year post treatment'}]",3.0,,,MALE,False,OTHER,0.0,25.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01376206,Drug Use Investigation for ALLERMIST,Fluticasone,['Fluticasone'],1,OBSERVATIONAL,[],,COMPLETED,Rhinitis,GlaxoSmithKline,2025-09-01T16:18:08.355016,True,,,,,Drug Use Investigation for ALLERMIST,,['Rhinitis'],[],,2009-12,2011-05,"[{'measure': 'The number of adverse events in Japanese subjects with allergic rhinitis treated with fluticasone nasal spray', 'timeFrame': 'Four weeks'}]",[],1.0,,,ALL,False,INDUSTRY,0.0,2000.0,ACTUAL,v2_robust,False,True,False,True,
NCT01853306,"A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",Veliparib,['Veliparib'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Oncology,AbbVie,2025-09-01T16:18:08.355022,True,,,,,"A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors",,"['Oncology', 'BRCA Mutated', 'High Grade Serous Ovarian Cancer', 'BRCA Mutated Breast Cancer']","['High grade serous ovarian cancer', 'BRCA mutated breast cancer', 'BRCA mutated', 'Oncology']",,2013-03-18,2017-06-29,"[{'measure': 'Part 2 - Dose Escalation Cohort: Pharmacokinetic testing', 'description': 'Cmax, Tmax ,and AUC, and safety parameters', 'timeFrame': 'Up to 36 months'}, {'measure': 'Part 1 - Pharmacokinetic profile', 'description': 'The following pharmacokinetic parameters will be analyzed: Tmax, the terminal phase elimination rate constant (β), the natural logarithms of Cmax, AUCt and AUC∞.', 'timeFrame': 'Up to Day 6'}, {'measure': 'Part 3 - Safety Expanded Cohort: Number of subjects with adverse events', 'timeFrame': 'Up to 36 months'}, {'measure': 'Part 3 - Safety Expanded Cohort: Vital signs', 'description': 'Blood pressure, Heart rate', 'timeFrame': 'Up to 36 months'}, {'measure': 'Part 3 - Safety Expanded Cohort: Laboratory tests', 'description': 'Hematology, Chemistry, Urinalysis', 'timeFrame': 'Up to 36 months'}]","[{'measure': 'The number of participants with adverse events who receive the extended release formulations of veliparib.', 'timeFrame': 'Up to 36 months'}]",6.0,18 Years,99 Years,ALL,False,INDUSTRY,0.0,71.0,ACTUAL,v2_robust,True,True,False,True,
NCT00890604,Outcomes Associated With Application of a Normothermia Protocol in Patients With Severe Neurological Insult and Fever,Ibuprofen,"['Ibuprofen', 'Acetominophen']",2,INTERVENTIONAL,['NA'],,COMPLETED,Subarachnoid Hemorrhage,University of Washington,2025-09-01T16:18:08.355087,True,,,,,Outcomes Associated With the Application of the Normothermia Protocol in Patients With Severe Neurological Insult and Fever,,"['Subarachnoid Hemorrhage', 'Severe Traumatic Brain Injury']",[],,2009-07,2011-07,"[{'measure': 'Glasgow Coma Score', 'timeFrame': '24 hour'}]","[{'measure': 'temperature', 'timeFrame': 'hourly'}, {'measure': 'length of stay (intensive care, hospital)', 'timeFrame': 'discharge'}]",3.0,18 Years,85 Years,ALL,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,False,
NCT00694304,"Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults",Vortioxetine (Lu AA21004),"['Vortioxetine (Lu AA21004)', 'Brintellix']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Major Depressive Disorder,H. Lundbeck A/S,2025-09-01T16:18:08.355101,True,,,,,"A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder",,['Major Depressive Disorder'],"['Major Depressive Disorder', 'Long-term', 'Safety', 'Open-label']",,2008-05,2010-04,"[{'measure': 'Number of Patients With Adverse Events (AEs)', 'timeFrame': 'Baseline to end of the 4-week safety follow-up period'}, {'measure': 'Percentage of Patients Who Withdrew Due to Intolerance to Treatment', 'timeFrame': 'Baseline to Week 52'}]","[{'measure': 'Change From Baseline in MADRS Total Score After 52 Weeks of Treatment', 'description': 'The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment', 'description': 'The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in CGI-S Score After 52 Weeks of Treatment', 'description': 'The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)', 'timeFrame': 'Week 52'}, {'measure': 'Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)', 'timeFrame': 'Week 52'}, {'measure': 'Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in SDS Total Score After 52 Weeks of Treatment', 'description': 'The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.', 'timeFrame': 'Baseline and Week 52'}]",10.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,535.0,ACTUAL,v2_robust,True,True,False,True,
NCT00975104,AMG 745 in Subjects With Age-associated Muscle Loss,AMG 745 0.3 mg/kg,"['AMG 745 0.3 mg/kg', 'AMG 745 3.0 mg/kg', 'AMG 745 1.0 mg/kg', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Age-associated Muscle Loss,Amgen,2025-09-01T16:18:08.355173,True,,,,,"A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss",,['Age-associated Muscle Loss'],"['Aging', 'Frailty', 'Sedentary', 'Immobilization', 'Atrophy', 'Muscle Wasting', 'Physical Activity']",Amgen has chosen at this time not to continue with AMG 745 study 20080733,2010-04,2011-08,"[{'measure': 'To evaluate the effect of AMG 745 weekly IV doses of 0.3 mg/kg, 1.0 mg/kg, or 3.0 mg/kg, compared with weekly IV placebo on thigh muscle CSA in subjects ≥ 65 yrs old with limited exercise tolerance and functional limitations', 'timeFrame': '12 Weeks'}]","[{'measure': 'To evaluate the effect of treatment with AMG 745 on muscle strength (hand grip strength) and function (gait speed, 10-step stair climb power, chair stand and 6 minute walk distance) and to evaluate the PK of AMG 745 following multiple IV administrations', 'timeFrame': '12 Weeks'}]",2.0,65 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Amgen has chosen at this time not to continue with AMG 745 study 20080733
NCT03753204,Salt-Sensitivity and Immunity Cell Activation,Furosemide 40 mg,"['Lasix', 'Furosemide 40 mg']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,High Blood Pressure,Vanderbilt University Medical Center,2025-09-01T16:18:08.355249,True,,,,,Salt-Sensitivity and Immunity Cell Activation,,"['High Blood Pressure', 'Salt; Excess', 'Inflammation']",[],,2021-09-01,2025-09-15,"[{'measure': 'The percent of participants with salt sensitive blood pressure', 'description': 'A reduction in systolic blood pressure \\>9 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive', 'timeFrame': 'Over 3 days'}]","[{'measure': 'Percent of participants with immune cell activation', 'description': 'We will collect blood before and after a salt-loading (Weinberger) protocol and assess immune cell activation.', 'timeFrame': 'Over 3 days'}]",2.0,18 Years,60 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01029704,Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus,EGT0001442,"['EGT0001442', 'Placebo capsules to match EGT0001442', 'Human SGLT2 inhibitor']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Diabetes Mellitus Type 2,Theracos,2025-09-01T16:18:08.355266,True,,,,,"A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Subjects With Type 2 Diabetes Mellitus With an Ascending Dose Safety and Pharmacokinetic Evaluation Period",,['Diabetes Mellitus Type 2'],['Diabetes Mellitus Type 2'],,2009-12,2010-07,"[{'measure': 'Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study', 'description': 'Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.', 'timeFrame': 'Baseline; Day -2 and Day 1. End of Treatment: Day 27 and Day 29'}, {'measure': 'Pharmacokinetics of EGT0001442 (Cmax) at 4 Dose Levels at Week 4', 'description': 'Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.', 'timeFrame': 'Pre-dose to 48 h post-dose'}, {'measure': 'Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4', 'description': 'Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.', 'timeFrame': 'Pre-dose to 48 h post-dose'}]","[{'measure': 'Change in the Body Weight From Baseline at Week 4', 'description': 'Changes in the body weight during the study period was calculated by subtracting body weight on day 1 from body weight at the end of treatment on day 29.', 'timeFrame': 'Baseline and Day 29'}, {'measure': 'Changes in Hemoglobin A1c (HbA1c) From Baseline at Week 4', 'description': 'HbA1c levels were measured at two time points; on day 1 and day 29 (end of treatment). Changes in the HbA1c level during the study period was calculated by subtracting HbA1c level on day 1 from HbA1c level at the end of treatment (day 29)', 'timeFrame': 'Baseline and Day 29'}, {'measure': 'Change in Urinary Glucose Excretion From Baseline to Day 1 and Day 28', 'description': 'Urinary glucose levels were measured at three time points; on Day 0 (baseline), Day 1 and Day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (Day 1) from urinary glucose level at end of treatment (Day 28) (i.e urinary glucose level on Day 28 minus urinary glucose level on Day 1).', 'timeFrame': 'Baseline, Day 1 and Day 28'}, {'measure': 'Change in FPG Following Cessation of Treatment', 'description': 'The mean change in FPG following cessation of treatment was obtained by calculating the difference between FPG values obtained on End of treatment (average of FPG values on days 27 and 29) and on Post Treatment (average of FPG values on days 41 and 43).', 'timeFrame': 'Days 27/29 to Days 41/43'}]",7.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,151.0,ACTUAL,v2_robust,True,True,False,False,
NCT01491204,Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer,Paclitaxel+HM30181,['Paclitaxel+HM30181'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Advanced Solid Tumors,Hanmi Pharmaceutical Company Limited,2025-09-01T16:18:08.355343,True,,,,,Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer,,['Advanced Solid Tumors'],[],,2006-08,2008-10,"[{'measure': 'MTD determination', 'timeFrame': 'Dose limiting Toxicity will be evaluated on Day 28 during Cycle 1'}]",[],1.0,19 Years,70 Years,ALL,False,INDUSTRY,0.0,25.0,ACTUAL,v2_robust,True,True,False,False,
NCT07030504,"To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects",SAL0133,"['placebo group', 'SAL0133 placebo', 'SAL0133', 'active drug group']",4,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Pharmacokinetics,"Shenzhen Salubris Pharmaceuticals Co., Ltd.",2025-09-01T16:18:08.355431,True,,,,,"The Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of SAL0133 Tablets in Chinese Adult Healthy Subjects",,['Pharmacokinetics'],[],,2023-01-10,2025-06,"[{'measure': 'The rate of AE', 'description': 'The rate of AE occurred in the whole study', 'timeFrame': 'from Day 1 to Day 5 or Day 10'}, {'measure': 'The rate of SAE', 'description': 'The rate of SAE occurred in the whole study', 'timeFrame': 'from Day 1 to Day 5 or Day 10'}, {'measure': 'blood pressure', 'description': 'the change (mmHg) of blood pressure including SBP and DBP in the whole study', 'timeFrame': 'from Day 1 to Day 5 or Day 10'}]",[],3.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,72.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05287984,Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL,"Zanubrutinib, Fludarabine, cyclophosphamide and rituximab","['Zanubrutinib, bendamustine, rituximab', 'Zanubrutinib, Fludarabine, cyclophosphamide and rituximab', 'ZFCR regimen', 'ZBR regimen']",4,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Chronic Lymphocytic Leukemia,"Institute of Hematology & Blood Diseases Hospital, China",2025-09-01T16:18:08.355469,True,,,,,A Phase 2 Clinical Trial to Evaluate the Efficacy of Zanubrutinib Followed Zanubrutinib Plus FCR (Fludarabine Cyclophosphamide and Rituximab) / BR(Bendamustine and Rituximab) in Newly Diagnosed Symptomatic CLL/SLL (STOP Trial),,"['Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma', 'Newly Diagnosed']","['chronic lymphocytic leukemia', 'Small Lymphocytic Lymphoma', 'newly diagnosed', 'Zanubrutinib']",,2022-03-22,2024-11-29,"[{'measure': 'MRD negative rate of CR patients', 'description': 'The negative MRD rate of patients with CR at the end of 16 cycles of treatment', 'timeFrame': 'up to the end of 16 cycles of treatment (each cycle is 28 days)'}]","[{'measure': 'overall response rate(ORR)', 'description': 'Defined as the proportion of patients whose BICR was assessed for CR, CRi, or PR according to IWCLL 2018 criteria at or before initiation of subsequent antitumor therapy.', 'timeFrame': 'up to the end of 16 cycles of treatment (each cycle is 28 days)'}, {'measure': 'Complete response (CR)', 'description': 'Defined as the percentage of subjects who achieved CR after treatment in the conformance population and the intentionality treatment population.', 'timeFrame': 'up to the end of 16 cycles of treatment (each cycle is 28 days)'}, {'measure': 'Duration of tumor remission(DOR)', 'description': 'Defined as the time interval between the first documented remission of disease and the first documented evidence of PD for patients in the intentional-treatment population (ITT). Exit with no progress or no recorded time of disease progression, with the date of the last examination as the end date.', 'timeFrame': 'up to 5 years'}, {'measure': 'time to next treatment(TTNT)', 'description': 'Patients in the treatment-intentionality population (ITT) were defined from the beginning of first-line treatment to the beginning of back-line treatment or the time of death.', 'timeFrame': 'up to 5 years'}, {'measure': 'Progress-free survival(PFS)', 'description': 'the time from treatment initiation until disease progression or death, If there was no progress at the time of withdrawal or the time of disease progression was not recorded, the end date was the date of the last examination.', 'timeFrame': 'up to 5 years'}, {'measure': 'The time at which the median MRD turned positive', 'description': 'It was defined as the time for the median peripheral and/or bone marrow MRD to become positive in patients with CR/CRi and MRD negative in bone marrow and peripheral blood after the 16th cycle of treatment.', 'timeFrame': 'up to 5 years'}, {'measure': 'overall survival', 'description': 'Defined as the time interval from enrollment to death for patients in the treatment-intentionality population (ITT). If the patient remains alive or if it is not known whether the patient is alive or dead, the date of death will be adopted at the most recent point in time when the patient is known to be alive.', 'timeFrame': 'up to 5 years'}, {'measure': 'Safety of treatment regimens', 'description': 'Defined as treatment-related toxicity', 'timeFrame': 'up to 5 years'}]",9.0,18 Years,,ALL,False,OTHER,0.0,63.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00938184,Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects,Paroxetine 12.5 milligrams tablet,"['Paroxetine 12.5 milligrams tablet', 'Paroxetine 25 milligrams tablet', 'Paroxetine 50 milligrams tablet']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Depressive Disorder,GlaxoSmithKline,2025-09-01T16:18:08.355495,True,,,,,"An Open Label, Randomized, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Doses of the Controlled-release Paroxetine Tablets at the Dose Levels of 12.5, 25 and 50mg in Healthy Japanese Male Subjects",,['Depressive Disorder'],"['tolerance', 'single dose', 'paroxetine', 'controlled-release tablet', 'safety', 'pharmacokinetics', 'Japanese healthy male subjects']",,2009-07-14,2009-09-02,"[{'measure': 'Pharmacokinetic parameters of plasma paroxetine after single doses of paroxetine CR at 12.5mg, 25mg and 50mg in healthy Japanese male volunteers', 'timeFrame': 'up to 120 hours after a single dose in all dosing sessions'}]","[{'measure': 'Safety and tolerability after single doses of paroxetine CR at 12.5mg, 25mg and 50mg in healthy Japanese male volunteers', 'timeFrame': 'up to 120 hours after a single dose in all dosing sessions'}]",2.0,20 Years,64 Years,MALE,True,INDUSTRY,0.0,18.0,ACTUAL,v2_robust,True,True,False,True,
NCT03171584,Antifungal Drugs in Treatment of Onychomycosis,Terbinafine,"['Itraconazole', 'Fluconazole', 'Terbinafine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Antifungal Drugs in Onychomycosis,Assiut University,2025-09-01T16:18:08.355515,True,,,,,Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis,,['Antifungal Drugs in Onychomycosis'],[],,2017-07-01,2019-11-01,"[{'measure': 'cure rate of patients', 'description': 'Percentage of patients with complete cure in every group', 'timeFrame': 'one year'}]",[],1.0,20 Years,60 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05975684,Baclofen for Children With Rumination Syndrome,Baclofen,"['Baclofen', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Rumination Syndrome,Nationwide Children's Hospital,2025-09-01T16:18:08.355522,True,,,,,A Randomized Controlled Pilot Trial of Baclofen for Children With Rumination Syndrome,,['Rumination Syndrome'],[],,2023-01-31,2024-07,"[{'measure': 'Vomiting once a week or less', 'description': 'Percentage of participants in each group who are vomiting once a week or less. This will be evaluated using a rumination severity survey.', 'timeFrame': 'The investigators will assess this specific metric at the end of four weeks.'}]",[],1.0,4 Years,18 Years,ALL,True,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02591784,Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer,Nimotuzumab,['Nimotuzumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Esophageal,"Biotech Pharmaceutical Co., Ltd.",2025-09-01T16:18:09.624878,True,,,,,The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer,,['Esophageal'],['nimotuzumab esophageal radiotherapy'],,2008-11,2011-12,"[{'measure': 'The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.)', 'description': 'assement of advers event after using medication based TAAE evaluation form', 'timeFrame': '3 months'}]","[{'measure': 'Complete response', 'timeFrame': '3 months'}, {'measure': 'Partial response (PR)', 'timeFrame': '3 months'}, {'measure': 'Stable disease (SD)', 'timeFrame': '3 months'}, {'measure': 'Progressive disease (PD)', 'timeFrame': '3 months'}, {'measure': 'Median survival time (MST)', 'timeFrame': '2 years'}, {'measure': 'Overall survival (OS)', 'timeFrame': '1 year,2 years'}]",7.0,18 Years,75 Years,ALL,False,OTHER,0.0,42.0,ACTUAL,v2_robust,True,True,False,True,
NCT02366884,Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011),Anti-Bacterial Agents,"['Anti-Bacterial Agents', 'Anti-Protozoal Agents', 'Anti-Fungal Agents']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Neoplasms,Dr. Frank Arguello Cancer Clinic,2025-09-01T16:18:09.624922,True,,,,,"Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments",,['Neoplasms'],"['malignant', 'atavistic chemotherapy', 'cancer']",,2011-07-26,2023-12-31,"[{'measure': 'Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response', 'description': 'Tumor regression will be measrued objectively and assessments appropriate for the type of cancer treated. Outcome measures may include 1) Changes in signs and symptoms; (2) Visual inspection of tumors using weekly photographs and measurements (as appropriate); (3)Monthly chest X-rays to monitor lung tumors, lung metastases and/or fluid in the chest; (4) Ultrasound to evaluate abdominal tumors (e.g., liver metastases), and breast and armpit lymph nodes; (5) CT, MRI and PET scans; (6) Tumor markers in blood such as Carcinoembryonic Antigen (CEA), CA-15.3, CA-19-9 and other laboratory studies to monitor response.', 'timeFrame': '6 Months'}]","[{'measure': 'Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response', 'description': 'Tumor regression will be measrued objectively and assessments appropriate for the type of cancer treated. Outcome measures may include 1) Changes in signs and symptoms; (2) Visual inspection of tumors using weekly photographs and measurements (as appropriate); (3)Monthly chest X-rays to monitor lung tumors, lung metastases and/or fluid in the chest; (4) Ultrasound to evaluate abdominal tumors (e.g., liver metastases), and breast and armpit lymph nodes; (5) CT, MRI and PET scans; (6) Tumor markers in blood such as Carcinoembryonic Antigen (CEA), CA-15.3, CA-19-9 and other laboratory studies to monitor response.', 'timeFrame': '12 Months'}, {'measure': 'Clinical safety as measured by the incidence of adverse events in each intervention group', 'description': 'Determine the percentage of incidence of adverse events in each intervention group.', 'timeFrame': '12 Months'}]",3.0,1 Year,75 Years,ALL,False,INDUSTRY,1.0,250.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02329184,"Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461",MYK-461,['MYK-461'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hypertrophic Cardiomyopathy,"MyoKardia, Inc.",2025-09-01T16:18:09.624943,True,,,,,"Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy",,['Hypertrophic Cardiomyopathy'],[],,2014-12,2016-04,"[{'measure': 'Safety: Incidence of adverse events', 'timeFrame': '28 Days'}]","[{'measure': 'Determination of pharmacokinetics parameters as measured by Cmax', 'description': 'maximum concentration (Cmax)', 'timeFrame': '28 Days'}, {'measure': 'Determination of pharmacokinetics parameters as measured by Tmax', 'description': 'time of the maximum measured concentration (Tmax)', 'timeFrame': '28 Days'}, {'measure': 'Determination of pharmacokinetics parameters as measured by AUC', 'description': 'area under the concentration-time curve (AUC)', 'timeFrame': '28 Days'}, {'measure': 'Determination of pharmacokinetics parameters as measured by t1/2', 'description': 'half-life (t1/2)', 'timeFrame': '28 Days'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,15.0,ACTUAL,v2_robust,True,True,False,True,
NCT00760084,Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome,Decitabine,"['Dacogen', 'Decitabine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acute Myelogenous Leukemia,Eisai Inc.,2025-09-01T16:18:09.625070,True,,,,,An Expanded Access Protocol to Administer Decitabine to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome,,"['Acute Myelogenous Leukemia', 'Myelodysplastic Syndrome']","['Acute Myelogenous Leukemia', 'Myelodysplastic Syndrome', 'Dacogen', 'Decitabine']",,2005-07,2008-02,"[{'measure': 'The Number of Subjects With Adverse Events', 'description': 'Generate safety information when patients were also taking concomitant medications and/or therapies without trial restrictions when decitabine was administered at a dose of 20 milligrams per meter squared (mg/m\\^2) over a 1-hour intravenous (IV) infusion for 5 consecutive days every 4 weeks in patients with MDS (\\< 30% blasts) or AML (\\> 30% blasts).', 'timeFrame': '3 months'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,True,False,True,
NCT00000284,Role of Metabolites in Nicotine Dependence (1) - 1,Cotinine fumarate,['Cotinine fumarate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Tobacco Use Disorder,National Institute on Drug Abuse (NIDA),2025-09-01T16:18:09.625082,True,,,,,Role of Metabolites in Nicotine Dependence (1),,['Tobacco Use Disorder'],['nicotine dependence'],,1995-02,2001-12,"[{'measure': 'Subjective effects'}, {'measure': 'Physiological effects'}, {'measure': 'Performance effects'}]",[],3.0,21 Years,45 Years,ALL,False,NIH,1.0,0.0,,v2_robust,True,True,False,False,
NCT06281184,A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA.,Methotrexate,['Methotrexate'],1,OBSERVATIONAL,[],,ENROLLING_BY_INVITATION,Hand Osteoarthritis,Diakonhjemmet Hospital,2025-09-01T16:18:09.625135,True,,,,,Long-term Effects of Methotrexate in Adults With Erosive Hand Osteoarthritis: A 30-month Follow-up of Former MERINO Participants (MERINO:2).,,"['Hand Osteoarthritis', 'Erosive Osteoarthritis']",['Erosive hand osteoarthritis'],,2024-07-29,2027-12-01,"[{'measure': 'Effect of MTX on radiographic progression of erosive hand OA.', 'description': 'Effect of MTX on radiographic progression of erosive hand OA according to Verbruggen-Veys anatomical atlas score at 12 months', 'timeFrame': '18 months'}]","[{'measure': 'Effect of MTX on pain, function and life quality', 'description': '• Finger joint pain previous 48 hours (VAS) at 18 months • Thumb base joint pain previous 48 hours (VAS) at 18 months • Pain most painful finger joint previous 48 hours (VAS) at 18 months • AUSCAN pain and function subscales at 18 months • OMERACT-OARSI responder criteria at 18 months • Patient-reported disease activity previous 48 hours (VAS) at 18 months • EQ-5D at 18 months', 'timeFrame': '18 months'}, {'measure': 'Effect of MTX on radiographic progression of hand OA.', 'description': '• KL grades • OARSI atlas (osteophytes, joint space narrowing, erosions)', 'timeFrame': '18 months'}]",3.0,18 Years,,ALL,False,OTHER,0.0,108.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01723384,Intermittent Naltrexone Among Polysubstance Users,Intermittent Oral Naltrexone,"['Placebo', 'Intermittent Oral Naltrexone']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Methamphetamine,"University of California, San Francisco",2025-09-01T16:18:09.625158,True,,,,,,,"['Methamphetamine', 'Alcohol']","['methamphetamine', 'alcohol', 'HIV', 'sexual behavior']",,2013-05,2014-11,"[{'measure': 'Feasibility of Retaining Participants in Trial', 'description': 'Proportion of persons retained by study arm.', 'timeFrame': 'proportions eligible and enrolled assessed on ongoing basis throughout the study, proportion of visits completed assessed bi-weekly for each participant; overall retention assessed over 2 month follow-up for each participant'}, {'measure': 'Acceptability to Taking Medication', 'description': 'Mean number of pills taken weekly, as determined by recorded openings from an electronic monitoring device for study medication pill dispensers', 'timeFrame': '2 month follow-up'}, {'measure': 'Tolerability to Study Drug, as Measured by Adverse Events', 'description': 'Frequency of Adverse Events, by arm', 'timeFrame': '2 months'}]",[],3.0,18 Years,70 Years,MALE,True,OTHER,1.0,30.0,ACTUAL,v2_robust,True,True,False,True,
NCT07061184,Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial,FLCWK,"['FLCWK', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Irritable Bowel Syndrome - Diarrhoea,Peking Union Medical College Hospital,2025-09-01T16:18:09.625173,True,,,,,"The Efficacy of Fengliao Changweikang Keli for Patients With Diarrhea-predominant Irritable Bowel Syndrome: Study Protocol for a Multicenter, Randomized, Placebo-controlled N-of-1 Trial",,"['Irritable Bowel Syndrome - Diarrhoea', 'Traditional Chinese Medicine (TCM)', 'N of 1 Study Design', 'Efficacy and Safety']",[],,2025-11,2028-05,"[{'measure': 'IBS-SSS score', 'description': 'The severity score questionnaire consists of 5 items and each item is rated on a scale of 0-100 points, leading to a total score of 0-500 points. An improvement of more than 50 points for IBS-SSS questionnaire is considered clinical effective.', 'timeFrame': 'At the end of run-in period (week 2) and at the end of each washout period (week 8, 14, 20, 26, 32) and during each treatment period (week 6, 12, 18, 24, 30, 36).'}]","[{'measure': 'IBS-QOL score', 'description': ""IBS-QOL is a 34-item questionnaire assessing patient's health related quality of life, and higher scores indicate a better quality of life. IBS-QOL focuses on eight domains, namely dysphoria, activity interference, body image, health worry, food avoidance, social reaction, sexual and relationships, and an increase of more than 14 points indicates clinical improvement in quality of life. The minimal clinically important difference (MCID) on the IBS-QOL is defined as a change of 10 points in the total score."", 'timeFrame': 'At the end of run-in period (week 2) and at the end of each washout period (week 8, 14, 20, 26, 32) and during each treatment period (week 6, 12, 18, 24, 30, 36).'}, {'measure': 'self-reported symptoms including abdominal pain and diarrhea', 'description': 'The score of worst abdominal pain in the past 24 hours will be evaluated by visual analogue scale (VAS) ranging from 0 to 10. The stool consistency of the past 24 hours will also be rated by BSFS, based on a 1 to 7 scale where 1 corresponds to a hard stool and 7 corresponds to watery diarrhea.', 'timeFrame': 'At the end of run-in period (week 2) and at the end of each washout period (week 8, 14, 20, 26, 32) and during each treatment period (week 6, 12, 18, 24, 30, 36).'}]",3.0,18 Years,75 Years,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04195633,"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",Cyclophosphamide,"['Fosfaseron', 'Claphene', 'Gengraf', 'Sandimmune', 'Carloxan', 'Cyclophosphan', 'Neosar', 'Cytoxan', 'WR- 138719', 'ERL 080A', '27-400', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Cyclophosphamide Monohydrate', 'Genuxal', 'Revimmune', 'Cycloblastine', 'Cicloxal', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cyclophosphamidum', 'Cycloblastin', 'Cyclophosphamide', 'Ledoxina', 'Cellcept', 'Cyclostine', 'Neoral', 'SangCya', 'Dihydroxybusulfan', 'Fludarabine', 'Treosulfan', 'Cyclophospham', 'CP monohydrate', 'CTX', 'Cyclosporine Modified', 'Cytophosphan', 'Cyclophosphane', 'Socium Mycophenolate', 'Clafen', 'CsA', 'Genoxal', '1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-', 'Tresulfon', 'Treosulphan', 'Ovastat', 'OL 27-400', 'Mycophenolate Mofetil', 'Syklofosfamid', 'ERL 080', 'Cyclophosphanum', 'Cyclosporine', 'MMF', 'Mycophenolate Sodium', 'Cytophosphane', 'Ciclosporin', 'Ciclofosfamida', 'Cyclophosphamid monohydrate', 'Cyclosporin', 'Fluradosa', 'Cyclosporin A', 'CYCLO-cell', 'Mitoxan']",62,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Acute Leukemia,Fred Hutchinson Cancer Center,2025-09-01T16:18:09.625221,True,,,,,Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen,,"['Acute Leukemia', 'Acute Lymphoblastic Leukemia', 'Acute Myeloid Leukemia', 'Adult Diffuse Large Cell Lymphoma', 'Anaplastic Large Cell Lymphoma', 'Burkitt Lymphoma', 'Chronic Myeloid Leukemia, BCR-ABL1 Positive', 'Chronic Myelomonocytic Leukemia', 'Hodgkin Lymphoma', 'Lymphoblastic Lymphoma', 'Lymphoplasmacytic Lymphoma', 'Mantle Cell Lymphoma', 'Mixed Phenotype Acute Leukemia', 'Myelodysplastic Syndrome', 'Prolymphocytic Leukemia', 'Refractory Chronic Lymphocytic Leukemia', 'Refractory Follicular Lymphoma', 'Refractory Marginal Zone Lymphoma', 'Refractory Small Lymphocytic Lymphoma']",[],,2021-01-25,2028-01-10,"[{'measure': 'Graft failure/rejection', 'description': 'The analysis for graft failure will be conducted among all patients as well as separately among patients by Arm A versus Arm B.', 'timeFrame': 'Up to 2 years post-transplant'}]","[{'measure': 'Overall survival', 'timeFrame': 'At 1- and 2-years post-transplant'}, {'measure': 'Progression free survival', 'description': 'Defined as the probability of being alive without sign of disease relapse or progression. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'At 1 year post-transplant'}, {'measure': 'Non-relapse mortality', 'description': 'Defined as death from any cause without sign of disease progression or relapse. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'At day 100 and 1 year post-transplant'}, {'measure': 'Cumulative incidence of relapse', 'timeFrame': 'At 1- and 2-years post-treatment'}, {'measure': 'Acute graft versus host disease', 'description': 'Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'Up to 2 years post-transplant'}, {'measure': 'Chronic graft versus host disease', 'description': 'Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'Up to 2 years post-transplant'}, {'measure': 'Clinically significant infections', 'description': ""Clinically significant infections include infections that have a significant impact on patient's clinical recovery, for instance infections that require in-patient hospitalization or prolongs existing hospitalization. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate."", 'timeFrame': 'Up to 2 years post-transplant'}, {'measure': 'Platelet engraftment', 'description': 'Defined as the first of three consecutive days with platelet count \\>= 20,000/uL on the peripheral blood, without platelet transfusion in the previous seven days. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'At day 100 post-transplant'}]",9.0,6 Months,,ALL,True,OTHER,1.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06586333,Optimizing Stress Ulcer Prophylaxis Practices and Reducing Associated Costs in Intensive Care Units: a Nonrandomized Controlled Study,stress ulcer prophylaxis,"['stress ulcer prophylaxis', 'clinical pharmacist']",2,INTERVENTIONAL,['NA'],,COMPLETED,Stress Ulcer,Altinbas University,2025-09-01T16:18:09.625315,True,,,,,Evaluation of the Effect of an Education Program on Reducing the Efficacy and Costs of Inappropriate Stress Ulcer Prophylaxis in Intensive Care Units,,['Stress Ulcer'],"['guidelines', 'adherence', 'stress ulcer', 'intensive care']",,2023-06-01,2023-12-01,"[{'measure': 'Adherence rates to ASHP guidelines', 'description': '% of physician who adhere to ASHP guidelines', 'timeFrame': '6 months'}]","[{'measure': 'Cost saving', 'description': 'The cost saving by adhere to ASHP guidelines', 'timeFrame': '6 months'}]",2.0,18 Years,,ALL,False,OTHER,0.0,196.0,ACTUAL,v2_robust,True,True,False,False,
NCT05161533,"Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial",Carboplatin,"[""Peyrone's Chloride"", 'DDP', 'Blastocarb', 'Cisplatyl', 'Metaplatin', 'Neoplatin', 'Placis', 'Carboplatinum', 'Platinol', 'Platinum Diamminodichloride', 'Paraplatin', 'Carboplatino', 'Paraplatine', 'Citoplatino', 'Lastet', 'Ribocarbo', 'Platinoxan', 'Platistin', 'Cis-diamminedichloridoplatinum', 'Ercar', 'Novoplatinum', 'Carbotec', 'Carboplat', 'Cysplatyna', 'Cis-platinous Diamine Dichloride', 'Carboplatin', 'Platinum', 'Vepesid', 'Platinex', ""Peyrone's Salt"", 'Carbosol', 'Blastolem', 'Cis-platinum II', 'Carbosin', 'Cisplatinum', 'Platinol-AQ', 'Plastistil', 'Lederplatin', 'Platiran', 'Platinwas', 'Nealorin', 'Displata', 'Cisplatin', 'CBDCA', 'Abiplatin', 'Cis-diammine-dichloroplatinum', 'Cis-diamminedichloro Platinum (II)', 'Platamine', 'Briplatin', 'Cis-diamminedichloroplatinum', 'VP-16', 'Platiblastin-S', 'CDDP', 'Platinol- AQ', 'Platinol-AQ VHA Plus', 'JM-8', 'Etoposide', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'Paraplatin AQ', 'Platiblastin', 'Cis-platinum', 'Carboplatin Hexal', 'Toposar', 'Citosin', 'VP-16-213', 'Cisplatina', 'Platosin', 'Cis-dichloroammine Platinum (II)', 'VP 16', 'VP 16-213', 'VP16', 'EPEG', 'Cismaplat', 'Cis-platinum II Diamine Dichloride']",74,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Extensive Stage Lung Small Cell Carcinoma,University of Washington,2025-09-01T16:18:09.625375,True,,,,,CASPIAN-RT Trial: Hypofractionated Consolidative Radiation Therapy After Durvalumab (MEDI4736) Plus Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer,,"['Extensive Stage Lung Small Cell Carcinoma', 'Stage IV Lung Cancer AJCC v8', 'Stage IVA Lung Cancer AJCC v8', 'Stage IVB Lung Cancer AJCC v8']",[],Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled.,2023-10-19,2024-12-31,"[{'measure': 'Progression free survival', 'description': ""The distribution of time to event outcomes will be evaluated using the method of Kaplan-Meier. Confidence intervals for median times will be determined using the Brookmeyer-Crowley method. Confidence intervals around landmark times will be determined using Greenwood's formula for the variance and based on a log-log transformation applied on the survival function. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as response. Means and/or medians will be calculated for continuous outcomes. Confidence bounds will be provided for means and quartiles and ranges for median values. All confidence bounds will be presented as 95% bounds."", 'timeFrame': 'Up to 3 years'}]","[{'measure': 'Incidence of grade 2 or higher pneumonitis', 'description': 'The incidence of grade 2 or worse pneumonitis attributable to treatment will be evaluated and compared against the CASPIAN trial results. All toxicities of all grades will be monitored on study and reported. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as toxicity.', 'timeFrame': 'Up to 90 days after the last dose of durvalumab'}, {'measure': 'Overall survival', 'description': ""The distribution of time to event outcomes will be evaluated using the method of Kaplan-Meier. Confidence intervals for median times will be determined using the Brookmeyer-Crowley method. Confidence intervals around landmark times will be determined using Greenwood's formula for the variance and based on a log-log transformation applied on the survival function. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as response. Means and/or medians will be calculated for continuous outcomes. Confidence bounds will be provided for means and quartiles and ranges for median values. All confidence bounds will be presented as 95% bounds."", 'timeFrame': 'Up to 3 years'}, {'measure': 'Response rate', 'description': ""The distribution of time to event outcomes will be evaluated using the method of Kaplan-Meier. Confidence intervals for median times will be determined using the Brookmeyer-Crowley method. Confidence intervals around landmark times will be determined using Greenwood's formula for the variance and based on a log-log transformation applied on the survival function. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as response. Means and/or medians will be calculated for continuous outcomes. Confidence bounds will be provided for means and quartiles and ranges for median values. All confidence bounds will be presented as 95% bounds."", 'timeFrame': 'Up to 3 years'}, {'measure': 'Healthcare related quality of life: EORTC QLQ-C30', 'description': 'Will be measured by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).', 'timeFrame': 'Up to 3 years'}, {'measure': 'Healthcare related quality of life: EORTC QLQ-LC13', 'description': 'Will be measured by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - QLQ-Lung Cancer (LC)13 (EORTC QLQ-LC13).', 'timeFrame': 'Up to 3 years'}]",6.0,18 Years,,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled.
NCT04135833,A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711,BPI-7711,"['Rifampicin', 'Itraconazole', 'Rifampicin capsule', 'BPI-7711 capsule', 'Itraconazole capsule', 'BPI-7711']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,NSCLC,"Beta Pharma, Inc.",2025-09-01T16:18:09.625470,True,,,,,A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711 in Chinese Healthy Volunteers,,['NSCLC'],[],,2019-12-12,2020-07-22,"[{'measure': 'Cmax', 'description': 'Pharmacokinetics of BPI-7711 by assessment of maximum plasma concentration', 'timeFrame': 'Blood samples collected on Day 1 and Day 20 (arm 1)/Day 25 (arm 2) at pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 and 336 hours post BPI-7711 dose'}, {'measure': 'AUC(0-last)', 'description': 'Pharmacokinetics of BPI-7711 by assessment of area under the plasma concentration time curve from zero to last assessed timepoint', 'timeFrame': 'Blood samples collected on Day 1 and Day 20 (arm 1)/Day 25 (arm 2) at pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 and 336 hours post BPI-7711 dose'}]",[],2.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,31.0,ACTUAL,v2_robust,True,True,False,False,
NCT02250833,CKD-828 (80/5mg) Pharmacokinetic Study,CKD-828,"['S-amlodipine', 'Anydipine s', 'Telminuvo', 'CKD-828', 'Micardis', 'Telmisartan']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hypertension,Chong Kun Dang Pharmaceutical,2025-09-01T16:18:09.625518,True,,,,,To Compare the Pharmacokinetics and Safety of CKD-828 80/5mg to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers,,['Hypertension'],"['Hypertension', 'CKD-828', 'Telmisartan', 'S-amlodipine', 'Pharmacokinetic']",,2014-09,2014-12,"[{'measure': 'Cmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.', 'timeFrame': 'up to 168 hours post dose'}, {'measure': 'AUClast after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.', 'timeFrame': 'up to 168 hours post dose'}]","[{'measure': 'Tmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.', 'timeFrame': 'up to 168 hours post dose'}, {'measure': 't1/2 after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.', 'timeFrame': 'up to 168 hours post dose'}, {'measure': 'AUCinf after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.', 'timeFrame': 'up to 168 hours post dose'}, {'measure': 'Number of participants with adverse events', 'description': '* Adverse Event monitoring\n* Evaluated safety parameters included: Physical examination, Vital sign, ECG, laboratory test', 'timeFrame': 'up to 31days post dose'}]",6.0,19 Years,55 Years,MALE,True,INDUSTRY,0.0,69.0,ACTUAL,v2_robust,True,True,False,True,
NCT01836133,An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT),Erlotinib 150 mg,['Erlotinib 150 mg'],1,OBSERVATIONAL,[],,COMPLETED,Non-Squamous Non-Small Cell Lung Cancer,Hoffmann-La Roche,2025-09-01T16:18:09.625623,True,,,,,"Efficacy and Safety of Erlotinib (Tarceva® ) Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) , Subtype Adenocarcinoma, Who Have Good Performance Status (PS 0-1) - ELEMENT",,['Non-Squamous Non-Small Cell Lung Cancer'],[],,2013-05,2016-01,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS was defined as the time from initial dose of erlotinib to progression or death from any cause.', 'timeFrame': 'Approximately 3 years'}]","[{'measure': 'Percentage of Participants With Overall Response', 'description': 'Overall response was defined, based on response evaluation criteria in solid tumours (RECIST) v 1.1, as complete response (CR) plus partial response (PR). CR: complete disappearance of all target lesions; PR: at least 30% decrease in the sum of the longest diameter of all target lesions taking as reference the baseline sum of all target lesions.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Proportions of Participants With Adverse Events (AEs), Serious AEs, and AEs of Special Interest (AESIs)', 'description': 'An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant, according to national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) criteria version 4.0. An AESI was defined as interstitial pulmonary disease.', 'timeFrame': 'Baseline up to 3 years'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,70.0,ACTUAL,v2_robust,False,True,False,True,
NCT01005433,Dexmedetomidine for Cesarean Delivery,Dexmedetomidine,"['Dexmedetomidine', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pregnant Women Undergoing Cesarean Delivery,King Faisal University,2025-09-01T16:18:09.625646,True,,,,,A Dose - Dependent Study of Dexmedetomidine in Suppressing Cardiovascular and Hormonal Responses for Cesarean Delivery,,['Pregnant Women Undergoing Cesarean Delivery'],"['dexmedetomidine', 'stress response', 'cesarean delivery']",,2009-12,2011-12,"[{'measure': 'identifying the effects of 0.2, 0.4 and 0.6 µg/kg/h dexmedetomidine for on 1. Hemodynamic [heart rate, systolic and mean blood pressure] changes. 2. The perioperative changes in plasma cortisol and catecholamines concentrations', 'timeFrame': 'before and 15 min after infusion; each 1 min for 10 min after induction; 15 and 30 min after delivery; and 0, 1, 5, 15, 30, and 60 min after extubation'}]","[{'measure': 'Apgar score, the neurologic and adaptive capacity score (NACS), and umbilical cord venous and arterial blood gases analyses.The quality of extubation and analgesia.major complications (respiratory, cardiovascular events, and neonatal adverse outcome', 'timeFrame': 'after delivery, and postoperative'}]",2.0,18 Years,45 Years,FEMALE,False,OTHER,0.0,68.0,ACTUAL,v2_robust,True,True,False,True,
NCT04942652,Study to Evaluate Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers,Itraconazole 200 mg,"['Nexium', 'Sporanox capsule', 'Esomeprazole 40 mg', 'Itraconazole 200 mg']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Achlorhydria,Seoul National University Hospital,2025-09-01T16:18:09.625694,True,,,,,"An Open-label, Three-period, One-sequence Crossover Clinical Trial to Evaluate the Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers",,['Achlorhydria'],[],,2021-07-13,2021-08-24,"[{'measure': 'Cmax of itraconazole', 'description': 'Pharmacokinetic parameters of itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'AUClast of itraconazole', 'description': 'Pharmacokinetic parameters of itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'AUCinf of itraconazole', 'description': 'Pharmacokinetic parameters of itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'Tmax of itraconazole', 'description': 'Pharmacokinetic parameters of itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 't1/2 of itraconazole', 'description': 'Pharmacokinetic parameters of itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'CL/F of itraconazole', 'description': 'Pharmacokinetic parameters of itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'Vd/F of itraconazole', 'description': 'Pharmacokinetic parameters of itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'Cmax of hydroxy-itraconazole', 'description': 'Pharmacokinetic parameters of hydroxy-itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'AUClast of hydroxy-itraconazole', 'description': 'Pharmacokinetic parameters of hydroxy-itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'AUCinf of hydroxy-itraconazole', 'description': 'Pharmacokinetic parameters of hydroxy-itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'Tmax of hydroxy-itraconazole', 'description': 'Pharmacokinetic parameters of hydroxy-itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 't1/2 of hydroxy-itraconazole', 'description': 'Pharmacokinetic parameters of hydroxy-itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}, {'measure': 'metabolic ratio of hydroxy-itraconazole', 'description': 'Pharmacokinetic parameters of hydroxy-itraconazole', 'timeFrame': 'Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose'}]",[],13.0,19 Years,50 Years,ALL,True,OTHER,0.0,13.0,ACTUAL,v2_robust,True,True,False,False,
NCT04752852,Use of Prophylactic Steroids in the Prevention of Post-thyroidectomy Hypocalcaemia and Voice Dysfunction,Dexamethasone,"['Dexamethasone', 'normal saline (0.9%)', 'Placebo']",3,INTERVENTIONAL,['NA'],,COMPLETED,Thyroid Diseases,"Holy Family Hospital, Pakistan",2025-09-01T16:18:09.625720,True,,,,,Randomised Control Trial on the Use of Prophylactic Steroids in the Prevention of Post-thyroidectomy Hypocalcaemia and Voice Dysfunction,,"['Thyroid Diseases', 'Hypocalcemia', 'Vocal Cord Dysfunction']","['Thyroidectomy', 'Postoperative Hypocalcaemia', 'Postoperative Vocal cord dysfunction', 'Dexamethasone']",,2014-01,2020-07,"[{'measure': 'Hypocalcaemia', 'description': 'Hypocalcaemia was defined as a corrected serum calcium level of less than 2 mmol/L.', 'timeFrame': '3 days'}, {'measure': 'Voice dysfunction', 'description': 'Signs and symptoms of voice dysfunction at 24 hours after thyroidectomy. Voice dysfunction was defined on voice analogue score from 0-100. Participants with Voice Analogue Score of less than 50 were labelled as having voice dysfunction, and participants with score more than 50 were considered as normal.', 'timeFrame': '24 hours'}]",[],2.0,18 Years,60 Years,ALL,True,OTHER,0.0,192.0,ACTUAL,v2_robust,True,True,False,False,
NCT00322452,First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia,Gefitinib,"['Paclitaxel', 'Iressa', 'Carboplatin', 'ZD1839', 'Gefitinib']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Non-Small Cell Lung Cancer,AstraZeneca,2025-09-01T16:18:09.625750,True,,,,,"Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia",,['Non-Small Cell Lung Cancer'],"['NSCLC', 'Gefitinib']",,2006-03,2010-06,"[{'measure': 'Median Progression Free Survival (PFS) in Months', 'description': 'PFS was defined as the interval from the date of randomization to the date of objective disease progression (as per RECIST) or the date of death (from any cause) in the absence of objective disease progression. The median PFS in months is presented here.', 'timeFrame': 'Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).'}]","[{'measure': 'Median Overall Survival (OS) in Months at OS Data Cut Off (14th June 2010)', 'description': 'Overall Survival was assessed via calculation of the time to death due to any cause. If a participant was known to have died, the time to death was defined as the time from the date of randomization to the date of death. Otherwise, a participant was censored at the last date they were known to be alive. Median Overall Survival in months is presented here.', 'timeFrame': 'Following the PFS DCO on 14th April 2008 information on survival status was collected every 8 weeks.'}, {'measure': 'Objective Tumour Response Rate According to RECIST', 'description': 'Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response.', 'timeFrame': 'Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).'}, {'measure': 'Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Neutropenia', 'description': 'Number of patients with a neutropenia event, identified from the lab data as a worsening in absolute neutrophil count from baseline to a CTC grade 3 or above which Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel).', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Thrombocytopenia', 'description': 'Number of patients with a thromboctyopenia event, identified from the lab data as a worsening in platelet count from baseline to a CTC grade 3 or above. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel).', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Leukopenia', 'description': 'Number of patients with a leukopenia event, identified from the lab data as a worsening in white blood cell count from baseline to a CTC grade 3 or above. Based on the evaluable for-safety-population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel).', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Anaemia', 'description': 'Number of patients with an anaemia event, identified from the lab data as a worsening in haemoglobin from baseline to a CTC grade 3 or above. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel).', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Neurotoxicity', 'description': 'Number of patients with a neurotoxicity event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel)', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Rashes/Acnes', 'description': 'Number of patients with a rashes/acnes event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel)', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Diarrhoea', 'description': 'Number of patients with a diarrhoea event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel)', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Nausea', 'description': 'Number of patients with a nausea event. Based on the evaluable for-safety-population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel)', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Vomiting', 'description': 'Number of patients with a vomiting event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel)', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Liver Transaminases', 'description': 'Number of patients with an elevated liver transaminase event, identified from the lab data as a worsening in ALT or AST from baseline to a CTC grade 3 or above. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel).', 'timeFrame': 'Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel'}, {'measure': 'Quality of Life (QoL) as Measured by the Total Score of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire', 'description': 'Number of patients improving: a patient was described as improved if they had 2 visits (at least 21 days apart) where there was an increase in FACT-L score (from baseline) of 6 or more, and there were no intervening visits showing a decrease from baseline of 6 or more. Includes all patients with QoL data at baseline \\& at least 1 post-baseline visit', 'timeFrame': 'FACT-L data were collected at baseline, week 1, every 3 weeks (from baseline) until day 127, then every 42 days until the patient was confirmed as having objectively progressed (via RECIST), and at treatment discontinuation.'}, {'measure': 'Quality of Life (QoL) as Measured by the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire', 'description': 'Number of patients improving: a patient was described as improved if they had 2 visits (at least 21 days apart) where there was an increase in TOI score (from baseline) of 6 or more, and there were no intervening visits showing a decrease from baseline of 6 or more. Includes all patients with QoL data at baseline \\& at least 1 post-baseline visit', 'timeFrame': 'FACT-L data were collected at baseline, week 1, every 3 weeks (from baseline) until day 127, then every 42 days until the patient was confirmed as having objectively progressed (via RECIST), and at treatment discontinuation.'}, {'measure': 'Symptom Improvement as Measured by the Lung Cancer Subscale (LCS) of the FACT-L Questionnaire', 'description': 'Number of patients improving: a patient was described as improved if they had 2 visits (at least 21 days apart) where there was an increase in LCS score (from baseline) of 2 or more, and there were no intervening visits showing a decrease from baseline of 2 or more. Includes all patients with QoL data at baseline \\& at least 1 post-baseline visit', 'timeFrame': 'FACT-L data were collected at baseline, week 1, every 3 weeks (from baseline) until day 127, then every 42 days until the patient was confirmed as having objectively progressed (via RECIST), and at treatment discontinuation.'}]",16.0,18 Years,,ALL,False,INDUSTRY,0.0,1329.0,ACTUAL,v2_robust,True,True,False,True,
NCT01359852,"A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers",[11C] JNJ-42491293,"['[11C] JNJ-42491293 + JNJ-40411813', '[11C] JNJ-42491293']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",2025-09-01T16:18:09.625798,True,,,,,"An Open-Label Study to Investigate the Dosimetry of the Positron Emission Tomography Ligand for the Metabotropic Glutamate Receptor-2 (mGlu2R), [11C]JNJ-42491293, and Displacement by the mGlu2R Positive Allosteric Modulator JNJ-40411813 in Healthy Male Subjects",,['Healthy'],"['JNJ-42491293', 'JNJ-40411813', 'Metabotropic glutamate subtype 2 receptor (mGlu2R)', 'Positive allosteric modulator (PAM)', 'positron emission tomography (PET)']",,2010-12,2011-07,"[{'measure': 'Metabolism (uptake, distribution, and clearance) of [11C] JNJ-42491293 in brain (Part B)', 'timeFrame': 'Up to approximately 8 days'}, {'measure': 'Adverse events (All Parts)', 'timeFrame': 'Up to approximately 8 days (Part A); Up approximately 8 days (Part B); Up to 16 days (Part C); Up to approximately 9 days (Part D)'}, {'measure': 'Biodistribution of [11C] JNJ-42491293 (Part A)', 'timeFrame': 'Up to approximately 8 days'}, {'measure': 'Radiation dosimetry of [11C] JNJ-42491293 (Part A)', 'timeFrame': 'Up to approximately 8 days'}, {'measure': 'Peripheral metabolism of [11C] JNJ-42491293 (Part B)', 'timeFrame': 'Up to approximately 8 days'}]","[{'measure': 'Distribution of [11C] JNJ-42491293 in the brain by pre-treatment with single oral doses of JNJ-40411813 (Part C and Part D)', 'timeFrame': 'Up to approximately 16 days (Part C); Up to approximately 9 days (Part D)'}, {'measure': 'Clearance rate of JNJ-40411813 from the brain (Part D)', 'timeFrame': 'Up to approximately 9 days'}]",7.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,
NCT03590652,"Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma",Ixazomib,"['Ninlaro', 'Pomalidomide', 'Ixazomib', 'Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)', 'Darzalex Faspro', 'Dexamethasone', 'Decadron', 'Pomalyst']",8,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Relapsed/Refractory Multiple Myeloma,"University of California, San Diego",2025-09-01T16:18:09.625811,True,,,,,"Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)",,['Relapsed/Refractory Multiple Myeloma'],"['multiple myeloma', 'relapsed/refractory multiple myeloma', 'Daratumumab', 'Pomalidomide', 'Ixazomib', 'Dexamethasone', 'cancer', 'Phase 2', 'Darzalex', 'Pomalyst', 'Ninlaro', 'Decadron']",,2018-10-17,2026-10-01,"[{'measure': 'Overall Response Rate', 'description': 'Anti-cancer response as defined by the International Uniform Response Criteria Consensus Recommendations', 'timeFrame': '2 years'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Treatment-emergent Grade 2-5 adverse events (AEs) will be assessed using NCI CTCAE v4.03 toxicity criteria', 'timeFrame': '2 years'}]","[{'measure': 'Clinical benefit rate', 'description': 'CBR: minimal response +ORR', 'timeFrame': '2 years'}, {'measure': 'Progression free survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as the duration of time from start of treatment until objective tumor progression or death', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}, {'measure': 'Time to progression', 'description': 'Time to progression is defined as the duration of time from start of treatment until objective tumor progression.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival is defined as the duration of time from start of treatment to death', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}, {'measure': 'Minimal Residual Disease (MRD)', 'description': 'Assessment on the presence of minimal residual disease for those in stringent complete response', 'timeFrame': '1 year'}, {'measure': 'Quality of life (QOL) scores', 'description': 'Cancer Therapy Satisfaction Questionnaire and EORTC QLQ-MY20', 'timeFrame': '2 years'}]",8.0,18 Years,,ALL,False,OTHER,3.0,46.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04842552,Effect of Hydralazine on Alzheimer's Disease,Hydralazine hydrochloride 25mg tablets,"['Hydralazine hydrochloride 25mg tablets', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,2025-09-01T16:18:09.625821,True,,,,,The Effect of Hydralazine on the Early Stage of Alzheimer's Disease: A Randomized Clinical Trial,,['Alzheimer Disease'],"['Alzheimer Disease', 'Hydralazine', 'Early stage', 'Olfactory sense']",,2021-08-02,2023-12-20,"[{'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Three months after recruitment.'}, {'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Six months after recruitment.'}, {'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Nine months after recruitment.'}, {'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Twelve months after recruitment.'}]","[{'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Three months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Six months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Nine months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported three month after recruitment. Urgent matter can be reported any time to the provided hotline.'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported six month after recruitment. Urgent matter can be reported any time to the provided hotline.'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported nine month after recruitment. Urgent matter can be reported any time to the provided hotline.'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported twelve month after recruitment. Urgent matter can be reported any time to the provided hotline.'}]",28.0,49 Years,,ALL,False,OTHER,2.0,424.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03789552,Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina,T89 capsule,"['Placebo capsule', 'T89 capsule']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Chronic Stable Angina Pectoris,"Tasly Pharmaceuticals, Inc.",2025-09-01T16:18:09.625886,True,,,,,"A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Phase 3 Study to Confirm the Safety and Efficacy of T89 in Patients With Stable Angina Pectoris, With an Extended Open-label Period to Evaluate the Long-term Safety",,['Chronic Stable Angina Pectoris'],['angina pectoris'],,2019-08-01,2027-03,"[{'measure': 'Change in symptom-limited total exercise duration (TED) at trough drug levels on standard Bruce protocol from baseline to Day 57', 'description': 'Exercise, a common physiological stress, can elicit cardiovascular abnormalities that are not present at rest, and it can be used to determine the adequacy of cardiac function. Clinical exercise tolerance test (ETT) is an established non-invasive procedure that provides diagnostic and prognostic information for the evaluation of several pathologies, the most common of which is coronary heart disease. Total exercise duration (TED) is the time from starting ETT to terminating ETT, usually presented by minutes and seconds. Standard Bruce protocol, one of the protocols used for the conduction of an ETT as a pre-defined speed and gradient in different time interval, will be applied in this study. The TED at each ETT will be collected and recorded as primary parameter, and the change from baseline of symptom-limited TED at trough drug levels on standard Bruce protocol to Day 57 of treatment in high-dose and low-dose groups will be compared with that in placebo group.', 'timeFrame': 'Day 57 (post drug administration from randomization)'}]","[{'measure': 'The trend of TED changes over time (Slop) from Day 1 to Day 57', 'description': 'The trend of TED changes from Day 1 to Day 57 double-blind treatment period will be compared among high dose group, low dose group and placebo group.', 'timeFrame': 'Day 57 (post drug administration from randomization)'}, {'measure': 'Percent change in the average frequency of angina episodes (average over 14 days) from baseline [Day -14 to 1] to end of double-blind treatment period [Day 43 to 57]', 'description': 'A Wearable Cardiac Monitor (WCM) is a device similar to a Holter but quite smaller in size. This is a FDA-approved device used for recording the ECG up to for 7 days when patients may suffer from transient symptoms such as palpitations, dizziness, anxiety, fatigue, syncope, pre-syncope, light-headedness, shortness of breath. The WCM device is safe and easy for patients to use even when they are taking a short shower. Angina episodes during the past 7 days will be mainly collected from this device and recorded by site staff at due visit until Day 57. And percent change in the average frequency of angina episodes (average over 14 days) from baseline \\[Day -14 to 1\\] to end of double-blind treatment period \\[Day 43 to 57\\] in high-dose and low-dose groups will be compared with that in placebo group.', 'timeFrame': 'Day 57 (post drug administration from randomization)'}, {'measure': 'Percent change in the average on-demand consumption of short-acting nitroglycerin (average over 14 days) from baseline [Day -14 to 1] to end of double-blind treatment period [Day 43 to 57].', 'description': 'The amount of used short-acting nitroglycerin since last visit will be counted and recorded at each visit (except for the first visit), and percent change in the average on-demand consumption of short-acting nitroglycerin (average over 14 days) from baseline \\[Day -14 to 1\\] to end of double-blind treatment period \\[Day 43 to 57\\] in high-dose and low-dose groups will be compared with that in placebo group.', 'timeFrame': 'Day 57 (post drug administration from randomization)'}, {'measure': 'Change in symptom-limited total exercise duration (TED) at trough drug levels on standard Bruce protocol from baseline to Day 43', 'description': 'The TED at each ETT will be collected and recorded as primary parameter, and change in symptom-limited total exercise duration (TED) at trough drug levels on standard Bruce protocol from baseline to Day 43 in high-dose and low-dose groups will be compared with that in placebo group.', 'timeFrame': 'Day 43(post drug administration from randomization)'}, {'measure': 'Percent change in the average frequency of angina episodes (average over 14 days) from baseline [Day -14 to 1] to Week-6 visit of double-blind treatment period [Day 29 to 43]', 'description': 'A Wearable Cardiac Monitor (WCM) is a device similar to a Holter but quite smaller in size. This is a FDA-approved device used for recording the ECG up to for 7 days when patients may suffer from transient symptoms such as palpitations, dizziness, anxiety, fatigue, syncope, pre-syncope, light-headedness, shortness of breath. The WCM device is safe and easy for patients to use even when they are taking a short shower. Angina episodes during the past 7 days will be mainly collected from this device and recorded by site staff at due visit until Day 57. And percent change in the average frequency of angina episodes (average over 14 days) from baseline \\[Day -14 to 1\\] to Week-6 visit of double-blind treatment period \\[Day 29 to 43\\] in high-dose and low-dose groups will be compared with that in placebo group.', 'timeFrame': 'Day 43 (post drug administration from randomization)'}, {'measure': 'Change in time to onset of angina during ETT from baseline to Day 57', 'description': 'Commonly, exercise will make heart pump harder and faster, and further cause angina event during ETT as a result of myocardial ischemia. The time from the beginning of ETT to onset of angina during ETT will be collected and recorded at each ETT, and change in time to onset of angina during ETT from baseline to Day 57 in high-dose and low-dose groups will be compared with that in placebo group.', 'timeFrame': 'Day 57 (post drug administration from randomization)'}, {'measure': 'Change in time to 1 mm ST depression during ETT from baseline to Day 57', 'description': 'Commonly, exercise will make heart pump harder and faster, and further cause angina event during ETT as a result of myocardial ischemia, sometimes accompanied by horizontal or down-slopping ST segment depression in electrocardiograph (ECG) in some patients with stable angina. The time from the beginning of ETT to onset of at least of 1 millimeter (mm) horizontal or down-slopping ST segment depression during ETT will be collected and recorded at each ETT, and the change in time to onset of at least of 1 mm horizontal or down-slopping ST segment depression during ETT from baseline to Day 57 of treatment in high-dose and low-dose groups will be compared with that in placebo group.', 'timeFrame': 'Day 57 (post drug administration from randomization)'}]",8.0,18 Years,90 Years,ALL,False,INDUSTRY,0.0,765.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03723252,Dapagliflozin Efficacy and Action in NASH,Dapagliflozin,"['Placebo', 'Dapagliflozin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Nonalcoholic Steatohepatitis,"Nanfang Hospital, Southern Medical University",2025-09-01T16:18:09.625941,True,,,,,"Efficacy and Safety of Dapagliflozin in Non-alcoholic Steatohepatitis: a Multicentre, Randomized, Placebo-controlled Trial",,['Nonalcoholic Steatohepatitis'],"['Nonalcoholic Steatohepatitis', 'SGLT-2 inhibitor']",,2019-03-20,2024-03-28,"[{'measure': 'Improvement in scored liver histological improvement over 12 months', 'timeFrame': 'Baseline to 12 months'}]","[{'measure': 'Resolution of NASH', 'description': 'defined as a hepatocellular ballooning score of 0, and lobular inflammation score of 0 or 1) without worsening of fibrosis', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Improvement of fibrosis', 'description': 'defined as reduction in fibrosis of at least 1 stage) without worsening of NASH', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in fibrosis score', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in each component score in the NAS', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in body weight', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in waist circumference', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in visceral fat', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in liver fat', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in HbA1C', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in blood pressure', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in serum lipids', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in insulin resistance', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in inflammatory markers of NASH', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in health related quality of life scores (SF-36)', 'timeFrame': 'Baseline to 12 months'}]",15.0,18 Years,,ALL,False,OTHER,0.0,154.0,ACTUAL,v2_robust,True,True,False,False,
NCT03896152,"Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria",LNP023,"['iptacopan', 'LNP023']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Paroxysmal Nocturnal Hemoglobinuria,Novartis Pharmaceuticals,2025-09-01T16:18:09.626074,True,,,,,"A Multi-center, Randomized, Open-label, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Active Hemolysis",,['Paroxysmal Nocturnal Hemoglobinuria'],"['Complement', 'alternative pathway', 'paroxysmal nocturnal hemoglobinuria', 'hemolysis', 'LNP023', 'PNH', 'LDH', 'hemoglobin', 'Iptacopan']",,2019-04-05,2022-02-09,"[{'measure': 'Summary of Lactate Dehydrogenase (LDH) Responders', 'description': 'A responder was defined as a patient with at least 60% reduction in LDH compared to Baseline or LDH below the upper limit of normal at any time up to and including Week 12 for that patient.', 'timeFrame': 'Week 2, week 4, week 8 and week 12'}]","[{'measure': 'Percent Change From Baseline in LDH Levels', 'description': 'LDH was used as a hemolysis marker to determine the dose-response effect of iptacopan on the reduction of Paroxysmal nocturnal hemoglobinuria (PNH)-associated hemolysis.\n\nActive hemolysis is defined by an LDH value ≥ 1.5x upper limit of normal (ULN) Baseline LDH was calculated as the average of the last three screening values prior to randomization.\n\nSerum was used to calculate the LDH values', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Change From Baseline in Hemoglobin', 'description': 'Hemoglobin was used as a hemolysis marker to determine the dose-response effect of iptacopan on the reduction of PNH-associated hemolysis. Whole blood was used to calculate the hemoglobin values.', 'timeFrame': 'Baseline, Week 2, week 4, week 8 and week 12'}, {'measure': 'Change From Baseline in Free Hemoglobin', 'description': 'Free hemoglobin was used as a hemolysis marker to determine the dose-response effect of iptacopan on the reduction of PNH-associated hemolysis.\n\nWhole blood was used to calculate the hemoglobin values.', 'timeFrame': 'Baseline, Week 2, week 4, week 8 and week 12'}, {'measure': 'Change From Baseline in Carboxyhemoglobin', 'description': 'Carboxyhemoglobin was used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan.\n\nWhole blood was used to calculate the carboxyhemoglobin values.', 'timeFrame': 'Baseline, Week 2, week 4, week 8 and week 12'}, {'measure': 'Change From Baseline in Absolute Reticulocyte Count (ARC)', 'description': 'Reticulocyte count was used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan.\n\nWhole blood was used to calculate the absolute reticulocyte count.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Red Blood Cell Count: Change From Baseline in Erythrocytes', 'description': 'Erythrocytes were used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan.\n\nWhole blood was used to calculate erythrocytes values.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Change From Baseline in C3 Fragment Deposition on PNH RBC', 'description': 'C3 fragment deposition on paroxysmal nocturnal hemoglobinuria red blood cell (PNH RBC) was used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan. Accumulation of C3 fragments on red blood cells make them prone to phagocytosis causing extravascular hemolysis.\n\nWhole blood was used to calculate C3 fragment deposition on PNH RBC values.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Mean Haptoglobin Levels', 'description': 'Haptoglobin levels were used as a hemolysis marker to determine the effect of iptacopan on the reduction of PNH-associated hemolysis.\n\nSerum was used to calculate haptoglobin levels.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Change From Baseline in Total Bilirubin', 'description': 'Bilirubin levels were used as a hemolysis marker to determine the effect of iptacopan on the reduction of PNH-associated hemolysis.\n\nSerum was used to calculate bilirubin levels.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Mean Platelets Count', 'description': 'Platelet counts were used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan.\n\nWhole blood was used to calculate platelets count.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Mean Ferritin Levels', 'description': 'Ferritin levels were used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan.\n\nSerum was used to calculate ferritin levels.', 'timeFrame': 'Baseline, Week 4, Week 8 and week 12'}, {'measure': 'Mean Clone Size', 'description': 'PNH clone size was used as a marker of intravascular and extravascular hemolysis to assess the effect of iptacopan.\n\nWhole blood was used to calculate clone size values.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Pharmacokinetics Profile: Maximum Plasma Concentration (Cmax)', 'description': 'Cmax is the maximum (peak) observed plasma drug concentration after single dose administration (mass x volume-1).\n\nPK parameters were determined, using non-compartmental method(s) with Phoenix WinNonlin (Version 8.3), from the plasma concentration-time data.', 'timeFrame': 'Day 29 and 57'}, {'measure': 'Pharmacokinetics Profile: Area Under the Curve Tau (AUCtau)', 'description': ""The AUCtau is the area under the plasma concentration-time curve calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).\n\nAUCtau was estimated by imputing the 12-hour iptacopan plasma concentration as the PK profile's corresponding pre-dose (0-hour) value, that is, by assuming that at steady-state the iptacopan plasma concentration is the same as the beginning (pre-dose) and end (12 hours postdose) of the dosing interval.\n\nPK parameters were determined, using non-compartmental method(s) with Phoenix WinNonlin (Version 8.3), from the plasma concentration-time data."", 'timeFrame': 'Days 29 and 57'}, {'measure': 'Pharmacokinetics Profile: Minimum Plasma Concentration (Cmin)', 'description': 'Cmin is the lowest plasma concentration observed during a dosing interval at steady state \\[mass / volume\\].\n\nPK parameters were determined, using non-compartmental method(s) with Phoenix WinNonlin (Version 8.3), from the plasma concentration-time data.', 'timeFrame': 'Days 29 and 57'}, {'measure': 'Pharmacokinetics Profile: Time to Reach Maximum Plasma Concentration (Tmax)', 'description': 'Tmax is the time to reach maximum (peak) plasma drug concentration after single dose administration (time).\n\nPK parameters were determined, using non-compartmental method(s) with Phoenix WinNonlin (Version 8.3), from the plasma concentration-time data.', 'timeFrame': 'Days 29 and 57'}, {'measure': 'Mean Fibrinogen Levels', 'description': 'Fibrinogen level was used as a marker associated with risk of thrombosis. Plasma was used to calculate fibrinogen levels.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Mean Prothrombin Time (PT)', 'description': 'Prothrombin time was used as a marker associated with risk of thrombosis. Plasma was used to calculate prothrombin time.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Mean Activated Partial Thromboplastin Time (aPTT)', 'description': 'Activated partial thromboplastin time was used as a marker associated with risk of thrombosis.\n\nPlasma was used to calculate activated partial thromboplastin time.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Mean D-dimer Levels', 'description': 'D-dimer levels were used as a marker associated with risk of thrombosis. Plasma was used to calculate D-dimer levels.', 'timeFrame': 'Baseline, week 2, week 4, week 8 and week 12'}, {'measure': 'Mean Thrombin Clotting Time', 'description': 'thrombin clotting time was used as a marker associated with risk of thrombosis. Plasma was used to calculate thrombin clotting time.', 'timeFrame': 'Baseline, Week 4, Week 8 and Week 12'}]",22.0,18 Years,,ALL,False,INDUSTRY,0.0,13.0,ACTUAL,v2_robust,True,True,False,False,
NCT05832047,Aggressive Hydration With Lactated Ringer's Solution Versus Plasma Solution for the Prevention of Post ERCP Pancreatitis,Plasma solution (4-hour aggressive hydration),"['Plasma solution (4-hour aggressive hydration)', 'Hartmann Solution inno.N', '8-h AH', 'Plasma solution-A Inj.', '8-hour aggressive hydration', 'Lactated Ringer solution (4-hour aggressive hydration)']",6,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Pancreatic Disease,Do Hyun Park,2025-09-01T16:18:09.626239,True,,,,,"Aggressive Hydration With Lactated Ringer's Solution Versus Plasma Solution for the Prevention of Post ERCP (Endoscopic Retrograde Cholangiopancreatography) Pancreatitis : Multicenter, Double Blind, Randomized Controlled Trial",,['Pancreatic Disease'],"['ERCP', 'Endoscopic retrograde cholangiopancreatography', 'Pancreatitis']",,2023-06-19,2025-01-20,"[{'measure': 'Occurrence of pancreatitis after ERCP', 'description': 'The new onset or worsening of pain in the upper abdomen, accompanied by an elevation of pancreatic enzymes to at least three times the upper normal level within 24 hours after the procedure, requiring hospitalization for a minimum of two nights.', 'timeFrame': 'the next morning or within 24 hours after ERCP'}]","[{'measure': 'Occurrence of pancreatitis after ERCP at 4 hours after ERCP', 'description': 'The new onset or worsening of pain in the upper abdomen and the level of pancreatic enzymes is elevated\\>3 times the upper limit of normal level after 4 hours after ERCP', 'timeFrame': '4 hours after ERCP'}, {'measure': 'Number of Participants with Clinical signs of fluid overload', 'description': 'Clinical signs of fluid overload, for example, peripheral edema, pulmonary rales, increased jugular venous pressure, hepatojugular reflux, or both wll be monitored by investigator. If these signs are observed, hemodynamic testing or imaging studies will be done to investigate the evidence of pulmonary oedema, peripheral oedema, cardiac insufficiency and hypernatraemia.', 'timeFrame': '4 hours and, and the next morning or within 24 hours after ERCP'}, {'measure': 'Number of Participants with Asymptomatic Hyperamylasemia', 'description': 'Elevated level of serum amylase without upper abdominal pain', 'timeFrame': '4 hours and, the next morning or within 24 hours after ERCP'}, {'measure': 'Occurrence or aggravation of upper abdominal pain', 'description': 'Occurrence or aggravation of upper abdominal pain', 'timeFrame': '4 hours and, the next morning or within 24 hours after ERCP'}, {'measure': 'Days of ERCP-related hospital stay', 'description': 'Time for upper abdominal pain to disappear after the date of ERCP', 'timeFrame': 'Time for upper abdominal pain to disappear after the date of ERCP - up to 20 days'}]",6.0,18 Years,,ALL,False,OTHER,1.0,844.0,ACTUAL,v2_robust,True,True,False,False,
NCT01919047,Drug Use-Results Survey of Betanis Tablets in Japan,Betanis,"['Mirabegron', 'Betanis', 'YM178']",3,OBSERVATIONAL,[],,COMPLETED,Overactive Bladder,Astellas Pharma Inc,2025-09-01T16:18:09.626262,True,,,,,Drug Use-Results Survey of Betanis Tablets 25 and 50 mg,,['Overactive Bladder'],"['overactive bladder', 'mirabegron', 'occurrence of adverse events', 'Overactive Bladder Symptom Score']",,2012-04,2014-07,"[{'measure': 'Occurrence of adverse events and adverse drug reactions', 'timeFrame': 'For 12 weeks'}]","[{'measure': 'Changes in OABSS (overactive bladder symptom score)', 'timeFrame': 'baseline and at 12 weeks (or last observation period)'}, {'measure': 'Items of particular interest', 'timeFrame': 'baseline and at 12 weeks (or last observation period)'}]",3.0,,,ALL,False,INDUSTRY,0.0,10711.0,ACTUAL,v2_robust,False,True,False,True,
NCT02500147,Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS),Metformin,"['Fortamet', 'Placebo pill', 'Placebo', 'Metformin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Polycystic Ovary Syndrome,Columbia University,2025-09-01T16:18:09.626270,True,,,,,Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion,,"['Polycystic Ovary Syndrome', 'Non-Alcoholic Fatty Liver Disease', 'Metabolic Syndrome']","['Polycystic Ovary Syndrome', 'Non-Alcoholic Fatty Liver Disease', 'Adolescents', 'Young Women', 'MRI', 'MRS', 'DXA', 'PNPLA3', 'Metformin', 'Randomized Clinical Trial', 'Placebo', 'Hirsutism', 'Acne', 'Amenorrhea', 'Metabolic Syndrome', 'Dyslipidemia', 'Percentage liver fat']","Poor enrollment, administrative challenges, and lack of funding",2011-09-08,2021-03-03,"[{'measure': 'Percentage Liver Fat in Participants', 'description': 'To compare percentage liver fat by magnetic resonance spectroscopy in the metformin group and placebo group to baseline and between the groups in order to determine if metformin is efficacious for reducing liver fat compared to placebo in adolescents and young women with Polycystic Ovary Syndrome (PCOS)', 'timeFrame': '6 months'}]","[{'measure': 'The Association of Percentage Liver Fat by Magnetic Resonance Spectroscopy With Insulin Resistance as Measured by HOMA-IR in Adolescents With PCOS', 'description': 'The association of percent liver fat with insulin resistance as measured by HOMA-IR will be measured by correlation/regression. Change in HOMA-IR with change in percent liver fat following metformin will be assessed using multiple regression analysis.', 'timeFrame': '6 months'}]",2.0,13 Years,25 Years,FEMALE,False,OTHER,0.0,3.0,ACTUAL,v2_robust,True,False,True,False,"Poor enrollment, administrative challenges, and lack of funding"
NCT06294847,Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery,Ursolvan,"['Ursolvan', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Retinal Detachment,Hopital Foch,2025-09-01T16:18:09.626284,True,,,,,Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery,,['Retinal Detachment'],[],,2024-08-20,2027-11,"[{'measure': 'Difference in visual recovery (difference between preoperative and postoperative visual acuity) at 3 months postoperative (after a successful reapplication procedure) of at least 6 letters (ETDRS scale) between the two groups (treatment and placebo)', 'description': 'Difference in visual recovery (difference between preoperative and postoperative visual acuity) at 3 months postoperative (after a successful reapplication procedure) of at least 6 letters (Early Treatment Diabetic Retinopathy Study (ETDRS scale) between the two groups (treatment and placebo).\n\nThe minimum and maximums valus :\n\nMinimum value is 6/95 equivalent in ETDRS letter score read at 4 m = 55. Maximum value is 6/6 equivalement in ETDRS letter score read at 4 m= 115. Higher score mean better ourcome', 'timeFrame': '3 months'}]","[{'measure': 'Central Nervous Epithelium (CNE) thickness', 'description': 'Central Nervous Epithelium (CNE) thickness, measured by SD-OCT (Spectral-Domain Optical Coherence Tomography), within the central 1mm compared to the contralateral eye in the treated group versus the placebo group (measurement adjusted to the contralateral eye to account for interindividual variability) at 1, 3, and 6 months.', 'timeFrame': '1, 3, and 6 months'}, {'measure': 'Automated microperimetry at 1, 3, and 6 months: Macular sensitivity difference between the two groups.', 'description': 'Automated microperimetry at 1, 3, and 6 months: Macular sensitivity difference between the two groups.', 'timeFrame': '1, 3, and 6 months'}, {'measure': 'Contrast sensitivity measurement using the Clinic CSF2.0 application.', 'description': 'Contrast sensitivity measurement using the Clinic CSF2.012 application (Contrast sensitivity function 2.0 application).', 'timeFrame': 'Day 7, Day 30, Day 60, Day 60, Day 90 and Day 180'}, {'measure': 'Presence/absence of abnormal signs on optical coherence tomography (OCT) images (cysts, folds, membrane, ellipsoid zone, external limiting membrane).', 'description': 'Presence/absence of abnormal signs on optical coherence tomography (OCT) images (cysts, folds, membrane, ellipsoid zone, external limiting membrane).', 'timeFrame': '1, 3 and 6 months'}, {'measure': 'Retinal thickness measured by OCT (retinal layers and presence of cysts, layer segmentation and measurement in the central 1 and 3 mm in ETDRS quadrants).', 'description': 'Retinal thickness measured by OCT (retinal layers and presence of cysts, layer segmentation and measurement in the central 1 and 3 mm in ETDRS quadrants).', 'timeFrame': '1, 3 and 6 months'}, {'measure': 'Number of macular cones and retinal pigment epithelium (RPE) cells measured by Adaptive Optics at 1, 3, and 6 months with the ""Cellularis"" device that allows visualization of cones and RPE.', 'description': 'Number of macular cones and retinal pigment epithelium (RPE) cells measured by Adaptive Optics at 1, 3, and 6 months with the ""Cellularis"" device that allows visualization of cones and RPE.', 'timeFrame': '1, 3 and 6 months'}, {'measure': 'Blood test: liver parameters - AST (SGOT), ALT (SGPT), PAL, and γ-GT.', 'description': 'Blood test: liver parameters - AST (SGOT), ALT (SGPT), PAL, and γ-GT.', 'timeFrame': 'Day 7 and Day 30'}, {'measure': 'Evolution of the best visual acuity measured at Day 0, Day 7, Day 30, Day 60, Day 90, and Day 180: Difference between the treated and placebo groups in the progression curves of visual acuity.', 'description': 'Evolution of the best visual acuity measured at Day 0, Day 7, Day 30, Day 60, Day 90, and Day 180: Difference between the treated and placebo groups in the progression curves of visual acuity.', 'timeFrame': 'Day 7 and Day 30'}, {'measure': 'Presence of metamorphopsia.', 'description': 'Presence of metamorphopsia.', 'timeFrame': '1, 3 and 6 months'}, {'measure': 'Tolerance and occurrence of adverse events.', 'description': 'Tolerance and occurrence of adverse events.', 'timeFrame': '1, 3 and 6 months'}, {'measure': 'National Eye Institute Visual Functioning Questionnaire-25 (NEIVFQ-25) quality of life questionnaire before surgery, at ±7 days postoperative, and at 3 months postoperative.', 'description': 'National Eye Institute Visual Functioning Questionnaire-25 (NEIVFQ-25) quality of life questionnaire before surgery, at ±7 days postoperative, and at 3 months postoperative.', 'timeFrame': '1, 3 and 6 months'}, {'measure': 'Correlation between protein levels, bile acids, or other molecular markers in ocular and/or blood fluids and functional and anatomical ocular parameters pre- and post-operatively at different observation times.', 'description': 'Correlation between protein levels, bile acids, or other molecular markers in ocular and/or blood fluids and functional and anatomical ocular parameters pre- and post-operatively at different observation times.', 'timeFrame': '1 month'}, {'measure': 'Correlation between the effective duration of treatment and functional and anatomical outcomes at different observation times.', 'description': 'Correlation between the effective duration of treatment and functional and anatomical outcomes at different observation times.', 'timeFrame': '6 months'}]",14.0,18 Years,,ALL,False,OTHER,0.0,120.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01324947,Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma,pomalidomide,"['pomalidomide', 'CC-4047']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Multiple Myeloma,Celgene,2025-09-01T16:18:09.626327,True,,,,,"Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003",,['Multiple Myeloma'],"['Myeloma', 'Multiple Myeloma', 'Relapsed Multiple Myeloma', 'Relapsed and Refractory Multiple Myeloma', 'Refractory Myeloma', 'Resistant Multiple Myeloma', 'Treatment-resistant Multiple Myeloma', 'Pomalidomide', 'Lenalidomide-resistant', 'Bortezomib-resistant', 'Companion']",,2011-03-01,2014-07-31,"[{'measure': 'Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment', 'description': 'Objective response defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on Investigator Assessment.\n\nSCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \\<100 mg/24 hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \\<200 mg/24 hours. A ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.', 'timeFrame': 'From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.'}]","[{'measure': 'Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria Based on Investigator Assessment', 'description': 'Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the CR and requires all of the following:\n\n* Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days.\n* \\<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed.\n* No increase in size or number of lytic bone lesions.\n* Disappearance of soft tissue plasmacytomas.\n\nPR requires all of the following:\n\n* ≥50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days.\n* Reduction in 24-hour urinary light chain extraction by ≥90% or to \\<200 mg, maintained at least 42 days.\n* For patients with non-secretory myeloma, ≥50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days.', 'timeFrame': 'From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.'}, {'measure': 'Number of Participants With Adverse Events and Type of Adverse Events', 'description': 'An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that:\n\n* Results in death;\n* Is life-threatening;\n* Requires or prolongs existing inpatient hospitalization;\n* Results in persistent or significant disability/incapacity;\n* Is a congenital anomaly/birth defect;\n* Constitutes an important medical event.\n\nThe Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0):\n\nGrade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required);-Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death', 'timeFrame': 'From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 31 July 2014. Maximum time on treatment was 94.1 weeks.'}, {'measure': 'Kaplan Meier Estimates for Progression Free Survival (PFS) by Investigator Based on IMWG', 'description': 'Progression-free survival was calculated as the time from randomization to disease progression as determined by the Investigator based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier.\n\nProgressive disease requires 1 of the following:\n\n* Increase of ≥ 25% from nadir in:\n\n  * Serum M-component (absolute increase ≥ 0.5 g/dl)\n  * Urine M-component (absolute increase ≥ 200 mg/24 hours)\n  * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \\> 100 mg/dl)\n  * Bone marrow plasma cell percentage (absolute % ≥ 10%)\n* Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.', 'timeFrame': 'From randomization through the follow-up phase; Maximum duration of follow-up for PFS was 90.3 weeks.'}, {'measure': 'Kaplan-Meier Estimate for Time to Progression (TTP) Based on Investigator Assessment Using IMWG Criteria', 'description': 'Time to progression (TTP) was calculated as the time from randomization to the first documented progression confirmed by the investigator and based on the International Myeloma Working Group Uniform Response criteria (IMWG).\n\nProgressive disease requires 1 of the following:\n\n* Increase of ≥ 25% from nadir in:\n\n  * Serum M-component (absolute increase ≥ 0.5 g/dl)\n  * Urine M-component (absolute increase ≥ 200 mg/24 hours)\n  * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \\> 100 mg/dl)\n  * Bone marrow plasma cell percentage (absolute % ≥ 10%)\n* Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.\n* Development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dl) attributed solely to plasma cell proliferative disease.', 'timeFrame': 'From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to progression follow-up was 90.3 weeks.'}, {'measure': 'Kaplan-Meier Estimate Duration of Response Based on Investigator Assessment Using IMWG Criteria', 'description': 'Duration of Response (calculated for responders only) is defined as the time from the initial documented response (partial response or better) to confirmed disease progression by the investigator based on IMWG criteria.', 'timeFrame': 'From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum duration of response follow-up was 90.3 weeks.'}, {'measure': 'Kaplan-Meier Estimate for Overall Survival', 'description': 'Overall survival was calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.', 'timeFrame': 'From randomization through the follow-up phase; Maximum time on follow-up was 141.1 weeks.'}, {'measure': 'Time to Response Based on IMWG and Assessed by the Investigator', 'description': 'Time to Response was calculated as the time from enrollment to the initial response (PR or better) based on IMWG and assessed by the investigator.', 'timeFrame': 'From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to response was 23.1 weeks'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,74.0,ACTUAL,v2_robust,True,True,False,True,
NCT06307847,Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis,SP5M001 inj,"['SP5M001 inj', 'Synovian inj']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Osteoarthritis Thumb,Shin Poong Pharmaceutical Co. Ltd.,2025-09-01T16:18:09.626393,True,,,,,"A Multi-center, Randomized, Double-Blinded, Active Controlled, Non-Inferiority, Phase III Clinical Trial to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis",,['Osteoarthritis Thumb'],"['osteoarthritis, Knee', 'Intra-articular injection', 'hexamethylenediamine', 'Cross-linked hyaluronate']",,2021-04-14,2022-10-25,"[{'measure': 'Change in [Weight-Bearing Pain (WBP)-100mm-visual analogue scale (VAS)] at Week 12 from baseline (visit 2)', 'description': '\\* Weight Bearing Pain (WBP) - 100mm-visual analogue scale (VAS)', 'timeFrame': 'week 12'}]","[{'measure': 'Changes in the following at each visit : Weight Bearing pain(WBP) (Weeks 2, 6, 24, and 36) from baseline (Visit 2)', 'description': 'Outcome Measurement of Weight Bearing pain(WBP): 100mm-visual analogue scale (VAS)', 'timeFrame': 'week 2, 6, 24, 36'}, {'measure': 'Changes in the following at each visit : Rest pain (RP) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2)', 'description': 'Outcome Measurement of Rest pain (RP): 100mm-visual analogue scale (VAS)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Changes in the following at each visit : Night pain (NP) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2)', 'description': 'Outcome Measurement of Night pain (NP): 100mm-visual analogue scale (VAS)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Changes in the following at each visit : Motion pain (MP) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2)', 'description': 'Outcome Measurement of Motion pain (MP): 100mm-visual analogue scale (VAS)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Changes in the following at each visit : Patient Global Assessment(PGA) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2)', 'description': 'Outcome Measurement of Patient Global Assessment(PGA): 100mm-visual analogue scale (VAS)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Changes in the following at each visit : Investigator Global Assessment (IGA) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2)', 'description': 'Outcome Measurement of Investigator Global Assessment (IGA) : 100mm-visual analogue scale (VAS)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Changes in the following at each visit : Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total score and individual score evaluation (Pain, function, stiffness) (Weeks 2, 6, 12, 24, and 36) from baseline (Visit 2)', 'description': 'Outcome Measurement of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total score and individual score evaluation (Pain, function, stiffness)\n\n: WOMAC-Likert Assessment (5-point Likert scale)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Physical assessments at each post-administration visit: Swelling (Weeks 2, 6, 12, 24, and 36)', 'description': 'Outcome Measurement of Swelling: 4-point scale\n\n\\*4-point scale: 0(none)/1(mild)/2(moderate)/3(severe)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Physical assessments at each post-administration visit: joint-line tenderness on pressure (Weeks 2, 6, 12, 24, and 36)', 'description': 'Outcome Measurement of joint-line tenderness: 4-point scale\n\n\\*4-point scale: 0(none)/1(mild)/2(moderate)/3(severe)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Physical assessments at each post-administration visit: range of motion (Weeks 2, 6, 12, 24, and 36)', 'description': 'The angle was recorded as is for the range of motion.', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Proportion of participants who took rescue medication at each post-administration visit and dose of rescue medication (Weeks 2, 6, 12, 24, and 36)', 'timeFrame': 'week 2, 6, 12, 24, 36'}, {'measure': 'Post-administration response rate A. Proportion at which WBP decreases by at least 20 mm or improves by at least 40% from baseline at the time of evaluation (B section-Description)', 'description': ""\\*B. Response rate of OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Research Society International) I. At least 50% improvement in WOMAC pain or function at the time of evaluation; or at least a 20 point improvement from baseline; or II. meeting 2 of the 3 conditions below\n\n* At least 20% improvement in WOMAC pain, at least a 10 point improvement from each baseline\n* At least 20% improvement in WOMAC function, at least a 10 point improvement from each baseline\n* At least 20% improvement in patient's global assessment (100 mm-VAS) and at least a 10 point improvement from each baseline"", 'timeFrame': 'week 2, 6, 12, 24, 36'}]",13.0,40 Years,,ALL,False,INDUSTRY,0.0,223.0,ACTUAL,v2_robust,True,True,False,False,
NCT01732549,A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy,Tasquinimod,"['Tasquinimod', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Metastatic Castrate Resistant Prostate Cancer,Ipsen,2025-09-01T16:18:09.626522,True,,,,,"A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy",,['Metastatic Castrate Resistant Prostate Cancer'],[],Development of tasquinimod in prostate cancer discontinued,2013-01,2015-05,"[{'measure': 'Time to Radiological Progression Free Survival [PFS]', 'description': 'The time from the date of randomisation to the date of radiological progression or death due to any cause.\n\nRadiological progression was defined\n\n\\- Using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue lesions (Eisenhauer, EJC 2009), as at least a 20% relative and a 5 mm absolute increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters recorded on study (including Screening or the appearance of one or more new lesions) for target Lesions.\n\nAppearance of one or more new lesions and/or unequivocal progression of existing non-target lesions\n\n\\- Using Prostate Cancer Clinical Working Group in March 2008 (PCWG2) criteria for bone lesions (Scher, JCO 2008). Progression was defined as appearance of 2 or more bone lesions.', 'timeFrame': 'Every 8 weeks until disease progression documentation (approximately up to 2.5 years)'}]","[{'measure': 'Overall Survival Based on Number of Subjects Who Died', 'description': 'Overall survival is defined as the time from randomisation to death due to any cause.\n\nThe number of participants who died is presented since the Median was not reached for this assessment.\n\nTasquinimod: Patients censored = 63, Patients at risk (t=0) = 71 Placebo: Patients censored = 67, Patients at risk (t=0) = 73', 'timeFrame': 'Every 3 months after study treatment stop until death (approximately up to 2.5 years)'}, {'measure': 'Time to Progression Free Survival [PFS] on Next-line Therapy (PFS 2)', 'description': 'The time from the date of randomisation to the date of radiological progression free survival \\[PFS\\] on next-line therapy (PFS 2) or death due to any cause.\n\nRadiological progression was defined\n\n\\- Using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue lesions (Eisenhauer, EJC 2009), as at least a 20% relative and a 5 mm absolute increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters recorded on study (including Screening or the appearance of one or more new lesions) for target Lesions.\n\nAppearance of one or more new lesions and/or unequivocal progression of existing non-target lesions\n\n\\- Using Prostate Cancer Clinical Working Group in March 2008 (PCWG2) criteria for bone lesions (Scher, JCO 2008). Progression was defined as appearance of 2 or more bone lesions.', 'timeFrame': 'Every 3 months after study treatment stop (follow-up) until progression under the next line therapy (approximately up to 2.5 years)'}, {'measure': 'Symptomatic PFS Based on Number of Subjects Who Had Symptomatic Progression or Death', 'description': 'Symptomatic PFS is defined as the time from the date of randomisation to the date of symptomatic progression or death due to prostate cancer, whichever occurs first \\[symptomatic progression as assessed by Brief Pain Inventory (BPI) and analgesic use\\].\n\nSymptomatic progression was defined by the occurrence of pain with documented disease, skeleton related adverse events.\n\nThe median symptomatic PFS for placebo and tasquinimod groups was not reached.\n\nTasquinimod: Patients censored = 48, Patients at risk (t=0) = 71 Placebo: Patients censored = 54, Patients at risk (t=0) = 73', 'timeFrame': 'Every 8 weeks until symptomatic or radiological progression documentation (approximately up to 2.5 years)'}, {'measure': 'Time to Further Anticancer Treatment for Prostate Cancer', 'description': 'Time from randomisation to further treatment for prostate cancer', 'timeFrame': 'Every 3 months after study treatment stop until further anticancer therapy for prostate cancer (approximately up to 2.5 years)'}, {'measure': 'Time to Deterioration in Functional Assessment of Cancer Therapy - Prostate (FACT-P)', 'description': 'End of Study visit (within 14 days of last dose of study treatment)\n\nImpact of tasquinimod on health related quality of life (QoL) - Analysis of time to deterioration in FACT-P\n\nThe FACT-P measurement system is a validated collection of health related quality of life (HRQOL) questionnaires used to assess HRQOL in men with prostate cancer. It is appropriate for use with patients with any form of cancer and extensions of it have been used and validated in other chronic illness condition. The FACT-P is a self-administered 39-item scale comprising five domains: physical well-being, social/family well-being, functional well-being, emotional well-being and additional concerns. The individual subscale scores range from 0 to a high between 24 and 48 and the total score ranges between 0 and 156, with higher scores representing better Quality of Life (QoL)', 'timeFrame': 'Up to End of Study visit (approximately up to 2.5 years)'}, {'measure': 'Change From Baseline of EuroQol-5 Dimension QoL Instrument (EQ-5D) VAS Score', 'description': 'Baseline is defined as last measurement collected prior to the first dose of study drug. End of Study visit (within 14 days of last dose of study treatment)\n\nThe EQ-5D, a 5-item scale useful in health resource utilisation and cost comparisons between treatment groups designed for self-completion by patients consists of two pages \\[EQ-5 descriptive system and EQ Visual Analogue Scale(VAS)\\]. The EQ-5 descriptive system comprises five dimensions: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, severe problems. The EQ-VAS records the respondent\'s self-rated health on a vertical VAS. The respondents are asked to mark health status on the day of the interview on a 10cm vertical scale with end points of 0 to100. There are notes at the both ends of the scale that the bottom rate(0) corresponds to ""the worst health you can imagine"", and the highest rate(100) corresponds to ""the best health you can imagine""', 'timeFrame': 'Baseline and End-of-study Visit (approximately up to 2.5 years)'}, {'measure': 'Safety Profile of Tasquinimod', 'description': 'Number of subjects reporting adverse events', 'timeFrame': 'At regular intervals during the study treatment period and every 3 months during the follow-up until death (approximately up to 2.5 years)'}]",8.0,18 Years,,MALE,False,INDUSTRY,0.0,144.0,ACTUAL,v2_robust,True,False,True,True,Development of tasquinimod in prostate cancer discontinued
NCT02851849,A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus,LGD-6972-5 mg,"['LGD-6972-15 mg', 'LGD-6972-5 mg', 'LGD-6972 sodium salt capsules', 'LGD-6972-10 mg']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Type 2 Diabetes Mellitus,Ligand Pharmaceuticals,2025-09-01T16:18:09.626713,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus",,['Type 2 Diabetes Mellitus'],[],,2016-09,2017-06,"[{'measure': 'Change from baseline in HbA1c', 'timeFrame': '12 Weeks'}]","[{'measure': 'Change from baseline in HbA1C', 'timeFrame': 'Baseline to Weeks 2,4,8'}, {'measure': 'Change from baseline in fasting glucose', 'timeFrame': 'Baseline to Weeks 2,4,8 and 12'}, {'measure': 'Change from baseline values for fasting glucagon', 'timeFrame': 'Baseline to Weeks 2,4,8 and 12'}, {'measure': 'Change from baseline values for fasting GLP-1 (total and active)', 'timeFrame': 'Baseline to Weeks 2,4,8 and 12'}, {'measure': 'Change from baseline values for fasting insulin', 'timeFrame': 'Baseline to Weeks 2,4,8 and 12'}, {'measure': 'Change from baseline values for fasting lipids (total, LDL, and HDL cholesterol and triglycerides)', 'timeFrame': 'Baseline to Weeks 2,4,8, and 12'}, {'measure': 'Change from baseline in blood pressure (systolic and diastolic)', 'timeFrame': 'Baseline to Weeks 2,4,8, and 12'}, {'measure': 'Change from baseline in body weight', 'timeFrame': 'Baseline to Weeks 2,4,8 and 12'}]",9.0,21 Years,70 Years,ALL,False,INDUSTRY,0.0,148.0,ACTUAL,v2_robust,True,True,False,False,
NCT04651049,Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas,propranolol,['propranolol'],1,OBSERVATIONAL,[],,COMPLETED,Infantile Haemangiomas,Qilu Hospital of Shandong University,2025-09-01T16:18:09.626730,True,,,,,Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas,,['Infantile Haemangiomas'],[],,2010-07-15,2020-02-10,"[{'measure': 'Change on the height of the patients', 'description': 'we recorded the height of the patients in meters.', 'timeFrame': 'at the beginning of the treatment, at the end of treatment and 2 years after the treatment'}, {'measure': 'Change on the weight of the patients', 'description': 'we recorded the weight of the patients in kilograms.', 'timeFrame': 'at the beginning of the treatment, at the end of treatment and 2 years after the treatment'}]",[],2.0,2 Weeks,54 Weeks,ALL,False,OTHER,0.0,128.0,ACTUAL,v2_robust,False,True,False,False,
NCT01445938,Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria,SAR97276A,"['arthemeter + lumefantrine (ACTs)', 'SAR97276A']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Malaria,Sanofi,2025-09-01T16:18:09.626754,True,,,,,"An Open-label, Randomized Multicenter Study to Investigate the Anti-parasitic Activity, Pharmacokinetic and Safety of IM SAR97276A With Oral ACTs as Positive Control in Children Presenting With Symptomatic Plasmodium Falciparum Uncomplicated Malaria",,['Malaria'],[],Data Monitoring Committee recommendation,2011-10,2012-01,"[{'measure': 'Parasite Reduction Ratio (PRR)', 'timeFrame': 'at 72 hours'}]","[{'measure': 'Evolution of mean Parasitaemia over time (nb/µL)', 'timeFrame': 'every 6 hours from baseline up to 72 hours (day 4)'}, {'measure': 'Evolution of mean Gametocytes count over time (nb/µL)', 'timeFrame': 'from baseline to end of study (day 28 ± 2)'}, {'measure': 'Fever Clearance (time to reach Temperature < 38°C)', 'timeFrame': 'every 6 hours from baseline up to 72 hours (day 4)'}, {'measure': 'General conditions improvement: mean total symptom score over time', 'timeFrame': 'every 6 hours from baseline up to 72 hours (day 4)'}, {'measure': 'SAR97276 pharmacokinetic profile in plasma and blood', 'timeFrame': 'from baseline up to 12 hours after the last study drug intake on (Day 3'}]",6.0,2 Years,17 Years,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,False,True,False,Data Monitoring Committee recommendation
NCT05007938,Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer,Icotinib,"['Conmana', 'Befotertinib', 'D-0316', 'Icotinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Non-Small Cell Lung Cancer,"Betta Pharmaceuticals Co., Ltd.",2025-09-01T16:18:09.626783,True,,,,,"A Phase II, Single Arm, Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Sensitising EGFR Mutation",,['Non-Small Cell Lung Cancer'],[],,2021-08-12,2024-12-31,"[{'measure': 'Objective Response Rate （ORR）', 'description': 'ORR, per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR).', 'timeFrame': '24 months'}]","[{'measure': 'Duration of response（DOR）', 'description': 'DOR, defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death in the absence of disease progression.', 'timeFrame': '24 months'}, {'measure': 'Disease control rate（DCR）', 'description': 'DCR, defined as proportion of complete response, partial response, and disease stabilization to the proportion of patients with evalueable tumors.', 'timeFrame': '24 months'}, {'measure': 'Progression-free survival（PFS）', 'description': 'PFS, defined as time from study drug administration to progression or death due to any cause.', 'timeFrame': '36 months'}, {'measure': 'Intracranial objective response rate（iORR）', 'description': 'iORR, defined as the proportion of subjects with complete intracranial response, partial intracranial response to subjects with brain metastasis target lesions at baseline.', 'timeFrame': '24 months'}, {'measure': 'Overall survival （OS）', 'description': 'OS, defined as the time from study drug administration until the date of death due to any cause.', 'timeFrame': '36 months'}, {'measure': 'Adverse event（AE）', 'description': 'AE,defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study medication, whether or not considered related to the study drugs. AEs are summarized by type, incidence, severity and relationship to study drugs.', 'timeFrame': '36 months'}]",7.0,18 Years,,ALL,False,INDUSTRY,1.0,30.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04104438,Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant,Basiliximab 20 MG,"['Basiliximab 20 MG', 'Everolimus']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Asses Immunosuppression Modulation on Renal Recovery Post LT,"Fady M Kaldas, M.D., F.A.C.S.",2025-09-01T16:18:09.626876,True,,,,,"A Study in Adults on Pre LT Dialysis With Basiliximab, Delayed Tacrolimus (TAC), Mycophenolate (MMF), Steroids (Grp 1) vs. Basiliximab, Delayed TAC, MMF, Steroids, With Everolimus 30d Post LT(Grp 2), vs. TAC, MMF, Steroids (Grp 3).",,['Asses Immunosuppression Modulation on Renal Recovery Post LT'],[],,2021-01-15,2024-09-30,"[{'measure': 'Renal Function', 'description': 'Assessment of dialysis independence (patients no longer requiring dialysis post LT)', 'timeFrame': '6 months'}]",[],1.0,18 Years,78 Years,ALL,False,OTHER,0.0,71.0,ACTUAL,v2_robust,True,True,False,False,
NCT01768338,Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma,Ofatumumab combined with SB-485232,['Ofatumumab combined with SB-485232'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Non-Hodgkin's Lymphoma,Michael John Robertson,2025-09-01T16:18:09.626937,True,,,,,A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma,,"[""Non-Hodgkin's Lymphoma""]",[],,2013-02,2017-08-03,"[{'measure': 'To evaluate the the number of subjects with adverse events who receive SB-485232 when given in combination with ofatumumab', 'description': 'Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 which uses a scale of 1 (mild) to 5 (caused death).', 'timeFrame': '8 weeks'}]","[{'measure': 'To evaluate the biologic effects of SB-485232 given in combination with ofatumumab', 'description': 'Biologic effects will be assessed by flow cytometric analysis of PBMCs and ELISA tests to measure plasma cytokines and chemokines.', 'timeFrame': '8 weeks'}]",2.0,18 Years,,ALL,False,OTHER,1.0,9.0,ACTUAL,v2_robust,True,True,False,True,
NCT05271058,Effect of Intracameral Steroids During Phacoemulsification on the Cornea,Dexamethasone group,"['Dexamethasone group', 'Intracameral Dexamethasone', 'Intracameral triamcinolone (TA)', 'Triamcinolone (TA) group']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Corneal Edema,Cairo University,2025-09-01T16:18:09.627031,True,,,,,Effect of Intracameral Steroids Injection During Phacoemulsification on Postoperative Corneal Edema and Corneal Endothelium,,['Corneal Edema'],[],,2019-06-16,2020-08-15,"[{'measure': 'Corneal edema', 'description': 'Clinical grade of corneal edema on the first postoperative day', 'timeFrame': 'First day postoperative'}, {'measure': 'Central corneal thickness (CCT)', 'description': 'Central corneal thickness in microns after phacoemulsification that was compared to preoperative values', 'timeFrame': 'Three months'}, {'measure': 'Endothelial cell loss', 'description': 'Corneal endothelial cell count (cell/ square mm) after phacoemulsification that was compared to preoperative values', 'timeFrame': 'Three months'}]","[{'measure': 'IOP', 'description': 'Intraocular pressure in mmHg rise after after phacoemulsification', 'timeFrame': 'Three months'}]",4.0,50 Years,80 Years,ALL,False,OTHER,1.0,69.0,ACTUAL,v2_robust,True,True,False,False,
NCT05102058,Magnesium and Dexmedetomidine in Pheochromocytoma,Magnesium-Dexmedetomidine,['Magnesium-Dexmedetomidine'],1,OBSERVATIONAL,[],,COMPLETED,Phaeochromocytoma Crisis,Istanbul University,2025-09-01T16:18:09.627045,True,,,,,Magnesium and Dexmedetomidine Combination Reduces Sodium Nitroprusside Requirement in Laparoscopic Pheochromocytoma,,"['Phaeochromocytoma Crisis', 'Hemodynamic Instability']","['Magnesium', 'Dexmedetomidine', 'Nitroprusside', 'Pheochromocytoma']",,2011-01-01,2020-03-01,"[{'measure': 'Sodium nitroprusside (SNP) requirement', 'description': 'intraoperative hypertensive episodes requiring SNP therapy', 'timeFrame': 'intraoperative period'}]","[{'measure': 'vasoactive therapy', 'description': 'hemodynamic fluctuations (hypotension, tachycardia, severe hypertensive crisis) which needed vasoactive therapy.', 'timeFrame': 'intraoperative period'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,108.0,ACTUAL,v2_robust,False,True,False,False,
NCT05776758,Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt,cisplatin based neoadjuvant chemotherapy,['cisplatin based neoadjuvant chemotherapy'],1,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Muscle-Invasive Bladder Carcinoma,Regina Elena Cancer Institute,2025-09-01T16:18:09.627054,True,,,,,Neoadjuvant Chemotherapy Plus Cystectomy vs Cystectomy Alone for cT0 Muscle-invasive Bladder Cancer After Maximal TURBt: Multicentre Prospective Randomized Controlled Trial,,"['Muscle-Invasive Bladder Carcinoma', 'Chemotherapy Effect', 'Surgery']","['Bladder cancer', 'Muscle-invasive bladder cancer', 'Radical cystectomy', 'Survival outcomes']",,2024-11-29,2027-01,"[{'measure': 'To demonstrate the non-inferiority of radical cystectomy (RC) alone versus neoadjuvant chemotherapy plus RC on 2 years Overall Survival (OS) rates, defined as the length of time from surgery until death from any cause.', 'description': 'Overall Survival rates', 'timeFrame': '2 years'}]","[{'measure': 'To compare disease free survival (DFS) rates, defined as the length of time from surgery to local disease recurrence', 'description': 'To evaluate early (6 months), mid-term (1 year) and long-term (2 years) DFS rates', 'timeFrame': '6 months, 1 year, 2 years'}, {'measure': 'To evaluate metastasis free survival (MFS) rates, defined as the length of time from surgery to metastasis recurrence.', 'description': 'To evaluate early (6 months), mid-term (1 year) and long-term (2 years) MFS rates', 'timeFrame': '6 months, 1 year, 2 years'}, {'measure': 'To evaluate recurrence free survival (RFS), rates defined as the length of time from surgery to disease recurrence.', 'description': 'To evaluate early (6 months), mid-term (1 year) and long-term (2 years) RFS rates', 'timeFrame': '6 months, 1 year, 2 years'}, {'measure': 'To evaluate impact of NAC on perioperative complications rate (described accordingly to Clavien Dindo classification into minor o major complications)', 'description': 'To evaluate impact of NAC on perioperative complications rate within hospital stay', 'timeFrame': 'Within hospital stay'}, {'measure': 'To evaluate impact of NAC on postoperative complications rate described accordingly to Clavien Dindo classification into minor o major complications)', 'description': 'To evaluate impact of NAC on postoperative complications rate at 30 days, 90 days and 180 days', 'timeFrame': '30 days, 90 days and 180 days'}, {'measure': 'To evaluate impact of NAC on readmission rates (defined as postoperative rehospitalization)', 'description': 'To evaluate impact of NAC on readmission rates at 30 days, 90 days and 180 days', 'timeFrame': '30 days, 90 days and 180 days'}, {'measure': 'To compare health-related quality of life (HRQoL) outcomes, using EORTC self-assessed questionnaires', 'description': 'To compare health-related quality of life (HRQoL) outcomes at 3 months, 6 months, 1 year and 2 years', 'timeFrame': '3 months, 6 months, 1 year and 2 years'}]",8.0,18 Years,,ALL,False,OTHER,0.0,236.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",BAF312,"['BAF312', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Relapsing-remitting Multiple Sclerosis,Novartis Pharmaceuticals,2025-09-01T16:18:09.627128,True,,,,,"A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.",,['Relapsing-remitting Multiple Sclerosis'],"['Multiple Sclerosis (MS)', 'Relapsing-Remitting', 'Demyelinating Autoimmune Diseases', 'Disseminated sclerosis', 'Encephalomyelitis disseminate', 'Inflammatory disease', 'Demyelination', 'Auto-inflammatory disease', ""Devic's disease"", 'Balo concentric sclerosis', ""Schilder's diffuse sclerosis""]",,2009-03-30,2011-05-04,"[{'measure': 'Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL)', 'description': 'Combined unique active lesions (CUAL) were defined as new gadolinium \\[Gd\\]-enhanced lesions on T1-weighted MRI scans or new or enlarging lesions on T2-weighted MRI scans, without double-counting of lesions.\n\nED50 is the dose that gives half of the asymptotic maximum change over placebo. ED90 is the dose that gives 90% of the asymptotic maximum change over placebo.', 'timeFrame': '3 months of treatment'}]","[{'measure': 'Number of Confirmed Relapses - Period 1', 'description': 'confirmed relapse: A relapse was to be confirmed by the Independent Evaluating Physician (examining neurologist) performing the EDSS. It was recommended that this occurred within 7 days of the onset of symptoms. A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the Expanded Disability Status Scale (EDSS) or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS).', 'timeFrame': '6 months'}, {'measure': 'Proportion of Participants With Relapse-free Patients - Period 1 + 2', 'description': 'To explore the effect of BAF312 on the proportion of relapse-free patients (confirmed relapses only)', 'timeFrame': '3 month'}, {'measure': 'Proportion of Participants With Relapse-free Patients - Period 1 Only', 'description': 'To explore the effect of BAF312 on the proportion of relapse-free patients (confirmed relapses only)', 'timeFrame': '6 months'}, {'measure': 'Number of New [Gd]-Enhanced T1 Lesions Monthly - Period 1 +2 at Month 3', 'description': 'Results for Month 1 through Month 3 inclusive include patients from both Period 1 and Period 2. New lesions at a specific visit were assessed relative to the previous scheduled visit scan. The number of lesions of each type was available from the central MRI reader. No derivation was performed. Lesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '3 months'}, {'measure': 'Number of New [Gd]-Enhanced T1 Lesions Monthly - Period 1 Only at 6 Months', 'description': 'Month 4 through Month 6 include patients from Period 1 only. New lesions at a specific visit were assessed relative to the previous scheduled visit scan.\n\nThe number of lesions of each type was available from the central MRI reader. No derivation was performed.\n\nLesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '6 months'}, {'measure': 'Number of All New Gd-enhanced T1 Lesions - Period 1 +2 at Month 3', 'description': 'The results for Month 1 through Month 3 includes patients from both Period 1 and Period 2. New lesions at a specific visit were assessed relative to the previous scheduled visit scan.\n\nThe number of lesions of each type was available from the central MRI reader. No derivation was performed.\n\nLesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '3 months'}, {'measure': 'Number of All Gd-enhanced T1 Lesions - Period 1 Only at 6 Months', 'description': 'The results for Month 4 through Month 6 inclusive includes patients from Period 1 only. New lesions at a specific visit were assessed relative to the previous scheduled visit scan.\n\nThe number of lesions of each type was available from the central MRI reader. No derivation was performed.\n\nLesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '6 months'}, {'measure': 'Number of Monthly New/Enlarging T2 Lesions - Period 1 +2 at 3 Months', 'description': 'The results for Month 1 through Month 3 inclusive include patients from both Period 1 and Period 2. New lesions at a specific visit were assessed relative to the previous scheduled visit scan.\n\nThe number of lesions of each type was available from the central MRI reader. No derivation was performed.\n\nLesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '3 months'}, {'measure': 'Number of Monthly New/Enlarging T2 Lesions - Period 1 Only at 6 Months', 'description': 'Month 4 through Month 6 inclusive include patients from Period 1 only. New lesions at a specific visit were assessed relative to the previous scheduled visit scan.\n\nThe number of lesions of each type was available from the central MRI reader. No derivation was performed.\n\nLesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '6 months'}, {'measure': 'Number of Patients Without Any New MRI Disease Activity - Period 1 +2', 'description': 'The proportion of patients who were free of new Gd-enhanced T1 lesions, and/or free of new or enlarging T2 lesions, i.e. free of new MRI activity (CUAL).', 'timeFrame': '3 months'}, {'measure': 'Number of Patients Without Any New MRI Disease Activity - Period 1 Only', 'description': 'The proportion of patients who were free of new Gd-enhanced T1 lesions, and/or free of new or enlarging T2 lesions, i.e. free of new MRI activity (CUAL).', 'timeFrame': '6 months'}, {'measure': 'Number of Monthly New Gd-enhanced T1 Lesions With High Baseline Disease Activity - Period 1 +2 at 3 Months', 'description': 'In patients with high baseline disease activity, the relative reduction in new Gd-enhanced T1 lesions compared to placebo at Month 3.\n\nHigh baseline disease activity is defined as \\>=2 Gd-enhanced T1 lesions at baseline.\n\nThe number of lesions of each type was available as such from the central MRI reader. No derivation was performed.\n\nLesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '3 months'}, {'measure': 'Number of Monthly New Gd-enhanced T1 Lesions With High Baseline Disease Activity - Period 1 Only at 6 Months', 'description': 'In patients with high baseline disease activity, the relative reduction in new Gd-enhanced T1 lesions compared to placebo at Month 6. High baseline disease activity is defined as \\>=2 Gd-enhanced T1 lesions at baseline.\n\nThe number of lesions of each type was available from the central MRI reader. No derivation was performed.\n\nLesion ratio (and 95% CI) is set between the estimated number of lesions on active treatment compared to placebo. Estimates are computed at Month 3 and Month 6. New lesions at a specific visit were assessed relative to the previous visit. The computation was based upon the mean number of monthly new \\[Gd\\]- enhanced lesions. Month 3 and Month 6 results are based on two negative binomial GEE regression models accounting for repeated measures on a patient. Both models were adjusted for baseline number of Gd-enhanced T1 lesions and treatment group x month interaction, using the log link.', 'timeFrame': '6 months'}, {'measure': 'Number of CUAL - Period 1', 'description': 'Combined unique active lesions (CUAL) are defined as new Gd-enhanced T1 lesions or new or enlarging T2 lesions, withput double counting of lesions at any specific point in time.', 'timeFrame': '6 months'}, {'measure': 'Geometric Mean BAF312 Plasma Trough Concentrations', 'description': 'Geometric mean BAF312 plasma concentrations by treatment and by visit', 'timeFrame': 'Month 1, Month 3, Month 6'}]",16.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,297.0,ACTUAL,v2_robust,True,True,False,False,
NCT00406458,Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy,SB-509,['SB-509'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Diabetes Mellitus, Type 1",Sangamo Therapeutics,2025-09-01T16:18:09.627220,True,,,,,A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy,,"['Diabetes Mellitus, Type 1', 'Diabetes Mellitus, Type 2', 'Diabetic Polyneuropathy']","['Diabetic neuropathy', 'Diabetes Type I or II', 'Mild to moderate sensorimotor diabetic polyneuropathy']",,2006-11,2009-05,"[{'measure': 'Visual analog scale for pain intensity (VASPI), Nerve Conduction Velocity (NCV), Total Neuropathy Score (TNS), Epidermal Nerve Fiber Density (ENFD) & Epidermal Nerve Fiber Density Regeneration (ENFDR)', 'timeFrame': 'One year'}]","[{'measure': 'Safety', 'timeFrame': 'One year'}]",2.0,18 Years,70 Years,ALL,False,INDUSTRY,1.0,110.0,ACTUAL,v2_robust,True,True,False,True,
NCT00271258,Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents,SODIUM DIVALPROATE,['SODIUM DIVALPROATE'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bipolar Disorder,Sanofi,2025-09-01T16:18:09.627229,True,,,,,"STUDY OF THE TOLERANCE OF SODIUM DIVALPROATE (DEPAKOTE) IN ADOLESCENTS IN MANIC, MIXED OR HYPOMANIC EPISODES OF BIPOLAR DISORDER",,['Bipolar Disorder'],[],,2005-01,2007-01,[{'measure': 'clinical examination'}],[],1.0,13 Years,18 Years,ALL,False,INDUSTRY,0.0,200.0,,v2_robust,True,True,False,False,
NCT01048658,Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures,Sevoflurane,"['Sevoflurane', 'Ultane']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Blood Loss,Oregon Health and Science University,2025-09-01T16:18:09.627237,True,,,,,Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures: Does it Increase Blood Loss and Interventions for Blood Loss and Why Do Anesthesiologists Choose to Use It?,,"['Blood Loss', 'Anesthesia']","['Sevoflurane', 'anesthesia', 'abortion', 'blood loss']",,2009-09,2011-08,"[{'measure': 'Number of Participants Needing Intervention to Treat Blood Loss (a Composite of Use of Uterotonics, Re-aspiration, and Bimanual Massage)', 'description': 'Provider report for need to intervene due to blood loss (yes/no)', 'timeFrame': 'At time of uterine evacuation and immediately post-operatively, an average of 7.1 minutes'}]","[{'measure': 'Number of Participants With Estimated Blood Loss Greater Than 300 mL (Yes/no)', 'description': 'Procedural blood loss greater than 300 mL. Blood loss was measured in a standardized fashion (amniotic fluid was discarded, blood was separated from tissue, and all gauze surgical drapes weighed).', 'timeFrame': 'At time of uterine evacuation, an average of 7.1 minutes'}, {'measure': 'Procedure Time: T-test (Time of Speculum Placement to Time Speculum Removed)', 'description': 'Length of procedure from time of speculum placement to time of speculum removal, in minutes.', 'timeFrame': 'Time of speculum place to time of speculum removal, an average of 7.1 minutes'}, {'measure': 'Number of Participants Experiencing Side Effects (Nausea, Dizziness)', 'timeFrame': 'Post-procedure, within 30 minutes'}, {'measure': 'Patient and Provider Satisfaction With Anesthesia', 'description': 'Scores reported on 10-cm Visual Analog Scale (VAS anchors: 0= not satisfied at all, 10= completely satisfied) . Reported as mean +/- standard deviation. Subjects and providers were blinded to anesthesia method. Subjects and providers completed post-operative questionnaire within 30 minutes of procedure completion.', 'timeFrame': 'Post-procedure, within 30 minutes'}]",5.0,18 Years,50 Years,FEMALE,True,OTHER,0.0,160.0,ACTUAL,v2_robust,True,True,False,False,
NCT01854658,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",GFF MDI (PT003),"['(GFF MDI)', 'GP MDI (PT001)', 'glycopyrrolate/formoterol fumarate metered-dose inhaler', 'glycopyrrolate metered dose inhaler (GP MDI)', 'formoterol fumarate metered dose inhaler (FF MDI)', 'Placebo', 'FF MDI (PT005)', 'GFF MDI (PT003)']",8,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Obstructive Pulmonary Disease (COPD),"Pearl Therapeutics, Inc.",2025-09-01T16:18:09.627283,True,,,,,"A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo",,['Chronic Obstructive Pulmonary Disease (COPD)'],[],,2013-07,2015-03,"[{'measure': 'Change From Baseline in Morning Pre-dose Trough FEV1', 'description': 'Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24.', 'timeFrame': 'At Week 24'}]","[{'measure': 'Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks', 'description': 'Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.', 'timeFrame': 'Over 24 weeks'}, {'measure': 'Peak FEV1', 'description': 'Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24', 'timeFrame': 'At week 24'}, {'measure': 'St. George Respiratory Questionnaire (SGRQ) Score', 'description': 'Change from baseline in the SGRQ total score at Week 24. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.', 'timeFrame': '24 weeks'}, {'measure': 'Rescue Ventolin HFA Use', 'description': 'Change from baseline in average daily rescue Ventolin HFA use over 24 weeks', 'timeFrame': '24 weeks'}, {'measure': 'Onset of Action as Assessed by FEV1', 'description': 'Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant', 'timeFrame': 'Day 1'}]",6.0,40 Years,80 Years,ALL,False,INDUSTRY,0.0,1615.0,ACTUAL,v2_robust,True,True,False,False,
NCT06186648,Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome,Glofitamab + Obinutuzumab,['Glofitamab + Obinutuzumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Richter Syndrome,French Innovative Leukemia Organisation,2025-09-01T16:18:09.627393,True,,,,,"A Phase 2 Study Evaluating the Bispecific CD3xCD20 Antibody GLOfitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in Patients With RIchter Syndrome as Frontline therapY",,['Richter Syndrome'],[],,2024-03-21,2027-03-01,"[{'measure': 'Objective response regarding Richter Syndrome to R/G-CHOP + glofitamab combination.', 'description': 'Percentage of patients with a complete response (CR) assessed using the Cheson IWG 2014 Lugano Classification (i.e. Deauville scale 1-3)', 'timeFrame': '6 cycles (each cycle is 21 days)'}]","[{'measure': 'Safety and toxicity of the R/G-CHOP + glofitamab combination', 'description': 'Advers events evaluation according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5 and American Society for Transplantation and Cellular Therapy (ASTCT) Consensus grading for International Conference on Harmonization (ICANS) and Cytokine Release Syndrom (CRS)', 'timeFrame': 'Through treatment completion, an average of 8 months'}]",2.0,18 Years,,ALL,False,OTHER,1.0,40.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01198548,High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer,leucovorin calcium,"['fluorouracil', 'leucovorin calcium', '5-fluorouracil', 'Dacplat', '5-Fluracil', 'Dacotin', 'Eloxatin', 'CF', 'L-OHP', '1-OHP', 'LV', 'CFR', '5-FU', 'oxaliplatin']",14,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Stage IV Colon Cancer,Roswell Park Cancer Institute,2025-09-01T16:18:09.627511,True,,,,,A Phase II Clinical Trial of High Dose Vitamin D3 Supplementation in Combination With FOLFOX + Bevacizumab in the 1st Line Treatment of Metastatic Colorectal Cancer,,"['Stage IV Colon Cancer', 'Stage IV Rectal Cancer']",[],Lack of funding,2010-08,2012-06,"[{'measure': 'Median PFS', 'description': 'The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method. The corresponding 95% confidence intervals for the estimated probability will be computed using the method proposed in Clopper and Pearson.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Rate of Sufficient Cholecalciferol', 'timeFrame': 'By week 16'}]","[{'measure': 'RR of Patients Receiving Study Treatment', 'timeFrame': 'Up to 3 years'}, {'measure': 'Toxicity Rates as Assessed by NCI CTCAE Version 4', 'timeFrame': 'Up to 30 days post-treatment'}, {'measure': 'OS of Patients Receiving Study Treatment', 'description': 'The estimated distribution of OS will be obtained using the product-limit based Kaplan-Meier method.', 'timeFrame': 'Up to 3 years'}, {'measure': 'PFS of Patients Receiving Study Treatment', 'description': 'The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method.\n\n3 Year Survival Rate', 'timeFrame': 'Defined as the time from the start of the study treatment until the date of progression or death from any cause, whichever comes first, assessed up to 3 years'}]",6.0,18 Years,79 Years,ALL,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,False,True,False,Lack of funding
NCT04548648,A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas,Acalabrutinib,"['CALQUENCE', 'ACP-196', 'Acalabrutinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Central Nervous System Lymphoma,UNC Lineberger Comprehensive Cancer Center,2025-09-01T16:18:09.627529,True,,,,,LCCC1841: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas,,['Central Nervous System Lymphoma'],['CNS Lymphoma'],,2020-10-15,2030-03-14,"[{'measure': 'Overall response rate', 'description': 'The overall response rate (ORR) will be assessed based on the International Primary CNS Lymphoma Collaborative Group Response assessment criteria. Responder = Partial Response + Complete Response).\n\nComplete response (CR) as complete disappearance of contrast enhancement on magnetic resonance imaging (MRI), no evidence of ocular lymphoma, negative cerebrospinal fluid (CSF) cytology, and discontinuation of corticosteroid use for at least 2 weeks prior to the evaluation of response. Unconfirmed CR (Cru) is used to characterize radiographic findings that fulfill the criteria for a CR, but the patient remains on corticosteroids, or MRI that continues to show small but persistent enhancing abnormalities possibly related to biopsy or surgery. Partial response (PR) is defined as a 50% decrease in enhancing tumor or residual disease on eye examinations, or persistent or suspicious CSF cytology.', 'timeFrame': '2 months'}]","[{'measure': 'Number of different types of toxicities', 'description': ""Toxicity will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)."", 'timeFrame': '3 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS) is defined from the date of initiating study treatment to the date of disease progression per the International Primary CNS Lymphoma Collaborative Group response assessment criteria or death as a result of any cause.', 'timeFrame': '5 years'}, {'measure': 'Complete response (CR) rate', 'description': 'Complete Response (CR) is defined using the International Primary CNS Lymphoma Collaborative Group response assessment criteria for primary CNS lymphoma.', 'timeFrame': '2 years'}, {'measure': 'Duration of response (DoR)', 'description': 'Duration of response (DoR) is defined as time from documentation of tumor response to disease progression according to the International Primary CNS Lymphoma Collaborative Group response assessment criteria.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS will be measured from the date of initiating study treatment to the date of death or 5 years (whichever is first). Subjects who have not died by the analysis data cut-off date will be censored at their last date of contact.', 'timeFrame': '5 years'}]",6.0,18 Years,,ALL,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,False,False,True,
NCT06303648,"A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects",Methylone,['Methylone'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Post Traumatic Stress Disorder,Transcend Therapeutics,2025-09-01T16:18:09.627555,True,,,,,"A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects",,['Post Traumatic Stress Disorder'],[],,2024-03-20,2024-05-11,"[{'measure': 'Cmax: Maximum Observed Plasma Concentration for methylone', 'timeFrame': '48 hours following the dose'}, {'measure': 'AUC: Area under the plasma concentration-time curve for methylone', 'timeFrame': '48 hours following the dose'}]","[{'measure': 'Incidence and frequency of adverse events', 'timeFrame': '10 days after the dose'}, {'measure': 'Change overtime in Visual Analog Scales', 'timeFrame': '12 hours after the dose'}]",4.0,25 Years,55 Years,ALL,True,INDUSTRY,0.0,24.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06479655,Compare the Efficacy and Outcome Between Fentanyl and Morphine as Analgo-sedation in Mechanically Ventilated Patients,Fentanyl,"['Morphine', 'Fentanyl']",2,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Effect of Drug,Universiti Sains Malaysia,2025-09-01T16:18:09.627654,True,,,,,Compare the Efficacy and Outcome Between Fentanyl and Morphine as Analgo-sedation in Mechanically Ventilated Patients,,['Effect of Drug'],[],,2024-07-15,2025-09-30,"[{'measure': 'RASS score at 12 and 24 hours', 'description': 'To determine the proportion of patients achieving the targeted sedation guided by RASS score at 12 and 24 hours in both fentanyl and morphine group.', 'timeFrame': '24 hours from study drug initiation'}, {'measure': 'Rescue sedation doses', 'description': 'To determine the proportion of patients requiring rescue sedation doses between fentanyl and morphine group', 'timeFrame': '24 hours from study drug initiation'}]","[{'measure': 'Duration of mechanical ventilation', 'description': 'To compare the duration of mechanical ventilation between the fentanyl and morphine groups', 'timeFrame': '90 Days'}, {'measure': 'Length of ICU stay', 'description': 'To compare the length of ICU stay between the fentanyl and morphine groups', 'timeFrame': '90 days'}, {'measure': '14 days mortality rate', 'description': 'To compare 14-day mortality rates between the fentanyl and morphine groups', 'timeFrame': '14 days from randomization'}]",5.0,18 Years,,ALL,False,OTHER,0.0,116.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03847155,Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery,Nicotine patch,['Nicotine patch'],1,INTERVENTIONAL,['NA'],,COMPLETED,Nicotine Dependence,University Hospital Ostrava,2025-09-01T16:18:09.627736,True,,,,,Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery,,['Nicotine Dependence'],"['nicotine patch', 'placebo', 'critically ill patients', 'delirium', 'prevention']",,2015-09-23,2021-02-08,"[{'measure': 'Incidence of delirium episodes', 'description': 'The number of delirium episodes, defined according to the CAM-ICU test, in the course of the seven days with the patch attached will be measured in both groups of study subjects.', 'timeFrame': 'maximum of 7 days'}]","[{'measure': 'Change in the number of days with delirium', 'description': 'Change in the number of days with delirium, defined according to the CAM-ICU test, by 20%, in the course of the seven days with the patch attached among the study subjects with the nicotine patch.', 'timeFrame': 'maximum of 7 days'}, {'measure': 'Ventilator-hours', 'description': 'The number of ventilator-hours will be observed in both groups of study subjects.', 'timeFrame': 'maximum of 7 days'}]",3.0,18 Years,,ALL,False,OTHER,0.0,52.0,ACTUAL,v2_robust,True,True,False,False,
NCT00877955,Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation,alprazolam sublingual tablet commercial,"['alprazolam sublingual tablet test', 'alprazolam sublingual tablet commercial']",2,INTERVENTIONAL,['PHASE1'],PHASE1,WITHDRAWN,Healthy,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,2025-09-01T16:18:09.627749,True,,,,,"Open-label, Randomized, Single-dose, 2-way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet",,['Healthy'],"['bioequivalence', 'pharmacokinetic', 'alprazolam', 'sublingual']",,2012-09,2012-10,"[{'measure': 'Alprazolam bioavailability assessed as area under the concentration-time curve (AUC) and maximum concentration (Cmax)', 'timeFrame': '11 days'}]","[{'measure': 'Alprazolam time of maximum concentration (Tmax) and half life', 'timeFrame': '11 days'}, {'measure': 'Adverse events, clinical laboratory tests, vital signs', 'timeFrame': '11 days'}]",3.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,
NCT05724355,CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC,"Dalpiciclib Isetionate Tablets, Camrelizumab","['Dalpiciclib Isetionate Tablets, Camrelizumab']",1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Nasopharyngeal Carcinoma,Sun Yat-sen University,2025-09-01T16:18:09.627759,True,,,,,Dalpiciclib Combined With Camrelizumab for PD-1 Inhibitor Refractory R/M NPC,,['Nasopharyngeal Carcinoma'],[],,2022-09-01,2024-10,"[{'measure': 'Objective response rate (ORR)', 'description': 'Objective response rate is the rate of patients achieving complete response or partial response for a certain period of time after intervention.', 'timeFrame': '1 year'}]","[{'measure': 'Median progression-free survival (PFS)', 'description': 'Progression-free survival is defined as the time to the date of death of any cause or the first progress at any site, censored on the last date of tumor evaluation if no progress has happened.', 'timeFrame': '1 year'}, {'measure': 'Median overall survival (OS)', 'description': 'Overall survival is defined as the time to the date of death of any cause, censored on the last date of known survival if no death has happened.', 'timeFrame': '3 years'}, {'measure': 'Duration of response (DoR)', 'description': 'Defined as the time from first documentation of objective response to radiological disease progression', 'timeFrame': '1 year'}, {'measure': 'Disease control rate (DCR)', 'description': 'Disease control rate is the rate of patients achieving complete response, partial response or stable disease', 'timeFrame': '1 year'}, {'measure': 'Incidence of adverse events', 'description': 'NCI-CTCAE 5.0 standard is adopted.', 'timeFrame': '1 year'}]",6.0,18 Years,70 Years,ALL,False,OTHER,0.0,32.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02818855,Treatment of Multiple Gingival Recessions,Collagen Matrix,"['Mucograft', 'Collagen Matrix']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Gingival Recession,University of Sao Paulo,2025-09-01T16:18:09.627793,True,,,,,Treatment of Multiple Gingival Recessions With Collagen Matrix Versus Subepithelial Connective Tissue Graft: A Non-inferiority Randomized Clinical Trial,,['Gingival Recession'],"['Root coverage', 'Gingival recession', 'Plastic surgery', 'Connective tissue graft', 'Mucograft']",,2014-03,2016-04,"[{'measure': 'Percentage of root coverage (RC)', 'description': 'The primary clinical outcome will be percentage of root coverage (RC) at 12 months', 'timeFrame': '12-months'}]","[{'measure': 'Reductions in recession depth (RRD)', 'description': 'Measured from the cementum-enamel junction (CEJ) up to the highest point of the gingival margin', 'timeFrame': 'At the baseline, 3-month, 6-month and 12-months'}, {'measure': 'Complete root coverage of the gingival recessions (CRC)', 'timeFrame': 'At the baseline, 3-month, 6-month and 12-months'}, {'measure': 'Recession width (RW) at the cemento-enamel junction', 'timeFrame': 'At the baseline, 3-month, 6-month and 12-months'}, {'measure': 'Relative clinical attachment level (RCAL)', 'description': 'Measured from a fixed point (stent) prepared on the acrylic guide up to the base of the gingival sulcus.', 'timeFrame': 'At the baseline, 3-month, 6-month and 12-months'}, {'measure': 'Probing depth (PD)', 'description': 'Calculated as RCAL- PD;', 'timeFrame': 'At the baseline, 3-month, 6-month and 12-months'}, {'measure': 'keratinized tissue width (KT)', 'description': 'From the free gingival margin to the mucogingival junction.', 'timeFrame': 'At the baseline, 3-month, 6-month and 12-months'}, {'measure': 'Gain in thickness of gingival tissue (GT)', 'description': 'With an injection needle and a silicon marker, 2mm below the gingival margin.', 'timeFrame': 'At the baseline, 3-month, 6-month and 12-months'}]",8.0,18 Years,,ALL,True,OTHER,0.0,15.0,ACTUAL,v2_robust,True,True,False,False,
NCT04917055,iPACK Block With Dexamethasone For Total Knee Replacement,ropivacaine 0.25% with epinephrine and 6mg dexamethasone,"['Saline', 'ropivacaine 0.25% with epinephrine and 6mg dexamethasone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Knee Osteoarthritis,"University of California, San Diego",2025-09-01T16:18:09.627820,True,,,,,Impact of Adding iPACK Block With Dexamethasone to Existing APS Multimodal Analgesia Protocol for Patients Undergoing Total Knee Arthroplasty,,"['Knee Osteoarthritis', 'Acute Pain', 'Anesthesia, Local', 'Regional Anesthesia']","['acute postoperative pain', 'knee replacement']",staffing,2021-06-07,2022-06-07,"[{'measure': 'Average Opioid Use POD 0-1', 'description': 'Average Opioid Use', 'timeFrame': 'Postoperative day (POD) 0-1, as defined by 24 hours after iPACK block placement'}, {'measure': 'Average Pain Score at Rest', 'description': 'Average Pain Score at Rest', 'timeFrame': 'Postoperative day (POD) 0-1, as defined by 24 hours after iPACK block placement'}, {'measure': 'Average Pain Score with Motion', 'description': 'Average Pain Score with Motion', 'timeFrame': 'Postoperative day (POD) 0-1, as defined by 24 hours after iPACK block placement'}]","[{'measure': 'Gait Distance', 'description': 'Distance patient can walk on with physical therapy (PT)', 'timeFrame': 'POD0-1 (first PT session)'}, {'measure': 'Knee Range of motion', 'description': 'Range of motion with Physical Therapy (PT)', 'timeFrame': 'POD0-1 (first PT session)'}, {'measure': 'Length of stay', 'description': 'From admission to hospital for surgery to discharge', 'timeFrame': 'Total number of days requiring hospitalization for surgical procedure. Up to 1 month'}, {'measure': 'Average Opioid Use postoperative day (POD) 1-2', 'description': 'Average Opioid Use in morphine equivalents', 'timeFrame': 'Postoperative day (POD) 1-2.'}, {'measure': 'Average Pain Score, postoperative day (POD) 1-2.', 'description': 'Average Pain Score', 'timeFrame': 'Postoperative day (POD) 1-2.'}]",8.0,18 Years,,ALL,False,OTHER,0.0,14.0,ACTUAL,v2_robust,True,False,True,False,staffing
NCT03949855,Belimumab With Rituximab for Primary Membranous Nephropathy,Belimumab,"['Belimumab', 'Placebo for Belimumab', 'Rituximab', 'Benlysta®', 'Belimumab placebo', 'Rituxan®']",6,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Membranous Nephropathy,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:09.627843,True,,,,,Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI),,"['Membranous Nephropathy', 'Nephrotic Syndrome']","['Primary Membranous Nephropathy', 'nephrotic syndrome', 'Pharmacokinetics (PK) Analysis', 'Double-Blind (Masked), Placebo-Controlled Clinical Trial', 'Co-administered belimumab and rituximab']",,2020-03-06,2030-03-01,"[{'measure': 'Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 104.', 'description': '. CR is defined as proteinuria of ≤ 0.3 g/day with a serum albumin ≥ 3.5 g/dL. PR is defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria \\< 3.5 g/day glomerular filtration rate (eGFR) from baseline.', 'timeFrame': 'Week 104'}]","[{'measure': 'Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 52 and Week 156.', 'timeFrame': 'Week 52, Week 156'}, {'measure': 'Proportion of Participants in Complete Remission (CR) at Week 52, Week 104 and Week 156.', 'timeFrame': 'Week 52, Week 104, Week 156'}, {'measure': 'Proportion of Participants in PR but not CR at Week 52, Week 104, Week 156.', 'timeFrame': 'Week 52, Week 104, Week 156'}, {'measure': 'Time to Relapse for Participants who Achieved CR or PR.', 'timeFrame': 'Up to 156 Weeks (3 Years)'}, {'measure': 'Level of Proteinuria at Week 52, Week 104 and Week 156.', 'timeFrame': 'Week 52, Week 104, Week 156'}, {'measure': 'Proportion of participants meeting criteria for a second course of rituximab at week 30', 'timeFrame': 'Week 30'}, {'measure': 'Proportion of Participants in CR or PR and Anti-PLA2R Negative at week 52, 104, and 156', 'timeFrame': 'Week 52, Week 104, Week 156'}, {'measure': 'Proportion of Participants in PR and Anti-PLA2R Negative at week 52, 104, and 156', 'timeFrame': 'Week 52, Week 104, Week 156'}, {'measure': 'Proportion of participants in PR but not CR and who are anti-PLA2R negative at week 52, 104, and 156', 'timeFrame': 'Week 52, Week104, Week 156'}, {'measure': 'Proportion of Participants who are Anti-PLA2R Negative at week 52, 104, and 156', 'timeFrame': 'Week 52, Week104, Week 156'}, {'measure': 'Quality of life at weeks 52, 104, and 156', 'timeFrame': 'Week 52, Week104, Week 156'}, {'measure': 'Incidence of Adverse Events (AEs).', 'timeFrame': 'Week 0 to Week 52'}, {'measure': 'Incidence of Grade 3 or Higher Infectious Adverse Events (AEs): By Treatment Group', 'description': 'Reference: NCI-CTCAE manual titled, National Cancer Institute (NCI)s Common Terminology Criteria for Adverse Events Version 5.0 (published November 27, 2017).', 'timeFrame': 'Week 0 to Week 52'}, {'measure': 'Incidence of Arterial Thromboembolic Events: By Treatment Group', 'description': 'Peripheral vascular embolism, mesenteric infarct, or myocardial infarction.', 'timeFrame': 'Week 0 to Week 52'}, {'measure': 'Incidence of Venous Thromboembolic Events: By Treatment Group', 'description': 'Venous thromboembolic event (VTE) is defined as a symptomatic deep vein thrombosis (DVT): the formation of a blood clot in a deep vein, detected by systematic compression ultrasonography, symptomatic DVT, or symptomatic fatal or non-fatal pulmonary embolism (PE). An embolism is a clot in the blood that forms and blocks a blood vessel. A pulmonary embolism is a blood clot that has travelled from elsewhere in the body through the blood stream to block the main artery of the lung or one of its branches.', 'timeFrame': 'Week 0 to Week 52'}]",16.0,18 Years,75 Years,ALL,False,NIH,4.0,58.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02990455,Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder,Reduced nicotine cigarettes,"['Reduced nicotine cigarettes', 'Nicotine research cigarettes']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Alcohol Drinking,Battelle Memorial Institute,2025-09-01T16:18:09.627874,True,,,,,Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder,,"['Alcohol Drinking', 'Cigarette Smoking Toxicity']","['alcohol', 'drinking', 'smoking', 'cigarette', 'nicotine']",,2017-11-14,2021-04-21,"[{'measure': 'Alcohol drinks per day', 'timeFrame': '7 days'}]","[{'measure': 'Toxicant exposure', 'description': '(1) boost in (a) exhaled carbon monoxide, (b) plasma nicotine, and (c) plasma cotinine, and (2) solanesol after laboratory smoking', 'timeFrame': '7 days'}, {'measure': 'Subjective acceptability', 'description': 'subjective response', 'timeFrame': '7 days'}, {'measure': 'Smoking compensation', 'description': 'number of cigarettes per day during each 7-day period', 'timeFrame': '7 days'}]",4.0,21 Years,65 Years,ALL,True,OTHER,0.0,47.0,ACTUAL,v2_robust,True,True,False,False,
NCT06454955,Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors,[68Ga] B7H3 Affibody-BCH,['[68Ga] B7H3 Affibody-BCH'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,RECRUITING,B7H3,Peking University Cancer Hospital & Institute,2025-09-01T16:18:09.627900,True,,,,,Study of B7-H3 Mediated Tumor Immune Response Using a Whole-Body Kinetic Approach in Whole-Body PET,,"['B7H3', 'CD276 Affibody', 'PET/CT Imaing']",[],,2024-01-01,2026-11-30,"[{'measure': 'SUV', 'description': 'Standardized Uptake Values (SUV) of \\[68Ga\\] B7H3 Affibody-BCH at various time points within the imaging window for target lesions or suspected tumor lesions in subjects with malignant tumors.', 'timeFrame': '1 hour and 2 hour after injection'}]",[],1.0,18 Years,75 Years,ALL,True,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01768455,Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects,Gemigliptin and Glimepiride,"['Gemigliptin and Glimepiride', 'Glimepiride']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,LG Life Sciences,2025-09-01T16:18:09.627932,True,,,,,"A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Gemigliptin and Glimepiride in Healthy Male Subjects",,['Healthy'],[],,2013-02,,"[{'measure': 'AUC', 'description': 'To evaluate AUCτ,ss of gemigliptin and AUClast of glimepiride', 'timeFrame': 'up to 24h post-dose'}, {'measure': 'Cmax', 'description': 'To evaluate Cmax,ss of gemigliptin and Cmax of glimepiride', 'timeFrame': 'up to 24h post-dose'}]","[{'measure': 'Tmax', 'description': 'To evaluate Tmax,ss of gemigliptin/LC15-0636 and Tmax of glimepiride/M1', 'timeFrame': 'up to 24h post-dose'}, {'measure': 't1/2β', 'description': 'To evaluate t1/2β of gemigliptin/LC15-0636/glimepiride/M1', 'timeFrame': 'up to 24h post-dose'}, {'measure': 'AUC', 'description': 'To evaluate AUCτ,ss of LC15-0636 and AUClast of M1', 'timeFrame': 'up to 24h post-dose'}, {'measure': 'Cmax', 'description': 'To evaluate Cmax,ss of LC15-0636 and Cmax of M1', 'timeFrame': 'up to 24h post-dose'}]",6.0,20 Years,45 Years,MALE,True,INDUSTRY,0.0,27.0,ACTUAL,v2_robust,True,True,False,False,
NCT01041755,Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.,L-ornithine-L-aspartate,"['LOLA', 'Lactose', 'L-ornithine-L-aspartate']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hepatic Encephalopathy,Centro Regional para el Estudio de las Enfermedades Digestivas,2025-09-01T16:18:09.627959,True,,,,,The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy.,,['Hepatic Encephalopathy'],"['Encephalopathy', 'Cirrhosis']",,2009-11,2011-06,"[{'measure': 'Improvement of at least one grade in mental state based on the West Haven Criteria', 'description': 'Improvement was assessed at 0, 24, 48 and 72 hours. The mental state was scored from trivial lack of awareness to deep coma from grade 1 to grade 4.', 'timeFrame': '72 hours'}]","[{'measure': 'Improvement of at least one grade in mental state assessed by the Glasgow Coma Scale', 'description': 'Improvement was assessed at 0, 24, 48 and 72 hours. The Glasgow Coma Scale assesses three aspects of responsiveness: eye-opening, motor, and verbal responses. The eye-opening was quantified from 1 to 4 points, the motor response from 1 to 6 points and the verbal response from 1 to 5 points.', 'timeFrame': '72 hours'}, {'measure': 'Improvement of at least one grade in mental state assessed by the Clinical Hepatic Encephalopathy Staging Scale (CHESS)', 'description': 'Improvement was assessed at 0, 24, 48 and 72 hours. The CHESS scale has 9 dichotomous questions that assess mental state, intellectual function, behavior, verbal and motor response and orientation. It was quantified from 0 to 9 points.', 'timeFrame': '72 hours'}, {'measure': 'Improvement of asterixis grade', 'description': 'Improvement was assessed at 0, 24, 48 and 72 hours. Asterixis was graded as follows: Grade 0 = without flapping motion, Grade 1 ≤ 5 flaps per minute, Grade 2 = 6 to 10 flaps per minute, Grade 3 = 11 to 20 flaps per minute and Grade 4, continuous flap or patient in coma unable to maintain wrist dorsiflexion. Asterixis grade was evaluated at 0. 24, 48 and 72 hours.', 'timeFrame': '72 hours'}, {'measure': 'Improvement in electroencephalographic tracing grade', 'description': 'Improvement was assessed at 0 and 72 hours. EEG tracing was graduated from 0 to 4: Grade 0 = normal alpha rhythm, Grade 1 =7 to 8 cycles per second, Grade 2= 5 to 6 cycles per second, Grade 3 = 3 to 4.5 cycles per second and Grade 4 \\< than 3 cycles per second or delta rhythm. EEG was assessed at 0 and 72 hours.', 'timeFrame': '72 hours'}, {'measure': 'Improvement in serum ammonia', 'description': 'Ammonia determination was performed at 0, 24, 48 and 72 hours.', 'timeFrame': '72 hours'}, {'measure': 'Improvement in Number connection tests', 'description': 'The mental state of the patients included in the study did not allow them to perform the number connection test, therefore, they were all assigned to the worst score (Grade 4)', 'timeFrame': '72 hours'}, {'measure': 'Improvement in Portosystemic Encephalopathy Index.', 'description': 'Improvement was assessed at 0 and 72 hours. The PSE Index was calculated by multiplying the grade of mental state by a factor of 3; and the grades of asterixis, number connection tests, serum ammonia and EEG were multiplied times a factor of 1. The results were divided by the maximal possible PSE sum.', 'timeFrame': '72 hours'}]",8.0,18 Years,75 Years,ALL,False,OTHER,1.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT04071626,Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure,Ertugliflozin 5 mg,"['Ertugliflozin 5 mg', 'Placebo oral tablet']",2,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,"Heart Failure, Diastolic",University Hospitals Cleveland Medical Center,2025-09-01T16:18:09.628148,True,,,,,The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure,,"['Heart Failure, Diastolic', 'Diabetes Mellitus, Type 2']","['ertugliflozin', 'SGLT2 inhibtion', 'Cardiovascular Diseases', 'Sodium-Glucose Transporter 2 Inhibitors', 'Glucose Metabolism Disorders', 'Physiological Effects of Drugs', 'Diabetes Mellitus', 'Diabetes Mellitus, Type 2', 'Endocrine System Diseases']",Lack of enrollment,2020-03-01,2023-01-11,"[{'measure': 'Peak VO2, ml/kg/Min, as Measured by Metabolic Gas Exchange', 'description': 'The difference in peak oxygen uptake as measured by peak VO2 (ml/kg/min) between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment', 'timeFrame': '12 weeks'}]","[{'measure': 'Left Ventricular Mass Index (gm/m2), as Measured by Cardiac MRI', 'description': 'The difference in LV mass index (gm/m2) measured by cardiac MRI between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment', 'timeFrame': '12 weeks'}, {'measure': 'Serum Ketone Bodies (Betahydroxybutyrate)', 'description': 'The difference in serum ketone bodies (betahydroxybutyrate) levels between ertugliflozin and placebo as measured at baseline and after 12 weeks of treatment', 'timeFrame': '12 weeks'}]",3.0,18 Years,75 Years,ALL,False,OTHER,0.0,9.0,ACTUAL,v2_robust,True,False,True,False,Lack of enrollment
NCT00145626,HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies,Chemotherapy and antibodies,"['Chemotherapy and antibodies', 'OKT3', 'Cyclophosphamide', 'Fludarabine', 'Thiotepa', 'Melphalan']",6,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acute Myeloid Leukemia,St. Jude Children's Research Hospital,2025-09-01T16:18:09.628162,True,,,,,HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies,,"['Acute Myeloid Leukemia', 'Acute Lymphocytic Leukemia', 'Myelodysplasia', 'Chronic Myeloid Leukemia', 'Histiocytosis']","['Stem cell transplantation', 'Stem cell transplant', 'Haploidentical transplant']",,2004-05,2016-07,"[{'measure': 'One-year Survival', 'description': 'The one-year survival of infants with high-risk hematologic malignancies who receive a haploidentical transplant procedure using a total body irradiation (TBI)-excluding conditioning regimen followed by an HLA-nonidentical family donor hematopoietic stem cell (HSC) graft depleted of T cells ex vivo using the CliniMACS CD34+ selection system, with a subsequent infusion of donor NK cells purified ex vivo using the CliniMACS CD3+ depletion and CD56+ enrichment system.\n\nThe Kaplan-Meier estimate for one-year survival is reported.', 'timeFrame': 'One year after transplant'}]","[{'measure': 'Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality', 'description': 'The cumulative incidences of regimen-related mortality will be estimated using method of Kalbfleisch and Prentice.', 'timeFrame': '100 days post-transplantation'}, {'measure': 'Number of Transplant-Related Adverse Outcomes: Engraftment Failure', 'description': 'Engraftment failure is defined as \\<10% donor cell chimerism at any time point between 28 and 100 days after transplant with no evidence of disease relapse or requiring stem cell boost.', 'timeFrame': '100 days post-transplantation'}, {'measure': 'Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)', 'description': 'The cumulative incidence estimate for occurrence of fatal acute GVHD by the end of the first 100 days post-transplant was calculated using method of Kalbfleisch and Prentice.', 'timeFrame': '100 days post-transplantation'}, {'measure': 'Number of Incidences of Chronic GVHD.', 'description': ""Chronic GVHD was graded according to Seattle Criteria: limited or extensive. Limited is defined as localized skin and/or hepatic dysfunction. Extensive is defined as one or more of the following:\n\n* generalized skin involvement\n* liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis\n* eye dryness with Schirmer's test \\<5 mm wetting\n* oral: involvement of salivary glands or oral mucosa\n* other: another target organ involvement"", 'timeFrame': 'Up to 5 years after transplant'}, {'measure': 'Factors Affecting One-year Survival: Median Age of Donor at HSCT', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Median Dose of CD34', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Median Dose of NK Cells', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Disease Status at HSCT', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Donor Type', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Match N/6 HLA Loci', 'description': 'HLA typing determined the degree of match by looking at 6 different HLA loci. The results indicate the number of the 6 loci that matched for each participant. Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Minimal Residual Disease (MRD)', 'description': 'Detection of leukemia blasts in bone marrow by flow cytometry', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Incidence of and Risk Factors for Organ Dysfunction.', 'description': 'The organ dysfunction will be summarized using summary statistics and assessed in a longitudinal manner and analyzed accordingly.', 'timeFrame': 'Up to 5 Years after transplant'}, {'measure': 'Incidence of and Risk Factors for Long-term Neurocognitive Deficit.', 'description': 'The long-term neurocognitive deficit will be summarized using summary statistics and assessed in a longitudinal manner and analyzed accordingly.', 'timeFrame': 'Up to 5 Years after transplant'}, {'measure': 'Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation', 'description': 'The presence or absence of MRD before and after the bone marrow transplant (BMT) and its frequency distribution will be obtained for each time point separately.', 'timeFrame': 'Baseline before HSCT, 1 year post HSCT, and up to 5 years post HSCT'}, {'measure': 'Kinetics of Lymphohematopoietic Reconstitution', 'description': 'The lymphohematopoietic reconstitution will be summarized using summary statistics and assessed in a longitudinal manner and analyzed accordingly.', 'timeFrame': 'From 0-3 months after HSCT through 4-5 years after HSCT'}]",16.0,,24 Months,ALL,False,OTHER,1.0,40.0,ACTUAL,v2_robust,True,True,False,True,
NCT04539626,Estrogen Therapy in Non-severe COVID-19 Patients,Estrogen Therapy,"['Norelgesetromin', 'Ethinyl estradiol', 'Estrogen Therapy']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Covid-19,"CMN ""20 de Noviembre""",2025-09-01T16:18:09.628186,True,,,,,Estrogen Therapy in Non-severe COVID-19 Patients: Proposed Treatment Scheme in a Tertiary Hospital,,['Covid-19'],"['COVID-19', 'Estrogens', 'Severe Acute Respiratory Syndrome Coronavirus-2']",,2020-10-01,2023-12-31,"[{'measure': 'Clinical improve to estrogen therapy in non-severe COVID-19 patients Clinical improve to estrogen therapy in non-severe COVID-19 patients', 'description': '* Success rate in reducing hospitalization days\n* Success rate in no oxygen therapy use (low or high-flow oxygen)\n* Success rate in no intubation and/or mechanical ventilation\n* Success rate in non mortality occurrence', 'timeFrame': 'Day 7'}, {'measure': 'Clinical improve to estrogen therapy in non-severe COVID-19 patients', 'description': '* Success rate in reducing hospitalization days\n* Success rate in no oxygen therapy use (low or high-flow oxygen)\n* Success rate in no intubation and/or mechanical ventilation\n* Success rate in non mortality occurrence', 'timeFrame': 'Day 14'}, {'measure': 'Clinical improve to estrogen therapy in non-severe COVID-19 patients', 'description': '* Success rate in reducing hospitalization days\n* Success rate in no oxygen therapy use (low or high-flow oxygen)\n* Success rate in no intubation and/or mechanical ventilation\n* Success rate in non mortality occurrence', 'timeFrame': 'Day 21'}]","[{'measure': 'Symptomatic improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain.', 'timeFrame': 'Day 7'}, {'measure': 'Symptomatic improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain.', 'timeFrame': 'Day 14'}, {'measure': 'Symptomatic improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain.', 'timeFrame': 'Day 21'}, {'measure': 'Biochemical improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'Percentage change from hemoglobin, hematocrit, leukocytes, erythrocytes, platelets, prothrombin, partial thromboplastin activation time, anti-thrombin activity, fibrinogen, fibrin degradation products, D-Dimer, ALT, AST, ALP, GGT, LD, albumin, cholesterol, triglycerides, HDL, LDL, C-reactive protein, estrogens and progesterone levels, pro inflammatory cytokine and nitric oxide profile.', 'timeFrame': 'Day 7'}, {'measure': 'Biochemical improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'Percentage change from hemoglobin, hematocrit, leukocytes, erythrocytes, platelets, prothrombin, partial thromboplastin activation time, anti-thrombin activity, fibrinogen, fibrin degradation products, D-Dimer, ALT, AST, ALP, GGT, LD, albumin, cholesterol, triglycerides, HDL, LDL, C-reactive protein, estrogens and progesterone levels, pro inflammatory cytokine and nitric oxide profile.', 'timeFrame': 'Day 14'}, {'measure': 'Angiotensin 1-7 change after estrogen therapy in non-severe COVID-19 patientsCOVID-19 patients', 'description': 'Percentage change from Angiotensin 1-7, measured with the Human Angiotensin 1-7 ELISA kit (colorimetric) \\[pg/mL\\]', 'timeFrame': 'Day 21'}]",9.0,18 Years,70 Years,ALL,False,OTHER,0.0,44.0,ACTUAL,v2_robust,True,False,False,False,
NCT03256526,6-week Safety and PD Study in Adults With NAFLD,Placebo,"['PF-06835919 Low Dose', 'PF-06835919 High Dose', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Non-alcoholic Fatty Liver Disease,Pfizer,2025-09-01T16:18:09.628230,True,,,,,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE",,['Non-alcoholic Fatty Liver Disease'],[],,2017-09-27,2018-04-27,"[{'measure': 'Percent Change From Baseline in Whole Liver Fat at Week 6', 'description': 'The percent change from baseline in whole liver fat at Week 6 was assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF).\n\nMRI-PDFF generates measures of the fraction of mobile protons in the liver attributable to fat content and provides whole liver coverage so that fat content can be assessed across 8 Couinaud liver segments. Whole liver PDFF was calculated as follows:\n\nWhole Liver PDFF= PDFFs for (Segment I+Segment II+Segment III+Segment IVa+Segment IVb+Segment V+Segment VI+Segment+VII+Segment VIII) / (number of segments assessed).\n\nThe same segments were to be used at both baseline and post-baseline time points in the calculation of whole liver PDFF to derive the percent change from baseline.\n\nThe values of whole liver PDFF ranges from 0 to 100 and higher values represent higher liver fat.', 'timeFrame': 'Baseline and Week 6'}]","[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'All-causality adverse events (AEs) were any untoward medical occurrence in a study participant who administered a product or medical device, the event need not necessarily have a causal relationship with the treatment or usage. Treatment-related AEs were any untoward medical occurrence in a study participant who administered a product or medical device, the event needed to have a causal relationship with the treatment or usage.\n\nA TEAE was defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.', 'timeFrame': 'Baseline up to Day 77 (28-35 days post last dose)'}, {'measure': 'Number of Participants With Post-dose Vital Signs Data Meeting Categorical Criteria', 'description': 'The vital sign categorical criteria included:\n\nSitting DBP (diastolic blood pressure) millimeter of mercury (mmHg) Change \\>= 20 mmHg increase Sitting SBP (systolic blood pressure) (mmHg) Change \\>= 30 mmHg increase Sitting DBP (mmHg) Change \\>= 20 mmHg decrease Sitting SBP (mmHg) Change \\>= 30 mmHg decrease Sitting DBP (mmHg) Value \\< 50 mmHg Sitting Pulse Rate (bpm) Value \\< 40 bpm or Value \\> 120 bpm Sitting SBP (mmHg) Value \\< 90 mmHg', 'timeFrame': 'Baseline up to Day 56 (Week 8)'}, {'measure': 'Number of Participants With Post-dose ECG Data Meeting Categorical Criteria', 'description': ""The ECG categorical criteria included:\n\nPR Interval (msec) percent (%)Change \\>= 25% increase when baseline \\>200 or \\>=50% increase when baseline \\<=200 QRS Interval (msec) %Change \\>= 50% increase QTcF Interval (Fridericia's Correction) (msec) increase 30 \\<= Change \\< 60 or Change \\>= 60 PR Interval (msec) Value \\>= 300 QRS Interval (msec) Value \\>= 140 QTcF Interval (Fridericia's Correction) (msec) 450 \\<= Value \\<480 or 480 \\<=Value \\<500 or Value \\>= 500"", 'timeFrame': 'Baseline up to Day 56 (Week 8)'}, {'measure': 'Number of Participants With Laboratory Abnormalities', 'description': 'Below parameters were evaluated for laboratory tests: Hemoglobin, Hematocrit, Erythrocytes, Ery. Mean Copuscular Volume, Ery. Mean Copuscular Hemoglobin, Ery. Mean Corpuscular HGB Concentration, Platelets, Leukocytes, Lymphocytes, Neuprophils, Basophils, Eosinophils, Monocytes, Bilirubin, Direct Biliirubin, Indirect Bilirubin, Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase, Protein, Albumin, Albumin, Blood Urea Nitrogen, Creatinine, Urate, Sodium, Potassium, Chloride, Calcium, Bicarbonate, Glucose-Fasting, pH, Urine Glucose, Ketone, Urine Protein, Urine Hemoglobin, Urobilinogen, Urine Bilirubin, Nitrite, Leukocyte Esterase, Urine Erythocytes, Urine leukocytes, Hyaline Casts, Urine Creatinine.', 'timeFrame': 'Baseline up to Day 56 (Week 8)'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,53.0,ACTUAL,v2_robust,True,True,False,True,
NCT01519726,CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug,Midazolam,['Midazolam'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Morbid Obesity,St. Antonius Hospital,2025-09-01T16:18:09.628256,True,,,,,CYP3A4 Metabolism Before and After Surgery Induced Weight Loss in Morbidly Obese Patients Using Midazolam as a Model Drug,,['Morbid Obesity'],[],,2011-12,2013-12,"[{'measure': 'Difference in midazolam clearance in morbidly obese patients before and 0.5-2 years after surgery', 'timeFrame': '0.5-2 years'}]",[],1.0,18 Years,60 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,True,False,False,
NCT02839226,"Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds",AR/101,"['AR/101', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Wounds,Arava Bio Tech Ltd.,2025-09-01T16:18:09.628390,True,,,,,"Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients",,"['Wounds', 'Other Ulcers Wounds and Skin Problems']","['ulcers', 'wounds', 'diabetes', 'venous ulcers', 'arterial ulcers', 'granulation tissue', 'protein kinase c']",,2016-08,2017-12,"[{'measure': 'comparison of the formation of new granulation tissue according to a Granulation Score, between the AR/101 treated group and the placebo group, during the treatment phases', 'timeFrame': '28 days'}]","[{'measure': ""Percentage of patients ready for skin grafting or healing by secondary intention during treatment phase 1 and treatment phase 2 based on physician's assessment"", 'timeFrame': '28 days'}, {'measure': 'Percent of patient responders of equal or more then 75% granulation tissue during two weeks of treatment phase 1', 'timeFrame': '14 days'}, {'measure': 'Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 1', 'timeFrame': '14 days'}, {'measure': 'Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 2', 'timeFrame': '14 days'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00430326,Juvista (Avotermin) in Scars Following Varicose Vein Removal,Avotermin,['Avotermin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Varicose Veins,Renovo,2025-09-01T16:18:09.628417,True,,,,,A Dose Response Trial to Investigate the Efficacy of Juvista (Avotermin) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins Following Bilateral Varicose Vein Removal.,,"['Varicose Veins', 'Cicatrix']",[],,2006-11,2009-04,"[{'measure': 'Investigator scar assessment', 'timeFrame': '7 & 12 months'}, {'measure': 'Patient scar assessment', 'timeFrame': 'up to 12 months'}, {'measure': 'Independent scar assessment', 'timeFrame': '7 & 12 months'}]","[{'measure': 'Local tolerance', 'timeFrame': 'ongoing to 12 months'}, {'measure': 'Adverse events', 'timeFrame': 'ongoing to12 months'}]",5.0,18 Years,85 Years,ALL,False,INDUSTRY,1.0,156.0,ESTIMATED,v2_robust,True,True,False,True,
NCT06969326,Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy,Use of topical estradiol,['Use of topical estradiol'],1,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Postoperative Bleeding,Women and Infants Hospital of Rhode Island,2025-09-01T16:18:09.628429,True,,,,,Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy,,"['Postoperative Bleeding', 'Gender Dysphoria', 'Hysterectomy']","['gender dysphoria', 'gender affirmation', 'hysterectomy']",,2025-05-01,2026-12-01,"[{'measure': 'Evaluate the efficacy of one-time topical estrogen application for reducing postoperative health system contacts for vaginal bleeding in the first two weeks post hysterectomy.', 'description': 'The investigators hypothesize that administration of postoperative estrogen cream vaginally in the operating room will decrease the need for health system contact for bleeding in the initial postoperative period.\n\nPatients will be asked to complete a brief email survey on postoperative days: 1, 3, 7, \\& 14 as well as at final postoperative visit \\~42 days. This survey will target multiple things\n\nOutcome 1: Quantity of bleeding Determined by patient report: 1) small amount of spotting with wiping; 2) Staining pad, changing every 3-4 hours; 3) Bleeding like a light period; 4) Passing clots/heavy bleeding\n\nAdditionally, chart review will be completed to assess for ED visits, office phone calls, MyChart Messages and any after-hours pages will be recorded.', 'timeFrame': '2 weeks'}, {'measure': 'Examine the impact of topical estrogen application on postoperative healing as defined by number of days of bleeding and patient Quality of Life Measures.', 'description': 'The investigators hypothesize that this intervention will demonstrate improved patient bleeding and dysphoria symptoms during the postoperative recovery period. The investigators will also measure mental health impact.\n\nPre and postoperative Vanderbilt Mini Patient-Reported Outcome Measure - Gender (VMP-G)) scores will be obtained. This is a validated tool that assesses gender identity and gender affirming procedures as well as quality of life, self-concept, satisfaction, and gender dysphoria. (Hung 2023).', 'timeFrame': '6 weeks'}]",[],2.0,18 Years,,FEMALE,False,OTHER,0.0,48.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02564978,Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration,Minocycline,['Minocycline'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Age-Related Macular Degeneration,National Eye Institute (NEI),2025-09-01T16:18:09.628561,True,,,,,Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration,,['Age-Related Macular Degeneration'],"['Eye Disease', 'Degenerative']",,2016-12-14,2023-03-08,"[{'measure': 'Difference in Square-Root Transformed GA Area Expansion Rates in the Study Eye Between the Treatment Phase and Run-in Phase Based on Fundus Autofluorescence (FAF)', 'description': 'The difference in the square-root transformed GA area expansion rates in the study eye based on fundus autofluorescence (FAF) between the treatment phase (Month 9 to Month 33) and the run-in phase (baseline to Month 9) was compared using a linear spline regression model with a fixed knot at Month 9, at a Type I error rate of 2.5%.', 'timeFrame': 'Run-in phase (baseline to Month 9) before initiation of IP and 24 months treatment phase after initiation of IP (Month 9 to Month 33)'}]","[{'measure': 'Difference in Square-root Transformed GA Area Expansion Rates Between the Treatment Phase and Run-in Phase Based on Fundus Autofluorescence (FAF)', 'description': ""The difference in the square-root transformed of GA area expansion rates based on fundus autofluorescence (FAF) between the treatment phase (Month 9 to Month 33) and the run-in phase (baseline to Month 9) in the study eyes alone, the qualifying fellow eyes alone, and the study eyes and qualifying fellow eyes together, analyzed via a two-sided Student's paired t-test at a Type I error rate of 5%."", 'timeFrame': 'Run-in phase (baseline to Month 9) before initiation of IP and 24 months treatment phase after initiation of IP (Month 9 to Month 33)'}, {'measure': 'Difference in the Square-root Transformed GA Area Expansion Rates Between the Treatment Phase and Run-in Phase Based on Color Fundus Photography (CFP)', 'description': 'The difference in the square-root transformed of GA area expansion rates based on color fundus photography (CFP) between the treatment phase (Month 9 to Month 33) and the run-in phase (baseline to Month 9) in the study eyes alone, qualifying fellow eyes alone, and study eyes and qualifying fellow eyes together was compared using a linear spline regression model with a fixed knot at Month 9 at a Type I error rate of 2.5%.', 'timeFrame': 'Run-in phase (baseline to Month 9) before initiation of IP and 24 months treatment phase after initiation of IP (Month 9 to Month 33)'}, {'measure': 'Difference in the Mean Rate of Change in Best Corrected Visual Acuity (BCVA) Between the Treatment Phase and Run-in Phase', 'description': ""The difference in the mean rate of change in Best Corrected Visual Acuity (BCVA) between the treatment phase (Month 9 to Month 33) and the run-in phase (baseline to Month 9) for the study eyes alone, the qualifying fellow eyes alone, and the study eyes and qualifying fellow eyes together, analyzed via a two-sided Student's paired t-test at a Type I error rate of 5%."", 'timeFrame': 'Run-in phase (baseline to Month 9) before initiation of IP and 24 months treatment phase after initiation of IP (Month 9 to Month 33)'}, {'measure': 'Difference in the Mean Rate of Change in Low-Luminance Visual Acuity (LLVA) Between the Treatment Phase and Run-in Phase', 'description': ""The difference in the mean rate of change in Low-Luminance Visual Acuity (LLVA) between the treatment phase (Month 9 to Month 33) and the run-in phase (baseline to Month 9) for the study eyes alone, the qualifying fellow eyes alone, and the study eyes and qualifying fellow eyes together, analyzed via a two-sided Student's paired t-test at a Type I error rate of 5%."", 'timeFrame': 'Run-in phase (baseline to Month 9) before initiation of IP and 24 months treatment phase after initiation of IP (Month 9 to Month 33)'}, {'measure': 'Difference in the Mean Rate of Change of Central Retinal Thickness as Measured on Optical Coherence Tomography (OCT) Between the Treatment Phase and Run-in Phase', 'description': ""The difference in the mean rate of change of central retinal thickness as measured on Optical Coherence Tomography (OCT) between the treatment phase (Month 9 to Month 33) and the run-in phase (baseline to Month 9) for the study eyes alone, the qualifying fellow eyes alone, and the study eyes and qualifying fellow eyes together, analyzed via a two-sided Student's paired t-test at a Type I error rate of 5%."", 'timeFrame': 'Run-in phase (baseline to Month 9) before initiation of IP and 24 months treatment phase after initiation of IP (Month 9 to Month 33)'}]",6.0,55 Years,,ALL,False,NIH,0.0,37.0,ACTUAL,v2_robust,True,True,False,False,
NCT05107778,Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV,ASC42 10mg,"['ih PEG-IFN α-2a', 'Entecavir', 'ASC42 10mg', 'ASC42 15mg', 'Placebo']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Hepatitis B, Chronic","Ascletis Pharmaceuticals Co., Ltd.",2025-09-01T16:18:09.628611,True,,,,,"A Phase II Multi-center, Randomized, Single-blind, Placebo-controlled to Evaluate Safety and Efficacy of ASC42 Tablets in Combination With Entecavir and Pegylated Interferon α-2a in Subjects With Chronic Hepatitis B Virus",,"['Hepatitis B, Chronic']","['Hepatitis B, Chronic', 'ASC42']",,2022-01-10,2023-12-14,"[{'measure': 'Serum HBsAg change compared with baseline', 'timeFrame': 'Week 12 of intervention\\Week 24 of follow-up'}, {'measure': 'Serum HBV pgRNA change compared with baseline', 'timeFrame': 'Week 12 of intervention\\Week 24 of follow-up'}]","[{'measure': 'Serum HBsAg change compared with baseline', 'timeFrame': 'Week 2, 4 ,8 of intervention\\Week 4,12 of follow-up'}, {'measure': 'Serum HBV pgRNA change compared with baseline', 'timeFrame': 'Week 2, 4 ,8 of intervention\\Week 4,12 of follow-up'}]",4.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,43.0,ACTUAL,v2_robust,True,True,False,False,
NCT00808678,Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium,ABT-143,"['ABT-143', 'ABT-335', 'rosuvastatin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,AstraZeneca,2025-09-01T16:18:09.628688,True,,,,,,,['Healthy'],['Adverse Events'],,2008-12,,"[{'measure': 'To determine the safety and tolerability of ABT-143 vs (ABT-335 + rosuvastatin) in healthy adults', 'timeFrame': '7 days'}, {'measure': 'To determine the pharmacokinetic profile(s) for ABt-143 vs. (ABT-335 + rosuvastatin) in healthy adults', 'timeFrame': '7 days'}]",[],2.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,90.0,ACTUAL,v2_robust,True,True,False,True,
NCT06895278,Articular Damage in Patients With Juvenile Idiopathic Arthritis After Transition to Adult Care,Methotrexate,"['Biological Drug', 'Methotrexate']",2,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Juvenile Chronic Arthritis,IRCCS Burlo Garofolo,2025-09-01T16:18:09.628740,True,,,,,Evaluation of Articular Damage in Patients With Juvenile Idiopathic Arthritis (JIA) After Transition to Adult Care and Correlation With Disease Characteristics and Treatments.,,['Juvenile Chronic Arthritis'],"['Juvenile idiopathic arthritis', 'JIA', 'transition to adult', 'articular damage']",,2025-04-01,2025-12-31,"[{'measure': 'Mean difference between groups in the radiographic Sharp/Van der Heijde score', 'description': 'Radiological examinations of small joints (hands/wrists) will be pseudo-anonymized and centralized to a blinded radiologist to evaluate damage using the Sharp/Van der Heijde score, evaluating joint space narrowing and erosion with a range from 0 to 4 and from 0 to 5, respectively. The total Sharp/van der Heijde score is calculated as the sum of the scores for joint space narrowing (range 0-120) and erosion (range 0-160) and ranges from 0 to 280.', 'timeFrame': 'At transition from pediatric to adult care, on average at the age of 18'}, {'measure': 'Mean difference between groups in the radiographic Larsen score', 'description': 'Radiological examinations of knees and hips will be pseudo-anonymized and centralized to a blinded radiologist to evaluate damage using the Larsen score. The grading scale ranges from 0 to 5 (0=intact bony outlines and normal joint space, 5=mutilating changes). The Larsen score ranges from 0 to 120.', 'timeFrame': 'At transition from pediatric to adult care, on average at the age of 18'}]","[{'measure': 'Associations between the radiographic Sharp/Van der Heijde score and clinical characteristics', 'description': ""The following variables will be included in multivariate analysis: age, age at onset, gender, family history of autoimmunity; clinical features of the disease during pediatric age (i.e., number and type of involved joints, JIA category according to 2001 International League of Associations for Rheumatology classification criteria, presence of enthesitis, tenosynovitis, psoriasis and uveitis in the patients' history); laboratory data (i.e., blood count, inflammation indexes, immunoglobulin levels, predisposing HLA, antinuclear antibodies, rheumatoid factor; disease activity score (JADAS-27 score) in the period closest to the radiography execution; therapies taken during the pediatric disease course."", 'timeFrame': 'At transition from pediatric to adult care, on average at the age of 18'}, {'measure': 'Associations between the radiographic Larsen score and clinical characteristics', 'description': ""The following variables will be included in multivariate analysis: age, age at onset, gender, family history of autoimmunity; clinical features of the disease during pediatric age (i.e., number and type of involved joints, JIA category according to 2001 International League of Associations for Rheumatology classification criteria, presence of enthesitis, tenosynovitis, psoriasis and uveitis in the patients' history); laboratory data (i.e., blood count, inflammation indexes, immunoglobulin levels, predisposing HLA, antinuclear antibodies, rheumatoid factor; disease activity score (JADAS-27 score) in the period closest to the radiography execution; therapies taken during the pediatric disease course."", 'timeFrame': 'At transition from pediatric to adult care, on average at the age of 18'}]",4.0,16 Years,25 Years,ALL,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01565278,Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition,Soybean oil (Standard treatment),"['Soybean oil (Standard treatment)', 'Intralipid', 'Soybean oil + Fish oil', 'Intralipid, Omegaven']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Total Parenteral Nutrition-induced Cholestasis,Johane Allard,2025-09-01T16:18:09.628840,True,,,,,Effect of n-3 Polyunsaturated Fatty Acid Lipid Emulsion on Parenteral Nutrition Associated Liver Disease,,['Total Parenteral Nutrition-induced Cholestasis'],"['Parenteral nutrition', 'fish oil', 'liver disease', 'Omegaven', 'hepatic', 'liver biopsy', 'bilirubin']",No more eligible patients could be identified.,2012-02,2015-08,"[{'measure': 'Response to treatment at 3 months', 'description': 'Response is defined as improvement of at least one PNALD parameter by 20% or more; PNALD parameters are: ALP, GGT, ALT, total bilirubin Yes/No', 'timeFrame': '3 months'}]","[{'measure': 'Change in total and conjugated bilirubin over time', 'timeFrame': '0, 3, 6 months on Omegaven'}, {'measure': 'Changes in liver function test (ALP, AST, GGT) over 6 months', 'timeFrame': '0, 3, 6 months on Omegaven'}, {'measure': 'Changes in liver histology between baseline and 6 months on Omegaven', 'timeFrame': '0, 6 months on Omegaven'}, {'measure': 'Changes in liver fatty acid composition between baseline and 6 months on Omegaven', 'description': 'Fatty acid composition by gas chromatography', 'timeFrame': '0, 6 months on Omegaven'}, {'measure': 'Changes in liver oxidative stress between baseline and 6 months', 'description': 'Lipid peroxides in liver tissue (test-kit)', 'timeFrame': '0, 6 months'}, {'measure': 'Changes in hepatic gene expression between baseline and 6 months on Omegaven', 'description': 'Hepatic gene expression (mRNA) by microarray', 'timeFrame': '0, 6 months on Omegaven'}]",7.0,18 Years,,ALL,True,OTHER,7.0,2.0,ACTUAL,v2_robust,True,False,True,False,No more eligible patients could be identified.
NCT03302078,Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects,BI 1015550,['BI 1015550'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:09.629018,True,,,,,Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects,,['Healthy'],[],,2017-10-16,2017-12-13,"[{'measure': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)', 'timeFrame': 'up to 120 hours'}, {'measure': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': 'up to 120 hours'}]","[{'measure': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'up to 120 hours'}]",3.0,18 Years,55 Years,MALE,True,INDUSTRY,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,
NCT00067678,Soy Protein in Early Diabetic Nephropathy,soy protein,['soy protein'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Diabetic Nephropathy,National Center for Complementary and Integrative Health (NCCIH),2025-09-01T16:18:09.629032,True,,,,,Soy Protein in Early Diabetic Nephropathy,,"['Diabetic Nephropathy', 'Diabetes Mellitus']","['diabetic nephropathy', 'nephropathy', 'diabetes', 'diabetes mellitus', 'type I diabetes', 'soy protein']",,2001-07,2003-06,[],[],0.0,18 Years,40 Years,ALL,False,NIH,0.0,,,v2_robust,True,True,False,False,
NCT00362778,Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia,Insulin,['Insulin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Diabetes,Hospital Clinic of Barcelona,2025-09-01T16:18:09.629038,True,,,,,Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia,,"['Diabetes', 'Hyperglycemia', 'Acute Myocardial Infarction']",[],,2006-01,2007-06,"[{'measure': 'Glycemic control', 'timeFrame': 'first 48 hours'}]","[{'measure': 'High-sensitivity C-reactive protein levels', 'timeFrame': 'At 48 hours and aat hospital discharge'}]",2.0,18 Years,,ALL,False,OTHER,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,
NCT06499285,"The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)",Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Myelodysplastic Syndromes,"Keros Therapeutics, Inc.",2025-09-01T16:18:09.629125,True,,,,,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)",,['Myelodysplastic Syndromes'],"['Anemia', 'Elritercept', 'Myelodysplastic neoplasms', 'KER-050', 'MDS']",,2025-06,2032-05,"[{'measure': 'Efficacy evaluation of KER-050: Proportion of participants achieving TI for ≥ 8 weeks', 'description': 'To evaluate the efficacy of KER-050 in reducing RBC transfusions', 'timeFrame': 'from baseline through week 24'}]","[{'measure': 'Efficacy evaluation of KER-050: Proportion of participants achieving TI for ≥ 24 weeks', 'description': 'To evaluate the efficacy of KER-050 in reducing RBC transfusions over longer intervals', 'timeFrame': 'from baseline through week 48'}, {'measure': 'Efficacy evaluation of KER-050: Proportion of participants with HTB achieving TI for ≥ 8 weeks', 'description': 'To evaluate the efficacy of KER-050 in reducing RBC transfusions in participants with HTB', 'timeFrame': 'from baseline through week 24'}, {'measure': 'Safety and tolerability assessment of KER-050: Incidence of TEAEs and SAEs, change in clinical laboratory values, vital signs, and ECGs', 'description': 'To assess the safety and tolerability of KER-050', 'timeFrame': 'change from baseline'}]",4.0,18 Years,,ALL,False,INDUSTRY,1.0,225.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00957385,Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients,Revlimid,"['Lenalidomide', 'Revlimid']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acute Myeloid Leukemia,"University Health Network, Toronto",2025-09-01T16:18:09.629150,True,,,,,A Randomized Phase II Study of Lenalidomide Maintenance Therapy in AML Patients Aged > 60 Years in CR1 or Higher and < 60 Years in CR2 or Higher,,['Acute Myeloid Leukemia'],"['Leukemia', 'Remission']",,2008-06,2015-04,"[{'measure': 'To assess the feasibility and assess the effect on relapse free survival by giving Revlimid in the post complete remission maintenance setting', 'timeFrame': 'The 1st interim analysis will be done once all subjects have completed 12 cycles, and the 2nd interim analysis will be done once all subjects have completed treatment.'}]","[{'measure': 'To determine the toxicity of Revlimid when given in the maintenance setting.', 'timeFrame': 'The 1st interim analysis will be done after all subjects have receieved 12 cycles and the 2nd when all subjects have completed treatment.'}]",2.0,18 Years,,ALL,False,OTHER,1.0,24.0,ACTUAL,v2_robust,True,True,False,False,
NCT05838885,A Trial of YPEG-rhGH in Children With Short Stature,YPEG-rhGH,"['rhGH', 'YPEG-rhGH']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Idiopathic Short Stature,"Xiamen Amoytop Biotech Co., Ltd.",2025-09-01T16:18:09.629162,True,,,,,"A Multicenter, Randomized, Open-label, Positive-controlled Phase 2 Study to Explore the Optimal Dose of Y- Shaped Pegylated Recombinant Growth Hormone (YPEG-rhGH) in Children With Short Stature (ISS, SGA, TS)",,"['Idiopathic Short Stature', 'Small for Gestational Age', 'Turner Syndrome']","['Growth hormone', 'Somatotropin', 'Short stature', 'Idiopathic short stature', 'Small for gestational age', 'Turner syndrome']",,2022-02-15,2023-12-19,"[{'measure': 'Pharmacokinetic-area under plasma concentration versus time curve', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-maximum serum concentration', 'timeFrame': 'up to 52weeks'}, {'measure': 'Pharmacokinetic-time to reach the maximum plasma concentration', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-terminal disposition phase half-life', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-terminal elimination rate constant', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-apparent clearance after extravascular administration', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-apparent volume of distribution', 'timeFrame': 'up to 52 weeks'}]","[{'measure': 'Pharmacodynamics-the properties of Insulin-like growth facto1 and Insulin-like growth factor binding receptor 3.', 'timeFrame': 'up to 57 weeks'}, {'measure': 'Height velocity (HV, cm/year)', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Change of height velocity compared to baseline (ΔHV, cm/year)', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Height standard deviation according to chronological age (Ht SDS CA)', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Change in bone age', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Adverse events (including injection site reactions), changes from baseline in vital signs and laboratory tests', 'timeFrame': 'up to 57 weeks'}]",13.0,4 Years,11 Years,ALL,False,INDUSTRY,1.0,78.0,ACTUAL,v2_robust,True,True,False,True,
NCT00039585,"Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor",imatinib mesylate,['imatinib mesylate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Fallopian Tube Cancer,National Cancer Institute (NCI),2025-09-01T16:18:09.629250,True,,,,,"Phase II Clinical Trial With Proteomic Profiling Of Imatinib Mesylate (Gleevec; STI571), A PDGFR And C-Kit Inhibitor, In Patients With Refractory Or Relapsed Epithelial Ovarian Cancer, Fallopian Tube And Primary Peritoneal Cancer",,"['Fallopian Tube Cancer', 'Ovarian Cancer', 'Primary Peritoneal Cavity Cancer']","['recurrent ovarian epithelial cancer', 'fallopian tube cancer', 'primary peritoneal cavity cancer', 'borderline ovarian surface epithelial-stromal tumor']",,2002-05,,"[{'measure': 'Clinical response in patients with epithelial ovarian cancer as measured by CT scan of chest, abdomen, and pelvis every 8 weeks'}]","[{'measure': 'Corr. of biochem. modulation of signal transduction pathways downstream of platelet-derived growth factor receptor (PDGFR) and c-kit tyrosine kinase by tumor lysate microarray analysis in biopsy tissue with patient outcome at baseline and at 4 wks'}, {'measure': 'Correlation of PDGFR and c-kit expression with response and outcome in patients with epithelial ovarian cancer as measured by tumor microarray analysis on biopsy tissue at baseline and at 4 weeks'}, {'measure': 'Antiangiogenic activity as measured by tumor lysate microarray on biopsy tissue at baseline and at 4 weeks'}, {'measure': 'Collateral receptor tyrosine kinase inhibition as measured by tumor lysate microarray on biopsy tissue at baseline and at 4 weeks'}, {'measure': 'Prediction of response and/or toxicity as measured by Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight (SELDI-TOF) proteomics and Artificial Intelligence bioinformatics on serum samples at baseline and every 4 wks'}]",6.0,,,FEMALE,False,NIH,0.0,,,v2_robust,True,True,False,False,
NCT03188185,A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD),ALKS 5461,"['ALKS 5461', 'ALKS 5461 Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Major Depressive Disorder,"Alkermes, Inc.",2025-09-01T16:18:09.629334,True,,,,,A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder,,['Major Depressive Disorder'],"['Alkermes', 'Major Depressive Disorder', 'Treatment Refractory MDD', 'ALKS 5461']",,2017-06-12,2020-03-05,"[{'measure': 'Change From Baseline to the End of Treatment (EOT) in the Montgomery Asberg Depression Rating Scale-10 (MADRS-10) Scores', 'description': 'The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of Major Depressive Disorder (MDD) symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts.', 'timeFrame': 'Baseline and 5 weeks for Stage 1, Baseline and 6 weeks for Stage 2'}]","[{'measure': 'Montgomery Asberg Depression Rating Scale (MADRS) Response Rate', 'description': 'The percentage of subjects demonstrating a MADRS-10 treatment response, defined as a \\>/= 50% reduction in MADRS-10 score from baseline to the end of the efficacy period (Week 5 for Stage 1, Week 6 for Stage 2). The MADRS-10 scale is a measure of the severity of Major Depressive Disorder (MDD) symptoms and includes the following 10 items: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms).', 'timeFrame': 'Baseline and 5 weeks for Stage 1, Baseline and 6 weeks for Stage 2'}, {'measure': 'Montgomery Asberg Depression Rating Scale (MADRS) Remission Rate', 'description': 'The percentage of subjects achieving remission, defined as a subject with a score \\</= 10 at the end of the efficacy period (Week 5 for Stage 1, Week 6 for Stage 2). The MADRS-10 scale is a measure of the severity of Major Depressive Disorder (MDD) symptoms and includes the following 10 items: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms).the end of the efficacy period.', 'timeFrame': '5 weeks for Stage 1, 6 weeks for Stage 2'}]",3.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,278.0,ACTUAL,v2_robust,True,True,False,False,
NCT03284385,Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2,Adavosertib,"['AZD-1775', 'Adavosertib', 'AZD 1775', 'AZD1775', 'MK 1775', 'MK-1775', 'MK1775']",7,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Clear Cell Renal Cell Carcinoma,National Cancer Institute (NCI),2025-09-01T16:18:09.629360,True,,,,,A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies,,"['Clear Cell Renal Cell Carcinoma', 'Locally Advanced Clear Cell Renal Cell Carcinoma', 'Locally Advanced Malignant Solid Neoplasm', 'Metastatic Malignant Solid Neoplasm', 'Metastatic Renal Cell Carcinoma', 'Stage III Renal Cell Cancer AJCC v8', 'Stage IV Renal Cell Cancer AJCC v8']",[],,2019-01-29,2025-08-30,"[{'measure': 'Objective response rate', 'description': 'Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The median duration of response will be descriptively reported using Kaplan-Meier product limit method along with 95% confidence interval. The objective response rate between cohorts will be compared using the chi-squared test.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Clinical benefit rate', 'description': 'Will be defined as patients who experience either objective response or stable disease for \\>= 6 months from start of study treatment. The clinical benefit rate across the entire study cohort will be descriptively reported along with 95% confidence interval.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Duration of response', 'description': 'The median duration of response will be descriptively reported using Kaplan-Meier product limit method along with 95% confidence interval.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Incidence and severity of adverse events', 'description': 'Will be graded by Common Toxicity Criteria version 5.0, will be descriptively reported for the safety-evaluable population.', 'timeFrame': 'Up to 2 years'}, {'measure': 'H3K36me3 mark', 'description': 'Will be assessed by immunohistochemistry.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression free survival', 'description': 'The median progression-free survival for each cohort will be determined using the Kaplan-Meier product limit method and compared between cohorts using the log-rank test.', 'timeFrame': 'Up to 2 years'}]",6.0,18 Years,,ALL,False,NIH,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01238185,Aspirin Mouthwash in Treating Patients With Oral Leukoplakia,acetylsalicylic acid,['acetylsalicylic acid'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Precancerous Condition,"Institute of Head and Neck Studies and Education, United Kingdom",2025-09-01T16:18:09.629376,True,,,,,Oral Topical Cyclooxygenase Inhibitor (Aspirin) Mouthwash for Treatment of Oral Dysplasia,,['Precancerous Condition'],['oral leukoplakia'],,2010-02,2011-10,"[{'measure': 'PGE2 levels as assessed by enzyme immunosorbent assay'}, {'measure': 'COX-1 and COX-2 mRNA as assessed by qRT-PCR'}, {'measure': 'COX-1 and COX-2 protein expression as assessed by immunohistochemistry and quantified by immunoblotting to determine whether COX inhibition in oral dysplasia tissues is actually possible by use of the mouthwash formulation'}]","[{'measure': 'Comparison of WHO histological grade and clinical size of dysplastic lesions before and after treatment and assessment of proliferating cell nuclear antigen'}, {'measure': 'Tolerability and possible oral and other adverse effects using a questionnaire'}, {'measure': 'VEGF mRNA expression as assessed by qRT-PCR'}, {'measure': 'Protein expression as assessed by ELISA and immunohistochemistry for VEGFA'}, {'measure': 'Global gene response of dysplastic tissue as assessed by Affymetrix gene expression microarrays'}]",8.0,,,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,True,False,True,
NCT06900543,"Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere",NRT6003 Injection,"['cTACE', 'Yttrium-90 carbon microspheres', 'NRT6003 Injection', 'transarterial chemoembolization']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Unresectable Hepatocellular Carcinoma,Chengdu New Radiomedicine Technology Co. LTD.,2025-09-01T16:18:09.629402,True,,,,,"A Randomized, Open-label, Multicenter Study Comparing the Efficacy and Safety of NRT6003 Injection With Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)",,['Unresectable Hepatocellular Carcinoma'],"['Selective internal radiation therapy', 'Yttrium-90', 'Transarterial Radioembolization', 'Conventional Transarterial Chemoembolization']",,2025-04-15,2027-12,"[{'measure': 'Time to Progression (TTP)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Localized Time to Progression (localized TTP)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Time to Progression', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Localized Time to Progression', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Objective Response Rate', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Duration of Response', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Surgery Rate', 'description': 'Resection rate of liver target lesions', 'timeFrame': 'From the administration to study completion, at least 18 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Based on survival follow-up information', 'timeFrame': 'From the administration to study completion, at least 18 months'}, {'measure': 'Changes in Tumor Biomarkers', 'description': 'The variation of alpha fetoprotein (AFP) levels', 'timeFrame': 'From the administration to study completion, at least 18 months'}, {'measure': 'Incidence and severity of adverse events (AE) and severe adverse events (SAE)', 'description': 'In accordance with NCI-CTCAE 5.0', 'timeFrame': 'Throughout the study, at least 18 months'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,108.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04825743,A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI,zalunfiban,"['zalunfiban', 'RUC-4', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,ST-elevation Myocardial Infarction (STEMI),CeleCor Therapeutics,2025-09-01T16:18:09.629501,True,,,,,"A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting",,['ST-elevation Myocardial Infarction (STEMI)'],[],,2021-04-24,2026-05-13,"[{'measure': 'primary efficacy -clinical outcome', 'description': 'As assessed by a 7-point scale. The 7 outcomes, ranking from worst to best are:\n\n1. Death (all cause) at 30 days follow-up\n2. Stroke at 30 days follow-up\n3. Recurrent MI (type 1 to 4 MI) at 30 days follow-up\n4. Acute stent thrombosis at 24 hours post-PCI/angiography\n5. New onset heart failure or rehospitalization for heart failure at 30 days follow-up\n6. MI with hs-cTnT levels ≥10x ULN at 24 hours post-PCI/angiography\n7. None of the above', 'timeFrame': 'at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo'}, {'measure': 'primary safety- bleeding events [BARC criteria]', 'description': '• To assess bleeding events (according to Global Use of Strategies to Open Occluded Coronary Arteries \\[GUSTO\\] severe or life threatening criterion for safety assessment and according to the Bleeding Academic Research Consortium \\[BARC\\] 3C and 5 criteria for information only)', 'timeFrame': 'after a single subcutaneous injection of zalunfiban versus placebo at 30 days post-PCI/angiography'}]","[{'measure': 'secondary efficacy-restoration of the coronary artery blood flow', 'description': 'To assess restoration of the culprit coronary artery blood flow (corrected Thrombolysis in Myocardial Infarction \\[TIMI\\] Frame Count) before intended PCI (or post coronary angiography in case no PCI is performed) after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'before PCI (or coronary angiography if no PCI is performed)'}, {'measure': 'efficacy-resolution of ST segment deviation', 'description': 'To assess resolution of ST segment deviation post-PCI/angiography after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': '1 hour post-PCI/angiography'}, {'measure': 'Efficacy-composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist', 'description': 'To assess a composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist', 'timeFrame': 'at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo'}, {'measure': 'Efficacy-acute stent thrombosis', 'description': 'To assess incidence of definite, probable or possible acute stent thrombosis after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'up to 24 hours post-PCI'}, {'measure': 'Safety throughout the study by AE reporting', 'description': 'Recording of AEs and SAEs fibrillation up to 12-months follow-up', 'timeFrame': 'AEs up to 30 days follow-up; SAEs up to resolution/stabilization, the SAEs mortality, hospitalization for heart failure and atrial fibrillation up to 12-months follow-up'}, {'measure': 'Safety-platelet count', 'description': 'To assess platelet count after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'before PCI/angiography, at the end of the PCI/angiography, 6 and 24 hours post-PCI/angiography and at hospital discharge/72-hours post-PCI/angiography (whichever occurs first)'}, {'measure': 'Safety-bleeding events (ISTH and TIMI)', 'description': 'To assess bleeding events (according to International Society on Thrombosis and Haemostasis \\[ISTH\\] Major and TIMI Major for information only) after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'at 30 days follow-up'}, {'measure': 'Safety-bleeding events (GUSTO mild and moderate, BARC type 2, 3 and 5, ISTH minor and/or major and TIMI minor and major)', 'description': 'To assess incidence of bleeding events according to GUSTO mild and moderate criteria, BARC type 2, 3 and 5 criteria, ISTH minor and or major bleeding, TIMI minor and major criteria', 'timeFrame': '30 days follow-up'}, {'measure': 'Safety-injection site reactions', 'description': 'To assess the injection site reactions of a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'baseline, 1-hour post-PCI/angiography, hospital discharge/72-hours post-PCI/angiography, and at 30 days follow-up'}]",11.0,18 Years,,ALL,False,INDUSTRY,0.0,2463.0,ACTUAL,v2_robust,True,False,False,True,
NCT03465943,Different Preloads for Prevention of Hypotension in Patients Undergoing Elective CS Under Intrathecal Anesthesia,Ringer,"['Ringer', 'Hydroxyethyl starch 6%', 'Crystalloid', 'Voluven']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,Hypotension Drug-Induced,Assiut University,2025-09-01T16:18:09.629526,True,,,,,Crystalloid Versus Crystalloid and Colloid Combination Preload for Prevention of Hypotension in Patients Undergoing Elective Caesarean Section Under Intrathecal Anesthesia,,['Hypotension Drug-Induced'],[],,2018-03,2019-04,"[{'measure': 'Incidence of hypotension', 'description': 'Decrease in systolic blood pressure more than 20% of base line', 'timeFrame': '1 hour'}]","[{'measure': 'Perfusion index', 'description': 'Derived from pulse oximeter', 'timeFrame': '1 hour'}, {'measure': 'Heart rate', 'timeFrame': '1 hour'}, {'measure': 'Urine output', 'timeFrame': '1 hour'}]",4.0,18 Years,40 Years,FEMALE,True,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05599243,Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.,Dutasteride,['Dutasteride'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Male Androgenetic Alopecia,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,2025-09-01T16:18:09.629537,True,,,,,Exploratory Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.,,['Male Androgenetic Alopecia'],[],,2022-09-29,2023-08-11,"[{'measure': 'Safety and Tolerability', 'description': 'Local adverse events (AEs) and systemic adverse reactions\n\n\\- Hair microbiome analysis', 'timeFrame': '7 months'}]","[{'measure': 'Efficacy in hair loss reduction', 'description': 'Clinical improvement. Standardized photographs will be taken', 'timeFrame': '7 months'}]",2.0,18 Years,,MALE,False,OTHER,0.0,45.0,ACTUAL,v2_robust,True,True,False,True,
NCT05501743,Evaluation of the Efficacy of an Intra-articular Injection of Autologous Microfat Combined With Autologous Platelet-enriched Plasma in the Treatment of Radiocarpal Osteoarthritis: a Randomized Controlled Non-inferiority Trial Versus Total Wrist Denervation (Established Standard Treatment).,Intra-articular injection of microfat and PRP,['Intra-articular injection of microfat and PRP'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Arthrosis,Assistance Publique Hopitaux De Marseille,2025-09-01T16:18:09.629544,True,,,,,Evaluation of the Efficacy of an Intra-articular Injection of Autologous Microfat Combined With Autologous Platelet-enriched Plasma in the Treatment of Radiocarpal Osteoarthritis: a Randomized Controlled Non-inferiority Trial Versus Total Wrist Denervation.,,['Arthrosis'],[],,2023-02-17,2026-06,"[{'measure': 'Pain intensity measured on the visual analog scale (EVA)', 'description': ""The patient will indicate his or her pain using a cross on a 10 cm scale called the VAS score. The VAS is rated from 0 to 100 by the evaluator. The higher the patient's score, the greater the pain."", 'timeFrame': '6 Months'}]","[{'measure': 'Pain intensity measured on the visual analog scale (EVA)', 'description': ""The patient will indicate his or her pain using a cross on a 10 cm scale called the VAS score. The VAS is rated from 0 to 100 by the evaluator. The higher the patient's score, the greater the pain."", 'timeFrame': 'Day 7, 3 Months and 1 Year'}, {'measure': 'Combined assessment of function and pain by the PRWE score', 'description': 'The PRWE (Patient-Rated Wrist Evaluation) is a specific wrist function and pain assessment score. The questionnaire consists of 15 items, 5 of which focus on pain (50 points) and 10 on wrist function (100 points). We will use the combined score in which the total points for wrist function are divided by 2 and added to the pain score to obtain a total score out of 100 points.', 'timeFrame': '3 Months, 6 Months and 1 Year'}, {'measure': 'Assessment of upper limb function by the DASH score', 'description': 'The DASH (Disabilities of the Arm, Shoulder and Hand) is a subjective self-assessment questionnaire of the overall functional capacity of both upper limbs. The questionnaire consists of 30 questions covering difficulty with specific activities of daily living, social relationships, and specific symptoms: pain, strength, mobility and sleep. The overall score is presented as a score out of 100 by the following calculation method: \\[(sum of n responses)-1\\] x 25n. The score is only valid if 90% of the questions have been filled in by the patient (i.e. 3 missing values at most).', 'timeFrame': '3 Months, 6 Months and 1 Year'}, {'measure': 'Assessment of wrist strength by dynamometry', 'description': 'Wrist grip strength will be assessed by the average score of 3 consecutive measurements on the Jamar hydraulic hand dynamometer.', 'timeFrame': '3 Months, 6 Months and 1 Year'}, {'measure': 'Measurement of wrist joint amplitudes', 'description': 'The joint amplitudes of the wrist will be measured with a goniometer :\n\n* in radial tilt\n* in ulnar tilt\n* in flexion\n* in extension These measurements are noted for the wrist with osteoarthritis and the contralateral wrist.', 'timeFrame': '3 Months, 6 Months and 1 Year'}, {'measure': 'Overall change perceived by the patient', 'description': 'The patient\'s overall perceived change will be assessed using the 7-level Likert scale (Check the box that best describes the current condition of your wrist, compared to before the procedure."" Much better, Better, Slightly better, No change, Slightly worse, Worse, Much worse).', 'timeFrame': '3 Months, 6 Months and 1 Year'}, {'measure': 'Patient satisfaction', 'description': 'The patient will answer using the 3-level Likert scale if he/she is satisfied with the therapeutic procedure (Denervation or intra-articular injection of the product under study) (""Check the box that best describes your level of satisfaction with the intervention."" (satisfied vs. neither satisfied-nor dissatisfied or dissatisfied; improved vs. no change or worse)The patient will also be asked if he/she would recommend this procedure to a loved one.', 'timeFrame': 'Day 7, 3 Months'}, {'measure': 'MRI evaluation of cartilage lesions in the ""study treatment"" group', 'description': 'Pre- and post-operative MRI analysis in the ""study treatment"" group will allow quantitative assessment of the variation in cartilage relaxation time on gradient echo and 3D high-resolution 3T MRI sequences.', 'timeFrame': '6 Months'}]",9.0,18 Years,,ALL,False,OTHER,0.0,36.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01894243,Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment,Olaparib tablet dosing,['Olaparib tablet dosing'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Solid Tumours,AstraZeneca,2025-09-01T16:18:09.629584,True,,,,,"An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment",,['Solid Tumours'],"['oncology,', 'cancer,', 'neoplasm,', 'anticancer drug,', 'pharmacokinetics,', 'area under curve,', 'olaparib,', 'solid tumour,', 'mild hepatic impairment,', 'moderate hepatic impairment']",,2014-03-13,2017-03-30,"[{'measure': 'Maximum Plasma Concentration (Cmax)', 'description': 'Summary of Geometric Least Squares (GLS) Mean for normal, mild and moderate hepatic impairment', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Ratio of Maximum Plasma Concentration (Cmax) - Mild vs Normal and Moderate vs Normal', 'description': 'Summary of ratio of Geometric Least Squares (GLS) Means', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC)', 'description': 'Summary of Geometric Least Squares (GLS) Mean', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Ratio of Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC) - Mild vs Normal and Moderate vs Normal', 'description': 'Summary of Ratio of Geometric Least Squares (GLS) Means', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Area Under the Plasma Concentration Time Curve From Zero to the Last Measureable Time Point(AUC 0-t)', 'description': 'Summary of Geometric Least Squares (GLS) Mean for ratio of mild hepatic impairment compared to normal', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Ratio of Area Under the Plasma Concentration Time Curve From Zero to the Last Measureable Time Point(AUC 0-t)', 'description': 'Summary of Ratio of Geometric Least Squares (GLS) Means', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Apparent Clearance Following Oral Administration (CL/F)', 'description': 'Summary of Geometric Least Squares (GLS) Means', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Ratio of Apparent Clearance Following Oral Administration (CL/F)', 'description': 'Summary of Ratio of Geometric Least Squares (GLS) Means', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Time to Reach Maximum Plasma Concentration (Tmax)', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Terminal Half-life (t½)', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}, {'measure': 'Apparent Volume of Distribution (Vz/F)', 'timeFrame': 'Blood samples are collected at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post olaparib dose in Part A.'}]",[],11.0,18 Years,130 Years,ALL,False,INDUSTRY,0.0,31.0,ACTUAL,v2_robust,True,True,False,False,
NCT05647343,Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers,Ciclopirox Olamine Oral,['Ciclopirox Olamine Oral'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Adverse Effect of Drugs and Medicaments in Therapeutic Use,Atlas Molecular Pharma,2025-09-01T16:18:09.629616,True,,,,,"A Phase I, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers",,['Adverse Effect of Drugs and Medicaments in Therapeutic Use'],[],,2023-03-31,2024-04-08,"[{'measure': 'Incidence of adverse events (AEs)', 'description': 'Incidence of adverse events (AEs) and of clinically relevant changes in vital signs values, electrocardiogram (ECG) data, physical examination and laboratory safety data for four different doses of ATL-001', 'timeFrame': '3.5 months, with up to 66 days per participant'}]","[{'measure': 'Derived pharmacokinetic parameters for ATL-001', 'description': 'Area under the plasma drug concentration', 'timeFrame': '6 days per participant'}, {'measure': 'Derived pharmacokinetic parameters for ATL-001', 'description': 'Time curve (AUC(0-last), AUC(0-12), AUC(0-24))', 'timeFrame': '6 days per participant'}, {'measure': 'Derived pharmacokinetic parameters for ATL-001', 'description': 'Maximum observed plasma drug concentration (Cmax)', 'timeFrame': '6 days per participant'}, {'measure': 'Derived pharmacokinetic parameters for ATL-001', 'description': 'Time to maximum observed plasma drug concentration (tmax)', 'timeFrame': '6 days per participant'}, {'measure': 'Derived pharmacokinetic parameters for ATL-001', 'description': 'Apparent terminal half-life (t1/2)', 'timeFrame': '6 days per participant'}, {'measure': 'Derived pharmacokinetic parameters for ATL-001', 'description': 'Apparent total body clearance (CL/F)', 'timeFrame': '6 days per participant'}, {'measure': 'Derived pharmacokinetic parameters for ATL-001', 'description': 'Apparent volume of distribution (Vz/F)', 'timeFrame': '6 days per participant'}]",8.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,42.0,ACTUAL,v2_robust,True,True,False,True,
NCT06855043,Little Lungs Study,Calfactant,"['Calfactant', 'Budesonide']",2,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Invasive Mechanical Ventilation,"University of Wisconsin, Madison",2025-09-01T16:18:09.629624,True,,,,,Pilot Study of Late Surfactant Therapy With Budesonide for Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Infants,,"['Invasive Mechanical Ventilation', 'Severe Respiratory Distress Syndrome']",['premature birth'],,2026-03,2028-01,"[{'measure': 'Change in respiratory severity score (RSS)', 'description': 'RSS is the mean airway pressure multiplied by the fraction of inspired oxygen, a change toward higher scores indicates more severe respiratory symptoms.', 'timeFrame': 'Baseline to 48 hours'}]","[{'measure': 'Change in RSS', 'description': 'RSS is the mean airway pressure multiplied by the fraction of inspired oxygen, a change toward higher scores indicates more severe respiratory symptoms.', 'timeFrame': 'Baseline to 7 days'}, {'measure': 'Presence or absence of acute clinical deterioration', 'description': 'Oxygen saturation less than 80 percent and/or heart rate less than 100 beats per minute (bpm).', 'timeFrame': 'Up to 3 days'}, {'measure': 'Presence or absence of severe acute clinical deterioration', 'description': 'Oxygen saturation less than 60 percent and/or heart rate less than 80 bpm.', 'timeFrame': 'Up to 3 days'}, {'measure': 'Change in average daily apnea bradycardia desaturation (ABD) events', 'description': 'ABD events are defined as (1) Apnea greater than 20 seconds, or (2) Apnea less than 20s that is associated with heart rate less than 100bpm and/or oxygen saturation less than 80 percent.', 'timeFrame': 'Baseline to 5 days'}, {'measure': 'Occurrence of pneumothorax', 'description': 'A yes or no question of whether there was pneumothorax (air in the pleural cavity) detected via chest x-ray, needing evacuation.', 'timeFrame': 'Up to 5 days'}, {'measure': 'Occurrence of pulmonary hemorrhages', 'description': 'A yes or no question of whether there was pulmonary hemorrhage (bleeding in lungs) was observed in the endotracheal tube.', 'timeFrame': 'Up to 5 days'}, {'measure': 'Compare observed Bronchopulmonary Dysplasia (BPD) grades with estimated BPD grade', 'description': 'To see if there has been a change in the observed BPD grade after completion of the study intervention compared to the estimated BPD grade prior to study enrollment, the ratio of estimated BPD grades based on 2022 Neonatal Research Network (NRN) BPD estimator to observed BPD grades at 36 0/7 weeks will be reported.', 'timeFrame': 'up to 36 weeks post menstrual age'}]",8.0,7 Days,14 Days,ALL,False,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04132843,Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions,Gadobenate Dimeglumine,"['MultiHance', 'ZK 135079', 'Gd-BOPTA', 'Gadobenate Dimeglumine', 'BAY86-4875', 'Gadovist', 'Gadavist', 'Gadobutrol', 'Protovis', 'Gadograf']",10,INTERVENTIONAL,['NA'],,COMPLETED,Brain Neoplasm,M.D. Anderson Cancer Center,2025-09-01T16:18:09.629650,True,,,,,Novel Multi-Parameter Mapping and Analysis Techniques for Characterization and Treatment Assessment of High Grade Brain Lesions,,"['Brain Neoplasm', 'Lymphoma', 'Metastatic Malignant Neoplasm in the Brain', 'Recurrent Malignant Brain Neoplasm']",[],,2020-01-10,2022-09-01,"[{'measure': 'Differences in T2 spin parameters', 'description': 'Will use 3-dimensional (3D) quantitative mapping to determine whether different in T2 spin parameters exist between the peritumoral area and normal brain in the contralateral hemisphere. If the data are normal, will calculate 95% confidence intervals around the mean paired difference in baseline T2 between the peritumoral and normal regions. If the data are not normally distributed, ordered statistics will be calculated, and bootstrapping will be used to estimate the 2.5th and 97.5th percentiles for the median.', 'timeFrame': 'Baseline'}, {'measure': 'Differences between peritumoral and normal brain', 'description': 'Will use 3D quantitative mapping to examine how differences between peritumoral and normal brain in the contralateral hemisphere change before and after treatment. The regions of interest drawn on measured magnetic resonance (MR) spin parameter and MR perfusion parameter values will be grouped according to time point (pre- or post-treatment) and area (peritumoral, tumoral, and normal brain in the contralateral hemisphere). Descriptive statistics and boxplots of these measurements, paired differences between areas and paired differences between time points will be calculated. Will calculate 95% confidence intervals around the mean paired change between area differences at baseline and post-treatment.', 'timeFrame': 'Baseline up to 120 days'}]","[{'measure': 'Usefulness of T2 values in distinguishing non-enhancing components of the tumor', 'description': 'Will use area under an receive operating curve to determine whether T2 values might be useful in distinguishing non-enhancing components of the tumor as well as predicting response to treatment. Paired data from all patients will be used in this analysis.', 'timeFrame': 'Up to 120 days'}, {'measure': 'Quantification of T1 and proton density (PD) parameters', 'description': 'Will quantify T1 and PD spin parameters of the peritumoral area and their differences before and after treatment.', 'timeFrame': 'Baseline up to 120 days'}, {'measure': 'Post-contrast T1 spin parameters with perfusion characteristics', 'description': 'Will examine post-contrast T1 spin parameters with perfusion characteristics as measured by an established dynamic susceptibility contrast technique.', 'timeFrame': 'Up to 120 days'}, {'measure': 'Differences in measured perfusion parameters before and after treatment.', 'description': 'Will examine differences in measured perfusion parameters before and after treatment.', 'timeFrame': 'Baseline up to 120 days'}]",6.0,18 Years,,ALL,False,OTHER,1.0,6.0,ACTUAL,v2_robust,True,True,False,False,
NCT03239743,Effects of Virtual Reality on Pre-Operative Anxiety and Induction of Anesthesia in Children and Adolescents,Midazolam,"['Midazolam', 'Versed']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Tonsillectomy,Valley Anesthesiology Consultants,2025-09-01T16:18:09.629678,True,,,,,A Pilot Study to Evaluate the Efficacy of Virtual Reality on Pre-Operative Anxiety and Induction of Anesthesia in a Children's Hospital,,['Tonsillectomy'],"['virtual reality', 'adenoidectomy', 'induction of anesthesia', 'pre-operative anxiety']",,2017-07-20,2019-05,"[{'measure': 'Pre-Operative Anxiety measured by mYPAS anxiety scores', 'description': 'Determine if the use of a VR device will result in lower mYPAS anxiety scores during the preoperative period', 'timeFrame': 'Baseline'}]","[{'measure': 'Induction Compliance of Anesthesia measured by the induction compliance checklist', 'description': 'Determine if the use of a VR device will result in greater induction of anesthesia measured by the induction compliance checklist.', 'timeFrame': 'Baseline'}, {'measure': 'Post-Operative Emergence Delirium measured by the PAED scale', 'description': 'Determine if VR use will reduce incidence of post-operative emergence delirium measured by the PAED scale.', 'timeFrame': 'up to 3 hours post operative'}, {'measure': 'Post-Operative Pain', 'description': 'Measure if VR use will reduce post-operative pain scores compared to patients receiving standard of care.', 'timeFrame': 'up to 3 hours post operative'}, {'measure': 'Post-Operative Opioid Use', 'description': 'Measure VR use will reduce opioid use compared to patients receiving standard of care', 'timeFrame': 'up to 3 hours post operative'}]",5.0,5 Years,11 Years,ALL,True,OTHER,2.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05768243,Hyaluronic Acid Versus Red Injectable Platelet Rich Fibrin in Treatment of Periodontitis,Hyaluronic acid,"['Hyaluronic acid', 'GENGIGEL®']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Periodontitis Chronic Generalized Severe,Beirut Arab University,2025-09-01T16:18:09.629695,True,,,,,Efficiency of Hyaluronic Acid Versus Red Injectable Platelet-Rich Fibrin (i-PRF) in Treatment of Stage III Periodontitis (Randomized Controlled Clinical Trial),,['Periodontitis Chronic Generalized Severe'],[],,2021-03-01,2022-09-17,"[{'measure': 'Clinical Attachment Level', 'description': 'used to assess the loss of periodontal tissue support in periodontitis. It is the distance from the cemento-enamel junction (fixed point on the tooth) to the depth of the pocket', 'timeFrame': '4 weeks'}, {'measure': 'Probing Depth', 'description': 'used to detect the depth of the periodontal pocket. It is the distance from the gingival margin to the base of the pocket.', 'timeFrame': '4 weeks'}]","[{'measure': 'Bleeding on Probing', 'description': 'It is an indicator of periodontal tissue inflammatory response. The probe is carefully introduced to the bottom of the pocket and gently moved laterally along the pocket wall. Depending on the severity of inflammation, bleeding can vary from a tenuous red line along the gingival sulcus to profuse bleeding (immediately after probing or few seconds after).', 'timeFrame': '4 weeks'}, {'measure': 'Plaque index', 'description': 'used to evaluate the level and rate of plaque formation on tooth surfaces. It measures the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth, except the third molars. The amount of plaque is determined with disclosing solution and a range of scores of 0-5 is assigned with 0 denoting no plaque and 5 denoting heavy plaque (covering 2/3 of the tooth crown)', 'timeFrame': '4 weeks'}, {'measure': 'Gingival index', 'description': 'used to assess the severity of gingival inflammation. Scores ranges from 0-3 with 0 being normal and 3 being severe inflammation characterized by edema, redness, swelling, and spontaneous bleeding. This measurement is based on the presence or absence of bleeding on gentle probing', 'timeFrame': '4 weeks'}]",5.0,20 Years,60 Years,ALL,False,OTHER,0.0,75.0,ACTUAL,v2_robust,True,True,False,False,
NCT03962543,MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas,Mirdametinib (PD-0325901) oral capsule or dispersible tablet,"['Mirdametinib', 'PD-0325901', 'Mirdametinib (PD-0325901) oral capsule or dispersible tablet']",3,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Plexiform Neurofibroma,"SpringWorks Therapeutics, Inc.",2025-09-01T16:18:09.629727,True,,,,,A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity,,"['Plexiform Neurofibroma', 'Neurofibromatosis Type 1 (NF1)']","['Neurofibromatosis', 'Neurofibromatosis 1', 'Plexiform Neurofibroma', 'PD-0325901', 'MEK Inhibitor', 'Neurofibroma', 'Mirdametinib']",,2019-09-29,2028-12-22,"[{'measure': 'Confirmed Objective Response Rate at the End of the Treatment Phase.', 'description': 'Response will be determined by a blinded centralized review of volumetric MRI. The confirmed objective response rate (complete or partial response) by the end of Treatment Phase (i.e., Cycle 24) is defined as the proportion of participants who have a confirmed ≥ 20% reduction in target tumor volume as compared to baseline as assessed by a BICR, and the response needs to be confirmed by BICR in a consecutive tumor assessment within 2 - 6 months. Partial response is defined as a ≥ 20% reduction in target tumor volume from baseline. Complete response is defined as the complete resolution of the target tumor.', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Percentage of Patients With Treatment-Emergent Adverse Events.', 'description': 'All adverse events were coded using MedDRA Version 24.0. Adverse events will be assessed according to toxicities graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.', 'timeFrame': 'All SAEs and AEs were collected from the time of signing ICF until 30 days after the last dose of study treatment, an average of 1 year and 10 months and up to 3 years and 10 months.'}, {'measure': 'Duration of Response (DOR) for Participants Who Meet Criteria for Confirmed Objective Response.', 'description': 'Duration of response is defined as the time in months between the first instance of response that is subsequently confirmed, until the date of radiographic disease progression or death, whichever occurs first. For participants who enter the LTFU Phase, all MRI assessments in both the Treatment Phase and LTFU Phase will be used to determine duration of response. Participants without radiographic disease progression or death while on study will have their results censored to their most recent adequate (i.e. evaluable) tumor assessment date.', 'timeFrame': 'Starting on the onset of confirmed objective response in the Treatment Phase and afterwards on the 15th day of every 4 cycles (each cycle is 28 days) until disease progression or death, whichever comes first, assessed up to approximately 3 years'}, {'measure': 'Change From Baseline on Quality of Life (QOL) as Measured by the Pediatric Quality of Life Inventory (PedsQL) at Cycle 13, Acute Version.', 'description': 'The PedsQL consists of a 23-item core measure of global QOL that can be completed in approximately 5 minutes. There is a total score and four subscales: physical functioning, emotional functioning, social functioning and school/work functioning. Participants ≥ 5 years of age complete an age-appropriate self-report; and parents/guardians of children ages 2-17 complete a parent proxy report of the age-specific QOL. The recall period is 7 days. PedsQL items are answered on a Likert scale with responses ranging from 0 to 4 (where 0 means it is never a problem and 4 means it is almost always a problem). These items are then reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. On this scale, higher scores indicate better outcomes. Overall scale scores are calculated as the mean of the scores for the questions in said scale (or of all questions for the total score). The change from baseline is modelled using a mixed-model for repeated measures.', 'timeFrame': 'Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months'}, {'measure': 'Change From Baseline in Pain as Measured by the Numeric Rating Scale-11 (NRS-11) at Cycle 13.', 'description': 'The NRS-11 is a self-reported 11-point numerical scale that assesses pain severity. Participants ≥ 8 years of age are asked to select a number from 0 (no pain) to 10 (worst pain you can imagine) that best describes their worst pain. The recall period is 24 hours. The change from baseline is modelled using a mixed-model for repeated measures.', 'timeFrame': 'Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months'}, {'measure': 'Change From Baseline in Pain as Measured by the Pain Interference Index (PII) at Cycle 13.', 'description': 'The PII assesses relevant aspects of one\'s life, including pain interference with activities, spending time with family/friends, mood, sleep and attention. Participants ≥ 6 years of age complete a self-report, and parents/guardians of children aged 6-17 complete a parent proxy report. The recall period is 24 hours. The PII consists of 6 questions, each asking the responder to select one number from 0 to 6 that best describes how their/their proxy\'s pain has impacted various items over the past 24 hours with 0 representing ""Not at all"" and 6 representing ""Completely"". The mean of the completed items is taken as the PII score for a single assessment. The PII score presented each visit will be taken as the average of the PII scores over the 7 consecutive days up to and including visit day, with no transformation applied. The change from baseline is modelled using a mixed-model for repeated measures.', 'timeFrame': 'Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months'}]",6.0,2 Years,,ALL,False,INDUSTRY,0.0,114.0,ACTUAL,v2_robust,True,False,False,True,
NCT02821715,Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients,Active comparator: Modafinil + placebo,"['Flecainide Placebo', 'Flecainide 3 mg', 'THN102 300/3', 'Modafinil 300 mg', 'Active comparator: Modafinil + placebo', 'THN102 300/27', 'Flecainide 27 mg']",7,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Narcolepsy,Theranexus,2025-09-01T16:18:09.629763,True,,,,,Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients,,['Narcolepsy'],[],,2016-09,2019-02,"[{'measure': 'Epworth Sleepiness Scale (ESS)', 'description': 'Range 0 to 24, low score indicates good outcome', 'timeFrame': '14 days after the beginning of treatment period'}]","[{'measure': '14-item Fatigue Scale', 'description': 'Fatigue scale is a rating scale completed by the participants at each visit starting from baseline to last visit; 14 questions to be ticked off by ""yes"" or ""No"" by the patient. 0 : No fatigue 14 : worst fatigue condition', 'timeFrame': '14 days after the beginning of treatment period'}, {'measure': 'Questionnaire EQ-5D (European Quality of Life EQ-5D) (Questionnaire Part)', 'description': 'EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).\n\nThe EQ-5D assesses the status on the day of visit and not over the past week. It has two parts:\n\nThe first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.\n\nThe second part is a 100 mm VAS (EQ-VAS). An increase in VAS indicates an improvement in health state.', 'timeFrame': '14 days after the beginning of the screening'}, {'measure': 'Patient Global Impression of Change (PGI-C)', 'description': 'PGI-C is a scale completed by the participants starting from screening to last Last visit (all the visits).\n\nParticipants have to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)', 'timeFrame': '14 days after the beginning of treatment period'}, {'measure': 'Clinical Global Impression of Change (CGI-C) Global Impression', 'description': 'CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for global impression the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.\n\nFor each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)', 'timeFrame': '14 days after the end of treatment period I'}, {'measure': 'Beck Depression Inventory (BDI)', 'description': 'Beck Depression Inventory (BDI) evaluation for depressive symptoms (including suicidal thoughts). The scale is completed by the participants from baseline, to last visit (all except screening visit). The questionnaire contains 21 items. Each must be scored from 0 to 3, minimum score = 0, maximum score = 63. A high score indicates increased severity of depression.', 'timeFrame': '14 days'}, {'measure': 'Patient Global Impression for Severity (PGI-S) Global Score', 'description': 'PGI-S us a scale filled by the participant from screening to last visit (all the visits) Participants have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among the most extremely ill patient\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)', 'timeFrame': '14 days'}, {'measure': 'Clinical Global Impression of Change (CGI-C) Sleepiness', 'description': 'CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for sleepiness\n\nthe investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.\n\nFor each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)', 'timeFrame': '14 days after the end of treatment period I'}, {'measure': 'Clinical Global Impression of Change (CGI-C) Cataplexy', 'description': 'CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for Cataplexy\n\nthe investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.\n\nFor each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)', 'timeFrame': '14 days after the end of treatment period I'}, {'measure': 'Clinical Global Impression for Severity (CGI-S) Global Score', 'description': 'CGI-S is a scale completed by the investigator at each visit : Item global impression\n\nCGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 normal-not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among hte most extremely ill patient\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)\n\nCGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy', 'timeFrame': '14 days after the end of treatment period I'}, {'measure': 'Clinical Global Impression for Severity (CGI-S) Sleepiness', 'description': 'CGI-S is a scale completed by the investigator at each visit for Sleepiness\n\nCGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)\n\nCGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy', 'timeFrame': '14 days after the end of treatment period I'}, {'measure': 'Clinical Global Impression for Severity (CGI-S) Cataplexy', 'description': 'CGI-S is a scale completed by the investigator at each visit for Cataplexy\n\nCGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient\n\n1 is the best score (very much improved) 7 is the worse score (very much worse)\n\nCGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy', 'timeFrame': '14 days after the end of treatment period I'}, {'measure': 'EQ-5D European Quality of Life EQ-5D (Visual Analogic Scale Part)', 'description': 'EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).\n\nThe EQ-5D is a questionnaire assessing the quality of life of the patient. It has two parts:\n\nThe first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.\n\nThe second part is a 100 mm Visual analogic scale (EQ-VAS). An higher score in VAS indicates a better health state.\n\nThe questionnaire is assessed at baseline and all subsequent visits', 'timeFrame': '14 days'}]",13.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,51.0,ACTUAL,v2_robust,True,True,False,False,
NCT00112515,Modafinil in Treating Fatigue in Patients With Cancer,modafinil,['modafinil'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Cognitive/Functional Effects,University of Virginia,2025-09-01T16:18:09.629909,True,,,,,"Pilot Study Evaluating the Safety and Efficacy of Modafinil in Improving Fatigue, Mood, Cognitive Ability, Functional Status, and Quality of Life of Cancer Patients",,"['Cognitive/Functional Effects', 'Depression', 'Fatigue', 'Unspecified Adult Solid Tumor, Protocol Specific']","['depression', 'cognitive/functional effects', 'fatigue', 'unspecified adult solid tumor, protocol specific']",,2004-02,,"[{'measure': 'Safety, in terms of adverse events and dose-limiting toxicity, as measured by NCI CTC v2.0 at up to 4 weeks after the start of treatment'}, {'measure': 'Fatigue as measured by Brief Fatigue Inventory at 2 and 4 weeks after the start of treatment'}]","[{'measure': 'Mood as measured by Hamilton Rating Scale for Depression at 2 and 4 weeks after the start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Hopkins Verbal Learning Test at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Grooved Pegboard Test at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Controlled Oral Word Association Test from the Multilingual Aphasia Examination at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Trail Making Test A and B at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Recall and Recognition of Word List encoded from the Hopkins Verbal Learning Test at 2 and 4 weeks after start of treatment'}, {'measure': 'Functional status as measured by Barthel Index and ECOG performance status at 2 and 4 weeks after the start of treatment'}, {'measure': 'Quality of life as measured by Functional Assessment of Cancer Therapy-Br at 2 and 4 weeks after the start of treatment'}]",10.0,18 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,False,False,True,
NCT05657015,Lepidium Sativum Extract Versus Simvastatin as an Adjunctive Local Delivery Agents to Non-Surgical Periodontal Therapy,Lepidium Sativum,"['Garden cress', 'Lepidium Sativum', 'Simvastatin']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Periodontitis,Ain Shams University,2025-09-01T16:18:09.629916,True,,,,,Lepidium Sativum Extract Versus Simvastatin as an Adjunctive Local Delivery Agents to Non-Surgical Periodontal Therapy: A Randomized Controlled Clinical Trial With Biochemical Analysis,,['Periodontitis'],"['In situ gel', 'High Performance Thic Layer Chromatography', 'Local Drug Delivery']",,2021-09-01,2022-07-01,"[{'measure': 'Assess clinically the plaque index (PI) in periodontitis patients', 'description': 'Percentage of tooth surfaces with bacterial deposits. Plaque index scores were recorded at six sites per tooth (mesiobuccal, buccal, disto-buccal, mesio-lingual, lingual, disto-lingual).The plaque index visually records the score such as 0,1,2, and 3 using the standard probe.', 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}, {'measure': 'Asses clinically the mean sulcus bleeding index (MSBI) in periodontitis patients', 'description': 'Percentage of tooth surfaces with bleeding point sites on probing. Bleeding index scores were recorded at six sites (mesiobuccal, buccal, disto-buccal, mesio-lingual, lingual, disto-lingual). The scores were recorded as 0,1,2,3,4, and 5.', 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}, {'measure': 'Assess clinically the probing depth (PD) in periodontitis patients', 'description': ""The distance between the margin of the gingiva and the base of the pocket was recorded at four points (mesio-facial, mid-facial, disto-facial, and mid-lingual) to the nearest millimeter using the University of Michigan O' probe with Williams' graduations in conjunction with an occlusal stent for the standardization of readings. The probe was inserted parallel to the long axis of the tooth."", 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}, {'measure': 'Assess clinically the clinical attachment level (CAL) in periodontitis patients', 'description': ""The CAL was measured in millimeters from the cemento-enamel junction (CEJ) to the base of the pocket using the University of Michigan O' probe with Williams' graduations in conjunction with an occlusal stent for the standardization of readings."", 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}]","[{'measure': 'Detect biochemically the nuclear factor kappa B (NF-κB) level in the gingival crevicular fluid (GCF).', 'description': ""Levels of NF-κB (ng/ml) in GCF samples were determined by using a commercially available means of Enzyme Linked Immuno Sorbent Assay (ELISA) according to the manufacturer's recommendations. The GCF samples were collected using perio-paper strips (Oraflow Inc., Smithtown, New York, USA). Perio-paper strips visually contaminated with blood were discarded. The samples were immediately placed into a sterile, labeled Eppendorf tube and stored at -20 ºC for subsequent assays. Each perio-paper was soaked with 200ul of phosphate buffering saline (PBS), vortexed, and centrifuged. A supernatant was used for the detection of NF-κB. The kit was provided by Bioassay Technology Laboratory (China) Cat No E7121 Hu."", 'timeFrame': 'Change from baseline to 1 month, from 1 month to 3 months, and from baseline to 3 months'}]",5.0,25 Years,50 Years,ALL,True,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT02711215,Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR),Citalopram,"['Saline, NaCL', 'Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)', 'Placebo', 'Citalopram', 'Cipralex', 'Seropram']",6,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Major Depressive Disorder,Medical University of Vienna,2025-09-01T16:18:09.629991,True,,,,,,,['Major Depressive Disorder'],[],,2015-05,2020-01,"[{'measure': 'Hamilton Depression Scale (HDRS)', 'timeFrame': '12 weeks'}]",[],1.0,18 Years,55 Years,ALL,True,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT07053215,Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC,Camrelizumab,"['Platinum-based doublet chemotherapy', 'Camrelizumab']",2,INTERVENTIONAL,['NA'],,COMPLETED,Non-small Cell Lung Cancer (NSCLC),The First Hospital of Hebei Medical University,2025-09-01T16:18:09.630010,True,,,,,Efficacy of Argon-Helium Cryoablation Combined With PD-1 Inhibitors in Non-Small Cell Lung Cancer: A Randomized Controlled Trial,,['Non-small Cell Lung Cancer (NSCLC)'],"['Argon-helium cryoablation', 'PD-1 inhibitor', 'Non-small cell lung cancer', 'Randomized controlled trial', 'Efficacy', 'Immune function']",,2020-12-01,2024-12-01,"[{'measure': 'Overall Survival (OS)', 'description': 'Time from randomization to death from any cause.', 'timeFrame': 'From randomization until death, assessed through study completion, an average of 1 year.'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'Time from randomization to disease progression (RECIST 1.1) or death from any cause, whichever occurred first.', 'timeFrame': 'From randomization until disease progression or death, assessed through study completion, an average of 1 year.'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Proportion of patients achieving Complete Response (CR) or Partial Response (PR) according to mRECIST criteria.', 'timeFrame': 'Assessed after 4 cycles of treatment (each cycle is 21 days), at approximately 12 weeks from randomization.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Proportion of patients achieving CR, PR, or Stable Disease (SD) according to mRECIST criteria.', 'timeFrame': 'Assessed after 4 cycles of treatment (each cycle is 21 days), at approximately 12 weeks from randomization.'}, {'measure': 'Change in CD4+ T lymphocyte counts', 'description': 'Change in peripheral blood CD4+ T lymphocyte subset counts from baseline.', 'timeFrame': 'Baseline (Day 1, prior to treatment) and at the end of Cycle 4 (each cycle is 21 days).'}, {'measure': 'Change in CD8+ T lymphocyte counts', 'description': 'Change in peripheral blood CD8+ T lymphocyte subset counts from baseline.', 'timeFrame': 'Baseline (Day 1, prior to treatment) and at the end of Cycle 4 (each cycle is 21 days).'}, {'measure': 'Change in CD4+/CD8+ T lymphocyte ratio', 'description': 'Change in the ratio of peripheral blood CD4+ to CD8+ T lymphocytes from baseline.', 'timeFrame': 'Baseline (Day 1, prior to treatment) and at the end of Cycle 4 (each cycle is 21 days).'}, {'measure': 'Incidence and severity of Adverse Events (AEs)', 'description': 'Number and grade of AEs according to NCI-CTCAE v5.0.', 'timeFrame': 'From the first dose of study treatment until 30 days after the last dose of study medication (up to approximately 16 weeks).'}, {'measure': '1-year Progression-Free Survival Rate', 'description': 'Proportion of patients alive and without disease progression at 1 year from randomization.', 'timeFrame': 'At 1 year from randomization.'}]",9.0,18 Years,,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,True,
NCT04871815,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,sodium pyruvate nasal spray,"['sodium pyruvate nasal spray', 'N115']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Long COVID,"Cellular Sciences, inc.",2025-09-01T16:18:09.630042,True,,,,,Preliminary Examination of the Effects of Sodium Pyruvate Nasal Spray (N115) on Symptoms Associated With COVID19 Long Haulers.,,['Long COVID'],"['COVID19, Long Haulers']",,2021-04-27,2022-03-07,"[{'measure': 'Change in the Symptoms of Long COVID-19 Patients', 'description': 'A patient log was used to measure body ache, headache, chills, coughing/sneezing, sore throat, congestion, trouble breathing and other (patient supplied). The patients used a Likert scale from 0 to 10 to assess symptoms with 10 representing the most severe symptom and zero no symptom. The score for each individual symptom was combined into one overall symptom score for the 7 days of baseline (days 1-7) and a separate score for the 7 days of treatment (days 8-14). Therefore, a maximum 7-day score was 70 and a minimum of 0 was possible.', 'timeFrame': '14 days'}, {'measure': 'Change in Body Temperature in Long COVID-19 Patients', 'description': 'Body temperature will be measured twice daily by thermometer in degrees Fahrenheit. Average body temperature for the first 7 days (days 1-7) was used as a baseline with no treatment and was compared to the average body temperature for the next 7 days (days 8-14) with 20mM sodium pyruvate treatment.', 'timeFrame': '14 days'}, {'measure': 'Change in Pulse Rate in Long COVID-19 Patients', 'description': 'Patient heart rate will be measured as beats per minute.', 'timeFrame': 'Day 1 (1st day Baseline), Day 8 (8th day Baseline), Day 8 (1st day Post-treatment) and Day 14 (7th day post-treatment)'}, {'measure': 'Change in Blood Oxygenation in Long COVID-19 Patients', 'description': 'Blood oxygenation will be measured as %O2 saturation.', 'timeFrame': 'Day 1 (1st day Baseline), Day 8 (8th day Baseline), Day 8 (1st day Post-treatment) and Day 14 (7th day post-treatment)'}]",[],4.0,18 Years,40 Years,ALL,False,INDUSTRY,4.0,22.0,ACTUAL,v2_robust,True,True,False,False,
NCT00655135,Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients,LDP-02,"['Placebo', 'LDP-02', 'MLN0002, MLN02']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Crohn's Disease,"Millennium Pharmaceuticals, Inc.",2025-09-01T16:18:09.630071,True,,,,,"Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients With Mildly to Moderately Active Crohn's Disease",,"[""Crohn's Disease""]",[],,2000-02,,"[{'measure': 'The primary outcome measure was the proportion of patients with a clinical response, defined as a reduction from baseline in the CDAI score of at least 70 points at Day 57', 'timeFrame': 'Days 1-57'}]",[],1.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,185.0,ACTUAL,v2_robust,True,True,False,False,
NCT05972135,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,Teclistamab,"['(TECVAYLI™)', 'Actemra', 'Teclistamab', 'Tocilizumab', 'Talquetamab', 'TALVEY™']",6,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Multiple Myeloma,"SCRI Development Innovations, LLC",2025-09-01T16:18:09.630116,True,,,,,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,,['Multiple Myeloma'],"['Teclistamab (TECVAYLI™)', 'Humanized IgG-4 PAA bispecific antibody', 'CD3 receptor complex', 'RRMM-Relapsed or Refractory Multiple Myeloma', 'MM-Multiple Myeloma', 'Tocilizumab prophylaxis', 'CRS- Cytokine Release Syndrome', 'Neurologic toxicity', 'ICANS-Immune Effector Cell-associated Neurotoxicity Syndrome', 'Talquetamab (TALVEY™)', 'GPRC5D', 'BCMA']",,2023-10-23,2026-03,"[{'measure': 'Incidence of CRS of any grade during the first two cycles', 'description': 'Evaluate the overall incidence of CRS in the first 2 cycles after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}]","[{'measure': 'Incidence of recurrent CRS of any grade', 'description': 'Evaluate the incidence of recurrent CRS after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of CRS of any grade', 'description': 'Evaluate the incidence of CRS after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of recurrent CRS of any grade', 'description': 'Evaluate the incidence of recurrent CRS after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of Recurrent Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab .', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles and throughout the study after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of Recurrent Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles and throughout the study after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of Grade ≥3 and any grade infections', 'description': 'Evaluate the risk of Grade ≥3 and any grade infections throughout the study based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of All grade and Grade ≥3 neurotoxicity', 'description': 'Evaluate neurotoxicity in the setting of prophylactic tocilizumab based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of All grade and Grade ≥3 ICANS', 'description': 'Evaluate neurotoxicity including ICANS in the setting of prophylactic tocilizumab based on the American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS (Grade 1 to 4 with grade 4 representing a worse outcome)', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of All grade neutropenia and Grade ≥3 neutropenia', 'description': 'Evaluate treatment-emergent neutropenia in the setting of teclistamab or talquetamab plus prophylactic tocilizumab based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of all grade febrile neutropenia and Grade ≥3 febrile neutropenia', 'description': 'Evaluate treatment-emergent febrile neutropenia in the setting of teclistamab or talquetamab plus prophylactic tocilizumab based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Total length of each hospital stay', 'description': 'Evaluate the length of each hospital stay in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Number of hospitalizations per participant', 'description': 'Evaluate the number of hospitalizations per participant, in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Healthcare resource utilization in the outpatient setting', 'description': 'Monitor the utilization of healthcare resources in the outpatient setting to mitigate the AEs associated with CRS/ICANS in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Overall response rate (ORR)', 'description': 'Overall response rate (ORR) will be defined as the proportion of participants who achieve a PR or better response according to the IMWG response criteria', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Time to initial response (TTR)', 'description': 'Time to initial response (TTR) will be defined as the time between the date of the first dose of teclistamab or talquetamab and the first efficacy evaluation that the participants have met all criteria for PR or better response according to the IMWG response criteria', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Time to best response (TTBR)', 'description': 'Time to best response (TTBR) will be defined as the time between the date of the first dose of teclistamab or talquetamab and the first efficacy evaluation that the participants have the best response according to the IMWG response criteria', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Duration of response (DOR)', 'description': 'Duration of response (DOR) will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG response criteria', 'timeFrame': 'Day 1 of every 2 cycles From Cycle 1 Day 1 and up to approximately 12 months of teclistamab treatment or 6 months for talquetamab. (each cycle is 28 days)'}, {'measure': 'Time to next treatment (TTNT)', 'description': 'Time to next treatment (TTNT) is defined as the time from the date of the first dose of teclistamab or talquetamab to the date of next treatment, or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) is defined as the time from the date of the first dose of teclistamab or talquetamab to the date of death, due to any cause.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as the time from the date of the first dose of teclistamab or talquetamab, to the date of first documented disease progression, as defined in the IMWG response criteria, or death due to any cause, whichever occurs first.', 'timeFrame': 'Day 1 of every 2 cycles From Cycle 1 Day 1 and up to approximately 12 months of teclistamab or 6 months for talquetamab treatment. (each cycle is 28 days)_'}, {'measure': 'Timing of each hospital stay', 'description': 'Evaluate the timing of each hospital stay in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Number of participants who have had a change in health-related quality of life parameters, from baseline to end of treatment', 'description': 'Talquetamab Arm only: Assess health-related quality of life parameters related to overall health as well as specific impact of taste changes, xerostomia, dysphagia, oral mucositis, and other aspects of oral toxicity using EORTC-QLQ and Epstein taste scale', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Number of participants with oral toxicities', 'description': 'Talquetamab Arm only: Assess health-related quality of life parameters related to overall health as well as specific impact of taste changes, xerostomia, dysphagia, oral mucositis, and other aspects of oral toxicity using Epstein taste scale, PRO-CTCAE, STTA and SXI', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Number of patients with overall side effects', 'description': 'Talquetamab Arm only: Assess health-related quality of life parameters related to overall health as well as specific impact of taste changes, xerostomia, dysphagia, oral mucositis, and other aspects of oral toxicity using PGI-S and EORTC Q168/EORTC-IL46', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Rate of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'description': 'Talquetamab Arm only: To assess rate of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Time to first onset of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'description': 'Talquetamab Arm only: To assess time to first onset of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'timeFrame': 'Up 6 to months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Duration of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'description': 'Talquetamab Arm only: To assess duration of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'timeFrame': 'Up 6 to months for talquetamab treatment'}]",30.0,18 Years,,ALL,False,OTHER,1.0,75.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03914235,Anesthesia Tumescent for Surgical Management of Tenosynovitis.,Lidocaine,"['Lidocaine', 'Lidocaine 1%']",2,INTERVENTIONAL,['NA'],,COMPLETED,Tenosynovitis,Instituto Mexicano del Seguro Social,2025-09-01T16:18:09.630291,True,,,,,Efficacy of Tumescent Local Anesthesia in the Surgical Management of Tenosynovitis.,,['Tenosynovitis'],"['Tumescent anesthesia', 'tenosynovitis', 'Visual Analog Scale', 'Tourniquets', 'Epinephrine']",,2018-08-01,2019-04-08,"[{'measure': 'Procedure pain: Visual Analog Scale', 'description': 'Evaluated by Visual Analog Scale, A subjective psychometric response scale used to measure distinct behavioral or physiological phenomena based on linear numerical gradient, with values from 0 to 10. In the value 0 the absence or less intensity is located and in 10 the greater intensity of pain.', 'timeFrame': 'immediate post surgery'}]","[{'measure': 'Bleeding', 'description': 'Bleeding estimated in consensus between anesthesiologist and surgeon, based on the gauze used during surgery', 'timeFrame': 'immediate post surgery'}, {'measure': 'Anesthesia application time', 'description': 'The interval of time in minutes that is required to apply the anesthetic method chosen in the area to be used', 'timeFrame': 'at the beginning of the application of anesthesia'}]",3.0,18 Years,,ALL,False,OTHER_GOV,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT05537935,Low Dose Naltrexone for Pain in Patients With HIV,Low Dose Naltrexone,"['Questionnaires', 'Low Dose Naltrexone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Human Immunodeficiency Virus,Emory University,2025-09-01T16:18:09.630351,True,,,,,"Low Dose Naltrexone (LDN) for the Treatment of Chronic Neuropathic Pain in Patients With Human Immunodeficiency Virus (HIV), a Prospective, Pragmatic, Open Label Clinical Trial",,"['Human Immunodeficiency Virus', 'Chronic Neuropathic Pain']","['Low dose Naltrexone', 'Naltrexone', 'Pain']",,2023-04-28,2026-12,"[{'measure': 'Changes in Numerical Pain Score', 'description': 'The study team will give participants a link to the online PROMIS questionnaire that includes a numerical pain rating scale (NPRS) to complete using an iPad or computer and will verbally ask questions to establish baseline information required for the study. If they have no computer access, they will be given a hard copy of the PROMIS questionnaire and NPRS to complete for future visits.\n\nThe Numerical Pain Rating Scale (NPRS) is a subjective measure in which individuals rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).\n\nChanges in pain scores, measured on the numerical pain score (NPS) on the Pain Intensity section of the PROMIS-29 Profile v2.0. This will be measured weekly during the 12-week study period.', 'timeFrame': 'Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11 and 12'}]","[{'measure': 'Changes in PROMIS pain Score', 'description': 'The study team will give participants the PROMIS questionnaire to complete using an iPad or computer, or a paper form, and will verbally ask questions to establish baseline information required for the study. If they have no computer access, they will be given a hard copy of the PROMIS questionnaire to complete for future visits.\n\nChanges in the overall score of the PROMIS-29 Profile v2.0 questionnaire collected at baseline, 4, 8, and 12 weeks will be assessed.\n\nThe participants\' answers to PROMIS-29 are scored from 1-5. The sum of the PROMIS results in the raw score, which lies between 4 and 20. There is no total score, but each axis forms its own score. PROMIS assessments use an Item Response Theory (IRT) based score called ""Expected A Posteriori"" or EAP scores, which are then transformed onto a final T-score metric. The scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and a standard deviation of 10.', 'timeFrame': 'Study weeks 0, week 4, week 8 and week 12'}, {'measure': 'Changes in Average pain Score', 'description': 'The study team will give participants a link to the online PROMIS questionnaire that includes a numerical pain rating scale (NPRS) to complete using an iPad or computer and will verbally ask questions to establish baseline information required for the study. If they have no computer access, they will be given a hard copy of the PROMIS questionnaire and NPRS to complete for future visits.\n\nThe study team will compare the average weekly pain scores of the study group with the control group.', 'timeFrame': 'Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11 and 12'}, {'measure': 'Changes in IL-1 levels', 'description': 'Blood will be drawn by phlebotomy services according to institutional practice. Samples for will be sent to the Emory Medical Laboratory at EUH or Emory University Hospital Midtown (EUHM) for processing and analysis.\n\nSerum cytokines values will be measured at the 12-week visit and will be compared to baseline visit values.', 'timeFrame': 'Study week 0 and week 12'}, {'measure': 'Changes in IL-18 levels', 'description': 'Blood will be drawn by phlebotomy services according to institutional practice. Samples for will be sent to the Emory Medical Laboratory at EUH or Emory University Hospital Midtown (EUHM) for processing and analysis.\n\nSerum cytokines values will be measured at the 12-week visit and will be compared to baseline visit values.', 'timeFrame': 'Study week 0 and week 12'}, {'measure': 'Changes in Met-Enkephalin Levels', 'description': 'Blood will be drawn and collected by phlebotomy services according to institutional practices into 2 purple top tubes (EDTA, 10 ml) at the baseline and 12-week visits. These samples will be sent to the Emory Research Hemostasis and Coagulation Core Laboratory (ERHCCL) Changes in Met-Enkephalin levels at the 12-week visit compared to baseline visit levels.', 'timeFrame': 'Study week 0 and week 12'}, {'measure': 'Changes in endorphin levels', 'description': 'Blood will be drawn and collected by phlebotomy services according to institutional practices into 2 purple top tubes (EDTA, 10 ml) at the baseline and 12-week visits. These samples will be sent to the Emory Research Hemostasis and Coagulation Core Laboratory (ERHCCL) Changes in endorphin levels at the 12-week visit compared to baseline visit levels.', 'timeFrame': 'Study week 0 and week 12'}, {'measure': 'Changes in CD4 counts', 'description': 'Blood will be drawn and collected by phlebotomy services according to institutional practices into 2 purple top tubes (EDTA, 10 ml) at the baseline and 12-week visits. These samples will be sent to the Emory Research Hemostasis and Coagulation Core Laboratory (ERHCCL) Changes in CD4 counts levels at the 12-week visit compared to baseline visit levels.', 'timeFrame': 'Study week 0 and week 12'}]",8.0,18 Years,75 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03732235,TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer,FOLFIRI+Bevacizumab,['FOLFIRI+Bevacizumab'],1,OBSERVATIONAL,[],,UNKNOWN,Liver Metastasis Colon Cancer,Giammaria Fiorentini,2025-09-01T16:18:09.630399,True,,,,,Observational Study on Transarterial Chemoembolization With Irinotecan-loaded Embolics Associated With Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer,,['Liver Metastasis Colon Cancer'],"['Liver Metastases', 'Transarterial chemoembolization', 'Bevacizumab', 'Anti-angiogenesis', 'Irinotecan', 'Embolics', 'FOLFIRI']",,2018-10-01,2021-12,"[{'measure': 'time to progression', 'description': 'time from first treatment to progression will be computed', 'timeFrame': '1 year'}]","[{'measure': 'Tumor response', 'description': 'CT scan will be performed to assess tomuor response', 'timeFrame': '3 months'}, {'measure': 'Number of adverse events', 'description': 'Number of adverse events will be monitored', 'timeFrame': '3 motnhs'}]",3.0,18 Years,,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,False,False,False,True,
NCT06291935,Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene,VG901,"['AAV2.NN-CNGA1', 'VG901']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Retinitis Pigmentosa,VeonGen Therapeutics GmbH,2025-09-01T16:18:09.630410,True,,,,,"A Prospective, Open-label, Phase 1b, Single-arm, Safety Study of an Intravitreal Application of a Recombinant Adeno-associated Virus Vector Expressing CNGA1 (AAV2.NN-CNGA1) in Patients With Retinitis Pigmentosa Due to CNGA1 Mutations",,['Retinitis Pigmentosa'],"['CNGA1 mutation', 'AAV2', 'Gene Therapy', 'Eye disease']",,2023-09-01,2026-04,"[{'measure': 'Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'Number of Adverse Events (AEs) and Serious Adverse Events (SAEs). Ocular inflammation is defined as an adverse event of special interest (AESI). AESI follow the same reporting requirements as SAE.', 'timeFrame': 'Baseline to Month 12'}]","[{'measure': 'Physical Examination', 'description': 'A complete physical examination will be done at Screening and at Baseline and then at Month 12. On the other timepoints during the 1-year active follow-up phase, symptom-directed physical examination will be conducted. Abnormal examination results will be recorded.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Pulse rate', 'description': 'Will be recorded in beats per minute.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Blood pressure', 'description': 'Systolic and diastolic blood pressure will be recorded in mmHg.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Body temperature', 'description': 'Will be recorded in °C.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Respiratory rate', 'description': 'Will be recorded in breaths per minute.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Slit lamp examination', 'description': 'Abnormal examination results of conjunctiva, cornea, sclera, lens, anterior segment, and anterior chamber cells as well as quantification of vitreous inflammation and grading of anterior chamber flare will be recorded.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Fundus biomicroscopy', 'description': 'Cup-to-Disc (C/D) ratio and abnormal examination results will be recorded.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Optical coherence tomography (OCT)', 'description': 'Abnormal examination results will be recorded.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Fundus autofluorescence', 'description': 'Abnormal examination results will be recorded.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Tonometry', 'description': 'Intraocular Pressure (IOP) will be recorded in mmHg.', 'timeFrame': 'Screening to Month 12'}, {'measure': 'Adeno-associated virus (AAV) spread', 'description': 'As detected by quantitative polymerase chain reaction (qPCR) in peripheral blood, urine, and tear. Recorded in vector copies per µL of fluid DNA.', 'timeFrame': 'From Baseline until two consecutive samples test negative'}, {'measure': 'Immunopathology', 'description': 'Using specific enzyme-linked immunosorbent assays (ELISA) for humoral antibodies against rAAV2 capsid protein.', 'timeFrame': 'Baseline to Month 12'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,6.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03117335,Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer,Placebos,"['Sulijia', 'Placebos', 'Recombinant endostatin injection', 'Sodium Chloride Injection']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Advanced Non-small Cell Lung Cancer,"Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:09.630420,True,,,,,"Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study",,['Advanced Non-small Cell Lung Cancer'],"['Non-small Cell Lung Cancer', 'Sulijia', 'Recombinant endostatin', 'Vinorelbine', 'Cisplatin']",,2011-11-10,2017-01-17,"[{'measure': 'Progression Free Survival(PFS)', 'description': 'A duration from date of randomization until the date of first documented progression (as defined by RECIST 1.1) or date of death from any cause, whichever came first. A participant will be censored at the last date they are known not to be progressed.', 'timeFrame': 'Assessed up to 24 months'}]","[{'measure': 'Objective response rate(ORR)', 'description': 'Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR) (as defined by RECIST 1.1).', 'timeFrame': 'Assessed up to 24 months'}, {'measure': 'Disease control rate(DCR)', 'description': 'Disease Control Rate is defined as the proportion of patients with complete response(CR), partial response(PR), or stable disease(SD) (as defined by RECIST 1.1).', 'timeFrame': 'Assessed up to 24 months'}, {'measure': 'Overall survival(OS)', 'description': 'Overall Survival is assessed via calculation of the time to death due to any cause. A participant will be censored at the last date they are known to be alive.', 'timeFrame': 'Assessed up to 72 months'}]",4.0,18 Years,70 Years,ALL,False,INDUSTRY,1.0,560.0,ACTUAL,v2_robust,True,True,False,False,
NCT00214435,"Once Daily 3TC, Efavirenz and ddI for HIV Infection",once daily minimum 3-drug regimen of anti-retroviral medications,['once daily minimum 3-drug regimen of anti-retroviral medications'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,HIV Infection,407 Doctors,2025-09-01T16:18:09.630435,True,,,,,"A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily",,"['HIV Infection', 'AIDS']","['HIV infection', 'AIDS', 'Adherence', 'MEMS caps', 'Treatment Experienced']",,2004-05,,[{'measure': '- levels of adherence'}],"[{'measure': '- proportion of patients with treatment failure where treatment failure is defined'}, {'measure': '- HIV-1 RNA viral load of >400 copies/ml on two consecutive occasions more than one month apart, OR discontinuation of treatment for any reason (where subsequent therapy does not comply with the study regimen change guidelines outlined in section 3.3.3)'}, {'measure': '- proportion of patients with plasma HIV-RNA less than 50 copies/ml (using an ultrasensitive assay) at 24 and 48 weeks'}, {'measure': '- change from baseline in CD4 cell count at 24 and 48 weeks'}, {'measure': ""- changes from baseline in subjects' quality of life at 24 and 48 weeks""}, {'measure': '- changes from baseline based on DASS 21 scores at 24 and 48 weeks'}, {'measure': '- incidence and severity of adverse events and abnormal'}, {'measure': '- laboratory values (grade 3 & 4) at 24 and 48 weeks'}, {'measure': '- proportion of patients remaining on assigned treatment'}]",10.0,18 Years,,ALL,False,OTHER,2.0,120.0,,v2_robust,True,False,False,True,
NCT00017108,Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia,chlorambucil,"['chlorambucil', 'fludarabine phosphate', 'cyclophosphamide']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Leukemia,European Organisation for Research and Treatment of Cancer - EORTC,2025-09-01T16:18:09.630589,True,,,,,Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3),,['Leukemia'],"['stage III chronic lymphocytic leukemia', 'stage IV chronic lymphocytic leukemia', 'B-cell chronic lymphocytic leukemia']",,2001-03,,[],[],0.0,18 Years,75 Years,ALL,False,NETWORK,0.0,,,v2_robust,True,False,False,False,
NCT00027508,Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma,trabectedin,['trabectedin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Malignant Mesothelioma,PharmaMar,2025-09-01T16:18:09.630653,True,,,,,Phase II Study Of ET-743 In Patients With Unresectable Malignant Pleural Mesothelioma,,['Malignant Mesothelioma'],"['advanced malignant mesothelioma', 'recurrent malignant mesothelioma']",Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained.,2001-07,2002-02,[],[],0.0,18 Years,,ALL,False,INDUSTRY,1.0,,,v2_robust,True,False,True,False,Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained.
NCT02722408,"Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)",Gemcabene,['Gemcabene'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hypercholesteremia,NeuroBo Pharmaceuticals Inc.,2025-09-01T16:18:09.630819,True,,,,,"A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)",,['Hypercholesteremia'],"['LDL-C', 'Lipid Regulator']",,2016-06,2017-07,"[{'measure': 'Percent Change From Baseline in LDL-C at Day 28', 'timeFrame': 'Baseline, day 28'}, {'measure': 'Percent Change From Baseline in LDL-C at Day 56', 'timeFrame': 'Baseline, day 56'}, {'measure': 'Percent Change From Baseline in LDL-C at Day 84', 'timeFrame': 'Baseline, day 84'}]","[{'measure': 'Change From Baseline in Fasting LDL-C', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Non-HDL-C', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Non-HDL-C', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Total Cholesterol (TC)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Total Cholesterol (TC)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Triglycerides (TG)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Triglycerides (TG)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting HDL-C', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting HDL-C', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting VLDL-C', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting VLDL-C', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting LDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting LDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Non-HDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Non-HDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting VLDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting VLDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting HDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting HDL-C as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting TC as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting TC as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting TG as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting TG as Per Receptor Mutation Status', 'description': 'Receptor mutation status was categorized as LDLr status and EAS clinical diagnosis of HoFH which was reported in this outcome measure.', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Number of Participants Achieving LDL-C Reduction of ≥15%', 'timeFrame': 'Days 28, 56 and 84'}, {'measure': 'Number of Participants Achieving LDL-C Reduction of ≥20%', 'timeFrame': 'Days 28, 56 and 84'}, {'measure': 'Number of Participants Achieving LDL-C Reduction of ≥25%', 'timeFrame': 'Days 28, 56 and 84'}, {'measure': 'Number of Participants Achieving LDL-C Reduction of ≥30%', 'timeFrame': 'Days 28, 56 and 84'}, {'measure': 'Number of Participants Achieving an LDL-C Value <100 mg/dL (2.59 mmol/L)', 'timeFrame': 'Days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fibrinogen', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fibrinogen', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Lipoprotein(a)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Lipoprotein(a)', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein B', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Apolipoprotein B', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein A-I', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Apolipoprotein A-I', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein A-II', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Apolipoprotein A-II', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein C-II', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Apolipoprotein C-II', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein C-III', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Apolipoprotein C-III', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein E', 'timeFrame': 'Baseline, days 28, 56 and 84'}, {'measure': 'Change From Baseline in Fasting Apolipoprotein E', 'timeFrame': 'Baseline, days 28, 56 and 84'}]",49.0,17 Years,,ALL,False,INDUSTRY,0.0,8.0,ACTUAL,v2_robust,True,True,False,False,
NCT00043108,"Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer",carboplatin,"['paclitaxel', 'carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Lung Cancer,Fox Chase Cancer Center,2025-09-01T16:18:09.630927,True,,,,,"Trimodality Protocol for the Treatment of Locally Advanced, Potentially Resectable Non-Small Cell Lung Cancer Targeting",,['Lung Cancer'],"['stage II non-small cell lung cancer', 'stage IIIA non-small cell lung cancer', 'stage IIIB non-small cell lung cancer']",,2002-07,2018-02,"[{'measure': 'Toxic Death Rate', 'timeFrame': '5 years'}, {'measure': 'Complete Resection Rates', 'timeFrame': '5 years'}]","[{'measure': 'Survival', 'timeFrame': '5 years'}, {'measure': 'Event-free Survival', 'timeFrame': '5 years'}, {'measure': 'Pathologic Complete Remission (pCR)', 'timeFrame': '5 years'}]",5.0,18 Years,120 Years,ALL,False,OTHER,1.0,19.0,ACTUAL,v2_robust,True,True,False,False,
NCT00793325,Long Term Use of Somatropin in Patients Small for Gestational Age,Somatropin,"['Genotropin', 'Somatropin']",2,OBSERVATIONAL,[],,COMPLETED,Small for Gestational Age,Pfizer,2025-09-01T16:18:09.631117,True,,,,,Special Investigation Of Long Term Use Of Genotropin For SGA (Regulatory Post Marketing Commitment Plan),,['Small for Gestational Age'],[],,2009-02,2012-12,"[{'measure': 'Number of Participants With Treatment Related Adverse Events.', 'description': 'Adverse events mean all unfavorable events that occur in participants after administration of somatropin, irrespective of causal relationship to somatropin (including clinically problematic abnormal changes in laboratory test values). Treatment related adverse events were evaluated in company with the causal relationship to somatropin.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert.', 'description': 'Adverse events mean all unfavorable events that occur in participants after administration of somatropin, irrespective of causal relationship to somatropin (including clinically problematic abnormal changes in laboratory test values). Treatment related adverse events were evaluated in company with the causal relationship to somatropin. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction according to Japanese package insert.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin: <15 Years of Age vs. >=15 Years of Age.', 'description': 'To determine whether age is a significant risk factor in the frequency of treatment related adverse events.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin by Gender.', 'description': 'To determine whether gender is a significant risk factor in the frequency of treatment related adverse events.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin Based on SGA Severity.', 'description': 'To determine whether severity of SGA is a significant risk factor in the frequency of treatment related adverse events. The severity of SGA was comprehensively evaluated on the basis of information including height and weight at birth and height measured one year before the start of administration.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin: With Past History of Any Disease vs. Without Past History of Any Disease.', 'description': 'To determine whether past history of any disease is a significant risk factor in the frequency of treatment related adverse events.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin: With Complications vs. Without Complications', 'description': 'To determine whether having complication(s) is a significant risk factor in the frequency of treatment related adverse events.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin: With Hepatic Function Disorder vs. Without Hepatic Function Disorder.', 'description': 'To determine whether hepatic function disorder is a significant risk factor in the frequency of treatment related adverse events.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin: With Renal Impairment vs. Without Renal Impairment.', 'description': 'To determine whether renal impairment is a significant risk factor in the frequency of treatment related adverse events.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of Participants With Treatment Related Adverse Events of Somatropin: With Concomitant Drug(s) vs. Without Concomitant Drug(s).', 'description': 'To determine whether taking concomitant drug(s) is a significant risk factor in the frequency of treatment related adverse events.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Change in the Growth Rate Standard Deviation (SD) Score for Calendar Age.', 'description': ""Growth rate SD score = (Growth rate - Average growth rate for calendar age of gender) / SD score for growth rate for each calendar age of gender). An SD score indicates how far a participant's score deviates from the mean of the reference population; an SD score higher than the mean gives a positive SD score whereas an SD score lower than the mean gives a negative SD score. In addition, when the bone age was described, it was to be read as the calendar age for men who were 11 years or older and women who were 9 years or older, as necessary."", 'timeFrame': 'Up to 3 years'}, {'measure': 'Change in Height SD Score for Calendar Age.', 'description': 'The change in height standard SD for calendar age = (Height SD score for each calendar age - Height SD score for calendar age of the previous year) / (the date on which the height was measured - the date of the previous year on which the height was measured) × 365.25.', 'timeFrame': 'Up to 3 years'}]",[],12.0,,,ALL,False,INDUSTRY,0.0,920.0,ACTUAL,v2_robust,False,True,False,True,
NCT02081625,Exploratory Study of NS-065/NCNP-01 in DMD,NS-065/NCNP-01,['NS-065/NCNP-01'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Duchenne Muscular Dystrophy,"National Center of Neurology and Psychiatry, Japan",2025-09-01T16:18:09.631151,True,,,,,Exploratory Study of NS-065/NCNP-01 in Duchenne Muscular Dystrophy,,['Duchenne Muscular Dystrophy'],"['Duchenne muscular dystrophy', 'NS-065/NCNP-01', 'exon 53 skipping', 'morpholino']",,2013-06,2015-08,"[{'measure': 'Safety and tolerability (adverse event and adverse drug reaction)', 'timeFrame': 'Up to 15-17 weeks (12 weeks treatment period and 3-5 weeks follow up period)'}]","[{'measure': 'Expression of dystrophin protein', 'timeFrame': 'At 14-15 weeks (2-3 week after from 12 weeks treatment period)'}, {'measure': 'Detection of exon53 skipped mRNA of dystrophin', 'timeFrame': 'At 14-15 weeks (2-3 week after from 12 weeks treatment period)'}, {'measure': 'NS-065/NCNP-01 concentration of the blood plasma', 'timeFrame': '12 weeks'}, {'measure': 'NS-065/NCNP-01 concentration of the urine', 'timeFrame': '12 weeks'}, {'measure': 'Serum Creatine kinase concentration', 'timeFrame': '14 weeks'}]",6.0,5 Years,18 Years,MALE,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,True,
NCT00548925,A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain,ABT-894,"['ABT-894', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Diabetic Neuropathic Pain,"AbbVie (prior sponsor, Abbott)",2025-09-01T16:18:09.631170,True,,,,,"A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 Versus Placebo in Subjects With Diabetic Neuropathic Pain",,['Diabetic Neuropathic Pain'],[],,2007-11,2008-12,"[{'measure': 'Weekly mean of 24-hour average pain score', 'timeFrame': 'Change from Baseline to final'}]","[{'measure': 'Pain improvement from Baseline to the final evaluation', 'timeFrame': '8-week'}, {'measure': 'Weekly mean of 24-hour worst pain severity; weekly average night pain and morning pain', 'timeFrame': '8-week'}, {'measure': 'Global assessments of study drug and pain status', 'timeFrame': '8-week'}, {'measure': 'Short-Form McGill Pain Questionnaire (SF-MPQ), Neuropathic Pain Scale (NPS)', 'timeFrame': '8-week'}]",5.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,124.0,ACTUAL,v2_robust,True,True,False,False,
NCT03791125,Phase I Single-dose Escalation Clinical Trial of Salvianolic Acid A Tablets,Salvianolic Acid A,"['Placebo Oral Tablet', 'Salvianolic Acid A']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Neuropathy of Diabetes,Peking University First Hospital,2025-09-01T16:18:09.631183,True,,,,,"Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Evaluation of Safety, Tolerability, and Pharmacokinetic Properties of Salvianolic Acid A Tablets in Healthy Volunteers",,['Neuropathy of Diabetes'],[],,2018-11-20,2019-05-20,"[{'measure': 'Subject incidence of treatment-emergent adverse events', 'timeFrame': '7 days'}, {'measure': 'Percentage of participants with change from baseline in vital signs', 'description': 'Heart rate, Blood Pressure，auxillary temperature', 'timeFrame': '7 days'}, {'measure': 'Change from baseline in electrocardiograms (ECGs)', 'description': 'PR interval, QT interval, QTc interval, QTcF, and rhythm abnormalities', 'timeFrame': '7 days'}, {'measure': 'Percentage of participants with change from baseline in clinical laboratory parameters', 'description': 'blood routine, urine routine, biochemical parameters of blood and urine，coagulation tests', 'timeFrame': '7 days'}, {'measure': 'PK profile of Salvianolic acid A following administration of multiple doses assessed by area under the curve [AUC]', 'timeFrame': '2 days'}, {'measure': 'PK profile of Salvianolic acid A following administration of multiple doses assessed by maximum observed concentration [Cmax]', 'timeFrame': '2 days'}, {'measure': 'PK profile of Salvianolic acid A following administration of multiple doses assessed by time of occurrence of Cmax [tmax]', 'timeFrame': '2 days'}]",[],7.0,18 Years,45 Years,ALL,True,OTHER,2.0,40.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00229125,Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam,Gabapentin,"['Gabapentin', 'Lorazepam']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Alcohol Withdrawal Syndrome(AWS),National Institute on Alcohol Abuse and Alcoholism (NIAAA),2025-09-01T16:18:09.631237,True,,,,,Gabapentin Vs. Lorazepam in Alcohol Withdrawal,,['Alcohol Withdrawal Syndrome(AWS)'],"['Alcohol Withdrawal Syndrome', 'CIWA-Ar', 'Acoustic Startle Procedure', 'Rebound Effect']",,2001-07,2005-09,"[{'measure': 'Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar).'}, {'measure': 'Timeline Followback (TLFB) of drinking behaviors.'}]","[{'measure': 'Lower startle reflex magnitudes as an index of CNS excitability or arousal.'}, {'measure': 'Lower anxiety (Zung Anxiety Scale) and depression (Beck Depression.'}, {'measure': 'Inventory) scores.'}, {'measure': 'Subjective reports of sleep quality.'}]",6.0,21 Years,70 Years,ALL,True,NIH,0.0,160.0,,v2_robust,True,True,False,False,
NCT03509025,Follow-up Study for Participants Jointstem Clinical Trial,Jointstem,"['autologous adipose-derived mesenchymal stem cells', 'Jointstem']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Knee Osteoarthritis,R-Bio,2025-09-01T16:18:09.631327,True,,,,,"Open, Multicenter Follow-up Trial About Active Group of Phase IIb Clinical Trial of JOINTSTEM in Patients With Degenerative Arthritis",,['Knee Osteoarthritis'],[],,2017-02-08,2020-12-09,"[{'measure': 'Adverse Events', 'description': 'Incidence of adverse events from baseline to 60 months', 'timeFrame': '60 months'}]","[{'measure': 'WOMAC score', 'description': 'Change from baseline on WOMAC (Western Ontario and McMaster Universities Arthritis Index) score', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'WOMAC 3 subscale score', 'description': 'Change from baseline on WOMAC 3 subscale (Pain, stiffness, and physical function) score', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'X-ray', 'description': 'X-ray perform to measure with Kellgren-Lawrence grade', 'timeFrame': 'Baseline and 12 months'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,11.0,ACTUAL,v2_robust,True,True,False,True,
NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)","Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)","['Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)']",1,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Multiple Sclerosis,Bayer,2025-09-01T16:18:09.631416,True,,,,,"A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis",,['Multiple Sclerosis'],"['Multiple Sclerosis', 'Early secondary progressive Multiple Sclerosis']",,,,"[{'measure': 'Magnetic Resonance Imaging (MRI): T2-lesions', 'timeFrame': 'At week 104'}]","[{'measure': 'Further Magnetic Resonance Imaging (MRI) parameters', 'timeFrame': 'At week 104'}, {'measure': 'Relapses', 'timeFrame': 'At week 104'}, {'measure': 'Changes in Expanded Disability Status Score (EDSS) and Multiple Sclerosis Impact Scale (MSIS)', 'timeFrame': 'At week 104'}, {'measure': 'Hospitalizations', 'timeFrame': 'At week 104'}, {'measure': 'Neutralizing antibodies', 'timeFrame': 'At week 104'}, {'measure': 'Adverse events', 'timeFrame': 'At week 104'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,
NCT01455376,Effect of Exogenous Lactate on Neurocognitive in Brain Trauma,hyperosmolar sodium lactate,"['hyperosmolar sodium lactate', 'Totilac']",2,INTERVENTIONAL,['NA'],,COMPLETED,Traumatic Brain Injury,Universitas Padjadjaran,2025-09-01T16:18:09.631429,True,,,,,Effect of Exogenous Lactate Infusion on Neurocognitive Function of Patients With Mild Traumatic Brain Injury,,['Traumatic Brain Injury'],"['brain injury', 'cognitive function', 'sodium lactate', 'MMSE score']",,2010-03,2010-06,"[{'measure': 'Changes in neurocognitive function', 'description': 'The investigators evaluate the changes in neurocognitive function at several time points (24 hours, 30 days, and 90 days post surgery) using Mini Mental State Examination (MMSE) score in both groups. Osmolality and sodium level are also recorded in order to confirm that hyperosmolar sodium lactate is safe for traumatic brain injury patients', 'timeFrame': '24 hours, 30 days, and 90 days post surgery'}]",[],1.0,14 Years,60 Years,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT03790176,ZAVI APD ELF Protocol v2.2,Intravenous Infusion,['Intravenous Infusion'],1,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Peritonitis,Markus Zeitlinger,2025-09-01T16:18:09.631449,True,,,,,"Plasma, ELF and Intraperitoneal Pharmacokinetics of Ceftazidime/Avibactam in Critically Ill and Peritoneal Dialysis Patients",,"['Peritonitis', 'Pneumonia']",[],,2018-10-01,2022-12,"[{'measure': 'Area under the concentration time curve (AUC) from 0 to 8 hours (AUC0-8)', 'timeFrame': 'on study days'}]",[],1.0,18 Years,85 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04311476,Autologous Cord Blood Cells for Prevention of BPD in Preterm,0.9% Sodiun Chloride,['0.9% Sodiun Chloride'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Safety Issues,yangjie,2025-09-01T16:18:09.631464,True,,,,,Autologous Cord Blood Cells for Prevention of BPD in Preterm,,"['Safety Issues', 'BPD - Bronchopulmonary Dysplasia', 'Neonatal Death']","['ACBMNC', 'very premature infants', 'BPD']",,2018-07-01,2020-01-01,"[{'measure': 'number of patients without bronchopulmonary dysplasia', 'description': 'bronchopulmonary dysplasia incidence', 'timeFrame': 'at 36 weeks of postmenstrual age or discharge home, whichever came first'}]","[{'measure': 'number of patients who died， severe bronchopulmonary dysplasia', 'description': 'mortaliity rate', 'timeFrame': 'at 36 weeks of postmenstrual age'}]",2.0,28 Weeks,32 Weeks,ALL,False,OTHER,0.0,62.0,ACTUAL,v2_robust,True,True,False,False,
NCT00672776,Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD),paroxetine,"['paroxetine', 'placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Posttraumatic Stress Disorder (PTSD),Emory University,2025-09-01T16:18:09.631477,True,,,,,Effects of Paxil CR on Neural Circuits in PTSD,,['Posttraumatic Stress Disorder (PTSD)'],"['hippocampus', 'paroxetine', 'stress', 'PTSD']",,2003-05,2007-09,"[{'measure': 'Brain Function with Traumatic Reminders', 'description': 'PET measurement of brain activation before and after paroxetine or placebo treatment.', 'timeFrame': 'three months'}]",[],1.0,18 Years,50 Years,ALL,False,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT03424876,To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.,Imatinib 400mg,"['Sunitinib 37.5Mg Oral Capsule', 'Imatinib 400mg']",2,OBSERVATIONAL,[],,UNKNOWN,GIST,Peking University,2025-09-01T16:18:09.631569,True,,,,,A Retrospective Cohort Study,,['GIST'],['Sunitinib Imatinib'],,2017-06-02,2018-08-08,"[{'measure': 'Efficiency', 'description': 'The curative effect was evaluated by measuring the unprogression-survival (PFS) each treatment group.', 'timeFrame': '12 months'}, {'measure': 'Security', 'description': 'Clinical and laboratory toxicity/symptoms will be graded according to the nci-ctc toxicity criteria.', 'timeFrame': '12 months'}, {'measure': 'Molecular marker detection', 'description': 'Gene mutation of c-kit/PDGFRA of imatinib resistance', 'timeFrame': '12 months'}]",[],3.0,18 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,False,False,False,False,
NCT03687476,Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease,VTS-270,['VTS-270'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,"Niemann-Pick Disease, Type C","Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company",2025-09-01T16:18:09.631674,True,,,,,"An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease",,"['Niemann-Pick Disease, Type C']",[],Business decision to Cancel,2020-05,2022-10-30,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Part A', 'description': 'An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. SAEs were AEs excluding non-serious AEs.', 'timeFrame': 'Baseline up to Week 20 (End of Part A)'}, {'measure': 'Number of Participants With Clinically Significant Vital Signs: Part A', 'description': 'Clinically significant vital sign is defined as an abnormal vital sign result that results in a treatment-emergent AEs. Abnormal clinically significant vital signs included absolute systolic blood pressure (BP) values less than (\\<) 90 millimeter of mercury (mmHg), maximum increase or decrease of greater than or equal to (\\>=) 30 mmHg from baseline for systolic BP; absolute diastolic BP \\<50 mmHg with maximum increase or decrease of \\>=20 mmHg from baseline and absolute heart rate values \\<40 beats per minute (bpm), \\>120 bpm for supine or sitting measurement, \\>140 bpm for standing measurement, temperature \\<32 or \\>40 degree centigrade, respiratory rate of \\<10 or \\>50 breaths/minute.', 'timeFrame': 'Baseline up to Week 20 (End of Part A)'}, {'measure': 'Number of Participants With Clinically Significant Change from Baseline in Body Weight: Part A', 'description': 'Any change from baseline in body weight is considered by the investigator to be clinically significant and will be recorded as treatment-emergent AE.', 'timeFrame': 'Baseline up to Week 20 (End of Part A)'}, {'measure': 'Number of Participants With Clinically Significant Change from Baseline in Body Height: Part A', 'description': 'Any change from baseline in body height is considered by the investigator to be clinically significant and will be recorded as treatment-emergent AE.', 'timeFrame': 'Baseline up to Week 20 (End of Part A)'}, {'measure': 'Number of Participants With Clinically Significant Laboratory Test Abnormalities: Part A', 'description': 'Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (\\< 0.8\\*lower limit of normal\\[LLN\\]); leucocytes (\\<0.6/\\>1.5\\*upper limit of normal \\[ULN\\]); platelets (\\<0.5\\*LLN/\\>1.75\\*ULN); neutrophils, lymphocytes (\\<0.8\\*LLN/\\>1.2\\*ULN); eosinophils, basophils, monocytes (\\>1.2\\*ULN); total bilirubin (\\>1.5\\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (\\>3\\*ULN), total protein, albumin (\\<0.8\\*LLN/\\>1.2\\*ULN); creatinine, urea (\\>1.3\\*ULN); glucose (\\<0.6\\*LLN/\\>1.5\\*ULN); uric acid (\\>1.2\\*ULN); sodium, potassium, chloride, calcium, bicarbonate (\\<0.9\\*LLN/\\>1.1\\*ULN); urine red blood cells (RBCs), urine white blood cells (WBCs), urine epithelial cells (\\>=6 high-powered field), urine bacteria \\>20 high-powered field; qualitative urine glucose, ketones, protein values \\>=1 in urine dipstick test. Total number of participants with any laboratory abnormalities was reported.', 'timeFrame': 'Baseline up to Week 20 (End of Part A)'}]","[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Part B', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. SAEs were AEs excluding non-serious AEs.', 'timeFrame': 'Week 22 up to 3 years (End of Study or Part B)'}, {'measure': 'Number of Participants With Clinically Significant Vital Signs: Part B', 'description': 'Clinically significant vital sign is defined as an abnormal vital sign result that results in a treatment-emergent AEs. Abnormal clinically significant vital signs included absolute systolic blood pressure (BP) values less than (\\<) 90 millimeter of mercury (mmHg), maximum increase or decrease of greater than or equal to (\\>=) 30 mmHg from baseline for systolic BP; absolute diastolic BP \\<50 mmHg with maximum increase or decrease of \\>=20 mmHg from baseline and absolute heart rate values \\<40 beats per minute (bpm), \\>120 bpm for supine or sitting measurement, \\>140 bpm for standing measurement, temperature \\<32 or \\>40 degree centigrade, respiratory rate of \\<10 or \\>50 breaths/minute.', 'timeFrame': 'Week 22 up to 3 years (End of Study or Part B)'}, {'measure': 'Number of Participants With Clinically Significant Change from Baseline in Body Weight: Part B', 'description': 'Any change from baseline in body weight is considered by the investigator to be clinically significant and will be recorded as treatment-emergent AE.', 'timeFrame': 'Week 22 up to 3 years (End of Study or Part B)'}, {'measure': 'Number of Participants With Clinically Significant Change from Baseline in Body Height: Part B', 'description': 'Any change from baseline in body height is considered by the investigator to be clinically significant and will be recorded as treatment-emergent AE.', 'timeFrame': 'Week 22 up to 3 years (End of Study or Part B)'}, {'measure': 'Number of Participants With Clinically Significant Laboratory Test Abnormalities: Part B', 'description': 'Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (\\< 0.8\\*lower limit of normal\\[LLN\\]); leucocytes (\\<0.6/\\>1.5\\*upper limit of normal \\[ULN\\]); platelets (\\<0.5\\*LLN/\\>1.75\\*ULN); neutrophils, lymphocytes (\\<0.8\\*LLN/\\>1.2\\*ULN); eosinophils, basophils, monocytes (\\>1.2\\*ULN); total bilirubin (\\>1.5\\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (\\>3\\*ULN), total protein, albumin (\\<0.8\\*LLN/\\>1.2\\*ULN); creatinine, urea (\\>1.3\\*ULN); glucose (\\<0.6\\*LLN/\\>1.5\\*ULN); uric acid (\\>1.2\\*ULN); sodium, potassium, chloride, calcium, bicarbonate (\\<0.9\\*LLN/\\>1.1\\*ULN); urine red blood cells (RBCs), urine white blood cells (WBCs), urine epithelial cells (\\>=6 high-powered field), urine bacteria \\>20 high-powered field; qualitative urine glucose, ketones, protein values \\>=1 in urine dipstick test. Total number of participants with any laboratory abnormalities was reported.', 'timeFrame': 'Week 22 up to 3 years (End of Study or Part B)'}, {'measure': 'Change From Baseline in Audiological Examinations at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)', 'description': 'Standard developmentally appropriate audiological examinations suited to the individual participants will be used to assess auditory system function (physical tests: tympanometry and otoacoustic emissions) and hearing sensitivity (behavioral test: word recognition and pure-tone and speech thresholds).', 'timeFrame': 'Baseline, Week 6, 12, 20, 44, every 24 Week thereafter until EOT (3 years)'}, {'measure': 'Change From Baseline in Cognitive and Motor Development Assessed Using Mullen Scale of Early Learning (MSEL) at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)', 'description': 'The MSEL is a standardized developmental test for children consisting of five subscales: fine motor, visual reception, expressive language, receptive language and an optional fifth gross motor scale (scale includes standing, walking and running) that only measures skills to 36 months. The raw score is reported for each subscale domain. The potential score ranges are as follows: Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. A higher raw score indicates more advanced abilities in that section.', 'timeFrame': 'Baseline, Week 6, 12, 20, 44, every 24 Week thereafter until EOT (3 years)'}, {'measure': 'Change From Baseline in Auditory Brainstem Response (ABR) Assessed Using Standard Clinical Pediatric Score at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)', 'description': 'The ABR is a voltage response evoked by acoustic stimuli as sound is processed along the auditory pathway. It consists of electrical signals resulting from the sum of sound-evoked activity along the auditory nerve and brainstem nuclei. The ABR analysis determines the sound intensity at which a neural response first appears (hearing threshold). Other parameters of interest include amplitude (the number of neurons firing), latency (the speed of transmission), interpeak latency (the time between peaks), and interaural latency (the difference in wave V latency between ears). The interpeak latency I-V interval (or central transmission time) is considered the most reliable index of brainstem function. Auditory brainstem response assessments were based on standard clinical pediatric score criteria: mild hearing loss: 21-40 decibels hearing level (dBHL), moderate hearing loss: 41-70 dBHL, severe hearing loss: 71-90 dBHL, profound hearing loss: 91dBHL.', 'timeFrame': 'Baseline, Week 6, 12, 20, 44, every 24 Week thereafter until EOT (3 years)'}, {'measure': 'Change From Baseline in Clinician Global Impression of Change (CGIC) Using Likert Score at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)', 'description': 'The Clinician-CGIC is conducted by a clinician who is trained in performing neurological examinations. CGIC is measured using 7-point Likert scale ranging from 1 = ""very much improved"" to 7 = ""very much worse"". If the rater notes an improvement or worsening on the scale, the rater should indicate the major factor for the reported changes in score.', 'timeFrame': 'Baseline, Week 6, 12, 20, 44, every 24 Week thereafter until EOT (3 years)'}, {'measure': 'Change From Baseline in Caregiver Global Impression of Change (CGIC) Using Likert Score at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)', 'description': 'The caregiver-CGIC is to be completed by the responsible parent or legal guardian. CGIC is measured using 7-point Likert scale ranging from 1 = ""very much improved"" to 7 = ""very much worse"". If the caregiver notes an improvement or worsening on the scale, the caregiver should indicate the major reason for the reported changes in score.', 'timeFrame': 'Baseline, Week 6, 12, 20, 44, every 24 Week thereafter until EOT (3 years)'}]",15.0,,4 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Business decision to Cancel
NCT02506517,A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene,Afatinib,"['Afatinib', 'GIOTRIF']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Solid Tumors,"University Health Network, Toronto",2025-09-01T16:18:09.631769,True,,,,,Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies,,['Solid Tumors'],['HER pathway aberrations'],,2015-08,2023-05-04,"[{'measure': 'Number of patients with complete response', 'timeFrame': '2 years'}, {'measure': 'Number of patients with partial response', 'timeFrame': '2 years'}]","[{'measure': 'Number of Grade 1 side effects', 'timeFrame': '2 years'}, {'measure': 'Number of Grade 2 side effects', 'timeFrame': '2 years'}, {'measure': 'Number of Grade 3 side effects', 'timeFrame': '2 years'}, {'measure': 'Number of Grade 4 side effects', 'timeFrame': '2 years'}, {'measure': 'Timeframe of Progression Free Survival', 'timeFrame': '2 years'}]",7.0,18 Years,,ALL,False,OTHER,1.0,12.0,ACTUAL,v2_robust,True,True,False,False,
NCT05297617,Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk,Anti-aromatase inhibitor,['Anti-aromatase inhibitor'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Breast Cancer,UNICANCER,2025-09-01T16:18:09.631854,True,,,,,Single-arm Study to De-escalate Adjuvant Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk of Metastasis,,['Breast Cancer'],[],,2022-10-12,2035-11,"[{'measure': 'Distant relapse-free interval (DRFI)', 'description': 'Distant relapse-free interval (DRFI) is defined as the time from date of beginning of hormonotherapy to the date of first event of distant recurrence or breast cancer related death', 'timeFrame': 'From date of beginning of hormonotherapy to onset of metastases or death, up to 5-years.'}]","[{'measure': 'Distant Disease-Free Survival (DDFS)', 'description': 'DDFS is defined as the time from date of beginning of hormonotherapy to the date of first event of distant recurrence, death from any cause or secondary non-breast cancer.', 'timeFrame': 'From date of beginning of hormonotherapy to the date of first event of distant recurrence, death from any cause or secondary non-breast cancer up to 10 years'}, {'measure': 'Invasive disease free survival (iDFS)', 'description': 'Invasive disease free survival is defined as duration of time from date of registration until first appearance of invasive local, regional, or distant recurrence (including invasive ipsilateral breast cancer recurrence), invasive contralateral breast cancer, second primary non breast invasive cancer (excluding non-melanoma skin cancer), or death from any cause.', 'timeFrame': 'From date of beginning of hormonotherapy to onset of invasive event, second cancer, or death, up to 10 years.'}, {'measure': 'Invasive breast cancer-free survival (iBCFS)', 'description': 'Invasive disease free survival is defined as the delay between date of inclusion and first appearance of invasive local, regional, or distant recurrence (including invasive ipsilateral breast cancer recurrence), invasive contralateral breast cancer, or death from any cause.', 'timeFrame': 'From date of beginning of hormonotherapy to onset of invasive event or death, up to 10 years.'}, {'measure': 'Breast cancer-specific survival (BCSS)', 'description': 'Breast cancer-specific survival is defined as the time from inclusion to death from breast cancer.', 'timeFrame': 'From date of beginning of hormonotherapy to death from breast cancer, up to 10 years.'}, {'measure': 'Overall survival (OS)', 'description': 'The overall survival is the length of time from inclusion to death from any cause.', 'timeFrame': 'From date of beginning of hormonotherapy to death from any cause, up to 10 years.'}, {'measure': 'Quality of life (QoL) questionnaire - Core 30 (QLQ-C30)', 'description': 'Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'At baseline, 1 year, 2 years, 3 years, 4 years, 5 years'}, {'measure': 'Quality of life (QoL) questionnaire - EORTC QLQ-BR23/QLQ-BR45', 'description': 'This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30.\n\nThe QLQ-BR23 contains 23 items incorporating five multi-item scales to assess systemic therapy side effects, arm symptoms, breast symptoms, body image and sexual functioning. In addition, single items assess sexual enjoyment, hair loss and future perspective. All items are rated on a four-point Likert-type scale (1 = ""not at all"", 2 = ""a little"", 3 = ""quite a bit"", and 4 = ""very much""), and are linearly transformed to a 0-100 scale. For all items but sexual functioning and sexual enjoyment, higher scores indicate more severe symptoms. The QLQ-BR-23 was updated and 22 new questions were added to provide a more accurate and comprehensive assessment of the impact of new and scalable treatments on patients\'QoL', 'timeFrame': 'At baseline, 1 year, 2 years, 3 years, 4 years, 5 years'}, {'measure': 'Quality of life (QoL) questionnaire - Cancer related fatigue (QLQ-FA12)', 'description': 'This EORTC cancer related fatigue questionnaire is intended to supplement the QLQ-C30.\n\nThe QLQ-FA12 contains 12 items organized in three subscales: physical fatigue (5 items), emotional fatigue (3 items), and cognitive fatigue (2 items). The remaining two items serve as global indicators for interference of fatigue with daily activities and social sequelae of fatigue.\n\nAll items are rated on a four-point Likert-type scale (1 = ""not at all"", 2 = ""a little"", 3 = ""quite a bit"", and 4 = ""very much""), and are linearly transformed to a 0-100 scale with higher scores indicating greater degree of fatigue.', 'timeFrame': 'At baseline, 1 year, 2 years, 3 years, 4 years, 5 years'}, {'measure': 'Hospital anxiety and depression scale (HADS)', 'description': 'The HADS is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale. Scores for items in each subscale of the HADS are summed to produce an anxiety score (HADS-A) or a depression score (HADS-D), or can be added to produce a total score corresponding to emotional distress (HADS-T). Each item is rated on a 4-point Likert scale (1 = ""not at all"", 2 = ""a little"", 3 = ""quite a bit"", and 4 = ""very much""), for a total score ranging from 0-21 for each subscale. The entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.', 'timeFrame': 'At baseline, 1 year, 2 years, 3 years, 4 years, 5 years'}, {'measure': 'Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog)', 'description': 'The FACT-Cog is a self-assessment questionnaire to estimate memory, attention, concentration, language, and thinking abilities of patients before, during, and after chemotherapy. This questionnaire, composed of 37 items consists of four subscales: cognitive impairments perceived by the patient (20 items), comments from others (4 items), cognitive abilities perceived by the patient (9 items), and impact on quality of life (4 items). The Perceived Cognitive Impairments and the Comments from Others subscales are rated on 5-point Likerttype scale (from 0 = ""Never"" to 4 = ""Several times a day""). An intensity 5-point Likert-type scale (from 0 ""Not at all"" to 4 ""Very much"") is used to rate perceived cognitive abilities and the impact on quality of life. For all subscales, a higher score represents better cognitive functioning or quality of life.', 'timeFrame': 'At baseline, 1 year, 2 years, 3 years, 4 years, 5 years'}, {'measure': 'Impact of Cancer (including fear of recidivism)', 'description': 'The Impact of Cancer Version 2 (IOCv2) is a 47-item questionnaire. The first 37 items are intended to measure 4 positive (Altruism/Empathy, Health Awareness, Meaning of Cancer, and Positive SelfEvaluation) and 4 negative (Appearance Concerns, Body Change Concerns, Life Interferences, and Worry) subscales, which total to two summary scores (Positive and Negative Impact). The 10 additional items constitute conditional dimensions applicable to subsets of survivors assessing employment concerns, relationship concerns for individuals with a partner, and relationship concerns for those without a partner. All items are scored on a five-point scale (1 = ""strongly disagree"", 2 = disagree, 3 = neutral, 4 = agree, and 5 = ""strongly agree""). Higher scores on the positive impact indicate greater positive impacts, while higher scores on the negative impact indicate greater negative impacts.', 'timeFrame': 'At baseline, 1 year, 2 years, 3 years, 4 years, 5 years'}, {'measure': 'Geriatric Core Dataset (G-CODE)', 'description': 'The G-CODE was developed by the DIalog for personALization of management in geriatric OncoloGy (DIALOG) intergroup to assess the general health status of the older patient.\n\nThe G-Code contains 10 tools incorporating seven scales to assess social environment, functional status, mobility, nutritional status, cognitive status, depressive mood, and comorbidities. The total scale range 0-62. High score indicate better condition.', 'timeFrame': 'At baseline, 1 year, 2 years, 3 years, 4 years, 5 years'}, {'measure': 'Evaluate the safety of the treatment in the study population', 'description': 'The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5.0) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = ""mild"", 2 = ""moderate"", 3 = ""severe"", 4 = ""life-threatening"", and 5 = ""death"") determined by the investigator, will make it possible to assess the severity of the disorders.', 'timeFrame': 'Throughout study completion, up to 10 years.'}]",14.0,51 Years,,FEMALE,False,OTHER,1.0,696.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05219617,Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults,Carisbamate,['Carisbamate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Seizures,"SK Life Science, Inc.",2025-09-01T16:18:09.631993,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension",,"['Seizures', 'Lennox Gastaut Syndrome']","['Seizures', 'Lennox Gastaut Syndrome', 'Pediatrics', 'Adults']",,2022-04-28,2028-12,"[{'measure': 'Primary outcome will be the percentage change from baseline in the total frequency (average per 28 days) of countable drop seizures with potential to fall (tonic, atonic, tonic-clonic) seizures during the double-blind treatment period.', 'description': 'Efficacy of Carisbamate YKP509', 'timeFrame': '3 years'}]","[{'measure': 'The percentage of subjects with at least a 50% reduction from baseline in the total frequency of drop seizures (tonic, atonic, tonic-clonic) during the double-blind treatment period.', 'description': 'Efficacy of Carisbamate YKP509', 'timeFrame': '3 years'}, {'measure': 'Percentage change from baseline in the frequency of all types of seizures (total seizures) during the double-blind treatment period.', 'description': 'Efficacy of Carisbamate YKP509', 'timeFrame': '3 years'}, {'measure': 'Subject/Caregiver Global Impression of Change (S/CGIC) in overall condition score at the last visit.', 'description': 'Efficacy of Carisbamate YKP509- Scoring will be from 1 to 7 with 1 (very much improved) to 7 (very much worse)', 'timeFrame': '3 years'}]",4.0,4 Years,55 Years,ALL,False,INDUSTRY,0.0,252.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02937740,"Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™",NATESTO Testosterone Nasal Gel,"['NATESTO Testosterone Nasal Gel', 'NATESTO']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hypogonadism,Acerus Pharmaceuticals Corporation,2025-09-01T16:18:09.632186,True,,,,,"A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™)",,['Hypogonadism'],['Hypogonadism'],,2016-10,2017-11,"[{'measure': 'Patient Satisfaction - Change From Baseline', 'description': 'The primary objective of this study is to measure patient satisfaction with testosterone replacement therapy before, during and after treatment with NATESTO. Patient satisfaction with treatment will be measured by TSQM (Treatment Satisfaction Questionnaire for Medication) Version 9, a 9-item validated instrument. TSQM domains include - Effectiveness, Convenience, Global Satisfaction. The score for each domain is converted into a scale out of 100. Higher values imply a better outcome.', 'timeFrame': 'Baseline and 3 months for BID, 4 months for TID'}]","[{'measure': 'Change in Hypogonadism Symptoms', 'description': 'Change in hypogonadism symptoms from baseline as measured by qADAM, a 10 point validated instrument. qADAM is a 10-item, patient-reported outcome measure used to evaluate the symptom severity of hypogonadism. Responses can range from 1 to 5 per question allowing for a minimum to maximum score range of 10 to 50. Higher values imply a better outcome.', 'timeFrame': 'Baseline and 3 months for BID, 4 months for TID'}, {'measure': 'Patient Treatment Preference Versus Prior Testosterone Replacement Therapy', 'description': 'Patient treatment preference versus prior testosterone replacement therapy measured by the Treatment Preference questionnaire.', 'timeFrame': 'Last visit, i.e. 3 months for BID, 4 months for TID'}, {'measure': 'Frequency of Daily Dose of NATESTO by the End of the Study', 'description': 'Frequency of daily dosing, i.e. how many patients remained on BID vs how many were uptitrated to TID by the end of the study.', 'timeFrame': '3 months for those who remained on BID, 4 months for those uptitrated to TID'}]",4.0,18 Years,65 Years,MALE,False,INDUSTRY,0.0,117.0,ACTUAL,v2_robust,True,True,False,False,
NCT00000740,Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects,Sitamaquine,['Sitamaquine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Pneumonia, Pneumocystis Carinii",National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:09.632288,True,,,,,Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects,,"['Pneumonia, Pneumocystis Carinii', 'HIV Infections']","['Pneumonia, Pneumocystis carinii', 'Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex', 'WR 6026']",,,1993-09,[],[],0.0,18 Years,,ALL,False,NIH,0.0,44.0,,v2_robust,True,True,False,False,
NCT00846040,Reduced Carbohydrate Versus Fat in Obese Subjects,Drug: f-18 fallypride,['Drug: f-18 fallypride'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Obesity,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),2025-09-01T16:18:09.632294,True,,,,,"Selective Reduction of Dietary Carbohydrate Versus Fat: Effects on Metabolism, Endocrine Physiology, Brain Activity and Reward Circuitry",,['Obesity'],"['Obesity', 'Weight Loss', 'Carbohydrate', 'Fat', 'Macronutrient Balance', 'Healthy Volunteer']",,2009-02-13,2014-10-20,"[{'measure': 'Change in Respiratory Quotient (RQ)', 'description': 'Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for at least 23 continuous hours on days 2 and 5 of the baseline diet and days 1, 4, and 6 of the reduced-energy diets.', 'timeFrame': 'Baseline and day 14'}]","[{'measure': 'Change in 24 Hour Energy Expenditure', 'description': '24 hour energy expenditure was measured in a respiratory chamber.', 'timeFrame': 'Baseline and 14 days'}, {'measure': 'Change in Cumulative Fat Imbalance', 'description': 'Measured as the difference between dietary fat intake and fat oxidation by the body as measured in the respiratory chamber', 'timeFrame': 'Baseline and 14 days'}, {'measure': 'Caudate Dopamine D2-like Receptor Binding Potential (D2BP)', 'description': 'The time-activity curves for \\[18F\\]fallypride tracer concentration in the ROIs were measured by PET and kinetic parameters were fit to a four compartment mathematical model (with the cerebellum used as the reference tissue). D2BP was expressed as the dimensionless ratio of rate constants quantifying binding and unbinding of tracer in the regions of interest.', 'timeFrame': 'Day 2 of in-patient admission'}, {'measure': 'Putamen Dopamine D2-like Receptor Binding Potential (D2BP)', 'description': 'The time-activity curves for \\[18F\\]fallypride tracer concentration in the ROIs were measured by PET and kinetic parameters were fit to a four compartment mathematical model (with the cerebellum used as the reference tissue). D2BP was expressed as the dimensionless ratio of rate constants quantifying binding and unbinding of tracer in the regions of interest.', 'timeFrame': 'Day 2 of in-patient admission'}, {'measure': 'Accumbens Dopamine D2-like Receptor Binding Potential (D2BP)', 'description': 'The time-activity curves for \\[18F\\]fallypride tracer concentration in the ROIs were measured by PET and kinetic parameters were fit to a four compartment mathematical model (with the cerebellum used as the reference tissue). D2BP was expressed as the dimensionless ratio of rate constants quantifying binding and unbinding of tracer in the regions of interest.', 'timeFrame': 'Day 2 of in-patient admission'}]",6.0,18 Years,45 Years,ALL,False,NIH,0.0,43.0,ACTUAL,v2_robust,True,True,False,False,
NCT00484640,Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing,Coumadin,['Coumadin'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Atrial Fibrillation,Agency for Healthcare Research and Quality (AHRQ),2025-09-01T16:18:09.632340,True,,,,,Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing,,"['Atrial Fibrillation', 'Deep Venous Thrombosis', 'Heart Valve Replacement', 'Pulmonary Embolism']",[],,2007-06,2008-05,"[{'measure': 'weighted time in therapeutic range'}, {'measure': 'absolute deviation from clinically optimal dose'}]","[{'measure': 'time to stable dose in therapeutic target range'}, {'measure': 'warfarin related adverse drug events'}, {'measure': 'time to first INR above 4'}]",5.0,40 Years,,ALL,False,FED,1.0,260.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01028040,AZD Single Ascending Dose Study In Healthy Japanese Subjects,AZD3043,['AZD3043'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,AstraZeneca,2025-09-01T16:18:09.632350,True,,,,,"Phase I, Single Centre, Open Label Study to Access The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After A) a Single Ascending Bolus Dose and B) a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Japanese Volunteers (Age Range 20-45 Years)",,['Healthy'],"['Phase I', 'AZD3043', 'Japanese healthy volunteer']",,2009-12,2010-08,"[{'measure': 'To assess the safety and tolerability of AZD3043 following administration of SAD bolus (Part A) and SAD bolus followed by infusion (Part B).', 'timeFrame': 'From screening period to follow-up visit 42 days (Maximum)'}]","[{'measure': 'To characterize the PK of AZD3043 and its main metabolite (THRX-108893) & provisionally assess the dose-proportionality of the PK', 'timeFrame': 'Blood and urine sampling from pre-dose until follow-up visit, 10 days (approximately)'}, {'measure': 'To evaluate the onset, level and recovery of/from sedation/anaesthesia.', 'timeFrame': 'Assessed on Day 1'}]",3.0,20 Years,45 Years,ALL,True,INDUSTRY,0.0,72.0,ESTIMATED,v2_robust,True,True,False,True,
NCT05490940,Sensory Recovery of Digital Nerves After Microsurgical Epineural Neurorrhaphy Alone or in Combination With Tisseel - RET,Tisseel®,"['Neurorraphy alone', 'Tisseel®']",2,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Digital Nerve Injuries,"Insel Gruppe AG, University Hospital Bern",2025-09-01T16:18:09.632380,True,,,,,"A Prospective Randomized Study to Evaluate Sensory Recovery of Digital Nerves After Primary Repair Performed by Microsurgical Epineural End-to-end Neurorrhaphy Alone, or in Combination With an Enwrapping With Fibrin Sealant Tisseel®",,['Digital Nerve Injuries'],[],,2023-03-01,2025-12-31,"[{'measure': 'two point discrimination', 'description': 'For this purpose a standardized two-point-discriminator (PADGETT DeMayo Two-Point Discrimination Device, Used for Post hand surgery diagnostic. MFID: PM-855) is used', 'timeFrame': 'preoperative'}, {'measure': 'two point discrimination', 'description': 'For this purpose a standardized two-point-discriminator (PADGETT DeMayo Two-Point Discrimination Device, Used for Post hand surgery diagnostic. MFID: PM-855) is used', 'timeFrame': '6 weeks postoperative'}, {'measure': 'two point discrimination', 'description': 'For this purpose a standardized two-point-discriminator (PADGETT DeMayo Two-Point Discrimination Device, Used for Post hand surgery diagnostic. MFID: PM-855) is used', 'timeFrame': '12 weeks postoperative'}, {'measure': 'two point discrimination', 'description': 'For this purpose a standardized two-point-discriminator (PADGETT DeMayo Two-Point Discrimination Device, Used for Post hand surgery diagnostic. MFID: PM-855) is used', 'timeFrame': '24 weeks postoperative'}]","[{'measure': 'Neuroma formation', 'description': '* presence of Hofmann-Tinel sign\n* Allodynographia/Mapping (Semmes-Weinstein Monofilament (SWMF) assessment as described by Spicher et al. (17); Sammons Preston Rolyan) performed by a trained hand therapist\n* detection of a neuroma in ultrasound examination (measurement of three cross-section areas: proximal, distal and at the level of the neurorrhaphy) performed by a therefore certified hand surgeon (Philips iU22 Medical system or Philips 70 affiniti)', 'timeFrame': '6 weeks postoperative'}, {'measure': 'Grip strength', 'description': 'using a JAMAR dynamometer', 'timeFrame': '12 weeks postoperative'}, {'measure': 'Active range of motion', 'description': 'using a goniometer', 'timeFrame': '6 weeks postoperative'}, {'measure': 'Pain with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'description': 'with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'timeFrame': '6 weeks postoperative'}, {'measure': 'quickDASH score (Disabilities of the Shoulder, Arm and Hand)', 'description': 'a 11 item questionnaire: filled out by the patient', 'timeFrame': 'preoperative'}, {'measure': 'STI-Test: (Shape-Texture Identification test)', 'description': 'This test is a standardized outcome measure of sensory function of the median and ulnar nerves of the hand: max. score for completed test = 6 points, min. score = 0', 'timeFrame': '12 weeks postoperative'}, {'measure': 'Neuroma formation', 'description': '* presence of Hofmann-Tinel sign\n* Allodynographia/Mapping (Semmes-Weinstein Monofilament (SWMF) assessment as described by Spicher et al. (17); Sammons Preston Rolyan) performed by a trained hand therapist\n* detection of a neuroma in ultrasound examination (measurement of three cross-section areas: proximal, distal and at the level of the neurorrhaphy) performed by a therefore certified hand surgeon (Philips iU22 Medical system or Philips 70 affiniti)', 'timeFrame': '12 weeks postoperative'}, {'measure': 'Neuroma formation', 'description': '* presence of Hofmann-Tinel sign\n* Allodynographia/Mapping (Semmes-Weinstein Monofilament (SWMF) assessment as described by Spicher et al. (17); Sammons Preston Rolyan) performed by a trained hand therapist\n* detection of a neuroma in ultrasound examination (measurement of three cross-section areas: proximal, distal and at the level of the neurorrhaphy) performed by a therefore certified hand surgeon (Philips iU22 Medical system or Philips 70 affiniti)', 'timeFrame': '24 weeks postoperative'}, {'measure': 'Neuroma formation', 'description': '* presence of Hofmann-Tinel sign\n* Allodynographia/Mapping (Semmes-Weinstein Monofilament (SWMF) assessment as described by Spicher et al. (17); Sammons Preston Rolyan) performed by a trained hand therapist\n* detection of a neuroma in ultrasound examination (measurement of three cross-section areas: proximal, distal and at the level of the neurorrhaphy) performed by a therefore certified hand surgeon (Philips iU22 Medical system or Philips 70 affiniti)', 'timeFrame': '48 weeks postoperative'}, {'measure': 'Grip strength', 'description': 'using a JAMAR dynamometer', 'timeFrame': '24 weeks postoperative'}, {'measure': 'Grip strength', 'description': 'using a JAMAR dynamometer', 'timeFrame': '48 weeks postoperative'}, {'measure': 'Active range of motion', 'description': 'using a goniometer', 'timeFrame': '12 weeks postoperative'}, {'measure': 'Active range of motion', 'description': 'using a goniometer', 'timeFrame': '24 weeks postoperative'}, {'measure': 'Active range of motion', 'description': 'using a goniometer', 'timeFrame': '48 weeks postoperative'}, {'measure': 'Pain with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'description': 'with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'timeFrame': '12 weeks postoperative'}, {'measure': 'Pain with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'description': 'with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'timeFrame': '24 weeks postoperative'}, {'measure': 'Pain with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'description': 'with the Numeric Rating Scale (NRS): 0 indicating no and 10 indicating maximum pain', 'timeFrame': '48 weeks postoperative'}, {'measure': 'quickDASH score (Disabilities of the Shoulder, Arm and Hand)', 'description': 'a 11 item questionnaire: filled out by the patient', 'timeFrame': '6 weeks postoperative'}, {'measure': 'quickDASH score (Disabilities of the Shoulder, Arm and Hand)', 'description': 'a 11 item questionnaire: filled out by the patient', 'timeFrame': '12 weeks postoperative'}, {'measure': 'quickDASH score (Disabilities of the Shoulder, Arm and Hand)', 'description': 'a 11 item questionnaire: filled out by the patient', 'timeFrame': '24 weeks postoperative'}, {'measure': 'quickDASH score (Disabilities of the Shoulder, Arm and Hand)', 'description': 'a 11 item questionnaire: filled out by the patient', 'timeFrame': '48 weeks postoperative'}, {'measure': 'STI-Test: (Shape-Texture Identification test)', 'description': 'This test is a standardized outcome measure of sensory function of the median and ulnar nerves of the hand: max. score for completed test = 6 points, min. score = 0', 'timeFrame': '24 weeks postoperative'}, {'measure': 'STI-Test: (Shape-Texture Identification test)', 'description': 'This test is a standardized outcome measure of sensory function of the median and ulnar nerves of the hand: max. score for completed test = 6 points, min. score = 0', 'timeFrame': '48 weeks postoperative'}]",27.0,18 Years,,ALL,False,OTHER,1.0,74.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01545440,A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE),lebrikizumab,"['lebrikizumab', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Asthma,"Genentech, Inc.",2025-09-01T16:18:09.632437,True,,,,,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication",,['Asthma'],[],,2012-03,2013-07,"[{'measure': 'Rate of asthma exacerbations during the 52-week placebo-controlled period', 'timeFrame': 'weeks 0-52'}]","[{'measure': 'Change in lung function: pre-bronchodilator FEV1', 'timeFrame': 'from baseline to week 52'}, {'measure': 'Time to first asthma exacerbation', 'timeFrame': 'from baseline to week 52'}, {'measure': 'Change in fractional exhaled nitric oxide (FeNO)', 'timeFrame': 'from baseline to week 52'}, {'measure': 'Change in asthma-specific health-related quality of life, assessed by the Standardized Asthma Quality of Life Questionnaire (AQLQ[S])', 'timeFrame': 'from baseline to week 52'}, {'measure': 'Change in asthma rescue medication use', 'timeFrame': 'from baseline to week 52'}, {'measure': 'Rate of urgent asthma-related health care utilization during the 52-week placebo-controlled period', 'timeFrame': 'from baseline to week 52'}]",7.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,258.0,ACTUAL,v2_robust,True,True,False,False,
NCT06422689,Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care,Albuterol and budesonide inhalation aerosol,"['Albuterol and budesonide inhalation aerosol', 'PT027']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Asthma,AstraZeneca,2025-09-01T16:18:09.632611,True,,,,,ANCHOR - Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care,,['Asthma'],"['Effectiveness', 'Asthma', 'Exacerbation', 'Healthcare resource utilization', 'Cost', 'Albuterol/budesonide', 'Short-acting beta-agonist (SABA)', 'Inhaled corticosteroids (ICS)', 'Rescue', 'Switch', 'Oral corticosteroid', 'Patients reported asthma symptoms', 'PT027']",,2024-05-10,2026-04-29,"[{'measure': 'Asthma exacerbation', 'description': 'Annualized Severe Asthma exacerbation rate', 'timeFrame': 'During 12-month pre-switch and 12-month post-switch periods'}]","[{'measure': 'Asthma exacerbation-related HCRU', 'description': 'Percentage of patients with Asthma exacerbation-related HCRU', 'timeFrame': 'During 12-month pre-switch and 12-mont post switch periods'}, {'measure': 'Asthma exacerbation-related cost', 'description': 'Asthma exacerbation-related cost in US Dollars', 'timeFrame': 'During 12-month pre-switch and 12-month post-switch periods'}, {'measure': 'Asthma-related cost', 'description': 'Asthma-related cost in US Dollars', 'timeFrame': 'During 12-month pre-switch and 12-month post-switch periods'}, {'measure': 'Asthma- related Oral Corticosteroid (OCS) use', 'description': 'Mean number of Asthma- related Oral Corticosteroid (OCS) prescriptions', 'timeFrame': 'During 12-month pre-switch and 12-month post-switch periods'}, {'measure': 'Change in asthma exacerbation-related HCRU at health system level', 'description': 'Percentage of patients with Asthma exacerbation-related HCRU at the health system level', 'timeFrame': 'During 12-month pre-switch and 12-month post-switch periods'}]",6.0,18 Years,130 Years,ALL,False,INDUSTRY,1.0,2000.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02299089,Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs),octreotide FluidCrystal® injection depot,"['octreotide FluidCrystal® injection depot', 'CAM2029']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acromegaly,Camurus AB,2025-09-01T16:18:09.632629,True,,,,,"A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR®",,"['Acromegaly', 'Neuroendocrine Tumors']","['acromegaly', 'neuroendocrine tumour (NET)', 'carcinoid syndrome', 'octreotide', 'Sandostatin LAR']",,2015-01,2016-06,"[{'measure': 'Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC', 'description': 'Pharmacokinetics (PK) of octreotide after injection of Sandostatin Long-acting Release (LAR) was determined for the dosing period Day -28 to Day 0; AUC0-28d (day\\*ng/mL).\n\nAUC0-28d: AUC from 0 to 28 days over the final dosing interval (day\\*ng/mL) for Sandostatin LAR.', 'timeFrame': 'Pre-dose; study Day -28- to Day 0 (PK analysis:Sandostatin (LAR®) sampling time points: 0, 1hour, 24hours, 7days, 14days, 21days and 28days)'}, {'measure': 'Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC.', 'description': 'Pharmacokinetics (PK) of octreotide after administrations of CAM2029 was determined for the dosing period Day 0 to Day 84 ; AUC0-28d (day\\*ng/mL).\n\nAUC0-28d: AUC from 0 to 28 days over the dosing intervals (day\\*ng/mL) for CAM2029 20 mg q4w and CAM2029 10 mg q2w (to estimate AUC0-28d for those patients receiving CAM2029 10 mg q2w, AUC0-14d was multiplied by a factor of 2 as an estimate of the AUC0-28d) dosing intervals', 'timeFrame': '(Day 0) to Day 84 (PK analysis:CAM2029 sampling time points: CAM2029 10mg q2w; 0, 2hours, 24hours, 48hours, 7days and 14days CAM2029 20mg q4w; 0, 2hours, 24hours, 48hours, 7days, 21days and 28days)'}, {'measure': 'Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Ctrough', 'description': 'Pharmacokinetics (PK) of octreotide after injection of Sandostatin Long-acting Release (LAR) was determined for the dosing period Day -28 to Day 0; Ctrough (ng/mL).\n\nCtrough; Concentration levels assessed prior to next injection for the final (Sandostatin LAR) dosing interval (ng/mL).', 'timeFrame': 'Pre-dose; study Day -28- to Day 0 (PK analysis:Sandostatin (LAR®) sampling time points: 0, 1hour, 24hours, 7days, 14days, 21days and 28days)'}, {'measure': 'Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Cmax', 'description': 'Pharmacokinetics (PK) of octreotide after injection of Sandostatin Long-acting Release (LAR) was determined for the dosing period Day -28 to Day 0; Cmax (ng/mL).\n\nCmax (ng/mL): Maximum observed plasma concentration over the final (Sandostatin LAR) dosing interval (ng/mL)', 'timeFrame': 'Pre-dose; study Day -28- to Day 0 (PK analysis:Sandostatin (LAR®) sampling time points: 0, 1hour, 24hours, 7days, 14days, 21days and 28days)'}, {'measure': 'Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Ctrough', 'description': 'Pharmacokinetics (PK) of octreotide after administrations of CAM2029 was determined for the dosing period Day 0 to Day 84; Ctrough (ng/mL).\n\nCtrough; Concentration levels assessed prior to next injection for CAM2029 20 mg q4w and CAM2029 10 mg q2w dosing intervals (ng/mL)', 'timeFrame': '(Day 0) to Day 84 (PK analysis:CAM2029 sampling time points: CAM2029 10mg q2w; 0, 2hours, 24hours, 48hours, 7days and 14days CAM2029 20mg q4w; 0, 2hours, 24hours, 48hours, 7days, 21days and 28days)'}, {'measure': 'Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Cmax.', 'description': 'Pharmacokinetics (PK) of octreotide after administrations of CAM2029 was determined for the dosing period Day 0 to Day 84 ; Cmax (ng/mL).\n\nCmax (ng/mL): Maximum observed plasma concentration over CAM2029 20 mg q4w and CAM2029 10 mg q2w dosing intervals (ng/mL)', 'timeFrame': '(Day 0) to Day 84 (PK analysis:CAM2029 sampling time points: CAM2029 10mg q2w; 0, 2hours, 24hours, 48hours, 7days and 14days CAM2029 20mg q4w; 0, 2hours, 24hours, 48hours, 7days, 21days and 28days)'}]","[{'measure': 'Number of Adverse Events and Serious Adverse Events', 'description': 'Safety (number of adverse events and serious adverse events) after repeated doses of CAM2029 (assessment period from Day 0 to Day 84) and single dose Sandostatin LAR (assessment period Day -28 to Day 0)', 'timeFrame': 'Day -28 to Day 84'}, {'measure': 'CAM2029 Effect on Insulin-like Growth Factor (IGF-1) (Acromegaly)', 'description': 'Data is presented as number of patients\n\n* Within the reference limits (see below)\n* Above ULN (Upper Limits of Normal)\n\nIn the Acromegaly group both males and females were included the age was between 42-70 years. The IGF normal range for the different genders and age are presented below.\n\nREFERENCE VALUES\n\nMales (NMOL/L) 8.34-27.44 (41-45 years) 7.7-26.36 (46-50 years) 7.3-26.34 (51-55 years) 6.64-25.44 (56-60 years) 6.17-25.02 (61-65 years) 5.96-25.48 (66-70 years)\n\nFemales (NMOL/L) 8.06-26.89 (41-45 years) 7.39-25.44 (46-50 years) 6.92-24.98 (51-55 years) 5.92-22.7 (56-60 years) 5.42-21.96 (61-65 years) 5.07-21.97 (66-70 years)', 'timeFrame': 'Day 84'}, {'measure': 'CAM2029 Effect on Growth Hormone (GH) (Acromegaly)', 'description': 'GH (growth hormone) levels measured on Day 84 in patients with acromegaly', 'timeFrame': 'Day 84'}]",9.0,18 Years,,ALL,False,INDUSTRY,1.0,12.0,ACTUAL,v2_robust,True,True,False,True,
NCT02006589,Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions,"Candesartan cilexetil (GW615775, Test formulation)","['Candesartan cilexetil (Reference treatment)', 'Candesartan cilexetil (GW615775, Test formulation)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hypertension,GlaxoSmithKline,2025-09-01T16:18:09.632726,True,,,,,"An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 8mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 8mg Reference Tablet of Candesartan Cilexetil (Atacand) in Healthy Adult Human Subjects Under Fasting Conditions",,['Hypertension'],"['Bioequivalence', 'Candesartan cilexetil', 'Healthy adult human subjects']",,2013-12-11,2014-01-22,"[{'measure': 'Plasma pharmacokinetic (PK) parameters assessed by Cmax, AUC(0-infinity) and AUC(0-t)', 'description': 'PK parameters include: Maximum observed concentration (Cmax), area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC\\[0-infinity\\]) and area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration within a subject across all treatments \\[AUC(0-t)\\].', 'timeFrame': 'Pre-dose, 0.5 hour (hr), 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 4.5 hr, 5 hr, 5.5 hr, 6 hr, 7 hr, 8 hr, 10 hr, 12 hr, 16 hr, 24 hr, 36 hr and 48 hr of each treatment period.'}]","[{'measure': 'PK parameters assessed by tmax, %AUCex and t1/2', 'description': 'PK parameters include: Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex), time of occurrence of Cmax (tmax), terminal phase half-life (t1/2).', 'timeFrame': 'Pre dose, 0.5 hr, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 4.5 hr, 5 hr, 5.5 hr, 6 hr, 7 hr, 8 hr, 10 hr, 12 hr, 16 hr, 24 hr, 36 hr and 48 hr of each treatment period.'}, {'measure': 'Safety and tolerability assessment as assessed by adverse events (AEs)', 'timeFrame': 'Up to 35 days'}, {'measure': 'Safety and tolerability assessment as assessed by vital signs', 'description': 'Vital sign measurements will include systolic and diastolic blood pressure, and pulse rate.', 'timeFrame': 'Up to 35 days'}, {'measure': 'Safety and tolerability assessment as assessed by clinical laboratory values', 'description': 'Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters.', 'timeFrame': 'Up to 35 days'}]",5.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT03020589,Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients,Tacrolimus,"['Prograf, Advagraf', 'Tacrolimus']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Renal Transplant,"University of North Carolina, Chapel Hill",2025-09-01T16:18:09.632744,True,,,,,Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients,,['Renal Transplant'],"['Renal Transplant', 'Tacrolimus', 'UNC', 'Phase IV']",,2017-02-06,2022-06-28,"[{'measure': 'Proportion of Patients Reaching Target Tacrolimus Levels (8-10 ng/mL) on Day 3 After Kidney Transplantation', 'timeFrame': 'Day 3 after transplantation'}, {'measure': 'Proportion of Patients Reaching Target Tacrolimus Levels (8-10 ng/mL) on Day 7 After Kidney Transplantation', 'timeFrame': 'Day 7 after transplantation'}]","[{'measure': 'Number of Events of Biopsy Proven Acute Rejection (BPAR)', 'description': 'The number of events of BPAR within the first 3 months (Days 0 through 90), 91-180, and 181-365 days after transplantation', 'timeFrame': 'first 3 months (Days 0 through 90), 91-180, and 181-365 days after transplantation'}, {'measure': 'Tacrolimus Level', 'description': 'Time to achieve tacrolimus therapeutic range at 0 to 4 months (8-10 ng/mL)', 'timeFrame': '4 months'}, {'measure': 'Mean Number of Dose Adjustments and/or Drug Alterations', 'description': 'Mean number of dose adjustments and/or drug alteration or addition due to insufficient immunosuppression.', 'timeFrame': '12 months'}, {'measure': 'Percent of Participants With Chronic Renal Impairment by eGFR Category', 'description': 'Renal function will be assessed using estimated Glomerular Filtration Rate (eGFR). Creatinine clearance (CrCl) may also be calculated as a reference. Patients will be categorized as having either mild (eGFR of 60 mL/min/1.73m\\^2 to 89 mL/min/1.73m\\^2), moderate (eGFR of 30 mL/min/1.73m\\^2 to 59 mL/min/1.73m\\^2), or severe renal impairment (eGFR \\<30 mL/min/1.73m\\^2).', 'timeFrame': '12 months'}, {'measure': 'Number of Adverse Outcomes', 'description': 'Number of adverse outcomes (i.e., graft loss, infection, and death)', 'timeFrame': '12 months'}]",7.0,18 Years,65 Years,ALL,False,OTHER,0.0,97.0,ACTUAL,v2_robust,True,True,False,True,
NCT05952089,A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure,Danicamtiv,"['MYK-491', 'Midazolam', 'BMS-986434', 'Danicamtiv']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Heart Failure With Reduced Ejection Fraction,Bristol-Myers Squibb,2025-09-01T16:18:09.632766,True,,,,,"An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction",,['Heart Failure With Reduced Ejection Fraction'],"['HFrEF', 'Danicamtiv', 'BMS-986434', 'MYK-491', 'Midazolam']",,2023-08-17,2024-03-19,"[{'measure': 'Maximum observed plasma concentration (Cmax)', 'timeFrame': 'Up to Day 12'}, {'measure': 'Area under the plasma concentration time curve from time zero extrapolated to infinite time (AUC[INF])', 'timeFrame': 'Up to Day 12'}, {'measure': 'Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])', 'timeFrame': 'Up to Day 12'}]","[{'measure': 'Time of maximum observed plasma concentration (Tmax)', 'timeFrame': 'Up to Day 12'}, {'measure': 'Terminal elimination half-life (T-HALF)', 'timeFrame': 'Up to Day 12'}, {'measure': 'Number of participants with adverse events (AEs) and serious adverse events (SAEs)', 'timeFrame': 'Up to Day 12'}, {'measure': 'Number of participants with vital sign abnormalities', 'timeFrame': 'Up to Day 12'}, {'measure': 'Number of participants with electrocardiogram (ECG) abnormalities', 'timeFrame': 'Up to Day 12'}, {'measure': 'Number of participants with physical examination abnormalities', 'timeFrame': 'Up to Day 12'}, {'measure': 'Number of participants with clinical laboratory abnormalities', 'timeFrame': 'Up to Day 11'}]",10.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,13.0,ACTUAL,v2_robust,True,True,False,True,
NCT05732389,Immunotherapy in Patients With Early dMMR Rectal Cancer,Nivolumab,"['Ipilimumab', 'Nivolumab', 'Opdivo', 'Yervoy']",4,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Cancer of Rectum,Odense University Hospital,2025-09-01T16:18:09.632848,True,,,,,Immunotherapy in Patients With Early dMMR Rectal Cancer,,['Cancer of Rectum'],[],,2023-02-01,2052-02,"[{'measure': 'Complete clinical response', 'description': 'Proportion of patients with complete clinical response Complete clinical response will be defined as no visible or palpable tumor examined by rectal exploration (if low tumors), endoscopy and MR-scan. Patients with definite but less than complete regression BUT with a representative biopsy without viable tumor cells will also be classified as cCR in this trial.', 'timeFrame': 'Evaluated at day 93 (+/- 7 days) after one or two cycles of immunotherapy. (Each cycle is 7 weeks)'}]","[{'measure': 'Complete biological response', 'description': 'Proportion of patients with complete biological response', 'timeFrame': 'Evaluated at day 93 (+/- 7 days) after one or two cycles of immunotherapy. (Each cycle is 7 weeks)'}, {'measure': '12 months recurrence', 'description': 'Proportion of patients without any sign of recurrence after 12 months.', 'timeFrame': 'after 12 months'}, {'measure': 'Respons rate', 'description': 'Response rate according to mrTRG.', 'timeFrame': 'after 1 or 2 cycles of immunotherapy. (Each cycle is 7 weeks)'}, {'measure': 'Adverse events', 'description': 'Adverse events assessed by the investigator according to the definitions in NCI-CTC, version 5.0', 'timeFrame': 'after 1 or 2 cycles of immunotherapy and months 4, 10, 16, and 24. (Each cycle is 7 weeks)'}, {'measure': 'Bio-marker predictive models for treatment response and survival.', 'description': 'Correlation between bio-markers (ctDNA and CEA) and outcome.', 'timeFrame': 'after 1 or 2 cycles of immunotherapy. (Each cycle is 7 weeks)'}, {'measure': 'Quality of life (EORCT QLQ-C30)', 'description': 'Change in Quality of life (EORCT QLQ-C30)', 'timeFrame': 'after 1 or 2 cycles of immunotherapy and months 4, 10, 16, and 24. (Each cycle is 7 weeks)'}, {'measure': 'Quality of life (EORCT QLQ-CR29)', 'description': 'Change in Quality of life (EORCT QLQ-CR29)', 'timeFrame': 'after 1 or 2 cycles of immunotherapy and months 4, 10, 16, and 24. (Each cycle is 7 weeks)'}]",8.0,18 Years,,ALL,False,OTHER,7.0,39.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05048589,Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting,Standard-Dose Quadrivalent Influenza Vaccine,"['QIV-HD', 'QIV-SD', 'Standard-Dose Quadrivalent Influenza Vaccine', 'High-Dose Quadrivalent Influenza Vaccine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Influenza,Tor Biering-Sørensen,2025-09-01T16:18:09.632867,True,,,,,Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting,,['Influenza'],"['Influenza', 'Vaccination', 'Pragmatic', 'Registry']",,2021-10-01,2022-05-31,"[{'measure': 'Number of persons contacted by recruitment letter', 'timeFrame': 'Up to 8 months'}, {'measure': 'Number of participants included and randomized to QIV-HD or QIV-SD', 'timeFrame': 'Up to 8 months'}, {'measure': 'Agreement between randomization assignment and actual received vaccine', 'timeFrame': 'Up to 8 months'}, {'measure': 'Balance between groups in terms of number of subjects in each arm and baseline characteristics', 'timeFrame': 'Up to 8 months'}, {'measure': 'Comparison of baseline characteristics for the QIV-HD and QIV-SD groups to the overall Danish general population aged 65-79 years', 'timeFrame': 'Up to 8 months'}, {'measure': 'Comparison of baseline characteristics for the QIV-HD and QIV-SD groups to the population aged 65-79 years in the DLVS database used for recruitment', 'timeFrame': 'Up to 8 months'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for influenza and/or pneumonia', 'description': 'First hospitalization with a primary (A) diagnosis code for influenza or pneumonia of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for respiratory disease', 'description': 'First hospitalization with a primary (A) diagnosis code for respiratory disease of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for cardio-respiratory disease', 'description': 'First hospitalization with a primary (A) diagnosis code for cardio-respiratory disease of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for cardiovascular disease', 'description': 'First hospitalization with a primary (A) diagnosis code for cardiovascular disease of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization from any cause', 'description': 'First hospitalization with any diagnosis code of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for all-cause mortality', 'description': 'Death from any cause', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for COVID-19', 'description': 'First hospitalization with a primary (A) diagnosis code for COVID-19 of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}]",[],13.0,65 Years,79 Years,ALL,True,OTHER,1.0,12551.0,ACTUAL,v2_robust,True,True,False,False,
NCT02920489,Individualized Timing of Analgesia and Effectiveness of Labor Analgesia,Individualized epidural analgesia,"['Individualized epidural analgesia', 'Individualized analgesia with sufentanil and ropivacaine', 'Routine epidural analgesia', 'Routine analgesia with sufentanil and ropivacaine']",4,INTERVENTIONAL,['NA'],,COMPLETED,Labor Pain,Peking University First Hospital,2025-09-01T16:18:09.632897,True,,,,,Impact of Individualized Timing of Analgesia on the Effectiveness of Labor Analgesia: a Randomized Controlled Trial,,"['Labor Pain', 'Analgesia, Obstetrical', 'Early Medical Intervention']","['severity of labor pain', 'individualized administration', 'neuraxial labor analgesia']",,2016-08,2017-07,"[{'measure': 'The most severe labor pain score during labor', 'description': 'Assessed with numeric rating scale, where 0 indicates no pain and 10 the worst pain.', 'timeFrame': 'Assessed at 24 hours after delivery'}]","[{'measure': 'Incidence of instrumental delivery', 'description': 'Incidence of instrumental delivery', 'timeFrame': 'At the time of delivery'}, {'measure': 'Incidence of Cesarean delivery', 'description': 'Incidence of Cesarean delivery', 'timeFrame': 'At the time of delivery'}, {'measure': 'Neonatal Apgar score', 'description': 'Neonatal Apgar score', 'timeFrame': 'At 1 and 5 minutes after delivery'}, {'measure': 'Maternal satisfaction with labor analgesia', 'description': 'Assessed with the Likert scale, where 1=extremely dissatisfaction, 2=dissatisfaction, 3=neither dissatisfaction nor satisfaction, 4=satisfaction, 5=extremely satisfaction.', 'timeFrame': 'Assessed at 24 hours after delivery'}, {'measure': 'Persistent pain score at 24 hours and 42 days after delivery', 'description': 'Assessed with numeric rating scale, where 0 indicates no pain and 10 the worst pain.', 'timeFrame': 'At 24 hours and 42 days after delivery'}, {'measure': 'Rate of breast-feeding', 'description': 'Rate of breast-feeding', 'timeFrame': 'At 24 hours and 42 days after delivery'}, {'measure': 'Incidence of postpartum depression', 'description': 'Postpartum depression will be diagnosed as Edinburgh postnatal depression scale of 10 or higher.', 'timeFrame': 'At 42 days after delivery'}]",8.0,18 Years,36 Years,FEMALE,False,OTHER,0.0,200.0,ACTUAL,v2_robust,True,True,False,False,
NCT02778789,Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers,Tocilizumab,"['Tocilizumab', 'Adalimumab, Etanercept, Golimumab, Certolizumab-Pegol, Infliximab', 'TNF-alpha Inhibitor', 'RoActemra']",4,OBSERVATIONAL,[],,COMPLETED,Rheumatoid Arthritis,University of Erlangen-Nürnberg Medical School,2025-09-01T16:18:09.632919,True,,,,,Non Randomized Parallel-group Clinical Study to Compare the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers.,,['Rheumatoid Arthritis'],[],,2015-10,2018-03-31,"[{'measure': 'Change in erosion volume in the HR-pQCT', 'timeFrame': '12 months'}]","[{'measure': 'Change in the Disease activity score 28 (DAS28)', 'timeFrame': '12months'}, {'measure': 'Change in the Clinical Disease Activity Index (CDAI)', 'timeFrame': '12 months'}, {'measure': 'Changes in the Simple Disease Activity Index (SDAI)', 'timeFrame': '12 months'}, {'measure': 'Change in the Health Assessment Questionnaire (HAQ)', 'timeFrame': '12 months'}, {'measure': 'Number of patients in Remission (DAS28 < 2.6)', 'timeFrame': '12 months'}, {'measure': 'Number of patients in Low Disease Activity (DAS28 ≥ 2.6 und ≤ 3.2)', 'timeFrame': '12 months'}]",7.0,18 Years,,ALL,False,OTHER,0.0,66.0,ACTUAL,v2_robust,False,True,False,False,
NCT06860789,AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN),AK135,['AK135'],1,INTERVENTIONAL,['PHASE1'],PHASE1,NOT_YET_RECRUITING,Chemotherapy-induced Peripheral Neuropathy (CIPN),Akeso,2025-09-01T16:18:09.632967,True,,,,,"A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AK135 for the Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients With Malignant Tumors",,['Chemotherapy-induced Peripheral Neuropathy (CIPN)'],[],,2025-02-28,2027-12-31,"[{'measure': 'Adverse events', 'description': 'Incidence and severity of participants with adverse events', 'timeFrame': 'From time ICF is signed until 90 days after last dose of AK135'}, {'measure': 'DLT', 'timeFrame': 'During the first treatment cycle of AK135 （14 days）'}]","[{'measure': 'EORTC-QLQ-CIPN20', 'description': 'Patient-assessed European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale', 'timeFrame': 'through study completion, an average of 12 weeks'}, {'measure': 'BPI-SF', 'description': 'Patient-assessed Brief Pain Inventory-Short Form', 'timeFrame': 'through study completion, an average of 12 weeks'}, {'measure': 'CTCAE-Neuropathy', 'description': 'Physician-assessed Common Terminology Criteria for Adverse Events-Neurotoxicity', 'timeFrame': 'through study completion, an average of 12 weeks'}, {'measure': 'Cmax of AK135', 'timeFrame': 'through study completion, an average of 12 weeks'}, {'measure': 'AUC', 'timeFrame': 'through study completion, an average of 12 weeks'}, {'measure': 't1/2', 'timeFrame': 'through study completion, an average of 12 weeks'}, {'measure': 'ADAs', 'description': 'Number of subjects who develop detectable anti-drug antibodies', 'timeFrame': 'From first dose of study drug through 30 days after last dose of study drug.'}]",9.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,85.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01470989,β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3),ACZ885,"['Triamcinolone acetonide 40 mg', 'ACZ885', 'Triamcinolone acetonide', 'Canakinumab']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acute Gouty Arthritis Flares,Novartis Pharmaceuticals,2025-09-01T16:18:09.632975,True,,,,,"An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective",,['Acute Gouty Arthritis Flares'],['gouty arthritis'],,2011-11,2013-05,"[{'measure': 'Number of Incidence Rate (IR) of Adverse Events, Serious Adverse Events and Death Per 100 Patient-years in Participants', 'description': 'Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline,or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.', 'timeFrame': 'From start of the core studies (CACZ885H2357 [NCT01080131] and CACZ885H2361 [NCT01356602]) up to end of the current study (36 weeks)'}]","[{'measure': 'Number of New Flares Per Participant', 'description': 'Flare rate was calculated as the number of new flares over the period of observation in years. New flares occurred before first study medication dose in extension 3 study were considered.', 'timeFrame': 'From start of the core studies (CACZ885H2357 [NCT01080131] and CACZ885H2361 [NCT01356602]) up to end of the current study (36 weeks)'}, {'measure': ""Patient's Assessment of Gout Pain Intensity in the Most Affected Joint"", 'description': 'Participant scored their current pain intensity in the most affected joint of the gout flare on a 5-point Likert Scale (none or mild).', 'timeFrame': 'up to 7 days post-dose'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,136.0,ACTUAL,v2_robust,True,True,False,True,
NCT00002289,The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients,Thymopentin,['Thymopentin'],1,INTERVENTIONAL,['NA'],,COMPLETED,HIV Infections,Immunobiology Research Institute,2025-09-01T16:18:09.633006,True,,,,,Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients,,['HIV Infections'],"['Semen', 'Thymopentin', 'Leukocytes, Mononuclear', 'HIV Seropositivity', 'AIDS-Related Complex']",,,,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,,,v2_robust,True,True,False,False,
NCT04112368,"Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach",Estradiol Transdermal Patch 0.1 mg/24 hrs,"['Placebo capsule', 'Oral Micronized Progesterone 200mg', 'Climara', 'Sugar pill', 'Placebo transdermal patch', 'Estradiol Transdermal Patch 0.1 mg/24 hrs', 'Prometrium', 'Inactive Clear Patch']",8,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Suicidal Ideation,University of Illinois at Chicago,2025-09-01T16:18:09.633014,True,,,,,"Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach",,['Suicidal Ideation'],[],,2020-09-15,2024-08-01,"[{'measure': 'Perimenstrual Change in Daily Adult Suicidal Ideation Questionnaire (ASIQ) Scores', 'description': ""The Adult Suicidal Ideation Questionnaire (ASIQ) is a 25-item self-report questionnaire assessing suicidality. Each day, individuals rate each of 25 items on a scale from 1 (Not at All) to 6 (Extreme). Mean scores are computed, providing a single number for each day that represents the participant's mean suicidal ideation (1 to 6), with higher daily values representing more severe suicidal ideation.\n\nPerimenstrual change scores are calculated for each person in each condition as the mean of scores in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean in the midluteal phase (days +0 to +5). Therefore, positive values represent a perimenstrual increase in suicidal ideation, and negative values represent a perimenstrual decrease."", 'timeFrame': 'Mean daily rating in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean daily rating in the midluteal phase (days +0 to +5)'}, {'measure': 'Perimenstrual Change in Daily Columbia Suicide Severity Rating Scale (C-SSRS) Screening Interview Planning Item Scores', 'description': 'The Columbia Suicide Severity Rating Scale is an interview designed to assess various aspects of suicide risk. In the present study, this questionnaire is administered daily via phone interview as part of a risk screening process. Here, we utilize a single dichotomous outcome from a single item representing suicidal planning from the C-SSRS interview: ""Today, have you thought about how or when you might kill yourself?"". Each day, individuals chose either ""Yes"" (coded as 1) or ""No"" (coded as 0).\n\nPerimenstrual change scores are calculated for each person in each condition as the mean of scores in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean in the midluteal phase (days +0 to +5). Therefore, positive values represent a perimenstrual increase in suicidal planning, and negative values represent a perimenstrual decrease.', 'timeFrame': 'Mean daily rating in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean daily rating in the midluteal phase (days +0 to +5)'}]","[{'measure': 'Perimenstrual Change in Daily Beck Hopelessness Scale (BHS) Short Form Scores', 'description': 'Hopelessness is assessed with a daily Beck Hopelessness Scale (short form), a 10-item self-report measure with true-false items that assess hopelessness and the extent of positive and negative beliefs about the future. Summed scores range from 0 to 10. Scores provide a measure of the severity of self-reported hopelessness, with higher scores representing greater hopelessness.\n\nPerimenstrual change scores are calculated for each person in each condition as the mean of scores in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean in the midluteal phase (days +0 to +5). Therefore, positive values represent a perimenstrual increase in hopelessness, and negative values represent a perimenstrual decrease.', 'timeFrame': 'Mean daily rating in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean daily rating in the midluteal phase (days +0 to +5)'}, {'measure': 'Perimenstrual Change in Daily Brief Agitation Measure (BAM) Scores', 'description': 'Agitation is assessed with a daily Brief Agitation Measure (BAM), a 3-item self-report measure in which participants rate their symptoms of agitation ranging from 0 (Strongly Disagree) to 6 (Strongly Agree). Mean daily scores (ranging from 0 to 6) provide a measure of the severity of self-reported agitation, with higher scores representing greater agitation.\n\nPerimenstrual change scores are calculated for each person in each condition as the mean of scores in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean in the midluteal phase (days +0 to +5). Therefore, positive values represent a perimenstrual increase in agitation, and negative values represent a perimenstrual decrease.', 'timeFrame': 'Mean daily rating in the perimenstrual phase (days +12 to +17 following a positive luteinizing hormone surge in urine on day=0) minus the mean daily rating in the midluteal phase (days +0 to +5)'}]",4.0,18 Years,45 Years,FEMALE,False,OTHER,0.0,90.0,ACTUAL,v2_robust,True,True,False,False,
NCT00149968,Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife),Enteric-Coated Mycophenolate Sodium (EC-MPS),"['Myfortic', 'Enteric-Coated Mycophenolate Sodium (EC-MPS)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Renal Transplantation,Novartis,2025-09-01T16:18:09.633062,True,,,,,Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife),,"['Renal Transplantation', 'Gastrointestinal Problems']","['Renal transplantation', 'MMF', 'EC-MPS', 'GI problems']",,2005-04,2007-01,"[{'measure': 'Changes in gastrointestinal symptom severity after conversion from MMF to enteric-coated mycophenolate sodium', 'timeFrame': 'week 0, week 6-8'}]","[{'measure': 'Gastrointestinal symptoms under MMF-based immunosuppressive therapy', 'timeFrame': 'week 0, week 6-8'}, {'measure': ""Assessment of quality of life, impact of immunosuppressive-induced gastrointestinal symptoms on patient's perception of symptom severity and quality of life"", 'timeFrame': 'week 0, week 6-8'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,196.0,ACTUAL,v2_robust,True,True,False,False,
NCT00642668,A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia,methoxy polyethylene glycol-epoetin beta,"['Mircera', 'methoxy polyethylene glycol-epoetin beta']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Anemia,Hoffmann-La Roche,2025-09-01T16:18:09.633074,True,,,,,Subcutaneous Treatment of Anemia in Patients With a GFR Below 45 ml/Min/1.73m2 Through Injections With Mircera as Low Frequent as Once Monthly (STABILO),,['Anemia'],[],,2008-06-30,2009-12-31,"[{'measure': 'Percentage of Participants Maintaining Average Hemoglobin Concentration During Efficacy Evaluation Period (EEP) Within Target Range', 'description': 'The EEP was week 29 through week 36. The target range for average hemoglobin concentration was 10.0 - 12.0 g/dL.', 'timeFrame': 'Weeks 29-36'}]","[{'measure': 'Change From Baseline in Hemoglobin Concentration to Efficacy Evaluation Period (EEP)', 'description': 'The mean change Baseline Hemoglobin to the time adjusted average of Hemoglobin during the EEP.', 'timeFrame': 'Weeks 0-36'}, {'measure': 'Percentage of Participants Maintaining Hemoglobin Concentrations Within Range of 10-12 Grams/Deciliter (g/dL) Throughout Efficacy Evaluation Period (EEP)', 'timeFrame': 'Weeks 29-36'}, {'measure': 'Mean Time Spent in Hemoglobin Range of 10-12 g/dL During Efficacy Evaluation Period (EEP)', 'timeFrame': 'Weeks 29-36'}, {'measure': 'Percentage of Participants With Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'timeFrame': 'Weeks 1-40'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,35.0,ACTUAL,v2_robust,True,True,False,True,
NCT01513668,A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fed Condition,Acetaminophen,['Acetaminophen'],1,INTERVENTIONAL,['NA'],,COMPLETED,Healthy,Ranbaxy Laboratories Limited,2025-09-01T16:18:09.633272,True,,,,,"An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gel Tabs (Containing Acetaminophen 650 mg) of OHM Laboratories (Subsidiary of Ranbaxy) With Tylenol 8 Hour 650 mg Gel Tabs (Containing Acetaminophen 650 mg) of Mc Neil, Consumer & Speciality Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fed Condition",,['Healthy'],[],,2006-05,2006-07,"[{'measure': 'Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of Acetaminophen', 'timeFrame': '0 to 24 hours'}]",[],1.0,18 Years,39 Years,MALE,True,INDUSTRY,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT00511368,Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*,matching placebo,"['matching placebo', 'PA103001-04', 'PA-457N', 'Bevirimat']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV Infections,Myrexis Inc.,2025-09-01T16:18:09.633312,True,,,,,"Phase 2 Dose-escalating, P-C, D-B, Parallel Group Study in HIV Treatment-experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days *(PART B)",,['HIV Infections'],"['HIV', 'treatment experienced', 'AIDS']",,2006-04,2008-07,"[{'measure': 'HIV-1 RNA change from baseline over the first 14 days of study', 'timeFrame': '14 days'}]","[{'measure': 'safety and tolerability; pharmacokinetics', 'timeFrame': '14 days'}]",2.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,92.0,ACTUAL,v2_robust,True,True,False,True,
NCT01690468,PTX-200 and Carboplatin in Ovarian Cancer,Triciribine,"['TCN', 'Paraplatin®', 'Carboplatin', 'NSC #241240', 'AKT inhibitor', 'triciribine phosphate monohydrate', 'Triciribine', 'TCN-PM']",8,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Ovarian Cancer,"Prescient Therapeutics, Ltd.",2025-09-01T16:18:09.633321,True,,,,,A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer,,['Ovarian Cancer'],[],"Enrollment stopped prior to Phase 1b, change in strategic focus",2014-09,2019-12,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'To determine the maximum tolerated dose of TCN-PM when combined with carboplatin in a Phase I clinical trial of biomarker-selected women with platinum-resistant, recurrent or persistent epithelial ovarian, fallopian tube and primary peritoneal cancer (OVCA).', 'timeFrame': '6 months'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'The best overall response is the best time point response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest sum recorded since baseline).\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.\n\nResponse and progression will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST version 1-1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.', 'timeFrame': '2 years'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Progression-Free Survival (PFS) is defined as the duration of time from study entry to time of progression or death, whichever occurs first.\n\nProgressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).\n\nResponse and progression will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST version 1-1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.', 'timeFrame': '2 years'}, {'measure': 'Duration of Stable Disease (SD)', 'description': 'Stable Disease (SD): Neither sufficient shrinkage to qualify for Partial Response (PR) nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study.\n\nResponse and progression will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST version 1-1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.', 'timeFrame': '2 years'}]",4.0,18 Years,,FEMALE,False,INDUSTRY,0.0,15.0,ACTUAL,v2_robust,True,False,True,False,"Enrollment stopped prior to Phase 1b, change in strategic focus"
NCT06484868,Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy,Metreleptin,['Metreleptin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Partial Lipodystrophy,Amryt Pharma,2025-09-01T16:18:09.633381,True,,,,,"A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy",,['Partial Lipodystrophy'],['Metreleptin'],,2024-02-08,2028-02,"[{'measure': 'Number of patients with decrease of at least 0.5% in glycated haemoglobin (HbA1c) at Month 12 compared to Baseline or HbA1c <6.5 % at Month 12, in patients with baseline HbA1c ≥6.5%.', 'description': 'To evaluate the efficacy (HbA1c) of metreleptin treatment in patients with PL', 'timeFrame': '12 months'}, {'measure': 'Number of patients with decrease of at least 30% in triglycerides (TG) at Month 12 compared to Baseline, in patients with baseline TG levels ≥500 mg/dL (5.65 mmol/L)', 'description': 'To evaluate the efficacy (TG) of metreleptin treatment in patients with PL', 'timeFrame': '12 months'}]","[{'measure': 'Number of patients with decrease of at least 0.5% in HbA1c at Month 24 compared to Baseline or HbA1c <6.5 % at Month 24, in patients with baseline HbA1c ≥6.5%.', 'description': 'To evaluate the long-term efficacy of metreleptin treatment in patients with PL', 'timeFrame': '24 months'}, {'measure': 'Number of patients with decrease of at least 30% in TG levels at Month 24 compared to Baseline, in patients with baseline TG levels ≥500 mg/dL (5.65 mmol/L).', 'description': 'To evaluate the long-term efficacy of metreleptin treatment in patients with PL', 'timeFrame': '24 months'}, {'measure': 'Change from baseline in liver volume at Month 12 and Month 24', 'description': 'To assess changes in liver volume.', 'timeFrame': '12 months and 24 months'}, {'measure': 'Incidence of, Treatment emergent adverse events (TEAEs), Deaths and other serious adverse events (SAEs), Treatment related adverse events (AEs), AEs of special interest (AESIs) and AEs leading to study drug discontinuation', 'description': 'To evaluate the safety of metreleptin treatment in patients with PL', 'timeFrame': '24 months'}]",6.0,12 Years,,ALL,False,INDUSTRY,0.0,12.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00989768,Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A,Botulinum Toxin Type A (Dysport®),"['Botulinum Toxin Type A (Dysport®)', 'Botulinum Toxin Type A/Dysport®', 'Botulinum Toxin Type A/Botox®']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Wrinkles in Frontal Area,Brazilan Center for Studies in Dermatology,2025-09-01T16:18:09.633414,True,,,,,Field Effects of Two Commercial Preparations of Botulinum Toxin Type a Administered to the Frontalis Muscles,,['Wrinkles in Frontal Area'],"['Botulinum toxin type A', 'field effects', 'dose-equivalence', 'anhydrotic action halos']",,2005-05,2007-12,"[{'measure': 'Horizontal Action Halo Diameter at 28 Days', 'description': ""The colorful complex formed by Minor's test allows the visualization of the area covered by the effects of botulinum toxin on sweat glands, also known as action halos. The horizontal diameter at day 28 were expressed in centimeters and quantified by the software Mirror® (Canfield Scientific Inc., USA)."", 'timeFrame': '28 Days'}, {'measure': 'Horizontal Action Halo Diameter at 112 Days', 'description': ""The colorful complex formed by Minor's test allows the visualization of the area covered by the effects of botulinum toxin on sweat glands, also known as action halos. The horizontal diameter at day 112 were expressed in centimeters and quantified by the software Mirror® (Canfield Scientific Inc., USA)."", 'timeFrame': '112 days'}]","[{'measure': 'ECMAP in m. Frontialis', 'description': 'The measurement of the ECMAP(Evoked Compound Muscle Action Potentials) used surface electrodes on the forehead and electrical stimulation of the facial nerve, according to standard neurophysiological procedures. The amplitude of the ECMAP in the m. frontalis on stimulation of the facial nerve was performed by an experienced neurologist. ECMAP was assessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).', 'timeFrame': '28 days'}, {'measure': 'ECMAP in m. Frontialis', 'description': 'The measurement of the ECMAP(Evoked Compound Muscle Action Potentials) used surface electrodes on the forehead and electrical stimulation of the facial nerve, according to standard neurophysiological procedures. The amplitude of the ECMAP in the m. frontalis on stimulation of the facial nerve was performed by an experienced neurologist. ECMAP was assessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).', 'timeFrame': '112 days'}]",4.0,18 Years,60 Years,FEMALE,True,OTHER,0.0,29.0,ACTUAL,v2_robust,True,True,False,False,
NCT04521868,A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients,Sulforaphane,"['Sulforaphane', 'Nutramax']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Schizophrenia,Central South University,2025-09-01T16:18:09.633459,True,,,,,A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Negative Symptoms and Cognition Impairment of Schizophrenia Patients,,['Schizophrenia'],"['schizophrenia', 'sulforaphane']",,2020-08-31,2022-08-12,"[{'measure': 'Change of clinical symptoms by PANSS', 'description': 'The change of Positive And Negative Syndrome Scale (PANSS) total, positive and negative symptoms before and after treatment at different follow up point. The PANSS total score ranges from 30-210 points,the higher the score, the worse the symptoms.', 'timeFrame': '24 weeks'}, {'measure': 'Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score', 'description': 'The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure.The MCCB total score is about 50 in healthy participants, patients with schizophrenia are reported to have scores as low as two standard deviations below the mean points; the higher the score, the better the cognition performance.', 'timeFrame': '24 weeks'}]","[{'measure': 'side effects by TESS', 'description': 'The investigators will evaluate side effect by Treatment Emergent Symptom Scale. It is consisted of behavioural toxicity, laboratory abnormalities, nervous system, automatic nervous system, cardiovascular system and six other aspects, was used to evaluate adverse drug reactions based on the scores, ranging from 0 to 4 (the higher the score, the more serious the adverse reactions).', 'timeFrame': '24 weeks'}, {'measure': 'Change of clinical symptoms by SANS', 'description': 'The change of Scale for Assessment of Negative Symptoms (SANS) to evaluate negative symptoms before and after treatment at different time point. It measures 25 items of negative symptoms across 5 categories: affective blunting, alogia, avolition-apathy, anhedonia-asociality, and inattention, ranging from 0-120.', 'timeFrame': '24 weeks'}, {'measure': 'Change of clinical symptoms of CGI', 'description': 'The change of Clinical Global Impression (CGI) before and after treatment at different follow up point. Its assess Severity of Illness (CGI-S), Global Improvement (CGI-I), and Efficacy Index (CGI-E). CGI-S is a 7-point scale, the higher score means the more severe the illness; CGI-I is a 7 point scale, the higher score means the less improved symptoms after treatment; CGI-E is is a 4×4 rating scale that assesses the therapeutic effect of treatment with psychiatric medication and associated side effects.', 'timeFrame': '24 weeks'}, {'measure': 'Change of psychological, social, and occupational functioning by GAF', 'description': 'The change of Global Assessment of Functioning (GAF) Scale before and after treatment at different follow up point.ranging from 0 to 100.The higher scores means the better functioning performance.', 'timeFrame': '24 weeks'}]",6.0,18 Years,50 Years,ALL,False,OTHER,0.0,125.0,ACTUAL,v2_robust,True,True,False,True,
NCT00135668,Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room,Nitroprusside,"['Sodium Nitroprusside IV infusion 2 mcg/kg/ min', 'Sodium Nitroprusside IV infusion 3 mcg/kg/ min', 'Sodium Nitroprusside IV infusion 1 mcg/kg/ min', 'Sodium Nitroprusside IV infusion 0.3 mcg/kg/ min', 'Nitroprusside']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hypotension,"The Emmes Company, LLC",2025-09-01T16:18:09.633496,True,,,,,"A Phase 2 Multicenter, Randomized, Double-blind, Parallel Group, Dose-ranging, Effect-controlled Study to Determine the Pharmacokinetics and Pharmacodynamics of Sodium Nitroprusside in Pediatric Subjects",,['Hypotension'],"['children', 'sodium nitroprusside', 'controlled hypotension', 'dose-response', 'pharmacokinetics', 'pharmacodynamics', 'safety', 'efficacy']",,2005-08,2009-02,"[{'measure': 'Change in Mean Arterial Pressure (MAP) From the Baseline MAP', 'description': 'From the Baseline MAP until the end of the blinded phase; scheduled for 30 min', 'timeFrame': 'Approximately 30 minutes'}, {'measure': 'Overall Summary of Tolerability/Adverse Events (AEs) for ITT Safety Population', 'description': 'Treatment-emergent AEs (TEAEs) were defined as an AE experienced by the patient that was either first observed after the initiation of study drug (blinded or open-label) or represented an exacerbation (usually in severity) of a pre existing condition observed prior to treatment. Subjects will be followed for 30 days after discontinuation of study drug. The occurrence of Serious Adverse Events (SAEs) will be monitored for 30 days.', 'timeFrame': '30 days'}]","[{'measure': 'Change From Baseline MAP Nitroprusside Infusion During the Blinded Infusion;', 'description': 'Change From Baseline in MAP (mmHg) After 20 and 25 Minutes Double-Blind Infusion (Overall) for ITT Efficacy Evaluable Population.', 'timeFrame': '25 minutes'}, {'measure': 'Infusion Rate of Sodium Nitroprusside That Reduces MAP to a Predetermined Clinically Meaningful Target Value +/- 10%;', 'description': 'Infusion rate of sodium nitroprusside at which a predetermined clinically meaningful target value (+/- 10%) of MAP was achieved during study drug administration', 'timeFrame': 'Up to the end of open label treatment (Approximately 120 minutes)'}, {'measure': 'Number of Participants Who Reach Target MAP;', 'description': 'Blinded Study Drug Administration Period: Started with study drug administration following stabilization of anesthesia. Patients were administered a blinded dose of SNP for up to 30 mins.\n\nThis period ended at the start of open-label study drug infusion or at the completion of the blinded infusion if no open-label study drug was given. The follow-up period immediately followed for those patients not receiving open-label infusion.\n\nBlinded Treatment Phase II - gap between the end of blinded study drug infusion and the start of open-label study drug infusion\n\nOpen-label treatment phase began with the start of open-label study drug infusion and was at least 90 mins in duration. SNP was initiated at a dose deemed appropriate by the investigator and was gradually adjusted to reach a target MAP based on clinical presentation and needs of the patient. Target MAP was not to be \\< 50 mmHg (40 mmHg for patients \\< 30 days of age). This period ended at the completion of open-label infusion.', 'timeFrame': 'To the end of open label treatment (approximately 120 minutes)'}]",5.0,,17 Years,ALL,False,INDUSTRY,2.0,211.0,ACTUAL,v2_robust,True,True,False,True,
NCT02796950,The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion,Acipimox,"['Acipimox', 'Olbetam']",2,INTERVENTIONAL,['NA'],,COMPLETED,Diabetes Mellitus Type 2,University of Aarhus,2025-09-01T16:18:09.633506,True,,,,,The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study,,['Diabetes Mellitus Type 2'],"['Acipimox', 'GLP-1', 'Insulin secretion']",,2016-06,2017-01-20,"[{'measure': 'Levels of GLP-1 in plasma', 'timeFrame': '9 months'}]","[{'measure': 'Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels', 'timeFrame': '9 months'}, {'measure': 'Insulin sensitivity by measuring blood glucose after an OGTT', 'timeFrame': '5 months'}]",3.0,20 Years,50 Years,MALE,True,OTHER,0.0,8.0,ACTUAL,v2_robust,True,True,False,False,
NCT01762150,Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma,Sorafenib,"['Gemzar', 'Nexavar', 'Cisplatin', 'Gemcitabine', 'Cis-Dichlorodiamineplatinum', 'Sorafenib']",6,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Renal Cell Carcinoma,Peking University Cancer Hospital & Institute,2025-09-01T16:18:09.633517,True,,,,,"Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma:A Pilot, Open Study",,['Renal Cell Carcinoma'],"['collected duct carcinoma', 'sorafenib']",,2011-06,2018-06,"[{'measure': 'progress-free survival,PFS', 'description': 'Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause.', 'timeFrame': 'Time from enrollment to the dates of disease progression,death from any cause or last tumor assessment reported between date of first patient enrollment until 30 June 2015 cut of date'}]","[{'measure': 'adverse event, AE', 'description': 'Any events,no matter related to interventions,occur during the period from the enrollment to death or 30 days after withdrawal from the trial', 'timeFrame': 'Time from enrollment to the dates of disease progression,death from any cause or last tumor assessment reported between date of first patient enrollment until 30 June 2015 cut of date'}]",2.0,18 Years,70 Years,ALL,False,OTHER,1.0,26.0,ACTUAL,v2_robust,True,True,False,True,
NCT07001150,Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease,levodopa-carbidopa,"['levodopa-carbidopa', 'Silymarin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Parkinson Disease,Tanta University,2025-09-01T16:18:09.633541,True,,,,,Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease,,['Parkinson Disease'],[],,2025-06-30,2026-05-30,"[{'measure': ""Unified Parkinson's Disease Rating Scale (UPDRS)"", 'description': ""The Unified Parkinson's Disease Rating Scale (UPDRS) is a rating tool used to determine the severity and progression of Parkinson's disease in patients"", 'timeFrame': '6 months'}]",[],1.0,45 Years,65 Years,ALL,False,OTHER,2.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06022250,"The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor",JS207,['JS207'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Advanced Malignant Tumor,"Shanghai Junshi Bioscience Co., Ltd.",2025-09-01T16:18:09.633602,True,,,,,"A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor",,['Advanced Malignant Tumor'],[],,2023-09-26,2026-06-30,"[{'measure': 'Dose-limiting toxicity （DLT）、adverse event（AE）', 'description': 'Incidence and severity of DLT, adverse events (AE), Abnormal changes in laboratory and other tests with clinical significance', 'timeFrame': '2 Years'}, {'measure': 'Maximum tolerated dose (MTD),RP2D', 'description': 'Maximum tolerated dose (MTD), Recommended dose for phase II trial', 'timeFrame': '2 Years'}]","[{'measure': 'Peak concentration（Cmax）', 'description': 'The highest plasma drug concentration that can be achieved after medication', 'timeFrame': '2 years'}, {'measure': 'Time to peak（Tmax）', 'description': 'After a single dose, the time of peak blood concentration', 'timeFrame': '2 years'}, {'measure': 'Elimination half life（t1/2）', 'description': 'The time it takes the blood to reduce the concentration of the drug to half', 'timeFrame': '2 years'}, {'measure': 'Progression free survival(PFS)', 'description': 'The time from first dose to Disease progression or death', 'timeFrame': '2 years'}, {'measure': 'Overall survival (OS)', 'description': 'The time from first dose to death from any cause', 'timeFrame': '2 years'}, {'measure': 'Immunogenicity', 'description': 'Incidence of Anti-Drug Antibody (ADA)', 'timeFrame': '2 years'}, {'measure': 'Objective response rate (ORR) based on Response Evaluation Criteria In Solid Tumors 1.1 (RECIST1.1)', 'description': 'Defined as the proportion of subjects who achieved partial response (PR) or complete response (CR)', 'timeFrame': '2 years'}]",9.0,18 Years,80 Years,ALL,False,OTHER,1.0,192.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05413850,Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection,Lutetium (177Lu) rhPSMA-10.1 Injection,"['Lutetium (177Lu) rhPSMA-10.1 Injection', '177Lu-rhPSMA-10.1']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Prostate Cancer,Blue Earth Therapeutics Ltd,2025-09-01T16:18:09.633613,True,,,,,"An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer",,"['Prostate Cancer', 'Metastatic Castration-resistant Prostate Cancer', 'mCRPC', 'Urogenital Neoplasms', 'Prostatic Neoplasms', 'Prostatic Diseases']","['PSMA', 'mCRPC', 'Prostate cancer', '177Lu rhPSMA-10.1', '18F-rhPSMA-7.3', 'BET-PSMA-121', 'Blue Earth Therapeutics Limited', 'Radiohybrid', 'Radiopharmaceuticals']",,2022-07-20,2028-03-31,"[{'measure': 'Phase 1 Incidence of DLTs', 'description': 'Incidence of DLTs during the DLT observation period.', 'timeFrame': '6 weeks post final IMP'}, {'measure': 'Phase 1 Frequency and nature of TEAEs', 'description': 'Frequency and nature of treatment-emergent adverse events (TEAEs).', 'timeFrame': 'End of study'}, {'measure': 'Phase 2 Evaluate the efficacy of Lutetium (177Lu) rhPSMA-10.1 Injection', 'description': 'The number of subjects with an anti-tumour response defined as ≥50% reduction in PSA level from baseline to the end of treatment.', 'timeFrame': '6 weekly intervals'}]",[],3.0,18 Years,,MALE,False,INDUSTRY,1.0,82.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03389750,A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.,Intravenous Challenge Drug,"['Intravenous Challenge Drug', 'Oxycodone, Oxymorphone, Hydromorphone, or Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Opioid Use Disorder,New York State Psychiatric Institute,2025-09-01T16:18:09.633630,True,,,,,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists in Physically Dependent Opioid Users With Moderate-to-Severe Opioid Use Disorder",,['Opioid Use Disorder'],[],,2018-03-15,2023-06-28,"[{'measure': 'Positive Subjective Drug Effects (i.e., Drug ""Liking"").', 'description': 'The positive subjective effects of the most efficacious dose of the intravenous challenge drugs. These are measured using self-reported assessment by the participant in terms of drug ""liking"" rated on a visual analog scale of 0-100. Higher values indicate a greater drug effect.', 'timeFrame': 'Throughout study enrollment period (8-9 weeks)'}]",[],1.0,21 Years,55 Years,ALL,False,OTHER,1.0,16.0,ACTUAL,v2_robust,True,True,False,False,
NCT00818350,Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer,SUNITINIB,"['SUTENT', 'SUNITINIB']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Urinary Bladder Neoplasms,Campania Younger Oncologists Association,2025-09-01T16:18:09.633640,True,,,,,Phase II Study of Sunitinib in Metastatic and Pretreated Urothelial Cancer,,['Urinary Bladder Neoplasms'],[],,2009-01,2011-01,"[{'measure': 'To determine the antitumor efficacy ( response rate) of sunitinib', 'timeFrame': '12 weeks'}]","[{'measure': 'QOL', 'timeFrame': '6 WEEKS'}, {'measure': 'TOXICITY ACCORDING NCI VERSION 3 CRITERIA', 'timeFrame': 'EVERY WEEK'}]",3.0,18 Years,75 Years,ALL,True,OTHER,0.0,25.0,ACTUAL,v2_robust,True,False,False,False,
NCT03469050,Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.,Rifaximin delayed released 400mg Tablet,"['Rifaximin-EIR', 'Rifaximin delayed released 400mg Tablet']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Diverticulitis,Alfasigma S.p.A.,2025-09-01T16:18:09.633656,True,,,,,"Rifaximin Delayed Release (400 mg Tablet) for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. A Phase II, Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial",,['Diverticulitis'],"['Recurrent acute diverticulitis', 'Prevention', 'Diverticular complications', 'Rifaximin delayed release', 'Diverticulitis', 'SIBO']",Sponsor's decision,2018-07-02,2020-12-22,"[{'measure': 'Rate of patients with recurrence of diverticulitis and/or diverticular complications over the 12-month treatment period.', 'timeFrame': '12-month treatment period'}]","[{'measure': 'Rate of patients with an acute episode of prolonged (≥24 hours) left-lower quadrant abdominal pain plus leukocytosis/elevation of CRP [Time Frame: 12-month treatment period]', 'timeFrame': '12-month treatment period'}, {'measure': 'Time to diverticulitis recurrence or complication', 'timeFrame': '12-month treatment period'}, {'measure': 'Rate of patients with diverticulitis-associated fever', 'timeFrame': '12-month treatment period'}, {'measure': 'Left-lower quadrant abdominal pain intensity', 'timeFrame': '12-month treatment period'}, {'measure': 'Left-lower quadrant abdominal pain duration', 'timeFrame': '12-month treatment period'}, {'measure': 'Number of days in a year with left-lower quadrant abdominal pain', 'timeFrame': '12-month treatment period'}, {'measure': 'Number of weeks in a year with episodes of prolonged (≥24 hours) left-lower quadrant abdominal pain', 'timeFrame': '12-month treatment period'}, {'measure': 'Number of days in a year with any abdominal pain', 'timeFrame': '12-month treatment period'}, {'measure': 'Number of weeks in a year with bloating', 'timeFrame': '12-month treatment period'}, {'measure': 'Change in bowel habits', 'description': 'Evaluated by Bristol Stool Scale', 'timeFrame': '12-month treatment period'}, {'measure': 'Rate of any hospitalization for diverticulitis', 'timeFrame': '12-month treatment period'}, {'measure': 'Rate of hospitalization for diverticulitis without surgery', 'timeFrame': '12-month treatment period'}, {'measure': 'Rate of elective surgery for diverticulitis', 'timeFrame': '12-month treatment period'}, {'measure': 'Rate of emergency surgery for diverticulitis', 'timeFrame': '12-month treatment period'}, {'measure': 'Change in Quality of Life', 'description': 'Evaluated by SF36 Quality of Life Questionnaire', 'timeFrame': '12-month treatment period'}]",16.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,193.0,ACTUAL,v2_robust,True,False,True,False,Sponsor's decision
NCT00299650,Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients,cisatracurium,"['Cisatracurium besilate', 'Placebo', 'cisatracurium']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,ARDS,Assistance Publique Hopitaux De Marseille,2025-09-01T16:18:09.633689,True,,,,,Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients,,['ARDS'],"['ARDS', 'mortality', 'mechanical ventilation', 'pneumonia', 'muscle relaxants']",,2006-03,2008-10,"[{'measure': 'Reduction of the mortality rate of ARDS patients at d90', 'timeFrame': '36 months'}]","[{'measure': 'Mortality at day 28, day 60, day 180 and ICU mortality, Ventilator-free days and alive at day 28 and day 60, Exposure time to FIO2 > 80% or PEEP > 10 cmH2O during the first 7 days, Sedatives and analgesics requirements during the first 7 days', 'timeFrame': 'march 2009'}, {'measure': 'Organ failure-free days and alive at day 28, Incidence of barotrauma, Incidence of critical illness neuromyopathy, Incidence of ventilator-associated pneumonia, Quality of life at day 180', 'timeFrame': 'march 2009'}]",3.0,18 Years,90 Years,ALL,False,OTHER,1.0,340.0,ESTIMATED,v2_robust,True,True,False,False,
NCT06776250,Study of How Safe and Effective Tarlatamab is in Brain Cancers,Tarlatamab,['Tarlatamab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Astrocytic Tumor,"University Health Network, Toronto",2025-09-01T16:18:09.633700,True,,,,,"A Phase II Study Evaluating the Safety, Efficacy, and Intracranial Activity of Tarlatamab in Recurrent/Refractory Gliomas With IDH Mutation (TARGID)",,"['Astrocytic Tumor', 'Oligodendroglial Tumor']",[],,2025-03-03,2028-03-03,"[{'measure': 'Percent change in CD8+ T cell infiltrate', 'timeFrame': '3 years'}]","[{'measure': 'Percent change in CD3/CD45RA/RO T cells', 'timeFrame': '3 years'}, {'measure': 'Percent change in T cell subsets', 'timeFrame': '3 years'}, {'measure': 'Percentage change in M1 vs M2 macrophage populations', 'timeFrame': '3 years'}, {'measure': 'Tumour concentrations of tarlatamab', 'timeFrame': '3 years'}, {'measure': 'Serum concentrations of tarlatamab', 'timeFrame': '3 years'}]",6.0,18 Years,,ALL,False,OTHER,1.0,44.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06916650,"Comparing HILT, Steroid Injection, and Manual Therapy for Frozen Shoulder",Ultrasound-Guided Intra-articular Corticosteroid Injection,['Ultrasound-Guided Intra-articular Corticosteroid Injection'],1,INTERVENTIONAL,['NA'],,RECRUITING,Frozen Shoulder,Al Hayah University In Cairo,2025-09-01T16:18:09.633712,True,,,,,"Comparative Effectiveness of High-Intensity Laser Therapy Versus Corticosteroid Injection Versus Manual Therapy, Each Combined With Standard Exercise, for Frozen Shoulder (Adhesive Capsulitis): A Randomized Controlled Trial",,['Frozen Shoulder'],[],,2025-04-25,2027-08-01,"[{'measure': 'Change in Shoulder Pain Intensity', 'description': 'Visual Analogue Scale (VAS) for Pain. Change from baseline in average shoulder pain over the past week, measured on a 10 cm horizontal VAS, where 0 cm = no pain and 10 cm = worst imaginable pain. Lower scores indicate less pain. MCID estimated at 1.4 cm.', 'timeFrame': 'Baseline (T0), 6 weeks (T1), 12 weeks (T2), 6 months (T3)'}, {'measure': 'Change in Shoulder Pain and Disability', 'description': 'Shoulder Pain and Disability Index (SPADI). Change from baseline in the total SPADI score. SPADI consists of 13 items assessing pain (5 items) and disability (8 items). Total score ranges from 0-100, with lower scores indicating less pain and disability.', 'timeFrame': 'Baseline (T0), 6 weeks (T1), 12 weeks (T2), 6 months (T3)'}]","[{'measure': 'Change in Passive Shoulder Range of Motion (ROM)', 'description': 'Change from baseline in passive shoulder ROM measured in degrees for: External Rotation (at side), Abduction (in scapular plane), Flexion, and Internal Rotation (vertebral level reached). Measured using a standard goniometer.', 'timeFrame': 'Baseline (T0), 6 weeks (T1), 12 weeks (T2), 6 months (T3)'}, {'measure': 'Patient Global Rating of Change', 'description': 'Global Rating of Change (GRC) Scale. Patient\'s self-rated overall change in their shoulder condition since starting the study, measured on a Likert scale (e.g., 7-point scale from ""very much worse"" to ""very much improved""). Assessed relative to baseline.', 'timeFrame': '6 weeks (T1), 12 weeks (T2), 6 months (T3)'}, {'measure': 'Incidence of Adverse Events', 'description': 'Number, type, and severity of any adverse events (AEs) reported by participants or observed by study staff throughout the study duration, categorized by potential relationship to the assigned intervention (e.g., post-injection flare, skin reaction to HILT, increased pain after manual therapy/exercise).', 'timeFrame': 'Throughout study participation (up to 6 months)'}]",5.0,40 Years,70 Years,ALL,False,OTHER,0.0,180.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00927550,Lithium and Standard Therapy in Resistant Depression,lithium,"['lithium', 'usual care', 'Carbolithium']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Depression,Universita di Verona,2025-09-01T16:18:09.633895,True,,,,,"Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial",,['Depression'],"['resistant depression', 'lithium', 'RCT', 'lithium therapy', 'standard therapy']",,2009-06,2012-12,"[{'measure': 'Suicide completion and acts of deliberate self harm (DSH) will constitute the composite primary outcome', 'timeFrame': 'One year'}]","[{'measure': 'All-cause mortality', 'timeFrame': 'One year'}, {'measure': 'Suicide mortality', 'timeFrame': 'One year'}, {'measure': 'Deliberate self-harm or attempted suicide', 'timeFrame': 'One year'}, {'measure': 'Change in severity of depressive symptoms from baseline', 'timeFrame': 'One year'}, {'measure': 'Adverse reactions during the study', 'timeFrame': 'One year'}]",6.0,18 Years,,ALL,False,OTHER,0.0,230.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02961491,Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma,Ultratrace Iobenguane I131,"['Ultratrace Iobenguane I131', 'Azedra', 'MIBG']",3,EXPANDED_ACCESS,[],,APPROVED_FOR_MARKETING,Pheochromocytoma,"Molecular Insight Pharmaceuticals, Inc.",2025-09-01T16:18:09.633994,True,,,,,Expanded Access Program of AZEDRA (Ultratrace Iobenguane I131) in Subjects With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma: A Sub-study of Protocol MIP-IB12B,,"['Pheochromocytoma', 'Paraganglioma']","['MIBG', 'Azedra', 'Rare neuroendocrine tumors', 'Iobenguane I 131', 'Progenics']",,,,[],[],0.0,12 Years,,ALL,,INDUSTRY,0.0,,,v2_robust,False,False,False,False,
NCT03498391,A Study of Human Multi-Sensory Integration,Propofol,"['Propofol', 'Ketalar', 'Ketamine Injectable Product', 'Diprivan']",4,INTERVENTIONAL,['PHASE2'],PHASE2,SUSPENDED,Anesthesia Awareness,University of Pennsylvania,2025-09-01T16:18:09.634020,True,,,,,A Study of Human Multi-Sensory Integration: A Neurophysiologic Correlate of Conscious Perception,,['Anesthesia Awareness'],[],Due to the impact of COVID-19,2018-07-30,2023-05,"[{'measure': 'Multi-sensory Evoked Responses Measured using Electroencephalography', 'description': 'The primary study endpoint is multi-sensory evoked responses measured using EEG in units of millivolts squared per hertz at Richmond Agitation and Sedation Scale scores of 0, -1, -2, -3 and -4. Multisensory evoked responses will be compared to those evoked by each uni-sensory modality (auditory and visual) individually. Evoked responses will be assessed in the frequency domain using spectral analysis techniques which quantify power of each neuronal oscillation (e.g. alpha, delta, theta and gamma) in terms of mV\\^2/Hz. Analysis will be performed separately during the period before drug administration and at different levels of sedation quantified with RASS scores. The investigators will test the hypothesis that with increasing doses of intravenous anesthetics, audiovisual (multisensory) responses will approximate algebraic sum of neuronal responses elicited by visual and auditory stimuli presented separately.', 'timeFrame': '2-6 hours per subject'}]","[{'measure': 'Single Modality Evoked Potentials', 'description': 'The secondary endpoint is to use EEG recordings to demonstrate changes in the characteristics of evoked potentials under anesthesia using single sensory modality (visual, auditory) and across sensory modalities. Conventional evoked potentials will be computed as average waveforms aligned with respect to stimulus onset on a channel-by-channel basis.', 'timeFrame': '2-6 hours per subject'}]",2.0,18 Years,65 Years,ALL,True,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,True,False,Due to the impact of COVID-19
NCT00183391,Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children,Atomoxetine,"['Atomoxetine', 'Methylphenidate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Attention Deficit Disorder With Hyperactivity,Icahn School of Medicine at Mount Sinai,2025-09-01T16:18:09.634041,True,,,,,Measuring and Predicting Response to Atomoxetine and Methylphenidate,,['Attention Deficit Disorder With Hyperactivity'],"['ADHD', 'Child', 'Adolescent', 'School']",,2005-07,2011-06,"[{'measure': 'ADHD-RS Total Score', 'description': 'ADHD-RS Total Score Attention Deficit Hyperactivity Disorder Rating Scale. Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. Higher score indicates higher probability of diagnosis.', 'timeFrame': 'up to 14 weeks'}]","[{'measure': 'Treatment Preference Survey', 'timeFrame': 'Measured at ends of treatments one and two'}, {'measure': 'ADHD - H/I', 'description': 'Attention deficit/hyperactivity disorder - hyperactivity/impulsivity (ADHD- H/I). Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'ADHD-RS Inattention', 'description': 'Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Clinical Global Impressions (CGI)- Severity', 'description': ""The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill."", 'timeFrame': 'up to 14 weeks'}, {'measure': 'Social Skills Rating Scale (SSRS)- Parent Version', 'description': 'Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Child Conflict Index (CCI)', 'description': 'Measure of conflict within the home over the past 24 hours. The CCI is a validated measure of family conflicts in the home and is completed by parents. It consists of 42 items (for boys) or 36 items (for girls) reflecting attention-seeking and conflictual behavior, as well as negativity and withdrawal. Items are scored as yes (1 point) or no (0 points). Mean score between 0 and 1 reported, with higher score indicating greater conflict.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Continuous Performance Test (CPT)', 'description': 'CPT Commissions, impulsive responses, higher score is worse. This scale is based on t-scores and does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': ""Children's Sleep Questionnaire"", 'description': ""Children's Sleep Problems Severity, sum of scores, higher is worse.The scale assessed contains 16 items, each scored 0 to 3, with 0 representing no problems and 3 representing daily problems. total range from 0 to 48. This score does not have psychometrics available."", 'timeFrame': 'up to 14 weeks'}, {'measure': 'Assessment of Affective Range (AAR)', 'description': 'Affective problems. This scale consists of 8 items, scored 0-3, with 0 representing no problems and 3 representing extreme problems. This analysis presents sum of scores, higher is worse. Full range from 0 to 24. This score does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Tics: Total Motor', 'description': 'Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Tics: Total Phonic', 'description': 'Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Tics: Total Impairment', 'description': 'Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Vital Signs - Systolic Blood Pressure', 'description': 'Systolic blood pressure - the amount of pressure in arteries during contraction of the heart muscle Normal range varies by age, sex, height and weight and can range from 80mm Hg to 130mmHg', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Vital Signs - Diastolic Blood Pressure', 'description': 'Diastole blood pressure - blood pressure when the heart muscle is between beats. normal range varies by age, sex, height and weight and can range from 34mm Hg to 90mmHg', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Vital Signs - Pulse', 'description': 'Heartbeats per minute. Range varies from 50-205 depending on age and level of activity.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'SES (Hollingshead)', 'description': 'Measure of socioeconomic status, score calculated from averaging likert responses, lower = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Conners-Wells Adolescent Self Report', 'description': 'Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Conners Teacher Rating Scale- Short', 'description': 'Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Child Behavior Checklist (CBCL)', 'description': 'CBCL Total Score, measure of psychosocial problems, higher is worse.', 'timeFrame': 'Measured at screening'}, {'measure': 'Social Skills Rating Scale (SSRS)- Teacher Version', 'description': 'Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Permanent Mathematics Product Test (PERMP)', 'description': 'Measure of fluency in performance of simple mathematics, sum, lower = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Actigraphy', 'description': 'Measure of physical activity', 'timeFrame': 'Measured daily throughout the study'}, {'measure': 'Sleep Logs', 'description': 'Questionnaire, qualitative', 'timeFrame': 'Measured daily throughout the study'}, {'measure': 'Hyperactivity, Attention, and Learning Problems (HALP) Medical and Developmental History Questionnaire', 'description': 'Questionnaire, qualitative designed to collect family history, prenatal environmental influences, and developmental history.', 'timeFrame': 'Measured at screening'}, {'measure': 'HALP Rebound Effects Questionnaire', 'description': 'Questionnaire, qualitative assesses symptoms of rebound (moodiness, irritability, aggression, and ADHD symptoms) when the medication wears off at night.', 'timeFrame': 'up to 14 weeks'}]",26.0,6 Years,17 Years,ALL,False,OTHER,1.0,232.0,ACTUAL,v2_robust,True,True,False,False,
NCT01831791,A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia,Dutasteride 0.5 mg,['Dutasteride 0.5 mg'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Alopecia,GlaxoSmithKline,2025-09-01T16:18:09.634173,True,,,,,Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia,,['Alopecia'],"['male pattern hair loss', 'hair growth', 'hair restoration', 'Dutasteride', 'Androgenetic alopecia', 'safety', 'efficacy']",,2013-04-14,2014-07-19,"[{'measure': 'Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)', 'description': 'An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, drug-induced liver injury, breast cancer in male participants, prostate cancer, spontaneous abortion in female partner of male participants', 'timeFrame': 'From Baseline (Week 0) until Week 52'}, {'measure': 'Number of Participants With Drug-related, Treatment-emergent AEs and AE Leading to Premature Study Drug Discontinuation and Possible Suicidality-related Adverse Event (PSRAE)', 'description': ""An AE is considered drug-related if the relationship variable indicates so, or if the variable value is missing. Any AE with a start date on or after the treatment start date and on or before the last dose of treatment is considered on-treatment (treatment-emergent). This includes an AE with a missing onset date. Any AE which occurred, in the investigator's judgement and is possibly related to suicidality, is defined as possible suicidality-related adverse event (PSRAE). Suicidality was assessed by using the columbia-suicide severity rating scale (C-SSRS) as determined by the investigator. The C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors."", 'timeFrame': 'From Baseline (Week 0) until Week 52'}, {'measure': 'Number of Participants With Change From Baseline in Breast Examination Results Any Time Post-Baseline Visit', 'description': ""A qualitative breast examination was performed at Baseline (Week 0), at the Week 26 Visit and at the Week 52 Visit (and at the early withdrawal visit, if applicable). Participants were assessed for presence (reported as yes) and absence (reported as no) of palpable breast tissue (PBT) or nipple tenderness (NT) and/or clinically significant (CS) PBT or NT at Baseline (BL), at each scheduled Post-BL assessment. Change from BL in breast examination results included the number of participants with change from 'no (N)' at BL to 'yes (Y)' at any Post-BL assessment for the presence of PBT or NT, and the number of participants with change from N at BL in CS to Y at any Post-BL assessment in CS for PBT and for NT. BL value of an assessment is defined as the latest assessment on or before the BL date (latest non-missing value of either the treatment start date or the randomization date)."", 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Mean Change From Baseline in Hemoglobin, Albumin and Total Protein at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of hemoglobin, albumin and total protein at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the hemoglobin, albumin and total protein values are summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Hematocrit at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of hematocrit at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the hematocrit value is summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Platelet Count and White Blood Cell Count at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of platelet count and white blood cell count at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the platelet count and white blood cell count values are summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Red Blood Cells Count at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of the red blood cell count at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the red blood cell count value is summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of ALT, ALP and AST at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the ALT, ALP and AST values are summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Total Bilirubin and Creatinine at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of total bilirubin and creatinine at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the total bilirubin and creatinine values are summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Potassium, Sodium, Glucose and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of potassium, sodium, glucose and urea/BUN at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the potassium, sodium, glucose and urea/BUN values are summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Prostate-specific Antigen at the Indicated Time Points', 'description': 'Blood samples were collected for the measurement of prostate-specific antigen at Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. Change from Baseline in the prostate-specific antigen value is summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Number of Participants With Any Laboratory Value Shifts From Baseline at Any Time Post-baseline', 'description': 'Blood samples for the assessment of the indicated laboratory parameters were taken at the Baseline, Week 26 and Week 52 visits and the early withdrawal visit where applicable. The laboratory parameters included ALP, ALT, AST, total bilirubin, total protein, sodium, potassium, albumin, glucose, creatinine, urea/BUN, hemoglobin, hematocrit, red blood cell (RBC) count, platelet count, white blood cell (WBC) count, and prostate-specific antigen (PSA). A laboratory value (LV) that is within the normal range is considered normal. A LV that is above the upper limit of the normal range is considered high abnormal. A LV that is below the lower limit of the normal range is considered low abnormal. Number of participants with any LV shifts from BL at any time post-BL are presented for, normal at BL to abnormal; normal at BL to high; normal at BL to low; normal or low at BL to high; normal or high at BL to low.', 'timeFrame': 'Baseline, Week 26 and 52 visits and/or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at the Indicated Time Points', 'description': 'Blood pressure measurements were taken to observe vital signs and included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the Screening visit, Baseline visit, Weeks 13, 26, 39, and 52 visits and the early withdrawal visit if applicable. Change from Baseline in SBP and DBP is summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline, Weeks 13, 26, 39, and 52 visits and or early withdrawal visit'}, {'measure': 'Mean Change From Baseline in Heart Rate at the Indicated Time Points', 'description': 'Vital sign monitoring included heart rate measurement at the Screening visit, Baseline visit, Weeks 13, 26, 39, and 52 visits and the early withdrawal visit if applicable. Change from Baseline in heart rate is summarized for each post-Baseline assessment as well as for the final assessment (the last post-Baseline value in the study \\[final value\\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date).', 'timeFrame': 'Baseline visit, Weeks 13, 26, 39, and 52 visits and or early withdrawal visit'}, {'measure': 'Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'The C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. The number of participants answering yes/no responses to questions about suicidal ideation (Question \\[Que\\] 1 and Que 2) at Baseline and post-Baseline (since last visit) and suicidal behaviors (Que 6 - Que 10) at post-Baseline (since last visit) are presented. Questions included the presence (yes) or absence (no) of the following: Que 1 - a wish to be dead; Que 2 - nonspecific (NS) active suicidal thoughts; Que 6 - preparatory acts or behavior; Que 7 - aborted attempt; Que 8 - interrupted attempt (int. att.); Que 9 - non-fatal actual suicide attempt; Que 10 - completed suicide and non-suicidal self-injurious behavior. Final assessment (FA) is the last post-Baseline measurement during the study.', 'timeFrame': 'Baseline, Week 26 and Week 52'}]","[{'measure': 'Mean Change From Baseline (BL) in Target Area Hair Count Within a 2.54 Centimeter (cm) Diameter Circle at Week 26 and Week 52', 'description': 'Target area hair count is based on the nonvellus hair(\\>= 30 micrometer\\[μm\\] in width) count within a target 2.54cm(1 inch) diameter circle at the vertex and was assessed by macrophotographic technique. A cosmetic ink dot was placed by means of a tattoo at BL on the scalp in the center of the circle as a marker to guide the placement of the hair count area at subsequent time points. If the ink dot faded between study visits, it was redone. For the macrophotography, hair was clipped before each photograph. Change from BL is defined as post-BL value minus BL value. The BL value is defined as the latest assessment on or before the BL date(latest non-missing value of either treatment start date or randomization date). The last observation carried forward(LOCF) method for missing data was used by carrying forward the last non-missing post-BL assessment value for participants with missing data and/or for participants who discontinued from the study.', 'timeFrame': 'Baseline, Week 26, and Week 52'}, {'measure': 'Mean Change From Baseline (BL) in Target Area Hair Width Within a 2.54 cm Diameter Circle at Week 26 and Week 52', 'description': 'Target area hair width was based on the total width of the nonvellus hairs(\\>=30μm in width) within a target 2.54cm(1 inch) diameter circle at the vertex and was assessed by macrophotographic technique. A cosmetic ink dot was placed by means of a tattoo at BL on the scalp in the center of the circle as a marker to guide the placement of the hair count area at subsequent time points. If the ink dot faded between study visits, it was redone. For the macrophotography, hair was clipped before each photograph. Change from BL is defined as the post-BL value minus the BL value. The BL value of an assessment is defined as the latest assessment on or before the BL date(latest non-missing value of either the treatment start date or the randomization date). The LOCF method for missing data was used by carrying forward the last non-missing post-BL assessment value for participants with missing data and/or for participants who discontinued from the study.', 'timeFrame': 'Baseline, Week 26, and Week 52'}, {'measure': 'Mean Change From Baseline (BL) in Terminal Hair Count Within a 2.54 cm Diameter Circle at Week 26 and Week 52', 'description': 'Terminal hair count was based on the terminal hair(\\>=60 μm in width) count within a target 2.54cm(1 inch) diameter circle at the vertex and was assessed by macrophotographic technique. A cosmetic ink dot was placed by means of a tattoo at BL on the scalp in the center of the circle as a marker to guide the placement of the hair count area at subsequent time points. If the ink dot faded between study visits, it was redone. For the macrophotography, hair was clipped before each photograph. Change from BL is defined as the post-BL value minus the BL value. BL value of an assessment is defined as the latest assessment on or before the BL date(latest non-missing value of either the treatment start date or the randomization date). The LOCF method for missing data was used by carrying forward the last non-missing post-BL assessment for participants with missing data and/or for participants who discontinued from the study.', 'timeFrame': 'Baseline, Week 26 and Week 52'}, {'measure': 'Mean of Median Score for Panel Global Assessment of Improvement From Baseline to 26 Weeks and 52 Weeks for Vertex and Frontal Views', 'description': 'A central panel of 3 dermatologists independently assessed change in hair growth from Baseline to Week 26 and Week 52 using a 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). The median score, across the 3 panel members, is summarized. This assessment was performed by comparing the global photographs obtained at Baseline (Screening) with those subsequently obtained at Week 26 and Week 52. This assessment was made separately based on the global photography of the vertex and frontal views. The LOCF method for missing data was used for the assessment, if a participants was missing the Week 26 global photograph, but has a global photograph from an earlier assessment (i.e., a withdrawal visit), then that photograph was assessed during the panel review.', 'timeFrame': 'Baseline, Week 26 and Week 52'}, {'measure': 'Number of Participants With the Indicated Change From Baseline (BL) in the Stage of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at 26 Weeks and 52 Weeks', 'description': 'The investigator/designee assessed the stage (Stage I to Stage VII) of AGA (i.e., male pattern baldness \\[MPB\\]) by utilizing the Norwood-Hamilton scale, used to measure the progression of MPB. Stage VII indicates worse balding than Stage I. Assessment was made by direct visual examination (aided by pictures) of the participant at Screening (Baseline), Week 26, and Week 52. ""v,"" vertex; most of the hair loss (commonly seen with advancing age) is on the vertex. ""a,"" type a variant; major features are (1) the entire anterior hairline border recedes in unison; (2) there is no simultaneous balding of the vertex. The number of participants with stage changes from Baseline are summarized. The LOCF method for missing data was used by carrying forward the last non-missing post-Baseline assessment for participants with missing data and/or for participants who discontinued from the study.', 'timeFrame': 'Baseline, Week 26 and Week 52'}, {'measure': 'Change From Baseline in Sexual Problems as Assessed by the Problem Assessment Scale of the Sexual Function Inventory (PAS SFI) at Week 13, Week 26, Week 39, and Week 52', 'description': 'The Problem Assessment Scale of the Sexual Function Inventory (PAS SFI) questionnaire was used to assess participant-perceived problems in sexual function using 3 questions assessing problems with sex drive, erections and ejaculation. They are scored on a 5-point scale of 0 to 4 (0=big problem, 1= medium problem, 2=small problem, 3=very small problem, 4=no problem). Total scores range from 0-12. Change from Baseline in PAS SFI scores is defined as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date). The LOCF method for missing data was used by carrying forward the last non-missing post-Baseline assessment for participants with missing data and/or for participants who discontinued from the study.', 'timeFrame': 'Baseline, Week 13, Week 26, Week 39 and Week 52'}, {'measure': 'Change From Baseline in Quality of Life as Assessed by Dermatology Life Quality Index (DLQI) at Week 13, Week 26, Week 39, and Week 52', 'description': 'The DLQI is a 10-item validated measure developed specifically to assess quality of life (QoL) in participants with dermatological conditions. It assesses six domains: symptoms and feelings, daily activities, leisure, work ⁄school, personal relationships, and treatment. The DLQI total is the sum of 10 questions, each ranging from 0 (unanswered/not relevant,not at all) to 3 (very much). The higher the score, the greater the impairment of (QoL). Change from Baseline in DLQI scores is defined as the post-Baseline value minus the Baseline value. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date). The LOCF method for missing data was used by carrying forward the last non-missing post-Baseline assessment for participants with missing data and/or for participants who discontinued from the study.', 'timeFrame': 'Baseline, Week 13, Week 26, Week 39, and Week 52'}, {'measure': 'Serum Concentrations of Dihydrotestosterone (DHT) at Baseline, and After 26 Weeks and 52 Weeks', 'description': 'Blood samples for DHT analysis was collected at Baseline, Week 26 and Week 52. DHT values at a lower limit of quantification (LLQ) were imputed using 1/2 LLQ. The Baseline value of an assessment is defined as the latest assessment on or before the Baseline date (latest non-missing value of either the treatment start date or the randomization date). The LOCF method for missing data was used by carrying forward the last non-missing post-Baseline assessment for participants with missing visit data and/or for participants who discontinued from the study.', 'timeFrame': 'Baseline, Week 26 and Week 52'}]",23.0,20 Years,50 Years,MALE,False,INDUSTRY,0.0,120.0,ACTUAL,v2_robust,True,True,False,True,
NCT00102791,A Stratified Sickle Event Randomized Trial (ASSERT),ICA-17043,['ICA-17043'],1,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Sickle Cell Disease,Icagen,2025-09-01T16:18:09.634231,True,,,,,"A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months",,['Sickle Cell Disease'],['Sickle Cell Anemia'],Because of the low probability of achieving the primary endpoint.,2005-02,2007-06,"[{'measure': 'Sickle Cell Crisis Rate', 'timeFrame': '52 weeks'}]","[{'measure': 'Time to First, Second, and Third Crisis', 'timeFrame': '52 Weeks'}, {'measure': 'Maximum Crisis Morbidity Ranking', 'timeFrame': '52 Weeks'}, {'measure': 'Efficacy Related Laboratory Parameters', 'timeFrame': '52 Weeks'}, {'measure': 'Quality of Life', 'timeFrame': '52 Weeks'}, {'measure': 'Health Economics', 'timeFrame': '52 Weeks'}]",6.0,16 Years,65 Years,ALL,False,INDUSTRY,1.0,297.0,ACTUAL,v2_robust,True,False,True,False,Because of the low probability of achieving the primary endpoint.
NCT02581891,"Managing Neovascular (Known as ""Wet"") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye","Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)","['Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)']",1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Macular Degeneration,Bayer,2025-09-01T16:18:09.634274,True,,,,,"Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)",,['Macular Degeneration'],"['Neovascular age-related macular degeneration', 'nAMD)']",,2015-11-19,2019-04-26,"[{'measure': 'Change in BCVA as Measured by the ETDRS Letter Score', 'description': 'BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.', 'timeFrame': 'From Week 16 to Week 104'}]","[{'measure': 'Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline', 'description': 'Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.', 'timeFrame': 'at Week 104'}, {'measure': 'Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52', 'description': 'BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.', 'timeFrame': 'from baseline to Week 52, baseline to Week 104, and Week 16 to Week 52'}, {'measure': 'Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline', 'description': 'Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.', 'timeFrame': 'At week 52'}, {'measure': 'Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline', 'description': 'Participants gained 3 lines (15 letters) in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.', 'timeFrame': 'At Week 52 and Week 104'}, {'measure': 'Change in Central Retinal Thickness (CRT)', 'description': 'CRT were evaluated using spectral domain Optical coherence tomograph (OCT).', 'timeFrame': 'From baseline to Week 52, baseline to Week 104, Week 16 to Week 52, and Week 16 to Week 104'}, {'measure': 'Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104', 'timeFrame': 'At Week 52 and Week 104'}, {'measure': 'Duration of Last Treatment Interval', 'timeFrame': 'Early-Start T&E: from week 16 up to Week 104 or early termination; Late-Start T&E: From end of Year 1 up to Week 104 or early termination'}, {'measure': 'Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Treatment Interval', 'timeFrame': 'at 8 weeks, 10 weeks, 12 weeks, 14 weeks, and 16 weeks'}]",9.0,50 Years,,ALL,False,INDUSTRY,1.0,287.0,ACTUAL,v2_robust,True,True,False,False,
NCT03760991,Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin,INSULIN GLARGINE (U300),"['INSULIN GLARGINE (U300)', 'HOE901, Toujeo, Gla-300']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Type 2 Diabetes Mellitus,Sanofi,2025-09-01T16:18:09.634310,True,,,,,"A Multicenter, Multinational, Prospective, Interventional, Single-arm, Phase IV Study Evaluating the Clinical Efficacy and Safety of 26 Weeks of Treatment With Insulin Glargine 300 U/mL (Gla-300) in Patients With Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin",,['Type 2 Diabetes Mellitus'],[],,2018-12-18,2020-09-23,"[{'measure': 'Change in glycated hemoglobin (HbA1c)', 'description': 'Absolute change in HbA1c', 'timeFrame': 'Baseline to Week 26'}]","[{'measure': 'Change in glycated hemoglobin (HbA1c)', 'description': 'Absolute change in HbA1c', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Participants with HbA1c below 7%', 'description': 'Percentage of participants with HbA1c below 7%', 'timeFrame': 'Week 12 and 26'}, {'measure': 'Participants with fasting self-monitored plasma glucose (SMPG) of 80 to 110 mg/dL (4.4 to 7.2 mmol/L)', 'description': 'Percentage of participants reaching targeted fasting SMPG of 80 to 110 mg/dL (4.4 to 7.2 mmol/L)', 'timeFrame': 'Week 12 and 26'}, {'measure': 'Change in fasting SMPG', 'description': 'Absolute change in fasting SMPG', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Change in SMPG profile', 'description': 'Absolute change in SMPG profile', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Change in fasting plasma glucose (FPG)', 'description': 'Absolute change in FPG', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Percentage of participants requiring rescue therapy', 'description': 'Percentage of participants requiring rescue therapy by additional antidiabetic medication', 'timeFrame': 'Baseline to Week 12 and 26'}, {'measure': 'Number of participants with hypoglycemia events', 'description': 'Number of participants with at least 1 hypoglycemia event', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Number of participants with adverse events (AEs)', 'description': 'Number of participants with AEs, serious adverse events (SAEs) (including hypoglycemic episodes associated with seizures, coma, or unconsciousness).', 'timeFrame': 'Baseline to Week 27'}, {'measure': 'Change in Treatment satisfaction', 'description': 'Change in treatment satisfaction as measured by insulin treatment satisfaction questionnaire', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Number of participants with health care utilization', 'description': 'Number of participants with health care utilization, including hospitalization, emergency room visits, and office \\[or specialty\\] visits', 'timeFrame': 'Baseline to Week 26'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,372.0,ACTUAL,v2_robust,True,True,False,True,
NCT03675191,Orlistat/Phentermine Versus Placebo/Phentermine,Orlistat 120Mg Cap,"['Phentermine Pill 37.5mg', 'Phentermine Pill', 'Lipidown Cap', 'Orlistat 120Mg Cap']",4,INTERVENTIONAL,['NA'],,COMPLETED,Obesity,Gangnam Severance Hospital,2025-09-01T16:18:09.634362,True,,,,,The Effects of Orlistat/Phentermine Versus Placebo/Phentermine Treatment on Weight Loss and Vascular Function of Overweight Patients With Back Pain,,"['Obesity', 'Overweight']",[],,2018-10-16,2019-08-12,"[{'measure': 'Body mass index changes', 'description': 'Body mass index in kg/m2.', 'timeFrame': '12weeks'}, {'measure': 'Vascular function changes', 'description': 'Vascular function will be assessed using the flow mediated dilatation (%).', 'timeFrame': '12weeks'}]","[{'measure': 'Back pain', 'description': 'Assessments using a Visual Analog Score for pain Visual Analog Scale (total score 10, minimum;0, no pain, maximum; 10, severe pain)', 'timeFrame': '12weeks'}]",3.0,20 Years,,ALL,False,OTHER,0.0,114.0,ACTUAL,v2_robust,True,True,False,False,
NCT01892891,Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing,VBY-036,['VBY-036'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Virobay Inc.,2025-09-01T16:18:09.634374,True,,,,,"A Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects",,['Healthy'],"['Healthy', 'Subjects', 'Safety', 'Tolerability', 'VBY036', 'maximum', 'pharmacodynamic', 'pharmacokinetic']",,2013-07,2013-11,"[{'measure': 'Highest safe and tolerated VBY-036 dose', 'description': 'Single dose of VBY-036 given daily for 7-days in a row for each cohort in an ascending manner.\n\nCohort B1 with 30 mg dose or placebo; Cohort B2 with 100 mg dose or placebo; Cohort B3 with 300 mg dose or placebo; Cohort B4 with 600 mg dose or placebo; Cohort B5 with 900 mg dose or placebo', 'timeFrame': '7 days of dosing'}]","[{'measure': 'Confirmation of cathepsin-S inhibition', 'description': 'Based on the accumulation of Iip 10 and/or cathepsin S protein levels', 'timeFrame': '7 days'}]",2.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT05506891,Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy,Astragalus,['Astragalus'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Parkinsonism,Fujian Medical University Union Hospital,2025-09-01T16:18:09.634450,True,,,,,Efficacy and Safety of Astragalus for Non-Motor Symptoms of α-Synucleinopathy：an Open-Label Self-Controlled Before-and-After Study,,['Parkinsonism'],[],,2023-10-01,2024-07-01,"[{'measure': 'Change from baseline mean arterial pressure after 3 minutes of upright posture versus decubitus position (mmHg) at 3 months.', 'description': 'Mean arterial pressure was calculated as ⅓ pulse pressure + diastolic pressure.', 'timeFrame': 'Baseline vs 3 months after treatment.'}]","[{'measure': 'OH Questionnaire score', 'description': 'ΔHR/ΔSBP means heart rate (HR) and systolic blood pressure (SBP) from baseline OH Questionnaire score', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline Rate of change in ΔHR/ΔSBP at 3months.', 'description': 'ΔHR/ΔSBP means heart rate (HR) and systolic blood pressure (SBP) from baseline lying position to standing for 3 minutes', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline HRV (ms) at 3months.', 'description': 'Heart rate variability (HRV) was calculated as the maximum bpm - minimum bpm.', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline decumbent and orthostatic digit span (DDS) difference at 3months.', 'description': 'DDS is an executive function measurement tool', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline decumbent and orthostatic character conversion (CDS) difference at 3months.', 'description': 'CDS is an executive function measurement tool', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline MoCA scores at 3 months.', 'description': 'The Montreal Cognitive Assessment (MoCA)', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline CDR scores at 3 months.', 'description': 'The Clinical Dementia Rating (CDR)', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline RAVLT scores at 3 months.', 'description': 'The Rey Auditory Verbal Learning Test (RAVLT)', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline HAS scores at 3 months.', 'description': 'The Hamilton Anxiety Scale (HAS)', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline HDS scores at 3 months.', 'description': 'The Hamilton Depression Scale (HDS)', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline NPI scores at 3 months.', 'description': 'The Neuropsychiatric Inventory (NPI)', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from the baseline plasma α-synuclein levels (ng/ml) at 3 months.', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline Vic at 3 months.', 'description': 'The intra-cellular compartment (Vic) of the Neurite Orientation Dispersion and Density Imaging (NODDI) model represents diffusion within the axons and cells.', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline ODI at 3 months.', 'description': 'NODDI models the dispersion of axonal fibers with the use of an Orientation Dispersion Index (ODI).', 'timeFrame': 'Baseline vs 3 months after treatment.'}, {'measure': 'Change from baseline PAF (Hz) at 3 months.', 'description': 'The alpha-peak frequency (PAF) is the frequency with the highest power within the alpha-band.', 'timeFrame': 'Baseline vs 3 months after treatment.'}]",16.0,30 Years,85 Years,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06940674,Adjunctive Cannabidiol for Recovery From Opioid Study,Cannabidiol,"['Cannabidiol', 'CBD', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Opioid Use Disorder (OUD),Icahn School of Medicine at Mount Sinai,2025-09-01T16:18:09.634751,True,,,,,Adjunctive Cannabidiol for Recovery From Opioid Study (ACROS),,['Opioid Use Disorder (OUD)'],[],,2025-06-13,2028-05-01,"[{'measure': 'Percentage of study participants with negative urine toxicology for illicit opioid use', 'description': 'Percentage of study participants with negative urine toxicology for illicit opioid use over the course of 24 weeks.', 'timeFrame': '24 weeks'}]","[{'measure': 'Concentration of illicit opioids', 'description': 'Concentration of illicit opioids in quantitative plasma toxicology (plasma every four weeks)', 'timeFrame': 'Duration of the trial, 24 weeks'}, {'measure': 'Weeks of abstinence', 'description': 'Weeks of abstinence of illicit opioid use', 'timeFrame': 'Duration of the trial, 24 weeks'}, {'measure': 'Use of non-opioid illicit substances', 'description': 'Number of weeks using other non-opioid illicit substances', 'timeFrame': 'Duration of the trial, 24 weeks'}, {'measure': 'Duration of first opioid abstinence', 'description': 'Duration of first opioid abstinence, defined as the number of weeks from randomization to first opioid test positive or urine test missed.', 'timeFrame': 'Duration of the trial, 24 weeks'}, {'measure': 'Cue-induced Visual Analog Scale for craving (VASC)', 'description': 'Cue-induced Visual Analog Scale for craving (VASC)\n\nCue-induced Visual Analog Scale for craving is used to measure subjective craving responses to a drug and neutral video cues evaluated in the clinic. Total scale ranges from 0-10, with higher scores indicating extreme cravings.', 'timeFrame': 'At 12 and 24-week time points'}, {'measure': 'Cue-induced Visual Analog Scale for anxiety (VASA)', 'description': 'Cue-induced Visual Analog Scale for anxiety (VASA)\n\nCue-induced Visual Analog Scale Anxiety is used to measure subjective anxiety responses to a drug and neutral video cue evaluated in the clinic. Total scale from 0-10, with higher score indicating extreme anxiety.', 'timeFrame': 'At 12 and 24-week time points'}, {'measure': 'Change in illicit opioids in plasma toxicology', 'description': 'Change in illicit opioids in plasma toxicology', 'timeFrame': '24 weeks'}, {'measure': 'Change in illicit opioids in urine toxicology', 'description': 'Change in illicit opioids in urine toxicology', 'timeFrame': '24 weeks'}, {'measure': 'Study Retention', 'description': 'Number of participants remaining in the study', 'timeFrame': '24 weeks'}, {'measure': 'Opioid Craving Questionnaire (OCQ)', 'description': 'General craving self-report using Opioid Craving Questionnaire (OCQ)\n\nTotal scale from 0-9, with higher score indicating more severe craving', 'timeFrame': 'Every 4 weeks up to 24 weeks'}, {'measure': 'Generalized Anxiety Disorder Scale (GAD7)', 'description': 'General anxiety self-report using the Generalized Anxiety Disorder Scale (GAD7).\n\nThe General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire that asks user to rank how often they have been bothered by seven problems over the past two weeks from ""0"" (not at all) to ""3"" (nearly every day). The items that users are asked to rank levels of nervousness, anxiousness, relaxing, restlessness, irritability and fearfulness. Full scale from 0-21, with higher score indicating more symptoms.', 'timeFrame': 'Every 4 weeks up to 24 weeks'}, {'measure': 'Substance use other than opioids', 'description': 'Proportion of substance use other than opioids', 'timeFrame': 'Duration of the trial, 24 weeks'}, {'measure': 'Methadone plasma concentrations', 'description': 'Methadone plasma concentrations', 'timeFrame': 'Duration of the trial, 24 weeks'}, {'measure': 'Buprenorphine and metabolite plasma concentrations', 'description': 'Buprenorphine and metabolite plasma concentrations', 'timeFrame': 'Duration of the trial, 24 weeks'}, {'measure': 'Retention in opioid agonist therapy', 'description': 'Proportion of participants who remained in treatment with opioid agonist therapy', 'timeFrame': 'Duration of the trial, 24 weeks'}]",16.0,18 Years,65 Years,ALL,False,OTHER,3.0,450.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06670274,A Dose Escalating Study of HC002 in Healthy Adult Volunteers,HC002 SAD,"['HC002 MAD', 'HC002 SAD', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Inflammatory Disease,Holoclara Aus Pty Ltd,2025-09-01T16:18:09.634822,True,,,,,"A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-Human Dose Escalation Study of HC002 to Evaluate Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers",,"['Inflammatory Disease', 'Autoimmune Diseases']",[],,2024-11-21,2025-05-07,"[{'measure': 'To assess the safety of HC002 by the incidence of adverse events', 'timeFrame': 'SAD- Screening to Day 4 post first dose administration; MAD- screening to Day 11 post first dose administration'}, {'measure': 'Number of participants with abnormal laboratory values and/or adverse events that are related to treatment', 'timeFrame': 'SAD- Screening to Day 4 post first dose administration; MAD- screening to Day 11 post first dose administration'}, {'measure': 'Number of participants with changes to the electrocardiogram (ECG) from baseline recorded as adverse events', 'timeFrame': 'SAD- Screening to Day 4 post first dose administration; MAD- screening to Day 11 post first dose administration'}]","[{'measure': 'Plasma PK parameters- Maximum plasma concentration (Cmax) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration'}, {'measure': 'Plasma PK parameters- Time for maximum plasma concentration (Tmax) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration'}, {'measure': 'Plasma PK parameters-- Area under curve (AUC) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration'}, {'measure': 'Plasma PK parameters- Apparent clearance (CL/F) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration'}, {'measure': 'Plasma PK parameters- terminal half-life (t1/2) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration'}, {'measure': 'Plasma PK parameters- Vz/F (apparent volume of distribution) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected on Day 1 to Day 3 post first dose administration; MAD-Samples collected across 11 timepoints on Day 1 and Day 7 post first dose administration'}, {'measure': 'Urine PK parameters- Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected 4 timepoints from Day1 to Day 2 post first dose administration; MAD- Samples collected across 5 time-intervals from Day 1 to Day 7 post first dose administration]'}, {'measure': 'Urine PK parameters- fet1-t2 (fraction of analyte excreted in urine from time point t1 to t2) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected 4 timepoints from Day1 to Day 2 post first dose administration; MAD- Samples collected across 5 time-intervals from Day 1 to Day 7 post first dose administration'}, {'measure': 'Urine PK parameters-Clearance rate (CLr) after first dose of HC002', 'timeFrame': 'SAD-Samples will be collected 4 timepoints from Day1 to Day 2 post first dose administration; MAD- Samples collected across 5 time-intervals from Day 1 to Day 7 post first dose administration'}]",12.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,56.0,ACTUAL,v2_robust,True,True,False,True,
NCT04673474,A Food-Effect Study of Hemay022 in Healthy Participants,Hemay022,['Hemay022'],1,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Food-drug Interaction,"Tianjin Hemay Oncology Pharmaceutical Co., Ltd",2025-09-01T16:18:09.634829,True,,,,,A PhaseⅠFood-Effect Study of Hemay022 in Healthy Subjects,,['Food-drug Interaction'],[],,2020-12-09,2021-05,"[{'measure': 'Cmax', 'description': 'Maximum Observed Plasma Concentration for Hemay022', 'timeFrame': 'Day 1: 0-48 hours; Day 8: 0-48 hours'}, {'measure': 'Tmax', 'description': 'Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Hemay022', 'timeFrame': 'Day 1: 0-48 hours; Day 8: 0-48 hours'}, {'measure': 'AUC0-t', 'description': 'AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Hemay022', 'timeFrame': 'Day 1: 0-48 hours; Day 8: 0-48 hours'}, {'measure': 'AUC0-∞', 'description': 'Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for Hemay022', 'timeFrame': 'Day 1: 0-48 hours; Day 8: 0-48 hours'}]",[],4.0,18 Years,40 Years,ALL,True,INDUSTRY,0.0,12.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01709474,Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus,Vitamin D3 6000 IU,"['high-dose 25(OH)D', 'Vitamin D3 400 IU', 'high-dose cholecalciferol (D3)', 'standard-dose vitamin D', 'Vitamin D3 6000 IU', 'standard-dose 25(OH)D', 'standard-dose cholecalciferol (D3)', 'high-dose vitamin D']",8,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Systemic Lupus Erythematosus,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:09.634848,True,,,,,Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE),,['Systemic Lupus Erythematosus'],"['SLE', 'Vitamin D3', 'Vitamin D deficiency', 'IFN alpha expression']",Due to slow enrollment,2013-06,2014-07,"[{'measure': 'Change in Average IFN Module Expression Level', 'description': 'No mechanistic analyses were performed due to recruitment feasibility issues.', 'timeFrame': 'Baseline to Week 18'}, {'measure': 'Percentage of Subjects by Treatment Arm Experiencing Any Adverse Event (AE) ≥ Grade 3', 'description': 'Adverse event grading based on National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0', 'timeFrame': 'Baseline to 18 Weeks'}]",[],2.0,5 Years,20 Years,ALL,False,NIH,1.0,7.0,ACTUAL,v2_robust,True,False,True,True,Due to slow enrollment
NCT02057874,3-Tesla MRI Response to TACE in HCC (Liver Cancer),Magnevist® (Intravenous (IV) administration of MRI contrast agent),"['Magnevist® (Intravenous (IV) administration of MRI contrast agent)', 'intravenous (IV) injection of Magnevist® (gadopentetate dimeglumine); IV contrast infusion; IV gadolinium (Gd)']",2,INTERVENTIONAL,['NA'],,TERMINATED,Adult Primary Hepatocellular Carcinoma,Vanderbilt-Ingram Cancer Center,2025-09-01T16:18:09.634862,True,,,,,Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC),,"['Adult Primary Hepatocellular Carcinoma', 'Advanced Adult Primary Liver Cancer', 'Localized Resectable Adult Primary Liver Cancer', 'Localized Unresectable Adult Primary Liver Cancer', 'Stage A Adult Primary Liver Cancer (BCLC)', 'Stage B Adult Primary Liver Cancer (BCLC)']",[],Funding unavailable,2014-02,2015-12-04,"[{'measure': 'Correlation of Changes in Imaging Biomarkers (Ktrans, ADC, MTR, and APTasym) as Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively, With Changes in Tumor Volume (mRECIST).', 'description': 'The following will be longitudinally measured using 3 Tesla (3T) magnetic resonance imaging (MRI) prior to transarterial chemoembolization (TACE) and 2-4, 4-8, and 12 weeks following TACE: 1) the volume transfer coefficient (Ktrans), measured by dynamic contrast-enhanced (DCE) MRI; 2) the apparent diffusion coefficient (ADC), measured by diffusion-weighted (DW) MRI; 3) the magnetization transfer ratio (MTR), measured by magnetization transfer (MT) MRI; and 4) the amide proton transfer asymmetry (APTasym), measured by chemical exchange saturation transfer (CEST) MRI. We will use a general linear model (GLM) approach to measure the association between changes in each of the above imaging metrics (relative to pretreatment baseline) and changes in tumor volume (according to standard-of-care modified RECIST) at 3 or 6 month follow-up, accounting for the effect of potential confounders, e.g., age and size of the tumor at baseline.', 'timeFrame': 'Baseline to up to 12 weeks post-TACE'}]","[{'measure': 'Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Time-to-progression (TTP).', 'description': 'Proportional hazard model will be employed to assess the ability of the longitudinal change (relative to pretreatment baseline) in each of the 3T MR imaging metrics (Ktrans, ADC, MTR, and APTasym) to predict patient survival outcomes, time-to-progression (TTP) and progression-free survival (PFS) as well as overall survival (OS). The calibration of prediction will be validated by computing the difference between predicted survival and Kaplan-Meier survival estimates at a fixed time, which estimates the over-optimism of the difference using bootstrapping.', 'timeFrame': 'Baseline to up to 6 months post-TACE'}, {'measure': 'Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Changes in the Ratio of Viable-to-necrotic Tumor Volume', 'description': 'Longitudinal changes in 3T MRI-derived measures and the change in the ratio of viable vs. necrotic tumor will be assessed by using a GLM approach in which the underlying temporal correlation can be modeled via an autoregressive order one (AR(1)) structure, validated by computing Akaike Information Criterion (AIC) against the other common structures, e.g., unstructured and constant correlation.', 'timeFrame': 'Baseline to up to 12 weeks post-TACE'}, {'measure': 'Correlation of Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Pathological Response Within Explanted Tissue Following Orthotopic Liver Transplant (OLT)', 'description': 'Histopathological features on explanted livers following OLT, including percentage necrosis and cellular density as determined by hematoxylin and eosin staining, as well as the extent of fibrosis as determined by collagen staining, will be assessed for correspondence with findings on ex vivo 3T MRI.', 'timeFrame': 'Subset of patients undergoing OLT: within 12 hours following surgery'}, {'measure': 'Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Overall Survival (OS)', 'description': 'Proportional hazard model will be employed to assess the ability of the longitudinal change (relative to pretreatment baseline) in each of the 3T MR imaging metrics (Ktrans, ADC, MTR, and APTasym) to predict patient survival outcomes, time-to-progression (TTP) and progression-free survival (PFS) as well as overall survival (OS). The calibration of prediction will be validated by computing the difference between predicted survival and Kaplan-Meier survival estimates at a fixed time, which estimates the over-optimism of the difference using bootstrapping.', 'timeFrame': 'Baseline to up to 6 months post-TACE'}]",5.0,18 Years,,ALL,False,OTHER,1.0,2.0,ACTUAL,v2_robust,True,False,True,False,Funding unavailable
NCT06337474,An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia,anti-CD19 CAR NK cells (KN5501),['anti-CD19 CAR NK cells (KN5501)'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,RECRUITING,Thrombocytopenia Alloimmune,Changzhou No.2 People's Hospital,2025-09-01T16:18:09.634961,True,,,,,An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injections for the Treatment of Refractory Primary Immune Thrombocytopenia,,['Thrombocytopenia Alloimmune'],[],,2024-08-30,2026-07-30,"[{'measure': 'Incidence of Dose Limiting Toxicity (DLTs)', 'description': 'To characterize the Dose Limiting Toxicities (DLTs) of anti-CD19 CAR NK Cells for refractory immune thrombocytopenia', 'timeFrame': 'within 4 weeks after infusion; 12, 24, 36 and 52 weeks after infusion'}, {'measure': 'Treatment Emergent Adverse Events (TEAEs)', 'description': 'To characterize the Treatment Emergent Adverse Events (TEAEs) of anti-CD19 CAR NK Cells for refractory immune thrombocytopenia', 'timeFrame': 'within 4 weeks after infusion; 12, 24, 36 and 52 weeks after infusion'}]","[{'measure': 'Objective Response Rate of subjects', 'description': 'Objective Response is assessed according to definitions of International ITP Working Group. Objective Response Rate is defined as proportion of patients with PLT content.', 'timeFrame': 'Time Frame: 2, 4, 8, 12, 16, 24, 28, 40 and 52 weeks after first infusion'}]",3.0,18 Years,65 Years,ALL,False,OTHER,1.0,9.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01593774,Melatonin for Prevention of Metabolic Side Effects of Olanzapine,Melatonin,"['Melatonin', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Schizophrenia,Guilan University of Medical Sciences,2025-09-01T16:18:09.634973,True,,,,,Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.,,['Schizophrenia'],"['Melatonin', 'Olanzapine', 'Metabolic side effects', 'Psychosis', 'Hyperlipidemia', 'Hyperglycemia', 'Weight gain', 'Diabetes']",,2012-05,2013-03,"[{'measure': 'Change from baseline in weight at week eight', 'timeFrame': 'Baseline and week eight'}]","[{'measure': 'Change from baseline in Triglyceride at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in HDL at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in LDL at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in Total Cholesterol at week 4', 'timeFrame': 'Baseline and Week 4'}, {'measure': 'Change from baseline in weight at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in Fasting blood sugar at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in blood pressure at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in body mass index (BMI) at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in waist to hip ratio at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in Positive and negative syndrome scale (PANSS) at week 4', 'timeFrame': 'Baseline and week 4'}, {'measure': 'Change from baseline in Positive and negative syndrome scale (PANSS) at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in Triglyceride at week 48', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in HDL at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in LDL at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in Total Cholesterol at week 8', 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Change from baseline in Fasting blood sugar at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in blood pressure at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in body mass index (BMI) at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in waist to hip ratio at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Change from baseline in Insulin at week 8', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Number of adverse events at the end of the study in each group', 'timeFrame': 'Baseline, week 4, and 8'}, {'measure': 'Changes from baseline in HOMA-IR values at week 8', 'timeFrame': 'Baseline and week 8'}]",23.0,18 Years,65 Years,ALL,False,OTHER,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,
NCT02974374,Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects,PF-06835919,['PF-06835919'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Non-alcoholic Fatty Liver Disease,Pfizer,2025-09-01T16:18:09.635038,True,,,,,"A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects",,['Non-alcoholic Fatty Liver Disease'],[],,2016-10,2017-01,"[{'measure': 'Number of Subjects experiencing an Adverse Event', 'description': 'Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements. Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.', 'timeFrame': 'Screening up to 28 days after last dose of study medication'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax) for PF-06835919', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Time to Reach Maximum Observed Concentration for PF-06835919', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06835919', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06835919', 'description': 'AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity).', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Plasma Decay Half-Life (t1/2) for PF-06835919 (as permitted)', 'description': 'Plasma Decay Half-Life (t1/2)', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Apparent Total Body Clearance (CL/F) for PF-06835919 (as permitted)', 'description': 'Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after apparent total body clearance is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Apparent Volume of Distribution (Vz/F) for PF-06835919 (as permitted)', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}]",8.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT00089674,AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer,AMG 162,"['AMG 162', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Prostate Cancer,Amgen,2025-09-01T16:18:09.635078,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer",,['Prostate Cancer'],"['Prostate Cancer', 'Bone Loss with Prostate Cancer', 'Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).']",,2004-08-01,2010-05-11,"[{'measure': 'Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24', 'description': 'Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.', 'timeFrame': '24 months'}]","[{'measure': 'Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24', 'description': 'Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.', 'timeFrame': '24 months'}, {'measure': 'Total Hip Bone Mineral Density Percent Change From Baseline at Month 24', 'description': 'Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.', 'timeFrame': '24 months'}, {'measure': 'Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36', 'description': 'Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.', 'timeFrame': '36 months'}, {'measure': 'Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36', 'description': 'Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.', 'timeFrame': '36 months'}, {'measure': 'Total Hip Bone Mineral Density Percent Change From Baseline at Month 36', 'description': 'Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.', 'timeFrame': '36 months'}, {'measure': 'Number of Participants With Any Fracture Through Month 36', 'description': 'Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.', 'timeFrame': '36 months'}, {'measure': 'Number of Participants With a New Vertebral Fracture Through Month 36', 'description': 'New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.', 'timeFrame': '36 months'}, {'measure': 'Time to First Clinical Fracture Through Month 36', 'description': 'A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.', 'timeFrame': '36 months'}, {'measure': 'Number of Participants With Any Fracture Through Month 24', 'description': 'Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.', 'timeFrame': '24 months'}]",10.0,18 Years,,MALE,False,INDUSTRY,0.0,1468.0,ACTUAL,v2_robust,True,True,False,False,
NCT04102618,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer,Letrozole,"['Trastuzumab', 'Atezolizumab', 'Letrozole']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,TERMINATED,Breast Cancer,Oncolytics Biotech,2025-09-01T16:18:09.635248,True,,,,,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1),,['Breast Cancer'],"['Breast', 'Breast Cancer', 'Primary Breast', 'Primary Breast Cancer', 'Pelareorep', 'Atezolizumab', 'Reovirus', 'Oncolytic virus', 'Letrozole', 'Early Breast Cancer', 'Triple-negative breast cancer', 'HR+ breast cancer', 'HER2+ breast cancer']",Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.,2019-03-29,2022-04-20,"[{'measure': 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with operable early breast cancer. CelTIL is a combined IHC-based score based on tumor cellularity and stromal TILs.', 'description': 'CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:\n\nCelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.', 'timeFrame': 'The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days).'}]","[{'measure': 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HR+/HER2-negative breast cancer.', 'timeFrame': 'The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days).'}, {'measure': 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HER2-positive breast cancer.', 'timeFrame': 'The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days).'}, {'measure': 'To identify biological changes, as defined by gene expression between posttreatment and pretreatment samples following pelareorep in combination with different therapies.', 'timeFrame': 'throughout'}, {'measure': 'To describe the safety profile of the combination therapies', 'timeFrame': 'throughout'}]",5.0,18 Years,,FEMALE,False,INDUSTRY,1.0,26.0,ACTUAL,v2_robust,True,False,True,True,Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.
NCT00161018,New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia,"Quetiapine, Risperidone, Fluphenazine","['Quetiapine, Risperidone, Fluphenazine']",1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Schizophrenia,"University of Maryland, Baltimore",2025-09-01T16:18:09.635284,True,,,,,,,['Schizophrenia'],[],,2003-11,2004-11,"[{'measure': 'To evaluate the efficacy and safety of the new antipsychotics, quetiapine(300-500mg/day) and risperidone(3-5mg/day) compared to each other and to fluphenazine(10-15mg/day), a high potency typical antipsychotic'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,150.0,,v2_robust,True,True,False,True,
NCT01130818,First-in-Human Single Ascending Dose of GLPG0492,GLPG0492,"['GLPG0492', 'placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Galapagos NV,2025-09-01T16:18:09.635292,True,,,,,"Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of GLPG0492 in Healthy Subjects and Open Relative Bioavailability Study of Oral Solution Versus Solid Formulation, Fasted and Fed, in Elderly Subjects",,['Healthy'],"['Safety', 'Tolerability', 'Pharmacokinetics', 'Bioavailability (solid vs solution, fasting vs fed)', 'Young healthy subjects', 'Elderly healthy subjects']",,2010-05,2010-09,"[{'measure': 'Safety and tolerability of single ascending doses in healthy young and elderly subjects.', 'timeFrame': 'up to 10 days postdose'}]","[{'measure': 'Pharmacokinetics of single oral doses (solution) in young and elderly subjects.', 'timeFrame': 'up to 10 days postdose'}, {'measure': 'Determine oral bioavailability of GLPG0492 given to elderly subjects as oral solution or solid dosage form with or without food.', 'timeFrame': 'up to 10 days postdose'}, {'measure': 'Determine the maximum tolerated dose in young subjects.', 'timeFrame': 'Up to 10 days postdose'}]",4.0,18 Years,,MALE,True,INDUSTRY,0.0,28.0,ACTUAL,v2_robust,True,True,False,True,
NCT06003218,Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation,Dexmedetomidine-esketamine combination,"['Remifentanil', 'Dexmedetomidine-esketamine combination', 'Oxycodone']",3,INTERVENTIONAL,['NA'],,COMPLETED,Liver Cancer,Peking University First Hospital,2025-09-01T16:18:09.635299,True,,,,,Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study,,"['Liver Cancer', 'Radiofrequency Ablation', 'Esketamine', 'Dexmedetomidine']","['Liver cancer', 'Radiofrequency ablation', 'Esketamine', 'Dexmedetomidine']",,2023-10-16,2024-09-28,"[{'measure': 'Area under curve of Numerical Rating Scale of pain during and within 24 hours after surgery.', 'description': 'Numerical Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) of pain will be assessed after percutaneous liver puncture, start of radiofrequency-ablation, every 5±1 minutes during radiofrequency-ablation, end of radiofrequency-ablation, and 10 minutes after needle removal during surgery, as well as at 0.5, 1, 2, 3-8, \\>8-12h,and 24 hours after surgery.', 'timeFrame': 'During and within 24 hours after surgery.'}]","[{'measure': 'The highest Numerical Rating Scale of pain during surgery.', 'description': 'Numerical Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) of pain will be assessed after percutaneous liver puncture, start of radiofrequency-ablation, every 2 minutes during radiofrequency-ablation, end of radiofrequency-ablation, and 10 minutes after needle removal during surgery', 'timeFrame': 'During surgery.'}, {'measure': 'Number of intraoperative adjustment of study drug infusion rate.', 'description': 'Number of adjustment of study drug infusion rate during surgery.', 'timeFrame': 'During surgery.'}, {'measure': 'Number of additional oxycodone or other analgesics during and within 24 hours after surgery.', 'description': 'Number of additional oxycodone or other analgesics during and within 24 hours after surgery.', 'timeFrame': 'During and within 24 hours after surgery.'}, {'measure': 'Dose of analgesics during and within 24 hours after surgery.', 'description': 'Dose of opioids (excluding remifentanil administered as study drugs) will be converted to intravenous morphine equivalent.', 'timeFrame': 'During and within 24 hours after surgery.'}, {'measure': 'Pain intensity and opioid consumption (PIOC) index during and within 24 hours after surgery.', 'description': 'Pain intensity will be calculated as area under curve (AUC) of Numerical Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) of pain during and within 24 hours after surgery. Opioid consumption (OC) during and within 24 hours after surgery will be calculated after excluding remifentanil administered as study drugs. Pain intensity and opioid consumption (PIOC) index will be calculated as: PIOC=\\[(AUCmean rank - AUCrank)/AUCmean rank\\] + \\[(OCmean rank - OCrank)/OCmean rank\\]. The range of the sum is -200% to +200%. Values above 0 indicate increased summed AUC and OC compared to the all patients.', 'timeFrame': 'During and within 24 hours after surgery.'}, {'measure': 'Numeric Rating Scale of subjective sleep quality on the first and second nights after surgery.', 'description': 'Numerical Rating Scale (NRS, an 11-point scale where 0=the best sleep and 10=the worst sleep) of sleep quality on the first and second nights after surgery.', 'timeFrame': 'On the first and second nights after surgery.'}]",7.0,18 Years,85 Years,ALL,False,OTHER,0.0,88.0,ACTUAL,v2_robust,True,True,False,False,
NCT05396118,Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients,18F-FDG,"['fluorodeoxyglucose-F-18', '18F-FDG', '18F-fluorodeoxyglucose', 'Injection of hyperpolarized [1-13C]Pyruvate', '[18F]F-FDG']",5,INTERVENTIONAL,['PHASE2'],PHASE2,ENROLLING_BY_INVITATION,Breast Cancer,"Rigshospitalet, Denmark",2025-09-01T16:18:09.635347,True,,,,,Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients With Cancer,,"['Breast Cancer', 'Neuroendocrine Tumors', 'Neuroendocrine Carcinoma', 'Neuroendocrine Carcinoma Metastatic', 'Lymphoma', 'Sarcoma']",[],,2022-05-18,2024-12,"[{'measure': 'Whole-tumor lactate/pyruvate ratio measured with MRS', 'description': 'Whole-tumor lactate/pyruvate ratio measured with MRS in regions-of-interest covering the tumor lesion(s) following injection of hyperpolarized \\[1-13C\\]Pyruvate', 'timeFrame': 'Up to 10 minutes after injection of hyperpolarized [1-13C]Pyruvate'}, {'measure': 'Whole-tumor glucose uptake measured with PET (static)', 'description': 'Whole-tumor standardized uptake values (SUV): SUVmean and SUVmax measured with PET in regions-of-interest covering the tumor lesion(s) approximately 60 minutes after injection of 18F-FDG', 'timeFrame': 'Approximately 60 minutes after injection of 18F-FDG'}, {'measure': 'Whole-tumor glucose uptake measured with PET (dynamic)', 'description': 'Whole-tumor glucose influx rate constant (Ki) derived from dynamic PET in regions-of-interest covering the tumor lesion(s) following injection of 18F-FDG', 'timeFrame': 'Up to 90 minutes after injection of 18F-FDG'}, {'measure': 'Correlation between whole-tumor lactate/pyruvate ratio measured with MRS and tumor glucose uptake measured with PET (static)', 'description': 'Correlation between whole-tumor lactate/pyruvate ratio measured with MRS and whole-tumor SUVmean and SUVmax measured with PET in regions-of-interest covering the tumor lesion(s)', 'timeFrame': 'Approximately 60 minutes after injection of 18F-FDG'}, {'measure': 'Correlation between whole-tumor lactate/pyruvate ratio measured with MRS and tumor glucose uptake measured with PET (dynamic)', 'description': 'Correlation between whole-tumor lactate/pyruvate ratio measured with MRS and whole-tumor Ki measured with PET in regions-of-interest covering the tumor lesion(s)', 'timeFrame': 'Up to 90 minutes after injection of 18F-FDG'}]","[{'measure': 'Correlation between measurements of in vivo glycolytic markers based on PET/MRS and enzymes involved in glycolytic metabolism based on ex vivo analyses', 'description': 'Ex vivo measurements of enzymes, regulatory proteins and transporters involved in glucose and pyruvate/lactate transcellular transport and in glycolysis on resected matched tumor tissue samples (if available) and the correlation with the primary endpoints (whole-tumor lactate/pyruvate ratio, SUVmax, SUVmean, and Ki)', 'timeFrame': 'Up to 90 minutes after injection of 18F-FDG'}]",6.0,18 Years,,ALL,False,OTHER,0.0,15.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05972018,Liposomal Bupivacaine/Bupivacaine in RS Blocks vs. Ropivacaine in RS Blocks And Catheters,Liposomal bupivacaine,"['Exparel', 'Ropivacaine', 'Bupivacain', 'Bupivacaine HCL', 'Naropin', 'Liposomal bupivacaine']",6,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,"Aortic Aneurysm, Abdominal",Hartford Hospital,2025-09-01T16:18:09.635485,True,,,,,"Liposomal Bupivacaine/Bupivacaine A Single-Dose Bilateral Rectus Sheath Blocks Vs. Ropivacaine in Bilateral RS Blocks And Catheters, Comparing Pain Scores And Opioid Use Following Open Abdominal Vascular Surgery",,"['Aortic Aneurysm, Abdominal', 'Abdominal Aortic Occlusion', 'Aortoiliac Occlusive Disease', 'Aortic Diseases']","['Open abdominal aortic repair surgery', 'Rectus Sheath Block', 'Rectus Sheath Block and Catheter', 'Liposomal Bupivacaine', 'Exparel', 'Ropivacaine continuous infusion']",,2023-10-18,2025-12-30,"[{'measure': 'The maximum, average, minimum, and current pain scores at the end of the period 24-48 post-op hours', 'description': 'The maximum, average, minimum, and current pain scores for the past 24 hours, on a scale from 0-10 where 0 is no pain and 10 is severe pain reported by participants at the end of 24-48 post-op hours using the validated tool; Brief Pain Inventory-Short Form.', 'timeFrame': 'At the end of the 24 - 48 post-op hours'}]","[{'measure': 'Other postoperative pain scores.', 'description': 'The maximum, average, minimum, and current pain scores for the past 24 hours, on a scale from 0-10 where 0 is no pain and 10 is severe pain reported by participants, daily and up to the end of the 168 postoperative hours and at 2 weeks after discharge using the validated tool; Brief Pain Inventory-Short Form.', 'timeFrame': 'Up to 168 postoperative hours and at 2 weeks after discharge'}, {'measure': 'The time to extubation', 'description': 'The time to extubation: from anesthesia end time to the time of removing the endotracheal tube in the Intensive Care Unit.', 'timeFrame': 'From anesthesia end date and time to the date and time of extubation, assessed up to 168 postoperative hours'}, {'measure': 'Intraop, postop, and total opioid consumption', 'description': 'The intraoperative, postoperative, and total opioid consumption during hospitalization using morphine milliequivalent doses (MME) between the groups.', 'timeFrame': 'Up to discharge, assessed as 2 weeks'}, {'measure': 'Hospital and Intensive Care Unit (ICU) length of stay (LOS)', 'description': 'Determine whether patients receiving ropivacaine in RSC versus B/LB in RSB have any the difference in the duration of ICU stay, in addition to the duration of hospitalization if \\> or \\< 7 days.', 'timeFrame': 'From the date and time of admission to the date and time of discharge, up to 2 weeks.'}, {'measure': 'The occurrence of block-related and catheter-related complications, or local anesthetics-related adverse events up to hospital discharge or up to one week.', 'description': 'Determine whether patients receiving ropivacaine in rectus sheath catheter versus Bupivacaine/Liposomal Bupivacaine in rectus sheath block have any difference in the occurrence of any related complications or adverse events up to hospital discharge or up to one week.', 'timeFrame': 'From the date of the block until the date of discharge, assessed up to 1 week'}, {'measure': 'Hospital readmission and ED visits', 'description': 'Incidences of hospital readmission and emergency visits within 2 weeks after discharge', 'timeFrame': 'up to 2 weeks after discharge'}, {'measure': 'Postoperative nausea and vomiting', 'description': 'Compare the occurrence of postoperative nausea and vomiting using the Simplified Postoperative Nausea and Vomiting Impact Scale which consists of two questions, with a possible response total score of 0-6. Response score totals of 0-2 require no intervention. Response score totals of 3-4 may necessitate antiemetic medication. Response score totals of 5-6 are considered clinically important nausea requiring medication intervention, as this would constitute patients with excessive vomiting. This scale will be used daily through the duration of in-hospital care (1-7 days)', 'timeFrame': 'Up to 168 postoperative hours'}, {'measure': 'Quality of Recovery-40 Questionnaire', 'description': 'Determine any differences between the two groups in the quality of recovery using the ""Quality of Recovery Questionnaire-40 questionnaire"" which consists of 40 questions categorized into 5 dimensions; emotional state (9 questions), physical comfort (12 questions), psychological support (7 questions), physical independence (5 questions), and pain (7 questions). All questions scored from 1-5; positive items are scored from 1 (worst) to 5 (best); whereas scores are reversed for negative items 1 (best) to 5 (worst).', 'timeFrame': 'On postop day 4, postop day 7, and at 2 weeks after the 168 postoperative hours'}, {'measure': 'Sensory function test', 'description': 'to compare any difference in the sensory function test that will be performed at the site of the block and catheter at the ICU and every postoperative day up to the end of the 168 postoperative hours.', 'timeFrame': 'Up to the end of the 168 postoperative hour'}, {'measure': 'Antiemetics use', 'description': 'The time from the intraoperative standard of care antiemetic dose to the first postoperative use of antiemetic and the number of antiemetic use at any time throughout hospitalization up to 1 week.', 'timeFrame': 'Up to 168 postoperative hour'}, {'measure': 'Patient satisfaction with pain management using CSAT', 'description': 'Patient satisfaction with pain management after surgery using the CSAT score: 5 very satisfied, 4 satisfied, 3 neutral, 2 unsatisfied, 1 very unsatisfied. this assessment on the day of discharge (estimated 168 postoperative hours) and at 2 weeks after discharge, via a phone call.', 'timeFrame': 'at the end of 168 postoperative hours and at 2 weeks after the 168 postoperative hours'}, {'measure': 'The cost of care during hospitalization.', 'description': 'To compare the resources consumed by each intervention from many different perspectives (e.g. anesthesia staff cost per time spent to perform the study intervention and the successive daily evaluations, facility cost per length of stay, block and catheter medication cost, block and catheter supply cost.)', 'timeFrame': 'From the time of the blocks until the date of discharge, assessed as 2 weeks'}, {'measure': 'The time to the first rescue opioid.', 'description': 'The time from the last intraoperative opioid given to the time of the first rescue opioid given after surgery is measured in hours.', 'timeFrame': 'Up to 168 postoperative hour'}, {'measure': 'The time to first postop antiemetics', 'description': 'The time from the last intraoperative antiemetic medication given to the time of the first rescue antiemetic medication given after surgery is measured in hours.', 'timeFrame': 'Up to 168 postoperative hour'}, {'measure': 'Opioid use and refills within 2 weeks after hospital discharge', 'description': 'Opioid use and refills within 2 weeks after hospital discharge (yes or no)', 'timeFrame': 'Up to 2 weeks after discharge'}]",16.0,18 Years,80 Years,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04110418,Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate,Methylene Blue,"['terlipressin acetate', 'Methylene Blue']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Neonatal Sepsis,Ain Shams University,2025-09-01T16:18:09.635512,True,,,,,Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate,,"['Neonatal Sepsis', 'Refractory Shock']","['methylene blue', 'terlipressin', 'septic shock', 'preterm neonate']",,2019-02-19,2020-02-19,"[{'measure': 'to assess the efficancy of each intervention in improving hemodymaic status: time taken to reach adequate mean blood pressure', 'description': 'The time taken to reach adequate mean blood pressure\n\nReduction in the dosage of the standard inotropic support', 'timeFrame': '24hours'}]","[{'measure': 'to assess the effect of intervention on survival', 'description': 'mortality rate', 'timeFrame': '4 days'}]",2.0,,,ALL,False,OTHER,0.0,36.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01355718,"Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea",repaglinide,['repaglinide'],1,OBSERVATIONAL,[],,COMPLETED,Diabetes,Novo Nordisk A/S,2025-09-01T16:18:09.635522,True,,,,,"A 26-week, Multicentre, Open-labelled, Non-randomised, Non-interventional, Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea",,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],,2011-08,2013-03,"[{'measure': 'Incidence of serious Adverse Drug Reactions (SADRs) including major (serious) hypoglycaemic episodes', 'timeFrame': 'weeks 0-26'}]","[{'measure': 'Incidence of Adverse Drug Reactions (ADRs)', 'timeFrame': 'week 13 and 26'}, {'measure': 'Incidence of Adverse Events (AEs)', 'timeFrame': 'week 13 and 26'}, {'measure': 'Incidence of Serious Adverse Event (SAEs)', 'timeFrame': 'week 13 and 26'}, {'measure': 'Change in HbA1c', 'timeFrame': 'after 13 and 26 weeks of NovoNorm® and insulin analogue combination therapy'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,120.0,ACTUAL,v2_robust,False,True,False,True,
NCT06520618,Clinical Study on the Efficacy and Safety of Qingre Heji in the Treatment of Acute Upper Respiratory Tract Infection,Qing Re He Ji,"['Shuanghuanglian Oral Liquid', 'Qing Re He Ji']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Acute Upper Respiratory Tract Infection,Shengjing Hospital,2025-09-01T16:18:09.635540,True,,,,,Clinical Study on the Efficacy and Safety of Qingre Heji in the Treatment of Acute Upper Respiratory Tract Infection,,"['Acute Upper Respiratory Tract Infection', 'Traditional Chinese Medicine', 'Randomised Controlled Trial']",[],,2023-02-01,2024-02-01,"[{'measure': 'Overall Symptom and Sign Score Improvement Rate', 'description': 'We use both traditional Chinese medicine (TCM) and Western medicine scales to assess the condition.', 'timeFrame': 'At days 0 (baseline) and 6'}, {'measure': 'Onset time', 'description': 'Defined as the duration from medication administration to a 0.5°C decrease in body temperature.', 'timeFrame': 'At days 0 (baseline) and 6'}, {'measure': 'Antipyretic time', 'description': 'Measured as the time taken for axillary temperature to drop below 37.3°C after the first dose and maintained for at least 24 hours without recurrence', 'timeFrame': 'At days 0 (baseline) and 6'}, {'measure': 'Single Symptom and Sign Disappearance Rate', 'description': 'Disappearance rate of individual TCM symptoms and signs', 'timeFrame': 'At days 0 (baseline) and 6'}]",[],4.0,18 Years,85 Years,ALL,False,OTHER,0.0,268.0,ACTUAL,v2_robust,True,True,False,False,
NCT00454090,AZD8330 First Time in Man in Patients With Advanced Malignancies,AZD8330,"['ARRY-424704', 'AZD8330']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Cancer,AstraZeneca,2025-09-01T16:18:09.635591,True,,,,,"A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies",,['Cancer'],['Advanced Malignancies'],,2007-03,2011-03,"[{'measure': 'To assess safety and tolerability of AZD8330 in patient with advanced malignancies.'}, {'measure': 'Outcome variables: Adverse Events, Clinical Chemistry, Haematology, Urinalysis, Vital signs, MUGA scans/echocardiography, ECGs, Ophthalmologic examination, O2 saturation'}]","[{'measure': 'To determine the PK of AZD8330.'}, {'measure': 'To investigate possible PD/PK relationships'}, {'measure': 'To investigate effect of AZD8330 on pERK in PBMCs'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,83.0,ACTUAL,v2_robust,True,True,False,True,
NCT03919890,"A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers",ONO-7684,"['ONO-7684', 'ONO-7684 Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Venous Thromboembolism,Ono Pharmaceutical Co. Ltd,2025-09-01T16:18:09.635597,True,,,,,"A First-in-human, Randomised, Placebo-controlled, Double-blind, Single and Multiple Dose Study to Explore the Safety, Tolerability, PK and PD of Oral Doses of ONO-7684 in Healthy Subjects Under Fed and Fasted Conditions",,['Venous Thromboembolism'],[],,2019-01-17,2019-08-23,"[{'measure': 'Number of participants with clinically significant changes in vital signs (Part A & B)', 'description': 'Pulse rate (bpm), systolic and diastolic blood pressure (mmHg), Respiratory rate (bpm)', 'timeFrame': 'Part A: Day 1-4 & Follow-up and Part B: Day 1-15, 17 & Follow up'}, {'measure': 'Number of participants with clinically significant changes observed on 12-lead electrocardiogram (ECG) (Part A & B)', 'description': 'Ventricular rate (beats/min), PR interval (msec), QRS interval (msec), QT (msec), QTcF interval (msec)', 'timeFrame': 'Part A: Day 1-4 & Follow up & Part B: Day 1,3,5,7,9,11,14,17 & Follow up'}, {'measure': 'Number of participants with clinically significant changes in cardiac telemetry (Part A only)', 'description': 'Number of participants with cardiac telemetry abnormalities will be reported.', 'timeFrame': 'Part A: From 0.5-1 hours pre-dose until 12 hours after dosing at Day 1'}, {'measure': 'Number of participants with clinically significant changes in physical examination (Part A & B)', 'description': 'Number of participants with physical examination abnormalities will be reported.', 'timeFrame': 'Part A: Day -1, 1-4 & Follow-up and Part B: Day-1, 1-17 & Follow up'}, {'measure': 'Number of participants with clinically significant changes in laboratory safety tests (haematology, biochemistry and urinalysis) (Part A & B)', 'description': 'Number of participants with abnormalities in laboratory safety tests will be reported.', 'timeFrame': 'Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up'}, {'measure': 'Number of participants with adverse events (AE) (Part A & B)', 'description': 'AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.', 'timeFrame': 'Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up'}]","[{'measure': 'Pharmacokinetics (Cmax)', 'description': 'Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1 and Day 14'}, {'measure': 'Pharmacokinetics (tmax)', 'description': 'Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1 and Day 14'}, {'measure': 'Pharmacokinetics (AUClast)', 'description': 'Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 14'}, {'measure': 'Pharmacokinetics (AUCinf)', 'description': 'Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 14'}, {'measure': 'Pharmacokinetics (AUCt)', 'description': 'Assessment of the area under the curve of concentration of ONO-7684 and 3-hydroxybenzoic acid - time from zero up to a definitive time, t in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1'}, {'measure': 'Pharmacokinetics (%AUCextrap)', 'description': 'Assessment of the percentage of AUC∞ extrapolated from tlast to infinity of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 14'}, {'measure': 'Pharmacokinetics (t1/2)', 'description': 'Assessment of the elimination half-time of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 14'}, {'measure': 'Pharmacokinetics (CL/F)', 'description': 'Assessment of the apparent clearance rate of ONO-7684 and 3-hydroxybenzoic acid in Part A only', 'timeFrame': 'Day 1 through Day 4'}, {'measure': 'Pharmacokinetics (Terminal Rate Constant)', 'description': 'Assessment of the terminal rate constant (slowest rate constant of the disposition) of ONO-7684 and 3-hydroxybenzoic acid in plasma in Part A only', 'timeFrame': 'Day 1 through Day 4'}, {'measure': 'Pharmacokinetics (Aet)', 'description': 'Assessment of the amount of ONO-7684 excreted in urine over the period of sample collection in Part A only', 'timeFrame': 'Day 1 through Day 4'}, {'measure': 'Pharmacokinetic (fe/F)', 'description': 'Assessment of the fraction of orally administered ONO-7684 excreted into urine in Part A only', 'timeFrame': 'Day 1 through Day 4'}, {'measure': 'Pharmacokinetic (CLr)', 'description': 'Assessment of the renal clearance of ONO-7684 from plasma in Part A only', 'timeFrame': 'Day 1 through Day 4'}, {'measure': 'Pharmacokinetic (Ctrough)', 'description': 'Assessment of the trough plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Part B only', 'timeFrame': 'Day 1 through Day 14'}, {'measure': 'Pharmacokinetic (AUCtau)', 'description': 'Assessment of the area under the plasma concentration of ONO-7684 and 3-hydroxybenzoic acid -time during a dosing interval in Part B only', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic (CLSS/F)', 'description': 'Assessment of total clearance of ONO-7684 from plasma after oral administration in Part B only', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic (VZ/F)', 'description': 'Assessment of apparent volume of distribution of ONO-7684 after non-intravenous administration calculated at steady state in Part B only', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacodynamic (change from baseline in aPTT activity) in serum', 'description': 'Assessment of the effect of ONO-7684 in activated partial thromboplastin time in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1 through Day 17'}, {'measure': 'Pharmacodynamic (change from baseline in PT activity) in serum', 'description': 'Assessment of the effect of ONO-7684 in prothrombin time in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1 through Day 17'}, {'measure': 'Pharmacodynamic (change from baseline in PT-INR activity) in serum', 'description': 'Assessment of the effect of ONO-7684 in prothrombin time-international normalised ratio in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1 through Day 17'}, {'measure': 'Pharmacodynamic (change from baseline in FXIa activity) in serum', 'description': 'Assessment of the effect of ONO-7684 in blood coagulation activated factor XI in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1 through Day 17'}, {'measure': 'Pharmacodynamic (correlation of aPTT and FXIa activity) in serum', 'description': 'Assessment of the effect of ONO-7684 in the correlation of activated partial thromboplastin time to blood coagulation activated factor XI in Parts A and B', 'timeFrame': 'Part A: Day 1 through Day 4. Part B: Day 1 through Day 17'}]",27.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,72.0,ACTUAL,v2_robust,True,True,False,True,
NCT01552590,Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites,Tolvaptan,"['Placebo', 'Tolvaptan']",2,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Hyponatremia and Extracellular Fluid in Cirrhotic,"Korea Otsuka Pharmaceutical Co., Ltd.",2025-09-01T16:18:09.635633,True,,,,,Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites,,['Hyponatremia and Extracellular Fluid in Cirrhotic'],[],,2012-04,2012-04,"[{'measure': 'Serum Na', 'timeFrame': '2 weeks (Baseline, Day 14)'}]","[{'measure': 'BCM (body composition monitoring)', 'timeFrame': '7 days'}, {'measure': 'body weight', 'timeFrame': '7 days'}, {'measure': 'A composite endpoint of ascites worsening', 'timeFrame': 'in case'}, {'measure': 'Serum Na normalization rate', 'timeFrame': '14 days'}, {'measure': 'Biochemistry', 'description': 'Total protein, Albumin, ALP, ALT, AST, r-GT, BUN, Creatinine, Glucose, Cl, K, Na, Ca, Total bilirubin, Uric acid), Hematology (WBC count, Hemoglobin, Hematocrit, Platelets, Serum osm, NT pro-BNP', 'timeFrame': '7 days'}, {'measure': 'ECG', 'timeFrame': '7 days'}, {'measure': 'Adverse event', 'timeFrame': 'Daily'}, {'measure': 'Physical examination', 'description': 'HEENT, Thorax, Abdomen, Urogenital, Extremities, Neurological, Skin and Mucosae', 'timeFrame': '7 days'}, {'measure': 'Vital signs', 'timeFrame': 'Daily'}, {'measure': 'Blood coagulation', 'description': 'PT, INR', 'timeFrame': '7 days'}, {'measure': 'Urinalysis', 'description': 'Protein, pH, Glucose, Blood, Bilirubin, Urobilinogen, Random urine Na/K, Urine osm', 'timeFrame': '7 days'}]",12.0,20 Years,,ALL,False,INDUSTRY,0.0,74.0,ACTUAL,v2_robust,True,False,True,True,
NCT04209790,Neoadjuvant Chemoradiation for Resectable Glioblastoma,Drug Therapy with Temozolomide (benzolamide) (Standard of Care),"['Neoadjuvant therapy', 'Drug Therapy with Temozolomide (benzolamide) (Standard of Care)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,SUSPENDED,Glioblastoma,Geisinger Clinic,2025-09-01T16:18:09.635681,True,,,,,Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio),,"['Glioblastoma', 'Surgery', 'High Grade Glioma']",['Glioblastoma'],Identification of a permanent PI at site level.,2020-04-01,2026-12-31,"[{'measure': 'No study related undue toxicity or progression in >6 of 11 patients.', 'description': 'No study related undue toxicity (as defined below) or progression within the limits of stage one patients. Toxicity is defined as: progression precluding surgery, unanticipated neurological decompensation, non-completion of neoadjuvant therapy (other than protocol defined dose adjustments or discontinuation), treatment related delay of \\>6 weeks to surgery, and/or major unforeseen surgical complication requiring repeat surgical intervention including other than non-life-threatening infection like meningitis/encephalitis or septicemia.', 'timeFrame': '7 months for each patient from registration.'}, {'measure': 'Progression Free Survival', 'description': 'Progression Free Survival defined as MRI defined progression (increasing FLAIR, enhancement, diffusion and or perfusion) 3 months after completion of therapy (to allow for excluding pseudo progression) OR clinical progression with new or worsening neurological symptoms related to the tumor (by MRI or clinical correlation with location) and not due to non-tumor or study related symptoms.', 'timeFrame': '7 months after completion of therapy'}]",[],2.0,18 Years,89 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,True,False,Identification of a permanent PI at site level.
NCT04326790,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Colchicine,"['Colchicine', 'Standard treatment']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Corona Virus Disease 19 (Covid 19),National and Kapodistrian University of Athens,2025-09-01T16:18:09.635706,True,,,,,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,,['Corona Virus Disease 19 (Covid 19)'],[],Slow enrollment as a result of the rapid flattening of the curve of COVID-19 cases in Greece,2020-04-03,2020-04-27,"[{'measure': 'Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee', 'description': 'Time to clinical deterioration (2 levels in the WHO R\\&D Blueprint scale)', 'timeFrame': '3 weeks'}, {'measure': 'Maximal concentration of cardiac troponin', 'description': 'Maximal concentration of high-sensitivity cardiac troponin', 'timeFrame': '10 days'}]",[],2.0,18 Years,,ALL,False,OTHER,0.0,105.0,ACTUAL,v2_robust,True,False,True,False,Slow enrollment as a result of the rapid flattening of the curve of COVID-19 cases in Greece
NCT02231190,GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage,GSK1278863,"['GSK1278863', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Tendon Injuries,GlaxoSmithKline,2025-09-01T16:18:09.635715,True,,,,,"A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers",,['Tendon Injuries'],"['muscle soreness', 'Muscle damage and recovery', 'muscle function', 'eccentric exercise']",,2015-01-15,2015-06-12,"[{'measure': 'Maximal voluntary contraction (MVC) following eccentric exercise in subjects treated with GSK1278863 or placebo', 'description': 'Muscle strength is a measure of the amount of force produced during a maximal voluntary contraction of the elbow flexors. It will be assessed in the non-dominant arm by a maximal isometric (fixed length) contraction using Cybex ergometer in a seated position after completion of eccentric exercise', 'timeFrame': 'Up to 72 hours (hrs)'}]","[{'measure': 'Change in MVC following eccentric exercise from pre-eccentric exercise in subjects treated with GSK1278863 or placebo', 'description': 'Change in muscle strength from pre-eccentric exercise to completion of eccentric exercise will be assessed', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Percent change in MVC following eccentric exercise from pre-eccentric exercise in subjects treated with GSK1278863 or placebo', 'description': 'Percent change in muscle strength from pre-eccentric exercise to completion of eccentric exercise will be assessed', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Number of subjects with adverse events(AE)', 'description': 'An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product', 'timeFrame': 'Up to Day 15'}, {'measure': 'Vital signs assessment as a safety measure', 'description': 'Vital signs includes systolic and diastolic blood pressure, pulse rate and respiratory rate', 'timeFrame': 'Up to Day 15'}, {'measure': 'Electrocardiogram (ECG) assessment as a safety measure', 'description': ""Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, Total cardiac output (QT), and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals"", 'timeFrame': 'Up to Day 15'}, {'measure': 'Laboratory parameters assessment as a safety measure', 'description': 'Laboratory parameters include hematology, clinical chemistry, and urinalysis', 'timeFrame': 'Up to Day 15'}, {'measure': 'Change in subject pain assessment using a visual analog scale', 'description': 'Arm pain will be assessed for the exercised arm with a visual analog scale on a scale of 0-100 millimeter (mm) during two stimuli; during passive stretching and during MVC contraction, post-exercise and after completion of eccentric exercise', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Change in degree of motion and resting arm angle from post-exercise', 'description': 'Subjects will be asked to maximally flex their elbow and then maximally extend their elbow, joint angle will be measured using a manual goniometer at maximum flexion and maximum extension. Range of motion will be calculated by subtracting the flexion angle from the extension angle', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Composite of PK parameters', 'description': 'PK parameters include maximum observed concentration (Cmax), time of occurrence of Cmax (tmax), and Area under the concentration-time curve from zero (pre-dose) to 24h \\[AUC(0-24)\\]', 'timeFrame': 'Up to Day 2'}]",10.0,18 Years,35 Years,MALE,True,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,True,
NCT00212290,Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes,pioglitazone,"['pioglitazone', 'placebo', 'nateglinide']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Insulin Resistance,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),2025-09-01T16:18:09.635742,True,,,,,,,"['Insulin Resistance', 'Type 2 Diabetes Mellitus']",['impaired glucose tolerance'],,2002-11,2006-12,"[{'measure': 'Verbal memory (main study)'}, {'measure': 'Selective attention (main study)'}, {'measure': 'Plasma beta-amyloid levels (main study)'}, {'measure': 'Cerebral glucose metabolism (sub-study)'}, {'measure': 'Inflammatory markers in spinal fluid (sub-study)'}, {'measure': 'Beta-amyloid in spinal fluid (sub-study)'}]","[{'measure': 'Psychomotor speed'}, {'measure': 'Verbal fluency'}, {'measure': 'Blood levels of insulin, insulin degrading enzyme, cortisol and inflammatory markers'}]",9.0,55 Years,,ALL,True,NIH,0.0,140.0,ESTIMATED,v2_robust,True,True,False,False,
NCT05180890,A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea,Danavorexton,"['TAK-925', 'Placebo', 'Danavorexton']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Sleep Apnea,Takeda,2025-09-01T16:18:09.635755,True,,,,,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Effects of Overnight Intravenous TAK-925 in Patients With Obstructive Sleep Apnea",,['Sleep Apnea'],['Drug Therapy'],,2022-03-10,2022-11-23,"[{'measure': 'Number of Participants With at Least one Treatment-emergent Adverse Event (TEAE)', 'timeFrame': 'From the first dose of danavorexton in Treatment Period 1 up to approximately 7 days after the last dose of danavorexton in Treatment Period 3 (up to 41 days)'}]","[{'measure': 'Change From Baseline in Upper Airway Collapsibility Index (UACI)', 'description': 'The UACI is a 10-minute evaluation that tests the key biological mechanism that causes obstructive sleep apnea (OSA).', 'timeFrame': 'Baseline (-15 minutes from the start of infusion [first UACI]), and at 20 minutes (second UACI), and 55 minutes (third UACI) on Day 1 of each Treatment Period'}, {'measure': 'Apnea-Hypopnea Index (AHI) Observed During Overnight Polysomnographys (PSGs)', 'description': 'PSG analysis will be performed to determine an apnea hypopnea index. AHI score is used to indicate the severity of sleep apnea. The AHI is calculated by dividing the number of apnea events by the number of hours of sleep. An apnea hypopnea index less than five events per hour is considered within normal limits.', 'timeFrame': 'Day 1 up to Day 2 of each Treatment Period'}]",3.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,13.0,ACTUAL,v2_robust,True,True,False,True,
NCT04263090,Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment,Rigosertib,"['Nivolumab', 'Rigosertib']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Non-small Cell Lung Cancer,Icahn School of Medicine at Mount Sinai,2025-09-01T16:18:09.635771,True,,,,,A Phase1/2a Study of Rigosertib Plus Nivolumab in Stage IV Lung Adenocarcinoma Patients With KRAS Mutation Who Progressed on First-Line Treatment,,"['Non-small Cell Lung Cancer', 'Adenocarcinoma', 'Stage IV']","['KRAS', 'Metastatic', 'Rigosertib', 'Immunotherapy', 'Nivolumab']",,2020-06-29,2023-12-20,"[{'measure': 'Maximal Tolerated Dose (MTD)', 'description': 'MTD is defined as the highest dose for which at most 1 patient out of 6 experiences a dose-limiting toxicity (DLT)', 'timeFrame': 'DLTs will be evaluated at the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'ORR is defined as achieving an objective response of either complete response or partial response', 'timeFrame': '2 years'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'Phase 2: PFS is defined as the duration of time from start of treatment to the first occurrence of disease progression or death on study from any cause, whichever occurs earlier.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival (OS) at MTD', 'description': 'Phase 2: OS at MTD is defined as the time from the first dose of study treatment to the date of death (whatever the cause).', 'timeFrame': '2 years'}]",4.0,18 Years,,ALL,False,OTHER,2.0,25.0,ACTUAL,v2_robust,True,True,False,False,
NCT02485990,"Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",Tremelimumab,"['Tremelimumab', 'LYNPARZA', 'Olaparib']",3,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Primary Peritoneal Carcinoma,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2025-09-01T16:18:09.635786,True,,,,,"An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",,['Primary Peritoneal Carcinoma'],"['Fallopian Tube', 'Epithelial Ovarian', 'EOC']",Withdrawal of sponsor support,2016-01-08,2020-03-05,"[{'measure': 'Adverse events as a measure of the safety and tolerability profile of tremelimumab in combination with olaparib', 'description': 'Number of participants experiencing study drug-related dose limiting toxicities (DLTs). Dose escalation (phase I) portion of the trial only.', 'timeFrame': '4 years'}, {'measure': 'Fold change from baseline in the ratio of peripheral CD4+ICOShi T cells and Regulatory T cells', 'description': 'Dose escalation (phase I) portion of the trial only.', 'timeFrame': '4 years'}, {'measure': 'Maximum Tolerated Dose (MTD) of tremelimumab combined with olaparib', 'description': 'Dose escalation (phase I) portion of the trial only.', 'timeFrame': '4 years'}]","[{'measure': 'Progression Free Survival (PFS) Rate at 6 months by RECIST', 'description': 'PFS rate is defined as the percentage of patients with disease progression (PD or relapse from CR as assessed using RECIST 1.1 criteria) or death due to any cause at 6 months. Per RECIST 1.1 criteria, Complete Response (CR) = disappearance of all target lesions, Partial Response (PR) is =\\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \\>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.', 'timeFrame': '6 months'}, {'measure': 'Progression Free Survival (PFS) Rate at 6 months by irRECIST', 'description': 'PFS rate is defined as the percentage of patients with disease progression (irPD or relapse from irCR as assessed using irRECIST criteria) or death due to any cause at 6 months. Per irRECIST criteria, irCR = disappearance of all lesions, irPR is =\\>30% decrease in tumor burden, irPD is \\>20% increase in tumor burden compared with nadir, irSD is \\<30% decrease in tumor burden compared with baseline cannot be established nor \\<20% increase compared with nadir. Estimation based on the Kaplan-Meier curve.', 'timeFrame': '6 months'}, {'measure': 'Objective Response Rate (ORR) by RECIST', 'description': 'Objective Response Rate (ORR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. Per RECIST 1.1 criteria, CR = disappearance of all target lesions and PR is =\\>30% decrease in sum of diameters of target lesions.', 'timeFrame': '4 years'}, {'measure': 'Objective Response Rate (ORR) by irRECIST', 'description': 'Objective Response Rate (irORR) is defined as the percentage of patients achieving a complete response (irCR) or partial response (irPR) based on irRECIST criteria. Per irRECIST criteria, irCR = disappearance of all lesions and irPR is =\\>30% decrease in tumor burden.', 'timeFrame': '4 years'}, {'measure': 'Duration of Response by RECIST', 'description': 'Number of months from the start date of PR or CR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions, and PD is \\>20% increase in sum of diameters of target lesions.', 'timeFrame': '4 years'}, {'measure': 'Duration of Response by irRECIST', 'description': 'Number of months from the start date of irPR or irCR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented. Per irRECIST criteria, irCR = disappearance of all lesions, irPR is =\\>30% decrease in tumor burden, and irPD is is \\>20% increase in tumor burden compared with nadir.', 'timeFrame': '4 years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR is defined as the number of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST 1.1 criteria at any time during the study. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions, PD is \\>20% increase in sum of diameters of target lesions, SD is \\<30% decrease or \\<20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.', 'timeFrame': '4 years'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the number of patients with disease progression (progressive disease \\[PD\\] or relapse from complete response \\[CR\\] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \\>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.', 'timeFrame': '4 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS will be measured from date of first dose until death or end of followup (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.', 'timeFrame': '4 years'}]",12.0,18 Years,,ALL,False,OTHER,2.0,24.0,ACTUAL,v2_robust,True,False,True,True,Withdrawal of sponsor support
NCT02805790,"Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study",Elamipretide,"['Bendavia', 'MTP-131', 'Elamipretide', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Primary Mitochondrial Disease,Stealth BioTherapeutics Inc.,2025-09-01T16:18:09.635793,True,,,,,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate Safety, Tolerability, and Efficacy of Subcutaneous Injections of MTP-131 in Subjects With Mitochondrial Myopathy Previously Treated in the SPIMM-201 Study",,['Primary Mitochondrial Disease'],"['Primary Mitochondrial Disease', 'Mitochondrial Myopathy', 'Elamipretide', 'MTP-131', 'Bendavia™']",,2016-08-22,2017-03-23,"[{'measure': 'Distance Walked on the 6-minute Walk Test (6MWT) by Visit', 'description': 'Distance in meters walked on the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of week 4 for Period 1 and end of week 12 for Period 2.', 'timeFrame': 'End of Week 4 and End of Week 12'}]","[{'measure': 'Wrist Accelerometer Counts by Day', 'description': 'Wrist Accelerometer Counts by the last 7 days prior to the date of the end of treatment visit; End of treatment being end of Week 4 for Treatment Period 1 and end of Week 12 for Treatment Period 2. Subjects wore an activity monitor, or wrist accelerometer, on their wrist daily (from the Screening Visit to the End-of-Study/Early Discontinuation Visit). As a measure of physical activity and mobility, subjects wore an activity monitor, or wrist accelerometer, which measured mean vector magnitude of accelerations per daywith higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data were used for the analysis of as the vector magnitude of the wrist data.', 'timeFrame': 'Last 7 days prior to the date of end of treatment visit'}, {'measure': 'Average Hip Accelerator Counts by Day', 'description': 'Average Hip Accelerator Counts by last 7 days predose, and prior to end of treatment; End of treatment being Week 4 for Treatment Period 1 and Week 12 for Treatment Period 2. As a measure of physical activity and mobility, subjects wore an activity monitor, or hip accelerometer, on their hip (or belt line) daily during waking hours (minimum of at least 7 consecutive days immediately prior to study drug administration in each Treatment Period \\[Predose; at Visit 2 for Treatment Period 1 and at Visit 4 for Treatment Period 2\\]), and at the end of each Treatment Period \\[at Visit 3 for Treatment Period 1 and Visit 5 for Treatment Period 2\\]), which measured average acceleration per day, with higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data was used for the analysis of mean vertical axis (Y) cou', 'timeFrame': 'Last 7 days prior to the date of end of treatment visit'}, {'measure': 'Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8)', 'description': 'Participants respond to the following statements of the Quality of Life in Neurological Disorders Fatigue Assessment (Neuro-QOL Fatigue Item Bank at end of treatment: I felt exhausted;I felt that I had no energy; I felt fatigued; I was too tired to do my household chores;I was too tired to leave the house;I was frustrated by being too tired to do the things I wanted to do; I felt tired; I had to limit my social activity because I was tired.Individual response options range from a score of 1 to 5, where 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always for end of treatment, where end of treatment period is end of week 4 for period 1, and end of week 12 for period 2. Raw scores are calculated as simple summed scores to an Item Response Theory Metric referred to as the T-score metric. Higher T-score means more fatigue, which means a worse outcome, with possible scores ranging from 29.5 to 74.1. Mean population T-score and standard deviation was reported.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week', 'description': 'Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue score at end of treatment (sum of Q1 to Q4; tiredness/muscle weakness) is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Participants rate the following: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period, where end of treatment period is the weekly average of the last 7 days of week 4 for period 1 and the last 7 days of week 12 for period 2.', 'timeFrame': 'Last 7 days of Week 4 and Last 7 days of Week 12'}, {'measure': 'Triple Timed Up and Go (3TUG) Test by Visit', 'description': 'Participant performed 3TUG test after the 6MWT, and after at least 15 minutes rest prior to study drug administration in each Treatment Period (End of Week 4 for Period 1 and End of Week 12 for Period 2.) Participant was directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away,turn, walk back to the chair at normal pace, sit down again; activity was timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Patient Global Assessment [PGA] Score by Visit, Continuous', 'description': 'Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Patient Global Assessment by Visit, Categorical', 'description': 'Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Physician Global Assessment (PhGA) By Visit, Continuous', 'description': 'Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Physician Global Assessment (PhGA) By Visit, Categorical', 'description': 'Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}]",10.0,16 Years,,ALL,False,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT06629090,Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort,Prazosin,"['Prazosin', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Magnetic Resonance Imaging,"University of Wisconsin, Madison",2025-09-01T16:18:09.635906,True,,,,,Cerebrovascular Responses to Acute Hypoperfusion,,"['Magnetic Resonance Imaging', 'Cerebrovascular Circulation']","['Magnetic Resonance Imaging', 'Brain Blood Flow', 'Lower Body Negative Pressure', 'Carbon Dioxide']",,2025-09,2026-10,"[{'measure': 'Change in blood velocity', 'description': 'The change in blood velocity during breathing and simulated postural change tasks will be measured with MRI', 'timeFrame': 'Two study visits, up to 240 minutes'}, {'measure': 'Change in blood flow', 'description': 'The change in intracranial blood flow during breathing and simulated postural change tasks will be measured with MRI', 'timeFrame': 'Two study visits, up to 240 minutes'}]",[],2.0,20 Years,40 Years,ALL,True,OTHER,0.0,36.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03667690,Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis,Rezafungin for Injection,"['encapsulated cellulose', 'generic fluconazole', 'Fluconazole', 'Caspofungin', 'oral placebo', 'intravenous placebo', 'placebo infusion', 'Rezafungin for Injection', 'Cancidas']",9,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Candidemia,Cidara Therapeutics Inc.,2025-09-01T16:18:09.635928,True,,,,,"A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis",,"['Candidemia', 'Mycoses', 'Fungal Infection', 'Invasive Candidiases']","['Mycoses', 'Candidiasis', 'Candidiasis, Invasive', 'Candidemia', 'Fungemia', 'Sepsis', 'Invasive Fungal Infections', 'Systemic Inflammatory Response Syndrome', 'Pathologic Processes', 'Fluconazole', 'Caspofungin', 'Echinocandins', 'Antifungal Agents', 'Anti-infective Agents', '14-alpha Demethylase Inhibitors', 'Cytochrome P-450 Enzyme Inhibitors', 'Enzyme Inhibitors', 'Molecular Mechanisms of Pharmacological Action', 'Steroid Synthesis Inhibitors', 'Physiological Effects of Drugs', 'Cytochrome P-450 CYP2C9 Inhibitors', 'Cytochrome P-450 CYP2C19 Inhibitors']",,2018-10-07,2021-10-07,"[{'measure': 'All-Cause Mortality (US FDA Only)', 'description': 'The number and percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.', 'timeFrame': 'Day 30 (-2 days)'}, {'measure': 'Global Response as Assessed by Data Review Committee (EU European Medicines Agency [EMA] Only)', 'description': 'The number and percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure \\[for qualifying invasive candidiasis subjects at baseline\\], and mycological eradication, as confirmed by the Data Review Committee \\[DRC\\]), failure and indeterminate in the mITT population. A global response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the global responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 7 (Global Response) of the clinical protocol.', 'timeFrame': 'Day 14 (±1 day)'}]","[{'measure': 'Global Response as Assessed by Data Review Committee (US FDA Only)', 'description': 'The number and percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure \\[for qualifying invasive candidiasis subjects at baseline\\], and mycological eradication, as confirmed by the Data Review Committee \\[DRC\\]), failure and indeterminate in the mITT population. A global response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the global responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 7 (Global Response) of the clinical protocol.', 'timeFrame': 'Day 14 (±1 day)'}, {'measure': 'All-Cause Mortality (EU EMA Only)', 'description': 'The number and percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.', 'timeFrame': 'Day 30 (-2 days)'}, {'measure': 'Comparison of Global Response (as Assessed by the DRC) by Visit', 'description': 'The number and percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure \\[for qualifying invasive candidiasis subjects at baseline\\], and mycological eradication, as confirmed by the Data Review Committee \\[DRC\\]), failure and indeterminate in the mITT population. A global response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the global responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 7 (Global Response) of the clinical protocol.', 'timeFrame': 'Day 5, Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose) and Follow-up (Days 52-59)'}, {'measure': 'Comparison of Mycological Eradication by Visit', 'description': 'The number and percentage of subjects in each treatment group who have a mycological response of eradication, failure, or indeterminate in the mITT population. A mycological response of eradication means clearance of objective evidence of infection and is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was eradication or failure. Definitions for the mycological responses of eradication, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 8 (Mycological Response) of the clinical protocol.\n\nNote: Eradication includes both documented and presumed eradication.', 'timeFrame': 'Day 5, Day 14 (±1 day), Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose), and Follow-up (Days 52-59)'}, {'measure': ""Comparison of Investigators' Assessment of Clinical Response by Visit"", 'description': ""The number and percentage of subjects in each treatment group for whom the Investigator determined a clinical response of cure, failure, or indeterminate in the mITT population. A clinical response of cure, as assessed by the Investigator, is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the clinical responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 9 (Investigator's Assessment of Clinical Response) of the clinical protocol."", 'timeFrame': 'Day 5, Day 14 (±1 day), Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose), and Follow-up (Days 52-59)'}, {'measure': 'Comparison of Radiological Response by Investigator by Visit', 'description': 'The number and percentage of subjects with invasive candidiasis (documented by radiologic/imaging evidence at baseline) in each treatment group who have a radiological response (as assessed by the Investigator) of cure, failure, and indeterminate in the mITT population. A radiological response of cure is indicative of an efficacious outcome and the desired result, whereas a response of failure is indicative of a non-efficacious outcome and the undesired response. Indeterminate responses indicate there was not enough data obtained to determine if the response was cure or failure. Definitions for the radiological responses of cure, failure, and indeterminate are complex. Detailed definitions for the possible responses to this outcome measure type are provided in Table 10 (Radiological Response) of the clinical protocol.', 'timeFrame': 'Day 5, Day 14 (±1 day), Day 30 (-2 days), End of Treatment (EOT) (≤2 days of last dose), and Follow-up (Days 52-59)'}, {'measure': 'Number of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'The number and percentage of subjects in each treatment group that experienced at least one treatment-emergent adverse event (TEAE) based on clinical chemistry, hematology and urine analysis laboratory test, vital sign, physical exams and electrocardiogram (ECG) abnormalities.\n\nNotes: A subject with multiple adverse events (AEs) was counted only once. TEAE was defined as an AE that occurred during or after study drug administration and up through the Follow-up visit. The maximum severity and strongest relationship were counted for subjects with multiple events.', 'timeFrame': 'Day 1 through Follow-up Visit (Days 52-59)'}, {'measure': 'Evaluate Pharmacokinetics (Cmax)', 'description': 'Evaluate the maximum plasma concentration (Cmax) of rezafungin for injection.', 'timeFrame': 'Day 1, 10 minutes before the end of infusion'}, {'measure': 'Evaluate Pharmacokinetics (Cmin)', 'description': 'Evaluate the minimum plasma concentration (Cmin) of rezafungin for injection.', 'timeFrame': 'Day 8, pre-dose, within 30 minutes prior to the start of infusion'}, {'measure': 'Evaluate Pharmacokinetics (Cmin)', 'description': 'Evaluate the minimum plasma concentration (Cmin) of rezafungin for injection.', 'timeFrame': 'Day 15, pre-dose, within 30 minutes prior to the start of infusion'}, {'measure': 'Evaluate Pharmacokinetics (Cmin)', 'description': 'Evaluate the minimum plasma concentration (Cmin) of rezafungin for injection.', 'timeFrame': 'Day 22, pre-dose, within 30 minutes prior to the start of infusion'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,199.0,ACTUAL,v2_robust,True,True,False,True,
NCT02906397,Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC),Galunisertib 150mg by mouth twice a day,"['Galunisertib 150mg by mouth twice a day', 'LY2157299']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,ADVANCED HEPATOCELLULAR CARCINOMA (HCC),Abramson Cancer Center at Penn Medicine,2025-09-01T16:18:09.636048,True,,,,,A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC),,['ADVANCED HEPATOCELLULAR CARCINOMA (HCC)'],[],,2017-03-30,2021-07-21,"[{'measure': 'Safety based upon standard laboratory and clinical adverse event monitoring', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4', 'timeFrame': 'Cycle 1 Day 15 through date of progression assessed up to 90 months'}]","[{'measure': 'Progression free survival (PFS) who are receiving the combination of galunisertib plus SBRT as compared to the PFS of Galunisertib alone in historical controls.', 'description': 'From Cycle 1 Day 1 to progression of disease', 'timeFrame': 'Cycle 1 Day 15 through date of progression assessed up to 90 months'}, {'measure': 'Response rate', 'description': 'by conventional CT and MRI', 'timeFrame': 'Cycle 3 Day 1 and every 8 weeks thereafter up to 90 months'}, {'measure': 'Overall survival (OS)', 'description': 'start of treatment to death due to any cause or last patient contact alive', 'timeFrame': 'Cycle 1 Day 1 to death due to any cause or last patient contact alive up to 90 months'}, {'measure': 'Inhibition of TGF-β signaling by intervention as evidenced by downstream changes in this pathway', 'timeFrame': 'Cycle 1 Day 15 through date of progression assessed up to 90 months'}, {'measure': 'Promotion of anti-tumor immunity with addition of intervention to SBRT', 'timeFrame': 'Cycle 1 Day 15 through date of progression assessed up to 90 months'}]",6.0,18 Years,,ALL,False,OTHER,0.0,15.0,ACTUAL,v2_robust,True,True,False,True,
NCT00996697,Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD),Budesonide/formoterol and tiotropium,"['Budesonide/formoterol and placebo', 'Budesonide/formoterol and tiotropium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,COPD,Brian J Lipworth,2025-09-01T16:18:09.636079,True,,,,,A Proof Of Concept Study To Evaluate Tiotropium as Add-on Therapy to Inhaled Budesonide/Formoterol Combination in COPD,,['COPD'],['COPD (chronic obstructive pulmonary disease)'],,2006-10,2008-09,"[{'measure': 'Change in trough FEV1 for tiotropium compared to placebo when added to formoterol/budesonide combination', 'timeFrame': '2 weeks'}]","[{'measure': 'Change in IOS and bodyplethysmography at trough for tiotropium compared to placebo when added to formoterol/budesonide combination', 'timeFrame': '2 weeks'}, {'measure': 'Change in spirometry, IOS and Bodyplethysmography at trough for formoterol/budesonide compared to washed-out baseline', 'timeFrame': '4 weeks'}]",3.0,50 Years,,ALL,False,OTHER,0.0,23.0,ACTUAL,v2_robust,True,True,False,False,
NCT02321397,To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain,Oxycodone,"['Oxycodone', 'Naloxone']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Malignant Pain,Mundipharma Research GmbH & Co KG,2025-09-01T16:18:09.636107,True,,,,,"Randomised, Double-blind, Double-dummy, Cross-over Multicenter Study to Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Taking Oxycodone Equivalents of 120 & 160 mg Per Day as Achieved With the Higher OXN PR Tablet Strengths (OXN60/30 mg PR, OXN80/40 mg PR) BID Compared to the Identical Daily Dose Taken as a Combination of Lower Tablet Strengths in Subjects With Non-malignant or Malignant Pain That Requires Around-the-clock Opioid Therapy.",,"['Malignant Pain', 'Non-malignant Pain']","['oxycodone naloxone combination', 'severe chronic and non-malignant pain', 'Malignant and non-malignant pain that requires around-the clock opioid therapy']",,2014-11,2016-09,"[{'measure': '(mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale.)', 'description': 'Pain scores based on the mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale. To demonstrate equivalence between multiple lower strength OXN PR tablets and a single higher strength OXN PR tablet taken at the same overall total daily dose', 'timeFrame': '24 hours at one day in week 2, 3 5 and 6 from date of randomisation.'}, {'measure': 'Equivalent bowel function as assessed by the Bowel Function Index (BFI).', 'timeFrame': 'Week 2, 3 5 and 6 from date of randomisation.'}]","[{'measure': 'Pain scores of subjects average pain over the last 24 hours and rescue medication use.', 'timeFrame': 'Week 1,2,3,4,5 and 6 from date of randomisation'}, {'measure': 'To assess bowel function (assess BFI and laxative use)', 'description': 'To assess BFI and laxative use', 'timeFrame': 'Week 1,2,3,4,5 and 6 from date of randomisation'}, {'measure': 'To assess quality of life based on the EuroQol EQ-5D.', 'description': 'EuroQol EQ-5D is a standardized instrument for use as a measure of health outcome.', 'timeFrame': 'Visit 3 and visit 6 from date of randomisation'}, {'measure': 'Number of participants with adverse events, high/low laboratory values and clinically significant ECG findings.', 'timeFrame': 'Up to 35 weeks'}, {'measure': 'Pain right now scores at intake of oxycodone/naloxone tablets.', 'timeFrame': 'Week 2,3,5 and 6 from date of randomisation'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,155.0,ACTUAL,v2_robust,True,True,False,True,
NCT03822897,De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma,Cisplatin,"['No available', 'Cisplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Oropharyngeal Cancer,Canadian Cancer Trials Group,2025-09-01T16:18:09.636158,True,,,,,A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma,,['Oropharyngeal Cancer'],[],,2019-06-28,2025-06-30,"[{'measure': 'Event-free Survival', 'description': 'Time to first progress event or censoring in year', 'timeFrame': '5 years'}]","[{'measure': 'Overall Survival', 'description': 'Time to death or censoring in year', 'timeFrame': '5 years'}, {'measure': 'Local control', 'description': 'Percentage of patients with local control', 'timeFrame': '5 years'}, {'measure': 'Regional Control', 'description': 'Percentage of patients with regional control', 'timeFrame': '5 years'}, {'measure': 'Locoregional control', 'description': 'Percentage of patients with local and regional control', 'timeFrame': '5 years'}, {'measure': 'Distant Metastasis-Free Survival', 'description': 'Time to distant metastasis or censoring in year', 'timeFrame': '5 years'}]",6.0,18 Years,,ALL,False,NETWORK,0.0,103.0,ACTUAL,v2_robust,True,False,False,False,
NCT02755597,A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,Venetoclax,"['VENCLYXTO', 'Placebo for venetoclax', 'VENCLEXTA', 'Bortezomib', 'Venetoclax', 'Dexamethasone', 'Velcade']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Relapsed/Refractory Multiple Myeloma,AbbVie,2025-09-01T16:18:09.636195,True,,,,,"A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors",,['Relapsed/Refractory Multiple Myeloma'],"['Relapsed/refractory multiple myeloma', 'Relapsed multiple myeloma', 'Refractory multiple myeloma', 'Multiple myeloma']",,2016-07-11,2022-08-15,"[{'measure': 'Progression-free Survival (PFS)', 'description': 'PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.', 'timeFrame': 'Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group'}]","[{'measure': 'Very Good Partial Response (VGPR) or Better Response Rate', 'description': 'The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \\[CR\\], or Stringent complete response \\[sCR\\]) per 2016 standard International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC) was computed.', 'timeFrame': 'Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group'}, {'measure': 'Progression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression', 'description': 'PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) per investigator assessment or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.\n\nBCL-2 expression was determined through central laboratory testing by immunohistochemistry (IHC) and based on a pre-specified scoring algorithm. High clinical score of 2+: ≥50% of tumor cells with moderate or higher cytoplasmic staining but \\< 50% of tumor cells with strong staining intensity; high clinical score of 3+: ≥50% of tumor cells with strong cytoplasmic staining.', 'timeFrame': 'Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group'}, {'measure': 'Duration of Response (DOR)', 'description': ""DOR is defined as the number of days from the participant's date of first documented response (partial response \\[PR\\] or better) to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan-Meier methodology."", 'timeFrame': 'Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group'}, {'measure': 'Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain', 'description': 'The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its ""worst in last 24 hours,"" ""least in last 24 hours,"" ""average,"" and ""now"" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.', 'timeFrame': 'Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment'}, {'measure': 'Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)', 'description': 'The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as ""not at all"" and 4 as ""very much."" The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.', 'timeFrame': 'Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment'}, {'measure': 'Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)', 'description': 'The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as ""very poor"" and 7 as ""excellent."" The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.', 'timeFrame': 'Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment'}, {'measure': 'Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score', 'description': 'PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \\[PROMIS\\] Cancer Fatigue Short Form \\[SF\\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.', 'timeFrame': 'Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment'}, {'measure': 'Overall Survival (OS).', 'description': 'OS is defined as the number of days from the date of randomization to the date of death due to any cause. All events of death were to be included, regardless of whether the event occurred while the participant was still taking study drug or after the participant discontinued study drug. If a participant is not known to have died, OS was censored at the date of last contact. The distribution of OS was estimated using Kaplan-Meier methodology.', 'timeFrame': 'Median duration of follow-up was 45.6 months for the venetoclax group and 45.6 months for the placebo group'}, {'measure': 'Time to Progression (TTP)', 'description': 'TTP is defined as the number of days from the date of randomization to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan-Meier methodology.', 'timeFrame': 'Median time on follow-up up was 28.6 months for the venetoclax group and 28.6 months for the placebo group'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \\[VGPR\\], Complete response \\[CR\\], or Stringent complete response \\[sCR\\]) per International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC).', 'timeFrame': 'Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group'}, {'measure': 'Minimal Residual Disease (MRD) Negativity Rate', 'description': 'MRD negativity rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any time point after randomization and before progression or starting subsequent therapy. MRD negativity was defined at 10\\^-5 threshold (less than one residual myeloma cell per 10\\^5 total nucleated cells) as measured by centralized testing of bone marrow aspirate by Next Generation Sequencing (NGS). MRD positive participants include those of which all tested samples were found to be MRD positive or indeterminate. Participants with missing or unevaluable MRD status were considered as MRD positive.', 'timeFrame': 'Assessed at Screening; to confirm a stringent Complete Response (sCR) or Complete Response (CR); at 6 months and 12 months post-confirmed CR/sCR'}]",12.0,18 Years,99 Years,ALL,False,INDUSTRY,1.0,291.0,ACTUAL,v2_robust,True,True,False,False,
NCT02099110,"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)",Matching Placebo to Ertugliflozin 5 mg,"['Matching Placebo to Ertugliflozin 5 mg', 'AMARYL', 'JANUVIA®', 'Ertugliflozin 10 mg', 'Glimepiride Rescue Medication', 'Metformin >= 1500 mg/day', 'Ertugliflozin 5 mg', 'Matching Placebo to Ertugliflozin 10 mg', 'Sitagliptin 100 mg', 'Glucophage XR', 'Matching Placebo to sitagliptin 100 mg', 'MK-8835', 'Glucophage', 'PF-04971729']",14,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,2025-09-01T16:18:09.636292,True,,,,,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy",,['Type 2 Diabetes Mellitus'],[],,2014-04-22,2016-05-26,"[{'measure': 'Change From Baseline in A1C at Week 26: Excluding Rescue Approach', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.', 'timeFrame': 'Up to 54 weeks'}, {'measure': 'Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.', 'timeFrame': 'Up to 52 weeks'}]","[{'measure': 'Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach', 'description': 'This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach', 'description': 'Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach', 'description': 'A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Week 26'}, {'measure': 'Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach', 'description': 'Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \\* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \\[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\\] and model-based \\[beta cell function and insulin secretion rate at 9 mM glucose\\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\\^-9 min\\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': '30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26'}, {'measure': 'Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach', 'description': 'This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}]",8.0,18 Years,,ALL,False,INDUSTRY,1.0,1233.0,ACTUAL,v2_robust,True,True,False,True,
NCT03226210,Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes,aspart insulin or lipro insulin,['aspart insulin or lipro insulin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Diabetes Mellitus, Type 2","Nanjing First Hospital, Nanjing Medical University",2025-09-01T16:18:09.636306,True,,,,,Comparison of Efficacy and Safety of Prandilin and NovoRapid Evaluated by Continuous Glucose Monitoring System in Newly Diagnosed Type 2 Diabetes,,"['Diabetes Mellitus, Type 2']","['Diabetes Mellitus', 'Rapid-acting insulin analogues', 'Continuous glucose monitoring system (CGMS)', 'Continuous subcutaneous insulin infusion (CSII)']",,2015-02-01,2016-07-01,"[{'measure': 'The primary endpoint was the between-group difference of MAGE', 'description': 'the 24-h mean amplitude of glycemic excursions (MAGE)', 'timeFrame': '14 days'}]",[],1.0,18 Years,70 Years,ALL,False,OTHER,0.0,110.0,ACTUAL,v2_robust,True,True,False,False,
NCT02816710,Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy,Conbercept,['Conbercept'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Proliferative Diabetic Retinopathy,Ruijin Hospital,2025-09-01T16:18:09.636314,True,,,,,Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy,,"['Proliferative Diabetic Retinopathy', 'Tractional Retinal Detachment']","['Conbercept', 'Proliferative diabetic retinopathy', 'Silicone oil tamponade']",,2016-07,2017-09,"[{'measure': 'Best-corrected Visual Acuity', 'timeFrame': '6 months'}, {'measure': 'Duration of Surgery', 'description': 'To evaluate the influence of these three methods to the final duration of surgery. We carefully estimated the time of the vitrectomy from insertion to extraction of the 23-gauge three-port trocars.', 'timeFrame': 'during the operation time'}, {'measure': 'Intraoperative Bleeding', 'description': 'The grading criteria for intraoperative bleeding: Grade 1, spontaneous cessation of minor bleeding or bleeding that stopped by transient elevation of perfusion pressure; Grade 2, moderate bleeding requiring endodiathermy or broad blood clots formed far away from the bleeding site; Grade 3, thick blood clots exceeding half of the posterior pole or affecting the operation field.', 'timeFrame': 'Time between the insertion and extraction of three 23-gauge vitrectomy ports'}]","[{'measure': 'Postoperative Preretinal Blood', 'description': 'The grading criteria for postoperative preretinal blood: Grade 1, isolated blood clots within 10 disk area but without covering the posterior pole; Grade 2, broad blood clots exceeding 10 disk area regardless of involvement of the posterior pole; Grade 3, broad blood clots exceeding 10 disk area as well as involving the posterior pole. Maximal extent of preretinal blood within 1 week postoperatively was used for grading the extent of hemorrhage.', 'timeFrame': 'postoperatively, up to 1 week'}, {'measure': 'Reabsorption Time of Blood', 'description': 'To monitor the reabsorption time of preretinal blood.', 'timeFrame': 'follow up period, up to an average of 6 months after the operation'}, {'measure': 'Recurrent Vitreous Hemorrhage', 'description': 'Recurrent vitreous hemorrhage(VH) was referred to any new episode of VH occurring after one week postoperatively, dividing into early stage (≤ 4 weeks) and late stage (\\> 4 weeks).', 'timeFrame': 'follow up period, up to an average of 6 months after the operation'}, {'measure': 'Frequency of Intraoperative Electrocoagulation', 'description': 'The number of times electrocoagulation, which was used to stop bleeding, was carefully counted.', 'timeFrame': 'during the operation time'}, {'measure': 'Number of Participants With Neovascular Glaucoma (NVG)', 'timeFrame': 'follow up period, up to an average of 6 months after the operation'}, {'measure': 'Recurrent Retinal Detachment', 'timeFrame': 'follow up period, up to an average of 6 months after the operation'}, {'measure': 'Need for Reoperation', 'description': 'due to recurrent retinal detachment or unclear vitreous hemorrhage', 'timeFrame': 'follow up period, up to an average of 6 months after the operation'}]",10.0,18 Years,,ALL,False,OTHER,0.0,112.0,ACTUAL,v2_robust,True,True,False,False,
NCT04081610,Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution,lagricel ofteno multidose,"['lagricel ofteno single dose', 'sodium hyaluronate 0.4%', 'lagricel ofteno multidose']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Dry Eye,Laboratorios Sophia S.A de C.V.,2025-09-01T16:18:09.636399,True,,,,,Phase I Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Compared to Lagricel® Ofteno Single Dose on the Ocular Surface of Clinically Healthy Subjects,,['Dry Eye'],"['Dry eye', 'eye lubricant', 'sodium hyaluronate']",,2019-09-09,2019-11-13,"[{'measure': 'Presence of Adverse Events (AEs)', 'description': 'the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent', 'timeFrame': 'during the 10 days of evaluation, including the safety call (day 11).'}, {'measure': 'Eye Comfort Index (ECI)', 'description': 'It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).', 'timeFrame': 'will be evaluated at the end of the treatment (day 8, final visit)'}]","[{'measure': 'Visual Acuity (VA)', 'description': 'Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.', 'timeFrame': 'will be evaluated at the end of the treatment (day 8, final visit)'}, {'measure': 'Epithelial Defects (ED) Fluorescein Stain', 'description': 'The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.', 'timeFrame': 'will be evaluated at the end of the treatment (day 8, final visit)'}, {'measure': 'Epithelial Defects (ED) Green Lissamine', 'description': 'The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.', 'timeFrame': 'will be evaluated at the end of the treatment (day 8, final visit)'}, {'measure': 'Conjunctival Hyperemia (CH)', 'description': 'Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.', 'timeFrame': 'will be evaluated at the end of the treatment (day 8, final visit)'}, {'measure': 'Chemosis', 'description': 'It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening', 'timeFrame': 'will be evaluated at the end of the treatment (day 8, final visit)'}]",7.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,34.0,ACTUAL,v2_robust,True,True,False,True,
NCT04821310,Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years,Full dose Pantoprazole plus matching placebo,"['Half Dose Pantoprazole plus matching placebo', 'Full dose Pantoprazole plus matching placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Esophagitis,Pfizer,2025-09-01T16:18:09.636418,True,,,,,"AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEARS WHO REQUIRE MAINTENANCE THERAPY FOR HEALED EROSIVE ESOPHAGITIS",,['Esophagitis'],"['Erosive', 'esophagitis']",,2022-01-13,2030-05-09,"[{'measure': 'Proportion of patients with endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24, considering patients with excessive use of rescue medication as treatment failures', 'description': 'Endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24.', 'timeFrame': 'Week 24'}]","[{'measure': 'Number of Participants With Change From Baseline in Physical Examinations and Vital Signs', 'description': 'Safety and tolerability will be assessed by physical examinations, blood pressure, and pulse rate.', 'timeFrame': 'Baseline up to 36 weeks'}, {'measure': 'Incidence of Adverse Events (AEs)', 'timeFrame': 'Baseline up to 36 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Laboratory Tests Results', 'description': 'Safety and tolerability will be assessed by clinical laboratory measurements', 'timeFrame': 'Baseline up to 36 weeks'}]",4.0,1 Year,17 Years,ALL,False,INDUSTRY,0.0,110.0,ACTUAL,v2_robust,True,False,False,True,
NCT07044310,5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss,WBF-038,"['Synbiotic Formulation WBF-038 (SY)', 'WBF-038', 'WBF-038 (CN)', 'Akkermansia muciniphila/Anaerobutyricum hallii/Bifidobacterium infantis/Clostridium beijerinckii/Clostridium butyricum/Inulin WBF-038', 'WBF038 (CN)', 'WBF 038 (CN)', 'Pendulum WBF-038 (SY)', 'Probiotic/Prebiotic Formulation WBF-038 (SY)']",8,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8,Mayo Clinic,2025-09-01T16:18:09.636429,True,,,,,Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss,,"['Anatomic Stage 0 Breast Cancer AJCC v8', 'Anatomic Stage I Breast Cancer AJCC v8', 'Anatomic Stage II Breast Cancer AJCC v8', 'Anatomic Stage III Breast Cancer AJCC v8', 'Hormone Receptor-Positive Breast Carcinoma']",[],,2025-07-25,2027-07-25,"[{'measure': 'Change in C-terminal telopeptide of type 1 collagen (CTx)', 'description': 'Assessed by standard lab tests at baseline (at study enrollment/eligibility assessment before any therapy) followed by 6 study visits. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.', 'timeFrame': 'Baseline; 90 days after start of AI therapy (before beginning WBF-038); 14 days after start of WBF-038; 90 days after start of WBF-038; 180 days after start of WBF-038; 365 days after start of WBF-038; 90 days after stopping WBF-038'}]","[{'measure': 'Change in lumbar spine mineral density', 'description': 'Will be measured by central dual energy x-ray absorptiometry. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.', 'timeFrame': 'Baseline; 365 days after start of WBF-038'}, {'measure': 'Change in hip bone mineral density', 'description': 'Will be measured by central dual energy x-ray absorptiometry. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.', 'timeFrame': 'Baseline; 365 days after start of WBF-038'}, {'measure': 'Incidence of adverse events', 'description': 'Will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': 'Baseline; 90 days after start of AI therapy (before beginning WBF-038); 90 days after start of WBF-038; 365 days after starting WBF-038; 90 days after stopping WBF-038;'}]",4.0,18 Years,,FEMALE,False,OTHER,0.0,38.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06069310,"Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma",Mepolizumab 100 MG,"['nucala', 'Mepolizumab 100 MG']",2,OBSERVATIONAL,[],,RECRUITING,Chronic Rhinosinusitis With Nasal Polyps,National and Kapodistrian University of Athens,2025-09-01T16:18:09.636495,True,,,,,Evaluation of Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis With Nasal Polyps and Comorbid Severe Eosinophilic Asthma: an Integrative Multi-omics Approach to Assess Biomarker Signatures of Responsive Disease Endotypes,,"['Chronic Rhinosinusitis With Nasal Polyps', 'Severe Eosinophilic Asthma', 'Chronic Rhinosinusitis Without Nasal Polyps']","['Chronic Rhinosinusitis', 'Severe Eosinophilic Asthma', 'Microbiome', 'Nasal Polyps', 'Mepolizumab']",,2023-09-01,2025-12-20,"[{'measure': 'Mean change from baseline in Sino-nasal outcome test-22 (SNOT-22) score', 'description': 'SNOT-22 score will be considered as a measure of post-treatment alterations in CRSwNP clinical symptoms', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Asthma control test (ACT)', 'description': 'ACT will assess potential treatment-induced alterations in asthma symptoms', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}]","[{'measure': 'Mean change of nasal endoscopic polyps score', 'description': 'Nasal endoscopic polyps score will be considered as a measure of post-treatment alterations in CRSwNP participants', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Mean change of the polyposis severity visual analog scale (VAS) score', 'description': 'Polyposis severity VAS score will estimate potential post-treatment changes in CRSwNP participants', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Forced Expiratory Volume at 1 s % (%FEV1: FEV1/FEV1 predicted) and Morning Peak Expiratory Flow measurements', 'description': 'FEV1: FEV1/FEV1 predicted and Morning Peak Expiratory Flow measurements will assess potential treatment-induced alterations in pulmonary function', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Fractional Exhaled Nitric Oxide Testing (FENO)', 'description': 'FENO measurements will assess potential treatment-induced alterations in airways inflamation', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Forced oscillation technique (FOT) measurements at baseline and after 3, 6 and 12 months of mepolizumab treatment', 'description': 'FOT measurements will estimate post-treatment changes in respiratory mechanics', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Hospital Anxiety and Depression Scale (HADS) questionnaire', 'description': 'HADS questionnaire will track evolution of psychological symptoms in response to treatment', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Mean change from baseline in Asthma Quality of Life Questionnaire (AQLQ)', 'description': 'AQLQA will assess changes in asthma-specific health-related quality of life in response to mepolizumab therapy', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Mean change from baseline in immune cells (eosinophil/neutrophil) counts in nasal, sputum and blood samples', 'description': 'Immune cells measurements will indicate the potential alterations in airway (nasal, sputum) and systemic (blood) inflammation in response to mepolizumab treatment', 'timeFrame': 'at baseline and in 3, 6 and 12 months'}, {'measure': 'Mean change from baseline of cytokines/chemokines levels in blood and airways samples', 'description': 'Multiplex measurements of cytokines/chemokines levels will inform for treatment-induced alterations in airway (nasal, sputum) and systemic (blood) inflammation', 'timeFrame': 'at baseline and in 3 months'}, {'measure': 'Differential gene expression (fold changes) in nasal and sputum samples', 'description': 'Differential gene expression will evaluate the treatment-mediated alterations in the airway transcriptome', 'timeFrame': 'at baseline and in 3 months'}, {'measure': 'Differential single-cell gene expression (fold changes) of Peripheral Blood Mononuclear Cells (PBMC) from responders and non-responders to mepolizumab treatment', 'description': 'Differential single-cell gene expression analysis will estimate the potential treatment-induced changes in single-cell gene expression in responders versus non-responders to mepolizumab treatment', 'timeFrame': 'at baseline and in 3 months'}, {'measure': 'Mean change from baseline in airway (sputum, nasal) microbiome alpha and beta diversity indices at 3 months post-treatment in airway samples', 'description': 'Measurement of the alpha and beta microbiome diversity indices will assess the treatment-induced alterations in the microbiome characteristics', 'timeFrame': 'at baseline and in 3 months'}, {'measure': 'Differential abundances of microbial taxa (fold changes) from baseline at 3 months post-treatment in nasal and sputum samples', 'description': 'Differential taxa abundance will evaluate the treatment-mediated alterations in the abundance of specific airway microbial taxa', 'timeFrame': 'at baseline and in 3 months'}, {'measure': 'Differential abundances of predicted metabolic pathways (fold changes) from baseline at 3 months post-treatment in nasal and sputum microbiome', 'description': 'Differential abundance of metabolic pathways will estimate the treatment-mediated alterations in the microbiome function', 'timeFrame': 'at baseline and in 3 months'}, {'measure': 'Predictive biomarker classifiers of responsive disease endotypes', 'description': 'Harness associations between host and microbiome variables for building up diagnostic and predictive biomarker classifiers of responsive disease endotypes', 'timeFrame': 'two years'}]",17.0,18 Years,,ALL,True,OTHER,0.0,60.0,ESTIMATED,v2_robust,False,False,False,False,
NCT00025610,Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma,carboplatin,"['doxorubicin hydrochloride', 'cyclophosphamide', 'vincristine sulfate', 'etoposide', 'carboplatin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Neuroblastoma,European Infant Neuroblastoma Study Group - 1999,2025-09-01T16:18:09.636570,True,,,,,"European Infant Neuroblastoma Study - Stage 4S and Stage 4 (No Bone, Lung, Pleura or CNS); MYCN Not Amplified",,['Neuroblastoma'],"['disseminated neuroblastoma', 'stage 4S neuroblastoma']",,1999-07,2009-03,[],[],0.0,,1 Year,ALL,False,OTHER,0.0,,,v2_robust,True,True,False,False,
NCT05691010,A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer,Carboplatin,"['Paclitaxel', 'Carboplatin']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,RECRUITING,Endometrial Cancer,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:09.636577,True,,,,,A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer,,"['Endometrial Cancer', 'Stage III Endometrial Cancer', 'Stage III Endometrial Carcinoma', 'Endometrial Carcinoma', 'Endometrial Carcinoma Stage III']","['endometrial cancer', 'endometrial cancer stage III', 'endometrial carcinoma stage III', 'stage III endometrial cancer', 'stage III endometrial carcinoma', 'Memorial Sloan Kettering Cancer Center', '22-405']",,2023-01-10,2026-01-10,"[{'measure': 'Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel in patients with stage III endometrial cancer', 'description': 'Feasibility of study treatment is defined as defined as the number of participants who complete all 6 planned cycles of carboplatin and paclitaxel with no delays in chemotherapy cycles greater than 21 days.', 'timeFrame': 'up to 3 years'}]",[],1.0,18 Years,,FEMALE,False,OTHER,0.0,28.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00660010,Study of Lupron Depot In The Treatment of Central Precocious Puberty,Lupron (leuprolide acetate),"['Lupron (leuprolide acetate)', 'Lupron']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Puberty, Precocious",Abbott,2025-09-01T16:18:09.636586,True,,,,,Study of Lupron Depot In The Treatment of Central Precocious Puberty,,"['Puberty, Precocious']","['CPP', 'central precocious puberty', 'pediatrics', 'suppression of LH', 'Lupron', 'leuprolide acetate', 'depot formulation', 'GnRHa', 'GnRH agonist', 'GNRH analog', 'LH', 'Tanner staging']",,1991-01,2009-04,"[{'measure': 'Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)', 'description': 'Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).', 'timeFrame': 'Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)', 'description': 'Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).', 'timeFrame': 'Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}]","[{'measure': 'Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations', 'description': 'Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.', 'timeFrame': 'Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Mean Stimulated Estradiol Concentrations in Females', 'description': 'Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.', 'timeFrame': 'Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Mean Stimulated Testosterone Concentrations in Males', 'description': 'Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.', 'timeFrame': 'Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Mean Ratio of Bone Age to Chronological Age', 'description': 'Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.', 'timeFrame': 'Week 24 and Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}]",6.0,,10 Years,ALL,False,INDUSTRY,0.0,55.0,ACTUAL,v2_robust,True,True,False,False,
NCT01575613,Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission,Artemether-lumefantrine combination,['Artemether-lumefantrine combination'],1,INTERVENTIONAL,['NA'],,COMPLETED,Malaria,Radboud University Medical Center,2025-09-01T16:18:09.636616,True,,,,,Reducing the Burden of Malaria by Targeting Hotspots of Transmission and Improving Malaria Control Measures in the Highlands of Western Kenya: Simultaneous Rollout of Four Malaria Control Interventions and Evaluation by Cross-sectional Surveys,,['Malaria'],"['malaria', 'heterogeneity', 'transmission', 'elimination']",,2012-04,2012-11,"[{'measure': 'Parasite prevalence in the evaluation zone surrounding malaria hotspots', 'description': 'Parasite prevalence, determined by PCR, in the evaluation zone surrounding hotspots in intervention and control clusters', 'timeFrame': '3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season)'}]","[{'measure': 'Parasite prevalence inside malaria hotspots', 'description': 'Parasite prevalence, determined by PCR, inside hotspot of malaria transmission in intervention and control clusters', 'timeFrame': '3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season)'}, {'measure': 'Parasite prevalence in the evaluation zone as function of distance to the hotspot boundary', 'description': 'Parasite prevalence, determined by PCR, in relation to distance to the boundary of malaria hotspots in intervention and control clusters', 'timeFrame': '3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season)'}, {'measure': 'Anopheles mosquito density', 'description': 'Indoor and outdoor anopheles mosquito density inside and outside hotspots of malaria transmission in intervention and control clusters', 'timeFrame': 'determined during fortnightly trapping, starting at enrolment and continuing until up to 210 days after enrolment'}, {'measure': 'Passive case detection', 'description': 'Number of malaria cases reporting at health facilities, coming from intervention and control clusters', 'timeFrame': 'determined continuously for a period of up to 210 days after enrolment'}, {'measure': 'Safety and acceptability of interventions', 'description': 'Side effects of FSAT, LLINs and IRS in targeted households', 'timeFrame': 'at a single cross-sectional survey 15-45 days after enrolment'}, {'measure': 'Mosquito breeding site productivity', 'description': 'The presence and density of anopheles larvae in mosquito breeding sites in malaria hotspots in intervention and control clusters', 'timeFrame': 'determined on a weekly basis for a period of up to 210 days after enrolment'}]",7.0,6 Months,,ALL,True,OTHER,5.0,17506.0,ACTUAL,v2_robust,True,True,False,True,
NCT04453813,Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma,Toripalimab plus concurrent chemo-radiotherapy,"['Concurrent chemo-radiotherapy', 'Toripalimab plus concurrent chemo-radiotherapy']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Nasopharyngeal Carcinoma,Sun Yat-sen University,2025-09-01T16:18:09.636687,True,,,,,A Multicenter Randomized Clinical Phase 3 Trial of Toripalimab Plus Concurrent Chemo-radiotherapy vs Concurrent Chemo-radiotherapy Alone for Unresectable Locally Recurrent Nasopharyngeal Carcinoma,,"['Nasopharyngeal Carcinoma', 'Chemotherapy', 'Radiotherapy', 'PD-1 Treatment']",[],,2020-07-03,2027-07,"[{'measure': 'Progress-free survival (PFS)', 'description': 'Defined as time from randomization to locoregional or distant metastasis relapse or death from any cause, whichever occurred first.', 'timeFrame': '3 years'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Defined as the time interval from randomization to death due to any cause.', 'timeFrame': '3 years'}, {'measure': 'Distant Metastasis-Free Survival (DMFS)', 'description': 'Defined as the time interval from randomisation to the date of first distant metastases.', 'timeFrame': '3 years'}, {'measure': 'Locoregional Relapse-Free Survival (LRRFS)', 'description': 'Defined as the time from randomisation to the date of first locoregional relapse.', 'timeFrame': '3 years'}, {'measure': 'Incidence of treatment related acute complications', 'description': 'The proportion of patients with treatment related acute complications according to NCI-CTC5.0 criteria and RTOG criteria.', 'timeFrame': 'up to 1 years'}, {'measure': 'Incidence of treatment related late complications', 'description': 'The proportion of patients with treatment related late complications according to NCI-CTC5.0 criteria and RTOG criteria.', 'timeFrame': 'up to 3 years'}, {'measure': 'Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0)', 'description': 'Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) before treatment, during treatment, after treatment.', 'timeFrame': 'up to 3 years'}, {'measure': 'Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35)', 'description': 'Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H\\&N35) before treatment, during treatment, after treatment.', 'timeFrame': 'up to 3 years'}]",8.0,18 Years,70 Years,ALL,False,OTHER,5.0,226.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00261313,ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer,Neulasta,"['Aranesp', 'Neulasta']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Breast Cancer,Amgen,2025-09-01T16:18:09.636784,True,,,,,An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer,,['Breast Cancer'],"['Breast cancer', 'Doses dense chemotherapy', 'Growth factor support', 'Adjuvant Breast Cancer']",,2005-12,2007-12,"[{'measure': 'The proportion of subjects experiencing any delay in any cycle of chemotherapy over the course of the study', 'timeFrame': '3 months'}]","[{'measure': 'Febrile neutropenic events and adverse event profile will be assessed', 'timeFrame': '4 months'}, {'measure': 'To assess chemotherapy and subject dose delays and reductions which are specific and/or non specific to haematological toxicities', 'timeFrame': '3 months'}, {'measure': 'Frequency of red blood cell (RBC) transfusions', 'timeFrame': '3 months'}]",4.0,18 Years,,FEMALE,False,INDUSTRY,0.0,80.0,ACTUAL,v2_robust,True,True,False,True,
NCT03303313,"A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome",Cemdisiran,['Cemdisiran'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Atypical Hemolytic Uremic Syndrome,Alnylam Pharmaceuticals,2025-09-01T16:18:09.636800,True,,,,,"A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic Syndrome",,['Atypical Hemolytic Uremic Syndrome'],"['RNAi therapeutic', 'Atypical Hemolytic Uremic Syndrome', 'Hemolysis', 'Thrombocytopenia', 'Renal insufficiency', 'Thrombotic Microangiopathy', 'aHUS', 'TMA']",Study terminated early due to lack of enrollment.,2017-09-19,2018-09-12,"[{'measure': 'The effect of Cemdisiran on platelet count', 'timeFrame': 'Week 32'}]","[{'measure': 'The effect of Cemdisiran on hematological response as measured by platelet count', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on hematological response as measured by lactate dehydrogenase (LDH)', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on hematological response as measured by rescue plasma therapy', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on LDH response as measured by LDH', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on LDH response as measured by rescue plasma therapy', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by platelet count', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by LDH', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by serum creatinine levels', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on complete Thrombotic microangiopathy (TMA) response as measured by rescue plasma therapy', 'timeFrame': 'after 32 weeks of treatment'}, {'measure': 'The effect of Cemdisiran on serum creatinine levels', 'timeFrame': 'up to 84 weeks'}, {'measure': 'The effect of Cemdisiran on estimated glomerular filtration rate (eGFR)', 'timeFrame': 'up to 84 weeks'}, {'measure': 'The effect of Cemdisiran on adverse events (AEs)', 'timeFrame': 'up to 108 weeks'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Study terminated early due to lack of enrollment.
NCT01768013,The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris,LEO 90105,['LEO 90105'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Psoriasis Vulgaris,LEO Pharma,2025-09-01T16:18:09.636834,True,,,,,,,['Psoriasis Vulgaris'],[],,2012-07,2012-10,"[{'measure': 'Pharmacokinetic: Cmax of Betamethasone Dipropionate', 'description': 'The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined.', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: Cmax of Betamethasone Dipropionate', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: Cmax of Betamethasone Dipropionate', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic: AUClast of Betamethasone Dipropionate', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: AUClast of Betamethasone Dipropionate', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: AUClast of Betamethasone Dipropionate', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic: Cmax of Betamethasone 17-propionate', 'description': 'The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: Cmax of Betamethasone 17-propionate', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: Cmax of Betamethasone 17-propionate', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic: AUClast of Betamethasone 17-propionate', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: AUClast of Betamethasone 17-propionate', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: AUClast of Betamethasone 17-propionate', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic: Cmax of Calcipotriol', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: Cmax of Calcipotriol', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: Cmax of Calcipotriol', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic: AUClast of Calcipotriol', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: AUClast of Calcipotriol', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: AUClast of Calcipotriol', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic: Cmax of MC1080', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: Cmax of MC1080', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: Cmax of MC1080', 'description': 'The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetic: AUClast of MC1080', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetic: AUClast of MC1080.', 'description': 'To assess the The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined', 'timeFrame': 'Day 7'}, {'measure': 'Pharmacokinetic: AUClast of MC1080.', 'description': 'The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined', 'timeFrame': 'Day 14'}]","[{'measure': 'Efficacy: Percentage Change in m-PASI From Baseline to Day 28', 'description': ""Psoriasis Area and Severity Index (PASI) is based on the investigator's assessment of the disease.\n\nThe extent and severity of redness, thickness and scaliness of psoriasis are recorded for three regions (arms, trunk and legs) and these are used to calculate PASI. The PASI can range between 0 (best) to 64.8 (worst). m-PASI indicate that the scale is modified."", 'timeFrame': 'Baseline to Day 28'}, {'measure': ""Efficacy: Subjects With 'Clear' or 'Almost Clear' Disease by Investigator's Global Assessment at Day 28."", 'description': ""Subjects with 'clear' or 'almost clear' disease by investigator's globala ssessment at day 28.\n\nInvestigator global assessment (IGA) is based on the investigator's assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear,Almost clear, Mild,Moderate, Severe, and Very severe). The assessment represents the average lesion severity on the trunk and limbs. IGA can range between 1 (best) and 6 (worst). The assessment is based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit."", 'timeFrame': 'Day 28'}]",26.0,20 Years,,ALL,False,INDUSTRY,0.0,13.0,ACTUAL,v2_robust,True,True,False,False,
NCT06308913,"Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma",INCB081776,"['INCB081776', 'Pembrolizumab']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,RECRUITING,Head and Neck Squamous Cell Carcinoma,"University of Wisconsin, Madison",2025-09-01T16:18:09.636921,True,,,,,Pilot Study of INCB081776 Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade With Pembrolizumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),,['Head and Neck Squamous Cell Carcinoma'],['metastatic'],,2024-09-18,2027-08-31,"[{'measure': 'Incidence of Adverse Events (AEs)', 'description': 'Frequency of AEs through physical examinations, by evaluating changes in vital signs, through clinical laboratory blood sample evaluations.', 'timeFrame': 'Participants will be followed for 30 days (+/- 7 days) after the last dose of treatment (up to 12 months on study)'}, {'measure': 'Duration of Adverse Events', 'description': 'Duration of AEs through physical examinations, by evaluating changes in vital signs, through clinical laboratory blood sample evaluations.', 'timeFrame': 'Participants will be followed for 30 days (+/- 7 days) after the last dose of treatment (up to 12 months on study)'}, {'measure': 'Severity of Adverse Events', 'description': 'Severity of AEs through physical examinations, by evaluating changes in vital signs, through clinical laboratory blood sample evaluations. Severity will be reported by Grade between 1 (mild) and 5 (death).', 'timeFrame': 'Participants will be followed for 30 days (+/- 7 days) after the last dose of treatment (up to 12 months on study)'}]","[{'measure': 'Overall response rate (ORR)', 'description': 'Defined as the percentage of participants having CR or PR per RECIST 1.1. The irradiated lesion (lesion A) will not be included in the analysis.', 'timeFrame': 'up to 12 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'Defined as the percentage of participants having complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1.', 'timeFrame': 'up to 12 months'}, {'measure': 'Duration of response (DoR)', 'description': 'Defined as the time from earliest date of response until the earliest date of disease progression or death per RECIST 1.1 due to any cause, if occurring sooner than progression.', 'timeFrame': 'up to 12 months'}]",6.0,18 Years,,ALL,False,OTHER,2.0,12.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04460560,Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE),Terlipressin,['Terlipressin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hepatorenal Syndrome,University of Pennsylvania,2025-09-01T16:18:09.636958,True,,,,,"A Multi-Center, Open Label, Collaborative Research Study to Treat HRS-AKI Patients With Continuous Terlipressin Infusion",,['Hepatorenal Syndrome'],[],,2020-12-11,2023-12-27,"[{'measure': 'Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline SCr Will Also be Entered.', 'description': 'SCr will be collected daily, from Day 1 thru end of treatment. Complete response (CR) defined as ≥30% decrease in SCr with EOT SCr≤1.5, partial response (PR) as ≥30% decrease in SCr with EOT SCr\\>1.5, and non-response (NR) as \\<30% decrease in SCr.', 'timeFrame': '14 days or reversal of HRS-AKI, whichever occur first'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT06011460,Observation of Clozapine Treatment Safety in Bipolar Disorder.,Clozapine,['Clozapine'],1,OBSERVATIONAL,[],,ENROLLING_BY_INVITATION,Bipolar Disorder,Medical University of Gdansk,2025-09-01T16:18:09.637171,True,,,,,Observation of Clozapine Treatment Safety in Bipolar Disorder.,,['Bipolar Disorder'],"['clozapine', 'bipolar disorder', 'suicidality', 'adverse events']",,2023-02-23,2027-06-30,"[{'measure': 'Safety measures of clozapine treatment in patients with bipolar disorder.', 'description': 'Incidence of possible occurrence of adverse events during treatment with clozapine in patients with bipolar disorder.', 'timeFrame': '1 year'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,False,False,False,True,
NCT03637660,Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection,Benzathine Penicillin,['Benzathine Penicillin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Syphilis,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:09.637219,True,,,,,A Phase 4 Comparative Trial of Benzathine Penicillin G 2.4 Million Units Administered as a Single Dose Versus Three Successive Weekly Doses for Treatment of Early Syphilis in Subjects With or Without HIV Infection,,['Syphilis'],"['Benzathine penicillin G', 'Early Syphillis', 'HIV', 'Phase 4']",,2018-10-31,2023-03-20,"[{'measure': 'The Number of Participants With a Serological Response by Month 6.', 'description': 'Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated:\n\n* 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR\n* RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion).', 'timeFrame': 'Day 1 to Day 180'}]","[{'measure': 'Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire', 'description': 'Gender identity, sexual orientation, sexual partner, sex history in last 60 days', 'timeFrame': 'Day 1'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire', 'description': 'Sex history in last 60 days', 'timeFrame': 'Day 1'}, {'measure': 'Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire', 'description': 'Highest level of education completed, stage of syphilis, prior syphilis history', 'timeFrame': 'Day 1'}, {'measure': 'Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire', 'description': 'Years of formal education', 'timeFrame': 'Day 1'}, {'measure': 'Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire', 'description': 'Sex, Ethnicity, Race', 'timeFrame': 'Day 1'}, {'measure': 'Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire', 'description': 'Age', 'timeFrame': 'Day 1'}, {'measure': 'The Number of Participants Who Receive All Assigned Doses Within the Assigned Visit Windows', 'description': 'Compliance with study product will be defined as the participant received all assigned doses within the assigned visit windows. A participant is not adherent to study product if they miss at least one dose or receive at least one dose out of the visit window.', 'timeFrame': 'Through Month 12'}, {'measure': 'The Number of Participants Who Report Jarisch-Herxheimer Reaction Manifestations', 'description': 'Approximately 24 hours after Visit 1, participants were contacted and evaluated for symptoms of a JHR, which included fever, chills, myalgia, weakness, flushing, worsening of skin rash, tachycardia, heart palpitations, arthralgia, nausea, headache, and dizziness, including time of onset and time of resolution of each symptom reported.', 'timeFrame': 'Day 1 through Day 2'}, {'measure': 'Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection', 'description': 'Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated:\n\n* 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR\n* RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion).\n\nSerological response to therapy by Month 6 was examined among participants with and without HIV infection,', 'timeFrame': 'Day 1 to Day 180'}, {'measure': 'Number of Participants With Serological Response (Defined as Either a 4-fold or Greater Decline in Rapid Plasma Regain (RPR) Titer Compared to Baseline or Being Rapid Plasma Regain -Negative [Seroreversion]) by Month 12.', 'description': 'Serological response to therapy by Month 12 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 12 visit window (i.e., scheduled visits up to and including the Month 12 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 12 visit window) were evaluated:\n\n* 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 12 visit window compared to baseline, OR\n* RPR-negative at any visit prior to the end of the Month 12 visit window (i.e., seroreversion).', 'timeFrame': 'Through month 12'}, {'measure': 'Number of Participants With Serological Response by Month 12 Among Subjects With or Without HIV Infection', 'description': 'Serological response to therapy by Month 12 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 12 visit window (i.e., scheduled visits up to and including the Month 12 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated:\n\n* 4-fold or greater decline in RPR titer at any visit prior to the end of the Month 12 visit window compared to baseline, OR\n* RPR-negative at any visit prior to the end of the Month 12visit window (i.e., seroreversion).\n\nSerological response to therapy by Month 12 was examined among participants with and without HIV infection,', 'timeFrame': 'Through month 12'}, {'measure': 'Categorical Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit.', 'timeFrame': 'Through week 1'}, {'measure': 'Categorical Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit.', 'timeFrame': 'Through week 2'}, {'measure': 'Categorical Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit.', 'timeFrame': 'Through month 1'}, {'measure': 'Categorical Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit.', 'timeFrame': 'Through month 3'}, {'measure': 'Categorical Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit.', 'timeFrame': 'Through month 6'}, {'measure': 'Categorical Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit.', 'timeFrame': 'Through month 9'}, {'measure': 'Categorical Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit.', 'timeFrame': 'Through month 12'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Week 1 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit', 'timeFrame': 'Through week 1'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Week 2 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit', 'timeFrame': 'Through week 2'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Month 1 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit', 'timeFrame': 'Through month 1'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Month 3 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit', 'timeFrame': 'Through month 3'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Month 6 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit', 'timeFrame': 'Through month 6'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Month 9 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit', 'timeFrame': 'Through month 9'}, {'measure': 'Continuous Descriptive Statistics of Sexual History at Month 12 Collected Via a Study-specific Questionnaire', 'description': 'Sex history since last visit', 'timeFrame': 'Through month 12'}]",26.0,18 Years,99 Years,ALL,False,NIH,0.0,249.0,ACTUAL,v2_robust,True,True,False,False,
NCT03560960,Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease,Pramlintide challenge test,"['Pramlintide challenge test', 'Symlin']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,ACTIVE_NOT_RECRUITING,Alzheimer Disease,Boston University,2025-09-01T16:18:09.637290,True,,,,,Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease,,"['Alzheimer Disease', 'Mild Cognitive Impairment']","['Early AD diagnosis', 'Pramlintide challenge test', 'Amyloid', 'Amyloid PET imaging', 'CSF Aβ', 'CSF pTau', 'Cognitive evaluation']",,2020-02-04,2026-11,"[{'measure': 'Plasma Aβ 1-40 levels', 'description': ""Plasma Aβ1-40, also known as beta-amyloid 1-40, is a biomarker measured in the blood, and it is associated with the development of Alzheimer's disease. Specifically, higher plasma concentrations of Aβ1-40, particularly when combined with lower levels of Aβ1-42, are linked to an increased risk of dementia. The normal range for Aβ 1-40 levels in human plasma is generally considered to be less than 100 pg/mL, with most studies reporting values between 30 to 60 pg/mL."", 'timeFrame': 'baseline, 5, 30, 60, and 180 min after challenge test'}, {'measure': 'Plasma Aβ1-42 levels', 'description': ""Plasma Aβ1-42, also known as beta-amyloid 1-42, is a protein fragment involved in the development of Alzheimer's disease. It is a form of amyloid-beta (Aβ) that is associated with the formation of plaques in the brain. Aβ1-42 is a key biomarker for Alzheimer's disease. Specifically, lower plasma concentrations of Aβ1-42, particularly when combined with higher levels of Aβ1-402, are linked to an increased risk of dementia. The reference interval for plasma Aβ1-42 levels in cognitively normal subjects is typically between 8.12 and 29.00 pg/mL."", 'timeFrame': 'baseline, 5, 30, 60, and 180 min after challenge test'}, {'measure': 'Plasma Aβ and t-tau changes', 'description': 'Plasma total tau (t-tau) levels can indicate subclinical brain and cognitive deficits, potentially predicting the risk of neurodegenerative conditions in normal aging. Higher plasma t-tau levels have been associated with poorer cognitive function, reduced glucose uptake, thinning of the temporal lobe, and even increased risk of all-cause dementia. The reference range for plasma total tau (t-tau) is typically reported as 0.20-3.12 pg/mL', 'timeFrame': 'baseline, 5, 30, 60, and 180 min after challenge test'}]",[],3.0,60 Years,90 Years,ALL,False,OTHER,1.0,57.0,ACTUAL,v2_robust,True,False,False,False,
NCT00146120,Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result,Idarubicin,"['Cytosin-Arabinosid', 'All-trans Retinoid acid', 'Etoposide', 'Idarubicin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acute Myeloid Leukemia,University of Ulm,2025-09-01T16:18:09.637340,True,,,,,Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result,,['Acute Myeloid Leukemia'],[],,1998-05,2005-05,"[{'measure': 'relapse-free survival', 'timeFrame': 'two years'}]","[{'measure': 'overall survival', 'timeFrame': 'two years'}]",2.0,16 Years,60 Years,ALL,False,OTHER,0.0,400.0,,v2_robust,True,True,False,False,
NCT02253420,COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients,Copanlisib (BAY80-6946),"['Copanlisib (BAY80-6946)', 'Itraconazole', 'Rifampin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Medical Oncology,Bayer,2025-09-01T16:18:09.637392,True,,,,,"An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and Non-Hodgkin's Lymphoma",,['Medical Oncology'],"['Phase 1', 'Advanced solid tumor', ""non-Hodgkin's lymphoma"", 'PI3 Kinase inhibitor', 'Drug-drug Interaction']",,2014-10-08,2019-08-13,"[{'measure': 'AUC (0-168)', 'description': 'AUC (0-168): Area under the curve from dosing to 168 h after dosing', 'timeFrame': 'Within cycle 1, at pre-dose and at 10 min, 1, 1.33 (arm B)1.5 (arm A), 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120, and 168 hours after start of drug infusion on Days 1 and 15.'}, {'measure': 'AUC', 'description': 'AUC: Area under the curve', 'timeFrame': 'Within cycle 1, at pre-dose and at 10 min, 1, 1.33 (arm B)1.5 (arm A), 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120, and 168 hours after start of drug infusion on Days 1 and 15.'}, {'measure': 'Cmax', 'description': 'Cmax: Maximum concentration attained after dosing', 'timeFrame': 'Within cycle 1, at pre-dose and at 10 min, 1, 1.33 (arm B)1.5 (arm A), 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120, and 168 hours after start of drug infusion on Days 1 and 15.'}, {'measure': 'QTcF', 'description': ""QTcF: Time-matched largest change of QT interval (Frederica's correction)"", 'timeFrame': 'Holter Monitoring performed on Cycle 1 Day -1 (baseline) and Cycle 1 Day 1 (each cycle is 28 days)'}]","[{'measure': 'AUC(0-tlast)', 'description': 'AUC(0-tlast): Area under the curve from dosing to last measurable concentration', 'timeFrame': 'Within cycle 1, at pre-dose and at 10 min, 1, 1.33 (arm B)1.5 (arm A), 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120, and 168 hours after start of drug infusion on Days 1 and 15.'}, {'measure': 'tmax', 'description': 'tmax: Time from dosing to attainment of Cmax', 'timeFrame': 'Within cycle 1, at pre-dose and at 10 min, 1, 1.33 (arm B)1.5 (arm A), 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120, and 168 hours after start of drug infusion on Days 1 and 15.'}, {'measure': 'tlast', 'description': 'tlast: Time from dosing to last measurable concentration', 'timeFrame': 'Within cycle 1, at pre-dose and at 10 min, 1, 1.33 (arm B)1.5 (arm A), 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120, and 168 hours after start of drug infusion on Days 1 and 15.'}, {'measure': 't1/2', 'description': 't1/2: Terminal half-life', 'timeFrame': 'Within cycle 1, at pre-dose and at 10 min, 1, 1.33 (arm B)1.5 (arm A), 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120, and 168 hours after start of drug infusion on Days 1 and 15.'}, {'measure': 'Urine [AE,ur(0-24)]', 'description': 'Amount of drug excreted via urine during the collection interval 0 - 24 hours post administration', 'timeFrame': 'From 0-8 hours and >8 up to 24 hours after the start of copanlisib infusion on Days 1 and 15 of Cycle 1'}, {'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'description': 'Safety analysis will be conducted continuously until safety follow-up', 'timeFrame': 'At approximately 29 months'}, {'measure': 'PR intervals', 'timeFrame': 'Holter Monitoring performed on Cycle 1 Day -1 (baseline) and Cycle 1 Day 1 (each cycle is 28 days)'}, {'measure': 'QRS intervals', 'timeFrame': 'Holter Monitoring performed on Cycle 1 Day -1 (baseline) and Cycle 1 Day 1 (each cycle is 28 days)'}, {'measure': 'ECG waveform morphology', 'timeFrame': 'Holter Monitoring performed on Cycle 1 Day -1 (baseline) and Cycle 1 Day 1 (each cycle is 28 days)'}, {'measure': 'Left ventricular ejection fraction (LVEF)', 'description': 'MUGA scans', 'timeFrame': 'At baseline, in the last week of Cycle 1, and in the last 2 weeks of Cycle 2, Cycle 3, Cycle 6 and every third cycle (Cycle 9, Cycle 12, etc.) and end of treatment'}, {'measure': 'QTcB', 'description': ""QTcB: Bazett's corrected QT interval"", 'timeFrame': 'Holter Monitoring performed on Cycle 1 Day -1 (baseline) and Cycle 1 Day 1 (each cycle is 28 days)'}]",15.0,18 Years,,ALL,False,INDUSTRY,0.0,51.0,ACTUAL,v2_robust,True,True,False,True,
NCT01993420,A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis,DRM02,['DRM02'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Atopic Dermatitis,"Dermira, Inc.",2025-09-01T16:18:09.637419,True,,,,,"A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Atopic Dermatitis",,['Atopic Dermatitis'],[],,2013-10,2014-03,"[{'measure': ""Change in Physician's Lesion Assessment"", 'timeFrame': 'Week 6'}]","[{'measure': ""Physician's Lesion Assessment analyzed for treatment effect"", 'timeFrame': 'From baseline to weeks 1, 2, 3, 4 and 6'}]",2.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,21.0,ACTUAL,v2_robust,True,True,False,False,
NCT00087620,A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer,XELODA [capecitabine],['XELODA [capecitabine]'],1,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Breast Cancer,Hoffmann-La Roche,2025-09-01T16:18:09.637485,True,,,,,,,['Breast Cancer'],[],,2004-09,2004-10,[],[],0.0,18 Years,,FEMALE,False,INDUSTRY,0.0,,,v2_robust,True,False,True,False,
NCT00252720,DIabetic Retinopathy Candesartan Trials.,candesartan,"['ATACAND', 'candesartan']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 1 Diabetes,AstraZeneca,2025-09-01T16:18:09.637633,True,,,,,DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.,,['Type 1 Diabetes'],['Diabetes mellitus type 1'],,2001-08,2008-04,"[{'measure': 'Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale', 'description': 'Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments.', 'timeFrame': 'From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.'}]","[{'measure': 'Number of Participants With a Regression of Diabetic Retinopathy.', 'description': 'Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11).', 'timeFrame': 'From baseline to the end of the study, i.e., 5 years'}, {'measure': 'Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).', 'description': 'Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs.', 'timeFrame': 'From baseline to end of study, i.e. 5 years.'}, {'measure': 'Rate of Change in Urinary Albumin Excretion Rate (UAER).', 'description': 'An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient', 'timeFrame': 'From baseline to end of study, i.e. 5 years.'}]",4.0,18 Years,55 Years,ALL,False,INDUSTRY,1.0,1850.0,ACTUAL,v2_robust,True,True,False,False,
NCT02504320,"Phase 1, Febuxostat XR Relative Bioavailability Study",Febuxostat XR 80 mg Capsule F1,"['Febuxostat XR 80 mg Capsule F4', 'Febuxostat XR 80 mg Capsule F1', 'Febuxostat XR 80 mg Capsule F2', 'Febuxostat XR 80 mg Capsule F3']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,Takeda,2025-09-01T16:18:09.637729,True,,,,,"A Phase 1, Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Assess the Relative Bioavailability of Four 80 mg Febuxostat XR Formulations",,['Healthy Volunteers'],['Drug therapy'],,2015-08,2015-10,"[{'measure': 'Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat', 'description': 'Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose'}, {'measure': 'Mean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat', 'description': 'AUCt is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration.', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose'}, {'measure': 'Mean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat', 'description': 'AUC∞ is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose'}]",[],3.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,78.0,ACTUAL,v2_robust,True,True,False,False,
NCT00178620,Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization,Reteplase 10 Units (U) plus a second dose of reteplase 10 U,"['Reteplase 10 U', 'Retavase', 'Reteplase 10 Units (U) plus a second dose of reteplase 10 U']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Heart Disease,"The University of Texas Health Science Center, Houston",2025-09-01T16:18:09.637749,True,,,,,"PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization",,"['Heart Disease', 'Myocardial Infarction', 'Acute Myocardial Infarction']","['Heart Disease', 'Heart Attack', 'Myocardial Infarction', 'Thrombolytic Therapy', 'Emergency Medicine']",,2003-09,2009-12,"[{'measure': 'Mortality at 30 Days', 'timeFrame': '30 day'}]","[{'measure': 'Infarction Size as Measured by Cardiac Magnetic Resonance Imaging (MRI)', 'timeFrame': '1 year'}, {'measure': 'Reduction in Time From Onset of Pain to Reperfusion', 'timeFrame': '1 year'}, {'measure': 'Angiographic Documentation of Reperfusion', 'timeFrame': '1 year'}, {'measure': 'Electrocardiogram (ECG) ST Segment Elevation Recovery', 'timeFrame': '1 year'}]",5.0,18 Years,,ALL,False,OTHER,0.0,390.0,ACTUAL,v2_robust,True,True,False,False,
NCT00565682,Pain Post Abdominal Laparoscopy Prevention With Arcoxia,etoricoxib 120 mg,"['etoricoxib 120 mg', 'Arcoxia']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Laparoscopic Surgery for Appendicitis,Hospital Vozandez,2025-09-01T16:18:09.637960,True,,,,,Pain Post Abdominal Laparoscopy Prevention With Arcoxia,,"['Laparoscopic Surgery for Appendicitis', 'Laparoscopic Surgery for Cholecystitis', 'Laparoscopic Surgery for Ovarian Cysts']",[],,2006-04,2006-12,"[{'measure': 'To measure the amount of rescue medication (opioid) needed to relief', 'timeFrame': 'Every hour after surgery'}]","[{'measure': 'To determine the overall analgesic effect using the visual analog scale (VAS)', 'timeFrame': 'Every hour after surgery'}]",2.0,18 Years,70 Years,ALL,False,OTHER,1.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT03744182,A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD,HM15211,"['Placebo of HM15211', 'HM15211']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,NAFLD,Hanmi Pharmaceutical Company Limited,2025-09-01T16:18:09.637977,True,,,,,"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD",,['NAFLD'],[],,2018-11-01,2020-03-18,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'Cardiovascular events, rash/inflammatory dermatitis and other skin disorders, GI events, and gallstone formation \\[cholelithiasis\\] were managed following a separate AE guidance document', 'timeFrame': '12 weeks'}, {'measure': 'Incidence of Clinical Renal Function Lab Abnormalities', 'description': 'Observed Values and Change from Baseline in Renal Function of Urea Nitrogen', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'Vital Signs', 'description': 'Change from baseline in vital signs (Systolic Blood)', 'timeFrame': 'baseline and 12 weeks'}, {'measure': '12-lead ECG', 'description': 'Change from baseline in 12-lead ECG; the primary ECG endpoint was QTcF', 'timeFrame': 'baseline and 12 weeks'}]","[{'measure': 'Body Mass Index', 'description': 'Change of Body Mass Index from baseline to 12 weeks after IP injection', 'timeFrame': 'baseline and 12 weeks'}]",5.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,66.0,ACTUAL,v2_robust,True,True,False,True,
NCT04528082,Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease,Apremilast,"['Otezla®', 'Placebo', 'Apremilast']",3,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Behçet Disease,Amgen,2025-09-01T16:18:09.638044,True,,,,,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)",,['Behçet Disease'],"[""Behçet's Disease"", 'Oral ulcers', 'Apremilast']",,2021-09-09,2030-12-17,"[{'measure': 'Area Under the Curve for the Number of Oral Ulcers from Week 0 Through Week 12 (AUCw0-12)', 'timeFrame': 'Week 0 to Week 12'}]","[{'measure': 'Number of Oral Ulcers from Week 0 to Week 12', 'timeFrame': 'Week 0 to Week 12'}, {'measure': 'Change from Week 0 to Week 12 in the Pain of Oral Ulcers in Participants 5 Years of Age and Older', 'description': 'Pain of oral ulcers will be measured by a visual analog scale (VAS). The participants will be asked to place a vertical line on a 100 mm VAS at the point that represents the severity of oral ulcer pain. The scale will range from ""no pain"" (left hand boundary) to ""worst possible pain"" (right hand boundary).', 'timeFrame': 'Week 0 to Week 12'}, {'measure': 'Complete Response Rate for Oral Ulcers', 'description': 'Complete response rate for oral ulcers is defined as the proportion of participants who are oral ulcer free at Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Proportion of Participants at Week 12 Whose Number of Oral Ulcers is Reduced by Greater Than or Equal to 50% from Week 0', 'timeFrame': 'Week 0 to Week 12'}, {'measure': 'Complete Response Rate for Genital Ulcers', 'description': 'Complete response rate for genital ulcers is defined as the proportion of participants (with genital ulcers at week 0) who are genital ulcer free at Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Change from Week 0 to Week 12 in Disease Activity', 'description': ""Disease activity is measured by Behçet's Disease Current Activity (BDCAF) scores. The BDCAF consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement. The Patient's Perception of Disease Activity and the Clinician's Overall Perception of Disease Activity were assessed by the subject and the clinician, respectively, using a scale of 1 to 7, where a higher score indicates a higher level of disease activity."", 'timeFrame': 'Week 0 to Week 12'}, {'measure': ""Proportion of Participants at Week 12 Who Have New-onset or Recurrence of Behçet's-related Manifestations (Other than Oral and Genital Ulcers)"", 'timeFrame': 'Week 12'}, {'measure': 'Change from Week 0 to Week 12 on the Short Form Survey (SF-10)', 'description': 'The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning.', 'timeFrame': 'Week 0 to Week 12'}, {'measure': 'Number of Participants with a Treatment-emergent Adverse Event', 'timeFrame': 'Up to Week 56'}, {'measure': 'Occurrence, Severity, and Frequency of Suicide/Suicide-related Ideations and Behaviors as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior is defined as the number of participants who answer ""yes"" at any time during the study (up to end of safety follow-up, Week 56) to one of the 10 categories:\n\nCategory 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide', 'timeFrame': 'Up to Week 56'}, {'measure': 'Change from Week 0 to Week 52 in Tanner Staging', 'description': 'Tanner Staging of sexual development assessment will be used to assess sexual maturity. Tanner Staging assessment consists of 3 domains (pubic hair, breast development, and other changes) for girls and 4 domains (pubic hair, penis development, testes development, and other changes) for boys. Stages range from 1-5, with 1 indicating preadolescent and 5 adult.', 'timeFrame': 'Week 0 to Week 52'}, {'measure': 'Change in Body Weight Measurements', 'timeFrame': 'Week 0 to Week 56'}, {'measure': 'Change in Height Measurements', 'timeFrame': 'Week 0 to Week 56'}, {'measure': 'Change in Body Mass Index (BMI)', 'description': 'BMI assessed as weight/(height/100)\\^2', 'timeFrame': 'Week 0 to Week 56'}, {'measure': 'Plasma Concentrations of Apremilast', 'timeFrame': 'Up to Week 52'}, {'measure': 'Taste and Acceptability of Apremilast', 'description': 'Taste and acceptability will be assessed using a questionnaire with a 7-point faces Likert Scale, with 1 ranging from ""super bad"" to 7 ""super good"" and questions to determine whether the participants are able to take the treatment medication.', 'timeFrame': 'Week 0 and Week 2'}, {'measure': ""Proportion of Participants Who Require Protocol-prohibited Medications due to Worsening of Behçet's Disease"", 'timeFrame': 'Week 0 to Week 12'}]",18.0,2 Years,17 Years,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00004682,Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis,immune globulin,['immune globulin'],1,INTERVENTIONAL,['NA'],,TERMINATED,Myasthenia Gravis,University of Texas,2025-09-01T16:18:09.638173,True,,,,,,,['Myasthenia Gravis'],"['myasthenia gravis', 'neurologic and psychiatric disorders', 'rare disease']",,1995-03,1999-03,[],[],0.0,15 Years,,ALL,False,OTHER,0.0,100.0,,v2_robust,True,False,True,False,
NCT04859582,Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension,Cisplatin,"['Oxaliplatin', 'Placebo for Pembrolizumab', '5FU', 'PLATINOL®', 'ADRUCIL®', 'Cisplatin', 'Capecitabine', 'XELODA®', 'ELOXATIN®', '5-fluorouracil']",10,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Stomach Neoplasms,Merck Sharp & Dohme LLC,2025-09-01T16:18:09.638220,True,,,,,"A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-859)",,['Stomach Neoplasms'],"['programmed cell death 1 (PD-1, PD1)', 'programmed cell death ligand 1 (PD-L1, PDL1)', 'programmed cell death ligand 2 (PD-L2, PDL2)']",Withdrawn due to protocol amendment,2018-11-08,2024-11-29,"[{'measure': 'Overall Survival (OS)', 'description': 'OS is the time from randomization to death due to any cause.', 'timeFrame': 'Up to approximately 65 months'}]","[{'measure': 'Progression-free Survival (PFS)', 'description': 'PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR).', 'timeFrame': 'Up to approximately 65 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 as assessed by BICR.', 'timeFrame': 'Up to approximately 65 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR is determined by disease assessment and is defined as the time from first response (CR or PR) to disease progression, or death from any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 65 months'}, {'measure': 'Percentage of Participants Experiencing Adverse Events (AEs)', 'description': 'Percentage of participants experiencing an AE defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study treatment.', 'timeFrame': 'Up to approximately 65 months'}, {'measure': 'Percentage of Participants Discontinuing Study Drug Due to AEs', 'description': 'Percentage of participants discontinuing study treatment due to an AE.', 'timeFrame': 'Up to approximately 36 months'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Withdrawn due to protocol amendment
NCT01222182,Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA),atorvastatin,"['atorvastatin, (Lipitor®),', 'interchanged to simvastatin, pravastatin', 'atorvastatin']",3,OBSERVATIONAL,[],,COMPLETED,Hypercholesterolemia,Mayo Clinic,2025-09-01T16:18:09.638241,True,,,,,Statin Therapeutic Interchange by Pharmacist Collaborative Practice Process,,['Hypercholesterolemia'],"['low density lipoprotein (LDL) cholesterol', 'statin', 'dose equivalent', 'Hypercholesterolemia (defined by LDL guidelines)']",,2009-09,2011-06,"[{'measure': 'Determine if a process of pharmacist practice agreement is effective in changing from atorvastatin 10, 20mg to a therapeutic equivalent dose.', 'description': 'We compared doses selected for therapeutic equivalency for the new statin Did the process result in selecting a safe and effective statin alternative?', 'timeFrame': '3 to 9 months after conversion from atorvastatin'}]","[{'measure': 'Was the process regarded as efficient and satisfying to physician compared to usual practice.', 'description': 'A satisfaction survey of physicians who utilized the pharmacist collaborative practice agreement(CPA) will be compared to satisfaction of phycians who were not able to use the CPA. Was the process regarded as efficient and satisfying to physician compared to usual practice.', 'timeFrame': '5 months post conversion'}, {'measure': ""Did the patients' low density lipoprotein(LDL) cholesterol require further statin dose intervention?"", 'description': 'Of patients who had a follow up LDL cholesterol, how many required another intervention after failing to stay within treatment goal. Physicians usually measure each of these patients within 3 months of a change of treatment and annually thereafter. We will look at follow up LDL cholesterol and liver function test (LFT) as recommended.', 'timeFrame': '6-12 months'}]",3.0,25 Years,,ALL,True,OTHER,0.0,260.0,ACTUAL,v2_robust,False,True,False,False,
NCT02910882,"PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer",PEGylated Recombinant Human Hyaluronidase (PEGPH20),"['PEGylated rHuPH20', 'Gemzar', 'Gemcitabine', 'PEGylated Recombinant Human Hyaluronidase (PEGPH20)']",4,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Pancreatic Adenocarcinoma Non-resectable,Scripps Health,2025-09-01T16:18:09.638259,True,,,,,"A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma",,['Pancreatic Adenocarcinoma Non-resectable'],"['Pancreas Cancer', 'Unresectable', 'Chemoradiation', 'PEGPH20']",Safety,2017-01-03,2018-08-31,"[{'measure': 'Number of Participants with Treatment Related Adverse Events (AEs)', 'description': 'Adverse events will be assessed weekly, from Day1 Treatment through up to 8 weeks after the end of treatment. Safety will be assessed during the study by evaluation of AEs, clinical safety laboratory tests (hematology, blood chemistry (including C-reactive protein \\[CRP\\]), coagulation, urinalysis, and PEGPH20 immunogenicity), vital signs, 12-lead ECGs, and physical examinations.\n\nThe severity of AEs will be graded by Investigators using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03', 'timeFrame': 'Up to 8 Weeks After the End of Treatment'}]","[{'measure': 'Overall Tumor Response Rate', 'description': 'CT Chest/Abdomen/Pelvis will be completed at End of Study Visit. End of Study visit will be done 6-8 weeks after the last day of radiotherapy. The evaluation of overall lesion response will be a composite of the target lesion response, non-target lesion response and presence of new lesions, per RECIST 1.1 criteria.', 'timeFrame': 'Change from Baseline through 8 Weeks After End of Radiation Therapy'}, {'measure': 'Conversion to Resectability Rate', 'description': 'Number of enrolled subjects completing at least 2 weeks of PEGPH20 plus concurrent gemcitabine and radiotherapy who meet institutional surgical criteria for surgical resectability, as determined by End of Study CT imaging. End of Study CT imaging will be done up to 8 weeks after the end of radiation therapy.', 'timeFrame': 'Up to 8 Weeks After End of Radiation Therapy'}, {'measure': 'Carcinoembryonic Antigen (CEA) Response', 'description': 'Change in CEA serum levels from Day 1 through 8 weeks after end of treatment will be assessed.', 'timeFrame': 'Change from Day 1 through 8 Weeks After End of Treatment'}, {'measure': 'CA 19-9 Response', 'description': 'Change in CA 19-9 serum levels from Day 1 through 8 weeks after end of treatment will be assessed.', 'timeFrame': 'Change from Day 1 through 8 Weeks After End of Treatment'}, {'measure': 'Determine the Maximum or Peak Plasma PEGPH20 Concentration (cmax) at End of Infusion', 'description': 'Maximum Plasma PEGPH20 concentration (cmax) will be analyzed in all patients, at the following time points:\n\nDay 1: Pre-Dose; Day 1 Post-Dose @ 1hr, 2hr, 6hr; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37 (24 Hr Post Dose); Day 38 (48Hr Post Dose); Day 39 (72 Hr Post Dose);\n\nPharmacokinetic (PK) data will analyzed by non-compartmental analysis (NCA).', 'timeFrame': 'At Specific Timepoints from Day 1 through Day 39 During Treatment'}, {'measure': 'Determine Plasma PEGPH20 Area Under the Curve (AUC) After Day 1 PEGPH20 Infusion', 'description': 'Plasma PEGPH20 Area Under the Curve (AUC) will be analyzed in all patients, at the following time points:\n\nDay 1: Pre-Dose; Day 1 Post-Dose @ 1hr, 2hr, 6hr; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37 (24 Hr Post Dose); Day 38 (48Hr Post Dose); Day 39 (72 Hr Post Dose);\n\nPharmacokinetic (PK) data will analyzed by non-compartmental analysis (NCA).', 'timeFrame': 'At Specific Timepoints from Day 1 through Day 39 During Treatment'}, {'measure': 'Determine the Maximum or Peak Plasma Hyaluronan Concentration (cmax) After First Dose of PEGPH20', 'description': 'Plasma Hyaluronan (HA) will be analyzed in all patients, at the following time points:\n\nDay 1: Pre-Dose; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37(24 Hr Post Dose); Day 38(48Hr Post Dose); Day 39 (72 Hr Post Dose);\n\nHyaluronan pharmacodynamic (PD) data will analyzed by non-compartmental analysis (NCA).', 'timeFrame': 'At Specific Timepoints from Day 1 through Day 39 During Treatment'}, {'measure': 'Determine Plasma Hyaluronan Area Under Effect Curve (AUEC) After First Dose of PEGPH20', 'description': 'Plasma Hyaluronan (HA) will be analyzed in all patients, at the following time points:\n\nDay 1: Pre-Dose; Day 2 (24Hr Post Dose); Day 3 (48Hr Post Dose); Day 4 (72Hr Post Dose); Day 8: Pre-Dose; Day 9 (24Hr Post Dose); Day 10 (48Hr Post Dose); Day 11 (72 Hr Post Dose); Day 36: Pre-Dose; Day 37(24 Hr Post Dose); Day 38(48Hr Post Dose); Day 39 (72 Hr Post Dose);\n\nHyaluronan pharmacodynamic (PD) data will analyzed by non-compartmental analysis (NCA).', 'timeFrame': 'At Specific Timepoints from Day 1 through Day 39 During Treatment'}]",9.0,,90 Years,ALL,False,OTHER,0.0,4.0,ACTUAL,v2_robust,True,False,True,True,Safety
NCT02952924,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants",Midazolam,"['Midazolam', 'RO7049389']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Hepatitis B, Chronic",Hoffmann-La Roche,2025-09-01T16:18:09.638282,True,,,,,"A Safety, Tolerability, Pharmacokinetics and Efficacy Study of ro7049389 in: (1) Single- (With or Without Food) and Multiple- (With Midazolam) Ascending Doses in Healthy Volunteers; (2) Patients Chronically Infected With Hepatitis b Virus (3) Patients With Chronic Hepatitis B.",,"['Hepatitis B, Chronic']",[],,2016-12-14,2022-03-16,"[{'measure': 'Part 1: Percentage of Participants With Adverse Events', 'timeFrame': 'Up to Day 29 (Part 1a), Day 44 (Part 1b), Day 42 (Part 1c)'}, {'measure': 'Parts 1a and 1b: SAD Cohort: Time to Reach Maximum Concentration (Tmax) of RO7049389', 'timeFrame': 'Up to 28 days'}, {'measure': 'Parts 1a and 1b: SAD Cohort: Maximum Observed Plasma Concentration (Cmax) of RO7049389', 'timeFrame': 'Up to 28 days'}, {'measure': 'Parts 1a and 1b: SAD Cohort: AUC From Time Zero to Infinity (AUC0-inf) of RO7049389', 'timeFrame': 'Up to 28 days'}, {'measure': 'Parts 1a and 1b: SAD Cohort: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of RO7049389', 'timeFrame': 'Up to 28 days'}, {'measure': 'Parts 1a and 1b: SAD Cohort: Half-life (T1/2) of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Parts 1a and 1b: SAD Cohort: Apparent Oral Clearance (CL/F) of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Parts 1a and 1b: SAD Cohort: Cumulative Amount Excreted Unchanged in Urine (Ae) of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Parts 1a and 1b: SAD Cohort: Renal Clearance (CLr) of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Part 2: Percentage of Participants With Adverse Events', 'timeFrame': 'Up to Day 112'}, {'measure': 'Part 2: Quantitative Plasma HBV DNA Level', 'timeFrame': 'Baseline - Day 112'}, {'measure': 'Part 3: Proportion of Patients Achieving Functional Cure', 'description': 'Functional cure is defined as HBV DNA \\< lower limit of quantification (LLOQ, 20 IU/mL) with HBsAg loss (\\< 0.05 IU/mL) at 24 weeks post-treatment.', 'timeFrame': 'Every 2-4 weeks from Baseline through Week 72'}]","[{'measure': 'Part 1b: Food Effect on Cmax of RO7049389', 'description': 'This outcome measure evaluated the effect of food on the pharmacokinetics (PK) of RO7049389 after the administration of a single dose. Participants were fed a high-fat, high-calorie breakfast (per FDA food effect bioavailability and bioequivalence study recommendations) 30 minutes prior to dosing after fasting overnight for at least 8 hours. ANOVA (factors fasted/fed state and subject) was performed for measurements available in subjects in both fasted and fed states.', 'timeFrame': 'Day 16'}, {'measure': 'Part 1b: Food Effect on AUCinf of RO7049389', 'description': 'This outcome measure evaluated the effect of food on the pharmacokinetics (PK) of RO7049389 after the administration of a single dose. Participants were fed a high-fat, high-calorie breakfast (per FDA food effect bioavailability and bioequivalence study recommendations) 30 minutes prior to dosing after fasting overnight for at least 8 hours. ANOVA (factors fasted/fed state and subject) was performed for measurements available in subjects in both fasted and fed states.', 'timeFrame': 'Day 16'}, {'measure': 'Part 1c: Cmax of Midazolam', 'description': 'This endpoint presents the geometric mean ratio (after RO7049389/before RO7049389).', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: AUCinf of Midazolam', 'description': 'This endpoint presents the geometric mean ratio (after RO7049389/before RO7049389).', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: Tmax of RO7049389', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: Cmax of RO7049389', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: AUC0-12hr of RO7049389', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: CLr of RO7049389', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: Accumulation Ratio of RO7049389', 'description': 'This endpoint presents the geometric mean ratio of AUC after a single dose (Day 1) and AUC after having received multiple doses (Day 14) within each arm.', 'timeFrame': 'Day 1, Day 14'}, {'measure': 'Part 1c: T1/2 of RO7049389', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: Ae of RO7049389', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 1c: Ctrough of RO7049389', 'timeFrame': 'Up to Day 14'}, {'measure': 'Part 2: HBV DNA < Lower Limit of Quantification (LLOQ)', 'timeFrame': 'Baseline - Day 112/Follow-up Day 84'}, {'measure': 'Part 2: Tmax of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Part 2: Cmax of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Part 2: AUCtau of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Part 2: Accumulation Ratio of RO7049389', 'description': 'This endpoint presents the geometric mean ratio of AUC after a single dose (Day 1) and AUC after having received multiple doses (Day 28) within each arm.', 'timeFrame': 'Day 1, Day 28'}, {'measure': 'Part 2: T1/2 of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Part 2: Ctrough of RO7049389', 'timeFrame': 'Up to Day 28'}, {'measure': 'Part 3: Percentage of Participants With AEs', 'timeFrame': '72 weeks'}, {'measure': 'Part 3: Hepatitis B Surface Antigen (HBsAg) Level', 'timeFrame': 'Baseline - Week 72'}, {'measure': 'Part 3: Hepatitis B e-Antigen (HBeAg) Levels', 'timeFrame': 'Baseline - Week 72'}, {'measure': 'Part 3: HBV RNA Level', 'timeFrame': 'Baseline - Week 72'}, {'measure': 'Part 3: HBV Core-Related Antigen (HBcrAg) Levels', 'timeFrame': 'Baseline - Week 72'}, {'measure': 'Part 3: Alanine Transaminase (ALT) Normalization in Participants With Baseline ALT Elevation', 'timeFrame': 'Week 12 - Week 72'}, {'measure': 'Part 3: Percentage of Participants With Anti-Hepatitis B Core Antigen (HBc) Antibodies', 'timeFrame': 'Up to Week 72'}, {'measure': 'Part 3: HBV DNA Level', 'timeFrame': 'Baseline - Week 72'}, {'measure': 'Part 3: HBV DNA < Lower Limit of Quantification (LLOQ)', 'timeFrame': 'Baseline - Week 72'}, {'measure': 'Part 3: Tmax of RO7049389', 'timeFrame': 'Day 1 - Week 48'}, {'measure': 'Part 3: Cmax of RO7049389', 'timeFrame': 'Day 1 - Week 48'}, {'measure': 'Part 3: AUCtau of RO7049389', 'timeFrame': 'Day 1 - Week 48'}, {'measure': 'Part 3: T1/2 of RO7049389', 'timeFrame': 'Day 1 - Week 48'}]",44.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,192.0,ACTUAL,v2_robust,True,True,False,True,
NCT00338624,An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.,oxybutynin chloride extended release,['oxybutynin chloride extended release'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Urination Disorders,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",2025-09-01T16:18:09.638289,True,,,,,"A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride) for the Treatment of Lower Urinary Tract Symptoms.",,['Urination Disorders'],"['lower urinary tract symptoms', 'DITROPAN XL', 'oxybutynin extended release tablets']",,2004-05,2005-06,[{'measure': 'Change of the total International Prostate Symptom Score (I-PSS) from baseline to Week 12 or the Final Visit.'}],"[{'measure': 'At all timepoints assessed and final visit: I-PSS (total score, irritative component score, quality of life score); Symptom Problem Index score; Urgency and frequency scales scores; Incontinence Indicator scale score'}]",2.0,45 Years,,MALE,False,INDUSTRY,0.0,420.0,ACTUAL,v2_robust,True,True,False,False,
NCT02998424,Pupillary Diameter Under Different Concentrations of Propofol,Propofol,['Propofol'],1,INTERVENTIONAL,['NA'],,COMPLETED,Anesthesia,Hôpital Armand Trousseau,2025-09-01T16:18:09.638316,True,,,,,Pupillary Diameter Without Stimulation Under Different Concentrations of Propofol Alone,,['Anesthesia'],"['propofol', 'pupillary diameter']",,2016-05,2016-12,"[{'measure': 'Pupillary diameter', 'timeFrame': 'Instantaneous measure, 10 minutes after the beginning of the study period'}]","[{'measure': 'Bispectral Index (BIS)', 'timeFrame': 'continuous measure, recorded10 minutes after the beginning of the study period'}, {'measure': 'Heart rate', 'timeFrame': 'continuous measure, recorded10 minutes after the beginning of the study period'}, {'measure': ""Observer's Assessment of Alertness/Sedation Scale (OAAS)"", 'description': 'Clinical score', 'timeFrame': '10 minutes after the beginning of the study'}]",4.0,13 Years,50 Years,ALL,False,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT01473524,Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis,Obeticholic Acid (OCA),"['Obeticholic Acid (OCA)', '6α-ethyl chenodeoxycholic acid (6-ECDCA)', 'Placebo', 'INT-747']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Primary Biliary Cirrhosis,Intercept Pharmaceuticals,2025-09-01T16:18:09.638349,True,,,,,"A Phase 3, Double-Blind, Placebo-Controlled Trial and Long-Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis",,['Primary Biliary Cirrhosis'],"['Primary Biliary Cholangitis', 'Primary Biliary Cirrhosis', 'PBC', 'Cirrhosis', 'Liver']",,2012-01,2018-12-17,"[{'measure': 'DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo', 'description': 'Percentage of participants at Month 12 with ALP \\< 1.67 x upper limit of normal (ULN) and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 12'}, {'measure': 'LTSE Phase: Composite Endpoint ALP And Total Bilirubin', 'description': 'Percentage of participants at Months 24, 36, 48, and 60 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. DB Month 12 is the baseline for the LTSE phase.', 'timeFrame': 'Baseline (DB Month 12), LTSE Months 24, 36, 48, and 60'}]","[{'measure': 'DB Phase: Composite Endpoint ALP And Total Bilirubin, 10 mg Versus Placebo', 'description': 'Percentage of participants at Month 6 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 6'}, {'measure': 'DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo', 'description': 'Percentage of participants at Month 12 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 12'}, {'measure': 'DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo', 'description': 'Percentage of participants at Month 6 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 6'}, {'measure': 'DB Phase: ALP Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for ALP levels. ALP Absolute Change From Baseline (ALP at Month 12 - ALP at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Total Bilirubin Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for bilirubin levels. Total bilirubin absolute change from baseline (total bilirubin at Month 12 - total bilirubin at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Direct Bilirubin Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for bilirubin levels. Direct bilirubin absolute change from baseline (direct bilirubin at Month 12 - direct bilirubin at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Alanine Aminotransferase (ALT) Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for ALT levels. ALT absolute change from baseline (ALT at Month 12 - ALT at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Aspartate Aminotransferase (AST) Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for AST levels. AST absolute change from baseline (AST at Month 12 - AST at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Gamma-glutamyltransferase (GGT) Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for GGT levels. GGT absolute change from baseline (GGT at Month 12 - GGT at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'LTSE Phase: ALP Levels', 'description': 'Blood samples were evaluated for ALP levels.', 'timeFrame': 'LTSE Day 0 and LTSE Months 12, 24, 36, 48, and 60'}, {'measure': 'LTSE Phase: ALP Change From DB Baseline', 'description': 'Blood samples were evaluated for ALP levels. ALP Change From Baseline (ALP at LTSE Months 12, 24, 36, 48, and 60 - ALP at Baseline) is presented. DB baseline is the mean of all available evaluations prior to DB treatment.', 'timeFrame': 'DB Baseline, LTSE Months 12, 24, 36, 48, and 60'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,217.0,ACTUAL,v2_robust,True,True,False,False,
NCT02153723,Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone),Glatiramer Acetate,"['Glatiramer Acetate', 'Copaxone']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Rett Syndrome,Montefiore Medical Center,2025-09-01T16:18:09.638403,True,,,,,Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone),,['Rett Syndrome'],"['Treatment trial, Rett syndrome, Glatiramer acetate']",,2013-08,2016-01,"[{'measure': 'Gait Velocity as Measured by GAITRite System', 'description': 'To perform quantitative gait assessments a computerized walkway (457 × 90.2 × 0.64cm) with embedded pressure sensors (GAIT Rite system) was used. Subjects walked on the walkway for two trials, while wearing comfortable footwear.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}]","[{'measure': 'Breath Hold Index (Number of Breath Holds Per Hour; Assessed in the Sleep Monitoring Lab)', 'description': 'Breath hold index is defined as number of breath holds/hour. Respirations were monitored with sleep monitoring equipment during the daytime at the polysomnography laboratory with additional oronasal airflow, electromyography (EMG), EEG and video monitoring to confirm wakefulness during the period of study.', 'timeFrame': 'Baseline and during final week of treatment (week 32)'}, {'measure': 'Breath Hold Time (Assessed in the Sleep Monitoring Lab)', 'description': 'Breath Hold Time is defined as percentage of time spent holding the breath in a specific time unit. It is measured by a standard medical technique where belts are placed on the chest and abdomen to record movement and sensors are used to record nasal flow. Wake respiration was monitored with sleep monitoring equipment during the daytime at the polysomnography laboratory with additional oronasal airflow, EMG, EEG and video monitoring to confirm wakefulness during the period of study.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}, {'measure': 'Visual Memory Novelty Score as Assessed by TX300 Tobii Computer.', 'description': 'Eye-tracking is considered an indication of visual memory. Eye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 computer (Tobii Technology, Danderyd, Sweden). The actual data given by the computer represents the percentage of time spent looking at a novel visual target - this is called the novelty score. Visual memory, as indexed by the novelty score, is the percentage of time spent looking at a novel target during the test (""visual paired comparison paradigm""). Duration of testing was 2 minutes.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}, {'measure': 'Visual Attention (Number of Fixations) Assessed by Eye-tracking TX300 Tobii Computer.', 'description': 'Visual attention is indexed by duration and number of fixations on novel target on testing. The standard method of assessing visual attention in neuropsychology is by measuring:\n\nA)number of fixations (how many times the subject looks at each of the 2 visual targets). The higher number of fixations, the more attentive the subject to that visual target.\n\nB) duration of fixations in seconds (the longer the fixation the more attentive). Duration of fixations correlates with intelligence: the smarter the person is the shorter his fixations are.\n\nEye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 (Tobii Technology AB, Danderyd, Sweden). The measured index is called the Novelty Score which indicates the percentage of time spent looking at novel visual target. Duration of testing session was 2 minutes.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}, {'measure': 'Visual Attention (Fixation Length) Assessed by Eye-tracking TX300 Tobii Computer.', 'description': 'The standard method of assessing visual attention in neuropsychology is by measuring:\n\nA)number of fixations (how many times the subject looks at each of the 2 visual targets). The higher number of fixations, the more attentive the subject to that visual target.\n\nB) duration of fixations in seconds (the longer the fixation the more attentive). Duration of fixations correlates with intelligence: the smarter the person is the shorter his fixations are.\n\nEye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 (Tobii Technology AB, Danderyd, Sweden). The measured index is called the Novelty Score which indicates the percentage of time spent looking at novel visual target. Visual attention is indexed by number of fixations on novel target on test.\n\nDuration of testing session was 2 minutes.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}]",6.0,10 Years,,FEMALE,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,False,
NCT04177823,"A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",Belantamab mafodotin,['Belantamab mafodotin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Multiple Myeloma,GlaxoSmithKline,2025-09-01T16:18:09.638459,True,,,,,"A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Chinese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed At Least Two Lines of Previous Treatment, Containing an Alkylator, a Proteasome Inhibitor and an Immunomodulatory Agent",,['Multiple Myeloma'],"['belantamab mafodotin', 'DLT', 'RRMM']",,2019-12-09,2021-12-30,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to 24 months and 21 days'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs)', 'description': 'An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; important medical events that may jeopardize the participant or may require medical or surgical intervention; is associated with liver injury and impaired liver function.', 'timeFrame': 'Up to 24 months and 21 days'}, {'measure': 'Number of Participants With Dose Limited Toxicities (DLTs)', 'description': 'An event was considered DLT if it occurred within 21 days of treatment and met any of the following criteria within same period:\n\n* Any Grade (Gr.) 3 or greater non-hematologic toxicity as described in NCI-CTCAE Version 5.0, other than corneal events that persists for \\>48 hours despite supportive treatment or leads to hospitalization.\n* Hematologic toxicity such as Gr. 3 or greater febrile neutropenia lasting \\>48 hours despite adequate treatment (Gr. 3 defined as absolute neutrophil count (ANC) \\<1000/millimeter cube (mm\\^3) at a single temperature \\>38.3 degree celsius or a sustained temperature \\>=38 degree celsius for more than 1 hour) and, Gr. 4 thrombocytopenia defined as platelet count \\<25000/mm\\^3 with clinically significant bleeding, or if platelet transfusion is required.\n* Gr. 4 per the corneal grading scale.\n* Liver toxicity meeting pre-specified by GSK liver stopping criteria.', 'timeFrame': 'Day 1 to day 21 of cycle 1'}]","[{'measure': 'Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC[0-t]) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis. AUC\\[0-t\\] was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'AUC[0-t] of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis. AUC\\[0-t\\] was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'AUC[0-t] of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis. AUC\\[0-t\\] was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on Day 1, anytime on Day 2, 4, 8, 15 and 22 of Cycle 1 (each cycle is of 21 days)'}, {'measure': 'Area Under the Concentration-time Curve During the Dosing Interval (AUC[0-tau]) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on Day 1, anytime on Day 2, 4, 8, 15 and 22 of Cycle 1 (each cycle is of 21 days)'}, {'measure': 'AUC[0-tau] of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Area Under the Concentration-time Curve From Time 0 to 168h (AUC[0-168]) of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Up to 168 hours'}, {'measure': 'Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-infinity]) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'AUC[0-infinity] of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'AUC[0-infinity] of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on Day 1, anytime on Day 2, 4, 8, 15 and 22 of Cycle 1 (each cycle is of 21 days)'}, {'measure': 'Observed Plasma Concentration at the End of Infusion (CEOI) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion) on day 1 of cycle 2, 4, 6, 9 and 12 (each cycle is of 21 days)'}, {'measure': 'CEOI of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion) on day 1 of cycle 2, 4, 6, 9 and 12 (each cycle is of 21 days)'}, {'measure': 'CEOI of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion) on day 1 of cycle 2, 4, 6, 9 and 12 (each cycle is of 21 days)'}, {'measure': 'Maximum Observed Concentration (Cmax) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis. Maximum observed plasma concentration, determined directly from the concentration-time data for each cycle.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Cmax of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis. Maximum observed plasma concentration, determined directly from the concentration-time data for each cycle.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on Day 1, anytime on Day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Cmax of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis. Maximum observed plasma concentration, determined directly from the concentration-time data for each cycle.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on Day 1, anytime on Day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Time to Reach Maximum Observed Concentration (Tmax) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Tmax of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Tmax of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Tlast of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Tlast of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Systemic Clearance (CL) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'CL of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Systemic Clearance Normalized by Body Weight (CL/Weight) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'CL/Weight of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on Day 1, anytime on Day 2, 4, 8, 15 and 22 of Cycle 1 (each cycle is of 21 days)'}, {'measure': 'Volume of Distribution at Steady State (Vss) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Vss of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Volume of Distribution at Steady State Normalized by Body Weight (Vss/Weight) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Vss/Weight of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Apparent Terminal Half-life (t1/2) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 't1/2 of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 't1/2 of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on day 1, anytime on day 2, 4, 8, 15 and 22 of cycle 1 (each cycle is of 21 days)'}, {'measure': 'Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) of Belantamab Mafodotin Antibody-drug Conjugate (ADC)', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion) on day 1 of cycle 1, 3, 5, 8 and 11 (each cycle is of 21 days)'}, {'measure': 'Ctrough of Belantamab Mafodotin Total Antibody', 'description': 'Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis.', 'timeFrame': 'Pre-dose (within 30 minutes prior to start of infusion) on day 1 of cycle 1, 3, 5, 8 and 11 (each cycle is of 21 days)'}, {'measure': 'Number of Participants With Abnormal Vital Signs', 'description': 'Abnormal vital signs were defined as any abnormal findings in the vital signs parameters (temperature, blood pressure and pulse rate).', 'timeFrame': 'Up to 21 months'}, {'measure': 'Number of Participants With Worst- Case Grade Changes Post-baseline in Hematology Parameter: Hemoglobin, Lymphocytes, Neutrophils, Platelets, Leukocytes', 'description': 'Blood samples were collected at indicated time points to assess change from baseline in hemoglobin, lymphocytes, neutrophils, platelets, leukocytes. Worst case grade increase from baseline grade was provided for all the hematology tests that were gradable by National Cancer Institute Common Terminology Criteria (NCI CTCAE, Version 5.0, 2017). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Data for any participants with worst-case grade changes (Increase to Grade 3 or Increase to Grade 4) post-baseline were presented. Baseline was defined as latest pre-dose assessment (day 1) with a non-missing value, including those from unscheduled visits.', 'timeFrame': 'Baseline (day 1) and up to 21 months'}, {'measure': 'Number of Participants With Worst- Case Grade Changes Post-baseline in Clinical Chemistry Parameters', 'description': 'Blood samples were collected at indicated time points to assess change from baseline in albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bilirubin, creatine kinase, gamma glutamyl transferase, potassium, lactate dehydrogenase, magnesium. Worst case grade (G) increase from baseline grade was provided for all the chemistry tests that were gradable by National Cancer Institute Common Terminology Criteria (NCI CTCAE, Version 5.0, 2017). Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE. Data for any participants with worst-case grade changes (Increase to Grade 3 or Increase to Grade 4) post-baseline were presented. Baseline was defined as latest pre-dose assessment (day 1) with a non-missing value, including those from unscheduled visits.', 'timeFrame': 'Baseline (day 1) and up to 21 months'}, {'measure': 'Percentage of Participants With Objective Response Rate (ORR)', 'description': 'ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., very good partial response \\[VGPR\\], complete response \\[CR\\] and stringent complete response \\[sCR\\]) as assessed by International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma 2016. PR=response greater than or equal to (\\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to less than (\\<) 200 mg per 24 hours. CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates. sCR=complete response below plus normal free light chain (FLC) ratio and absence of clonal plasma cells in bone marrow by immunohistochemistry or 8-color, 2 tube multiparametric flow cytometry. VGPR=Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-component level \\<100 mg/24 h.', 'timeFrame': 'Up to 21 months'}, {'measure': 'Number of Participants With Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin', 'description': 'Serum samples were analyzed for the presence of anti-belantamab mafodotin antibodies by a validated electro chemiluminescent immunoassay. All samples were tested in a screening assay to identify potentially positive samples.', 'timeFrame': 'Up to 24 months and 21 days'}, {'measure': 'Titers of ADAs Against Belantamab Mafodotin', 'description': 'Samples were analyzed for the presence of anti-belantamab mafodotin antibodies by a validated electro chemiluminescent immunoassay. All samples were tested in a screening assay to identify potentially positive samples. Screened positive was further characterized for the antibody titer values.', 'timeFrame': 'Up to 24 months and 21 days'}, {'measure': 'Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score', 'description': 'The OSDI instrument measures vision-related function. The total OSDI score was calculated as (sum of scores for all questions answered\\*100) divided by (total number of questions answered\\*4). The 12 items questionnaire assessed ocular symptoms, visual-related functioning and environmental triggers. Scores ranged from 0 to 100, with higher scores indicating a worse status. Baseline was defined as latest pre-dose assessment (day 1) with a non-missing value, including those from unscheduled visits.', 'timeFrame': 'Baseline (day 1) Up to 24 months and 21 days'}]",44.0,18 Years,,ALL,False,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,True,False,True,
NCT04402723,Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML,Donafenib,"['Donafenib', 'Cytarabine and Daunorubicin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Acute Myeloid Leukemia (AML),"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",2025-09-01T16:18:09.638468,True,,,,,A Dose-escalated Phase Ⅰ Trial to Assess the Tolerance and Pharmacokinetics of Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML Patient,,['Acute Myeloid Leukemia (AML)'],[],Corporate policy adjustments,2018-11-06,2022-02-09,"[{'measure': 'Safety(including the type, severity and frequency of AE)', 'description': 'Safety of combination of donafenib with Cytarabine/Daunorubicin in relapsed AML patients.', 'timeFrame': 'through study completion, an average of 2 months'}]",[],1.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,8.0,ACTUAL,v2_robust,True,False,True,True,Corporate policy adjustments
NCT01306123,Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration,"Nascobal nasal spray (cyanocobalamin, USP)","['Vitamin B12-ratiopharm N, injection solution', 'Nascobal nasal spray (cyanocobalamin, USP)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Focus: Bioavailability,Swedish Orphan Biovitrum,2025-09-01T16:18:09.638476,True,,,,,"An Open, Randomized, Single-dose, Two-way Crossover Study to Characterize the Pharmacokinetic Properties of Cyanocobalamin When Administered as an Intranasal Spray and an Intramuscular Injection to Healthy Volunteers",,['Focus: Bioavailability'],"['bioavailability', 'pharmacokinetics', 'cyanocobalamin', 'intranasal', 'intramuscular']",,2011-02,2011-05,"[{'measure': 'Relative bioavailability', 'description': 'Relative bioavailability (Frel) based on the area under the serum concentration-time curve during 72 hours (AUC0-72h) for the test and reference products.', 'timeFrame': '0-72 hours'}]","[{'measure': 'Additional PK characteristics', 'description': 'Maximum serum concentration (Cmax), time of Cmax (tmax) and AUC0-24h.', 'timeFrame': '0-72h'}]",2.0,18 Years,40 Years,ALL,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,False,
NCT00882323,Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA),"Cyclophosphamide, Fludarabine, Thymoglobulin","['Cyclophosphamide, Fludarabine, Thymoglobulin']",1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Aplastic Anemia,The Korean Society of Pediatric Hematology Oncology,2025-09-01T16:18:09.638511,True,,,,,"Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia",,['Aplastic Anemia'],[],,2008-11,2012-10,"[{'measure': 'To evaluate engraftment potential of reduced toxicity fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}]","[{'measure': 'To evaluate toxicities of reduced toxicity fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for UBMT/PBSCT in SAA.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}, {'measure': 'To evaluate overall and EFS rate after UBMT/PBSCT.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}, {'measure': 'To evaluate GVHD and immunologic recovery after UBMT/PBSCT.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}]",4.0,1 Year,21 Years,ALL,False,NETWORK,0.0,33.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01343823,Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema,ecallantide 60 mg,"['placebo', 'ecallantide 60 mg', 'ecallantide 30 mg', 'placebo match for 10 mg ecallantide arm', 'placebo match for 30 mg ecallantide arm', 'ecallantide 10 mg']",6,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,ACE Inhibitor Induced Angioedema,Shire,2025-09-01T16:18:09.638533,True,,,,,Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema,,['ACE Inhibitor Induced Angioedema'],[],Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.,2011-06-01,2012-06-01,"[{'measure': 'Safety and Efficacy of Ecallantide', 'description': 'Compare the proportion of patients meeting prespecified discharge criteria in the group receiving ecallantide with conventional therapy to patients receiving placebo with conventional therapy. Patients were evaluated against 6 discharge eligibility criteria at 1,2,3,4,5, and 6 hours after study drug administration or until discharged from the ER. A responder was defined as a patient meeting all six discharge eligibility criteria as below: • Improvement of edema to ""a little better"" or ""a lot better"" as assessed by health care provider using a five point scale • Stable vital signs (within an acceptable range) • Absence of stridor • Absence of dyspnea or use of accessory muscles during respiration • Absence of drooling • Able to drink without difficulty', 'timeFrame': '6 hours'}]","[{'measure': 'Time to Symptom Resolution Based on the Visual Analog Scale (VAS)', 'description': 'Compare the time to onset of symptom resolution between the ecallantide-treated and placebo-treated groups. The patient assessed severity of the angioedema attack using a VAS at baseline and following study drug administration every 15 minutes for the first 2 hours and then every 30 minutes through 6 hours post dosing or until the time of discharge from the ER (whichever occurred first). The scale ranged from ""totally resolved"" to ""very severe"".', 'timeFrame': '6 hours'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,79.0,ACTUAL,v2_robust,True,False,True,True,Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.
NCT05798923,A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension,LAM-001,['LAM-001'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Pulmonary Hypertension,OrphAI Therapeutics,2025-09-01T16:18:09.638546,True,,,,,"A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 for the Treatment of Pulmonary Hypertension",,['Pulmonary Hypertension'],['Pulmonary Hypertension'],,2023-04-03,2027-09-30,"[{'measure': 'Change from baseline VO2 max', 'timeFrame': '24 weeks'}]","[{'measure': 'Change in VE/VCO2 slope (ventilatory efficiency)', 'timeFrame': '24 weeks'}, {'measure': 'Change in cardiac output (CO)', 'timeFrame': '24 weeks'}, {'measure': 'Change in cardiac index (CI)', 'timeFrame': '24 weeks'}, {'measure': 'Change in stroke volume (SV)', 'timeFrame': '24 weeks'}, {'measure': 'Change in mean pulmonary arterial pressure (mPAP)', 'timeFrame': '24 weeks'}, {'measure': 'Change in pulmonary capillary wedge pressure (PCWP)', 'timeFrame': '24 weeks'}, {'measure': 'Change in pulmonary vascular resistance (PVR)', 'timeFrame': '24 weeks'}, {'measure': 'Change in pulmonary arterial compliance (PAC)', 'timeFrame': '24 weeks'}, {'measure': 'Change in pulmonary arterial distensibility', 'timeFrame': '24 weeks'}, {'measure': 'Change in CavO2 (arteriovenous O2 content difference)', 'timeFrame': '24 weeks'}, {'measure': 'Change from baseline in RV SV, RV ESV, RV EDV, RV EF, RV SVI, RV ESVI and RV EDVI by cardiac magnetic resonance (MR) imaging', 'timeFrame': '24 weeks'}, {'measure': 'Pharmacokinetic (PK) : Whole Blood Concentration of LAM-001', 'timeFrame': '24 weeks'}, {'measure': 'Change from baseline in 6MWD', 'timeFrame': '24 weeks'}, {'measure': 'Change from baseline in WHO functional class', 'timeFrame': '24 weeks'}, {'measure': 'Time to clinical worsening (from time of randomization until study discontinuation due to clinical worsening).', 'timeFrame': '24 weeks'}, {'measure': 'Change from baseline in supplemental oxygen requirements', 'timeFrame': '24 weeks'}, {'measure': 'Change from baseline in pulse oximetry', 'timeFrame': '24 weeks'}, {'measure': 'Change from baseline in pulmonary function tests (PFTs)', 'timeFrame': '24 weeks'}, {'measure': 'Exacerbations of underlying lung disease (WSPH Group-3)', 'timeFrame': '24 weeks'}]",20.0,18 Years,,ALL,False,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,False,False,False,
NCT06373523,MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin,Dapagliflozin 10mg Tab,"['Dartdapa', 'Dapagliflozin 10mg Tab', 'Placebo', 'LT4', 'Levothyroxine Replacement daily', 'Placib']",6,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,NOT_YET_RECRUITING,Hepatic Steato-Fibrosis,"Post Graduate Institute of Medical Education and Research, Chandigarh",2025-09-01T16:18:09.638583,True,,,,,MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin,,"['Hepatic Steato-Fibrosis', 'Non-Alcoholic Fatty Liver Disease']","['Dapaglifozin', 'MRI-PDFF', 'Primary hypothyroidism']",,2024-09-01,2025-07-30,"[{'measure': 'Change in liver fat content', 'description': 'Difference in the change in liver fat content between the two groups at week 28 from the baseline as measured by MRI-PDFF', 'timeFrame': '28 weeks'}]","[{'measure': 'Proportion of participants achieving 1 Stage decrease in steatosis at 6 months asassessed by Transient Elastography', 'description': 'Proportion of participants achieving 1 Stage decrease in steatosis at 6 months as assessed by Transient Elastography', 'timeFrame': '28 weeks'}, {'measure': 'Changes in Improvement in hepatic fibrosis measured by non invasive parameters like Fib4 score at 3 and 6 months', 'description': 'Changes in Improvement in hepatic fibrosis measured by non invasive parameters like Fib4 score at 3 and 6 months', 'timeFrame': '28 weeks'}, {'measure': 'Changes in Lipid Profile at 3 and 6 months', 'description': 'Changes in Lipid Profile at 3 and 6 months', 'timeFrame': '28 weeks'}]",4.0,18 Years,75 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01420523,Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy,Raltegravir-Maraviroc,"['Raltegravir-Maraviroc', 'Isentress and Celsentri']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Human Immunodeficiency Virus,"ANRS, Emerging Infectious Diseases",2025-09-01T16:18:09.638602,True,,,,,Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).,,"['Human Immunodeficiency Virus', 'Lipohypertrophy']","['HIV', 'Lipohypertrophy']",,2011-12,2013-04,"[{'measure': 'Virological failure', 'description': 'Occurrence of virological failure, as verified by 2 consecutive plasma viral load measurements \\> 50 copies/mL, taken 2 to 4 weeks apart at most, during the first 24 weeks.', 'timeFrame': 'Week 24'}]","[{'measure': 'Viro-immunological efficacy', 'description': '* Proportion of patients with a HIV RNA viral load \\< 50 copies/mL.\n* Proportion of patients discontinuing the therapy:\n* Plasma genotypic resistance profile where the viral load is \\> 50 copies/mL.\n* Evaluation of DNA/RNA tropism in the event of failure.\n* Evaluation of plasma HIV RNA where the viral load is \\< 50 copies/mL, through ultrasensitive PCR testing.\n* Evolution of the CD4 and CD8 T-cell counts.\n* Blood concentration of raltegravir and maraviroc.', 'timeFrame': 'Between baseline and W48'}, {'measure': 'Tolerability criteria and metabolic impact', 'description': '* Changes in glucose and lipid balance.\n* Changes in anthropometric measurements.\n* Number and severity of clinical and biological adverse effects.\n* Changes in bone mineral density and body composition, as measured by DEXA scan.\n* Changes in inflammation and endothelial activation markers between baseline and W48\n* Measurement of fat cells differentiation markers in adipose tissue biopsy samples', 'timeFrame': 'Between baseline and W48'}, {'measure': 'Compliance', 'description': '• Assessment of compliance conducted at screening and at W24 and 48.', 'timeFrame': 'Between baseline and W48'}, {'measure': 'Quality of life', 'description': '• Assessment of health-related quality of life conducted at baseline and at W24 and 48.', 'timeFrame': 'Between baseline and W48'}]",5.0,18 Years,,ALL,False,OTHER_GOV,2.0,48.0,ACTUAL,v2_robust,True,False,True,True,
NCT00003123,Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome,amifostine trihydrate,['amifostine trihydrate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Myelodysplastic Syndromes,Providence Hospital,2025-09-01T16:18:09.638621,True,,,,,A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes,,['Myelodysplastic Syndromes'],"['refractory anemia', 'refractory anemia with ringed sideroblasts', 'refractory anemia with excess blasts', 'refractory anemia with excess blasts in transformation']",,1997-08,,[],[],0.0,17 Years,,ALL,False,OTHER,0.0,36.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01068223,A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers,A:JNJ-39758979/Placebo #1,"['A:JNJ-39758979/Placebo #1', 'C:Cetirizine/JNJ-39758979 Matching Placebo', 'B: JNJ-39758979 Matching Placebo /Placebo #2']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Histamine Induced Itch,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",2025-09-01T16:18:09.638690,True,,,,,"A Single-Center, Single-Dose, Double-Blind, Modified-Double-Dummy, Placebo and Active-Controlled, Randomized, Three-Way, Six-Sequence Cross-Over Study to Investigate the Effect of JNJ-39758979 on Histamine Induced Pruritus in Healthy Male Subjects",,['Histamine Induced Itch'],"['Cetirizine, CR016609']",,2010-02,2010-05,"[{'measure': 'Participant-assessed pruritis score following histamine challenge', 'timeFrame': 'at 30 second intervals for the first 5 minutes and then at 1 minute intervals through 10 minutes'}]","[{'measure': 'To evaluate the effect of single oral dose of JNJ-39758979 (600mg) on histamine-induced wheal and flare in healthy volunteers', 'timeFrame': 'at 10 minutes following histamine challenge'}]",2.0,18 Years,55 Years,MALE,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,False,
NCT00337623,Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.,Prednisolone,['Prednisolone'],1,INTERVENTIONAL,['NA'],,COMPLETED,Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy,"University Hospital, Clermont-Ferrand",2025-09-01T16:18:09.638700,True,,,,,Corticosteroids and Cataracts : Prospective Study of the Impact of Systemic Corticosteroid Therapy on Lens Transparency Evaluated by Scheimpflug Photography and Quantification of Lens Autofluorescence.,,['Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy'],"['Cataracts', 'Corticosteroids', 'Scheimpflug', 'Lens autofluorescence']",,2000-06,2006-07,"[{'measure': ""Cataracts on Ophthalmologist's Examination""}, {'measure': 'Increase of Lens Autofluorescence'}, {'measure': 'Increase of Lens Density on Scheimpflug Photography'}]","[{'measure': 'Potential risk factor of cataracts related to the underlying disease or the individual'}, {'measure': 'Potential effect of time allowed from the beginning of treatment, duration and dosage of corticosteroids.'}]",5.0,18 Years,60 Years,ALL,True,OTHER,0.0,22.0,,v2_robust,True,True,False,False,
NCT04938323,Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly,BCG Vaccine,"['BCG Vaccine', 'Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,WITHDRAWN,Acute Respiratory Infection,Harvard Medical School (HMS and HSDM),2025-09-01T16:18:09.638710,True,,,,,Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly (PARITIE),,['Acute Respiratory Infection'],[],Covid-19 related delays in project launch,2022-05,2022-09,"[{'measure': 'To measure the impact of one-time BCG vaccination compared to placebo in reducing the occurrence of acute respiratory infection leading to hospitalization in the elderly in Taiwan', 'description': 'Number of hospitalizations for acute respiratory infection as defined by list of ICD codes', 'timeFrame': '6 months'}]","[{'measure': 'To measure the impact of one-time BCG vaccination compared to placebo in reducing the occurrence of medically attended acute respiratory infection', 'description': 'Number of medically attended acute respiratory infection', 'timeFrame': '6 months'}, {'measure': 'To measure the impact of one-time BCG vaccination compared to placebo on microbiologically confirmed viral respiratory illness', 'description': 'Number of microbiologically confirmed viral respiratory illness by viral pathogen as measure by BioFire® Respiratory 2.1 PCR panel', 'timeFrame': '6 months'}, {'measure': 'To measure the impact of one-time BCG vaccination compared to placebo on duration of hospitalization due to acute respiratory infection during the study follow-up period', 'description': 'Total duration of days spent hospitalized due to acute respiratory infection during the study follow-up period', 'timeFrame': '6 months'}, {'measure': 'To measure the impact of one-time BCG vaccination compared to placebo on critical admissions during the follow-up period', 'description': 'Number of critical are admissions during the follow-up period', 'timeFrame': '6 months'}, {'measure': 'To measure the impact of one-time BCG vaccination compared to placebo on all-cause mortality deaths', 'description': 'Number of all-cause mortality deaths', 'timeFrame': '6 months'}, {'measure': 'To measure the impact of one-time BCG vaccination compared to placebo on local and systemic adverse events', 'description': 'Number of local and systemic adverse events to BCG vaccination following randomization', 'timeFrame': '6 months'}, {'measure': 'To measure the impact of one-time BCG vaccination compared to placebo on changes of antibody profiles', 'description': 'Number of changes in antibody profiles between enrollment and follow-up', 'timeFrame': '6 months'}]",8.0,55 Years,85 Years,ALL,True,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,True,Covid-19 related delays in project launch
NCT01715259,A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function,Abiraterone acetate: participants with end-stage renal disease,"['Abiraterone acetate: participants with end-stage renal disease', 'Abiraterone acetate: matched control participants with normal renal function']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Renal Insufficiency,"Cougar Biotechnology, Inc.",2025-09-01T16:18:09.638875,True,,,,,A Phase 1 Single Dose Open-Label Reduced/Staged Pharmacokinetic Study of Abiraterone Acetate in Male Subjects With Impaired Renal Function Compared to Matched Control Subjects With Normal Renal Function,,['Renal Insufficiency'],"['Renal insufficiency', 'Renal impairment', 'End-stage renal disease', 'Abiraterone acetate', 'Pharmacokinetics']",,2009-08,2010-01,"[{'measure': 'Maximum observed plasma concentration of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}, {'measure': 'Time to maximum plasma concentration of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}, {'measure': 'Area under the concentration-time curve from time 0 to the last measurable plasma concentration of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}, {'measure': 'Area under the concentration-time curve from time 0 to infinity of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}, {'measure': 'Terminal phase rate constant of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}, {'measure': 'Terminal plasma elimination half-life of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}, {'measure': 'Oral clearance of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}, {'measure': 'Apparent volume of distribution of abiraterone', 'timeFrame': 'Within 0.5 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose'}]","[{'measure': 'Number of participants affected by an adverse event', 'timeFrame': 'Up to Day 22'}]",9.0,40 Years,80 Years,MALE,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT01149759,Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy,Cyclosporine A,"['Neoral', 'Cyclosporine A']",2,INTERVENTIONAL,['NA'],,COMPLETED,Atopic Dermatitis,Rockefeller University,2025-09-01T16:18:09.638951,True,,,,,Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis With Suppression of Immune Activation During Cyclosporine Therapy,,"['Atopic Dermatitis', 'Eczema']","['Atopic Dermatitis', 'Eczema']",,2010-06,2014-12,"[{'measure': 'SCORAD Change Score', 'description': 'SCORAD (""SCORing Atopic Dermatitis"") is a clinical tool for assessing the severity (i.e., extent, intensity) of atopic dermatitis (AD) as objectively as possible with scores ranging from 0-100. The higher the score indicates more severe AD. For this outcome the SCORAD change score is computed as an absolute number which is comparing improvement in the SCORAD score of participants at week 12 compared to their SCORAD score at baseline.', 'timeFrame': '12 weeks'}]","[{'measure': 'Change in Epidermal Thickness', 'description': 'Change in lesional skin epidermal thickness at week 12 compared to baseline', 'timeFrame': '12 weeks'}]",2.0,18 Years,,ALL,False,OTHER,0.0,9.0,ACTUAL,v2_robust,True,True,False,False,
NCT01802359,A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction,No intervention,['No intervention'],1,OBSERVATIONAL,[],,TERMINATED,Erectile Dysfunction,"Janssen Korea, Ltd., Korea",2025-09-01T16:18:09.638978,True,,,,,Post-Marketing Surveillance of Bravonto in Korea,,['Erectile Dysfunction'],"['Erectile dysfunction', 'Mirodenafil', 'Bravonto']",This prodect will be transferred to another company.,2011-11-07,2012-05-31,"[{'measure': 'Number of participants with adverse events', 'timeFrame': 'Up to 4 weeks'}]","[{'measure': 'International Index of Erectile Function', 'description': 'The International Index of Erectile Function is used for the assessment of erectile dysfunction, with scores ranging from 0 to 30. Evaluation of points are as follows: 1-10 = severe erectile dysfunction, 11-16 = moderate dysfunction, 17-21 = mild to moderate dysfunction, 22-25 = mild dysfunction, 26-30 = no dysfunction. Lower scores indicate worsening.', 'timeFrame': 'Baseline (Week 0), Week 4, Week 8, and Week 12'}, {'measure': 'Sexual Encounter Profile', 'description': 'The Sexual Encounter Profile is assessed after each sexual attempt consisting of a series of yes/no questions regarding specific aspects of each encounter. Question 1 asks, ""Were you able to insert your penis into your partner\'s vagina?"" and question 2 asks, ""Did your erection last long enough for you to complete intercourse with ejaculation?"".', 'timeFrame': 'Baseline (Week 0), Week 4, Week 8, and Week 12'}, {'measure': 'Global assessment Questionnaire', 'description': 'The Global Assessment Questionnaire is a self-administered questionnaire (Yes/No) that allows men to rate improvement in erectile function. Question 1 asks ""Has the treatment you have been taking over the past 4 weeks improved your erections?"" and if the answer is yes, question 2 then asks ""Has the treatment improved your ability to engage in sexual activity""', 'timeFrame': 'Baseline (Week 0), Week 4, Week 8, and Week 12'}, {'measure': 'Number of participants with adverse events', 'timeFrame': 'Up to 12 weeks'}]",5.0,19 Years,,MALE,False,INDUSTRY,0.0,379.0,ACTUAL,v2_robust,False,False,True,True,This prodect will be transferred to another company.
NCT00330759,Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.,Zoledronic Acid,"['Zoledronic Acid', 'Zometa']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bone Metastases,Amgen,2025-09-01T16:18:09.639112,True,,,,,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.",,['Bone Metastases'],"['Bone metastases', 'lytic bone lesions', 'advanced cancer', 'multiple myeloma', 'lymphoma', 'solid tumors', 'skeletal related events', 'skeletal fractures', 'spinal cord compressions, radiation to bone', 'surgery to bone, bisphosphonates', 'denosumab']",,2006-06-01,2011-10-01,"[{'measure': 'Time to the First On-Study Skeletal-Related Event (Non-Inferiority)', 'description': 'Time to the first on-study skeletal-related event (SRE) using a non-inferiority analysis. Median was estimated using the Kaplan-Meier method.', 'timeFrame': 'up to 33 months'}]","[{'measure': 'Time to First On-Study Skeletal-Related Event (Superiority)', 'description': 'Time to first on-study skeletal-related event (SRE) using a test for superiority. Median was estimated using the Kaplan-Meier method.', 'timeFrame': 'up to 33 months'}, {'measure': 'Time to the First-and-Subsequent On-Study Skeletal-Related Event', 'description': 'Time to the first-and-subsequent on-study skeletal-related event (SRE) using multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE.\n\nThis outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.', 'timeFrame': 'up to 33 months'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,1779.0,ACTUAL,v2_robust,True,True,False,False,
NCT01128959,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,Intravenous Carbamazepine (IV CBZ),['Intravenous Carbamazepine (IV CBZ)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Epilepsy,Lundbeck LLC,2025-09-01T16:18:09.639129,True,,,,,Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy,,['Epilepsy'],"['Epilepsy', 'Intravenous Carbamazepine', 'Oral Carbamazepine']",,2010-06,2013-01,"[{'measure': 'Adverse Events', 'timeFrame': 'Baseline to after last iv dose on day 4'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,3.0,108.0,ACTUAL,v2_robust,True,True,False,True,
NCT05298059,The Association of CPP-ACPF Associated With LASER in the Treatment of Tooth Sensitivity After at Home Bleaching,CPP-ACPF,"['CPP-ACPF', 'MI paste plus']",2,INTERVENTIONAL,['NA'],,COMPLETED,"Sensitivity, Tooth",Universidade Federal do Para,2025-09-01T16:18:09.639190,True,,,,,The Effect of Photobiomodulation Therapy Associated With Casein Phosphopeptide-amorphous Calcium Phosphate Fluoride Paste on the Treatment of Post-home Whitening Tooth Sensitivity: a Randomized Clinical Trial,,"['Sensitivity, Tooth']","['Sensitivity, Tooth', 'Laser', 'Tooth Bleaching', 'Dentin Desensitizing Agents']",,2022-03-20,2023-06-20,"[{'measure': 'Sensitivity assessment', 'description': 'Aplly Repeated Measures ANOVA to analyze tooth sensitivity data reported by patients', 'timeFrame': 'Afeter 21 days of tooth whitening'}]",[],1.0,18 Years,30 Years,ALL,True,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT00984880,"Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043",AZD3043,['AZD3043'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,AstraZeneca,2025-09-01T16:18:09.639198,True,,,,,"Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After a Single Ascending Bolus Dose, and a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Volunteers",,['Healthy'],"['Sedation', 'anaesthesia', 'Safety', 'Tolerability', 'Pharmacokinetics', 'Pharmacodynamics']",,2009-09,2009-12,"[{'measure': 'Assessment of vital signs data, heart rate, ECG', 'timeFrame': 'The measure will be taken between -20 to 120 min relative to stop of administration of AZD3043'}, {'measure': 'Respiratory signs data (SpO2, EtCO2, PaO2, blood gases, respiratory frequency and pattern, occurrence of apnoea)', 'timeFrame': 'The measure will be taken between -20 to 120 min relative to stop of administration of AZD3043'}]","[{'measure': 'PK parameters for AZD3043: Cmax (in part B: bolus Cmax and infusion Cmax), AUClast, AUC, lz, t½lz, CL, Vc, Vss, Vz, tmax, tlast and MRT arterial and venous plasma.', 'timeFrame': 'Part A: Arterial: Predose and continously up to 120 min after start of dosing. Part B: Arterial: Predose and continously up to 150 min after start of dosing. Venous: Predose and continously up to 24 h after start of dosing'}, {'measure': 'PK parameters for the metabolite (THRX 108893): Cmax (in part B: bolus Cmax and infusion Cmax), AUClast, AUC, tmax, tlast, lz and t½lz in arterial and venous plasma.', 'timeFrame': 'Part A: Arterial: Predose and continously up to 120 min after start of dosing. Part B: Arterial: Predose and continously up to 150 min after start of dosing. Venous: Predose and continously up to 24 h after start of dosing'}]",4.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,72.0,ESTIMATED,v2_robust,True,True,False,False,
NCT03539380,TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease,TRx0237,['TRx0237'],1,EXPANDED_ACCESS,[],,AVAILABLE,Alzheimer Disease,TauRx Therapeutics Ltd,2025-09-01T16:18:09.639233,True,,,,,TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease: Intermediate-Size Patient Population,,['Alzheimer Disease'],[],,,,[],[],0.0,,,ALL,,INDUSTRY,0.0,,,v2_robust,False,False,False,False,
NCT04718480,Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients,Placebo,"['Fluvoxamine', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Covid19,SigmaDrugs Research Ltd.,2025-09-01T16:18:09.639245,True,,,,,"A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients",,['Covid19'],['moderate COVID-19; fluvoxamine'],,2020-11-27,2022-05-31,"[{'measure': 'Time to clinical recovery after treatment', 'description': 'days from randomization (Day 1) to ANY THREE items of the following four:\n\n1. resolution from fever (oral or tympanic temperature ≤ 37.5 °C, axillary ≤ 37.0 °C for at least 48 hours without antipyretics)\n2. return of respiratory rate to normal (≤ 20 / min)\n3. normalization of SpO2 ( ≥95% on room air )\n4. cough remission (any reduction in cough-burden Visual Analogue Scale, compared to Day 1 baseline)', 'timeFrame': '74 days'}]",[],1.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,66.0,ACTUAL,v2_robust,True,True,False,False,
NCT01123980,Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment,biphasic insulin aspart 30,"['insulin glargine', 'metformin', 'biphasic insulin aspart 30', 'glimepiride']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Diabetes,Novo Nordisk A/S,2025-09-01T16:18:09.639265,True,,,,,"An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes",,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],,2010-05,2011-06,"[{'measure': 'Change in Glycosylated Haemoglobin (HbA1c)', 'timeFrame': 'Week 0, week 24'}]","[{'measure': '9-point Plasma Glucose Profiles', 'description': 'Glycaemic control measured by 9-point plasma glucose (SPMG) profiles. The 9 timepoints for self-measurement during the day were: before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, before bedtime, at 2-4 a.m. and before breakfast the following day.', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of Subjects Achieving HbA1c Below 7.0%', 'description': 'The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of Subjects Achieving HbA1c Below or Equal to 6.5%', 'description': 'The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment', 'timeFrame': 'Week 24'}, {'measure': 'Number of Hypoglycaemic Episodes - All', 'timeFrame': 'Weeks 0-24'}, {'measure': 'Number of Hypoglycaemic Episodes - Severe and Minor', 'description': 'Hypoglycaemic episodes (hypos) summarised based on American Diabetes Association classification (severe, documented symptomatic, asymptomatic, probable symptomatic, and relative hypoglycaemia) and according to additional definition (minor hypoglycaemia). Severe hypos: requiring another person to actively administer resuscitative actions. Minor hypos: symptoms with plasma glucose below 3.1 mmol/L (56 mg/dl), or any asympomatic plasma glucose below 3.1 mmol/L.', 'timeFrame': 'Weeks 0-24'}, {'measure': 'Number of Hypoglycaemic Episodes', 'description': 'All episodes classified into nocturnal (time of onset between 00:00 (included) and 05:59 (included)).', 'timeFrame': 'Weeks 0-24'}]",7.0,20 Years,79 Years,ALL,False,INDUSTRY,0.0,521.0,ACTUAL,v2_robust,True,True,False,False,
NCT05692180,"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)",Benralizumab,"['Benralizumab', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Asthma,AstraZeneca,2025-09-01T16:18:09.639299,True,,,,,Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA),,['Asthma'],"['Eosinophilic asthma', 'Pediatric Patients', 'Severe asthma']",,2023-04-05,2032-05-16,"[{'measure': 'Time to first asthma exacerbation', 'description': 'The effect of benralizumab on asthma exacerbations in paediatric and adolescent patients with uncontrolled asthma will be evaluated.', 'timeFrame': 'From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period'}]","[{'measure': 'Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA)', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in Asthma symptom score', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in rescue medication use', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in night-time awakenings due to asthma', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in peak expiratory flow (PEF)', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Serum benralizumab trough concentration', 'description': 'The pharmacokinetics of benralizumab will be characterised.', 'timeFrame': 'During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period'}, {'measure': 'Anti-benralizumab antibodies', 'description': 'The immunogenicity of benralizumab will be characterised.', 'timeFrame': 'During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score', 'description': 'The effect of benralizumab on asthma health-related quality of life will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)', 'description': 'The effect of benralizumab on pulmonary function (FEV1) will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1', 'description': 'The effect of benralizumab on pulmonary function (FEV1) will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'The Annualised asthma exacerbation rate (AAER) in the DB treatment period', 'description': 'The asthma exacerbations reported during the DB treatment period of the study will be described.', 'timeFrame': 'From Screening until the EOT double blind treatment period'}]",12.0,6 Years,18 Years,ALL,False,INDUSTRY,1.0,200.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03527680,Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins in Hemodialysis,Placebo - Cap,"['placebo', 'Placebo - Cap']",2,INTERVENTIONAL,['NA'],,COMPLETED,Hemodialysis Complication,nooshin dalili,2025-09-01T16:18:09.639350,True,,,,,Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins (Phenol and P-Cresol ) in Hemodialysis Patients: A Double Blind Randomized Clinical Trial,,['Hemodialysis Complication'],[],,2016-09-01,2016-12-30,"[{'measure': 'pre- and post-treatment p-cresol levels', 'timeFrame': '4 weeks'}]",[],1.0,20 Years,,ALL,False,OTHER,0.0,42.0,ACTUAL,v2_robust,True,True,False,False,
NCT00654680,Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury,"Vardenafil (Levitra, BAY38-9456)","['Vardenafil (Levitra, BAY38-9456)', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Erectile Dysfunction,Bayer,2025-09-01T16:18:09.639363,True,,,,,"A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Subjects With ED Solely Secondary to Traumatic Spinal Cord Injury",,['Erectile Dysfunction'],"['Erectile Dysfunction', 'Traumatic spinal cord injury', 'Vardenafil']",,2002-10,2004-01,"[{'measure': 'International Index of Erectile Function-Erectile Function domain', 'timeFrame': '12 weeks'}]","[{'measure': 'Sexual Encounter Profile Question 2', 'timeFrame': '12 weeks'}, {'measure': 'Sexual Encounter Profile Question 3', 'timeFrame': '12 weeks'}, {'measure': 'Other diary based variables', 'timeFrame': '12 weeks'}, {'measure': 'Safety and tolerability', 'timeFrame': '12 weeks'}]",5.0,18 Years,,MALE,False,INDUSTRY,1.0,418.0,ACTUAL,v2_robust,True,True,False,True,
NCT04022980,Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma,Nivolumab,['Nivolumab'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Brain and Nervous System,Wake Forest University Health Sciences,2025-09-01T16:18:09.639390,True,,,,,A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma,,"['Brain and Nervous System', 'Eye and Orbit']","['Lymphoma', 'Central Nervous System Malignancy']",,2020-03-31,2025-12,"[{'measure': 'Safety of Nivolumab in Older Subjects', 'description': 'The primary endpoint for the Stage 1 phase of the study is dose-limiting toxicity which will be assessed for each Stage 1 subject using the DLT criteria', 'timeFrame': 'Until up to 6 subjects can be adequately assessed for DLT.'}, {'measure': 'Efficacy of Nivolumab', 'description': 'The primary endpoint for the Stage 1 phase of the study is the 2-year progression-free endpoint which will be determined for each subject as a binary variable indicating if they are alive and progression-free at 2 years (PFS2)', 'timeFrame': '2 years'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the duration of time from enrollment to first occurrence of either progressive disease or death.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the duration from enrollment to the date of death from any cause.', 'timeFrame': '2 years'}, {'measure': 'Objective and Complete Response Rates', 'description': 'Objective response will be determined for each subject as a binary variable indicating if they have achieved a best overall response of CR or PR as determined by the International Criteria for PCNSL (IPCG). Complete response will be determined for each subject as a binary variable indicating if they have achieved a best overall response of CR as determined by the International Criteria for PCNSL(IPCG).', 'timeFrame': 'approx. 2 years'}, {'measure': 'Conversion Rate from Partial to Complete Response', 'description': 'Response conversion will be determined for each subject who achieve a best overall response of PR during induction therapy as a binary variable indicating if the subsequently achieve a best overall response of CR to nivolumab consolidation therapy.', 'timeFrame': 'approx. 2 years'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Adverse events will be collected for each subject using NCI CTCAE v5.0 criteria. A binary variable will be determined for each subject indicating whether or not the subject experienced an AESI during treatment with nivolumab consolidation therapy, across any cycle nivolumab treatment administration.', 'timeFrame': 'up to 30 days after last dose of Nivolumab'}, {'measure': 'Subset Analysis of 2 Year Progression Free Survival', 'description': 'A subset analysis of the primary population will be performed on those members of the evaluable population for the primary objective completing at least two cycles of nivolumab. PFS is defined as the duration of time from enrollment to first occurrence of either progressive disease or death.', 'timeFrame': '2 years'}]",8.0,65 Years,,ALL,False,OTHER,2.0,14.0,ACTUAL,v2_robust,True,False,False,True,
NCT03865680,Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride Varnish on Remineralization of White Spot Lesion in Primary Teeth,CPP-ACP,"['CPP-ACP', 'Sodium Fluoride varnish', 'Duraphat', 'Casein phosphopeptide-amorphous calcium phosphate fluoride varnish', 'MI varnish']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,White Spot Lesion,Nourhan M.Aly,2025-09-01T16:18:09.639422,True,,,,,Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride Varnish on Remineralization of White Spot Lesion in Primary Teeth (Randomized Clinical Trial),,['White Spot Lesion'],"['Fluoride varnish', 'Casein', 'MI varnish']",,2019-04-28,2020-04-10,"[{'measure': 'Oral hygiene index (OHI-S) assessment', 'description': 'For primary dentition, the modified version of the OHI-S by Miglani et al will be used, it is divided into two scores debris index and calculus index only the debris index will be used in which the index teeth are: The buccal surface of maxillary right second molar (tooth 55), The buccal surface of the maxillary right central incisor (tooth 51), The buccal surface maxillary left second molar (tooth 65), The lingual surface of the mandibular left second molar (tooth 75),The buccal surface of the mandibular left central incisor (tooth 71),The lingual surface of the mandibular right second molar (tooth 85). Each surface will take a score from 0-3. The scores of the involved surfaces will be totaled and divided by the number of teeth scored to get the index value.', 'timeFrame': 'Baseline'}, {'measure': 'Oral hygiene index (OHI-S) assessment', 'description': 'For primary dentition, the modified version of the OHI-S by Miglani et al will be used, it is divided into two scores debris index and calculus index only the debris index will be used in which the index teeth are: The buccal surface of maxillary right second molar (tooth 55), The buccal surface of the maxillary right central incisor (tooth 51), The buccal surface maxillary left second molar (tooth 65), The lingual surface of the mandibular left second molar (tooth 75),The buccal surface of the mandibular left central incisor (tooth 71),The lingual surface of the mandibular right second molar (tooth 85). Each surface will take a score from 0-3. The scores of the involved surfaces will be totaled and divided by the number of teeth scored to get the index value.', 'timeFrame': '6 weeks'}, {'measure': 'Oral hygiene index (OHI-S) assessment', 'description': 'For primary dentition, the modified version of the OHI-S by Miglani et al will be used, it is divided into two scores debris index and calculus index only the debris index will be used in which the index teeth are: The buccal surface of maxillary right second molar (tooth 55), The buccal surface of the maxillary right central incisor (tooth 51), The buccal surface maxillary left second molar (tooth 65), The lingual surface of the mandibular left second molar (tooth 75),The buccal surface of the mandibular left central incisor (tooth 71),The lingual surface of the mandibular right second molar (tooth 85). Each surface will take a score from 0-3. The scores of the involved surfaces will be totaled and divided by the number of teeth scored to get the index value.', 'timeFrame': '18 weeks'}, {'measure': 'Oral hygiene index (OHI-S) assessment', 'description': 'For primary dentition, the modified version of the OHI-S by Miglani et al will be used, it is divided into two scores debris index and calculus index only the debris index will be used in which the index teeth are: The buccal surface of maxillary right second molar (tooth 55), The buccal surface of the maxillary right central incisor (tooth 51), The buccal surface maxillary left second molar (tooth 65), The lingual surface of the mandibular left second molar (tooth 75),The buccal surface of the mandibular left central incisor (tooth 71),The lingual surface of the mandibular right second molar (tooth 85). Each surface will take a score from 0-3. The scores of the involved surfaces will be totaled and divided by the number of teeth scored to get the index value.', 'timeFrame': '30 weeks'}, {'measure': 'Visio-tactile evaluation of the white spot lesion', 'description': 'Using a dental light reflector, visual inspection of all tooth surfaces for WSLs will be undertaken, with wet tooth surfaces and again after 5 seconds of drying with a gentle air stream. Each lesion will be scored according to ICDAS II criteria for severity, selecting only lesions scored as 1, 2 or 3.', 'timeFrame': 'Baseline'}, {'measure': 'Visio-tactile evaluation of the white spot lesion', 'description': 'Using a dental light reflector, visual inspection of all tooth surfaces for WSLs will be undertaken, with wet tooth surfaces and again after 5 seconds of drying with a gentle air stream. Each lesion will be scored according to ICDAS II criteria for severity, selecting only lesions scored as 1, 2 or 3.', 'timeFrame': '6 weeks'}, {'measure': 'Visio-tactile evaluation of the white spot lesion', 'description': 'Using a dental light reflector, visual inspection of all tooth surfaces for WSLs will be undertaken, with wet tooth surfaces and again after 5 seconds of drying with a gentle air stream. Each lesion will be scored according to ICDAS II criteria for severity, selecting only lesions scored as 1, 2 or 3.', 'timeFrame': '18 weeks'}, {'measure': 'Visio-tactile evaluation of the white spot lesion', 'description': 'Using a dental light reflector, visual inspection of all tooth surfaces for WSLs will be undertaken, with wet tooth surfaces and again after 5 seconds of drying with a gentle air stream. Each lesion will be scored according to ICDAS II criteria for severity, selecting only lesions scored as 1, 2 or 3.', 'timeFrame': '30 weeks'}, {'measure': 'White spot lesion evaluation using DIAGNOdent', 'description': ""Probe B OF Laser fluorescence (LF) examination for each lesion will be performed using DIAGNOdent. It operates with a diode laser having a wavelength of 655 nm and 1 mW peak power. Sound enamel does not fluoresce at this wavelength, but caries and bacteria do. The instrument is calibrated according to manufacturer's instructions. A baseline zero value for each patient is obtained by choosing a clear non carious patch of enamel usually middle third of an anterior tooth. By pointing the pen perpendicular to this area and touching the set button for 2 seconds until set 0 appears, the button is then released. Zero baseline value has been set. Under cotton roll isolation and after air drying with an air syringe, the DIAGNOdent probe will be placed perpendicular to the test site and rotated along the lesion to scan the area completely. Three measurements of each lesion will be taken and averaged to give the final score."", 'timeFrame': 'Baseline'}, {'measure': 'White spot lesion evaluation using DIAGNOdent', 'description': ""Probe B OF Laser fluorescence (LF) examination for each lesion will be performed using DIAGNOdent. It operates with a diode laser having a wavelength of 655 nm and 1 mW peak power. Sound enamel does not fluoresce at this wavelength, but caries and bacteria do. The instrument is calibrated according to manufacturer's instructions. A baseline zero value for each patient is obtained by choosing a clear non carious patch of enamel usually middle third of an anterior tooth. By pointing the pen perpendicular to this area and touching the set button for 2 seconds until set 0 appears, the button is then released. Zero baseline value has been set. Under cotton roll isolation and after air drying with an air syringe, the DIAGNOdent probe will be placed perpendicular to the test site and rotated along the lesion to scan the area completely. Three measurements of each lesion will be taken and averaged to give the final score."", 'timeFrame': '6 weeks'}, {'measure': 'White spot lesion evaluation using DIAGNOdent', 'description': ""Probe B OF Laser fluorescence (LF) examination for each lesion will be performed using DIAGNOdent. It operates with a diode laser having a wavelength of 655 nm and 1 mW peak power. Sound enamel does not fluoresce at this wavelength, but caries and bacteria do. The instrument is calibrated according to manufacturer's instructions. A baseline zero value for each patient is obtained by choosing a clear non carious patch of enamel usually middle third of an anterior tooth. By pointing the pen perpendicular to this area and touching the set button for 2 seconds until set 0 appears, the button is then released. Zero baseline value has been set. Under cotton roll isolation and after air drying with an air syringe, the DIAGNOdent probe will be placed perpendicular to the test site and rotated along the lesion to scan the area completely. Three measurements of each lesion will be taken and averaged to give the final score."", 'timeFrame': '18 weeks'}, {'measure': 'White spot lesion evaluation using DIAGNOdent', 'description': ""Probe B OF Laser fluorescence (LF) examination for each lesion will be performed using DIAGNOdent. It operates with a diode laser having a wavelength of 655 nm and 1 mW peak power. Sound enamel does not fluoresce at this wavelength, but caries and bacteria do. The instrument is calibrated according to manufacturer's instructions. A baseline zero value for each patient is obtained by choosing a clear non carious patch of enamel usually middle third of an anterior tooth. By pointing the pen perpendicular to this area and touching the set button for 2 seconds until set 0 appears, the button is then released. Zero baseline value has been set. Under cotton roll isolation and after air drying with an air syringe, the DIAGNOdent probe will be placed perpendicular to the test site and rotated along the lesion to scan the area completely. Three measurements of each lesion will be taken and averaged to give the final score."", 'timeFrame': '30 weeks'}]",[],12.0,3 Years,5 Years,ALL,False,OTHER,1.0,180.0,ACTUAL,v2_robust,True,True,False,False,
NCT00568880,Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma,bortezomib,"['bortezomib', 'hydroxychloroquine', 'Plaquenil', 'Velcade']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Multiple Myeloma and Plasma Cell Neoplasm,Abramson Cancer Center at Penn Medicine,2025-09-01T16:18:09.639547,True,,,,,A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma,,['Multiple Myeloma and Plasma Cell Neoplasm'],"['stage I multiple myeloma', 'stage II multiple myeloma', 'stage III multiple myeloma', 'refractory multiple myeloma']",,2010-09-08,2011-06-22,"[{'measure': 'Overall response rate', 'description': 'This is assessed using International Working Group criteria.', 'timeFrame': 'Day 1 of each cycle (each cycle is 21 days)'}]","[{'measure': 'Effects of regimen on the autophagy pathway', 'description': 'Measure peripheral blood mononuclear cells', 'timeFrame': 'at baseline, prior to bortezomib on Day1 and 8 of cycle 1, prior to bortezomib on Day 1 of cycle 2 (each cycle is 21 days)'}, {'measure': 'AV accumulation during therapy', 'description': 'mean AVs / Bone Marrow plasma cell', 'timeFrame': 'Day 1 and 8 of the first cycle and on Day 1 of each subsequent treatment cycle (each cycle is 21 days)'}]",3.0,18 Years,120 Years,ALL,False,OTHER,0.0,25.0,ACTUAL,v2_robust,True,True,False,False,
NCT01668680,Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma,"CAPECITABINE, CELECOXIB and METHOTREXATE","['Metronomic Chemotherapy', 'CAPECITABINE, CELECOXIB and METHOTREXATE']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Colorectal Cancer Metastatic,"HaEmek Medical Center, Israel",2025-09-01T16:18:09.639574,True,,,,,Metronomic Chemotherapy With Anti-angiogenic Effect as Maintenance Treatment for Metastatic Colorectal Carcinoma Following Response to FOLFIRI+Bevacizumab: Clinical and Laboratory Studies,,['Colorectal Cancer Metastatic'],"['Metronomic Chemotherapy', 'Anti-Angiogenic', 'Maintenance Treatment', 'Colorectal Cancer Metastatic']",No satisfactory acrual,2012-09,2014-12,"[{'measure': 'Length of progression free survival (PFS), measured in months.', 'description': 'From start of the experimental treatment until the date of first documented progression or date of death of any cause,whichever came first, assessed up to 12 months.', 'timeFrame': 'Up to 12 months.'}]","[{'measure': 'Toxicity profile of treatment, defined by CTCAE Version 4.0.', 'description': 'From start of the experimental treatment until the date of first documented progression or date of death of any cause,whichever came first, assessed up to 12 months.', 'timeFrame': 'up to12 months'}, {'measure': 'Changes in levels of angiogenic factors while under treatment: VEGF, PDGF, TSP-1', 'description': 'Change from baseline in levels of angiogenic factors at 4 months of treatment.', 'timeFrame': 'Up to 4 months.'}, {'measure': 'Quality of life, as expressed by FACT-C.', 'description': 'Change from baseline in parameters of Quality of life until the end of treatment, assessed up to 12 months.', 'timeFrame': 'Up to 12 months.'}]",4.0,18 Years,80 Years,ALL,False,OTHER,1.0,80.0,ESTIMATED,v2_robust,True,False,True,False,No satisfactory acrual
NCT03600480,A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese,NNC0174-0833,"['NNC0174-0833', 'Placebo (NNC0174-0833)', 'Semaglutide']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Obesity,Novo Nordisk A/S,2025-09-01T16:18:09.639589,True,,,,,"Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity",,"['Obesity', 'Overweight']",[],,2018-07-25,2020-06-12,"[{'measure': 'Number of treatment emergent adverse events (TEAEs)', 'description': 'Count of events', 'timeFrame': 'From first administration of NNC0174-0833 (Day 1) to completion of the post-treatment follow-up (Day 176)'}]","[{'measure': 'AUC0-168h,AM833,SS: the area under the NNC0174-0833 plasma concentration-time curve from 0 to 168 hours at steady state', 'description': 'Measured in nmol\\*h/L', 'timeFrame': 'From last dose (Day 134) until end of treatment (Day 141)'}, {'measure': 'Cmax,AM833,SS: the maximum concentration of NNC0174-0833 in plasma at steady state', 'description': 'Measured in nmol/L', 'timeFrame': 'From last dose (Day 134) until end of treatment (Day 141)'}, {'measure': 'AUC0-168h,sema,SS: the area under the semaglutide plasma concentration-time curve from 0 to 168 hours at steady state', 'description': 'Measured in nmol\\*h/L', 'timeFrame': 'From last dose (Day 134) until end of treatment (Day 141)'}, {'measure': 'Cmax,sema,SS: the maximum concentration of semaglutide in plasma at steady state', 'description': 'Measured in nmol/L', 'timeFrame': 'From last dose (Day 134) until end of treatment (Day 141)'}]",5.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,96.0,ACTUAL,v2_robust,True,True,False,True,
NCT02624180,Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV,Colchicine,"['Placebo', 'Colchicine', 'Colcrys']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Coronary Artery Disease,Johns Hopkins University,2025-09-01T16:18:09.639596,True,,,,,Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV,,"['Coronary Artery Disease', 'Human Immunodeficiency Virus']",[],,2015-11,2020-09-01,"[{'measure': 'Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks', 'description': 'Percent change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 8 weeks.', 'timeFrame': 'Difference between measurements at baseline compared to measurement at 8 weeks'}]","[{'measure': 'Coronary Endothelial Function at 24 Weeks;', 'description': 'Change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stress at 24 weeks.', 'timeFrame': 'At 24 weeks.'}, {'measure': 'Change in Coronary Artery Cross-sectional Area (CSA) at 8 Weeks', 'description': 'Change in CSA as measured by the difference between CSA at rest and under IHE stress at 8 weeks', 'timeFrame': 'Difference between measurements at baseline compared to measurement at 8 weeks'}, {'measure': 'Change in Coronary Artery Cross-sectional Area (CSA) at 24 Weeks', 'description': 'Change in CSA as measured by the difference between CSA at rest and under IHE stress at 24 weeks', 'timeFrame': 'At 24 weeks'}, {'measure': 'High-sensitivity C-reactive Protein (hsCRP) at 8 Weeks.', 'description': 'High-sensitivity C-reactive protein (hsCRP) at 8 weeks', 'timeFrame': 'At 8 weeks.'}, {'measure': 'Brachial Flow Mediated Dilatation (FMD) at 8 Weeks.', 'description': 'Brachial flow mediated dilatation (FMD) at 8 weeks.', 'timeFrame': 'At 8 weeks'}, {'measure': 'Interleukin-6 (IL-6) at 8 Weeks', 'description': 'Interleukin-6 (IL-6) at 8 weeks', 'timeFrame': 'At 8 weeks'}, {'measure': 'High-sensitivity C-reactive Protein (hsCRP) at 24 Weeks', 'description': 'High-sensitivity C-reactive Protein (hsCRP) at 24 weeks', 'timeFrame': 'At 24 weeks'}, {'measure': 'Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.', 'description': 'Brachial Flow Mediated Dilatation (FMD) at 24 Weeks.', 'timeFrame': 'At 24 weeks'}]",9.0,21 Years,,ALL,False,OTHER,1.0,81.0,ACTUAL,v2_robust,True,True,False,False,
NCT06160479,The Incidence of Hypocalcemia in Pregnant Women at Siriraj Hospital,Calcium supplement,['Calcium supplement'],1,INTERVENTIONAL,['NA'],,ACTIVE_NOT_RECRUITING,Hypocalcemia in Pregnancy,Siriraj Hospital,2025-09-01T16:18:09.639778,True,,,,,The Incidence of Hypocalcemia in Pregnant Women at Siriraj Hospital,,['Hypocalcemia in Pregnancy'],[],,2022-05-05,2024-05-31,"[{'measure': 'The incidence of hypocalcemia in pregnant women at Siriraj Hospital', 'description': 'The incidence of hypocalcemia in pregnant women in the first half of pregnancy. Material blood will be taken for calcium level. The hypocalcemia is defined as total calcium level less than 8.5 mg/dl.', 'timeFrame': '1.5 year'}]","[{'measure': 'The demographic and pregnant factors are associating with maternal calcium level in the first half of pregnancy assessed by the questionnaire and scrupulous chart review', 'description': 'The different characteristics between normal calcium and hypocalcemia group in the first half of pregnancy will be studied. The data will be received by interviewing the patients, answering the questionnaire and scrupulous chart review; including age, education, occupations, income, marital status, food and nutrition status, previous pregnancy outcomes, family history, mode of conception in this pregnancy, gestational age of blood drawing, caffeine intake, smoking, and maternal hematocrit.', 'timeFrame': '1.5 year'}, {'measure': 'The calcium level in pregnant women in the third trimester', 'description': 'Comparison of maternal serum calcium level in pregnant women in the third trimester between who receive and do not receive calcium supplement. In the normal calcium level group, pregnant women will be divided into 2 groups: receiving CaCO3 1 g/day and no receiving. In the hypocalcemia group, pregnant women will be divided into 2 groups: receiving CaCO3 1g/day and 2g/day. Maternal blood taking for serum calcium level will be done in all participants. Comparison of maternal calcium level between groups will be reported. Statistical analysis will be used t-test and p-value is less than 0.5.', 'timeFrame': '2 year'}]",3.0,18 Years,,FEMALE,True,OTHER,0.0,444.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01850979,Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops,Tacrolimus,"['FK 506', 'Olive Oil', 'placebo', 'Tacrolimus']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Sjogren Syndrome,University of Sao Paulo General Hospital,2025-09-01T16:18:09.639821,True,,,,,Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study,,"['Sjogren Syndrome', 'Dry Eye Syndrome']",['CYCLOSPORINE/TACROLIMUS [VA Drug Interaction]'],,2010-02,2011-11,"[{'measure': 'Evaluation of the quantity of lacrimal film', 'description': 'Schirmer I test was performed using a Whatman 41 paper strip placed in the lateral lower conjunctival sac, and the measurement was recorded after 5 minutes (at least 30 minutes after BUT and staining scoring).The exam was made in the same room with control of humidity and temperature by the same examinator', 'timeFrame': '90 days'}]","[{'measure': 'Evaluation of quality of lacrimal film', 'description': 'The BUT(break up time) was measured 3 times and averaged, using a chronometer in the same room with control of temperature and humidity by the same examinator.', 'timeFrame': '90 days'}]",2.0,40 Years,60 Years,ALL,False,OTHER,0.0,24.0,ACTUAL,v2_robust,True,True,False,False,
NCT00592579,A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma,2-methoxyestradiol,"['2-methoxyestradiol', 'Panzem']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Relapsed Multiple Myeloma,"CASI Pharmaceuticals, Inc.",2025-09-01T16:18:09.639948,True,,,,,"Phase 2, Open-Label, Safety, and Efficacy Study of 2-Methoxyestradiol Administered to Patients With Plateau Phase or Relapsed Multiple Myeloma",,"['Relapsed Multiple Myeloma', 'Plateau Phase Multiple Myeloma']",[],,2001-03,2008-09,"[{'measure': 'To determine tumor response of 2ME2 administered orally by evaluation of objective responses in patients with plateau phase or relapsed multiple myeloma', 'timeFrame': 'At least yearly'}]","[{'measure': 'To assess the safety and tolerability of 2ME2 administered orally by evaluation of the frequency, severity, and duration of treatment-emergent adverse events in patients with plateau phase or relapsed multiple myeloma', 'timeFrame': 'As reported'}, {'measure': 'To determine the minimum 2ME2 levels achieved in plasma following daily oral administration in patients with plateau phase or relapsed multiple myeloma', 'timeFrame': 'At least yearly'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ACTUAL,v2_robust,True,True,False,True,
NCT00327379,Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery,"Trasylol (Aprotinin, BAYA0128)","['Trasylol (Aprotinin, BAYA0128)', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,"Blood Loss, Surgical",Bayer,2025-09-01T16:18:09.639993,True,,,,,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery",,"['Blood Loss, Surgical', 'Postoperative Hemorrhage']","['Bloodloss', 'Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery']",,2006-02-27,2007-03-01,"[{'measure': 'Percent of patients requiring a blood transfusion (blood or packed red blood cells, autologous or allogenic)', 'timeFrame': 'anytime in the intra-operative or postoperative period (up to the earlier of Day 7 or discharge).'}]","[{'measure': 'The percent of patients receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge', 'timeFrame': 'surgery to discharge'}, {'measure': 'The percent of patients who did and did not predonate blood receiving an allogenic transfusion of blood or packed red cells during surgery and up to the earlier of Day 7 or discharge', 'timeFrame': 'surgery to discharge'}, {'measure': 'The number of units of blood or packed red cells transfused. There will be analyses for the combination of autologous and allogenic transfusion and for allogenic alone', 'timeFrame': 'surgery to discharge'}, {'measure': 'The number of units of blood or packed red cells transfused per patient requiring transfusion', 'timeFrame': 'surgery to discharge'}, {'measure': 'Drainage (in milliliters) from the operative site in the first 8 hours postoperatively, and total drainage until removal of drains or until hospital discharge (whichever is earlier)', 'timeFrame': 'surgery to discharge'}, {'measure': 'Blood loss during surgery, based on qualitative and quantitative estimates', 'timeFrame': 'surgery'}, {'measure': 'The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration (obtained in the morning of Day 3, or, if transfused earlier, prior to transfusion).', 'timeFrame': 'pre-op and day 3 post surgery'}, {'measure': 'Surgeons assessment of the degree to which bleeding obscured his/her view of the surgical field, relative to past, similar procedures', 'timeFrame': 'surgery to discharge'}, {'measure': 'The percent of patients receiving colloid or other blood products, and the number of units transfused', 'timeFrame': 'surgery to discharge'}, {'measure': 'Changes in blood markers related to inflammation and blood coagulation', 'timeFrame': 'surgery to discharge'}, {'measure': 'Changes in FEV1', 'timeFrame': 'surgery to discharge'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,54.0,ACTUAL,v2_robust,True,False,True,False,
NCT02976779,"A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers",OWC MGC cream,"['OWC Control Cream', 'OWC psoriasis cream', 'OWC MGC cream']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Safety Study for Future Treatment of Psoriasis,One World Cannabis Ltd.,2025-09-01T16:18:09.640122,True,,,,,"A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers",,['Safety Study for Future Treatment of Psoriasis'],[],,2017-02-03,2019-01-25,"[{'measure': 'Incidence rate of AEs/ SAEs', 'description': 'Collection of Adverse events and Serious Adverse Events', 'timeFrame': '24 hours'}, {'measure': 'Incidence rate of AEs/ SAEs', 'description': 'Collection of Adverse events and Serious Adverse Events', 'timeFrame': '6 weeks'}]","[{'measure': 'Specific AEs/ SAEs', 'description': 'Erythema Edema Swelling Itching Heat Pain Cellulitis Other', 'timeFrame': 'Baseline to 24 hours'}, {'measure': 'Specific AEs/ SAEs', 'description': 'Erythema Edema Swelling Itching Heat Pain Cellulitis Other', 'timeFrame': 'baseline to 6 weeks'}]",4.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,True,
NCT00080496,Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia,Tigecycline,"['Tigecycline', 'Cilastatin', 'Imipenem']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bacterial Pneumonia,Wyeth is now a wholly owned subsidiary of Pfizer,2025-09-01T16:18:09.640160,True,,,,,"A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia",,['Bacterial Pneumonia'],['Pneumonia'],,2003-07,2006-12,[{'measure': 'The co-primary efficacy endpoints are clinical response at the TOC assessment for the clinically evaluable population and the clinical modified intent-to-treat population.'}],[],1.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,430.0,,v2_robust,True,True,False,False,
NCT03616496,Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits,Neuraceq PET/CT imaging,"['Blood and urine sampling for protein electrophoresis', 'Neuraceq PET/CT imaging', 'Bone scintigraphy']",3,INTERVENTIONAL,['NA'],,COMPLETED,Cardiac Amyloidosis,"Central Hospital, Nancy, France",2025-09-01T16:18:09.640245,True,,,,,Assessment of 18F-Florbetaben Whole-body PET Imaging for the Comprehensive Detection of Cardiac and Extracardiac Sites of Amyloid Deposits,,['Cardiac Amyloidosis'],"['PET imaging', 'Cardiac Amyloidosis', 'Florbetaben', 'Heart failure', 'Cardiology']",,2019-06-06,2025-02-10,"[{'measure': 'Definitive diagnosis of cardiac ATTR- or AL-amyloidosis upon current diagnosis standard (including cardiac or extracardiac biopsies),', 'description': 'The diagnosis will be made with standard parameters (including cardiac or extracardiac biopsies), Importantly, a "" control "" population, including patients with left ventricular hypertrophy definitively unrelated to amyloidosis (even for low to mild forms) will be added for the analysis (this hypertrophy is mandatory for reaching a comparable partial volume effect than with amyloidosis patients when recording myocardial PET activity).', 'timeFrame': 'upon 24 months'}]","[{'measure': 'To assess the diagnostic performance of whole-body PET/CT recordings, as reported in the main objective, to identify AL and ATTR amyloidosis individually.', 'description': 'Identical to the primary endpoint, except that the analyses will be planned separately for AL and ATTR amyloidosis.', 'timeFrame': 'upon 24 months'}, {'measure': 'To determine whether (18)F-florbetaben whole-body PET/CT images can reveal extracardiac areas with increased activity', 'description': 'Areas of abnormal (18)F-florbetaben uptake will be studied on whole-body PET/CT', 'timeFrame': 'upon 24 months'}, {'measure': 'To compare the cardiac kinetics of (18)F-florbetaben and an early myocardial retention index, within the first 10 minutes following injection, between patients with cardiac amyloidosis and the control population', 'description': 'Comparative analysis of the evolution of myocardial SUV (Standard Uptake Value) and TBRtarget-to-blood pool ratio) ( values and of an early myocardial retention index during the 10 minutes post-injection period in patients and controls', 'timeFrame': 'upon 24 month'}, {'measure': 'To determine whether most patients with true-positive MRI for cardiac amyloidosis', 'description': 'the comparison of the analysis will be made with myocardial tissue-to-background ratios (TBR) where the activities measured in SUV will be expressed relative to a mean blood background activity.', 'timeFrame': 'upon 24 month'}, {'measure': 'To assess the intra- and inter-observer agreements for the analysis of (18)F-florbetaben whole-body PET/CT images.', 'description': 'Intra-observer and inter-observer reproducibility measurements of SUV and TBR values obtained at cardiac and extracardiac sites from whole-body PET / CT images of 20 patients with amyloidosis (10 with Type AL and 10 with an ATTR type).', 'timeFrame': 'upon 24 month'}]",6.0,18 Years,,ALL,False,OTHER,0.0,67.0,ACTUAL,v2_robust,True,True,False,False,
NCT01367496,Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose,SC Methylnaltrexone (MNTX),"['IV Methylnaltrexone (MNTX)', 'SC Methylnaltrexone (MNTX)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Subjects,"Bausch Health Americas, Inc.",2025-09-01T16:18:09.640297,True,,,,,"An Open-Label, Phase I Study of the Pharmacokinetics and Bioavailability of Single, Ascending Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose in Normal, Healthy Male Volunteers",,['Healthy Subjects'],[],,2002-06,2002-08,"[{'measure': 'Peak Plasma Concentration of MNTX', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}]","[{'measure': 'Time to Maximum Plasma Concentration (Tmax) of MNTX', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}, {'measure': 'Clearance of MNTX', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}, {'measure': 'Half-live of MNTX', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}, {'measure': 'Volume of Distribution of MNTX', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}, {'measure': 'Area Under the Plasma Concentration versus Time Curve (AUC) of MNTX', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}, {'measure': 'Urinary Clearance of MNTX', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}, {'measure': 'Percentage of MNTX Excreted in Urine', 'description': 'The objective of this study is to determine the plasma pharmacokinetic of single, ascending, subcutaneous doses and a single intravenous dose of methylnaltrexone (MNTX) in normal healthy male subjects.', 'timeFrame': '32 days'}]",8.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,True,False,False,
NCT01318096,Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients,raltegravir and tenofovir and lamivudine,"['efavirenz+tenofovir+lamivudine', 'efavirenz: Sustiva', 'raltegravir and tenofovir and lamivudine', 'raltegravir: Isentress']",4,INTERVENTIONAL,['NA'],,UNKNOWN,HBV Coinfection,Yunnan AIDS Care Center,2025-09-01T16:18:09.640317,True,,,,,"A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients",,"['HBV Coinfection', 'HIV Infections']","['safety', 'efficacy', 'raltegravir', 'HBV/HIV co-infection']",,2011-03,2013-09,"[{'measure': 'Frequency and severity of adverse events', 'description': 'The investigators will collect the adverse events at every follow-up, and record them in CRFs. All AEs during the study will be analyzed according to the type, frequency and severity.', 'timeFrame': 'In 48 weeks (from baseline to study completion at 48 weeks)'}]","[{'measure': 'Change of plasma HIV-1 RNA levels', 'timeFrame': 'week 0,24 and 48'}, {'measure': 'Change of Peripheral blood CD4 cell counts', 'timeFrame': 'week 0,4,8,12,24,36 and 48'}, {'measure': 'Change of plasma HBV-DNA levels', 'timeFrame': 'week 0,12,24,36,and 48'}, {'measure': 'Change of serum total bilirubin levels（TBI）', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Proportion of subjects with HBeAg seroconversion (HBeAg loss and presence of anti HBe)', 'timeFrame': 'week 0,12,24,36,and week 48'}, {'measure': 'Emergence of drug resistance mutations, if appropriate', 'timeFrame': 'week 0, 24 and 48'}, {'measure': 'Paired liver biopsy comparison according to inflammatory activity and fibrosis score', 'timeFrame': 'week 0 and 48'}, {'measure': 'Change of serum alanine aminotransferase levels (ALT)', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Change of serum aspartate aminotransferase levels (AST)', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Change of blood urine nitrogen levels (BUN)', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Change of serum creatinine levels (SCr)', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Change of blood haemoglobin levels (HB)', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Change of white blood cell counts (WBC)', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Change of blood platelet counts (PLT)', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}, {'measure': 'Change of urine protein levels', 'timeFrame': 'week 0,2,4,8,12,24,36 and 48'}]",16.0,18 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05228496,A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC,Tislelizumab,"['Tislelizumab', 'Sitravatinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,"Lung Cancer, Small Cell",Zhejiang Cancer Hospital,2025-09-01T16:18:09.640325,True,,,,,"A Phase II, Open-Label, Single-Arm, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy Following Tislelizumab and Chemotherapy for Treatment Naïve Extensive Stage Small Cell Lung Cancer",,"['Lung Cancer, Small Cell']",[],,2022-03-17,2025-06-01,"[{'measure': '1-year Progression-Free-Survival (PFS) rate assessed by investigator in maintenance phase-patient analysis set per RECIST v1.1', 'description': '1-year PFS rate assessed by investigator in maintenance phase-patient analysis set per RECIST v1.1. PFS is defined as the time from the first dose of study drug(s) in maintenance phase to the first occurrence of disease progression as determined by investigator using RECIST v1.1 or death from any cause, whichever occurs first.', 'timeFrame': 'Start of maintenance therapy until 1-year follow-up'}]","[{'measure': 'Progression-Free-Survival (PFS)', 'description': 'PFS assessed by investigators per RECIST v1.1 in maintenance phase-patient analysis set and induction phase-patient analysis set, respectively.', 'timeFrame': 'up to 2 year'}, {'measure': 'Overall Survival (OS)', 'description': 'OS, defined as the time from first dose of study drug(s) to death from any cause, in maintenance phase-patient analysis set and induction phase-patient analysis set, respectively.', 'timeFrame': 'up to 2 year'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR, defined as the proportion of patients with partial response or complete response as determined by the investigators based on RECIST v1.1 in maintenance phase-patient analysis set and induction phase-patient analysis set, respectively.', 'timeFrame': 'up to 2 year'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR, defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD) as determined by the investigators based on RECIST v1.1 in maintenance phase-patient analysis set and induction phase-patient analysis set, respectively.', 'timeFrame': 'up to 2 year'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR is defined as the duration from the date of patients achieve CR or PR to the date of PD or death, which occurs first, for patients with an objective response in maintenance phase-patient analysis set and induction phase-patient analysis set, respectively.', 'timeFrame': 'up to 2 year'}, {'measure': 'Adverse events (per CTCAE v5.0 criteria)', 'description': 'Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events (AEs) and serious adverse events (SAEs) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.', 'timeFrame': 'Up to 2 years'}]",7.0,18 Years,75 Years,ALL,False,OTHER,0.0,21.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01501396,Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite,Megestrol Acetate,"['Megestrol Acetate', 'Remeron', 'Megestil', 'Pallace', 'BDH 1298', 'Megace', 'Mirtazapine', 'Maygace', 'Niagestin']",9,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Anorexia,Washington University School of Medicine,2025-09-01T16:18:09.640350,True,,,,,Treatment of Cancer Anorexia-cachexia Syndrome (CACS) With Mirtazapine and Megestrol Acetate,,['Anorexia'],[],,2013-09,2015-09,"[{'measure': 'Response rates for weight gain', 'description': 'Determine the rates of \\>= 5% weight gain in the treatment groups. Compare the difference of the response rate between the 2 groups.', 'timeFrame': 'Baseline to 8 weeks'}]","[{'measure': 'Safety and tolerability of MA alone and MA + MRZ', 'description': 'NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.', 'timeFrame': 'Baseline to 12 weeks (30 days after end of study)'}, {'measure': 'Weight change (in lbs)', 'description': 'Change over time as well as the difference between groups for weight (in lbs) will be analyzed.', 'timeFrame': 'Baseline to 8 weeks'}, {'measure': 'Appetite stimulation', 'description': 'Assessed using Simplified Nutritional Appetite Questionnaire (SNAQ). The change over time as well as the difference between groups will be analyzed.', 'timeFrame': 'Baseline to 8 weeks'}, {'measure': 'Quality of life', 'description': 'Assessed using the Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The Change over time as well as the difference between groups will be analyzed.', 'timeFrame': 'Baseline to 8 weeks'}, {'measure': 'Mood assessments', 'description': 'Measured using CES-D. The Change over time as well as the difference between groups will be analyzed.', 'timeFrame': 'Baseline to 8 weeks'}, {'measure': 'Evaluation of biochemical markers', 'description': 'Explore the relationship between weight gain and serum markers of nutritional status (prealbumin, transferrin, C-reactive protein, TNF-alpha, and IL-1 and IL-6).', 'timeFrame': 'Baseline to 8 weeks'}]",7.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,
NCT05760196,Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors,GM-CSF,"['GM-CSF', 'PD-1 antibody']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Objective Response Rate,Xiangpan Li,2025-09-01T16:18:09.640372,True,,,,,"A Prospective, Multicenter, High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors and GM-CSF in the Treatment of Advanced Recurrent Metastatic Head and Neck Tumors",,['Objective Response Rate'],[],,2022-10-01,2025-09-30,"[{'measure': 'Objective response rate (ORR)', 'description': 'Objective tumor response, including CR and PR, was assessed using RECIST version 1.1.', 'timeFrame': '36 months'}]","[{'measure': 'Toxic reaction', 'description': 'Guidelines for Toxicity Management of CTC 5.0 Standard CSCO ESMO irAE.', 'timeFrame': '36 months'}, {'measure': 'Overall survival', 'description': 'The time between enrolment in the study and death from any cause.', 'timeFrame': '36 months'}, {'measure': 'Duration of remission', 'description': 'The time from the first confirmed CR or PR to the first occurrence of PD, or to death if it occurs during treatment.', 'timeFrame': '36 months'}, {'measure': 'Disease control rate', 'description': 'Refers to the percentage of cases with CR, PR, and SD (≥4 weeks) in patients with evaluable efficacy.', 'timeFrame': '36 months'}, {'measure': 'Progression-free survival', 'description': 'The time between initial use of the investigational drug and tumor progression/recurrence or death from any cause', 'timeFrame': '36 months'}]",6.0,18 Years,,ALL,False,OTHER,0.0,56.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02632396,Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission,Ixazomib,"['Ninlaro', 'Ixazomib Citrate', 'MLN9708', 'Ixazomib']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Mantle Cell Lymphoma,Emory University,2025-09-01T16:18:09.640404,True,,,,,A Phase I/II Study of MLN9708 as Post-Transplant Maintenance for Patients With Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplant in First Remission,,['Mantle Cell Lymphoma'],[],,2016-03-01,2024-08,"[{'measure': 'Recommended phase 2 dose of ixazomib, defined as the dose where 1 or fewer of 6 treated patients experience a dose limiting toxicity graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase I)', 'timeFrame': '28 days'}, {'measure': 'Progression-free survival (PFS), defined as the percentage of patients who have received at least one dose of study therapy who are alive and free of disease progression or relapse at 1-year post autologous stem cell transplant (Phase II)', 'description': 'Determined using the Kaplan-Meier method.', 'timeFrame': '1 year'}]","[{'measure': 'Conversion rate from MRD positive to MRD negative during therapy (Phase I & II)', 'timeFrame': 'Up to 10 months (10 courses of treatment)'}, {'measure': 'Incidence of adverse events graded according to CTCAE version 4.03 (Phase I & II)', 'description': 'Adverse events will be tabulated across all patients who received any treatment with a focus on severe (grade 3-5) adverse events and toxicities as well as commonly encountered lower grade adverse events. All adverse events will be reported in tabular form, and as, possible, identification of adverse events possibly, probably, or definitely related to study therapy will be noted.', 'timeFrame': 'Up to 30 days after administration of the last dose of study treatment'}, {'measure': 'Median OS (Phase II)', 'description': 'The relationship between cytogenetic variables and OS will be explored using the Kaplan-Meier method.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Median PFS (Phase II)', 'description': 'The relationship between cytogenetic variables and PFS will be explored using the Kaplan-Meier method.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival (OS) (Phase II)', 'description': 'The relationship between cytogenetic variables and OS will be explored using the Kaplan-Meier method.', 'timeFrame': '1 year'}, {'measure': 'PFS for all patients and for those patients with a complex karyotype and other high-risk clinical or cytogenetic features (Phase I)', 'description': 'The relationship between cytogenetic variables and PFS will be explored using the Kaplan-Meier method.', 'timeFrame': '1 year'}, {'measure': 'PFS for patients with a complex karyotype and other high risk clinical or cytogenetic features (Phase II)', 'description': 'The relationship between cytogenetic variables and PFS will be explored using the Kaplan-Meier method.', 'timeFrame': '1 year'}, {'measure': 'Rate of MRD positivity (Phase I & II)', 'timeFrame': 'Baseline'}, {'measure': 'Rate of patients maintaining MRD negativity from study entry to completion of therapy (Phase I & II)', 'timeFrame': 'Up to 10 months (10 courses of treatment)'}]",11.0,18 Years,,ALL,False,OTHER,3.0,12.0,ACTUAL,v2_robust,True,False,False,True,
NCT04912596,Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma,Albuterol Sulfate inhalation aerosol 108 mcg per actuation,"['Albuterol Sulfate inhalation aerosol 108 mcg per actuation', 'Albuterol Sulfate', 'Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation']",3,INTERVENTIONAL,['NA'],,RECRUITING,Mild Asthma,Intech Biopharm Ltd.,2025-09-01T16:18:09.640434,True,,,,,"A Randomized, Single-dose, Double-blind, Double-dummy, Placebo and Active Controlled, Crossover Design Study Using Bronchoprovocation to Evaluate the Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma",,['Mild Asthma'],[],,2022-08-15,2025-06,"[{'measure': 'Post-dose PC20 Concentration', 'description': 'Post-dose PC20, which are the provocative concentrations, respectively, of the methacholine challenge agent required to reduce the forced expiratory volume in one second (FEV1) by 20% following administration of differing concentrations of albuterol (or placebo) by inhalation.', 'timeFrame': '15 minutes post-dose'}]",[],1.0,20 Years,65 Years,ALL,False,INDUSTRY,0.0,148.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05056896,ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension,Aspirin,"['Aspirin', 'acetylsalicylic acid (ASA)', 'Salicylic Acid Acetate']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,ACTIVE_NOT_RECRUITING,Colorectal Cancer,Massachusetts General Hospital,2025-09-01T16:18:09.640539,True,,,,,ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension,,['Colorectal Cancer'],['Colorectal Cancer'],,2022-06-03,2025-12-31,"[{'measure': 'Change of ISC marker gene expression', 'description': 'Assess the difference in the change of ISC marker using scRNA-seq data analysis', 'timeFrame': '2 months'}]","[{'measure': 'Change in Urinary PGE-M', 'description': 'Comparing change in PGE-M between treatment groups (aspirin and placebo) using a two-sample t-test.', 'timeFrame': '2 months'}, {'measure': 'Change in urinary Plasma GDF-15', 'description': 'Comparing change inGDF-15 between aspirin and placebo groups, using a two-sample t-test.', 'timeFrame': '2 months'}, {'measure': 'ChIP-seq Analysis of Colonic Epithelium', 'description': 'Analysis of the ChIP-seq data (\\>60 million reads, 50-bp paired end) using the publicly available Cistrome Analysis Pipeline', 'timeFrame': '2 months'}, {'measure': 'Gene Expression Analysis of Colonic Epithelium', 'description': 'RNA-seq sequence data (\\> 50 million reads) will be mapped to hg19 through use of TopHat2.', 'timeFrame': '2 months'}, {'measure': 'Change in Microbiome', 'description': 'Aspirin use and dose will be associated with microbial operational taxonomic units (OTUs) using the Biobakery3 computational analysis pipeline.', 'timeFrame': '2 months'}]",6.0,18 Years,,ALL,False,OTHER,3.0,161.0,ACTUAL,v2_robust,True,False,False,False,
NCT00852696,Over Active Bladder Patients Having Sling Surgery,Solifenacin,"['Tolterodine Tartrate', 'Solifenacin']",2,INTERVENTIONAL,['NA'],,TERMINATED,Overactive Bladder,Cleveland Clinic Florida,2025-09-01T16:18:09.640663,True,,,,,"A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures.",,['Overactive Bladder'],"['Overactive Bladder', 'Incontinence', 'Solifenacin', 'Women', 'Postoperative']",Investigator left Cleveland Clinic and absolutely no data is available.,2008-02,2010-02,"[{'measure': 'To Determine Whether Treatment With Anti-muscarinic Medications Following Sub-urethral Sling Procedures Improves Overall Subjective and Objective Outcomes in Women With Mixed Incontinence With Primary Stress Symptoms.', 'description': 'Women with mixed incontinence with primary stress symptoms undergoing Sub-Urethral Sling Procedures will be randomized to peri-operative placebo or solifenacin. Subjects in the placebo group will take orally once daily for 9 weeks. Subjects in the Solifenacin group will take orally once daily for 9 weeks.', 'timeFrame': '9 weeks'}]",[],1.0,18 Years,100 Years,FEMALE,True,OTHER,1.0,1.0,ACTUAL,v2_robust,True,False,True,False,Investigator left Cleveland Clinic and absolutely no data is available.
NCT06888362,Trial to Investigate GZ21T in Healthy Volunteers,GZ21T,['GZ21T'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Actinic Keratosis,"Genzada Pharmaceuticals USA, Inc.",2025-09-01T16:18:09.640674,True,,,,,"A Double-blind, Randomised, Placebo-controlled Phase I Trial to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Topical Doses of GZ21T in Healthy Volunteers",,['Actinic Keratosis'],['Actinic keratosis'],,2024-08-19,2025-03-31,"[{'measure': 'AE', 'description': 'Frequency, severity and intensity of adverse events (AEs).', 'timeFrame': 'Day 1 to Day 7'}, {'measure': 'Skin reactions', 'description': ""Local tolerability reactions, such as Erythema, swelling, pruritus, burning, blistering and urticaria, discolouration and dryness (Investigator's assessment 0-3 none/mild/moderate/severe)."", 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Clinically significant changes in vital signs', 'description': 'Number of participants with clinically significant changes in vital signs (blood pressure)', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Clinically significant changes in vital signs', 'description': 'Number of participants with clinically significant changes in vital signs (pulse).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Clinically significant changes in electrocardiograms (ECGs)', 'description': 'Number of participants with clinically significant changes in ECG results (resting heart rate).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Clinically significant changes in electrocardiograms (ECGs)', 'description': 'Number of participants with clinically significant changes in ECG results (PQ/PR).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Clinically significant changes in electrocardiograms (ECGs)', 'description': 'Number of participants with clinically significant changes in ECG results (QRS).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Clinically significant changes in electrocardiograms (ECGs)', 'description': 'Number of participants with clinically significant changes in ECG results (QT).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Clinically significant changes in electrocardiograms (ECGs)', 'description': 'Number of participants with clinically significant changes in ECG results (QTcF intervals).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Number of subjects with clinically significant abnormal laboratory test results (haematology, clinical chemistry, coagulation)', 'description': 'Number of participants with clinically significant abnormal laboratory tests results (clinical chemistry, hematology and coagulation parameters).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Number of participants with clinically significant changes in physical examination findings.', 'description': 'Number of participants with clinically significant changes in physical examination findings', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'Cream absorption after single dose applications.', 'description': 'Cream absorption measured on a 4-point scale', 'timeFrame': '0-2 hours after IMP administration'}]","[{'measure': 'Plasma concentrations', 'description': 'Plasma concentrations of GZ21T after single dose applications.', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'PK parameters- AUCinf', 'description': 'PK parameters after a single dose application (to be calculated if data permits): area under the plasma concentration curve from time 0 to infinity (AUCinf).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'PK parameters - AUClast', 'description': 'PK parameters after a single dose application (to be calculated if data permits): AUC from time 0 to the last measurable concentration (AUClast).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'PK parameters - Cmax', 'description': 'PK parameters after a single dose application (to be calculated if data permits): maximum plasma concentration (Cmax).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'PK parameters - Tmax', 'description': 'PK parameters after a single dose application (to be calculated if data permits): time to Cmax (Tmax).', 'timeFrame': 'Day 1 to Day 7.'}, {'measure': 'PK parameters - T½', 'description': 'PK parameters after a single dose application (to be calculated if data permits): terminal elimination half-life (T½).', 'timeFrame': 'Day 1 to Day 7.'}]",18.0,18 Years,70 Years,ALL,True,INDUSTRY,1.0,41.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03135262,A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),Idasanutlin,"['Idasanutlin', 'Venetoclax', 'Obinutuzumab', 'Rituximab']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Follicular Lymphoma,Hoffmann-La Roche,2025-09-01T16:18:09.640690,True,,,,,A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,"['Follicular Lymphoma', 'Lymphoma, Large B-Cell, Diffuse']",[],Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.,2017-06-15,2020-04-30,"[{'measure': 'RP2D of Idasanutlin When Given in Combination With Obinutuzumab or Rituximab', 'description': 'It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place. phases.\n\nThe study was closed because at escalation doses 100 (in combination with venetoclax 400 mg) and 150 mg (in combination with venetoclax 200 mg) Idasanutlin, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts. The subpopulations of DLBCL and FL were showed no difference in their genetic subtype make-up, therefore, Cohorts Safety, 1, 2, 3 contain both populations.\n\nThe safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.', 'timeFrame': 'Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)'}, {'measure': 'RP2D of Venetoclax When Given in Combination With Obinutuzumab or Rituximab', 'description': 'It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place.\n\nThe study was closed because at escalation doses 200 (in combination with 150 mg idasanutlin) and 400 (in combination with 100 mg idasanutlin) mg Venetoclax, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts.\n\nThe safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.', 'timeFrame': 'Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)'}, {'measure': 'Percentage of Participants With Dose-Limiting Toxicities (DLTs)', 'description': ""DLT is defined as any one of the following events occurring during first two Cycles of treatment and assessed by the investigator as clearly not related to patient's underlying disease: - Any Grade 5 adverse event (AE) unless unequivocally due to the underlying malignancy or extraneous causes; - AE of any grade that leads to a delay of more than 14 days at the start of next treatment cycle; - Hematologic AEs (neutropenia, thrombocytopenia); - Non-hematologic AE, except IRRs, laboratory TLS without manifestations of clinical TLS, AST or ALT, diarrhea, nausea or vomiting, fatigue, asthenia, anorexia, or constipation, hepatic transaminase."", 'timeFrame': 'Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'description': 'An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a casual relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'timeFrame': 'From Baseline up to approximately 48 months'}, {'measure': 'Percentage of Participants With Complete Response (CR), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography-Computed Tomography (PET-CT) Scans Using Modified Lugano 2014 Criteria', 'description': 'The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I). Therefore the result data not derived and not reported.', 'timeFrame': 'At end of Induction (EOI) (within 6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days])'}]","[{'measure': 'Percentage of Participants With CR, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria', 'description': 'The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based complete response (CR), which required a complete metabolic response with a score of 1, 2 or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to \\[\\<=\\] mediastinum; 3 = uptake greater than \\[\\>\\] mediastinum and \\<= liver; 4 = uptake moderately \\> liver; 5 = uptake markedly \\> liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if intermediate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.', 'timeFrame': 'At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]'}, {'measure': 'Percentage of Participants With CR, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria', 'description': 'The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required to complete radiologic response with all of the following: target nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion \\[LDi\\]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. Therefore the result data not derived and not reported.', 'timeFrame': 'At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]'}, {'measure': 'Percentage of Participants With CR, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria', 'description': 'The investigator evaluated responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion (LDi); no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who received at least 2 cycles of Induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. This outcome measure therefore not derived and not reported.', 'timeFrame': 'At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]'}, {'measure': 'Percentage of Participants With Objective Response, Determined by the IRC on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria', 'description': 'The IRC was to evaluate responses at the end of induction treatment using Luagno 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2 or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 \\[no uptake above background\\] to 5 \\[uptake markedly higher than liver and/or new lesions\\]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Therefore the result data not derived and not reported. The study was pre-maturely terminated.', 'timeFrame': 'At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]'}, {'measure': 'Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria', 'description': 'The investigator was to evaluate responses at end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 \\[no uptake above background\\] to 5 \\[uptake markedly higher than liver and/or new lesions\\]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.', 'timeFrame': 'At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]'}, {'measure': 'Percentage of Participants With Objective Response, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria', 'description': 'The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a \\>=50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/nomal, regressed, but no increase; and spleen must have regressed by \\>50% in length. Therefore the result data not derived and not reported. The study was pre-maturely terminated.', 'timeFrame': 'At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]'}, {'measure': 'Percentage of Participants With Objective Response at EOI, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria', 'description': 'The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a \\>=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by \\>50% in length. The study was pre-maturely terminated at escalation phase.', 'timeFrame': 'At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]'}, {'measure': 'Percentage of Participants With Objective Response During the Study, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria', 'description': 'The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a \\>=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by \\>50% in length. The study was pre-maturely terminated at escalation phase.', 'timeFrame': 'From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months'}, {'measure': 'Observed Serum Concentration of Obinutuzumab in Participants With FL', 'description': ""Observed Serum Concentration of Obinutuzumab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.\n\nThe result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study."", 'timeFrame': 'From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)'}, {'measure': 'Observed Serum Concentration of Obinutuzumab in Participants With DLBCL', 'description': 'Observed Serum Concentration of Obinutuzumab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.', 'timeFrame': 'Induction: Pre-dose (any time prior to dose on same day) and 30 min post-dose on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) and 30 min post-dose on Day 1 of Cycles 2, 4 and 6 (each cycle = 28 days)'}, {'measure': 'Observed Serum Concentration of Rituximab in Participants With FL', 'description': 'Observed Serum Concentration of Rituximab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.', 'timeFrame': 'Induction: Pre-dose (any time prior to dose on same day) on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) on Day 1 of Cycles 2, 4, 6; 30 min post-dose on Day 1 of Cycles 1 and 6 (each cycle = 28 days)'}, {'measure': 'Observed Serum Concentration of Rituximab in Participants With DLBCL', 'description': 'Observed Serum Concentration of Rituximab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.', 'timeFrame': 'From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)'}, {'measure': 'Observed Plasma Concentration of Idasanutlin in Participants With FL', 'description': 'Observed Plasma Concentration of Idasanutlin in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported', 'timeFrame': 'From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)'}, {'measure': 'Observed Plasma Concentration of Idasanutlin in Participants With DLBCL', 'description': 'Observed Plasma Concentration of Idasanutlin in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported', 'timeFrame': 'From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)'}, {'measure': 'Observed Plasma Concentration of Venetoclax in Participants With FL', 'description': 'Observed Plasma Concentration of Venetoclax in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.', 'timeFrame': 'From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)'}, {'measure': 'Observed Plasma Concentration of Venetoclax in Participants With DLBCL', 'description': 'Observed Plasma Concentration of Venetoclax in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.\n\nThe study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.', 'timeFrame': 'From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)'}]",21.0,18 Years,,ALL,False,INDUSTRY,0.0,29.0,ACTUAL,v2_robust,True,False,True,True,Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.
NCT06334562,The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery,SUGAMMADEX SODIUM 100 Mg in 1 mL,"['Neostigmine', 'Sugammadex Sodium', 'SUGAMMADEX SODIUM 100 Mg in 1 mL']",3,INTERVENTIONAL,['NA'],,RECRUITING,Neuromuscular Blockade,The Fourth Affiliated Hospital of Zhejiang University School of Medicine,2025-09-01T16:18:09.640733,True,,,,,An Observational Study on the Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery,,['Neuromuscular Blockade'],"['Sugammadex Sodium', 'Postoperative Neuromuscular Block Antagonism', 'thoracic surgery']",,2024-06-01,2025-12-31,"[{'measure': 'Muscle relaxation recovery time', 'description': 'The time from using antagonists to TOFr recovery to 0.9', 'timeFrame': 'Usually from half an hour to several hours（depending on the length of the procedure）'}]",[],1.0,19 Years,75 Years,ALL,True,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06538662,An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations,FID 123320 Ophthalmic Solution,"['FID 123320 Ophthalmic Solution', 'Vehicle']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Ocular Redness,Alcon Research,2025-09-01T16:18:09.640780,True,,,,,"A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Efficacy and Safety Study of FID 123320 Ophthalmic Solution for the Reduction of Ocular Redness in Pediatric and Adult Populations",,"['Ocular Redness', 'Eye Irritation']",['Reduction of ocular redness'],,2024-10-07,2025-04-03,"[{'measure': 'Mean change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation on Day 1 (Visit 2) - Adult Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale. This is a co-primary endpoint.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 15 minutes post-instillation'}, {'measure': 'Mean change from baseline in investigator-assessed ocular redness at 10 hours (600 minutes) post-instillation on Day 1 (Visit 2) - Adult Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale. This is a co-primary endpoint.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 10 hours (600 minutes) post-instillation'}, {'measure': 'Mean change from baseline in investigator-assessed ocular redness at 1 hour (60 minutes) post-instillation on Day 1 (Visit 2) - Pediatric Cohort (12-17 years)', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 1 hour (60 minutes) post-instillation'}]","[{'measure': 'Mean change from baseline in the investigator-assessed ocular redness at 1 minute post-instillation on Day 1 (Visit 2) - Adult Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 1 minute post-instillation'}, {'measure': 'Mean change from baseline in the investigator-assessed ocular redness at 8 hours (480 minutes) post-instillation on Day 1 (Visit 2) - Adult Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 8 hours (480 minutes) post-instillation'}, {'measure': 'Mean change from baseline in the investigator-assessed ocular redness at 12 hours (720 minutes) post-instillation on Day 1 (Visit 2) - Adult Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 12 hours (720 minutes) post-instillation'}, {'measure': 'Mean change from baseline in the investigator-assessed ocular redness at 30 seconds post-instillation on Day 1 (Visit 2) - Adult Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 30 seconds post-instillation'}, {'measure': 'Mean change from baseline in investigator-assessed ocular redness at 1 minute post-instillation on Day 1 (Visit 2) - Pediatric Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale. This endpoint is pre-specified for pediatric subjects in the age range of 12-17 years.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 1 minute post-instillation'}, {'measure': 'Mean change from baseline in investigator-assessed ocular redness at 8 hours (480 minutes) post-instillation on Day 1 (Visit 2) - Pediatric Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale. This endpoint is pre-specified for pediatric subjects in the age range of 12-17 years.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 8 hours (480 minutes) post-instillation'}, {'measure': 'Mean change from baseline in investigator assessed ocular redness at 30 seconds post-instillation on Day 1 (Visit 2) - Pediatric Cohort', 'description': 'Ocular redness will be assessed by the investigator using a 0-4 unit ocular hyperemia scale. This endpoint is pre-specified for pediatric subjects in the age range of 12-17 years.', 'timeFrame': 'Day 1 (Visit 2) pre-instillation; Day 1 (Visit 2) at 30 seconds post-instillation'}]",10.0,5 Years,,ALL,False,INDUSTRY,0.0,283.0,ACTUAL,v2_robust,True,True,False,False,
NCT03975062,Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study),dabigatran etexilate,['dabigatran etexilate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Atrial Fibrillation,Ural State Medical University,2025-09-01T16:18:09.640812,True,,,,,"""Prospective Open Label Randomized Evaluation of Abbreviated Course of Dabigatran Etexilate With tranSesophageal echOcardiography (TEE) Control vs Conventional 3-week coUrse With dabigatraN Etexilate Before Cardioversion: Analysis of MRI-detecteD Cerebral Embolism"" (RE-SOUND Study), № 1160.242",,['Atrial Fibrillation'],"['atrial fibrillation', 'cardioversion', 'anticoagulation', 'dabigatran', 'magnetic resonance imaging']",,2017-12-28,2020-12-30,"[{'measure': 'the proportion of patients with new magnetic resonance imaging (MRI) detected cerebral embolic events', 'description': 'patients with new (not visible at pre-cardioversion MRI) cerebral ischemic lesions revealed at MRI after cardioversion and without a history of acute neurological dysfunction attributable to the lesion or with symptomatic cerebral ischemic stroke after cardioversion confirmed by MRI examination', 'timeFrame': '30 days after cardioversion'}]","[{'measure': 'the incidence of symptomatic cerebral thromboembolic events (stroke or TIA)', 'description': 'An acute episode of focal or global neurological dysfunction caused by brain, spinal cord or retinal vascular injury as a result of hemorrhage or infarction (with imaging, pathological or other objective evidence of cerebral, spinal cord or retinal injury or clinical evidence with symptoms persisting ≥24 hours or until death and other etiology excluded) or transient (\\<24 hours) episode of focal neurological dysfunction caused by brain, spinal cord or retinal ischemia without acute infarction', 'timeFrame': 'within 30 days after cardioversion'}, {'measure': 'the proportion of patients with major bleeding events after cardioversion', 'description': 'major bleeding as defined by the International Society of Thrombosis and Hemostasis (ISTH) criteria', 'timeFrame': 'within 30 days after cardioversion'}, {'measure': 'the proportion of patients with any bleeding events after cardioversion', 'description': 'any clinical obvious bleeding', 'timeFrame': 'within 30 days after cardioversion'}, {'measure': 'the proportion of patients with intracranial bleeding events after cardioversion', 'description': 'symptomatic intraparenchymal, intraventricular, subarachnoid, subdural, epidural hemorrhage with imaging or pathological evidence', 'timeFrame': 'within 30 days after cardioversion'}, {'measure': 'the proportion of patients with at least one bleeding event since the first dose of dabigatran', 'description': 'any clinical obvious bleeding', 'timeFrame': 'from the first dose of dabigatran etexilate till 30th day after cardioversion'}, {'measure': 'the proportion of patients with at least one major bleeding event since the first dose of dabigatran', 'description': 'major bleeding as defined by the ISTH criteria', 'timeFrame': 'from the first dose of dabigatran etexilate till 30th day after cardioversion'}, {'measure': 'the proportion of patients with intracranial bleeding events since the first dose of dabigatran', 'description': 'symptomatic intraparenchymal, intraventricular, subarachnoid, subdural, epidural hemorrhage with imaging or pathological evidence', 'timeFrame': 'from the first dose of dabigatran etexilate till 30th day after cardioversion'}]",8.0,19 Years,74 Years,ALL,False,OTHER,1.0,400.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06773962,A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease,TB006,"['TB006', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Parkinson's Disease (PD),"TrueBinding, Inc.",2025-09-01T16:18:09.640949,True,,,,,"A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants With Parkinson's Disease",,"[""Parkinson's Disease (PD)""]","['PD', 'TB006', 'Monoclonal Antibody', ""Parkinson's Disease""]",,2025-03-20,2025-12-29,"[{'measure': ""Change from Baseline in Parkinson's Disease Rating Scale Score"", 'timeFrame': 'Baseline to 28 weeks'}, {'measure': 'Number of Participants Experiencing Adverse Events', 'timeFrame': '28 weeks'}, {'measure': 'Number of Participants Experiencing Serious Adverse Events', 'timeFrame': '28 weeks'}]","[{'measure': ""Change from Baseline in Parkinson's Disease Rating Scale Sub-score"", 'timeFrame': 'Baseline to 28 weeks'}, {'measure': 'Change from Baseline in Patient Perceived Severity of Disease', 'timeFrame': 'Baseline to 28 weeks'}, {'measure': 'Change from Baseline in Clinician Perceived Severity of Disease', 'timeFrame': 'Baseline to 28 weeks'}]",6.0,50 Years,80 Years,ALL,False,INDUSTRY,0.0,62.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00338962,Naltrexone & SSRI in Alcoholics With Depression/PTSD,paroxetine,"['paroxetine', 'Naltrexone', 'Placebo', 'desipramine', 'paxil', 'Norpramin', 'Vivitrol']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Alcoholism,Yale University,2025-09-01T16:18:09.641016,True,,,,,Naltrexone & SSRI in Alcoholics With Depression/PTSD,,"['Alcoholism', 'Depression', 'PTSD']","['SSRI', 'treatment', 'naltrexone', 'alcohol dependence', 'Desipramine', 'depression', 'PTSD']",,2001-10,2015-07,"[{'measure': 'Mean Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)', 'description': 'The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48.', 'timeFrame': 'beginning of treatment (week 1), and end of treatment (13 weeks)'}, {'measure': 'Clinician-Administered PTSD Scale (CAPS)', 'description': 'The CAPS is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to:\n\nMake current (past month) diagnosis of PTSD Make lifetime diagnosis of PTSD Assess PTSD symptoms over the past week Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD \\>80=Extreme PTSD', 'timeFrame': 'beginning of treatment (week 1), and end of treatment (13 weeks)'}, {'measure': 'Hamilton Depression Rating Scale (HAM-D)', 'description': 'The HAM-D ranges from 0 (Normal) to \\>23 (Very Severe Depression)', 'timeFrame': 'beginning of treatment (week 1), and end of treatment (13 weeks)'}, {'measure': 'Mean Number of Side Effects', 'description': 'Differences in mean number of side effects reported for each group. Side effects and common adverse symptoms were evaluated by the research staff weekly, using a modified version of the ystematic Assessment for Treatment Emergent Events. The symptoms that are known to be associated with treatment with desipramine, paroxetine, and naltrexone were specifically screened or on a weekly basis. The symptoms were then clustered into the following categories: gastrointestinal, emotional, cold and flu symptoms, skin, sexual, neurological, and cardiac.', 'timeFrame': '12 weeks'}]",[],4.0,21 Years,75 Years,ALL,False,OTHER,0.0,88.0,ACTUAL,v2_robust,True,True,False,True,
NCT03107962,Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma,Pembrolizumab (PD-1 Blocking Antibody),"['Pembrolizumab (PD-1 Blocking Antibody)', 'Pembrolizumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",Mingzhi Zhang,2025-09-01T16:18:09.641041,True,,,,,PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma,,"['Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type']","['NK/T cell lymphoma', 'immunotherapy', 'clinical trial', 'RR', 'PFS', 'OS']",,2017-02-19,2018-12,"[{'measure': 'Response rate', 'description': '21 days (3 weeks) for one cycle, Efficacy was evaluated every two cycles.', 'timeFrame': 'every 6 weeks, up to completion of treatment (approximately 18 weeks, unless the disease progresses or patients cannot tolerate the drug)'}]","[{'measure': 'Progression-free survival', 'description': 'Progression-free survival', 'timeFrame': 'up to end of follow-up-phase (approximately 24 months)'}, {'measure': 'Overall survival', 'description': 'Overall survival', 'timeFrame': 'up to the date of death (approximately 3 years)'}, {'measure': 'Median survival time', 'description': 'Median survival time', 'timeFrame': '2 years'}]",4.0,14 Years,70 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03306446,Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab,Start adalimumab in monotherapy,"['Start adalimumab in monotherapy', 'begin humira in monotherapie in Early crohn disease patient']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,CD,Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives,2025-09-01T16:18:09.641061,True,,,,,Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab,,['CD'],[],,2015-03-17,2025-03,"[{'measure': 'Sustained deep remission rate', 'description': 'Number of patients with sustained deep remission at one year', 'timeFrame': '12 months'}]","[{'measure': '2-year deep remission rate', 'description': 'Number of patients with 2-year deep remission rate among patients who did not achieve 1-year remission', 'timeFrame': '2 years'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,203.0,ACTUAL,v2_robust,True,False,False,False,
NCT00352846,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Zoledronic Acid,"['Zoledronic Acid', 'Vitamin D', 'Zoledronate', 'Zometa', 'Calcium Carbonate']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Non-Hodgkin's Lymphoma,M.D. Anderson Cancer Center,2025-09-01T16:18:09.641180,True,,,,,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy,,"[""Non-Hodgkin's Lymphoma"", 'Lymphoma']","[""Non-Hodgkin's Lymphoma"", 'Lymphoma', 'Zoledronic Acid', 'Zoledronate', 'Zometa', 'Vitamin D', 'Calcium Carbonate', 'Bone Loss']",,2006-01,2011-09,"[{'measure': 'Percentage Change in Bone Mineral Density (BMD) T-Score From Baseline to 12 Months', 'description': 'The 12-month change from baseline in BMD at the total lumbar spine. BMD evaluation was performed at baseline and at 12 months after initiation of therapy at the lumbar spine. BMD was measured by dual-energy, x-ray absorptiometry scanners. T-Score is the number of standard deviations above or below the mean. A T-score \\>= -1 indicates a normal BMD, while T-scores between -1 and -2.5 indicate osteopenia and T-scores \\<= -2.5 indicate osteoporosis.', 'timeFrame': 'From baseline to 12 Months'}]",[],1.0,18 Years,,ALL,False,OTHER,1.0,135.0,ACTUAL,v2_robust,True,True,False,False,
NCT00915746,A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers,JNJ-31001074; ketoconazole,['JNJ-31001074; ketoconazole'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",2025-09-01T16:18:09.641205,True,,,,,An Open-Label Drug-Drug Interaction Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of JNJ-31001074 in Healthy Subjects,,"['Healthy', 'Pharmacokinetics', 'Drug Interactions']","['Phase I', 'ketoconazole', 'CYP3A4 inhibitor', 'drug interaction', 'metabolism', 'Healthly Volunteer', 'JNJ-31001074']",,2009-11,2009-12,"[{'measure': 'The primary objective is to assess the effects of repeated daily administration of 400 mg of ketoconazole on the single-dose pharmacokinetics of JNJ-31001074 in healthy volunteers', 'timeFrame': 'Multiple blood samples will be obtained over the 11 day open-label treatment phase'}]","[{'measure': 'To assess the safety and tolerability of JNJ-31001074 with and without coadministration of ketoconazole', 'timeFrame': 'up to 32 days (including a 21 day screening phase)'}]",2.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,14.0,ACTUAL,v2_robust,True,True,False,True,
NCT06455046,Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer,AK104,"['Recombinant Human Adenovirus Type 5 Injection', 'Recombinant Human Adenovirus 5 Injection', 'Cadonilimab', 'AK104']",4,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Cervical Cancer Recurrent,Fujian Cancer Hospital,2025-09-01T16:18:09.641251,True,,,,,"Efficacy and Safety of AK104 Combined With Pemetrexed, Carboplatin and Recombinant Human Adenovirus 5 Injection in Advanced Recurrent Cervical Cancer: a Multicenter, Single-arm, Prospective Phase II Clinical Study",,['Cervical Cancer Recurrent'],[],,2023-10-11,2025-10-10,"[{'measure': 'ORR', 'description': 'Objective Response Rate', 'timeFrame': '2years'}]","[{'measure': 'PFS', 'description': 'Progression Free Survival', 'timeFrame': '2years'}]",2.0,18 Years,75 Years,FEMALE,False,OTHER_GOV,1.0,37.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03552146,Evaluating the Effects of Propofol vs. Dexmedetomidine,Propofol,"['Propofol', 'Precedex', 'Dexmedetomidine', 'Diprivan']",4,OBSERVATIONAL,[],,UNKNOWN,Sedative Adverse Reaction,Children's Healthcare of Atlanta,2025-09-01T16:18:09.641273,True,,,,,Evaluation of the Effects on Efficiency of a Sedation Service by Switching From Propofol to Dexmedetomidine,,['Sedative Adverse Reaction'],['sedation'],,2018-07-24,2019-09-30,"[{'measure': 'Procedural times to achieve optimal sedation', 'description': 'Measuring the amount of time it takes for a patient to be discharged starting from induction (start of infusion).', 'timeFrame': 'Start of procedure to discharge (up to 8 hours)'}]","[{'measure': 'Sedation related events', 'description': 'Adverse events related to the sedation (i.e., apnea, desaturation, change in heart rate)', 'timeFrame': 'Start of procedure to up to 36 hours post-discharge'}]",2.0,3 Months,36 Months,ALL,True,OTHER,1.0,60.0,ESTIMATED,v2_robust,False,False,False,True,
NCT03059446,Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis,Cenicriviroc,"['Cenicriviroc', 'CVC']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Nonalcoholic Steatohepatitis,"Tobira Therapeutics, Inc.",2025-09-01T16:18:09.641294,True,,,,,Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH),,"['Nonalcoholic Steatohepatitis', 'Liver Cirrhosis', 'Non-alcoholic Fatty Liver Disease']",[],This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.,2017-02-14,2021-01-05,"[{'measure': 'Number of Participants With Treatment-emergent Adverse Events (AE)', 'description': 'An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. A treatment-emergent AE is an AE that occurs after a participant receives study drug.', 'timeFrame': 'Day 1 until the study was terminated (up to approximately 4 years)'}]",[],1.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,167.0,ACTUAL,v2_robust,True,False,True,True,This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.
NCT01179646,Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets,Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet,"['Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)', 'Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Kremers Urban Development Company,2025-09-01T16:18:09.641304,True,,,,,"A Pharmacokinetic Study to Determine the Bioequivalence of a Test 40 mg Pantoprazole Delayed-Release Tablet, Compared to a Marketed 40 mg Pantoprazole Delayed-Release Tablet (Protonix, Wyeth Pharmaceuticals) When Administered to Healthy Adult Subjects in the Fasted State",,['Healthy'],['Bioequivalency'],,2004-06,2004-08,"[{'measure': 'Cmax (maximum observed concentration of drug substance in plasma)', 'timeFrame': '16 hours'}, {'measure': 'AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)', 'timeFrame': '16 hours'}, {'measure': 'AUC0-inf area under the concentration-time curve from time zero to infinity)', 'timeFrame': '16 hoyurs'}]",[],3.0,19 Years,50 Years,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,False,
NCT05229588,Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations,Lurbinectedin 4 MG Injection [Zepzelca],"['PM01183', 'Lurbinectedin 4 MG Injection [Zepzelca]']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Gastrointestinal Malignancies,HonorHealth Research Institute,2025-09-01T16:18:09.641328,True,,,,,A Phase II Pilot Clinical Trial of Lurbinectedin (Zepzelca™ PM01183) in Patients With Gastrointestinal Malignancies With DNA Repair Mutations,,['Gastrointestinal Malignancies'],"['Gastrointestinal Malignancies', 'phase II']",,2022-06-14,2025-08-04,"[{'measure': 'Evaluate the antitumor activity', 'description': 'To evaluate the antitumor activity of Lurbinectedin in terms of overall response rate (ORR), according to RECIST v.1.1, in patients with advanced pancreatic cancer with DNA repair mutations.', 'timeFrame': 'Initiation of study treatment up to 10 cycles (each cycle is 21 days ± 48 hours)'}]","[{'measure': 'Duration of response (DOR)', 'description': 'Duration of response (DOR), defined as the time from the date when the response criteria (PR or CR) are fulfilled to the date of PD, recurrence or death.', 'timeFrame': 'Initiation of study treatment up to study completion, up to 2 years'}, {'measure': 'Clinical benefit', 'description': 'Clinical benefit, defined as the percentage of patients with ORR or SD ≥4 months, according to RECIST v.1.1.', 'timeFrame': 'Initiation of study treatment up to study completion, up to 2 years'}, {'measure': 'Measure amount of CA19-9, CEA, or CA125', 'description': 'Measure amount of CA19-9, CEA, or CA125 (whichever is being followed) in blood during treatment.', 'timeFrame': 'Initiation of study treatment up to 12 cycles (each cycle is 21 days ± 48 hours)'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS), defined as the time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation.', 'timeFrame': 'Initiation of study treatment up to 12 cycles (each cycle is 21 days ± 48 hours)'}, {'measure': 'Progression-free survival rate at three months (PFS3)', 'description': 'Progression-free survival rate at three months (PFS3), defined as the percentage of patients who are alive and progression-free three months after the first infusion.', 'timeFrame': 'Initiation of study treatment up to three months after the first infusion'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS), defined as the time from the date of first infusion to the date of death (of any cause) or last patient contact.', 'timeFrame': 'Initiation of study treatment up to 2 years'}, {'measure': 'Overall survival rate at six months (OS6)', 'description': 'Overall survival rate at six months (OS6), defined as the percentage of patients who were alive six months after the first infusion', 'timeFrame': 'Initiation of study treatment up to six months after the first infusion'}, {'measure': 'Overall survival rate at 12 months (OS12)', 'description': 'Overall survival rate at 12 months (OS12), defined as the percentage of patients who were alive 12 months after the first infusion', 'timeFrame': 'Initiation of study treatment up to 12 months after the first infusion'}, {'measure': 'Treatment safety', 'description': 'Treatment safety: AEs, serious AEs (SAEs) and laboratory abnormalities graded according to the NCI-CTCAE v.5', 'timeFrame': 'Initiation of study treatment up to 2 years'}]",10.0,18 Years,,ALL,False,OTHER,1.0,8.0,ACTUAL,v2_robust,True,True,False,True,
NCT02344888,Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS,Clomiphene citrate and Prednisolone,"['Clomid and Hostacortin-H', 'Clomid and folic acid', 'Clomiphene citrate and Prednisolone', 'Clomiphene citrate and folic acid']",4,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Infertility,Mahmoud Thabet,2025-09-01T16:18:09.641371,True,,,,,Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome,,"['Infertility', 'Polycystic Ovarian Syndrome']","['PCOS', 'Clomiphene citrate resistant', 'Prednisolone']",,2015-02,2019-01,"[{'measure': 'Ovulation rate', 'description': 'Number of ovulatory cycles divided by the number of stimulation cycles', 'timeFrame': '3 months'}]","[{'measure': 'Number of ovarian follicles ≥ 18 mm on day of HCG administration', 'description': 'Number of ovarian follicles ≥ 18 mm by TVS on day of HCG administration', 'timeFrame': '3 months'}, {'measure': 'Endometrial thickness on day of HCG administration', 'description': 'Endometrial thickness by TVS on day of HCG administration', 'timeFrame': '3 months'}, {'measure': 'Clinical pregnancy rate', 'description': 'Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women', 'timeFrame': '6-8 weeks gestational age'}]",4.0,20 Years,35 Years,FEMALE,False,OTHER,0.0,300.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03678688,A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis,10 mg OPC-167832,"['3 mg OPC-167832', '30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ', '10 mg OPC-167832', '30 mg OPC-167832 + 400 mg BDQ', '90 mg OPC-167832', '30 mg OPC-167832', 'RHEZ', '30 mg OPC-167832 + 300 mg delamanid']",8,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Pulmonary TB,"Otsuka Pharmaceutical Development & Commercialization, Inc.",2025-09-01T16:18:09.641508,True,,,,,"A Phase 1/2, Active-controlled, Randomized, Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Oral Doses of OPC-167832 Tablets in Subjects With Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis",,['Pulmonary TB'],[],,2018-10-18,2022-03-11,"[{'measure': 'Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA)', 'description': 'Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.', 'timeFrame': 'Baseline to Day 14'}, {'measure': 'Stage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'description': 'T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable from non-compartmental analysis (NCA). The values reported for this outcome measure (OM) are estimates and not actual observed data.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Cmax of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: Cmax,ss of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Tmax of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: Tmax of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: AUC0-24 of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: AUCτ of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: T1/2,z of Delamanid', 'description': 'T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: CLss/F of Delamanid From Plasma', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: RCmax of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: RAUC of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Cmax/Dose of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: AUCτ/Dose of Delamanid', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Cmax of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: Cmax,ss of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Tmax of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: Tmax of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: AUC0-24 of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: AUCτ of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: T1/2,z of Bedaquiline', 'description': 'T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: CLss/F of BDQ From Plasma', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Cmax/Dose of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: AUCτ/Dose of Bedaquiline', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs)', 'description': 'An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all AEs which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.', 'timeFrame': 'From first dose of study drug to end of follow up period (up to 34 days)'}, {'measure': 'Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Vital Sign Values', 'timeFrame': 'From first dose of study drug to end of follow up period (up to 34 days)'}, {'measure': 'Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters', 'timeFrame': 'From first dose of study drug to end of follow up period (up to 34 days)'}]","[{'measure': 'Stage 1 and Stage 2: Change From Baseline in Lipoarabinomannan (LAM) in the Mycobacteria Growth Indicator Tube® (MGIT) System', 'description': 'LAM is a key component of the M. tuberculosis cell wall and the decline of sputum LAM concentrations has been shown to correlate closely with CFU decreases in sputum counted on agar media during the first 14 days of TB treatment. Sputum LAM concentration at each collection time point was measured using MGIT system. Baseline LAM was calculated as the log 10 of the average from Day -2 and Day -1 and the change from baseline in log10 was calculated as post-baseline minus baseline for each parameter.', 'timeFrame': 'Baseline to Day 14'}, {'measure': 'Stage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System', 'description': 'TTD is the time from start of inoculation of a sputum sample until a MGIT machine detects a positive signal during the 42-day incubation period. One TTD measurement, reported in days and hours was taken at each of the visits at Days -2, -1, 2, 4, 6, 8, 10, 12 and 14. TTD values were then calculated as ""days + hours/24"" to be used in deriving the analysis values of TTD. Each sample collected from Day -2 to Day 14 were inoculated for 42 days. Baseline TTD was derived using Day -2 and Day -1 MGIT culture with a pure positive result for Mycobacterium tuberculosis. Postbaseline TTD analysis values from Day 1 were derived based on the MGIT culture result as follows: If MGIT culture result was negative for MTB complex, TTD was set to 42 days; If the MGIT culture was pure positive for MTB, but the TTD took longer than 42 days, TTD was capped at 42 days.', 'timeFrame': 'Day 1 to Day 14 of treatment period + 42 days of inoculation period (up to 56 days)'}, {'measure': 'Stage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA', 'description': 'Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.', 'timeFrame': 'Baseline to Day 14'}, {'measure': 'Stage 2: Plasma Concentration of Rifampin', 'timeFrame': '2 hours and 6 hours post-dose on Day 14'}, {'measure': 'Stage 1: Plasma Concentration of Isoniazid', 'timeFrame': '2 hours and 6 hours post-dose on Day 14'}, {'measure': 'Stage 2: Cmax of DM-6705', 'description': 'DM-6705 is a metabolite of delamanid.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: Cmax,ss of DM-6705', 'description': 'DM-6705 is a metabolite of delamanid.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Tmax of DM-6705', 'description': 'DM-6705 is a metabolite of delamanid.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: AUC0-24 for DM-6705', 'description': 'DM-6705 is a metabolite of delamanid.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: T1/2,z of DM-6705', 'description': 'T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) was determined in the terminal phase after drug administration, which was calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Cmax of N-Desmethyl Bedaquiline', 'description': 'N-Desmethyl Bedaquiline is a metabolite of BDQ.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1'}, {'measure': 'Stage 2: Cmax,ss of N-Desmethyl Bedaquiline', 'description': 'N-Desmethyl Bedaquiline is a metabolite of BDQ.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Tmax of N-Desmethyl Bedaquiline', 'description': 'N-Desmethyl Bedaquiline is a metabolite of BDQ.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours (±15 minutes) postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: AUC0-24 for N-Desmethyl Bedaquiline', 'description': 'N-Desmethyl Bedaquiline is a metabolite of BDQ.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14'}, {'measure': 'Stage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline', 'description': 'An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all adverse events which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.', 'timeFrame': 'From first dose of study drug to end of follow up period (up to 34 days)'}, {'measure': 'Stage 2: Number of Participants With Clinically Significant Vital Sign Changes on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline', 'timeFrame': 'From first dose of study drug to end of follow up period (up to 34 days)'}, {'measure': 'Stage 2: Number of Participants With Clinically Significant Changes in ECG Evaluations on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline', 'timeFrame': 'From first dose of study drug to end of follow up period (up to 34 days)'}]",55.0,18 Years,64 Years,ALL,False,INDUSTRY,1.0,122.0,ACTUAL,v2_robust,True,True,False,True,
NCT02753088,Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis,BCD-063,"['mannitol', 'glatiramer acetate', 'Copaxone-Teva', 'Placebo', 'BCD-063']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Relapsing-remitting Multiple Sclerosis,Biocad,2025-09-01T16:18:09.641618,True,,,,,"International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC ""BIOCAD"", Russia) and Copaxone®-Teva (""Teva Pharmaceutical Industries Limited"", Israel) in Patients With Relapsing-remitting Multiple Sclerosis",,['Relapsing-remitting Multiple Sclerosis'],"['Equivalence', 'BCD-063', 'Copaxone-Teva']",,2013-10,2015-11,"[{'measure': 'Cumulative Unique Activity lesions', 'description': 'Cumulative Unique Activity (CUA) detected by MRI', 'timeFrame': '48 weeks'}]","[{'measure': 'Annual relapse rate', 'description': 'Relapse per patient per year', 'timeFrame': '48 weeks'}, {'measure': 'Proportion of patients without relapses', 'description': 'Proportion of patients without confirming relapses with magnetic resonance imaging (MRI)', 'timeFrame': '48 weeks'}, {'measure': 'Changing in volume of hypointense T1 lesions', 'timeFrame': '48 weeks'}, {'measure': 'Changing in volume of T2 lesions', 'timeFrame': '48 weeks'}, {'measure': 'Amount of new or extended lesions in T2 regimen', 'timeFrame': '48 weeks'}, {'measure': 'Patients proportion without lesions', 'timeFrame': '48 weeks'}, {'measure': 'T1 lesions amount', 'timeFrame': '48 weeks'}, {'measure': 'Expanded Disability Status Scale dynamics', 'description': 'Expanded Disability Status Scale (EDSS) scale count at 24th and 48th week, comparing count at week 24 to week 48 for each group', 'timeFrame': 'Week 24, Week 48'}, {'measure': 'Progression on Multiple Sclerosis Functional Composite scale comparing to the baseline', 'timeFrame': '48 weeks'}, {'measure': 'Risk of relapse', 'description': 'Relative Risk Ratio for relapse in each group', 'timeFrame': '48 weeks'}, {'measure': 'Time till the first relapse', 'timeFrame': '48 weeks'}, {'measure': 'Multiple Sclerosis Functional Composite scale dynamics', 'description': 'Multiple Sclerosis Functional Composite (MSFC) scale count at 24th and 48th week, comparing count at week 24 to week 48 for each group', 'timeFrame': '24, 48 weeks'}]",13.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,158.0,ACTUAL,v2_robust,True,True,False,False,
NCT03945188,Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis,Etrasimod,"['APD334', 'Etrasimod', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Ulcerative Colitis,Arena Pharmaceuticals,2025-09-01T16:18:09.641643,True,,,,,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis",,['Ulcerative Colitis'],"['Ulcerative Colitis', 'Etrasimod', 'APD334']",,2019-06-13,2022-02-16,"[{'measure': 'Percentage of Participants Achieving Clinical Remission at Week 12', 'description': 'Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily eDiary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants Achieving Clinical Remission at Week 52', 'description': 'Clinical remission was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Week 52'}]","[{'measure': 'Percentage of Participants Achieving Endoscopic Improvement at Week 12', 'description': 'Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants Achieving Endoscopic Improvement at Week 52', 'description': 'Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants Achieving Symptomatic Remission at Week 12', 'description': 'Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants Achieving Symptomatic Remission at Week 52', 'description': 'Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants With Mucosal Healing at Week 12', 'description': 'Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \\< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants With Mucosal Healing at Week 52', 'description': 'Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \\< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 52', 'description': 'Corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 52', 'description': 'Sustained clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability) at both Week 12 and Week 52. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Weeks 12 and 52'}, {'measure': 'Percentage of Participants Achieving Clinical Response at Week 12', 'description': 'Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants Achieving Clinical Response at Week 52', 'description': 'Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB sub-score ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants Achieving Clinical Response at Both Weeks 12 and 52', 'description': 'Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Weeks 12 and 52'}, {'measure': 'Percentage of Participants With Mucosal Healing at Both Weeks 12 and 52', 'description': 'Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \\< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.', 'timeFrame': 'At Weeks 12 and 52'}, {'measure': 'Percentage of Participants Achieving Endoscopic Normalization at Week 12', 'description': 'Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants Achieving Endoscopic Normalization at Week 52', 'description': 'Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 52', 'description': 'Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).', 'timeFrame': 'At Weeks 12 and 52'}, {'measure': 'Percentage of Participants Achieving Symptomatic Remission by Study Visit', 'description': 'Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.', 'timeFrame': 'At Weeks 2, 4, 8, 16, 20, 24, 32, 40, and 48'}, {'measure': 'Percentage of Participants Achieving Complete Symptomatic Remission by Study Visit', 'description': 'Complete symptomatic remission was defined as an SF subscore = 0 and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.', 'timeFrame': 'At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48 and 52'}, {'measure': 'Percentage of Participants Achieving Non-invasive Clinical Response by Study Visit', 'description': 'Non-invasive clinical response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores, and a ≥ 1-point decrease from Baseline in RB subscore or RB subscore ≤ 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.', 'timeFrame': 'At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52'}, {'measure': 'Percentage of Participants Achieving Symptomatic Response by Study Visit', 'description': 'Symptomatic response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores. The SF subscore ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.', 'timeFrame': 'At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52'}, {'measure': 'Percentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline', 'description': 'Four-week corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1, and have not received corticosteroids for ≥ 4 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 12', 'description': 'Clinical remission and clinical response were based on the MMS which is a composite of 3 assessments: SF, RB and ES. Clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'At Week 52'}]",23.0,16 Years,80 Years,ALL,False,INDUSTRY,0.0,433.0,ACTUAL,v2_robust,True,True,False,False,
NCT02688803,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC),Dose dense AC-P,"['doxorubicin', 'paclitaxel', 'cyclophosphamide', 'Dose dense AC-P', 'Dose dense AC', 'FEC-D', 'docetaxel', '5-FU']",8,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Breast Cancer,Ottawa Hospital Research Institute,2025-09-01T16:18:09.641837,True,,,,,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) OTT 15-04,,['Breast Cancer'],['HER2 Negative'],,2016-08,2017-10,"[{'measure': 'Percentage of patients who receive chemotherapy in the neoadjuvant/adjuvant setting for TNBC', 'description': 'Percentage of patients who receive chemotherapy in the neoadjuvant/adjuvant setting for TNBC compared to the number of participants who after being approached subsequently agree to randomization.', 'timeFrame': 'One year'}, {'measure': 'Participant satisfaction', 'description': 'Participant satisfaction survey. Overall participant satisfaction will be determined using the participant survey', 'timeFrame': 'One year'}]","[{'measure': 'Percentage of participants who complete study treatment', 'description': 'Percentage of participants who complete study treatment compared to the percentage who discontinue their treatment while on study (compliance) will be calculated using the sites chemotherapy treatment records and data from New Patient Registration.', 'timeFrame': 'One hour'}, {'measure': 'Hospitalization', 'description': 'Rate of adverse effects requiring hospitalization', 'timeFrame': 'One year'}, {'measure': 'Treatment delays', 'description': 'Rate of adverse effects requiring treatment delays', 'timeFrame': 'One year'}]",5.0,18 Years,,FEMALE,False,OTHER,0.0,2.0,ACTUAL,v2_robust,True,True,False,True,
NCT01187303,Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL),Ofatumumab,['Ofatumumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Relapsed NLPHL,University of Cologne,2025-09-01T16:18:09.641853,True,,,,,Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL),,['Relapsed NLPHL'],[],,2011-05,2015-09,"[{'measure': 'Overall response rate', 'timeFrame': '12 months after end of treatment'}]","[{'measure': 'duration of response', 'timeFrame': '12 months after end of treatment'}, {'measure': 'Progression free survival', 'timeFrame': '12 months after end of treatment'}, {'measure': 'adverse events', 'timeFrame': '12 months after end of treatment'}]",4.0,18 Years,75 Years,ALL,False,OTHER,0.0,28.0,ACTUAL,v2_robust,True,True,False,True,
NCT00902603,Ventavis® Registry Protocol,Commercial Ventavis® (iloprost),['Commercial Ventavis® (iloprost)'],1,OBSERVATIONAL,[],,TERMINATED,Pulmonary Arterial Hypertension,Actelion,2025-09-01T16:18:09.641884,True,,,,,Registry to Prospectively Evaluate Use of Ventavis® in Patients With Pulmonary Arterial Hypertension,,['Pulmonary Arterial Hypertension'],"['pulmonary arterial hypertension', 'Ventavis®', 'iloprost']",low enrollment and difficulty recruiting eligible patients in adequate time,2009-03,2014-02,"[{'measure': 'Adherence with instructions for use of Ventavis®', 'timeFrame': '2 years'}]","[{'measure': 'Persistence of use of Ventavis®', 'timeFrame': '2 years'}]",2.0,19 Years,,ALL,False,INDUSTRY,0.0,148.0,ACTUAL,v2_robust,False,False,True,False,low enrollment and difficulty recruiting eligible patients in adequate time
NCT00972803,"The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms",pistacia Mutica extract,"['pistacia Mutica extract', 'Chlorhexidine', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Gingivitis,Tabriz University,2025-09-01T16:18:09.642020,True,,,,,"The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms",,['Gingivitis'],"['gingivitis', 'dental plaque', 'mouthrinse']",,2008-05,2009-05,"[{'measure': 'The effects of pistacia Mutica extract (PM) on de novo plaque formation.', 'timeFrame': 'In a 4 days experimental periods followed by a 10 days wash-out periods.'}]","[{'measure': 'staining effects of pistacia Mutica extract in comparison to placebo or Chlorhexidine', 'timeFrame': 'In a 4 days experimental periods followed by a 10 days wash-out periods'}]",2.0,18 Years,65 Years,ALL,,OTHER,0.0,25.0,ACTUAL,v2_robust,True,True,False,False,
NCT04051203,Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia,Depo-Medrol and lidocaine,['Depo-Medrol and lidocaine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Occipital Neuralgia,University of Calgary,2025-09-01T16:18:09.642115,True,,,,,Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study,,"['Occipital Neuralgia', 'Headache']","['GON', 'greater occipital neuralgia', 'post traumatic headache', 'post concussive headache']",,2019-02-01,2023-12-01,"[{'measure': 'Evaluate the feasibility of platelet-rich plasma for patients with post-traumatic greater occipital neuralgia', 'description': 'The feasibility will be determined based on recruitment (greater than 30% of those screened eligible), attendance (70% intervention appointment attendance), retention (70% complete study protocol), and the acceptability of the protocol', 'timeFrame': 'Screening, pre-injection to 3-months post injection'}, {'measure': 'Evaluate the safety profile of platelet-rich plasma for the treatment of post-traumatic greater occipital neuralgia', 'description': 'Safety will be determined based on adverse reactions monitored through daily headache diary reporting and communication with the study team', 'timeFrame': 'from immediately post-injection to 3-months, daily recording'}]","[{'measure': 'Change in headache severity as measured by the Numerical Pain Raiting Scale (NPRS)', 'description': 'This will be measured as a greater than a 2-point decrease on the NPRS at 3 months post-injection in the PRP group as compared to steroid and saline groups.', 'timeFrame': 'Pre-injection to 3 months post injection, daily recording.'}, {'measure': 'Change in headache frequency (days per month with headache).', 'description': 'Using daily headache diaries, headache frequency will be collected.', 'timeFrame': 'Pre-injection to 3 months post injection, daily recording.'}, {'measure': 'Headache Impact Test-6', 'description': 'A valid and reliable 6-item questionnaire for assessment of the impact of headaches across different diagnostic groups of headaches. The HIT-6 items measure the adverse impact of headache on social functioning, role functioning, vitality, cognitive functioning and psychological distress. The HIT-6 also measures the severity of headache pain.', 'timeFrame': 'Pre-injection, 1 month, and 3 month time points.'}, {'measure': 'Quality of Life in Following Brain Injury Questionnaire', 'description': 'The QOLIBRI (Quality of Life after Brain Injury) is the first instrument specifically developed to assess health-related quality of life (HRQoL) of individuals after traumatic brain injury. The QOLIBRI is a comprehensive questionnaire with 37 items covering six dimensions of HRQoL after TBI. The questionnaire provides a profile of quality of life together with a total score.', 'timeFrame': 'Pre-injection, 1 month, and 3 month follow-ups.'}]",6.0,18 Years,,ALL,True,OTHER,0.0,35.0,ACTUAL,v2_robust,True,True,False,True,
NCT04331327,Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis,allogenic lyophilized growth factors,['allogenic lyophilized growth factors'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Osteo Arthritis Knee,Rasmia Elgohary,2025-09-01T16:18:09.642953,True,,,,,Clinical and Ultrasonographic Assessment of Effectiveness of Intra-articular Knee Injection Using Platelet Derived Lyophilized Growth Factors in Egyptian Patients With Symptomatic Primary Knee Osteoarthritis,,['Osteo Arthritis Knee'],"['osteoarthritis', 'allogenic platelet rich plasma', 'lyophilization', 'growth factors']",,2017-05-01,2018-04-28,"[{'measure': 'Change from Baseline WOMAC scores at 6 months', 'description': 'Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores consist of 24 questions in 3 sections regarding; five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). A sum of the scores for all three sub-scales gives a total WOMAC score. The higher scores mean a worse outcome.', 'timeFrame': 'At baseline and after 6 months.'}, {'measure': 'Change from Baseline structural outcomes scores at 6 months', 'description': 'Knee ultrasonography assessment of effusion, femoral cartilage, anterior horn medial meniscus, synovial hypertrophy', 'timeFrame': 'At baseline and after 6 months.'}]","[{'measure': 'post injection complications of the intervention treatment', 'description': 'The patients of the intervention group were asked if they experienced any adverse events following the injection, with special concern on:\n\n1. Post-injection pain: Both the duration and intensity were documented. The pain intensity was measured by 0-10 visual analogue scale (VAS).\n2. General symptoms or signs related to infection and allergy such as fever, chills, pruritus, dyspnea, urticaria, or rash.\n3. Erythema, swelling, or abnormal discharge from the site of injection.', 'timeFrame': 'at each time following the injection'}]",3.0,18 Years,,ALL,False,OTHER,0.0,31.0,ACTUAL,v2_robust,True,True,False,True,
NCT00509327,Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery,bisacodyl,"['bisacodyl', 'glucosemonohydricum']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postoperative Ileus,"University Hospital, Basel, Switzerland",2025-09-01T16:18:09.642984,True,,,,,Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery,,['Postoperative Ileus'],"['postoperative ileus', 'colorectal surgery', 'bisacodyl', 'laxatives']",,2004-11,2007-02,"[{'measure': 'Time to recovery of gastrointestinal function, defined as the mean time to the occurrence of the following three events (GI-3): first flatus passed, first defecation and first solid food tolerated', 'timeFrame': '10 days'}]","[{'measure': 'Incidence of NGT reinsertion, duration of NGS reinsertion, incidence of postoperative vomiting and length of hospital stay', 'timeFrame': '10 days'}]",2.0,18 Years,90 Years,ALL,False,OTHER,0.0,200.0,ACTUAL,v2_robust,True,True,False,False,
NCT01538927,Effect of Fibrin Sealant on Early Wound Healing,Fibrin Sealant,"['TISSEEL™ Kit, Two component Fibrin Sealant, Steam - treated', 'Ethicon', 'Suture', 'Fibrin Sealant']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Periodontitis,Chhattisgarh Dental College and Research Institute,2025-09-01T16:18:09.643071,True,,,,,Evaluation of Early Wound Healing Following Use of Fibrin Sealant (FS) in Periodontal Surgery. A Controlled Randomized Clinical Trial.,,['Periodontitis'],"['fibrin sealant', 'tissue adhesive', 'wound healing', 'interleukin 1 beta', 'interleukin 8']",,2012-04,2012-12,"[{'measure': 'Concentration of cytokines.', 'description': 'Assess the concentration of Interleukin 1beta and Interleukin 8 in GCF of test and control sites after 7 days.', 'timeFrame': '7 days'}]","[{'measure': 'Clinical inflammation', 'description': 'Gingival inflammation will be assessed at a clinical level.', 'timeFrame': '7, 14 and 21 days'}]",2.0,18 Years,60 Years,ALL,False,OTHER,1.0,15.0,ESTIMATED,v2_robust,True,True,False,False,
NCT03734627,Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery,Octreotide Acetate,"['Paracetamol', 'Saline Solution', 'Octreotide Acetate', 'Sulfasalazine']",4,OBSERVATIONAL,[],,COMPLETED,Esophageal Cancer,"St. James's Hospital, Ireland",2025-09-01T16:18:09.643115,True,,,,,Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery,,"['Esophageal Cancer', 'Nutrition Disorders', 'Appetite Disorders', 'Dumping Syndrome', 'Delayed Gastric Emptying', 'Surgery']","['Gut hormones', 'GLP-1', 'Enteroendocrine L-cell', 'Early satiety', 'Dumping syndrome', 'Gastrointestinal transit', 'Insulin', 'Octreotide', 'Somatostatin', 'Esophagectomy']",,2016-07-01,2021-07-01,"[{'measure': 'Area under the curve for paracetamol at 30 minutes after a 400kcal mixed meal stimulus', 'timeFrame': '30 minutes post meal'}]","[{'measure': 'Peak paracetamol level', 'timeFrame': 'Within 300 minutes post meal'}, {'measure': 'GLP-1 area under the curve over 300 minutes after a 400kcal mixed meal stimulus', 'timeFrame': 'Within 300 minutes post meal'}, {'measure': 'Glucose area under the curve over 300 minutes after a 400kcal mixed meal stimulus', 'timeFrame': 'Within 300 minutes post meal'}, {'measure': 'Insulin area under the curve over 300 minutes after a 400kcal mixed meal stimulus', 'timeFrame': 'Within 300 minutes post meal'}, {'measure': 'Visual analogue scales', 'timeFrame': 'Within 300 minutes post meal'}, {'measure': 'EORTC health related quality of life', 'timeFrame': 'At one year post surgery, on the day of assessment'}]",7.0,18 Years,,ALL,True,OTHER,0.0,40.0,ACTUAL,v2_robust,False,True,False,False,
NCT03388827,Laminaria and Misoprostol Before Operative Hysteroscopy,Laminaria plus Misoprostol,"['Laminaria plus Misoprostol', 'cytotec,']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Cervical Spasm,Zagazig University,2025-09-01T16:18:09.643175,True,,,,,The Use of Laminaria Versus Laminaria Plus Misoprostol Before Operative Hysteroscopy in Nulliparous Women . A Double Blinded Randomized Trial.,,['Cervical Spasm'],[],,2017-12-20,2019-01,"[{'measure': 'Preoperative cervical width', 'description': 'cervical width in Hegar dilators number', 'timeFrame': '12 hours'}]","[{'measure': 'adverse effects', 'description': 'adverse effects of the method used or hysteroscopy', 'timeFrame': '24 hours'}]",2.0,18 Years,45 Years,FEMALE,True,OTHER_GOV,0.0,100.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00290927,Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus,insulin glulisine,['insulin glulisine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Diabetes Mellitus, Type 2",Sanofi,2025-09-01T16:18:09.643184,True,,,,,"Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents (OHA); OHA Therapy Controlled, Open, Randomized, Parallel Group, Comparative (Superiority), 16-week, Multinational, Multicenter Study",,"['Diabetes Mellitus, Type 2']","['HMR1964, insulin glulisine, Diabetes Mellitus, Type 2']",,2003-12,,"[{'measure': 'Efficacy: change in HbA1C from baseline to endpoint (superiority of HMR1964 and OHA combination therapy as compared to OHA therapy, superiority of HMR1964 mono-therapy as compared to OHA therapy)'}, {'measure': 'Safety of HMR1964'}]","[{'measure': 'change in HbA1C from baseline to week 16,consecutive change in HbA1C every 4 wks,plasma glucose parameters, symptomatic hypoglycemia (comparison of HMR1964 intensive therapy, mono-or OHA combination therapy, with OHA therapy).'}]",3.0,20 Years,75 Years,ALL,False,INDUSTRY,0.0,390.0,,v2_robust,True,True,False,True,
NCT02125227,Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers,"Rosuvastatin, Metformin, YH14755","['YH14755', 'Crestor, GlucodaunOR, YH14755', 'Rosuvastatin, Metformin, YH14755']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Yuhan Corporation,2025-09-01T16:18:09.643214,True,,,,,"A Randomized, Open-label, Single-dose, 2-Way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the Effect of Food on the Pharmacokinetics of YH14755",,['Healthy'],[],,2014-04,2014-09,"[{'measure': 'AUClast of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': 'Cmax of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}]","[{'measure': 'Tmax of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': 't1/2 of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': '%AUC of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': 'AUCinf of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}]",6.0,19 Years,55 Years,ALL,True,INDUSTRY,0.0,56.0,ACTUAL,v2_robust,True,True,False,False,
NCT06278727,Development and Validation of the Prediction Model for Functional Mitral Regurgitation Regression in Heart Failure Patients Taking Guideline-directed Medical Therapy,angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor,"['angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor', 'mineralcorticoid recept antagonist', 'sodium-glucose linked transporter-2 inhibitor', 'beta-blockers']",4,OBSERVATIONAL,[],,RECRUITING,Mitral Regurgitation,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2025-09-01T16:18:09.643225,True,,,,,Development and Validation of the Prediction Model for Functional Mitral Regurgitation Regression in Heart Failure Patients Taking Guideline-directed Medical Therapy,,"['Mitral Regurgitation', 'Heart Failure']",[],,2024-01-01,2025-12-31,"[{'measure': 'FMR regression rate', 'description': 'the rate of FMR regression by at least 1 grade by 3 months', 'timeFrame': '3 months'}]","[{'measure': 'FMR regression rate', 'description': 'the rate of FMR regression by at least 1 grade by 6 months', 'timeFrame': '6 months'}, {'measure': 'composite endpoint', 'description': 'the composite endpoint includes all-cause mortality, worsening heart failure, and mitral intervention. The worsening heart failure includes heart failure hospitalization, NYHA cardiac function upgrades ≥1 grade, and acute heart failure needing diuretic or outpatient adjustment of prescription.', 'timeFrame': 'one year'}]",3.0,18 Years,,ALL,False,OTHER,0.0,270.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01337427,Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis,BIIB017,"['PEG IFN β-1a', 'BIIB017', 'PEGylated Interferon beta-1a']",3,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,Johns Hopkins University,2025-09-01T16:18:09.643279,True,,,,,"Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis",,['Relapsing Remitting Multiple Sclerosis'],"['multiple sclerosis', 'relapsing', 'MS', 'injectable', 'subcutaneous', 'SC', 'PEGylated', 'interferon', 'PEG', 'OCT', 'Optical Coherence Tomography']",The study was not feasible to conduct in the US and abroad.,2010-08,2013-08,"[{'measure': 'To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 12 in the BIIB-17 vs. placebo arms.', 'timeFrame': '1 year'}, {'measure': 'To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 24 in the BIIB-17 vs. placebo arms.', 'timeFrame': '2 years'}]","[{'measure': 'Analysis of proportion of patients with a decrease of >10 percent of baseline value in any RNFL quadrant from baseline to month 12 in the BIIB-17 vs. placebo arms.', 'timeFrame': 'baseline and 1 year'}, {'measure': 'Analysis of decrease between baseline scans and 3 month scan (to examine for pseudoatrophy) in this study population.', 'timeFrame': 'baseline and 3 months'}, {'measure': 'Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (12 months) in this study population.', 'timeFrame': '3 months and 1 year'}, {'measure': 'Analysis of macular volume decreases from baseline or 3 months to follow up scans at 12 months in this study population.', 'timeFrame': 'baseline and 1 year'}, {'measure': 'Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 12 months in this study population.', 'timeFrame': 'baseline and 1 year'}, {'measure': 'Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.', 'timeFrame': '1 year'}, {'measure': 'Analysis of proportion of patients with a decrease of >10 percent of baseline value in any RNFL quadrant from baseline to month 24 in the BIIB-17 vs. placebo arms.', 'timeFrame': 'baseline and 2 years'}, {'measure': 'Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (24 months) in this study population.', 'timeFrame': '3 months and 2 years'}, {'measure': 'Analysis of macular volume decreases from baseline or 3 months to follow up scans at 24 months in this study population.', 'timeFrame': 'baseline and 2 years'}, {'measure': 'Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 24 months in this study population.', 'timeFrame': 'baseline and 2 years'}, {'measure': 'Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.', 'timeFrame': '2 years'}]",13.0,18 Years,55 Years,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,The study was not feasible to conduct in the US and abroad.
NCT00951561,A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen,Ibuprofen,"['Ibuprofen', 'Ibuprofen, NSAIDs']",2,INTERVENTIONAL,['NA'],,COMPLETED,Dysmenorrhea,Another Way Products,2025-09-01T16:18:09.643305,True,,,,,A Randomized Four-Way Crossover Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen,,['Dysmenorrhea'],['Dysmenorrhea'],,2006-11,2009-09,"[{'measure': 'Percentage of Intervention Uses That Resulted in at Least 1 Point Decrease in Pain and Requiring no Rescue Medication Using the Modified Melzack-McGill Scale Using a Mixed Model', 'description': 'Modified Melzack-McGill Scale measures general pain (0=none, 1-3=mild, 4-6=moderate, 7-9=severe, 10=worst pain) Total Number of Uses Analyzed is a sum of the Number of Uses collected at each time point.', 'timeFrame': '1 month, 2 months, 3 months, 4 months'}]",[],1.0,18 Years,,FEMALE,True,INDUSTRY,0.0,115.0,ACTUAL,v2_robust,True,True,False,False,
NCT03842761,A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems,BI 685509,"['BI 685509', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:09.643337,True,,,,,"Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 685509 Over 28 Days in Patients With Mild and Moderate Hepatic Impairment and of Single Oral BI 685509 Dose Compared to Healthy Volunteers",,"['Healthy', 'Hepatic Insufficiency']",[],,2019-03-06,2021-05-20,"[{'measure': 'The percentage of subjects with drug-related Adverse Events (AEs) among different dose regimes over each up-titration', 'timeFrame': 'Up to day 28'}]","[{'measure': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to time of the last quantifiable data point)', 'timeFrame': 'Baseline and Up to 72 hours'}, {'measure': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': 'Up to 72 hours'}, {'measure': 'AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) [AUCτ,ss will be AUC0-12,ss for bid dosing]', 'timeFrame': 'Up to 72 hours'}, {'measure': 'Cmax,ss (maximum measured concentration of the analyte in plasma at steady)', 'timeFrame': 'Up to 72 hours'}, {'measure': 'Change from baseline in seated systolic blood pressure (SBP)', 'timeFrame': 'Baseline and Up to 28 days'}, {'measure': 'Change from baseline in seated diastolic blood pressure (DBP)', 'timeFrame': 'Baseline and Up to 28 days'}, {'measure': 'Change from baseline in heart rate (HR)', 'timeFrame': 'Baseline and Up to 28 days'}, {'measure': 'Change from baseline in body weight', 'timeFrame': 'Baseline and Up to 28 days'}]",9.0,18 Years,,ALL,False,INDUSTRY,0.0,64.0,ACTUAL,v2_robust,True,True,False,True,
NCT04728061,"Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124",Gen1E-1124,"['Gen1E-1124', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,GEn1E Lifesciences,2025-09-01T16:18:09.643402,True,,,,,"A Phase 1a/1b, Randomized, Double-blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124 After Single and Multiple IV Infusion Dosing in Healthy Volunteers",,['Healthy'],[],,2021-01-07,2021-06-18,"[{'measure': 'The incidence of adverse events from the start of randomization through the final follow-up visit', 'timeFrame': 'Up to 14 days post-dose'}]","[{'measure': 'Plasma levels of GEn1E-1124 and potential metabolites', 'timeFrame': 'Through 24 hours post-dose'}, {'measure': 'Urine levels of GEn1E-1124 and potential metabolites', 'timeFrame': 'Through 24 hours post-dose'}, {'measure': 'Cytokines measured in whole blood', 'timeFrame': 'Up to 24 hours post-dose'}, {'measure': 'Selected biomarkers measured in whole blood', 'timeFrame': 'Up to 24 hours post-dose'}]",5.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,
NCT01435161,Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF,"Nifedipine,","['anti-hypertensive drugs, Atrial fibrillation', 'Telmisartan', 'Nifedipine,', 'anti-hypertensive drugs, atrial fibrillation']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Atrial Fibrillation,The Second Affiliated Hospital of Chongqing Medical University,2025-09-01T16:18:09.643410,True,,,,,The Effect of Nifedipine Versus Telmisartan on Prevention of Atrial Fibrillation Recurrence in Hypertensive Patients With Paroxysmal Atrial Fibrillation by Intensive Lower Blood Pressure,,['Atrial Fibrillation'],"['paroxysmal atrial fibrillation, hypertension']",,2007-05,2011-08,"[{'measure': 'Recurrence of Atrial Fibrillation', 'description': 'Recurrence of Atrial Fibrillation ( at least one readable conventional and Holter ECG recording)', 'timeFrame': 'four years'}]",[],1.0,40 Years,65 Years,ALL,False,OTHER,0.0,160.0,ACTUAL,v2_robust,True,True,False,False,
NCT00266461,A Tolerability and Efficacy Study of TU-100 For The Treatment of Postoperative Ileus,Daikenchuto Extract Granules (TU-100),['Daikenchuto Extract Granules (TU-100)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Postoperative Ileus,Tsumura USA,2025-09-01T16:18:09.643418,True,,,,,"A Randomized, Controlled, Open-Label Tolerability And Efficacy Study Of TU-100 For The Treatment Of Postoperative Ileus In Patients Undergoing Laparotomy For Large Bowel Resection",,['Postoperative Ileus'],['Postoperative Ileus'],,2005-12,2008-01,"[{'measure': 'Evaluate the tolerability of TU-100 for the treatment of postoperative ileus (POI) in patients undergoing laparotomy for large bowel resection based on the incidence of adverse events (AEs).', 'timeFrame': 'Up to 10 days'}]","[{'measure': 'To evaluate the safety of TU-100 in the treatment of POI based on an assessment of objective and subjective symptoms and clinical laboratory data', 'timeFrame': 'Up to 10 days'}, {'measure': 'To evaluate the efficacy of TU-100 in the treatment of POI based on the length of time from the end of surgery to gastrointestinal(GI) function recovery and time to discharge order, and', 'timeFrame': 'Up to 10 days'}, {'measure': 'To determine the acceptability of TU-100 to American patients based on the number of discontinuations due to noncompliance and an assessment of taste.', 'timeFrame': 'Up to 10 days'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,
NCT02453061,"A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease",Triheptanoin oil,"['Triheptanoin oil', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Huntington Disease,"Institut National de la Santé Et de la Recherche Médicale, France",2025-09-01T16:18:09.643445,True,,,,,"A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease",,['Huntington Disease'],[],,2015-06-29,2019-12-03,"[{'measure': 'volumetric magnetic resonance imaging', 'description': 'A decrease in the rate of caudate atrophy, using volumetric MRI', 'timeFrame': '6 months'}]","[{'measure': 'motor function after 6 months', 'description': ""Decrease in the progression of the UHDRS United Huntington's Disease Rating Scale after 6 months of treatment"", 'timeFrame': '6 months'}, {'measure': '31- Phosphorus Magnetic Resonance Spectroscopy', 'description': 'An increase in the index of brain energy restoration - as defined by the difference between Pi/PCr ration during visual stimulation and the mean of the Pi/PCr ratio during rest and recovery - using 31P-MRS', 'timeFrame': '3 months'}, {'measure': 'Caudal Atrophy', 'description': 'Rate of caudate atrophy, using volumetric MRI', 'timeFrame': '12 months'}, {'measure': 'motor function after 12 months', 'description': ""Decrease in the progression of the UHDRS United Huntington's Disease Rating Scale after 12 months of treatment"", 'timeFrame': '12 months'}, {'measure': 'Patient autonomy after 6 months', 'description': 'Stability of the Total Functional Capacity (TFC) after 6 months of treatment', 'timeFrame': '6 months'}, {'measure': 'Patient autonomy after 12 months', 'description': 'Stability of the Total Functional Capacity (TFC) after 12 months of treatment', 'timeFrame': '12 months'}, {'measure': 'Sustained restoration of brain energy metabolism after 6 months', 'description': 'Sustained restoration of brain energy metabolism using 31P-MRS after 6 months of treatment', 'timeFrame': '6 months'}, {'measure': 'Sustained restoration of brain energy metabolism after 12 months', 'description': 'Sustained restoration of brain energy metabolism using 31P-MRS after 12 months of treatment', 'timeFrame': '12 months'}, {'measure': 'Symbol Digit Modalities Test after 6 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 6 months using a neuropsychological battery including the SDMT (Symbol Digit Modalities Test), a test of visuomotor coordination', 'timeFrame': '6 months'}, {'measure': 'Symbol Digit Modalities Test after 12 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 12 months using a neuropsychological battery including the SDMT (Symbol Digit Modalities Test), a test of visuomotor coordination', 'timeFrame': '12 months'}, {'measure': 'Stroop test after 6 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 6 months using a neuropsychological battery including the Stroop test, a test evaluating concentration and capacity for inhibition', 'timeFrame': '6 months'}, {'measure': 'Stroop test after 12 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 12 months using a neuropsychological battery including the Stroop test, a test evaluating concentration and capacity for inhibition', 'timeFrame': '12 months'}, {'measure': 'Trail making test after 6 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 6 months using a neuropsychological battery including the Trail making test, a test to evaluate mental flexibility', 'timeFrame': '6 months'}, {'measure': 'Trail making test after 12 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 12 months using a neuropsychological battery including the Trail making test, a test to evaluate mental flexibility', 'timeFrame': '12 months'}, {'measure': 'Digit span test after 6 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 6 months using a neuropsychological battery including the Digit span test, a test evaluating attention and working memory', 'timeFrame': '6 months'}, {'measure': 'Digit span test after 12 months', 'description': 'The benefit of triheptanoin on cognitive function will be evaluated after 12 months using a neuropsychological battery including the Digit span test, a test evaluating attention and working memory', 'timeFrame': '12 months'}, {'measure': 'psychiatric symptoms after 3 months', 'description': 'The effect of triheptanoin on psychiatric symptoms will be evaluated after 3 months with the PBA-S, an evaluation of problem behaviors associated with HD', 'timeFrame': '3 months'}, {'measure': 'psychiatric symptoms after 6 months', 'description': 'The effect of triheptanoin on psychiatric symptoms will be evaluated after 6 months with the PBA-S, an evaluation of problem behaviors associated with HD', 'timeFrame': '6 months'}, {'measure': 'psychiatric symptoms after 9 months', 'description': 'The effect of triheptanoin on psychiatric symptoms will be evaluated after 9 months with the PBA-S, an evaluation of problem behaviors associated with HD', 'timeFrame': '9 months'}, {'measure': 'psychiatric symptoms after 12 months', 'description': 'The effect of triheptanoin on psychiatric symptoms will be evaluated after 12 months with the PBA-S, an evaluation of problem behaviors associated with HD', 'timeFrame': '12 months'}, {'measure': ""patients' daily life"", 'description': ""The global impact of triheptanoin on patients' daily life will be evaluated at the end of the blinded treatment period using qualitative research methods. To statistically test whether experts classify treated and not treated patients better than could be expected by chance, a permutation test based on a modified version of Fisher's Lady tasting tea procedure will be used (Fischer 1935)."", 'timeFrame': '6 months'}, {'measure': 'quality of life questionnaire after 6 months', 'description': 'A standardized quality of life questionnaire, the Short Form-36 Health Survey, will be used after 6 months', 'timeFrame': '6 months'}, {'measure': 'quality of life questionnaire after 12 months', 'description': 'A standardized quality of life questionnaire, the Short Form-36 Health Survey, will be used after 12 months', 'timeFrame': '12 months'}, {'measure': 'Number of adverse events', 'description': 'Safety of triheptanoin will be evaluated based on review of adverse events', 'timeFrame': '12 months'}, {'measure': 'clinical exam for Long term tolerance', 'description': 'Long-term tolerance will be confirmed by clinical exam at study visits', 'timeFrame': '12 months'}, {'measure': 'home nurse visits for Long term tolerance', 'description': 'Long-term tolerance will be confirmed by patient report during home nurse visits', 'timeFrame': '12 months'}]",27.0,18 Years,,ALL,False,OTHER_GOV,1.0,100.0,ACTUAL,v2_robust,True,True,False,True,
NCT00395161,The CRISIS Prevention Study,Metoclopramide,"['Selenium', 'Reglan', 'Metoclopramide', 'Zinc']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Sepsis,Michael Dean,2025-09-01T16:18:09.643566,True,,,,,The Critical Illness Stress-induced Immune Suppression Prevention Trial,,['Sepsis'],"['sepsis', 'prevention', 'mineral supplementation']",Terminated for futility on 11/30/09 based on the recommendation of the DSMB,2007-04,2009-11,"[{'measure': 'The Primary Endpoint of This Study is the Median Time Between Admission to the PICU and Occurrence of Nosocomial Infection or Clinical Sepsis in PICU Patients Who Have Endotracheal Tubes, Central Venous Catheters, or Urinary Catheters.', 'timeFrame': '48 hours after admission until 5 days after discharged from the PICU'}]","[{'measure': 'Rate of Nosocomial Infection or Clinical Sepsis Per 100 Study Days', 'timeFrame': '48 hours after PICU admission till discharge from PICU'}, {'measure': 'Antibiotic-free Days', 'timeFrame': '48 hours after admission until PICU discharge'}, {'measure': 'Incidence of Prolonged Lymphopenia (Absolute Lymphocyte Count Less Than or Equal to 1,000/mm³ for > or Equal to 7 Days)', 'description': 'What is reported is the number of participants with counts qualifying as lymphopenia.', 'timeFrame': 'from time of PICU admission till discharge from PICU'}, {'measure': 'All-cause 28-day Mortality Rate.', 'timeFrame': '28 days after admission to the PICU'}]",5.0,12 Months,17 Years,ALL,False,OTHER,9.0,293.0,ACTUAL,v2_robust,True,False,True,False,Terminated for futility on 11/30/09 based on the recommendation of the DSMB
NCT04330742,The Effect of Fluids on Aortic VTI During C-section,lactated ringers,"['lactated ringers', 'crystalloid']",2,OBSERVATIONAL,[],,RECRUITING,Pregnancy Related,Baylor College of Medicine,2025-09-01T16:18:09.643614,True,,,,,The Influence of Intravascular Fluid Administration on Aortic Velocity Time Integral in Obstetric Patients Undergoing Cesarean Section,,"['Pregnancy Related', 'Hemorrhage', 'Fluid Overload', 'Labor Complication']","['obstetrics', 'fluid responsiveness', 'fluid resuscitation']",,2020-03-25,2025-12-31,"[{'measure': 'aortic velocity time integral', 'description': 'the percent change in aortic velocity time integral as measured by transthoracic echo', 'timeFrame': 'at baseline measure, right after spinal placement (250mL LR), at 500mL LR infusion, and at 1 L LR infusion (approximately 20mins)'}]","[{'measure': 'inferior vena cava collapsibility', 'description': 'the percent change in diameter of inferior vena cava as measured by transthoracic echo', 'timeFrame': 'at baseline measure, right after spinal placement (250mL LR), at 500mL LR infusion, and at 1 L LR infusion (approximately 20mins)'}, {'measure': 'change in systolic blood pressure', 'description': 'percent change in systolic blood pressure', 'timeFrame': 'every 2.5 mins for 20 mins (when 1L LR is administered) once the pt has a spinal placement'}, {'measure': 'change in heart rate', 'description': 'percent change in heart rate', 'timeFrame': 'every 2.5 mins for 20 mins (when 1L LR is administered) once the pt has a spinal placement'}]",4.0,18 Years,35 Years,FEMALE,True,OTHER,0.0,50.0,ESTIMATED,v2_robust,False,False,False,False,
NCT04892342,Study of ESG401 in Adults With Solid Tumors,ESG401,['ESG401'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,"Neoplasms, Breast","Shanghai Escugen Biotechnology Co., Ltd",2025-09-01T16:18:09.643638,True,,,,,"An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG401 in Subjects With Locally Advanced/Metastatic Solid Tumors",,"['Neoplasms, Breast', 'Neoplasms, Lung', 'Neoplasms,Colorectal', 'Neoplasms, Bladder', 'Neoplasm of Stomach', 'Neoplasms,Ovarian']",[],,2021-09-14,2025-12,"[{'measure': 'Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events', 'description': ""Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0. An AE that met one or more of the following outcomes was classified as serious:\n\nFatal Life-threatening Disabling/incapacitating Results in hospitalization or prolongs a hospital stay A congenital abnormality Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above"", 'timeFrame': 'First dose date up to last dose plus 30 days'}, {'measure': 'Objective Response Rate (ORR) by Independent Central Review (ICR)', 'description': 'ORR is defined as the rate an overall best response of either complete response (CR) or partial response (PR) by ICR assessment according to RECIST1.1. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \\<10 mm. PR was defined as ≥ 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by ICR will be assessed for the TNBC Target Population in phase 2 only.', 'timeFrame': 'Up to 49 months'}]","[{'measure': 'Cmax', 'description': 'Maximum observed plasma concentration', 'timeFrame': 'Up to 49 months'}, {'measure': 'AUC0-inf', 'description': 'Area under the serum concentration time curve from time 0 extrapolated to infinity', 'timeFrame': 'Up to 49 months'}, {'measure': 'Objective Response Rate by Local Assessment', 'description': 'ORR is defined as the rate an overall best response of either complete response (CR) or partial response (PR) by local assessment. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \\<10 mm. PR was defined as ≥3 0% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by local assessment will be assessed for the Target Population both in phase 1 and phase 2.', 'timeFrame': 'Up to 49 months'}, {'measure': 'Progression Free Survival (PFS) by Local Assessment', 'description': 'Progression-free survival (PFS) is defined as the interval from the first dose start date to the date of disease progression defined as documented progressive disease (PD) or death from any cause, whichever occurs first.', 'timeFrame': 'Up to 49 months'}, {'measure': 'Overall Survival by Local Assessment', 'description': 'Overall survival is defined as the time from the date of the first dose start date to the date of death due to any cause.', 'timeFrame': 'Up to 49 months'}, {'measure': 'ADA', 'description': 'Incidence of anti-drug antibodies', 'timeFrame': 'Up to 49 months'}]",8.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,177.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04277442,Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia,Decitabine,"['Dacogen', 'Venclexta', 'GDC-0199', 'ABT 199', 'GDC0199', ""5-Aza-2'-deoxycytidine"", 'ABT199', 'Decitabine for Injection', 'Dezocitidine', 'ABT-0199', 'ABT-199', 'Decitabine', 'RG7601', 'Venclyxto', 'Deoxyazacytidine', 'GDC 0199', 'Venetoclax']",17,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Acute Myeloid Leukemia,National Cancer Institute (NCI),2025-09-01T16:18:09.643656,True,,,,,A Pilot Study of Nivolumab in Combination With Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia,,['Acute Myeloid Leukemia'],[],,2020-03-11,2022-09-06,"[{'measure': 'Incidence of Adverse Events', 'description': 'Toxicity will be graded and reported according to the revised National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to day 15 of cycle 1 (each cycle is 28 days)'}, {'measure': 'Number of Patients That Are Able to Complete 3 Cycles of Therapy', 'description': 'Feasibility will be met if 10 of 13 patients are able to complete 3 cycles of therapy.', 'timeFrame': 'Up to day 15 of cycle 1 (each cycle is 28 days)'}, {'measure': 'Response', 'description': 'Response will be defined as being able to achieve complete remission, complete remission with incomplete count recovery, or complete remission with incomplete hematological recovery by cycle 3.', 'timeFrame': 'Up to day 15 of cycle 1 (each cycle is 28 days)'}]","[{'measure': 'Anti-tumor Activity', 'description': ""Patients will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability. Data that are collected serially over time will be explored graphically using box plots and/or individual time plots as well as analytically with either repeated measures analysis of variance or Friedman's nonparametric test."", 'timeFrame': 'Up to 3 years'}, {'measure': 'Progression-free Survival', 'description': '95% confidence intervals will be given.', 'timeFrame': 'Up to 2 years 5 months'}, {'measure': 'Overall Survival', 'description': '95% confidence intervals will be given.', 'timeFrame': 'Up to 2 years 5 months'}, {'measure': 'Minimal Residual Disease (MRD)', 'description': 'Will assess MRD by measuring the TP53 mutational burden with variant allele frequency before and after response is achieved to see if there is a change. Will also evaluate its association with MRD status at each time point using chi-square test of independence.', 'timeFrame': 'Up to 3 years'}, {'measure': 'T Cell Response', 'description': 'Will study the T cell response against both tumor associated antigen and tumor specific antigen. Analyses of the data will be primarily descriptive in nature given the relatively small sample size.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Deoxyribonucleic Acid (DNA) Methylation', 'description': 'Will study the level of global DNA methylation as well as methylation levels of specific genes involved in immune checkpoint, such as PD-L1, PD-L2, PD-1 and CTLA4. Analyses of the data will be primarily descriptive in nature given the relatively small sample size.', 'timeFrame': 'Up to 3 years'}]",9.0,18 Years,,ALL,False,NIH,0.0,1.0,ACTUAL,v2_robust,True,True,False,True,
NCT05381142,"A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years",Elinzanetant (BAY3427080),"['NT-814', 'Elinzanetant (BAY3427080)', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men,Bayer,2025-09-01T16:18:09.643672,True,,,,,"A Randomized, Single-blind, Placebo-controlled Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single and Multiple Doses of Elinzanetant in Chinese Healthy Female Participants 40 to 65 Years of Age",,"['Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men', 'Hot Flashes', 'Healthy Volunteers']",[],,2022-05-23,2022-07-11,"[{'measure': 'Cmax: maximum observed drug concentration in measured matrix after single dose administration', 'timeFrame': 'From pre-dose up to 168 hours after first dosing'}, {'measure': 'AUC: area under the concentration vs. time curve from zero to infinity after single dose', 'description': 'AUC(0-tlast) will be used as the main parameter if AUC cannot be reliably determined', 'timeFrame': 'From pre-dose up to 168 hours after first dosing'}, {'measure': 'Cmax,md: maximum observed drug concentration in measured matrix after multiple dose administration', 'timeFrame': 'From pre-dose up to 180 hours after last dosing'}, {'measure': 'AUC(0-24)md: AUC from time 0 to 24 hours for multiple dosing', 'timeFrame': 'From pre-dose up to 180 hours after last dosing'}]","[{'measure': 'Number of participants with and severity of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'From first dose of study intervention until follow-up visit on day 21'}]",5.0,40 Years,65 Years,FEMALE,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT05739942,Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma,[177Lu]Lu-NeoB,"['Lu-NeoB', '[177Lu]Lu-NeoB', 'Ga-NeoB', '[68Ga]Ga-NeoB']",4,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Newly Diagnosed and Recurrent Glioblastoma,Novartis Pharmaceuticals,2025-09-01T16:18:09.643694,True,,,,,Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma,,['Newly Diagnosed and Recurrent Glioblastoma'],"['Glioblastoma,', 'GBM,', 'Radioligand Therapy,', 'RLT,', '[68Ga]Ga-NeoB,', '[177Lu]Lu-NeoB,', 'Temozolomide,', 'TMZ,', 'O-6-methylguanine-DNA methyltransferase,', 'MGMT']",,2024-05-15,2031-08-28,"[{'measure': 'Incidence and nature of Dose Limiting Toxicity (DLTs)', 'description': 'A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness/injury, or concomitant medications that occurs within the DLT observation period of \\[177Lu\\]Lu-NeoB. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 5.0 will be used for all grading.\n\nIn Group 1 (newly diagnosed GBM), the DLT observation period is defined as a total of 8 weeks (56 days) from the first administration of \\[177Lu\\]Lu-NeoB, to cover the entire duration of concomitant RT and TMZ combination with the first two administrations of \\[177Lu\\]Lu-NeoB.\n\nIn Group 2 (recurrent GBM), the DLT observation period is 6 weeks (42 days) starting from the first administration of \\[177Lu\\]Lu-NeoB (at Week 1 Day 1) and accounting for assessment of the safety profile during 2 full cycles of \\[177Lu\\]Lu-NeoB.', 'timeFrame': 'Up to 8 weeks (newly diagnosed glioblastoma (GBM)) or 6 weeks (recurrent GBM) after the first administration of [177Lu]Lu-NeoB'}]","[{'measure': 'Incidence and severity of Adverse Events (AEs) and serious Adverse Events (SAEs), changes in laboratory parameters, vital signs and Electrocardiogram (ECGs)', 'description': 'The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.', 'timeFrame': 'From date of enrollment till 28 days after end of Treatment, assessed up to approximately 17 months'}, {'measure': 'Absorbed radiation doses of [177Lu]Lu-NeoB in organs and tumor lesions', 'description': 'The \\[177Lu\\]Lu-NeoB absorbed dose by body organs and tumor lesions will be determined by calculation of TACs obtained from the radiotracer uptake (as percentage of injected dose) in selected organs and lesions (coming from image quantification).', 'timeFrame': 'Cycles 1, 3 and 5: Day 1 (1-4 hours post-dose/post-infusion (p.i.)), Day 2 (24 hours p.i), Day 3 (48 hours p.i), Day 8 (168 hours p.i) (1 cycle = 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Concentration of [177Lu]Lu-NeoB in blood over time', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \\[177Lu\\]Lu-NeoB. Blood concentration of \\[177Lu\\]Lu-NeoB will be summarized with descriptive statistics.', 'timeFrame': 'Cycle 1: Day1 (Pre-dose (before start of infusion), end of infusion, 0.5, 1, 2, 4 and 6 hours (hr) post-dose/post-infusion (p.i.)), Day2 (24 hr p.i), Day3 (48 hr p.i), Day8 (168 h p.i) (1 cycle= 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Observed maximum blood concentration (Cmax) of [177Lu]Lu-NeoB', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \\[177Lu\\]Lu-NeoB. Cmax will be listed and summarized using descriptive statistics.', 'timeFrame': 'Cycle 1: Day1 (Pre-dose (before start of infusion), end of infusion, 0.5, 1, 2, 4 and 6 hours (hr) post-dose/post-infusion (p.i.)), Day2 (24 hr p.i), Day3 (48 hr p.i), Day8 (168 h p.i) (1 cycle= 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Time of maximum observed drug concentration occurrence (Tmax) of [177Lu]Lu-NeoB', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \\[177Lu\\]Lu-NeoB. Tmax will be listed and summarized using descriptive statistics.', 'timeFrame': 'Cycle 1: Day1 (Pre-dose (before start of infusion), end of infusion, 0.5, 1, 2, 4 and 6 hours (hr) post-dose/post-infusion (p.i.)), Day2 (24 hr p.i), Day3 (48 hr p.i), Day8 (168 h p.i) (1 cycle= 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Area under the blood concentration-time curve (AUC) of [177Lu]Lu-NeoB', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \\[177Lu\\]Lu-NeoB. AUC will be listed and summarized using descriptive statistics.', 'timeFrame': 'Cycle 1: Day1 (Pre-dose (before start of infusion), end of infusion, 0.5, 1, 2, 4 and 6 hours (hr) post-dose/post-infusion (p.i.)), Day2 (24 hr p.i), Day3 (48 hr p.i), Day8 (168 h p.i) (1 cycle= 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Total systemic clearance for intravenous administration (CL) of [177Lu]Lu-NeoB', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \\[177Lu\\]Lu-NeoB. CL will be listed and summarized using descriptive statistics.', 'timeFrame': 'Cycle 1: Day1 (Pre-dose (before start of infusion), end of infusion, 0.5, 1, 2, 4 and 6 hours (hr) post-dose/post-infusion (p.i.)), Day2 (24 hr p.i), Day3 (48 hr p.i), Day8 (168 h p.i) (1 cycle= 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Volume of distribution during the terminal phase following intravenous elimination (Vz) of [177Lu]Lu-NeoB', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \\[177Lu\\]Lu-NeoB. Vz will be listed and summarized using descriptive statistics.', 'timeFrame': 'Cycle 1: Day1 (Pre-dose (before start of infusion), end of infusion, 0.5, 1, 2, 4 and 6 hours (hr) post-dose/post-infusion (p.i.)), Day2 (24 hr p.i), Day3 (48 hr p.i), Day8 (168 h p.i) (1 cycle= 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Terminal half-life (T^1/2) of [177Lu]Lu-NeoB', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \\[177Lu\\]Lu-NeoB. T\\^1/2 will be listed and summarized using descriptive statistics.', 'timeFrame': 'Cycle 1: Day1 (Pre-dose (before start of infusion), end of infusion, 0.5, 1, 2, 4 and 6 hours (hr) post-dose/post-infusion (p.i.)), Day2 (24 hr p.i), Day3 (48 hr p.i), Day8 (168 h p.i) (1 cycle= 3 weeks (recurrent GBM) or 4 weeks (newly diagnosed GBM))'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the time from the date of first dose to the date of confirmed progression according to modified RANO or death due to any cause. If no PFS event is observed, PFS will be censored at the date of the last adequate tumor assessment prior to data cut-off date and start of new anti-neoplastic therapy, whichever comes first.', 'timeFrame': 'From date of first dose to date of confirmed progression, assessed up to approximately 17 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from date of first dose to date of death due to any cause. If a participant is not known to have died, then OS will be censored at the latest date the participant was known to be alive (on or before the cut-off date).', 'timeFrame': 'From date of first dose to date of death due to any cause, assessed up to approximately 17 months'}, {'measure': 'Incidence and severity of AEs following [68Ga]Ga-NeoB administration', 'description': 'Incidence and severity of AEs following \\[68Ga\\]Ga-NeoB administration at screening will be done via the analysis of frequencies for Adverse Event (AEs), Serious Adverse Event (SAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.', 'timeFrame': 'At date of screening and every 8 weeks until disease progression.'}]",13.0,18 Years,100 Years,ALL,False,INDUSTRY,0.0,48.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06092242,The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer,Tas-102(Suyuan) combined with bevacizumab,['Tas-102(Suyuan) combined with bevacizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Colorectal Cancer,The Second Affiliated Hospital of Shandong First Medical University,2025-09-01T16:18:09.643706,True,,,,,The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer,,['Colorectal Cancer'],['Colorectal Cancer'],,2023-10-15,2027-10-15,"[{'measure': 'Progression Free Survival', 'description': 'The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse', 'timeFrame': '2 years'}]","[{'measure': 'Overall Survival', 'description': 'Time from randomization to death from any cause', 'timeFrame': '3 year'}, {'measure': 'Objective Response Rate', 'description': 'It refers to the proportion of patients (mainly solid tumors) whose tumor has shrunk to a certain extent and remained there for a certain period of time, including Complete Response (CR) and Partial Response (PR)', 'timeFrame': '2 year'}, {'measure': 'Quality of life score', 'description': ""Quantitative scoring system for patients' self-subjective self-assessment of current symptom tolerance"", 'timeFrame': '3 year'}]",4.0,18 Years,85 Years,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00285142,Effect of Rosiglitazone,rosiglitazone,['rosiglitazone'],1,INTERVENTIONAL,['NA'],,COMPLETED,Healthy,"University Hospital, Montpellier",2025-09-01T16:18:09.643736,True,,,,,Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers,,['Healthy'],"['rosiglitazone', 'insulin secretion', 'clinical trial', 'healthy', 'persons']",,2004-06,2004-11,"[{'measure': 'insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake'}]","[{'measure': 'insulin clearance'}, {'measure': 'basal glycemia and insulinemia'}, {'measure': 'tolerance'}]",4.0,18 Years,35 Years,MALE,True,OTHER,0.0,12.0,,v2_robust,True,True,False,False,
NCT00034086,Study of Anti-HIV Therapy Intensification,Lopinavir/Ritonavir,"['Zidovudine', 'Lamivudine/Zidovudine', 'Stavudine', 'Lopinavir/Ritonavir', 'Lamivudine', 'Didanosine', 'Tenofovir disoproxil fumarate']",7,INTERVENTIONAL,['NA'],,COMPLETED,HIV Infections,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:09.643936,True,,,,,Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375,,['HIV Infections'],"['Lopinavir', 'OspA Protein', 'HIV-1', 'HIV Protease Inhibitors', 'CD4 Lymphocyte Count', 'Ritonavir', 'Haemophilus Vaccines', 'HAART', 'Pneumococcal Vaccines', 'tenofovir disoproxil']",,,2006-06,[],[],0.0,,,ALL,False,NIH,0.0,22.0,,v2_robust,True,True,False,False,
NCT05815186,Ladarixin With Sotorasib in Advanced NSCLC - Phase II,Sotorasib,"['Sotorasib', 'Ladarixin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,NYU Langone Health,2025-09-01T16:18:09.643993,True,,,,,Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),,['Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation'],[],Study record has been combined with NCT05815173 (Phase I/II study).,2024-04,2026-04,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is the amount of time (months) from initial treatment to disease progression or death from any cause.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}]","[{'measure': 'Percent of Participants who Experience Grade 5 Treatment-Related Adverse Events per CTCAE 5.0', 'description': 'Number of participants whose most severe treatment-related adverse event was rated Grade 5 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, where Grade 5 = death related to adverse event.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Grade 4 Treatment-Related Adverse Events per CTCAE 5.0', 'description': 'Number of participants whose most severe adverse event related to treatment was rated Grade 4 according to CTCAE version 5.0, where Grade 4 = life-threatening consequences; urgent intervention indicated.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Grade 3 Treatment-Related Adverse Events per CTCAE 5.0', 'description': 'Number of participants whose most severe treatment-related adverse event was rated Grade 3 according to CTCAE version 5.0, where Grade 3 = Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living (ADL).', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Grade 2 Treatment-Related Adverse Events per CTCAE 5.0', 'description': 'Number of participants whose most severe treatment-related adverse event was rated Grade 2 according to CTCAE version 5.0, where Grade 2 = Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Grade 1 Treatment-Related Adverse Events per CTCAE 5.0', 'description': 'Number of participants whose most severe treatment-related adverse event was rated Grade 1 according to CTCAE version 5.0, where Grade 1 = Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Complete Response (CR)', 'description': 'Percent of participants whose best response is a CR according to RECIST 1.1, where CR = disappearance of all target lesions.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Partial Response (PR)', 'description': 'Percent of participants who best response is a PR according to RECIST 1.1, where PR = at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Unconfirmed Complete Response (UCR)', 'description': 'Percent of participants who best response is a CR according to RECIST 1.1, but the response has not been confirmed.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Percent of Participants who Experience Unconfirmed Partial Response (PR)', 'description': 'Percent of participants who best response is a PR according to RECIST 1.1, but the response has not been confirmed.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is the amount of time (months) from initial treatment to death due to any cause.', 'timeFrame': 'Up to End of Survival Follow-Up (Up to Month 36)'}]",11.0,18 Years,100 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Study record has been combined with NCT05815173 (Phase I/II study).
NCT01939886,Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2),Mefloquine - Artesunate,"['Artemether-lumefantrine combination', 'Mefloquine - Artesunate', 'Coartem', 'Artequin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Malaria,London School of Hygiene and Tropical Medicine,2025-09-01T16:18:09.644152,True,,,,,Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2),,['Malaria'],"['Malaria treatment efficacy', 'Malaria transmission']",,2013-04,2013-11,"[{'measure': 'the number of participants with clinical and parasitological treatment failure after treatment artemether-lumefantrine (AL) and mefloquine-artesunate MQ-AS', 'description': 'Parasite prevalence will be determined by microscopy and molecular methods on days 3-42 after intitiation of treatment. Clinical (fever+parasitological failure) and parasitological efficacy will be determined in relation to treatment arm and parasite clearance dynamics', 'timeFrame': '42 day follow-up'}]","[{'measure': 'the number of individuals with gametocytes after treatment with AL or MQ-AS', 'description': 'gametocyte carriage will be determined by microscopy and molecular QT-NASBA to generate gametocyte prevalence estimates on follow-up days and the mean duration of gametocyte carriage in days.', 'timeFrame': '42 days follow-up'}]",2.0,6 Months,10 Years,ALL,False,OTHER,3.0,219.0,ACTUAL,v2_robust,True,True,False,False,
NCT02721186,Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar,MDA with DHAp and SLD Primaquine,"['MDA with DHAp and SLD Primaquine', 'Mass drug administration with DHAp and SLD Primaquine', 'MDA with Dihydroartemisinin-Piperaquine and SLD Primaquine', 'MDA with D-ARTEPP and single low dose Primaquine']",4,INTERVENTIONAL,['NA'],,COMPLETED,Malaria,Ulrika Morris,2025-09-01T16:18:09.644167,True,,,,,Effectiveness of Mass Drug Administration (MDA) for Reducing Seasonal Malaria Transmission Towards Its Elimination in Hotspot Areas in Zanzibar - a Cluster-randomised Controlled Trial,,"['Malaria', 'Plasmodium Infections']","['Malaria', 'Plasmodium', 'Mass drug administration', 'Malaria elimination', 'Zanzibar', 'Dihydroartemisinin-Piperaquine', 'Single low dose Primaquine']",,2016-04-30,2017-09-30,"[{'measure': 'Cumulative notified malaria incidence in the MDA and control Shehias', 'description': 'Cumulative notified malaria incidence determined as the number of confirmed malaria cases notified at health facilities (monitored through the malaria case notification system during the period of six months) over the Shehia population size determined by population enumeration at the time of the intervention.', 'timeFrame': '6 months after second round of MDA'}]","[{'measure': 'PCR determined community prevalence of Plasmodium infections in the MDA and control Shehias', 'description': 'PCR determined community prevalence of Plasmodium infections determined by cross-sectional screening in every other household in the study area at the time of the first round of MDA, and at six months after the second round of MDA.', 'timeFrame': 'Baseline and 3 months after second round of MDA'}]",2.0,6 Months,,ALL,True,OTHER,6.0,22500.0,ACTUAL,v2_robust,True,True,False,False,
NCT03088670,Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.,Gosogliptin,"['Gosogliptin', 'Metformin', 'Vildagliptin']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Diabetes Mellitus, Type 2",SatRx LLC,2025-09-01T16:18:09.644269,True,,,,,Evaluate Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.,,"['Diabetes Mellitus, Type 2']",[],,2013-04-23,2014-10-03,"[{'measure': 'Mean change of HbA1c', 'description': 'Gosogliptin treatment group vs. Vildagliptin treatment group', 'timeFrame': 'at Weeks 12 and 36 from baseline'}]","[{'measure': 'HbA1c level of ≤7%', 'description': 'Percent of patients who reach the target HbA1c', 'timeFrame': 'at Weeks 12 and 36 from baseline'}, {'measure': 'Hypoglycemic episodes', 'description': 'Incidence of hypoglycemic episodes during the monotherapy and in combination with Metformin', 'timeFrame': 'up to 36 week'}, {'measure': 'Fasting plasma glucose', 'description': 'Change of fasting plasma glucose from baseline', 'timeFrame': 'at Weeks 12 and 36'}, {'measure': 'Change of Body Mass', 'description': 'Change of Body Mass from baseline', 'timeFrame': 'at Weeks 12 and 36'}, {'measure': 'Adverse event', 'description': 'AE rate', 'timeFrame': 'up to 40 week'}]",6.0,18 Years,78 Years,ALL,False,INDUSTRY,0.0,299.0,ACTUAL,v2_robust,True,True,False,True,
NCT04402970,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Dornase Alfa Inhalation Solution,"['Dornase Alfa Inhalation Solution', 'Pulmozyme']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,SARS-CoV 2,University of Missouri-Columbia,2025-09-01T16:18:09.644399,True,,,,,Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,,"['SARS-CoV 2', 'ARDS']",[],,2020-06-19,2020-12-31,"[{'measure': 'Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2)', 'description': 'Daily evaluation of PaO2/FiO2 ratio at baseline prior to starting therapy and on days 1,2,3,4,5 and 14 if applicable', 'timeFrame': '14 days'}]","[{'measure': 'Change in Static Lung Compliance', 'description': 'Daily evaluation of static lung compliance, measured by change in driving pressure over volume delivered, at baseline prior to starting therapy and on days 1,2,3,4,5 and 14 if applicable', 'timeFrame': '14 days'}, {'measure': 'Duration of Mechanical Ventilation', 'description': 'Number of days on mechanical ventilation', 'timeFrame': 'From start of mechanical ventilation until extubation or date of death from any cause, whichever came first, assessed up to 6 months'}, {'measure': 'Length of ICU Stay', 'description': 'Number of days in the medical intensive care unit', 'timeFrame': 'From date of first admission to intensive care unit until discharge/transfer out of the ICU or date of death from any cause, whichever came first, assessed up to 6 months'}, {'measure': 'Length of Hospitalization', 'description': 'Number of days as an inpatient at the University of Missouri', 'timeFrame': 'From date of hospital admission until discharge from acute care hospital or date of death from any cause, whichever came first, assessed up to 6 months'}, {'measure': 'Secondary Bacterial Infections', 'description': 'Determination of secondary bacterial infections based upon positive culture results and clinical diagnosis by treating physician.', 'timeFrame': 'From date of randomization until first positive culture or clinical diagnosis of infection if occurs, assessed up to 3 months'}, {'measure': 'Mortality', 'description': 'All cause mortality', 'timeFrame': '28 and 90 day evaluation'}]",7.0,18 Years,,ALL,False,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,
NCT00359970,"Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea",Azithromycin 500 mg,"['Zithromax, Zmax', 'Azithromycin 500 mg', 'Azithromycin 1000 mg', 'Loperamide', 'IModium, Loperamide HCl']",5,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Diarrhea,"The University of Texas Health Science Center, Houston",2025-09-01T16:18:09.644432,True,,,,,Loperamide Plus Azithromycin More Effectively Treats Travelers' Diarrhea In Mexico Than Azithromycin Alone,,['Diarrhea'],"['Diarrhea', 'Travel', ""Travelers' diarrhea"", 'Azithromycin', 'Loperamide', 'Treatment', 'Antibiotic']",,2002-06,2003-08,"[{'measure': 'Hours from beginning treatment to passage of last unformed stool', 'timeFrame': 'subjects recorded the time and form of all stools passed during a 4 day observation period'}]","[{'measure': 'Number of unformed stools passed per 24 hour period', 'timeFrame': '24 hours after treatment'}, {'measure': 'Number of subjects with symptoms of enteric disease per 24 hour period', 'description': 'Symptoms of enteric disease include nausea, vomiting, abdominal cramps, gas, urgency, and tenesmus.', 'timeFrame': '24 hours after treatment'}, {'measure': 'Number of treatment failures', 'description': 'Treatment failure is defined as persisting ill after 72 hours', 'timeFrame': '72 hours after treatment'}, {'measure': 'Percent of subjects in whom enteropathogen isolated from an enrollment stool sample was eradicated from a day 5 stool', 'timeFrame': '5 days after treatment'}, {'measure': 'Percent of subjects continuing to pass 3 or more (enrollment criteria) unformed stools in a 24 hour period', 'timeFrame': '24 hours after treatment'}]",6.0,18 Years,,ALL,False,OTHER,0.0,176.0,ACTUAL,v2_robust,True,True,False,False,
NCT03076970,Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants,lasmiditan 200 mg,"['matching placebo', 'Sumatriptan', 'LY573144', 'lasmiditan 200 mg']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Migraine,Eli Lilly and Company,2025-09-01T16:18:09.644537,True,,,,,"A Randomized, Double-Blind, Three Period, Cross-Over Study to Evaluate the Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan (Imitrex) in Healthy Male and Female Subjects",,['Migraine'],[],,2017-03-21,2017-04-13,"[{'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Systolic Blood Pressure', 'description': 'Vital signs were measured in semi-supine position after 5 minutes rest. Serial vital signs assessed when lasmiditan is administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Diastolic Blood Pressure', 'description': 'Vital signs were measured in semi-supine position after 5 minutes rest. Serial vital signs assessed when lasmiditan is administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Pulse Rate', 'description': 'Vital signs were measured in semi-supine position after 5 minutes rest. Serial vital signs assessed when lasmiditan is administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Temperature', 'description': 'Vital signs were measured in semi-supine position after 5 minutes rest. Serial vital signs assessed when lasmiditan is administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Respiratory Rate', 'description': 'Vital signs were measured in semi-supine position after 5 minutes rest. Serial vital signs assessed when lasmiditan is administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Heart Rate', 'description': 'A standard, digital 12-lead ECG with a 10-second rhythm strip was used to assess cardiac function after participants have been at least 5 minutes supine. Serial ECGs collected when lasmiditan administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) PR Duration', 'description': 'A standard, digital 12-lead ECG with a 10-second rhythm strip was used to assess cardiac function after participants have been at least 5 minutes supine. Serial ECGs collected when lasmiditan administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QRS Duration', 'description': 'A standard, digital 12-lead ECG with a 10-second rhythm strip was used to assess cardiac function after participants have been at least 5 minutes supine. Serial ECGs collected when lasmiditan administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': ""Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcB - Bazett's Correction Formula"", 'description': 'A standard, digital 12-lead ECG with a 10-second rhythm strip was used to assess cardiac function after participants have been at least 5 minutes supine. Serial ECGs collected when lasmiditan administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': ""Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcF - Fridericia's Correction Formula"", 'description': 'A standard, digital 12-lead ECG with a 10-second rhythm strip was used to assess cardiac function after participants have been at least 5 minutes supine. Serial ECGs collected when lasmiditan administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QT Duration', 'description': 'A standard, digital 12-lead ECG with a 10-second rhythm strip was used to assess cardiac function after participants have been at least 5 minutes supine. Serial ECGs collected when lasmiditan administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) RR Duration', 'description': 'A standard, digital 12-lead ECG with a 10-second rhythm strip was used to assess cardiac function after participants have been at least 5 minutes supine. Serial ECGs collected when lasmiditan administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.', 'timeFrame': 'Pre-dose, 24 hours post-dose'}, {'measure': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'Safety assessed from time of consent through end of study. A summary of all reported serious adverse events (SAE) and other adverse events regardless of causality are provided in the adverse events module of this record.', 'timeFrame': 'Up to 6 weeks'}]","[{'measure': 'Pharmacokinetics - Cmax', 'description': 'Maximum plasma concentration of lasmiditan alone compared to lasmiditan in combination with sumatriptan.', 'timeFrame': 'Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours following the dose at time 0 in each dosing period'}, {'measure': 'Pharmacokinetics - AUC0-t', 'description': 'Area under the plasma concentration versus time curve from time 0 to the time t of the last quantifiable concentration, calculated by means of the mixed log-linear trapezoidal rule of lasmiditan alone compare to lasmiditan in combination with sumatriptan.', 'timeFrame': 'Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours following the dose at time 0 in each dosing period'}, {'measure': 'Pharmacokinetics - Tmax', 'description': 'Time to maximum plasma concentration of lasmiditan alone compared to lasmiditan in combination with sumatriptan.', 'timeFrame': 'Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 and 30 hours following the dose at time 0 in each dosing period'}]",16.0,18 Years,60 Years,ALL,True,INDUSTRY,2.0,42.0,ACTUAL,v2_robust,True,True,False,True,
NCT01424670,Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis,Delamanid + OBR,"['Delamanid + OBR', 'Placebo + OBR']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Multidrug-resistant Tuberculosis,"Otsuka Pharmaceutical Development & Commercialization, Inc.",2025-09-01T16:18:09.644576,True,,,,,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis",,['Multidrug-resistant Tuberculosis'],['Multidrug-resistant tuberculosis'],,2011-09-02,2016-07-04,"[{'measure': 'Time To Sputum Culture Conversion (SCC) During 6-Month Intensive Period Using The Mycobacteria Growth Indicator Tube (MGIT) System', 'description': 'SCC at 6 months was determined by the observation of a sputum specimen negative for growth of mycobacterium tuberculosis (MTB) using the MGIT culture system, followed by at least 1 confirmatory negative sputum culture at least 25 days after the first negative and not followed by a confirmed positive (defined as at least 2 observed positive results, not taking into account indeterminate, missing, or contaminated results). 2 specimens were collected at each visit and an algorithm in the statistical analysis plan (SAP) was used to define a single representative result. Time to SCC was then defined as the interval between the date of first dose of IMP and the date of first of 2 consecutive negative single representative time points that were at least 25 days apart. The median time in days to SCC up to Month 6 is presented.', 'timeFrame': 'Month 6'}]","[{'measure': 'Proportion of Participants With SCC At 2 And 6 Months Using MGIT', 'description': 'SCC was evaluated at 2 and 6 months (6-month Intensive Period) using MGIT. SCC at 2 months was defined to occur at the date of collection of the first sputum specimen with mycobacterial culture negative for growth of MTB using MGIT culture, followed by at least 1 confirmatory negative MGIT culture result at least 25 days after the first negative specimen and not followed by any sputum specimens positive for growth in the MGIT culture at any point up to 3 months (Week 12).\n\nSCC at 6 months was determined by the observation of a sputum specimen negative for growth of MTB using the MGIT culture system, followed by at least 1 confirmatory negative sputum culture at least 25 days after the first negative and not followed by a confirmed positive (defined as at least 2 observed positive results, not taking into account indeterminate, missing, or contaminated results). 2 specimens were collected at each visit and an algorithm in the SAP was used to define a single representative result.', 'timeFrame': 'Month 2 and Month 6'}, {'measure': 'Proportion of Participants With Sustained SCC At Month 18, Month 24, And Month 30 Using MGIT', 'description': 'Sustained SCC was defined as SCC achieved by Month 6 and not followed by a confirmed positive thereafter, where confirmed positive was defined as 2 or more observed positive single representative culture results, not taking into account indeterminate, missing, or contaminated results. Sustained SCC was analyzed at Month 18 to 30 using MGIT.', 'timeFrame': 'Month 18, Month 24, and Month 30'}, {'measure': 'Treatment Outcomes Assessed By Principal Investigators (PI)At The End Of Treatment With OBR', 'description': 'Final treatment outcomes were assessed by the Principal Investigator (PI) at the end of treatment with OBR (24 months post randomization) according to the 2008 World Health Organization (WHO) outcome definitions for treating participants with multidrug-resistant tuberculosis (MDR TB). Frequency counts and percentage of participants achieving favorable and unfavorable outcomes were provided by treatment group. Participants who had non-missing Principal Investigator assessed treatment outcomes at the end of treatment with OBR were included in the analysis.', 'timeFrame': 'Month 24'}, {'measure': 'Number of Participants Who Developed Resistance To Delamanid', 'description': 'Acquired resistance was defined as a post-baseline resistant result at any time point after a Baseline susceptible result. The overall resistance to delamanid during the trial was assessed.', 'timeFrame': 'Up to Month 30'}, {'measure': 'Mean (Time Averaged) Area Under The Curve (AUC) Of Change From Baseline In Time To Detection (TTD) To Month 6 Using MGIT', 'description': 'The value for TTD was defined (in days) as the time interval from inoculation until a MGIT machine detects a positive signal for a sputum culture. The AUC of the change from Baseline for TTD in days (from Baseline to Month 6) summarizes the overall participant response for the treatment period. The change from Baseline in original time to detection of MGIT positive signal, in days, up to 6 months was performed using AUC in MGIT. The Baseline was defined as the average of Day -1 and Day 1 values if cultures on both days were positive; if only 1 culture was positive, the value for TTD for the positive culture was used as the Baseline.\n\nThe TTD is Time to Detection measured by day, so the unit of AUC of change from baseline in TTD is day\\*day. Since ""Mean AUC"" is reported, which is actually ""Time Averaged AUC,"" the AUC was divided by the duration of the observation, and thus the unit of the Mean AUC is day.', 'timeFrame': 'Baseline, up to Month 6'}, {'measure': 'Mean Change From Baseline In TTD Using The MGIT System', 'description': 'The value for TTD was defined (in days) as the time interval from inoculation until a MGIT machine detects a positive signal for a sputum culture during the routine 42-day incubation period. TTD analysis was based only on the corresponding qualitative sputum results of pure positive and pure negative cultures in days and hours of the initial positive signal for a culture from the MGIT printout. Mean change is reported for Baseline, Week 1, Week 2, Week 3, Week 24, Week 26, and Last visit (Month 18 or last visit for participants treated beyond Month 18).', 'timeFrame': 'Baseline, Week 1, Week 2, Week 3, Week 24, Week 26, and Last visit (Month 18 or last visit for participants treated beyond Month 18)'}, {'measure': 'Proportion of Participants With Final Outcome At Month 30 As A Treatment Success Or Failure (Including Relapse) Using MGIT', 'description': 'Treatment success was defined as achieving SCC by 6 months using MGIT, completing the trial out to 30 months with sustained SCC and alive at the last contact for follow-up. All other participants were treatment failures who failed to achieve SCC by Month 6, achieved SCC but have a confirmed positive, early terminate from the trial prior to the Month 30 visit but are alive at the last contact for follow-up, lost to follow-up and vital status unknown and death.', 'timeFrame': 'Month 30'}]",8.0,18 Years,69 Years,ALL,False,INDUSTRY,0.0,511.0,ACTUAL,v2_robust,True,True,False,False,
NCT02017873,Longevity and Effectiveness of Bleaching in Healthy and Smokers Patients,Peroxide Carbamide 10% - Dental bleaching treatment,"['Peroxide Carbamide 10% - Dental bleaching treatment', 'FGM Peroxide Carbamide ( Joinville , Brazil )']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Dentin Sensitivity,University of Chile,2025-09-01T16:18:09.644679,True,,,,,"""Evaluation of the Effectiveness and Longevity Post Whitening Carbamide Peroxide 10% in Smokers and Nonsmokers. Double-blind Multicenter Clinical Trial. """,,['Dentin Sensitivity'],"['bleaching', 'smokers', 'effectiveness', 'pain']",,2013-12,2014-01,"[{'measure': 'Color', 'description': 'Objective ( Vita Easy shade ), Subjective measurement', 'timeFrame': '1, 2, 3, 4, 8 weeks and 3, 6, 9 and 12 month'}]","[{'measure': 'Sensitivity', 'description': 'VAS Scale 0-4 Pain Scale', 'timeFrame': '1, 2, 3, 4, 8 weeks 3, 6, 9,12 month'}]",2.0,18 Years,,ALL,True,OTHER,0.0,120.0,ACTUAL,v2_robust,True,True,False,False,
NCT00788073,"Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome",STX209,"['STX209', 'arbaclofen', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Fragile X Syndrome,"Seaside Therapeutics, Inc.",2025-09-01T16:18:09.644824,True,,,,,"A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome",,['Fragile X Syndrome'],"['fragile X syndrome', 'irritability', 'behavior problems']",,2008-11,2010-05,"[{'measure': 'Aberrant Behavior Checklist Irritability Subscore', 'description': 'The Aberrant Behavior Checklist-Community Edition (ABC-C) is a 58-item questionnaire composed of five different independent subscales. The questionnaire is completed by the parent/caregiver and lists aberrant behaviors and asks about the severity of the problem. ABC-Irritability is one of the subscales and comprises of 15 items. Minimum score is 0, maximum is 45. A decreased score indicates few aberrant behaviors and clinical improvement. The entire ABC-C assessment is administered at baseline and then at the end of each Intervention Period (4 weeks after Baseline).', 'timeFrame': 'After 4 weeks of treatment'}]",[],1.0,6 Years,40 Years,ALL,False,INDUSTRY,0.0,63.0,ACTUAL,v2_robust,True,True,False,False,
NCT00719173,Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer,aprepitant,"['aprepitant', 'cyclophosphamide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Breast Cancer,UNC Lineberger Comprehensive Cancer Center,2025-09-01T16:18:09.644846,True,,,,,Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics,,"['Breast Cancer', 'Nausea and Vomiting']","['nausea and vomiting', 'breast cancer']",,2005-08,2010-10,"[{'measure': 'Effect of aprepitant on cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics as measured by plasma AUC', 'description': 'Cyclophosphamide, 4-OH cyclophosphamide, and DCE PK with and without aprepitant', 'timeFrame': '05/2005 to 10/2010'}]",[],1.0,18 Years,120 Years,ALL,False,OTHER,1.0,19.0,ACTUAL,v2_robust,True,True,False,False,
NCT00603473,A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures,gabapentin,['gabapentin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Epilepsies, Partial",Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,2025-09-01T16:18:09.644855,True,,,,,"An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects",,"['Epilepsies, Partial']",[],,2008-01,2009-12,"[{'measure': 'Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures', 'description': 'The Response Ratio calculated by the following equation was assessed as the primary endpoint: R Ratio = (T-B) / (T+B) where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.', 'timeFrame': '12 weeks'}]","[{'measure': 'Responder Rate', 'description': 'Responder Rate was defined as the percentage of subjects with a 50% or greater reduction in the seizure frequency per 28 days for the 12-week treatment period in comparison with the frequency per 28 days for the 6-week baseline period.', 'timeFrame': '12 weeks'}, {'measure': 'Percent Change in Seizure Frequency (PCH)', 'description': 'PCH calculated by the following equation was assessed as secondary endpoint: PCH = 100 (T-B) / B where T is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 12-week treatment period, and B is seizure frequency per 28 days (i.e., the number of seizures per 28 days) calculated from the total number of seizures for the 6-week baseline period.', 'timeFrame': '12 weeks'}]",3.0,3 Years,15 Years,ALL,False,INDUSTRY,0.0,92.0,ACTUAL,v2_robust,True,True,False,False,
NCT00240773,A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee,acetaminophen,"['naproxen', 'acetaminophen']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Osteoarthritis, Hip",Johnson & Johnson Consumer and Personal Products Worldwide,2025-09-01T16:18:10.909230,True,,,,,"A Randomized, Double-Blind, Long-Term Comparative Study Evaluating the Safety and Efficacy of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee",,"['Osteoarthritis, Hip', 'Osteoarthritis, Knee']","['osteoarthritis hip', 'osteoarthritis knee', 'acetaminophen, naproxen']",,,2003-06,[{'measure': 'Change from baseline in the WOMAC Osteoarthritis Index pain subscale score at Month 6 or at the final visit at the time of subject discontinuation from baseline during the first six months after baseline.'}],[{'measure': 'Change from baseline to Month 6 (or Month 12 for subjects participating in Group 1) or final visit in the WOMAC Osteoarthritis Index stiffness and physical function subscale scores.'}],2.0,40 Years,75 Years,ALL,False,INDUSTRY,1.0,581.0,ACTUAL,v2_robust,True,True,False,False,
NCT04476173,ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction,Methoxyflurane - Penthrox,"['Methoxyflurane - Penthrox', 'Morphine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,ST Elevation Myocardial Infarction,Collegium Medicum w Bydgoszczy,2025-09-01T16:18:10.909243,True,,,,,ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction,,"['ST Elevation Myocardial Infarction', 'Non ST Segment Elevation Acute Coronary Syndrome']",[],,2020-06-01,2024-12-30,"[{'measure': 'Measure of pain intensity according to the Numeric Pain Rating Scale (NPRS) 2-3 minutes after drug administration in relation to pain intensity assessed before drug administration', 'description': 'NPRS score before and 2-3 minutes after drug administration in each study arm', 'timeFrame': '2-3 mins'}, {'measure': 'Measure of pain intensity according to the Numeric Pain Rating Scale (NPRS) immediately after PCI in relation to pain intensity assessed before drug administration', 'description': 'NPRS score before drug administration and and immediately after PCI in each study arm', 'timeFrame': 'immediately after PCI'}]","[{'measure': 'Adverse effects of evaluated therapies', 'description': 'nausea, vomiting, dry mouth, respiratory failure - need for intubation, headache, dizziness, drowsiness, loss of consciousness, death', 'timeFrame': '24 hours'}, {'measure': 'Need for GPIIb/IIIa (glycoprotein IIb/IIIa) inhibitor administration during PCI due to large intracoronary thrombus', 'description': 'The percentage of patients who required GP IIb/IIIa administration in each study arm', 'timeFrame': '24 hours'}, {'measure': 'Angiographic effect of PCI using Thrombolysis In Myocardial Infarction (TIMI) scale', 'description': 'central analysis of coronary angiography after PCI according to Thrombolysis In Myocardial Infarction (TIMI) scale (TIMI 0 to TIMI 3; where TIMI 0 corresponds with no antegrade flow beyond the point of occlusion whereas TIMI 3 - normal flow with complete filling of the distal territory)', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Angiographic effect of PCI using TIMI Myocardial Perfusion Grade (TMPG) scale', 'description': 'central analysis of coronary angiography after PCI according to TIMI Myocardial Perfusion Grade (TMPG) scale (TMPG 0 to TMPG 3, where TMPG 0 corresponds with failure of dye to enter the microvasculature, indicating a lack of tissue level perfusion whereas TMPG 3 - normal entry and exit of dye from the microvasculature)', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'ST elevation resolution in STEMI patients after PCI', 'description': 'central analysis of ST elevation reduction in STEMI patients with a 70% resolution cut-off', 'timeFrame': '1 hour after PCI'}]",7.0,18 Years,80 Years,ALL,False,OTHER,0.0,200.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00845273,Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration,Pegaptanib sodium,"['Macugen', 'Pegaptanib sodium']",2,OBSERVATIONAL,[],,COMPLETED,Macular Degeneration,Pfizer,2025-09-01T16:18:10.909334,True,,,,,Special Investigation For Long-term Use Of Macugen (Regulatory Post Marketing Commitment Plan).,,['Macular Degeneration'],['Subfoveal choroidal neovascularization secondary to age-related macular degeneration'],,2008-11,2014-02,"[{'measure': 'Factors considered to affect the safety and/or efficacy of this drug.', 'timeFrame': '2 years'}, {'measure': 'The incidence of adverse drug reactions in this surveillance.', 'timeFrame': '2 years'}, {'measure': 'Adverse drug reaction not expected from the LPD (unknown adverse drug reaction).', 'timeFrame': '2 years'}]",[],3.0,,,ALL,False,INDUSTRY,0.0,3538.0,ACTUAL,v2_robust,False,True,False,True,
NCT00170573,Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer,Caelyx,['Caelyx'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Ovarian Cancer,North Eastern German Society of Gynaecological Oncology,2025-09-01T16:18:10.909344,True,,,,,"Comparison of Quality of Life in Patients With Platinum-sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer When Treated With Treatment With Trabectedin/PLD or Standard Platinum-based Therapy",,['Ovarian Cancer'],"['Pegylated liposomal doxorubicin', 'PPE', 'Ovarian Cancer']",,2001-09,2010-08,"[{'measure': 'Occurrence of Palmar-plantar Erythrodysesthesia (PPE)', 'description': 'The outcome will be measured by number of participants with reported skin toxicity PPE of CTC (Common Toxicity Criteria)-Grade I / II / III / IV.\n\nGrade I - Dysesthesia/paraesthesia tingling of hands and feet; Grade II - Discomfort in holding objects and upon walking, painless swelling and erythema; Grade III - painful erythema and swelling of palms and soles, periungual erythema and swelling; Grade IV - Desquamation, ulceration, blistering, severe pain', 'timeFrame': 'through study completion, an average of 18 months'}]","[{'measure': 'Overall Survival', 'description': 'Overall survival estimated by the Kaplan-Meier method', 'timeFrame': 'for up to 3 years'}]",2.0,18 Years,,FEMALE,False,OTHER,0.0,77.0,ACTUAL,v2_robust,True,True,False,False,
NCT02858973,"A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers",Q203,"['Q203', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,"Qurient Co., Ltd.",2025-09-01T16:18:10.909362,True,,,,,"A Phase 1B, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Q203 When Administered Orally to Healthy Adult Subjects",,['Healthy Volunteers'],[],,2016-08,2018-05-08,"[{'measure': 'Safety assessment through adverse event, vital signs, ECG, laboratory results, and telemetry monitoring', 'timeFrame': '16 days post dose'}]","[{'measure': 'Pharmacokinetic analysis: Area under the curve', 'timeFrame': '16 days post dose'}, {'measure': 'Pharmacokinetic analysis: Maximum observed plasma drug concentration', 'timeFrame': '16 days post dose'}, {'measure': 'Pharmacokinetic analysis: Time of maximum observed concentration', 'timeFrame': '16 days post dose'}]",4.0,19 Years,55 Years,ALL,True,INDUSTRY,0.0,47.0,ACTUAL,v2_robust,True,True,False,True,
NCT04556773,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,Trastuzumab deruxtecan,"['Paclitaxel', 'Anastrozol', 'Taxol A', 'MEDI4736', 'DS-8201a, T-DXd', 'Fulvestrant', 'Capecitabine', 'AZD5363', 'Capivasertib', 'Anastrozole', 'Trastuzumab deruxtecan', 'Durvalumab']",12,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,AstraZeneca,2025-09-01T16:18:10.909375,True,,,,,"A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)",,['Metastatic Breast Cancer'],"['Breast Cancer', 'HER2-negative', 'HER2-low', 'Trastuzumab Deruxtecan', 'T-DXd', 'DS-8201a', 'DESTINY-Breast08', 'Anti-HER2 Antibody Drug Conjugate (ADC)', 'Triple-negative breast cancer (TNBC)']",,2020-12-17,2025-12-04,"[{'measure': 'Occurrence of adverse events (AEs)- Part 1', 'description': 'Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Occurrence of serious adverse events (SAEs)- Part 1', 'description': 'Occurrence of SAEs in Part 1 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Occurrence of adverse events (AEs)- Part 2', 'description': 'Occurrence of AEs in Part 2 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Occurrence of serious adverse events (SAEs)- Part 2', 'description': 'Occurrence of SAEs in Part 2 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}]","[{'measure': 'Objective Response Rate (ORR)- Part 2', 'description': 'ORR defined as the proportion of patients who have a confirmed CR or PR, as determined by the investigator at local site per RECIST 1.1', 'timeFrame': 'Until progression, assessed up to approximately 24 months'}, {'measure': 'Progression Free Survival (PFS)- Part 2', 'description': 'PFS defined as time from the date of first dose until the date of progression as determined by the investigator at local site per RECIST 1.1, or death due to any cause', 'timeFrame': 'Until progression or death, assessed up to approximately 24 months'}, {'measure': 'Duration of Response (DoR)- Part 2', 'description': 'DoR defined as time from the date of first documented response (which is subsequently confirmed) until the date of documented progression or death in the absence of disease progression', 'timeFrame': 'Until progression or death, assessed up to approximately 24 months'}, {'measure': 'Overall Survival (OS)- Part 2', 'description': 'OS defined as time from the date of first dose until the date of death by any cause', 'timeFrame': 'Until death, assessed up to approximately 24 months'}, {'measure': 'Serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a', 'description': 'Determination of trastuzumab deruxtecan concentration in serum at different time points after trastuzumab deruxtecan administration', 'timeFrame': 'While on study drug up to study completion, approximately 24 months'}, {'measure': 'Immunogenicity of trastuzumab deruxtecan', 'description': 'Percentage of patients who develop ADA for trastuzumab deruxtecan', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Serum Concentration of durvalumab', 'description': 'Determination of durvalumab concentration in serum at different time points after administration', 'timeFrame': 'While on study drug up to study completion, approximately 24 months'}, {'measure': 'Immunogenicity of durvalumab', 'description': 'Percentage of patients who develop ADAs for durvalumab', 'timeFrame': 'Up to follow-up period, approximately 24 months'}]",12.0,18 Years,,ALL,False,INDUSTRY,2.0,138.0,ACTUAL,v2_robust,True,False,False,True,
NCT05556473,F-Tryptophan PET/CT in Human Cancers,1-(2-[18F]FLUOROETHYL)-L-Tryptophan,"['1-(2-[18F]FLUOROETHYL)-L-Tryptophan', '[18F]FETrp PET radiotracer']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Intracranial Glioma,Barbara Ann Karmanos Cancer Institute,2025-09-01T16:18:10.909498,True,,,,,A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging in Human Cancers,,"['Intracranial Glioma', 'Metastatic Brain Tumor', 'Breast Cancer', 'Neuroendocrine Tumors', 'Rectal Cancer']",[],,2022-09-29,2026-12-31,"[{'measure': 'The percent difference in tracer uptake values between the tumor mass and the background (non-tumor tissue)', 'description': 'The percent difference in 1-(2-\\[18F\\]fluoroethyl)-L-tryptophan tracer standardized uptake values, measured between tumor and non-tumor (normal) tissues by PET/CT imaging, in each subject, will be calculated. Mean and standard deviation of the percent differences will be calculated for each tumor type.', 'timeFrame': 'During procedure (from right after tracer injection to 1-hour post-injection)'}, {'measure': 'Correlation between the 1-(2-[18F]fluoroethyl)-L-tryptophan tracer uptake values and the tracer transport rates measured in the same breast tumor tissue.', 'description': 'The 1-(2-\\[18F\\]fluoroethyl)-L-tryptophan tracer standardized uptake values and the volume of distribution (characterizing the tracer transport rates) will be measured by PET/CT imaging in the same breast tumor tissues, and the correlation of these two measures will be calculated.', 'timeFrame': 'During procedure (from right after tracer injection to 1-hour post-injection)'}]","[{'measure': 'Radiation doses to the various organs.', 'description': 'Radiation doses received by the various organs (heart, lungs, pancreas, gallbladder, liver, small intestines, kidneys, muscle, bladder, ovaries/testes) will be measured from the dynamic 1-(2-\\[18F\\]fluoroethyl)-L-tryptophan PET/CT images. Mean and standard deviation of the radiation doses will be calculated for each organ.', 'timeFrame': 'During procedure (from right after tracer injection to 1-hour post-injection)'}, {'measure': 'Overall radiation dose to the study participants.', 'description': 'Overall radiation dose received by the study participants from the PET/CT scan will be calculated from the dynamic 1-(2-\\[18F\\]fluoroethyl)-L-tryptophan PET/CT images. Mean and standard deviation of the overall radiation dose will be calculated.', 'timeFrame': 'During procedure (from right after tracer injection to 1-hour post-injection)'}]",4.0,18 Years,,ALL,False,OTHER,1.0,24.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00136773,Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus,amlodipine/benazepril,['amlodipine/benazepril'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Albuminuria,Novartis,2025-09-01T16:18:10.909533,True,,,,,Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus,,['Albuminuria'],"['Albuminuria', 'Type 2 diabetes mellitus', 'Hypertension']",,2003-04,2005-11,[{'measure': 'Change from baseline in the urine albumin/creatinine ratio after 52 weeks'}],"[{'measure': 'Percentage of patients who have progressed to diabetic kidney disease (urine albumin/creatinine ratio ≥ 300 µg/mg creatinine) after 52 weeks'}, {'measure': 'Change from baseline in the ratio of urine albumin/creatinine ratio an estimate of kidney function after 52 weeks'}, {'measure': 'Change from baseline in insulin resistance after 52 weeks'}, {'measure': 'Change from baseline in urine albumin secretion after 52 weeks'}, {'measure': 'Change from baseline in a marker of heart failure after 52 weeks'}]",6.0,21 Years,85 Years,ALL,,INDUSTRY,0.0,332.0,ACTUAL,v2_robust,True,True,False,False,
NCT00986973,Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy,Sapropterin,"['KUVAN', 'Sapropterin', 'BH4']",3,INTERVENTIONAL,['NA'],,COMPLETED,Phenylketonuria,Children's Hospital of Philadelphia,2025-09-01T16:18:10.909568,True,,,,,A Pilot Study of FDG PET Findings in Patients With Phenylketonuria Before and After BH4 Supplementation,,['Phenylketonuria'],"['PKU', 'BH4', 'KUVAN', 'PET scan', 'Neurodevelopment']",,2010-03,2011-09,"[{'measure': 'Plasma Phenylalanine Level (mg/dl)', 'description': 'Plasma phenylalanine level (mg/dl) served as the primary means of evaluating brain glucose metabolism before and after sapropterin (KUVAN) therapy. Blood tests for phenylalanine levels (Phe) were collected before and 4 months after sapropterin (KUVAN) therapy. All subjects received KUVAN at a dose of 20/mg/kg/day for four months. The goal was to estimate the change in blood glucose metabolism after treatment with Sapropterin (if any), with the hypothesis that treatment would decrease plasma Phe levels.', 'timeFrame': 'Measurements were obtained at the beginning and conclusion of each study period (baseline and 4 months)'}]","[{'measure': 'Hopkins Verbal Learning Test (HVLT) Total Recall', 'description': 'The Hopkins Verbal Learning Test-Revised (HVLT) is a neuropsychological test designed to assess verbal memory. The test consists of 12 nouns (targets) with four words drawn from each of three semantic categories. Raw scores are derived for Total Recall (across three learning trials), Delayed Recall (after 20-25 minute delay), Retention (% retained), and a Recognition Discrimination Index (true positives minus false positives). The maximum total for each recall trial (Learning Trials 1 to 3, Delayed Recall Trial 4) is 12. Raw scores are converted to ""T-scores"" by means of age-based tables provided in test manual (T-scores can go from 0 - 100, with higher scores correlating with higher verbal memory function). Median HVLT Total Recall and HVLT Delayed Recall T-scores at baseline and 4 months after Sapropterin therapy were compared.', 'timeFrame': 'Measures were obtained at the beginning and conclusion of each study period (baseline and 4 months)'}, {'measure': 'Hopkins Verbal Learning Test (HVLT) Delayed Recall', 'description': 'The Hopkins Verbal Learning Test-Revised (HVLT) is a neuropsychological test designed to assess verbal memory. The test consists of 12 nouns (targets) with four words drawn from each of three semantic categories. Raw scores are derived for Total Recall (across three learning trials), Delayed Recall (after 20-25 minute delay), Retention (% retained), and a Recognition Discrimination Index (true positives minus false positives). The maximum total for each recall trial (Learning Trials 1 to 3, Delayed Recall Trial 4) is 12. Raw scores are converted to ""T-scores"" by means of age-based tables provided in test manual (T-scores can go from 0 - 100, with higher scores correlating with higher verbal memory function). Median HVLT Total Recall and HVLT Delayed Recall T-scores at baseline and 4 months after Sapropterin therapy were compared.', 'timeFrame': 'Measures were obtained at the beginning and conclusion of each study period (baseline and 4 months)'}, {'measure': 'Paced Auditory Serial Addition Task (PASAT)', 'description': 'The Adapted Paced Auditory Serial Addition Task (PASAT) is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. For Rates #1 and #2, single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. The score for PASAT is the total number of correct answers (out of 60, for a total possible score ranging from 0-60 with higher score preferred as it indicates higher auditory processing speed) for each trial. All scores are expressed as ""z-scores"" which are generated based on norms for 101 healthy adults, with separate norms for \\<12 years of education versus \\>12years of education. Using a reference population as a basis of comparison, the ""z-score"" is the number of standard deviations the score is above (positive) or below (negative) the mean of the reference population (zero). Possible z-scores lie on a continuous scale.', 'timeFrame': 'Measures were obtained at the beginning and conclusion of each study period (baseline and 4 months)'}, {'measure': 'Symbol-Digit Modalities Test (SMTD)', 'description': 'The symbol-digit modalities test (SDMT) was developed to identify individuals with neurological impairment. The SDMT requires individuals to identify nine different symbols corresponding to the numbers 1 through 9, and to practice writing the correct number under the corresponding symbol. Then they manually fill the blank space under each symbol with the corresponding number. A second oral administration is then completed. The participant is given a blank copy of the test and asked to state the correct number for each corresponding symbol. The participant is given 90 s to complete each of these administrations. A written and oral score is calculated by totaling the number of correct answers for each section. The score is the number of correctly coded items from 0-110 in 90 seconds, with a higher score representing less neurological impairment with respect to attention, scanning abilities and motor skills. The total raw score was used for purposes of this study.', 'timeFrame': 'Measures were obtained at the beginning and conclusion of each study period (baseline and 4 months)'}, {'measure': 'Wechsler Adult Intelligence Scale (WAIS-IV)-Digit Span', 'description': 'The Wechsler Adult Intelligence Scale (WAIS) is a test designed to measure intelligence in adults and older adolescents. It is composed of 10 core subtests and five supplemental subtests, with the 10 core subtests comprising the Full Scale intelligence quotient (IQ). Contained within the WAIS is an assessment of digit-coding which consists of nine digit-symbol pairs followed by a list of digits. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time (e.g. 90 or 120 sec) is measured, with a higher score representative of a higher performance component of IQ/intelligence.', 'timeFrame': 'Measures were obtained at the beginning and conclusion of each study period (baseline and 4 months)'}, {'measure': 'Delis-Kaplan Executive Function System Verbal Fluency Subtest (D-KEFS)', 'description': 'The Delis-Kaplan Executive Function System (D-KEFS) is a neuropsychological test is used to measure a variety of verbal and nonverbal executive functions for both children and adults. Among the 9 subtests is the Verbal Fluency Test which measures letter fluency, category fluency, and category switching. Verbal Fluency Test. This subtest requires an individual to randomly generate words based upon given parameters (ex., as words beginning with the letter F) and the believed areas of executive function assessed are cognitive flexibility, response inhibition, and verbal fluency. Raw scores are calculated based on the number of correct answers, which are then converted to scaled scores with a mean of 10 and standard deviation of 3. Higher scaled score represents a higher level of executive verbal and nonverbal function.', 'timeFrame': 'Measures were obtained at the beginning and conclusion of each study period (baseline and 4 months)'}]",7.0,18 Years,50 Years,ALL,False,OTHER,0.0,6.0,ACTUAL,v2_robust,True,True,False,False,
NCT04034173,Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation,Panitumumab,"['Panitumumab', '5-FU', 'Irinotecan', 'Folinic acid']",4,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Treatment Related Cancer,Ludwig-Maximilians - University of Munich,2025-09-01T16:18:10.909664,True,,,,,FIRE-5 -Study: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation,,['Treatment Related Cancer'],"['colorectal cancer', 'FIRE', 'low-RAS', 'mCRC', 'Panitumumab']",,2019-08-01,2026-08-01,"[{'measure': 'Overall Response Rate', 'description': 'As primary endpoint ORR according to RECIST 1.1 will be evaluated separately for each arm of patients with defined low-frequency RAS mutation', 'timeFrame': 'up to 60 months'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'PFS, separately for each arm of patients with defined low-frequency RAS mutation', 'timeFrame': 'up to 60 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS, separately for each arm of patients with defined low-frequency RAS mutation', 'timeFrame': 'up to 60 months'}, {'measure': 'Investigation of Early Tumor shrinkage (ETS) as an alternative early-on-treatment predictor of treatment efficacy', 'description': 'ETS, separately for each group of patients with defined low-frequency RAS mutation', 'timeFrame': 'up to 48 months'}, {'measure': 'Investigation of Depth of Response (DpR) to define the nadir of tumour response', 'description': 'DpR, separately for each arm of patients with defined low-frequency RAS Mutation.', 'timeFrame': 'up to 48 months'}]",5.0,18 Years,,ALL,False,OTHER,2.0,120.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04057573,Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2),Ruxolitinib cream,"['Ruxolitinib cream', 'Vehicle', 'INCB018424 cream']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Non-segmental Vitiligo,Incyte Corporation,2025-09-01T16:18:10.909684,True,,,,,"Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo",,['Non-segmental Vitiligo'],"['Vitiligo', 'non-segmental', 'JAK inhibitor']",,2019-10-03,2021-10-01,"[{'measure': 'Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24', 'description': ""An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \\[BSA\\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 24'}]","[{'measure': 'Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24', 'description': ""An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24', 'description': ""An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24', 'description': ""A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24', 'description': 'The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.', 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24', 'description': 'F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area ""Face"" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area ""Face"" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant\'s entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant\'s thumb was considered as 0.1% BSA. Percentage change = (\\[post-Baseline (BL) value minus BL value\\]/BL value) X 100.', 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.', 'timeFrame': 'from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 24)'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period', 'description': 'An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.', 'timeFrame': 'from the completion of the Week 24 assessments until at least 30 days after the last application of study drug (up to Week 52 + 30 days)'}, {'measure': 'Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24', 'description': ""An F-VASI25 responder achieved at least 25% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52', 'description': ""An F-VASI25/50/75/90 responder achieved at least 25/50/75/90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 52'}, {'measure': 'Percentage Change From Baseline in F-VASI at Week 24', 'description': ""F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\\[post-BL value minus BL value\\]/BL value) X 100."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage Change From Baseline in F-VASI at Week 52', 'description': ""F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\\[post-BL value minus BL value\\]/BL value) X 100."", 'timeFrame': 'Baseline; Week 52'}, {'measure': 'Percentage Change From Baseline in F-BSA at Week 52', 'description': 'F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area ""Face"" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area ""Face"" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant\'s entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant\'s thumb was considered as 0.1% BSA. Percentage change = (\\[post-BL value minus BL value\\]/BL value) X 100.', 'timeFrame': 'Baseline; Week 52'}, {'measure': 'Percentage Change From Baseline in T-VASI at Week 24', 'description': ""T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\\[post-BL value minus BL value\\]/BL value) X 100."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage Change From Baseline in T-VASI at Week 52', 'description': ""T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\\[post-BL value minus BL value\\]/BL value) X 100."", 'timeFrame': 'Baseline; Week 52'}, {'measure': 'Percentage Change From Baseline in T-BSA at Week 24', 'description': ""T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\\[post-BL value minus BL value\\]/BL value) X 100."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage Change From Baseline in T-BSA at Week 52', 'description': ""T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\\[post-BL value minus BL value\\]/BL value) X 100."", 'timeFrame': 'Baseline; Week 52'}, {'measure': 'Percentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24', 'description': ""A T-VASI25/75/90 responder achieved at least 25/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Percentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52', 'description': ""A T-VASI25/50/75/90 responder achieved ≥25/50/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement)."", 'timeFrame': 'Baseline; Week 52'}, {'measure': 'Percentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)', 'description': 'The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.', 'timeFrame': 'Baseline; Week 24 and Week 52'}, {'measure': 'Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24', 'description': 'The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, ""Prevented work or studying"" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.', 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Change From Baseline in DLQI at Week 52', 'description': 'The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, ""Prevented work or studying"" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.', 'timeFrame': 'Baseline; Week 52'}, {'measure': ""Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)"", 'description': 'The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI is the youth/children\'s version of the DLQI and was completed by adolescents aged ≥ 12 years to \\< 16 years. Each question is scored as: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. For Question 7: ""Prevented school"" = 3. The CDLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.', 'timeFrame': 'Baseline; Week 24 and Week 52'}, {'measure': 'Trough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40', 'description': 'Trough plasma concentration was defined as the measurement of the plasma concentration of ruxolitinib before drug application.', 'timeFrame': 'pre-dose at Weeks 4, 24, and 40'}]",24.0,12 Years,,ALL,False,INDUSTRY,0.0,344.0,ACTUAL,v2_robust,True,True,False,True,
NCT00725569,Homeopathy for Post-operative (C. Section) Recovery,Bellis perennis and Staphysagria (C6),"['Bellis perennis and Staphysagria (C30)', 'Bellis perennis and Staphysagria (C6)', 'Placebo']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Cesarean Section,Shaare Zedek Medical Center,2025-09-01T16:18:10.909811,True,,,,,"Effect of Homeopathic Drugs Bellis Perennis ו- Staphysagria on the Post-operative Recovery, of Women Undergoing Cesarean Section- (an Exploratory) Double Blind, Placebo Controlled Study",,['Cesarean Section'],"['Caesarian Section', 'Homeopathy', 'Pain', 'Analgesia']",,2008-08,2009-04,"[{'measure': 'pain, to be evaluated using a numerical rating score (NRS) on a 100mm scale (0= no pain whatsoever, 100 = unbearable pain).', 'timeFrame': '4 weeks'}]","[{'measure': 'Analgesic Use', 'timeFrame': '4 weeks'}, {'measure': 'Duration of Hospital Stay', 'timeFrame': '4 weeks'}, {'measure': 'Time from Surgery to First Bowel Movement', 'timeFrame': '4 days'}, {'measure': 'Blood Loss', 'timeFrame': '4 days'}, {'measure': 'Post-operative Complications the following complications will be noted: Nausea, vomiting, abdominal distension, fever, urinary tract infection, thrombophlebitis, wound infection, wound hematoma, ileus, vaginal bleeding.', 'timeFrame': '4 weeks'}, {'measure': 'Quality of Life Assessment', 'timeFrame': '4 weeks'}, {'measure': 'Adverse Effects of Treatment', 'timeFrame': '4 days'}]",8.0,18 Years,,FEMALE,True,OTHER,0.0,90.0,ESTIMATED,v2_robust,True,True,False,True,
NCT07090369,Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer,Olaparib (300 mg BID),"['Pembrolizumab', 'Olaparib (300 mg BID)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,NOT_YET_RECRUITING,Metastatic Castrate Resistant Prostate Cancer (mCRPC),"Peter MacCallum Cancer Centre, Australia",2025-09-01T16:18:10.909829,True,,,,,Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer,,['Metastatic Castrate Resistant Prostate Cancer (mCRPC)'],"['prostate cancer', 'olaparib', 'pembrolizumab', '177Lu-PSMA', 'metastatic castrate resistant prostate cancer', 'triplet therapy']",,2025-11-01,2028-12-01,"[{'measure': 'Progression Free Survival', 'description': 'To describe the radiological progression free survival (modified RECIST 1.1 and/or PCWG3 criteria) of the combination of 177Lu-PSMA-I\\&T, olaparib and pembrolizumab', 'timeFrame': '24 months from recruitment of last patient'}, {'measure': 'Safety of Combination Therapy', 'description': ""To evaluate the safety of 177Lu-PSMA-I\\&T in combination with olaparib and pembrolizumab. All adverse events (AE's) will be reported using CTCAE 5.0, with the severity (grade) and causality (relationship to investigational products) recorded for each participant."", 'timeFrame': '24 months from recruitment of last patient'}]","[{'measure': 'PSA50 response rate', 'description': 'To evaluate the PSA50 response rate', 'timeFrame': '24 months from recruitment of last patient'}, {'measure': 'PSA90 response rate', 'description': 'To evaluate the PSA90 response rate', 'timeFrame': '24 months from recruitment of last patient'}, {'measure': 'PSA progression free survival', 'description': 'To evaluate PSA progression free survival', 'timeFrame': '24 months from recruitment of last patient'}, {'measure': 'Overall Survival', 'description': 'To evaluate the overall survival', 'timeFrame': '24 months from recruitment of last patient'}, {'measure': 'Objective Response Rates', 'description': 'To evaluate objective response rates in patients with measurable disease by modified RECIST 1.1', 'timeFrame': '24 months from recruitment of last patient'}]",7.0,18 Years,,MALE,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05843669,A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis.,Guafenesin tablets,"['Mucinex®', 'Guafenesin tablets']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Bronchitis,American Health Research,2025-09-01T16:18:10.909842,True,,,,,"An Open-label, Multicenter, Single-group Study to Evaluate the Effects of Long-term Use of Mucinex® in Patients With Stable Chronic Bronchitis.",,['Chronic Bronchitis'],"['Stable chronic bronchitis', 'Real-world study', 'Mucinex', 'Guafenesin']",,2023-07-17,2024-11-13,"[{'measure': 'Describe patient-reported real-world clinical use of Mucinex® (i.e., prior to study start) in patients with SCB.', 'description': 'Patient-reported quantitative data via ""Prior usage of Mucinex®"" bespoke survey. This comprises three questions regarding patients\' previous use of Mucinex, the approximate timing of use, and the frequency of use.', 'timeFrame': 'At baseline (week 0).'}, {'measure': 'Describe change in patient-reported real-world clinical use of Mucinex® (i.e., treatment compliance) in patients with SCB.', 'description': 'Patient-reported quantitative data via ""Treatment compliance"" bespoke survey.', 'timeFrame': 'Every 1 week during 12 week period of receiving Mucinex® (week 2 to 14).'}, {'measure': 'Describe change in patient-reported real-world clinical use of Mucinex® (i.e., treatment satisfaction) in patients with SCB.', 'description': 'Patient-reported quantitative data via ""Treatment satisfaction"" bespoke survey.', 'timeFrame': 'Every 2 weeks during 12 week period of receiving Mucinex® (week 2 to 14).'}, {'measure': 'Describe change in patient-reported real-world clinical use of Mucinex® (i.e., symptoms) in patients with SCB.', 'description': 'Patient-reported quantitative data via ""Symptoms"" bespoke survey.', 'timeFrame': 'Every 1 week during 12 week period of receiving Mucinex® (week 2 to 14).'}, {'measure': 'Describe change in patient-reported real-world clinical use of Mucinex® (i.e., cough and sputum production and its impact) in patients with SCB.', 'description': 'Patient-reported quantitative data via the Cough and Sputum Assessment Questionnaire, CASA-Q (web- and app-based). This is a validated instrument to measure cough and sputum production, and their impact in patients with chronic obstructive pulmonary disease (COPD) and/or chronic bronchitis', 'timeFrame': 'Every 1 week during 12 week period of receiving Mucinex® (week 2 to 14).'}, {'measure': 'Describe change in HCP-reported real-world clinical use of Mucinex® (i.e., treatment-emergent adverse events) in patients with SCB.', 'description': 'HCP-reported quantitative data via electronic case report forms (""Treatment-emergent adverse events"" survey).', 'timeFrame': 'As many times as needed during 12 week period of receiving Mucinex® (week 2 to 14).'}, {'measure': 'Describe change in HCP-reported real-world clinical use of Mucinex® (i.e., treatment satisfaction) in patients with SCB.', 'description': 'HCP-reported quantitative data via electronic case report forms (""Treatment satisfaction"" survey).', 'timeFrame': 'At final visit (week 14).'}, {'measure': 'Describe change in HCP-reported real-world clinical use of Mucinex® (i.e., energy levels) in patients with SCB.', 'description': 'HCP-reported quantitative data via electronic case report forms (""Energy levels"" survey).', 'timeFrame': 'At week 8, and at final visit (week 14).'}, {'measure': 'Describe change in HCP-reported real-world clinical use of Mucinex® (i.e., healthcare resource use) in patients with SCB.', 'description': 'HCP-reported quantitative data via electronic case report forms (""Healthcare resource use"" survey).', 'timeFrame': 'At baseline visit (week 0), at week 8, and at final visit (week 14).'}]","[{'measure': 'Describe the rate of patient-reported chronic bronchitis ePRO improvements while on treatment with Mucinex® compared to patient history or baseline.', 'description': 'Patient-reported quantitative data via the Cough and Sputum Assessment Questionnaire, CASA-Q (web- and app-based).', 'timeFrame': 'At baseline (week 0), and every 1 week during 14 week study period.'}, {'measure': 'Describe the rate of concomitant rescue and/or maintenance inhaler use while on treatment with Mucinex® compared to patient history/baseline established as part of Medication Record Log completed by HCP in the eCRF at baseline visit.', 'description': 'HCP-reported quantitative data via electronic case report forms (""Treatment-emergent adverse events"" survey).', 'timeFrame': 'As many times as needed during 12 week period of receiving Mucinex® (week 2 to 14).'}, {'measure': 'Describe the HCP-reported rate of healthcare resource utilization while on treatment with Mucinex® compared to patient history or baseline.', 'description': 'HCP-reported quantitative data via electronic case report forms (""Healthcare resource use"" survey).', 'timeFrame': 'At baseline visit (week 0), at week 8, and at final visit (week 14).'}, {'measure': 'Assess HCP-reported treatment satisfaction of patients while on treatment with Mucinex®.', 'description': 'HCP-reported quantitative data via electronic case report forms (""Treatment satisfaction"" survey).', 'timeFrame': 'At final visit (week 14).'}, {'measure': 'Assess patient-reported treatment satisfaction while on treatment with Mucinex®.', 'description': 'Patient-reported quantitative data via ""Treatment satisfaction"" bespoke survey.', 'timeFrame': 'Every 2 weeks during 12 week period of receiving Mucinex® (week 2 to 14).'}]",14.0,40 Years,90 Years,ALL,False,OTHER,1.0,82.0,ACTUAL,v2_robust,True,True,False,True,
NCT01522469,Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations,"Crenolanib Besylate (CP-868,596-26)","['Crenolanib Besylate (CP-868,596-26)']",1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations,"Arog Pharmaceuticals, Inc.",2025-09-01T16:18:10.909894,True,,,,,A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations,,['Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations'],"['FLT3', 'Crenolanib', 'Acute', 'myeloid', 'leukemia', 'relapsed', 'refractory']",,2012-07,2014-11,"[{'measure': 'Overall Response Rate', 'description': 'To determine the response rate to crenolanib.Complete remission (CR) response criteria include a post-baseline bone marrow (BM) biopsy or aspiration % blasts \\<5%, absolute neutrophil count (ANC) \\>1×10\\^9/L and platelet count \\>100×10\\^9/L. CRi response included all CR criteria met, except participant did not experience either platelet recovery or ANC recovery. Partial Response (PR) response included a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline but \\>5%. Hematologic improvement (HI) response included erythroid response where Hgb increased ≥ 1.5 g/dL, platelet response where platelets increased ≥ 30 x 10\\^9/L for patient starting with \\>20 x 10\\^9/L platelets or increase from \\<20 x 10\\^9/L to \\>20 x 10\\^9/L and by at least 100% and neutrophil response where at least 100% increase and an increase \\>0.5 x 10\\^9/L. Resistant Disease (RD) was defined as the absence of CR, CRi, CRp, PR or HI.', 'timeFrame': 'From the date of first dose to the end of protocol treatment, 1 year.'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,
NCT06848569,Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study,Sintilimab in combination with AVD chemotherapy,['Sintilimab in combination with AVD chemotherapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Classical Hodgkin Lymphoma,Sun Yat-sen University,2025-09-01T16:18:10.909926,True,,,,,"Prospective, Single-Arm, Multicenter, Phase II Study of Sintilimab in Combination With AVD for Pediatric and Adolescent Low/Moderate Risk Classical Hodgkin Lymphoma",,['Classical Hodgkin Lymphoma'],[],,2024-10-23,2031-10-23,"[{'measure': '4-year event-free survival', 'description': 'The 4-year event-free survival (EFS) rate of pediatric and adolescent patients with low-to-intermediate risk classical Hodgkin lymphoma (cHL) treated with sintilimab in combination with the AVD regimen. EFS is defined as the time from study entry to the occurrence of disease progression, relapse, second primary malignancy, or death.', 'timeFrame': '4 years'}]",[],1.0,1 Year,18 Years,ALL,False,OTHER,0.0,73.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05727969,Dexmedetomidine Infusion and Surgical Pleth Index In Pediatrics,Dexmedetomidine,"['Lactated Ringer', 'Precedex', 'Dexmedetomidine', 'Solution']",4,INTERVENTIONAL,['NA'],,COMPLETED,Pain,Fayoum University Hospital,2025-09-01T16:18:10.909940,True,,,,,Effect Of Dexmedetomidine Infusion On Surgical Pleth Index In Pediatrics Undergoing Hypospadias Repair; A Prospective Observational Study,,"['Pain', 'Hypospadias']","['Dexmedetomidine', 'Hypospadias', 'Postoperative analgesia', 'Surgical pleth index']",,2023-01-15,2023-12-15,"[{'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute at end of the operation after skin closure.'}]","[{'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute before induction of anesthesia.'}, {'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute after insertion of endotracheal tube.'}, {'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute after beginning of surgery with skin incision.'}, {'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '5 minutes after recovery at post anesthesia care unit.'}, {'measure': 'Mean arterial blood pressure', 'description': 'in mmHg', 'timeFrame': '5 minutes after recovery at post anesthesia care unit.'}, {'measure': 'Mean arterial blood pressure', 'description': 'in mmHg', 'timeFrame': '1 minute before induction of anesthesia.'}, {'measure': 'Mean arterial blood pressure', 'description': 'in mmHg', 'timeFrame': '1 minute after beginning of surgery with skin incision.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '1 minute after beginning of surgery with skin incision.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '1 minute before induction of anesthesia.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '5 minutes after recovery at post anesthesia care unit.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '1 minute at end of the operation after skin closure.'}, {'measure': 'Mean arterial blood pressure', 'description': 'mmHg', 'timeFrame': '1 minute at end of the operation after skin closure.'}, {'measure': 'Need of vasoactive drugs', 'description': 'Yes or no', 'timeFrame': '1minute after infusion until end of surgery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '5 minutes after recovery in postanesthesia care unit'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '2 hours after recovery in postanesthesia care unit'}, {'measure': 'Ramsay sedation score', 'description': '0:5 with 0:deeply sedation to 5:no sedation', 'timeFrame': '5 minutes after recovery in postanesthesia care unit'}, {'measure': 'Ramsay sedation score', 'description': '0:5 with 0:deeply sedation to 5:no sedation', 'timeFrame': '2 hours after recovery in postanesthesia care unit'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '4 hours after discharge from recovery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '6 hours after discharge from recovery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '12 hours after discharge from recovery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '24 hours after discharge from recovery'}, {'measure': 'Surgical time', 'description': 'from when the surgeon of record starts the procedure until complete skin closure in minutes', 'timeFrame': '1 minute after skin'}, {'measure': 'Anesthesia time', 'description': 'from the start of anesthesia to the end of an anesthesia service in minutes', 'timeFrame': '5 minutes after insertion of endotracheal tube'}, {'measure': 'Total opioid consumption', 'description': 'in milligram', 'timeFrame': '24 hours after operation'}, {'measure': 'Time of 1st analgesia dose', 'description': 'time when first analgesic drug is injected for pain (in hours)', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Total non-steroidal consumption', 'description': 'time when first usage of non-steroidal anti-inflammatory drug is injected for pain (in hours)', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Extubation time', 'description': 'time from the end of surgery to airway extubation (in minutes)', 'timeFrame': '2 minutes after removal of endotracheal tube'}]",28.0,1 Year,7 Years,ALL,True,OTHER,0.0,90.0,ACTUAL,v2_robust,True,True,False,False,
NCT03919669,A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking,All Subjects,['All Subjects'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Alzheimer Disease,"University of Wisconsin, Madison",2025-09-01T16:18:10.910043,True,,,,,Longitudinal Evaluation of [18-F]MK-6240 as a Novel Tau PET Radiotracer in Patients With Alzheimer's Disease Dementia or Mild Cognitive Impairment Compared to Healthy Volunteers,,"['Alzheimer Disease', 'Mild Cognitive Impairment']",[],,2019-04-02,2022-05-19,"[{'measure': 'Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake', 'description': 'Composite mean SUVR across standard regions including: numerator was the entorhinal, amygdala, fusiform, inferior temporal, middle temporal cortex; denominator was the inferior cerebellum cortex. The SUVR is a ratio and has a theoretic interpretable minimum of 1.0. This primary outcome is reported by the three primary groups: Healthy Volunteers, Mild Cognitive Impairment, and Dementia.', 'timeFrame': 'Baseline to 12 months'}]","[{'measure': ""The Correlation Between the Change in [18F]MK-6240 Uptake and the Change in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) Using Items 1-11"", 'description': ""This outcome is correlational and therefore the arms/groups are collapsed to All Subjects so that we can assess the overall pattern of relationship between cognition and tau signal across the entire continuum of Alzheimer's disease. The ADAS-cog is one of the most frequently used tests to measure cognition in clinical trials in AD. The first 11 items of the ADAS-cog were used for this outcome. The ADAS was developed as a two-part scale: one that measured cognitive functions and one that measured non-cognitive functions such as mood and behavior. Most current research, including this study, uses the ADAS-Cog, which is the sub-scale that measures cognitive ability. The ADAS-cog score is based on incorrect items or errors and has a range of 0-50, where lower scores indicate better cognitive functioning."", 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Correlate the Changes in [18F]MK-6240 Uptake and Changes in Clinical Cognitive Assessments by Clinical Dementia Rating Scale (CDR).', 'description': ""This outcome is correlational and therefore the arms/groups are collapsed to All Subjects so that we can assess the overall pattern of relationship between cognition and tau signal across the entire continuum of Alzheimer's disease. The CDR was developed primarily for use in persons with dementia of the Alzheimer type. The six domains of CDR are: Memory, Orientation, Judgment and Problem-solving, Community Affairs, Home and Hobbies, and Personal Care. Each domain is rated on a 5-point scale of functioning: 0 no impairment; 0.5 questionable impairment; 1 mild impairment; 2 moderate impairment; and 3 severe impairment. The Sum of Boxes is the score used which is simply the sum of the 6 Domain Box Scores. The range is 0-18 with lower scores indicating better cognitive function."", 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Correlate the Changes in [18F]MK-6240 Uptake and Changes in Clinical Cognitive Assessments by Mini-Mental Status Exam (MMSE)', 'description': ""This outcome is correlational and therefore the arms/groups are collapsed to All Subjects so that we can assess the overall pattern of relationship between cognition and tau signal across the entire continuum of Alzheimer's disease. The MMSE is a sensitive, valid and reliable 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. It is commonly used as screening tool for dementia. It is also used to estimate the severity and progression of cognitive impairment and to follow the course of cognitive changes in an individual over time; thus, making it an effective way to document an individual's response to treatment. The range is 0-30 with higher scores indicating better cognitive functioning."", 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake', 'description': 'Composite mean SUVR across standard regions including: numerator was the entorhinal, amygdala, fusiform, inferior temporal, middle temporal cortex; denominator was the inferior cerebellum cortex. The SUVR is a ratio and has a theoretic interpretable minimum of 1.0. This primary outcome is reported by the three primary groups: Healthy Volunteers, Mild Cognitive Impairment, and Dementia.', 'timeFrame': 'Baseline to 24 months'}, {'measure': 'Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake', 'description': 'Composite mean SUVR across standard regions including: numerator was the entorhinal, amygdala, fusiform, inferior temporal, middle temporal cortex; denominator was the inferior cerebellum cortex. The SUVR is a ratio and has a theoretic interpretable minimum of 1.0. This primary outcome is reported by the three primary groups: Healthy Volunteers, Mild Cognitive Impairment, and Dementia.', 'timeFrame': 'Baseline to 6 months'}]",6.0,50 Years,85 Years,ALL,True,OTHER,1.0,27.0,ACTUAL,v2_robust,True,True,False,False,
NCT03663569,A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler,Spiolto® Respimat®,['Spiolto® Respimat®'],1,OBSERVATIONAL,[],,COMPLETED,"Pulmonary Disease, Chronic Obstructive",Boehringer Ingelheim,2025-09-01T16:18:10.910130,True,,,,,Changes in Clinical Control of COPD Patients Measured by the Clinical COPD Questionnaire During Therapy With Spiolto®Respimat® in Routine Clinical Practice,,"['Pulmonary Disease, Chronic Obstructive']",[],,2018-08-15,2019-10-04,"[{'measure': 'Percentage of Patients With Therapeutic Success of Spiolto® Respimat® Treatment at Visit 2', 'description': 'Therapeutic success of Spiolto® Respimat® treatment was defined as 0.4 point decrease in the Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire - Clinical COPD Questionnaire (CCQ) score from visit 1 to visit 2. Each of the 10 CCQ questions is scored by the patient on a 7-point scale between 0 (Never/Not limited at all) and 6 (Almost all the time/Totally limited or unable to do) at baseline (Visit 1) and at the end of the observation after approximately 6 weeks (Visit 2). The sum of the scores divided by 10 gives the CCQ score, which measures the health and functional status. A higher CCQ score is indicative of worse status.', 'timeFrame': 'At Visit 2 (6 weeks after baseline visit 1)'}]","[{'measure': 'Changes in the Clinical COPD Questionnaire (CCQ) and the CCQ Symptom, Mental State and Functional State Domain Scores From Visit 1 (Baseline) to Visit 2', 'description': 'The CCQ questionnaire contained 10 questions about symptoms, functional status and mental status. Each of the 10 CCQ questions was scored by the patient on a 7-point scale between 0 and 6 at baseline and at the end of observation after approximately 6 weeks. Symptom domain covered 4 questions (number 1, 2, 5, 6), Functional state domain covered 4 questions (number 7, 8, 9, 10), and Mental state domain covered 2 questions (number 3, 4). Scores for the questions in each domain were summed up and divided by the number of questions in each domain giving the resulting score for respective domain. The sum of the scores divided by 10 gives the CCQ score which measures the health and functional status. A higher CCQ score is indicative of worse status. Change of the score was calculated as visit 2 minus visit 1.', 'timeFrame': 'At baseline visit 1 and 6 weeks thereafter at visit 2'}, {'measure': ""Physician's Global Evaluation (PGE) Score at Visit 1(Baseline)"", 'description': 'PGE score assessed the general condition of the patient on an 8-point ordinal scale from 1 (very poor) to 8 (excellent).', 'timeFrame': 'At visit 1'}, {'measure': ""Physician's Global Evaluation (PGE) Score at Visit 2"", 'description': 'PGE score assessed the general condition of the patient on an 8-point ordinal scale from 1 (very poor) to 8 (excellent).', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Patient Overall Satisfaction With Spiolto® Respimat® Treatment at Visit 2', 'description': 'Patient overall satisfaction with Spiolto® Respimat® treatment at visit 2 was reported.', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Patient Satisfaction With Inhaling From the Respimat® Device at Visit 2', 'description': 'Patient satisfaction with inhaling from the Respimat® device at visit 2 was reported', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Patient Satisfaction With Handling of the Respimat® Inhalation Device at Visit 2', 'description': 'Patient satisfaction with handling of the Respimat® inhalation device at visit 2 was reported.', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Number of Participants Willing to Continue Treatment With Spiolto® Respimat® at Visit 2', 'description': 'Number of participants willing to continue treatment with Spiolto® Respimat® at visit 2 was reported.', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}]",8.0,40 Years,,ALL,False,INDUSTRY,0.0,4819.0,ACTUAL,v2_robust,False,True,False,False,
NCT06615869,A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011),Molnupiravir,"['MK-4482', 'EIDD-2801', 'Molnupiravir', 'LAGEVRIO', 'MOV']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Merck Sharp & Dohme LLC,2025-09-01T16:18:10.910325,True,,,,,A Study to Evaluate the Pharmacokinetics and Definitive Bioequivalence of Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants,,['Healthy'],[],,2023-01-20,2023-03-15,"[{'measure': 'Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of N-Hydroxycitidine (NHC) in plasma: Treatment A versus Treatment B', 'description': 'AUC0-inf of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Area Under the Concentration-Time Curve From Time Zero to last measurable timepoint (AUC0-last) of NHC in plasma: Treatment A versus Treatment B', 'description': 'AUC0-last of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Area Under the Concentration-Time Curve From Time Zero to 12 hours (AUC0-12) of (NHC) in plasma: Treatment A versus Treatment B', 'description': 'AUC0-12 of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 12 hours postdose'}, {'measure': 'Maximum plasma concentration (Cmax) of NHC: Treatment A versus Treatment B', 'description': 'Cmax of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Time to maximum plasma concentration (Tmax) of NHC: Treatment A versus Treatment B', 'description': 'Tmax of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Apparent terminal half-life (t1/2) of NHC in plasma: Treatment A versus Treatment B', 'description': 't1/2 of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Apparent Clearance (CL/F) of NHC in plasma: Treatment A versus Treatment B', 'description': 'CL/F of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Apparent volume of distribution during terminal phase (Vz/F) of NHC in plasma: Treatment A versus Treatment B', 'description': 'Vz/F of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}]","[{'measure': 'AUC0-inf of NHC in plasma: Treatment B versus Treatment C', 'description': 'AUC0-inf of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'AUC0-last of NHC in plasma: Treatment B versus Treatment C', 'description': 'AUC0-last of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'AUC0-12 of NHC in plasma: Treatment B versus Treatment C', 'description': 'AUC0-12 of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 12 hours postdose'}, {'measure': 'Cmax of NHC in plasma: Treatment B versus Treatment C', 'description': 'Cmax of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Tmax of NHC in plasma: Treatment B versus Treatment C', 'description': 'Tmax of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 't1/2 of NHC in plasma: Treatment B versus Treatment C', 'description': 't1/2 of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'CL/F of NHC in plasma: Treatment B versus Treatment C', 'description': 'CL/F of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Vz/F of NHC in plasma: Treatment B versus Treatment C', 'description': 'Vz/F of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'AUC0-inf of NHC in plasma: Treatment D versus Treatment A', 'description': 'AUC0-inf of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'AUC0-last of NHC in plasma: Treatment D versus Treatment A', 'description': 'AUC0-last of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'AUC0-12 of NHC in plasma: Treatment D versus Treatment A', 'description': 'AUC0-12 of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 12 hours postdose'}, {'measure': 'Cmax of NHC in plasma: Treatment D versus Treatment A', 'description': 'Cmax of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Tmax of NHC in plasma: Treatment D versus Treatment A', 'description': 'Tmax of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 't1/2 of NHC in plasma: Treatment D versus Treatment A', 'description': 't1/2 of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'CL/F of NHC in plasma: Treatment D versus Treatment A', 'description': 'CL/F of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Vz/F of NHC in plasma: Treatment D versus Treatment A', 'description': 'Vz/F of NHC in plasma will be determined.', 'timeFrame': 'Pre-dose, and at designated timepoints up to 72 hours postdose'}, {'measure': 'Number of participants who experience one or more adverse events (AEs)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to ~ 38 days'}, {'measure': 'Number of participants who discontinue study intervention due to an AE', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to ~ 38 days'}]",26.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,64.0,ACTUAL,v2_robust,True,True,False,True,
NCT02311569,Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation,Mirabegron,"['Mirabegron', 'Betmiga®']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Myeloproliferative Neoplasm,Swiss Cancer Institute,2025-09-01T16:18:10.910373,True,,,,,Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.,,"['Myeloproliferative Neoplasm', 'Primary Myelofibrosis', 'Essential Thrombocythemia', 'Polycythemia Vera']","['JAK2', 'Mirabegron', 'Primary myelofibrosis', 'beta-3-mimetic drugs', 'Myeloproliferative neoplasm', 'Essential thrombocythemia', 'Polycythemia vera', 'Betmiga', 'JAK2-V617F']",,2015-04,2016-12,"[{'measure': 'Reduction in the burden of mutated alleles of ≥50% at 24 weeks.', 'description': 'Primary endpoint of the trial is reduction in the burden of mutated alleles of ≥50% at 24 weeks (Red-50@24). Patients are defined as success for this endpoint, if they show a reduction of the JAK2-V617F allelic burden of 50% or more 24 weeks ± 4 weeks after registration when compared to baseline, and if they did not start a new MPN treatment before. All other evaluable patients will be considered as failures for this endpoint.', 'timeFrame': 'at 24 weeks'}]","[{'measure': 'Reduction in the burden of mutated alleles of ≥50%', 'description': 'Reduction in the burden of mutated alleles of ≥50% at 12 weeks (Red-50@12) defined in the same way as the primary endpoint, but evaluated at 12 weeks ± 4 weeks after registration.', 'timeFrame': 'at 12 weeks'}, {'measure': 'Reduction in the burden of mutated alleles of ≥25%', 'description': 'Reduction in the burden of mutated alleles of ≥25% at 24 weeks (Red-25@24): Patients are defined as success for the Red-25@24 endpoint, if they show a reduction of the Jak2-V617F allelic burden of 25% or more 24 weeks ± 4 weeks after registration when compared to baseline, and if they did not start a new MPN treatment before. All other evaluable patients will be considered as failures for this endpoint.', 'timeFrame': 'at 24 weeks'}, {'measure': 'Reduction in the burden of mutated alleles of ≥25%', 'description': 'Reduction in the burden of mutated alleles of ≥25% at 12 weeks (Red-25@12) defined in the same way as the Red-25@24 endpoint, but evaluated at 12 weeks ± 4 weeks after registration.', 'timeFrame': 'at 12 weeks'}]",4.0,18 Years,,ALL,False,OTHER,0.0,39.0,ACTUAL,v2_robust,True,True,False,False,
NCT01515969,Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC),Erlotinib hydrochloride,"['Receptor tyrosine kinase (RTK) inhibitor TKI258', 'Dovitinib lactate', 'OSI-774', 'Erlotinib HCl', 'CP-358,774', 'Tarceva', 'CHIR-258', 'Erlotinib hydrochloride', 'TKI258']",9,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,"Non-small Cell Lung Cancer (NSCLC), Recurrent",Heather Wakelee,2025-09-01T16:18:10.910414,True,,,,,A Phase I Study of Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer,,"['Non-small Cell Lung Cancer (NSCLC), Recurrent', 'Non-small Cell Lung Cancer (NSCLC), Stage IV']",[],Patient safety - Unacceptable toxicity,2012-07,2014-12,"[{'measure': 'Measure toxicity to determine the MTD of the combination of erlotinib hydrochloride and dovitinib lactate', 'description': 'Dose limiting toxicity (DLT) is defined as a CTCAE v4.0 toxicity \\>= grade 3 or 4 occurring after 3 weeks of treatment. If 2 of 6 patients experience a DLT, then the MTD will be defined as the dose tolerated by the cohort preceding the cohort experiencing the DLT.', 'timeFrame': '1 year'}]","[{'measure': 'ORR (complete response [CR]+ partial response [PR])', 'timeFrame': '1 year'}, {'measure': 'PFS', 'timeFrame': '1 year'}, {'measure': 'OS', 'timeFrame': '1 year'}]",4.0,18 Years,,ALL,False,OTHER,2.0,9.0,ACTUAL,v2_robust,True,False,True,False,Patient safety - Unacceptable toxicity
NCT01411969,Impact of External Nasal Dilator on the Rhinogram,External Nasal Dilator Strip; 0.05% oxymetazoline chloride,"['External Nasal Dilator Strip; 0.05% oxymetazoline chloride', 'Breath Right®']",2,OBSERVATIONAL,[],,COMPLETED,Nasal Obstruction,University of Sao Paulo General Hospital,2025-09-01T16:18:10.910429,True,,,,,Acoustic Rhinometry: Impact of External Nasal Dilator on the Two First Notches of the Rhinogram,,['Nasal Obstruction'],"['external nasal dilator strip', 'nasal valve', 'acoustic rhinometry']",,2010-06,2010-12,[],[],0.0,18 Years,50 Years,ALL,True,OTHER,0.0,16.0,ACTUAL,v2_robust,False,True,False,False,
NCT01743469,"A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers",Tasquinimod,"['ABR-215050', 'Tasquinimod']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Advanced or Metastatic Hepatocellular Cancer,Ipsen,2025-09-01T16:18:10.910436,True,,,,,"A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas",,"['Advanced or Metastatic Hepatocellular Cancer', 'Advanced or Metastatic Ovarian Cancer', 'Metastatic Renal Cell Cancer', 'Advanced or Metastatic Gastric Carcinoma']","['Advanced', 'Metastatic', 'Hepatocellular cancer', 'Ovarian cancer', 'Renal cell cancer', 'Gastric carcinoma']",,2012-12,2016-04,"[{'measure': 'Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).', 'description': ""Progression (prog.) defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in sum of longest diameter of target lesions,or a measurable increase in a nontarget lesion,or appearance of new lesions.\n\n'Progressed or Died' when time between start of study drug \\&first date of the following events was ≤ to analysis timepoint +3 days:1) Disease prog. according to central review using RECIST v1.1:date of disease prog. or if missing,first exam date of the visit showing a disease prog.2) Death due to any cause.\n\n'Neither progressed, nor died' if central assessment by RECIST v1.1 confirmed no disease prog. was observed at the considered timepoint,i.e. time between start of study medication \\&last examination/visit date of complete response (CR),partial response (PR) or stable disease (SD) ≥ analysis timepoint 7days.In other cases, such as patient withdrawal due to AEs without tumor assessment proving prog.,the patient was considered as 'not assessable'."", 'timeFrame': 'Week 12 (Gastric Carcinoma Cohort); Week 16 (Hepatocellular and Renal Cell Carcinoma Cohorts); Week 24 (Ovarian Carcinoma Cohort).'}]","[{'measure': 'PFS Rate Measured by Choi Criteria (Hepatocellular Carcinoma Cohort).', 'description': 'PFS rate was defined as the percentage of patients who had neither progressed nor died. Tumour progression was assessed centrally using the Choi criteria.\n\nResponse was measured using the following criteria:\n\nCR: Disappearance of all lesions, no new lesions; PR: A decrease in size ≥10% or a decrease in tumour attenuation (Hounsfield unit \\[HU\\]) ≥15% on CT, no new lesions, no obvious progression of non-measurable disease; SD: Does not meet criteria for CR, PR, or progressive disease (PD), no symptomatic deterioration attributed to tumour progression; PD: An increase in tumour size ≥10% and does not meet criteria of PR by tumour attenuation on CT, new lesions.', 'timeFrame': 'Week 16.'}, {'measure': 'Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed).', 'description': 'Best overall response was derived as the best overall response documented before the prespecified timepoint (gastric carcinoma cohort: 12 weeks; Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.', 'timeFrame': 'Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).'}, {'measure': 'Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort).', 'description': 'Per Choi Criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=10% decrease in the sum of the longest diameter of target lesions; Progression, as a 10% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.', 'timeFrame': 'Every 8 weeks until disease progression, up to 36 months.'}, {'measure': 'Clinical Benefit (All Cohorts).', 'description': 'Clinical benefit was defined as CR, PR or SD lasting at least 12 weeks using centrally or locally assessed RECIST v1.1.', 'timeFrame': 'Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).'}, {'measure': 'PFS From First Study Treatment to Progression or Death Due to Any Cause Based on Choi Criteria (Hepatocellular Carcinoma Cohort).', 'description': 'PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally assessed Choi criteria (i.e. increase in tumor size ≥10%) or death due to any cause before initiation of new systemic treatment.', 'timeFrame': 'Every 8 weeks until disease progression, up to 36 months.'}, {'measure': 'PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts).', 'description': 'PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally and locally assessed RECIST v1.1 (i.e. increase in tumor size ≥20%) or death due to any cause before initiation of new systemic treatment.', 'timeFrame': 'Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).'}, {'measure': 'Time to Progression (TTP) by Choi Criteria (Hepatocellular Carcinoma Cohort).', 'description': 'TTP defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally assessed Choi criteria (i.e. increase in tumor size ≥10%) or death due to disease progression before initiation of a new systemic treatment.', 'timeFrame': 'Every 8 weeks until disease progression, up to 36 months.'}, {'measure': 'TTP by RECIST v1.1 (All Cohorts).', 'description': 'TTP was defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally and locally assessed RECIST v1.1 criteria (i.e. increase in tumor size ≥20%) or death due to disease progression before initiation of a new systemic treatment.', 'timeFrame': 'Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).'}, {'measure': 'Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts).', 'description': 'OS is the time (in weeks) from the first study medication date to death due to any cause. Patients were censored at the date of last contact (the latest between the time of EoST/WD assessment and follow-up visits).\n\nOS was estimated using Kaplan-Meier analysis.', 'timeFrame': 'Time from first study treatment to death, up to 36 months.'}, {'measure': 'Further Cancer-related Treatment During Follow-up Period (All Cohorts).', 'description': 'Further systemic treatment was coded using World Health Organization (WHO) Drug Dictionary (versions: June 2014 for the hepatocellular carcinoma cohort and June 2013 for the ovarian, renal cell and gastric carcinoma cohorts).\n\nA frequency table of the number and percentage of patients was provided by Anatomical Therapeutic Chemical (ATC) decode and preferred name.', 'timeFrame': '16 weeks, Last Patient First Treatment + 16 weeks.'}]",11.0,18 Years,,ALL,False,INDUSTRY,0.0,201.0,ACTUAL,v2_robust,True,True,False,False,
NCT06372483,Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant,VMX-C001,"['Rivaroxaban 20 mg Oral Tablet', 'VMX-C001', 'Edoxaban 60 mg Oral Tablet', 'Placebo', 'Apixaban 5 mg Oral Tablet']",5,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Coagulation Disorder,VarmX B.V.,2025-09-01T16:18:10.910651,True,,,,,"A Randomised, Double-Blind, Placebo-Controlled, Single Dose Trial Evaluating Different Doses of Intravenously Administered VMX-C001 and to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VMX-C001 in Healthy Subjects (Part 1) and in Combination with a Selected FXa Direct Oral Anticoagulant (DOAC) in Healthy Older Subjects (Part 2)",,['Coagulation Disorder'],[],,2024-02-21,2026-08,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Part 1)', 'description': 'Number of Subjects with One of More Drug Related Adverse Events (AEs) or any Serious AEs', 'timeFrame': 'From dosing up to Day 28'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Part 2)', 'description': 'Number of Subjects with One of More Drug Related Adverse Events (AEs) or any Serious AEs', 'timeFrame': 'From dosing up to Day 31'}, {'measure': 'PK of VMX-C001 in plasma - Cmax', 'description': 'Maximal concentration in plasma', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'PK of VMX-C001 in plasma - tmax', 'description': 'Time of maximal concentration in plasma', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'PK of VMX-C001 in plasma - t1/2', 'description': 'Terminal elimination half-life in plasma', 'timeFrame': 'Up to 7 days post VMX-C001dose'}, {'measure': 'PK of VMX-C001 in plasma - AUC0-last', 'description': 'Area under the concentration-time curve from time of dosing to last measurable concentration in plasma', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'PK of VMX-C001 in plasma - AUC0-inf', 'description': 'Area under the concentration-time curve from time of dosing extrapolated to infinity in plasma', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'PK of VMX-C001 in plasma - Lambda z', 'description': 'Terminal elimination rate constant', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'PK of VMX-C001 in plasma - CL', 'description': 'Total body clearance', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'PK of VMX-C001 in plasma - Vz', 'description': 'Apparent volume of distribution', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'DOAC plasma concentrations (Part 2)', 'timeFrame': 'Up to Day 10'}, {'measure': 'Change in Prothrombin time (PT) following dosing with VMX-C001', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in activated partial thromboplastin time (aPTT) following dosing with VMX-C001', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in D-dimer following dosing with VMX-C001', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in prothrombin fragments F1 and 2 following dosing with VMX-C001', 'description': 'Mean and median values, subjects on active treatment per group versus placebo', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in thrombin generation, measured by lag time, following dosing with VMX-C001', 'description': 'Mean and median values, subjects on active treatment per group versus placebo', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in thrombin generation, measured by endogenous thrombin potential, following dosing with VMX-C001', 'description': 'Mean and median values, subjects on active treatment per group versus placebo', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in thrombin generation, measured by peak height, following dosing with VMX-C001', 'description': 'Mean and median values, subjects on active treatment per group versus placebo', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in thrombin generation, measured by time to peak, following dosing with VMX-C001', 'description': 'Mean and median values, subjects on active treatment per group versus placebo', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in thrombin generation, measured by velocity index, following dosing with VMX-C001', 'description': 'Mean and median values, subjects on active treatment per group versus placebo', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in thrombin generation, measured by time to tail, following dosing with VMX-C001', 'description': 'Mean and median values, subjects on active treatment per group versus placebo', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in diluted prothrombin time (dPT) following dosing with VMX-C001', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in diluted Russell Viper Venom time (dRVVT) following dosing with VMX-C001', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}, {'measure': 'Change in real time activated clotting time (ACT) following dosing with VMX-C001', 'timeFrame': 'Up to 7 days post VMX-C001 dose'}]","[{'measure': 'Antibodies against VMX-C001 in plasma', 'description': 'Percentage of patients positive (active vs placebo), and titer (percentage of patients tested positive for each titer measured)', 'timeFrame': 'Up to 28 days post VMX-C001 dose'}, {'measure': 'Antibodies against human coagulation FX in plasma', 'description': 'Percentage of patients positive (active vs placebo), and titer (percentage of patients tested positive for each titer measured)', 'timeFrame': 'Up to 28 days post VMX-C001 dose'}]",26.0,18 Years,79 Years,ALL,True,INDUSTRY,0.0,40.0,ACTUAL,v2_robust,True,False,False,True,
NCT05020483,FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients,FEIBA,"['activated prothrombin complex concentrate (aPCC) FEIBA', 'FEIBA', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Cardiac Disease,Mayo Clinic,2025-09-01T16:18:10.910791,True,,,,,Activated Prothrombin Complex Concentrate FEIBA to Optimize Postcardiopulomonary Bypass Hemostasis in Pediatric Cardiac Patients,,['Cardiac Disease'],['Cardiac Surgery'],Patient population changed and no subjects eligible for the study.,2021-10,2023-12,"[{'measure': 'Number of units of allogeneic blood products required early perioperatively in pediatric cardiac patients.', 'description': 'Number of units of transfused allogeneic blood products after cardiopulmonary bypass in the operating room (OR) and in the intensive care unit (ICU) on postoperative day (POD) 0 and 1.', 'timeFrame': 'approximately 1 day postoperatively'}]","[{'measure': 'Hospital length of stay', 'description': 'Number of days admitted to the hospital', 'timeFrame': 'Through hospital discharge, approximately 3 days'}, {'measure': 'Mortality', 'description': 'Total number of subject deaths', 'timeFrame': 'Through hospital discharge, approximately 3 days'}, {'measure': 'Intravascular and intracardiac thromboses', 'description': 'Number of subjects to experience intravascular and/or intracardiac thromboses up to POD 3', 'timeFrame': 'approximately 3 days postoperatively'}]",4.0,,5 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Patient population changed and no subjects eligible for the study.
NCT01263483,Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan,Alogliptin and voglibose,"['SYR-322', 'BASEN®', 'Alogliptin and voglibose', 'Voglibose']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Type 2 Diabetes Mellitus,Takeda,2025-09-01T16:18:10.910832,True,,,,,"A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan",,['Type 2 Diabetes Mellitus'],"['Diabetes Mellitus - Type 2', 'Diabetes Mellitus', 'Drug Therapy']",,2007-01,2008-04,"[{'measure': 'Change From Baseline in Glycosylated Hemoglobin (Week 12).', 'description': 'The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.', 'timeFrame': 'Baseline and Week 12.'}]","[{'measure': 'Change From Baseline in Glycosylated Hemoglobin (Week 2).', 'description': 'The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.', 'timeFrame': 'Baseline and Week 2.'}, {'measure': 'Change From Baseline in Glycosylated Hemoglobin (Week 4).', 'description': 'The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.', 'timeFrame': 'Baseline and Week 4.'}, {'measure': 'Change From Baseline in Glycosylated Hemoglobin (Week 8).', 'description': 'The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.', 'timeFrame': 'Baseline and Week 8.'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (Week 2).', 'description': 'The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.', 'timeFrame': 'Baseline and Week 2'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (Week 4).', 'description': 'The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.', 'timeFrame': 'Baseline and Week 4.'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (Week 8).', 'description': 'The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.', 'timeFrame': 'Baseline and Week 8.'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (Week 12).', 'description': 'The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline.', 'timeFrame': 'Baseline and Week 12.'}, {'measure': 'Change From Baseline in Fasting C-peptide (Week 2).', 'description': 'The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline.', 'timeFrame': 'Baseline and Week 2.'}, {'measure': 'Change From Baseline in Fasting C-peptide (Week 4).', 'description': 'The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline.', 'timeFrame': 'Baseline and Week 4.'}, {'measure': 'Change From Baseline in Fasting C-peptide (Week 8).', 'description': 'The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline.', 'timeFrame': 'Baseline and Week 8.'}, {'measure': 'Change From Baseline in Fasting C-peptide (Week 12).', 'description': 'The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline.', 'timeFrame': 'Baseline and Week 12.'}, {'measure': 'Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value).', 'description': 'The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.', 'timeFrame': 'Baseline and Week 12.'}, {'measure': 'Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)).', 'description': 'The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.', 'timeFrame': 'Baseline and Week 12.'}, {'measure': 'Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2).', 'description': 'The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2).', 'description': 'The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.', 'timeFrame': 'Baseline and Week 12.'}, {'measure': 'Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).', 'description': 'The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.', 'timeFrame': 'Baseline and Week 12'}]",17.0,33 Years,85 Years,ALL,False,INDUSTRY,0.0,230.0,ACTUAL,v2_robust,True,True,False,False,
NCT02762383,Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT),Peginterferon Alfa-2,"['Pegasys', 'Peginterferon Alfa-2']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,HIV/HCV Coinfection,Hoffmann-La Roche,2025-09-01T16:18:10.910927,True,,,,,"A Pilot, Open-Label, Multicentre Study Evaluating the Long-Term Safety and Tolerability of a Low-Dose Peginterferon Alfa-2a Maintenance Monotherapy in Chronic Hepatitis C Patients Co-Infected With Human Immunodeficiency Virus and Who Do Not Respond to a Standard Regimen of Peginterferon Alfa-2a Plus Ribavirin",,['HIV/HCV Coinfection'],[],Low recruitment,2005-03,2009-06,"[{'measure': 'Percentage of Participants with Adverse Events (AEs)', 'timeFrame': 'From Baseline to end of treatment (up to 18 months)'}]","[{'measure': 'Percentage of Participants with Histological Response According to Paired Biopsy', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'HIV RNA Viral Load in Copies per Milliliter (copies/mL)', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'Cluster of Differentiation (CD) 4 Cell Count in Cells per Microliter (cells/mcL)', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'Percentage of Participants with Virological Response According to HCV RNA Viral Load', 'timeFrame': 'At 6, 12, and 18 months during treatment, and at 24 weeks after end of treatment (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Biochemical Response According to Alanine Aminotransferase (ALT) Level', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'Percentage of Participants with Sustained Biochemical Response According to ALT Level', 'timeFrame': 'At 24 weeks after end of treatment (up to 2 years overall)'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,19.0,ACTUAL,v2_robust,True,False,True,True,Low recruitment
NCT04409483,Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger,Lopinavir-Ritonavir Drug Combination,['Lopinavir-Ritonavir Drug Combination'],1,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Covid-19,Epicentre,2025-09-01T16:18:10.910954,True,,,,,Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger,,['Covid-19'],[],Epidemic dynamics,2020-06-01,2020-12-31,"[{'measure': 'Hospitalization or death', 'description': 'Hospitalization associated with desaturation (SpO2 ≤92%) or death due to any cause', 'timeFrame': '15 days following randomization'}]","[{'measure': 'All-cause mortality', 'description': 'Death due to any cause', 'timeFrame': '15 days following randomization'}, {'measure': 'All-cause mortality', 'description': 'Death due to any cause', 'timeFrame': '28 days following randomization'}, {'measure': 'Time to hospitalization', 'description': 'Length of time between randomization and hospitalization associated with desaturation (SpO2 ≤92%)', 'timeFrame': '28 days following randomization'}, {'measure': 'Length of hospitalization', 'description': 'Total duration of hospitalization associated with desaturation (SpO2 ≤92%)', 'timeFrame': '28 days following randomization'}, {'measure': 'Admission to intensive care', 'description': 'Proportion of participants admitted to an intensive care unit', 'timeFrame': '28 days following randomization'}, {'measure': 'Adverse events', 'description': 'Proportion of participants having an adverse event', 'timeFrame': '28 days following randomization'}, {'measure': 'Serious adverse events', 'description': 'Proportion of participants having a serious adverse event', 'timeFrame': '28 days following randomization'}]",8.0,12 Years,,ALL,False,OTHER,3.0,0.0,ACTUAL,v2_robust,True,False,True,True,Epidemic dynamics
NCT00113841,Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma,Curcumin,"['Bioperine', 'Curcumin']",2,INTERVENTIONAL,['NA'],,COMPLETED,Multiple Myeloma,M.D. Anderson Cancer Center,2025-09-01T16:18:10.911093,True,,,,,Pilot Study of Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma,,['Multiple Myeloma'],"['Multiple Myeloma', 'Diferuloylmethane Derivative', 'Curcumin', 'Bioperine']",,2004-11,2009-08,"[{'measure': 'Percent Change of NF-kB Protein Expression in Peripheral Blood Mononuclear Cells From Baseline Through 4 Weeks of Treatment', 'description': 'Percent change of NF-kB =\\[(expression at 4 weeks- expression at baseline)/expression at baseline\\]\\*100%. Bone marrow aspirate/biopsy for expression of NF-kB and related genes/proteins markers at baseline and after 4 weeks.', 'timeFrame': 'Baseline through 4 weeks of treatment'}]",[],1.0,,,ALL,False,OTHER,0.0,42.0,ACTUAL,v2_robust,True,True,False,False,
NCT03677141,"A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma",Mosunetuzumab,"['Vincristine', 'Doxorubicin', 'Rituxumab', 'Polatuzumab Vedotin', 'Cyclophosphamide', 'Prednisone', 'Tocilizumab', 'Mosunetuzumab']",8,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,B-cell Non-Hodgkin Lymphoma,Hoffmann-La Roche,2025-09-01T16:18:10.911150,True,,,,,"A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma",,['B-cell Non-Hodgkin Lymphoma'],[],,2019-03-08,2023-10-12,"[{'measure': 'Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)', 'description': 'The CR rate was defined as the percentage of participants with CR. Assessments were made according to the Lugano 2014 Response Criteria.', 'timeFrame': '6-8 weeks after either C6D1 or last dose of study treatment'}]","[{'measure': 'CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II)', 'timeFrame': '6-8 weeks after C6D1 or last dose of study treatment'}, {'measure': 'Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II)', 'description': 'ORR is defined as a CR or PR at the time of primary assessment based on PET-CT, as determined by the investigator.', 'timeFrame': '6-8 weeks after C6D1 or last dose of study treatment'}, {'measure': 'ORR at PRA Based on CT Only as Determined by the Investigator (Phase II)', 'description': 'ORR is defined as a CR or PR at the time of primary assessment based on CT only, as determined by the investigator.', 'timeFrame': '6-8 weeks after C6D1 or last dose of study treatment'}, {'measure': 'Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II)', 'description': 'Best ORR was defined as CR or PR at any time on study and based on PET-CT or CT only as determined by the investigator.', 'timeFrame': 'Up to approximately 50 months'}, {'measure': 'Duration of Response (DOR) as Determined by the Investigator (Phase II)', 'description': 'DOR is defined as the time from the first occurrence of a documented objective response to disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).', 'timeFrame': 'Up to approximately 50 months'}, {'measure': 'Progression-free Survival (PFS) as Determined by the Investigator (Phase II)', 'description': 'PFS is defined as the time from randomization to the first occurrence of disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The earliest contributing event to PFS is reported. The range (min-max) values are based on censored observations (participants without a baseline-evaluable tumor assessment were censored at the date of randomization or first study treatment, plus 1 day).', 'timeFrame': 'Up to approximately 50 months'}, {'measure': 'PFS at 1 Year as Determined by the Investigator (Phase II)', 'description': 'PFS at 1 year is defined as the proportion of participants with disease progression or relapse as determined by the investigator, or death from any cause within 1 year of randomization.', 'timeFrame': '1 year'}, {'measure': 'Event-free Survival (EFS) as Determined by the Investigator (Phase II)', 'description': 'EFS is defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, initiation of new anti-lymphoma therapy (NALT), or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).', 'timeFrame': 'Up to 50 months'}, {'measure': 'Time to Deterioration in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale', 'timeFrame': 'C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)'}, {'measure': 'Time to Deterioration in Physical Functioning and Fatigue as Measured by the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30)', 'timeFrame': 'C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)'}, {'measure': 'Polatuzumab Vedotin Serum Concentrations', 'timeFrame': 'C2D1, C6D1'}, {'measure': 'Polatuzumab Vedotin Antibody-conjugated Monomethyl Auristatin E (acMMAE) Serum Concentrations', 'timeFrame': 'C1D1-C6D1'}, {'measure': 'Polatuzumab Vedotin Unconjugated Mono-methyl Auristatin E (MMAE) Serum Concentrations', 'timeFrame': 'C1D1-C6D1'}, {'measure': 'Mosunetuzumab Serum Concentrations', 'timeFrame': 'C1D1-C5D1'}, {'measure': 'Baseline Prevalence and Incidence of Treatment Emergent Anti-drug Antibodies (ADA) to Mosunetuzumab', 'description': 'Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).', 'timeFrame': 'Cycles 1, 2, 6, 16, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)'}, {'measure': 'Baseline Prevalence and Incidence of Treatment Emergent ADA to Polatuzumab Vedotin', 'description': 'Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).', 'timeFrame': 'Cycles 1, 2, 6, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)'}]",17.0,18 Years,,ALL,False,INDUSTRY,0.0,117.0,ACTUAL,v2_robust,True,True,False,False,
NCT06465641,Methylphenidate in KBG Syndrome: N-of-1 Series,Methylphenidate Hydrochloride,"['Placebo', 'Methylphenidate Hydrochloride']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Kbg Syndrome,Radboud University Medical Center,2025-09-01T16:18:10.911210,True,,,,,Effectiveness of Methylphenidate in Children and Adolescents With KBG Syndrome: An N-of-1 Series,,"['Kbg Syndrome', 'ADHD - Combined Type']",[],,2024-11-13,2027-10-01,"[{'measure': 'Strenghts and difficulties questionnaire, ADHD subscale', 'description': 'Minimum score 1, maximum score 10 (higher score is worse outcome).', 'timeFrame': 'Baseline, and daily in week 1,3,5,7,9,11'}]","[{'measure': 'Strenghts and difficulties questionnaire, emotional problems subscale', 'description': 'Minimum score 1, maximum score 10 (higher score is worse outcome).', 'timeFrame': 'Baseline, and daily in week 1,3,5,7,9,11'}, {'measure': 'Dutch shortened version of the Emotion Dysregulation Inventory (EDI) reactivity index', 'description': 'Minimum score 0, maximum score 28 (higher score is worse outcome)', 'timeFrame': 'Baseline, and daily in week 1,3,5,7,9,11'}, {'measure': 'Goal Attainment Scoring (GAS)', 'description': 'Personal goals, no minimum or maximum score', 'timeFrame': 'Baseline, and at the end of week 1,3,5,7,9,11'}, {'measure': 'Personal Questionnaire (PQ)', 'description': 'Personal goals, no minimum or maximum score', 'timeFrame': 'Baseline, and at the end of week 1,3,5,7,9,11'}, {'measure': 'Adverse Effects checklist for methylphenidate', 'description': 'Checklist of adverse effects', 'timeFrame': 'Baseline, and daily in week 1,3,5,7,9,11'}, {'measure': 'McMaster Family assessment device (FAD), subscale General Functioning', 'description': '10 items, 4 point scale, maximum score 40', 'timeFrame': 'Baseline, and at the end of week 1,3,5,7,9,11'}, {'measure': 'Autism diagnostic observation scale (ADOS-2)', 'description': 'Minimum score 15, maximum score 60 (cut-off score for autism is 30)', 'timeFrame': 'Baseline'}]",8.0,6 Years,20 Years,ALL,False,OTHER,0.0,15.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00200941,Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome,Topiramate,['Topiramate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Restless Legs Syndrome,Neurocare,2025-09-01T16:18:10.911393,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS)",,['Restless Legs Syndrome'],"['Restless Legs Syndrome', 'Topiramate', 'Actigraphy', 'Polysomnography']",,2001-08,2005-04,[{'measure': 'The average number of periodic leg movements during three consecutive nights of actigraphy beginning at the end of the double blind phase'}],"[{'measure': 'Proportion of time in bed without leg movements during the three consecutive nights of actigraphy beginning at the end of the double blind phase'}, {'measure': 'SF-36 at the last visit of the double blind phase'}, {'measure': 'Score on the RLS Rating Scale (modified) questionnaire at the last visit of the double blind phase'}, {'measure': 'Periodic leg movements during sleep and wakefulness during the PSG recorded at the end of the double blind phase'}, {'measure': 'PSG measures including periodic leg movement arousal index, latency until sustained sleep, sleep efficacy, and wake after sleep onset'}, {'measure': 'Sleep diaries at the last double-blind visit'}, {'measure': 'Epworth sleepiness scale at the last double-blind visit'}]",8.0,18 Years,70 Years,ALL,True,OTHER,1.0,44.0,,v2_robust,True,True,False,False,
NCT05703841,A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants,JNJ-77242113,"['PN-235', 'PN-21235', 'JNJ-77242113']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Janssen Research & Development, LLC",2025-09-01T16:18:10.911519,True,,,,,"An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants",,['Healthy'],[],,2023-02-14,2023-04-12,"[{'measure': 'Area Under the Plasma Concentration versus Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC[0-last]) of JNJ-77242113', 'description': 'AUC(0-last) is defined as area under the plasma concentration versus time curve from time zero to time of the last measurable concentration of JNJ-77242113.', 'timeFrame': 'Predose up to Day 3'}, {'measure': 'Area Under the Plasma Concentration versus Time Curve From Time Zero to Infinite Time (AUC[0-infinite]) of JNJ-77242113', 'description': 'AUC(0-infinite) is defined as area under the plasma concentration versus time curve from time zero to infinite time of JNJ-77242113.', 'timeFrame': 'Predose up to Day 3'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of JNJ-77242113', 'description': 'Cmax is defined as maximum observed plasma concentration of JNJ-77242113.', 'timeFrame': 'Predose up to Day 3'}, {'measure': 'Time to Reach the Maximum Observed Plasma Concentration (Tmax) of JNJ-77242113', 'description': 'Tmax is defined as time to reach the maximum observed plasma concentration of JNJ-77242113.', 'timeFrame': 'Predose up to Day 3'}, {'measure': 'Apparent Elimination Half-life (T1/2) of JNJ-77242113', 'description': 'T1/2 is defined as apparent elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of JNJ-77242113.', 'timeFrame': 'Predose up to Day 3'}, {'measure': 'Apparent Total Systemic Clearance (CL/F) of JNJ-77242113', 'description': 'CL/F is defined as apparent total systemic clearance after extravascular administration of JNJ-77242113.', 'timeFrame': 'Predose up to Day 3'}, {'measure': 'Apparent Volume of Distribution (Vz/F) of JNJ-77242113', 'description': 'Vz/F is defined as apparent volume based on terminal phase after extravascular administration of distribution of JNJ-77242113.', 'timeFrame': 'Predose up to Day 3'}]","[{'measure': 'Number of Participants with Abnormalities in Physical Examinations', 'description': 'Number of participants with abnormalities in physical examinations will be reported.', 'timeFrame': 'Up to Day 35'}, {'measure': 'Number of Participants with Abnormalities in 12-Lead Electrocardiogram (ECG)', 'description': 'Number of participants with abnormalities in 12-lead ECGs will be reported.', 'timeFrame': 'Up to Day 35'}, {'measure': 'Number of Participants with Abnormalities in Vital Signs', 'description': 'Number of participants with abnormalities in vital signs (including body temperature, pulse rate, respiratory rate, and blood pressure) will be reported.', 'timeFrame': 'Up to Day 35'}, {'measure': 'Number of Participants with Abnormalities in Clinical Laboratory Tests', 'description': 'Number of participants with abnormalities in clinical laboratory tests (including hematology, clinical chemistry, and urinalysis) will be reported.', 'timeFrame': 'Up to Day 35'}, {'measure': 'Number of Participants with Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.', 'timeFrame': 'Up to Day 35'}]",12.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,True,False,True,
NCT00302341,DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP),Pafuramidine maleate (DB289),"['Bactrim', 'Trimethoprim-Sulfamethoxazole (TMP-SMX)', 'Pafuramidine maleate (DB289)']",3,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,"Pneumonia, Interstitial Plasma Cell","Immtech Pharmaceuticals, Inc",2025-09-01T16:18:10.911550,True,,,,,"International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS",,"['Pneumonia, Interstitial Plasma Cell', 'Pneumocystis Carinii Pneumonia', 'Pneumonia, Pneumocystis Carinii', 'HIV Infections']","['Pulmonary disease', 'Dyspnea', 'Hypoxemia', 'AIDS', 'Pneumocystis jiroveci']",FDA Clinical Hold as of 12/21/07 due to safety concerns,2006-05,2008-12,"[{'measure': 'The primary efficacy endpoint will be the proportion of subjects with clinical success at the End of Treatment (Day 22) for the Modified Intent-to-Treat population (mITT).', 'timeFrame': 'Day 22'}]","[{'measure': 'The secondary efficacy endpoints will be the proportion of subjects with clinical success at the End of Treatment (Day 22)for the Per Protocol population and sustained clinical success at the End of Study (Day 42)in the Per Protocol and mITT populations.', 'timeFrame': 'Day 22'}]",2.0,13 Years,65 Years,ALL,False,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,False,True,False,FDA Clinical Hold as of 12/21/07 due to safety concerns
NCT03721341,Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors,Chemotherapy,"['Chemotherapy', 'Hormones', 'Immunotherapy']",3,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Metastatic Tumors,David Palma,2025-09-01T16:18:10.911569,True,,,,,A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10),,['Metastatic Tumors'],[],,2019-02-22,2029-01,"[{'measure': 'Overall Survival at Study Completion', 'description': 'Time from randomization to death from any cause.', 'timeFrame': 'At approximately end of year 6 (study completion)'}]","[{'measure': 'Progression-free Survival', 'description': 'Time from randomization to disease progression at any site or death.', 'timeFrame': 'At approximately year 3, and end of year 6 (study completion)'}, {'measure': 'Time from randomization to development of new metastatic lesions', 'description': 'New metastatic lesions will be detected using computed tomography, magnetic resonance imaging, and/or bone scans.', 'timeFrame': 'At approximately end of year 6 (study completion)'}, {'measure': 'Quality of Life as measured by the Functional Assessment of Cancer Therapy- General (FACT-G) questionnaire', 'timeFrame': 'At approximately end of year 6 (study completion)'}, {'measure': 'Quality of Life as measured by the EuroQOL Group EQ-5D-5L questionnaire', 'timeFrame': 'At approximately end of year 6 (study completion)'}, {'measure': 'Toxicity as measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0', 'timeFrame': 'End of years 1, 2, 3, 4, 5, and 6 (study completion)'}, {'measure': 'Overall Survival at midpoint of Study', 'timeFrame': 'At approximately year 3 (midpoint)'}]",7.0,18 Years,,ALL,False,OTHER,4.0,204.0,ACTUAL,v2_robust,True,False,False,True,
NCT03198741,Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation,Aspirin + clopidogrel,"['Aspirin monotherapy', 'Clopidogrel monotherapy', 'Aspirin + clopidogrel', 'Clopidogrel + placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Gastrointestinal Injury,Shenyang Northern Hospital,2025-09-01T16:18:10.911633,True,,,,,COmparison of Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation for Prevention of Gastrointestinal Injury Evaluated by Ankon Magnetically Controlled Capsule Endoscopy,,"['Gastrointestinal Injury', 'Ischemic Heart Disease']",[],,2017-07-13,2020-08-13,"[{'measure': 'Gastrointestinal mucosal Injury (erosion, ulceration or bleeding)', 'description': 'Detected by AMCE', 'timeFrame': '12 months after enrollment (i.e. 6 months after randomization)'}]","[{'measure': 'The severity of gastric and intestinal mucosal lesions', 'description': 'Detected by AMCE and calculated with a score system', 'timeFrame': 'During the first 6 months after study enrollment (prior to randomization)'}, {'measure': 'The severity of gastric and intestinal mucosal lesions', 'description': 'Detected by AMCE and calculated with a score system', 'timeFrame': 'After randomization (i.e. between 6 months and 12 months after study enrollment)'}, {'measure': 'Clinical indicated bleeding of the upper gastrointestinal tract', 'description': '1. Hematemesis is defined as vomiting of blood or blood clots, and generally indicates bleeding of the upper gastrointestinal tract.\n2. Hematochezia is the passage of fresh blood per anus, usually in or with stools, and typically signifies lower GI tract bleeding.\n3. Melena is the passage of black, tarry stool and typically signifies upper tract GI bleeding.\n4. The positive fecal occult blood refers to blood in the feces that is not visibly apparent (unlike other types of blood in stool such as melena or hematochezia).', 'timeFrame': 'During 6 months after study enrollment (prior to randomization)'}, {'measure': 'Clinical indicated evident gastrointestinal hemorrhage', 'description': '1. Hematemesis is defined as vomiting of blood or blood clots, and generally indicates bleeding of the upper gastrointestinal tract.\n2. Hematochezia is the passage of fresh blood per anus, usually in or with stools, and typically signifies lower GI tract bleeding.\n3. Melena is the passage of black, tarry stool and typically signifies upper tract GI bleeding.\n4. The positive fecal occult blood refers to blood in the feces that is not visibly apparent (unlike other types of blood in stool such as melena or hematochezia).', 'timeFrame': 'After randomization (i.e. between 6 months and 12 months after study enrollment)'}, {'measure': 'Clinical indicated gastrointestinal hemorrhage', 'description': '1. Hematemesis is defined as vomiting of blood or blood clots, and generally indicates bleeding of the upper gastrointestinal tract.\n2. Hematochezia is the passage of fresh blood per anus, usually in or with stools, and typically signifies lower GI tract bleeding.\n3. Melena is the passage of black, tarry stool and typically signifies upper tract GI bleeding.\n4. The positive fecal occult blood refers to blood in the feces that is not visibly apparent (unlike other types of blood in stool such as melena or hematochezia).', 'timeFrame': '12 months after enrollment (i.e. 6 months after randomization)'}, {'measure': 'Gastrointestinal symptoms', 'description': 'pain, nausea/vomiting, dysphagia, other discomfort', 'timeFrame': '12 months after enrollment (i.e. 6 months after randomization)'}, {'measure': 'All bleeding', 'description': 'BARC types 1-5', 'timeFrame': '12 months after enrollment (i.e. 6 months after randomization)'}, {'measure': 'Target lesion failure', 'description': 'TLF: cardiac death, target-vessel MI, or clinically-driven target lesion revascularization', 'timeFrame': '12 months after enrollment (i.e. 6 months after randomization)'}, {'measure': 'Net adverse clinical events', 'description': 'NACE, defined as TLF or BARC type 2-5 bleeding', 'timeFrame': '12 months after enrollment (i.e. 6 months after randomization)'}, {'measure': 'Stent thrombosis', 'description': 'ARC definite, probable, or definite/probable', 'timeFrame': '12 months after enrollment (i.e. 6 months after randomization)'}]",11.0,18 Years,80 Years,ALL,False,OTHER,2.0,783.0,ACTUAL,v2_robust,True,True,False,True,
NCT03040141,Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A,Low dose of VIS410,"['oseltamivir', 'Low dose of VIS410', 'Placebo', 'High dose of VIS410']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Influenza A,"Visterra, Inc.",2025-09-01T16:18:10.911681,True,,,,,"Phase 2b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of IV VIS410 in Addition to Oseltamivir Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support",,['Influenza A'],[],,2018-01-03,2018-11-22,"[{'measure': 'Clinical Status of Participants on Day 7', 'description': 'Evaluate the effect of 2 dose levels of VIS410 + oseltamivir on clinical status using a seven-level ordinal scale. Comparison between treatment groups and between all VIS410 recipients versus placebo were assessed.', 'timeFrame': '7 days'}, {'measure': 'The Number of Participants With Adverse Events and Serious Adverse Events Following Administration of VIS410', 'description': 'Safety and tolerability of 2 dose levels of a single intravenous (IV) dose of VIS410 when administered in combination with oseltamivir in hospitalized participants with influenza A infection. Data presents the count of participants who experienced an adverse event (AE) or serious treatment emergent adverse events (TEAE).', 'timeFrame': '56 days'}]","[{'measure': 'Time to Cessation of Oxygen Support Compared to Oseltamivir Alone Among Patients Requiring Supplemental Oxygen Therapy With Baseline Room Air <= 92%', 'description': 'Time to cessation of O2 support in patients with supplemental oxygen with baseline room air \\<= 92%. Patients with treatment resulting in a stable SpO2 by pulse oximetry. Stable SpO2 is defined as two consecutive SpO2 values of \\>92% on room air that are at least 8 hours apart.', 'timeFrame': 'Baseline to Day 56'}, {'measure': 'Time to Cessation of Oxygen Support for Any Patient Requiring Supplemental Oxygen Therapy', 'description': 'Time to cessation of oxygen support in all patients with supplemental oxygen (regardless of oxygen saturation).', 'timeFrame': 'Baseline to Day 56'}, {'measure': 'Viral Titer in Upper Respiratory Samples by qRT-PCR', 'description': 'The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in peak viral load by qRT-PCR from nasopharyngeal swabs through Day 14', 'timeFrame': 'Day 14'}, {'measure': 'Viral Nasopharyngeal AUC', 'description': 'The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in nasopharyngeal qRT-PCR area under the viral load-time curve (AUC) from baseline to Day 5.', 'timeFrame': 'Day 1 Predose, Day 1 End of Infusion, Day 3, Day 5'}, {'measure': 'Area Under the Viral Load-Time Curve (VL AUC) Based on qRT-PCR From Nasopharyngeal Swabs Through Day 7', 'description': 'The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in nasopharyngeal qRT-PCR area under the viral load-time curve (AUC) from baseline to Day 7.', 'timeFrame': 'Day 1 Predose, Day 1 End of Infusion, Day 3, Day 5, Day 7'}, {'measure': 'Area Under the Viral Load-Time Curve (VL AUC) Based on qRT-PCR From Nasopharyngeal Swabs Through Day 14', 'description': 'The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in nasopharyngeal qRT-PCR area under the viral load-time curve (AUC) from baseline to Day 14.', 'timeFrame': 'Day 1 Predose, Day 1 End of Infusion, Day 3, Day 5, Day 7, Day 14'}, {'measure': 'Median Time to Resolution of Viral Load by Treatment Arm by qRT-PCR - From End of Infusion', 'description': 'Number of days from the end of infusion until virus is no longer detectable (at or below the limit of detection) with no samples following that are greater than the BLQ through the Day 14 (quantitative reverse-transcription polymerase chain reaction - qRT-PCR)', 'timeFrame': '14 days'}, {'measure': 'Number of Participants in Whom Peak Viral Load Occurred Post Baseline Measured by qRT-PCR', 'description': 'Number of participants in whom peak viral load is observed post-baseline based on quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Post-baseline was considered the day 3 sample or later.', 'timeFrame': '14 days'}, {'measure': 'Peak Viral Load by TCID50', 'description': 'Peak viral load based on TCID50 from nasopharyngeal swabs', 'timeFrame': 'Day 7'}, {'measure': 'Number of Participants in Whom Peak Viral Load Occurred Post Baseline Measured by TCID50', 'description': 'Number of participants in whom peak viral load occurred post-baseline measured by TCID50. Post-baseline was considered the day 3 sample or later.', 'timeFrame': '56 days'}, {'measure': 'Viral Nasopharyngeal AUC by TCID50', 'description': 'The area under the viral load-time curve (AUC) for VIS410 + oseltamivir and oseltamivir alone treatment groups from baseline to Day 5 measured by TCID50 from nasopharyngeal swabs.', 'timeFrame': '5 days'}, {'measure': 'Viral Nasopharyngeal AUC by TCID50', 'description': 'The area under the viral load-time curve (AUC) for VIS410 + oseltamivir and oseltamivir alone treatment groups from baseline to Day 7 measured by TCID50 from nasopharyngeal swabs.', 'timeFrame': '7 days'}, {'measure': 'Negative Viral Cultures by Study Day', 'description': 'Number of participants negative for viral titer by study day determined by TCID50 on nominal days 3, 5, 7', 'timeFrame': 'Nominal days 3, 5, 7'}, {'measure': 'Median Time to Resolution of Viral Load by Treatment Arm by TCID50 - From End of Infusion', 'description': 'Number of days from the end of infusion until virus is no longer detectable (at or below the limit of detection) with no samples following that are greater than the BLQ through the Day 7 (TCID50)', 'timeFrame': '7 Days'}, {'measure': 'Median Time to Resolution of Viral Load by Treatment Arm by TCID50 - From Onset of Symptoms', 'description': 'Number of days from the onset of symptoms until virus is no longer detectable (at or below the limit of detection) with no samples following that are greater than the BLQ through the Day 7 (TCID50)', 'timeFrame': '7 Days'}, {'measure': 'Time to Clinical Response (4 Out of 5 Vital Signs)', 'description': 'Median time to clinical response defined by resolution of at least 4 of 5 vital signs:\n\n* Afebrile with core temperature ≤ 37.8°C, without use of antipyretics (oral ≤ 37.2°C)\n* Oxygen saturation ≥ 95% on room air without support or a return to preinfection status, if pre-infection status was \\< 95%\n* Pulse rate ≤ 100/min\n* Systolic blood pressure ≥ 90 mm/Hg, without vasopressor use\n* Respiratory rate ≤ 24 beats per minute', 'timeFrame': 'Day 56'}, {'measure': 'Time to Complete Clinical Response (Resolution of All Vital Signs)', 'description': 'Median time to clinical response defined by resolution of at all 5 vital signs:\n\n* Afebrile with core temperature ≤ 37.8°C, without use of antipyretics (oral ≤ 37.2°C)\n* Oxygen saturation ≥ 95% on room air without support or a return to pre-infection status, if pre-infection status was \\< 95%\n* Pulse rate ≤ 100/min\n* Systolic blood pressure ≥ 90 mm/Hg, without vasopressor use\n* Respiratory rate ≤ 24 beats per minute', 'timeFrame': 'Day 56'}, {'measure': 'Clinical Status Ordinal Scale Mean Area Under the Curve Through Day 7', 'description': 'Summary of area under the curve (AUC) over time for seven-level ordinal scale. Area under the curve (AUC) is calculated using the linear trapezoidal rule. Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities. Time frame is from baseline to day 7. Therefore, maximum and minimum values possible for the AUC Clinical Status Ordinal Scale scores range from 7 to 49.', 'timeFrame': 'Baseline to Day 7'}, {'measure': 'Clinical Status Ordinal Scale Mean Area Under the Curve Through Day 14.', 'description': 'Summary of area under the curve (AUC) over time for seven-level ordinal scale. Area under the curve (AUC) is calculated using the linear trapezoidal rule. Seven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities. Time frame is from baseline to day 14. Therefore, maximum and minimum values possible for the AUC Clinical Status Ordinal Scale scores range from 14 to 98.', 'timeFrame': 'Baseline to Days 14'}, {'measure': 'Comparison of Clinical Status on Seven-level Ordinal Scale Scores', 'description': 'Summary of Clinical Outcome on Seven-Level Ordinal Scale through Day 14. Worst post-baseline assessment observed.\n\nSeven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.', 'timeFrame': 'Day 14'}, {'measure': 'Total Number of Days on Ventilation', 'description': 'Total number of days on ventilation for participants who used ventilation, including participants on ventilation at baseline', 'timeFrame': '56 days'}, {'measure': 'Comparison of Ordinal Scale Parameters - Days on Ventilation', 'description': 'Total number of days on ventilation for participations who used ventilation, including participants on ventilation at baseline. Better and worse outcome groups defined based on the Seven-Level Ordinal Scale scores, ""\\<= 4 Seven-Level Ordinal Scale Score"" is better; ""\\> 4 Seven-Level Ordinal Scale Score"" is worse group.\n\nSeven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.', 'timeFrame': '56 days'}, {'measure': 'Total Number of Days in ICU', 'description': 'Total number of days in intensive care (ICU) for participants who admitted to the ICU, including participants in ICU at baseline', 'timeFrame': '56 days'}, {'measure': 'Comparison of Ordinal Scale Parameters - Days in ICU', 'description': 'Total number of days in intensive care for participants who admitted to ICU, including participants in ICU at baseline. Better and worse outcome groups defined based on the Seven-Level Ordinal Scale scores, ""\\<= 4 Seven-Level Ordinal Scale Score"" is better; ""\\> 4 Seven-Level Ordinal Scale Score"" is worse group.\n\nSeven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.', 'timeFrame': '56 days'}, {'measure': 'Number of Days to Resumption of Usual Activities', 'description': 'Number of days until resumption of usual activities by treatment group', 'timeFrame': 'Day 56'}, {'measure': 'All Cause and Attributable Mortality at Day 14', 'description': 'Number of patients experiencing all-cause and attributable mortality rates at Day 14. Attributable mortality was derived from the Complication of Influenza eCRF; all-cause mortality was derived from Complication of Influenza, Seven-Level Ordinal Scale, AE and Study Completion eCRFs', 'timeFrame': 'Day 14'}, {'measure': 'All Cause and Attributable Mortality by Day 28', 'description': 'Number of patients experiencing all-cause and attributable mortality by Day 28. Attributable mortality was derived from the Complication of Influenza eCRF; all-cause mortality was derived from Complication of Influenza, Seven-Level Ordinal Scale, AE and Study Completion eCRFs', 'timeFrame': 'Day 28'}, {'measure': 'All Cause and Attributable Mortality Day 56', 'description': 'Number of patients experiencing all-cause and attributable mortality by Day 56. Attributable mortality was derived from the Complication of Influenza eCRF; all-cause mortality was derived from Complication of Influenza, Seven-Level Ordinal Scale, AE and Study Completion eCRFs', 'timeFrame': 'Day 56'}, {'measure': 'Healthcare Resource Utilization. Days in Hospital and/or ICU', 'description': 'Total number of days in hospital and/or ICU from admission to discharge', 'timeFrame': 'Day 56'}, {'measure': 'Comparison of Ordinal Scale Parameters - Days in Hospital/ICU', 'description': 'Total number of days in hospital or intensive care for participations who were admitted to Hospital/ICU, including participants in Hospital/ICU at baseline. Better and worse outcome groups defined based on the Seven-Level Ordinal Scale scores, ""\\<= 4 Seven-Level Ordinal Scale Score"" is better; ""\\> 4 Seven-Level Ordinal Scale Score"" is worse group.\n\nSeven-Level Ordinal Scale is a hierarchical scale with the classifications presented from the worst clinical outcome to the best clinical outcome in descending order with 7=death, 6=Intensive care unit (ICU) stay with mechanical ventilation , 5=ICU stay without mechanical ventilation, 4=Non-ICU hospitalization with supplemental oxygen, 3=Non-ICU hospitalization without supplemental oxygen, 2=Discharge with partial resumption of normal activities, 1=Discharge with full resumption of normal activities.', 'timeFrame': '56 days'}, {'measure': 'Number of Participants With Rehospitalization Due to Relapse', 'description': 'Number of participants with rehospitalization due to influenza A relapse', 'timeFrame': 'Day 56'}, {'measure': 'Number of Participants With Influenza-related Complications', 'description': 'Summary of influenza symptom complications, including baseline and incident complications', 'timeFrame': 'Day 56'}, {'measure': ""The Maximum Concentration (Cmax) of VIS410 in Participant's Serum"", 'description': ""Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by maximum concentration (Cmax) of VIS410 in participant's serum."", 'timeFrame': 'Baseline, end of infusion, Day 5, Day 14, Day 28, Day 56'}, {'measure': ""The Area Under the Concentration/Time Curve of VIS410 in Participant's Serum"", 'description': ""Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by the area under the concentration/time curve from 0 to infinity (AUC0-inf) of VIS410 in participant's serum."", 'timeFrame': 'Baseline, end of infusion, Day 5, Day 14, Day 28, Day 56'}, {'measure': ""The Clearance Rate (Cl) of VIS410 in Participant's Serum"", 'description': ""Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by the clearance rate (Cl) of VIS410 in participant's serum."", 'timeFrame': 'PK samples were collected on days 1, 5, 14, 28 and 56.'}, {'measure': ""The Half-life of VIS410 in Participant's Serum"", 'description': ""Summary of Serum VIS410 Pharmacokinetic Parameters in PK Population by the half-life (t1/2) of VIS410 in participant's serum."", 'timeFrame': 'PK samples were collected on days 1, 5, 14, 28 and 56.'}, {'measure': 'Anti-VIS410 Antibody Testing', 'description': 'Summary of the maximum fold increase for anti-VIS410 antibody testing for VIS410 groups and placebo.', 'timeFrame': 'From anti-VIS410 antibody samples collected on days 28 and 56.'}]",39.0,18 Years,,ALL,False,INDUSTRY,0.0,89.0,ACTUAL,v2_robust,True,True,False,True,
NCT00141154,"Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan",Celecoxib,"['Celecoxib', 'Loxoprofen', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Low Back Pain,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,2025-09-01T16:18:10.911693,True,,,,,"A Randomized, Multicenter, Active And Placebo Controlled Parallel Group Study To Evaluate The Efficacy And Safety Of Celecoxib (Ym177) 200 Bid Compared To Loxoprofen 60 Mg Tid In Patients With Low Back Pain",,['Low Back Pain'],[],,2004-10,,"[{'measure': ""Patient's pain assessment (VAS: Visual Analogue Scale)""}]","[{'measure': ""Patient's global assessment (VAS), Physician's global assessment (VAS), Roland Morris Disability Questionnaire (RDQ)""}]",2.0,20 Years,,ALL,False,INDUSTRY,0.0,1234.0,ACTUAL,v2_robust,True,True,False,False,
NCT00002054,A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients,Pentamidine isethionate,['Pentamidine isethionate'],1,INTERVENTIONAL,['NA'],,COMPLETED,"Pneumonia, Pneumocystis Carinii",Fisons,2025-09-01T16:18:10.911746,True,,,,,A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients,,"['Pneumonia, Pneumocystis Carinii', 'HIV Infections']","['AIDS-Related Opportunistic Infections', 'Pneumonia, Pneumocystis carinii', 'Pentamidine', 'Dose-Response Relationship, Drug', 'Acquired Immunodeficiency Syndrome']",,,,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,,,v2_robust,True,True,False,False,
NCT01064154,"Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions",Carvedilol,"['Carvedilol', 'Coreg Tablets 25 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Dr. Reddy's Laboratories Limited,2025-09-01T16:18:10.911753,True,,,,,"Randomized,2-way Crossover, Bioequivalence Study of Carvedilol 25 mg Film-coated Tablets and COREG® 25 mg Film-coated Tablets Administered as 1 x 25 mg Film-coated Tablet in Healthy Subjects Under Fasting Conditions",,['Healthy'],[],,2002-05,2002-05,"[{'measure': 'Carvedilol Tablets, 25 mg Bioequivalence Study Of Dr Reddys under fasting condition', 'timeFrame': '4 months'}]",[],1.0,18 Years,,ALL,True,INDUSTRY,0.0,36.0,ACTUAL,v2_robust,True,True,False,False,
NCT06554054,A Study of GZR18 Tablet in Chinese Healthy Subjects,GZR18,['GZR18'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2","Gan and Lee Pharmaceuticals, USA",2025-09-01T16:18:10.911760,True,,,,,"A Randomized, Open Phase I Trial to Evaluate the Bioavailability, Pharmacokinetics, Pharmacodynamics, Safety and Tolerance of GZR18 Tablet and Evaluate the Effect of Meal Time on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerance of GZR18 Tablet in Chinese Healthy Adult Subjects",,"['Diabetes Mellitus, Type 2']",[],,2024-04-01,2024-12-09,"[{'measure': 'AE and SAE', 'description': 'Incidence of Adverse Events and Severe Adverse Events', 'timeFrame': '22 days and 35 days'}, {'measure': 'Relative bioavailability of GZR18 tablet', 'description': 'Fr =AUC0-t(GZR18 tablets)/AUC0-t(GZR18 injection)×100%', 'timeFrame': '22 days and 35 days'}, {'measure': 'ADA and NAb', 'description': 'Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab)', 'timeFrame': '22 days and 35 days'}]","[{'measure': 'Cmax', 'description': 'Maximum plasma drug concentration', 'timeFrame': '22 days and 35 days'}, {'measure': 'AUC0-t', 'description': 'Area under the curve from 0 through the time of the last accurately measurable concentration', 'timeFrame': '22 days and 35 days'}, {'measure': 'AUC0-24h', 'description': 'Area under the curve from 0 h to 24 hours', 'timeFrame': '22 days and 35 days'}]",6.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,92.0,ACTUAL,v2_robust,True,False,False,True,
NCT00364754,Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer,Tesmilifene (YMB 1002),['Tesmilifene (YMB 1002)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Metastatic/Recurrent Breast Cancer,YM BioSciences,2025-09-01T16:18:10.911769,True,,,,,"A PHARMACOKINETIC INTERACTION PHASE I, MULTI-CENTRE, OPEN-LABEL, CROSS-OVER Study Evaluating the Effect of Tesmilifene on the Plasma Pharmacokinetics of Epirubicin and Cyclophosphamide in Patients With Metastatic/Recurrent Breast Cancer",,['Metastatic/Recurrent Breast Cancer'],"['Tesmilifene', 'DPPE', 'Breast cancer', 'Cyclophosphamide', 'Epirubicin', 'Pharmacokinetic']",,2004-05,2006-01,[{'measure': 'The distribution of the pharmacokinetic variables will be summarized by treatment. The variables AUC and CMAX expressed as geometric means and ratios of geometric means on the original scale of measurement.'}],"[{'measure': 'Adverse experiences will be collected and graded using the NCI Expanded Common Terminology Criteria for Adverse Events version 3.0.'}, {'measure': 'Blood pressure, temperature, pulse and respiration will be tabulated across time and shift tables will be presented.'}, {'measure': 'The tesmilifene concentration, haematology and biochemistry values will be tabulated across time.'}, {'measure': 'Although response is not the endpoint of this trial, patients with measurable disease will be assessed by standard institutional criteria.'}]",5.0,18 Years,55 Years,FEMALE,False,INDUSTRY,0.0,28.0,ACTUAL,v2_robust,True,True,False,True,
NCT02236754,Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass,18 F-FP-DTBZ,['18 F-FP-DTBZ'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Healthy Volunteers,Columbia University,2025-09-01T16:18:10.911778,True,,,,,Scan Re-Scan Pancreatic Beta Cell Imaging Using PET Imaging and 18 F-FP-DTBZ,,"['Healthy Volunteers', 'Diabetes Mellitus, Type 1']","['dihydrotetrabenazine', 'beta cell mass', 'diabetes mellitus']",,2013-07-02,2014-04-23,"[{'measure': 'Mean VMAT2 Functional Binding Capacity in the β Cells to 18 F-FP-DTBZ', 'description': 'The VMAT2 functional binding capacity in the body and tail of the pancreas is calculated as BPND (VMAT2 binding potential) × PET ROI (region-of-interest) Volume. BPND is unitless, and ROI unit is mL. Higher values of the VMAT functional binding capacity indicates greater β cell mass.', 'timeFrame': 'Up to 2 months from enrollment'}]",[],1.0,18 Years,70 Years,ALL,True,OTHER,1.0,23.0,ACTUAL,v2_robust,True,True,False,False,
NCT05415254,Calcitriol Supplementation in COVID-19 Patients,Calcitriol,"['Rocaltrol', 'Calcitriol']",2,INTERVENTIONAL,['NA'],,UNKNOWN,COVID-19,RenJi Hospital,2025-09-01T16:18:10.911824,True,,,,,A Randomized Open Label Study to Evaluate Efficacy of Calcitriol Supplementation in COVID-19 Patients With Vitamin D Deficiency,,"['COVID-19', 'Vitamin D Deficiency']",[],,2022-06-12,2022-09-19,"[{'measure': 'The cycle threshold (Ct) value of COVID-19 nucleic acid after treatment', 'description': 'Nucleic acid test of COVID-19', 'timeFrame': 'The 6th day after treatment'}]","[{'measure': 'Clinical symptoms changes', 'description': 'fever, cough, sore throat，etc', 'timeFrame': 'The 6th day after treatment'}, {'measure': 'Laboratory examination changes', 'description': 'Complete Blood Count， inflammatory markers ，cytokines', 'timeFrame': 'The 6th day after treatment'}]",3.0,18 Years,70 Years,ALL,False,OTHER,0.0,86.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05501054,"Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.",Ipilimumab,"['Ipilimumab', 'Nivolumab', 'Opdivo', 'Yervoy', 'BMS-936558', 'MDX010', 'BMS-734016', 'Ciforadenant']",8,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,ACTIVE_NOT_RECRUITING,Renal Cell Carcinoma,M.D. Anderson Cancer Center,2025-09-01T16:18:10.911875,True,,,,,"Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.",,['Renal Cell Carcinoma'],[],,2023-02-09,2026-11-01,"[{'measure': 'To establish the objective response rate (ORR)', 'timeFrame': 'through study completion and average of 1 year.'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,False,False,False,
NCT00033254,Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases,thalidomide,"['THAL', 'Synovir', 'Thalomid', 'Kevadon', 'thalidomide']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Tumors Metastatic to Brain,National Cancer Institute (NCI),2025-09-01T16:18:10.911890,True,,,,,A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC#66847) Versus Conventional Radiation Therapy for Multiple Brain Metastases,,['Tumors Metastatic to Brain'],[],,2002-03,,"[{'measure': 'Overall survival', 'description': 'The log-rank statistic will be used.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Time to tumor progression', 'description': 'Cumulative incidence model will be used to analyze the data. A multivariate Cox model analysis will be performed.', 'timeFrame': 'Date of randomization to documentation of progression, assessed up to 6 years'}, {'measure': 'Time to neuro-cognitive progression as assessed by the Mini Mental State Exam', 'description': 'Cumulative incidence model will be used to analyze the data.', 'timeFrame': 'Up to 6 years'}]","[{'measure': 'Cause of death distribution', 'timeFrame': 'Up to 6 years'}, {'measure': 'Frequency of toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0', 'timeFrame': 'Up to 6 years'}, {'measure': 'Quality of life as measured by the Spitzer Quality of Life Index (SQLI)', 'timeFrame': '6 months'}, {'measure': 'Quality of life as measured by the SQLI', 'timeFrame': '12 months'}]",7.0,18 Years,,ALL,False,NIH,1.0,332.0,ACTUAL,v2_robust,True,True,False,True,
NCT00822705,Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36,Placebo tablet,['Placebo tablet'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Anti Obesity Agent,"University Hospital, Basel, Switzerland",2025-09-01T16:18:10.912039,True,,,,,Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36: a Phase 1 Study,,['Anti Obesity Agent'],"['Appetite, energy consumption, gastrointestinal hormones']",,2008-08,2009-01,"[{'measure': 'Energy consumption', 'timeFrame': '1 hour food consumption'}]","[{'measure': 'Appetite feelings, plasma kinetics adverse events', 'timeFrame': 'adeverse events during study (3 months)'}]",2.0,18 Years,45 Years,MALE,True,OTHER,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT03619005,Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study,Placebo Vaginal Insert,"['Placebo Vaginal Insert', 'Prasterone 6.5 mg (0.50%) Vaginal Insert']",2,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Hypoactive Sexual Desire Disorder (HSDD),EndoCeutics Inc.,2025-09-01T16:18:10.912102,True,,,,,"Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)",,['Hypoactive Sexual Desire Disorder (HSDD)'],"['Prasterone', 'DHEA', 'Menopause', 'Sexual Disorder', 'HSDD']",Business decision to not continue this study (only few subjects were screened).,2018-11-13,2019-12-06,"[{'measure': 'Sexual desire', 'description': 'Change from Baseline in sexual desire as evaluated by Questions 1 \\& 2 of the 19-items questionnaire titled Female Sexual Function Index (FSFI). For this outcome, Question 1 and Question 2 (corresponding to the desire domain) will be graded from 1 to 5 (score range) and then be multiplied by 0.6 (domain factor). The desire domain (sum of scores from Questions 1 \\& 2) has a minimum score of 1.2 and a maximum score of 6. Higher values represent a better outcome.', 'timeFrame': '28 weeks'}, {'measure': 'Distress from low sexual desire', 'description': 'Change from Baseline in distress from low sexual desire as evaluated by Question 13 of the 15-items questionnaire titled Female Sexual Distress Scale - Desire Arousal Orgasm (FSDS-DAO). For this outcome, Question 13 is graded from 0 to 4 and a lower value represents a better outcome.', 'timeFrame': '28 weeks'}]","[{'measure': 'Satisfying sexual events (SSEs)', 'description': 'Change from Baseline in the number of SSEs from a daily log of sexual activity.', 'timeFrame': '28 weeks'}]",3.0,40 Years,80 Years,FEMALE,False,INDUSTRY,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Business decision to not continue this study (only few subjects were screened).
NCT01531205,Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA,Androgen Ablation,"['leuprolide acetate (Lupron®)', 'Neoadjuvant Treatment - Cabazitaxel', 'goserelin acetate (Zoladex®)', 'Salvage Therapy', 'Neoadjuvant Treatment - Hormonal Therapy', 'prostatectomy', 'Jevtana®', 'Cabazitaxel', 'bicalutamide (Casodex®)', 'Androgen Ablation']",10,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Prostate Cancer,H. Lee Moffitt Cancer Center and Research Institute,2025-09-01T16:18:10.912147,True,,,,,Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Failure With Biopsy Proven Local Recurrence After Initial Definitive Radiotherapy,,['Prostate Cancer'],"['recurrent', 'high risk']",low accrual,2012-05,2013-10,"[{'measure': 'Surgical Margin Negative Rate (SM Rate)', 'description': 'Post surgery percentage of participants with negative surgical margin. To determine the surgical margin negative rate in patients who have undergone chemohormonal therapy followed by surgery for biopsy proven androgen-dependent high risk locally recurrent prostate cancer following primary radiation therapy. Margin: The edge or border of the tissue removed in cancer surgery. The margin is described as negative or clean when the pathologist finds no cancer cells at the edge of the tissue, suggesting that all of the cancer has been removed. The margin is described as positive or involved when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed.', 'timeFrame': 'One Year'}]","[{'measure': 'Incidence of PSA Progression Free Survival (PFS)', 'description': 'Percentage of participants with stable (has not increased) or undetectable PSA post surgery. To assess Prostate-specific antigen(PSA)-progression free survival and prostate cancer specific survival for patients treated by chemohormonal therapy followed by salvage surgery for biopsy proven androgen-dependent high-risk locally recurrent prostate cancer following radiation therapy.', 'timeFrame': 'Four Months'}, {'measure': 'Incidence of Complete Response (CR)', 'description': 'Percentage of participants with CR post surgery. To evaluate the pathological complete response rate to androgen ablation plus Cabazitaxel in patients with locally recurrent prostate cancer following radiation therapy. Pathological Complete Response (pCR): Participants with no residual cancer in the local resection specimen and pelvic lymph nodes will be considered pCR.', 'timeFrame': 'One Year'}, {'measure': 'Incidence of Perioperative and Postoperative Morbidity', 'description': 'Number of events. To access the perioperative and postoperative morbidity with salvage surgery after neoadjuvant hormonal ablation and Cabazitaxel.', 'timeFrame': 'One Year'}, {'measure': 'Incidence of Detecting Circulating Tumor Cells (CTC)', 'description': 'To determine the feasibility of detecting circulating tumor cells in this patient population. CTC results per patient in milliliters.', 'timeFrame': 'One Year'}]",5.0,18 Years,,MALE,False,OTHER,1.0,2.0,ACTUAL,v2_robust,True,False,True,False,low accrual
NCT06633705,Changes in Neighbouring Microbiota in Genitourinary Syndrome,Vaginal Cream with Applicator,['Vaginal Cream with Applicator'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Genitourinary Syndrome of Menopause,Koc University Hospital,2025-09-01T16:18:10.912174,True,,,,,"Investigation of the Effects of Local Estrogen Administration on Vaginal, Periurethral and Urinary Microbiota in Genitourinary Syndrome",,['Genitourinary Syndrome of Menopause'],"['Genitourinary Syndrome of Menopause', 'vaginal microbiota', 'periurethral microbiota', 'urobiome']",,2023-11-10,2024-07-10,"[{'measure': 'Vaginal, periurethral and urinary bladder microbiota', 'description': 'Microbiota contents of 3 areas (vagina, periurethra and bladder) will be obtain and compared to each other', 'timeFrame': '3 months'}]",[],1.0,40 Years,,FEMALE,True,OTHER,0.0,31.0,ACTUAL,v2_robust,True,True,False,False,
NCT05363605,A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours,[225Ac]-FPI-1966,"['[225Ac]-FPI-1966', '[111In]-FPI-1967']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Advanced Solid Tumor,Fusion Pharmaceuticals Inc.,2025-09-01T16:18:10.912212,True,,,,,"A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours",,"['Advanced Solid Tumor', 'Head and Neck Squamous Cell Carcinoma', 'Bladder Carcinoma', 'Susceptible FGFR3 Genetic Alterations', 'FGFR3', 'FGFR3 Overexpression', 'FGFR3 Receptor', 'FGFR3 Protein Overexpression', 'Ovarian Cancer', 'Colorectal Cancer', 'Breast Cancer', 'Liver Cancer', 'Lung Cancer', 'Gastric Cancer']","['Actinium-225', 'Targeted Alpha Therapy', 'Radiopharmaceutical', 'Radioimmunoconjugate', 'Theranostic', 'Theragnostic', 'Radioligand', 'Antineoplastic agents', '[225Ac]-FPI-1966']",Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.,2022-04-20,2023-09-08,"[{'measure': 'Phase 1: Phase 1: Incidence of AEs to evaluate safety and tolerability of [225Ac]-FPI-1966, [111In]-FPI-1967, and vofatamab.', 'timeFrame': 'Approximately 2 years post final administration'}, {'measure': 'Phase 1: Maximum tolerated dose (MTD) of [225Ac]-FPI-1966', 'timeFrame': 'Approximately 42 days post administration.'}, {'measure': 'Phase 1: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest)', 'timeFrame': 'Within one week of administration'}, {'measure': 'Phase 1: Effect of pre-dose administration of vofatamab on the radiation dosimetry of [111In]-FPI-1967 and [225Ac]-FPI-1966.', 'timeFrame': 'Within one week of administration'}, {'measure': 'Phase 2: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.', 'timeFrame': 'Up to two years post final administration.'}]","[{'measure': 'Phase 1 and 2: Anti-tumour activity of [225Ac]-FPI-1966 regimen measured by response per RECIST v1.1', 'timeFrame': 'Approximately 2 years post final administration'}, {'measure': 'Phase 1 and 2: Tumour uptake of [111In]-FPI-1967 by evaluating SPECT/CT and/or planar images', 'timeFrame': 'Within one week of administration'}, {'measure': 'Phase 2: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest)', 'timeFrame': 'Within one week of administration'}, {'measure': 'Phase 1 and 2: Clearance for radioactivity and for the targeting antibody.', 'timeFrame': '28 days post final [225Ac]-FPI-1966administration'}, {'measure': 'Phase 1 and 2: Area under the curve (AUC) for radioactivity and targeting antibody', 'timeFrame': '28 days post final [225Ac]-FPI-1966administration.'}, {'measure': 'Phase 1 and 2: Maximum concentration after dosing (Cmax) for radioactivity and targeting antibody.', 'timeFrame': '28 days post final[225Ac]-FPI-1966 administration'}, {'measure': 'Phase 1 and 2: Half-life for radioactivity and targeting antibody.', 'timeFrame': '28 days post final [225Ac]-FPI-1966 administration'}, {'measure': 'Phase 1: Changes in clearance for radioactivity and targeting antibody following pre-dose administration of vofatamab', 'timeFrame': '28 days post final [225Ac]-FPI-1966 administration'}, {'measure': 'Phase 1: Changes in AUC for radioactivity and targeting antibody following pre-dose administration of vofatamab.', 'timeFrame': '28 days post final [225Ac]-FPI-1966 administration'}, {'measure': 'Phase 1: Changes in Cmax for radioactivity and targeting antibody following pre-dose administration of vofatamab.', 'timeFrame': '28 days post final [225Ac]-FPI-1966 administration'}, {'measure': 'Phase 1: Changes in half-life for radioactivity and targeting antibody following pre-dose administration of vofatamab', 'timeFrame': '28 days post final [225Ac]-FPI-1966 administration'}]",16.0,18 Years,,ALL,False,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,False,True,True,Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.
NCT03088605,Safety and Efficacy of TOP1630 for Dry Eye Syndrome,TOP1630 Ophthalmic Solution,"['TOP1630 Ophthalmic Solution', 'Placebo to TOP1630 Ophthalmic Solution']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Dry Eye Syndrome,"ORA, Inc.",2025-09-01T16:18:10.912345,True,,,,,"A Single-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of TOP1630 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Syndrome",,['Dry Eye Syndrome'],[],,2017-02-20,2017-06-15,"[{'measure': 'Visual Acuity', 'description': 'Visual Acuity will be measured using the EDTRS chart to assess changes from baseline', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}, {'measure': 'Slit-lamp Biomicroscopy', 'description': 'Slit lamp biomicroscopy exams will be performed to assess any changes from baseline; outcome measure is number of patients with no abnormalities', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}, {'measure': 'Drop Comfort Assessment', 'description': 'The comfort of the eye drop will be performed to assess changes from baseline. Drop Comfort Assessment Scale; 0-10; 0 being very comfortable and 10 being very uncomfortable', 'timeFrame': 'Part 1: 12 days time frame'}, {'measure': 'Intraocular Pressure', 'description': 'a non-contact tonometer will be used to perform IOP to assess changes from baseline.', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}, {'measure': 'Corneal Sensitivity', 'description': 'The aesthesiometer will be used to perform corneal sensitivity to assess changes from baseline. Corneal Sensitivity Scale. Scale of 0-6', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}, {'measure': 'Undilated Fundoscopy', 'description': 'Non-Contact undilated fundoscopy exam will be performed to assess changes from baseline; outcome measure is number of patients with no abnormalities', 'timeFrame': 'Part 2: 35 days time frame'}, {'measure': 'Vital Signs - Pulse', 'description': 'Changes in vital signs is performed to assess changes from baseline', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}, {'measure': 'Vital Signs - O2 Saturation', 'description': 'Changes in vital signs is performed to assess changes from baseline', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}, {'measure': 'Vital Signs - Systolic Blood Pressure', 'description': 'Changes in vital signs is performed to assess changes from baseline', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}, {'measure': 'Vital Signs - Diastolic Blood Pressure', 'description': 'Changes in vital signs is performed to assess changes from baseline', 'timeFrame': 'Part 1: 12 days time frame; Part 2: 35 days time frame'}]","[{'measure': 'Ocular Discomfort', 'description': 'Ocular discomfort Scale severity assessment (0-4 scale where 0 = none and 4 = constant)', 'timeFrame': 'Part 2: 35 days time frame'}, {'measure': 'Dry Eye Symptoms', 'description': 'Dry eye syndrome symptom assessment Scale (grittiness) (0-5 scale where 0 = none and 5 = worst)', 'timeFrame': 'Part 2: 35 days time frame'}, {'measure': 'Dry Eye Signs', 'description': 'Dry eye syndrome staining Score assessments (total lissamine green staining score, 0-20 where 0 = no staining)', 'timeFrame': 'Part 2: 35 days time frame'}, {'measure': 'Tear Film Break up Time', 'description': 'Tear film break up time measured (in seconds) after instillation of sodium fluorescein solution', 'timeFrame': 'Part 2: 35 days time frame'}, {'measure': ""Schirmer's Test"", 'description': 'Measurement of Schirmer test strips (mm length of moistened area after 5 minutes)', 'timeFrame': 'Part 2: 35 days time frame'}, {'measure': 'Daily Symptom Assessment', 'description': 'Daily symptom assessment using diary cards - outcome for worst symptom, ie symptom with highest severity score at baseline for each patient; calculated using the daily average between visit 3b to visit 4b Ora Calibra Ocular Discomfort \\& 4-Symptom Questionnaire (0-5 scale where 0 = none and 5 = worst)', 'timeFrame': 'Assessed daily between visit 3b (day 27) to visit 4b (day 35)'}]",16.0,18 Years,,ALL,False,INDUSTRY,1.0,69.0,ACTUAL,v2_robust,True,True,False,False,
NCT01796405,Clofarabine for Langerhans in Pedi,Clofarabine,['Clofarabine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Langerhans Cell Histiocytosis,Dana-Farber Cancer Institute,2025-09-01T16:18:10.912677,True,,,,,Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis,,['Langerhans Cell Histiocytosis'],[],,,,"[{'measure': 'Estimated Response Rate', 'description': 'To estimate the response rate of participants with recurrent LCH to clofarabine within each of two strata: a) low-risk participants with disease reactivation; and b) high-risk participants with risk-organ involvement that is refractory to standard treatment.', 'timeFrame': '2 years'}]","[{'measure': 'Estimated of Progression Free Survival', 'description': 'To estimate the progression-free survival after clofarabine treatment', 'timeFrame': '2 years'}, {'measure': 'Estimated survival with risk organ involvement', 'description': 'To estimate survival of participants with refractory multi-system LCH with risk organ involvement treated with clofarabine', 'timeFrame': '2 years'}, {'measure': 'Chemotherapy feasibility', 'description': ""To determine if clofarabine therapy can be delivered as planned ('chemotherapy feasibility'), and to describe toxicities of clofarabine in participants with LCH."", 'timeFrame': '2 years'}]",4.0,,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,
NCT02536105,PK/PD Pediatric ADHD Classroom Study,Methylphenidate HCl ER tablets 1,"['Methylphenidate HCl ER for suspension', 'Methylphenidate HCl ER tablets 2', 'Methylphenidate HCl ER tablets 1', 'Placebo']",4,INTERVENTIONAL,['NA'],,COMPLETED,Attention Deficit Hyperactivity Disorder,Massachusetts General Hospital,2025-09-01T16:18:10.912754,True,,,,,Pharmacokinetic Pharmacodynamic Studies of Methylphenidate Extended Release Products in Pediatric Attention Deficit Hyperactivity Disorder,,['Attention Deficit Hyperactivity Disorder'],"['Attention Deficit Hyperactivity Disorder', 'ADHD']",,2016-05,2018-07,"[{'measure': 'Permanent Product Measure of Performance (PERMP) for Three Methylphenidate Hydrochloride Extended-release Drug Products', 'description': 'The Permanent Product Measure of Performance (PERMP) involves objective individualized mathematics tests. Scores will be obtained ten times on each classroom day at pre-dose, and at approximately 0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose. PERMP Attempted is reported here. Scale ranges 0 math questions answered to 400 math questions answered. The more number of questions answered (better score), the higher the PERMP Attempted score is.', 'timeFrame': '0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose on each classroom day'}, {'measure': 'Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Rating Scale for Three Methylphenidate Hydrochloride Extended-release Drug Products', 'description': ""The Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scale is a validated, 13-item rating of subjective impairment of classroom behaviors (0 = normal/no impairment; 1 = slight impairment; 2 = mild impairment; 3 = moderate impairment; 4 = severe impairment; 5 = very severe impairment; 6 = maximal impairment). The SKAMP consists of four subscales: SKAMP-Attention, SKAMP-Deportment, SKAMP-Quality of Work, and SKAMP-Compliance, in addition to SKAMP-Total (reported here). SKAMP-Total is a sum of the four sub-scales and has a range of 0-78. The higher the score, the higher the impairment. Scores will be obtained during each classroom cycle during each full laboratory classroom day at pre-dose, and at 0.5, 1.5, 2.5, 4, 5, 6, 8, 10, and 12 hours post-dose. The scores will be based on the child's behavior during 20 minutes of each cycle."", 'timeFrame': '0.5, 1.5, 2.5, 4, 5, 6, 8, 10 and 12 hours post-dose on each classroom day'}, {'measure': 'Maximum Drug Concentration Observed (Cmax) for Three Methylphenidate Hydrochloride Extended-release Drug Products', 'description': 'PK samples will be taken eight times on each classroom day at approximately 0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose, and Cmax will be measured. The objectives of this measure is to estimate PK metrics, including Cmax, appropriate for characterizing rate and extent of absorption in each phase of the drug release and the evaluate the disposition and eliminating processes for each medication studied. The minimum value is pg/mL and there is was no maximum defined prior to the interventions.', 'timeFrame': '0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose on each classroom day'}, {'measure': 'Time to Reach Cmax (Tmax) for Three Methylphenidate Hydrochloride Extended-release Drug Products', 'description': 'PK samples will be taken eight times on each classroom day at approximately 0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose, and Tmax will be measured', 'timeFrame': '0.5, 1.5, 2.5, 4, 5, 6, 8, and 12 hours post-dose on each classroom day'}]",[],4.0,6 Years,12 Years,ALL,False,OTHER,2.0,88.0,ACTUAL,v2_robust,True,True,False,False,
NCT03036605,The Effect of Dexamethasone Added to Bupivacain in Nasal Surgery,Bupivacaine,"['Bupivacaine plus dexamethasone', 'Bupivacaine only', 'Bupivacaine', 'Dexamethasone']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Nasal Surgery,Ataturk University,2025-09-01T16:18:10.912785,True,,,,,The Postoperative Analgesic Effect of Dexamethasone Added to Topical Bupivacaine in Endoscopic Nasal Surgery,,['Nasal Surgery'],"['dexamethasone', 'bupivacaine', 'nasal surgery', 'nasal packing']",,2017-03-15,2017-05-15,"[{'measure': 'Analgesic consumption', 'description': 'Analgesic consumption first 24 hours', 'timeFrame': 'Postoperative 24 hours'}]","[{'measure': 'Visual analog pain score', 'description': 'Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at first hour postoperatively.', 'timeFrame': 'postoperative first hour'}, {'measure': 'Visual analog pain score', 'description': 'Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at second hour postoperatively.', 'timeFrame': 'postoperative second hour'}, {'measure': 'Visual analog pain score', 'description': 'Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at 4th hour postoperatively.', 'timeFrame': 'postoperative 4th hour'}, {'measure': 'Visual analog pain score', 'description': 'Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at 8th hour postoperatively.', 'timeFrame': 'postoperative 8th hour'}, {'measure': 'Visual analog pain score', 'description': 'Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at 12th hour postoperatively.', 'timeFrame': 'postoperative 12th hour'}, {'measure': 'Visual analog pain score', 'description': 'Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at 24th hour postoperatively.', 'timeFrame': 'postoperative 24th hour'}]",7.0,18 Years,65 Years,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT00477594,Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia,mipomersen sodium,"['ISIS 301012', 'mipomersen sodium', 'Kynamro™']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Lipid Metabolism, Inborn Errors","Kastle Therapeutics, LLC",2025-09-01T16:18:10.912832,True,,,,,An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia,,"['Lipid Metabolism, Inborn Errors', 'Hypercholesterolemia, Autosomal Dominant', 'Hyperlipidemias', 'Metabolic Diseases', 'Hyperlipoproteinemia Type II', 'Metabolism, Inborn Errors', 'Genetic Diseases, Inborn', 'Infant, Newborn, Diseases', 'Metabolic Disorder', 'Congenital Abnormalities', 'Hypercholesterolemia', 'Hyperlipoproteinemias', 'Dyslipidemias', 'Lipid Metabolism Disorders']","['Familial Hypercholesterolemia', 'Heterozygous Familial Hypercholesterolemia', 'Homozygous Familial Hypercholesterolemia', 'ISIS 301012', 'mipomersen', 'Open Label Extension']",,2007-05,2011-07,"[{'measure': 'Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)', 'description': ""LDL cholesterol was measured in mg/dL. Samples were taken following an overnight fast. For patients with triglycerides \\<400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study."", 'timeFrame': 'Baseline and Weeks 52 and 104'}, {'measure': 'Low-density Lipoprotein Cholesterol (LDL-C) Over Time', 'description': ""Samples were taken following an overnight fast. For patients with triglycerides \\<400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study."", 'timeFrame': 'Baseline and Weeks 52 and 104.'}]","[{'measure': 'Percent Change From Baseline in Apolipoprotein B', 'description': 'Apolipoprotein B was measured in mg/dL. Samples were taken following an overnight fast. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.', 'timeFrame': 'Baseline and Weeks 52 and 104'}, {'measure': 'Apolipoprotein B Over Time', 'description': 'For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.', 'timeFrame': 'Baseline and Weeks 52 and 104.'}, {'measure': 'Percent Change From Baseline in Total Cholesterol', 'description': 'Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast.', 'timeFrame': 'Baseline and Weeks 52 and 104.'}, {'measure': 'Total Cholesterol Over Time', 'description': 'For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.', 'timeFrame': 'Baseline and Weeks 52 and 104.'}, {'measure': 'Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol', 'description': 'Non-high-density lipoprotein cholesterol was measured in mg/dL. Samples were taken following an overnight fast.', 'timeFrame': 'Baseline and Weeks 52 and 104.'}, {'measure': 'Non-High-Density Lipoprotein Cholesterol Over Time', 'description': 'For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.', 'timeFrame': 'Baseline and Weeks 52 and 104.'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs)', 'description': 'AEs were considered as related if assessed by the Investigator as possibly, probably or definitely related to study drug. The severity of each event was assessed using the following categories: Mild (symptom(s) barely noticeable to the patient or do not make the patient uncomfortable); Moderate (symptom(s) of a sufficient severity to make the patient uncomfortable, performance of daily activities is influenced) or Severe (symptom(s) of a sufficient severity to cause the patient severe discomfort, may cause cessation of treatment with the study drug). Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.', 'timeFrame': '2 years'}, {'measure': 'Percent Change From Baseline in Clinical Chemistry Parameters', 'timeFrame': 'Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.'}, {'measure': 'Percent Change From Baseline in Hematology Parameters', 'timeFrame': 'Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment'}, {'measure': 'Percent Change From Baseline in Blood Pressure', 'timeFrame': 'Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.'}, {'measure': 'Percent Change From Baseline in Pulse Rate', 'timeFrame': 'Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.'}, {'measure': 'Percent Change From Baseline in Respiratory Rate', 'timeFrame': 'Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.'}]",14.0,12 Years,,ALL,False,INDUSTRY,1.0,21.0,ACTUAL,v2_robust,True,True,False,True,
NCT02496494,The Effects of Conversion From Cyclosporine to Tacrolimus on the Changes of Cardiovascular Risk Profiles and Serum Metabolites in Renal Transplant Recipients,Tacrolimus,"['TacroBell', 'Tacrolimus']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,CYCLOSPORINE/TACROLIMUS,Kyungpook National University Hospital,2025-09-01T16:18:10.913017,True,,,,,,,['CYCLOSPORINE/TACROLIMUS'],[],,2012-09,2015-12,"[{'measure': 'Change from Baseline in Blood Pressure at 6 months', 'timeFrame': '3 months, 6 months'}, {'measure': 'Change from Baseline in Lipid Profile at 6 months', 'timeFrame': '3 months, 6 months'}]","[{'measure': 'Assessing glucose regulation using blood glucose and hemoglobin A1c', 'timeFrame': '3 months, 6 months'}, {'measure': 'Assessing other metabolic cardiovascular risk factors using fibrinogen, tPA, PAI-I, homocysteine, pro-BNP, hs-CRP, uric acid', 'timeFrame': '24 weeks'}, {'measure': 'Assessing serum metabolite using ELISA', 'timeFrame': '3 months, 6 months'}, {'measure': 'Assessing renal function using blood urea nitrogen and creatinine', 'timeFrame': '3 months, 6 months'}]",6.0,20 Years,70 Years,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03914794,A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors,Pemigatinib,"['INCB054828', 'Pemigatinib', 'FGFR inhibitor INCB054828']",3,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Bladder Cancer,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2025-09-01T16:18:10.913032,True,,,,,Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors,,"['Bladder Cancer', 'NMIBC', 'Non-Muscle Invasive Bladder Cancer', 'Urothelial Carcinoma Recurrent']","['Bladder Cancer', 'Non Muscle Invasive Bladder Cancer', 'Non-Muscle Invasive Bladder Cancer (NMIBC)', 'NMIBC', 'Urothelial Carcinoma', 'Urothelial Cancer', 'Urinary Bladder Neoplasm', 'Bladder Neoplasm', 'Fibroblast inhibitors', 'Pemigatinib', 'FGFR inhibitor']",,2020-10-02,2027-05,"[{'measure': 'Complete response rate of pemigatinib therapy', 'description': 'The number of participants with a complete response to pemigatinib therapy. Tumor complete response is defined as the complete absence of any stage bladder tumor on post-treatment Transurethral Resection of a Bladder Tumor (TURBT) and no evidence of recurrent urothelial carcinoma on post-treatment urine cytology.', 'timeFrame': '6 weeks'}]","[{'measure': 'Characterize the safety profile of pemigatinib therapy', 'description': 'Number of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 toxicities', 'timeFrame': '4 years'}, {'measure': 'Number of Participants with Complete Response and FGFR3 Mutational Status', 'timeFrame': 'Up to 4 weeks'}, {'measure': 'Number of Participants with Non-Muscle Invasive Bladder Cancer (NMIBC) and Complete Response', 'description': 'Number of participants with complete response rate and baseline NMIBC risk group (low- vs. intermediate-risk)', 'timeFrame': 'Up to 4 years'}, {'measure': 'Maximal concentration (Cmax, nmol/L) of pemigatinib in urothelial tissue at post-treatment TURBT', 'timeFrame': 'Up to 4 weeks'}, {'measure': 'Relapse Free Survival (RFS) at 6 months', 'description': 'Number of months from achieving a complete response at initial post-treatment TURBT until relapse.', 'timeFrame': '6 months'}, {'measure': 'Relapse Free Survival (RFS) at 12 months', 'description': 'Number of months from achieving a complete response at initial post-treatment TURBT until relapse.', 'timeFrame': '12 months'}, {'measure': 'Relapse Free Survival (RFS) at 24 months', 'description': 'Number of months from achieving a complete response at initial post-treatment TURBT until relapse.', 'timeFrame': '24 months'}]",8.0,18 Years,,ALL,False,OTHER,1.0,43.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06422494,The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II,hyperinsulinaemic hypoglycaemic clamp,"['Phentolamine', 'hyperinsulinaemic hypoglycaemic clamp', 'Propranolol Hydrochloride 1 MG/ML']",3,INTERVENTIONAL,['NA'],,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 1",Radboud University Medical Center,2025-09-01T16:18:10.913046,True,,,,,The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II,,"['Diabetes Mellitus, Type 1', 'Inflammation']",[],,2025-01-01,2025-10,"[{'measure': 'Monocyte count after 60 minutes of hypoglycaemia and adrenergic blockade', 'description': 'The number of monocytes following 60 minutes hypoglycaemia and adrenergic blockade compared to baseline. Adrenergic blockade using Phentolamine and Propranolol intravenously. Expressed in 10\\^3/µl measured using a sysmex machine.', 'timeFrame': 'After 60 minutes of hypoglycaemia and adrenergic blockade'}]","[{'measure': 'Leukocyte count at the time points', 'description': 'Leukocyte count at the time points 0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia, +1 day, +3 days and 1 week after of hypoglycaemia (e.g. Monocytes, granulocytes, lymphocytes).', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia, +1 day, +3 days and 1 week after of hypoglycaemia'}, {'measure': 'Ex vivo production of pro- and anti-inflammatory cytokines and chemokines', 'description': 'Ex vivo production of pro- and anti-inflammatory cytokines and chemokines after ex vivo stimulation of isolated leukocytes, including Tumor necrosis factor-α, Interleukin-6, Interleukin-10 and Interleukin-1β, 1β', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia, +1 day, +3 days and 1 week after of hypoglycaemia'}, {'measure': '92 circulating inflammatory proteins', 'description': '92 circulating inflammatory proteins using Olink Proteomics inflammation panel', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Inflammatory plasma protein ( e.g. high-sensitive crp)', 'description': 'Inflammatory plasma protein using ELISA,(e.g high sensitive-crp)', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Atherogenic parameters', 'description': 'Atherogenic parameters using ELISA including but not limited to, vascular endothelial cell adhesion molecule-1, vascular endothelial cell adhesion molecule-1, E-Selectin, P-selectin, Plasminogen activator inhibitor-1, Plasma Endothelin', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Plasma levels of hormones', 'description': 'Plasma levels of hormones ( Cortisol, insulin, glucagon, growth-hormone, adrenaline, noradrenaline)', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Amount of hypoglycaemic events measured by the blinded continuous glucose monitor', 'description': 'Amount of events', 'timeFrame': 'During the full study, 3 days before and 7 days after each investigational day'}, {'measure': 'Variability measured by the blinded continuous glucose monitor', 'description': 'Variability of glucose expressed as a standard deviation of the mean glucose', 'timeFrame': 'During the full study, 3 days before and 7 days after each investigational day'}, {'measure': 'Average glucose measured by the blinded continuous glucose monitor', 'description': 'Average glucose during the 10 days of measuring expressed as mmol/L', 'timeFrame': 'During the full study, 3 days before and 7 days after each investigational day'}, {'measure': 'Time in range measured by the blinded continuous glucose monitor', 'description': 'Amount of time that glucose is between 3.8 and 10 mmol/L expressed as a percentage', 'timeFrame': 'During the full study, 3 days before and 7 days after each investigational day'}, {'measure': 'Amount of plasma glycerol', 'description': 'Amount of plasma glycerol during and after hypoglycaemia', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Amount of Non-esterified fatty acids', 'description': 'Amount of Non-esterified fatty acids (NEFAs) during and after hypoglycaemia', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Untargeted metabolomics profiling', 'description': 'Measuring a panel of amino acids', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Gene expression changes in leukocytes', 'description': 'Gene expression changes in leukocytes (e.g. using RNA sequencing, quantitative PCR)', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Epigenetic changes in leukocytes', 'description': 'Epigenetic changes in leukocytes (e.g. using Assay for Transposase- Accessible Chromatin using sequencing (ATACseq), DNA methylation analysis)', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Functional changes in monocytes', 'description': 'Functional changes in monocytes (e.g. using adhesion assays, differentiation experiments)', 'timeFrame': '0, 30 minutes after euglycaemia, 60 minutes during hypoglycaemia'}, {'measure': 'Adrenergic symptoms assessed using the validated Edinburgh Hypoglycaemia Score', 'timeFrame': '0, 30 minutes after euglycaemia, 30 minutes and 60 minutes during hypoglycaemia'}, {'measure': 'Hypoglycaemia awareness using the modified Clarke score', 'timeFrame': 'At screening'}]",19.0,16 Years,75 Years,ALL,True,OTHER,0.0,24.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00034866,Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals,Protease inhibitor tipranavir,['Protease inhibitor tipranavir'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV Infections,Boehringer Ingelheim,2025-09-01T16:18:10.913132,True,,,,,"Double-Blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-Experienced Subjects.",,['HIV Infections'],"['HIV', 'treatment experienced', 'Boehringer', 'tipranavir', 'ritonavir']",,2002-04,2002-10,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,165.0,,v2_robust,True,True,False,False,
NCT00147966,Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study),rituximab,"['rituximab', 'rituxan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Rheumatoid Arthritis,"University of California, San Diego",2025-09-01T16:18:10.913196,True,,,,,Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies,,['Rheumatoid Arthritis'],['active disease despite concomitant methotrexate'],,2008-06,2009-12,"[{'measure': 'American College of Rheumatology (ACR) 20 at Week 12', 'description': 'ACR 20, the American College of Rheumatology (ACR) definition of 20% improvement is based on a 20% improvement (compared to baseline values) in tender and swollen joint counts and 20% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function) and one acute phase reactant value (CRP).', 'timeFrame': '0 and 12 weeks'}]",[],1.0,18 Years,75 Years,ALL,False,OTHER,1.0,24.0,ACTUAL,v2_robust,True,True,False,False,
NCT02224066,Platelet Reactivity After TAVI: A Multicenter Pilot Study,Ticagrelor 90 mg twice per day during three months following TAVI,"['Ticagrelor 90 mg twice per day during three months following TAVI', 'Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Severe Aortic Valve Stenosis,Hospital de Meixoeiro,2025-09-01T16:18:10.913260,True,,,,,Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation,,"['Severe Aortic Valve Stenosis', 'Transcatheter Aortic Valve Implantation', 'Transcatheter Aortic Valve Replacement']","['Aortic stenosis', 'TAVI', 'TAVR', 'Transcatheter aortic valve implantation', 'Ticagrelor', 'Antiplatelet reactivity']",,2016-01,2018-08,"[{'measure': ""Evaluate the effectiveness of ticagrelor compared to clopidogrel and aspirin for the suppression of residual platelet reactivity by a system to verify the patient's platelet reactivity (VerifyNow P2Y12 assay)."", 'timeFrame': 'Three months after antiplatelet treatment initiation following procedure.'}]","[{'measure': 'Evaluate the effectiveness of ticagrelor compared to clopidogrel and aspirin for the suppression of residual platelet reactivity by VerifyNow P2Y12 assay.', 'timeFrame': 'Six hours after antiplatelet treatment initiation following procedure.'}]",2.0,18 Years,,ALL,False,OTHER_GOV,0.0,65.0,ACTUAL,v2_robust,True,True,False,False,
NCT06745466,"Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women",ganirelix acetate,"['Antagon', 'ganirelix acetate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Estrogen,University of Delaware,2025-09-01T16:18:10.913283,True,,,,,"Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women",,"['Estrogen', 'Premenopause']","['Premenopause', 'Estrogen', 'Stress', 'Sleep', 'Vascular function']",,2024-11-15,2027-10,"[{'measure': 'Endothelium-dependent dilation (EDD)', 'description': 'EDD will be calculated as the area under the dose-response curve (AUC) to ascending concentrations of acetylcholine.', 'timeFrame': 'Immediately before and after each 10-day measurement burst'}, {'measure': 'Negative affective response to daily stressors', 'description': 'Within-person composite slope between daily stressors and daily negative affect', 'timeFrame': '10-day measurement burst'}, {'measure': 'Sleep variability', 'description': 'Sleep onset standard deviation (minutes) estimated via actigraphy', 'timeFrame': '10-day measurement burst'}]",[],3.0,40 Years,55 Years,FEMALE,True,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00003266,Methylphenidate in Treating Patients With Melanoma,methylphenidate hydrochloride,['methylphenidate hydrochloride'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Fatigue,Eastern Cooperative Oncology Group,2025-09-01T16:18:10.913296,True,,,,,Double-Blind Randomized Trial of Methylphenidate for Alleviation of Fatigue and Lethargy Associated With Interferon Alpha 2b,,"['Fatigue', 'Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific', 'fatigue']",,1999-10-12,,[],[],0.0,18 Years,120 Years,ALL,False,NETWORK,1.0,200.0,ESTIMATED,v2_robust,True,True,False,False,
NCT00664066,DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment),DYNEPO (epoetin delta),['DYNEPO (epoetin delta)'],1,OBSERVATIONAL,[],,TERMINATED,Anemia,Shire,2025-09-01T16:18:10.913303,True,,,,,"A Non-Interventional, Post-Authorisation Study to Assess Adverse Events and Drug Utilisation Among Chronic Kidney Disease Patients Treated With DYNEPO",,"['Anemia', 'Kidney Diseases', 'Renal Failure, Chronic', 'Kidney Failure, Chronic']",[],The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA,2008-04-25,2008-07-30,"[{'measure': 'Assess the Incidence and Severity of All Predefined Cardiovascular Events in Subjects Treated With Dynepo', 'description': 'This study was terminated on July 31, 2008 as a result of a decision by Shire Pharmaceutical to permanently cease marketing Dynepo and withdraw the Marketing Authorisation. The decision was for commercial reasons, it was not the result of any safety signal.', 'timeFrame': 'up to 3 years'}]",[],1.0,,,ALL,False,INDUSTRY,0.0,3.0,ACTUAL,v2_robust,False,False,True,True,The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA
NCT00497666,Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study,Rosiglitasone (retrospective observation),['Rosiglitasone (retrospective observation)'],1,OBSERVATIONAL,[],,UNKNOWN,Diabetes,Assaf-Harofeh Medical Center,2025-09-01T16:18:10.913328,True,,,,,Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study,,"['Diabetes', 'Diabetic Nephropathy', 'Renal Protection']","['Diabetes', 'Diabetic nephropathy', 'renal protection']",,2007-08,2007-12,[],[],0.0,18 Years,90 Years,ALL,,OTHER_GOV,0.0,,,v2_robust,False,False,False,False,
NCT00752466,A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately,Topiramate; flunarizine,['Topiramate; flunarizine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Human Volunteers,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",2025-09-01T16:18:10.913333,True,,,,,A Drug Interaction Study of the Pharmacokinetics of Flunarizine and Topiramate (RWJ-17021-000) During Mono- and Concomitant Therapy,,"['Human Volunteers', 'Migraine']","['Healthy volunteers', 'drug interaction', 'Flunarizine', 'Topiramate', 'Migraine']",,2003-03,2004-03,"[{'measure': 'For each treatment and each group, the plasma concentration at each time point and the pharmacokinetic parameters of interest will be summarized using descriptive summary statistics.'}]",[{'measure': 'Incidence and severity of treatment-emergent adverse events and abnormal findings of other safety evaluations. Changes in clinical laboratory test and vital sign results from Baseline to End of Study or early termination will be evaluated.'}],2.0,18 Years,55 Years,ALL,True,INDUSTRY,4.0,75.0,ACTUAL,v2_robust,True,True,False,True,
NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,Ipilimumab,"['Ipilimumab', 'Corticosteroid: Triamcinolone', 'Corticosteroid: Betamethasone', 'Corticosteroid: Hydrocortisone', 'BMS-734016', 'Corticosteroid: Prednisone', 'Corticosteroid: Methylprednisolone', 'Corticosteroid: Meprednisone', 'Corticosteroid: Prednisolone', 'MDX-010', 'Corticosteroid: Fludrocortisone', 'Corticosteroid: Dexamethasone']",12,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Melanoma,Bristol-Myers Squibb,2025-09-01T16:18:10.913345,True,,,,,A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases,,['Melanoma'],[],,2008-07,2012-10,"[{'measure': 'Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria', 'description': 'Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) (global, in brain, or outside of brain) based on mWHO criteria divided by the number of patients who received treatment. By mWHO criteria: CR=complete disappearance of all index lesions. PR=decrease, relative to baseline, of 50% or greater in the sum of the 2 largest perpendicular diameters of all index lesions. SD=does not meet criteria for CR or PR, in the absence of progressive disease (PD). Patients with PR or CR not confirmed after at least 4 weeks are scored as SD unless they have new primary lesions. PD=at least 25% increase in the sum of the diameters of all index lesions (taking as reference the smallest sum recorded at or following baseline) and/or the appearance of any new lesions. CNS=central nervous system.', 'timeFrame': 'From Day 1, first dose to end of Week 12'}]","[{'measure': 'Disease Control Rate by Immune-related Response Criteria (irRC)', 'description': 'Disease control rate is defined as the number of patients with a best overall response of immune-related (ir) complete response (irCR), partial response (irPR), or stable disease (irSD) divided by the total number of patients who received treatment. By irRC definition: irCR=complete disappearance of all index lesions. irPR=decrease, relative to baseline, of 50% or greater in the sum of the products of the 2 largest perpendicular diameters of all index lesions. irSD=does not meet criteria for irCR or irPR, in the absence of ir progressive disease (irPD). irPD=at least 25% increase in the sum of the products of all index lesions (taking as reference the smallest sum recorded at or following baseline). CNS=central nervous system; non-CNS compartment=extracranial, or outside of the brain.', 'timeFrame': 'From Day 1, first dose to end of Week 12'}, {'measure': 'Best Overall Response Rate (BORR) by Modified World Health Organization (mWHO) Criteria and by Immune-relate Response Criteria (irRC)', 'description': 'BORR is defined as the number of patients whose global best overall response (BOR) was complete (CR) or partial response (PR), divided by the total number of participants who received treatment. CR=complete disappearance of all index lesions. PR=decrease, relative to baseline, of 50% or greater in the sum of the products of the 2 largest perpendicular diameters of all index lesions. The global BOR is the best overall response (OR) designation over the study as a whole for an individual in the study based on overall tumor burden. Both central nervous system (CNS) (brain lesions) and non-CNS compartments (lesions outside the brain) are considered for the global BOR. For the analysis of global BOR of CR or PR (by both modified WHO criteria and immune-related response criteria \\[irRC\\]), the OR assessment must be confirmed by a second (confirmatory) evaluation meeting the criteria for response and must be performed no less than 4 weeks after the criteria for response are first met.', 'timeFrame': 'From Day 1, first dose until the last tumor assessment, Week 12'}, {'measure': 'Duration of Response (DOR) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)', 'description': 'DOR is defined in patients whose global best overall response is complete (CR) or partial response (PR) as the time between the date of response of confirmed CR or PR, whichever occurs first, and the date of progressive disease or death, whichever occurs first. For patients who remain alive and have not progressed following response, duration of response will be censored on the date of last evaluable tumor assessment.', 'timeFrame': 'From Day 1, first dose to last tumor assessment up to 18.2 months'}, {'measure': 'Progression-free Survival (PFS) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)', 'description': 'PFS is defined as the time between the date of the first dose of study therapy and the date of progression or death, whichever occurs first. A patient who dies without reported prior progression will be considered to have progressed on the date of death. For those who remain alive and have not progressed, PFS will be censored on the date of last evaluable tumor assessment. Participants who have not died and have no recorded postbaseline tumor assessment will be censored on the date of first dose of study therapy. Those who die without any recorded postbaseline tumor assessment will be considered to have progressed on the date of death.', 'timeFrame': 'From Day 1, first dose to the date of progression or death, whichever occurred first up to 22 months'}, {'measure': 'Number of Participants Surviving at 6, 12, 18, 24, and 36 Months (Overall Survival [OS] Rate)', 'description': 'OS is defined as the time from the first dose of study drug until the date of death. Overall survival rate is the percentage of participants known to be alive at a timepoint. For those patients who did not die, OS was censored at the recorded last date of patient contact, and those with a missing recorded last date of contact will be censored at the last date the patient was known to be alive. The survival rate at a specified time-point is the probability that a patient is alive at that time following randomization. The rate is calculated for each treatment group using the Kaplan-Meier product-limit method. A corresponding 2-sided 95% bootstrap confidence interval will be calculated.', 'timeFrame': 'From first dose to Months 6, 12, 18, 24, and 36 months'}, {'measure': 'Number of Participants Who Died or Had a Treatment-related Adverse Event (AE), Immune-related AE, Immune-related Serious Adverse Event (SAE), Nervous System Disorder, Treatment-related Nervous System Disorder, SAE, and AE Leading to Discontinuation', 'description': 'AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.', 'timeFrame': 'Continuously from Day 1, first dose, to 70 days following last dose of ipilimumab'}, {'measure': 'Onset of Response by Modified World Health Organization (mWHO) Criteria and Immune-related Response Criteria (irRC)', 'description': 'Onset of response is defined as the time between the first dose of study therapy and the date when measurement criteria are first met for global best overall response of partial (PR) or complete (CR), whichever occurs first. CR=complete disappearance of all index lesions. PR=decrease, relative to baseline, of 50% or greater in the sum of the 2 largest perpendicular diameters of all index lesions.', 'timeFrame': 'From Day 1, first dose to a maximum of 4.2 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from date of first dose of study drug until the date of death. For those patients who did not die, OS was censored at the recorded last date of patient contact, and those missing a recorded last date of contact will be censored at the last date the patient was known to be alive.', 'timeFrame': 'From first dose to 24 months'}]",9.0,16 Years,,ALL,False,INDUSTRY,1.0,99.0,ACTUAL,v2_robust,True,True,False,True,
NCT01536366,Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide,BIA 9-1067,"['OPC, Opicapone', 'Novonorm®', 'BIA 9-1067', 'Repaglinide']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Parkinson Disease,Bial - Portela C S.A.,2025-09-01T16:18:10.913407,True,,,,,Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers,,['Parkinson Disease'],"['Parkinson Disease', 'BIA 9-1067']",,2009-06,2011-01,"[{'measure': 'Cmax - Maximum Observed Plasma Concentration', 'timeFrame': 'pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose.'}]","[{'measure': 'Tmax - Time of Occurrence of Cmax', 'timeFrame': 'pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose.'}, {'measure': 'AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration', 'timeFrame': 'pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose.'}, {'measure': 'AUC0-∞ - Area Under the Plasma Concentration-time Curve From Time 0 to Infinity', 'timeFrame': 'pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose.'}]",4.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,27.0,ACTUAL,v2_robust,True,True,False,False,
NCT05086666,A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547,AZD4547,"['AZD4547', 'ABSK091']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Urothelial Carcinoma,"Abbisko Therapeutics Co, Ltd",2025-09-01T16:18:10.913500,True,,,,,A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability of AZD4547 in Patients With Solid Tumors and Its Efficacy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma With FGFR2/3 Gene Alterations,,['Urothelial Carcinoma'],"['urothelial carcinoma', 'FGFR2/3']",,2021-06-03,2024-05-27,"[{'measure': 'DLT', 'description': 'Incidence of dose limiting toxicity (DLT)', 'timeFrame': '21 days'}, {'measure': 'AEs and SAEs', 'description': 'Incidence and grade of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESI) (based on Common Terminology Criteria for Adverse Events, CTCAE 5.0) .', 'timeFrame': 'at least 6 months'}, {'measure': 'ORR', 'description': 'To confirm objective response rate (assessed by RECIST 1.1) in FGFR2/3 gene altered (including mutations and/or fusions) subjects with locally advanced or metastatic urothelial cancer with treated with AZD4547', 'timeFrame': '6 months'}]","[{'measure': 'DOR', 'description': 'Duration of response (DoR): The time from the first evaluation of \\[CR\\] or \\[PR\\] until disease progression;', 'timeFrame': 'at least 6 months'}, {'measure': 'DCR', 'description': 'Disease control rate (DCR): DCR = \\[CR\\] + \\[PR\\] + stable disease \\[SD\\];', 'timeFrame': 'at least 6 months'}, {'measure': 'PFS', 'description': 'Progression-free survival (PFS): time to progression or death from the first day subjects receive AZD4547;', 'timeFrame': 'at least 6 months'}]",6.0,25 Years,,ALL,False,INDUSTRY,0.0,108.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00003466,Temozolomide in Treating Patients With Progressive Low-Grade Glioma,temozolomide,['temozolomide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Brain and Central Nervous System Tumors,Duke University,2025-09-01T16:18:10.913510,True,,,,,Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal,,['Brain and Central Nervous System Tumors'],"['recurrent adult brain tumor', 'adult mixed glioma', 'childhood mixed glioma', 'adult pilocytic astrocytoma', 'adult subependymoma', 'recurrent childhood cerebral astrocytoma', 'adult brain stem glioma', 'recurrent childhood brain stem glioma', 'untreated childhood brain stem glioma', 'recurrent childhood visual pathway and hypothalamic glioma', 'untreated childhood visual pathway and hypothalamic glioma', 'adult oligodendroglioma', 'adult diffuse astrocytoma']",,1998-03,2005-07,"[{'measure': 'Response rate'}, {'measure': 'Activity of temozolomide'}]",[],2.0,4 Years,,ALL,False,OTHER,1.0,100.0,ESTIMATED,v2_robust,True,True,False,False,
NCT02461056,Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain,Ibuprofen,"['Dilid', 'Hydromorphone', 'Ibuprofen', 'Caldolor']",4,INTERVENTIONAL,['NA'],,COMPLETED,Breast Cancer,Samsung Medical Center,2025-09-01T16:18:10.913640,True,,,,,Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain,,['Breast Cancer'],"['ibuprofen', 'hydromorphone', 'drug interactions']",,2014-06,2014-07,"[{'measure': 'Pain scores on the numeric rating scale (NRS)', 'timeFrame': 'postoperative 1 hour'}]",[],1.0,19 Years,80 Years,FEMALE,False,OTHER,0.0,90.0,ACTUAL,v2_robust,True,True,False,False,
NCT03367156,Dexamethasone in Controlling Dyspnea in Patients With Cancer,Dexamethasone,"['TaperDex', 'Dexa-sine', 'Alin', 'Deronil', 'Desameton', 'Dexameth', 'Dexa-Rhinosan', 'Fluorodelta', 'ZoDex', 'Dinormon', 'Dexacortin', 'Dexinoral', 'Hexadrol', 'Mymethasone', 'Dexalocal', 'Cortidexason', 'Dexafluorene', 'Baycadron', 'Lokalison-F', 'Millicorten', 'Auxiloson', 'Methylfluorprednisolone', 'Desamethasone', 'Alin Depot', 'Aknichthol Dexa', 'Dexamethasone Intensol', 'Hexadecadrol', 'Orgadrone', 'Decacort', 'Dexa-Scheroson', 'Decalix', 'Dexapos', 'Baycuten N', 'Gammacorten', 'Auricularum', 'Decadron', 'Dexafarma', 'Dexamecortin', 'Dexone', 'Visumetazone', 'Baycuten', 'Anemul mono', 'Dexa-Mamallet', 'Fortecortin', 'Cortisumman', 'Alin Oftalmico', 'Aacidexam', 'Dexamethasone', 'Alba-Dex', 'Decadrol', 'Decasone R.p.', 'Amplidermis', 'Spersadex', 'Dexacortal', 'Dectancyl', 'Loverine', 'Dexamethasonum', 'Decadron DP', 'Dexamonozon', 'Dekacort', 'Decameth', 'Deltafluorene', 'Adexone']",63,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Dyspnea,M.D. Anderson Cancer Center,2025-09-01T16:18:10.913661,True,,,,,A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients,,"['Dyspnea', 'Malignant Neoplasm']",[],,2017-12-04,2025-12-31,"[{'measure': 'Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 7 Average Intensity', 'description': 'The average dyspnea intensity over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea scores between Baseline and Day 7 were measured. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 7'}]","[{'measure': 'Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 14 Average Intensity', 'description': 'The average dyspnea intensity over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea scores between Baseline and Day 14 were measured. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 14'}, {'measure': 'Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 7 Average Unpleasantness', 'description': 'The average dyspnea unpleasantness over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea unpleasantness scores between Baseline and Day 7 were measured. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 7'}, {'measure': 'Change in Edmonton Symptom Assessment Scale (ESAS) Dyspnea Score Between Baseline and Day 7', 'description': 'ESAS (Edmonton Symptom Assessment Scale) is a validated scale ranging from 0 (not at all) to 10 (very much) used to assess 10 symptoms commonly experienced by cancer patients during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep and feeling of well being. The change in ESAS fatigue score between Baseline and Day 7 were measured. Total ESAS fatigue score ranged from 0-10, with a higher score indicating higher fatigue. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 7'}, {'measure': 'Change in European Organization for Research and Treatment of Cancer-Quality of Life (EORTC QLQ-C30) Dyspnea Score Between Baseline and Day 7', 'description': 'European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated quality-of-life assessment for patients with cancer, consisting of 30 questions that encompass three symptom scales (pain, fatigue, and nausea/vomiting) and six questions about single symptoms, as well as five functional scales (physical, cognitive, role, emotional, and social) and one scale assessing global health status/quality of life. Each single symptoms have four response categories (1=not at all, and 4=very much). The change in EORTC fatigue score between Baseline and Day 7 were measured. Total scores using a complex scoring procedures ranges from 0 to 100 with a higher scores indicating higher fatigue. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 7'}, {'measure': 'Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 14 Average Unpleasantness', 'description': 'The average dyspnea unpleasantness over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea unpleasantness scores between Baseline and Day 14 were measured. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 14'}, {'measure': 'Change in Edmonton Symptom Assessment Scale (ESAS) Dyspnea Score Between Baseline and Day 14', 'description': 'ESAS (Edmonton Symptom Assessment Scale) is a validated scale ranging from 0 (not at all) to 10 (very much) used to assess 10 symptoms commonly experienced by cancer patients during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep and feeling of well being. The change in ESAS fatigue score between Baseline and Day 14 were measured. Total ESAS fatigue score ranged from 0-10, with a higher score indicating higher fatigue. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 14'}, {'measure': 'Change in European Organization for Research and Treatment of Cancer Quality of Life (EORTC) Dyspnea Score Between Baseline and Day 14', 'description': 'European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated quality-of-life assessment for patients with cancer, consisting of 30 questions that encompass three symptom scales (pain, fatigue, and nausea/vomiting) and six questions about single symptoms, as well as five functional scales (physical, cognitive, role, emotional, and social) and one scale assessing global health status/quality of life. Each single symptoms have four response categories (1=not at all, and 4=very much). The change in EORTC fatigue score between Baseline and Day 14 were measured. Total scores using a complex scoring procedures ranges from 0 to 100 with a higher scores indicating higher fatigue. Linear model analysis was used for analysis.', 'timeFrame': 'Baseline and Day 14'}]",8.0,18 Years,,ALL,False,OTHER,1.0,135.0,ACTUAL,v2_robust,True,False,False,False,
NCT00958256,Study of Bortezomib in Combination With Cyclophosphamide and Rituximab,Bortezomib,"['GCSF', 'Mesna', 'Mesnex', 'G-CSF', 'Rituxan', 'Rituximab', 'Filgrastim', 'Granulocyte-colony stimulating factor', 'Cyclophosphamide', 'Neosar', 'Bortezomib', 'Cytoxan', 'Neupogen', 'Velcade']",14,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Mantle Cell Lymphoma,M.D. Anderson Cancer Center,2025-09-01T16:18:10.913716,True,,,,,Phase II Study of Bortezomib in Combination With Cyclophosphamide and Rituximab for Relapsed/Refractory Mantle Cell Lymphoma,,"['Mantle Cell Lymphoma', 'Lymphoma']","['Mantle Cell Lymphoma', 'Lymphoma', 'Bortezomib', 'Velcade', 'Rituximab', 'Rituxan', 'Cyclophosphamide', 'Cytoxan', 'Neosar', 'Mesna', 'Mesnex', 'G-CSF', 'Filgrastim', 'Neupogen']",,2009-08,2014-03,"[{'measure': 'Response Rate', 'description': ""Response rate to regimen defined as the percentage of number of complete response or partial response in total number of participants treated. The response assessed after the first 2 cycles. Response (complete and partial remission) according to International Workshop Response Criteria for Non-Hodgkin's Lymphoma: A complete response is the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. A partial response is regression of measurable disease and no new sites of disease. Stable disease is failure to attain a complete response/partial response or progressive disease. A cycle is 21 days with 6-8 cycles administered depending on response."", 'timeFrame': 'Evaluation of disease after 2 cycles (approximately 6 weeks).'}]",[],1.0,18 Years,85 Years,ALL,False,OTHER,1.0,22.0,ACTUAL,v2_robust,True,True,False,False,
NCT06983756,""" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance """,Erythropoietin,['Erythropoietin'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Erythropoietin Resistant Anemia (EPO Resistant Anemia),Fayoum University,2025-09-01T16:18:10.913765,True,,,,,""" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance """,,['Erythropoietin Resistant Anemia (EPO Resistant Anemia)'],[],,2025-06-01,2026-01-01,"[{'measure': 'HB', 'description': 'Hemoglobin in blood', 'timeFrame': '6 month'}]",[],1.0,18 Years,,ALL,,OTHER,0.0,66.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01947556,Insulin by Jet-injection for Hyperglycemia in Diabetes,insulin aspart,"['Novorapid', 'insulin aspart']",2,INTERVENTIONAL,['NA'],,COMPLETED,Diabetes Mellitus,University Medical Center Nijmegen,2025-09-01T16:18:10.913862,True,,,,,The Effect of Rapid-acting Insulin Injected by Needle-free Jet-injection in the Management of Hyperglycemia in Patients With Diabetes,,['Diabetes Mellitus'],"['diabetes', 'insulin administration', 'hyperglycaemia', 'insulin aspart']",,2014-03,2014-11,"[{'measure': 'T-BG≥10', 'description': 'the time in minutes until plasma glucose concentration has dropped with ≥ 10mmol/l (T-BG≥10).', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}]","[{'measure': 'T-BG5 and 8 (min)', 'description': 'the time in minutes until plasma glucose values drop below 8 an 5 mmol/l, respectively', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'Rfall', 'description': 'the slope of the glucose fall (mmol • l-1 • min-1), calculated from the time- glucose curve', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'BG-AUC 0-2h', 'description': 'the area under the time-glucose curve, reflecting post-injection hyperglycaemic burden, from 0 to 2h after insulin injection.', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'BG-AUC 0-6h', 'description': 'the area under the time-glucose curve (mmol • min-1 • l-1), from 0 to 6h after insulin injection.', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'C-INSmax (pmol/l)', 'description': 'maximal insulin concentration', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'T-INSmax', 'description': 'time to maximal insulin concentration in minutes(C-INSmax)', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'T-INSBL', 'description': 'the time until plasma insulin values drop below baseline values (minutes)', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'INSAUC', 'description': 'area under the insulin concentration curve (pmol • min-1 • l-1)(from timepoint 0), reflects total insulin absorption', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}, {'measure': 'T-INSAUC50%', 'description': 'time until 50% of insulin absorption in minutes(mean residence time, MRT)', 'timeFrame': 'participants will be followed for the duration of the study, an expected average of 4 weeks'}]",10.0,18 Years,75 Years,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT04767256,Intravenous Dexamethasone and Dexmedetomidine on the Analgesic Efficacy of Erector Spinae Plane Block,Dexamethasone and dexmedetomidine,"['Dexmedetomidine', 'Dexamethasone and dexmedetomidine']",2,INTERVENTIONAL,['NA'],,COMPLETED,Dexamethasone,Huazhong University of Science and Technology,2025-09-01T16:18:10.913904,True,,,,,Intravenous Dexamethasone and Dexmedetomidine on the Analgesic Efficacy of Erector Spinae Plane Block for Posterior Lumbar Interbody Fusion Surgery,,"['Dexamethasone', 'Dexmedetomidine', 'Nerve Block']",[],,2021-03-01,2021-12-30,"[{'measure': 'The cumulative opioid consumption', 'timeFrame': 'At 24 postoperative hours'}, {'measure': 'The time to ﬁrst rescue analgesic request', 'timeFrame': 'Up to 48 postoperative hrs'}]","[{'measure': 'The pain scores determined by the numeric rating scale (NRS, 0-10)', 'timeFrame': 'At 6, 12, 18, 24, 30, 36, 42, and 48 hrs after the surgery'}, {'measure': 'Incidence of postoperative nausea and vomiting', 'timeFrame': 'Up to 24 postoperative hrs'}, {'measure': 'Postoperative hospital length of stay', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Adverse events', 'timeFrame': 'Up to 48 postoperative hrs'}]",6.0,18 Years,65 Years,ALL,False,OTHER,0.0,120.0,ACTUAL,v2_robust,True,True,False,True,
NCT01066156,Post-Traumatic Stress Disorder (PTSD) and Seroquel,Seroquel,"['quetiapine', 'Seroquel']",2,INTERVENTIONAL,['NA'],,COMPLETED,Post-Traumatic Stress Disorder,Cambridge Health Alliance,2025-09-01T16:18:10.913982,True,,,,,Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes,,['Post-Traumatic Stress Disorder'],"['Post-traumatic Stress Disorder', 'PTSD', 'Seroquel', 'fMRI']",,2010-02,2015-03,"[{'measure': 'Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.', 'description': ""We will compare patients' symptomatology at baseline vs. at 8 week timepoint\n\nSpecify Full Scale Name and Construct (i.e., indicate what the scale measures if not clear from name): Clinician-Administered PTSD Scale (CAPS)\n\nInclude all scale ranges (i.e., minimum and maximum scores) required to interpret any values in the data table: 0-136\n\nFor each scale range provided, specify which values are considered to be a better or worse outcome: 0-best, 136 worst\n\nIf subscales are combined to compute a total score, consider indicating how subscales are combined (summed, averaged, etc.): summed"", 'timeFrame': '8 weeks'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,34.0,ACTUAL,v2_robust,True,True,False,False,
NCT02733822,Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study,Naloxone,"['naloxone-hydrochloride', 'Naloxone']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Drug Overdose,King's College London,2025-09-01T16:18:10.913999,True,,,,,"A Pilot, Phase 1, Open-Labelled, 4 Period, Randomised, Crossover Study to Evaluate the Pharmacokinetics of Naloxone When Given by the IV, IM and Buccal Routes of Administration in Healthy Male Subjects",,"['Drug Overdose', 'Opioid-Related Disorders']","['opiate', 'heroin', 'opioid', 'overdose', 'naloxone']",,2016-06,2017-06,"[{'measure': 'Tmax', 'description': 'Time elapsed till peak concentration', 'timeFrame': 'Within 8-hour sampling period'}]","[{'measure': 'Peak plasma concentration is assessed as Cmax', 'description': 'Peak concentration', 'timeFrame': 'Within 8-hour sampling period'}, {'measure': 'Absorption of the active ingredient is determined as Area under the Curve (AUC)', 'description': 'Overall absorption (AUC = Area Under the Curve)', 'timeFrame': 'Within 8-hour sampling period'}, {'measure': 'Absolute bioavailability of buccal naloxone relative to intravenous naloxone is assessed as F%', 'description': 'Absolute bioavailability relative to the IV reference (dose-corrected AUC for non-intravenous Buccal AUC divided by intravenous AUC multiplied by 100', 'timeFrame': 'Within 8-hour sampling period'}, {'measure': 'Mean terminal half-life is assessed for all participants as T1/2', 'description': 'mean terminal half-life', 'timeFrame': 'Within 8-hour sampling period'}]",5.0,18 Years,64 Years,MALE,True,OTHER,0.0,4.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01879722,"Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants",TAK-063,"['TAK-063', 'TAK-063 Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Schizophrenia,Takeda,2025-09-01T16:18:10.914017,True,,,,,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects",,['Schizophrenia'],['Drug therapy'],,2013-06,2014-06,"[{'measure': 'Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) After 7 Days of Dosing', 'description': 'An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.', 'timeFrame': 'Day 1 to Day 14'}, {'measure': 'Percentage of Participants With Markedly Abnormal Safety Laboratory Tests', 'description': 'The percentage of participants with any markedly abnormal standard safety laboratory values, including hematology, serum chemistries, and urinalysis, during the treatment period.', 'timeFrame': 'Day 1 to Day 8'}, {'measure': 'Percentage of Participants With Markedly Abnormal Vital Sign Measurements', 'description': 'The percentage of participants who meet markedly abnormal criteria for vital signs, including oral body temperature, respiration rate, pulse, and resting blood pressure and after standing', 'timeFrame': 'Day 1 to Day 8'}, {'measure': 'Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters', 'description': 'The percentage of participants who meet markedly abnormal criteria specified by the protocol and statistical analysis plan during the treatment period.', 'timeFrame': 'Day 1 to Day 8'}]","[{'measure': 'Cmax: Maximum Observed Plasma Concentration for TAK-063 and TAK-063 Metabolite M-I', 'description': 'Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-063 and TAK-063 Metabolite M-I', 'description': 'Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-063 and TAK-063 Metabolite M-I', 'description': 'AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the Last Quantifiable Concentration.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-063 and TAK-063 Metabolite M-I', 'description': 'AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'CL/F: Oral Clearance of TAK-063', 'description': 'CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by area under the curve from time 0 to 24 hours post-dose, after multiple dosing (at steady state).', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'Average Plasma Concentration on Day 1 (Cav) and Day 7 (Cavss) for TAK-063 and TAK-063 Metabolite M-I', 'description': 'Cav is the Average plasma concentration on Day 1, calculated as AUC(0-24)/24 on Day 1. Cavss is the average plasma concentration on Day 7, calculated as AUC(0-24)/24 on Day 7.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'Cmax Molar Ratio: Ratio of TAK-063 Metabolite Cmax to TAK-063 Cmax', 'description': 'Cmax Molar Ratio is the ratio of Cmax molar values of the metabolite compared to the parent calculated by dividing Cmax molar values of metabolite M-I with those of TAK-063.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'AUC(0-24) Ratio: Ratio of TAK-063 Metabolite AUC(0-24) to TAK-063 AUC(0-24)', 'description': 'AUC(0-24) Ratio is the ratio of AUC(0-24) values of the metabolite compared to the parent calculated by dividing AUC(0-24) values of metabolite M-I with those of the parent drug TAK-063.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'Accumulation Ratios Between Day 7 AUC(0-24) and Day 1 AUC(0-24)', 'description': 'Accumulation ratios between Day 7 AUC(0-24) and Day 1 AUC(0-24), (Day 7/Day 1). Estimated Ratio (Day 7/Day 1) is the exponentiated results of the difference between Day 7 and Day 1 in log-transformed values which resolves to the ratio of Day 7/Day 1 estimates.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'Ae(0-24): Total Amount Excreted in the Urine From Time 0 to 24 Hours Postdose for TAK-063 and TAK-063 Metabolite M-I', 'description': 'Ae(0-24) is a measure of the total amount of study drug excreted in the urine from time 0 to 24 hours postdose.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'Fe: Fraction of Drug Excreted in Urine for TAK-063', 'description': 'Fe is a measure of the fraction of drug excreted in urine and is calculated as Fe = (total amount excreted in the urine from time 0 to 24 hours post-dose / dose)×100', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}, {'measure': 'CLr: Renal Clearance of TAK-063 and TAK-063 Metabolite M-I', 'description': 'CLr is a measure of apparent clearance of the drug from the urine calculated as total amount excreted in the urine from time 0 to 24 hours postdose / plasma area under the curve from time 0 to 24 hours post-dose.', 'timeFrame': 'Days 1 and 7 pre-dose and multiple time-points post-dose (Up to 24 hours)'}]",16.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,77.0,ACTUAL,v2_robust,True,True,False,True,
NCT01437722,Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV),1% SPL7013 Gel,"['1% SPL7013 Gel', '3% SPL7013 Gel', 'placebo gel']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Recurrent Bacterial Vaginosis (BV),Starpharma Pty Ltd,2025-09-01T16:18:10.914031,True,,,,,"A Double-blind, Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel®) Administered Vaginally to Prevent the Recurrence of Bacterial Vaginosis",,['Recurrent Bacterial Vaginosis (BV)'],"['BV', 'Bacterial vaginosis', 'recurrent', 'SPL7013 Gel', 'VivaGel']",,2011-08,,"[{'measure': 'Number of women who have experienced a recurrent episode of BV as a measure of efficacy', 'description': ""Number of women who have BV as measured by subject-reported symptoms and Amsel's Criteria"", 'timeFrame': 'Day 112 +/- 5'}]",[],1.0,18 Years,45 Years,FEMALE,False,INDUSTRY,0.0,205.0,ACTUAL,v2_robust,True,True,False,False,
NCT04133922,Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes,GLP-1,"['GLP-1', 'Dextrose 20 % in Water', 'Insulin']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,WITHDRAWN,Type 1 Diabetes,University of Virginia,2025-09-01T16:18:10.914041,True,,,,,Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes,,"['Type 1 Diabetes', 'Insulin Sensitivity/Resistance']",[],the study drug could not be obtained,2019-10-14,2024-10,"[{'measure': 'change in microvascular blood volume between baseline and 2 hour insulin clamp', 'description': 'vascular measurement', 'timeFrame': 'baseline and after 2 hour insulin clamp'}, {'measure': 'change in insulin sensitivity between baseline and 2 hour insulin clamp', 'description': 'vascular measurement', 'timeFrame': 'baseline and after 2 hour insulin clamp'}]","[{'measure': 'change in augmentation index between baseline and 2 hour insulin clamp', 'description': 'vascular measurement', 'timeFrame': 'baseline and after 2 hour insulin clamp'}, {'measure': 'change in flow-mediated dilation between baseline and 2 hour insulin clamp', 'description': 'vascular measurement', 'timeFrame': 'baseline and after 2 hour insulin clamp'}, {'measure': 'change in pulse wave velocity between baseline and 2 hour insulin clamp', 'description': 'vascular measurement', 'timeFrame': 'baseline and after 2 hour insulin clamp'}]",5.0,18 Years,40 Years,ALL,True,OTHER,2.0,0.0,ACTUAL,v2_robust,True,False,True,False,the study drug could not be obtained
NCT06174922,"A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis",Prednisolone,"['Prednisolone', 'Itraconazole']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Allergic Bronchopulmonary Aspergillosis,"Post Graduate Institute of Medical Education and Research, Chandigarh",2025-09-01T16:18:10.914065,True,,,,,"A Randomized Trial Comparing the Role of Prednisolone, Itraconazole, or Their Combination in Patients with Acute Stage of Allergic Bronchopulmonary Aspergillosis",,['Allergic Bronchopulmonary Aspergillosis'],[],,2023-12-01,2026-06,"[{'measure': 'Asthma or ABPA exacerbations', 'description': 'Proportion of subjects experiencing exacerbation (asthma or ABPA) 12 months after treatment completion', 'timeFrame': '12 months after treatment completion'}]","[{'measure': 'Composite response', 'description': 'Proportion of subjects experiencing composite response defined as symptomatic improvement by at least 50%; and, major radiological improvement, and a decline in serum total IgE by at least 20% of baseline', 'timeFrame': '8 weeks'}, {'measure': 'IgE decline', 'description': 'Percentage decline in IgE (baseline IgE minus IgE after eight weeks/baseline IgE', 'timeFrame': '8 weeks'}, {'measure': 'Time to first ABPA exacerbation', 'description': 'Time to first ABPA exacerbation in days', 'timeFrame': '12 months after treatment completion'}, {'measure': 'Time to first asthma exacerbation', 'description': 'Time to first asthma exacerbation in days', 'timeFrame': '12 months after treatment completion'}, {'measure': 'Weight gain', 'description': 'Treatment-related adverse effects', 'timeFrame': 'Two months'}, {'measure': 'Hyperglycemia', 'description': 'Treatment-related adverse effects', 'timeFrame': 'Two months'}, {'measure': 'Cushingoid habitus', 'description': 'Treatment-related adverse effects', 'timeFrame': 'Two months'}, {'measure': 'Transaminitis', 'description': 'Treatment-related adverse effects', 'timeFrame': 'Two months'}]",9.0,18 Years,,ALL,False,OTHER,0.0,300.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03902522,PRO 140 in Treatment-Experienced HIV-1 Subjects,PRO 140,"['Leronlimab', 'PRO 140']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,ACTIVE_NOT_RECRUITING,HIV-1-infection,"CytoDyn, Inc.",2025-09-01T16:18:10.914085,True,,,,,"A Multi-center, Two-Part, Single-Arm, Open Label, 25-Week Trial With PRO 140 in Treatment-Experienced HIV-1 Subjects",,['HIV-1-infection'],[],,2018-06-25,2022-08-30,"[{'measure': 'Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the initial 1-week treatment period', 'timeFrame': '1-week'}]","[{'measure': 'Proportion of participants with ≥ 1 log10 reduction in HIV-1 RNA viral load from baseline at the end of the initial 1-week treatment period', 'timeFrame': '1-week'}, {'measure': 'Mean change from Baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the initial 1-week treatment period', 'timeFrame': '1-week'}, {'measure': 'Percentage of participants achieving HIV-1 RNA < 400 copies/mL at week 25', 'timeFrame': 'week 25'}, {'measure': 'Percentage of participants achieving HIV-1 RNA < 50 copies/mL at week 25', 'timeFrame': 'week 25'}, {'measure': 'Mean change from Baseline in HIV-1 RNA levels (log10 copies/mL)', 'timeFrame': 'week 25'}, {'measure': 'Mean change from Baseline in CD4 cell count at the end of the initial 1-week treatment period', 'timeFrame': '1-week'}, {'measure': 'Mean change from Baseline in CD4 cell count at week 25', 'timeFrame': 'week 25'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,25.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06466122,Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi,Pirtobrutinib,"['Pirtobrutinib', 'LOXO 305', 'Venclexta', 'BTK Inhibitor LOXO-305', 'LY3527727', 'Jaypirca', 'GDC-0199', '5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide', 'ABT199', 'LOXO305', 'Venclyxto', 'ABT-0199', 'ABT-199', 'RG7601', 'Venetoclax', 'LOXO-305']",16,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Chronic Lymphocytic Leukemia,Kerry Rogers,2025-09-01T16:18:10.914131,True,,,,,Phase 2 Study of Combination Pirtobrutinib (LOXO-305) and Venetoclax in CLL Patients With Resistance to Covalent BTKi,,"['Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma']",[],,2024-11-07,2025-12-31,"[{'measure': 'Rate of undetectable minimal residual disease (uMRD)', 'description': 'The rate of uMRD will be defined as the percentage of patients who have uMRD in both the peripheral blood and bone marrow at C21D1.', 'timeFrame': 'At cycle 21 day 1 (C21D1) [each cycle lasts 28 days]'}]","[{'measure': 'Best overall response rate (ORR)', 'description': 'Best ORR will be estimated with exact 95% confidence intervals.', 'timeFrame': 'At cycle 21 day 1 (C21D1) [each cycle lasts 28 days]'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'ORR will be estimated with exact 95% confidence intervals.', 'timeFrame': 'At cycle 21 day 1 (C21D1) [each cycle lasts 28 days]'}, {'measure': 'Progression-free survival (PFS) for all patients', 'description': 'Clinical disease progression will be assessed by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria. PFS will be described using the method of Kaplan-Meier. Median and/or estimates at clinically meaningful time points for PFS will be reported with 95% confidence intervals.', 'timeFrame': 'At start of treatment to progression or death up to 18 months after completion of study treatment'}, {'measure': 'PFS in patients who achieve uMRD and those who do not achieve uMRD with pirtobrutinib and venetoclax', 'description': 'Clinical disease progression will be assessed by iwCLL 2018 criteria. PFS will be described using the method of Kaplan-Meier. Median and/or estimates at clinically meaningful time points for PFS will be reported with 95% confidence intervals.', 'timeFrame': 'At end of treatment to progression or death up to 18 months after completion of study treatment'}, {'measure': 'Overall survival (OS) for all patients', 'description': 'OS will be described using the method of Kaplan-Meier. Median and/or estimates at clinically meaningful time points for OS will be reported with 95% confidence intervals.', 'timeFrame': 'At start of treatment to death up to 18 months after completion of study treatment'}, {'measure': 'OS for patients who achieve uMRD and those who do not achieve uMRD with pirtobrutinib and venetoclax', 'description': 'OS will be described using the method of Kaplan-Meier. Median and/or estimates at clinically meaningful time points for OS will be reported with 95% confidence intervals.', 'timeFrame': 'At end of treatment to death up to 18 months after completion of study treatment'}, {'measure': 'Incidence of adverse events (AEs)', 'description': 'AEs will be summarized by type, severity and perceived attribution according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Hematologic AEs will be graded according to CLL specific criteria described in the iwCLL 2018 guidelines. The maximum grade for each type of AE will be recorded for each patient, and at a minimum, frequency tables will be reviewed to determine AE patterns. The number of patients who discontinue treatment due to AE will be summarized.', 'timeFrame': 'Up to 28 days after last dose of study drugs'}]",8.0,18 Years,,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05102422,Quantitative Electroencephalogram and Bispectral Index Brain Mapping During Propofol vs Sevoflurane General Anesthesia,Propofol 1 % Injectable Suspension,"['Sevorane', 'Diprivan', 'Sevoflurane inhalant product', 'Propofol 1 % Injectable Suspension']",4,OBSERVATIONAL,[],,COMPLETED,Neurophysiology,Pierre Pandin,2025-09-01T16:18:10.914193,True,,,,,Quantitative Electroencephalogram and Bispectral Index Brain Mapping During Propofol vs Sevoflurane General Anesthesia A Randomized Comparative Trial,,['Neurophysiology'],"['General anesthetics', 'Bispectral index', 'Quantitative electroencephalography', 'Monitoring']",,2007-08-21,2009-12-15,"[{'measure': 'Frequency domain analysis QEEG', 'description': 'Spectral Edge Frequency (Hz) and Median EEG Frequency (Hz) in the four cerebral cortical territories considered (PreFrontal Fp1; Temporal T7; Parietal and Occipital)', 'timeFrame': 'intraoperatively'}, {'measure': 'Time domain analysis QEEG', 'description': 'BSR (Burst Suppression Ratio) in % in the four cerebral cortical territories considered', 'timeFrame': 'intraoperatively'}, {'measure': 'Power domain analysis QEEG', 'description': 'Total Spectral Power (TSP) in the four cerebral cortical territories considered', 'timeFrame': 'intraoperatively'}, {'measure': 'BIS', 'description': 'BIS recordings in the four cerebral cortical territories studied', 'timeFrame': 'intraoperatively'}]",[],4.0,18 Years,87 Years,ALL,True,OTHER,0.0,40.0,ACTUAL,v2_robust,False,True,False,False,
NCT02672722,Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound,Definity,"['ultrasound contrast agent or microbubbles', 'Definity']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Healthy,University of Virginia,2025-09-01T16:18:10.914208,True,,,,,Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound,,"['Healthy', 'Physiology']",['This term was found doing the MeSH search and is the only thing that fits since we will be working with healthy subjects with no conditions.'],,2016-01,2017-10,"[{'measure': 'Change in renal blood flow in exercise as assessed by CEUS', 'description': 'Total, cortical and medullary kidney blood flow will be measured using contrast-enhanced ultrasonography', 'timeFrame': 'Before and immediately after exercise'}]",[],1.0,18 Years,50 Years,ALL,True,OTHER,0.0,19.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03801122,Evolution of Thromboelastography During Tranexamic Acid Treatment,Tranexamic acid,['Tranexamic acid'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hematological Malignancies Treated With Intensive Chemotherapy,Centre Hospitalier Universitaire de Saint Etienne,2025-09-01T16:18:10.914216,True,,,,,Study of Thromboelastography During Tranexamic Acid Treatment in Preventing Bleeding in Patients With Haematological Malignancies Presenting Severe Thrombocytopenia (TTRAP-bleeding),,['Hematological Malignancies Treated With Intensive Chemotherapy'],"['Tranexamic acid', 'bleeding', 'hematological malignancies', 'thrombocytopenia']",,2019-03-05,2022-07-11,"[{'measure': 'Level of amplitude observed in thromboelastography', 'description': 'Amplitude levels observed in thromboelastography will be reported', 'timeFrame': '30 days'}]","[{'measure': 'Time at the beginning of the clot', 'description': 'Time at the beginning of the clot will be reported in minutes', 'timeFrame': '30 minutes'}, {'measure': 'Clot formation time', 'description': 'Clot formation time will ne reported in minutes', 'timeFrame': '30 minutes'}, {'measure': 'Alpha angle', 'description': 'Alpha angle will be measured in degrees', 'timeFrame': '30 days'}, {'measure': 'Percentage of lysis after 30min', 'description': 'Percentage of lysis after 30min will be measured', 'timeFrame': '30 minutes'}, {'measure': 'Proportion of patients experiencing bleeding of WHO (World Health Organisation ) grade 2 or above', 'description': 'Proportion of patients experiencing bleeding of WHO (World Health Organisation ) grade 2 or above will be reported', 'timeFrame': '30 days'}, {'measure': 'Number of adverse events', 'description': 'Number of adverse events will be reported', 'timeFrame': '3 months'}]",7.0,18 Years,,ALL,False,OTHER,1.0,18.0,ACTUAL,v2_robust,True,True,False,True,
NCT03686722,Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin,Metformin,"['Daclatasvir', 'Metformin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 2",Mohamed Raslan,2025-09-01T16:18:10.914256,True,,,,,Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetics and Pharmacodynamics of Metformin,,"['Diabetes Mellitus, Type 2', 'Hepatitis C', 'Drug Interactions']",[],,2017-09-09,2017-12-06,"[{'measure': '(AUC0→12)', 'description': 'Area under the plasma concentration-time curve measured in (nanogram(ng).hr/ml)', 'timeFrame': 'From first sampling interval(time zero) up to 12 hours'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to infinity (AUC0→∞)', 'description': 'Area under the plasma concentration-time curve from time 0 to infinity measured in(ng.hr/ml)', 'timeFrame': 'From first sampling interval up to infinity'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to tau(AUC0→tau)', 'description': 'Area under the plasma concentration-time curve from time 0 to tau measured in(ng.hr/ml)', 'timeFrame': 'From first sampling interval up to dosing interval(Tau)'}, {'measure': 'Maximum drug concentration in plasma at steady state(Cpss)', 'description': 'Maximum drug concentration in plasma at steady state measured in (ng/ml)', 'timeFrame': 'Time corresponding to maximum drug concentration in plasma at steady state'}, {'measure': 'Half life( t½) of drug in plasma', 'description': 'Half life of drug measured in Hours(hr)', 'timeFrame': 'Up to 12 hours'}, {'measure': 'Mean residence time of drug(MRT)', 'description': 'Mean residence time of drug in plasma measured in (hr)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'steady state Clearance of drug(CLss)', 'description': 'steady state Clearance of drug measured in (ml/min)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'Renal Clearance of drug(CLr)', 'description': 'Renal Clearance of drug measured in (ml/min)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'Cumulative amount of drug eliminated in urine (Ae)', 'description': 'Cumulative amount of drug eliminated in urine measured in (microgram(ug)/ml)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'Maximum excretion rate (Urate max)', 'description': 'Maximum excretion rate for the drug measured in (milligram(mg)/hr)', 'timeFrame': 'From first sampling interval up to 12 hours'}]","[{'measure': 'Blood Glucose(BG) levels', 'description': 'Blood glucose levels measured in (mg/dl)', 'timeFrame': 'up to 3 hours'}, {'measure': 'Area under the BG-time curve(AUG)0-3hr', 'description': 'Area under the BG-time curve measured in (mg.hr/dl)', 'timeFrame': 'up to 3 hours'}, {'measure': 'Maximum Glucose concentration(Gmax)', 'description': 'Maximum Glucose concentration measured in (mg/dl)', 'timeFrame': 'up to 3 hours'}]",13.0,18 Years,55 Years,MALE,True,OTHER,2.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT01104922,Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,Cetuximab,"['Cetuximab', 'Erbitux']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Squamous Cell Carcinoma of the Head and Neck,"David A. Clump, MD, PhD",2025-09-01T16:18:10.914327,True,,,,,Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,,['Squamous Cell Carcinoma of the Head and Neck'],['Fractionated Stereotactic Radiosurgery'],,2007-12-26,2018-07-26,"[{'measure': '1-year Local Progression-free Survival (PFS)', 'description': 'Progression (response as assessed by subjective interpretation of the first PET-CT) per Response Evaluation Criteria in Solid Tumors (RECIST v1.0) was defined as greater than 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum and longest diameter recorded since the baseline measurements or the appearance of 1 or more new lesion(s). If the measurable disease was restricted to a solitary lesion, the protocol specified that neoplastic nature should be confirmed by cytology and histology.', 'timeFrame': 'At 1-year'}, {'measure': '1-year Locoregional Progression-free Survival (PFS)', 'description': 'Progression (response as assessed by subjective interpretation of the first PET-CT) per Response Evaluation Criteria in Solid Tumors (RECIST v1.0) was defined as greater than 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum and longest diameter recorded since the baseline measurements or the appearance of 1 or more new lesion(s). If the measurable disease was restricted to a solitary lesion, the protocol specified that neoplastic nature should be confirmed by cytology and histology.', 'timeFrame': 'At 1-year'}, {'measure': '1-year Distant Progression-free Survival (PFS)', 'description': 'Progression (response as assessed by subjective interpretation of the first PET-CT) per Response Evaluation Criteria in Solid Tumors (RECIST v1.0) was defined as greater than 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum and longest diameter recorded since the baseline measurements or the appearance of 1 or more new lesion(s). If the measurable disease was restricted to a solitary lesion, the protocol specified that neoplastic nature should be confirmed by cytology and histology.', 'timeFrame': 'At 1-year'}]","[{'measure': '1-year Progression-free Survival (PFS)', 'description': 'Progression was defined as greater than 20% increase in the sum of the longest diameters of target lesions, per Response Evaluation Criteria in Solid Tumors (RECIST v1.0), taking as reference the smallest sum and longest diameter recorded since the baseline measurements or the appearance of 1 or more new lesion(s). If the measurable disease was restricted to a solitary lesion, the protocol specified that neoplastic nature should be confirmed by cytology and histology.', 'timeFrame': 'At 1-year'}, {'measure': 'Overall Survival (OS)', 'description': 'Number of months patients remaining alive after study treatment.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall Response (OR)', 'description': 'Response by number and percentage of patients assessed by subjective interpretation of the first PET-CT. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response(CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Changes in Tumor Glucose Metabolism', 'description': 'Glucose metabolism was assessed by FDG PET. FDG uptake reflects the tissue glucose metabolism and is usually high in high-grade tumors and relatively low in low-grade tumors.', 'timeFrame': 'Up to 24 months / post therapy'}, {'measure': 'Changes in Tumor Hypoxia.', 'description': 'Changes in tumor hypoxia (tumor cells deprived of oxygen) as a result of Stereotactic radiosurgery (SRS) through assessment by pre-and post-treatment fluorodeoxyglucose (FDG)- and fluoromisonidazole (FMISO)-PET.', 'timeFrame': 'Up to 24 months; before and after treatment'}, {'measure': 'Quality of Life (QoL)', 'description': 'Percentage of patients that reported stable and/or improved of quality of life after SBRT as indicated by a quantitative increase or maintenance in overall score. Quality of Life was assessed by longitudinal collection of the University of Washington Quality of Life Registry (UW-QoL-R) survey data, both pre- and post-SBRT. Patients completed the previously validated UW-QoL-R survey at enrollment and again after SBRT. UW-QoL-R measures patient reported QoL in 12 head and neck-specific and 3 global health domains, using a single Likert-scale question with an assigned score of 0 to 100 with 100 representing normal function.', 'timeFrame': 'Baseline, 6-8 weeks post-treatment; up to 16 months'}]",9.0,18 Years,,ALL,False,OTHER,0.0,48.0,ACTUAL,v2_robust,True,True,False,False,
NCT02518451,Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg,Valsartan 160 mg film-coated caplets (test formulation),"['Valsartan 160 mg film-coated caplets (reference formulation)', 'Valsartan 160 mg film-coated caplets (test formulation)', 'Valsartan 160 mg of PT Dexa Medica', 'Diovan® 160']",4,INTERVENTIONAL,['NA'],,COMPLETED,Healthy,Dexa Medica Group,2025-09-01T16:18:10.914410,True,,,,,"Bioequivalence Study of 160 mg Valsartan Film-coated Caplets Produced by PT Dexa Medica in Comparison With the Innovator Film-coated Tablets (Diovan® 160, Novartis Pharma AG)",,['Healthy'],"['antihypertensive', 'bioequivalence', 'formulation', 'pharmakokinetic', 'valsartan', 'subjects', 'Fasting conditions']",,2013-06,2014-03,"[{'measure': 'AUCt', 'description': 'Area under the curve of plasma concentrations versus time from time zero to the time of last observed quantifiable concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)', 'timeFrame': '48 hours'}, {'measure': 'AUCinf', 'description': 'Area under the curve of plasma concentrations versus time from time zero to infinity was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)', 'timeFrame': '48 hours'}, {'measure': 'Cmax', 'description': 'The maximum (peak) plasma concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)', 'timeFrame': '48 hours'}]","[{'measure': 'Tmax', 'description': 'The time of peak plasma concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)', 'timeFrame': '48 hours'}, {'measure': 'T1/2', 'description': 'The elimination half-life was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)', 'timeFrame': '48 hours'}]",5.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,False,
NCT00003751,"Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma",penicillamine,['penicillamine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Brain and Central Nervous System Tumors,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2025-09-01T16:18:10.914428,True,,,,,Phase II Study of Penicillamine and Reduction of Copper for Angiosuppressive Therapy of Adults With Newly Diagnosed Glioblastoma,,['Brain and Central Nervous System Tumors'],"['adult glioblastoma', 'adult giant cell glioblastoma', 'adult gliosarcoma']",,1999-03,2005-07,[],[],0.0,18 Years,,ALL,False,OTHER,1.0,40.0,ESTIMATED,v2_robust,True,True,False,False,
NCT02220751,Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic,non-surgical periodontal therapy + systemic doxycycline,"['non-surgical periodontal therapy + systemic doxycycline', 'Doxilegrand, Legrand, São Bernardo do Campo, SP, Brazil.']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Periodontitis,University of Sao Paulo,2025-09-01T16:18:10.914539,True,,,,,Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic,,"['Periodontitis', 'Type 2 Diabetes Mellitus']","['Periodontal Attachment Loss', 'Genes', 'Saliva', 'Diagnosis']",,2009-03,2012-06,"[{'measure': 'clinical attachment level', 'description': 'relative clinical attachment level (rCAL) was recorded at six sites per tooth with the aid of a computerized periodontal probe.', 'timeFrame': 'baseline and two months'}]","[{'measure': 'Gene expression', 'description': 'Gingival tissue samples were obtained from periodontal sites (active or non-active) of the each patient in both groups during regular periodontal surgery. The samples are immediately submerged into liquid nitrogen to be then stored at -80º Celsius for RNA extraction and cDNA synthesis. The Real Time-PCR Array allowed simultaneous analysis of 84 genes involved in specific signaling pathways, including specific human inflammatory cytokines and receptors.', 'timeFrame': 'Two months'}, {'measure': 'Salivary proteins levels', 'description': 'Non-stimulated whole expectorated saliva was collected (\\~ 3 ml) from each subject into sterile tubes and stored at -80º Celsius. The salivary inflammatory proteins levels were identified simultaneously using Multiplex Cytokine Profiling Assay, which allows the simultaneous detection of multiple analytes in saliva sample size.', 'timeFrame': 'baseline and two months'}]",3.0,35 Years,65 Years,ALL,True,OTHER,1.0,56.0,ACTUAL,v2_robust,True,True,False,False,
NCT00463151,An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis,rebamipide,['rebamipide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Colitis, Ulcerative","Otsuka Pharmaceutical Co., Ltd.",2025-09-01T16:18:10.914567,True,,,,,An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis,,"['Colitis, Ulcerative']","['Rebamipide', 'Enema', 'Ulcerative Colitis']",,2007-06,2008-08,"[{'measure': 'Clinical Improvement Rate (Number of Subjects Showing Clinical Improvement/Number of Subjects Evaluated x 100)', 'description': 'Definition of clinical improvement: a decrease of Disease Activity Index \\[DAI\\] score for ""rectal bleeding"" to either 0 or 1 point and a decrease of ≥1 point in the DAI score for ""findings on endoscopy"" from the baseline', 'timeFrame': 'Week 6'}]","[{'measure': 'Clinical Remission (Number of Subjects Showing Remission/Number of Subjects Evaluated x 100)', 'description': 'Definition of remission: a decrease of the total DAI scores for ""rectal bleeding"" and ""findings on endoscopy"" to 0 points', 'timeFrame': 'Week 6'}, {'measure': 'Mean Change From Baseline in Total DAI Score', 'description': ""DAI measures disease activity through assessment of 4 items/subscales: stool frequency, rectal bleeding, findings on endoscopy, and physician's global assessment. Each item of the score is assessed on a 4-point scale from 0 to 3; the total score ranges from 0 to 12 with a higher score representing greater severity. A negative change in mean score indicates improvement."", 'timeFrame': 'Baseline and Week 6'}, {'measure': 'Percentage of Subjects Showing Improvement in Each DAI Subscore', 'description': ""DAI measures disease activity through assessment of 4 items/subscales: stool frequency, rectal bleeding, findings on endoscopy, and physician's global assessment. Each item of the score is assessed on a 4-point scale from 0 to 3 with a higher score representing greater severity. A negative change from baseline indicates improvement."", 'timeFrame': 'Baseline and week 6'}, {'measure': 'Mean Change From Baseline in Total Endoscopic Index (EI) Score', 'description': 'The index consisted of 4 subscales: granulation scattering reflected light, vascular pattern, vulnerability of mucosa, and mucosal damage. Each subscale was scored on a scale of 0 to 4 and the total score (the sum of all 4 subscores) ranges from 0 to 12, higher scores indicate more severe disease.', 'timeFrame': 'Baseline and Week 6'}]",5.0,16 Years,,ALL,False,INDUSTRY,0.0,124.0,ACTUAL,v2_robust,True,True,False,False,
NCT03776851,Erythropoietin in Hemolytic Uremic Syndrome,erythropoietin,"['erythropoietin', 'EPO']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hemolytic-Uremic Syndrome,Hospital General de Niños Pedro de Elizalde,2025-09-01T16:18:10.914660,True,,,,,Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome: a Randomized Controlled Trial,,"['Hemolytic-Uremic Syndrome', 'Anemia']","['Hemolytic-Uremic Syndrome', 'erythropoietin', 'RBC transfusion']",,2019-01-01,2020-12-30,"[{'measure': 'Number of RBC transfusions', 'description': 'To determine if administration of erythropoietin decreases the number of RBC during the acute stage of hemolytic uremic syndrome', 'timeFrame': 'At the end of the 36 month study recruiting period'}]","[{'measure': 'Erythropoietin levels', 'description': 'To determine if erythropoietin levels correlate with RBC transfusions requirement.', 'timeFrame': 'At the end of the 36 month study recruiting period'}]",2.0,1 Month,18 Years,ALL,False,OTHER,0.0,24.0,ACTUAL,v2_robust,True,True,False,False,
NCT03080051,Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain,[18F]MNI-952,"['[18F]UCB-K', '[18F]Florbetapir', '[18F]MNI-952']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Progressive Supranuclear Palsy,Molecular NeuroImaging,2025-09-01T16:18:10.914673,True,,,,,Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers,,"['Progressive Supranuclear Palsy', 'Alzheimer Disease', 'Healthy Volunteers']","['PSP', 'AD', 'HV']",,2016-08,2017-03-06,"[{'measure': 'Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-952 binding/uptake and expressed in SUV by using established methods for normalization for 2 PSP, 2 AD, and 2 HV subjects.', 'description': 'Descriptive statistics will be applied to describe the tau deposition by region as measured by \\[18F\\]MNI-952.', 'timeFrame': '1 year'}]",[],1.0,18 Years,90 Years,ALL,True,OTHER,0.0,6.0,ACTUAL,v2_robust,True,True,False,False,
NCT02593851,"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection",JNJ-53718678,"['JNJ-53718678', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Respiratory Syncytial Virus Infections,Janssen Sciences Ireland UC,2025-09-01T16:18:10.914683,True,,,,,"A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection",,"['Respiratory Syncytial Virus Infections', 'Virus Diseases']","['Respiratory Syncytial Virus Infections', 'JNJ-53718678', 'Placebo', 'Infants']",Trial was cancelled due to availability of clinical supplies.,2015-12-04,2017-11-10,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of JNJ-53718678', 'description': 'The Cmax is the maximum observed plasma concentration.', 'timeFrame': 'Days 1, 2 and 3'}, {'measure': 'Trough Plasma Concentration (Ctrough) of JNJ-53718678', 'description': 'The Ctrough is the plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose in a multiple dosing regimen.', 'timeFrame': 'Days 1, 2 and 3'}, {'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)', 'description': 'The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval.', 'timeFrame': 'Days 1, 2 and 3'}, {'measure': 'Total Apparent Clearance (CL/F) of JNJ-53718678', 'description': 'Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.', 'timeFrame': 'Days 1, 2 and 3'}, {'measure': 'Apparent Volume of Distribution (Vd/F) of JNJ-53718678', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vd/F) is influenced by the fraction absorbed.', 'timeFrame': 'Days 1, 2 and 3'}, {'measure': 'Number of Participants With Adverse Events', 'description': 'An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.', 'timeFrame': 'Up to Follow-up (Day 28)'}]","[{'measure': 'Area Under the Viral Load-time Curve (VL AUC)', 'description': 'VL will be determined by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) assay of nasal swabs. The VL AUC (copies. hour/ml) will be calculated based on the trapezoidal method.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Amount of Viral Load Over Time', 'description': 'VL (copies/ml) at each assessment timepoint where a nasal sample is obtained.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Number of viral particles at Peak Viral Load', 'description': 'Peak viral load (copies/ml) is a measure of the maximum number of viral particles present in nasal swabs.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Time To Peak Viral Load', 'description': 'Time (hours) to peak viral load will be reported.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Number of Participants Reaching Undetectability of virus Between First Administration of Study Drug and Day 28', 'description': 'Non-detectability of virus in nasal swabs between first administration of study drug and Day 28 will be reported.', 'timeFrame': 'Day 1 to Day 28'}, {'measure': 'Total Number of Respiratory Syncytial Virus (RSV) Hospitalization Days from Admission to Discharge', 'description': 'The total number of Respiratory Syncytial Virus (RSV) hospitalization days from admission to discharge will be reported.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Total RSV Hospitalization Days with Supplemental Oxygen Requirement', 'description': 'The total number of RSV Hospitalization Days with Supplemental Oxygen Requirement will be reported.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'The Number of days in Intensive care unit (ICU) due to RSV', 'description': 'The number of days stayed in ICU due to RSV will be reported.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Total Days of non-invasive ventilator support During RSV Hospitalization', 'description': 'The total number of days with non-invasive ventilator support during RSV hospitalization will be reported.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Total Days of Mechanical Ventilation During RSV Hospitalization', 'description': 'The total number of days with Mechanical Ventilation during RSV hospitalization will be reported.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Changes in Peripheral Capillary Oxygen Saturation (SpO2)', 'description': 'The Percentage of Peripheral Capillary Oxygen Saturation (SpO2) will be assessed by the investigator during hospitalisation.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Change from Baseline in Respiratory Rate', 'description': 'The Respiratory rate (number of breaths per minute) will be assessed by the investigator and caregiver during hospitalisation.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Change from Baseline in Body Temperature', 'description': 'The body temperature (degrees Celcius) will be assessed by the investigator and caregiver during hospitalisation.', 'timeFrame': 'Up to Follow-up (Day 28)'}, {'measure': 'Clinical Symptom Score', 'description': 'The clinical symptom score will be assessed by the investigator (Clinician Outcome Assessment) and caregiver symptom Diary for each symptom. Clinical Symptom score ranges from 0 (best) to 4 (worst).', 'timeFrame': 'Up to Follow-up (Day 28)'}]",20.0,1 Month,24 Months,ALL,False,INDUSTRY,0.0,45.0,ACTUAL,v2_robust,True,False,True,True,Trial was cancelled due to availability of clinical supplies.
NCT05878951,Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms,OnabotulinumtoxinA,"['Botox', 'OnabotulinumtoxinA']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,RECRUITING,Urinary Incontinence,Northwestern University,2025-09-01T16:18:10.914707,True,,,,,A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms,,"['Urinary Incontinence', 'Overactive Bladder Syndrome', 'Overactive Bladder', 'Urologic Diseases']",[],,2023-07-13,2026-08-24,"[{'measure': 'Improve Overactive Bladder Symptoms (OAB) utilizing botox injections into the bladder.', 'description': 'Examine the safety and effect of intra-detrusor botulinum toxin injections at the time of helium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.', 'timeFrame': '12 months'}]","[{'measure': 'Difference in safety/ adverse effects', 'description': 'Identifying changes in post-op urinary retention, gross hematuria, UTI, ED visits and any additional complications.', 'timeFrame': '90 days'}, {'measure': 'Difference in patient REDCap surveys (gross hematuria dysuria, incontinence)', 'description': 'Identifying symptom resolution at different time points (1 month, 3 months, 6 months)', 'timeFrame': '6 months'}, {'measure': 'Difference in efficacy endpoints (3-month clinic/telephone follow-up)', 'description': 'Identifying efficacy endpoints as they relate to the use of anti-cholinergics, incontinence survey, post void residuals, continence pads requirements if any.', 'timeFrame': '3 months'}]",4.0,18 Years,89 Years,MALE,False,OTHER,3.0,80.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01564251,A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma,GDC-0575,"['RO6845979', 'Gemzar', 'GDC-0575', 'Gemcitabine']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Lymphoma, Solid Tumor","Genentech, Inc.",2025-09-01T16:18:10.914736,True,,,,,"An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma",,"['Lymphoma, Solid Tumor']",[],,2012-03-23,2018-01-11,"[{'measure': 'Percentage of Participants With Adverse Events (AEs)', 'timeFrame': 'Baseline up to approximately 5 years'}, {'measure': 'Percentage of Participants With Dose-Limiting Toxicities (DLTs)', 'timeFrame': 'Stage 1 Arm 1: Day 1 up to Day 21. Stage 1 Arm 2: Day 1 up to Day 22 or 29'}, {'measure': 'Maximum Tolerated Dose (MTD) of GDC-0575', 'timeFrame': 'Stage 1 Arm 1: Day 1 up to Day 21. Stage 1 Arm 2: Day 1 up to Day 22 or 29'}, {'measure': 'Recommended Phase II Dose of GDC-0575', 'timeFrame': 'Stage 1 Arm 1: Day 1 up to Day 21. Stage 1 Arm 2: Day 1 up to Day 22 or 29'}, {'measure': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 hours (h) postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only); predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'Minimum Observed Plasma Trough Concentration (Cmin) of GDC-0575', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes) on Day 2; predose (0.5h) on Day 9'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax) of GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'Apparent Terminal Half-Life (t1/2) of GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'Apparent Oral Clearance (CL/F) of GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'Accumulation Ratio (Rac) of GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'PK-dose Proportionality as Assessed With Cmax of GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'PK-dose Proportionality as Assessed With AUC of GDC-0575', 'description': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose (5 to 30 minutes) on Days 1, 2, 3, 8, 15; 0.5, 1, 1.5, 2, 4, 6, 8 h postdose on Days 1, 3; 2, 4h postdose on Days 2, 15; 2h postdose on Day 8; on Days 4, 5. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose (5 minutes), 0.5, 1, 1.5, 2, 4, 6h postdose on Day 2 (additionally at 8h postdose on Day 2 for Arm 2a only) ; predose (0.5h), 2h postdose on Day 9', 'timeFrame': 'Stage 1 Arm 1, Cycle 1 of 21 days: predose on Days 1, 2, 3, 8, 15; postdose on Days 1, 2, 3, 4, 5, 8, 15. Stage 1 Arm 2 and Stage 2, Cycle 1 of 21 days: predose and postdose on Days 2, 9 (detailed timeframe is provided in outcome measure description)'}, {'measure': 'Phospho-Cyclin-Dependent Kinase 2 (pCdk2) Levels in Fresh Tumor', 'description': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3 and 10 of Cycle 2. Stage 1 Arm 2b: Screening (Day -21 to -1), Day 3 of Weeks 4 and 5. Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 1 and 2', 'timeFrame': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3, 10 of Cycle 2. Stage1 Arm2b, Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 4, 5 (Stage1 Arm2b), Weeks 1, 2 (Stage 2)'}, {'measure': 'Phospho-Cyclin-Dependent Kinase 2 (pCdk2) Levels in Skin Tissue', 'description': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3 and 10 of Cycle 2. Stage 1 Arm 2b: Screening (Day -21 to -1), Day 3 of Weeks 4 and 5. Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 1 and 2', 'timeFrame': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3, 10 of Cycle 2. Stage1 Arm2b, Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 4, 5 (Stage1 Arm2b), Weeks 1, 2 (Stage 2)'}, {'measure': 'Gamma-H2Ax (γ-H2Ax) Levels in Fresh Tumor', 'description': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3 and 10 of Cycle 2. Stage 1 Arm 2b: Screening (Day -21 to -1), Day 3 of Weeks 4 and 5. Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 1 and 2', 'timeFrame': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3, 10 of Cycle 2. Stage1 Arm2b, Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 4, 5 (Stage1 Arm2b), Weeks 1, 2 (Stage 2)'}, {'measure': 'Gamma-H2Ax (γ-H2Ax) Levels in Skin Tissue', 'description': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3 and 10 of Cycle 2. Stage 1 Arm 2b: Screening (Day -21 to -1), Day 3 of Weeks 4 and 5. Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 1 and 2', 'timeFrame': 'Stage 1 Arm 1: Screening (Day -21 to -1), Cycle 1 Day 4 (Cycle length=21 days). Stage 1 Arm 2a: Screening (Day -21 to -1), Days 3, 10 of Cycle 2. Stage1 Arm2b, Stage 2: Screening (Day -21 to -1), Day 3 of Weeks 4, 5 (Stage1 Arm2b), Weeks 1, 2 (Stage 2)'}]","[{'measure': 'Percentage of Participants With Objective Response as Determined Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'timeFrame': 'Baseline until disease progression or death (up to approximately 5 years)'}, {'measure': 'Progression-Free Survival (PFS) as Determined Using RECIST v1.1', 'timeFrame': 'Baseline until disease progression or death (up to approximately 5 years)'}, {'measure': 'Duration of Objective Response as Determined Using RECIST v1.1', 'timeFrame': 'Baseline until disease progression or death (up to approximately 5 years)'}]",21.0,18 Years,,ALL,False,INDUSTRY,0.0,104.0,ACTUAL,v2_robust,True,True,False,True,
NCT03733951,KN046 in Subjects With Advanced Solid Tumors and Lymphoma,KN046,['KN046'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Advanced Solid Tumors,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",2025-09-01T16:18:10.914744,True,,,,,"An Open-Label, Multicenter, Dose-Escalation and Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KN046 Monotherapy in Subjects With Advanced Solid Tumors and Lymphoma",,"['Advanced Solid Tumors', 'Lymphoma']",[],,2018-12-18,2023-02-02,"[{'measure': 'In the dose escalation part, number of participants with dose limiting toxicity (DLT).', 'timeFrame': 'During the first 4 weeks of treatment.'}, {'measure': 'In the dose expansion part,Objective response rate (ORR).', 'description': 'Objective response is defined as complete response (CR) or partial response (PR)', 'timeFrame': 'up to 2 years.'}, {'measure': 'In the dose expansion part, Duration of response (DoR).', 'description': 'Duration of response is defined as the time period from the date of initial independent review committee assessed CR or PR until the date of PD or death from any cause, whichever occurs first.', 'timeFrame': 'up to 2 years.'}]",[],3.0,18 Years,,ALL,False,INDUSTRY,0.0,139.0,ACTUAL,v2_robust,True,True,False,False,
NCT04547829,Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy,pegylated recombinant human granulocyte-colony stimulating factor,['pegylated recombinant human granulocyte-colony stimulating factor'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Pediatric Cancer,Sun Yat-sen University,2025-09-01T16:18:10.914823,True,,,,,"Safety and Efficacy of Pegylated Recombinant Human Granulocyte-colony Stimulating Factor(PEG-rhG-CSF) in Preventing Neutropenia in Children With Tumor After Chemotherapy：A Multi-center, Single Arm Trial.",,['Pediatric Cancer'],[],,2020-10-10,2023-05-10,"[{'measure': 'safety of PEG-rhG-CSF in the prevention of neutropenia in children with tumor after chemotherapy', 'description': 'The incidence and severity of adverse events;', 'timeFrame': 'From the beginning of observation to the end of observation（6 weeks) of the last enrolled patient'}]","[{'measure': 'To evaluate the effectiveness of PEG-rhG-CSF in preventing neutropenia in children with tumor after chemotherapy.', 'description': 'The incidence of grade III / IV ANC reduction in each chemotherapy cycle', 'timeFrame': 'From the beginning of observation to the end of observation（6 weeks) of the last enrolled patient'}]",2.0,6 Years,18 Years,ALL,False,OTHER,0.0,108.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02336529,Nerveblocks for Persistent Pain After Breast Cancer Surgery,Bupivacaine,"['Bupivacaine', 'NaCl']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Pain,Kenneth Geving Andersen,2025-09-01T16:18:10.914859,True,,,,,Tenderpoint and Ultrasound Guided Nerveblocks for Persistent Pain After Breast Cancer Surgery,,"['Pain', 'Neuropathic Pain', 'Breast Cancer']",['postoperative'],,2016-07,2017-07,"[{'measure': 'Summed pain intensity', 'description': 'The summed pain intensity (of pain at rest (0-10), pain during movement (0-10) and pressure pain (at 100kPa in point of maximum pain) (0-10)) 0-30', 'timeFrame': 'At least 1 year after surgery'}]","[{'measure': 'Pain at rest, pain during movement and pressure pain', 'description': 'Pain intensity of pain at rest (0-10), pain during movement (0-10) and pressure pain (at 100kPa in point of maximum pain) (0-10)', 'timeFrame': 'At least 1 year after surgery'}, {'measure': 'Pain related reduction of physical function', 'description': 'Reduction of physical function', 'timeFrame': 'At least 1 year after surgery'}]",3.0,18 Years,,FEMALE,False,OTHER,0.0,48.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00259129,Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients,"Sorafenib (Nexavar, BAY43-9006)","['Sorafenib (Nexavar, BAY43-9006)']",1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Neoplasms,Bayer,2025-09-01T16:18:10.914941,True,,,,,Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients,,['Neoplasms'],[],,2005-08,2008-03,"[{'measure': 'Effect of sorafenib on cardiovascular safety parameters', 'timeFrame': 'up to 2 months'}]","[{'measure': 'Pharmacokinetics', 'timeFrame': 'after 16 months'}, {'measure': 'Anti-tumor activity', 'timeFrame': 'after 10 months'}, {'measure': 'Adverse Event Collection', 'timeFrame': 'after 11 months'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,53.0,ACTUAL,v2_robust,True,True,False,True,
NCT05138029,Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation,Ranibizumab Injection [Lucentis],"['Lucentis', 'Ranibizumab Injection [Lucentis]', 'Dexamethasone Implants', 'Dexamethasone intravitreal implant']",4,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Diabetic Retinopathy,Affiliated Hospital of Nantong University,2025-09-01T16:18:10.914999,True,,,,,Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time Optical Coherence Tomography During Operation,,['Diabetic Retinopathy'],[],,2021-11-15,2024-05,"[{'measure': ""Review the patient's vision before surgery"", 'description': 'Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.', 'timeFrame': ""The day before the patient's surgery""}]","[{'measure': ""Review the patient's vision for one day after surgery"", 'description': 'Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.', 'timeFrame': ""The patient's first day after surgery""}, {'measure': ""Review the patient's vision for 7 days after surgery"", 'description': 'Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.', 'timeFrame': '1st week after surgery'}, {'measure': ""Review the patient's vision for 1 month after surgery"", 'description': 'Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.', 'timeFrame': '4th week after surgery'}, {'measure': ""Review the patient's vision for 3 months after surgery"", 'description': 'Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.', 'timeFrame': '12th week after surgery'}, {'measure': ""Review the patient's vision for 6 months after surgery"", 'description': 'Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis.', 'timeFrame': '24th week after surgery'}]",6.0,18 Years,80 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03123029,Expanded Access to Venetoclax,Venetoclax,"['ABT-199', 'Venetoclax', 'GDC-0199']",3,EXPANDED_ACCESS,[],,AVAILABLE,Chronic Lymphocytic Leukemia (CLL),AbbVie,2025-09-01T16:18:10.915081,True,,,,,Expanded Access to Venetoclax,,"['Chronic Lymphocytic Leukemia (CLL)', 'Multiple Myeloma', 'Acute Myeloid Leukemia (AML)', ""Non-Hodgkin's Lymphoma"", 'Acute Lymphoblastic Leukemia (ALL)', 'Amyloidosis', 'Plasma Cell Leukemia']","['Expanded Access', 'Pre-approval Access', 'Compassionate Use', 'Special Access Program', 'Named Patient Basis', 'Special Access Scheme']",,,,[],[],0.0,,,ALL,False,INDUSTRY,0.0,,,v2_robust,False,False,False,False,
NCT01304329,Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin,BI 10773,"['BI 10773', 'simvastatin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:10.915126,True,,,,,"Relative Bioavailability of BI 10773 and Simvastatin After Single and Combined Administration - an Open-label, Randomised, Crossover Trial in Healthy Subjects",,['Healthy'],[],,2011-02,,"[{'measure': 'Empa: Area Under the Curve 0 to Infinity (AUC0-∞)', 'description': 'Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.\n\nThe geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.', 'timeFrame': '0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration'}, {'measure': 'Simvastatin: Area Under the Curve 0 to Infinity (AUC0-∞)', 'description': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity. Simvastatin acid is an active metabolite of simvastatin.\n\nThe geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.', 'timeFrame': '0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration'}, {'measure': 'Empa: Maximum Measured Concentration (Cmax)', 'description': 'Maximum measured concentration of the analyte in plasma, per period.\n\nThe geometric mean and geometric coefficient of variation (gCV) are adjusted values', 'timeFrame': '0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration'}, {'measure': 'Simvastatin: Maximum Measured Concentration (Cmax)', 'description': 'Maximum measured concentration of the analyte in plasma, per period.\n\nThe geometric mean and geometric coefficient of variation (gCV) are adjusted values.', 'timeFrame': '0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration'}]","[{'measure': 'Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)', 'description': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.\n\nThe geometric mean and geometric coefficient of variation (gCV) are adjusted values.', 'timeFrame': '0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration'}, {'measure': 'Simvastatin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)', 'description': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.\n\nThe geometric mean and geometric coefficient of variation (gCV) are adjusted values.', 'timeFrame': '0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration'}]",6.0,18 Years,50 Years,ALL,True,INDUSTRY,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT00970931,Hypertension Prevention in Pre-Hypertensive Individuals,Chlorthalidone plus amiloride,"['Chlorthalidone plus amiloride', 'diuretic', 'placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Pre-hypertension,Hospital de Clinicas de Porto Alegre,2025-09-01T16:18:10.915246,True,,,,,Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study,,"['Pre-hypertension', 'Hypertension', 'Cardiovascular Disease']","['hypertension', 'diuretics']",,2010-07,2014-09,"[{'measure': 'Incidence of hypertension, by blood pressure ≥ 140/90 mmHg in individuals without diabetes or ≥ 135/85 mmHg in participants with diabetes.', 'timeFrame': '18 months'}, {'measure': 'Adverse events.', 'timeFrame': '18 months'}, {'measure': 'Development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG', 'timeFrame': '18 months'}]","[{'measure': 'fatal or major cardiovascular events: myocardial infarction, stroke, coronary interventions, heart failure, duplication of creatinine', 'timeFrame': '18 months'}]",4.0,30 Years,70 Years,ALL,True,OTHER,1.0,730.0,ACTUAL,v2_robust,True,True,False,True,
NCT05359731,Pharmacokinetic Analysis of Bupivacaine in the Presence and Absence of Perineural Dexamethasone in Axillary Blockade,Bupivacaine Hydrochloride,"['Bupivacaine Hydrochloride', 'Bupivacaine Hydrochloride with Dexamethasone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Analgesia,University of Chile,2025-09-01T16:18:10.915258,True,,,,,Pharmacokinetic Analysis of Bupivacaine in the Presence and Absence of Perineural Dexamethasone in Axillary Brachial Plexus Blockade for Distal Forearm and Hand Surgery,,"['Analgesia', 'Acute Pain', 'Upper Extremity Injury']","['Dexamethasone', 'Nerve Block', 'Adjuvant', 'Pharmacokinetic Analysis']",,2022-06-28,2023-04-24,"[{'measure': 'Maximum plasma concentration (Cmax) of bupivacaine', 'description': 'Maximum plasmatic level of bupivacaine', 'timeFrame': '0 to 90 minutes after the ending time of local anesthetic injection'}]","[{'measure': 'Plasmatic concentration of bupivacaine at 15 minutes', 'description': 'Plasmatic level of bupivacaine 15 minutes after local anesthetic injection (ng/ml)', 'timeFrame': '15 minutes after the ending time of local anesthetic injection'}, {'measure': 'Plasmatic concentration of bupivacaine at 30 minutes', 'description': 'Plasmatic level of bupivacaine 30 minutes after local anesthetic injection (ng/ml)', 'timeFrame': '30 minutes after the ending time of local anesthetic injection'}, {'measure': 'Plasmatic concentration of bupivacaine at 45 minutes', 'description': 'Plasmatic level of bupivacaine 45 minutes after local anesthetic injection (ng/ml)', 'timeFrame': '45 minutes after the ending time of local anesthetic injection'}, {'measure': 'Plasmatic concentration of bupivacaine at 60 minutes', 'description': 'Plasmatic level of bupivacaine 60 minutes after local anesthetic injection (ng/ml)', 'timeFrame': '60 minutes after the ending time of local anesthetic injection'}, {'measure': 'Plasmatic concentration of bupivacaine at 90 minutes', 'description': 'Plasmatic level of bupivacaine 90 minutes after local anesthetic injection (ng/ml)', 'timeFrame': '90 minutes after the ending time of local anesthetic injection'}, {'measure': 'Time to obtain the maximum plasma concentration of bupivacaine (Tmax)', 'description': 'Time in minutes in which the maximum plasmatic level of bupivacaine is reached', 'timeFrame': '0 to 90 minutes after the ending time of local anesthetic injection'}, {'measure': 'Area under the curve of plasma concentration versus time at 90 minutes (AUC90)', 'description': 'Area under the curve at 90 minutes', 'timeFrame': '0 to 90 minutes after the ending time of local anesthetic injection'}, {'measure': 'Sensory and motor block score', 'description': 'The sensorimotor block will be assessed every 5 minutes until 30 minutes after the end of local anesthetic injection using a 16-point composite score evaluating sensory and motor block of musculocutaneous, medium, radial, and ulnar nerves.\n\nSensation will be assessed with ice in each nerve territory with a 0 to 2 point scale. 0= no block, patients can feel cold; 1= analgesic block, the patient can feel touch but not cold; 2= anesthetic block, the patient cannot feel cold or touch.\n\nThe motor function will be assessed for each nerve with a 0 to 2 points scale where 0= no motor block; 1= paresis; 2= paralysis.\n\nSuccessful blocks at 30 minutes correlate with a final score ( sum of all individual sensory and motor scores) of at least 14 points out of 16.', 'timeFrame': '30 minutes after the ending time of local anesthetic injection'}, {'measure': 'Block onset time', 'description': 'Time required to reach a minimal sensorimotor composite score of 14 points out of a maximum of 16 points. The sensorimotor score is described in outcome 9.', 'timeFrame': '30 minutes after the ending time of local anesthetic injection'}, {'measure': 'Incidence of successful block', 'description': 'Percentage of blocks with a minimal sensorimotor composite score of 14 points out of a maximum of 16 points at 30 minutes after the injection', 'timeFrame': '30 minutes after the ending time of local anesthetic injection'}, {'measure': 'Motor block duration', 'description': 'The elapsed period in minutes between the ending time of the local anesthetic injection and the time of return of hand and fingers movement.', 'timeFrame': '48 hours after the ending time of local anesthetic injection'}, {'measure': 'Sensory block duration', 'description': 'The elapsed period in minutes between the ending time of the local anesthetic injection and the time of the return of hand and fingers sensation', 'timeFrame': '48 hours after the ending time of local anesthetic injection'}, {'measure': 'Analgesic block duration', 'description': 'The elapsed period in minutes between the ending time of the local anesthetic injection and the time of the first sensation of pain in the surgical area', 'timeFrame': '48 hours after the ending time of local anesthetic injection'}, {'measure': 'Intensity of pain during block procedure', 'description': 'Evaluated with the Numeric Rating Scale for Pain. This scale is graduated from 0 to 10 points. A 0-point score represents the absence of pain, and a 10-points score represents the worst imaginable pain. Patients will be asked to rate their pain verbally with this scale. The blinded assessor will register the score reported.', 'timeFrame': 'During the execution of the nerve blockade'}, {'measure': 'Block performance time', 'description': 'Sum of: 1- the acquisition time of the ultrasonographic image. and 2- the time to perform the block itself (from the skin anesthesia to the end of local anesthetic injection)', 'timeFrame': 'From the skin anesthesia to the end of local anesthetic injection'}, {'measure': 'Incidence of nerve block side effects', 'description': 'Determined by the presence of paresthesia, local anesthetic systemic toxicity, vascular puncture after the block.', 'timeFrame': 'From the skin anesthesia to the end of local anesthetic injection'}, {'measure': 'Persistent neurologic deficit', 'description': 'Presence of persistent sensory or motor postoperative deficit.', 'timeFrame': '7 days after surgery'}]",18.0,18 Years,65 Years,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,
NCT05654831,FTIH of ECC5004 in Healthy and Diabetic Participants,Placebo,"['ECC5004', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Type 2 Diabetes Mellitus,Eccogene,2025-09-01T16:18:10.915411,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC5004 in Healthy Participants and in Patients With Type 2 Diabetes Mellitus",,['Type 2 Diabetes Mellitus'],[],,2022-12-01,2023-11-01,"[{'measure': 'Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations', 'description': 'Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.', 'timeFrame': 'SAD: Up to Day 8 and MAD: Up to Day 35'}]","[{'measure': 'Pharmacokinetic Parameters: AUC0-24', 'description': 'AUC from time 0 to 24 hour dosing interval', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: AUC0-tlast', 'description': 'AUC from time 0 to the time of last quantifiable non-zero concentration', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: AUC0-tau', 'description': 'AUC over a dosing interval from time 0 to time of last quantifiable concentration', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: AUC0-infinity', 'description': 'AUC from time 0 extrapolated to infinity', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: Cmax', 'description': 'Maximum observed plasma concentration', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: C24', 'description': 'Observed concentration at 24 hours post dose', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: Ctau', 'description': 'Observed concentration at the end of the dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: tmax', 'description': 'Time of the maximum observed plasma concentration', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: tlag', 'description': 'Lag time (time delay between dosing and first observed plasma concentration)', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: t1/2', 'description': 'Apparent terminal elimination half-life', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: Clast', 'description': 'Last measurable non-zero concentration', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: tlast', 'description': 'Time of last measurable non-zero concentration', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: CL/F', 'description': 'Apparent Clearance', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for glucose', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for insulin', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for glucagon', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for C-peptide', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Fasting plasma glucose', 'description': 'Change from baseline', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Mean daily glucose', 'description': 'Change from baseline', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Body Weight and Waist Circumference', 'description': 'Change from baseline', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Fasting plasma glucose homeostatic model assessment', 'description': 'Fasting plasma glucose homeostatic model assessment', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment', 'description': 'Fasting plasma insulin homeostatic model assessment', 'timeFrame': 'MAD: Up to Day 30'}]",23.0,18 Years,70 Years,ALL,True,INDUSTRY,0.0,69.0,ACTUAL,v2_robust,True,True,False,True,
NCT00627731,Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients,methylprednisolone sodium succinate (mPSL),"['methylprednisolone sodium succinate (mPSL)', 'prednisolone (PSL)', 'methlyprednisolone sodium succinate', 'prednisolone']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Asthma,Hamamatsu University,2025-09-01T16:18:10.915543,True,,,,,"Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients",,['Asthma'],['Asthma Patients'],,2007-06,2009-10,"[{'measure': 'Efficacy of oral prednisolone for the treatment of acute asthma', 'timeFrame': 'three-year'}]","[{'measure': 'The safety of oral prednisolone for the treatment of acute asthma', 'timeFrame': 'three-year'}]",2.0,16 Years,80 Years,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,True,
NCT00876031,Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma,"trofosfamide, idarubicin, etoposide","['trofosfamide, idarubicin, etoposide']",1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Soft Tissue Sarcoma,University Hospital Tuebingen,2025-09-01T16:18:10.915561,True,,,,,"A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults",,['Soft Tissue Sarcoma'],"['pediatric soft tissue sarcoma', 'rhabdomyosarcoma', 'extraosseous Ewing family tumours', 'synovial sarcoma', 'undifferentiated sarcoma']",,2009-07-01,2022-06-30,"[{'measure': 'event free survival (EFS)', 'timeFrame': '3 years'}]","[{'measure': 'Overall survival', 'timeFrame': '5 years'}]",2.0,6 Months,21 Years,ALL,False,OTHER,7.0,195.0,ACTUAL,v2_robust,True,True,False,False,
NCT00146731,A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania,SP,"['chlorproguanil-dapsone', 'AQ + artesunate', 'SP', 'SP + amodiaquine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Malaria,London School of Hygiene and Tropical Medicine,2025-09-01T16:18:10.915591,True,,,,,Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania,,['Malaria'],"['malaria', 'pregnancy', 'treatment', 'Africa', 'Tanzania']",,2004-01,2007-09,[{'measure': 'The primary end-point of the trial will be treatment failure. This is defined above.'}],"[{'measure': 'Incidence of foetal death during treatment, defined as absence of foetal heartbeat assessed by Doppler'}, {'measure': 'Hypoglycaemia requiring treatment'}, {'measure': 'Parasite recrudescence or re-infection on day 28'}, {'measure': 'Parasite clearance on day 3'}, {'measure': 'Level of recovery of haemoglobin on day 14'}, {'measure': 'Fever clearance time'}, {'measure': 'Incidence of perinatal and neonatal mortality, assessed 4-6 weeks after due date of delivery'}, {'measure': 'Clinically apparent neonatal abnormality, assessed 4-6 weeks after due date of delivery'}, {'measure': 'Placental malaria'}, {'measure': 'Preterm delivery'}, {'measure': 'Other adverse events during treatment'}]",12.0,15 Years,38 Years,FEMALE,False,OTHER,1.0,310.0,ACTUAL,v2_robust,True,True,False,True,
NCT00303602,Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height),Sublingual orally disintegrating olanzapine (SODO),"['Zydis', 'Oral olanzapine', 'LY170053', 'Zyprexa', 'Sublingual orally disintegrating olanzapine (SODO)']",5,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Schizophrenia,Eli Lilly and Company,2025-09-01T16:18:10.915628,True,,,,,BMI Evaluation: Placebo and Active Comparator Trial of Olanzapine Zydis Pills Used Sublingually (PLATYPUS),,"['Schizophrenia', 'Schizoaffective Disorder', 'Bipolar Disorder']",[],,2006-03,2007-12,"[{'measure': 'Time Course of Change From Baseline in Body Mass Index (BMI)', 'description': 'Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of changes at various time points throughout the study. Change = Time point value minus baseline (Visit 2) value.', 'timeFrame': 'Visit 2 (Baseline) to Visit 7 (16 Weeks)'}]","[{'measure': 'Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI)', 'description': 'Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of change from baseline to endpoint. Change = Endpoint (Week 16) minus Baseline (Week 0)', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) for the Treatment Completers', 'description': 'Body mass index is an estimate of body fat based on body weight divided by height squared. Comparisons of change from baseline to endpoint between participants who completed their treatment. Change = Endpoint value minus Baseline value.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (16 Weeks)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in Weight', 'description': 'Weight of undressed patient (undergarments allowed), measured preferably at the same time each day.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (16 Weeks)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in Waist Circumference', 'description': 'Waist circumference is measured on a bare abodomen just above the hip bone.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Number of Patients Achieving at Least 5% Loss of Body Weight in Any Post-Baseline Period', 'description': 'Percentage loss of body weight = 100\\*(postbaseline weight - baseline weight)/baseline weight', 'timeFrame': 'Visit 2 (Baseline) to Visit 7 (Week 16)'}, {'measure': 'Number of Participants Discontinuing the Trial by Visit (Week)', 'description': 'The number of participants who discontinued by visit (non-cumulative).', 'timeFrame': 'Visit 2 (Baseline) to Visit 7 (Week 16)'}, {'measure': 'Change From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale', 'description': 'Participant chooses where they think their appetite lies on a 10 centimeter line between two anchors (0 - very poor appetite and 10 - very strong appetite). The possible range of scores is 0 to 100 and represents millimeters on the 10 centimeter line.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in Blood Pressure', 'description': 'Sitting blood pressure, taken from the same arm.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in Fasting Lipoproteins (Total Cholesterol, High-Density Lipoprotein Cholesterol [HDL-Cholesterol], Low-Density Lipoprotein Cholesterol [LDL-Cholesterol] [Calculated], and Triglycerides)', 'description': 'Patients should be fasting a minimum of eight hours prior to lipoprotein measurements.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Change From Baseline to 16 Week Endpoint in Fasting Plasma Glucose', 'description': 'Patients should be fasting a minimum of eight hours prior to plasma glucose measurement.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin', 'description': 'Patients should be fasting a minimum of eight hours prior to serum insulin measurement.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated)', 'description': 'HOMA-S is an estimate of insulin sensitivity. The HOMA model is a computer model of the glucose insulin feedback system in the fasted state. The model consists of a number of non-linear empirical equations describing the functions of organs and tissues involved in glucose regulation.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Number of Participants Meeting a Definition for the Presence of Metabolic Syndrome as Defined by Adult Treatment Panel III (ATP III) Criteria at Baseline and 16 Week Endpoint', 'description': 'Patient meets definition of metabolic syndrome if they have \\>=3 risk factors: Waist circumference (men\\>102cm, women\\>88cm); triglycerides \\>=1.7mmol/L; HDL cholesterol (men\\<1.04mmol/L, women\\<1.30mmol/L); blood pressure \\>135/\\>=85 mmHg; Fasting glucose \\>=6.1mmol/L', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale', 'description': 'Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale', 'description': 'Measures subjective well-being for previous 7 days. 20 items covering 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). Subscale scores range from 1 to 24. Total score ranges from 1 to 120.', 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}, {'measure': 'Mean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale', 'description': ""Measures physician's judgment of a patient's overall level of functioning. Ratings are based on a scale of 1 to 100, with the following classification range: 1-10 (severely impaired) to 91-100 (superior functioning)."", 'timeFrame': 'Visit 2 (Baseline) and Visit 7 (Week 16)'}]",18.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,149.0,ACTUAL,v2_robust,True,True,False,False,
NCT00000302,Study Comparing Liquid and Tablet Buprenorphine Formulations - 5,Buprenorphine,['Buprenorphine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Heroin Dependence,National Institute on Drug Abuse (NIDA),2025-09-01T16:18:10.915765,True,,,,,"Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations",,['Heroin Dependence'],[],,,,"[{'measure': 'Drug use'}, {'measure': 'Retention'}, {'measure': 'Drug craving'}]",[],3.0,21 Years,50 Years,ALL,False,NIH,0.0,0.0,,v2_robust,True,True,False,False,
NCT03036202,Pharmacokinetics of Epinephrine During Cardiac Arrest,Epinephrine,"['Adrenaline', 'Epinephrine']",2,OBSERVATIONAL,[],,COMPLETED,Cardiac Arrest,Haukeland University Hospital,2025-09-01T16:18:10.915772,True,,,,,Pharmacokinetic Study of Epinephrine During Cardiac Arrest Determining T1/2 and Time to Peak Concentration,,['Cardiac Arrest'],['epinephrine'],,2017-06-26,2018-10-12,"[{'measure': 'Concentration of epinephrine (ng/mL) as a function of time the first five minutes following administration', 'description': 'Blood concentration of epinephrine will be determined the first five minutes following administration. For every minute starting With administration of epinephrine, blood samples will be drawn to determine the concentration (ng/mL). In total, six samples will be drawn. The administered dose (1 mg) will also be related to the patients weight, either estimated, or for those survivors admitted to hospital, measured in the Intensive Care Unit. Further, data according to the Utstein-template will be recorded.However, the primary outcome is to determine the plasma concentrations in every patients the first five minutes.', 'timeFrame': 'Blood samples will be drawn within minutes, and the survivors transported to hospital. The data according to Utstein-style, will also be collected. Blood samples will be analysed within weeks.Total timeframe for the study is estimated to one year.'}]",[],1.0,18 Years,85 Years,ALL,False,OTHER,0.0,8.0,ACTUAL,v2_robust,False,True,False,False,
NCT02394002,SEP Changes During Deep Anesthesia,Propofol,['Propofol'],1,INTERVENTIONAL,['NA'],,UNKNOWN,"Somatosensory Evoked Potentials, and Electroencephalography",Andrea Szelenyi,2025-09-01T16:18:10.915975,True,,,,,The Effect of Burst-suppression-pattern in EEG on Generating Somatosensory Evoked Potentials,,"['Somatosensory Evoked Potentials, and Electroencephalography']","['EEG, burst-suppression, N20, SEP, median nerve, facilitation']",,2015-03,2017-03,"[{'measure': 'SEP ampiltude in burst-suppression-EEG', 'timeFrame': '2 hours'}]",[],1.0,18 Years,,ALL,False,OTHER,2.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05589402,Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI,Lidocaine Cream 5%,"['Ebanel', 'UBER NUMB', 'Lidocaine Cream 5%']",3,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Spinal Cord Injuries,University of Texas Rio Grande Valley,2025-09-01T16:18:10.916040,True,,,,,Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI,,"['Spinal Cord Injuries', 'Spine Disease', 'Stroke']","['Rehabilitation', 'Numbing', 'temporary deafferentation-induced cortical plasticity']",,2019-06-04,2026-06-04,"[{'measure': 'Electromyography (EMG)', 'description': ""The investigators will use an electrical stimulator to send an electrical signal to a target muscle to initiate contraction, and an Electromyography (EMG) will be used to record the changes in target muscle response from baseline, pre-test, and post-test.\n\nAn electronic nerve stimulator will output a pulse ranging from 0 mV to 2 mV for an appropriate maximum muscle contraction to occur, and an Electromyography (EMG in root mean square) will capture the muscle's contraction via surface electrodes. A greater number of Root Mean Square (RMS) millivoltage registered on the EMG signifies a higher response from the muscle, additionally, any plateau of the RMS while administering higher mV from the Stimulator will signify a maximum contraction of the muscle."", 'timeFrame': 'Throughout Study Duration, an average of four weeks'}, {'measure': 'Transcranial Magnetic Stimulation (TMS)', 'description': ""Using Transcranial Magnetic Stimulation (TMS) to promote Motor Evoked Potentials (MEP), the Investigators will monitor changes in cortical excitability of the target muscle's motor hotspot by measuring the muscle excitability with Electromyography (EMG; in millivolts) from Baseline, Pre-test, and at Post-test.\n\nThe motor hotspot of the weak muscle will be defined as the site that evokes MEPs ≥50 mV at the lowest intensity (% device output), or the resting motor threshold (RMT). A decrease of the TMS's percentage output to promote MEPs of the weak muscle signifies a decrease in the cortical excitability, as measured by Active Motor Thresholds (AMT) and Active Motor Evoked Potentials (AMEP)."", 'timeFrame': 'Throughout Study Duration, an average of four weeks'}]",[],2.0,18 Years,75 Years,ALL,True,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00087802,Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC),gemcitabine/Eloxatin (GEMOX),"['gemcitabine/Eloxatin (GEMOX)', 'carboplatin/paclitaxel (CP)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Carcinoma, Non-Small-Cell Lung",Sanofi,2025-09-01T16:18:10.916076,True,,,,,A Phase III Randomized Trial of Gemcitabine/Oxaliplatin (GEMOX) Versus Carboplatin/Paclitaxel (CP) as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),,"['Carcinoma, Non-Small-Cell Lung']",[],,2004-03,,"[{'measure': 'To determine the relative efficacy, safety and clinical benefit of the GEMOX regimen compared to the standard combination regimen of CP as first-line treatment of Stage IIIB and IV NSCLC', 'timeFrame': '22 months'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,383.0,ACTUAL,v2_robust,True,True,False,True,
NCT06424002,"The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children",artemether-lumefantrine,['artemether-lumefantrine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,"Malaria,Falciparum",Kamuzu University of Health Sciences,2025-09-01T16:18:10.916137,True,,,,,"The Impact, Feasibility Acceptability and Cost Effectiveness of the RTS,S/AS01 Malaria Vaccine in School Aged Children",,"['Malaria,Falciparum']",[],,2024-06-01,2024-12-30,"[{'measure': 'Proportion of enrolled school children with clinical malaria incident events throughout the study period (PCD).', 'description': 'Based on symptoms of malaria plus a positive malaria rapid diagnostic test. A bood slide will also be collected for future assessment for malaria parasites', 'timeFrame': 'During 18 months of follow up, when the child presents with symptoms of malaria within 48 hours at the leaner treatment kit (LTK) program which is run by teachers'}, {'measure': 'Proportion of enrolled school children that are daily absent from class throughout the study period (using electronic classroom registers)', 'description': 'This will be based on electronic classroom registers', 'timeFrame': 'During 18 months of follow up, a daily register will be administered to record school attendance'}]","[{'measure': ""Proportion of enrolled school children who pass their examinations at the end of the year and proceed to the next class (Pupil's passing fraction based on classroom records)"", 'description': 'Pass rate based on classroom records', 'timeFrame': 'During 18 months of follow up, classroom records will record children passing end of year examinations'}, {'measure': 'Proportion of enrolled school children with clinical malaria incident events throughout the study period (ACD)', 'description': 'Based on symptoms of malaria plus a positive malaria rapid diagnostic test. A bood slide will also be collected for future assessment for malaria parasites', 'timeFrame': 'During 18 months of follow up, clinical malaria will be assessed during sick visits (PCD) and during active case detection'}, {'measure': 'Proportion of enrolled school children with P. falciparum infections during the study period (ACD).', 'description': 'Based dried blood spot (DBS) samples from index child', 'timeFrame': 'During 18 months of follow up, malaria infection will be assessed during the ACD visits'}, {'measure': 'Proportion of children with low levels of hemoglobin levels (hb<11g/dl) during the study period (ACD).', 'description': 'As measured by hemocue machines', 'timeFrame': 'At baseline, midline, endline and during ACD visits, hemoglobin levels will be measured during the 18 months follow up period'}, {'measure': 'Proportion of siblings of enrolled children with P. falciparum infections at the beginning and end of the study period (indirect or ""spill over"" effect) (ACD)', 'description': 'Based DBS samples from siblings of index child', 'timeFrame': 'During 18 months of follow up, malaria infection will be assessed during the ACD visits'}, {'measure': 'Levels of antibodies against N-4-azido-2-nitrophenylpyridoxyl-5-phosphate (NANP) and CSP', 'description': 'Magnitude of immunoglobulin G (IgG) against NANP. 2. Geometric mean of magnitude of antibodies against the two antigens, as well as avidity, and fractional catabolic rate (FcR) binding activity over time.', 'timeFrame': 'At endline and during ACD visits, levels of antibodies will be measured during 18 months of follow up'}]",8.0,6 Years,15 Years,ALL,True,OTHER,3.0,5400.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00936702,"Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary",carboplatin,"['everolimus', 'paclitaxel', 'carboplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Carcinoma of Unknown Primary Origin,Alliance for Clinical Trials in Oncology,2025-09-01T16:18:10.916171,True,,,,,"A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)",,['Carcinoma of Unknown Primary Origin'],"['Newly Diagnosed Carcinoma of Unknown Primary Origin', 'Squamous Cell Carcinoma of Unknown Primary Origin', 'Undifferentiated Carcinoma of Unknown Primary', 'newly diagnosed carcinoma of unknown primary']",,2009-09,2013-08,"[{'measure': 'Percentage of Participants With Confirmed Tumor Responses', 'description': 'Confirmed tumor response was defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart.\n\nResponse was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:\n\n* Complete Response (CR): disappearance of all target lesions;\n* Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;', 'timeFrame': 'First 6 Cycles of treatment (an average of 6 months)'}]","[{'measure': 'Overall Survival', 'description': 'Overall survival was defined as the time from study enrollment to the time of death from any cause or last follow-up.', 'timeFrame': 'Time from registration to death or last follow-up (up to 3 years)'}, {'measure': 'Progression-free Survival', 'description': 'The progression-free survival (PFS) was defined as the time from date of registration to the documentation of disease progression or death as a result of any cause, whichever comes first.', 'timeFrame': 'Time from registration to the disease progression or death (up to 3 years)'}, {'measure': 'Duration of Response', 'description': ""Duration of response was defined for all evaluable participants who have achieved an objective response as the date at which the participant's objective status is first noted to be either CR or PR to the date progression is documented."", 'timeFrame': 'Up to 3 years'}, {'measure': 'Time to Treatment Failure', 'description': 'Time to treatment failure was defined to be the time from the date of registration to the date at which the participant is removed from treatment due to progression, adverse events, or refusal.', 'timeFrame': 'Up to 3 years'}]",5.0,18 Years,,ALL,False,OTHER,1.0,46.0,ACTUAL,v2_robust,True,True,False,True,
NCT03447353,Opiates and Benzodiazepines on Driving,Xanax 1Mg Tablet,"['hydrocodone/acetaminophen', 'Xanax 1Mg Tablet', 'Placebo Oral Tablet', 'Norco 10Mg-325Mg Tablet', 'Alprazolam']",5,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Driving Behavior,Timothy L. Brown,2025-09-01T16:18:10.916301,True,,,,,SAFER-SIM: Opiates and Benzodiazepines on Driving,,['Driving Behavior'],"['driving', 'Xanax', 'Norco', 'simulation']",,2016-06-14,2016-10-25,"[{'measure': 'SDLP', 'description': 'Standard Deviation of Lane Position\n\nStandard deviation of lane position was analyzed using the SAS GLM function to identify changes in driver performance. Values represents means across the driving environments studied.', 'timeFrame': 'over course of each simulator drive, approximately 35 minutes per visit'}]","[{'measure': 'Lane Departures', 'description': 'Total number of lane departures per drive\n\nThe total number of lane departures across the drive were analyzed using the SAS GLM procedure.', 'timeFrame': 'over course of each simulator drive, approximately 35 minutes per visit'}]",2.0,18 Years,40 Years,ALL,True,OTHER,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
NCT02300753,Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON],EPI-743,"['Vatiquinone', 'Vincerinone (TM)', 'EPI-743']",3,EXPANDED_ACCESS,[],,NO_LONGER_AVAILABLE,Leber's Hereditary Optic Neuropathy,Edison Pharmaceuticals Inc,2025-09-01T16:18:10.916386,True,,,,,Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON],,"[""Leber's Hereditary Optic Neuropathy""]",[],,,,[],[],0.0,8 Years,65 Years,ALL,,INDUSTRY,0.0,,,v2_robust,False,False,False,False,
NCT04554953,A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia,Combination drug containing fimasartan and statins,['Combination drug containing fimasartan and statins'],1,OBSERVATIONAL,[],,COMPLETED,Hypertension and Dyslipidemia,"Boryung Pharmaceutical Co., Ltd",2025-09-01T16:18:10.916392,True,,,,,"A Multi-center, Prospective Observational Study to Evaluate the Effectiveness of a Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia",,['Hypertension and Dyslipidemia'],['Fimasartan and Statins'],,2020-04-13,2022-05-31,"[{'measure': 'Blood pressure controlled to the target level', 'description': ""Proportion of patients with blood pressure controlled to the target level (SiSBP, SiDBP) according to '2018 Guidelines for Management of Hypertension2' at Week 12. Site staff will be measuring Systolic and Diastolic Blood Pressure."", 'timeFrame': 'Week12'}, {'measure': 'LDL-C controlled to the target level', 'description': ""Proportion of patients with LDL-C controlled to the target level according to 'Guidelines for Management of Dyslipidemia 4th Edition1' at Week 12"", 'timeFrame': 'Week 12'}]","[{'measure': 'Medication Satisfaction Questionnaire', 'description': ""Score (or change in the scores) of Medication Satisfaction Questionnaire (MSQ) assessed by patients at Week 12/ The scale title is MSQ(Medication satisfaction Questionnaire). The minimum score is '1' and maximum score is '7'. Higher score means a better outcome."", 'timeFrame': 'Week 12'}, {'measure': 'Average cost-effectiveness ratio (ACER)', 'description': 'Average cost-effectiveness ratio (ACER) of the study drug at Week 12', 'timeFrame': 'Week 12'}, {'measure': 'both blood pressure and LDL-C controlled', 'description': 'Proportion of patients with both blood pressure and LDL-C controlled to the target level simultaneously at Week 12', 'timeFrame': 'Week 12'}, {'measure': 'non-HDL-C controlled', 'description': 'Proportion of patients with non-HDL-C controlled to the target level at Week 12', 'timeFrame': 'Week 12'}, {'measure': 'Change in blood pressure', 'description': 'Change in blood pressure at Week 12 from baseline', 'timeFrame': 'Week 12'}, {'measure': 'Change in Lipid panel', 'description': 'Lipid panel at Week 12 from baseline\n\n* Percent change in TC\n* Percent change in HDL-C\n* Percent change in TG\n* Percent change in LDL-C\n* Percent change in non-HDL-C', 'timeFrame': 'Week 12'}]",8.0,19 Years,,ALL,False,INDUSTRY,0.0,10877.0,ACTUAL,v2_robust,False,True,False,False,
NCT06469853,"Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients",MBF-015 16 mg oral capsules,['MBF-015 16 mg oral capsules'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Huntington Disease,Medibiofarma S.L.,2025-09-01T16:18:10.916417,True,,,,,"A Phase IIa, Open Label, Single Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Dosed MBF-015 in Huntington's Disease Patients",,['Huntington Disease'],[],,2024-02-01,2024-12-04,"[{'measure': 'Adverse Events', 'description': ""Evaluate safety and tolerability of MBF-015 in participants with Huntington's Disease (HD) on top of standard of care over 28 days, with follow-up to day 43."", 'timeFrame': '43 days'}]",[],1.0,25 Years,60 Years,ALL,False,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,True,False,True,
NCT03356353,Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation,Sildenafil Citrate,"['Revatio', 'Sildenafil Citrate']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,End Stage Heart Failure,University of Calgary,2025-09-01T16:18:10.916441,True,,,,,Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation (The REVAD Study),,['End Stage Heart Failure'],[],,2018-03-12,2022-01,"[{'measure': 'Pulmonary vascular resistance (PVR)', 'description': 'Change in PVR reported in Wood Units as measured invasively via right heart catheterization (RHC)', 'timeFrame': 'From baseline to postoperative day 14'}]","[{'measure': 'Right heart failure (RHF)', 'description': 'Proportion of participants experiencing RHF defined as INTERMACS criteria: i) Requirement of continuous-flow right ventricular assist device (RVAD) implantation for hemodynamic support any time prior to study end', 'timeFrame': 'From baseline to day 55 (end of study)'}, {'measure': 'RHF', 'description': 'Proportion of participants experiencing RHF defined as INTERMACS criteria: ii) Prolonged inotropic support beyond postoperative day 14 directed for clinical RHF', 'timeFrame': 'Postoperative day 14 to postoperative day 55 (end of study)'}, {'measure': 'RHF', 'description': 'Proportion of participants experiencing RHF defined as INTERMACS criteria: iii) Discontinuation of study drug for the purpose of introduction of additional pulmonary vasodilator for the purpose of treatment of clinical RHF at any time during the study protocol', 'timeFrame': 'From baseline to postoperative day 55 (end of study)'}, {'measure': 'Inotrope requirement', 'description': 'Proportion of patients requiring any inotrope medication at study end', 'timeFrame': 'From baseline to day 55 (study end)'}, {'measure': 'ICU', 'description': 'Total number of hours in ICU by study end', 'timeFrame': 'From baseline to day 55 (end of study)'}, {'measure': 'Hospitalization', 'description': 'Total hospital length of stay by study end', 'timeFrame': 'From baseline to day 55 (end of study)'}]",7.0,18 Years,,ALL,False,OTHER,1.0,24.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00621153,Candesartan Effect in Second Stage Arterial Hypertension,Candesartan Cilexetil,"['Candesartan Cilexetil', 'Atacand', 'HCTZ', 'Hydrochlorothiazide', 'Diazide']",5,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Stage II Hypertension,AstraZeneca,2025-09-01T16:18:10.916500,True,,,,,"Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults",,['Stage II Hypertension'],"['Candesartan Cilexetil', 'hydrochlorothiazide', 'severe hypertension']",,2008-02,2009-03,"[{'measure': 'Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy', 'description': 'Mean of the changed DBP from baseline after 4 weeks', 'timeFrame': '4 weeks'}]","[{'measure': 'Changes in Mean Sitting SBP From Baseline After 4 Weeks of Therapy', 'description': 'Mean of the changed SBP from baseline after 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 4 Weeks of Therapy', 'description': 'Percent of the patients achieving goal DBP and SBP after 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (<90 mmHg, But <80 mmHg for DM & Chronic Kidney Disease) and SBP (<140 mmHg, But <130 mmHg for DM & Chronic Kidney Disease) After 8 Weeks of Therapy', 'description': 'Percent of patients achieving goal of DBP', 'timeFrame': '8 weeks'}, {'measure': 'Changes in Mean Sitting SBP From Baseline After 8 Weeks of Therapy', 'description': 'Changed SBP from baseline after 8 weeks', 'timeFrame': '8 weeks'}, {'measure': 'Changes in Hs-CRP Level From Baseline After 8 Weeks of Therapy', 'description': 'Change of hs-CRP from basline after 8 weeks', 'timeFrame': '8 weeks'}, {'measure': ""Occurrence of Adverse Events (AE) and Discontinuation of Study Medication Due to AE's From Baseline (Randomisation) to the End of the Study (8 Weeks)"", 'description': 'Occurred number of AE and disconinuation of study medication due to the AE from basline after 8 weeks', 'timeFrame': '8 weeks'}, {'measure': 'Compliance Levels at 4 Weeks and 8 Weeks of Therapy', 'description': 'Percent of the number of returened pills to the number of prescrited pills', 'timeFrame': '8 weeks'}]",8.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,214.0,ACTUAL,v2_robust,True,True,False,True,
NCT01419353,Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol,estradiol valerate,['estradiol valerate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Infertility,Meir Medical Center,2025-09-01T16:18:10.916524,True,,,,,Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol,,['Infertility'],"['Infertility, IVF, Estrogen']",,2011-08,2013-06,"[{'measure': 'ovum pickup rate that took place between Sunday to Thursday without a compromise', 'description': 'number of Pickups that took place between Sunday to Thursday (without a compromise in treatment) \\\\ by the entire pickup number', 'timeFrame': 'a year'}]","[{'measure': 'pregnancy rate', 'description': 'comparison of pregnancy rate between the 2 groups. calculated per cycle', 'timeFrame': 'a year'}]",2.0,,38 Years,FEMALE,True,OTHER,0.0,63.0,ACTUAL,v2_robust,True,True,False,False,
NCT00311337,VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT),bortezomib,['bortezomib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Multiple Myeloma,University of Wuerzburg,2025-09-01T16:18:10.916615,True,,,,,"Evaluation of Safety and Efficacy of VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following High-Dose Melphalan Treatment and Autologous PBSCT (Minimal Residual Disease, Partial Remission or Stable Disease)",,['Multiple Myeloma'],"['VELCADE', 'bortezomib', 'maintenance treatment', 'multiple myeloma', 'primary disease']",,2005-10,2010-10,[{'measure': 'Primary endpoints are to study the safety of four cycles of VELCADE in patients with multiple myeloma following high-dose chemotherapy and autologous PBSCT.'}],"[{'measure': 'The secondary objectives of this study are to assess the efficacy of four cycles of VELCADE at two different dose levels as maintenance treatment in patients with multiple myeloma'}, {'measure': 'and detectable residual disease following high-dose chemotherapy and autologous PBSCT'}, {'measure': 'to assess the 2 year progression-free survival'}, {'measure': 'and to assess the 2 year overall survival.'}]",5.0,18 Years,,ALL,False,OTHER,0.0,61.0,,v2_robust,True,False,False,True,
NCT05901337,Cupping Therapy on Immune System in Post Covid -19,Convential medical treatment,['Convential medical treatment'],1,INTERVENTIONAL,['NA'],,COMPLETED,Covid-19 Patients,Cairo University,2025-09-01T16:18:10.916622,True,,,,,Influence of Cupping Therapy on Immune System in Post Covid- 19 Patients,,['Covid-19 Patients'],[],,2022-03-07,2023-06-01,"[{'measure': 'T-lymphocyte', 'description': '1- Lymphocyte subset were analyzed from fluorescence-labeled flow cytometry on a DxFLEX flow cytometry by Kenza 240 Tx', 'timeFrame': '3months'}, {'measure': 'Serum Cytokine', 'description': 'Cytokine detection Kenza reagents were provided from a 240 TX bio lap diagnostic apparatus by microsphere flow immunofluorescence', 'timeFrame': '3months'}, {'measure': 'ImmunoglobulinA,M,G', 'description': 'Kenza 240 TX for detection of immunoglobulin', 'timeFrame': '3 months'}]",[],3.0,21 Years,66 Years,ALL,False,OTHER,0.0,76.0,ACTUAL,v2_robust,True,True,False,False,
NCT05550337,"Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris",Trifarotene 0.005 % Topical Cream,"['AKLIEF®', 'Trifarotene 0.005 % Topical Cream', 'Vehicle of Test Product', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acne Vulgaris,Teva Pharmaceuticals USA,2025-09-01T16:18:10.916635,True,,,,,"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., USA), IN THE TREATMENT OF ACNE VULGARIS",,['Acne Vulgaris'],[],,2022-09-19,2023-05-09,"[{'measure': 'Primary Change in Inflammatory Lesion Counts', 'description': 'Mean percent change from screening/baseline to week 12 in the inflammatory (papules and pustules) lesion counts', 'timeFrame': 'Baseline and 12 Weeks'}, {'measure': 'Primary Change in Non-Inflammatory Lesion Count', 'description': 'Mean percent change from screening/baseline to week 12 in the noninflammatory (open and closed comedones) lesion counts.', 'timeFrame': 'Baseline and 12 Weeks'}]",[],2.0,12 Years,40 Years,ALL,True,INDUSTRY,1.0,807.0,ACTUAL,v2_robust,True,True,False,False,
NCT05095545,Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza,AV5080,['AV5080'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Influenza,Viriom,2025-09-01T16:18:10.916645,True,,,,,"Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Efficacy and Safety of the AV5080 Drug in Patients With Influenza",,['Influenza'],['Influenza treatment in adults'],,2017-11-13,2019-08-30,"[{'measure': 'Percentage of patients who reported resolution of influenza symptoms within 96 hours from the start of therapy', 'description': 'The absence of influenza symptoms or their reduction to mild severity for at least 24 hours indicates the resolution of influenza.', 'timeFrame': '30 days'}]","[{'measure': 'Time to symptoms resolution', 'description': 'The time before the resolution of influenza symptoms', 'timeFrame': '30 days'}, {'measure': 'Incidence rate of influenza virus elimination until Day 6', 'description': 'The incidence rate of influenza virus elimination from mucous membranes of the nasopharynx and oropharynx until Day 6', 'timeFrame': '6 days'}, {'measure': 'Change in titer of antibodies on Day 15 compared to baseline;', 'description': 'Change in titer of IgG and IgM antibodies to influenza A and B virus on Day 15 compared to baseline;', 'timeFrame': '15 Days'}, {'measure': 'The incidence rate of influenza complications', 'timeFrame': '29 Days'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,135.0,ACTUAL,v2_robust,True,True,False,False,
NCT00016445,Phase II Study of Growth Hormone in Children With Cystic Fibrosis,growth hormone,['growth hormone'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cystic Fibrosis,University of Utah,2025-09-01T16:18:10.916660,True,,,,,,,['Cystic Fibrosis'],"['cardiovascular and respiratory diseases', 'cystic fibrosis', 'disease-related problem/condition', 'genetic diseases and dysmorphic syndromes', 'quality of life', 'rare disease']",,2001-02,,[],[],0.0,5 Years,12 Years,ALL,False,OTHER,0.0,40.0,,v2_robust,True,True,False,False,
NCT05745545,Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over,Saline solution,['Saline solution'],1,INTERVENTIONAL,['NA'],,UNKNOWN,SARS-CoV-2,"AIM Vaccine Co., Ltd.",2025-09-01T16:18:10.916736,True,,,,,"A Single-center, Randomized, Blinded, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of One Dose of the SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in People Aged 18 Years and Older Who Had Received Two or Three Doses of Inactivated COVID-19 Vaccine",,['SARS-CoV-2'],[],,2023-01-04,2023-11,"[{'measure': 'Person-year incidence of symptomatic COVID-19 of any severity among persons 18 years of age and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Person-year incidence of symptomatic COVID-19 of any severity 14 days after vaccination (≥D14) with a booster dose of study vaccine or placebo among persons 18 years of age and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': '14 days after vaccination or placebo'}]","[{'measure': 'Person-year incidence of severe and critical COVID-19 in persons aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Person-year incidence of severe and critical COVID-19 after 14 days (≥D14) after booster immunization with 1 dose of study vaccine or placebo in persons aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': '14 days after vaccination or placebo'}, {'measure': 'Person-year incidence of COVID-19 resulting in death in persons aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Person-year incidence of COVID-19 resulting in death 14 days (≥D14) after booster vaccination with 1 dose of study vaccine or placebo in persons aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': '14 days after vaccination or placebo'}, {'measure': 'Person-year incidence of symptomatic COVID-19 of any severity among persons aged 18-59 years and ≥60 years who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Person-year incidence of symptomatic COVID-19 of any severity 14 days (≥D14) after booster immunization with 1 dose of study vaccine or placebo among persons aged 18-59 years and ≥60 years who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': '14 days after vaccination or placebo'}, {'measure': 'GMT of true virus neutralizing antibodies against the current major circulating strain of SARS-CoV-2 in subjects in the immunization subgroup', 'description': 'In the immunization subgroup, true virus neutralizing antibodies GMT against the current major circulating strain of SARS-CoV-2 were detected 7 days, 14 days, 28 days, 3 months, and 6 months after receiving one dose of study vaccine or placebo', 'timeFrame': '7 days, 14 days, 28 days, 3 months, and 6 months after vaccination or placebo'}, {'measure': 'GMI of true virus neutralizing antibodies against the current major circulating strain of SARS-CoV-2 in subjects in the immunization subgroup', 'description': 'In the immunization subgroup, true virus neutralizing antibodies GMI against the current major circulating strain of SARS-CoV-2 were detected 7 days, 14 days, 28 days, 3 months, and 6 months after receiving one dose of study vaccine or placebo', 'timeFrame': '7 days, 14 days, 28 days, 3 months, and 6 months after vaccination or placebo'}, {'measure': 'SCR of true virus neutralizing antibodies against the current major circulating strain of SARS-CoV-2 in subjects in the immunization subgroup', 'description': 'In the immunization subgroup, true virus neutralizing antibodies SCR against the current major circulating strain of SARS-CoV-2 were detected 7 days, 14 days, 28 days, 3 months, and 6 months after receiving one dose of study vaccine or placebo', 'timeFrame': '7 days, 14 days, 28 days, 3 months, and 6 months after vaccination or placebo'}, {'measure': 'GMT of S protein IgG against the current major circulating strain of SARS-CoV-2 in the immunization subgroup', 'description': 'GMT of S protein IgG against the current major circulating strain of SARS-CoV-2 7 days, 14 days, 28 days, 3 months, and 6 months after receiving one dose of study vaccine or placebo in the immunization subgroup', 'timeFrame': '7 days, 14 days, 28 days, 3 months, and 6 months after vaccination or placebo'}, {'measure': 'GMI of S protein IgG against the current major circulating strain of SARS-CoV-2 in the immunization subgroup', 'description': 'GMI of S protein IgG against the current major circulating strain of SARS-CoV-2 7 days, 14 days, 28 days, 3 months, and 6 months after receiving one dose of study vaccine or placebo in the immunization subgroup', 'timeFrame': '7 days, 14 days, 28 days, 3 months, and 6 months after vaccination or placebo'}, {'measure': 'SCR of S protein IgG against the current major circulating strain of SARS-CoV-2 in the immunization subgroup', 'description': 'SCR of S protein IgG against the current major circulating strain of SARS-CoV-2 7 days, 14 days, 28 days, 3 months, and 6 months after receiving one dose of study vaccine or placebo in the immunization subgroup', 'timeFrame': '7 days, 14 days, 28 days, 3 months, and 6 months after vaccination or placebo'}, {'measure': 'Incidence of adverse events in people aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Incidence of adverse events at 30 minutes, 0-14 days and 0-28 days after booster vaccination of 1 dose of study vaccine or placebo in people aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': '30 minutes, 0-14 days and 0-28 days after vaccination or placebo'}, {'measure': 'Incidence of serious adverse events (SAE) in people aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Incidence of serious adverse events (SAE) within 6 months after booster immunization with 1 dose of study vaccine or placebo in people aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': 'within 6 months after vaccination or placebo'}, {'measure': 'Incidence of AESI in people aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Incidence of AESI within 6 months after booster immunization with 1 dose of study vaccine or placebo in people aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': 'within 6 months after vaccination or placebo'}, {'measure': 'Pregnancy events among persons aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'description': 'Pregnancy events within 6 months after booster vaccination with 1 dose of study vaccine or placebo (including: pregnancy outcomes, delivery characteristics, delivery of newborns, and growth and development within 1 month after birth) among persons aged 18 years and older who had received 2 or 3 doses of inactivated COVID-19 vaccine', 'timeFrame': 'within 6 months after vaccination or placebo'}]",14.0,18 Years,,ALL,True,INDUSTRY,2.0,3200.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05402345,A Study of GlcNAc on Tear Production in NGLY1-CDDG,GlcNAc-GlcN,['GlcNAc-GlcN'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,NGLY1 Deficiency,Eva Morava-Kozicz,2025-09-01T16:18:10.916898,True,,,,,"A Phase II Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Effect Of GlcNAc On Tear Production In Individuals With NGLY1-CDDG",,['NGLY1 Deficiency'],[],,2025-01-24,2026-12,"[{'measure': 'Difference in tear production from baseline in placebo vs GlcNAc group', 'description': 'The primary endpoint of the study is the difference in tear production from baseline in individuals with NGLY1-CDDG between the placebo and the GlcNAc group after 6 weeks of blinded therapy, as measured by Schirmer II test which is a tool that helps assess the amount of tears in the eyes.', 'timeFrame': '6 weeks'}]","[{'measure': 'Frequency of eye infections needing treatments', 'description': 'Patient/family reported number of eye infections needing treatment in last month after 6 weeks of blinded therapy and at 12 weeks after 6 weeks of open-label administration of GlcNAc.', 'timeFrame': '6 weeks, 12 weeks'}, {'measure': 'Frequency of eye redness needing treatments', 'description': 'Patient/family reported frequency of eye redness after 6 weeks of blinded therapy and at 12 weeks after 6 weeks of open-label administration of GlcNAc.', 'timeFrame': '6 weeks, 12 weeks'}, {'measure': 'Frequency of eye tearing/watering', 'description': 'Patient/family reported frequency of eye tearing/watering after 6 weeks of blinded therapy and at 12 weeks after 6 weeks of open-label administration of GlcNAc.', 'timeFrame': '6 weeks, 12 weeks'}, {'measure': 'Frequency of light sensitivity', 'description': 'Patient/family reported frequency of light sensitivity after 6 weeks of blinded therapy and at 12 weeks after 6 weeks of open-label administration of GlcNAc.', 'timeFrame': '6 weeks, 12 weeks'}, {'measure': 'Frequency of wind sensitivity', 'description': 'Patient/family reported frequency of wind sensitivity after 6 weeks of blinded therapy and at 12 weeks after 6 weeks of open-label administration of GlcNAc.', 'timeFrame': '6 weeks, 12 weeks'}, {'measure': 'Difference in tear production from baseline', 'description': 'Difference in tear production, as measured by Schirmer II test, at 12 weeks after 6 weeks of open-label administration of GlcNAc.', 'timeFrame': '12 weeks'}]",7.0,1 Year,60 Years,ALL,False,OTHER,2.0,18.0,ACTUAL,v2_robust,True,False,False,False,
NCT05425745,Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.,Obicetrapib,"['Obicetrapib', 'CETP-inhibitor', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Dyslipidemias,NewAmsterdam Pharma,2025-09-01T16:18:10.916942,True,,,,,"A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies",,"['Dyslipidemias', 'High Cholesterol', 'Hypercholesterolemia', 'Familial Hypercholesterolemia', 'Lipid Metabolism Disorder', 'Metabolic Disease', 'Lipid Metabolism, Inborn Errors', 'Genetic Disease, Inborn', 'Hyperlipoproteinemias']","['Obicetrapib', 'BROOKLYN', 'Cholesteryl ester transfer protein (CETP) inhibitor', 'Heterozygous Familial Hypercholesterolemia (HeFH)', 'LDL-C']",,2022-07-25,2024-05-28,"[{'measure': 'Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]', 'description': 'LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \\[PUC\\]. LDL-C level was measured by preparative ultracentrifugation (PUC).', 'timeFrame': '84 Days'}]","[{'measure': 'Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins]', 'description': 'LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \\[Martin/Hopkins\\]. LDL-C value was calculated using the Martin/Hopkins equation unless TG \\>= 400 mg/dL or LDL-C \\<= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC).', 'timeFrame': '180 Days'}, {'measure': 'Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC]', 'description': 'LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \\[PUC\\]. LDL-C level was measured by preparative ultracentrifugation (PUC).', 'timeFrame': '365 Days'}, {'measure': 'Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 84', 'description': 'LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.', 'timeFrame': '84 Days'}, {'measure': 'Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 180', 'description': 'LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group', 'timeFrame': '180 Days'}, {'measure': 'Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365', 'description': 'LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group', 'timeFrame': '365 Days'}, {'measure': 'Percent Change in Non-HDL-C From Baseline to Day 84', 'description': 'LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group', 'timeFrame': '84 Days'}, {'measure': 'Percent Change in Non-HDL-C From Baseline to Day 180', 'description': 'LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group', 'timeFrame': '180 Days'}, {'measure': 'Percent Change in Non-HDL-C From Baseline to Day 365', 'description': 'LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group', 'timeFrame': '365 Days'}, {'measure': 'Percent Change in HDL-C From Baseline to Day 84', 'description': 'LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group', 'timeFrame': '84 Days'}, {'measure': 'Percent Change in HDL-C From Baseline to Day 180', 'description': 'LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group', 'timeFrame': '180 Days'}, {'measure': 'Percent Change in HDL-C From Baseline to Day 365', 'description': 'LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group', 'timeFrame': '365 Days'}, {'measure': 'Percent Change in Lp(a) From Baseline to Day 84', 'description': 'LS mean percent change from baseline to Day 84 in Lipoprotein (a) \\[Lp(a)\\] in obicetrapib group compared to the placebo group', 'timeFrame': '84 Days'}, {'measure': 'Percent Change in Lp(a) From Baseline to Day 365', 'description': 'LS mean percent change from baseline to Day 365 in Lipoprotein (a) \\[Lp(a)\\] in obicetrapib group compared to the placebo group', 'timeFrame': '365 Days'}, {'measure': 'Percent Change in Total Cholesterol From Baseline to Day 84', 'description': 'LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group', 'timeFrame': '84 Days'}, {'measure': 'Percent Change in Total Cholesterol From Baseline to Day 180', 'description': 'LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group', 'timeFrame': '180 Days'}, {'measure': 'Percent Change in Total Cholesterol From Baseline to Day 365', 'description': 'LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group', 'timeFrame': '365 Days'}, {'measure': 'Percent Change in Triglycerides From Baseline to Day 84', 'description': 'LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group', 'timeFrame': '84 Days'}, {'measure': 'Percent Change in Triglycerides From Baseline to Day 180', 'description': 'LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group', 'timeFrame': '180 Days'}, {'measure': 'Precent Change in Triglycerides From Baseline to Day 365', 'description': 'LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group', 'timeFrame': '365 days'}]",20.0,18 Years,,ALL,False,INDUSTRY,0.0,354.0,ACTUAL,v2_robust,True,True,False,False,
NCT02330445,6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection,PRTX-100,"['PRTX-100', 'Staphylococcal Protein A', 'SpA']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,"Arthritis, Rheumatoid","Protalex, Inc.",2025-09-01T16:18:10.917020,True,,,,,Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers,,"['Arthritis, Rheumatoid']",[],,2015-02,2016-11-30,"[{'measure': 'Safety (Analysis of Adverse Events)', 'description': 'Number, severity, and attribution of relatedness of Adverse Events will be analyzed.', 'timeFrame': '6 months'}]","[{'measure': 'ACR-28 joint count', 'description': 'ACR 28-joint counts (number of tender and swollen joints) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': ""Patient's global assessment of disease activity"", 'description': ""Patient's global assessment of disease activity (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity."", 'timeFrame': '6 months'}, {'measure': ""Patient's assessment of pain VAS"", 'description': ""Patient's assessment of pain VAS (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity."", 'timeFrame': '6 months'}, {'measure': ""Physician's global assessment of disease activity"", 'description': ""Physician's global assessment of disease activity (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity."", 'timeFrame': '6 months'}, {'measure': 'MDHAQ - Physical Function', 'description': 'MDHAQ Physical Function (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'MDHAQ - Joint Pain', 'description': 'MDHAQ Joint Pain (0-48) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'MDHAQ - Fatigue', 'description': 'MDHAQ Fatigue (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'RAPID 3', 'description': 'RAPID 3 (0-30) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'CDAI', 'description': 'Clinical Disease Activity Index (0-76) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'DAS28-CRP', 'description': 'DAS28-CRP (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'hsCRP', 'description': 'C-Reactive Protein (hsCRP) lab values (mg/dL) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'ESR', 'description': 'Erythrocyte Sedimentation Rate (mm/hr) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'Biomarker Correlation', 'description': 'Vectra-DA scores (1-100) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'Disease activity', 'description': ""ACR 28-joint counts (tender and swollen), patient's global assessment of disease activity, patient's assessment of pain VAS, physician's global assessment of disease activity, MDHAQ (overall, physical function, joint pain, and fatigue), RAPID 3, CDAI, DAS28-CRP, CRP, ESR, Vectra-DA, and UPD joint counts, will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity."", 'timeFrame': '6 months'}, {'measure': 'Ultrasound Power Doppler Joint Count', 'description': 'UPD joint counts (0-36) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.', 'timeFrame': '6 months'}, {'measure': 'Immunogenicity', 'description': 'The occurrence of anti-PRTX-100 antibodies (positive/negative) will be summarized descriptively for the observed values and change from baseline results.', 'timeFrame': '6 months'}]",17.0,18 Years,,ALL,True,INDUSTRY,0.0,13.0,ACTUAL,v2_robust,True,True,False,True,
NCT01939145,Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation,Normal saline,"['0.9% Saline', 'Normal saline']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Wound Infection,Georgetown University,2025-09-01T16:18:10.917042,True,,,,,A Prospective Randomized Trial Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation,,['Wound Infection'],['hospital admission'],,2013-09,2016-07,"[{'measure': 'Number of Operating Room Visits', 'description': 'Compare the number of operative room visits between Prontosan NPWTi and normal saline NPWTi.', 'timeFrame': 'Patients will be followed during their hospital stay which is an average of approximately 2 weeks.'}]","[{'measure': 'Hospital Admission Length of Stay', 'description': 'Compare the hospital admission length of stay between Prontosan NPWTi and normal saline NPWTi.', 'timeFrame': 'Patients will be followed during their hospital stay which is an average of approximately 2 weeks.'}]",2.0,18 Years,,ALL,False,OTHER,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,
NCT01228045,A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer,Trastuzumab in Combination with TS-ONE and cisplatin,['Trastuzumab in Combination with TS-ONE and cisplatin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Gastric Cancer,"National University Hospital, Singapore",2025-09-01T16:18:10.917053,True,,,,,A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer.,,['Gastric Cancer'],['Patients with histologically proved adenocarcinoma of advanced gastric cancer'],,2011-02,2016-12,"[{'measure': 'Overall Response Rate (ORR)', 'timeFrame': 'Fom the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented'}]","[{'measure': 'Progression free survival (PFS)', 'timeFrame': 'Time from registration until objective tumor progression or death for any reason that occurs by the end of the study.'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Time from registration to the date of death.'}, {'measure': 'Time to Treatment Failure (TTF)', 'timeFrame': 'Time from registration until discontinuation of treatment for any reason (including progression of disease, treatment toxicity, and death).'}, {'measure': 'Clinical Benefit Rate (CBR)', 'timeFrame': 'proportion of patients with confirmed CR, PR, and SD over 24 weeks.'}, {'measure': 'Duration of Response (DR)', 'description': 'Median time will be estimated using the Kaplan Meier method. 95% confidence interval of the median time will be estimated.', 'timeFrame': 'Time from first assessment of CR or PR until the first date of PD or death within 60 days of the last tumor assessment or registration, whichever is first.'}, {'measure': 'Safety Evaluations', 'description': 'AEs will be coded according to the Medical Dictionary for Regulatory Activities Terminology (MedDRA) and the severity of the toxicities will be graded according to the NCI CTCAE criteria, version 3.0, where applicable. Concomitant medications will be coded according to WHO Medication Dictionary for Concomitant Medication.\n\nAll AEs will be summarized (incidence) and listed by the System Organ Class (SOC), preferred term, toxicity/severity grade, and causal relationship. In addition, separate summaries of SAEs and Grade 3 or 4 AEs will be presented. Cardiac AEs including asymptomatic LVEF drops will also be summarized in separate tables.\n\nHematological and chemistry laboratory parameters will be graded according to the NCI CTCAE criteria, where applicable. Absolute values and changes from baseline will be summarized by cycle. In addition, worst severity grade will also be summarized.', 'timeFrame': 'Focus on AEs and laboratory assessments.'}]",7.0,21 Years,,ALL,False,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02635945,"A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.",PBF-680,"['PBF-680', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Asthma,Palobiofarma SL,2025-09-01T16:18:10.917102,True,,,,,"A Study to Assess the Efficacy of a 5-day, Once Daily 10- mg PBF-680 Oral Administration Course to Attenuate Allergen Bronchoprovocation-induced Late Asthmatic Responses (LAR) in Asthmatic Patients Controlled on Low-to-medium Dose Inhaled Corticosteroid Maintenance Monotherapy and Inhaled Short Acting Beta-2 Agonist as Rescue Bronchodilator",,['Asthma'],"['adenosine A1 receptor antagonist', 'adenosine receptor modulator', 'COPD', 'asthma']",,2016-04,2019-11-30,"[{'measure': 'Late Asthmatic Response (LAR) , measured as the fall of the forced expiratory volume (FEV1) between 3 and 10 hours postallergen bronchoprovocation', 'timeFrame': '3-to-10 hour post-allergen bronchoprovocation.'}]","[{'measure': 'Early Asthmatic Response (EAR), measured as the maximum FEV1 fall from the postdiluent value', 'timeFrame': 'within 1 hour post-allergen bronchoprovocation.'}, {'measure': 'hyperresponsiveness to AMP in terms of provocative concentration causing a 20% fall (PC20) increment in response to AMP airway challenge', 'timeFrame': '24-hour post-allergen bronchoprovocation'}, {'measure': 'Nitric oxide fraction in exhaled air (FeNO) on post-allergen bronchoprovocation day', 'timeFrame': '6th treatment period day'}, {'measure': 'Total leukocytes per mL in induced sputum on post-allergen bronchoprovocation day', 'timeFrame': '6th treatment period day'}, {'measure': 'Leukocyte differential counts per mL in induced sputum on post-allergen bronchoprovocation day.', 'description': 'Leukocyte subpopulations from cytocentrifuged, stained preparations will be counted and expressed as percentage cell numbers per volume unit.', 'timeFrame': '6th treatment period day'}, {'measure': 'Adverse events', 'description': 'The occurrence of adverse events will be monitored through the complete study. Adverse events will be recorded with the following information: severity grade (mild, moderate, severe); suspected/unsuspected relationship to the study drug; duration (date and time of onset, defined as precisely as possible, and end date or if continuing at final exam)', 'timeFrame': '2 Months'}, {'measure': 'Vital signs', 'description': 'Vital signs will include radial artery pulse rate (measured for 60 seconds), and systolic and diastolic blood pressure. Pulse rate and blood pressure will be assessed in the right arm after the patient has rested in the sitting position for at least 5 min. Vital sign values will be recorded as notable if: pulse rate \\<40 or \\>90 bpm; systolic blood pressure \\<90 or \\>140 mmHg; diastolic blood pressure \\<50 or \\>90 mmHg.', 'timeFrame': '9 times during 2 months'}, {'measure': 'Number of Participants With Abnormal Laboratory Values', 'description': 'On visits V2+24h, V4+24h and V6+24h, venipuncture will be performed for blood laboratory evaluations. The analysis will be performed at the local laboratory, and will include: hemogram with complete blood counts and differential leukocyte counts; clinical biochemistry including electrolytes (sodium, potassium, chloride), glucose, creatinine, urea, aspartate transaminase (AST), alanine transaminase (ALT), gammaglutamyl transpeptidase (GGT) and bilirubin; and serum immunoglobulin E (IgE) (only on visit V2+24h).', 'timeFrame': '4 times during 2 months'}, {'measure': 'Physical examination', 'timeFrame': '7 times during 2 months'}, {'measure': 'Electrocardiogram (EKG)', 'timeFrame': '3 times during 2 months'}]",11.0,18 Years,,ALL,False,INDUSTRY,2.0,8.0,ACTUAL,v2_robust,True,True,False,True,
NCT06670872,A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia,Eravacycline combination therapy group,['Eravacycline combination therapy group'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Pneumonitis,Peking University Third Hospital,2025-09-01T16:18:10.917145,True,,,,,A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia,,"['Pneumonitis', 'Acinetobacter Baumannii']",['Eravacycline'],,2024-10,2026-10,"[{'measure': 'clinical efficacy at the end of treatment', 'description': ""The primary endpoint is the clinical efficacy at the end of treatment (within 24 hours after the last dose of the trial medication) for all patients who have completed the trial according to the protocol. Clinical efficacy is assessed and the clinical response rate is calculated.\n\nClinical response is evaluated by PI，and defined as an improvement, reduction, or disappearance of the patient's multiple symptoms and signs compared to before treatment, along with improvement or normalization of imaging findings.\n\nClinical response rate = (number of patients with symptom relief) / (total number of patients included in the study)."", 'timeFrame': 'up to the end of treatment, up to 4 weeks(estimation)'}]","[{'measure': 'Incidence Rate of Adverse Event', 'description': 'safety data according to CTC-AE', 'timeFrame': 'up to the end of treatment, up to 4 weeks(estimation)'}, {'measure': 'The microbiological clearance rate', 'description': 'The microbiological clearance rate is at the end of treatment', 'timeFrame': 'up to the end of treatment, up to 4 weeks(estimation)'}, {'measure': 'The all cause mortality rate', 'description': 'The all-cause mortality rate within 28 days', 'timeFrame': '28 days'}]",4.0,18 Years,,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,False,False,False,True,
NCT02512172,A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,Oral CC-486,"['Oral CC-486', 'MK-3475', 'oral aza', 'pembrolizumab', 'Romidepsin', 'Istodax', 'oral azacitidine']",7,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Colorectal Cancer,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2025-09-01T16:18:10.917169,True,,,,,A Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer,,['Colorectal Cancer'],[],,2016-02-19,2021-11-20,"[{'measure': 'Degree of change in tumor infiltrating lymphocytes', 'description': 'Change in the number of CD8+ TILs and/or the ratio of CD8+/CD4+ TILs in tumors pre- and post- treatment.', 'timeFrame': '1 year'}, {'measure': 'Number of Patients Experiencing a DLT (dose-limiting toxicity) as defined by NCI CTCAE v4.0', 'description': 'Adverse events are defined by NCI CTCAE v4.0. The DLT observation period is one cycle (28 days).', 'timeFrame': '5 years'}]","[{'measure': 'Immune-related Progression-free Survival (irPFS) at 20 weeks', 'description': 'irPFS rate is defined as the percentage of patients with disease progression (irPD or relapse from irCR as assessed using irRC criteria) or death due to any cause at 20 weeks. Per irRC criteria, Complete Response (irCR) is the disappearance of all target lesions, Partial Response (irPR) is a decrease in tumor burden by 50% or greater by a consecutive assessment at least 4 weeks after first documentation, Stable Disease (irSD) is the failure to meet criteria for irCR or irPR (in absence of irPD), Progressive Disease (irPD) is at least 25% increase in tumor burden relative to nadir. Estimation based on the Kaplan-Meier curve.', 'timeFrame': '20 weeks'}, {'measure': 'Overall Survival (OS)', 'description': 'OS will be measured from date of first dose until death or end of followup (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.', 'timeFrame': '4 years'}]",4.0,18 Years,,ALL,False,OTHER,2.0,27.0,ACTUAL,v2_robust,True,True,False,True,
NCT03944772,Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD),Osimertinib,"['Loxo-292, Retevmo, Retsevmo', 'DS 1062a', 'Alectinib', 'Selumetinib', 'Koselugo', 'Carboplatin', 'IMFINZI', 'Savolitinib', 'Pemetrexed', 'Durvalumab', 'Selpercatinib', 'Iressa', 'Datopotamab deruxtecan', 'Cisplatin', 'Gefitinib', 'Alecensa', 'TAGRISSO', 'Etoposide', 'Osimertinib', 'Necitumumab', 'Portrazza']",21,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Non-Small Cell Lung Cancer,AstraZeneca,2025-09-01T16:18:10.917186,True,,,,,A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.,,['Non-Small Cell Lung Cancer'],"['Non-small cell lung cancer', 'NSCLC', 'tSCLC', 'NEC', 'Phase II', 'Platform study', 'Biomarker-directed', 'Durvalumab', 'Osimertinib', 'Savolitinib', 'Selumetinib', 'Etoposide', 'Gefitinib', 'Necitumumab', 'Platinum-containing doublet', 'Pemetrexed', 'EGFR positive', 'Carboplatin', 'Alectinib', 'Selpercatinib', 'Cisplatin', 'TKI-resistant', 'MET amplification', 'MET exon 14 skipping', 'EGFR', 'EGFR C797X', 'EGFR G724X', 'EGFR L718X', 'EGFR exon 20 insertion', 'EGFR amplification', 'BRAF V600E', 'ALK rearrangement', 'RET rearrangement', 'ROS1 rearrangement', 'NTRK fusion', 'KRAS G12C', 'Datopotamab deruxtecan']",,2019-06-25,2025-05-06,"[{'measure': 'Objective response rate (ORR)', 'description': 'The percentage of patients with a confirmed investigator-assessed complete or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST) 1.1. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).', 'timeFrame': 'Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average'}]","[{'measure': 'Progression-free survival (PFS)', 'description': 'The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression). Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST (Response Evaluation Criteria In Solid Tumours)1.1 defined disease progression or cessation of study treatment (if treating beyond progression).', 'timeFrame': 'Measured from first dose until progression. For each patient this is expected to be 6 months on average'}, {'measure': 'Duration of response (DoR)', 'description': 'The time from the date of first response until date of disease progression or death in the absence of disease progression. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).', 'timeFrame': 'Measured from response until progression. For each patient this is expected to be 6 months on average'}, {'measure': 'Overall survival (OS)', 'description': 'The time from the date of the first dose of study treatment until death due to any cause.', 'timeFrame': 'Measured from first dose until death or final cohort data cut-off. For each patient this is expected to be 20 months on average'}, {'measure': 'Plasma/serum concentrations of therapeutic agents', 'description': 'Blood samples will be collected at various timepoints to evaluate the sparse pharmacokinetics of study therapeutic agents.', 'timeFrame': 'Pre-dose and 1 hour post-dose blood samples on Day 1 of Cycles 1, 3 (Cycle 2 for durvalumab), 6 for all therapeutic agents and a sample at the 90-day safety follow up for durvalumab only. (One Cycle = 21 or 28 days, depending on treatment).'}, {'measure': 'Plasma/serum concentrations of therapeutic agents', 'description': 'Blood samples will be collected at various timepoints to evaluate the serial pharmacokinetics of study therapeutic agents', 'timeFrame': 'Pre-dose and serial post-dose blood samples (1 hour, 2 hours, 4 hours, 6 hours, 8 hours) on Day 15 of Cycle 1 for alectinib and selpercatinib only.'}, {'measure': 'Incidence of Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5', 'description': 'To evaluate safety and tolerability of each study treatment', 'timeFrame': 'Continuously from first dose to end of safety follow up after study treatment discontinuation (approximately up to 21 Months)'}]",7.0,18 Years,130 Years,ALL,False,INDUSTRY,0.0,247.0,ACTUAL,v2_robust,True,False,False,True,
NCT04138472,"Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy",dexmedetomidine,"['lidocaine', 'dexmedetomidine', 'fentanyl']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Laparoscopic Cholecystectomy,Sana Urooj,2025-09-01T16:18:10.917272,True,,,,,"Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy",,['Laparoscopic Cholecystectomy'],"['Dexmedetomidine', 'Fentanyl', 'Lignocaine', 'Laryngoscopy', 'Hemodynamic Response', 'Laparoscopic Cholecystectomy']",,2019-10-30,2020-02-29,"[{'measure': 'systolic blood pressure', 'description': 'hermodynamic response (Top number will be assessed of blood pressure)', 'timeFrame': 'at induction'}, {'measure': 'Diastolic blood pressure', 'description': 'hermodynamic response (bottom number will be assessed of blood pressure)', 'timeFrame': 'at induction'}, {'measure': 'mean atrial pressure', 'description': 'Hemodynamic responses (average blood pressure in an individual during a single cardiac cycle)', 'timeFrame': 'at induction'}, {'measure': 'Heart rate', 'description': 'Hemodynamic responses (average heart rate beats a minute)', 'timeFrame': 'at induction'}, {'measure': 'Oxygen saturation (SpO2)', 'description': 'Hemodynamic responses) (arterial oxy-hemoglobin saturation is measured non-invasively by a finger pulse oximeter or handheld pulse oximeter,', 'timeFrame': 'at induction'}]","[{'measure': 'Sedation assessment', 'description': 'Ramsey score use for sedation, it consist of 1-6 where 6 indicates worst(no response) and 6 indicates good response', 'timeFrame': 'at 10 minutes post operative'}, {'measure': 'Recovery assessment', 'description': 'Aldret score use for recovery assessment, it consist of 0-10 point where 0 indicates worst(no response) and 10 indicates good response', 'timeFrame': 'at 10 minutes post operatively'}, {'measure': 'Complications', 'description': 'Cough, Laryngospasm, Bradycardia, Regugitation, PONV, Hypertention, Hypotension', 'timeFrame': '1 week Post-operative(Operation -discharge)'}]",8.0,20 Years,65 Years,ALL,False,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04599972,An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2),CSF-1,"['pilocarpine HCl 0.4%', 'Vehicle', 'CSF-1']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Presbyopia,Orasis Pharmaceuticals Ltd.,2025-09-01T16:18:10.917521,True,,,,,"A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-2 Study: Near Eye-vision Acuity Restoration)",,['Presbyopia'],[],,2020-10-26,2022-01-28,"[{'measure': 'Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1.', 'description': 'The primary end-point was measured on Day 8, 1 hour post first CSF-1 dose, as the number of participants who are responders to the treatment.\n\nA responder was defined as as subject with a ≥ 3-line gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no loss in BDCVA ≥ 5 letters at 4m.', 'timeFrame': 'Baseline (Day 1) to Day 8 (1 hour post-Dose 1)'}]","[{'measure': 'Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m.', 'description': 'The key secondary endpoints were measured on Day 8 at different time points and were the percentage of subjects with a ≥ 3-line (15-letter) gain, from baseline, in BDCVA at 40 cm (Precision Vision Chart) and no loss in BDCVA ≥ 5 letters (ETDRS chart at 4 m) in the study eye.', 'timeFrame': 'Baseline (Day 1) to Day 8 (2 hours post-Dose 1)'}, {'measure': 'Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 1 Hour Post-Dose 2', 'description': 'The key secondary endpoints were measured on Day 8 at different time points and were the percentage of subjects with a ≥ 3-line (15-letter) gain, from baseline, in BDCVA at 40 cm (Precision Vision Chart) and no loss in BDCVA ≥ 5 letters (ETDRS chart at 4 m) in the study eye.', 'timeFrame': 'Baseline (Day 1) to Day 8 (1 hour post Dose 2; Dose 2 occurred 2 hours following Dose 1)'}, {'measure': 'Percentage of Subjects With a ≥ 3-line Gain in BDCVA at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8 at 2 Hours Post-dose 2', 'description': 'The key secondary endpoints were measured on Day 8 at different time points and were the percentage of subjects with a ≥ 3-line (15-letter) gain, from baseline, in BDCVA at 40 cm (Precision Vision Chart) and no loss in BDCVA ≥ 5 letters (ETDRS chart at 4 m) in the study eye.', 'timeFrame': 'Baseline (Day 1) to Day 8 (2 hours post Dose 2; Dose 2 occurred 2 hours following Dose 1)'}]",4.0,45 Years,64 Years,ALL,False,INDUSTRY,0.0,304.0,ACTUAL,v2_robust,True,True,False,False,
NCT00000672,"An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex",Didanosine,['Didanosine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV Infections,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:10.917579,True,,,,,"An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex",,['HIV Infections'],"['Didanosine', 'Zidovudine']",,,,[],[],0.0,12 Years,,ALL,False,NIH,1.0,660.0,,v2_robust,True,True,False,False,
NCT00495872,Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor,Dasatinib,"['Lenalidomide', 'Sorafenib', 'Lapatinib', 'Erlotinib Hydrochloride', 'Dasatinib', 'Valproic Acid', 'GW572016', 'Depakene', 'BAY 43-9006', 'Revlimid™', 'CC-5013', 'Tarceva', 'SU011248', 'OSI-774', 'Erlotinib', 'BMS-354825', 'Sprycel®', 'Sunitinib Malate', 'Sunitinib']",19,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Solid Tumors,M.D. Anderson Cancer Center,2025-09-01T16:18:10.917592,True,,,,,A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor,,['Solid Tumors'],"['Solid Tumors', 'Advanced Cancer', 'Dasatinib', 'Erlotinib', 'Lapatinib', 'Lenalidomide', 'Sorafenib', 'Erlotinib Hydrochloride', 'Sunitinib Malate', 'Sunitinib', 'Valproic Acid', 'SU011248']",,2007-06,,"[{'measure': 'Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities', 'timeFrame': 'At Day 28 (1 Cycle)'}]",[],1.0,,,ALL,False,OTHER,0.0,204.0,ACTUAL,v2_robust,True,True,False,False,
NCT01096095,Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3,Placebo,"['Sodium Phenylbutyrate', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Spinocerebellar Ataxia Type 3,Hospital de Clinicas de Porto Alegre,2025-09-01T16:18:10.917613,True,,,,,"Phenylbutyrate in SCA3: a Double-blind, Placebo-controlled Study to Determine Safety and Efficacy of Sodium Phenylbutyrate in Patients With SCA3",,['Spinocerebellar Ataxia Type 3'],"['SCA', 'Spinocerebellar Ataxia', 'Sodium Phenylbutyrate', 'Machado-Joseph Disease', 'Treatment']",Regulatory authorities did not allow the entrance of the study drug in the country,2010-06,2011-07,"[{'measure': 'Safety and tolerability of phenylbutyrate in patients with SCA3', 'description': 'The number of adverse events, interruptions and dose reductions in the two groups (cases and controls).', 'timeFrame': '6 months - 12 months'}]","[{'measure': 'Efficacy of phenylbutyrate in SCA3 on neurological dysfunction and quality of life', 'description': 'Efficacy outcomes are the following scores in both groups: NESSCA, SARA, 9-hole peg board test, BDI, and WHOQol.', 'timeFrame': '6 months - 12 months'}]",2.0,16 Years,80 Years,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,True,Regulatory authorities did not allow the entrance of the study drug in the country
NCT05492695,Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study,Galcanezumab,['Galcanezumab'],1,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Migraine,Diamond Headache Clinic,2025-09-01T16:18:10.917639,True,,,,,TOGETHER STUDY: Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study,,['Migraine'],[],Stopped from financial sponsor due to inability to enroll participants.,2022-10-01,2023-09-28,"[{'measure': 'Change in Monthly Migraine Days', 'timeFrame': 'Baseline to Treatment Month 3'}]","[{'measure': 'Change in Monthly Migraine days', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}, {'measure': 'Change in Monthly Headache days', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}, {'measure': 'Change in PROMIS Pain Interference scores', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}, {'measure': 'Change in Functional Assessment of Migraine Scale - Research (FAMS-R) scores', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}, {'measure': 'Change in Functional Assessment of Migraine Scale - Research Supplement (FAMS-RS) scores', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}, {'measure': 'Change in Migraine Disability Assessment (MIDAS) scores', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}, {'measure': 'Frequency of 50% Responders', 'description': '50% Responders is defined as at least 50% reduction in number of monthly migraine days compared to baseline', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}, {'measure': 'Monthly Acute Migraine Medication use', 'timeFrame': 'Baseline to Treatment Months 1, 2, & 3'}]",9.0,18 Years,65 Years,ALL,False,OTHER,0.0,2.0,ACTUAL,v2_robust,True,False,True,False,Stopped from financial sponsor due to inability to enroll participants.
NCT01755195,Cabozantinib for Adults With Advanced Soft Tissue Sarcoma,Cabozantinib,"['Cabozantinib', 'Cometriq']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Refractory Soft Tissue Sarcomas,National Cancer Institute (NCI),2025-09-01T16:18:10.917716,True,,,,,"A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma",,['Refractory Soft Tissue Sarcomas'],"['Dual Inhibitor of MET and VEGFR', 'XL184', 'Metastatic Refractory', 'Soft Tissue Sarcoma', 'Rare Heterogeneous Tumor']",,2013-01-15,2023-09-11,"[{'measure': 'Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas', 'description': 'Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.', 'timeFrame': 'Date treatment consent signed to date off study, approximately 86 months and 3 days.'}, {'measure': 'Percentage of Participants With 6 Month Progression Free Survival (PFS)', 'description': 'Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.', 'timeFrame': '6 months'}]","[{'measure': 'Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)', 'description': 'Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.', 'timeFrame': 'Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1'}, {'measure': 'Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)', 'description': 'Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.', 'timeFrame': 'Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1'}, {'measure': 'Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)', 'description': 'Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.', 'timeFrame': 'Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1'}, {'measure': 'Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)', 'description': 'Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome..', 'timeFrame': 'Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1'}]",6.0,18 Years,120 Years,ALL,False,NIH,0.0,55.0,ACTUAL,v2_robust,True,True,False,False,
NCT00530595,Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients,candesartan or valsartan or losartan,['candesartan or valsartan or losartan'],1,INTERVENTIONAL,['NA'],,COMPLETED,Cardiovascular Disease,Saitama Medical University,2025-09-01T16:18:10.917769,True,,,,,,,['Cardiovascular Disease'],['hemodialysis'],,,,[],[],0.0,30 Years,80 Years,ALL,False,OTHER,0.0,,,v2_robust,True,True,False,False,
NCT00605995,Add-on Simvastatin in Schizophrenia Trial,Simvastatin,"['Simvastatin', 'Zocor']",2,INTERVENTIONAL,['NA'],,TERMINATED,Schizophrenia,New York State Psychiatric Institute,2025-09-01T16:18:10.917830,True,,,,,Add-on Simvastatin in Schizophrenia Trial,,['Schizophrenia'],"['Schizophrenia', 'Randomized trial', 'Statin', 'Placebo']",Enrollment was slower than anticipated by the investigators and the funding research foundation.,2008-02,2011-08,"[{'measure': 'Positive and negative symptoms of schizophrenia', 'timeFrame': '12 weeks'}]","[{'measure': 'Serum inflammatory markers and cholesterol levels.', 'timeFrame': '12 weeks'}]",2.0,18 Years,70 Years,ALL,False,OTHER,3.0,15.0,ACTUAL,v2_robust,True,False,True,False,Enrollment was slower than anticipated by the investigators and the funding research foundation.
NCT05470595,A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung,Atezolizumab,['Atezolizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Large Cell Neuroendocrine Carcinoma of the Lung,Technische Universität Dresden,2025-09-01T16:18:10.917838,True,,,,,"A Phase II, Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung",,['Large Cell Neuroendocrine Carcinoma of the Lung'],"['Lung Cancer', 'LCNEC', 'Neuroendocrine Carcinoma']",,2022-01-18,2029-01-31,"[{'measure': 'Overall survival', 'description': 'To assess the efficacy of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC as measured by overall survival.', 'timeFrame': 'appr. 72 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'According to RECIST v1.1 as assessed by local investigator.', 'timeFrame': 'appr. 72 months'}, {'measure': 'Immune Objective Response Rate (iORR)', 'description': 'According to iRECIST as assessed by local investigator.', 'timeFrame': 'appr. 72 months'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'According to RECIST v1.1 as assessed by local investigator.', 'timeFrame': 'appr. 72 months'}, {'measure': 'Progression Free Survival (PFS)', 'timeFrame': 'appr. 72 months'}, {'measure': 'Immune Progression Free Survival (iPFS)', 'timeFrame': 'appr. 72 months'}, {'measure': 'Duration of Response (DoR)', 'timeFrame': 'appr. 72 months'}, {'measure': 'Progression Free Survival (PFS) rate at one year', 'timeFrame': '1 year'}, {'measure': 'Immune Progression Free Survival (iPFS) rate at one year', 'timeFrame': '1 year'}, {'measure': 'Overall survival at one year', 'timeFrame': '1 year'}, {'measure': 'Incidence, intensity, seriousness, relationship to Atezolizumab, and outcome of adverse events graded according to NCI CTCAE (v5.0).', 'timeFrame': 'appr. 72 months'}]",11.0,18 Years,,ALL,False,OTHER,1.0,67.0,ESTIMATED,v2_robust,True,False,False,True,
NCT01564095,TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion,Tacrolimus,"['HTK, histidin-tryptophane-ketoglurate organ preservation solution, Custodiol, Dr. Franz Köhler Chemie, Germany', 'HTK/Placebo', 'Tacrolimus, Prograf; Astellas Germany', 'Tacrolimus']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Terminal Liver Disease,Ludwig-Maximilians - University of Munich,2025-09-01T16:18:10.917868,True,,,,,TOP-Study (Tacrolimus Organ Perfusion): A Prospective Multicenter Trial for Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion,,"['Terminal Liver Disease', 'Ischemia Reperfusion Injury', 'Graft Dysfunction', 'Graft Failure', 'Poor Graft Quality']","['Liver transplantation', 'EDC', 'IRI', 'graft survival', 'graft function', 'graft preconditioning', 'Tacrolimus rinse', 'randomised multicenter trial']",Missing evidence of the effectiveness of the study medication,2011-10,2013-07,"[{'measure': 'Maximum serum ALT-level', 'timeFrame': '48 hrs following liver transplantation'}]","[{'measure': 'ALT', 'timeFrame': '1,2,4,7 days after surgery'}, {'measure': 'Graft survival', 'timeFrame': '7 days'}, {'measure': 'AST', 'timeFrame': '1,2,4,7 days after surgery'}, {'measure': 'Bilirubin', 'timeFrame': '1,2,4,7 days after surgery'}, {'measure': 'Creatinin', 'timeFrame': '1,2,4,7 days after surgery'}]",6.0,18 Years,,ALL,False,OTHER,0.0,25.0,ACTUAL,v2_robust,True,False,True,False,Missing evidence of the effectiveness of the study medication
NCT00005795,Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia,arsenic trioxide,['arsenic trioxide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Leukemia,Northwestern University,2025-09-01T16:18:10.917880,True,,,,,"Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old",,['Leukemia'],"['recurrent adult acute myeloid leukemia', 'untreated adult acute myeloid leukemia', 'adult acute erythroid leukemia (M6)', 'adult acute myeloblastic leukemia without maturation (M1)', 'adult acute myeloblastic leukemia with maturation (M2)', 'adult acute myelomonocytic leukemia (M4)', 'adult acute monoblastic leukemia (M5a)', 'adult acute megakaryoblastic leukemia (M7)', 'secondary acute myeloid leukemia', 'adult acute monocytic leukemia (M5b)', 'adult acute minimally differentiated myeloid leukemia (M0)']",,2000-02,2002-07,[],[],0.0,16 Years,,ALL,False,OTHER,1.0,11.0,ACTUAL,v2_robust,True,True,False,False,
NCT00920595,Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors,CEP-9722,['CEP-9722'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Solid Tumor,Cephalon,2025-09-01T16:18:10.917908,True,,,,,"An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 Inhibitor) as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors",,['Solid Tumor'],['Cancer'],,2009-06,2011-10,"[{'measure': 'Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data', 'timeFrame': 'Up to 42 days'}]","[{'measure': 'Pharmacokinetic parameters', 'timeFrame': 'Days 1 and 5 of Cycle 1 and on Day 5 of Cycle 2'}, {'measure': 'Pharmacodynamics assay', 'timeFrame': 'Days 1, 5, and 8 of both Cycle 1 and Cycle 2'}, {'measure': 'Efficacy - will be assessed by the proportion of patients who achieve tumor response during the study', 'timeFrame': 'A 14-day cycle and at least one 28-day cycle'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,False,
NCT06307795,A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors,ANS014004,['ANS014004'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Locally Advanced or Metastatic Solid Tumors,"Avistone Biotechnology Co., Ltd.",2025-09-01T16:18:10.917943,True,,,,,"A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors",,['Locally Advanced or Metastatic Solid Tumors'],[],,2024-06-24,2027-10,"[{'measure': 'Incidence of Adverse Events (AEs)', 'description': 'Number of patients with adverse events by system organ class and preferred term', 'timeFrame': 'From the time of first dose to 28 days post last dose of ANS014004'}, {'measure': 'Incidence of Serious Adverse Events (SAEs)', 'description': 'Number of patients with serious adverse events by system organ class and preferred term', 'timeFrame': 'From time of first dose to 28 days post last dose of ANS014004'}, {'measure': 'Incidence of dose-limiting toxicities (DLT) as defined in the protocol', 'description': 'Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol', 'timeFrame': 'From time of first dose of ANS014004 to end of DLT period (approximately 30 days)'}, {'measure': 'Incidence of baseline laboratory finding, ECG and vital signs changes', 'description': 'measured by laboratory and vital sign variables over time including change from', 'timeFrame': 'From time of first dose to 28 days post last dose of ANS014004'}, {'measure': 'Proportion of patients with radiological response (ORR)', 'description': 'Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1', 'timeFrame': 'From date of first dose of ANS014004 until progression, or the last evaluable assessment in the absence of progression （approximately 2 years)）'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)', 'timeFrame': 'From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)'}, {'measure': 'Duration of Response (DoR)', 'description': 'The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1)', 'timeFrame': 'From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression', 'timeFrame': 'From date of first dose of ANS014004 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)'}, {'measure': 'Progression free Survival (PFS)', 'description': 'The time from first dose until RECIST 1.1 defined disease progression or death due to any cause', 'timeFrame': 'rom date of first dose of ANS014004 up until date of progression or death due to any cause (approximately 2 years)'}, {'measure': 'Overall Survival (OS)', 'description': 'The time from the date of the first dose of study treatment until death due to any cause', 'timeFrame': 'From date of first dose of ANS014004 up until the date of death due to any cause (approximately 2 years)'}, {'measure': 'Pharmacokinetics of ANS014004: Plasma PK concentrations', 'description': 'Measurement of plasma concentrations of ANS014004, total antibody and total unconjugated warhead', 'timeFrame': 'From date of first dose up until 28 days post last dose'}, {'measure': 'Pharmacokinetics of ANS014004: Area under the concentration time curve (AUC)', 'description': 'Measurement of PK parameters: Area under the concentration time curve (AUC)', 'timeFrame': 'From date of first dose up until 28 days post last dose'}, {'measure': 'Pharmacokinetics of ANS014004: Maximum plasma concentration of the study drug (C-max)', 'description': 'Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)', 'timeFrame': 'From date of first dose up until 28 days post last dose'}, {'measure': 'Pharmacokinetics of ANS014004: Time to maximum plasma concentration of the study drug (T-max)', 'description': 'Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)', 'timeFrame': 'From date of first dose up until 28 days post last dose'}, {'measure': 'Pharmacokinetics of ANS014004: Clearance', 'description': 'Measurement of PK parameters: the volume of plasma from which the study drug is completely removed per unit time (Clearance)', 'timeFrame': 'From date of first dose up until 28 days post last dose'}, {'measure': 'Pharmacokinetics of ANS014004: Half-life', 'description': 'Measurement of PK parameters: Terminal elimination half-life (t 1/2)', 'timeFrame': 'From date of first dose up until 28 days post last dose'}]",16.0,18 Years,,ALL,False,INDUSTRY,0.0,63.0,ESTIMATED,v2_robust,True,False,False,True,
NCT07042295,Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System,Amivantamab and Recombinant Human Hyaluronidase,"['Amivantamab-Recombinant Human Hyaluronidase', 'Amivantamab and Recombinant Human Hyaluronidase', 'Amivantamab Plus Recombinant Human Hyaluronidase', 'Amivantamab/Recombinant Human Hyaluronidase', 'Amivantamab + Recombinant Human Hyaluronidase', 'Amivantamab with Recombinant Human Hyaluronidase', 'Amivantamab and Hyaluronidase']",7,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Locally Recurrent Skin Squamous Cell Carcinoma,National Cancer Institute (NCI),2025-09-01T16:18:10.918042,True,,,,,A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants With Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma,,"['Locally Recurrent Skin Squamous Cell Carcinoma', 'Metastatic Skin Squamous Cell Carcinoma']",[],,2025-09-20,2029-02-28,"[{'measure': 'Incidence of toxicity of interest (cohort A)', 'description': 'Defined as grade 3 or 4 skin rash that does not recover within 14 days, grade 3 or 4 non-hematologic toxicity that does not recover within 7 days, grade 4 hematologic toxicity including febrile neutropenia or organ transplant failure (for transplant patients only).', 'timeFrame': 'Up to completion of the first cycle (cycle length = 28 days)'}, {'measure': 'Progression free survival (PFS) (cohort B)', 'timeFrame': 'From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, up to 3 years'}]","[{'measure': 'Organ rejection', 'description': 'Will be monitored for participants with prior organ transplants.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall survival (OS)', 'description': 'Will estimate OS by cohort and treatment arm and within subgroups using the method of Kaplan-Meier. OS will be compared between arms using an un-stratified log-rank test. The hazard ratio and 95% confidence interval from an un-stratified Cox regression model with treatment as the only covariate will be descriptively reported for OS.', 'timeFrame': 'From date of registration to date of death due to any cause, up to 5 years'}, {'measure': 'PFS', 'description': 'Will estimate PFS by cohort and treatment arm and within subgroups using the method of Kaplan-Meier.', 'timeFrame': 'From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, up to 5 years'}, {'measure': 'Time to next treatment', 'description': 'will be estimated using cumulative incidence curves with death before event accounted for as a competing event.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Time to progression', 'description': 'will be estimated using cumulative incidence curves with death before event accounted for as a competing event.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Duration of objective response', 'description': 'Will be estimated using cumulative incidence curves with death before event accounted for as a competing event.', 'timeFrame': 'Up to 5 years'}]",8.0,18 Years,,ALL,False,NIH,0.0,86.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04512339,Dupilumab in Severe Chronic Hand Eczema,Dupilumab,"['Dupilumab', 'Dupixent', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Hand Eczema,University Medical Center Groningen,2025-09-01T16:18:10.918067,True,,,,,Dupilumab in Severe Chronic Hand Eczema With Inadequate Response or Intolerance to Alitretinoin,,['Hand Eczema'],"['Hand eczema', 'Dupilumab']",,2020-08-01,2022-08,"[{'measure': 'Response to treatment/hand eczema severity (Hand Eczema Severity Index, HECSI)', 'description': 'HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). A decrease in score relates to an improvement in signs and symptoms. Response is defined as HECSI-75: the proportion of patients wit a HECSI score of ≥75% improvement from baseline.', 'timeFrame': '16 weeks'}]","[{'measure': 'Response to treatment/hand eczema severity (Photographic guide)', 'description': 'The photographic guide is a five-point scale that provides a global clinical assessment of hand eczema severity ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is moderate, 4 is severe; and 5 indicates very severe hand eczema. A decrease in score relates to an improvement in signs and symptoms.', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Response to treatment/hand eczema/foot eczema severity (Physician Global Assessment)', 'description': 'A decrease in score relates to an improvement in signs and symptoms.', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Response to treatment/hand eczema/foot eczema severity (modified Total Lesion Symptom Score, mTLSS)', 'description': 'mTLSS combines an evaluation of hand and foot eczema lesions severity; scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 18 (more serious disease).', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Response to treatment/hand eczema severity (Hand Eczema Severity Index, HECSI)', 'description': 'HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). A decrease in score relates to an improvement in signs and symptoms.', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Patient reported change (Patient Global Assessment, PaGA)', 'description': 'Percentage of change of hand eczema symptoms assessed by PaGA. 0 indicates clear or almost clear (at least 90% clearing of disease signs and symptoms compared to baseline), 5 means worsening of symptoms compared to baseline.', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Changeof pruritus (Numerical Rating Scale, NRS)', 'description': ""Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus, both maximum and average intensity, during a 24-hour recall period. Maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable)."", 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Change of pain (Numerical Rating Scale, NRS)', 'description': ""Pain NRS is an assessment tool that is used to report the intensity of a patient's pain, both maximum and average intensity, during a 24-hour recall period. Maximum pain intensity on a scale of 0 - 10 (0 = no pain; 10 = worst pain imaginable)."", 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Change of hand eczema related quality of life (Quality of Life in Hand Eczema Questionnaire, QOLHEQ)', 'description': 'The Quality Of Life in Hand Eczema Questionnaire (QOLHEQ) is an instrument to assess disease specific Health Related Quality of Life (HRQOL) in patients suffering from hand eczema. The construct HRQOL includes all impairments or limiting conditions caused by the health state of an individual. The QOLHEQ is a disease specific instrument, thereby only assessing impairments caused by hand eczema. It consists out of 30 items which can be summarized according to four domains of HRQOL: Impairments because of (1) symptoms, (2) emotions, (3) limitations in functioning or (4) because of treatment and prevention. A high score is indicative of a poor hand eczema related HRQOL.', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Changeof quality of life (Dermatology Life Quality Index, DLQI)', 'description': ""DLQI is a 10-item, validated questionnaire to assess the impact of skin disease symptoms and treatment on quality of life (QOL); over the past week, with an overall scoring of 0 (disease has no effect on patient's life) to 30 (disease has an extremely large effect on patient's life); a high score is indicative of a poor QoL."", 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Change of work productivity and impairment (Work Productivity and Activity Impairment, WPAI)', 'description': 'The WPAI consists of 6 items, assessing absenteeism, presenteeism, work productivity loss and activity impairment. Higher scores indicate less productivity and a greater impairment.', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Change of anxiety and depression (Hospital Anxiety and Depression scale, HADS)', 'description': 'HADS is a 14-item questionnaire, 7 items for anxiety and 7 items for depression symptoms; possible scores range from 0 to 21 for each subscale. The following cut-off scores are recommended for both subscales: 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': ""Cost-utility. Quality-adjusted life-years (QALY's): registered direct/indirect costs, combined with EQ-5D-5L outcome"", 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Cost-effectiveness: registered direct/indirect costs combined with the primary and secondary effectiveness outcomes (HECSI and PG)', 'timeFrame': 'Week 4, 8, 12, 16'}, {'measure': 'Safety and tolerability (adverse events)', 'timeFrame': 'Up to 16 weeks'}]",15.0,18 Years,75 Years,ALL,False,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04326439,AflacLL1901 (CHOA-AML),Cytarabine,"['Etoposide', 'BAY 43-9006 Tosylate, BAY 54-9085 Nexavar', 'Cytarabine', 'Erwinaze, Erwinia L-Asparaginase, Erwinia Chrysanthemi L-asparaginase, Crisantaspase', 'Daunorubicin', 'Mylotarg®, CDP-771, CMA-676, hP67.6-calicheamicin', 'Gemtuzumab ozogamicin', 'Rubidomycin', 'Sorafenib', 'Erwinase', 'cytosine arabinoside, ARA-C', 'VePesid, VP-16']",12,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Acute Myeloid Leukemia,Emory University,2025-09-01T16:18:10.918157,True,,,,,CHOA-AML: A Pilot Study for Newly Diagnosed Pediatric Patients With Acute Myeloid Leukemia (AML),,"['Acute Myeloid Leukemia', 'AML, Childhood']",['acute myeloid leukemia'],"Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated.",2020-01-24,2022-03-15,"[{'measure': 'Event-free Survival (EFS) in Low Risk Patients and High Risk Patients', 'description': 'Event-free survival defined as the time from on study to death, failure to achieve remission or relapse in newly diagnosed patients with pediatric acute myeloid leukemia in the Low risk stratification group and High risk stratification group', 'timeFrame': 'Up to 2 years post-intervention'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Time from study entry and from end of first course of therapy for newly diagnosed patients with pediatric acute myeloid leukemia', 'timeFrame': 'Up to 2 years post-intervention'}, {'measure': 'Minimal Residual Disease (MRD) Negative Status', 'description': 'Number of patients that are in remission (MRD negative) after course 1 in participants receiving GO and those that did not receive GO.', 'timeFrame': 'Post-induction I, an average of 28 days'}, {'measure': 'Disease-free Survival (DFS) for Patients Who Are MRD Negative', 'description': 'Disease-free survival for patients who are MRD negative but lack high or low risk molecular and cytogenetic features, defined as time from end of first course of therapy to death or relapse', 'timeFrame': 'Up to 2 years post-intervention'}, {'measure': 'Cardiotoxicity in Patients With de Novo AML That Receive the Four-cycle Aflac-AML Regimen With the Inclusion of Dexrazoxane', 'description': 'Number of patients that develop cardiac ejection fraction \\<50% (CTCAE V5.0 grade 2 or greater dysfunction) either during therapy (early cardiotoxicity) or after completion of therapy (late cardiotoxicity)', 'timeFrame': 'At completion of Cycle 4 (each cycle average is 28 days)'}, {'measure': 'Proportion of Patients Who Develop Infection and/or Febrile Neutropenia During Each Treatment Course', 'description': 'Number of participants that developed infection and/or febrile neutropenia at the end of each treatment cycle.', 'timeFrame': 'At the end of each cycle (each cycle average is 28 days)'}, {'measure': 'Duration of Hospital Admission in Patients That Developed Infection and Febrile Neutropenia at the End of Each Treatment Cycle', 'description': 'Duration of hospital admission in patients that developed infection and febrile neutropenia at the end of each treatment cycle', 'timeFrame': 'At the end of each cycle (each cycle average is 28 days)'}]",7.0,,21 Years,ALL,False,OTHER,0.0,8.0,ACTUAL,v2_robust,True,False,True,False,"Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated."
NCT02398539,Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue,Silver Nitrate,"['Triamcinolone', 'Silver Nitrate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Hypergranulation Tissue; Gastrostomy Tube Site,Akron Children's Hospital,2025-09-01T16:18:10.918198,True,,,,,Randomized Clinical Trial Comparing Silver Nitrate Application With Topical Corticosteroids for Hypergranulation Tissue at Gastrostomy Sites,,['Hypergranulation Tissue; Gastrostomy Tube Site'],[],,2015-04,2016-04,"[{'measure': 'Maximal reduction in granulation tissue', 'timeFrame': 'During maximum of 4 weeks of therapy'}]",[],1.0,,18 Years,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01904539,Hepatic Impairment Trial of Obeticholic Acid,obeticholic acid 10 mg,"['6α-ethyl chenodeoxycholic acid', 'obeticholic acid 10 mg', '6-ECDCA', 'INT-747']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hepatic Impairment,Intercept Pharmaceuticals,2025-09-01T16:18:10.918206,True,,,,,"An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA)",,['Hepatic Impairment'],[],,2013-06,2013-10,"[{'measure': 'Peak plasma concentration (Cmax) of OCA and conjugates', 'description': 'maximum concentration', 'timeFrame': 'Up to 48 hours'}, {'measure': 'Area under the concentration versus time curve from time 0 to the last sampling time with measurable analyte concentration (AUCt) of OCA and conjugates', 'timeFrame': 'Post-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 216 hours post-dose'}, {'measure': 'Time to Cmax (Tmax) of OCA and conjugates', 'timeFrame': 'Up to 48 hours'}, {'measure': 'Area under the concentration versus time curve from time 0-24 hours with measurable analyte concentration of OCA and conjugates. (AUC 0-24)', 'timeFrame': '24 hours'}]","[{'measure': 'Urine concentration of unchanged OCA and conjugates', 'timeFrame': '0, 6, 12, 24, 30 hours'}, {'measure': 'Amount of OCA and conjugates excretion in urine', 'timeFrame': '-6to 0, 0 to 6, 6 to 12, 12 to 24, and 24 to 30 hours'}, {'measure': 'Total amount of OCA and conjugates excreted in urine', 'timeFrame': '0 to 30 hours'}, {'measure': 'Protein Binding', 'timeFrame': '0, 0.75, 1.5, 6, and 24 hours'}]",8.0,18 Years,,ALL,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,
NCT05404139,Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT),Enzalutamide,['Enzalutamide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Metastatic Prostate Cancer,"University Health Network, Toronto",2025-09-01T16:18:10.918225,True,,,,,Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate,,['Metastatic Prostate Cancer'],[],,2023-05-24,2026-03,"[{'measure': 'Progression free survival', 'description': 'Determine if progression free survival improves with the addition of intermittent enzalutamide to standard of care treatment.', 'timeFrame': '5 years'}]","[{'measure': 'Patient-reported quality of life', 'description': 'Determine if the addition of intermittent enzalutamide to standard of care treatment results in a patient-reported quality of life difference compared to standard of care treatment alone using quality of life questionnaires (EPIC-26).', 'timeFrame': '5 years'}, {'measure': 'Patient-reported quality of life', 'description': 'Determine if the addition of intermittent enzalutamide to standard of care treatment results in a patient-reported quality of life difference compared to standard of care treatment alone using quality of life questionnaires (FACT-P).', 'timeFrame': '5 years'}, {'measure': 'Patient-reported quality of life', 'description': 'Determine if the addition of intermittent enzalutamide to standard of care treatment results in a patient-reported quality of life difference compared to standard of care treatment alone using quality of life questionnaires (FACT-Fatigue).', 'timeFrame': '5 years'}, {'measure': 'Physician-reported toxicity', 'description': 'Determine if the addition of intermittent enzalutamide to standard of care treatment results in a physician-reported difference in acute and late toxicities compared to standard of care treatment alone assessed by CTCAE Toxicity 5.0.', 'timeFrame': '5 years'}]",5.0,18 Years,100 Years,MALE,False,OTHER,1.0,132.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01445639,Dexmedetomidine in Patients After Intracranial Surgery,Dexmedetomidine,"['Dexmedetomidine', 'Normal saline']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Central Nervous System Diseases,Capital Medical University,2025-09-01T16:18:10.918253,True,,,,,"Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients After Intracranial Surgery (Prophylactic Analgesia and Sedation Trial, PASTrial)",,['Central Nervous System Diseases'],"['dexmedetomidine', 'sedation', 'neurosurgery', 'postoperative care']",,2011-10,2013-02,"[{'measure': 'Mean percentage of hours of optimal sedation.', 'description': 'Optimal sedation is defined as SAS score 4.', 'timeFrame': '24 hours postoperative'}]","[{'measure': 'Percentage of patients with agitation and receiving additional sedatives.', 'description': 'Agitation is defined as SAS above 4. Patients are given midazolam as agitation.', 'timeFrame': 'During the first 24 hours postoperatively'}]",2.0,18 Years,,ALL,False,OTHER,0.0,192.0,ACTUAL,v2_robust,True,True,False,False,
NCT06800339,A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer,Nivolumab,"['Chemotherapy', 'Nivolumab']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Non-Small Cell Lung Cancer,"University of Maryland, Baltimore",2025-09-01T16:18:10.918264,True,,,,,"A Phase I, Single-Arm, Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer",,['Non-Small Cell Lung Cancer'],"['Radiation Treatment', 'SBRT', 'ChemoImmunotherapy']",,2025-04-22,2030-03,"[{'measure': 'Tolerability of Adding Sub-ablative, Immunosensitizing, Radiotherapy to Standard of Care Neoadjuvant Chemoimmunotherapy', 'description': 'Evaluate the tolerability of adding sub-ablative, immunosensitizing, radiotherapy to standard of care neoadjuvant chemoimmunotherapy prior to surgery for resectable NSCLC, measured by the rate of DLTs from time of neoadjuvant therapy initiation to start of definitive therapy (either surgery or chemoimmunotherapy initiation).', 'timeFrame': '20 weeks post initiation of neoadjuvant therapy'}]","[{'measure': 'Number of adverse events assessment by CTCAE v5.0 that are related to treatment', 'description': 'Determine the safety of adding sub-ablative, immunosensitizing, radiotherapy to standard of care neoadjuvant chemoimmunotherapy prior to definitive resection for resectable NSCLC, measured by the frequency of drug related adverse events, including serious adverse events, occurring up to the initiation of definitive therapy (either surgery or chemoimmunotherapy initiation). Safety will be measured by the frequency of drug related adverse events, including serious adverse events (defined by CTCAE version 5), occurring up until the time of definitive therapy initiation (either surgery or chemoradiotherapy).', 'timeFrame': '20-22 weeks post initiation of neoadjuvant therapy'}, {'measure': 'Pathologic Complete Response Rate (pCR)', 'description': 'Estimate the rate of pathologic complete response after adding immunosensitizing radiotherapy to neoadjuvant chemoimmunotherapy prior to definitive resection. pCR is defined as lack of any viable tumor cells after complete evaluation in the resected lung cancer specimen and all sampled regional lymph nodes as determined by central pathology review and described by IASLC 2020 assessment criteria. The measure of interest is the proportion of resected patients with 0% residual viable tumor cells within all resected tissue as assessed by the central pathology review.', 'timeFrame': '20-22 weeks post initiation of neoadjuvant therapy'}, {'measure': 'Major Pathologic Response Rate (MPR)', 'description': 'Estimate the rate of major pathologic response after adding immunosensitizing radiotherapy to neoadjuvant chemoimmunotherapy prior to definitive resection. MPR is defined as ≤ 10% viable tumor cells in resected tumor after complete evaluation in the resected lung cancer specimen as determined by central pathology review and described by IASLC 2020 assessment criteria. The measure of interest is the proportion of resected patients with ≤ 10% residual viable tumor cells within all resected tissue as assessed by the central pathology review.', 'timeFrame': '20-22 weeks post initiation of neoadjuvant therapy'}, {'measure': 'Measure rate of definitive resection', 'description': 'Establish the rate of definitive resection for patients with borderline resectable NSCLC treated with subablative radiotherapy followed by neoadjuvant chemoimmunotherapy.\n\nRate of definitive resection will be measured as the percentage of participants who undergo a complete R0 resection of their disease after receiving neoadjuvant subablative radiotherapy followed by chemoimmunotherapy out of all treated participants.', 'timeFrame': '1 year post completion of accrual'}]",5.0,18 Years,,ALL,False,OTHER,0.0,18.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06411639,Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases,ianalumab,"['ianalumab', 'VAY736']",2,INTERVENTIONAL,['PHASE1'],PHASE1,WITHDRAWN,Sjogren Disease,Novartis Pharmaceuticals,2025-09-01T16:18:10.918277,True,,,,,"A Multicenter, Open-label, Single-arm, Multiple-dose Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous Ianalumab in Chinese Adult Participants With Autoimmune Diseases",,"['Sjogren Disease', 'Systemic Lupus Erythematosus']","['Pharmacokinetic (PK)', 'Systemic lupus erythematosus (SLE)', 'Sjogren Disease (SjD)', 'VAY736', 'ianalumab', 'B cell depletion']",Strategic decision,2024-11-25,2028-06-24,"[{'measure': 'Area Under the Curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) of ianalumab after the 3rd dose', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. AUCtau of ianalumab will be summarized with descriptive statistics.', 'timeFrame': 'Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)'}, {'measure': 'Observed maximum blood concentration (Cmax)of ianalumab after the 3rd dose', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. Cmax of ianalumab will be summarized with descriptive statistics.', 'timeFrame': 'Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)'}, {'measure': 'Time of maximum observed drug concentration occurrence (Tmax) of ianalumab after the 3rd dose', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. Tmax of ianalumab will be summarized with descriptive statistics.', 'timeFrame': 'Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)'}]","[{'measure': 'Ctrough of ianalumab at the end of dosing interval', 'description': 'Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. Ctrough of ianalumab will be summarized with descriptive statistics.', 'timeFrame': 'Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)'}, {'measure': 'Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)', 'description': 'The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.', 'timeFrame': 'From date of enrollment till 30 days after end of Treatment, assessed up to approximately 44 months'}, {'measure': 'Anti-ianalumab antibodies (ADA)', 'description': 'Immunogenicity (IG) blood samples will be collected for anti-drug antibodies characterization. ADA of ianalumab will be summarized with descriptive statistics.', 'timeFrame': 'Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093'}, {'measure': 'Presence of anti-drug antibodies (ADA)', 'description': 'Immunogenicity (IG) blood samples will be collected to assess the presence ADA of ianalumab.', 'timeFrame': 'Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093'}]",7.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Strategic decision
NCT01487239,"Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects",[14C]-GDC-0980,['[14C]-GDC-0980'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteer,"Genentech, Inc.",2025-09-01T16:18:10.918298,True,,,,,"A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects",,['Healthy Volunteer'],[],,2011-12,2012-01,"[{'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: maximum observed concentration (Cmax)', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: time to maximum concentration (tmax)', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: area under the concentration-time curve from Hour 0 to the last measurable concentration (AUC0-t)', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: area under the concentration-time curve extrapolated to infinity', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: apparent terminal elimination half-life (t1/2)', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: apparent terminal phase elimination rate constant', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: apparent total clearance', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the plasma concentrations of total radioactivity and GDC-0980: apparent volume of distribution', 'timeFrame': 'up to approximately 5 weeks'}]","[{'measure': 'Pharmacokinetic based on the urine radioactivity concentrations: amount of drug excreted in the urine over sampling interval', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the urine radioactivity concentrations: renal clearance', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic based on the urine radioactivity concentrations: percent excreted in urine', 'timeFrame': 'up to approximately 5 weeks'}, {'measure': 'Pharmacokinetic parameters for the metabolites of [14C]-GDC-0980 calculated based on plasma, urine, and fecal concentration levels.', 'timeFrame': 'up to approximately 5 weeks'}]",12.0,18 Years,65 Years,FEMALE,True,INDUSTRY,0.0,4.0,ACTUAL,v2_robust,True,True,False,False,
NCT01839877,Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study,HIA DEBIRI + systemic FOLFOX,['HIA DEBIRI + systemic FOLFOX'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Colorectal Cancer With Non Resectable Hepatic Metastasis,Federation Francophone de Cancerologie Digestive,2025-09-01T16:18:10.918636,True,,,,,Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study,,['Colorectal Cancer With Non Resectable Hepatic Metastasis'],['Metastatic colorectal Cancer'],,2013-05,2019-01,"[{'measure': 'Progression-free Survival Rate at 9 Months', 'description': 'The primary endpoint was to evaluate the rate of patients alive without progression at 9 months after the start of treatment. Events to be considered for the endpoint were:\n\n* Progression : defined as radiological progression according to RECIST V1.1 criteria, as assessed by the investigator.\n* Death Patients who progressed or died (from any cause) within 9 months of starting treatment were considered as failure for the primary endpoint. The first event which occured will be taken into accoun', 'timeFrame': 'at 9 months after inclusion'}]","[{'measure': 'Overall Survival', 'description': 'It was defined as the time interval between the date of inclusion and the date of death (whatever the cause). Patients lost to follow-up or alive at the time of analysis were censored at the date of last news.', 'timeFrame': ""up to 4 years after patient's inclusion""}]",2.0,18 Years,,ALL,False,OTHER,1.0,58.0,ACTUAL,v2_robust,True,True,False,False,
NCT03761277,Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain,Preservative-free morphine sulfate (PFMS),['Preservative-free morphine sulfate (PFMS)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Non-malignant Pain,MedtronicNeuro,2025-09-01T16:18:10.918675,True,,,,,"Embrace TDD: Prospective, Multi-Center, Post Market Study to Evaluate Intrathecal (IT) Morphine as an Alternative to Systemic Opioids for the Treatment of Chronic, Intractable, Non-Malignant Primary Back Pain With or Without Leg Pain",,"['Chronic Non-malignant Pain', 'Chronic Pain', 'Pain, Back', 'Pain, Leg']","['Pain', 'Intrathecal', 'Targeted Drug Delivery (TDD)', 'Non-Malignant Pain', 'Systemic Opioids', 'Opioid Weaning', 'Pain Pump', 'Drug Pump', 'Medtronic Pump']",,2019-01-16,2021-12-06,"[{'measure': 'Number of Participants With Clinical Success at the 6-Month Visit', 'description': 'To characterize the number of subjects with Clinical Success at the 6-Month Visit. Clinical Success is defined as any of the following: 1) Reduced opioid-related side effects (at least a 20% reduction) with equal pain (less than 20% increase or decrease) 2) Reduced pain (at least a 20% reduction) with equal opioid-related side effects (less than 20% increase or decrease) 3) Reduced pain and reduced opioid-related side effects (at least a 20% reduction in both). The number of subjects with Clinical Success at the 6-Month Visit is presented.', 'timeFrame': 'Baseline to 6-Month Visit'}]","[{'measure': 'Visual Analog Scale (VAS) Pain Intensity at the 6-Month Visit', 'description': 'To demonstrate pain intensity scores (Visual Analog Scale, VAS) at the 6-Month Visit is non-inferior to VAS at Baseline, with a non-inferiority margin of 10mm. Pain was assessed using a Visual Analog Scale, ranging from 0-100, where 0 is no pain and 100 is the worst pain. The VAS is a 100mm line, with ""No pain"" on the left side of the line and ""Worst pain imaginable"" on the right side of the line. Subjects made a perpendicular mark on the VAS line that best describes their average pain in the last 24 hours. Change in VAS is calculated as 6-Months - Baseline, with a negative change indicating a reduction (i.e., improvement) in pain intensity.', 'timeFrame': 'Baseline to 6-Month Visit'}, {'measure': 'Numerical Opioid Side Effect (NOSE) Assessment Tool', 'description': 'To characterize the change in opioid-related side effects scores (NOSE) from Baseline to the 6-Month Visit. The Numerical Opioid Side Effect (NOSE) Assessment Tool is a tool to evaluate 10 opioid-related side effects using a 11-point numerical scale. Subjects are asked to evaluate each of the 10 opioid-related side effects on a scale of 0 - 10 with 0 being ""not present"" and 10 being ""as bad as you can imagine"". A total sum score can range from 0 - 100, where 0 is no opioid-related side effects and 100 is the worst opioid-related side effects. Change in NOSE is calculated as 6-Months - Baseline, with a negative change indicating a reduction (i.e., improvement) in opioid-related side effects.', 'timeFrame': 'Baseline to 6-Month Visit'}, {'measure': 'Number of Participants With Systemic Opioid Elimination Through the 6-Month Visit', 'description': 'To characterize the number of subjects who eliminate systemic opioids through the 6-Month Visit. Four drug tests for systemic opioid use are administered from intrathecal therapy initiation through the 6-Month Visit. If all of the available drug tests are negative for systemic opioid use, the subject is counted as eliminating systemic opioids through the 6-Month Visit. The number of subjects who eliminated systemic opioids through the 6-Month Visit is presented.', 'timeFrame': 'Baseline to 6-Month Visit'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,93.0,ACTUAL,v2_robust,True,True,False,False,
NCT02495077,Effects of Inhibiting Early Inflammation in Kidney Transplant Patients,Methylprednisolone,"['Solu-Medrol', 'Tylenol®', 'Benadryl', 'CellCept®', 'Mycophenolate Mofetil', 'Claritin®', 'Loratadine', 'FK-506', 'Diphenhydramine', 'MMF', 'Acetaminophen', 'Prograf®', 'Tacrolimus', 'FR-900506', 'Prednisone', 'Methylprednisolone']",16,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Kidney Transplant,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:10.918722,True,,,,,Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19),,['Kidney Transplant'],"['Kidney Transplantation', 'infliximab', 'Tissue Donors', 'Remicade', 'Induction Therapy', 'Deceased Donor Kidney Transplant Recipients']",,2015-11-02,2021-07-23,"[{'measure': 'The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups.', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the month 24 eGFR for each treatment group.', 'timeFrame': '24-Month post-transplantation'}]","[{'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR)', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of greater than or equal to IA with or without clinical symptoms within 6 months of transplant were determined to have met the endpoint. Severity is graded as IA, IB, IIA, IIB, or III, with IA being the mildest form of cellular rejection and III being the most severe form of cellular rejection.Criteria include: IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '6 month post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR).', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of greater than or equal to IA with or without clinical symptoms within 24 months of transplant were determined to have met the endpoint. Severity is graded as IA, IB, IIA, IIB, or III, with IA being the mildest form of cellular rejection and III being the most severe form of cellular rejection. Criteria include: IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'BANFF Grades of First Acute Cellular Rejections (ACR).', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of greater than or equal to IA with or without clinical symptoms within 6 months of transplant were determined to have met the endpoint. Severity is graded as IA, IB, IIA, IIB, or III, with IA being the mildest form of cellular rejection and III being the most severe form of cellular rejection.Criteria include: IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '6 month post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection.', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of borderline or greater than or equal to IA with or without clinical symptoms within 6 months of transplant were determined to have met the endpoint. Severity is graded as Borderline, IA, IB, IIA, IIB, or III, with borderline representing possible cellular rejection, IA being the mildest form of cellular rejection, and III being the most severe form of cellular rejection.Criteria include: Borderline-no intimal arteritis is present but foci of mild tubulitis; IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of borderline or greater than or equal to IA with or without clinical symptoms within 24 months of transplant were determined to have met the endpoint. Severity is graded as Borderline, IA, IB, IIA, IIB, or III, with borderline representing possible cellular rejection, IA being the mildest form of cellular rejection, and III being the most severe form of cellular rejection. Criteria include: Borderline-no intimal arteritis is present but foci of mild tubulitis; IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR)', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR within 6 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, or C4d staining positive.Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR).', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR within 24 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, or C4d staining positive. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR or suspicious for AMR within 6 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, C4d staining positive, or suspicious. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes; suspicious-when 2 of 3 factors for acute/active are present.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR.', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR or suspicious for AMR within 24 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, C4d staining positive, or suspicious. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes; suspicious-when 2 of 3 factors for acute/active are present', 'timeFrame': '24 months post-transplantation'}, {'measure': 'BANFF Grades of First AMR.', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR within 6 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, or C4d staining positive. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With BANFF Chronicity Scores > or Equal 2 on the 24 Month Biopsy.', 'description': 'The Banff 2013 classification involves scoring numerous characteristics of renal biopsy specimens. The ci (interstitial fibrosis) and ct (tubular atrophy) scores are two such characteristics. The scores can take values of 0, 1, 2, or 3 for each characteristic (ci and ct), indicating increasing severity of disease as the scores increase. Participants are considered to have met this endpoint if their ci + ct score on the 24 month biopsy summed to be \\> or equal to 2.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Change in BANFF Chronicity Scores Between Implantation and the 24 Month Biopsy.', 'description': 'The Banff 2013 classification involves scoring numerous characteristics of renal biopsy specimens. The ci (interstitial fibrosis) and ct (tubular atrophy) scores are two such characteristics. The scores can take values of 0, 1, 2, or 3 for each characteristic (ci and ct), indicating increasing severity of disease as the scores increase. For this endpoint, the sum of ci+ct scores from the implantation biopsy was subtracted from the sum of the ci+ct scores from the month 24 biopsy and the difference between the two time points was classified as 0, 1, 2, or 3+. Higher values of this difference indicate more severe disease.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.', 'description': 'Biopsies were read by the local pathologist at the hospital where the participant was a patient. These local reads informed clinical care for the participant, which may or may not include prescribing/administering medication to the participant to help with clinical concerns or findings noted on a biopsy. Participants were considered to have met this endpoint if they have a report of receiving treatment for clinical or biopsy-proven rejection during the first 6 months post-transplant.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.', 'description': 'Biopsies were read by the local pathologist at the hospital where the participant was a patient. These local reads informed clinical care for the participant, which may or may not include prescribing/administering medication to the participant to help with clinical concerns or findings noted on a biopsy. Participants were considered to have met this endpoint if they have a report of receiving treatment for clinical or biopsy-proven rejection during the 24 month post-transplant follow-up.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Change in eGFR Between 3 Months and 24 Months as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 3 and 24 was calculated as the month 24 eGFR minus the month 3 eGFR for each participant. A window of +/- 14 days was used for month 3 and +/- 1 month was used for month 24.', 'timeFrame': '3 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between 3 Months and 24 Months as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 3 and 24 was calculated as the month 24 eGFR minus the month 3 eGFR for each participant. A window of +/- 14 days was used for month 3 and +/- 1 month was used for month 24.', 'timeFrame': '3 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. Post-transplant nadir was defined as the lowest value of eGFR from the first 6 months post-transplant. The change in eGFR between nadir and month 24 was calculated as the month 24 eGFR minus the nadir eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. Post-transplant nadir was defined as the lowest value of eGFR from the first 6 months post-transplant. The change in eGFR between nadir and month 24 was calculated as the month 24 eGFR minus the nadir eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between 6 Months and 24 Months as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 6 and 24 was calculated as the month 24 eGFR minus the month 6 eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between 6 Months and 24 Months as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 6 and 24 was calculated as the month 24 eGFR minus the month 6 eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'eGFR Values as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Day 7 post-transplantation'}, {'measure': 'eGFR Values as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Days 30, 60, and 180 post-transplantation'}, {'measure': 'eGFR Values as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Day 7 post-transplantation'}, {'measure': 'eGFR Values as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Days 30, 90, and 180 post-transplantation'}, {'measure': 'Percent of Participants With Death or Graft Failure.', 'description': 'Participants who died or experienced graft failure were considered to have met this endpoint. Graft failure was defined as the need for post-transplant dialysis for more than 56 days.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Only Graft Failure.', 'description': 'Participants who experienced graft failure were considered to have met this endpoint. Graft failure was defined as the need for post-transplant dialysis for more than 56 days.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants That Required at Least One Dialysis Treatment.', 'description': 'Dialysis within the first week post-transplant is used in the setting of delayed graft function (DGF). Participants are considered to have had DGF if they had at least one dialysis treatment in the first week post-transplant.', 'timeFrame': '1 week post-transplantation'}, {'measure': 'Number of Dialysis Sessions.', 'description': 'The number of dialysis sessions a person had during their first 8 weeks post-transplant was used for this endpoint.', 'timeFrame': '8 weeks post-transplantation'}, {'measure': 'Duration of Delayed Graft Function (DGF), Defined as Time From Transplantation to the Last Required Dialysis Treatment.', 'description': 'Participants are considered to have had DGF if they had at least one dialysis treatment in the first week post-transplant. For this endpoint, duration was calculated as the date of last post-transplant dialysis treatment minus the date of the first post-transplant dialysis treatment.', 'timeFrame': 'First post-transplant dialysis treatment to last post-transplant dialysis treatment'}, {'measure': 'Percent of Participants With Primary Non-Function (PNF), Defined as Dialysis-dependency for More Than 3 Months.', 'description': 'Post-transplant dialysis is sometimes required in the setting of kidney transplant. If such dialysis continues for more than 3 months, the participant is considered to have PNF and, as such, meets this endpoint definition.', 'timeFrame': 'Transplantation through at least month 3 up to month 24'}, {'measure': 'Change From Baseline (Immediately After Surgery) in Serum Creatinine.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. eGFR values from 24, 48, and 72 hours post-transplant (i.e., days 1, 2, and 3) were used to generate an estimate of the serum creatinine at each time point of interest for each treatment group.', 'timeFrame': '24, 48 and 72 hours post-transplantation'}, {'measure': 'Days From Transplantation Until Event (ACR, AMR, or Hospitalization for Infection and/or Malignancy)', 'description': 'Participants are considered to have met this endpoint if they experienced biopsy-proven T-cell mediated rejection (ACR) or antibody mediated rejection (AMR) based on central pathology reading or were hospitalized for infection and/or malignancy. For participants who met one or more of these three components, the earliest event date of the three components was used as the time of meeting the endpoint. Participants who did not meet any of the three components were censored at their last date of follow-up. Event (or censor) day was calculated as event (or censor) date minus transplant date.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'The Percent of Participants With a Serum Creatinine of More Than 3 mg/dL.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. This endpoint is ascertaining slow graft function in the immediate days post-transplant. A participant was considered to have met this endpoint if their day 5 serum creatinine was greater than 3 mg/dL.', 'timeFrame': 'Day 5 post-transplantation'}, {'measure': 'Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 2 Divided by he First Creatinine After Surgery', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 2 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function.', 'timeFrame': 'Day 2 post-transplantation'}, {'measure': 'Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 5 Divided by the First Creatinine After Surgery.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 5 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function.', 'timeFrame': 'Day 5 post-transplantation'}, {'measure': 'The Percent of Participants Whose Day 5 Serum CRR Was Less Than 70%.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 5 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function. A participant was considered to have met this endpoint if their day 5 serum CRR was less than 70%.', 'timeFrame': 'Day 5 post-transplantation'}, {'measure': 'The Percent of Participants Whose Day 2 Serum CRR Was Less Than 30%.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 2 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function. A participant was considered to have met this endpoint if their day 2 serum CRR was less than 30%.', 'timeFrame': 'Day 2 post-transplantation'}, {'measure': 'The Percent of Participants Who Need Dialysis After Week 1.', 'description': 'Participants who needed dialysis after the first week post-transplant were considered to have met this endpoint.', 'timeFrame': '1 week to 24 months post-transplantation'}, {'measure': 'Percent of Participants With de Novo DSA.', 'description': ""Donor specific antibody (DSA) can be formed post-transplant as part of the recipient's alloimmune response to the transplanted organ. DSA was determined by a central laboratory. Participants with newly developed DSA (i.e., de novo) following transplant were considered to have met this endpoint."", 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Any Infection Requiring Hospitalization or Resulting in Death.', 'description': 'Participants were considered to have met this endpoint if they had an infection that required hospitalization or resulted in death.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Mycobacterial or Fungal Infections', 'description': 'Participants were considered to have met this endpoint if they had at least one mycobacterial of fungal infection.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With CMV Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site', 'description': 'Participants were considered to have met this endpoint if they had a reported case of CMV viremia that required a change in their existing immunosuppression or the use of anti-viral therapy.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With BK Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site.', 'description': 'Participants were considered to have met this endpoint if they had a reported case of BK viremia that required a change in their existing immunosuppression or the use of anti-viral therapy.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Malignancy.', 'description': 'Participants were considered to have met this endpoint if they had a reported case of malignancy.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Impaired Wound Healing Manifested by Wound Dehiscence, Wound Infection, or Hernia at the Site of the Transplant Incision', 'description': 'Participants were considered to have met this endpoint if they had a reported case of impaired wound healing at the site of the transplant incision manifested by one wound dehiscence, wound infection, or hernia.', 'timeFrame': '24 months post-transplantation'}]",46.0,18 Years,,ALL,False,NIH,2.0,290.0,ACTUAL,v2_robust,True,True,False,False,
NCT01133977,E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma,Lenvatinib,"['Dacarbazine', 'E7080', 'Lenvatinib', 'Dacarbazine (DTIC)-Dome']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Stage IV Melanoma,Eisai Inc.,2025-09-01T16:18:10.918949,True,,,,,"An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.",,['Stage IV Melanoma'],[],,2010-04,2014-11,"[{'measure': 'Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)', 'description': 'DLTs were defined as clinically significant adverse events (AEs) occurring less than or equal to 21 days after commencing study treatment and considered by the Investigator to be possibly or probably related to study treatment.', 'timeFrame': 'From Day 1 through 21 days (one cycle)'}, {'measure': 'Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)', 'description': 'Safety assessments consisted of monitoring and recording all AEs, including all Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) grades, and SAEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. Details of AEs and SAEs are provided in the reported adverse event section.', 'timeFrame': 'From signing of informed consent up to 30 days after the last dose, up to approximately 2 years'}]","[{'measure': 'Progression Free Survival (PFS) (for Phase 2)', 'description': ""PFS was defined as the time from the date of randomization of a participant until (1) the date of first documented progression of such participant's disease based on Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST v. 1.1) or (2) the date of such participant's death due to any cause. Progression was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions, based on Investigator assessment according to RECIST 1.1. If missing assessments, imputed dates were used in the analysis."", 'timeFrame': 'From the date of randomization until the date of disease progression or death (whichever was earlier) or up to approximately 2 years'}]",3.0,18 Years,,ALL,False,INDUSTRY,1.0,97.0,ACTUAL,v2_robust,True,True,False,True,
NCT01005875,Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma,Sorafenib,"['Sorafenib', 'BAY 43-9006', 'Nexavar']",3,INTERVENTIONAL,['NA'],,TERMINATED,Hepatocellular Carcinoma,University of Alabama at Birmingham,2025-09-01T16:18:10.918960,True,,,,,RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma,,"['Hepatocellular Carcinoma', 'Liver Cancer']","['Hepatocellular carcinoma', 'HCC', 'Liver Cancer', 'adult primary hepatocellular carcinoma']","Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.",2009-11,2013-06,"[{'measure': 'Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma', 'description': 'Number of subjects experiencing a Grade 5 toxicity related to SBRT and sorafenib', 'timeFrame': 'between baseline and 3 years'}]","[{'measure': 'The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Tumor Volume', 'description': 'mean tumor volume at baseline, 4 weeks and 10 weeks after start of treatment', 'timeFrame': 'baseline, 4 weeks and 10 weeks'}, {'measure': 'The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Ktrans (Volume Transfer Coefficient).', 'description': 'The initial mean Ktrans at baseline, 4 weeks and 10 week. K trans is used to describe the uptake of gadolinium contrast in tissue.', 'timeFrame': 'baseline, 4 weeks and 10 weeks'}, {'measure': 'The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Kep. Kep Describes How Fast Contrast Can Redistribute in Tissue.', 'description': 'The Kep as measures by MRI at baseline, 4 weeks after baseline, and 10 weeks after baseline.', 'timeFrame': 'baseline, 4 weeks after baseline and 10 weeks post baseline'}, {'measure': 'The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).', 'description': 'the measured ADC at baseline, 4 weeks after baseline and then 10 weeks after baseline. ADC quantifies the motion of water protons from an MRI.', 'timeFrame': 'baseline, 4 weeks post baseline, 10 weeks post baseline'}]",5.0,19 Years,,ALL,False,OTHER,1.0,5.0,ACTUAL,v2_robust,True,False,True,True,"Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes."
NCT02390375,Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia,DW-0929,"['DW-0929', 'Rosuvastatin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hypercholesterolemia,"Daewon Pharmaceutical Co., Ltd.",2025-09-01T16:18:10.918970,True,,,,,,,['Hypercholesterolemia'],[],,2014-11,2016-05,"[{'measure': 'LDL-C level', 'timeFrame': '8 weeks'}]",[],1.0,19 Years,,ALL,False,INDUSTRY,0.0,348.0,ACTUAL,v2_robust,True,True,False,False,
NCT00882375,Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy,Nicotine,"['NRT', 'Nicotine', 'Placebo']",3,INTERVENTIONAL,['NA'],,COMPLETED,Smoking Cessation,McNeil AB,2025-09-01T16:18:10.918986,True,,,,,"Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy. A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 52 Week Study in Smokers Motivated to Quit.",,['Smoking Cessation'],['Smoking Cessation'],,2009-03,2010-06,"[{'measure': 'Self-reported continuous abstinence from smoking verified by exhaled CO levels of less than 10 ppm.', 'timeFrame': 'at weeks 2, 6, 24 and 52'}]","[{'measure': 'Self-reported continuous abstinence from smoking, verified by exhaled CO levels of less than 10 ppm.', 'timeFrame': 'weeks 2, 4, 8, 12, 16, and 20'}, {'measure': 'Self-reported 7-day point prevalence abstinence from smoking verified by exhaled CO levels of less than 10 ppm.', 'timeFrame': 'weeks 4, 6, 8, 12, 16, 20, 24, and 52'}, {'measure': 'Ratings of craving/urge to smoke and withdrawal symptoms.', 'timeFrame': 'baseline to 24 weeks'}, {'measure': 'Cotinine levels in saliva.', 'timeFrame': 'baseline, and weeks 2, 6, 12 and 24'}, {'measure': 'Product acceptability', 'timeFrame': 'weeks 1, 6 and 12'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,479.0,ACTUAL,v2_robust,True,True,False,False,
NCT03523975,"Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",Venetoclax,"['Lenalidomide', 'Venetoclax', 'Rituximab']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Mantle Cell Lymphoma,City of Hope Medical Center,2025-09-01T16:18:10.919002,True,,,,,"Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",,['Mantle Cell Lymphoma'],[],,2018-12-24,2027-06-24,"[{'measure': 'Maximum Tolerated Dose (MTD) of the combination of lenalidomide, venetoclax and rituximab', 'timeFrame': '42 Days'}]","[{'measure': 'The proportion of patients with a Complete Response (CR)', 'description': 'Response will be assessed by the IRC (Immune-related Response Criteria) and the investigator on the basis of physical examinations and PET and CT scans using the Lugano 2014 criteria, taking into account results of bone marrow examinations for patients with bone marrow involvement at screening', 'timeFrame': 'Up to 4 Years'}, {'measure': 'The proportion of patients that respond to treatment', 'description': 'The proportion of patients who achieve either partial or complete response by PET, CT and marrow. Response will be assessed by the IRC and the investigator on the basis of physical examinations and PET and CT scans using the Lugano 2014 criteria, taking into account results of bone marrow examinations for patients with bone marrow involvement at screening', 'timeFrame': 'Up to 4 Years'}]",3.0,18 Years,,ALL,False,OTHER,0.0,28.0,ESTIMATED,v2_robust,True,False,False,False,
NCT03864575,"An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced "" Cold "" Solid Tumors",Celecoxib 400 mg,"['Nivolumab 240 mg q2w', 'Celecoxib 400 mg']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Metastatic Cancer,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,2025-09-01T16:18:10.919080,True,,,,,"NICE-COMBO: An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced "" Cold "" Solid Tumors",,['Metastatic Cancer'],"['Nivolumab', 'Celecoxib']",,2019-08-15,2021-06-15,"[{'measure': 'objective response rate', 'description': 'To evaluate the objective response rate (ORR) of Celecoxib in combination with anti-PD1 antibodies', 'timeFrame': 'at week 12 from onset of treatment'}]","[{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'All the patients that will receive at least one dose of nivolumab and celecoxib are assess for toxicity endpoint. All adverse events will be recorded and graded based on the CTCAE v4.0 scale.\n\nantibodies', 'timeFrame': 'from first dose to day 28 post last dose'}, {'measure': 'Efficacy - Duration of response (DOR)', 'description': 'defined as the time from earliest date of CR or PR (as determined by investigator assessment of radiographic disease burden per RECIST v1.1) until the earliest date of disease progression or death, due to any cause, if occurring sooner than disease progression.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months'}, {'measure': 'Efficacy - Time to response (TTR)', 'description': 'defined as the time from the date of first dose of study drug until the time of the earliest date of CR or PR (as determined by investigator assessment of radiographic disease burden per RECIST v1.1.', 'timeFrame': 'From onset of treatment to response of cancer through study completion, an average of 12 months is expected'}, {'measure': 'Disease control rate (DCR)', 'description': 'defined as the percentage of subjects having CR, PR, or stable disease (SD) for at least 8 weeks, as determined by investigator assessment of radiographic disease as per RECIST v1.1.', 'timeFrame': 'at week 12 from onset of treatment'}, {'measure': 'Progression-free survival (PFS)', 'description': 'defined as the time from the date of first dose of study drug until the earliest date of disease progression (as determined by investigator assessment of radiographic disease burden per RECIST v1.1), or death due to any cause, if occurring sooner than progression.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death, whichever comes first, assessed up to 60 months'}, {'measure': 'Overall survival (OS)', 'description': 'defined as the time from the date of first dose of study drug until death, due to any cause.', 'timeFrame': 'From date of randomization until the date of death, assessed up to 60 months'}]",7.0,18 Years,,ALL,False,OTHER,0.0,68.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05077475,A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers,C52R1H Tab. and C52R2 Tab.,"['Test Drug', 'C52R1H Tab. and C52R2 Tab.', 'Reference Drug', 'AJU-C52L']",4,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Hypertension,"AJU Pharm Co., Ltd.",2025-09-01T16:18:10.919172,True,,,,,"An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of AJU-C52L Compared to Coadministration of C52R1H With C52R2 in Healthy Adult Volunteers",,['Hypertension'],[],,2021-09-24,2022-04-30,"[{'measure': 'AUCt of AJU-C52', 'description': 'Area under the concentration-time curve from time zero to time', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours'}, {'measure': 'Cmax of AJU-C52', 'description': 'Cmax: Maximum plasma concentration of the drug', 'timeFrame': 'Pre-dose (0 hour), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours'}]",[],2.0,19 Years,,ALL,True,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00242775,"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg",Budesonide/formoterol Turbuhaler,"['Budesonide/formoterol Turbuhaler', 'Salmeterol/fluticasone Diskus', 'Symbicort']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Asthma,AstraZeneca,2025-09-01T16:18:10.919368,True,,,,,"Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).",,['Asthma'],['Asthma'],,2005-05,2006-05,[{'measure': 'Time to first severe asthma exacerbation'}],"[{'measure': 'Number of severe asthma exacerbations'}, {'measure': 'Mild asthma exacerbations'}, {'measure': 'FEV1'}, {'measure': 'Patient-reported outcomes regarding disease status (inlc. PEF), collected via questionnaires and diaries'}, {'measure': 'Healthcare utilization'}, {'measure': 'Safety (adverse events)'}, {'measure': '- all variables assessed over the 6 months treatment period'}]",8.0,12 Years,,ALL,False,INDUSTRY,0.0,2100.0,,v2_robust,True,True,False,True,
NCT00648375,Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder,Propanolol,"['Inderal', 'Propanolol', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Post-Traumatic Stress Disorder,Weill Medical College of Cornell University,2025-09-01T16:18:10.919381,True,,,,,Efficacy of Propanolol for Treatment of Posttraumatic Stress Disorder,,['Post-Traumatic Stress Disorder'],"['Propanolol', 'Beta Blockers', 'Reconsolidation', 'Cognitive Therapy', 'PTSD']",inadequate recruitment,2003-12,2009-09,"[{'measure': 'Change in Severity of PTSD Symptoms Measured by Clinician Administered PTSD Scale for DSM-IV (CAPS-DX)', 'description': 'Scores range from 0-70, higher scores represent more severe symptoms', 'timeFrame': 'Measured at Week 0, 2,4,6,8,10,12,14'}]","[{'measure': 'Change in Depression Measured by Beck Depression Inventory (BDI)', 'description': 'Scores range from 0-30, higher scores represent more severe symptoms', 'timeFrame': 'Measured at Weeks 0,2,4,6,8,10,12, 14'}, {'measure': 'Change in Post-traumatic Scale-Self Score (PS-SR)', 'description': 'This is a 17-item self-report scale. Scores range from 0-51, higher scores represent more severe symptoms.', 'timeFrame': 'Measured at Weeks 0,2,4,6,8,10,12, 14'}, {'measure': 'Change in Brief Symptoms Inventory-Short Form (BSI-SF)', 'description': 'BSI-SF is an 18 item scale used for a global score of general distress. Scores range from 0-72, higher scores represent more severe symptoms', 'timeFrame': 'Measured at Weeks 0,2,4,6,8,10,12, 14'}]",4.0,18 Years,50 Years,ALL,False,OTHER,1.0,12.0,ACTUAL,v2_robust,True,False,True,False,inadequate recruitment
NCT06118957,Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery,Enoxaparin,['Enoxaparin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Thromboembolism,University of Utah,2025-09-01T16:18:10.919429,True,,,,,A Pilot Randomized Controlled Trial of Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery,,['Thromboembolism'],"['Thromboembolism', 'Enoxaparin', 'Cesarean delivery']",,2023-10-11,2024-07-01,"[{'measure': 'Rate of eligible individuals enrolled and retained through full study procedures', 'description': 'Feasibility as defined by ≥35% enrollment of eligible individuals and retention ≥85% of enrolled individuals through all study procedures', 'timeFrame': '6 Weeks'}]","[{'measure': 'Rate of venous thromboembolism', 'description': 'Objectively (by imaging) diagnosed deep vein thrombosis or pulmonary embolism', 'timeFrame': '6 Weeks'}, {'measure': 'Rate of wound hematoma or infection', 'description': 'Clinically diagnosed', 'timeFrame': '6 Weeks'}, {'measure': 'Rate of bleeding complications', 'description': 'Clinically diagnosed as readmission to hospital for bleeding or delayed postpartum hemorrhage (\\>24 hours after delivery)', 'timeFrame': '6 Weeks'}]",4.0,18 Years,,FEMALE,True,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT06014957,Comparison of Hemodynamic Effect Between the Spinal Anesthesia and Saddle Block Using Levobupivacaine During Transurethral Resection of the Prostate in Cardiac Elderly Patients,spinal anesthesia,"['spinal anesthesia', 'saddle block']",2,INTERVENTIONAL,['NA'],,RECRUITING,TURP Syndrome,New Valley University,2025-09-01T16:18:10.919449,True,,,,,Comparison of Hemodynamic Effect Between the Spinal Anesthesia and Saddle Block Using Levobupivacaine During Transurethral Resection of the Prostate in Cardiac Elderly Patients: A Randomized Clinical Trial,,"['TURP Syndrome', 'Spinal Anesthesia']",[],,2023-08-30,2023-12,"[{'measure': 'mean arterial blood pressure', 'timeFrame': '24 hours'}]",[],1.0,65 Years,80 Years,MALE,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02250157,"A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies",Oratecan,"['Oratecan', 'Camptosar, HM30181']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Solid Tumor,"Athenex, Inc.",2025-09-01T16:18:10.919522,True,,,,,"A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies",,['Solid Tumor'],[],,2014-09-05,2020-03-04,"[{'measure': 'Number of participants with dose limiting toxicities', 'timeFrame': '2 years'}]","[{'measure': 'Number of patients with adverse events', 'timeFrame': '2 years'}, {'measure': 'Area under the plasma concentration versus time curve', 'description': 'Determine the amount of Oratecan in participants blood (pharmacokinetics)', 'timeFrame': '2 years'}, {'measure': 'Tumor measurements per RECIST 1:1', 'description': 'Assess preliminary anti-tumor activity', 'timeFrame': '2 years'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,35.0,ACTUAL,v2_robust,True,True,False,True,
NCT04976257,Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion,Gallium Ga-labeled PSMA-11,"['Gallium Ga-labeled PSMA-11', '68Ga-PSMA-11']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Prostate Adenocarcinoma,"Ryan Kohlbrenner, MD",2025-09-01T16:18:10.919531,True,,,,,Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA Radioligand Infusions in Treatment-Naïve Prostate Cancer Patients,,"['Prostate Adenocarcinoma', 'Prostate Carcinoma', 'Stage IIC Prostate Cancer AJCC v8', 'Stage III Prostate Cancer AJCC v8', 'Stage IIIA Prostate Cancer AJCC v8', 'Stage IIIB Prostate Cancer AJCC v8', 'Stage IIIC Prostate Cancer AJCC v8', 'Stage IV Prostate Cancer AJCC v8', 'Stage IVA Prostate Cancer AJCC v8', 'Stage IVB Prostate Cancer AJCC v8']",['Ga68-PSMA-11'],,2021-10-13,2023-03-22,"[{'measure': 'Maximum standardized uptake value (SUVmax)', 'description': 'A two-sided paired t-test will determine whether the ipsilateral SUVmax values obtained during selective arterial 68Ga-PSMA-11 infusions are greater than those obtained during venous infusions. A similar paired analysis will be made during arterial infusions to compare tumoral regions of interest (ROIs) ipsilateral and contralateral to the side of the infusion. Means/medians, ranges/standard deviations will be calculated for each endpoint.', 'timeFrame': 'Day 1 and from Day 2 up to Day 15 (2 days total)'}]","[{'measure': 'Comparison of Mean SUV (SUVmean)', 'description': 'Paired t-tests will determine whether SUVmean is different for intra-arterial (IA) time activity curves (TACs) when compared to intravenous (IV) TACs. Means/medians, ranges/standard deviations will be calculated for each endpoint.', 'timeFrame': 'Day 1 and from Day 2 up to Day 15 (2 days total)'}, {'measure': 'Comparison of Time to SUVmax (TSUV)', 'description': 'Paired t-tests will determine whether TSUV is different for IA TACs when compared to IV TACs. Means/medians, ranges/standard deviations will be calculated for each endpoint.', 'timeFrame': 'Day 1 and from Day 2 up to Day 15 (2 days total)'}, {'measure': 'Comparison of Area under the curve (AUC)', 'description': 'Paired t-tests will determine whether AUCs are different for IA TACs when compared to IV TACs. Means/medians, ranges/standard deviations will be calculated for each endpoint.', 'timeFrame': 'Day 1 and from Day 2 up to Day 15 (2 days total)'}, {'measure': 'Comparison of Rate of 68Ga-PSMA-11 uptake', 'description': 'To assess whether the rate of uptake is significantly different with selective arterial infusion, a two-sided paired t-test will compare the slopes for Selective arterial infusion, tumor ipsilateral to the side of radiotracer injection (IAIpsi) curves and Intravenous infusion, tumor ipsilateral to the side of corresponding arterial injection (IVIpsi) curves during each of the nine time intervals. Selective arterial infusion, tumor contralateral to the side of radiotracer injection (IACont) slopes will be similarly compared to those acquired from corresponding Intravenous infusion, tumor contralateral to the side of corresponding arterial injection (IVCont) data. Means/medians, ranges/standard deviations will be calculated for each endpoint.', 'timeFrame': 'Day 1 and from Day 2 up to Day 15 (2 days total)'}, {'measure': 'Comparison of Time to early saturation effects', 'description': 'Specific to the IAIpsi TACs, the time to early saturation effects (Tese) will represent the time at which the second derivative of the curve becomes negative (i.e. when concavity in the curve is first noted). For the purposes of Tese, the aforementioned curve partitioning method will not be used. Descriptive statistics of Tese will be established, along with statistics for the corresponding mass dose administered (MDese) at Tese. Means/medians, ranges/standard deviations will be calculated for each endpoint.', 'timeFrame': '1 day'}, {'measure': 'Comparison of Mass dose at saturation', 'description': 'Descriptive statistics of Tese will be established, along with statistics for the corresponding mass dose administered (MDese) at Tese. Means/medians, ranges/standard deviations will be calculated for each endpoint.', 'timeFrame': 'Day 1 and from Day 2 up to Day 15 (2 days total)'}, {'measure': 'Comparison of Mean SUV during 15-minute washout (SUVwashout)', 'description': 'The mean SUVwashout and its standard deviation will be calculated for the 15-minute post-injection periods.', 'timeFrame': '1 day'}]",8.0,18 Years,80 Years,MALE,False,OTHER,1.0,5.0,ACTUAL,v2_robust,True,True,False,False,
NCT00456157,"A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee",Intra-articular Injection of OP-1 to affected knee,['Intra-articular Injection of OP-1 to affected knee'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Osteoarthritis of the Knee,Stryker Biotech,2025-09-01T16:18:10.919614,True,,,,,"A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular Osteogenic Protein-1 OP-1 in Subjects With Osteoarthritis of the Knee",,['Osteoarthritis of the Knee'],"['Osteoarthritis', 'Osteophytes', 'Knee', 'Intra-articular', 'OP-1']",,2007-03,2008-11,[{'measure': 'Determine safety and tolerability as well as dose limiting toxicity (DLT) and maximal tolerated dose (MTD) of intraarticular OP-1'}],"[{'measure': 'Determine the proportion of patients with 20%, 50%, and 70% improvement in the Western Ontario and McMaster (WOMAC) pain, and function subscales at 4, 8, 12, and 24 weeks.'}, {'measure': 'Determine the change from baseline to 4, 8, 12, and 24 weeks in the pain, other symptoms, function in daily living, function in sports and recreation and knee related quality of life subscales of the Knee and Osteoarthritis Outcome Score (KOOS) survey.'}, {'measure': ""Determine the change from baseline to 4, 8, 12, and 24 weeks in the patient's global assessment and disease status and physician's global assessment and disease status using the 100-mm visual-analogue scale (VAS).""}, {'measure': 'Quality of life measured by the Short Form (SF)-36 at baseline and 4, 8,12 and 24 weeks'}, {'measure': 'Amount of rescue medications required at 4, 8, 12 and 24 weeks'}, {'measure': 'Knee cartilege and surrounding saft tissue changes by magnetic resonance imaging (MRI) of the index knee and proteoglycan content by delayed gadolinium enhanced MRI of cartilage (dGEMRIC)'}, {'measure': 'Analysis of efficacy data using the Outcome Measures in Arthritis Clinical Trials -Osteoarthritis Research Society (OMERACT-OARSI) Responder Index'}, {'measure': 'Blood levels of OP-1'}]",9.0,40 Years,,ALL,False,INDUSTRY,0.0,33.0,ESTIMATED,v2_robust,True,True,False,True,
NCT05702957,Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome,letrozole 2.5mg-7.5mg,"['tab lezra 2.5-7.5mg', 'letrozole 2.5mg-7.5mg', 'Clomiphene Citrate 50mg-150mg', 'tab clomid 50-150mg']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Polycystic Ovary Syndrome,"Services Institute of Medical Sciences, Pakistan",2025-09-01T16:18:10.919621,True,,,,,Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome: Randomised Control Trial,,"['Polycystic Ovary Syndrome', 'Infertility']","['polycystic ovary syndrome', 'Infertility', 'Clomiphene citrate', 'Letrozole']",,2016-09,2019-12,"[{'measure': 'Pregnancy rate', 'description': 'Total number of patients conceived after treatment', 'timeFrame': '5th week of cycle when periods missed'}]","[{'measure': 'ovulation rate', 'description': 'when follicle achieved diameter of 18-20mm,HCG given,ovulation confirmed by day 21 progesterone.', 'timeFrame': '10-22 day of cycle'}, {'measure': 'Live birth rate', 'description': 'total number of live births divided by total number of patients in a group', 'timeFrame': '9 months'}, {'measure': 'Monofollicular development', 'description': 'when only one follicle achieve diameter of greater than or equal to 18mm', 'timeFrame': '10-12 day of menstrual cycle'}, {'measure': 'Multifollicular development', 'description': 'when 2 or more follicles achieve diameter of \\>12mm', 'timeFrame': '10-12 day of menstrual cycle'}, {'measure': 'Miscarraige', 'description': 'spontaneous loss of pregnancy before 24 weeks of gestation', 'timeFrame': 'Less than 24weeks'}, {'measure': 'Adverse effects', 'description': 'hot flushes.', 'timeFrame': 'first 10days of cycle'}, {'measure': 'Adverse effects', 'description': 'Fatigue and dizziness', 'timeFrame': 'first 10days of cycle'}]",8.0,18 Years,40 Years,FEMALE,True,OTHER_GOV,0.0,220.0,ACTUAL,v2_robust,True,True,False,True,
NCT04458857,A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age,Fremanezumab,"['Fremanezumab', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Migraine,"Teva Branded Pharmaceutical Products R&D, Inc.",2025-09-01T16:18:10.919638,True,,,,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age",,['Migraine'],['episodic migraine'],,2020-07-15,2024-03-13,"[{'measure': 'Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug', 'description': 'A migraine day was defined as a day with any of the following: A day (0:00 to 23:59) with at least 2 hours of headache with ≥2 migraine symptom(s) or day (0:00 to 23:59) demonstrating a headache treated with migraine medications (e.g., non-steroidal anti-inflammatory drugs \\[NSAIDs\\], paracetamol etc.), or a headache associated with aura. Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over 12-week period/number of days with assessments recorded in electronic diary (e-diary) for 12-week period) \\* 28. Least square (LS) mean was calculated using analysis of covariance (ANCOVA). The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug and had at least 10 days of diary entries postbaseline for efficacy assessments on primary endpoint. Efficacy analysis was planned to be collected and evaluated combined for both fremanezumab dose treatment groups.', 'timeFrame': 'Baseline (Day -28 to Day -1), up to Week 12'}]","[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Baseline up to Month 3'}, {'measure': 'Number of Participants With Shift From Baseline to Last Assessment in Electrocardiogram (ECG) Findings (Assessed by Investigator)', 'description': ""The number of participants with a shift from Baseline (Normal, Abnormal CS \\[Clinically Significant\\], or Abnormal NCS \\[Not Clinically Significant\\]) in any of the following ECG parameters is reported by treatment group: Heart rate, PR interval, QRS interval, RR interval, QT interval, QT interval corrected using the Bazett's formula (QTcB), and QT interval corrected using the Fridericia formula (QTcF). Last assessment was defined as the last observed postbaseline interpretation. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section."", 'timeFrame': 'Baseline to last assessment (up to Month 3)'}, {'measure': 'Number of Participants With Shift From Baseline to Last Assessment in ECG Findings (Assessed by Cardiologist)', 'description': 'The number of participants with a shift from Baseline (Normal or Abnormal) in any of the following ECG parameters is reported by treatment group: Heart rate, PR interval, QRS interval, RR interval, QT interval, QTcB, and QTcF. Last assessment was defined as the last observed postbaseline interpretation. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Baseline to last assessment (up to Month 3)'}, {'measure': 'Number of Participants With Any One or More Potentially Clinically Significant Vital Signs Abnormalities', 'description': 'Potentially clinically significant abnormal vital signs findings included any one of the following: Pulse rate ≥120 beats per minute (bpm) and increase from baseline of ≥15 bpm, or ≤50 bpm and decrease from baseline of ≥15 bpm; Systolic blood pressure ≤85 millimeters of mercury (mmHg) and decrease from baseline of ≥20 mmHg; Diastolic blood pressure ≥100 mmHg and increase from baseline of ≥15 mmHg; Respiratory rate \\<15 breaths/minute. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Baseline up to Month 3'}, {'measure': 'Number of Participants With Potentially Clinically Significant Abnormal Laboratory (Serum Chemistry, Hematology, Coagulation, and Urinalysis) Results', 'description': 'Serum chemistry tests with potentially clinically significant abnormal findings included: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) both ≥2\\*upper limit of normal (ULN); and bilirubin ≥34.2 micromole/liter (umol/L). Hematology tests with potentially clinically significant abnormal findings included: hemoglobin ≤100 grams (g)/L, leukocytes ≤3\\*10\\^9 cells/L, neutrophils ≤1\\*10\\^9 cells/L, eosinophils/leukocytes ≥10%, and platelets ≥700\\*10\\^9 cells/L or ≤75\\*10\\^9 cells/L. Coagulation parameter test with potentially clinically significant abnormal findings included: prothrombin international normalized ratio (INR) \\>1.5. Urinalysis laboratory tests with potentially clinically significant abnormal findings included: urine protein ≥2 units (U) increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Baseline up to Month 3'}, {'measure': 'Number of Participants With Abnormal Physical Examination Findings as Identified by the Investigator', 'description': 'A complete physical examination included the following organ systems: general appearance; head, eyes, ears, nose, and throat (HEENT); chest and lungs; heart; abdomen; musculoskeletal; skin; lymph nodes; and neurological. Only the organ systems with abnormal physical findings in at least one treatment group have been reported. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Baseline up to Month 3'}, {'measure': 'Number of Participants With Suicidal Ideation or Suicidal Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'C-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. Suicidal behavior was defined as a ""yes"" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a ""yes"" answer to any one of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent.', 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Period After the First Dose of Study Drug', 'description': 'A headache day of at least moderate severity was defined as a calendar day (00:00 to 23:59) where the participant reported either of the following: A day with headache pain that lasted ≥2 hours with a peak severity of at least moderate severity or a day where the participant used acute medication (triptans, ergots, NSAIDs or paracetamol) to treat a headache of any severity or duration. Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over 12-week period/number of days with assessments recorded in e-diary for 12-week period) \\* 28. LS mean was calculated using ANCOVA.', 'timeFrame': 'Baseline (Day -28 to Day -1), up to Week 12'}, {'measure': 'Number of Participants Reaching at Least 50% Reduction in the Monthly Average Number of Migraine Days During the 12-week Period After the First Dose of Study Drug', 'description': 'A migraine day was defined as a calendar day where the participant reported either of the following: A calendar day (0:00 to 23:59) demonstrating at least 2 consecutive hours of a headache that was accompanied by ≥1 migraine symptom(s) or a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine specific medications (NSAIDs, paracetamol or triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over 12-week period/number of days with assessments recorded in e-diary for 12-week period) \\* 28.', 'timeFrame': 'Baseline (Day -28 to Day -1) up to Week 12'}, {'measure': 'Mean Change From Baseline in Monthly Average Number of Days of Use of Any Acute Headache Medications During 12-Week Period After the First Dose of Study Drug', 'description': 'Participants recorded any headache medications (name of drug, number of tablets/capsules, and the dose in milligrams per tablet/capsule) taken each day in their electronic headache diary device. Acute headache medication included triptans and ergot compounds, NSAIDs or paracetamol. Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over 12-week period/number of days with assessments recorded in e-diary for 12-week period) \\* 28. LS mean was calculated using ANCOVA.', 'timeFrame': 'Baseline (Day -28 to Day -1), up to Week 12'}, {'measure': 'Mean Change From Baseline in Migraine-related Disability Score at Week 12, as Measured by the Pediatric Migraine Disability Assessment (PedMIDAS) Questionnaire', 'description': 'The PedMIDAS is a scale developed to assess headache-related disability which can be self-administered by the participant or administered by a caregiver. It has been validated in participants aged 4 to 18 years and includes 3 subscales: the impact of headache on school performance (range of scores 0-92), disability at home (range of scores 0-92), social/sport functioning (range of scores 0-92). The subscales are added to get the total score with a range 0 to 276. The total score was used for grading of disability, with 4 score categories of 0 to 10, 11 to 30, 31 to 50, and 51-276 interpreted as disability grades 1 (little or no disability), 2 (mild disability), 3 (moderate disability), and 4 (severe disability), respectively. Higher total scores indicated severe disability. LS mean was calculated using ANCOVA. The change from baseline score is reported with a range of -276 to 276 with higher scores indicating more severe disability.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Mean Change From Baseline in Quality of Life at Week 12, as Measured by Pediatric Quality of Life Inventory (PedsQL) Questionnaire', 'description': 'PedsQL 4.0 is a brief 23-item health-related quality of life (QoL) instrument that evaluates QoL in 4 areas of functioning: physical, emotional, social, and school functioning. For child and adolescent self-report (8 - 18 years) and parent report forms, respondents used a 5-point Likert scale to rate item severity (0=never a problem;1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). For younger children (5 - 7 years), a simplified 3-point Likert scale, anchored with a happy and a sad face, was used (0=not at all a problem; 2=sometimes a problem; 4=a lot of a problem). PedsQL yields a total QoL score and 2 summary scores: Physical Health Summary Score and Psychosocial Health Summary Score. To obtain scores, items were reverse scored, transformed to a 0 through 100 scale (0=100, 1=75, 2=50, 3=25, 4=0), and averaged; total scores near 0 indicated lower QoL, while scores approaching 100 indicated higher QoL. LS mean was calculated using ANCOVA.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Number of Participants Developing Anti-drug Antibodies (ADAs) Throughout the Study', 'description': 'Number of participants who developed ADAs were reported.', 'timeFrame': 'Baseline up to Month 3'}]",14.0,6 Years,17 Years,ALL,False,INDUSTRY,0.0,235.0,ACTUAL,v2_robust,True,True,False,True,
NCT04486157,Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects,IN-A012,"['IN-A012', 'Akynzeo 300Mg-0.5Mg Capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,HK inno.N Corporation,2025-09-01T16:18:10.919690,True,,,,,"A Phase 1, Open Label, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Crossover Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects",,['Healthy'],[],,2021-03-18,2021-05-10,"[{'measure': 'AUC0-t of netupitant', 'description': 'Area under the plasma concentration versus time curve of netupitant', 'timeFrame': 'pre-dose(0hour), 0.5, 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96 , 120, 144, 168, 192, 216, and 240 hours post-dose'}]","[{'measure': 'Cmax of fosnetupitant, netupitant, netupitant metabolites and palonosetron', 'description': 'Peak Plasma Concentration of fosnetupitant, netupitant metabolites and palonosetron', 'timeFrame': 'pre-dose(0hour), 0.5, 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96 , 120, 144, 168, 192, 216, and 240 hours post-dose'}, {'measure': 'tmax of fosnetupitant, netupitant, netupitant metabolites and palonosetron', 'description': 'Time to reach maximum (peak) plasma concentration of fosnetupitant, netupitant, netupitant metabolites and palonosetron', 'timeFrame': 'pre-dose(0hour), 0.5, 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96 , 120, 144, 168, 192, 216, and 240 hours post-dose'}]",3.0,19 Years,45 Years,ALL,True,INDUSTRY,0.0,44.0,ACTUAL,v2_robust,True,True,False,False,
NCT00090857,Letrozole in Preventing Breast Cancer in Postmenopausal Women,Letrozole,"['Femara', 'Letrozole']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Breast Cancer,Dana-Farber Cancer Institute,2025-09-01T16:18:10.919745,True,,,,,A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels,,['Breast Cancer'],"['breast cancer', 'stage I breast cancer', 'stage II breast cancer', 'stage IIIA breast cancer', 'stage IIIB breast cancer', 'stage IIIC breast cancer', 'stage IV breast cancer', 'breast cancer in situ', 'ductal breast carcinoma in situ']",,2002-02,2013-03,"[{'measure': 'Change in Lumbar Density From Baseline to 12 Months', 'description': 'The bone mineral density (BMD) test was comprised of the following 4 measurements \\[total density (g/cm\\^2)\\]: lumbar, femoral neck, trochanter, hip.', 'timeFrame': 'Evaluation occurred at treatment initiation (BL) and after 12-months of treatment.'}, {'measure': 'Change in Femoral Neck Density From Baseline to 12 Months', 'description': 'The bone mineral density (BMD) test was comprised of the following 4 measurements \\[total density (g/cm\\^2)\\]: lumbar, femoral neck, trochanter, hip.', 'timeFrame': 'Evaluation occurred at treatment initiation (BL) and after 12-months of treatment.'}, {'measure': 'Change in Trochanter Density From Baseline to 12 Months', 'description': 'The bone mineral density (BMD) test was comprised of the following 4 measurements \\[total density (g/cm\\^2)\\]: lumbar, femoral neck, trochanter, hip.', 'timeFrame': 'Evaluation occurred at treatment initiation (BL) and after 12-months of treatment.'}, {'measure': 'Change in Hip Density From Baseline to 12 Months', 'description': 'The bone mineral density (BMD) test was comprised of the following 4 measurements \\[total density (g/cm\\^2)\\]: lumbar, femoral neck, trochanter, hip.', 'timeFrame': 'Evaluation occurred at treatment initiation (BL) and after 12-months of treatment.'}]","[{'measure': 'Worst Grade Hot Flashes', 'description': 'Participants reported worst grade hot flashes: 01: mild (\\<1qd) or 02: moderate (\\>1qd) during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}, {'measure': 'Worst Grade Muscle Aches/Pains', 'description': 'Participants reported worst grade muscle aches/pains defined as grade 01: mild, 02: moderate, 03: severe (CTCAEv3) or 04: disabling (CTCAEv3) during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}, {'measure': 'Worst Grade Nausea', 'description': 'Participants reported worst grade nausea grade 01: able to eat, 02: oral intake significantly decreased, 03: no significant intake, requiring IV fluids during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}, {'measure': 'Worst Grade Vomiting', 'description': 'Participants reported worst grade vomiting grade 01: 1x in 24 hours, 02: 2-5x in 24 hours, 03: \\>/= 6x in 24 hours, grade 04: requiring parenteral nutrition/intensive care during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}, {'measure': 'Worst Grade Abdominal Pain', 'description': 'Participants reported worst grade abdominal pain: 01: mild, 02: moderate, 03: severe (CTCAEv3), 04: disabling (CTCAEv3) during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}, {'measure': 'Worst Grade Bone Pain', 'description': 'Participants reported worst grade bone pain: 01: mild, 02: moderate, 03: severe (CTCAEv3), 04: disabling (CTCAEv3) during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}, {'measure': 'Worst Grade Headache', 'description': 'Participants reported worst grade headache: 01: mild, 02: moderate, 03: severe (CTCAEv3), 04: disabling (CTCAEv3) during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}, {'measure': 'Worst Grade Fatigue', 'description': 'Participants reported worst grade fatigue: 01: mild, 02: moderate, 03: severe (CTCAEv3), 04: disabling (CTCAEv3) during 12 months of treatment.', 'timeFrame': 'Heath assessments during treatment were administered at 3- and 9-months by telephone contact and during clinic visits at 6- and12-months.'}]",12.0,35 Years,120 Years,FEMALE,False,OTHER,2.0,49.0,ACTUAL,v2_robust,True,True,False,False,
NCT05645757,Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777),Ertapenem,"['WCK 6777', 'Zidebactam', 'Ertapenem']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Bacterial Infection,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:10.919784,True,,,,,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) In Healthy Adult Subjects",,['Bacterial Infection'],"['Double-blind', 'Intravenous Ertapenem', 'Phase 1', 'Safety', 'Zidebactam (WCK 6777)']",,2023-04-19,2023-11-03,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events', 'description': 'Adverse events (AEs) are defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, regardless of its causal relationship to the product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of the product, and are described as treatment-emergent AEs (TEAEs). Number of participants with a TEAE are summarized by dose group and by MedDRA System Organ Class (SOC).', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Treatment-Emergent Adverse Events Reported', 'description': 'Adverse events (AEs) are defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, regardless of its causal relationship to the product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of the product, and are described as treatment-emergent AEs (TEAEs). Number of TEAEs reported are summarized by dose group and MedDRA System Organ Class (SOC)..', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events Related to Study Product', 'description': 'Adverse events (AEs) are defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, regardless of its causal relationship to the product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of the product, and are described as treatment-emergent AEs (TEAEs). TEAEs are assessed by the investigator to determine relationship to the study drug. Number of participants with a related TEAE are summarized by dose group and by MedDRA System Organ Class (SOC).', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Serious Adverse Events Reported', 'description': 'Serious AEs (SAEs) meet one or more of the following criteria: death, life-threatening AEs, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, substantial disruption of the ability to conduct normal life function, congenital anomaly/birth defect, or important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. SAEs are listed.', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Participants With Abnormal Chemistry Laboratory Toxicity Results', 'description': 'Parameters and thresholds include alanine aminotransferase =33 (female (F) 19Y), =30 (F \\>19) or =47 U/L (male (M) =19Y); albumin =3.5 g/dL; alkaline phosphatase =129 (F 19Y), =126 (F =49Y), =170 (M 19Y) or =131 U/L (M =49Y); aspartate aminotransferase =33 (19Y) or =41 U/L (20-49Y); bilirubin =1.2 (19Y) or =1.3 mg/dL (\\>19Y); calcium =8.8 (4-19Y), =8.5 (20-49Y), =10.5 (4-19Y), =10.3 (F 20-49Y) or =10.4 mg/dL (M 20-49Y); carbon dioxide =19 or =33 mmol/L; creatinine =0.97 (F 18-29Y), =0.98 (F 30-39Y), =1.00 (F 40-49Y), =1.25 (M 18-29Y), =1.27 (M 30-39Y) or =1.30 mg/dL (M 40-49Y); direct bilirubin =0.3 mg/dL; glucose =64 or =100 mg/dL; potassium =3.7 (19Y), =3.4 (\\>19Y), = 5.2 (19Y) or = 5.4 mmol/L (\\>19Y); protein =6.2 (19Y) or =6.0 g/dL (\\>19Y); sodium =134 or =147 mmol/L; and urea nitrogen =21 (19Y) or =26 mg/dL (\\>19Y). All abnormal toxicity results are included, but Grade 1 values at screening/baseline allowed for enrollment were only considered TEAEs if they increased in severity.', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Participants With Abnormal Hematology Laboratory Toxicity Results', 'description': 'Parameters and thresholds include basophils =201 x106/L (\\>6Y); eosinophils =501 x106/L (\\>6Y); hemoglobin =11.4 (female (F) 18Y), =11.6 (F \\>18Y), =11.9 (male (M) 18Y) or =13.1 g/dL (M \\>18Y); leukocytes =4.4 (18Y), =3.7 (\\>18Y), =13.1 (18Y) or =10.9 x109/L (\\>18Y); lymphocytes =1199 (18Y) or =849 x106/L (\\>18Y); monocytes =901 (18Y) or =951 x106/L (\\>18Y); neutrophils =1799 (18Y) or =1499 x106/L (\\>18Y); and platelets \\<140 x109/L. All abnormal toxicity results are included, but Grade 1 values at screening/baseline allowed for enrollment were only considered TEAEs if they increased in severity.', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Participants With Abnormal Coagulation Laboratory Toxicity Results', 'description': 'Parameters and thresholds include activated partial thromboplastin time \\>32 s, prothrombin intl. normalized ratio \\>1.1 (ratio), and prothrombin time \\>11.5 s. All abnormal toxicity results are included, but Grade 1 values at screening/baseline allowed for enrollment were only considered TEAEs if they increased in severity.', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results', 'description': 'Parameters and thresholds include dipstick measurements of glucose =1+, leukocyte esterase =1+, occult blood =1+, protein =1+ and urinalysis with microscopy results of at least a few bacteria, red blood cells (RBC) =3 per high-powered field (HPF), and white blood cells (WBC) =6 per HPF. If dipstick results were abnormal, urinalysis with microscopy was performed. All abnormal toxicity results are included, but Grade 1 values at screening/baseline allowed for enrollment were only considered TEAEs if they increased in severity.', 'timeFrame': 'Day 1 through Day 11'}, {'measure': 'Number of Participants With Abnormal Electrocardiogram (ECG) Toxicity Results', 'description': 'The only ECG parameters graded were PR interval with a threshold of =211 msec and QTcF interval with a threshold of =471 msec (female) or =451 msec (male) or an increase of =30 msec above baseline. ECG values after dosing were considered as TEAEs if they met toxicity grading criteria.', 'timeFrame': 'Day 8 and Day 11'}, {'measure': 'Number of Participants With Abnormal Vital Signs (VS)', 'description': 'VS parameters and thresholds include diastolic blood pressure =90 mmHg, oral temperature =37.3 °C, pulse =49 or =101 beats/min, respiratory rate =21 breaths/min, and systolic blood pressure =88 or =131 mmHg. VS could be repeated up to twice more at rest and within at least 5 minutes of each other. The following rules were used to determine which vital sign measurement to use for analysis if repeat measurements occurred: 1. If the first replicate was normal, it was used. 2. If the first and second replicates were both abnormal, the replicate with the higher severity was used. 3. If the first replicate was abnormal, the second replicate was normal, and the third replicate was not performed, the first replicate was used. 4. If the first replicate was abnormal and the second and third replicates were normal, the second replicate was used. 5. If the first and third replicates were abnormal and the second replicate was normal, the abnormal replicate with the higher severity was used.', 'timeFrame': 'Day 1 through Day 11'}]","[{'measure': 'Maximum Observed Concentration (Cmax) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the Cmax (µg/mL) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group.', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Minimum Observed Concentration (Cmin) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the Cmin (µg/mL) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group.', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Predicted Concentration at the End of the Dosing Interval (Ctau) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the Ctau (µg/mL) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group. Ctau is estimated using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Dose-Normalized Maximum Observed Concentration (Cmax/Dose) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the dose-normalized Cmax ((µg/mL)/mg) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Time of Maximum Concentration (Tmax) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Median and minimum/maximum of the Tmax (h) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group.', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Time of Minimum Concentration (Tmin) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Median and minimum/maximum of the Tmin (h) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group.', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Area Under the Concentration-Time Curve From Dosing to the Predicted Time the Concentration Reaches the Lower Limit of Quantification (AUC(0-t)) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the total area under the concentration-time curve from dosing (time 0 h) extrapolated to the time the concentration is predicted to reach the lower limit of quantification (LLOQ), AUC(0-t) (µg\\*h/mL), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Area Under the Concentration-Time Curve From Dosing to Time of the Last Measured Concentration (AUC(0-last)) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the total area under the concentration-time curve from dosing (time 0 h) to the time of last measured concentration, AUC(0-last) (µg\\*h/mL),parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group.', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Area Under the Concentration-Time Curve From Dosing Taken to the Limit as the End Time Becomes Arbitrarily Large (AUC(0-inf)) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the total area under the concentration-time curve from dosing (time 0 h) taken to the limit as the end time becomes arbitrarily large, AUC(0-inf) (µg\\*h/mL), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Area Under the Concentration-Time Curve From Dosing Extrapolated to 24 Hours After Dosing (AUC(0-24)) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the total area under the concentration-time curve from dosing (time 0 h) extrapolated to 24 h after dosing, AUC(0-24) (µg\\*h/mL), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Area Under the Concentration-Time Curve From Dosing to the End of the Dosing Interval (AUC(0-tau)) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the total area under the concentration-time curve from dosing (time 0 h) to the end of the dosing interval (24 h post-infusion), AUC(0-tau) (µg\\*h/mL), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Dose-Normalized Area Under the Concentration-Time Curve From Dosing to the End of the Dosing Interval (AUC(0-tau)/Dose) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the dose-normalized total area under the concentration-time curve from dosing (time 0 h) to the end of the dosing interval (24 h post-infusion), AUC(0-tau)/Dose ((µg\\*h/mL)/mg), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Terminal Elimination Half-Life (t1/2) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the terminal elimination half-life, t1/2 (h), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Total Clearance (CLT) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the total clearance, CLT (L/h), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'First-Order Terminal Phase Elimination Rate Constant (Ke) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the first-order terminal phase elimination rate constant, Ke (1/h), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Apparent Volume of Distribution (Vd) for Dose 1 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the apparent volume of distribution, Vd (L), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 1 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Maximum Observed Concentration at Steady State (Cmax,ss) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the Cmax,ss (µg/mL) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group. These estimates assume steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Minimum Observed Concentration at Steady State (Cmin,ss) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the Cmin,ss (µg/mL) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group. These estimates assume steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Dose-Normalized Maximum Observed Concentration at Steady State (Cmax,ss/Dose) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the dose-normalized Cmax,ss ((µg/mL)/mg) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group. This estimate assumes steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Average Concentration Over the Dose 7 Dosing Interval (Cavg) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the average concentration over the Dose 7 dosing interval, Cavg (µg/mL) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). Cavg is calculated as AUC(0-tau,ss)/tau. These estimates assume steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Predicted Concentration at the End of the Dosing Interval at Steady State (Ctau,ss) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the predicted concentration at the end of the dosing interval at steady state, Ctau,ss (µg/mL), parameters estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). These estimates assume steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Time of Maximum Concentration at Steady State (Tmax,ss) for Dose 7 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Median and minimum/maximum of the Tmax,ss (h) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group. The estimate for Tmax,ss assumes steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Time of Minimum Concentration (Tmin) for Dose 7 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Median and minimum/maximum of the Tmin (h) parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Area Under the Concentration-Time Curve From Dose 7 Dosing Extrapolated to 24 Hours After Dosing at Steady State (AUC(0-24),ss) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the area under the concentration-time curve from dosing (time 0 h) extrapolated to 24 h after dosing at steady state, AUC(0-24),ss (µg\\*h/mL), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). This estimate assumes steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Area Under the Concentration-Time Curve From Dose 7 Dosing to the End of the Dosing Interval at Steady State (AUC(0-tau),ss) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the area under the concentration-time curve from dosing (time 0 h) to the end of the dosing interval (24 h post-infusion) at steady state, AUC(0-tau),ss (µg\\*h/mL), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). This estimate assumes steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Dose-Normalized Area Under the Concentration-Time Curve From Dose 7 Dosing to the End of the Dosing Interval at Steady State (AUC(0-tau),ss/Dose) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the dose-normalized total area under the concentration-time curve from dosing (time 0 h) to the end of the dosing interval (24 h post-infusion) at steady state, AUC(0-tau),ss/Dose ((µg\\*h/mL)/mg), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). This estimate assumes steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Terminal Elimination Half-Life (t1/2) for Dose 7 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the terminal elimination half-life, t1/2 (h), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Total Clearance (CLT) for Dose 7 of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the total clearance, CLT (L/h), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration).', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Apparent Volume of Distribution at Steady State (Vd,ss) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the apparent volume of distribution at steady state, Vd,ss (L), parameter estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h period following Dose 7 by dose group using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). This estimate assumes steady state has been achieved.', 'timeFrame': '=0.5 h prior to the start of Dose 7 (Day 7) dosing and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 7 infusion'}, {'measure': 'Linearity Index of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the linearity index (ratio) for the total ERT, free ERT, total ZID, and free ZID plasma concentration-time data by dose group. The linearity index is a measure of how linear the relationship is between increase in administered dose and increase in exposure. The linearity index is estimated as AUC(0-tau),ss (Dose 7)/AUC(0-inf) (Dose 1), where the areas under the concentration-time curves from Dose 7 to the end of the dosing interval at steady state and from Dose 1 taken to the limit as the end time becomes arbitrarily large, AUC(0-tau),ss and AUC(0-inf) respectively, are calculated using Phoenix WinNonlin Non-compartmental Analysis with Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). The AUC(0-tau),ss estimate assumes steady state was reached.', 'timeFrame': '=0.5 h prior to the start of and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) and Dose 7 (Day 7) infusions'}, {'measure': 'The Accumulation Ratio of the Area Under the Concentration-Time Curve (RAUC) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the accumulation ratio of the AUC, RAUC (ratio), parameter for the total ERT, free ERT, total ZID, and free ZID plasma concentration-time data by dose group. RAUC is estimated as AUC(0-tau),ss (Dose 7)/AUC(0-24) (Dose 1), where the areas under the concentration-time curves from Dose 7 to the end of the dosing interval at steady state and from Dose 1 extrapolated to 24 h after Dose 1, AUC(0-tau),ss and AUC(0-24) respectively, are calculated using Phoenix WinNonlin Non-compartmental Analysis with the Ke (first-order terminal phase elimination rate constant) acceptance criteria: Rsq\\_adjusted (adjusted R-squared) = 0.90 and includes at least 3 timepoints after Tmax (time of maximum concentration). The AUC(0-tau),ss estimate assumes steady state was reached.', 'timeFrame': '=0.5 h prior to the start of and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) and Dose 7 (Day 7) infusions'}, {'measure': 'The Accumulation Ratio of the Maximum Observed Concentration (RCmax) of Total ERT, Free ERT, Total ZID, and Free ZID in Plasma', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of the accumulation ratio of the Cmax, RCmax (ratio), parameter for the total ERT, free ERT, total ZID, and free ZID plasma concentration-time data by dose group. RCmax is estimated as Cmax (Dose 7)/Cmax (Dose 1), where the Cmax parameters are estimated from the total ERT, free ERT, total ZID, or free ZID plasma concentration-time data over the 24-h periods following Dose 1 and Dose 7, respectively.', 'timeFrame': '=0.5 h prior to the start of and 0.25 h (WCK 6777 2g group only), 0.5 h (WCK 6777 2g, ERT 2g, ZID 2g, and WCK 6777 4g groups only), 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 18 h, and 24 h post-start of Dose 1 (Day 1) and Dose 7 (Day 7) infusions'}, {'measure': 'Amounts of Unchanged ERT and Unchanged ZID Excreted in Urine (Ae,Urine) During Each Nominal Time Collection Interval Following Dose 1', 'description': 'Mean and minimum/maximum of the amount of unchanged ERT and the amount of unchanged ZID excreted in urine, Ae,urine (mg), during 0-4 h, 4-8 h, 8-12 h, and 12-24 h following Dose 1 by dose group. Ae,urine parameters are calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Cumulative Amounts of Unchanged ERT and Unchanged ZID Excreted in Urine From Zero (Predose) to 24 h Following Dose 1 (Ae,Urine(0-24))', 'description': 'Mean and minimum/maximum of the cumulative amount of unchanged ERT and the cumulative amount of unchanged ZID excreted in urine from zero (predose) to 24 h following Dose 1, Ae,urine(0-24) (mg), by dose group. This parameter is calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-1 h pre-start of Dose 1 (Day 1) infusion and 0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 1 infusion'}, {'measure': 'Fractions (%) of ERT and ZID Excreted Unchanged in Urine (fe,Urine) During Each Nominal Time Collection Interval Following Dose 1', 'description': 'Mean and minimum/maximum of the fraction of ERT and the fraction of ZID excreted unchanged in urine, fe,urine (%), during 0-4 h, 4-8 h, 8-12 h, and 12-24 h following Dose 1 by dose group. These fe,urine parameters are calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 1 (Day 1) infusion'}, {'measure': 'Fractions (%) of ERT and ZID Excreted Unchanged in Urine From Zero (Predose) to 24 h Following Dose 1 (fe,Urine(0-24))', 'description': 'Mean and minimum/maximum of the fraction of ERT and the fraction of ZID excreted unchanged in urine from zero (predose) to 24 h following Dose 1, fe,urine(0-24) (%), by dose group. This parameter is calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-1 h pre-start of Dose 1 (Day 1) infusion and 0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 1 infusion'}, {'measure': 'Renal Clearance of ERT and ZID From Dosing Until the Last Collected Concentration for Dose 1 (CLR(0-24))', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of renal clearance of ERT and ZID from dosing until the last collected concentration for Dose 1 (24 h postdose), CLR(0-24) (mL/h ), by dose group. This parameter is calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-1 h pre-start of Dose 1 (Day 1) infusion and 0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 1 infusion'}, {'measure': 'Amounts of Unchanged ERT and Unchanged ZID Excreted in Urine (Ae,Urine) During Each Nominal Time Collection Interval Following Dose 7', 'description': 'Mean and minimum/maximum of the amount of unchanged ERT and the amount of unchanged ZID excreted in urine, Ae,urine (mg), during 0-4 h, 4-8 h, 8-12 h, and 12-24 h following Dose 7 by dose group. Ae,urine parameters are calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 7 (Day 7) infusion'}, {'measure': 'Cumulative Amounts of Unchanged ERT and Unchanged ZID Excreted in Urine From Zero (Predose) to 24 h Following Dose 7 (Ae,Urine(0-24),SS)', 'description': 'Mean and minimum/maximum of the cumulative amount of unchanged ERT and the cumulative amount of unchanged ZID excreted in urine from zero (predose) to 24 h following Dose 7, Ae,urine(0-24) (mg), by dose group. This parameter is calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-1 h pre-start of Dose 7 (Day 7) infusion and 0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 7 infusion'}, {'measure': 'Fractions (%) of ERT and ZID Excreted Unchanged in Urine (fe,Urine) During Each Nominal Time Collection Interval Following Dose 7', 'description': 'Mean and minimum/maximum of the fraction of ERT and the fraction of ZID excreted unchanged in urine, fe,urine (%), during 0-4 h, 4-8 h, 8-12 h, and 12-24 h following Dose 7 by dose group. These fe,urine parameters are calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 7 (Day 7) infusion'}, {'measure': 'Fractions (%) of ERT and ZID Excreted Unchanged in Urine From Zero (Predose) to 24 h Following Dose 7 (fe,Urine(0-24),SS)', 'description': 'Mean and minimum/maximum of the fraction of ERT and the fraction of ZID excreted unchanged in urine from zero (predose) to 24 h following Dose 7, fe,urine(0-24) (%), by dose group. This parameter is calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-1 h pre-start of Dose 7 (Day 7) infusion and 0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 7 infusion'}, {'measure': 'Renal Clearance of ERT and ZID From Dosing Until the Last Collected Concentration for Dose 7 (CLR(0-24),SS)', 'description': 'Geometric mean (GM), and coefficient of variation percentage (CV%) of renal clearance of ERT and ZID from dosing until the last collected concentration for Dose 7 (24 h postdose), CLR(0-24) (mL/h), by dose group. This parameter is calculated using a combination of Phoenix WinNonlin and SAS version 9.4 or above.', 'timeFrame': '0-1 h pre-start of Dose 7 (Day 7) infusion and 0-4 h, 4-8 h, 8-12 h, and 12-24 h post-start of Dose 7 infusion'}]",52.0,18 Years,45 Years,ALL,True,NIH,0.0,54.0,ACTUAL,v2_robust,True,True,False,True,
NCT00805701,Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation,avodart,"['dutasteride', 'avodart', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Prostate Cancer,"Bay State Clinical Trials, Inc.",2025-09-01T16:18:10.919849,True,,,,,"Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy",,['Prostate Cancer'],"['prostate', 'cancer', 'avodart', 'dutasteride', 'mitcheson']",,2009-01,2014-04,"[{'measure': 'the effect of dutasteride on dysuria, voiding and LUTS', 'timeFrame': '16 months'}]",[],1.0,35 Years,90 Years,MALE,False,OTHER,1.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT05419401,"A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)","Capivasertib film-coated tablet, 200 mg","['[14C]AZD5363 (Capivasertib)', 'Capivasertib film-coated tablet, 200 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteer,AstraZeneca,2025-09-01T16:18:10.919901,True,,,,,"A Phase I Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) in Healthy Male Subjects",,['Healthy Volunteer'],['Healthy volunteer'],,2022-04-11,2022-07-12,"[{'measure': 'Absolute bioavailability (F)', 'description': 'Absolute bioavailability (F) of oral capivasertib compared to \\[14C\\]-capivasertib (part 1)', 'timeFrame': 'Plasma sample collection from pre-dose to 72 hours post dose'}, {'measure': 'tmax', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (part 1)', 'timeFrame': 'Plasma sample collection from pre-dose to 72 hours post dose'}, {'measure': 'Cmax', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (part 1)', 'timeFrame': 'Plasma samples collection from pre-dose to 72 hours post dose'}, {'measure': 'AUC0-t', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (Part 1)', 'timeFrame': 'Plasma samples collection from pre-dose to 72 hours post dose'}, {'measure': 'AUC0-inf', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (Part 1)', 'timeFrame': 'Plasma samples collection from pre-dose to 72 hours post dose'}, {'measure': 't1/2', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (Part 1)', 'timeFrame': 'Plasma samples collection from pre-dose to 72 hours post dose'}, {'measure': 'λz', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (Part 1)', 'timeFrame': 'Plasma samples collection from pre-dose to 72 hours post dose'}, {'measure': 'CL/F', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (Part 1)', 'timeFrame': 'Plasma samples collection from pre-dose to 72 hours post dose'}, {'measure': 'Vz/F', 'description': 'PK of capivasertib and \\[14C\\]AZD5363 (capivasertib) in plasma (Part 1)', 'timeFrame': 'Plasma samples collection from pre-dose to 72 hours post dose'}, {'measure': 'tmax', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose to 168 hours post dose'}, {'measure': 'Cmax', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose to 168 hours post dose'}, {'measure': 'AUC0-t', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose to 168 hours post dose'}, {'measure': 'AUC0-inf', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose until 168 hours post-dose'}, {'measure': 't1/2', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose until 168 hours post-dose'}, {'measure': 'λz', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose until 168 hours post-dose'}, {'measure': 'CL/F', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose until 168 hours post-dose'}, {'measure': 'Vz/F', 'description': 'PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose until 168 hours post-dose'}, {'measure': 'CLR', 'description': 'PK (plasma and urine) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)', 'timeFrame': 'Plasma sample collection from pre-dose to 72 hours post dose and urine samples collected from pre-dose until 168 hours post-dose'}, {'measure': 'CumAe', 'description': 'Mass balance recovery of \\[14C\\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)', 'timeFrame': 'Urine and faecal samples collected from pre-dose until 168 hours post-dose'}, {'measure': 'Cum%Ae', 'description': 'Mass balance recovery of \\[14C\\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)', 'timeFrame': 'Urine and faecal samples collected from pre-dose until 168 hours post-dose'}, {'measure': 'Ae', 'description': 'Mass balance recovery of \\[14C\\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)', 'timeFrame': 'Urine and faecal sample collection from pre-dose until 168 hours post-dose'}, {'measure': '%Ae', 'description': 'Mass balance recovery of \\[14C\\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)', 'timeFrame': 'Urine and faecal sample collection from pre-dose until 168 hours post-dose'}, {'measure': 'Blood:plasma concentration ratios', 'description': 'Blood:plasma concentration ratios of total radioactivity (Part 2)', 'timeFrame': 'Whole blood samples collected up to 24 hours post dose. Plasma sample collection from pre-dose until 72 hours post-dose'}]","[{'measure': 'Number of subjects with treatment-related adverse events', 'description': 'To provide additional safety and tolerability information for capivasertib by assessing the incidence of AEs (Part 1 and 2)', 'timeFrame': 'Through study duration, an average of 9 weeks.'}]",24.0,30 Years,65 Years,MALE,True,INDUSTRY,1.0,7.0,ACTUAL,v2_robust,True,True,False,True,
NCT06966401,Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD),NBI-1065845,"['TAK-653', 'NBI-1065845']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Major Depressive Disorder,Neurocrine Biosciences,2025-09-01T16:18:10.919998,True,,,,,"A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)",,['Major Depressive Disorder'],"['MDD', 'Depression', 'Major Depressive Disorder', 'NBI-1065845', 'TAK-653']",,2025-04-16,2030-05,"[{'measure': 'Number of Participants with Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Baseline through Week 52'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,600.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03063112,Radiofrequency and Chemical Neurolysis of Thoracic Splanchnic Nerve for Abdominal Cancer Pain,Lidocaine,"['Ethyl alcohol', 'Chemical neuolysis', 'Lidocaine']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Abdominal Cancer,South Egypt Cancer Institute,2025-09-01T16:18:10.920006,True,,,,,Comparative Study Between Radiofrequency Thermocoagulation and Chemical Neurolysis of Thoracic Splanchnic Nerve Bilaterally for the Management of Abdominal Cancer Pain,,['Abdominal Cancer'],[],,2016-10-01,2017-05-01,"[{'measure': 'Pain relief', 'description': 'Visual analogue pain scale', 'timeFrame': '3 months'}]","[{'measure': 'Decrease the need for analgesic drugs', 'description': 'Reduction of total oral morphine consumption dose in mg per day', 'timeFrame': '3 months'}]",2.0,18 Years,70 Years,ALL,False,OTHER,0.0,79.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02610712,Clinical Trial of the Use of Ketamine in Treatment Resistant Depression,Ketamine,['Ketamine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,"Depressive Disorder, Treatment-Resistant","National Institute of Neurology and Neurosurgery, Mexico",2025-09-01T16:18:10.920023,True,,,,,Clinical Trial of the Use of Ketamine in Treatment Resistant Depression,,"['Depressive Disorder, Treatment-Resistant']","['ketamine', 'treatment-resistant', 'depression', 'spectroscopy', 'neuroinflammation']",,2014-05,,"[{'measure': 'Hamilton Depression Rating Scale (HDRS) Score', 'timeFrame': 'Change from baseline HDRS Score at 24 hours'}]","[{'measure': 'Glutamate concentrations in the pregenual cingulate cortex (pgACC)', 'description': 'Glutamate concentrations in the pregenual cingulate cortex measured by Magnetic Resonance Spectroscopy', 'timeFrame': 'Change from baseline Glutamate concentrations in the pgACC at 24 hours'}, {'measure': 'Interleukin-1 (IL-1) and Tumoral Necrosis Factor-alpha (TNF-alpha) serum concentrations', 'description': 'Interleukin-1 and Tumoral Necrosis Factor-alpha concentrations in serum measured by ELISA', 'timeFrame': 'Change from baseline IL-1 and TNF-alpha serum concentrations from baseline at 24 hours'}]",3.0,18 Years,65 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01243112,Effectiveness Study of Different Local Anesthetic Mixtures,"1% Lidocaine with Epinephrine (1:100,000)","['0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)', '1% Lidocaine with Epinephrine (1:100,000)', '1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)', '0.25% Bupivacaine with Epinephrine (1:200,000)']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Pain,Scott and White Hospital & Clinic,2025-09-01T16:18:10.920037,True,,,,,"Onset and Duration of Effect of Lidocaine, Bupivacaine, and Lidocaine/Bupivacaine Mixture With Epinephrine.",,['Pain'],[],,2010-05,2010-09,"[{'measure': 'Length of Action', 'description': 'The time from onset of local anesthesia until cessation of effect by sensation of sharp measured in 15 minute increments.', 'timeFrame': 'Up to 12 hours'}, {'measure': 'Onset of Action', 'description': 'Time from infusion of local anesthetic to loss of sensation to sharp.', 'timeFrame': 'Up to 5 minutes'}]",[],2.0,18 Years,60 Years,ALL,True,OTHER,0.0,25.0,ACTUAL,v2_robust,True,True,False,False,
NCT04183712,Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA,gemcitabine and oxaliplatin.,"['Gemzar(Eli Lilly and Company) and Aiheng(Jiangsu Hengrui Medicine Co., Ltd.)', 'Gilotrif(Boehringer-Ingelheim)', 'gemcitabine and oxaliplatin.', 'Afatinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Gallbladder Carcinoma,Shanghai Jiao Tong University School of Medicine,2025-09-01T16:18:10.920084,True,,,,,"A Multicentre, Open-label, Randomised, Controlled Study of Target Therapy Based on Tumor Molecular Profiling With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA.",,['Gallbladder Carcinoma'],[],,2020-06-01,2025-12,"[{'measure': '3-year DFS', 'description': '3-year disease free survival rates:The progression is defined consistent with contrast enhanced MRI/CT.', 'timeFrame': 'up to 3 years'}]","[{'measure': '3-year OS', 'description': '3-year Overall survival rates', 'timeFrame': 'up to 3 years'}]",2.0,18 Years,80 Years,ALL,False,OTHER,12.0,102.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00675012,NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer,NGR-hTNF,"['Oxaliplatin', 'capecitabine', 'NGR-hTNF']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Colon Cancer,AGC Biologics S.p.A.,2025-09-01T16:18:10.920120,True,,,,,NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer,,['Colon Cancer'],"['NGR-hTNF', 'Capecitabine', 'Oxaliplatin', 'Colon cancer']",,2007-12,2013-05,"[{'measure': 'To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.', 'timeFrame': 'during the study'}]","[{'measure': 'Document the preliminary antitumor activity in terms of objective response rate (according to RECIST criteria) and progression-free survival', 'timeFrame': 'during the study'}, {'measure': 'Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII', 'timeFrame': 'before during and following the treatment'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,
NCT00369512,A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma,Erlotinib,"['Tarceva', 'Erlotinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cancer,University of Alabama at Birmingham,2025-09-01T16:18:10.920157,True,,,,,A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas,,['Cancer'],"['Phase II', 'Erlotinib', 'Radiotherapy', 'Squamous Cell Carcinomas', 'Cutaneous', 'Stage III']",,2006-08,2012-09,"[{'measure': 'Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments.', 'description': 'Number of gradeable toxicities (via CTCAE manual) experienced by patients on this protocol--number of events', 'timeFrame': '2 years'}, {'measure': 'Median Time to Cancer Recurrence', 'description': 'Per protocol, patients were followed every 3 months for recurrent disease by physical exam and imaging (MRI/CT). Recurrence, in most cases, is detected during routine history/physical exam. If disease was detected during follow-up, every attempt was made to obtain pathological confirmation of recurrence.', 'timeFrame': '2 years'}, {'measure': 'Number of Patients With Recurrence at 2 Years', 'description': 'Rate of recurrence at 2 years.', 'timeFrame': '2 years'}]",[],3.0,19 Years,,ALL,False,OTHER,2.0,15.0,ACTUAL,v2_robust,True,True,False,False,
NCT03356912,CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy,Cabazitaxel,"['Prednisone', 'Cabazitaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Prostate Cancer,Consorzio Oncotech,2025-09-01T16:18:10.920229,True,,,,,"CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer (mCRPC) Progressed During or After a Previous Docetaxel-based Chemotherapy:a Multi-center,Prospective,Two-arm, Open Label, Non Inferiority Phase II Study",,"['Prostate Cancer', 'Castration-resistant Prostate Cancer']",[],,2017-11-22,2021-05-04,"[{'measure': 'change from Baseline radiographic progression', 'description': 'Radiographic progression evaluated by RECIST 1.1 criteria with bone scan, chest abdominal and pelvi TC MRI', 'timeFrame': 'From date of randomization until the date of first documented progression or but also during follow-up in case study treatment was discontinued without radiographic progression up to 48 months""'}]","[{'measure': 'Health-Related Quality of Life and pain', 'description': 'Pain response will be calculated among patients with baseline median present pain intensity score (PPI) ≥2 on the McGill-Melzack scale and/or baseline mean analgesic score (AS) ≥10 points and with stable analgesia at baseline.', 'timeFrame': 'from the date of randomization and the date of either first documented pain progression or death due to any cause, whichever is earlier up to 48 months""'}, {'measure': 'Adverse events', 'description': 'Incidence of Treatment-Emergent Adverse Events', 'timeFrame': 'From date of randomization until the date of first documented progression or but also during follow-up in case study treatment was discontinued up to 48 months"" ""'}, {'measure': 'Health-Related Quality of Life', 'description': 'Functional Assessment of Cancer Therapy-Prostate"" (FACT-P) questionnaire, version 4. The results is summed to give a score in the range of 0-156, where higher values represent better HRQL. Questionnaires will be self-administered and takes approximately 10 minutes to complete.', 'timeFrame': 'From date of screening until the date of first documented progression up to 48 months""'}, {'measure': 'AR-V7 and RB status in circulating tumor cells', 'description': 'genetic blood evaluation', 'timeFrame': 'only at baseline'}]",5.0,18 Years,,MALE,False,OTHER,0.0,220.0,ESTIMATED,v2_robust,True,False,False,True,
NCT05599412,Post Marketing Surveillance(PMS) Study of Lorviqua in Korea,Lorviqua,['Lorviqua'],1,OBSERVATIONAL,[],,RECRUITING,Metastatic ALK+ Non Small Cell Lung Cancer,Pfizer,2025-09-01T16:18:10.920249,True,,,,,"A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Lorviqua (Registered)",,['Metastatic ALK+ Non Small Cell Lung Cancer'],[],,2023-05-22,2028-03-31,"[{'measure': 'Incidence of the adverse events from baseline', 'description': 'This is a prospective, observational, non-interventional, multi-center study in which subjects will be administered as part of routine practice at Korean health care centers by accredited physicians.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)', 'description': 'To assess the effectiveness of Lorviqua® in patients with ALK-positive metastatic NSCLC under routine clinical practice in Korea.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Partial Response (PR)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Stable Disease (SD)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progressive Disease (PD)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Complete Response (CR)', 'timeFrame': 'Up to 2 Years'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,600.0,ESTIMATED,v2_robust,False,False,False,True,
NCT00274612,Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM,Telmisartan,"['Ramipril', 'Telmisartan']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hypertension,Boehringer Ingelheim,2025-09-01T16:18:10.920398,True,,,,,A Prospective Randomised Open- Label Blinded-Endpoint (PROBE) Trial Comparing Telmisartan (MICARDIS®) (40-80-80mg QD) and Ramipril (2.5-5--10mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. PRISMA = Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM,,['Hypertension'],[],,2002-10,2003-11,"[{'measure': 'Changes in the last 6-hour mean (relative to dose time) diastolic and systolic blood pressure (DBP and SBP) as measured by ABPM', 'timeFrame': 'after 8 and 14 weeks'}]","[{'measure': 'Changes in the last 6-hour ABPM mean (relative to dosing time) for pulse pressure (PP)', 'timeFrame': 'after 8 and 14 weeks'}, {'measure': 'Changes in the 24-hour ABPM mean (relative to dosing time) for DBP, SBP and PP', 'timeFrame': 'after 8 and 14 weeks'}, {'measure': 'Changes in the ABPM mean (relative to clock-time) for DBP, SBP and PP during the morning, daytime and night-time periods of the 24-hour dosing interval.', 'timeFrame': 'after 8 and 14 weeks'}, {'measure': 'Changes in SBP and DBP load during the 24-hour dosing interval', 'timeFrame': 'after 8 and 14 weeks'}, {'measure': 'Changes in mean seated trough DBP and SBP as measured by manual in-clinic cuff sphygmomanometer', 'timeFrame': 'after 8 and 14 weeks'}, {'measure': 'Responder rates based on both the 24-hour ABPM mean (relative to dose time) BPs and manual in-clinic trough cuff measurements', 'timeFrame': 'after 8 and 14 weeks'}, {'measure': 'Changes from baseline in patient Health Related Quality of Life (HRQL) as measured by Psychological General Wellbeing Index (PGWB).', 'timeFrame': 'week 8 and 14'}, {'measure': 'Manually triggered BP measurements before going to bed and upon arising in the morning', 'timeFrame': 'after 8 and 14 weeks'}, {'measure': 'Incidence of adverse events', 'timeFrame': 'up to 14 weeks'}]",10.0,18 Years,,ALL,False,INDUSTRY,0.0,801.0,,v2_robust,True,True,False,True,
NCT00208312,ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI),Regadenoson,"['Lexiscan', 'Adenosine', 'Adenoscan', 'CVT-3146', 'Regadenoson']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Coronary Artery Disease,Gilead Sciences,2025-09-01T16:18:10.920421,True,,,,,"A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging",,['Coronary Artery Disease'],"['Lexiscan', 'Regadenoson', 'Adenoscan®', 'Adenosine', 'SPECT Myocardial Perfusion Imaging', 'Reversible Perfusion Defect']",,2004-04,2005-06,"[{'measure': 'Non-inferiority of regadenoson to Adenoscan for use in SPECT myocardial perfusion imaging in assessing reversible perfusion defects', 'timeFrame': 'After radiopharmaceutical administration'}]","[{'measure': 'Safety and tolerability comparison of regadenoson to Adenoscan', 'timeFrame': 'Up to two weeks'}, {'measure': 'Additional comparisons of images obtained with regadenoson to those obtained with Adenoscan', 'timeFrame': 'After radiopharmaceutical administration'}]",3.0,18 Years,,ALL,False,INDUSTRY,1.0,787.0,ACTUAL,v2_robust,True,True,False,True,
NCT01865812,Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis,Obeticholic Acid,"['6α-Ethyl chenodeoxycholic acid (6-ECDCA)', 'INT-747', 'Obeticholic Acid']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Primary Biliary Cirrhosis,Intercept Pharmaceuticals,2025-09-01T16:18:10.920431,True,,,,,A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis,,['Primary Biliary Cirrhosis'],[],,2013-12-03,2016-09-12,"[{'measure': 'Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Absolute Change From Baseline In HDL Particle Size', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Absolute Change From Baseline In HDL Particle Number', 'timeFrame': 'Baseline, Week 8'}]","[{'measure': 'Median Change From Baseline In HDL Cholesterol Concentration At Weeks 4, 8, and 12', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12'}, {'measure': 'Median Change From Baseline In HDL Particle Size At Weeks 4, 8, and 12', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12'}, {'measure': 'Median Change From Baseline In HDL Particle Number At Weeks 4, 8, and 12', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12'}, {'measure': 'Median Change From Week 8 In HDL Cholesterol Concentration At Week 12', 'timeFrame': 'Week 8, Week 12'}, {'measure': 'Median Change From Week 8 In HDL Particle Size At Week 12', 'timeFrame': 'Week 8, Week 12'}, {'measure': 'Median Change From Week 8 In HDL Particle Number At Week 12', 'timeFrame': 'Week 8, Week 12'}, {'measure': 'Maximum Plasma Concentration (Cmax) Of OCA And Conjugates', 'description': 'Results are reported in nanograms per milliliter (ng/mL).', 'timeFrame': 'Week 8'}, {'measure': 'Time To Reach Cmax (Tmax) For OCA And Conjugates', 'description': 'Results are reported in hours (h).', 'timeFrame': 'Week 8'}, {'measure': 'Area Under The Concentration-time Curve From Hour 0 To Last Sampling Time (Hour 6) (AUC0-6) For OCA And Conjugates', 'description': 'Results are reported in hour\\*nanograms per milliliter (h\\*ng/mL).', 'timeFrame': 'Week 8'}, {'measure': 'Median Change From Baseline In Total Cholesterol', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Total Triglycerides', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Low-density Lipoprotein (LDL) Cholesterol (Direct)', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In LDL Particle Size', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Total LDL Particles', 'description': 'Results are reported in nanomoles per liter (nmol/L).', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Very Low-density Lipoprotein (VLDL) Cholesterol', 'description': 'Results are reported in milligrams per deciliter (mg/dL).', 'timeFrame': 'Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In VLDL Particle Size', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In VLDL Particles', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Apolipoprotein A1 (ApoA1)', 'description': 'Results are reported in grams per liter (g/L).', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Apolipoprotein B (ApoB)', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In ApoA1/ApoB Ratio', 'timeFrame': 'Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Apolipoprotein E', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Lipoprotein-a', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT, Last Dose'}, {'measure': 'Median Change From Baseline In Lecithin-cholesterol Acyltransferase Activity', 'description': 'Results are reported in nanomoles/milliliter/hour (nmol/mL/h).', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Cholesteryl Ester Transfer Protein', 'description': 'Results are reported in picomole/milliliter/minute (pmol/mL/min).', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Prebeta-1 HDL Concentration', 'description': 'Results are reported in microgram/milliliter (ug/mL).', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Macrophage Cholesterol Efflux', 'description': 'Results are reported as a percentage of cholesterol.', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In C-reactive Protein', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Glycoprotein A', 'description': 'Results are reported in picograms/milliliter (pg/mL).', 'timeFrame': 'Baseline, Week 12, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Fibroblast Growth Factor-19', 'timeFrame': 'Baseline, Week 4, Week 8/End of Treatment (EOT), Week 12, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Participants With Lipoprotein X', 'description': 'Lipoprotein samples were assessed using nuclear magnetic resonance spectroscopy for the presence/absence of Lipoprotein X. Lipoprotein X sometimes appears with advanced cholestasis and can confound assessment of other lipoprotein concentrations, particularly LDL.', 'timeFrame': 'Week 12 and Last Dose'}, {'measure': 'Median Change From Baseline In Alkaline Phosphatase', 'description': 'Results are reported in units/Liter (U/L).', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Gamma-glutamyl Transferase', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Alanine Aminotransferase', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Aspartate Aminotransferase', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total And Unconjugated (Direct) Bilirubin', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Albumin', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Prothrombin Time', 'description': 'Results are reported in seconds (sec).', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Prothrombin International Normalized Ratio', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Enhanced Liver Fibrosis (ELF) Score', 'description': 'Change in ELF was calculated as ELF score at the end of the study minus ELF score prior to the intervention (at baseline). A decrease in the ELF score was considered good as it reflected a decrease in liver fibrosis, and an increase in ELF score was considered bad as it reflected an increase in liver fibrosis.\n\nChange in ELF scores ranged from -0.56 (good) to + 0.68 (bad).', 'timeFrame': 'Baseline, Month 12, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Hyaluronic Acid', 'timeFrame': 'Baseline, Month 12, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Amino-terminal Propeptide Of Type III Procollagen', 'description': 'Results are reported in micrograms/Liter (ug/L).', 'timeFrame': 'Baseline, Month 12, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Tissue Inhibitor Of Metalloproteinases 1', 'timeFrame': 'Baseline, Month 12, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Hepatic Stiffness', 'description': 'Results are reported in kilopascal (kPa).', 'timeFrame': 'Baseline, Month 12, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total Bile Acids', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total Endogenous Bile Acid', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total UDCA', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total Chenodeoxycholic Acid', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total Lithocholic Acid', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total Cholic Acid', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Median Change From Baseline In Total Deoxycholic Acid', 'timeFrame': 'Baseline, Month 6, Month 12, Month 18, Month 24/EOT'}, {'measure': 'Absolute Change From Baseline In HDL Cholesterol Concentration', 'timeFrame': 'Baseline, Month 24/EOT'}, {'measure': 'Absolute Change From Baseline In HDL Particle Size', 'timeFrame': 'Baseline, Month 24/EOT'}, {'measure': 'Absolute Change From Baseline In HDL Particle Number', 'timeFrame': 'Baseline, Month 24/EOT'}]",56.0,18 Years,,ALL,False,INDUSTRY,0.0,27.0,ACTUAL,v2_robust,True,True,False,False,
NCT01461512,Heme Arginate in Functional Magnetic Resonance Imaging (fMRI),heme arginate administration,"['Placebo administration', 'heme arginate administration']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Ischemia-reperfusion Injury,MWolzt,2025-09-01T16:18:10.920544,True,,,,,The Effects of Intravenous Heme Arginate on Functional Magnetic Resonance Imaging During Ischemia,,['Ischemia-reperfusion Injury'],[],,2009-01,2011-12,"[{'measure': 'BOLD MRI signal', 'description': 'functional MRI assessment of blood oxygen level dependent signal strength', 'timeFrame': '2 minutes prior to ischemia till 25 minutes after ischemia'}, {'measure': 'Serum markers of myocellular injury', 'description': '(myoglobin, creatine-kinase)', 'timeFrame': '24 hours after ischemia'}]","[{'measure': 'Blood pressure', 'description': 'in mmHg', 'timeFrame': '20 minutes prior to and 40 minutes after ischemia'}, {'measure': 'Heart rate', 'description': 'in beats per minute', 'timeFrame': 'prior to and after ischemia'}]",4.0,18 Years,46 Years,MALE,True,OTHER,0.0,16.0,ACTUAL,v2_robust,True,False,False,False,
NCT00454181,Treatment of Oral Warts in HIV+ Patients,Interferon-alpha,"['Veldona', 'IFN-alpha lozenge', 'Interferon-alpha', 'low dose IFN lozenge']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Papillomatosis,"Ainos, Inc. (f/k/a Amarillo Biosciences Inc.",2025-09-01T16:18:10.920617,True,,,,,Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial,,"['Papillomatosis', 'HIV Infections']","['human immunodeficiency virus', 'human papilloma virus', 'warts, oral', 'papillomatosis', 'treatment experienced']",,2007-02,2009-10,"[{'measure': 'Change in Total Oral Mucosal Area Covered by Warts.', 'description': 'Number of subjects with a 75% or greater decrease from baseline to week 24 in total oral wart area', 'timeFrame': '24 weeks, from baseline to the end of treatment'}]","[{'measure': 'Total Surface Area of the Lips Covered by Warts', 'description': 'Number of subjects with a 75% or greater decrease from baseline to week 24 in total lip wart area', 'timeFrame': '24 weeks, from baseline to the end of treatment'}, {'measure': 'Subject Questionnaire Regarding Changes in Warts', 'description': 'Number of subjects reporting change in oral warts from baseline to week 24 as ""better."" Scale was subjective with 3 choices: ""better,"" ""worse,"" or ""unchanged.""', 'timeFrame': '24 weeks, from baseline to the end of treatment'}, {'measure': 'Subject Questionnaire Regarding Global Oral Changes', 'description': 'Number of subjects reporting change in global oral health from baseline to week 24 as ""better."" Scale was subjective with 3 choices: ""better,"" ""worse,"" or ""unchanged.""', 'timeFrame': '24 weeks, from baseline to end of treatment'}, {'measure': 'Investigator Assessment Regarding Changes in Warts', 'description': 'Number of subjects with improvement in oral warts from baseline to week 24 as rated by the attending investigator. Scale was subjective with 3 choices: ""improved,"" ""worsened,"" or ""unchanged.""', 'timeFrame': '24 weeks, from baseline to the end of treatment'}, {'measure': 'Investigator Assessment Regarding Global Oral Changes.', 'description': 'Number of subjects with improvement from baseline to week 24 in global oral health as rated by the attending investigator. Scale was subjective with 3 choices: ""improved,"" ""worsened,"" or ""unchanged.""', 'timeFrame': '24 weeks, from baseline to the end of treatment'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,59.0,ACTUAL,v2_robust,True,True,False,False,
NCT04416581,Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy,PPI,"['P-CAB 50', 'PPI']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Coronary Artery Disease,"Duk-Woo Park, MD",2025-09-01T16:18:10.920915,True,,,,,"A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease",,"['Coronary Artery Disease', 'Percutaneous Coronary Intervention', 'Acute Coronary Syndrome', 'Myocardial Infarction']","['gastroduodenal ulcer', 'gastrointestinal hemorrhage', 'peptic ulcer', 'acute coronary syndrome', 'coronary artery stent placement', 'antiplatelet', 'anticoagulant therapy', 'PPI', 'P-CAB', 'Proton-pump inhibitors', 'Potassium-Competitive Acid Blockers']",,2021-05-12,2027-12-31,"[{'measure': 'The time from randomization to the first occurrence of a composite endpoint of upper GI clinical events, including during the treatment period', 'description': 'This composite outcome included:\n\n1. Overt upper gastrointestinal bleeding (confirmed by means of upper endoscopy or computed tomography);\n2. Overt upper gastrointestinal bleeding of unknown origin;\n3. Bleeding of presumed occult gastrointestinal origin with a documented decrease in haemoglobin of ≥ 2 g/dL or decrease in hematocrit ≥ 10% from baseline;\n4. Symptomatic gastroduodenal ulcer (confirmed by means of endoscopy or computed tomography) without evidence of gastrointestinal bleeding;\n5. Persistent pain of presumed gastrointestinal origin (duration ≥ 3 days) with underlying multiple erosive disease (5 or more gastroduodenal erosions confirmed by means of endoscopy);\n6. Gastrointestinal obstruction; or\n7. Gastrointestinal perforation.\n\nA composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any of several different events is observed.', 'timeFrame': '12 months'}]","[{'measure': 'The event rate of overt upper gastrointestinal bleeding (confirmed by means of upper endoscopy or computed tomography)', 'timeFrame': '12 months'}, {'measure': 'The event rate of overt upper GI bleeding of unknown origin', 'timeFrame': '12 months'}, {'measure': 'The event rate of bleeding of presumed occult GI origin with the documented decrease in Hgb of≥2g/dL or decrease in hematocrit≥10% from baseline', 'timeFrame': '12 months'}, {'measure': 'The event rate of symptomatic gastroduodenal ulcer(confirmed by means of endoscopy or computed tomography) without evidence of GI bleeding', 'timeFrame': '12 months'}, {'measure': 'The event rate of the existence of persistent pain of presumed GI origin(duration ≥ 3 days) with underlying multiple erosive diseases (5 or more gastroduodenal erosions confirmed by means of endoscopy)', 'timeFrame': '12 months'}, {'measure': 'The event rate of gastrointestinal obstruction', 'timeFrame': '12 months'}, {'measure': 'The event rate of gastrointestinal perforation', 'timeFrame': '12 months'}, {'measure': 'The time from randomization to discontinuation of study medication attributed to gastrointestinal signs or symptoms', 'timeFrame': '12 months'}, {'measure': 'The event rate of gastroesophageal reflux disease, as evidenced by symptomatic endoscopically confirmed erosive esophagitis', 'timeFrame': '12 months'}, {'measure': 'The event rate of composite cardiovascular safety endpoints', 'description': 'composite cardiovascular safety endpoints including:\n\n1. death from cardiovascular causes;\n2. myocardial infarction; or\n3. stroke\n\nA composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.', 'timeFrame': '12 months'}, {'measure': 'The event rate of death from cardiovascular causes', 'timeFrame': '12 months'}, {'measure': 'The event rate of myocardial infarction', 'timeFrame': '12 months'}, {'measure': 'The event rate of stroke', 'timeFrame': '12 months'}, {'measure': 'The event rate of any coronary or peripheral revascularization', 'timeFrame': '12 months'}, {'measure': 'The event rate of all-cause mortality', 'timeFrame': '12 months'}, {'measure': 'The event rate of any possible side effect of proton pump inhibitor (PPI) or Potassium-competitive acid blocker (PCAB)', 'timeFrame': '12 months'}]",17.0,19 Years,,ALL,False,OTHER,0.0,3320.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00909181,Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence,Oxybutynin,"['Oxybutynin', 'Anturol; Oxybutynin Gel 3%', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Urge Urinary Incontinence,Antares Pharma Inc.,2025-09-01T16:18:10.920982,True,,,,,"A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multicenter Study Evaluating the Effect of Treatment With Topically Administered Oxybutynin Gel in Patients With Urinary Frequency, and Urge and Mixed Urinary Incontinence With a Predominance of Urge Incontinence Episodes With an Open-Label Extension",,"['Urge Urinary Incontinence', 'Urinary Frequency']",[],,2009-03,2010-11,"[{'measure': 'Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12', 'description': 'Reduction in number of incontinent episodes, evaluated as mITT (modified intention to treat), after 12 weeks of treatment compared to baseline.', 'timeFrame': '12 weeks'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,626.0,ACTUAL,v2_robust,True,True,False,False,
NCT01301781,BLI801 Laxative in Constipated Adults,BLI801,"['BLI801', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Constipation,Braintree Laboratories,2025-09-01T16:18:10.921050,True,,,,,A Pilot Efficacy Evaluation of BLI801 Laxative in Constipated Adults,,['Constipation'],[],,2011-01,,"[{'measure': 'percentage of patients experiencing a bowel movement within 3 hours of the first study medication dose', 'timeFrame': '3 hours'}]","[{'measure': 'percentage of patients experiencing a complete/satisfactory bowel movement (BM) within 3 hours of first dose', 'timeFrame': '3 hours'}, {'measure': 'serum chemistry', 'timeFrame': '7 days'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,52.0,ACTUAL,v2_robust,True,True,False,False,
NCT05035381,PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer,Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen,"['Irinotecan', 'Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen', 'Fluorouracil', 'Leucovorin', 'Bevacizumab']",5,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,MSI-H Advanced Colorectal Cancer,Tianjin Medical University Cancer Institute and Hospital,2025-09-01T16:18:10.921127,True,,,,,Phase II Clinical Study on Efficacy and Safety of PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Unresectable Recurrent or Metastatic MSI-H Colorectal Cancer,,['MSI-H Advanced Colorectal Cancer'],[],,2019-01-01,2022-12-30,"[{'measure': 'Objective response rate', 'timeFrame': 'Up to one year'}]","[{'measure': 'Disease Control Rate', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival', 'timeFrame': 'up to 2 years'}, {'measure': 'Overall survival', 'timeFrame': 'up to 3 years'}, {'measure': 'Adverse Events', 'timeFrame': 'up to one year'}]",5.0,18 Years,75 Years,ALL,False,OTHER,0.0,10.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00132119,Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling,nalmefene HCl,['nalmefene HCl'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Pathological Gambling,Somaxon Pharmaceuticals,2025-09-01T16:18:10.921202,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling",,['Pathological Gambling'],[],,2005-08,2006-08,[{'measure': 'Assess efficacy in treatment of pathological gambling'}],[{'measure': 'Evaluate safety and tolerability in treatment of pathological gambling'}],2.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,233.0,ACTUAL,v2_robust,True,True,False,True,
NCT02669719,Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC,pemetrexed and carboplatin,['pemetrexed and carboplatin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Non Small Cell Lung Cancer,Shanghai Chest Hospital,2025-09-01T16:18:10.921210,True,,,,,A Randomized Phase II Study to Evaluate Efficacy and Safety of DCVAC/LuCa Added to Chemotherapy With Carboplatin and Pemetrexed vs Chemotherapy Alone in Patients With Stage IV Non-small Cell Lung Cancer,,['Non Small Cell Lung Cancer'],"['Lung Cancer', 'Chemotherapy', 'Immunotherapy']",,2016-01,2019-01,"[{'measure': 'Progression-free survival', 'description': 'randomization to the date of an event defined as the first progression or death due to any cause (institution of a new systemic anticancer treatment will also be considered as a progression event),whichever occurs first up to 24 months', 'timeFrame': 'the time from the date of randomization to the date of an event defined as the first progression or death due to any cause, whichever occurs first, up to 24 months'}]","[{'measure': 'Safety parameters in terms of AE, laboratory abnormalities, and vital signs', 'description': 'adverse events \\[AEs\\], serious adverse events \\[SAEs\\], adverse events of special interest \\[AESIs\\], laboratory abnormalities, and vital signs', 'timeFrame': 'through study completion, an average of 24 months'}, {'measure': 'Overall Survival', 'timeFrame': 'From study treatment to death due to any cause, up to 24 months'}, {'measure': 'Objective Response Rate', 'timeFrame': 'Objective Response Rate measured by RECIST criteria in ITT population, up to 24 months'}]",4.0,18 Years,,ALL,False,OTHER,1.0,70.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03149419,Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments,Paroxetine,"['Placebo oral capsule', 'Paroxetine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postmenopausal Flushing,Rio de Janeiro State University,2025-09-01T16:18:10.921305,True,,,,,"Endothelial, Autonomic and Pressure Effects of Paroxetine in Recent Postmenopause Women With Hot Flashes: a Randomized Placebo Controlled Clinical Trial",,"['Postmenopausal Flushing', 'Cardiovascular Risk Factor', 'Endothelial Dysfunction']","['postmenopause', 'paroxetine', 'endothelial dysfunction', 'blood pressure', 'heart rate variability', 'sleep quality', 'perceived stress', 'sleepiness']",,2016-03-01,2018-03-30,"[{'measure': 'Endothelial function in non invasive venous occlusion plethysmography', 'description': 'Forearm blood flow (ml/min per 100 ml)', 'timeFrame': '12 weeks'}]",[],1.0,45 Years,65 Years,FEMALE,True,OTHER,0.0,140.0,ACTUAL,v2_robust,True,True,False,False,
NCT05455619,Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer,Evexomostat,"['Evexomostat', 'SDX-7320']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,HR+/HER2-negative Breast Cancer,"SynDevRx, Inc.",2025-09-01T16:18:10.921321,True,,,,,"Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)",,"['HR+/HER2-negative Breast Cancer', 'Metastatic Breast Cancer']","['hyperglycemia', 'insulin', 'glucose', 'SDX-7320', 'fulvestrant', 'apelisib', 'PIK3CA mutation', 'evexomostat', 'HR+ Her2- metastatic breast cancer', 'hyperinsulinemia', 'capivasertib', 'AKT', 'PTEN']",,2022-08-26,2026-09,"[{'measure': 'Incidence of Adverse Events', 'description': 'Safety and tolerability profile will be assessed by Common Terminology Criteria for Adverse Events v5.0 and summarized by type, frequency, and severity of adverse events of evexomostat dosed in combination with alpelisib plus fulvestrant', 'timeFrame': 'Up to 48 months'}, {'measure': 'Hyperglycemic Events', 'description': 'Severity, number, and proportion of patients with hyperglycemic events', 'timeFrame': 'Up to 42 months'}]","[{'measure': 'Anti-tumor activity', 'description': 'Number of patients without disease progression', 'timeFrame': '6 months'}, {'measure': 'Glucose control', 'description': 'Number and type of anti-diabetic agents needed for glucose control will be measured', 'timeFrame': 'Up to 42 months'}, {'measure': 'Leptin activity', 'description': 'Changes from baseline in plasma levels of fasting leptin will be measured', 'timeFrame': 'Up to 42 months'}, {'measure': 'Adiponectin activity', 'description': 'Changes from baseline in plasma levels of fasting adiponectin will be measured', 'timeFrame': 'Up to 42 months'}, {'measure': 'Angiogenic activity (bFGF/FGF2)', 'description': 'Changes from baseline in plasma levels of angiogenic biomarkers (bFGF/FGF2, VEGFC) will be measured', 'timeFrame': 'Up to 42 months'}, {'measure': 'Angiogenic activity (VEGFC)', 'description': 'Changes from baseline in plasma levels of angiogenic and tumor biomarkers will be measured', 'timeFrame': 'Up to 42 months'}, {'measure': 'Insulin resistance', 'description': 'Changes from baseline in patients at risk for hyperglycemia using the homeostatic model assessment for insulin resistance (HOMA-IR) score of insulin resistance. HOMA-IR score is calculated as follows: (fasting serum insulin (μU/ml) × fasting plasma glucose (mmol per liter)/22.5).', 'timeFrame': 'Up to 42 months'}]",9.0,18 Years,,ALL,False,INDUSTRY,0.0,52.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04888819,Treatment Effect According to Timing of Administration of DWP14012 40 mg,DWP14012,"['DWP14012', 'fed state', 'fasted state']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Erosive Esophagitis,Konkuk University Medical Center,2025-09-01T16:18:10.921390,True,,,,,"A Multi-Center, Open-label, Randomized Trial to Evaluate the Efficacy and Safety Based on Timing of Administration of DWP14012 in Patients With Erosive Esophagitis",,['Erosive Esophagitis'],[],,2021-02-01,2021-12-31,"[{'measure': 'healing rate at week 4', 'description': 'Cumulative healing rate of erosive esophagitis at week 4 by endoscopy', 'timeFrame': 'up to 4 weeks'}]",[],1.0,19 Years,75 Years,ALL,False,OTHER,1.0,186.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04774419,Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery,Dostarlimab,"['TSR-042', 'Dostarlimab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Endometrial Cancer,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:10.921397,True,,,,,"Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer",,['Endometrial Cancer'],"['Dostarlimab', 'Radiation', '20-491']",,2021-04-02,2026-02,"[{'measure': 'Incidence of dose limiting toxicities (DLTs) (Safety Run-in only)', 'description': '6-18 patients will be enrolled during a safety run-in period to assess toxicities. (NCI Common Terminology Criteria for Adverse Events version 5.0)', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Progression-free (PFS)', 'description': 'PFS will be defined as the number of days from the date of the first dose of drug to the date of an event of disease progression/recurrence, according to RECIST criteria version 1.1', 'timeFrame': '2 years'}]",[],2.0,18 Years,,FEMALE,False,OTHER,1.0,62.0,ESTIMATED,v2_robust,True,False,False,True,
NCT04710719,Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids,Triamcinolone Injection,"['TAC', 'Triamcinolone Injection and 5-fluorouracil injection', 'Triamcinolone Injection', 'TAC + 5FU']",4,INTERVENTIONAL,['NA'],,COMPLETED,Keloid,Our Lady of the Lake Hospital,2025-09-01T16:18:10.921404,True,,,,,Efficacy of Post-Surgical Intralesional Injection With Triamcinolone Versus Triamcinolone Plus Fluorouracil in the Treatment of Keloids,,"['Keloid', 'Keloid Scar Following Surgery']",[],,2021-02-01,2022-07-01,"[{'measure': 'Keloid Recurrence by visual assessment meaning either there is or is not a keloid physically present (determined by number of keloids observed and rate of recurrence after treatment)', 'description': 'Treatment effective if no keloid recurrence is visible by 12 months post treatment', 'timeFrame': '12 months'}]","[{'measure': 'Symptomatology-assessed by Patient and Observer Scar Assessment Scale', 'description': 'Effectiveness of treatment on symptoms (pruritus, pain, hyperpigmentation or other side effects) as determined by changes in the POSAS survey (1 being ""not observed"" to 10 being ""present always"" and also by visual assessment by the physician', 'timeFrame': '3 months'}]",2.0,,,ALL,True,OTHER,1.0,7.0,ACTUAL,v2_robust,True,True,False,False,
NCT01576419,"Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients",PG201 tablet,"['PG201 tablet', 'botanical drug', 'Celebrex capsule', 'chemical drug']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Osteoarthritis of the Knee,"PMG Pharm Co., Ltd",2025-09-01T16:18:10.921427,True,,,,,"Double Blinded, Randomized, Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients",,['Osteoarthritis of the Knee'],"['PG201', 'Non-inferiority', '100mm pain VAS']",,2010-01,2011-09,"[{'measure': '100mm Pain VAS reduction', 'timeFrame': 'Screening, Day1, Day28'}]","[{'measure': 'Pain VAS total score on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)', 'timeFrame': 'Screening, Day1, Day28'}, {'measure': 'Sub-scale score and total score on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)', 'timeFrame': 'Screening, Day1, Day28'}, {'measure': 'The change in the quality of life score', 'timeFrame': 'Day1, Day28'}, {'measure': 'The change in the patient self-assessed & investigator-assessed overall symptom scores', 'timeFrame': 'Screening, Day1, Day28'}, {'measure': 'The responder index (RI)', 'timeFrame': 'screening, Day1, Day28'}]",6.0,40 Years,80 Years,ALL,False,INDUSTRY,0.0,309.0,ACTUAL,v2_robust,True,True,False,False,
NCT00535119,"Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer",Carboplatin,"['PARP-1 inhibitor ABT-888', 'ABT-888', 'Blastocarb', 'Taxol Konzentrat', 'Paraplatin', 'Carboplatino', 'Paraplatine', 'Ribocarbo', 'Paraplat', 'Bristaxol', 'Ercar', 'Paclitaxel', 'Novoplatinum', 'Carbotec', 'Carboplat', 'Asotax', 'Carboplatin', 'Carbosol', 'Carbosin', 'Taxol', 'Veliparib', 'Anzatax', 'Platinwas', 'Nealorin', 'Displata', 'CBDCA', 'Praxel', 'JM-8', 'Paraplatin AQ', 'Carboplatin Hexal']",30,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Adult Solid Neoplasm,National Cancer Institute (NCI),2025-09-01T16:18:10.921563,True,,,,,A Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies,,"['Adult Solid Neoplasm', 'BRCA1 Mutation Carrier', 'BRCA2 Mutation Carrier', 'Hereditary Breast and Ovarian Cancer Syndrome']",[],,2007-09,,"[{'measure': 'Recommended phase II dose (RP2D) for each stratum', 'description': 'The RP2D for each cohort will be defined by the study separately. Standard up \\& down dose-escalation scheme to determine the RP2D will be use, and toxicities will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0.', 'timeFrame': 'Up to 4 weeks'}]","[{'measure': 'Dose-limiting toxicity (DLT)', 'description': 'Toxicities should be attributable to the study drug(s) to constitute DLT. Patients will be considered evaluable for DLT if they are eligible, and if they receive any amount of treatment and experience DLT or complete the first course of treatment', 'timeFrame': 'During course 1'}, {'measure': 'Frequency of platinum-DNA adducts', 'description': 'Changes will be summarized as means and standard deviations. A statistical test of the null hypothesis of no change in each variable will be done using the Wilcoxon signed-ranks procedure. Measurements of the two variables at additional time points will be analyzed in a descriptive fashion using tables and plots.', 'timeFrame': 'At baseline and 4 weeks post-treatment'}, {'measure': 'Incidence of stable disease (SD)', 'description': 'SD is defined as neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter (LD) since the treatment started.', 'timeFrame': 'Measured from the start of the treatment until the criteria for progression are met, assessed up to 4 weeks post-treatment'}, {'measure': 'PAR levels', 'description': 'Changes will be summarized as means and standard deviations. A statistical test of the null hypothesis of no change in each variable will be done using the Wilcoxon signed-ranks procedure. Measurements of the two variables at additional time points will be analyzed in a descriptive fashion using tables and plots.', 'timeFrame': 'Up to 4 weeks post-treatment'}, {'measure': 'Responses to veliparib in combination with carboplatin and paclitaxel', 'description': 'Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.', 'timeFrame': 'Up to 4 weeks post-treatment'}, {'measure': 'Time to progression (TTP)', 'description': 'Progression will be evaluated in this study using the new international criteria proposed by RECIST. TTP will be displayed for all patients and for patients who have responded; no formal statistical analysis is planned.', 'timeFrame': 'Time from start of treatment to time of progression, assessed up to 4 weeks post-treatment'}, {'measure': 'Toxicities as assessed by CTCAE v.4.0', 'description': 'Toxicities will be defined as regimen-related if they are possibly, probably or definitely related to treatment. The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level. Serious (≥ Grade 3) toxicities will be described on a patient-by-patient basis and will include any relevant baseline data.', 'timeFrame': 'From the time of their first treatment with veliparib to up to 4 weeks post-treatment'}]",8.0,18 Years,,ALL,False,NIH,0.0,107.0,ACTUAL,v2_robust,True,True,False,True,
NCT03053830,Open Label Ketamine Treatment for Major Depressive Disorder in Veterans,Ketamine,['Ketamine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Major Depressive Disorder,VA Connecticut Healthcare System,2025-09-01T16:18:10.921818,True,,,,,An Open Label Study of the Effects of Ketamine on a Veteran Clinical Population With Major Depressive Disorder (MDD),,['Major Depressive Disorder'],"['Ketamine', 'Major Depressive Disorder']",,2017-01-31,2018-09-26,"[{'measure': 'Change in Montgomery-Asberg Depression Rating Scale (MADRS)', 'description': 'MADRS is a standardized instrument to ascertain depressed mood and neurovegetative signs and symptoms of a major depressive episode.', 'timeFrame': 'Baseline, 40 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Quick Inventory of Depressive Symptomatology-Self Report (QUIDS-SR)', 'description': 'A patient rated depression instrument', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Hamilton Anxiety Rating Scale (HAM-A)', 'description': 'Standardized instrument to evaluate anxiety severity', 'timeFrame': 'Frame: Baseline, 40 mins after infusion,140 mins after infusion, 240 mins after infusion'}, {'measure': 'Clinical Global Impression Scale', 'description': 'Widely used instrument which asses overall severity of illness on a 1-7 point scale, with 1 indicating, not at all ill and 7 indicating among the most extremely ill patients', 'timeFrame': 'Baseline'}, {'measure': 'Change in Brief Psychotic Rating Scale (BPRS)', 'description': 'The BPRS is a standardized instrument that contains scales assessing psychotic symptoms including positive and negative symptoms, activation and emotional distress.', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Clinician-Administered Dissociative States Scale (CADSS)', 'description': 'The CADSS has self and interviewer-administered items including 5 subscales, generated a priori, evaluating dissociation including altered environmental perception, time perception, spatial/body perception, derealization and memory impairment.', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Visual Analog Scale (VAS) of Mood States', 'description': 'The VAS includes scales for anxiety, drowsiness, high irritability, anger and sadness. The scales are 100 mm lines marked by subjects at a point corresponding to the apparent intensity of the feeling state (0 = none, to 100 = most ever).', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Time Line Follow Back (TLFB)', 'description': 'The TLFB is a standardized measure utilized for collecting information on daily alcohol use as well as other substance use.', 'timeFrame': 'Baseline'}, {'measure': 'Columbia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'The C-SSRS has both lifetime/recent and since last visit versions. The ""Lifetime/Recent"" version gathers information on lifetime history of suicidality and recent suicidal ideation/self-injurious behavior. The ""Since Last Visit"" version of the C-SSRS asks about any suicidal thoughts or behaviors the subject has exhibited since the last time administered the C-SSRS.', 'timeFrame': 'Baseline'}, {'measure': 'Quality of life enjoyment and satisfaction survey (Q-LES-Q)', 'description': 'The Q-LES-Q is a self-report measure of quality of life.', 'timeFrame': 'Baseline'}, {'measure': 'Cognition', 'description': 'A standard computerized battery will be done to assess cognitive ability post treatment of ketamine. The battery will include a wide range on cognitive tasks including but not\n\nlimited to attention, learning, and working memory. While it is know ketamine causes acute cognitive effects, the longer-term effects of ketamine are not known. When the cognitive battery is being conducted on test days it will be done at the end of the test day, to eliminate the confounding effects of acute treatment of ketamine..', 'timeFrame': '140 mins after infusion'}]",[],11.0,21 Years,75 Years,ALL,False,FED,0.0,11.0,ACTUAL,v2_robust,True,True,False,False,
NCT01651130,Carbetocin at Elective Cesarean Delivery Part 3,Carbetocin,"['Duratocin', 'Carbetocin']",2,INTERVENTIONAL,['NA'],,COMPLETED,Postpartum Hemorrhage,"Samuel Lunenfeld Research Institute, Mount Sinai Hospital",2025-09-01T16:18:10.921879,True,,,,,Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study Part 3,,['Postpartum Hemorrhage'],"['pregnancy', 'postpartum hemorrhage', 'Cesarean delivery', 'carbetocin']",,2012-06,2012-08,"[{'measure': 'Uterine tone', 'description': 'The obstetrician will assess uterine tone by palpation. Uterine tone will be rated as satisfactory (firm) or unsatisfactory (boggy). Unsatisfactory uterine tone will be treated with oxytocin as per the obstetrician.', 'timeFrame': '2 minutes'}]","[{'measure': 'Uterine tone', 'description': 'Uterine tone will be assessed by palpation 2 hours post-delivery by the nurse/obstetrician in the recovery room.', 'timeFrame': '2 hours'}, {'measure': 'Blood loss', 'description': 'Blood loss will be calculated through the difference in hematocrit values assessed prior to and at the end of 48 hours after the cesarean section.', 'timeFrame': '48 hours'}, {'measure': 'Side effects', 'description': 'Any of the following will be noted up to 2 hours post delivery: systolic blood pressure \\< 80% of pre-delivery values, tachycardia \\> 30% pre-delivery levels, bradycardia \\< 30% pre-delivery levels, other dysrhythmias, nausea, vomiting, chest pain, shortness of breath, headache, flushing, others', 'timeFrame': '2 hours'}]",4.0,18 Years,55 Years,FEMALE,True,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,
NCT06120530,Intraperitoneal Bupivacaine for Pelvic Organ Prolapse,Bupivacaine,['Bupivacaine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Pelvic Organ Prolapse,Indiana University,2025-09-01T16:18:10.921895,True,,,,,Effect of Intraperitoneal Bupivacaine on Postoperative Pain Control in Patients Undergoing Pelvic Organ Prolapse Repair,,['Pelvic Organ Prolapse'],[],,2023-08-16,2024-03-15,"[{'measure': 'Pain Score at 4 Hours', 'description': 'Patient pain will be measured by means of a numeric rating scale (scale from 0-10 with lower numbers indicating less pain and higher numbers indicating more pain) at 4 hours after surgical pelvic organ prolapse repair', 'timeFrame': '4 hours'}]","[{'measure': 'Pain Score at 8 Hours, 12 Hours and 24 Hours', 'description': 'Pain scores as determined by numeric rating scale (scale from 0-10 with lower numbers indicating less pain and higher numbers indicating more pain) at approximately 8, 12 and 24 hours', 'timeFrame': '8 hours, 12 hours and 24 hours'}, {'measure': 'Total Opiate Consumption', 'description': 'Total opiate consumption postoperatively while inpatient as determined by morphine milligram equivalents (MME)', 'timeFrame': 'First 24 hours postoperatively'}, {'measure': 'Time to First Narcotic', 'description': 'Time to first narcotic dose during inpatient stay', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Hospital Length of Stay', 'description': 'Hospital length of stay', 'timeFrame': 'Up to 24 hours'}]",5.0,18 Years,90 Years,FEMALE,False,OTHER,0.0,91.0,ACTUAL,v2_robust,True,True,False,False,
NCT00630630,Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy,Levetiracetam,"['Levetiracetam', 'Keppra, ucbL059']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Epilepsy,UCB Pharma,2025-09-01T16:18:10.921925,True,,,,,"A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Adult Female Subjects (18 to 40 Years of Age) With C1 Catamenial Epilepsy",,['Epilepsy'],"['Levetiracetam', 'Keppra']",,2002-11,2003-11,[{'measure': 'Percent change in catamenial seizure frequency.'}],"[{'measure': 'Responder rate'}, {'measure': 'Number of days free from seizures per week'}, {'measure': 'Ratio of catamenial seizure frequency to non-catamenial seizure frequency'}, {'measure': 'Catamenial seizure frequency during each cycle'}, {'measure': 'Seizure frequency of catamenial and non-catamenial combined'}, {'measure': 'Non-catamenial seizure frequency'}, {'measure': 'Catamenial seizure frequency separately for ovulatory and anovulatory cycles'}, {'measure': 'Safety'}]",9.0,18 Years,45 Years,FEMALE,False,INDUSTRY,0.0,3.0,ACTUAL,v2_robust,True,True,False,True,
NCT06556030,"A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.",Botulinum Toxin A,['Botulinum Toxin A'],1,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Botulinum Toxin Type A,Instituto de Investigación Hospital Universitario La Paz,2025-09-01T16:18:10.921992,True,,,,,Botulinum Toxin in Open Abdomen Closure,,"['Botulinum Toxin Type A', 'Open Abdomen', 'Abdominal Wall', 'Clinical Trial']","['botulinum toxin, open abdomen, laparostomy, abdominal wall closure, clinical trial.']",,2025-01,2026-12,"[{'measure': 'Main Endpoint', 'description': 'Percentage of patients achieving primary midline closure in the experimental group compared to the control group (within 20 days after the first procedure where the abdomen is left open).', 'timeFrame': '30 days'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,
NCT02173730,BIBR 953 ZW in Healthy Elderly Subjects,BIBR 1048 MS,"['BIBR 1048 MS', 'Pantoprazole']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:10.922001,True,,,,,Pharmacokinetics of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule Twice Daily Over Seven Days With or Without Pantoprazole Co-treatment to Healthy Male and Female Elderly Subjects,,['Healthy'],[],,2002-11,,"[{'measure': 'AUCτ,ss (area under the plasma concentration time curve during a dosing interval at steady state)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'Cmax,ss (maximum measured concentration of the analyse in plasma at steady state over a uniform dosing interval τ)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'Aeτ,ss (amount of dose excreted in urine over one dosing interval at steady state)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'feτ,ss (percent of dose excreted in urine over one dosing interval at steady state)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'AUC0-tz,ss (area under the plasma concentration time curve (AUC) from zero time (pre dose) to the time of the last quantifiable concentration (tz))', 'timeFrame': 'Day 4 and 7'}, {'measure': 'Cmin,ss (minimum measured concentration of the analyse in plasma at steady state over a uniform dosing interval τ)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'tmax,ss (time from last dosing to the maximum concentration of the analyse in plasma at steady state over a uniform dosing interval τ)', 'timeFrame': 'Day 4 and 7'}, {'measure': 't½,ss (terminal half-life, calculated from the terminal elimination rate constant)', 'timeFrame': 'Day 4 and 7'}]","[{'measure': 'CLR,ss (renal clearance at steady state following multiple dose administration)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'MRTss (steady state mean residence time)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'CL/F,ss (apparent clearance of the analyse in plasma at steady state after extravascular multiple dose administration)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'Vz/F,ss (apparent volume of distribution during the terminal phase at steady state following extravascular administration)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'Changes in activated partial thromboplastin time (aPTT)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'Changes in ecarin clotting time (ECT)', 'timeFrame': 'Day 4 and 7'}, {'measure': 'Occurrence of Adverse Events', 'timeFrame': 'up to 10 days'}]",15.0,65 Years,,ALL,True,INDUSTRY,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,
NCT03952130,A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes,LY900014,"['Ultra-Rapid Lispro', 'LY275585', 'LY900014', 'Insulin Lispro', 'Insulin Glargine', 'Humalog', 'Insulin Degludec']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 1 Diabetes Mellitus,Eli Lilly and Company,2025-09-01T16:18:10.922043,True,,,,,"A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes",,['Type 1 Diabetes Mellitus'],[],,2019-05-29,2022-01-10,"[{'measure': 'Change From Baseline in Hemoglobin A1c (HbA1c)', 'description': 'HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Pooled Country + Number of Bolus at Study Entry Stratum + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.', 'timeFrame': 'Baseline, Week 26'}]","[{'measure': '1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT)', 'description': 'A standardized MMTT was used to characterize postprandial glucose control following administration of the study insulin. Serum glucose measured at 1-hour timepoint after the start of meal minus fasting serum glucose. LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment (Type III sum of squares) as variables.', 'timeFrame': 'Week 26'}, {'measure': '2-hour PPG Excursion During MMTT', 'description': 'A standardized MMTT was used to characterize postprandial glucose control following administration of the study insulin. Serum glucose measured at 2-hour timepoint after the start of meal minus fasting serum glucose. LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment (Type III sum of squares) as variables.', 'timeFrame': 'Week 26'}, {'measure': 'Rate of Severe Hypoglycemia', 'description': 'Severe hypoglycemia is defined as an event requiring assistance of another person to administer carbohydrate, glucagon, or other resuscitative actions. Rate of severe hypoglycemia events per 100 years during a defined period was calculated by total number of severe hypoglycemia episodes within the period divided by the cumulative days on treatment from all participants within that treatment group \\*36525 days.', 'timeFrame': 'Baseline through Week 26'}, {'measure': 'Rate of Documented Symptomatic Post Meal Hypoglycemia', 'description': 'Documented symptomatic post meal hypoglycemia is an event during which typical symptoms of hypoglycemia are accompanied by blood glucose (BG) of ≤70 mg/dL \\[3.9 millimole per liter (mmol/L)\\]. The rate of documented symptomatic post meal hypoglycemia per year during a defined period is calculated by the total number of documented symptomatic post meal hypoglycemia events within the period divided by the cumulative days on treatment from all participants within that treatment group \\*365.25.', 'timeFrame': 'Baseline through Week 26'}, {'measure': 'Change From Baseline in 1,5-Anhydroglucitol (1,5-AG)', 'description': '1,5-anhydroglucitol (1,5-AG) is a marker of short-term glycemic control especially postprandial hyperglycemia. It accurately predicts rapid changes in glycemia and is tightly associated with glucose fluctuations and postprandial glucose. LS mean was determined by MMRM model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values', 'description': 'SMBG 10-point profiles were measured at morning (premeal-fasting, 1-hour post meal, 2-hour post meal), midday (premeal, 1-hour post meal, 2-hour post meal), evening (premeal, 1-hour post meal, 2-hour post meal) and bedtime. LS Mean was determined by MMRM model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Change From Baseline in Daily Insulin Dose', 'description': 'LS mean was determined by MMRM model with Baseline + Pooled Country + Hemoglobin A1c Stratum at Baseline + Use of Metformin at Study Entry + Type of Basal at Lead-in Stratum + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Percentage of Participants With HbA1c <7% and ≤6.5%', 'description': 'HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.', 'timeFrame': 'Week 26'}]",9.0,18 Years,,ALL,False,INDUSTRY,0.0,354.0,ACTUAL,v2_robust,True,True,False,False,
NCT02501928,Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.,Fesoterodine PR 4 mg,"['Fesoterodine BIC 4 mg', 'Fesoterodine PR 4 mg', 'Fesoterodine BIC 2 mg', 'Fesoterodine PR 8 mg']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Urinary Bladder, Neurogenic",Pfizer,2025-09-01T16:18:10.922222,True,,,,,LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047,,"['Urinary Bladder, Neurogenic']","['neurogenic detrusor overactivity', 'fesoterodine', 'Japan']",,2015-06-05,2020-04-01,"[{'measure': 'Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109', 'description': 'An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. TEAEs were summarized for each cohort (Cohort 1 and Cohort 2, irrespective of treatment received), each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)'}, {'measure': 'Change From Baseline in Visual Acuity at Week 12: Study A0221109', 'description': 'Visual acuity (VA) was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Visual Acuity at Week 28: Study A0221109', 'description': 'VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Visual Acuity at Final Visit: Study A0221109', 'description': 'VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Visual Accommodation at Week 12: Study A0221109', 'description': 'The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Visual Accommodation at Week 28: Study A0221109', 'description': 'The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Visual Accommodation at Final Visit: Study A0221109', 'description': 'The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Study A0221109', 'description': ""CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 28: Study A0221109', 'description': ""CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Final Visit: Study A0221109', 'description': ""CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 12: Study A0221109', 'description': ""CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 28: Study A0221109', 'description': ""CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Final Visit: Study A0221109', 'description': ""CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of Study A0221109 only.', 'timeFrame': 'A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10- or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Vital Sign (Blood Pressure) at Week 12: Study A0221109', 'description': 'Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Vital Sign (Blood Pressure) at Week 28: Study A0221109', 'description': 'Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Vital Sign (Blood Pressure) at Final Visit: Study A0221109', 'description': 'Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Vital Sign (Pulse Rate) at Week 12: Study A0221109', 'description': 'Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Vital Sign (Pulse Rate) at Week 28: Study A0221109', 'description': 'Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Vital Sign (Pulse Rate) at Final Visit: Study A0221109', 'description': 'Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Number of Participants With Adverse Event Urinary Tract Infections (UTI): Merged Data of Studies A0221047 and A0221109', 'description': 'UTI data were summarized for each cohort, each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)'}, {'measure': 'Number of Participants With Clinical Laboratory Abnormalities', 'description': 'Hematology: hemoglobin, hematocrit, erythrocytes \\<0.8\\*lower limit of normal (LLN); platelets\\<0.5\\*LLN\\>1.75\\*upper limit of normal (ULN); leukocytes \\<0.6\\*LLN\\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN \\>1.2\\*UL; basophils, eosinophils, monocytes \\>1.2\\*ULN. Clinical chemistry: bilirubin, direct bilirubin \\>1.5\\*ULN; aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase \\>3.0\\*ULN; protein, albumin \\<0.8\\*LLN \\>1.2\\*ULN; blood urea nitrogen, creatinine \\>1.3\\*ULN; urate \\>1.2\\*ULN, sodium\\<0.95\\*LLN\\>1.05\\*ULN; potassium, chloride, bicarbonate \\<0.9\\*LLN\\>1.1\\*ULN; glucose \\<0.6\\*LLN\\>1.5\\*ULN; creatine kinase \\>2.0\\*ULN. Urinalysis: specific gravity \\<1.003\\>1.030, pH \\<4.5\\>8, glucose, ketones, protein, hemoglobin, nitrite, leukocyte esterase \\>=1; erythrocytes, leukocytes \\>=20; epithelial cells \\>=6, bacteria \\>20, hyaline casts \\>1. Data for this outcome was planned to be analysed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline to 28 weeks'}, {'measure': 'Change From Baseline in Post-Void Residual (PVR) Volume at Week 12: Study A0221109', 'description': 'Post-void residual volume was assessed by an ultrasound. PVR volume was assessed only in participants who did not perform clean intermittent catheterization or in any participants who had \\>1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Post-Void Residual (PVR) Volume at Week 28: Study A0221109', 'description': 'Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had \\>1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Post-Void Residual (PVR) Volume at Final Visit: Study A0221109', 'description': 'Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had \\>1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}]","[{'measure': 'Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Maximum cystometric bladder capacity was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of \\>=40 centimeter (cm) water (H2O). Maximum cystometric bladder capacity was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Detrusor pressure (cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing. Detrusor pressure was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Number of Participants With Presence of Involuntary Detrusor Contraction (IDC) at Baseline and Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Participants with presence of IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Bladder volume at first IDC was measured using urodynamic testing. Bladder volume at first IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Bladder Compliance at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated). Bladder Compliance was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with \\>0 micturitions at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with \\>0 catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Micturitions or Catheterizations Combined Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of micturitions and catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour (hr) period. This outcome measure was only calculated for participants with \\>0 micturitions or catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with \\>0 incontinence episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': ""The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for sensate participants with \\>0 urgency episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned."", 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Volume Voided Per Micturition at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume \\>0. This outcome measure included only participants who actually had the records of volume voided per micturition. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Volume Voided Per Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume \\>0. This outcome measure included only participants who actually had the records of volume voided per catherization. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume \\>0. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}]",55.0,6 Years,17 Years,ALL,False,INDUSTRY,0.0,12.0,ACTUAL,v2_robust,True,True,False,True,
NCT00275665,The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.,Valganciclovir,['Valganciclovir'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bone Marrow Stem Cell Transplant,Mayo Clinic,2025-09-01T16:18:10.922362,True,,,,,A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.,,['Bone Marrow Stem Cell Transplant'],[],,2001-11,2007-07,"[{'measure': 'CMV disease'}, {'measure': 'Invasive bacterial and fungal infections'}]","[{'measure': 'The occurrence of CMV infection or the occurrence of CMV disease (whichever occurs first) between enrollment and day 270 after transplantation.'}, {'measure': 'Occurrence of CMV disease between randomization and day 270'}, {'measure': 'The occurrence of other documented clinically significant human herpesvirus infections after randomization and day 270.'}, {'measure': 'Survival to include a comparison of treatments at day 270 and day 640'}, {'measure': 'Safety-comparison of adverse events and serious adverse events that occur on the two arms during the study'}]",7.0,18 Years,,ALL,,OTHER,5.0,20.0,ACTUAL,v2_robust,True,True,False,True,
NCT03760965,Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise,sotagliflozin (SAR439954),"['sotagliflozin (SAR439954)', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Type 2 Diabetes Mellitus,Sanofi,2025-09-01T16:18:10.922375,True,,,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Chinese Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Diet and Exercise",,['Type 2 Diabetes Mellitus'],[],Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies.,2018-11-27,2020-04-24,"[{'measure': 'Change in hemoglobin A1c (HbA1c)', 'description': 'Absolute change from baseline to week 24 in HbA1c (for sotagliflozin dose1)', 'timeFrame': 'Baseline to Week 24'}]","[{'measure': 'Change in 2-hour postprandial glucose (PPG) following a mixed meal tolerance test (MMTT)', 'description': 'Absolute change from baseline to week 24 in 2-hour PPG following a MMTT (for sotagliflozin dose1 and 2)', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change in fasting plasma glucose (FPG)', 'description': 'Absolute change from baseline to week 24 in FPG (for sotagliflozin dose1 and 2)', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change in body weight', 'description': 'Absolute change from baseline to week 24 in body weight (for sotagliflozin dose1 and 2)', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change in HbA1c', 'description': 'Absolute change from baseline to week 24 in HbA1c (for sotagliflozin dose 2)', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change in systolic blood pressure (SBP) for all patients', 'description': 'Absolute change from baseline to week 12 in SBP for all patients (for sotagliflozin dose1 and 2)', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in SBP for patients with baseline SBP ≥130 mmHg', 'description': 'Absolute change from baseline to week 12 in SBP patients with baseline SBP ≥130 mmHg (for sotagliflozin dose1 and 2)', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Adverse events', 'description': 'Number of patients with adverse events', 'timeFrame': 'Up to Week 24'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,276.0,ACTUAL,v2_robust,True,False,True,True,Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies.
NCT03078465,Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI,Ticagrelor,"['BRILINTA', 'Plavix, Talcom', 'Ticagrelor', 'Clopidogrel']",4,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Coronary Artery Disease,"Nanjing First Hospital, Nanjing Medical University",2025-09-01T16:18:10.922399,True,,,,,Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial,,['Coronary Artery Disease'],[],"Competitive studies were conducted at the same time, and enrollment was suspended.",2017-06-20,2021-05-30,"[{'measure': '12-Month Freedom From MACE', 'description': 'Major adverse cardiovascular and cerebrovascular events consist of all-cause death, target vessel myocardial infarction, stroke, stent thrombosis.', 'timeFrame': '12 months'}]","[{'measure': '12-Month Freedom From Mortality', 'description': 'All-cause death', 'timeFrame': '12 months'}, {'measure': '12-Month Freedom From Cardiac death', 'description': 'Cardiac death', 'timeFrame': '12 months'}, {'measure': '12-Month Freedom From MI', 'description': 'Myocardial infarction', 'timeFrame': '12 months'}, {'measure': '12-Month Freedom From TLR', 'description': 'Target lesion revascularisation', 'timeFrame': '12 months'}, {'measure': '12-Month Freedom From TVR', 'description': 'Target vessel revascularisation', 'timeFrame': '12 months'}, {'measure': '12-Month Freedom From Stent Thrombosis', 'description': 'Stent thrombus was classified as definite, probable, or possible, according to the definitions provided by the Academic Research Consortium (ARC).Regarding timing, ST was defined as early (\\<30 days), late (30 days to 1 year), or too late (\\>1 year).', 'timeFrame': '12 months'}, {'measure': '12-Month Freedom From Stroke', 'description': 'Stroke', 'timeFrame': '12 months'}]",8.0,18 Years,80 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,"Competitive studies were conducted at the same time, and enrollment was suspended."
NCT01025765,The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin,Pioglitazone,"['Acarbose', 'Pioglitazone', 'Metformin']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Chronic Hepatitis C,National Taiwan University Hospital,2025-09-01T16:18:10.922491,True,,,,,"An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin",,['Chronic Hepatitis C'],[],,2009-11,2012-12,"[{'measure': 'Sustained Virologic Response', 'timeFrame': 'at the end of 24 weeks post-treatment follow-up'}]","[{'measure': 'serum ALT normalization, and histologic improvement', 'timeFrame': 'at the end of treatment and 24 weeks after the end of treatment'}]",2.0,18 Years,80 Years,ALL,False,OTHER,2.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01974765,"Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",Enzalutamide,['Enzalutamide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Advanced Epithelial Ovarian,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:10.922543,True,,,,,"A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",,"['Advanced Epithelial Ovarian', 'Recurrent Epithelial Ovarian', 'Fallopian Tube', 'Primary Peritoneal Carcinoma']","['Enzalutamide', 'Androgen Receptor Positive (AR+)', '13-119']",,2013-11-05,2022-02-28,"[{'measure': 'Overall Response Rate', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': '6 months'}, {'measure': 'Partial Response', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': '6 months'}]","[{'measure': 'Number of Participants Assessed for Treatment-Related Adverse Events', 'description': 'Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0. For each symptom i.e., frequency, severity, the worst score experienced by the patient will be recorded', 'timeFrame': 'up to 2 years'}, {'measure': 'Median Androgen Receptor/AR Expression Levels on Tissue', 'description': 'Median Androgen Receptor/AR expression levels on tissue will be determined using standard immunohistochemistry methodology', 'timeFrame': '2 years'}]",4.0,18 Years,,FEMALE,False,OTHER,1.0,59.0,ACTUAL,v2_robust,True,True,False,True,
NCT01833065,Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation,Elobixibat 10 mg/day,"['Elobixibat 10 mg/day', 'A3309', 'Elobixibat 5 mg/day', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Chronic Idiopathic Constipation,Ferring Pharmaceuticals,2025-09-01T16:18:10.922587,True,,,,,"A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period",,['Chronic Idiopathic Constipation'],[],Terminated due to a distribution issue with the trial medication,2013-04,2014-04,"[{'measure': 'Overall Complete Spontaneous Bowel Movement (CSBM) Response', 'description': 'This outcome measured the percentage of patients who were CSBM responders. A CSBM responder was defined as a patient with ≥3 CSBMs per week and an increase of ≥1 CSBM per week from Baseline, for at least 9 of the 12 weeks in the 12-week Treatment Period, including at least 3 weeks during Weeks 9-12.', 'timeFrame': 'During the first 12 weeks'}]","[{'measure': 'Occurrence of CSBM Response', 'description': ""This outcome measured the percentage of patients who had a CSBM within 24 hours after the first dose of treatment. A CSBM was defined as a spontaneous (occurring without laxative within the preceding 24 hours, including no rescue medication within the preceding 24 hours) bowel movement (as interpreted by the patient, with a beginning and an end, including single or multiple stools), accompanied by a patient reported sense of complete evacuation ('complete')."", 'timeFrame': 'Within first 24 hours of treatment initiation'}, {'measure': 'Change From Baseline in Weekly Frequency of Spontaneous Bowel Movement (SBMs)', 'description': 'The change from Baseline for the continuous variable was estimated using a repeated measures analysis of covariance (ANCOVA) model.', 'timeFrame': 'From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period'}, {'measure': 'Change From Baseline in Weekly Stool Consistency of SBMs', 'description': 'The stool consistency is measured using the seven-point ordinal Bristol Stool Form Scale (BSFS) score. The BSFS classifies human stool into seven types and points them accordingly.\n\nType 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid Types 1 and 2 indicate constipation, with 3 and 4 represents the ideal stool form (especially the latter), and 5, 6 and 7 tends towards diarrhoea .\n\nFor a given assessment week, the weekly stool consistency was defined as the sum of non-missing stool consistency score for SBMs during that week divided by the number of non-missing stool consistency score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.', 'timeFrame': 'From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period'}, {'measure': 'Total Patient Assessment of Constipation - Quality of Life (PAC-QOL) Score Responder', 'description': 'This outcome measured the percentage of patients who were PAC-QOL score responder at 12-week Treatment Period. A PAC-QOL score responder was defined as a patient with ≥50% reduction in total PAC-QOL score from Baseline at Week 12.\n\nPAC-QOL is a 28-item questionnaire for psychometric assessment of disease-specific quality of life. The questionnaire is based on 5-point Likert scale; ranging from 0 \\[none of the time or not at all\\] to 4 \\[all of the time or extremely\\]). A lower score indicates a better Quality of Life. The PAC-QOL questionnaire is developed specifically for patients with constipation.\n\nTotal PAC-QOL score was averaged from the individual item score.', 'timeFrame': 'At Week 12'}, {'measure': 'Change From Baseline in Weekly Degree of Straining of SBMs', 'description': 'The degree of straining was measured using the five-point ordinal scale (1=Not at all, 2=A little bit, 3=A moderate amount, 4=A great deal, and 5=An extreme amount).\n\nFor a given assessment week, the weekly degree of straining was defined as the sum of non-missing straining score for SBMs during that week divided by the number of non-missing straining score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.', 'timeFrame': 'From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period'}, {'measure': 'Change From Baseline in Weekly Abdominal Bloating Score', 'description': 'The abdominal pain score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).\n\nFor a given assessment week, the weekly abdominal bloating score was defined as the sum of non-missing abdominal bloating score for SBMs during that week divided by the number of non-missing abdominal bloating score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.', 'timeFrame': 'From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period'}, {'measure': 'Change From Baseline in Weekly Abdominal Discomfort Score', 'description': 'The abdominal discomfort score was measured using the five-point ordinal scale (1=None, 2=Mild, 3=Moderate, 4=Severe, and 5=Very severe).\n\nFor a given assessment week, the weekly abdominal discomfort score was defined as the sum of non-missing abdominal discomfort score for SBMs during that week divided by the number of non-missing abdominal discomfort score for SBMs during that week. The parameter was analysed using repeated measures ANCOVA model.', 'timeFrame': 'From Baseline (2-week Pretreatment Period) to overall first 12-weeks of Treatment Period'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,314.0,ACTUAL,v2_robust,True,False,True,False,Terminated due to a distribution issue with the trial medication
NCT00272467,Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy,Rebamipide,"['Losec', 'Mucosta', 'Rebamipide', 'Omeprazole']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Stomach Ulcer,Korea Otsuka International Asia Arab,2025-09-01T16:18:10.922689,True,,,,,A Comparative Study on the Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy,,['Stomach Ulcer'],"['Helicobacter pylori', 'Stomach ulcer', 'Rebamipide', 'Omeprazole']",,2005-07,2008-04,"[{'measure': 'Gastric ulcer healing rate', 'description': 'Rebamipide showed 81.5\\~87.8% of gastric ulcer healing rate which was not inferior to 82.5\\~87.8% healing rate of Omeprazole.', 'timeFrame': 'at 12 weeks after the initial administration of the study medication'}]","[{'measure': 'Gastric ulcer healing rate in cases with successful H.pylori eradication and H.pylori eradication failure (12 weeks after administration of the study medication.)', 'timeFrame': 'at 12 weeks after the initial administration of the study medication'}, {'measure': 'Serum gastrin level', 'timeFrame': 'at 8 and 12 weeks after the initial administration of study medication'}, {'measure': 'Economical efficiency', 'description': 'Rebamipide was more cost effective than Omeparzole for 7 weeks of gastric ulcer treatment.', 'timeFrame': 'drug cost/effect ratio'}]",4.0,20 Years,,ALL,False,INDUSTRY,2.0,132.0,ACTUAL,v2_robust,True,True,False,False,
NCT01425567,Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury,Intravenous Lipid Emulsion Comprised of Fish Oil,"['Omegaven', 'Intravenous Lipid Emulsion Comprised of Fish Oil']",2,EXPANDED_ACCESS,[],,APPROVED_FOR_MARKETING,Liver Disease,The University of Texas Health Science Center at San Antonio,2025-09-01T16:18:10.922756,True,,,,,Compassionate Use of an Intravenous Lipid Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Children,,['Liver Disease'],"['cholestasis', 'parenteral nutrition']",,,,[],[],0.0,14 Days,24 Months,ALL,False,OTHER,0.0,,,v2_robust,False,False,False,False,
NCT02685267,Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer,Docetaxel,"['Prednisone', 'Docetaxel', 'Enzalutamide']",3,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Prostate Cancer,Prostate Cancer Clinical Trials Consortium,2025-09-01T16:18:10.922763,True,,,,,A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide,,['Prostate Cancer'],[],,2016-02,2017-08,"[{'measure': 'Progression-free Survival (Radiographic or Per PCWG2 Criteria)', 'description': 'The primary endpoint of the study is progression-free survival (PFS), defined as the time from randomization to disease progression. Progression will be evaluated using a combination of RECIST and Prostate Cancer Working Group 2 guidelines.', 'timeFrame': '1 year'}]","[{'measure': 'PSA Response in the Standard Treatment Arm and Experimental Treatment Arm', 'description': 'PSA response measured according to Prostate Cancer Working Group 2 (PCWG2).\n\nThe study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm.', 'timeFrame': 'Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231, and every 21 days through study completion (an average of 1 year)'}, {'measure': 'Overall Survival', 'timeFrame': 'At both 1 year and 2 years from treatment start'}]",3.0,18 Years,,MALE,False,OTHER,2.0,9.0,ACTUAL,v2_robust,True,False,True,False,
NCT00000367,Prevention of Suicide in the Elderly,Treatment of depression,"['Suicide prevention treatment', 'Treatment of depression']",2,INTERVENTIONAL,['NA'],,COMPLETED,Depression,Weill Medical College of Cornell University,2025-09-01T16:18:10.922779,True,,,,,,,['Depression'],"['Depression', 'Family', 'Female', 'Human', 'Male', 'Practice Guidelines', 'Education, Medical, Continuing', 'Patient Education', 'Suicide']",,1998-09,2003-08,[],[],0.0,60 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,True,False,False,
NCT00446667,A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD,mannitol,['mannitol'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,WITHDRAWN,COPD,Syntara,2025-09-01T16:18:10.922830,True,,,,,A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD,,"['COPD', 'Exacerbation']",[],Failed to recruit,2006-10,2008-06,"[{'measure': 'FEV1', 'timeFrame': '2 days'}]","[{'measure': 'safety', 'timeFrame': '2 days'}]",2.0,35 Years,75 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Failed to recruit
NCT05391867,Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma,Lenvatinib,"['Sorafenib', 'Lenvatinib']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Hepatocellular Carcinoma,Sir Salimullah Medical College Mitford Hospital,2025-09-01T16:18:10.922936,True,,,,,Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma - An Open-label Randomized Clinical Control Trial in a Tertiary Care Hospital.,,['Hepatocellular Carcinoma'],[],,2022-01-01,2023-06-30,"[{'measure': 'Overall survivability', 'description': 'Overall survivability of hepatocellular carcinoma patients will be assessed and compared between two groups (Lenvatinib group vs Sorafenib group)', 'timeFrame': 'From the date of Randomization to next 3 months or till death'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER_GOV,0.0,70.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00303667,Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant,cyclophosphamide,"['Fludara', 'cyclophosphamide', 'CSA', 'fludarabine phosphate', 'Cyclosporin A', 'Cytoxan']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Acute Myelogenous Leukemia,"Masonic Cancer Center, University of Minnesota",2025-09-01T16:18:10.922950,True,,,,,Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation,,['Acute Myelogenous Leukemia'],"['NK cells', 'natural killer cells', 'immunotherapy', 'hematopoietic cell transplant', 'acute myelogenous leukemia']",,2005-01,2011-03,"[{'measure': 'Disease-free Survival at 6 Months', 'description': 'Number of patients alive without evidence of disease at 6 months after transplant', 'timeFrame': 'Month 6'}, {'measure': 'Disease-free Survival at 1 Year', 'description': 'Number of patients alive without evidence of disease at 1 year after transplant', 'timeFrame': '1 Year'}]","[{'measure': 'In Vivo Expansion of a Donor NK Cells NK Cell Product', 'description': 'Number of patients with in vivo expansion of donor NK cells. In vivo expansion of NK cell is defined as detection of \\>100 donor-derived NK cells per microliter of blood.', 'timeFrame': '12 - 14 days after NK cell infusion'}, {'measure': 'Number of Patients With Graft Failure', 'description': 'Number of patients with graft failure defined as \\<500 donor neutrophils count by day 28 in the absence of residual or relapsed leukemia', 'timeFrame': 'Day 28'}, {'measure': 'Incidence of Grade III-IV Acute Graft Versus Host Disease', 'description': 'Grade III-IV acute graft versus host disease is a severe short term complication created by infusion of donor cells into a foreign host', 'timeFrame': 'Month 6'}, {'measure': 'Number of Patients With Treatment-Related Mortality', 'description': 'Death within the first 100 days related to treatment in patients without relapse or persistent disease.', 'timeFrame': 'Day 100'}, {'measure': 'Incidence of Chronic Graft Versus Host Disease', 'description': 'Chronic graft versus host disease is a severe long term complication created by infusion of donor cells into a foreign host', 'timeFrame': '1 Year'}, {'measure': 'Number of Patients With Disease Relapse', 'description': 'Disease relapse is the recurrence of leukemia in patients who had cleared their leukemia after treatment. Patients with persistent leukemia are not evaluable for relapse.', 'timeFrame': '1 Year'}, {'measure': 'Incidence of Post-transplant Lymphoproliferative Disorder (PTLD)', 'description': 'Post-transplant lymphoproliferative disorder (PTLD) is a virally-driven cancer of the lymphoid cells caused by immunosuppressive drugs taken after allogeneic stem cell transplantation to prevent or control graft versus host disease.', 'timeFrame': '1 Year'}]",9.0,18 Years,70 Years,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT01130467,Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder,methylphenidate,"['Ritalin, Concerta', 'methylphenidate', 'Atomoxetine', 'Straterra']",4,OBSERVATIONAL,[],,UNKNOWN,Attention Deficit Disorders With Hyperactivity,Far Eastern Memorial Hospital,2025-09-01T16:18:10.922979,True,,,,,,,"['Attention Deficit Disorders With Hyperactivity', 'Attention Deficit Disorder', 'Hyperkinetic Syndrome']","['Attention Deficit Disorders with Hyperactivity', 'Attention Deficit Disorder', 'Event related potential']",,2009-09,,"[{'measure': 'Chinese version of SNAP-IV Rating Scale', 'timeFrame': '8 weeks'}]","[{'measure': 'Event-related potential', 'timeFrame': '8 weeks'}]",2.0,6 Years,18 Years,ALL,True,OTHER,2.0,150.0,ESTIMATED,v2_robust,False,False,False,False,
NCT01924767,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets",BI 10773 Placebo,"['BI 10773', 'BI 10773 Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,2025-09-01T16:18:10.922989,True,,,,,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses (2.5 mg to 100 mg) of BI 10773 Tablets in Male and Female Type 2 Diabetic Patients",,"['Diabetes Mellitus, Type 2']",[],,2007-07,2007-11,"[{'measure': 'Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests', 'description': 'Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).', 'timeFrame': 'day 1 to day 21'}, {'measure': 'Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results', 'description': 'Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results', 'timeFrame': 'day 1 to day 21'}, {'measure': 'Micturition Frequency', 'description': 'Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.', 'timeFrame': 'Baseline and Day 9'}, {'measure': 'Assessment of Tolerability by Investigator', 'description': 'Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.', 'timeFrame': 'day 21'}]","[{'measure': 'Concentration of the Analyte in Plasma', 'description': 'Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)', 'description': 'AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Time to Maximum Concentration of the Analyte in Plasma', 'description': 'Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Terminal Rate Constant in Plasma', 'description': 'Terminal rate constant in plasma after first dose and at steady-state', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Half-life and Mean Residence Time of the Analyte in Plasma', 'description': 'Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Apparent Volume of Distribution During the Terminal Phase', 'description': 'Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Amount of Analyte Eliminated in Urine', 'description': 'Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)', 'timeFrame': '0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9'}, {'measure': 'Fraction of Analyte Excreted Unchanged in Urine', 'description': 'Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100.\n\nFraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.', 'timeFrame': '0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9'}, {'measure': 'Apparent and Renal Clearance of the Analyte in Plasma', 'description': 'Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state.\n\nApparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state.\n\nRenal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Peak Trough Fluctuation', 'description': 'Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Linearity Index', 'description': 'The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Accumulation Ratios', 'description': 'Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state.\n\nAccumulation ratio for the respective doses were calculated using below mentioned equations:\n\nRA,Cmax = Cmax,ss/Cmax\n\nRA,AUC= AUCtau,ss/AUCtau', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Change From Baseline to Day 8 in Urinary Glucose Excretion', 'description': 'Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.', 'timeFrame': '-2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8'}, {'measure': 'Mean Daily Glucose', 'description': 'Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.', 'timeFrame': '0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8'}, {'measure': 'Fasting Plasma Glucose', 'description': 'Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.', 'timeFrame': '-0:30 (Pre dose samples)'}, {'measure': 'Serum Insulin', 'description': 'Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5.\n\nAUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.', 'timeFrame': '0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8'}, {'measure': 'Serum Insulin', 'description': 'Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12.\n\nEmax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) \\& Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)', 'timeFrame': '0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8'}]",21.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,
NCT03495167,Study of SyB C-1101 in Patients With Myelodysplastic Syndrome,SyB C-1101,['SyB C-1101'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Myelodysplastic Syndrome,SymBio Pharmaceuticals,2025-09-01T16:18:10.923001,True,,,,,"Multi-center, Open-label, Phase I Study of SyB C-1101 in Patients With Myelodysplastic Syndrome",,['Myelodysplastic Syndrome'],[],,2017-10-06,2019-05-28,"[{'measure': 'Identification of Dose-Limiting Toxicity (DLT) and Number of Patients with DLT in Each Cohort', 'description': 'Based on the number of patients with DLT and administration dose in each cohort, recommended dosage will be defined for the following clinical phase.\n\nA DLT is defined as an adverse event that occurred during the Cycle 1, for which a causality with the investigational products (IP) cannot be ruled out and meets the following criteria.\n\nCriteria: ≥ Grade3 non-hematological toxicity (except pyrexia). However nausea, vomiting, diarrhea, stomatitis and esophagitis/dysphagia are excluded (≥ Grade 3 nausea, vomiting, and diarrhea persist for ≥ 48 hours and uncontrolled by antiemetic or antidiarrheal agents, and ≥ Grade 3 stomatitis and esophagitis/dysphagia lasting for ≥ 4 days are regarded as DLTs). ≥ Grade 2 pyrexia uncontrolled by antipyretic agents. However, in case pyrexia of ˃ 39°C occurred within 24 hours after administration of SyB C-1101 and its cause is unclear, it is deemed that the causality to the IP cannot be ruled out.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Incidence of adverse events', 'description': 'Calculate from the rate between number of patients occurred AE and number of patients received SyB C-1101.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Severity of adverse events', 'description': 'Score as grade 1 to 5 according to criteria by CTCAE v4.0-JCOG.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Relationship of adverse events to SyB C-1101', 'description': 'Score as ""related "" or ""not related"".', 'timeFrame': 'Up to 2 years'}, {'measure': 'Change of laboratory test values', 'description': 'Number of patients with changes in laboratory values OR list each lab value separately (e.g.Hgb, Fe, Hct, etc.)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall hematologic response rate', 'description': 'Calculate from the rate of patients scored as CR, PR or marrow CR according to IWG 2006 criteria.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall hematologic improvement rate', 'description': 'Calculate from the rate of patients with hematologic improvement according to IWG 2006 criteria.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall cytogenetic response rate', 'description': 'Calculate from the rate of patients scored as complete cytogeneic response or partial cytogenetic response according to IWG 2006 criteria.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Cmax', 'description': 'Maximum plasma concentration', 'timeFrame': 'Up to 2 years'}, {'measure': 'tmax', 'description': 'Time to maximum plasma concentration', 'timeFrame': 'Up to 2 years'}, {'measure': 'AUC', 'description': 'Area under the plasma concentration curve', 'timeFrame': 'Up to 2 years'}, {'measure': 't 1/2', 'description': 'Half-life time', 'timeFrame': 'Up to 2 years'}]",12.0,20 Years,,ALL,False,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,True,False,True,
NCT03222167,Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b,Elbasvir/ Grazoprevir 50/100 mg fixed dose combination,['Elbasvir/ Grazoprevir 50/100 mg fixed dose combination'],1,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Chronic Hepatitis C Genotype 1B,"Institute Of Cardiology & Internal Diseases, Kazakhstan",2025-09-01T16:18:10.923034,True,,,,,Open-Label Multi-Center Single Arm Clinical Trial to Study the Efficacy and Safety of the Elbasvir/ Grazoprevir 50/100 mg Fixed Dose Combination Once Daily in Patients With Chronic HCV GT1b Infection Associated With Metabolic Syndrome,,"['Chronic Hepatitis C Genotype 1B', 'Metabolic Syndrome', 'Fibrosis, Liver', 'Cirrhoses, Liver']","['Elbasvir', 'Grazoprevir', 'SVR12', 'hepatitis C', 'metabolic syndrome']",,2017-10,2019-08,"[{'measure': 'SVR12 evaluation', 'description': 'The main outcome is SVR12, defined as HCV RNA \\< LLOQ (either TD\\[u\\] or TND)', 'timeFrame': '12 weeks after the end of all study therapy (treatment success).'}]","[{'measure': 'Death/Lost', 'description': 'Death or lost to follow-up before W24 will be considered as treatment failure (in full analysis set).', 'timeFrame': '24 weeks'}]",2.0,18 Years,70 Years,ALL,False,OTHER_GOV,2.0,60.0,ESTIMATED,v2_robust,True,False,False,False,
NCT05048667,Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction,Platelet Rich Plasma (PRP),['Platelet Rich Plasma (PRP)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Erectile Dysfunction,University of Miami,2025-09-01T16:18:10.923044,True,,,,,Novel Treatment for Microvascular Erectile Dysfunction Combining Shockwave Therapy and Platelet Rich Plasma,,['Erectile Dysfunction'],[],,2022-06-27,2025-03-14,"[{'measure': 'Change in IIEF-EF Scores', 'description': 'International Index of Erectile Function - Erectile Function Subdomain Score (IIEF-EF) is a 5-item subdomain self- evaluation questionnaire of erectile function with a total score ranging from 0-25 with the higher score indicating better erectile function.', 'timeFrame': 'Baseline, Month 3, Month 6'}, {'measure': 'Percentage of participants achieving MCID in IIEF-EF', 'description': 'IIEF-EF is a 5-item subdomain self- evaluation questionnaire of erectile function with a total score ranging from 0-25 with the higher score indicating better erectile function. Mild Clinically Important Difference (MCID) is attained via an increase of 2 points in IIEF-EF score for participants with mild ED and an increase of 5 points for participants with moderate ED.', 'timeFrame': 'Baseline, Month 3, Month 6'}, {'measure': 'Penile Blood Flow', 'description': 'Penile Blood Flow will be reported as Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV), both assessed in cm/sec, via Penile Doppler ultrasonography', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Circulating Angiogenic Factor levels', 'description': 'Circulating angiogenic factor levels including Vascular Endothelial Growth Factor (VEGF), Stromal Cell Derived Factor-1 (SDF-1 alpha) and Stem cell Factor (SCF), all reported in pg/mL, will be assessed via blood samples', 'timeFrame': 'Baseline, Month 3, Month 6'}]","[{'measure': 'Number of participants reporting a decrease or discontinue in use of PDE5 inhibitors', 'description': 'The number of participants reporting a decrease or discontinue in use of PDE5 inhibitors will be reported', 'timeFrame': 'Baseline, Month 3'}]",5.0,30 Years,80 Years,MALE,False,OTHER,1.0,60.0,ACTUAL,v2_robust,True,True,False,False,
NCT04768400,MEP and Neuromuscular Blocker,Arm I (MEP),['Arm I (MEP)'],1,INTERVENTIONAL,['NA'],,COMPLETED,Brain Tumor,Gangnam Severance Hospital,2025-09-01T16:18:10.923123,True,,,,,Quantitative Analysis Between Neuromuscular Blocking Agent and Motor Evoked Potential and Analysis of Risk Factors for the Coefficient of Variance of Motor Evoked Potential in Patients Undergoing Brain Tumor Removal Surgery: Population Approach,,['Brain Tumor'],[],,2021-03-09,2022-05-13,"[{'measure': 'Amplitude of the motor evoked potential', 'description': 'Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the start of the anesthetic induction.', 'timeFrame': 'At intraoperative 0 hr from the start of the anesthetic induction'}]","[{'measure': 'Amplitude of the motor evoked potential', 'description': 'Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the opening of the dura.', 'timeFrame': 'At intraoperative 0 h from the opening of the dura'}]",2.0,19 Years,,ALL,False,OTHER,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,
NCT02602600,Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis,Liraglutide,"['Victoza', 'Liraglutide']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Microvascular Angina,Eva Prescott,2025-09-01T16:18:10.923133,True,,,,,Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels,,['Microvascular Angina'],[],,2015-11-19,2017-04-18,"[{'measure': 'Change from baseline in Coronary Flow Reserve', 'description': 'Assessed by transthoracic doppler stress echocardiography', 'timeFrame': 'Assessed at baseline, week 4 and week 18'}, {'measure': 'Change from baseline in Angina Symptoms', 'description': 'Assessed by the Seattle Angina Questionnaire', 'timeFrame': 'Assessed at baseline, week 4 and week 18'}]","[{'measure': 'Change in endothelial function', 'description': 'Assessed by Flow Mediated Dilation of the brachial artery by ultrasound', 'timeFrame': 'Assessed at baseline, week 4 and week 18'}, {'measure': 'Change in cardiac function', 'description': 'Assessed by speckle tracking echocardiography', 'timeFrame': 'Assessed at baseline, week 4 and week 18'}, {'measure': 'Change in body weight', 'timeFrame': 'Assessed at baseline, week 4 and week 18'}, {'measure': 'Change in body composition', 'description': 'Assessed by dexa scan', 'timeFrame': 'Assessed before and after treatment (week 4 and week 18)'}]",6.0,40 Years,75 Years,FEMALE,False,OTHER,0.0,33.0,ACTUAL,v2_robust,True,True,False,False,
NCT00139100,Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area,antimicrobial agent in soap,['antimicrobial agent in soap'],1,INTERVENTIONAL,['NA'],,COMPLETED,Lymphedema,Centers for Disease Control and Prevention,2025-09-01T16:18:10.923149,True,,,,,Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis,,"['Lymphedema', 'Cellulitis']",[],,2001-02,2002-03,"[{'measure': 'Incidence of bacterial ""acute attacks"", assessed monthly.'}, {'measure': 'Reported or observed severity of these acute attacks.'}, {'measure': 'Duration of acute attacks.'}]","[{'measure': 'Process measures'}, {'measure': 'Number of bars of soap used per patient per month.'}, {'measure': 'Demonstrated knowledge and ability to wash leg appropriately during home visits.'}, {'measure': 'Reported patient satisfaction with soap.'}, {'measure': 'Reported frequency of leg washing.'}]",8.0,,,ALL,False,FED,2.0,200.0,,v2_robust,True,True,False,False,
NCT05020600,The Effect of Central Sensitization on Treatment Response in Patients With Fibromyalgia,Duloxetine,"['Dyloxia', 'Amitriptyline', 'Lyrica', 'Pregabalin', 'Laroxyl', 'Duloxetine']",6,OBSERVATIONAL,[],,UNKNOWN,Central Sensitisation,Marmara University,2025-09-01T16:18:10.923164,True,,,,,Investigation of the Effect of Initial Central Sensitization Severity on Treatment Response in Patients With Fibromyalgia,,"['Central Sensitisation', 'Fibromyalgia']",[],,2021-08-19,2024-12-01,"[{'measure': 'Visual analog scale ( VAS) pain', 'description': ""Pain rating scale. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')"", 'timeFrame': '2 year'}, {'measure': 'Symptom severity scale', 'description': 'The SS scale quantifies symptom severity on a 0-12 scale by scoring problems with fatigue, cognitive dysfunction and unrefreshed sleep over the past week', 'timeFrame': '2 year'}, {'measure': 'Fibromyalgia impact scale', 'description': 'The questionnaire was developed to determine the degree of being affected by the disease in patients with a diagnosis of fibromyalgia.The scale consists of 10 parts in total, and the first part is a Likert scale containing 11 questions. High scores indicate that the patient is overly affected.', 'timeFrame': '2 year'}, {'measure': 'Short Form-36', 'description': 'Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.', 'timeFrame': '2 year'}, {'measure': 'Central sensitization inventory', 'description': 'Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.', 'timeFrame': '2 year'}]",[],5.0,18 Years,70 Years,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,False,False,False,False,
NCT02688400,Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis,Diacerein,"['Artrodar, Artrodarin, Artrolyt, Fisiodar, Galaxdar, Glizolan, Verboril', 'Celebrex', 'Placebo', 'Diacerein', 'Celecoxib']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Osteoarthritis,TRB Chemedica International SA,2025-09-01T16:18:10.923215,True,,,,,"An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging",,"['Osteoarthritis', 'Osteoarthritis, Knee']","['Osteoarthritis', 'Knee', 'Osteoarthritis, Knee', 'Diacerein', 'Celecoxib', 'Phase III', 'Phase IV', 'Phase III-IV', 'Canada', 'Spain', 'Austria', 'Czech Republic', 'WOMAC']",,2016-05,2018-06-28,"[{'measure': 'Change Form Baseline in WOMAC A Pain Subscale', 'description': 'Change form baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) A pain subscale after 182 days of treatment.\n\nWOMAC A pain subscale: 0 - 50 cm; 50 = worse', 'timeFrame': 'baseline and 182 days'}]","[{'measure': 'Change From Baseline in WOMAC OA Scores', 'description': 'Absolute Changes from Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) after 182 days of treatment.\n\nWOMAC scale: 0 - 240 cm; 240 = worse - Intention-To-Treat (N=370) Pain subscale: 0-50cm; 50 = worse; Stifness subscale: 0-20cm; 20 = worse; Function subscale: 0-170cm; 170 = worse Absolute changes in WOMAC scores: \\<0 = improvement; 0 = stable; \\>0 = worsening', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Absolute Changes From Baseline in Pain Visual Analogue Scale', 'description': 'Absolute Changes from Baseline in Pain Visual Analogue Scale (VAS): 0-10 cm; 10 = worse', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'OARSI Responders', 'description': 'Osteoarthritis Research Society International (OARSI) Responders', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Assessment of Joint Swelling, Effusion or Both', 'description': 'Assessment of Joint Swelling, joint Effusion or Both', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Consumption of Acetaminophen', 'description': 'Overall Daily number of tablets taken during the 6 month study', 'timeFrame': 'Day 182 or early termination'}, {'measure': ""Change From Baseline in Patient's Global Assessment of Disease Activity"", 'description': 'Change from baseline in global assessment of disease activity was assessed using a VAS scale (0-10cm; 10=worse)', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Global Assessment of Response to Therapy', 'description': ""Between group comparison in Patient's and Investigator's Global Assessment of Response to Therapy using a 0-10 cm disease activity VAS scale: 0 cm = very well; 10 cm = very poorly"", 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Quality of Life SF-36', 'description': 'Absolute Changes from Baseline in Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from the Quality of Life questionnaire SF-36. Scale range for each component (PCS and MCS): minimum = 0, maximum = 100, with higher scores indicating better quality of life. Absolute changes in each component (PCS and MCS): \\>0 = improvement; 0 = stable; \\<0 = worsening.', 'timeFrame': 'Day 182 or early termination'}]",9.0,50 Years,,ALL,False,INDUSTRY,1.0,380.0,ACTUAL,v2_robust,True,True,False,False,
NCT05159700,"A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors",PRJ1-3024,['PRJ1-3024'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Advanced Solid Tumor,"Zhuhai Yufan Biotechnologies Co., Ltd",2025-09-01T16:18:10.923281,True,,,,,"A Phase I, First-In-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors",,"['Advanced Solid Tumor', 'Advanced Solid Malignancies']","['First in human', 'Maximum tolerated dose', 'Recommended Phase 2 dose', 'Dose Escalation', 'Hematopoietic progenitor kinase 1', 'PRJ1-3024']",,2022-03-31,2024-10-12,"[{'measure': 'Incidence of dose-limiting toxicity (DLT) events during the DLT monitoring period', 'description': 'Safety listings and pharmacokinetic listings will be used for evaluation', 'timeFrame': 'Day 1 to Day 21'}]","[{'measure': 'Incidence of adverse events (AEs)', 'description': 'Characterized by type, seriousness, relationship to study treatment, timing, and severity.', 'timeFrame': '24 months'}, {'measure': 'Pharmacokinetic parameter： Accumulation ratio', 'description': 'to estimate the accumulation of PRJ1-3024 from time 0 to the time of last quantifiable concentration after multiple administration', 'timeFrame': '24 months'}, {'measure': 'Objective response rate (ORR)', 'description': 'estimated by the proportion of subjects having a complete response (CR) or partial response (PR) with use of RECIST v1.1 criteria.', 'timeFrame': '24 months'}, {'measure': 'Duration of response (DOR)', 'description': 'defined as time from the first occurrence of a documented objective response to the time of relapse or death from any cause.', 'timeFrame': '24 months'}, {'measure': 'Pharmacokinetic parameter：AUC（0-last）', 'description': 'Area under the concentration-time curve AUC from time 0 to the time of the last quantifiable concentration', 'timeFrame': '24 months'}, {'measure': 'Pharmacokinetic parameter：Maximum observed concentration (Cmax)', 'description': 'assessed as time from time 0 to the time of the last quantifiable concentration', 'timeFrame': '24 months'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,39.0,ACTUAL,v2_robust,True,True,False,True,
NCT04464200,19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers,19(T2)28z1xx CAR T cells,['19(T2)28z1xx CAR T cells'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:10.923288,True,,,,,A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies,,"['Diffuse Large B Cell Lymphoma', 'Primary Mediastinal Large B Cell Lymphoma', 'Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma', 'Chronic Lymphocytic Leukemia', 'Indolent Non-Hodgkin Lymphoma', 'Marginal Zone Lymphoma', 'Waldenstrom Macroglobulinemia', ""Burkitt's Lymphoma"", 'Primary CNS Lymphoma']","['19(T2)28z1XX CAR T cells', '20-167']",,2020-07-06,2026-07,"[{'measure': 'Recommended Phase II Dose (RP2D)', 'description': 'Dose escalation will use a 3+3 design. DLT-evaluable participants are defined as those participants who were infused with 19(T2)28z1XX CAR T cells and who were monitored for toxicities during the first 28 days of post infusion.', 'timeFrame': '28 days post infusion'}]","[{'measure': 'overall response rate (ORR)', 'description': 'Response and progression of the disease will be evaluated in this study using the Lugano Classification', 'timeFrame': '2 years'}]",2.0,18 Years,,ALL,False,OTHER,1.0,30.0,ACTUAL,v2_robust,True,False,False,False,
NCT00347100,Insulin Glargine in Type 2 Diabetic Patients,Insulin Glargine,"['Glipizide', 'Glyclazide', 'Glimiperide', 'Insulin Glargine', 'Glyburide', 'Metformin']",6,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,"Diabetes Mellitus, Type 2",Sanofi,2025-09-01T16:18:10.923306,True,,,,,Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy,,"['Diabetes Mellitus, Type 2']",[],,2006-06,,"[{'measure': 'A1c values', 'timeFrame': 'At baseline and 24 weeks'}]","[{'measure': 'Adverse events including hypoglycemia', 'timeFrame': 'From the beginning to the end of the study'}]",2.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,387.0,ACTUAL,v2_robust,True,True,False,True,
NCT05363800,Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma,HRS-3738,['HRS-3738'],1,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma,"Jiangsu HengRui Medicine Co., Ltd.",2025-09-01T16:18:10.923314,True,,,,,Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma,,"[""Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma""]",[],,2022-06-17,2024-12-30,"[{'measure': 'Maximum tolerated dose (MTD)', 'description': 'Incidence and category of dose limiting toxicities (DLTs) during the first 28-day cycle of HRS-3738 treatment.', 'timeFrame': 'From Day 1 to Day 28'}, {'measure': 'RP2D', 'description': 'RP2D will be determined on the basis of evaluation on safety, PK, efficacy data in dose escalation and dose expansion stages.', 'timeFrame': 'From Day 1 to Day 28'}]","[{'measure': 'Safety endpoints: adverse events(AEs), serious adverse events（SAEs）', 'description': 'Assess safety and tolerability of HRS-3738 by way of adverse events (CTCAE v5.0).', 'timeFrame': 'From Day 1 to 30 days after last dose.'}, {'measure': 'Efficacy endpoints: Overall response rate (ORR)', 'description': 'Evaluated using Lugano 2014 criteria and IMWG criteria.', 'timeFrame': 'From Day 1 to 30 days after last dose.'}, {'measure': 'Efficacy endpoints: Best of response (BOR)', 'description': 'Evaluated using Lugano 2014 criteria and IMWG criteria', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 'Efficacy endpoints: time to response (TTR)', 'description': 'Evaluated using Lugano 2014 criteria and IMWG criteria.', 'timeFrame': 'From Day 1 to 30 days after last dose.'}, {'measure': 'Efficacy endpoints: Duration of response (DoR)', 'description': 'Evaluated using Lugano 2014 criteria and IMWG criteria', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 'Efficacy endpoints: Progression-free survival (PFS)', 'description': 'Evaluated using Lugano 2014 criteria and IMWG criteria', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 'Efficacy endpoints: overall survival (OS).', 'description': 'Evaluated using Lugano 2014 criteria and IMWG criteria.', 'timeFrame': 'From Day 1 to 30 days after last dose.'}, {'measure': 'Cmax', 'description': 'Maximal plasma concentration', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 'Tmax', 'description': 'Time to Cmax', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 'AUC', 'description': 'Area under the plasma concentration-time curve', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 't1/2', 'description': 'Terminal-phase elimination half-life', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 'Vz/F', 'description': 'Apparent volume of distribution during terminal phase after non-intravenous administration', 'timeFrame': 'From Day 1 to 30 days after last dose'}, {'measure': 'CL/F', 'description': 'Apparent total clearance of the drug from plasma after oral administration.', 'timeFrame': 'From Day 1 to 30 days after last dose'}]",15.0,18 Years,,ALL,False,INDUSTRY,0.0,198.0,ESTIMATED,v2_robust,True,False,False,True,
NCT02575300,Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors,Ibrutinib,"['Ibrutinib', 'IMBRUVICA®']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Carcinoid Tumors,H. Lee Moffitt Cancer Center and Research Institute,2025-09-01T16:18:10.923403,True,,,,,Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors,,"['Carcinoid Tumors', 'Pancreatic NET']","['neuroendocrine tumors (NETs)', 'gastroenteropancreatic NETs', 'pancreatic NETs', 'gastrointestinal (GI) tract NET', 'advanced carcinoid tumors']",,2015-10-09,2019-11-04,"[{'measure': 'Overall Radiographic Response Rate (ORR)', 'description': 'Response rate as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. For this study, measurable disease is defined as the presence of at least one measurable lesion.\n\nMeasurable lesions must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of: 10 mm by CT scan (CT scan slice thickness no greater than 5 mm (when CT scans have slice thickness \\>5 mm, the minimum size should be twice the slice thickness); 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable); 20 mm by chest X-ray.\n\nComplete Response (CR): complete disappearance of all target lesions, confirmed by repeat assessments at no less than 4 weeks after the criteria for response are first met. Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameter.', 'timeFrame': 'Up to 18 months'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'Progression free survival at one year. PFS, determined as the time from administration of the initial dose of ibrutinib until objective tumor progression using RECIST, or death. Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). The sum must also demonstrate an absolute increase of at least 5 mm.', 'timeFrame': '1 year'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall Survival determined from the time of drug administration to death from any cause.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Occurrence of Possibly Related Adverse Events (AEs)', 'description': 'Adverse events possibly related to study treatment with Ibrutinib. Safety and tolerability will be assessed according to the NIH/NCI Common TerminologyCriteria for Adverse Events version 4 (CTCAE v4).', 'timeFrame': 'Up to 18 months'}, {'measure': 'Duration of Response', 'description': 'Duration of response, defined as time from first observation of an objective response which is subsequently confirmed, to first disease progression or death due to any cause.', 'timeFrame': 'Up to 18 months'}]",5.0,18 Years,,ALL,False,OTHER,1.0,20.0,ACTUAL,v2_robust,True,True,False,True,
NCT01682200,Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne,ProOxy,"['ProOxy', '15% Oxygen solution spray']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Acne Vulgaris,Medivet Pty Ltd,2025-09-01T16:18:10.923430,True,,,,,An Open Label Pilot Clinical Trial on the Efficacy and Safety of ProOxy Facial Spray (Topical 15% Oxygen Solution) in the Treatment of Moderate Facial Acne Vulgaris Among Filipino Patients,,['Acne Vulgaris'],"['moderate', 'facial acne', 'acne vulgaris']",,2009-10,2011-09,"[{'measure': 'Changes in the appearances,sizes of the acne lesions as well as the disappearance of acne on the face.', 'description': 'Upon acceptance,pictures are taken and acne lesions are identified and counted and after 4,8, and 12 weeks during and after application of ProOxy.', 'timeFrame': '4,8,12 weeks post application of the spray'}]",[],1.0,18 Years,40 Years,ALL,True,INDUSTRY,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,
NCT06817200,The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial,Amantadine (100mg) as add on therapy.,"['Amantadine (100mg) as add on therapy.', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Parkinson Disease (PD),"University Hospital, Toulouse",2025-09-01T16:18:10.923440,True,,,,,The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial,,['Parkinson Disease (PD)'],"[""Parkinson's disease"", 'clinical trial', 'Motor fluctuations', 'Amantadine']",,2025-05-01,2027-08-31,"[{'measure': 'the change in motor fluctuation (Off-time)', 'description': 'The primary outcome of this study is the change from baseline to end-point (3 months) in motor fluctuation (Off-time) as assessed by the Hauser diaries (average of 3 consecutive days).', 'timeFrame': '3 months'}]","[{'measure': 'The rate of Off-time responders', 'description': 'The change from baseline to end-point (3 months) of the rate of Off-time responders', 'timeFrame': '3 months'}, {'measure': 'The change of the mean score of MDS-UPDRS part IV', 'description': ""The change from baseline to end-point (3 months) of The mean score of Movement disorders society - Unified Parkinson's disease rating scale (MDS-UPDRS part IV)"", 'timeFrame': '3 months'}, {'measure': 'The change of the mean score of UDysRS part 2A', 'description': 'The change from baseline to end-point (3 months) of the mean score of UDysRS part 2A', 'timeFrame': '3 months'}, {'measure': 'The change of the mean score of New freezing of gait questionnaire', 'description': 'The change from baseline to end-point (3 months) of the mean score of New freezing of gait questionnaire', 'timeFrame': '3 months'}, {'measure': 'The change of the mean score of Fatigue Severity Scale', 'description': 'The change from baseline to end-point (3 months) of the mean score of Fatigue Severity Scale', 'timeFrame': '3 months'}, {'measure': 'The change of the mean score of MDS-UPDRS Part I-II-III', 'description': ""The change from baseline to end-point (3 months) of the mean score of Movement disorders society - Unified Parkinson's disease rating scale (MDS-UPDRS Part I-II-III)"", 'timeFrame': '3 months'}, {'measure': 'The change of the mean score of PDQ-39', 'description': ""The change from baseline to end-point (3 months) of the mean score of Parkinson's Disease Questionnaire (PDQ-39)"", 'timeFrame': '3 months'}, {'measure': 'The safety of amantadine', 'description': ""The safety of amantadine, expressed as: the percentage of Adverse Events, of severe Adverse Events, of serious Adverse Events and of patients' discontinuation due to Adverse Events, all over the three months of treatment."", 'timeFrame': '3 months'}]",9.0,30 Years,80 Years,ALL,False,OTHER,0.0,132.0,ESTIMATED,v2_robust,True,False,False,True,
NCT00470600,Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients,Caldolor,"['Ibuprofen', 'Caldolor']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Pain,Cumberland Pharmaceuticals,2025-09-01T16:18:10.923464,True,,,,,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF IBUPROFEN INJECTION (IVIb) FOR TREATMENT OF PAIN IN POST-OPERATIVE ORTHOPEDIC ADULT PATIENTS",,['Pain'],[],,2007-05,2008-09,"[{'measure': 'AUC-VAS With Movement (Post-operative Period, Hour-6-28)', 'description': 'Measurement of the patient\'s self assessment of pain with movement using the validated visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient\'s self reported level of pain from ""No pain"" (0 mm) to ""Worst possible pain"" (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery \\[variable since every surgery has a unique length of time even if it is the same procedure\\] and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).', 'timeFrame': 'Study hour-6 through hour-28'}]","[{'measure': 'Secondary Endpoint: AUC-VAS at Rest (Post-operative Period, Hours 6-28)', 'description': 'Measurement of the patient\'s self assessment of pain at rest using a visual analog scale (VAS) during the post-operative period (study hour-6 through hour-28). VAS assessments document the patient\'s self reported level of pain from ""No pain"" (0 mm) to ""Worst possible pain"" (100 mm) on a 100 mm line. VAS assessments were performed immediately following surgery and at hours 6, 8, 12, 16, 20, 24 and 28 (for the primary endpoint).', 'timeFrame': 'Study hour-6 through hour-28'}, {'measure': 'Patient Demand of Narcotic Use (Post-operative Period, From Hour 6 to 28).', 'description': 'Patient demand of narcotic used by patients in each treatment group for analgesia, post-surgery.', 'timeFrame': 'Study hour-6 to hour-28'}]",3.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,185.0,ACTUAL,v2_robust,True,True,False,False,
NCT01965600,A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model,PF-06282999,"['PF-06282999', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Healthy,Pfizer,2025-09-01T16:18:10.923485,True,,,,,"A Phase 1, Randomized, Double Blind, Placebo Controlled, Multiple Dose, 2 Way Crossover Study To Evaluate The Safety And Pharmacodynamic Effects Of Pf 06282999 Using An Endotoxin (Lipopolysaccharide) Induced Inflammatory Response Model In Healthy Adult Subjects",,['Healthy'],['Endotoxin challenge'],,2014-03,2015-02,"[{'measure': 'Peak Myeloperoxidase (MPO) Activity Following Inflammatory Stimulus', 'description': 'MPO is a heme-containing peroxidase enzyme produced in the bone marrow and stored in the azurophilic granules of neutrophils, where it constitutes up to 5% of the cellular protein. Since PF-06282999 is a mechanism-based inactivator of MPO, it is of interest to evaluate the level of MPO activity in order to investigate the inhibition activity of PF-06282999.', 'timeFrame': 'Days 1, 3-5'}, {'measure': 'MPO Activity (Area Under the Concentration-time Profile From 0.5 to 2 Hours [AUC0.5-2hrs]) Following Inflammatory Stimulus', 'description': 'MPO is a heme-containing peroxidase enzyme produced in the bone marrow and stored in the azurophilic granules of neutrophils, where it constitutes up to 5% of the cellular protein. Since PF-06282999 is a mechanism-based inactivator of MPO, it is of interest to evaluate the level of MPO activity in order to investigate the inhibition activity of PF-06282999.', 'timeFrame': 'Days 1, 3-5'}, {'measure': 'MPO Activity (Area Under the Concentration-time Profile From 0 to 2 Hours [AUC0-2hrs]) Following Inflammatory Stimulus', 'description': 'MPO is a heme-containing peroxidase enzyme produced in the bone marrow and stored in the azurophilic granules of neutrophils, where it constitutes up to 5% of the cellular protein. Since PF-06282999 is a mechanism-based inactivator of MPO, it is of interest to evaluate the level of MPO activity in order to investigate the inhibition activity of PF-06282999.', 'timeFrame': 'Days 1, 3-5'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs', 'description': 'An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as newly occurring AEs or those worsening after first dose. Due to early termination of the study, only AE data from partial enrollment are reflected and comparisons between treatment arms should not be attempted.', 'timeFrame': 'From Day 0 till approximately 7-10 days following the last dose of PF-06282999/Placebo in Period 2 (up to approximately 2 months)'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities', 'description': 'Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick and microscopy). Due to early termination of the study, only laboratory data from partial enrollment are reflected and comparisons between treatment arms should not be attempted.', 'timeFrame': 'Baseline up to 7-10 days following the last dose of PF-06282999/Placebo in Period 2'}, {'measure': 'Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria', 'description': 'Categorical summarization criteria in vital signs included: sitting, supine, and standing systolic blood pressure (SBP) of less than (\\<)90 millimeters of mercury (mm Hg) or change (increase \\[inc\\] or decrease \\[dec\\]) in sitting, supine and standing SBP of more than or equal to (\\>=)30 mm Hg; supine, sitting, and standing diastolic blood pressure (DBP) of \\<50 mm Hg or change (inc or dec) in sitting, supine, and standing DBP of \\>=20 mm Hg; supine and sitting pulse rate (PR) of \\<40 or more than (\\>)120 beats per minute (bpm); and standing PR of \\<40 or \\>140 bpm. Due to early termination of the study, only vital signs data from partial enrollment are reflected and comparisons between treatment arms should not be attempted.', 'timeFrame': 'Screening and Days 1-2, 4-5, and approximately 7-10 days following the last dose of PF-06282999/Placebo in Period 2 for orthostatic (orth) measurements; Day 3 for supine measurements'}, {'measure': 'Number of Participants With Electrocardiogram (ECG) Values Meeting Categorical Summarization Criteria', 'description': 'Criteria for ECG (12-lead) values meeting categorical summarization criteria were: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval \\>=300 milliseconds (msec) and increase from baseline \\>=25/50%; time from the beginning of the ECG Q wave to the end of the S wave corresponding to ventricular depolarization (QRS) interval \\>=140 msec and increase of \\>=50%; the beginning of the Q wave to the end of the T wave corresponding to electrical systole (QT) interval \\>=500 msec; QT corrected using the Fridericia formula (QTcF) of 450 to \\<480 msec, 480 to \\<500 msec, and \\>=500 msec, or an increase of 30 to \\<60 msec or \\>=60 msec. Due to early termination of the study, only ECG data from partial enrollment are reflected and comparisons between treatment arms should not be attempted.', 'timeFrame': 'Screening; Days 1-5 and approximately 7-10 days following the last dose of PF-06282999/Placebo in Period 2'}, {'measure': 'Number of Participants With Abnormal Urinary Biomarker Values', 'description': 'Urinary biomarkers included albumin, neutrophil gelatinase-associated lipocalin (NGAL) and Cystatin-C.', 'timeFrame': 'Days 1-3 prior to dosing with PF-06282999/Placebo; and Days 4-5'}]","[{'measure': 'Concentrations of TNF-alpha, IL-1 Beta, IL-6, IL-8, and hsCRP', 'description': 'The effect of multiple oral doses of PF-06282999 on inflammatory biomarkers was a secondary objective in this study. The biomarkers are tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, IL-8, and high-sensitivity C-reactive protein (hsCRP).', 'timeFrame': 'Days 1, 3, and 4'}, {'measure': 'Peak (AUC0.5-2hours and AUC0-2hours) of MPO Activity/MPO Mass', 'description': 'MPO is a heme-containing peroxidase enzyme produced in the bone marrow and stored in the azurophilic granules of neutrophils, where it constitutes up to 5% of the cellular protein. Since PF-06282999 is a mechanism-based inactivator of MPO, it is of interest to evaluate the level of MPO activity in order to investigate the inhibition activity of PF-06282999.', 'timeFrame': 'Days 1, 3-5'}, {'measure': 'Maximum Plasma Concentration (Cmax) of PF-06282999', 'timeFrame': 'Day 3'}, {'measure': 'Area Under the Concentration-time Profile From Time 0 to End of Dosing Interval, Tau (AUCtau) of PF-06282999', 'timeFrame': 'Day 3'}, {'measure': 'Time to Cmax (Tmax) of PF-06282999', 'timeFrame': 'Day 3'}]",13.0,18 Years,40 Years,ALL,True,INDUSTRY,0.0,23.0,ACTUAL,v2_robust,True,False,True,True,
NCT01068600,Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks,Indacaterol,"['Indacaterol', 'Placebo to indacaterol']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Obstructive Pulmonary Disease,Novartis,2025-09-01T16:18:10.923545,True,,,,,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease",,['Chronic Obstructive Pulmonary Disease'],"['COPD', 'Indacaterol']",,2010-01,,"[{'measure': 'Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment', 'description': 'Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of albuterol, and FEV1 prior to and 50-70 minutes post inhalation of ipratropium as covariates.', 'timeFrame': 'after 12 weeks'}]","[{'measure': 'Transition Dyspnoea Index (TDI) Focal Score After 12 Weeks of Treatment', 'description': 'TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9 with a negative score indicating a deterioration from baseline. A 1 unit difference in the TDI focal score is clinically significant. Mixed model used baseline dyspnoea index, FEV1 prior to and 10-15 minutes post inhalation of albuterol, and FEV1 prior to and 50-70 minutes post inhalation of ipratropium as covariates.', 'timeFrame': 'after 12 weeks'}]",2.0,40 Years,,ALL,False,INDUSTRY,0.0,318.0,ACTUAL,v2_robust,True,True,False,False,
NCT04318600,Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis,human amniotic mesenchymal stem cell,['human amniotic mesenchymal stem cell'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Lupus Nephritis,Yan'an Affiliated Hospital of Kunming Medical University,2025-09-01T16:18:10.923560,True,,,,,Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis,,"['Lupus Nephritis', 'Mesenchymal Stem Cells']","['Lupus Nephritis', 'Human Amniotic Mesenchymal Stem Cell', 'cell therapy', 'clinical trail']",,2014-01-01,2019-01-01,"[{'measure': 'Incidence of Adverse Events', 'description': ""The patient's discomfort and clinical symptoms during the study were recorded, as well as the related laboratory test indicators and physical examination abnormalities of the subjects during the study. Describe the association with Amniotic mesenchymal stem cell therapy and calculate the incidence of treatment-related acute and chronic adverse events."", 'timeFrame': '60 weeks'}]","[{'measure': 'Changes in 24h urine protein quantification before and after treatment；', 'description': '24-hour urinary protein quantification from baseline to 60 weeks of treatment.', 'timeFrame': '60 weeks'}, {'measure': 'Changes in eGFR before and after treatment;', 'description': 'changes in estimated glomerular filtration rate (eGFR) from baseline to 60 weeks of treatment.', 'timeFrame': '60 weeks'}, {'measure': 'Changes in SLEDAI score before and after treatment；', 'description': 'changes in SLEDAI score from baseline to 60 weeks of treatment. SLEDAI score: 0\\~4 points basically no activity;5-9 minutes light activity;10-14 minutes of moderate activity;≥15 minutes of severe activity.', 'timeFrame': '60 weeks'}]",4.0,14 Years,60 Years,ALL,False,OTHER,1.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT03165500,Comparative Evaluation of Three Anxiety Control Protocols in Third Molar Extraction,Diazepam,"['Diazepam', 'Midazolam', 'Diazepam 5mg', 'Nitrous Oxide Inhalant Product', 'Valium', 'Dormonid', 'Midazolam Oral Tablet', 'Nitrous Oxide', 'Nitrous Oxide + Oxygen Gas']",9,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Anxiety Disease,Universidade Estadual Paulista Júlio de Mesquita Filho,2025-09-01T16:18:10.923571,True,,,,,"Comparative Evaluation of Three Anxiety Control Protocols in Third Molar Extraction With Midazolam, Diazepam and Nitrous Oxide - Randomized Clinical Trial.",,['Anxiety Disease'],"['Exodontia', 'Sedation', 'Nitrous Oxide', 'Benzodiazepines']",,2015-12-23,2017-05-04,"[{'measure': 'Assessment of blood pressure change', 'description': 'Evaluated in anxious patients submitted to the exodontia of third molars, sedated with diazepam, midazolam and nitrous oxide.The investigator evaluated with auscultatory instrument.', 'timeFrame': 'Immediately the arrival of the patient and before receiving sedation - 30 minutes after the patient receives oral sedation or 5 minutes after inhaled sedation- During the exodontia - 15 minutes after the end of surgery'}]","[{'measure': 'Assessment of heart rate change', 'description': 'Evaluated in anxious patients submitted to the exodontia of third molars, sedated with diazepam, midazolam and nitrous oxide.The investigator evaluated with oscillometric monitor.', 'timeFrame': 'Immediately the arrival of the patient and before receiving sedation - 30 minutes after the patient receives oral sedation or 5 minutes after inhaled sedation- During the exodontia - 15 minutes after the end of surgery'}, {'measure': 'Assessment of oxygen saturation change', 'description': 'Evaluated in anxious patients submitted to the exodontia of third molars, sedated with diazepam, midazolam and nitrous oxide. The investigator evaluated with pulse oximeter', 'timeFrame': 'Immediately the arrival of the patient and before receiving sedation - 30 minutes after the patient receives oral sedation or 5 minutes after inhaled sedation- During the exodontia - 15 minutes after the end of surgery'}]",3.0,18 Years,30 Years,ALL,True,OTHER,0.0,3.0,ACTUAL,v2_robust,True,True,False,False,
NCT02932007,Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study,Chloroquine Phosphate,['Chloroquine Phosphate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Atrial Fibrillation,University of South Florida,2025-09-01T16:18:10.923652,True,,,,,Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study,,['Atrial Fibrillation'],['persistent'],,2017-03-28,2020-09,"[{'measure': 'Proportion of patients with termination of AF', 'timeFrame': 'Within 2 weeks of study drug initiation'}]","[{'measure': 'Percentage of AF burden', 'description': 'AF burden reported on pacemaker/ICD interrogation or 2-week Holter reports from baseline and 2 weeks post drug initiation', 'timeFrame': 'Within 2 weeks of study drug initiation'}, {'measure': 'QT intervals', 'description': 'From baseline, pre-treatment ECG compared to 2 weeks post treatment ECG', 'timeFrame': 'Within 2 weeks of study drug initiation'}, {'measure': 'Time to AF termination', 'description': 'In days on pacemaker/ICD interrogation or Holter reports obtained at 2 weeks after study drug initiation', 'timeFrame': 'Within 2 weeks of study drug initiation'}, {'measure': 'Percentages of classifications of rhythms identified', 'description': 'From pacemaker/ICD interrogation or Holter reports obtained at 2 weeks after study drug initiation', 'timeFrame': 'Within 2 weeks of study drug initiation'}, {'measure': 'PR interval', 'description': 'From baseline, pre-treatment ECG compared to 2 weeks post treatment ECG', 'timeFrame': 'Within 2 weeks of study drug initiation'}, {'measure': 'QRS duration', 'description': 'From baseline, pre-treatment ECG compared to 2 weeks post treatment ECG', 'timeFrame': 'Within 2 weeks of study drug initiation'}]",7.0,18 Years,,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,
NCT06084507,Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants,GST-HG171/ritonavir,"['GST-HG171/ritonavir', 'ritonavir']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,COVID-19 Respiratory Infection,"Fujian Akeylink Biotechnology Co., Ltd.",2025-09-01T16:18:10.923669,True,,,,,Food Effects Study of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants,,['COVID-19 Respiratory Infection'],[],,2023-05-04,2023-12-27,"[{'measure': 'Cmax', 'description': 'Maximum Observed Plasma Concentration (Cmax) of GST-HG171', 'timeFrame': 'Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose'}, {'measure': 'AUCinf', 'description': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of GST-HG171', 'timeFrame': 'Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose'}, {'measure': 'AUClast', 'description': 'Area Under the Curve From Time Zero o Last quantifiable concentration (AUClast) of GST-HG171', 'timeFrame': 'Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose'}]","[{'measure': 'urine', 'description': 'Total recovery of GST-HG171 -related substances in urine', 'timeFrame': '120 hours from GST-HG171 administration'}, {'measure': 'feces', 'description': 'Total recovery of GST-HG171 -related substances in feces', 'timeFrame': '120 hours from GST-HG171 administration'}]",5.0,18 Years,50 Years,ALL,True,INDUSTRY,0.0,18.0,ESTIMATED,v2_robust,True,False,False,False,
NCT00696007,Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer,Gemcitabine and cisplatin,"['Neoadjuvant Chemotherapy', 'Gemcitabine and cisplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Transitional Cell Carcinoma,Lahey Clinic,2025-09-01T16:18:10.923887,True,,,,,Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer,,['Transitional Cell Carcinoma'],"['Upper GU Tract Transitional Cell Carinoma', 'Nephroureterectomy', 'Chemotherapy', 'Gemcitabine', 'Cisplatin']",Study was unable to recruit subjects meeting the study requirements.,2008-04,2010-04,"[{'measure': 'Neoadjuvant chemotherapy (Gemcitabine and Cisplatin) Regime (3 cycles) before Nephroureterectomy', 'timeFrame': '5 years: follow ups 1st year/every 4 mths, 2nd & 3rd year to every 6 months, 4th & 5th yr-annually for patients who remain disease free'}]","[{'measure': 'Overall survival compared to institutional historical cohort of subjects who have undergone a nephroureterectomy alone.', 'timeFrame': '5 years'}]",2.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Study was unable to recruit subjects meeting the study requirements.
NCT02833207,Peripheral Vasodilation in Obese Humans,Drug Trial 1 (EDD),"['ROV', 'EDD', 'Drug Trial 1 (EDD)', 'Drug Trial 2 (ROV)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Obesity,"University of Wisconsin, Madison",2025-09-01T16:18:10.923952,True,,,,,Peripheral Vasodilation in Obese Humans,,['Obesity'],"['blood flow', 'vasodilation', 'Doppler Ultrasound', 'endothelium dependent dilation']","Due to COVID-19, difficulty obtaining study drugs, difficulty recruiting obese subjects, and limited access to on-call physicians.",2012-04-16,2021-11,"[{'measure': 'Change in limb blood flow in response to stimuli that cause vasodilation (ATP, ISO, BK, Ach, muscle contractions).', 'description': 'Change in limb blood flow (ml/min), measured with Doppler ultrasound, in response potassium vasodilation (EDD or ROV). The change in blood flow will be calculated by taking the difference between the stimulus blood flow response and the baseline blood flow. These changes will be compared between lean and obese.', 'timeFrame': 'Through study completion'}, {'measure': 'Change in limb blood flow in response to barium chloride infusion which inhibits potassium channel vasodilation.', 'description': 'Change in limb blood flow (ml/min), measured with Doppler ultrasound, in response to barium chloride infusion (inhibition of K+ vasodilation). This will be calculated by taking the difference between the stimulus blood flow response and the stimulus blood flow response in the presence of barium chloride. These changes will be compared between lean and obese.', 'timeFrame': 'Through study completion'}]","[{'measure': 'Endothelial cell collection from arterial catheter to measure protein expression.', 'description': 'Protein expression in endothelial cells harvested from arterial catheter that may be responsible for EDD or ROV functional changes (optional for subjects). Immunohistochemical methods will be used. Differences in protein expression will be assessed semi-quantitatively by normalizing expression to standard human endothelial cell cultures.', 'timeFrame': 'Through study completion'}, {'measure': 'Change in blood flow in response to L-NMMA and ketorolac in the presence of barium chloride', 'description': 'Change in limb blood flow (ml/min), measured with Doppler ultrasound, in response to L-NMMA and ketorolac infusion in the presence of barium chloride infusion. This will be calculated by taking the difference between the stimulus blood flow response and the stimulus blood flow response in the presence of all inhibitors (barium chloride, ketorolac, and L-NMAA). These changes will be compared between lean and obese.', 'timeFrame': 'Minutes/seconds between baseline and peak response to stimuli'}]",4.0,18 Years,40 Years,ALL,True,OTHER,1.0,8.0,ACTUAL,v2_robust,True,False,True,False,"Due to COVID-19, difficulty obtaining study drugs, difficulty recruiting obese subjects, and limited access to on-call physicians."
NCT00269607,Naltrexone Implants as Relapse Prevention,Implantation of naltrexone implants,['Implantation of naltrexone implants'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Opioid Dependency,University of Oslo,2025-09-01T16:18:10.923999,True,,,,,Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction.,,['Opioid Dependency'],"['Substance abuse', 'Treatment', 'Relapse prevention', 'opioid antagonist']",Recruitment difficulties. Reframed as pilot study,2005-05,2006-12,"[{'measure': 'Primary Outcomes: drug use at 6(12/18)months by self report, hair analysis; days in work or education, number of drug-free friends at 6 (12/18)months by self report'}]",[{'measure': 'Secondary Outcomes: depression at 6(12/18)months by BDI and Hopkins SCL-25; quality of life at 6(12/18)months by EuropASI'}],2.0,19 Years,,ALL,False,OTHER,0.0,12.0,ACTUAL,v2_robust,True,False,True,False,Recruitment difficulties. Reframed as pilot study
NCT02669407,Splanchnic Nerve Anesthesia in Heart Failure,regional nerve block with a local anesthetic (Lidocaine),['regional nerve block with a local anesthetic (Lidocaine)'],1,INTERVENTIONAL,['NA'],,COMPLETED,Heart Failure,Duke University,2025-09-01T16:18:10.924017,True,,,,,Splanchnic Nerve Block for Acute Heart Failure,,['Heart Failure'],[],,2017-01-01,2018-10,"[{'measure': 'Central Venous Pressure', 'timeFrame': 'Baseline, 90 minutes'}, {'measure': 'Pulmonary Arterial Mean Pressure', 'timeFrame': 'baseline, 30 minutes'}, {'measure': 'Pulmonary Capillary Wedge Pressure', 'timeFrame': 'baseline, 30 minutes'}]","[{'measure': 'Cardiac Index', 'timeFrame': 'baseline, 30 minutes'}, {'measure': 'Ejection Fraction (LVEF)', 'timeFrame': 'Baseline, 90 minutes'}, {'measure': 'Pulmonary Artery Systolic Pressure', 'timeFrame': 'Baseline, 30 minutes'}, {'measure': 'Right Ventricular Diameter', 'timeFrame': 'Baseline, 30 mins'}, {'measure': 'Left Ventricular Diameter', 'timeFrame': 'Baseline, 30 mins'}, {'measure': 'N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Level', 'description': 'NT-proBNP level is elevated in heart failure and reflects its severity. A higher value indicates less stability.', 'timeFrame': 'Baseline; 90 minutes'}, {'measure': 'Urine Output Measured in ml Over 3 Hours', 'timeFrame': 'Baseline, post-procedure (0-3 hours)'}, {'measure': 'Change in Blood Urea Nitrogen (BUN)', 'description': 'BUN represents the major nitrogen excretion pathway and is used to evaluate renal function. Higher BUN levels indicate less stability.', 'timeFrame': 'Baseline; 90 minutes'}, {'measure': 'Change in Creatinine Level', 'description': 'Creatinine measurements are used to evaluate renal function. Higher creatinine levels indicate less stability.', 'timeFrame': 'Baseline; 90 minutes'}, {'measure': 'Dyspnea as Measured on Likert Scale', 'description': 'The scale ranges from -3 (markedly worse) to 3 (markedly improved). 0 = no change.', 'timeFrame': '15, 30, 45, 60, 75, 90 minutes; 24 hours'}, {'measure': 'Change in Clinical Symptoms, as Measured by 6 Minute Walk Test', 'description': 'The 6 Minute Walk Test (6MWT) is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.', 'timeFrame': 'Baseline, 90 minutes, 24 hours'}]",14.0,18 Years,90 Years,ALL,False,OTHER,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,
NCT00089492,A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients,Optimized Background ARVs,"['Optimized Background ARVs', 'enfuvirtide [Fuzeon]']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV Infections,Hoffmann-La Roche,2025-09-01T16:18:10.924068,True,,,,,"A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients.",,['HIV Infections'],[],,2004-07,2006-06,"[{'measure': 'Viral load.\\n\\n', 'timeFrame': 'Week 48'}]","[{'measure': 'CD4 lymphocyte count.', 'timeFrame': 'Week 48'}, {'measure': 'AEs, laboratory abnormalities, local injection site reactions, AIDS-defining events.\\n', 'timeFrame': 'Throughout study'}]",3.0,16 Years,,ALL,False,INDUSTRY,1.0,64.0,ACTUAL,v2_robust,True,True,False,False,
NCT00483392,Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients,"metformin, rosiglitazone","['metformin, rosiglitazone']",1,INTERVENTIONAL,['NA'],,COMPLETED,Insulin Resistance,University Medical Centre Ljubljana,2025-09-01T16:18:10.924128,True,,,,,,,['Insulin Resistance'],"['insulin', 'rosiglitazone', 'metformin', 'hiv', 'protease inhibitors']",,,,"[{'measure': 'fasting plasma glucose, basal insulin levels', 'timeFrame': '48 weeks'}]","[{'measure': 'insulin resistance, beta cell function', 'timeFrame': '48 week'}]",2.0,18 Years,60 Years,MALE,,OTHER,0.0,,,v2_robust,True,True,False,False,
NCT02719392,A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression,Minocycline,['Minocycline'],1,INTERVENTIONAL,['PHASE4'],PHASE4,SUSPENDED,Bipolar Disorder,Massachusetts General Hospital,2025-09-01T16:18:10.924172,True,,,,,A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression,,"['Bipolar Disorder', 'Bipolar Depression']",[],"Due to limited study staff and the COVID-19 pandemic, enrollment has been paused as staff hours for this project have been reduced and reallocated to other projects.",2017-08-09,2026-08,"[{'measure': 'Illness severity on the Clinical Global Impression Scale-Bipolar Version (CGI-BP)', 'description': 'The CGI-BP is a modified version of the CGI designed specifically for use in assessing global illness severity and change in patients with bipolar disorder. We will use the overall severity subscale to determine outcome.', 'timeFrame': '8 weeks'}]","[{'measure': 'Quality of life on the Quality of Life, Enjoyment, and Satisfaction Questionnaire (QLES-Q)', 'description': 'Assesses subjective quality of life (i.e. physical health, subjective feelings, leisure activities and social relationships).', 'timeFrame': '8 weeks'}, {'measure': 'Life satisfaction on the Longitudinal Interval Follow-up Evaluation - Range of Impaired Functioning Tool (LIFE-RIFT)', 'description': 'Assesses extent to which psychopathology has impacted current functioning in work, household chores, interpersonal relationships with partner, family, and friends, recreational activities, and life satisfaction.', 'timeFrame': '8 weeks'}, {'measure': 'Depression severity on the Montgomery-Asberg Depression Rating Scale (MADRS)', 'description': 'Assesses the severity of depressive symptoms', 'timeFrame': '8 weeks'}, {'measure': 'Mania severity on the Young Mania Rating Scale (YMRS)', 'description': 'Assesses the severity of mania and hypomania symptoms', 'timeFrame': '8 weeks'}]",5.0,18 Years,65 Years,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,True,False,"Due to limited study staff and the COVID-19 pandemic, enrollment has been paused as staff hours for this project have been reduced and reallocated to other projects."
NCT00441792,The Effect of Etomidate on Patient Outcomes After Single Bolus Doses,Etomidate,"['Etomidate', 'midazolam']",2,INTERVENTIONAL,['NA'],,COMPLETED,Sepsis,Advocate Hospital System,2025-09-01T16:18:10.924189,True,,,,,A Randomized Trial of Etomidate Versus Midazolam for Intubation of Patients With Sepsis.,,"['Sepsis', 'Trauma']","['Sepsis', 'Etomidate', 'midazolam', 'ketamine']",,2007-10,2010-12,"[{'measure': 'Length of Stay', 'description': 'The primary outcome of the study was hospital length of stay.', 'timeFrame': 'time in days of hospitalization'}]","[{'measure': 'Mortality', 'description': 'In-hospital mortality.', 'timeFrame': 'Duration of hospitalization.'}]",2.0,18 Years,,ALL,False,OTHER,1.0,122.0,ACTUAL,v2_robust,True,True,False,False,
NCT06972992,"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide",ASC47 +Semaglutide,"['ASC47 +Semaglutide', 'Placebo+Semaglutide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Chronic Weight Management,"Ascletis Pharma (China) Co., Limited",2025-09-01T16:18:10.924476,True,,,,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection, for Subcutaneous Use in Combination With Semaglutide in Participants With Obesity",,['Chronic Weight Management'],[],,2025-04-18,2025-12-18,"[{'measure': 'Adverse events', 'description': 'Evaluate the incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs)', 'timeFrame': 'up to 71 days'}]","[{'measure': 'Change From Baseline in Body Weight', 'description': 'Change from baseline (week 1) to week 10 in body weight was evaluated', 'timeFrame': 'up to 71 days'}, {'measure': 'Cmax of ASC47', 'description': 'Evaluate the Peak Plasma Concentration of ASC47 in combination with semaglutide.', 'timeFrame': 'up to 71 days'}, {'measure': 'AUC of ASC47', 'description': 'Evaluate the Area under the plasma concentration versus time curve of ASC47 in combination with semaglutide.', 'timeFrame': 'up to 71 days'}, {'measure': 'T1/2 of ASC47', 'description': 'Evaluate the Terminal-Phase Half-Life of ASC47 in combination with semaglutide.', 'timeFrame': 'up to 71 days'}, {'measure': 'CL/F of ASC47', 'description': 'Evaluate the Apparent Systemic Clearance of ASC47 in combination with semaglutide.', 'timeFrame': 'up to 71 days'}]",6.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,24.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06351592,First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS),ALN-SOD,"['ALN-SOD', 'Placebo (PB)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Amyotrophic Lateral Sclerosis (ALS),Regeneron Pharmaceuticals,2025-09-01T16:18:10.924534,True,,,,,"First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations",,"['Amyotrophic Lateral Sclerosis (ALS)', 'Mutation in the Superoxide Dismutase-1 (SOD1) Gene']","['Symptomatic', 'Known pathogenic mutation', 'Predicted pathogenic mutation']",,2024-08-28,2029-04-26,"[{'measure': 'Incidence of treatment-emergent adverse event (TEAEs) in participants treated with ALN-SOD', 'timeFrame': 'At week 4 and week 124'}, {'measure': 'Severity of TEAEs in participants treated with ALN-SOD', 'timeFrame': 'At week 4 and week 124'}]","[{'measure': 'Concentration of neurofilament light chain (NfL) in plasma over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Change in concentration of NfL in plasma over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Concentration of SOD1 protein in cerebrospinal fluid (CSF) over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Change in concentration of SOD1 protein in CSF over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Concentration of NfL in CSF over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Change in concentration of NfL in CSF over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Concentration of ALN-SOD in plasma over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Concentration of ALN-SOD in CSF over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Incidence of anti-drug antibodies (ADAs) to ALN-SOD in serum over time', 'timeFrame': 'Up to approximately week 124'}, {'measure': 'Titer of ADAs to ALN-SOD in serum over time', 'timeFrame': 'Up to approximately week 124'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,42.0,ESTIMATED,v2_robust,True,False,False,True,
NCT06035692,Application of Brachial Plexus Block in Patients Undergoing Cerebral Aneurysm Embolization Via Transradial Approach,Ropivacaine,"['brachial plexus block', 'Ropivacaine']",2,INTERVENTIONAL,['NA'],,RECRUITING,Intracranial Aneurysm,The First Affiliated Hospital with Nanjing Medical University,2025-09-01T16:18:10.924672,True,,,,,Effect of Brachial Plexus Block on Outcomes of Upper Extremity Arteries After Intracranial Aneurysm Interventional Surgery Via Transradial Access: A Randomized Clinical Trial,,"['Intracranial Aneurysm', 'Transradial Access(TRA)']",[],,2023-06-01,2024-06-30,"[{'measure': 'Assess the RAS by angiography at the begining of the operation', 'description': 'The RAS was assessed through radial artery angiography following the insertion of the arterial catheter.', 'timeFrame': 'During the operation'}, {'measure': 'Evaluate the degree of RAS by angiography at the end of the operation', 'description': 'The severity of RAS was classified as severe, moderate, or mild based on the degree of stenosis observed on radial arteriography: greater than 75%, 25-75%, and less than 25% of the vessel diameter, respectively. In addition, if the combined spasm length exceeded 2cm, the severity increased by 1 grade.', 'timeFrame': 'During the operation'}]","[{'measure': 'Assess unfavorable RA for repeated trans-radial interventions (TRI) at 1 month after surgery by ultrasonography.', 'description': 'The the radial artery was evaluated at 1 month after surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.The radial artery was considered unfavorable for repeated-TRI if it exhibited any of the following criteria: total occlusion, intima-media thickness (IMT) ≥0.5 mm and diameter \\<1.5mm, moderate and diffuse stenosis (\\> 10 mm in length), or severe focal or diffuse stenosis (regardless of length).', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Record the incidence of intima-media thickness (IMT) ≥0.5 mm and diameter <1.5mm at 1 month after surgery by ultrasonography.', 'description': 'The incidence of intima-media thickness (IMT) ≥0.5 mm and diameter \\<1.5mm as a component of unfavorable RA for repeated TRI was recorded at one month follow-up.', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Record the incidence of radial artery occlusion at 1 month after surgery by ultrasonography.', 'description': 'The incidence of radial artery occlusion as a component of unfavorable RA for repeated TRI was recorded at one month follow-up.', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Record the incidence of moderate and diffuse stenosis (> 10 mm in length) at 1 month after surgery by ultrasonography.', 'description': 'The incidence of moderate and diffuse stenosis (\\> 10 mm in length) as a component of unfavorable RA for repeated TRI was recorded at one month follow-up.', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Record the incidence of severe focal or diffuse stenosis (regardless of length) at 1 month after surgery by ultrasonography.', 'description': 'The incidence of severe focal or diffuse stenosis (regardless of length) as a component of unfavorable RA for repeated TRI was recorded at one month follow-up.', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Record the use of nitroglycerin during the operation', 'description': 'When the radial sheath was inserted, upper limb angiography was performed, and nitroglycerin 200ug was administered if any degree of vasospasm in the upper limb was observed on the angiography. The administration of nitroglycerin in each group was recorded.', 'timeFrame': 'During the operation'}, {'measure': 'Record the incidence of intraoperative hypotension', 'description': 'The definition of intraoperative hypotension was a mean arterial blood pressure below 60mmHg.', 'timeFrame': 'During the operation'}, {'measure': 'Record physician satisfaction by questionnaire', 'description': 'Physician satisfaction was scored on a scale of 1-10, with a score of 1 indicating very poor and dissatisfied experience and a score of 10 indicating very satisfied. The surgeons were asked to fill in the satisfaction questionnaire according to the operation situation after operation and recorded.', 'timeFrame': 'Day 0 after the surgery'}, {'measure': 'Record the duration of radial artery puncture', 'description': 'The time from the beginning of the radial artery puncture to the placement of the radial sheath was recorded.', 'timeFrame': 'At the begining of the operation'}, {'measure': 'Measured diameter and the hemodynamic parameters of radial artery by ultrasound 30min after BPB or control interventions', 'description': 'The radial artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': '30min after BPB or control interventions'}, {'measure': 'Measured diameter and the hemodynamic parameters of radial artery by ultrasound 24h after surgery', 'description': 'The radial artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': '24h after surgery'}, {'measure': 'Measured diameter and the hemodynamic parameters of radial artery by ultrasound 1 month after surgery', 'description': 'The radial artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Measured diameter and the hemodynamic parameters of ulnar artery by ultrasound 30min after BPB or control interventions', 'description': 'The ulnar artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': '30min after BPB or control interventions'}, {'measure': 'Measured diameter and the hemodynamic parameters of ulnar artery by ultrasound 24h after surgery', 'description': 'The ulnar artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': '24h after surgery'}, {'measure': 'Measured diameter and the hemodynamic parameters of ulnar artery by ultrasound 1 month after surgery', 'description': 'The ulnar artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Measured diameter and the hemodynamic parameters of brachial artery by ultrasound 30min after BPB or control interventions', 'description': 'The brachial artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': '30min after BPB or control interventions'}, {'measure': 'Measured diameter and the hemodynamic parameters of brachial artery by ultrasound 24h after surgery', 'description': 'The brachial artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': '24h after surgery'}, {'measure': 'Measured diameter and the hemodynamic parameters of brachial artery by ultrasound 1 month after surgery', 'description': 'The brachial artery was evaluated(include diameter, PSV,EDV,TAMAX,PI,RI) before the surgery using ultrasonography by an anesthesiologist who was blinded to the group assignments.', 'timeFrame': 'Month 1 after surgery'}, {'measure': 'Record mean arterial pressure at different time points', 'description': 'The mean intraoperative arterial pressure from T0 to T8 was recorded. T0 indicates time after entering the operating room; T1,30 minutes after BPB or control procedure; T2, 5 minutes after induction of general anesthesia; T3, angiography after the radial sheath enters the radial artery; T4,1minutes after angiography; T5, 3minutes after angiography; T6, 5minutes after angiography; T7, 10 minutes after angiography; T8, completion of the operation.', 'timeFrame': 'During the operation'}, {'measure': 'Record perioperative complications', 'description': 'Perioperative complications include puncture site complications, brachial plexus complications, and other cardiovascular and cerebrovascular complications', 'timeFrame': 'Day 1 after the surgery'}, {'measure': 'Recorded the levels of eight inflammatory factors', 'description': 'The hospital laboratory conducted an examination on 8 inflammatory factors (include IL-2,IL-4,IL-6,IL-10,IL-17,IL-12P70,IFN-r,TNF-a) to assess postoperative infection, and subsequently provided the results.', 'timeFrame': 'Day 1 after the surgery'}, {'measure': 'Recorded the incidence of postoperative acute embolism events', 'description': 'A head magnetic resonance imaging(MRI) was conducted to document the occurrence of postoperative embolic events, such as acute cerebral infarction.', 'timeFrame': 'Day 1 after the surgery'}]",24.0,18 Years,75 Years,ALL,False,OTHER,3.0,176.0,ESTIMATED,v2_robust,True,False,False,False,
NCT01718236,Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section,Rocuronium + sugammadex,"['Succinylcholine + Neostigmine', 'Rocuronium + sugammadex']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Caesarean Section,Brno University Hospital,2025-09-01T16:18:10.924751,True,,,,,Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section,,"['Caesarean Section', 'Pregnancy']","['caesarean section', 'rocuronium', 'sugammadex']",,2012-09,2015-01,"[{'measure': 'time needed to tracheal intubation', 'description': 'Quality: Rapid induction to general anesthesia with administration propofol and rocuronium for termination the pregnancy by Caesarean section are at least as good as the combination of propofol and succinylcholine iodide.Recording and evaluated will be the time from the beginning as the first drug in the rapid induction to general anesthesia will be administered until the discovery of the first wave of etCO2 after successful intubation (seconds), evaluation of intubation conditions (resistance to laryngoscopy, position of the vocal cords, response to the intubation attempt (limbs movement or cough) scored 1-3 according to level terms, conditions, entry scores for direct visualization of the vocal cords by Cormack-Lehane (I-IV)', 'timeFrame': '2 years'}]","[{'measure': 'total procedure time', 'description': 'Economics: After reversal of neuromuscular blockade using sugammadex are procedure time and turnovers shorter than the use of neostigmine in the recommended dosage for patients undergoing termination of pregnancy by Caesarean section. Recording and evaluated will be the total procedure time until the recovery from neuromuscular blockade to the level of TOF ratio of 0.9, the administration of the recovery dose will in group ROCSUG in the case for posttetanic count mode in the level of PTC1, 2 at a dose of sugammadex 4mg/kg , the TOF count 1.2 sugammadex at a dose of 2 mg / kg, in the case of failure to achieve these values the anesthesiologist wil wait with the administration of the recovery dose for their achievement. In group SUCNEO for achieving TOF count 1.2 and higher, the dose of atropine to 0.01 mg / kg and neostigmine 0.03 mg / kg will be administered.', 'timeFrame': '2 years'}]",2.0,14 Years,60 Years,FEMALE,False,OTHER,3.0,500.0,ACTUAL,v2_robust,True,True,False,False,
NCT04082936,A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma,imvotamab,['imvotamab'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Non-Hodgkin Lymphoma,"IGM Biosciences, Inc.",2025-09-01T16:18:10.924770,True,,,,,"A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas",,"['Non-Hodgkin Lymphoma', 'Follicular Lymphoma', 'DLBCL', 'Mantle Cell Lymphoma', 'Marginal Zone Lymphoma']","['Lymphoma', 'Non-Hodgkin Lymphoma', 'DLBCL', 'Follicular Lymphoma', 'relapsed or refractory']",Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases prioritized.,2019-09-30,2024-02-22,"[{'measure': 'Overall Frequency of Adverse Events', 'description': 'Percentage of Adverse Events', 'timeFrame': 'Baseline through approximately 30 days after last study treatment'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'Percentage of measurable disease in subjects who have achieved either complete response (CR) or partial response (PR)', 'timeFrame': 'Baseline up to 5 years'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Percentage of measurable disease in subjects who have achieved either complete response (CR) or partial response (PR)', 'timeFrame': 'Baseline up to 5 years'}, {'measure': 'Duration of Response (DOR)', 'description': 'measured from time of initial response until documented tumor progression', 'timeFrame': 'Baseline up to 5 years'}]",4.0,18 Years,,ALL,False,INDUSTRY,1.0,97.0,ACTUAL,v2_robust,True,False,True,True,Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases prioritized.
NCT06688136,QLESP Block Versus Periarticular Infiltration for Postoperative Analgesia in Hip Surgery,ropivacaine,['ropivacaine'],1,INTERVENTIONAL,['NA'],,RECRUITING,Regional Anaesthesia,Huazhong University of Science and Technology,2025-09-01T16:18:10.924806,True,,,,,Ultrasound-guided Transmuscular Quadratus Lumborum and Modified Erector Spinae Plane Block Versus Periarticular Infiltration for Pain Management After Total Hip Arthroplasty,,['Regional Anaesthesia'],[],,2024-11-18,2025-09-15,"[{'measure': 'The cumulative opioid consumption', 'timeFrame': 'At 24 postoperative hours'}]","[{'measure': 'The pain scores determined by the numeric rating scale (NRS, 0-10)', 'timeFrame': 'Postoperative 48 hours'}, {'measure': 'Quadriceps strength', 'timeFrame': 'Postoperative 48 hours'}, {'measure': 'Postoperative hospital length of stay', 'timeFrame': 'Up to 6 weeks'}]",4.0,18 Years,65 Years,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04323436,Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations,Spartalizumab,"['PDR001 placebo', 'INC280', 'Spartalizumab', 'PDR001', 'Capmatinib', 'spartalizumab placebo']",6,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,"Carcinoma, Non-Small-Cell Lung",Novartis Pharmaceuticals,2025-09-01T16:18:10.924862,True,,,,,"A Double-blind, Placebo Controlled, Randomized, Phase II Study Evaluating the Efficacy and Safety of Capmatinib and Spartalizumab vs Capmatinib and Placebo as 1st Line Treatment for Advanced NSCLC Patients With MET exon14 Skipping Mutations",,"['Carcinoma, Non-Small-Cell Lung']","['capmatinib', 'spartalizumab', 'MET mutation', 'EGFR wild-type', 'ALK negative mutation']",Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies,2020-08-19,2023-01-26,"[{'measure': 'Run-in Part: Overall Response Rate (ORR) by Investigator Assessment as Per RECIST 1.1', 'description': 'Tumor response was based on local investigator assessment as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. ORR per RECIST v1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR).\n\nFor RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.', 'timeFrame': 'Up to approximately 2 years and 4 months'}, {'measure': 'Randomized Part: Progression-Free Survival (PFS) by BIRC as Per RECIST 1.1', 'description': 'PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Tumor response based on blinded independent review committee (BIRC) assessment per RECIST v1.1.', 'timeFrame': 'Up to 6 years'}]","[{'measure': 'Run-in Part: Number of Participants With Dose Reductions and Dose Interruptions of Capmatinib', 'description': 'Number of participants with at least one dose reduction of capmatinib and number of participants with at least one dose interruption of capmatinib.', 'timeFrame': 'From first dose of capmatinib to last dose, up to 2.4 years'}, {'measure': 'Run-in Part: Number of Participants With Dose Reductions and Dose Interruptions of Spartalizumab', 'description': 'Number of participants with at least one dose reduction of spartalizumab and number of participants with at least one dose interruption of spartalizumab. Dose reductions were not allowed for spartalizumab.', 'timeFrame': 'From first dose of spartalizumab to last dose, up to 0.9 years'}, {'measure': 'Run-in Part: Dose Intensity of Capmatinib', 'description': 'Dose intensity of capmatinib was calculated as actual cumulative dose in milligrams divided by duration of exposure in days.', 'timeFrame': 'From first dose of capmatinib to last dose, up to 2.4 years'}, {'measure': 'Run-in Part: Dose Intensity of Spartalizumab', 'description': 'Dose intensity of spartalizumab was calculated as actual cumulative dose in milligrams divided by duration of exposure in days and then multiplied by the duration of one cycle (28 days).', 'timeFrame': 'From first dose of spartalizumab to last dose, up to 0.9 years'}, {'measure': 'Run-in Part: Disease Control Rate (DCR) by Investigator Assessment as Per RECIST 1.1', 'description': 'DCR is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and non-CR/non-progressive disease (for subjects without target lesions). Tumor response was based on local investigator assessment per RECIST v1.1.\n\nFor RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression).', 'timeFrame': 'Up to approximately 2 years and 4 months'}, {'measure': 'Run-in Part: Progression-Free Survival (PFS) by Investigator Assessment as Per RECIST 1.1', 'description': 'PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. Tumor response was based on investigator assessment per RECIST v1.1. Progression is defined using RECIST v1.1 as at least 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.\n\nPFS was analyzed using Kaplan-Meier estimates.', 'timeFrame': 'Up to approximately 2 years and 5 months'}, {'measure': 'Run-in Part: Maximum Observed Plasma Concentration (Cmax) of Capmatinib', 'description': 'Pharmacokinetic (PK) parameters were calculated based on capmatinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed plasma concentration following a dose.', 'timeFrame': 'pre-dose and 1, 2, 4 and 8 hours after morning dose on Cycle 3 Day 1. The duration of one cycle was 28 days.'}, {'measure': 'Run-in Part: Time to Reach Maximum Plasma Concentration (Tmax) of Capmatinib', 'description': 'PK parameters were calculated based on capmatinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) plasma concentration following a dose. Actual recorded sampling times were considered for the calculations.', 'timeFrame': 'pre-dose and 1, 2, 4 and 8 hours after morning dose on Cycle 3 Day 1. The duration of one cycle was 28 days.'}, {'measure': 'Run-in Part: Area Under the Plasma Concentration-time Curve From Time Zero to the End of a Dosing Interval (AUCtau) of Capmatinib', 'description': 'PK parameters were calculated based on capmatinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUCtau calculation. A dosing interval (tau) is defined as 12 hours. The portion of area under the curve between 8 hours and 12 hours post-dose was calculated by extrapolation based on terminal elimination slop.', 'timeFrame': 'pre-dose and 1, 2, 4 and 8 hours after morning dose on Cycle 3 Day 1. The duration of one cycle was 28 days.'}, {'measure': 'Run-in Part: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Capmatinib', 'description': 'PK parameters were calculated based on capmatinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.', 'timeFrame': 'pre-dose and 1, 2, 4 and 8 hours after morning dose on Cycle 3 Day 1. The duration of one cycle was 28 days.'}, {'measure': 'Run-in Part: Maximum Observed Serum Concentration (Cmax) of Spartalizumab', 'description': 'Pharmacokinetic (PK) parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose.', 'timeFrame': 'pre-infusion and 1, 72, 168, 336 and 672 hours after completion of the spartalizumab infusion on Cycle 3 Day 1. The duration of the infusion was approximately 30 minutes. The duration of one cycle was 28 days.'}, {'measure': 'Run-in Part: Time to Reach Maximum Serum Concentration (Tmax) of Spartalizumab', 'description': 'PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations.', 'timeFrame': 'pre-infusion and 1, 72, 168, 336 and 672 hours after completion of the spartalizumab infusion on Cycle 3 Day 1. The duration of the infusion was approximately 30 minutes. The duration of one cycle was 28 days.'}, {'measure': 'Run-in Part: Area Under the Serum Concentration-time Curve From Time Zero to the End of a Dosing Interval (AUCtau) of Spartalizumab', 'description': 'PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUCtau calculation. A dosing interval (tau) is defined as 28 days.', 'timeFrame': 'pre-infusion and 1, 72, 168, 336 and 672 hours after completion of the spartalizumab infusion on Cycle 3 Day 1. The duration of the infusion was approximately 30 minutes. The duration of one cycle was 28 days.'}, {'measure': 'Run-in Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Spartalizumab', 'description': 'PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.', 'timeFrame': 'pre-infusion and 1, 72, 168, 336 and 672 hours after completion of the spartalizumab infusion on Cycle 3 Day 1. The duration of the infusion was approximately 30 minutes. The duration of one cycle was 28 days.'}, {'measure': 'Randomized Part: Overall Survival (OS)', 'description': 'OS is defined as the time from date of start of treatment to date of death due to any cause.', 'timeFrame': 'Up to 12 years'}, {'measure': 'Randomized Part: Number of Participants With Dose Reductions and Dose Interruptions of Capmatinib and Spartalizumab', 'description': 'Number of participants with at least one dose reduction of capmatinib and spartalizumab and number of participants with at least one dose interruption of capmatinib and spartalizumab.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Dose Intensity of Capmatinib and Spartalizumab', 'description': 'Dose intensity is defined as the ratio of actual cumulative dose and duration of exposure.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Progression-Free Survival (PFS) by Investigator Assessment as Per RECIST 1.1', 'description': 'PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Tumor response based on investigator assessment per RECIST v1.1.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Disease Control Rate (DCR) by BIRC and Investigator Assessment as Per RECIST 1.1', 'description': 'DCR is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and non-CR/non-progressive disease (for subjects without target lesions). Tumor response based on BIRC and local investigator assessment per RECIST v1.1.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Overall Response Rate (ORR) by BIRC and Investigator Assessment as Per RECIST 1.1', 'description': 'ORR is defined as the percentage of participants with a best overall response of Complete Response (CR) and Partial Response (PR). Tumor response based on BIRC and local investigator assessment per RECIST v1.1.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Duration of Response (DOR) by BIRC and Investigator Assessment as Per RECIST 1.1', 'description': 'DOR is defined as the time from the date of first documented response (CR or PR) to the first documented progression per RECIST 1.1 or death due to any cause.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Time to Response (TTR) by BIRC and Investigator Assessment as Per RECIST 1.1', 'description': 'TTR is defined as the time from the date of start of treatment to the first documented response of either CR or PR, which must be subsequently confirmed, according to RECIST 1.1.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Change From Baseline in EORTC QLQ-C30', 'description': 'The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) contains 30 items and is composed of both multi-item scales and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive, and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact) and a global health status/QoL scale. All scales and single-item measures range in score from 0 to 100. For the functional and the global QoL scales, a higher score indicates better health. For the symptom scales, a higher score indicates more symptom burden. The QLQ-C30 summary score (0-100) is calculated as the mean of 13 of the 15 QLQ-C30 scale and item scores (excluding global QoL and financial impact), with a higher score indicating a better health-related QoL.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Change From Baseline in EORTC QLQ-LC13', 'description': 'EORTC QLQ-LC13 is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The five domains of the LC13 include pain, dyspnea, coughing and hemoptysis, and are based on their presence over the past week. All but the pain domain are scored on a 4 point Likert scale ranging from ""not at all"" to ""very much"". Pain score is based on its presence, hence yes or no. Scores are averaged and transformed to 0 to 100. A higher score indicates a higher presence of symptoms.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Change From Baseline in EQ-5D-5L', 'description': ""The EQ-5D-5L is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L contains one item for each of five dimensions of health-related quality of life (HRQOL) (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Response options for each item vary from having no problems to extreme problems. Subject responses to the five dimensions of HRQOL reflect a specific health state that corresponds to a population preference weight for that state on a continuous scale of 0 (death) to 1 (perfect health). A visual analog scale (ranging from 0 to 100) is also included to capture subject's rating of their overall health status. Higher scores of the EQ-5D-5L represent better health states."", 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Time to Definitive 10 Points Deterioration Symptom Scores for Pain in Chest, Coughing and Dyspnea Per QLQ-LC13 Questionnaire', 'description': 'EORTC QLQ-LC13 is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The five domains of the LC13 include pain in chest, dyspnea, coughing and hemoptysis, and are based on their presence over the past week. All but the pain domain are scored on a 4 point Likert scale ranging from ""not at all"" to ""very much"". Pain score is based on its presence, hence yes or no. Scores are averaged and transformed to 0 to 100. A higher score indicates a higher presence of symptoms.\n\nThe time to definitive 10 points deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10 points relative to baseline worsening of the corresponding scale score or death due to any cause.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Time to Definitive Deterioration in Global Health Status/QoL, Shortness of Breath and Pain Per EORTC QLQ-C30', 'description': 'The EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive, and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact) and a global health status/QoL scale. All scales and single-item measures range in score from 0 to 100. For the functional and the global QoL scales, a higher score indicates better health. For the symptom scales, a higher score indicates more symptom burden.\n\nThe time to definitive 10 points deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10 points relative to baseline worsening of the corresponding scale score or death due to any cause.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Maximum Observed Concentration (Cmax) of Capmatinib and Spartalizumab', 'description': 'Pharmacokinetic (PK) parameters calculated based on capmatinib and spartalizumab concentrations in plasma and serum, respectively, by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Time to Reach Maximum Concentration (Tmax) of Capmatinib and Spartalizumab', 'description': 'Pharmacokinetic (PK) parameters calculated based on capmatinib and spartalizumab concentrations in plasma and serum, respectively, by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Area Under the Concentration-time Curve From Time Zero to the End of a Dosing Interval (AUCtau) of Capmatinib and Spartalizumab', 'description': 'Pharmacokinetic (PK) parameters calculated based on capmatinib and spartalizumab concentrations in plasma and serum, respectively, by using non-compartmental methods.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Capmatinib and Spartalizumab', 'description': 'Pharmacokinetic (PK) parameters calculated based on capmatinib and spartalizumab concentrations in plasma and serum, respectively, by using non-compartmental methods.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Randomized Part: Number of Participants With Anti-spartalizumab Antibodies', 'description': 'Immunogenicity (IG) evaluated in serum samples. The assay to quantify and assess the IG was a validated homogeneous enzyme-linked immunosorbent assay (ELISA).', 'timeFrame': 'Baseline (pre-dose), up to 6 years'}]",34.0,18 Years,,ALL,False,INDUSTRY,0.0,31.0,ACTUAL,v2_robust,True,False,True,False,Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies
NCT04153136,The ENCHANTMENT HIV Study,Sacubitril-Valsartan 49-51Mg Oral Tablet,"['Placebo oral tablet', 'Sacubitril-Valsartan 49-51Mg Oral Tablet', 'Entresto']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV/AIDS,Massachusetts General Hospital,2025-09-01T16:18:10.925095,True,,,,,Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study,,"['HIV/AIDS', 'Heart Failure With Preserved Ejection Fraction']","['HIV', 'Sacubitril/valsartan', 'Heart Failure with Preserved Ejection Fraction', 'Aldosterone', 'Natriuretic Peptides', 'Myocardial Dysfunction', 'Cardiovascular Disease']",,2020-09-11,2025-07-09,"[{'measure': 'Myocardial Inflammation/Fibrosis', 'description': 'Myocardial Inflammation/Fibrosis measured by extracellular volume fraction via cardiac magnetic resonance imaging', 'timeFrame': '6 months'}, {'measure': 'Myocardial Dysfunction', 'description': 'Left Atrial Volume Index or Global Longitudinal Strain measured by cardiac transthoracic echocardiography', 'timeFrame': '6 months'}]","[{'measure': 'Other Indices of Myocardial Dysfunction', 'description': 'Alterations in other cardiac structure and function as measured by cardiac magnetic resonance imaging or cardiac transthoracic echocardiogram', 'timeFrame': '6 months'}, {'measure': 'Markers of Myocardial Inflammation and Fibrosis', 'description': 'Circulating biomarkers of myocardial inflammation and fibrosis: Gal3, ST2, GDF15, hs-cTnT', 'timeFrame': '6 months'}, {'measure': 'Cardiac Natriuretic Peptides', 'description': 'Circulating cardiac natriuretic peptides: ANP, BNP, NT-proBNP', 'timeFrame': '6 months'}]",5.0,40 Years,70 Years,ALL,False,OTHER,0.0,39.0,ACTUAL,v2_robust,True,True,False,False,
NCT03721211,Imaging With [11C]Martinostat in Breast Cancer,[11C]Martinostat,"['Martinostat', '[11C]Martinostat']",2,INTERVENTIONAL,['PHASE1'],PHASE1,WITHDRAWN,Breast Cancer,Christine Elizabeth Edmonds,2025-09-01T16:18:10.925133,True,,,,,Imaging With [11C]Martinostat in Breast Cancer,,['Breast Cancer'],['Breast Cancer'],Principal investigator left the study institution.,2020-02-01,2024-10-31,"[{'measure': 'PET-MRI Visualization and Quantification of Breast Tumor Uptake of [11C]Martinostat Above Background Uptake, as Assessed by SUV Measurements', 'description': 'Evaluate the ability of PET-MRI to visualize and quantify uptake of \\[11C\\]Martinostat in breast tumors above background tracer uptake. SUVmax will be collected from the primary breast tumor and the normal background breast tissue. The study is powered to detect a difference in mean background SUVmax of 0.4 in breast parenchyma uninvolved by tumor and breast parenchyma with breast tumor using a two-sample t-test.', 'timeFrame': 'up to 2 years'}]","[{'measure': 'Quantitative [11C]Martinostat-PET Uptake in Primary Breast Cancer, and Correlation with Expression of HDAC Isoforms', 'description': 'Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis. SUV measurements will be collected from the primary breast tumors on PET-MRI.', 'timeFrame': 'up to 2 years'}, {'measure': 'Correlation of Total Volume of Distribution of Dynamic [11C]Martinostat Uptake with Expression of HDAC Isoforms', 'description': 'Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis. The total volume of \\[11C\\]Martinostat distribution will be collected from each PET-MRI.', 'timeFrame': 'up to 2 years'}, {'measure': 'Comparison of HDAC Isoform Expression by Western Blot Across Breast Tumor Subtypes', 'description': 'Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis and will be analyzed for an association with the tumor subtype as determined by expression of the estrogen receptor, progesterone receptor, and HER2 receptor on clinical pathology.', 'timeFrame': 'up to 2 years'}, {'measure': 'HDAC Expression Levels in Breast Tumors Compared to HDAC Expression in Adjacent Normal Breast Parenchyma', 'description': 'Comparison of the expression of HDAC in breast tumors to the expression of HDAC in the adjacent normal breast parenchyma. Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis. Expression of HDAC isoforms in the normal breast parenchyma will be determined from biopsy tissue that is collected from the same breast with the cancer, but in a region of healthy breast parenchyma not involved by tumor.', 'timeFrame': 'up to 2 years'}]",5.0,18 Years,,FEMALE,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Principal investigator left the study institution.
NCT03151811,A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide,Melflufen,"['Dex', 'Melphalan Flufenamide', 'Pomalidomide', 'Fortecortin', 'Pepaxti', 'Imnovid', 'Melflufen', 'Dexamethasone', 'Decadron', 'Pomalyst']",10,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Multiple Myeloma,Oncopeptides AB,2025-09-01T16:18:10.925175,True,,,,,"A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide",,['Multiple Myeloma'],"['Refractory Multiple Myeloma', 'Relapsed Multiple Myeloma', 'Melphalan flufenamide (Melflufen)', 'Pomalidomide', 'Dexamethasone']",Sponsor assessed all endpoints and collected Overall Survival data for another two years following the primary completion date of 03Feb2021.,2017-06-12,2023-02-03,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'Progression Free Survival defined as the duration in months from randomization until first evidence of confirmed disease progression, as assessed by the Independent Review Committee (IRC) according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Disease progression was defined according to the IMWG-URC as progressive disease or death due to any cause, whichever occurs first.', 'timeFrame': 'From date of randomization until first evidence of confirmed disease progression or death due to any cause (whichever occurred first), up to the data cutoff date of 03 Feb 2021 (ie, assessed up to approximately 43 months).'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR defined as the proportion of patients for whom the best overall confirmed response is stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as assessed by IRC.', 'timeFrame': 'From randomization until best response achieved before confirmed disease progression or death due to any cause, up to data cutoff of 03 Feb 2021 (ie, assessed up to approx. 43 months). Median time to best response: Arm A=2.1 months and Arm B=2.0 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR defined as the duration in months from first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause.', 'timeFrame': 'From first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause, up to the data cutoff date of 03 Feb 2021 (ie, assessed up to approximately 43 months).'}, {'measure': 'Overall Survival (OS)', 'description': 'OS defined as the time in months from randomization to date of death due to any cause. Patients who were still alive at end of study, or lost to follow up, were censored at the last day the patient was known to be alive.', 'timeFrame': 'From date of randomization until up to 24 months following confirmed disease progression or initiation of subsequent therapy, up to the data cutoff date of 03 Feb 2023 (ie, assessed up to approximately 67 months).'}, {'measure': 'Safety and Tolerability: Number of Patients With Treatment-emergent Adverse Events (TEAEs), Including Clinical Laboratory and Vital Signs Abnormalities, as Assessed by CTCAE v4.0', 'description': 'Number of patients with TEAEs, including clinical laboratory and vital signs abnormalities, as assessed by CTCAE v4.0 are presented. No formal statistical analysis was performed for safety endpoints.', 'timeFrame': 'From start of dosing until 30 days after the last dose of study treatment, up to the data cutoff date of 03 Feb 2023 (ie, assessed up to approximately 67 months). Median duration of study treatment was 25.2 and 22.1 weeks for Arm A and B, respectively.'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,495.0,ACTUAL,v2_robust,True,False,True,True,Sponsor assessed all endpoints and collected Overall Survival data for another two years following the primary completion date of 03Feb2021.
NCT03134911,Health-related Quality of Life in Patients on Anticoagulants,DOAC or VKA,"['VKA', 'DOAC or VKA']",2,OBSERVATIONAL,[],,COMPLETED,Atrial Fibrillation,Boehringer Ingelheim,2025-09-01T16:18:10.925218,True,,,,,"Non-Interventional, Cross-sectional Study to Describe Health-related Quality of Life Among Controlled and Uncontrolled Patients With Nonvalvular Atrial Fibrillation on Anticoagulants. RE-QUOL Study.",,['Atrial Fibrillation'],[],,2017-04-24,2018-01-31,"[{'measure': 'Health Related Quality of Life (QoL) (HRQoL) Scores in the Spanish Adaptation of the Sawicki Questionnaire', 'description': 'Sawicki questionnaire includes 32 items grouped in 5 dimensions: 1) general treatment satisfaction, 2) self-efficacy, 3) strained social network, 4) daily hassles and 5) distress. Patients estimated the impact of each item on their self-perceived treatment-related QoL on a scale of 1 (total disagreement) to 6 (total agreement). Response options for each question were: 1=not at all, 2=very little, 3=a little, 4=somewhat, 5=a lot, 6=very much. High scores in general treatment satisfaction and self-efficacy dimensions indicate high perceived HRQoL. Low scores in the strained social network, daily hassles and distress dimensions indicate high perceived HRQoL. The summary score for each dimension was calculated by dividing the total score of the sum of the items that comprise each dimension into the number of items included in that dimension. For the general treatment satisfaction dimension, the scores of individual questions have to be inverted first to calculate the dimension score.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}]","[{'measure': 'Demographic Data of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Age group, work status and life status of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Height of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Height of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Weight of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Weight of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Body Mass Index (BMI) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'BMI of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Kidney Function (Creatinine Clearance) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Kidney function of uncontrolled non-valvular atrial fibrillation (NVAF) patients measured by creatinine clearance is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'History of Non-valvular Atrial Fibrillation (NVAF) - Time Since Diagnosis', 'description': 'Analysis of data regarding the specific NVAF profile of uncontrolled patients indicated that the average (± SD) time since diagnosis (calculated as the time from the date of diagnosis to the date of the baseline visit).', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'History of Non-valvular Atrial Fibrillation (NVAF) - Age at Diagnosis', 'description': 'Age at diagnosis of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Left Ventricular Ejection Fraction (LVEF) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Left ventricular ejection fraction (LVEF) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Percentage of Patients With Left Ventricular Ejection Fraction (LVEF) Depression of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Percentage of patients with left ventricular ejection fraction (LVEF) depression (% of LVEF depression) of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented qualitatively.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'CHA2DS2-VASc Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'CHA2DS2-VASc stroke risk score is calculated based on the following conditions: Congestive heart failure, Hypertension, Age (≥ 75), Diabetes Mellitus, Stroke/ Transient Ischaemic Attack (TIA), Vascular disease, Age 65-74, Sex category. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'HAS-BLED Score of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'HAS-BLED bleeding risk score is calculated based on the following conditions: Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (\\>65 years), Drugs and Alcohol. HAS-BLED bleeding risk score may range from 0 to 9 with 0 being the best outcome.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Thromboembolic Events by Categories', 'description': 'Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of thromboembolic events by categories are presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With History of Haemorrhagic Events by Categories', 'description': 'Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with history of haemorrhagic events by categories are presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Number of Visits to the Physician of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Number of visits to the internal medicine specialist per year of uncontrolled non-valvular atrial fibrillation (NVAF) patients is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Therapeutic Time in Range (TTR%) of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Therapeutic time in range (TTR%) of uncontrolled non-valvular atrial fibrillation (NVAF) patients determined by the Rosendaal method (poor control \\< 65%) or by the direct method (poor control \\< 60%).', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Time Since Treatment Initiation of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients', 'description': 'Time since treatment initiation of uncontrolled non-valvular atrial fibrillation (NVAF) patients was calculated as the time from the start date of treatment to the date of the baseline visit.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients Received Type of VKA Treatment', 'description': 'Percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients received type VKA treatment is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Diseases', 'description': 'The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with at least one other concomitant diseases recorded in the medical history.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Active Concomitant Diseases on Visit Day', 'description': 'The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with active concomitant diseases on visit day. The percentage was calculated on total patients who presented each of the diseases.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}, {'measure': 'The Percentage of Uncontrolled Non-valvular Atrial Fibrillation (NVAF) Patients With Concomitant Treatment', 'description': 'The percentage of uncontrolled non-valvular atrial fibrillation (NVAF) patients with concomitant treatment is presented.', 'timeFrame': 'The study consisted of a single visit between April 2017 and January 2018'}]",21.0,18 Years,,ALL,False,INDUSTRY,0.0,535.0,ACTUAL,v2_robust,False,True,False,False,
NCT00472771,INNO-206 in Patients With Small Cell Lung Cancer (SCLC),INNO-206,['INNO-206'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Small Cell Lung Cancer,CytRx,2025-09-01T16:18:10.925401,True,,,,,"A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy",,['Small Cell Lung Cancer'],['Recurrent extensive small cell lung cancer'],Terminated due to clinical trial material production delays,2008-05,2008-11,[{'measure': 'To determine the objective overall response rate (OR; complete [CR] and partial [PR] responses).'}],"[{'measure': 'To determine the rates of stable disease and progressive disease.'}, {'measure': 'To determine time to progression.'}, {'measure': 'To determine progression-free survival.'}, {'measure': 'To determine overall survival.'}, {'measure': 'To evaluate the treatment-related toxicities in this patient population.'}, {'measure': 'To determine the pharmacokinetic profile of INNO-206 in a minimum of 12 patients.'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Terminated due to clinical trial material production delays
NCT05277571,"A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)",Placebo,['Placebo'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,ACTIVE_NOT_RECRUITING,Atopic Dermatitis,UCB Biopharma SRL,2025-09-01T16:18:10.925413,True,,,,,"A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)",,['Atopic Dermatitis'],"['Atopic dermatitis', 'Phase 1/2A', 'Healthy study participants', 'Patients', 'UCB1381']",,2022-03-07,2025-09-22,"[{'measure': 'Incidents of treatment-emergent adverse events (TEAEs) from Baseline through the End of Study (EOS) Visit (Week 12) in Part A', 'description': 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.', 'timeFrame': 'From Baseline up to Week 12 in Part A'}, {'measure': 'Incidents of treatment-emergent serious adverse events (TESAEs) from Baseline through the EOS Visit (Week 12) in Part A', 'description': 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose:\n\n* Results in death\n* Is life-threatening\n* Requires inpatient hospitalisation or prolongation of existing hospitalisation\n* Results in persistent or significant disability/incapacity, or\n* Is a congenital anomaly/birth defect\n* Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above', 'timeFrame': 'From Baseline up to Week 12 in Part A'}, {'measure': 'Incidents of TEAEs from Baseline through the EOS Visit (Week 22) in Part B', 'description': 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.', 'timeFrame': 'From Baseline up to Week 22 in Part B'}, {'measure': 'Incidents of TESAEs from Baseline through the EOS Visit (Week 22) in Part B', 'description': 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose:\n\n* Results in death\n* Is life-threatening\n* Requires inpatient hospitalisation or prolongation of existing hospitalisation\n* Results in persistent or significant disability/incapacity, or\n* Is a congenital anomaly/birth defect\n* Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above', 'timeFrame': 'From Baseline up to Week 22 in Part B'}, {'measure': '≥75% improvement vs Baseline (Yes/No) in Eczema Area and Severity Index score (EASI75) at Week 12 in Part B', 'description': ""The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities\n\nThe severity of disease is evaluated by assessing each of 4 clinical signs for each area:\n\nErythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe."", 'timeFrame': 'From Baseline up to Week 12 in Part B'}]","[{'measure': 'UCB1381 Cmax from Baseline through the EOS Visit (Week 12) in Part A', 'description': 'Cmax: Maximum observed concentration', 'timeFrame': 'From Baseline up to Week 12 in Part A'}, {'measure': 'UCB1381 Tmax from Baseline through the EOS Visit (Week 12) in Part A', 'description': 'Tmax: Time of observed Cmax', 'timeFrame': 'From Baseline up to Week 12 in Part A'}, {'measure': 'UCB1381 AUC(0-t) from Baseline through the EOS Visit (Week 12) in Part A', 'description': 'AUC(0-t): Area under the concentration-time curve from time zero to the time of last detectable concentration.', 'timeFrame': 'From Baseline up to Week 12 in Part A'}, {'measure': 'UCB1381 AUC from Baseline through the EOS Visit (Week 12) in Part A', 'description': 'AUC: Area under the concentration-time curve from time zero to infinity.', 'timeFrame': 'From Baseline up to Week 12 in Part A'}, {'measure': 'UCB1381 F% from Baseline through the EOS Visit (Week 12) in Part A', 'description': 'F%: Bioavailability of subcutaneous administration', 'timeFrame': 'From Baseline up to Week 12 in Part A'}, {'measure': 'Percent change from Baseline in EASI score at Week 12 in Part B', 'description': ""The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities\n\nThe severity of disease is evaluated by assessing each of 4 clinical signs for each area:\n\nErythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe."", 'timeFrame': 'From Baseline up to Week 12 in Part B'}, {'measure': '≥50% improvements vs Baseline (Yes/No) in EASI score (EASI50) at Week 12 in Part B', 'description': ""The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities\n\nThe severity of disease is evaluated by assessing each of 4 clinical signs for each area:\n\nErythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe."", 'timeFrame': 'From Baseline up to Week 12 in Part B'}, {'measure': '≥90% improvements vs Baseline (Y/N) in EASI score (EASI90) at Week 12 in Part B', 'description': ""The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities\n\nThe severity of disease is evaluated by assessing each of 4 clinical signs for each area:\n\nErythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe."", 'timeFrame': 'From Baseline up to Week 12 in Part B'}, {'measure': 'Validated Investigator Global Assessment (vIGA) score of 0 or 1 (Y/N) at Week 12 in Part B', 'description': 'vIGA: Validated Investigator Global Assessment score is using descriptors that best describe the overall appearance of the lesions at a given time point. Assessment: vIGA 0=clear, vIGA 1=almost clear, vIGA 2=mild, vIGA 3=moderate, vIGA 4=severe', 'timeFrame': 'From Baseline up to Week 12 in Part B'}, {'measure': 'UCB1381 Cmax at week 12 after the final dose in Part B', 'description': 'Cmax: Maximum observed concentration', 'timeFrame': 'From Baseline up to Week 12 in Part B'}, {'measure': 'UCB1381 Tmax at week 12 after the final dose in Part B', 'description': 'Tmax: Time of observed Cmax', 'timeFrame': 'From Baseline up to Week 12 in Part B'}, {'measure': 'UCB1381 AUCtau at week 12 after the final dose in Part B', 'description': 'AUCtau: Area under the curve for the dosing interval after the final dose.', 'timeFrame': 'From Baseline up to Week 12 in Part B'}]",17.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,273.0,ACTUAL,v2_robust,True,False,False,True,
NCT00060671,Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma,rituximab,"['Pixantrone (BBR 2778)', 'rituximab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,"Lymphoma, Follicular",CTI BioPharma,2025-09-01T16:18:10.925483,True,,,,,"An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)",,"['Lymphoma, Follicular', 'Lymphoma, Mixed-Cell, Follicular', 'Lymphoma, Small Cleaved-Cell, Follicular', 'Lymphoma, Low-Grade']","['Pixantrone', 'BBR 2778', 'chemotherapy', 'DNA Intercalator', 'Anthracycline', 'Rituximab', 'Rituxan', 'Mabthera', 'monoclonal antibody', 'antibody', 'NHL', ""Non-Hodgkin's lymphoma"", 'indolent', 'low grade', 'Novuspharma']",,2005-01,2006-01,"[{'measure': 'Compare the time to tumor progression (TTP) of the combination of BBR 2778 (pixantrone) + rituximab with that of rituximab alone', 'timeFrame': 'For 5 years post treatment'}]","[{'measure': 'To compare BBR 2778 + rituximab versus rituximab for:', 'description': '* objective overall response rate (ORR; CR + PR)\n* objective complete response rate (CRR)\n* rate of molecular remission\n* time to response\n* time to complete response\n* duration of response\n* Time to Tumor Progression requiring treatment\n* Quality-Adjusted Time To Progression (QATTP)\n* overall survival\n* disease-specific survival\n* safety/tolerability', 'timeFrame': 'For 5 years post treatment'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,800.0,,v2_robust,True,False,True,True,
NCT06860971,A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma,AL2846 Capsules,"['AL2846 Placebo', 'AL2846 Capsules']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Thyroid Cancer,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:10.925494,True,,,,,"A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy",,['Thyroid Cancer'],[],,2025-04-18,2028-01,"[{'measure': 'Progression - Free Survival (PFS) evaluated by the Independent Review Committee (IRC)', 'description': 'Defined as the time from the date of randomization to the date of disease progression determined by IRC or death, whichever occurred firstly.', 'timeFrame': '34 months'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Defined as the time from the date of randomization to the date of death for any reason.', 'timeFrame': '34 months'}, {'measure': 'Compare the Progression - Free Survival (PFS) evaluated by the researchers in the treatment group and the placebo group', 'description': 'PFS: The time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.', 'timeFrame': '34 months'}, {'measure': 'Compare the objective response rate (ORR) between the treatment group and the placebo group', 'description': 'Objective Response Rate (ORR): It is defined as the percentage of subjects with a complete response (CR) or partial response (PR) as determined by the Independent Review Committee (IRC)/investigator according to RECIST 1.1.', 'timeFrame': '34 months'}, {'measure': 'Compare the Disease Control Rate (DCR) between the treatment group and the placebo group', 'description': 'Disease Control Rate (DCR): It is defined as the percentage of subjects with complete response (CR), partial response (PR), or stable disease (SD) as determined by the Independent Review Committee (IRC)/investigator according to RECIST 1.1.', 'timeFrame': '34 months'}, {'measure': 'Compare the Duration of Response (DOR) between the treatment group and the placebo group', 'description': 'Duration of Response (DOR): It is defined as the time from the first documented and confirmed objective response to disease progression or death from any cause (whichever occurs first), as determined by the IRC/investigator according to RECIST v1.1.', 'timeFrame': '34 months'}, {'measure': 'Evaluate the safety of AL2846 capsules compared with placebo in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy', 'description': 'The incidence and severity of adverse events, with severity determined according to the NCI CTCAE v5.0 grading scale.', 'timeFrame': '34 months'}]",7.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,144.0,ESTIMATED,v2_robust,True,False,False,True,
NCT03184571,Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC,Bemcentinib; pembrolizumab,"['BGB324; Keytruda', 'Bemcentinib; pembrolizumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Lung Cancer Metastatic,BerGenBio ASA,2025-09-01T16:18:10.925516,True,,,,,A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung,,"['Lung Cancer Metastatic', 'NSCLC Stage IV', 'Adenocarcinoma of Lung']","['bemcentinib', 'NSCLC', 'pembrolizumab', 'Keytruda', 'BGB324']",,2017-10-17,2022-10-27,"[{'measure': 'Objective Response Rate', 'description': 'Objective Response Rate includes all participants who have a partial or complete response.', 'timeFrame': 'The disease response is the best improvement or change in a participants cancer burden, as measured from baseline (screening) and then measured again at regular intervals over the whole period of the study, an average of 24 months.'}]","[{'measure': 'Disease Control Rate', 'description': 'Disease Control Rate includes all participants who have a partial or complete response, or who maintain stable disease.', 'timeFrame': 'Disease response is assessed every 9 weeks for the first 45 weeks and then every 12 weeks until disease progression (worsens) or study completion, an average of 24 months.'}, {'measure': 'Duration of Response', 'description': 'Duration of response includes participants with a partial or complete response and is measured from the date of response until the cancer progresses (worsens).', 'timeFrame': 'Disease response is assessed every 9 weeks for the first 45 weeks and then every 12 weeks until disease progression or study completion, an average of 24 months.'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'PFS is measured from the date of the 1st dose of the 1st cycle until the date of progression (the date on which the progression is initially observed) or the date of death (whichever is earlier).', 'timeFrame': 'Disease assessments are conducted at screening and then every 9 weeks for the first 45 weeks and then every 12 weeks until disease progression or death, whichever comes first, up to study completion (an average of 24 months)'}, {'measure': 'Overall survival', 'description': 'Time to death is measured from the date of first dose until the date of death or the date the participants is last known to be alive. It includes all participants.', 'timeFrame': 'Survival visits are conducted every 12 weeks after disease progression until death or until study completion (an average of 24 months).'}, {'measure': 'Number of participants with Adverse Events (as assessed by CTCAE v4.03)', 'description': 'The number of participants with each adverse event will be summarized.', 'timeFrame': 'Adverse events are collected from the date of consent until up to 120 days after cessation of both treatments.'}, {'measure': 'Pharmacokinetic (PK) Parameters: Maximum observed concentration (Cmax)', 'description': 'Cmax defined as the maximum observed concentration.', 'timeFrame': 'Up to 106 weeks'}, {'measure': 'PK Parameters: Area Under the Curve (AUC)', 'description': 'AUC defined as the area under the concentration versus time curve.', 'timeFrame': 'Up to 106 weeks'}, {'measure': 'PK Parameters: Elimination Half-life (T½)', 'description': 'T½ defined as the elimination half-life.', 'timeFrame': 'Up to 106 weeks'}, {'measure': 'Number of Participants with Clinical Laboratory, Vital Signs, and Electrocardiogram (ECG) Abnormalities', 'description': 'Number of participants with clinical laboratory (hematology, including coagulation, urinalysis), vital signs (temperature, systolic blood pressure, diastolic blood pressure, heart rate, and respiratory rate), and ECG abnormalities will be reported.', 'timeFrame': '106 weeks'}]",10.0,18 Years,,ALL,False,INDUSTRY,1.0,106.0,ACTUAL,v2_robust,True,True,False,True,
NCT04918771,Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old,Raphamin,"['Raphamin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acute Respiratory Viral Infection,Materia Medica Holding,2025-09-01T16:18:10.925542,True,,,,,Multicenter Double Blind Placebo-controlled Parallel-group Randomized Clinical Study of Efficacy and Safety of Raphamin in the Treatment of Acute Respiratory Viral Infection in Children Aged 12-18 Years Old,,['Acute Respiratory Viral Infection'],[],,2021-04-29,2023-07-21,"[{'measure': 'Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).', 'description': 'Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection.\n\nARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}]","[{'measure': 'Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).', 'description': 'The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score).\n\nTSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules:\n\nif temp \\<= 37.3 then score = 0 (none) if 37.3 \\< temp \\<= 38.0 then score = 1 (mild) if 38.0 \\< temp \\<= 39.0 then score = 2 (moderate) if 39.0 \\< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.', 'timeFrame': 'Day1 through Day6 of the treatment and observation'}, {'measure': 'Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).', 'description': 'ARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}, {'measure': 'Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).', 'description': 'ARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}, {'measure': 'Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).', 'description': 'Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection.\n\nARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}, {'measure': 'Dosing Frequency of Antipyretics.', 'description': 'Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.', 'timeFrame': '3 days of therapy'}, {'measure': 'Percentage of Patients Reporting Worsening of Illness.', 'description': 'Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.', 'timeFrame': 'Day 4 through day 14 of the treatment and observation period'}, {'measure': 'Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.', 'description': '1. The intensity (severity) of adverse events.\n2. Causal relationship of AEs to the sudy drug.\n3. Outcome of AEs. Based on medical records.', 'timeFrame': '14 days of observation'}, {'measure': 'Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).', 'description': ""The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7)."", 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}, {'measure': 'Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.', 'description': ""Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7)."", 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}, {'measure': 'Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).', 'description': ""Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7)."", 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}, {'measure': 'Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.', 'description': 'Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.', 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}]",12.0,12 Years,18 Years,ALL,False,INDUSTRY,0.0,435.0,ACTUAL,v2_robust,True,True,False,True,
NCT00004871,Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,azacitidine,"['sodium phenylbutyrate', 'azacitidine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Leukemia,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2025-09-01T16:18:10.925672,True,,,,,"Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate (PB, NSC 657802) in Combination With 5-Azacytidine (5-AZA, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)",,"['Leukemia', 'Myelodysplastic Syndromes', 'Myelodysplastic/Myeloproliferative Diseases']","['recurrent adult acute myeloid leukemia', 'untreated adult acute myeloid leukemia', 'refractory anemia', 'refractory anemia with ringed sideroblasts', 'refractory anemia with excess blasts', 'refractory anemia with excess blasts in transformation', 'chronic myelomonocytic leukemia', 'de novo myelodysplastic syndromes', 'previously treated myelodysplastic syndromes', 'secondary myelodysplastic syndromes', 'atypical chronic myeloid leukemia', 'myelodysplastic/myeloproliferative disease, unclassifiable']",,2000-05,,[],[],0.0,18 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,True,False,False,
NCT02697071,Ketamine for Acute Migraine in the Emergency Department,Ketamine,"['Ketamine', 'Normal Saline']",2,INTERVENTIONAL,['NA'],,COMPLETED,Headache,Carilion Clinic,2025-09-01T16:18:10.925763,True,,,,,A Randomized Placebo-Controlled Trial of Sub-Dissociative Ketamine for Treatment of Acute Migraine-Type Headache in the Emergency Department,,['Headache'],"['Ketamine', 'Migraine', 'Headache', 'Emergency Department']",,2016-02,2017-03,"[{'measure': 'Achievement of Pain Response After Ketamine Dose.', 'description': 'NRS (National rating scale) pain score change from baseline following ketamine dose. Minimum score is 0, maximum score is 10, and higher scores mean worse pain.', 'timeFrame': '30 minutes'}]","[{'measure': 'Categorical Pain Score Change From Baseline', 'description': 'change in baseline categorical pain score at 30 minutes (categorical pain intensity score from 0 to 3 where 0=""no headache"" and 3=""severe headache"")', 'timeFrame': '30 minutes'}]",2.0,18 Years,65 Years,ALL,True,OTHER,1.0,34.0,ACTUAL,v2_robust,True,True,False,False,
NCT00745771,"Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness",Diractin,['Diractin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Muscle Soreness,IDEA AG,2025-09-01T16:18:10.925774,True,,,,,"Multiple Dose, Double-Blind, Double-Dummy, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness From Exercise",,['Muscle Soreness'],"['pharmacokinetics', 'of Diractin®', 'safety', 'efficacy', 'exercise']",,2007-10,2008-11,[],[],0.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,168.0,ACTUAL,v2_robust,True,True,False,False,
NCT05697471,Comparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis,Dienogest,"['Danazol', 'Dienogest']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Endometriosis,Far Eastern Memorial Hospital,2025-09-01T16:18:10.925798,True,,,,,Far Eastern Memorial Hospital,,['Endometriosis'],[],,2023-02-25,2025-12-31,"[{'measure': 'The change of severity in dysmenorrhea', 'description': 'Between-group difference in the score of global response assessment of dysmenorrhea', 'timeFrame': '16 weeks'}]","[{'measure': 'The change of severity in urinary symptoms', 'description': 'Between-group difference in the score of UDI-6', 'timeFrame': '16 weeks'}, {'measure': 'The change of severity in quality of life related to urinary symptoms', 'description': 'Between-group difference in the score of IIQ-7', 'timeFrame': '16 weeks'}, {'measure': 'The change of severity in menstrual amount', 'description': 'Between-group difference in the score of global response assessment of menstrual amount', 'timeFrame': '16 weeks'}]",4.0,20 Years,,FEMALE,False,OTHER,0.0,120.0,ESTIMATED,v2_robust,True,False,False,False,
NCT04829344,A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution,AG-920,"['AG-920', 'articaine', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Anesthesia, Local","American Genomics, LLC",2025-09-01T16:18:10.925938,True,,,,,"A Randomized, Double-Masked, Vehicle-Controlled, Parallel Evaluation of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution",,"['Anesthesia, Local']","['AG-920', 'articaine', 'septocaine', 'Intravitreal Injection']",,2021-03-30,2021-05-10,"[{'measure': 'The Percentage of Patients Who Experienced Ocular Anesthesia Following Treatment of AG-920 Compared to Placebo at 5 Minutes', 'description': 'Immediately following EACH pinch test, subjects will be asked ""Was that painful"" ""Yes"" or ""NO.""', 'timeFrame': '5 minutes post dose'}]","[{'measure': 'How Long it Takes One Dose of AG-920 to Anesthetize the Eye', 'description': 'Mean time to no pain score (onset)', 'timeFrame': '20, 40 and 60 seconds following dosing or until pain stops. 5-minutes post dose. If subject became anesthetized before 5 minutes, every 5 minutes for up to 30 minutes or until pain resumes.'}, {'measure': 'How Long One Dose of AG-920 Anesthetizes the Eye', 'description': 'Mean duration of anesthetic effect', 'timeFrame': '20, 40 and 60 seconds following dosing or until pain stops. 5-minutes post dose. If subject became anesthetized before 5 minutes, every 5 minutes for up to 30 minutes or until pain resumes.'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'description': 'Total number of participants with TEAEs', 'timeFrame': 'from randomization through study completion (up to 5 days) on average of 2 days.'}, {'measure': 'Number of Participants With a Change in Biomicroscopy', 'description': 'Slit lamp biomicroscopy and external eye exam measures will be summarized at each measured timepoint using discrete summary statistics. Clinician examined the eyelid, conjunctiva, cornea, anterior chamber, iris, pupil, and lens of the eye with the aid of a slit lamp.', 'timeFrame': 'change from baseline through end of study at Day 5'}, {'measure': 'Change in Visual Acuity', 'description': 'Visual Acuity data will be summarized at each time point using continuous and discrete summaries of Logarithmic Minimum Angle of Resolution (logMAR).', 'timeFrame': 'change from baseline through end of study at Day 5'}]",6.0,18 Years,,ALL,True,INDUSTRY,0.0,120.0,ACTUAL,v2_robust,True,True,False,True,
NCT02694744,Patiromer With or Without Food for the Treatment of Hyperkalemia,patiromer,"['RLY5016 for Oral Suspension', 'patiromer', 'Veltassa']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hyperkalemia,"Relypsa, Inc.",2025-09-01T16:18:10.926079,True,,,,,"The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)",,['Hyperkalemia'],"['Treatment of Hyperkalemia', 'Hyperkalemia', 'Potassium', 'Chronic Kidney Disease']",,2016-02,2016-08,"[{'measure': 'Percentage of Subjects With Serum Potassium in the Target Range (3.8 - 5.0 mEq/L) at Either Week 3 or Week 4', 'timeFrame': '21 to 28 Days'}]","[{'measure': 'Mean Change in Serum Potassium From Baseline to Week 4', 'description': 'An ANCOVA model was used to estimate the mean serum potassium change from Baseline to Week 4 with baseline serum potassium as a covariate and treatment group, race (white vs all others), and history of Type 1 or 2 diabetes mellitus (yes or no) as factors in the model.', 'timeFrame': 'Baseline to Day 28'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,114.0,ACTUAL,v2_robust,True,True,False,False,
NCT01570244,Drug-drug Interaction of BI 201335 and Microgynon,levonorgestrel,"['BI 201335', 'Ethinylestradiol', 'levonorgestrel']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Hepatitis C, Chronic",Boehringer Ingelheim,2025-09-01T16:18:10.926096,True,,,,,"An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of 240 mg BI 201335 QD on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers",,"['Hepatitis C, Chronic']",[],,2012-04,2012-08,"[{'measure': 'AUCt,ss of Ethinylestradiol', 'description': 'Area under the curve over the dosing interval t under steady state conditions of ethinylestradiol', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 hours (h) after drug administration'}, {'measure': 'Cmax,ss of Ethinylestradiol', 'description': 'maximum measured concentration over the uniform dosing interval under steady state conditions of ethinylestradiol', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'C24,ss of Ethinylestradiol', 'description': 'measured concentration of the analyte at the end of dosing interval under steady state conditions of ethinylestradiol', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'AUCτ,ss of Levonorgestrel', 'description': 'Area under the curve over the dosing interval τ under steady state conditions of levonorgestrel', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'Cmax,ss of Levonorgestrel', 'description': 'maximum measured concentration over the uniform dosing interval under steady state conditions of levonorgestrel', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'C24,ss of Levonorgestrel', 'description': 'measured concentration of the analyte at the end of dosing interval under steady state conditions of levonorgestrel', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}]","[{'measure': 'Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG.', 'description': 'Clinical relevant abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.', 'timeFrame': 'from drug administration up to 14 days'}, {'measure': 'Number of Participants With Drug Related Adverse Events', 'description': 'number of participants with investigator-defined drug related adverse events', 'timeFrame': 'from drug administration up to 14 days'}]",8.0,18 Years,35 Years,FEMALE,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,
NCT00621244,A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies,LBH589,['LBH589'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Lymphoma,Novartis Pharmaceuticals,2025-09-01T16:18:10.926225,True,,,,,"A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies",,"['Lymphoma', 'Leukemia', 'Multiple Myeloma']","['HDAC inhibitor', 'Oral', 'LBH589', 'Lymphoma', 'Leukemia', 'Multiple myeloma']",,2003-03-01,2009-12-03,"[{'measure': 'Number of Participants DLT in Arm 1 in Dose Escalation Phase', 'description': 'Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for consecutive dosing schedule (MWF weekly). A 3-parameter version of a Bayesian logistic regression model with overdose control (Babb, Rogatko, and Zacks 1998) was used during the dose escalation phase for dose level selection and determination of the MTD.', 'timeFrame': 'Cycle 1 (28-day treatment cycle)'}, {'measure': 'Number of Participants DLT in Arm 2 in Dose Escalation Phase', 'description': 'Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for intermittent dosing schedule (MWF weekly).\n\nA 3-parameter version of a Bayesian logistic regression model with overdose control (Babb, Rogatko, and Zacks 1998) was used during the dose escalation phase for dose level selection and determination of the MTD.', 'timeFrame': 'Cycle 1 (28-day treamtent cycle)'}]","[{'measure': 'Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML)', 'description': 'Response as per investigator assessment for patients include complete response, progressive disease/failure, stable disease.', 'timeFrame': '3.5 years'}, {'measure': 'Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML) in Expansion Phase', 'description': 'Stage 2 did not open for enrollment.', 'timeFrame': '1.2 years'}, {'measure': ""Response as Per Investigator Assessment for Patients With Hodgkin's Lymphoma (HD)"", 'description': 'Response as per investigator assessment for patients include complete response, partial remission, stable disease, progressive disease (PD)/failure.', 'timeFrame': '3.5 years'}, {'measure': 'Response as Per Investigator Assessment for Patients With Myelodysplastic Syndromes (MDS)', 'description': 'Response as per investigator assessment for patients include complete response, stable disease, progressive disease/failure, partial remission.', 'timeFrame': '3.5 years'}, {'measure': 'Maximum Plasma Concentration of Panobinostat After the First Dose in Arms 1 and 2', 'timeFrame': 'Day 1'}, {'measure': 'Half Life of Panobinostat After the First Dose in Arms 1 and 2', 'timeFrame': 'Day 1'}, {'measure': 'Maximum Plasma Concentration of Panobinostat After Multiple Doses in Arm 1 on Day 15', 'description': 'From day 15 by dose with schedule: MWF every week', 'timeFrame': 'Day 15'}, {'measure': 'Half Life of Panobinostat After Multiple Doses in Arm 1 on Day 15', 'timeFrame': 'Day 15'}, {'measure': 'Geometric Mean Ratio (GMR) Comparing Treatment Days in Arm 1', 'description': 'MWF Every week schedule n = number of subjects with non-missing values.', 'timeFrame': 'Day 15/day 1'}, {'measure': 'Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group X', 'description': 'Reporting the number of patients with a reading at the timepoint in the dose group.', 'timeFrame': 'Days 1, 5, 8, 10, 15'}, {'measure': 'Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group Y', 'timeFrame': 'Days 5, 8, end of study (up to 3.5 years)'}, {'measure': 'Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group X', 'timeFrame': 'Days 5, 8, 10, 12, 15, End of study, Unscheduled (up to 3.5 years)'}, {'measure': 'Percentage of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group Y', 'timeFrame': 'Days 5, 8, 10, 12, 15, End of study (up to 3.5 years)'}, {'measure': 'Highest Percent Change in Fetal Hemoglobin From Baseline in Arm 1 (MWF Every Week)', 'description': 'All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (≤ 7 days post last dose (preferably ≥ 4 days \\[96 hours\\]))', 'timeFrame': 'Post dose to pre-dose (up to 3.5 years)'}, {'measure': 'Highest Percent Change of Fetal Hemoglobin From Baseline in Arm 2 (MWF Every Other Week)', 'description': 'All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (≤ 7 days post last dose (preferably ≥ 4 days \\[96 hours\\]))', 'timeFrame': 'Post dose to pre-dose (up to 3.5 years)'}]",17.0,18 Years,,ALL,False,INDUSTRY,0.0,175.0,ACTUAL,v2_robust,True,True,False,False,
NCT02316834,"Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",BMN 673,"['TALAZOPARIB', 'BMN 673']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Fallopian Tube Serous Adenocarcinoma,M.D. Anderson Cancer Center,2025-09-01T16:18:10.926323,True,,,,,POSITION: A Pilot Study of Induction PARP Inhibition in Ovarian Cancer,,"['Fallopian Tube Serous Adenocarcinoma', 'High Grade Ovarian Serous Adenocarcinoma', 'Ovarian Mass', 'Primary Peritoneal Serous Adenocarcinoma', 'Stage III Fallopian Tube Cancer AJCC v7', 'Stage III Ovarian Cancer AJCC v6 and v7', 'Stage III Primary Peritoneal Cancer AJCC v7', 'Stage IIIA Fallopian Tube Cancer AJCC v7', 'Stage IIIA Ovarian Cancer AJCC v6 and v7', 'Stage IIIA Primary Peritoneal Cancer AJCC v7', 'Stage IIIB Fallopian Tube Cancer AJCC v7', 'Stage IIIB Ovarian Cancer AJCC v6 and v7', 'Stage IIIB Primary Peritoneal Cancer AJCC v7', 'Stage IIIC Fallopian Tube Cancer AJCC v7', 'Stage IIIC Ovarian Cancer AJCC v6 and v7', 'Stage IIIC Primary Peritoneal Cancer AJCC v7', 'Stage IV Fallopian Tube Cancer AJCC v6 and v7', 'Stage IV Ovarian Cancer AJCC v6 and v7', 'Stage IV Primary Peritoneal Cancer AJCC v7']",[],,2015-06-02,2022-01-14,"[{'measure': 'Change in deoxyribonucleic acid (DNA) copy number', 'description': 'Will use descriptive statistics and graphical methods to summarize the change in DNA copy number. Will summarize these changes for untreated patients. Will use a paired t-test to test that mean changes are different from 0. Will test median changes with a Wilcoxon signed-rank test. Will use a 2-sample t-test to compare mean changes between treated and untreated patients. Will compare median changes between treated and untreated patients with a Wilcoxon rank sum test.', 'timeFrame': 'Baseline to the day of tumor reductive surgery'}, {'measure': 'Change in ribonucleic acid (RNA) protein expression', 'description': ""Will use descriptive statistics and graphical methods to summarize the change in RNA protein expression. Will summarize these changes for untreated patients. Will use a paired t-test to test that mean changes are different from 0. Will test median changes with a Wilcoxon signed-rank test. Will use a 2-sample t-test to compare mean changes between treated and untreated patients. Will compare median changes between treated and untreated patients with a Wilcoxon rank sum test. Will use McNemar's test to compare the changes based on homologous recombination deficiency (HRD) assay results."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}]","[{'measure': 'Overall survival', 'description': 'Will use Cox proportional hazards regression methods to model overall survival as a function of DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Tumor response', 'description': 'Will use logistic regression methods to model tumor response as a function of changes in DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Tumor volume', 'description': 'Will use linear regression methods to model tumor volume as a function of changes in DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Apoptosis', 'description': 'Will use linear regression methods to model apoptosis as a function of changes in DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Completion Rate of BMN 673 to determine feasibility', 'description': 'Treatment with BMN 673 considered feasible if 70% of patients complete all planned doses of talazoparib and post-operative chemotherapy.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Incidence of adverse events', 'description': 'Will tabulate toxicities by grade and relationship to treatment.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Proportion of patients that exhibit an increase (or decrease) in RNA protein expression greater than 50%', 'description': ""Will use Fisher's exact test to compare treated and untreated patients with respect to the proportion of patients that exhibit an increase (or decrease) in RNA protein expression. Will compare the mean change in RNA protein expression between those patients with and without a HRD on assay at baseline using a 2-sample t-test. Will compare the median changes between these 2 groups of patients with a Wilcoxon rank sum test. Will compare these 2 groups of patients with respect to HRD assay result using Fisher's exact test."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}, {'measure': 'Change in DNA copy number', 'description': ""Will use Fisher's exact test to compare treated and untreated patients with respect to the increase (or decrease) in DNA copy number. Will compare the mean change in DNA copy number between those patients with and without a HRD on assay at baseline using a 2-sample t-test. Will compare the median changes between these 2 groups of patients with a Wilcoxon rank sum test. Will compare these 2 groups of patients with respect to HRD assay result using Fisher's exact test."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}, {'measure': 'Change in RNA protein expression', 'description': ""Will use Fisher's exact test to compare treated and untreated patients with respect to the increase (or decrease) in RNA protein expression. Will compare the mean change in RNA protein expression between those patients with and without a HRD on assay at baseline using a 2-sample t-test. Will compare the median changes between these 2 groups of patients with a Wilcoxon rank sum test. Will compare these 2 groups of patients with respect to HRD assay result using Fisher's exact test."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}]",11.0,18 Years,,FEMALE,False,OTHER,1.0,4.0,ACTUAL,v2_robust,True,True,False,True,
NCT02706834,"Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants",TAK-828,"['TAK-828', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Dose Finding Study,Takeda,2025-09-01T16:18:10.926445,True,,,,,"A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Non-Japanese and Japanese Subjects",,['Dose Finding Study'],['Drug therapy'],,2016-03-01,2016-06-17,"[{'measure': 'Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE)', 'description': 'An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.', 'timeFrame': 'Day 1 up to 30 days after last dose of study drug (up to 85 days)'}, {'measure': 'Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)', 'timeFrame': 'Day 1 up to 30 days after last dose of study drug (up to 85 days)'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose', 'description': 'Hematology and Chemistry values that met the following criteria were considered to be markedly abnormal:\n\nErythrocytes, Hematocrit and Hemoglobin \\<0.8\\*Lower Limit of Normal (LLN) or \\>1.2\\*Upper Limit of Normal ULN.; Leukocytes \\<0.5\\*LLN or \\>1.5\\*ULN; Platelet \\<75 or \\>600 10\\^9/liter (L).\n\nAlanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase \\>3\\*ULN; Albumin \\<25 g/L; Bilirubin \\> 34.2 umol/L; Blood Urea Nitrogen \\>10.7 mmol/L; Chloride \\<75 or \\>126 mmol/L; Creatinine \\>177 umol/L; Direct Bilirubin \\>2\\*ULN; Glucose \\<2.8 or \\>19.4 mmol/L; Potassium \\<3.0 or \\>6.0 mmol/L; Protein \\<0.8\\*LLN or \\>1.2\\*ULN; Sodium \\<130 or \\>150 mmol/L.', 'timeFrame': 'Day 1 up to 7 days after last dose of study drug (up to 52 days)'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose', 'description': 'Vital signs measurements that met the following criteria were considered to be markedly abnormal:\n\nSystolic Blood Pressure (SBP) \\<85 mmHg or \\>180 mmHg supine laying face upward) or standing; Diastolic Blood Pressure (DBP) \\<50 mmHg or \\>110 mmHg supine or standing; Pulse Rate (PR) \\<50 beats/minute (bpm) or \\>120 bpm supine or standing; Temperature \\<35.6 degrees Celsius (C) or \\>37.7 degrees C.', 'timeFrame': 'Day 1 up to 7 days after last dose of study drug (up to 52 days)'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Measurements at Least Once Post-dose', 'description': ""Heart Rate \\<50 beats per minute (bpm) \\>120 bpm; QTcB (Bazett's Correction Formula) ≤50 milliseconds (msec) or ≥500 msec OR ≥30 msec change from Baseline and ≥450 msec; QTcF (Fridericia's Correction Formula) ≤50 msec or ≥500 msec OR ≥30 msec change from Baseline (CFB) and ≥450 msec."", 'timeFrame': 'Day 1 up to 7 days after last dose of study drug (up to 52 days)'}]","[{'measure': 'Cmax: Maximum Observed Plasma Concentration for TAK-828F (Free Base of TAK-828)', 'timeFrame': 'Day 1 pre-dose and at multiple timepoints (up to 72 hours) post-dose'}, {'measure': 'Tmax: Time of First Occurrence of Cmax for TAK-828F (Free Base of TAK-828)', 'timeFrame': 'Day 1 pre-dose and at multiple timepoints (up to 72 hours) post-dose'}, {'measure': 't1/2z: Terminal Disposition Phase Half-Life for TAK-828F (Free Base of TAK-828)', 'timeFrame': 'Day 1 pre-dose and at multiple timepoints (up to 72 hours) post-dose'}, {'measure': 'AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-828F (Free Base of TAK-828)', 'timeFrame': 'Day 1 pre-dose and at multiple timepoints (up to 72 hours) post-dose'}]",9.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,
NCT00849264,Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients,chemotherapy with endostar,"['treatment with CBP and 5-FU group', 'treatment with endostar, CBP and 5-FU', 'chemotherapy with endostar group', 'endostar, CBP and 5-FU group', 'treatment with CBP and 5-FU', 'chemotherapy with endostar']",6,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hepatocellular Carcinoma,Eastern Hepatobiliary Surgery Hospital,2025-09-01T16:18:10.926499,True,,,,,a Randomized Controlled Study of Surgical Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients,,"['Hepatocellular Carcinoma', 'Portal Vein Tumor Thrombus']","['hepatocellular carcinoma', 'portal vein tumor thrombus', 'surgical comprehensive treatment']",,2008-12,2010-12,"[{'measure': 'overall survival', 'timeFrame': '2010'}]","[{'measure': 'disease-free survival', 'timeFrame': '1,2 and 3 years'}]",2.0,30 Years,60 Years,ALL,False,OTHER,0.0,120.0,ACTUAL,v2_robust,True,True,False,False,
NCT03493464,BR55 in Characterization of Ovarian Lesions,BR55,['BR55'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Ovarian Cancer,"Bracco Diagnostics, Inc",2025-09-01T16:18:10.926545,True,,,,,BR55 Contrast Enhanced Ultrasound (CEUS) in Characterization of Ovarian Lesions,,['Ovarian Cancer'],[],Sponsor decision; expiration of available study agent due to long recruitment timeline.,2018-12-13,2021-07-31,"[{'measure': 'Visual Assessment of BR55 Enhancement', 'description': 'BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement=no focal targeted, stationary imaging signal was detectable; weak enhancement=weak focal targeted imaging signal was detectable and considered possibly stationary; strong enhancement=well-defined and strong focal targeted imaging signal was detectable and considered as definitely stationary).', 'timeFrame': '30 minutes post-dose on Day 1'}, {'measure': 'Adverse Events', 'description': 'Number of participants who received the contrast agent and experienced an adverse event.', 'timeFrame': '2 days (day of and 24 hours after BR55 administration)'}]",[],2.0,18 Years,,FEMALE,False,INDUSTRY,1.0,14.0,ACTUAL,v2_robust,True,False,True,True,Sponsor decision; expiration of available study agent due to long recruitment timeline.
NCT00352664,The Effect of Donepezil on Sedation and Other Symptoms,Donepezil,"['Donepezil', 'Aricept', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Advanced Cancer,M.D. Anderson Cancer Center,2025-09-01T16:18:10.926557,True,,,,,Donepezil for Cancer Patients With Sedation Related to Opioid Treatment: A Double-blind Placebo Controlled Randomized Study,,['Advanced Cancer'],"['Advanced Cancer', 'Cancer Pain', 'Donepezil', 'Sedation', 'Placebo']",Low patient accrual,2003-11,2007-07,"[{'measure': 'Sedation Mean Scores at 1-Week', 'description': 'Anderson Symptom Assessment Scale (ASAS) was used to measure sedation mean scores (SD) on a 0-10 scale with 0 representing ""not drowsy"" and 10 representing ""worst possible drowsiness.""', 'timeFrame': 'Baseline and Day 7'}]",[],1.0,18 Years,,ALL,False,OTHER,1.0,27.0,ACTUAL,v2_robust,True,False,True,False,Low patient accrual
NCT00382109,Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission,thiotepa,"['sirolimus', 'Rapamune', 'Prograf', 'Cytoxan', 'cyclophosphamide', 'Endoxan', 'AY 22989', 'amethopterin', 'thiotepa', 'SLM', 'Mexate', 'MTX', 'CTX', 'CPM', 'methotrexate', 'STEPA', 'rapamycin', 'tacrolimus', 'Oncotiotepa', 'TSPA', 'TESPA', 'Endoxana', 'FK 506', 'methylaminopterin', 'Folex', 'Tespamin']",26,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,B-cell Childhood Acute Lymphoblastic Leukemia,Children's Oncology Group,2025-09-01T16:18:10.926712,True,,,,,A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia,,"['B-cell Childhood Acute Lymphoblastic Leukemia', 'Childhood Acute Lymphoblastic Leukemia in Remission', 'Graft Versus Host Disease', 'L1 Childhood Acute Lymphoblastic Leukemia', 'L2 Childhood Acute Lymphoblastic Leukemia', 'T-cell Childhood Acute Lymphoblastic Leukemia']",[],,2007-03,2017-06-30,"[{'measure': 'Estimated Percentage of Participants With Event Free Survival', 'description': 'An event is defined as relapse or transplant-related mortality. Relapse is defined in section 3.3 study protocol.', 'timeFrame': 'at 2 years'}]","[{'measure': 'Rate of Relapses', 'description': 'An event is defined as relapse.', 'timeFrame': 'At 2 years'}, {'measure': 'Estimated Transplant Related Mortality Percentage', 'description': 'Death in a patient who had not relapsed after transplant is defined as transplant-related mortality event.', 'timeFrame': '100 days'}, {'measure': 'Estimated Rate of Acute Graft VS Host Disease (GVHD)', 'description': 'Any grade acute graft vs host disease (defined in APPENDIX II study protocol).', 'timeFrame': 'At 200 days'}, {'measure': 'Estimated Rate of Overall Chronic Graft VS Host Disease', 'description': 'Chronic graft vs host disease is defined in APPENDIX III of study protocol.', 'timeFrame': 'At 2 years'}, {'measure': 'Relative Contribution of Resistance by Acute Lymphoblastic Leukemia (ALL) Blasts to Cytolytic Therapy (e.g., Chemotherapy/Irradiation) as a Cause of Relapse Post-transplantation', 'description': 'An event is defined as relapse or transplant-related mortality.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Post Transplantation (Correlating Development of aGVHD With Relapse)', 'description': 'An event is defined as relapse; estimated probability of relapse.', 'timeFrame': 'At 1 year'}, {'measure': 'Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Pre-Transplantation (MRD)', 'description': 'An event is defined as relapse; relapse risk is reported. Not able to be performed given the low numbers of blast samples available.', 'timeFrame': 'At 2 months'}, {'measure': 'Chimerism', 'description': 'Evaluate the relative contribution of resistance by ALL blasts to the donor immune response as a cause of relapse post transplantation.', 'timeFrame': 'Up to 12 months'}]",9.0,1 Year,21 Years,ALL,False,NETWORK,1.0,146.0,ACTUAL,v2_robust,True,True,False,False,
NCT01258309,Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis,olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution,"['Patanol®', 'olopatadine hydrochloride 0.1% ophthalmic solution', 'olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Rhinitis, Allergic, Seasonal",Allergan,2025-09-01T16:18:10.926783,True,,,,,,,"['Rhinitis, Allergic, Seasonal', 'Conjunctivitis, Allergic']",[],,2010-12,2011-01,"[{'measure': 'Ocular Itching', 'timeFrame': 'Day 21'}]","[{'measure': 'Hyperemia', 'timeFrame': 'Day 21'}, {'measure': 'Chemosis', 'timeFrame': 'Day 21'}, {'measure': 'Ocular mucous discharge', 'timeFrame': 'Day 21'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,129.0,ACTUAL,v2_robust,True,True,False,False,
NCT00293709,Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists,etanercept,"['etanercept', 'Enbrel']",2,OBSERVATIONAL,[],,COMPLETED,"Arthritis, Psoriatic",Pfizer,2025-09-01T16:18:10.926793,True,,,,,Prospective Post Marketing Surveillance To Evaluate The Safety And Efficacy Of Etanercept Under Usual Care Settings In Patients With Psoriatic Arthritis (Psa) Treated By Dermatologists,,"['Arthritis, Psoriatic', 'Psoriasis', 'Skin Diseases, Papulosquamous']",['Arthritis'],,2006-01,2013-02,"[{'measure': 'Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and Week 52 (end of the observation period) that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.', 'timeFrame': 'Baseline up to Week 52'}]","[{'measure': 'Change From Baseline in Percent Body Surface Area (BSA) Affected by Psoriasis at Week 52', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 52', 'description': 'PASI: combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections (head, arms, trunk, and legs); each area was scored by itself and scores were combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90 - 100%), and severity was estimated by clinical signs: erythema, induration, and desquamation; scale: 0 (none) to 4 (maximum). Final PASI=sum of severity parameters for each section\\*area score\\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4; total score ranged from 0 (no disease) to 72 (maximal disease).', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change From Baseline in Disease Activity Score Based on 28 Joints Count (DAS 28) at Week 52', 'description': ""DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 100 mm; higher scores indicated greater affectation due to disease activity). DAS28 total score range: 0-10, where DAS28 less than or equal to (=\\<) 3.2 = low disease activity, DAS28 \\>3.2 to 5.1 = moderate disease activity and \\>5.1 = high disease activity."", 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change From Baseline in Ritchie Index at Week 52', 'description': ""Ritchie index: the numerical measurement of joint tenderness (28 joints) in participants with arthritis. The number of quantitative evaluations of the pain experienced by the participants when the joints were subjected to firm pressure when exerted over the articular margin or in some instances by passive movement of the joint. Participant's reaction to pressure exerted by the physician were documented on 4-point scale, 0=not tender, 1=tender, 2=tender and caused wince, 3=reflexive effort to withdraw. Ritchie index was calculated as the total of the individual grades for all joints; ranged from 0 to 84, where higher score indicated higher tenderness."", 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change From Baseline in Physician Global Assessment of Disease Activity at Week 52', 'description': 'Physician global assessment of disease activity was measured on a 0 to 100 millimeter (mm) visual analog scale (VAS), with 0 mm = no disease activity to 100 mm = most possible disease activity.', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Number of Participants With Nail Involvement', 'description': 'Number of participants with psoriatic arthritis affecting the nails are reported.', 'timeFrame': 'Baseline, Week 12, 52'}, {'measure': 'Change From Baseline in C-reactive Protein (CRP) at Week 52', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change From Baseline in Patient Assessment of Itching at Week 52', 'description': 'Participants rated the severity of their psoriasis itching on a 0 (none) to 100 (most possible) scale.', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change From Baseline in Patient Assessment of Pain at Week 52', 'description': 'Participants rated the severity of their psoriatic arthritis-related pain on a 0 (none) to 100 (most possible) scale.', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change From Baseline in 12-Item Short Form Health Survey (SF-12) at Week 52', 'description': ""SF-12 questionnaire was used to determine participants' quality of life (QoL). It comprised 12 items which covered 8 concepts : physical functionality, role impairment due to physical problems, physical pain, perception of general health, vitality, social functionality, role impairment due to emotional problems, and psychological wellbeing. Results were presented in the form of 2 meta-scores, the physical component and the mental component, each ranged from 0 to 100. Higher scores=better QoL, positive changes from baseline=improvement in QoL."", 'timeFrame': 'Baseline, Week 52'}]",11.0,18 Years,,ALL,False,INDUSTRY,0.0,129.0,ACTUAL,v2_robust,False,True,False,True,
NCT01688609,"Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer",lapatinib ditosylate,"['Lapatinib', 'Anzatax', 'paclitaxel', 'Asotax', 'lapatinib ditosylate', 'GSK572016', 'TAX', 'Taxol', 'GW-572016', 'GW2016', 'Tykerb']",11,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HER2-positive Breast Cancer,National Cancer Institute (NCI),2025-09-01T16:18:10.926831,True,,,,,"Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer",,"['HER2-positive Breast Cancer', 'Stage II Breast Cancer', 'Stage IIIA Breast Cancer']",[],,2012-07,2016-08-15,"[{'measure': 'Expression of ALDH1 and CD44v Change in the Binary Biomarkers From Baseline to 6 Weeks and 18 Weeks', 'description': ""For biomarkers ALDH1 and CD44v, the change in the proportions of CD44v-positive (CD44v+) tumor cells and ALDH1-positive (ALDH1+) tumor cells in tumor tissue from baseline to 6 weeks and 18 weeks time points were determined for each patient. For biomarker change, changes in the binary biomarkers between time points were assessed using McNemar's test in all patients and separately in patients with and without pCR."", 'timeFrame': 'From baseline to 18 weeks'}, {'measure': 'Number of Participants With Pathological Complete Response (pCR)', 'description': 'The point estimate of the pCR rate will be calculated for all patients. pCR is defined as the abscence of invasive cancer in the breast and regional lymph nodes following neoadjuvant chemotherapy.', 'timeFrame': 'Up to 12 weeks'}]","[{'measure': 'Cellular Response Rate, Defined as Patients With an Epithelial Phenotype Having Eradication of CTCs; Patients With a Mesenchymal Phenotype Having Eradication of Tumor Cells; Patients With a Mesenchymal Phenotype Converting to an Epithelial Phenotype', 'description': 'Cellular response will be documented and calculated for rate in all patients.', 'timeFrame': 'Up to 18 weeks'}, {'measure': 'EGFR-mutation Status of Tumors and Changes in the Ratio of Phosphorylated to Nonphosphorylated HER2, EGFR, ERK, Akt, and the Ki67 and TUNEL Indices Before and After Treatment', 'description': 'The EGFR mutation status will be a binary variable (yes vs. no), and the phosphorylation status of HER2 and EGFR will be a ratio variable (0-100%). The CART method to identify cut-off points for the phosphorylation ratio of molecules of interest will be used, such that ratios above the cut-off point will be considered ""high phosphorylation"" and ratios below the cut-off point will be considered ""low phosphorylation.""', 'timeFrame': 'From baseline to 24 weeks'}, {'measure': 'Number of Participants With Treatment-Related Toxicities', 'timeFrame': 'Up to 12 weeks after completion of study treatment'}]",5.0,20 Years,,FEMALE,False,NIH,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,
